data_2mwh_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2mwh _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.72 0 N-CA-C 110.246 -0.279 . . . . 0.0 110.246 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 2.3 tm? -91.43 128.32 37.21 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 -177.918 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . 0.442 ' CE2' ' HB ' ' A' ' 25' ' ' ILE . 83.1 m-85 -119.31 146.77 45.0 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-O 120.991 0.424 . . . . 0.0 111.645 -179.632 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 49.0 m-80 -97.31 138.74 34.32 Favored 'General case' 0 C--N 1.315 -0.932 0 N-CA-C 107.213 -1.403 . . . . 0.0 107.213 175.89 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 69.7 t -115.95 126.7 73.57 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.878 0 N-CA-C 113.108 0.781 . . . . 0.0 113.108 -175.17 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 94.4 mt-10 -120.72 135.66 55.07 Favored 'General case' 0 N--CA 1.443 -0.811 0 CA-C-N 114.817 -1.083 . . . . 0.0 108.21 175.21 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 12.7 m120 -125.44 148.43 48.82 Favored 'General case' 0 C--N 1.313 -0.994 0 CA-C-O 121.042 0.449 . . . . 0.0 111.738 -176.665 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 58.0 tt0 -125.92 119.38 27.61 Favored 'General case' 0 C--N 1.316 -0.857 0 N-CA-C 107.471 -1.307 . . . . 0.0 107.471 177.143 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 39.3 p90 -142.04 9.74 1.92 Allowed 'General case' 0 C--N 1.319 -0.721 0 N-CA-C 114.404 1.261 . . . . 0.0 114.404 -174.814 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -120.96 18.15 9.1 Favored Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 118.351 -1.881 . . . . 0.0 112.075 -176.767 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 110.83 159.58 16.47 Favored Glycine 0 N--CA 1.443 -0.879 0 C-N-CA 120.859 -0.686 . . . . 0.0 112.203 -179.761 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 41.3 m -56.18 -33.23 65.07 Favored 'General case' 0 C--N 1.323 -0.57 0 C-N-CA 122.74 0.416 . . . . 0.0 111.967 178.855 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 20.3 m -68.21 -14.18 62.79 Favored 'General case' 0 CA--C 1.539 0.535 0 CA-C-N 116.582 -0.281 . . . . 0.0 111.499 178.454 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -96.86 138.66 21.34 Favored Pre-proline 0 C--N 1.323 -0.549 0 N-CA-C 110.013 -0.366 . . . . 0.0 110.013 178.597 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_endo -77.9 -171.78 1.29 Allowed 'Trans proline' 0 CA--C 1.534 0.52 0 C-N-CA 122.954 2.436 . . . . 0.0 113.01 -178.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 96.9 m95 -91.34 136.06 33.37 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.103 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 90.8 m-20 -119.71 122.14 40.78 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.103 -179.288 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 75.3 tt0 -78.23 132.03 37.37 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 115.924 -0.58 . . . . 0.0 109.64 178.07 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . 0.44 ' O ' ' HB2' ' A' ' 94' ' ' SER . . . -137.1 29.8 2.69 Favored Glycine 0 N--CA 1.447 -0.612 0 C-N-CA 119.565 -1.303 . . . . 0.0 113.547 -178.919 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 137.33 179.43 16.85 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.023 -1.084 . . . . 0.0 113.333 178.564 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 98.9 mt-30 -123.02 147.56 46.53 Favored 'General case' 0 C--N 1.327 -0.384 0 C-N-CA 122.796 0.438 . . . . 0.0 110.099 179.351 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . 0.41 ' HE1' ' HB3' ' A' ' 94' ' ' SER . 45.5 m0 -121.83 171.81 8.62 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 178.813 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -127.23 117.41 22.25 Favored 'General case' 0 C--N 1.317 -0.829 0 C-N-CA 120.635 -0.426 . . . . 0.0 110.144 175.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.442 ' HB ' ' CE2' ' A' ' 4' ' ' TYR . 99.1 mt -133.98 144.49 35.39 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 CA-C-N 115.559 -0.746 . . . . 0.0 109.677 -177.827 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . 0.43 ' C ' ' H ' ' A' ' 28' ' ' ARG . . . 81.57 35.64 22.1 Favored Glycine 0 CA--C 1.506 -0.487 0 C-N-CA 120.231 -0.985 . . . . 0.0 111.921 179.536 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 11.4 m -74.05 21.62 0.09 Allowed 'General case' 0 C--N 1.317 -0.823 0 N-CA-C 111.9 0.333 . . . . 0.0 111.9 179.83 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . 0.482 ' NH1' ' HG3' ' A' ' 31' ' ' GLN . 54.4 ttt180 -92.61 10.46 30.36 Favored 'General case' 0 CA--C 1.544 0.748 0 CA-C-O 121.686 0.755 . . . . 0.0 109.075 178.807 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 29.3 m 72.57 -79.67 0.04 OUTLIER 'General case' 0 CA--C 1.541 0.619 0 CA-C-N 114.802 -1.09 . . . . 0.0 113.288 176.135 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 28.4 m-20 -88.98 2.68 53.57 Favored 'General case' 0 N--CA 1.473 0.683 0 N-CA-C 113.106 0.78 . . . . 0.0 113.106 -175.222 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . 0.482 ' HG3' ' NH1' ' A' ' 28' ' ' ARG . 8.4 mm-40 -122.47 117.18 25.34 Favored 'General case' 0 C--N 1.309 -1.167 0 N-CA-C 113.394 0.887 . . . . 0.0 113.394 -178.869 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . 0.57 ' OD1' ' HA3' ' A' ' 111' ' ' GLY . 28.2 t-20 -92.39 145.16 24.68 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 114.932 -1.031 . . . . 0.0 110.376 177.163 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.419 HG23 ' CH2' ' A' ' 90' ' ' TRP . 53.3 t -97.62 131.95 43.42 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.148 0 CA-C-N 115.586 -0.734 . . . . 0.0 111.089 -178.814 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 29.1 m -109.36 -19.15 7.04 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.155 0 N-CA-C 112.361 0.504 . . . . 0.0 112.361 -179.597 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.4 ' HB2' ' HB ' ' A' ' 52' ' ' THR . . . -148.3 143.4 26.89 Favored 'General case' 0 CA--C 1.515 -0.383 0 C-N-CA 120.403 -0.519 . . . . 0.0 111.228 179.078 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.406 ' HB ' HG21 ' A' ' 105' ' ' VAL . 90.9 mt -142.68 122.04 9.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.215 -178.99 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 11.7 m120 -127.7 106.78 9.37 Favored 'General case' 0 C--N 1.313 -0.989 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 175.141 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.492 HG11 ' CD1' ' A' ' 61' ' ' PHE . 29.2 m -149.17 154.53 9.44 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 C-N-CA 120.79 -0.364 . . . . 0.0 111.463 -173.693 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 73.8 tt0 -147.61 152.42 37.87 Favored 'General case' 0 N--CA 1.442 -0.844 0 N-CA-C 109.284 -0.635 . . . . 0.0 109.284 176.471 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 33.2 p -83.25 130.33 35.07 Favored 'General case' 0 C--N 1.312 -1.028 0 CA-C-N 116.498 -0.319 . . . . 0.0 111.78 -177.541 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -71.58 -43.41 52.65 Favored Glycine 0 N--CA 1.445 -0.712 0 N-CA-C 110.197 -1.161 . . . . 0.0 110.197 174.681 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . 0.417 ' HB3' ' H ' ' A' ' 43' ' ' ASP . 57.2 m-20 -104.71 -152.91 0.47 Allowed 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 114.898 -0.651 . . . . 0.0 109.764 178.338 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . 0.417 ' H ' ' HB3' ' A' ' 42' ' ' ASP . 6.4 m-20 -74.81 40.27 0.14 Allowed 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 123.683 0.793 . . . . 0.0 111.308 -179.907 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . 0.413 ' O ' ' HE2' ' A' ' 71' ' ' TYR . . . 92.92 -6.83 76.83 Favored Glycine 0 C--O 1.217 -0.924 0 C-N-CA 121.032 -0.604 . . . . 0.0 112.419 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 57.5 mt-30 -65.08 -38.84 92.05 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 112.736 0.643 . . . . 0.0 112.736 -178.086 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 5.4 t -126.06 110.84 14.01 Favored 'General case' 0 C--N 1.306 -1.285 0 CA-C-O 121.135 0.493 . . . . 0.0 110.515 179.806 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' LEU . . . . . 0.402 ' O ' ' HA ' ' A' ' 62' ' ' ARG . 79.4 mt -96.72 127.61 42.87 Favored 'General case' 0 C--N 1.316 -0.885 0 N-CA-C 108.936 -0.764 . . . . 0.0 108.936 177.354 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 24.7 p30 -135.28 152.84 51.89 Favored 'General case' 0 C--N 1.308 -1.204 0 CA-C-O 121.008 0.432 . . . . 0.0 110.966 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 162.53 -144.15 9.39 Favored Glycine 0 N--CA 1.438 -1.17 0 C-N-CA 120.447 -0.882 . . . . 0.0 112.683 179.258 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 61.6 m -127.91 130.9 49.26 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-O 120.94 0.4 . . . . 0.0 110.126 -178.013 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' MET . . . . . 0.553 ' HE1' ' CE2' ' A' ' 53' ' ' TYR . 15.0 tmm? -130.39 148.19 52.18 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-N 116.491 -0.322 . . . . 0.0 110.203 -178.414 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.4 ' HB ' ' HB2' ' A' ' 35' ' ' ALA . 30.5 m -126.21 128.2 46.86 Favored 'General case' 0 C--O 1.249 1.076 0 CA-C-O 120.909 0.385 . . . . 0.0 111.967 -176.849 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . 0.553 ' CE2' ' HE1' ' A' ' 51' ' ' MET . 52.1 m-85 -88.15 163.21 16.3 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-N 115.676 -0.693 . . . . 0.0 110.768 177.186 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -65.05 127.45 31.68 Favored 'General case' 0 C--O 1.24 0.571 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.078 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 76.45 3.64 78.19 Favored Glycine 0 N--CA 1.446 -0.67 0 CA-C-N 115.9 -0.591 . . . . 0.0 112.766 179.032 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 78.7 mm-40 -120.3 178.89 4.48 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-O 120.828 0.347 . . . . 0.0 111.075 -177.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -101.98 174.17 24.08 Favored Glycine 0 N--CA 1.437 -1.241 0 N-CA-C 111.157 -0.777 . . . . 0.0 111.157 178.507 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_endo -66.68 137.71 46.79 Favored 'Trans proline' 0 CA--C 1.531 0.359 0 C-N-CA 122.217 1.944 . . . . 0.0 112.538 179.709 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 44.2 pt -133.61 171.73 17.52 Favored 'Isoleucine or valine' 0 C--O 1.241 0.644 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.356 179.084 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -74.67 138.11 23.44 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.684 -0.77 . . . . 0.0 111.974 -178.835 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.492 ' CD1' HG11 ' A' ' 38' ' ' VAL . 55.4 t80 -127.01 129.57 48.33 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-O 120.488 0.185 . . . . 0.0 110.91 -178.94 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . 0.402 ' HA ' ' O ' ' A' ' 47' ' ' LEU . 59.9 ttp85 -141.74 133.05 26.51 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.305 -0.407 . . . . 0.0 109.96 175.978 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.451 ' HB1' ' HB3' ' A' ' 71' ' ' TYR . . . -133.53 139.85 46.86 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.67 -0.241 . . . . 0.0 111.373 -179.969 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 25.2 m -113.67 127.53 56.08 Favored 'General case' 0 CA--C 1.539 0.555 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.482 -179.286 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 58.0 tp -72.44 125.52 27.61 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 112.422 0.527 . . . . 0.0 112.422 -178.276 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 86.9 mt -76.28 -25.78 55.24 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.671 -0.695 . . . . 0.0 110.541 176.249 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 118.27 0.3 16.47 Favored Glycine 0 C--N 1.337 0.596 0 C-N-CA 120.808 -0.711 . . . . 0.0 113.175 178.761 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 29.0 p-10 -135.03 37.59 3.01 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-O 120.919 0.39 . . . . 0.0 111.008 -178.171 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 97.1 m-20 69.29 4.31 4.55 Favored 'General case' 0 N--CA 1.488 1.431 0 C-N-CA 123.417 0.687 . . . . 0.0 111.735 -177.708 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 16.3 t -95.43 126.07 40.48 Favored 'General case' 0 N--CA 1.435 -1.198 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 177.486 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.451 ' HB3' ' HB1' ' A' ' 63' ' ' ALA . 95.7 m-85 -116.98 129.31 55.95 Favored 'General case' 0 C--N 1.309 -1.172 0 CA-C-N 116.411 -0.359 . . . . 0.0 111.405 -178.023 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -81.52 116.25 21.21 Favored 'General case' 0 C--N 1.315 -0.907 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 175.144 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 54.2 t -102.53 132.96 47.52 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.198 0 N-CA-C 113.215 0.82 . . . . 0.0 113.215 -173.235 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 49.2 mt-10 -127.37 145.78 50.69 Favored 'General case' 0 N--CA 1.44 -0.933 0 CA-C-N 114.267 -1.333 . . . . 0.0 108.666 177.919 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 13.5 m120 -123.77 149.5 45.55 Favored 'General case' 0 C--N 1.316 -0.848 0 N-CA-C 110.246 -0.279 . . . . 0.0 110.246 -176.216 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' GLN . . . . . 0.428 ' HB2' ' CE3' ' A' ' 84' ' ' TRP . 63.1 tt0 -121.83 124.9 45.25 Favored 'General case' 0 C--N 1.315 -0.908 0 CA-C-N 116.464 -0.335 . . . . 0.0 110.385 179.724 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 8.3 p90 -144.05 162.73 35.49 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.876 -0.602 . . . . 0.0 109.628 179.063 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 101.17 -13.04 58.8 Favored Glycine 0 C--N 1.316 -0.583 0 C-N-CA 120.898 -0.667 . . . . 0.0 112.766 179.821 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 125.22 174.87 14.06 Favored Glycine 0 N--CA 1.444 -0.769 0 C-N-CA 120.505 -0.855 . . . . 0.0 112.367 178.626 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 7.5 p-10 -63.43 -34.59 78.08 Favored 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 112.303 0.483 . . . . 0.0 112.303 -179.581 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 73.1 p -78.95 -6.54 56.5 Favored 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 111.965 0.358 . . . . 0.0 111.965 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -85.34 146.18 44.21 Favored Pre-proline 0 C--N 1.322 -0.624 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.796 -179.95 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 84.5 Cg_endo -80.37 -175.09 2.52 Favored 'Trans proline' 0 C--O 1.236 0.404 0 C-N-CA 122.777 2.318 . . . . 0.0 112.768 -179.408 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' TRP . . . . . 0.428 ' CE3' ' HB2' ' A' ' 76' ' ' GLN . 90.5 m95 -94.9 144.87 25.32 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.793 -0.64 . . . . 0.0 109.979 179.412 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 87.9 m-70 -124.52 142.26 51.47 Favored 'General case' 0 C--N 1.316 -0.859 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 179.225 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 22.6 p -61.78 133.87 56.04 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-O 120.911 0.386 . . . . 0.0 111.5 -179.11 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -106.27 -46.26 1.17 Allowed Glycine 0 N--CA 1.445 -0.739 0 C-N-CA 120.667 -0.778 . . . . 0.0 111.639 178.859 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 156.25 -171.74 34.03 Favored Glycine 0 C--O 1.221 -0.685 0 C-N-CA 120.777 -0.725 . . . . 0.0 111.463 178.906 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 7.4 t30 -110.29 118.23 35.77 Favored 'General case' 0 C--N 1.312 -1.047 0 CA-C-N 117.147 0.474 . . . . 0.0 110.178 179.08 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' TRP . . . . . 0.419 ' CH2' HG23 ' A' ' 33' ' ' VAL . 28.6 m0 -107.63 150.16 27.22 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.574 -0.284 . . . . 0.0 110.399 -178.294 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 49.8 mm -107.72 114.61 46.8 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 N-CA-C 109.217 -0.66 . . . . 0.0 109.217 178.109 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 90.0 mt -127.15 79.94 1.92 Allowed 'General case' 0 C--O 1.265 1.893 0 CA-C-O 121.819 0.818 . . . . 0.0 111.814 -177.83 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 169.15 99.69 0.13 Allowed Glycine 0 N--CA 1.438 -1.201 0 CA-C-N 115.113 -0.949 . . . . 0.0 111.969 179.325 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' SER . . . . . 0.44 ' HB2' ' O ' ' A' ' 20' ' ' GLY . 71.6 p -86.19 -7.87 58.23 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 121.308 0.575 . . . . 0.0 110.148 178.604 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -103.68 146.35 28.72 Favored 'General case' 0 N--CA 1.438 -1.055 0 CA-C-N 115.475 -0.784 . . . . 0.0 109.289 179.878 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 -90.24 -19.8 23.72 Favored 'General case' 0 C--N 1.31 -1.138 0 N-CA-C 112.187 0.44 . . . . 0.0 112.187 -172.677 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 28.3 p-10 -117.7 14.52 14.4 Favored 'General case' 0 C--N 1.313 -0.988 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.107 -178.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' GLN . . . . . . . . . . . . . 56.7 tt0 -154.55 123.25 6.18 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 120.834 0.35 . . . . 0.0 110.18 -176.656 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 1.6 m-20 -98.48 162.59 13.07 Favored 'General case' 0 C--O 1.242 0.691 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.064 -175.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 54.3 t -77.55 133.75 29.95 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.579 0 C-N-CA 120.84 -0.344 . . . . 0.0 111.283 178.114 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 35.9 m -116.43 -34.63 1.88 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.503 0 N-CA-C 113.205 0.817 . . . . 0.0 113.205 -179.036 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . 0.455 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -142.73 138.91 30.85 Favored 'General case' 0 CA--C 1.512 -0.489 0 C-N-CA 120.019 -0.672 . . . . 0.0 111.486 179.523 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 40.4 mm -131.77 125.15 55.11 Favored 'Isoleucine or valine' 0 C--O 1.244 0.79 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.287 179.614 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 45.5 t30 -123.84 95.9 4.75 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.628 -0.714 . . . . 0.0 109.311 174.229 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.406 HG21 ' HB ' ' A' ' 36' ' ' ILE . 29.9 m -136.85 138.78 45.71 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.926 0 N-CA-C 112.516 0.562 . . . . 0.0 112.516 -176.442 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -138.36 136.86 36.77 Favored 'General case' 0 C--N 1.309 -1.182 0 CA-C-N 115.132 -0.94 . . . . 0.0 108.481 177.238 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 39.3 t -118.39 129.23 55.3 Favored 'General case' 0 C--N 1.302 -1.496 0 C-N-CA 120.85 -0.34 . . . . 0.0 110.663 -179.549 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -86.45 -6.86 80.23 Favored Glycine 0 N--CA 1.441 -1.001 0 N-CA-C 110.359 -1.096 . . . . 0.0 110.359 175.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . 0.513 ' CG ' ' H ' ' A' ' 110' ' ' ASP . 11.1 t70 -93.88 -164.27 1.15 Allowed 'General case' 0 N--CA 1.445 -0.699 0 CA-C-N 115.286 -0.457 . . . . 0.0 110.025 179.656 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 110' ' ' ASP . . . . . 0.513 ' H ' ' CG ' ' A' ' 109' ' ' ASP . 16.2 m-20 -95.49 19.49 10.89 Favored 'General case' 0 C--N 1.318 -0.784 0 C-N-CA 122.989 0.516 . . . . 0.0 110.682 -178.016 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . 0.57 ' HA3' ' OD1' ' A' ' 32' ' ' ASN . . . 101.73 2.22 52.71 Favored Glycine 0 N--CA 1.443 -0.861 0 C-N-CA 120.605 -0.807 . . . . 0.0 112.545 -179.79 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 35.4 tt0 -64.1 -41.64 97.2 Favored 'General case' 0 C--O 1.226 -0.163 0 CA-C-O 120.984 0.421 . . . . 0.0 110.275 179.417 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 8.6 p -132.24 147.74 52.42 Favored 'General case' 0 N--CA 1.441 -0.878 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.436 177.746 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 92.8 mt -114.76 125.77 54.08 Favored 'General case' 0 C--N 1.319 -0.752 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 179.159 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 18.4 m120 -118.55 137.54 53.16 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-N 116.515 -0.312 . . . . 0.0 111.098 -177.633 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 161.62 -139.91 6.29 Favored Glycine 0 N--CA 1.442 -0.934 0 C-N-CA 119.633 -1.27 . . . . 0.0 113.424 176.299 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 27.2 p -138.05 159.97 40.6 Favored 'General case' 0 C--N 1.312 -1.06 0 C-N-CA 123.037 0.535 . . . . 0.0 110.031 -178.703 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 118' ' ' MET . . . . . 0.402 ' HE1' ' HB2' ' A' ' 118' ' ' MET . 20.5 ptm -146.35 163.0 36.94 Favored 'General case' 0 C--N 1.31 -1.138 0 C-N-CA 121.027 -0.269 . . . . 0.0 111.071 -177.749 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 119' ' ' THR . . . . . 0.455 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 25.8 m -136.68 127.51 27.39 Favored 'General case' 0 C--O 1.251 1.175 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.177 178.727 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . 0.522 ' HB2' ' OE1' ' A' ' 123' ' ' GLU . 6.9 m-85 -94.67 162.7 13.67 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.215 -0.448 . . . . 0.0 109.946 174.705 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -58.79 119.17 6.66 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.695 0.283 . . . . 0.0 111.26 179.813 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 74.03 23.96 74.93 Favored Glycine 0 CA--C 1.52 0.376 0 C-N-CA 120.892 -0.67 . . . . 0.0 112.868 -179.792 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . 0.522 ' OE1' ' HB2' ' A' ' 120' ' ' TYR . 40.0 tt0 -130.2 158.38 39.9 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.769 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -89.14 162.89 31.31 Favored Glycine 0 N--CA 1.444 -0.791 0 N-CA-C 110.902 -0.879 . . . . 0.0 110.902 177.326 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_exo -58.43 131.54 43.38 Favored 'Trans proline' 0 CA--C 1.532 0.394 0 C-N-CA 122.261 1.974 . . . . 0.0 112.471 -179.237 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 43.1 pt -127.87 163.67 31.04 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.18 179.724 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -71.04 133.68 22.67 Favored Glycine 0 C--O 1.242 0.608 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.224 -178.89 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 87.7 t80 -118.02 133.87 55.51 Favored 'General case' 0 C--O 1.245 0.841 0 CA-C-O 121.091 0.472 . . . . 0.0 111.366 -178.083 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 76.5 tttt -137.74 111.0 7.88 Favored 'General case' 0 N--CA 1.44 -0.938 0 CA-C-N 115.165 -0.925 . . . . 0.0 108.887 178.026 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -112.16 143.65 17.56 Favored Glycine 0 C--N 1.311 -0.86 0 C-N-CA 120.377 -0.916 . . . . 0.0 111.843 179.885 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 41.3 m -130.36 130.45 44.42 Favored 'General case' 0 C--N 1.313 -0.998 0 CA-C-N 117.074 0.437 . . . . 0.0 110.401 179.203 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 64.8 tp -65.87 141.06 58.39 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.759 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 18.3 m . . . . . 0 C--O 1.251 1.132 0 CA-C-O 118.484 -0.77 . . . . 0.0 109.504 178.745 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 0.532 ' HB3' ' O ' ' A' ' 25' ' ' ILE . . . . . . . . 0 N--CA 1.474 0.775 0 N-CA-C 110.308 -0.256 . . . . 0.0 110.308 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' LEU . . . . . 0.43 HD12 HE21 ' A' ' 22' ' ' GLN . 0.9 OUTLIER -151.91 128.04 10.46 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 -178.474 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . 0.408 ' N ' HD13 ' A' ' 3' ' ' LEU . 61.7 m-85 -123.52 147.31 47.37 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 112.917 0.71 . . . . 0.0 112.917 -178.293 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 27.4 t-20 -97.92 129.72 44.83 Favored 'General case' 0 C--N 1.316 -0.864 0 N-CA-C 106.677 -1.601 . . . . 0.0 106.677 174.705 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 65.1 t -116.91 129.48 73.37 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.046 0 CA-C-O 121.437 0.637 . . . . 0.0 112.635 -173.818 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 -114.2 139.74 49.13 Favored 'General case' 0 C--O 1.249 1.032 0 CA-C-N 114.974 -1.012 . . . . 0.0 108.346 176.874 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 10.2 m120 -114.16 140.74 48.28 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 116.453 -0.34 . . . . 0.0 110.94 -176.699 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . 0.596 ' OE1' ' HA ' ' A' ' 13' ' ' SER . 36.6 tt0 -127.64 125.56 40.39 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 120.948 0.404 . . . . 0.0 111.289 177.784 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 22.8 p90 -137.29 144.75 42.81 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 116.042 -0.526 . . . . 0.0 109.83 177.192 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 99.52 9.64 49.75 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 120.568 -0.825 . . . . 0.0 111.98 179.039 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 111.17 154.95 13.4 Favored Glycine 0 N--CA 1.444 -0.773 0 C-N-CA 120.959 -0.638 . . . . 0.0 112.325 179.527 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' SER . . . . . 0.596 ' HA ' ' OE1' ' A' ' 9' ' ' GLN . 69.9 m -65.98 -14.76 62.19 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 112.883 0.697 . . . . 0.0 112.883 -179.627 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 46.9 m -84.21 -7.93 59.21 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 121.059 0.457 . . . . 0.0 110.481 177.132 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -84.84 150.16 55.25 Favored Pre-proline 0 N--CA 1.449 -0.478 0 CA-C-N 115.924 -0.58 . . . . 0.0 109.773 178.79 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -67.33 152.35 79.27 Favored 'Trans proline' 0 C--O 1.236 0.409 0 C-N-CA 122.458 2.105 . . . . 0.0 113.046 -178.231 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 90.8 m95 -83.78 130.46 34.94 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 115.52 -0.764 . . . . 0.0 109.056 178.422 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' ASN . . . . . 0.512 ' N ' HD21 ' A' ' 18' ' ' ASN . 0.8 OUTLIER -107.51 132.48 53.19 Favored 'General case' 0 C--N 1.313 -1.016 0 N-CA-C 107.524 -1.287 . . . . 0.0 107.524 179.168 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 71.8 tt0 -66.42 128.02 34.57 Favored 'General case' 0 C--N 1.308 -1.221 0 CA-C-O 121.58 0.705 . . . . 0.0 110.634 -176.793 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -100.96 -4.48 54.28 Favored Glycine 0 N--CA 1.435 -1.396 0 CA-C-N 115.026 -0.988 . . . . 0.0 113.345 -175.113 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 115.01 -153.52 17.58 Favored Glycine 0 N--CA 1.443 -0.851 0 C-N-CA 120.306 -0.95 . . . . 0.0 111.943 -178.142 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . 0.43 HE21 HD12 ' A' ' 3' ' ' LEU . 4.4 pt20 -132.52 139.41 47.88 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-O 120.701 0.286 . . . . 0.0 110.553 -179.812 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 38.4 m0 -117.29 161.44 19.49 Favored 'General case' 0 CA--C 1.508 -0.665 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.887 -178.517 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 73.4 tt0 -112.47 107.05 15.68 Favored 'General case' 0 N--CA 1.443 -0.825 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 175.11 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.532 ' O ' ' HB3' ' A' ' 2' ' ' ALA . 92.4 mt -123.22 132.07 72.06 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.843 0 CA-C-N 115.922 -0.581 . . . . 0.0 109.872 -177.36 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 90.85 116.33 1.9 Allowed Glycine 0 N--CA 1.446 -0.641 0 C-N-CA 120.33 -0.938 . . . . 0.0 112.432 178.707 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' SER . . . . . 0.455 ' OG ' ' HA3' ' A' ' 88' ' ' GLY . 13.2 t -112.56 14.96 20.23 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-O 121.071 0.463 . . . . 0.0 110.201 -179.848 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 75.7 mtp180 -127.64 138.69 52.91 Favored 'General case' 0 CA--C 1.513 -0.449 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.375 -179.426 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 19.4 m -93.01 -27.27 17.1 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.783 179.407 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 11.8 p-10 -77.32 -38.62 50.09 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.45 -177.618 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . 0.486 HE21 ' HA ' ' A' ' 31' ' ' GLN . 0.0 OUTLIER -130.21 121.41 26.15 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.302 179.709 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . 0.547 ' ND2' ' HA3' ' A' ' 111' ' ' GLY . 65.6 t30 -95.3 169.02 10.37 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 178.792 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 58.8 t -96.44 131.25 43.7 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.991 0 CA-C-N 116.568 -0.287 . . . . 0.0 110.934 -177.5 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 28.4 m -111.39 -20.25 6.38 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.163 0 N-CA-C 112.19 0.441 . . . . 0.0 112.19 179.002 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.452 ' HB2' ' HB ' ' A' ' 52' ' ' THR . . . -147.86 145.57 28.74 Favored 'General case' 0 CA--C 1.514 -0.435 0 C-N-CA 120.296 -0.562 . . . . 0.0 111.512 179.992 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 92.0 mt -144.87 127.95 11.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.042 -0.526 . . . . 0.0 109.893 -179.539 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' ASN . . . . . 0.429 ' HA ' ' O ' ' A' ' 103' ' ' ILE . 0.6 OUTLIER -133.17 112.11 11.46 Favored 'General case' 0 C--N 1.317 -0.81 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 174.967 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.499 HG13 ' CD2' ' A' ' 61' ' ' PHE . 15.5 m -147.67 150.21 14.72 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.804 0 N-CA-C 112.207 0.447 . . . . 0.0 112.207 -174.871 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 70.5 tt0 -133.22 143.11 48.93 Favored 'General case' 0 N--CA 1.442 -0.851 0 CA-C-N 114.976 -1.011 . . . . 0.0 108.703 176.485 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 21.2 p -73.75 146.34 44.43 Favored 'General case' 0 C--N 1.31 -1.128 0 CA-C-O 120.728 0.299 . . . . 0.0 111.216 178.591 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -92.11 -42.48 4.64 Favored Glycine 0 N--CA 1.447 -0.576 0 N-CA-C 109.687 -1.365 . . . . 0.0 109.687 175.333 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 23.0 m-20 -102.27 -161.36 0.84 Allowed 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 114.711 -0.745 . . . . 0.0 109.116 176.042 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 29.4 p-10 -84.12 47.79 1.38 Allowed 'General case' 0 C--N 1.315 -0.895 0 CA-C-O 121.325 0.583 . . . . 0.0 110.874 179.484 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 99.53 -14.4 60.72 Favored Glycine 0 C--O 1.22 -0.778 0 CA-C-N 115.923 -0.581 . . . . 0.0 112.665 -179.411 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 58.5 tp60 -64.87 -39.39 93.47 Favored 'General case' 0 CA--C 1.534 0.362 0 CA-C-O 120.803 0.335 . . . . 0.0 111.328 -179.162 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 61.3 p -128.45 142.87 50.96 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.604 -0.271 . . . . 0.0 110.742 179.07 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 86.0 mt -126.68 133.83 50.85 Favored 'General case' 0 C--O 1.236 0.369 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 179.168 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -136.22 147.91 47.83 Favored 'General case' 0 C--N 1.32 -0.692 0 C-N-CA 120.905 -0.318 . . . . 0.0 110.951 179.981 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 165.67 -144.17 9.02 Favored Glycine 0 N--CA 1.442 -0.922 0 C-N-CA 120.497 -0.858 . . . . 0.0 112.104 177.909 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 9.4 t -133.53 145.51 50.2 Favored 'General case' 0 N--CA 1.435 -1.177 0 CA-C-O 121.103 0.477 . . . . 0.0 110.558 -179.211 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' MET . . . . . 0.472 ' HE3' ' CZ ' ' A' ' 53' ' ' TYR . 14.6 tmm? -133.32 147.19 51.85 Favored 'General case' 0 C--N 1.314 -0.96 0 CA-C-N 115.918 -0.583 . . . . 0.0 109.685 -179.952 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.452 ' HB ' ' HB2' ' A' ' 35' ' ' ALA . 28.7 m -125.96 128.01 46.84 Favored 'General case' 0 C--O 1.249 1.054 0 N-CA-C 112.045 0.387 . . . . 0.0 112.045 -176.812 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . 0.472 ' CZ ' ' HE3' ' A' ' 51' ' ' MET . 86.0 m-85 -86.27 162.29 18.34 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.565 176.781 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -64.29 122.09 15.84 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.886 178.479 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.59 5.84 89.19 Favored Glycine 0 CA--C 1.517 0.198 0 C-N-CA 120.958 -0.639 . . . . 0.0 112.499 179.925 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 69.6 mm-40 -119.55 179.14 4.31 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 120.742 0.306 . . . . 0.0 110.874 -178.608 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -106.77 169.2 14.96 Favored Glycine 0 N--CA 1.44 -1.078 0 N-CA-C 111.237 -0.745 . . . . 0.0 111.237 178.881 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_exo -62.34 137.36 64.97 Favored 'Trans proline' 0 C--O 1.235 0.359 0 C-N-CA 122.583 2.189 . . . . 0.0 112.239 179.102 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . 0.468 ' HB ' ' O ' ' A' ' 76' ' ' GLN . 48.6 pt -130.32 170.98 18.3 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 CA-C-N 115.984 -0.553 . . . . 0.0 109.813 178.387 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -75.57 136.27 19.76 Favored Glycine 0 N--CA 1.446 -0.671 0 C-N-CA 120.2 -1.0 . . . . 0.0 110.889 -179.346 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.499 ' CD2' HG13 ' A' ' 38' ' ' VAL . 7.5 t80 -131.22 125.15 32.16 Favored 'General case' 0 C--N 1.31 -1.152 0 CA-C-O 120.958 0.409 . . . . 0.0 111.457 -178.046 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 61.9 ttp180 -130.03 130.99 45.66 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.608 -0.724 . . . . 0.0 110.338 178.039 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -130.99 138.98 49.93 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.782 179.382 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 63.6 m -121.16 130.18 53.6 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.392 179.838 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 61.7 tp -68.16 121.68 16.7 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 121.064 0.459 . . . . 0.0 111.365 -178.459 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 96.1 mt -71.32 -34.24 70.39 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.613 178.242 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 133.5 -12.16 4.91 Favored Glycine 0 CA--C 1.521 0.445 0 C-N-CA 120.485 -0.865 . . . . 0.0 113.31 -179.742 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 20.7 m120 -130.89 50.84 2.19 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-O 120.981 0.42 . . . . 0.0 111.4 -178.038 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 86.7 m-20 65.03 1.54 1.52 Allowed 'General case' 0 N--CA 1.486 1.336 0 C-N-CA 123.845 0.858 . . . . 0.0 111.98 178.835 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 25.7 t -102.62 138.19 39.84 Favored 'General case' 0 N--CA 1.436 -1.146 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 179.108 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.439 ' CE1' ' HB2' ' A' ' 92' ' ' LEU . 84.7 m-85 -118.1 140.87 49.14 Favored 'General case' 0 C--N 1.307 -1.263 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.742 -178.534 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -91.24 123.88 35.03 Favored 'General case' 0 N--CA 1.438 -1.063 0 N-CA-C 107.657 -1.238 . . . . 0.0 107.657 173.746 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 45.3 t -105.32 134.04 47.92 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.246 0 N-CA-C 113.413 0.894 . . . . 0.0 113.413 -173.057 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 84.7 mt-10 -129.25 126.27 38.72 Favored 'General case' 0 N--CA 1.438 -1.042 0 CA-C-N 114.367 -1.288 . . . . 0.0 107.69 176.369 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 92.8 m-20 -109.22 146.69 33.79 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-O 121.021 0.439 . . . . 0.0 111.789 -175.582 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' GLN . . . . . 0.468 ' O ' ' HB ' ' A' ' 59' ' ' ILE . 58.4 tt0 -114.47 121.26 42.99 Favored 'General case' 0 C--N 1.312 -1.061 0 CA-C-N 115.707 -0.678 . . . . 0.0 109.645 -179.955 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 5.8 p90 -140.46 159.47 42.12 Favored 'General case' 0 C--N 1.318 -0.79 0 C-N-CA 120.874 -0.33 . . . . 0.0 110.578 179.246 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 95.35 -7.16 68.83 Favored Glycine 0 N--CA 1.447 -0.575 0 C-N-CA 120.834 -0.698 . . . . 0.0 111.846 -179.704 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 146.58 154.93 6.33 Favored Glycine 0 N--CA 1.445 -0.725 0 N-CA-C 111.684 -0.566 . . . . 0.0 111.684 178.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -72.28 -25.56 61.64 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-O 120.965 0.412 . . . . 0.0 111.198 -179.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 4.6 m -82.47 -11.7 58.33 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.412 177.72 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -72.63 155.3 91.09 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.445 -177.236 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -69.38 169.02 19.38 Favored 'Trans proline' 0 C--N 1.347 0.485 0 C-N-CA 122.721 2.281 . . . . 0.0 112.141 178.342 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' TRP . . . . . 0.467 ' CE3' ' HB2' ' A' ' 76' ' ' GLN . 91.8 m95 -87.49 143.29 27.29 Favored 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 -178.409 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 85.8 m-70 -118.61 157.77 26.75 Favored 'General case' 0 C--N 1.313 -0.996 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 -179.705 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 48.3 m -63.81 143.74 57.61 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-O 120.837 0.351 . . . . 0.0 111.023 179.787 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -117.18 -58.91 0.3 Allowed Glycine 0 N--CA 1.439 -1.164 0 N-CA-C 110.931 -0.867 . . . . 0.0 110.931 178.556 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . 0.455 ' HA3' ' OG ' ' A' ' 27' ' ' SER . . . 149.38 -167.68 29.66 Favored Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 120.929 -0.653 . . . . 0.0 111.929 177.067 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' ASN . . . . . 0.417 ' C ' ' HD1' ' A' ' 90' ' ' TRP . 11.2 m120 -102.48 132.68 48.37 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-O 120.679 0.276 . . . . 0.0 110.624 178.747 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' TRP . . . . . 0.417 ' HD1' ' C ' ' A' ' 89' ' ' ASN . 12.5 m0 -130.63 151.58 50.93 Favored 'General case' 0 C--N 1.319 -0.744 0 N-CA-C 108.472 -0.936 . . . . 0.0 108.472 -179.222 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 95.8 mt -117.26 115.52 49.05 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.153 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 176.643 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . 0.439 ' HB2' ' CE1' ' A' ' 71' ' ' TYR . 88.8 mt -125.6 74.14 1.38 Allowed 'General case' 0 C--O 1.247 0.962 0 CA-C-O 121.683 0.754 . . . . 0.0 110.215 -177.577 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 167.72 87.39 0.07 OUTLIER Glycine 0 N--CA 1.431 -1.648 0 CA-C-N 114.892 -1.049 . . . . 0.0 110.73 -177.888 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 22.5 p -91.63 -5.68 53.46 Favored 'General case' 0 C--N 1.31 -1.116 0 CA-C-O 121.176 0.512 . . . . 0.0 110.586 -179.243 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' ARG . . . . . 0.401 HH11 ' HD3' ' A' ' 95' ' ' ARG . 61.7 mtt-85 -94.2 150.0 20.72 Favored 'General case' 0 N--CA 1.442 -0.849 0 CA-C-N 115.64 -0.709 . . . . 0.0 109.676 179.127 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 77.3 tt0 -70.06 -42.76 72.39 Favored 'General case' 0 C--N 1.315 -0.925 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.669 -174.048 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 94.4 m-20 -113.46 18.13 17.9 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.905 -176.871 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' GLN . . . . . . . . . . . . . 2.3 mt-30 -141.53 117.92 10.82 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 113.18 0.807 . . . . 0.0 113.18 -176.118 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 35.8 m-80 -98.25 166.44 11.4 Favored 'General case' 0 C--O 1.245 0.852 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.204 175.138 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 97.1 t -85.18 134.07 27.93 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.611 -179.063 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 27.9 m -115.23 -31.43 1.97 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-N 115.785 -0.643 . . . . 0.0 112.626 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . 0.491 ' HB2' ' HB ' ' A' ' 119' ' ' THR . . . -144.22 139.08 28.48 Favored 'General case' 0 CA--C 1.514 -0.409 0 C-N-CA 120.097 -0.641 . . . . 0.0 111.631 179.306 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.429 ' O ' ' HA ' ' A' ' 37' ' ' ASN . 92.0 mt -132.75 128.38 57.15 Favored 'Isoleucine or valine' 0 C--O 1.238 0.497 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.177 179.743 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 40.7 t30 -128.42 98.16 4.96 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.674 -0.694 . . . . 0.0 109.435 173.544 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 28.3 m -138.0 140.93 39.74 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 N-CA-C 112.331 0.493 . . . . 0.0 112.331 -176.634 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 42.4 tt0 -141.11 138.52 33.56 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.658 -0.701 . . . . 0.0 109.965 178.078 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 46.4 t -143.85 141.71 30.47 Favored 'General case' 0 N--CA 1.446 -0.634 0 CA-C-O 120.894 0.378 . . . . 0.0 111.24 179.18 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -106.81 6.22 37.6 Favored Glycine 0 N--CA 1.443 -0.873 0 N-CA-C 110.624 -0.991 . . . . 0.0 110.624 176.187 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 23.1 m-20 -95.78 14.33 23.62 Favored 'General case' 0 CA--C 1.516 -0.344 0 C-N-CA 123.004 0.522 . . . . 0.0 111.324 -178.176 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 85.7 m-20 63.59 23.38 13.56 Favored 'General case' 0 N--CA 1.47 0.561 0 CA-C-N 115.632 -0.713 . . . . 0.0 112.319 178.173 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . 0.547 ' HA3' ' ND2' ' A' ' 32' ' ' ASN . . . 103.45 5.21 46.05 Favored Glycine 0 N--CA 1.446 -0.653 0 C-N-CA 120.008 -1.092 . . . . 0.0 114.249 176.651 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 54.2 tt0 -62.63 -49.53 74.81 Favored 'General case' 0 C--O 1.249 1.059 0 CA-C-O 121.583 0.706 . . . . 0.0 109.891 177.612 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 14.4 p -136.12 133.17 36.99 Favored 'General case' 0 N--CA 1.442 -0.846 0 CA-C-N 115.034 -0.985 . . . . 0.0 109.555 177.163 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -107.38 122.76 47.24 Favored 'General case' 0 C--N 1.314 -0.97 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 178.787 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 88.9 m-20 -119.54 143.72 47.45 Favored 'General case' 0 C--N 1.311 -1.082 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.121 -179.063 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 160.87 -138.09 5.3 Favored Glycine 0 N--CA 1.442 -0.915 0 C-N-CA 120.216 -0.992 . . . . 0.0 112.685 177.568 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 2.1 p -131.68 153.34 50.1 Favored 'General case' 0 C--N 1.314 -0.978 0 CA-C-O 121.086 0.47 . . . . 0.0 110.789 -179.592 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 118' ' ' MET . . . . . 0.62 ' SD ' ' HD1' ' A' ' 128' ' ' PHE . 21.7 ptm -139.56 147.81 41.7 Favored 'General case' 0 C--N 1.314 -0.962 0 CA-C-N 115.813 -0.63 . . . . 0.0 109.993 -176.764 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 119' ' ' THR . . . . . 0.491 ' HB ' ' HB2' ' A' ' 102' ' ' ALA . 29.1 m -131.75 125.61 32.4 Favored 'General case' 0 C--O 1.249 1.063 0 C-N-CA 120.99 -0.284 . . . . 0.0 111.096 179.095 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . 0.538 ' CE2' ' HE3' ' A' ' 118' ' ' MET . 63.1 m-85 -94.11 163.7 13.36 Favored 'General case' 0 CA--C 1.513 -0.476 0 CA-C-N 116.159 -0.473 . . . . 0.0 109.969 175.52 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -53.51 -33.81 55.8 Favored 'General case' 0 N--CA 1.47 0.545 0 N-CA-C 113.503 0.927 . . . . 0.0 113.503 -176.544 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -138.0 25.31 2.93 Favored Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 119.596 -1.288 . . . . 0.0 112.776 -178.017 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 36.1 tp10 -111.28 -53.06 2.74 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-O 121.29 0.567 . . . . 0.0 110.326 -177.926 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 115.01 177.43 18.8 Favored Glycine 0 N--CA 1.439 -1.154 0 CA-C-N 115.541 -0.754 . . . . 0.0 111.452 -178.308 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 13.5 Cg_exo -71.16 117.13 5.0 Favored 'Trans proline' 0 N--CA 1.458 -0.561 0 C-N-CA 122.8 2.333 . . . . 0.0 112.051 179.053 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 36.7 pt -130.16 165.96 29.01 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.946 0 CA-C-N 115.93 -0.577 . . . . 0.0 109.891 178.388 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -70.26 135.72 26.0 Favored Glycine 0 C--O 1.241 0.532 0 C-N-CA 120.871 -0.68 . . . . 0.0 112.531 -178.5 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . 0.62 ' HD1' ' SD ' ' A' ' 118' ' ' MET . 72.8 t80 -112.5 132.3 55.15 Favored 'General case' 0 C--O 1.249 1.031 0 CA-C-O 120.832 0.349 . . . . 0.0 111.054 -178.793 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 61.0 tttm -137.59 108.9 6.85 Favored 'General case' 0 N--CA 1.447 -0.587 0 CA-C-N 115.599 -0.728 . . . . 0.0 109.213 175.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -114.03 137.12 13.85 Favored Glycine 0 N--CA 1.446 -0.648 0 C-N-CA 120.522 -0.847 . . . . 0.0 111.818 179.244 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 55.8 m -132.34 140.64 48.62 Favored 'General case' 0 C--N 1.308 -1.21 0 CA-C-N 116.645 0.223 . . . . 0.0 110.605 -179.241 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 88.1 mt -56.99 130.03 44.29 Favored 'General case' 0 N--CA 1.472 0.663 0 O-C-N 123.17 0.294 . . . . 0.0 110.939 177.5 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 14.8 p . . . . . 0 C--O 1.252 1.212 0 CA-C-O 118.145 -0.931 . . . . 0.0 110.326 178.313 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 0.581 0 N-CA-C 109.713 -0.477 . . . . 0.0 109.713 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' LEU . . . . . 0.469 HD11 ' NE2' ' A' ' 22' ' ' GLN . 3.0 tm? -94.81 127.12 40.59 Favored 'General case' 0 C--N 1.317 -0.823 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 -177.153 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 40.5 m-85 -117.16 136.66 52.87 Favored 'General case' 0 C--N 1.312 -1.023 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.305 178.444 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' ASN . . . . . 0.481 ' O ' ' HA2' ' A' ' 130' ' ' GLY . 0.9 OUTLIER -85.06 132.23 34.35 Favored 'General case' 0 CA--C 1.499 -0.989 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 175.378 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.506 HG23 ' CG ' ' A' ' 23' ' ' TRP . 53.2 t -114.35 128.13 71.51 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.115 0 N-CA-C 113.182 0.808 . . . . 0.0 113.182 -173.847 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 71.6 mt-10 -124.05 135.9 53.89 Favored 'General case' 0 N--CA 1.436 -1.143 0 CA-C-N 114.577 -1.192 . . . . 0.0 108.469 177.542 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 10.8 m120 -121.1 145.11 48.15 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 120.884 0.373 . . . . 0.0 111.415 -175.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . 0.427 ' NE2' ' HA ' ' A' ' 13' ' ' SER . 52.1 tt0 -124.97 123.39 39.77 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.717 178.264 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 40.1 p90 -133.44 142.56 48.37 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 116.653 -0.249 . . . . 0.0 110.922 179.264 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 105.16 10.31 32.22 Favored Glycine 0 CA--C 1.52 0.345 0 C-N-CA 120.327 -0.94 . . . . 0.0 112.945 177.164 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.36 171.51 33.52 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.574 -0.822 . . . . 0.0 112.887 179.56 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' SER . . . . . 0.427 ' HA ' ' NE2' ' A' ' 9' ' ' GLN . 16.4 m -57.8 -26.31 61.78 Favored 'General case' 0 CA--C 1.536 0.426 0 C-N-CA 122.993 0.517 . . . . 0.0 112.061 179.311 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 14.8 m -59.24 -24.76 63.46 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 122.62 0.368 . . . . 0.0 111.695 177.5 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -91.37 144.27 29.47 Favored Pre-proline 0 C--N 1.324 -0.51 0 CA-C-N 116.75 -0.204 . . . . 0.0 110.577 179.515 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -81.13 -176.05 2.95 Favored 'Trans proline' 0 C--O 1.239 0.538 0 C-N-CA 122.657 2.238 . . . . 0.0 112.32 179.397 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 99.1 m95 -87.22 128.8 35.14 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.213 -0.449 . . . . 0.0 109.908 179.64 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 34.0 m-80 -113.65 110.74 20.69 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.384 -177.093 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 73.1 tt0 -73.35 121.29 20.2 Favored 'General case' 0 C--N 1.317 -0.837 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 177.084 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -134.68 32.59 2.59 Favored Glycine 0 N--CA 1.447 -0.624 0 C-N-CA 119.792 -1.194 . . . . 0.0 112.967 -178.634 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 136.99 -167.22 24.71 Favored Glycine 0 N--CA 1.444 -0.821 0 C-N-CA 120.103 -1.046 . . . . 0.0 112.817 178.104 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . 0.469 ' NE2' HD11 ' A' ' 3' ' ' LEU . 10.9 pt20 -147.84 153.9 39.75 Favored 'General case' 0 C--N 1.316 -0.879 0 C-N-CA 122.236 0.214 . . . . 0.0 110.543 -179.715 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . 0.506 ' CG ' HG23 ' A' ' 6' ' ' VAL . 38.4 m0 -126.82 177.04 6.84 Favored 'General case' 0 N--CA 1.47 0.531 0 CA-C-N 116.343 -0.389 . . . . 0.0 110.347 -175.623 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . 0.402 ' HB3' HG12 ' A' ' 91' ' ' ILE . 83.7 tt0 -124.61 114.44 19.38 Favored 'General case' 0 CA--C 1.505 -0.768 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.031 174.74 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 98.2 mt -124.38 132.83 70.77 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.878 0 CA-C-N 115.446 -0.797 . . . . 0.0 109.632 -178.294 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 87.75 55.21 2.33 Favored Glycine 0 N--CA 1.447 -0.606 0 C-N-CA 120.077 -1.059 . . . . 0.0 112.45 178.283 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 36.1 t -61.57 -38.14 86.43 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.575 0.226 . . . . 0.0 110.558 178.993 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 70.4 ttt180 -49.98 -42.61 49.27 Favored 'General case' 0 CA--C 1.542 0.656 0 CA-C-N 116.199 -0.455 . . . . 0.0 112.174 179.501 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 14.9 m 74.16 -42.13 0.5 Allowed 'General case' 0 N--CA 1.48 1.052 0 N-CA-C 114.36 1.244 . . . . 0.0 114.36 175.6 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 3.9 p-10 -74.98 -4.33 37.59 Favored 'General case' 0 N--CA 1.487 1.411 0 CA-C-N 118.378 0.535 . . . . 0.0 111.782 -178.237 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 1.1 tm0? -150.71 119.7 6.68 Favored 'General case' 0 C--N 1.314 -0.968 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.755 178.525 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . 0.646 ' OD1' ' HA3' ' A' ' 111' ' ' GLY . 27.0 t-20 -85.59 145.74 27.21 Favored 'General case' 0 CA--C 1.534 0.357 0 CA-C-O 121.667 0.746 . . . . 0.0 111.97 -179.696 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 15.4 t -97.14 130.07 46.29 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.12 0 CA-C-N 115.085 -0.961 . . . . 0.0 110.531 -177.698 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 17.2 m -101.3 -24.52 4.05 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 N-CA-C 112.002 0.371 . . . . 0.0 112.002 -179.599 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.502 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -141.25 146.13 36.45 Favored 'General case' 0 C--N 1.323 -0.551 0 C-N-CA 120.273 -0.571 . . . . 0.0 111.12 179.327 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.425 ' HB ' ' CG2' ' A' ' 105' ' ' VAL . 98.2 mt -142.84 125.53 13.47 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.325 -177.427 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -130.81 113.36 13.98 Favored 'General case' 0 C--N 1.316 -0.869 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 174.898 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.47 HG22 ' HB ' ' A' ' 103' ' ' ILE . 28.7 m -144.73 145.64 20.95 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 C-N-CA 120.89 -0.324 . . . . 0.0 111.214 -175.785 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 79.6 tt0 -141.03 146.22 36.93 Favored 'General case' 0 N--CA 1.45 -0.453 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.163 178.263 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' SER . . . . . 0.551 ' OG ' ' HB ' ' A' ' 101' ' ' VAL . 26.0 p -81.89 144.86 30.69 Favored 'General case' 0 C--N 1.316 -0.864 0 N-CA-C 111.875 0.324 . . . . 0.0 111.875 -179.11 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -91.23 -21.62 34.75 Favored Glycine 0 N--CA 1.449 -0.454 0 N-CA-C 110.744 -0.942 . . . . 0.0 110.744 175.206 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . 0.444 ' C ' ' H ' ' A' ' 44' ' ' GLY . 28.2 m-20 -132.91 -150.2 0.4 Allowed 'General case' 0 CA--C 1.514 -0.415 0 N-CA-C 108.917 -0.772 . . . . 0.0 108.917 179.373 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -75.81 34.89 0.12 Allowed 'General case' 0 N--CA 1.471 0.614 0 C-N-CA 122.768 0.427 . . . . 0.0 110.818 178.517 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . 0.444 ' H ' ' C ' ' A' ' 42' ' ' ASP . . . 90.85 1.81 72.88 Favored Glycine 0 N--CA 1.442 -0.951 0 C-N-CA 121.057 -0.592 . . . . 0.0 112.655 -178.669 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 60.5 tp60 -62.89 -44.81 95.09 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-O 120.971 0.415 . . . . 0.0 110.547 -179.433 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 4.3 t -129.97 122.6 28.8 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.185 176.404 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 81.8 mt -102.48 132.8 48.28 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 116.139 -0.482 . . . . 0.0 109.777 178.782 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 13.0 m120 -121.34 133.39 55.11 Favored 'General case' 0 C--N 1.314 -0.964 0 N-CA-C 108.963 -0.755 . . . . 0.0 108.963 177.38 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . 0.403 ' HA3' ' HA ' ' A' ' 38' ' ' VAL . . . -173.2 -162.72 25.69 Favored Glycine 0 N--CA 1.436 -1.321 0 C-N-CA 119.367 -1.397 . . . . 0.0 113.243 179.876 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 90.4 m -131.65 130.48 42.16 Favored 'General case' 0 C--N 1.309 -1.176 0 C-N-CA 122.692 0.397 . . . . 0.0 111.4 -179.701 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 43.8 mtp -106.24 145.08 32.04 Favored 'General case' 0 N--CA 1.469 0.49 0 C-N-CA 122.689 0.396 . . . . 0.0 110.161 177.042 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.502 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 36.2 m -123.92 122.35 37.74 Favored 'General case' 0 C--O 1.249 1.076 0 CA-C-O 120.636 0.255 . . . . 0.0 110.64 177.727 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 24.0 m-85 -82.44 161.38 22.46 Favored 'General case' 0 N--CA 1.462 0.142 0 CA-C-N 115.654 -0.703 . . . . 0.0 111.491 -179.468 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -65.46 109.37 2.3 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.932 -0.576 . . . . 0.0 111.661 -179.545 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 83.32 14.93 72.94 Favored Glycine 0 N--CA 1.446 -0.649 0 C-N-CA 120.836 -0.697 . . . . 0.0 113.392 178.371 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 51.1 mt-10 -137.07 167.78 20.87 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.974 0.387 . . . . 0.0 111.513 -178.993 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -78.18 163.1 50.34 Favored Glycine 0 N--CA 1.448 -0.507 0 CA-C-N 115.87 -0.604 . . . . 0.0 113.36 -177.301 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_exo -67.5 142.85 60.78 Favored 'Trans proline' 0 CA--C 1.54 0.781 0 C-N-CA 123.188 2.592 . . . . 0.0 112.749 179.778 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . 0.506 ' HB ' ' O ' ' A' ' 76' ' ' GLN . 47.5 pt -127.14 166.0 24.71 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.329 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.818 -179.422 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -73.83 144.09 33.3 Favored Glycine 0 CA--C 1.517 0.217 0 C-N-CA 121.078 -0.582 . . . . 0.0 112.502 -177.852 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 41.5 t80 -130.45 127.8 39.99 Favored 'General case' 0 C--O 1.238 0.499 0 CA-C-O 120.829 0.347 . . . . 0.0 111.091 -178.791 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 67.3 ttp85 -136.32 127.58 28.21 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 175.585 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -135.07 146.91 49.38 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 120.565 0.221 . . . . 0.0 111.548 -178.175 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 64.3 m -124.54 129.41 50.55 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.598 178.875 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . 0.448 ' HB2' ' CE2' ' A' ' 71' ' ' TYR . 56.6 tp -74.58 130.21 39.15 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.879 -178.847 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . 0.415 ' HB2' ' OD1' ' A' ' 68' ' ' ASN . 85.8 mt -84.52 -17.83 37.69 Favored 'General case' 0 CA--C 1.536 0.429 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.077 177.094 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.432 ' N ' ' HG ' ' A' ' 65' ' ' LEU . . . 105.58 -8.99 44.32 Favored Glycine 0 C--O 1.222 -0.638 0 CA-C-N 115.761 -0.654 . . . . 0.0 112.198 178.49 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' ASN . . . . . 0.415 ' OD1' ' HB2' ' A' ' 66' ' ' LEU . 29.7 p-10 -110.85 34.72 3.84 Favored 'General case' 0 C--N 1.316 -0.858 0 CA-C-O 120.921 0.391 . . . . 0.0 110.749 -179.742 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . 0.481 HD22 ' HA ' ' A' ' 96' ' ' GLU . 90.8 m-20 66.83 7.99 5.67 Favored 'General case' 0 N--CA 1.484 1.225 0 CA-C-N 115.599 -0.728 . . . . 0.0 111.11 -179.399 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 7.3 m -107.94 133.35 52.4 Favored 'General case' 0 N--CA 1.436 -1.143 0 CA-C-N 115.685 -0.689 . . . . 0.0 109.932 -179.796 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.483 ' CE1' ' HB2' ' A' ' 92' ' ' LEU . 86.4 m-85 -114.8 134.99 54.68 Favored 'General case' 0 C--N 1.308 -1.205 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.654 -179.712 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 71.8 tt0 -86.95 119.98 27.73 Favored 'General case' 0 N--CA 1.442 -0.831 0 N-CA-C 106.967 -1.494 . . . . 0.0 106.967 173.39 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 63.1 t -108.71 134.13 51.61 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.073 0 N-CA-C 112.943 0.72 . . . . 0.0 112.943 -172.835 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 49.1 mt-10 -131.45 131.91 43.91 Favored 'General case' 0 N--CA 1.441 -0.912 0 CA-C-N 114.6 -1.182 . . . . 0.0 107.93 175.943 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 95.1 m-20 -119.28 160.62 21.87 Favored 'General case' 0 C--N 1.309 -1.18 0 CA-C-O 121.371 0.605 . . . . 0.0 112.257 -175.207 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' GLN . . . . . 0.506 ' O ' ' HB ' ' A' ' 59' ' ' ILE . 59.8 tt0 -118.95 114.26 22.28 Favored 'General case' 0 C--N 1.312 -1.025 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.569 -179.17 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 3.3 p90 -134.83 35.71 3.11 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 120.941 0.401 . . . . 0.0 111.416 -176.615 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -133.49 -6.9 2.56 Favored Glycine 0 C--N 1.318 -0.433 0 C-N-CA 120.225 -0.988 . . . . 0.0 112.742 -178.32 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 127.47 160.43 10.47 Favored Glycine 0 N--CA 1.445 -0.745 0 N-CA-C 109.805 -1.318 . . . . 0.0 109.805 -178.076 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 19.6 m-20 -58.97 -39.98 83.39 Favored 'General case' 0 N--CA 1.474 0.749 0 CA-C-N 117.72 0.76 . . . . 0.0 112.245 -177.114 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 4.7 p -81.24 -5.66 58.01 Favored 'General case' 0 C--N 1.316 -0.85 0 N-CA-C 112.436 0.532 . . . . 0.0 112.436 -177.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -83.93 149.21 55.87 Favored Pre-proline 0 C--N 1.321 -0.67 0 CA-C-N 116.755 -0.202 . . . . 0.0 110.995 -178.644 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_exo -67.33 161.31 43.73 Favored 'Trans proline' 0 C--N 1.346 0.443 0 C-N-CA 122.796 2.331 . . . . 0.0 111.939 178.242 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' TRP . . . . . . . . . . . . . 79.2 m95 -80.99 147.12 30.36 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.04 -179.496 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 89.9 m-70 -118.48 147.38 43.68 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.075 179.638 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 13.0 m -62.32 134.47 56.52 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-O 121.224 0.535 . . . . 0.0 111.565 -178.073 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -105.45 -48.5 1.04 Allowed Glycine 0 N--CA 1.441 -0.982 0 CA-C-N 115.451 -0.795 . . . . 0.0 111.463 179.082 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 144.92 -163.79 27.96 Favored Glycine 0 N--CA 1.442 -0.911 0 C-N-CA 120.544 -0.836 . . . . 0.0 112.251 177.535 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 16.5 m120 -104.72 127.16 52.41 Favored 'General case' 0 C--N 1.316 -0.858 0 CA-C-O 120.812 0.339 . . . . 0.0 110.341 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 12.4 m0 -119.7 144.45 47.2 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 179.825 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . 0.48 ' O ' ' HB3' ' A' ' 23' ' ' TRP . 45.5 mm -108.38 113.36 43.72 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.933 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.027 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . 0.483 ' HB2' ' CE1' ' A' ' 71' ' ' TYR . 77.9 mt -129.23 81.53 2.03 Favored 'General case' 0 C--O 1.261 1.699 0 CA-C-O 121.47 0.653 . . . . 0.0 111.894 -177.437 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 165.56 99.55 0.14 Allowed Glycine 0 N--CA 1.445 -0.751 0 CA-C-N 115.417 -0.811 . . . . 0.0 111.292 -179.813 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 3.2 p -101.69 -12.54 18.31 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 117.036 0.418 . . . . 0.0 111.844 -177.826 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' ARG . . . . . 0.404 HH12 ' CD ' ' A' ' 123' ' ' GLU . 96.6 mtt180 -83.49 -5.0 59.03 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.438 -0.346 . . . . 0.0 111.339 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . 0.481 ' HA ' HD22 ' A' ' 69' ' ' ASN . 72.3 tt0 71.29 -55.84 0.64 Allowed 'General case' 0 N--CA 1.47 0.553 0 C-N-CA 123.502 0.721 . . . . 0.0 112.724 177.113 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 44.7 m-80 -96.18 14.93 22.36 Favored 'General case' 0 C--N 1.315 -0.919 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.341 -175.309 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' GLN . . . . . 0.463 ' HG2' ' HB3' ' A' ' 120' ' ' TYR . 59.2 tt0 -152.36 115.43 4.66 Favored 'General case' 0 C--N 1.316 -0.883 0 CA-C-O 120.992 0.425 . . . . 0.0 109.944 -177.731 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 76.5 m-20 -78.71 160.97 27.2 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.581 -0.736 . . . . 0.0 111.421 -176.376 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 90.6 t -87.97 133.04 31.58 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.496 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.205 175.252 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . 0.551 ' HB ' ' OG ' ' A' ' 40' ' ' SER . 35.3 m -116.03 -28.02 2.39 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 N-CA-C 113.345 0.869 . . . . 0.0 113.345 -176.41 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . 0.428 ' HB2' ' HB ' ' A' ' 119' ' ' THR . . . -146.94 137.66 23.77 Favored 'General case' 0 C--N 1.325 -0.483 0 C-N-CA 120.341 -0.544 . . . . 0.0 111.285 179.237 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.47 ' HB ' HG22 ' A' ' 38' ' ' VAL . 91.5 mt -133.85 127.91 52.88 Favored 'Isoleucine or valine' 0 C--O 1.242 0.699 0 CA-C-N 116.354 -0.384 . . . . 0.0 110.608 179.011 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . 0.453 ' C ' HD21 ' A' ' 104' ' ' ASN . 0.2 OUTLIER -126.31 99.48 5.88 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 175.258 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.425 ' CG2' ' HB ' ' A' ' 36' ' ' ILE . 19.5 m -137.92 141.11 39.5 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 N-CA-C 112.546 0.573 . . . . 0.0 112.546 -176.925 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 70.4 tt0 -142.14 138.02 31.32 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.705 -0.679 . . . . 0.0 109.583 177.466 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 28.8 t -140.7 142.24 34.89 Favored 'General case' 0 N--CA 1.448 -0.529 0 CA-C-O 121.038 0.447 . . . . 0.0 111.801 -178.682 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -107.97 9.99 37.17 Favored Glycine 0 N--CA 1.443 -0.846 0 N-CA-C 110.759 -0.936 . . . . 0.0 110.759 175.361 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 20.5 m-20 -91.64 14.03 16.3 Favored 'General case' 0 N--CA 1.466 0.348 0 C-N-CA 122.909 0.484 . . . . 0.0 110.401 -177.829 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 12.4 m-20 63.37 30.88 15.45 Favored 'General case' 0 N--CA 1.471 0.612 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.741 -177.554 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . 0.646 ' HA3' ' OD1' ' A' ' 32' ' ' ASN . . . 89.03 7.11 70.79 Favored Glycine 0 N--CA 1.449 -0.456 0 CA-C-N 115.654 -0.703 . . . . 0.0 114.273 175.271 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 52.9 tt0 -65.21 -47.85 75.45 Favored 'General case' 0 C--O 1.237 0.438 0 CA-C-N 117.438 0.619 . . . . 0.0 110.198 177.67 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 113' ' ' THR . . . . . 0.437 ' HA ' ' O ' ' A' ' 130' ' ' GLY . 2.0 p -134.18 118.3 17.5 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-N 115.492 -0.776 . . . . 0.0 111.037 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -95.33 122.29 37.89 Favored 'General case' 0 C--N 1.319 -0.754 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.273 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 93.4 m-20 -123.42 148.6 45.98 Favored 'General case' 0 C--N 1.312 -1.036 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.703 -178.71 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 160.66 -135.29 3.95 Favored Glycine 0 N--CA 1.438 -1.184 0 C-N-CA 120.362 -0.923 . . . . 0.0 112.775 177.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 25.8 p -133.28 156.77 46.97 Favored 'General case' 0 C--N 1.316 -0.885 0 C-N-CA 122.858 0.463 . . . . 0.0 109.962 -178.532 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 11.3 ptm -151.4 157.61 42.64 Favored 'General case' 0 C--N 1.312 -1.046 0 CA-C-O 120.614 0.245 . . . . 0.0 110.822 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 119' ' ' THR . . . . . 0.428 ' HB ' ' HB2' ' A' ' 102' ' ' ALA . 38.0 m -132.51 131.02 41.18 Favored 'General case' 0 C--O 1.249 1.079 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.041 179.717 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . 0.463 ' HB3' ' HG2' ' A' ' 98' ' ' GLN . 78.3 m-85 -93.72 166.89 11.99 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.934 -0.575 . . . . 0.0 109.961 176.644 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -63.22 118.29 7.76 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.675 -0.239 . . . . 0.0 110.731 178.837 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 68.2 34.63 81.2 Favored Glycine 0 C--N 1.333 0.395 0 C-N-CA 120.819 -0.705 . . . . 0.0 111.613 -178.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . 0.404 ' CD ' HH12 ' A' ' 95' ' ' ARG . 31.6 tp10 -132.61 163.24 29.34 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 -176.723 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -94.41 159.21 23.2 Favored Glycine 0 N--CA 1.442 -0.947 0 N-CA-C 110.553 -1.019 . . . . 0.0 110.553 176.24 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_endo -62.52 132.78 39.58 Favored 'Trans proline' 0 C--O 1.237 0.464 0 C-N-CA 122.177 1.918 . . . . 0.0 111.885 -179.782 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 40.9 pt -132.79 166.19 30.1 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 CA-C-N 115.932 -0.577 . . . . 0.0 110.464 -179.742 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -70.61 141.49 33.6 Favored Glycine 0 C--O 1.242 0.615 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.176 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 82.7 t80 -123.67 135.57 53.98 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-O 120.824 0.345 . . . . 0.0 111.188 -178.725 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 62.4 tttm -139.3 118.93 13.06 Favored 'General case' 0 N--CA 1.445 -0.713 0 CA-C-N 115.497 -0.774 . . . . 0.0 109.313 177.178 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . 0.481 ' HA2' ' O ' ' A' ' 5' ' ' ASN . . . -125.26 137.94 10.67 Favored Glycine 0 N--CA 1.445 -0.737 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.054 179.67 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 59.4 m -123.63 129.69 51.53 Favored 'General case' 0 C--N 1.313 -0.98 0 CA-C-N 116.853 0.327 . . . . 0.0 110.817 -179.303 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -67.45 117.7 9.78 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-O 121.186 0.517 . . . . 0.0 111.429 -178.163 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 15.0 m . . . . . 0 C--O 1.25 1.1 0 CA-C-N 115.707 -0.678 . . . . 0.0 110.612 176.229 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.807 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' LEU . . . . . 0.405 HD11 ' NE2' ' A' ' 22' ' ' GLN . 2.2 tm? -89.99 126.71 35.85 Favored 'General case' 0 C--N 1.315 -0.917 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -178.987 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . 0.463 ' CE1' ' HB ' ' A' ' 25' ' ' ILE . 58.0 m-85 -114.53 141.46 47.7 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.225 -178.796 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 23.4 t-20 -93.72 137.85 32.55 Favored 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 106.719 -1.586 . . . . 0.0 106.719 174.918 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.433 HG22 ' CG ' ' A' ' 23' ' ' TRP . 59.0 t -114.48 128.31 71.58 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.894 0 N-CA-C 113.287 0.847 . . . . 0.0 113.287 -173.679 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -118.31 133.05 56.22 Favored 'General case' 0 C--O 1.245 0.833 0 CA-C-N 114.748 -1.114 . . . . 0.0 109.283 176.907 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 12.0 m120 -110.32 135.38 51.15 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.076 -177.411 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . 0.425 ' OE1' ' HA ' ' A' ' 13' ' ' SER . 36.0 tt0 -120.45 114.23 21.48 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 120.988 0.423 . . . . 0.0 110.448 175.713 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 2.4 p90 -112.12 175.66 5.34 Favored 'General case' 0 C--N 1.311 -1.097 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.487 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 69.87 -71.34 0.56 Allowed Glycine 0 CA--C 1.529 0.948 0 CA-C-N 115.706 -0.679 . . . . 0.0 112.956 -176.847 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -165.08 168.3 39.16 Favored Glycine 0 N--CA 1.446 -0.684 0 C-N-CA 121.014 -0.612 . . . . 0.0 112.304 -178.458 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' SER . . . . . 0.425 ' HA ' ' OE1' ' A' ' 9' ' ' GLN . 28.2 t -62.85 -19.55 64.23 Favored 'General case' 0 CA--C 1.54 0.563 0 N-CA-C 112.329 0.492 . . . . 0.0 112.329 -178.669 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 30.4 p -77.47 -6.83 54.92 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.873 0.368 . . . . 0.0 111.76 179.411 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -86.69 149.36 48.35 Favored Pre-proline 0 C--N 1.323 -0.584 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.548 179.131 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_endo -69.14 162.43 41.8 Favored 'Trans proline' 0 C--O 1.237 0.458 0 C-N-CA 122.529 2.153 . . . . 0.0 112.086 179.071 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 98.3 m95 -85.65 124.26 31.98 Favored 'General case' 0 C--N 1.317 -0.837 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 179.695 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 92.4 m-20 -111.44 113.42 25.86 Favored 'General case' 0 C--N 1.309 -1.154 0 CA-C-N 116.332 -0.394 . . . . 0.0 111.059 -175.89 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 80.6 tt0 -71.97 122.43 20.84 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-N 115.826 -0.625 . . . . 0.0 109.611 179.864 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -137.69 25.6 2.95 Favored Glycine 0 N--CA 1.446 -0.679 0 C-N-CA 120.29 -0.957 . . . . 0.0 112.559 -177.93 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . 0.402 ' HA3' ' HB3' ' A' ' 94' ' ' SER . . . 156.63 -172.39 34.33 Favored Glycine 0 N--CA 1.433 -1.524 0 C-N-CA 119.961 -1.114 . . . . 0.0 112.651 179.205 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . 0.405 ' NE2' HD11 ' A' ' 3' ' ' LEU . 19.6 pt20 -150.34 145.43 26.13 Favored 'General case' 0 C--N 1.31 -1.11 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 179.299 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . 0.433 ' CG ' HG22 ' A' ' 6' ' ' VAL . 43.7 m0 -122.47 159.45 27.61 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.749 -177.172 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 79.3 tt0 -118.05 119.71 35.59 Favored 'General case' 0 C--N 1.306 -1.316 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 176.079 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.463 ' HB ' ' CE1' ' A' ' 4' ' ' TYR . 98.9 mt -127.87 135.14 63.76 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-N 115.432 -0.804 . . . . 0.0 109.934 -175.011 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 89.07 71.83 1.27 Allowed Glycine 0 N--CA 1.435 -1.427 0 C-N-CA 119.718 -1.229 . . . . 0.0 111.944 -179.878 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' SER . . . . . 0.448 ' OG ' ' HA3' ' A' ' 88' ' ' GLY . 7.5 t -59.44 -39.38 83.39 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 176.829 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 73.3 ttt180 -82.22 113.03 19.77 Favored 'General case' 0 N--CA 1.439 -1.013 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 174.599 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 30.8 m -78.3 -13.71 59.73 Favored 'General case' 0 C--N 1.315 -0.892 0 CA-C-O 120.965 0.412 . . . . 0.0 111.777 -174.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 23.2 t70 -72.0 -33.43 68.09 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.403 0.62 . . . . 0.0 110.987 178.865 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . 0.556 HE21 ' HA ' ' A' ' 31' ' ' GLN . 0.0 OUTLIER -126.17 120.62 30.57 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.63 -0.713 . . . . 0.0 111.012 -177.369 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . 0.541 ' ND2' ' HA3' ' A' ' 111' ' ' GLY . 64.2 t30 -95.04 154.41 17.19 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.532 -0.304 . . . . 0.0 110.235 178.943 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.425 ' HA ' ' HA ' ' A' ' 53' ' ' TYR . 62.0 t -96.22 133.53 37.15 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.541 -176.457 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 28.4 m -113.49 -14.54 10.83 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.151 0 N-CA-C 112.299 0.481 . . . . 0.0 112.299 178.891 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.472 ' HB1' ' HB ' ' A' ' 52' ' ' THR . . . -147.49 138.96 23.86 Favored 'General case' 0 C--N 1.323 -0.565 0 C-N-CA 120.391 -0.524 . . . . 0.0 111.487 179.552 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 88.8 mt -141.42 123.3 13.97 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-N 116.058 -0.519 . . . . 0.0 109.912 -179.6 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -128.97 109.39 11.19 Favored 'General case' 0 C--N 1.309 -1.188 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 174.055 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 18.4 m -146.49 148.13 17.28 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 C-N-CA 120.674 -0.41 . . . . 0.0 112.012 -174.356 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 66.7 tt0 -138.42 140.54 39.36 Favored 'General case' 0 C--N 1.315 -0.899 0 CA-C-N 115.214 -0.903 . . . . 0.0 108.619 176.293 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' SER . . . . . 0.431 ' HA ' ' O ' ' A' ' 46' ' ' THR . 94.7 p -81.55 153.8 26.58 Favored 'General case' 0 C--N 1.308 -1.216 0 CA-C-O 120.921 0.391 . . . . 0.0 111.946 -176.84 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -97.43 -57.14 1.07 Allowed Glycine 0 N--CA 1.435 -1.393 0 CA-C-N 115.765 -0.652 . . . . 0.0 111.767 176.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -113.54 98.4 7.04 Favored 'General case' 0 CA--C 1.533 0.315 0 N-CA-C 111.924 0.342 . . . . 0.0 111.924 -178.477 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 14.1 m-20 47.76 34.53 3.88 Favored 'General case' 0 N--CA 1.492 1.667 0 N-CA-C 114.454 1.279 . . . . 0.0 114.454 175.222 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . 0.416 ' HA2' ' CB ' ' A' ' 40' ' ' SER . . . 80.11 0.65 86.45 Favored Glycine 0 C--N 1.319 -0.41 0 C-N-CA 120.438 -0.887 . . . . 0.0 113.793 178.196 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 59.9 mt-30 -77.4 -30.45 53.59 Favored 'General case' 0 CA--C 1.513 -0.458 0 CA-C-N 117.398 0.599 . . . . 0.0 111.331 178.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' THR . . . . . 0.431 ' O ' ' HA ' ' A' ' 40' ' ' SER . 5.1 p -122.83 107.02 11.42 Favored 'General case' 0 C--N 1.308 -1.229 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.999 -179.472 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' LEU . . . . . 0.493 ' O ' ' HA ' ' A' ' 62' ' ' ARG . 90.8 mt -89.91 129.16 36.3 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 177.534 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 15.4 m120 -126.65 136.99 53.23 Favored 'General case' 0 C--N 1.318 -0.804 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 171.03 -153.32 20.47 Favored Glycine 0 N--CA 1.443 -0.857 0 C-N-CA 118.876 -1.63 . . . . 0.0 114.057 178.813 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 52.4 m -127.43 131.92 50.16 Favored 'General case' 0 C--N 1.315 -0.899 0 C-N-CA 123.14 0.576 . . . . 0.0 109.455 -178.002 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' MET . . . . . 0.437 ' HE3' ' CZ ' ' A' ' 53' ' ' TYR . 15.5 tmm? -128.52 139.8 52.13 Favored 'General case' 0 C--N 1.315 -0.927 0 C-N-CA 121.31 -0.156 . . . . 0.0 110.65 -178.842 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.472 ' HB ' ' HB1' ' A' ' 35' ' ' ALA . 33.8 m -124.24 128.73 49.61 Favored 'General case' 0 C--O 1.253 1.286 0 CA-C-O 121.135 0.493 . . . . 0.0 111.773 -176.718 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . 0.437 ' CZ ' ' HE3' ' A' ' 51' ' ' MET . 78.4 m-85 -84.76 163.73 18.96 Favored 'General case' 0 N--CA 1.462 0.147 0 CA-C-N 115.532 -0.758 . . . . 0.0 110.951 177.958 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -58.06 109.14 0.69 Allowed 'General case' 0 N--CA 1.469 0.478 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.957 -179.228 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 72.81 18.45 78.87 Favored Glycine 0 C--O 1.225 -0.414 0 C-N-CA 121.133 -0.556 . . . . 0.0 113.054 178.007 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . 0.402 ' HB2' ' HB2' ' A' ' 53' ' ' TYR . 70.2 mm-40 -117.76 174.19 6.32 Favored 'General case' 0 C--N 1.317 -0.817 0 N-CA-C 110.197 -0.297 . . . . 0.0 110.197 -179.062 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -86.71 157.03 29.5 Favored Glycine 0 N--CA 1.444 -0.827 0 C-N-CA 120.685 -0.769 . . . . 0.0 111.733 178.418 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -67.86 141.23 53.19 Favored 'Trans proline' 0 C--O 1.234 0.286 0 C-N-CA 122.64 2.227 . . . . 0.0 111.986 179.497 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . 0.43 HD13 ' HB3' ' A' ' 75' ' ' ASN . 39.6 pt -131.33 165.53 31.33 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.852 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.678 179.92 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -72.83 136.84 23.43 Favored Glycine 0 N--CA 1.447 -0.598 0 C-N-CA 120.889 -0.672 . . . . 0.0 111.499 -179.634 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 47.9 t80 -121.48 124.85 45.43 Favored 'General case' 0 C--N 1.313 -0.999 0 CA-C-O 120.722 0.296 . . . . 0.0 110.943 -178.462 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . 0.493 ' HA ' ' O ' ' A' ' 47' ' ' LEU . 62.0 ttp180 -135.65 129.59 33.03 Favored 'General case' 0 N--CA 1.445 -0.691 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 173.824 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -127.65 136.72 52.0 Favored 'General case' 0 C--N 1.311 -1.077 0 CA-C-O 120.667 0.27 . . . . 0.0 110.584 -179.836 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 28.2 m -114.16 124.68 52.66 Favored 'General case' 0 N--CA 1.435 -1.199 0 CA-C-N 116.035 -0.53 . . . . 0.0 109.861 177.914 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . 0.532 HD12 ' O ' ' A' ' 67' ' ' GLY . 2.7 tm? -63.25 129.24 39.43 Favored 'General case' 0 C--N 1.31 -1.151 0 CA-C-N 115.604 -0.725 . . . . 0.0 110.945 -179.34 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 96.5 mt -95.74 -40.42 9.37 Favored 'General case' 0 C--O 1.225 -0.199 0 CA-C-O 121.103 0.478 . . . . 0.0 111.094 178.505 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.532 ' O ' HD12 ' A' ' 65' ' ' LEU . . . -140.27 -79.93 0.06 OUTLIER Glycine 0 CA--C 1.499 -0.964 0 N-CA-C 110.766 -0.933 . . . . 0.0 110.766 -178.3 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 65.1 m-80 -146.01 -71.32 0.25 Allowed 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 107.527 -1.286 . . . . 0.0 107.527 174.389 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 84.4 m-20 -67.77 -39.87 84.06 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.652 -0.704 . . . . 0.0 111.458 176.501 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 23.3 t -81.48 130.45 35.05 Favored 'General case' 0 CA--C 1.538 0.492 0 N-CA-C 113.025 0.75 . . . . 0.0 113.025 -174.334 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.436 ' OH ' ' HB3' ' A' ' 99' ' ' ASN . 56.9 m-85 -127.66 145.21 50.96 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.106 -0.952 . . . . 0.0 109.919 177.08 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -105.43 125.19 50.7 Favored 'General case' 0 C--N 1.312 -1.053 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 174.401 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 62.2 t -111.03 137.74 42.21 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.162 0 N-CA-C 113.225 0.824 . . . . 0.0 113.225 -171.914 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 63.9 mt-10 -126.53 129.74 49.22 Favored 'General case' 0 N--CA 1.442 -0.871 0 CA-C-N 114.578 -1.192 . . . . 0.0 108.257 176.344 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' ASN . . . . . 0.43 ' HB3' HD13 ' A' ' 59' ' ' ILE . 12.1 m120 -110.12 151.51 27.16 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-O 121.167 0.508 . . . . 0.0 111.693 -178.033 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' GLN . . . . . 0.447 ' HB2' ' CE3' ' A' ' 84' ' ' TRP . 62.3 tt0 -117.19 121.04 40.11 Favored 'General case' 0 C--N 1.311 -1.071 0 CA-C-N 115.359 -0.837 . . . . 0.0 110.113 -178.725 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 4.7 p90 -142.7 161.78 37.18 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.855 -179.241 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 99.83 -12.22 60.91 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 121.026 -0.607 . . . . 0.0 112.437 178.715 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 140.53 160.1 8.18 Favored Glycine 0 N--CA 1.441 -1.029 0 N-CA-C 111.087 -0.805 . . . . 0.0 111.087 179.388 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 24.7 m-20 -62.75 -35.04 78.49 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-O 120.828 0.347 . . . . 0.0 111.617 -179.319 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 5.1 m -72.53 -12.9 61.26 Favored 'General case' 0 CA--C 1.54 0.592 0 CA-C-N 116.228 -0.442 . . . . 0.0 112.003 -179.709 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -75.96 147.83 80.99 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-O 120.518 0.199 . . . . 0.0 111.217 -178.424 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -72.14 -178.44 3.23 Favored 'Trans proline' 0 C--O 1.24 0.602 0 C-N-CA 122.733 2.289 . . . . 0.0 112.289 178.762 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' TRP . . . . . 0.447 ' CE3' ' HB2' ' A' ' 76' ' ' GLN . 92.3 m95 -91.64 139.66 30.47 Favored 'General case' 0 C--N 1.319 -0.718 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 -179.358 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 93.7 m-70 -115.48 148.46 39.43 Favored 'General case' 0 C--N 1.315 -0.922 0 N-CA-C 109.689 -0.486 . . . . 0.0 109.689 -179.32 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 13.2 p -64.59 135.36 55.89 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-O 120.778 0.323 . . . . 0.0 110.856 -178.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -110.37 -52.36 0.6 Allowed Glycine 0 N--CA 1.442 -0.906 0 C-N-CA 120.52 -0.848 . . . . 0.0 111.958 -179.549 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . 0.448 ' HA3' ' OG ' ' A' ' 27' ' ' SER . . . 147.72 -162.87 28.77 Favored Glycine 0 N--CA 1.444 -0.824 0 C-N-CA 120.212 -0.994 . . . . 0.0 112.822 179.698 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 17.1 m120 -104.08 134.9 46.57 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 120.832 0.349 . . . . 0.0 110.953 -178.557 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 11.8 m0 -127.38 150.8 49.45 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.929 -0.578 . . . . 0.0 109.714 179.002 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 50.1 mm -113.93 110.03 30.67 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.927 0 N-CA-C 109.021 -0.733 . . . . 0.0 109.021 177.729 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . 0.401 ' O ' HG12 ' A' ' 100' ' ' VAL . 78.0 mt -132.84 75.8 1.65 Allowed 'General case' 0 C--O 1.26 1.649 0 CA-C-O 121.893 0.854 . . . . 0.0 111.835 -177.325 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . 0.409 ' O ' ' HB2' ' A' ' 94' ' ' SER . . . -150.15 -91.64 0.09 OUTLIER Glycine 0 N--CA 1.448 -0.504 0 CA-C-N 115.399 -0.819 . . . . 0.0 112.9 -178.901 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' SER . . . . . 0.409 ' HB2' ' O ' ' A' ' 93' ' ' GLY . 69.6 m 78.29 8.56 2.26 Favored 'General case' 0 N--CA 1.482 1.13 0 C-N-CA 124.092 0.957 . . . . 0.0 112.181 -177.378 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' ARG . . . . . 0.477 ' HB2' ' O ' ' A' ' 98' ' ' GLN . 95.9 mtt180 -137.6 145.03 42.29 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 116.083 -0.508 . . . . 0.0 109.725 177.557 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 78.1 tt0 -70.44 -45.64 65.44 Favored 'General case' 0 C--N 1.315 -0.906 0 N-CA-C 112.622 0.601 . . . . 0.0 112.622 -172.729 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 7.2 p30 -117.41 20.89 13.4 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.26 0.552 . . . . 0.0 111.207 -179.269 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' GLN . . . . . 0.477 ' O ' ' HB2' ' A' ' 95' ' ' ARG . 90.5 mt-30 -139.78 115.63 10.22 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-N 115.658 -0.701 . . . . 0.0 111.12 179.635 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' ASN . . . . . 0.436 ' HB3' ' OH ' ' A' ' 71' ' ' TYR . 85.2 m-20 -108.49 176.19 5.2 Favored 'General case' 0 C--N 1.306 -1.309 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 179.575 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . 0.401 HG12 ' O ' ' A' ' 92' ' ' LEU . 33.6 m -78.22 133.69 29.78 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.668 0 C-N-CA 119.565 -0.854 . . . . 0.0 111.352 179.348 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 35.4 m -113.92 -31.09 2.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.165 177.243 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . 0.484 ' HB1' ' HB ' ' A' ' 119' ' ' THR . . . -148.18 133.32 18.32 Favored 'General case' 0 CA--C 1.511 -0.546 0 C-N-CA 120.688 -0.405 . . . . 0.0 110.475 178.003 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 89.6 mt -130.16 125.1 59.39 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.785 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.961 179.78 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 10.0 t30 -126.19 100.38 6.29 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.704 -0.68 . . . . 0.0 109.574 175.631 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 27.7 m -141.46 140.96 30.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-N 115.983 -0.553 . . . . 0.0 112.326 -176.121 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 61.5 mt-10 -143.66 149.53 37.39 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.2 -0.909 . . . . 0.0 109.606 177.111 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 46.3 t -128.66 144.62 51.2 Favored 'General case' 0 C--N 1.313 -0.994 0 CA-C-O 120.966 0.412 . . . . 0.0 111.508 -178.842 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -91.63 -4.46 67.76 Favored Glycine 0 N--CA 1.439 -1.16 0 N-CA-C 110.656 -0.978 . . . . 0.0 110.656 175.161 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 35.4 m-20 -98.28 -167.62 1.53 Allowed 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 -179.528 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 110' ' ' ASP . . . . . 0.408 ' OD1' ' HG3' ' A' ' 112' ' ' GLN . 7.3 p-10 -93.86 21.22 6.79 Favored 'General case' 0 C--N 1.311 -1.082 0 CA-C-O 121.291 0.567 . . . . 0.0 109.864 178.041 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . 0.541 ' HA3' ' ND2' ' A' ' 32' ' ' ASN . . . 105.34 9.77 32.99 Favored Glycine 0 C--O 1.22 -0.753 0 C-N-CA 120.761 -0.733 . . . . 0.0 113.466 -178.525 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 112' ' ' GLN . . . . . 0.408 ' HG3' ' OD1' ' A' ' 110' ' ' ASP . 98.3 mt-30 -64.72 -43.8 92.26 Favored 'General case' 0 C--O 1.242 0.66 0 CA-C-N 117.439 0.62 . . . . 0.0 110.681 178.89 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 81.8 p -136.48 145.76 45.52 Favored 'General case' 0 N--CA 1.444 -0.758 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.937 176.445 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 88.8 mt -116.54 129.75 56.36 Favored 'General case' 0 C--N 1.315 -0.922 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 179.312 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 15.3 m120 -120.5 142.87 48.9 Favored 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 110.318 -0.253 . . . . 0.0 110.318 -178.916 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 163.77 -141.19 6.94 Favored Glycine 0 N--CA 1.444 -0.8 0 C-N-CA 119.385 -1.388 . . . . 0.0 113.426 176.586 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 3.0 p -130.91 151.02 51.79 Favored 'General case' 0 C--N 1.311 -1.1 0 C-N-CA 123.056 0.542 . . . . 0.0 110.209 -178.295 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 118' ' ' MET . . . . . 0.628 ' SD ' ' HD1' ' A' ' 128' ' ' PHE . 20.0 ptm -136.96 144.5 43.42 Favored 'General case' 0 C--N 1.31 -1.128 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.253 -177.792 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 119' ' ' THR . . . . . 0.484 ' HB ' ' HB1' ' A' ' 102' ' ' ALA . 24.5 m -128.8 126.47 39.95 Favored 'General case' 0 C--O 1.252 1.22 0 CA-C-O 120.737 0.303 . . . . 0.0 110.535 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . 0.543 ' CE2' ' HE3' ' A' ' 118' ' ' MET . 42.1 m-85 -98.39 162.62 13.07 Favored 'General case' 0 CA--C 1.509 -0.631 0 CA-C-N 115.616 -0.72 . . . . 0.0 111.167 179.563 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -59.17 114.91 2.85 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 115.489 -0.778 . . . . 0.0 111.169 176.842 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 78.04 17.49 78.26 Favored Glycine 0 N--CA 1.451 -0.354 0 CA-C-N 115.787 -0.642 . . . . 0.0 114.014 177.759 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 69.2 tt0 -142.26 144.02 33.12 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 117.47 0.635 . . . . 0.0 110.566 179.837 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -69.03 163.77 50.48 Favored Glycine 0 CA--C 1.522 0.53 0 CA-C-N 116.141 -0.481 . . . . 0.0 113.246 -177.436 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . 0.469 ' HA ' ' O ' ' A' ' 118' ' ' MET . 23.7 Cg_exo -63.46 138.72 66.88 Favored 'Trans proline' 0 C--N 1.347 0.492 0 C-N-CA 122.784 2.322 . . . . 0.0 112.887 -178.752 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 41.0 pt -131.04 167.75 25.4 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.806 0 CA-C-N 115.532 -0.758 . . . . 0.0 109.675 177.467 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -69.0 136.96 29.31 Favored Glycine 0 C--O 1.236 0.281 0 C-N-CA 120.994 -0.622 . . . . 0.0 112.354 -178.754 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . 0.628 ' HD1' ' SD ' ' A' ' 118' ' ' MET . 82.4 t80 -118.59 133.8 55.59 Favored 'General case' 0 C--O 1.249 1.072 0 CA-C-O 120.963 0.411 . . . . 0.0 111.526 -178.564 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 64.1 tttm -136.52 111.44 8.86 Favored 'General case' 0 N--CA 1.442 -0.861 0 CA-C-N 115.562 -0.745 . . . . 0.0 109.782 175.678 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -104.87 133.01 11.35 Favored Glycine 0 N--CA 1.441 -0.997 0 N-CA-C 110.94 -0.864 . . . . 0.0 110.94 178.314 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 25.7 m -128.97 132.9 47.63 Favored 'General case' 0 C--N 1.311 -1.102 0 CA-C-N 116.944 0.372 . . . . 0.0 110.092 -178.754 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 74.0 mt -59.81 130.52 47.19 Favored 'General case' 0 N--CA 1.467 0.396 0 C-N-CA 120.301 -0.559 . . . . 0.0 110.799 177.726 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 52.8 m . . . . . 0 C--O 1.247 0.929 0 CA-C-O 118.512 -0.756 . . . . 0.0 110.734 -179.196 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.741 0 CA-C-O 120.897 0.38 . . . . 0.0 110.749 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' LEU . . . . . 0.496 HD12 HE21 ' A' ' 22' ' ' GLN . 3.2 tm? -92.68 130.39 38.32 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.064 179.313 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 81.4 m-85 -119.27 144.9 46.53 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.954 -0.566 . . . . 0.0 111.777 -179.242 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' ASN . . . . . 0.5 ' O ' ' HA2' ' A' ' 130' ' ' GLY . 11.5 t-20 -96.32 136.03 37.36 Favored 'General case' 0 C--N 1.313 -0.988 0 N-CA-C 107.706 -1.22 . . . . 0.0 107.706 179.269 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 78.7 t -116.56 127.11 74.25 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 CA-C-O 121.529 0.681 . . . . 0.0 112.703 -174.59 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . 0.424 ' HB2' ' HB3' ' A' ' 129' ' ' LYS . 45.4 mt-10 -116.58 138.8 51.14 Favored 'General case' 0 N--CA 1.44 -0.926 0 CA-C-N 114.949 -1.023 . . . . 0.0 108.286 175.275 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 10.6 m120 -116.29 139.3 50.52 Favored 'General case' 0 C--N 1.306 -1.32 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.545 -178.442 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . 0.491 ' HB2' ' CE3' ' A' ' 17' ' ' TRP . 54.4 tt0 -129.36 124.3 33.9 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.703 -0.68 . . . . 0.0 109.767 179.33 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 20.1 p90 -122.99 136.84 55.01 Favored 'General case' 0 C--N 1.307 -1.262 0 CA-C-O 120.849 0.357 . . . . 0.0 111.222 179.213 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 111.17 -75.49 0.21 Allowed Glycine 0 N--CA 1.445 -0.752 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.851 -179.653 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -162.34 163.65 35.13 Favored Glycine 0 N--CA 1.449 -0.438 0 N-CA-C 111.617 -0.593 . . . . 0.0 111.617 179.725 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' SER . . . . . 0.406 ' HA ' ' NE2' ' A' ' 9' ' ' GLN . 12.1 m -64.07 -19.06 64.97 Favored 'General case' 0 CA--C 1.536 0.44 0 N-CA-C 112.279 0.474 . . . . 0.0 112.279 -179.002 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 35.3 p -72.42 -18.22 61.73 Favored 'General case' 0 CA--C 1.539 0.536 0 CA-C-O 120.988 0.423 . . . . 0.0 111.231 178.799 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -80.66 155.0 73.73 Favored Pre-proline 0 CA--C 1.533 0.317 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.695 -179.755 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 66.6 Cg_endo -72.11 158.68 51.7 Favored 'Trans proline' 0 C--O 1.236 0.393 0 C-N-CA 122.47 2.113 . . . . 0.0 112.783 178.701 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' TRP . . . . . 0.491 ' CE3' ' HB2' ' A' ' 9' ' ' GLN . 94.4 m95 -89.22 138.6 31.28 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.408 179.624 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 90.5 m-20 -124.08 129.9 51.64 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 109.141 -0.689 . . . . 0.0 109.141 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 42.6 tt0 -61.37 128.04 34.43 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-O 120.962 0.41 . . . . 0.0 111.299 -178.305 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -108.7 -0.63 32.38 Favored Glycine 0 N--CA 1.448 -0.52 0 CA-C-N 115.469 -0.787 . . . . 0.0 112.805 -178.821 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 130.27 -150.11 19.09 Favored Glycine 0 N--CA 1.443 -0.881 0 C-N-CA 120.335 -0.936 . . . . 0.0 112.249 -179.83 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . 0.496 HE21 HD12 ' A' ' 3' ' ' LEU . 4.2 pt20 -145.5 138.02 25.83 Favored 'General case' 0 C--N 1.319 -0.738 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.771 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 45.3 m0 -117.14 155.23 29.69 Favored 'General case' 0 C--N 1.318 -0.761 0 CA-C-O 120.89 0.376 . . . . 0.0 111.159 -178.429 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -109.11 112.64 24.93 Favored 'General case' 0 C--N 1.317 -0.812 0 N-CA-C 109.511 -0.551 . . . . 0.0 109.511 177.481 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 95.8 mt -130.7 136.82 57.47 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.585 0 CA-C-N 115.203 -0.908 . . . . 0.0 109.762 -178.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 91.55 106.81 1.49 Allowed Glycine 0 N--CA 1.442 -0.911 0 C-N-CA 120.208 -0.996 . . . . 0.0 111.966 -179.383 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 13.9 m -111.86 13.58 20.95 Favored 'General case' 0 C--N 1.31 -1.136 0 CA-C-O 121.208 0.528 . . . . 0.0 110.311 -178.699 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 94.7 mtt-85 -137.44 128.17 27.03 Favored 'General case' 0 N--CA 1.445 -0.72 0 CA-C-N 116.004 -0.544 . . . . 0.0 109.967 -177.069 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 34.5 t -76.77 -17.43 59.05 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-O 121.207 0.527 . . . . 0.0 110.215 179.353 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 15.8 m-20 -75.0 -47.56 28.52 Favored 'General case' 0 C--O 1.224 -0.275 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.904 -178.033 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 14.3 mm100 -128.71 123.19 32.45 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.603 -0.726 . . . . 0.0 111.234 -176.575 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . 0.659 ' ND2' ' HA3' ' A' ' 111' ' ' GLY . 62.5 t30 -101.18 161.74 13.39 Favored 'General case' 0 C--N 1.319 -0.751 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 178.348 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 46.6 t -94.69 130.73 43.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-O 120.572 0.225 . . . . 0.0 111.409 -173.771 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 28.7 m -110.59 -18.57 7.5 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.276 0 CA-C-N 116.464 -0.335 . . . . 0.0 111.731 179.224 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.451 ' HB2' ' HB ' ' A' ' 52' ' ' THR . . . -154.6 149.67 26.88 Favored 'General case' 0 C--O 1.237 0.416 0 C-N-CA 120.563 -0.455 . . . . 0.0 111.685 178.682 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.476 ' HB ' ' CG2' ' A' ' 105' ' ' VAL . 89.9 mt -144.09 123.63 7.84 Favored 'Isoleucine or valine' 0 C--O 1.235 0.308 0 CA-C-N 115.97 -0.559 . . . . 0.0 109.64 -179.743 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 13.4 m120 -124.82 106.58 10.14 Favored 'General case' 0 C--N 1.313 -1.012 0 N-CA-C 107.767 -1.197 . . . . 0.0 107.767 175.844 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 36.0 m -147.68 149.56 15.32 Favored 'Isoleucine or valine' 0 C--O 1.237 0.436 0 C-N-CA 120.146 -0.622 . . . . 0.0 111.957 -172.757 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 66.7 mt-10 -142.55 149.1 38.63 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.299 -0.864 . . . . 0.0 109.325 175.337 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 20.5 p -73.97 142.62 45.84 Favored 'General case' 0 C--N 1.307 -1.25 0 N-CA-C 112.104 0.409 . . . . 0.0 112.104 -177.444 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -88.62 -42.56 5.73 Favored Glycine 0 N--CA 1.443 -0.841 0 N-CA-C 109.148 -1.581 . . . . 0.0 109.148 174.755 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 48.8 m-20 -105.18 -161.55 0.82 Allowed 'General case' 0 C--N 1.317 -0.836 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 175.045 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -76.17 47.98 0.48 Allowed 'General case' 0 N--CA 1.474 0.766 0 N-CA-C 112.303 0.483 . . . . 0.0 112.303 -178.361 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 91.64 -8.55 78.51 Favored Glycine 0 C--O 1.222 -0.649 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.223 178.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 56.1 mt-30 -70.23 -36.23 74.39 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.99 0.424 . . . . 0.0 110.713 178.356 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 22.0 p -122.58 139.4 53.95 Favored 'General case' 0 C--N 1.311 -1.106 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.207 179.66 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 91.2 mt -125.94 127.05 45.36 Favored 'General case' 0 C--N 1.315 -0.932 0 N-CA-C 108.509 -0.923 . . . . 0.0 108.509 179.865 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 88.9 m-20 -125.3 138.07 54.08 Favored 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 109.376 -0.602 . . . . 0.0 109.376 -179.352 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 173.25 -151.23 13.26 Favored Glycine 0 N--CA 1.443 -0.873 0 C-N-CA 120.078 -1.058 . . . . 0.0 112.558 178.853 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' THR . . . . . 0.402 ' HA ' ' O ' ' A' ' 59' ' ' ILE . 33.6 p -132.49 146.87 52.25 Favored 'General case' 0 N--CA 1.443 -0.8 0 CA-C-O 121.003 0.43 . . . . 0.0 110.921 179.692 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 40.7 mtp -121.12 156.49 32.18 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.74 177.18 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.451 ' HB ' ' HB2' ' A' ' 35' ' ' ALA . 26.8 m -132.1 126.35 33.53 Favored 'General case' 0 C--O 1.247 0.965 0 N-CA-C 110.04 -0.356 . . . . 0.0 110.04 175.657 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 72.2 m-85 -98.19 162.64 13.1 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.272 178.607 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -63.6 125.21 23.51 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.577 178.541 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 74.56 12.94 82.27 Favored Glycine 0 N--CA 1.447 -0.608 0 C-N-CA 120.948 -0.644 . . . . 0.0 112.851 -179.705 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 73.8 mm-40 -127.41 177.31 6.82 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 110.137 -0.32 . . . . 0.0 110.137 -179.373 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -109.13 -179.9 21.19 Favored Glycine 0 N--CA 1.445 -0.724 0 C-N-CA 120.879 -0.677 . . . . 0.0 111.614 178.805 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_exo -63.76 137.64 59.6 Favored 'Trans proline' 0 C--N 1.349 0.555 0 C-N-CA 122.504 2.136 . . . . 0.0 112.222 178.88 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . 0.54 ' HB ' ' O ' ' A' ' 76' ' ' GLN . 45.4 pt -132.36 166.11 30.15 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 CA-C-N 115.706 -0.679 . . . . 0.0 109.713 179.316 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -75.73 145.96 33.34 Favored Glycine 0 C--N 1.321 -0.299 0 C-N-CA 120.703 -0.761 . . . . 0.0 111.886 -179.47 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 31.6 t80 -132.12 130.54 41.33 Favored 'General case' 0 C--N 1.317 -0.839 0 C-N-CA 122.477 0.311 . . . . 0.0 111.398 -178.831 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 59.3 ttp180 -138.71 130.49 27.81 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 174.015 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -134.87 146.66 49.43 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 120.704 0.288 . . . . 0.0 111.148 -179.648 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 48.9 m -128.33 136.26 50.71 Favored 'General case' 0 CA--C 1.544 0.724 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.748 179.065 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . 0.408 HD11 ' O ' ' A' ' 68' ' ' ASN . 59.8 tp -69.34 127.8 34.31 Favored 'General case' 0 CA--C 1.535 0.376 0 N-CA-C 112.274 0.472 . . . . 0.0 112.274 -178.539 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -91.18 -41.3 11.08 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-N 115.972 -0.558 . . . . 0.0 112.482 178.702 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -151.8 -68.34 0.01 OUTLIER Glycine 0 CA--C 1.499 -0.922 0 C-N-CA 119.63 -1.272 . . . . 0.0 113.244 -175.835 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' ASN . . . . . 0.408 ' O ' HD11 ' A' ' 65' ' ' LEU . 20.2 m120 -133.49 -81.07 0.47 Allowed 'General case' 0 C--O 1.209 -1.036 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 -178.706 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . 0.482 ' OD1' ' HA3' ' A' ' 93' ' ' GLY . 90.7 m-20 -98.72 -5.73 30.89 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 120.77 0.319 . . . . 0.0 110.486 179.43 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 8.7 m -88.66 123.56 33.23 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 121.291 0.567 . . . . 0.0 112.017 -176.647 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 60.2 m-85 -121.88 145.53 48.0 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.659 178.805 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 71.8 tt0 -100.26 122.56 43.26 Favored 'General case' 0 C--N 1.316 -0.869 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 173.007 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 66.5 t -103.98 132.46 50.4 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.016 0 CA-C-N 115.687 -0.688 . . . . 0.0 111.767 -175.156 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 99.6 mt-10 -127.34 125.75 41.33 Favored 'General case' 0 N--CA 1.446 -0.655 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 177.141 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 95.1 m-20 -111.61 155.57 23.16 Favored 'General case' 0 C--N 1.312 -1.065 0 CA-C-O 121.473 0.654 . . . . 0.0 112.427 -177.204 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' GLN . . . . . 0.54 ' O ' ' HB ' ' A' ' 59' ' ' ILE . 33.8 tt0 -117.69 121.65 41.42 Favored 'General case' 0 C--N 1.311 -1.07 0 CA-C-N 114.878 -1.055 . . . . 0.0 110.285 -177.291 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -107.45 107.84 18.89 Favored 'General case' 0 C--N 1.323 -0.548 0 C-N-CA 120.221 -0.592 . . . . 0.0 110.305 176.834 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 174.04 -158.83 27.86 Favored Glycine 0 N--CA 1.439 -1.146 0 N-CA-C 110.586 -1.006 . . . . 0.0 110.586 -178.655 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -96.41 -42.61 3.39 Favored Glycine 0 N--CA 1.441 -1.008 0 C-N-CA 120.113 -1.042 . . . . 0.0 111.496 178.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 20.9 t70 -176.3 150.31 0.91 Allowed 'General case' 0 C--O 1.236 0.374 0 C-N-CA 122.56 0.344 . . . . 0.0 110.223 179.641 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 23.2 t 52.79 33.25 13.74 Favored 'General case' 0 CA--C 1.549 0.935 0 C-N-CA 123.057 0.543 . . . . 0.0 112.357 177.257 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -91.59 165.22 21.46 Favored Pre-proline 0 CA--C 1.544 0.746 0 CA-C-N 116.463 -0.335 . . . . 0.0 110.752 -179.392 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 26.9 Cg_exo -62.66 152.57 77.32 Favored 'Trans proline' 0 C--N 1.354 0.856 0 C-N-CA 122.703 2.269 . . . . 0.0 112.521 178.703 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' TRP . . . . . . . . . . . . . 96.2 m95 -98.61 143.12 29.35 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.544 -177.586 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 80.1 m-70 -129.83 141.1 50.88 Favored 'General case' 0 C--N 1.318 -0.761 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 179.298 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 42.1 m -61.38 133.89 56.32 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-O 121.216 0.531 . . . . 0.0 111.42 -178.038 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -105.23 -43.3 1.63 Allowed Glycine 0 N--CA 1.438 -1.198 0 N-CA-C 111.561 -0.616 . . . . 0.0 111.561 178.296 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 153.65 -170.03 32.37 Favored Glycine 0 C--O 1.223 -0.535 0 C-N-CA 120.456 -0.878 . . . . 0.0 112.259 178.349 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 20.2 m120 -110.6 123.11 49.36 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.465 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 44.1 m0 -114.41 152.81 30.95 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-O 121.016 0.436 . . . . 0.0 111.704 -177.363 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . 0.438 ' HA ' ' O ' ' A' ' 69' ' ' ASN . 82.8 mt -108.02 112.29 39.6 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.751 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 176.785 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 70.0 mt -135.15 73.08 1.46 Allowed 'General case' 0 C--O 1.266 1.972 0 CA-C-O 121.692 0.758 . . . . 0.0 111.835 -175.592 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . 0.482 ' HA3' ' OD1' ' A' ' 69' ' ' ASN . . . -153.67 -78.85 0.02 OUTLIER Glycine 0 N--CA 1.447 -0.615 0 C-N-CA 120.228 -0.987 . . . . 0.0 113.278 -178.096 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 57.5 m 69.94 10.29 7.4 Favored 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 123.268 0.627 . . . . 0.0 111.869 -177.784 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' ARG . . . . . 0.71 ' HB2' ' O ' ' A' ' 98' ' ' GLN . 16.8 mmt180 -127.12 141.39 51.77 Favored 'General case' 0 N--CA 1.443 -0.783 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 177.308 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 16.6 pt-20 -67.38 -40.45 85.71 Favored 'General case' 0 C--N 1.311 -1.097 0 N-CA-C 112.96 0.726 . . . . 0.0 112.96 -176.298 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 91.8 m-20 -127.58 28.91 5.58 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 111.912 0.338 . . . . 0.0 111.912 -176.35 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' GLN . . . . . 0.71 ' O ' ' HB2' ' A' ' 95' ' ' ARG . 46.0 tt0 -155.64 132.52 10.61 Favored 'General case' 0 C--N 1.32 -0.688 0 C-N-CA 120.625 -0.43 . . . . 0.0 110.078 -177.946 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 91.3 m-20 -115.3 179.49 3.95 Favored 'General case' 0 C--O 1.26 1.638 0 C-N-CA 120.717 -0.393 . . . . 0.0 111.957 -177.909 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 22.5 m -81.06 143.33 12.48 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.427 0 CA-C-N 115.673 -0.694 . . . . 0.0 111.132 178.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 31.2 m -121.51 -36.43 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.694 178.223 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . 0.452 ' HB2' ' HB ' ' A' ' 119' ' ' THR . . . -133.4 130.41 38.7 Favored 'General case' 0 CA--C 1.51 -0.572 0 C-N-CA 119.943 -0.703 . . . . 0.0 111.153 178.76 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 96.5 mt -133.29 122.55 45.17 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.934 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.656 178.862 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 12.0 t30 -126.67 99.27 5.71 Favored 'General case' 0 C--N 1.316 -0.882 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 176.804 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.476 ' CG2' ' HB ' ' A' ' 36' ' ' ILE . 17.8 m -135.21 135.86 51.91 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.146 0 CA-C-N 115.513 -0.767 . . . . 0.0 112.429 -174.787 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 60.2 mt-10 -141.17 142.58 34.02 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.597 -0.728 . . . . 0.0 110.256 179.85 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 35.5 t -140.33 148.65 41.67 Favored 'General case' 0 C--N 1.315 -0.913 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.878 179.366 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -96.29 1.11 62.26 Favored Glycine 0 N--CA 1.444 -0.785 0 N-CA-C 110.769 -0.932 . . . . 0.0 110.769 176.234 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 84.6 m-20 -88.93 179.13 6.25 Favored 'General case' 0 CA--C 1.511 -0.539 0 CA-C-O 120.872 0.368 . . . . 0.0 110.601 -179.635 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 7.8 p-10 -88.83 16.41 6.91 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-O 121.568 0.699 . . . . 0.0 109.602 177.577 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . 0.659 ' HA3' ' ND2' ' A' ' 32' ' ' ASN . . . 113.25 7.82 20.45 Favored Glycine 0 N--CA 1.438 -1.232 0 CA-C-N 115.384 -0.826 . . . . 0.0 112.516 -177.526 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 98.6 mt-30 -62.71 -47.91 81.56 Favored 'General case' 0 C--O 1.238 0.45 0 CA-C-O 120.759 0.314 . . . . 0.0 110.363 178.783 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 70.7 p -130.44 155.39 46.5 Favored 'General case' 0 N--CA 1.444 -0.748 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 176.151 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 40.1 tp -136.39 108.38 7.16 Favored 'General case' 0 C--N 1.314 -0.946 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 178.352 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 89.0 m-20 -119.84 155.14 33.2 Favored 'General case' 0 C--N 1.316 -0.882 0 C-N-CA 120.597 -0.441 . . . . 0.0 111.737 -175.484 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 162.34 -136.15 4.21 Favored Glycine 0 N--CA 1.438 -1.176 0 C-N-CA 120.543 -0.837 . . . . 0.0 112.737 178.016 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 26.6 p -130.89 153.28 49.31 Favored 'General case' 0 C--N 1.312 -1.032 0 C-N-CA 122.752 0.421 . . . . 0.0 110.469 -178.343 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 25.6 ptm -143.57 146.23 33.15 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.074 179.899 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 119' ' ' THR . . . . . 0.452 ' HB ' ' HB2' ' A' ' 102' ' ' ALA . 36.7 m -129.8 126.6 38.49 Favored 'General case' 0 C--N 1.305 -1.358 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.533 179.294 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 67.0 m-85 -81.18 164.43 22.34 Favored 'General case' 0 CA--C 1.508 -0.645 0 O-C-N 123.716 0.635 . . . . 0.0 109.502 176.172 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -51.54 -31.63 24.96 Favored 'General case' 0 CA--C 1.54 0.586 0 N-CA-C 113.37 0.878 . . . . 0.0 113.37 -178.827 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -155.84 15.93 0.45 Allowed Glycine 0 CA--C 1.519 0.287 0 C-N-CA 119.189 -1.481 . . . . 0.0 114.263 -178.246 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 82.9 tt0 -100.19 -23.74 14.75 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 117.619 0.709 . . . . 0.0 111.327 -179.894 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 115.03 179.67 18.54 Favored Glycine 0 N--CA 1.448 -0.507 0 C-N-CA 120.235 -0.983 . . . . 0.0 112.935 178.039 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -90.39 122.06 0.91 Allowed 'Trans proline' 0 N--CA 1.449 -1.102 0 C-N-CA 123.767 2.978 . . . . 0.0 112.408 179.749 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 41.2 pt -128.53 163.12 33.8 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.803 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.58 179.487 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -70.08 137.01 27.58 Favored Glycine 0 C--O 1.244 0.728 0 CA-C-N 116.188 -0.46 . . . . 0.0 112.165 179.37 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 83.7 t80 -115.25 133.97 55.56 Favored 'General case' 0 C--N 1.316 -0.853 0 C-N-CA 122.51 0.324 . . . . 0.0 110.678 -178.966 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 129' ' ' LYS . . . . . 0.424 ' HB3' ' HB2' ' A' ' 7' ' ' GLU . 86.3 tttt -137.45 114.99 11.17 Favored 'General case' 0 N--CA 1.437 -1.09 0 N-CA-C 109.301 -0.629 . . . . 0.0 109.301 176.53 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . 0.5 ' HA2' ' O ' ' A' ' 5' ' ' ASN . . . -115.13 136.02 12.78 Favored Glycine 0 N--CA 1.433 -1.561 0 N-CA-C 111.157 -0.777 . . . . 0.0 111.157 177.837 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 52.5 m -128.7 136.72 50.99 Favored 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -179.905 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 58.3 tp -59.89 126.03 25.96 Favored 'General case' 0 C--N 1.327 -0.379 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 178.538 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 24.5 m . . . . . 0 N--CA 1.439 -1.024 0 CA-C-O 118.745 -0.645 . . . . 0.0 110.776 -178.275 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 0.603 ' O ' ' HG3' ' A' ' 24' ' ' GLU . . . . . . . . 0 N--CA 1.479 1.004 0 N-CA-C 110.144 -0.317 . . . . 0.0 110.144 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' LEU . . . . . 0.463 HD13 HE21 ' A' ' 22' ' ' GLN . 3.0 tm? -87.3 132.21 34.0 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-O 121.271 0.558 . . . . 0.0 110.713 -175.504 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . 0.423 ' N ' HD11 ' A' ' 3' ' ' LEU . 20.0 m-85 -115.45 134.78 54.76 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 115.486 -0.779 . . . . 0.0 111.392 178.542 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 46.6 t-20 -92.9 117.37 29.97 Favored 'General case' 0 C--N 1.309 -1.158 0 N-CA-C 106.992 -1.484 . . . . 0.0 106.992 176.814 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.437 HG13 HD22 ' A' ' 8' ' ' ASN . 58.5 t -102.04 104.89 17.08 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.146 0 CA-C-O 121.146 0.498 . . . . 0.0 112.307 -174.067 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -94.3 137.62 33.24 Favored 'General case' 0 C--N 1.312 -1.028 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 175.931 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . 0.437 HD22 HG13 ' A' ' 6' ' ' VAL . 63.2 m-80 -132.69 159.17 40.41 Favored 'General case' 0 C--N 1.314 -0.972 0 CA-C-O 121.627 0.727 . . . . 0.0 112.784 -175.075 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 36.4 tt0 -124.02 106.29 10.27 Favored 'General case' 0 C--N 1.309 -1.166 0 N-CA-C 106.828 -1.545 . . . . 0.0 106.828 173.118 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 1.4 p90 -125.68 0.21 7.45 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 114.056 1.132 . . . . 0.0 114.056 -173.289 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -116.3 21.4 11.9 Favored Glycine 0 N--CA 1.446 -0.647 0 C-N-CA 119.014 -1.565 . . . . 0.0 112.296 -177.74 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 122.14 157.21 9.91 Favored Glycine 0 N--CA 1.441 -1.01 0 C-N-CA 120.8 -0.714 . . . . 0.0 111.99 -179.726 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 21.3 p -59.46 -31.88 69.73 Favored 'General case' 0 C--N 1.317 -0.822 0 C-N-CA 123.018 0.527 . . . . 0.0 112.41 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 17.1 p -81.41 -7.56 59.6 Favored 'General case' 0 C--N 1.32 -0.703 0 N-CA-C 112.26 0.467 . . . . 0.0 112.26 179.449 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -78.99 142.11 59.59 Favored Pre-proline 0 C--N 1.328 -0.353 0 CA-C-O 120.801 0.334 . . . . 0.0 111.255 -178.674 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 64.2 Cg_endo -70.8 165.37 32.38 Favored 'Trans proline' 0 C--O 1.237 0.47 0 C-N-CA 123.084 2.523 . . . . 0.0 112.54 -179.81 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 93.5 m95 -81.69 137.81 35.35 Favored 'General case' 0 N--CA 1.452 -0.354 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.357 -178.731 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 3.1 p30 -145.32 137.78 25.9 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.99 -179.827 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 8.3 pt-20 -93.16 141.37 28.49 Favored 'General case' 0 C--N 1.317 -0.833 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 178.098 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -132.71 26.98 3.57 Favored Glycine 0 N--CA 1.442 -0.956 0 C-N-CA 120.45 -0.881 . . . . 0.0 111.21 179.726 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 154.76 169.34 19.29 Favored Glycine 0 N--CA 1.437 -1.263 0 C-N-CA 120.991 -0.623 . . . . 0.0 111.846 -179.475 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . 0.463 HE21 HD13 ' A' ' 3' ' ' LEU . 4.4 pt20 -122.0 132.8 54.71 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-O 120.835 0.35 . . . . 0.0 110.339 179.913 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 40.4 m0 -113.21 172.83 6.71 Favored 'General case' 0 CA--C 1.506 -0.718 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.165 -176.409 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . 0.603 ' HG3' ' O ' ' A' ' 2' ' ' ALA . 33.5 tt0 -131.23 114.66 15.34 Favored 'General case' 0 C--N 1.317 -0.837 0 N-CA-C 108.815 -0.809 . . . . 0.0 108.815 173.572 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.405 HG22 HD11 ' A' ' 36' ' ' ILE . 97.7 mt -105.54 -36.81 3.8 Favored 'Isoleucine or valine' 0 C--O 1.199 -1.6 0 CA-C-N 115.138 -0.937 . . . . 0.0 113.156 -173.053 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -109.07 126.98 8.32 Favored Glycine 0 C--N 1.307 -1.078 0 C-N-CA 119.888 -1.149 . . . . 0.0 112.387 -179.858 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 59.6 p -117.19 8.16 13.17 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 111.875 0.324 . . . . 0.0 111.875 -179.883 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 69.1 ttt180 -122.09 135.5 54.81 Favored 'General case' 0 N--CA 1.446 -0.629 0 CA-C-O 121.162 0.506 . . . . 0.0 111.904 -177.153 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 47.9 t -77.35 149.36 35.26 Favored 'General case' 0 N--CA 1.442 -0.846 0 CA-C-N 115.294 -0.866 . . . . 0.0 109.908 176.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.459 ' O ' ' HG2' ' A' ' 31' ' ' GLN . 8.9 m-20 59.62 22.71 11.42 Favored 'General case' 0 N--CA 1.479 0.99 0 C-N-CA 123.032 0.533 . . . . 0.0 111.433 176.902 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . 0.459 ' HG2' ' O ' ' A' ' 30' ' ' ASP . 4.5 mm-40 -163.06 91.26 0.71 Allowed 'General case' 0 CA--C 1.501 -0.91 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.241 -178.058 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . 0.573 ' ND2' ' HA3' ' A' ' 111' ' ' GLY . 63.6 t30 -94.69 162.02 13.95 Favored 'General case' 0 C--N 1.309 -1.174 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.239 -179.01 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 72.6 t -95.57 129.52 45.57 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.201 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.89 -176.51 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 33.0 m -110.39 -13.06 11.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 N-CA-C 112.187 0.439 . . . . 0.0 112.187 179.154 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.464 ' O ' ' HG2' ' A' ' 51' ' ' MET . . . -156.34 149.36 24.13 Favored 'General case' 0 CA--C 1.517 -0.304 0 C-N-CA 120.464 -0.494 . . . . 0.0 111.851 178.685 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.405 HD11 HG22 ' A' ' 25' ' ' ILE . 88.2 mt -148.54 119.18 1.29 Allowed 'Isoleucine or valine' 0 CA--C 1.513 -0.46 0 N-CA-C 107.935 -1.135 . . . . 0.0 107.935 178.565 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' ASN . . . . . 0.543 ' HA ' ' O ' ' A' ' 103' ' ' ILE . 57.5 m-80 -140.05 74.91 1.48 Allowed 'General case' 0 C--N 1.301 -1.534 0 C-N-CA 120.706 -0.398 . . . . 0.0 110.759 -179.375 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.576 HG13 ' CD1' ' A' ' 61' ' ' PHE . 17.1 m -120.18 171.32 8.74 Favored 'Isoleucine or valine' 0 C--O 1.235 0.319 0 N-CA-C 112.49 0.552 . . . . 0.0 112.49 178.541 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 75.3 tt0 -140.34 153.23 46.33 Favored 'General case' 0 N--CA 1.447 -0.593 0 CA-C-N 115.234 -0.893 . . . . 0.0 109.731 179.213 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' SER . . . . . 0.524 ' OG ' ' HB ' ' A' ' 101' ' ' VAL . 34.6 p -76.95 157.72 31.11 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-O 121.297 0.57 . . . . 0.0 112.487 -177.595 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -105.99 -49.46 0.94 Allowed Glycine 0 N--CA 1.438 -1.224 0 N-CA-C 110.177 -1.169 . . . . 0.0 110.177 174.427 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 18.9 m-20 -102.24 -149.68 0.39 Allowed 'General case' 0 C--N 1.325 -0.48 0 C-N-CA 122.889 0.476 . . . . 0.0 110.502 179.013 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 11.9 m-20 -71.96 38.19 0.07 Allowed 'General case' 0 N--CA 1.484 1.268 0 C-N-CA 123.747 0.819 . . . . 0.0 112.261 -177.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 83.69 2.93 89.81 Favored Glycine 0 C--N 1.316 -0.532 0 C-N-CA 120.669 -0.776 . . . . 0.0 111.571 -178.738 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' GLN . . . . . 0.436 ' HA ' ' HB3' ' A' ' 65' ' ' LEU . 62.3 mt-30 -80.5 -28.59 37.44 Favored 'General case' 0 C--O 1.218 -0.559 0 CA-C-O 120.981 0.419 . . . . 0.0 110.66 178.218 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' THR . . . . . 0.422 ' O ' ' HA ' ' A' ' 40' ' ' SER . 22.6 p -118.54 132.49 56.21 Favored 'General case' 0 C--N 1.306 -1.298 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.637 179.877 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 90.5 mt -126.46 132.64 51.4 Favored 'General case' 0 C--N 1.319 -0.759 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 179.754 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.405 ' HA ' ' O ' ' A' ' 61' ' ' PHE . 9.4 p30 -142.65 147.61 36.05 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-O 120.789 0.328 . . . . 0.0 110.585 179.234 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 158.68 -135.05 4.05 Favored Glycine 0 C--N 1.312 -0.786 0 C-N-CA 120.601 -0.809 . . . . 0.0 111.885 178.656 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 24.7 p -130.8 149.23 52.54 Favored 'General case' 0 N--CA 1.452 -0.347 0 CA-C-O 121.175 0.512 . . . . 0.0 111.812 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' MET . . . . . 0.541 ' HE1' ' CZ ' ' A' ' 53' ' ' TYR . 18.4 tmm? -142.45 148.47 37.81 Favored 'General case' 0 C--N 1.316 -0.853 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 177.399 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.422 ' HB ' ' HB2' ' A' ' 35' ' ' ALA . 66.1 m -129.53 127.64 41.17 Favored 'General case' 0 C--O 1.246 0.919 0 N-CA-C 112.385 0.513 . . . . 0.0 112.385 -177.04 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . 0.541 ' CZ ' ' HE1' ' A' ' 51' ' ' MET . 64.9 m-85 -87.99 161.76 17.22 Favored 'General case' 0 CA--C 1.515 -0.369 0 CA-C-N 115.507 -0.769 . . . . 0.0 109.458 174.46 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -66.71 129.99 41.7 Favored 'General case' 0 C--N 1.315 -0.918 0 N-CA-C 110.04 -0.356 . . . . 0.0 110.04 178.158 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 90.45 -19.99 40.53 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.869 -0.681 . . . . 0.0 113.081 179.228 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 81.5 mm-40 -107.56 170.17 8.14 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 120.736 0.303 . . . . 0.0 110.767 -178.589 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -95.46 -157.89 32.35 Favored Glycine 0 N--CA 1.446 -0.664 0 C-N-CA 120.943 -0.646 . . . . 0.0 112.354 179.52 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_endo -64.3 138.46 60.93 Favored 'Trans proline' 0 C--N 1.345 0.38 0 C-N-CA 122.462 2.108 . . . . 0.0 112.099 179.743 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 98.3 mt -132.89 142.5 42.14 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.026 0 CA-C-N 115.578 -0.737 . . . . 0.0 109.771 -179.12 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -73.82 128.27 10.97 Favored Glycine 0 N--CA 1.443 -0.898 0 N-CA-C 110.579 -1.009 . . . . 0.0 110.579 179.058 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.576 ' CD1' HG13 ' A' ' 38' ' ' VAL . 47.5 t80 -114.41 128.08 56.16 Favored 'General case' 0 C--N 1.311 -1.08 0 CA-C-O 120.594 0.235 . . . . 0.0 110.903 -176.177 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 64.9 ttp85 -135.49 129.61 33.39 Favored 'General case' 0 N--CA 1.448 -0.536 0 CA-C-N 116.016 -0.538 . . . . 0.0 109.986 176.024 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -138.94 149.66 45.02 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 120.773 0.321 . . . . 0.0 111.754 -178.517 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 27.6 m -125.35 131.5 52.98 Favored 'General case' 0 CA--C 1.54 0.596 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.359 179.204 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . 0.436 ' HB3' ' HA ' ' A' ' 45' ' ' GLN . 3.0 tm? -80.2 113.29 18.26 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 120.981 0.419 . . . . 0.0 110.503 -178.495 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 94.6 mt -88.4 -18.96 27.24 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.498 177.799 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 125.34 167.66 12.59 Favored Glycine 0 N--CA 1.442 -0.959 0 C-N-CA 121.02 -0.609 . . . . 0.0 111.596 179.765 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 94.8 m-20 56.47 36.66 27.91 Favored 'General case' 0 N--CA 1.473 0.721 0 C-N-CA 122.56 0.344 . . . . 0.0 111.707 178.279 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 16.3 m120 66.36 9.66 6.62 Favored 'General case' 0 N--CA 1.48 1.031 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.363 179.644 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 35.1 m -97.88 123.55 41.9 Favored 'General case' 0 C--O 1.24 0.562 0 CA-C-O 121.37 0.605 . . . . 0.0 111.586 -177.537 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.524 ' OH ' ' HB3' ' A' ' 99' ' ' ASN . 59.4 m-85 -112.98 138.51 49.75 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 115.468 -0.787 . . . . 0.0 110.83 -179.613 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 42.5 tt0 -92.52 116.64 29.17 Favored 'General case' 0 N--CA 1.439 -0.976 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 174.786 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 78.2 t -105.03 133.15 50.05 Favored 'Isoleucine or valine' 0 C--O 1.248 1.019 0 N-CA-C 112.75 0.648 . . . . 0.0 112.75 -173.615 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 68.7 mt-10 -133.33 134.42 43.78 Favored 'General case' 0 C--O 1.244 0.772 0 N-CA-C 107.899 -1.148 . . . . 0.0 107.899 175.253 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 92.8 m-20 -119.46 154.43 33.76 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 112.911 0.708 . . . . 0.0 112.911 -173.797 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 35.9 tt0 -132.52 127.76 35.87 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.07 -0.968 . . . . 0.0 108.999 179.389 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 37.9 p90 -137.58 157.47 46.44 Favored 'General case' 0 C--N 1.317 -0.835 0 C-N-CA 119.973 -0.691 . . . . 0.0 111.997 -177.046 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 81.19 12.13 82.69 Favored Glycine 0 N--CA 1.453 -0.216 0 CA-C-N 115.4 -0.818 . . . . 0.0 112.465 179.513 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 124.48 175.67 14.4 Favored Glycine 0 N--CA 1.445 -0.709 0 N-CA-C 111.259 -0.736 . . . . 0.0 111.259 -179.582 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 -89.74 -5.19 57.23 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 121.114 0.483 . . . . 0.0 110.373 -179.194 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 33.2 m -79.04 -12.96 60.03 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.413 179.367 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -90.8 128.69 47.21 Favored Pre-proline 0 C--N 1.321 -0.641 0 CA-C-N 116.54 -0.3 . . . . 0.0 110.484 -179.532 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 30.1 Cg_endo -63.21 136.2 54.59 Favored 'Trans proline' 0 N--CA 1.463 -0.289 0 C-N-CA 122.157 1.904 . . . . 0.0 111.736 179.735 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' TRP . . . . . . . . . . . . . 87.0 m95 -51.1 138.67 19.53 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-O 121.302 0.572 . . . . 0.0 112.261 178.667 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 96.1 m-70 -115.11 147.14 40.59 Favored 'General case' 0 C--N 1.314 -0.949 0 CA-C-N 115.325 -0.852 . . . . 0.0 109.299 179.361 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 6.3 m -58.37 148.59 27.26 Favored 'General case' 0 C--N 1.316 -0.851 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.629 179.004 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -124.32 -54.44 0.18 Allowed Glycine 0 N--CA 1.44 -1.065 0 N-CA-C 110.552 -1.019 . . . . 0.0 110.552 -179.591 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 149.48 -165.95 29.58 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.605 -0.807 . . . . 0.0 112.353 176.788 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 14.5 m120 -110.66 118.45 36.22 Favored 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 109.346 -0.613 . . . . 0.0 109.346 178.362 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 32.8 m0 -110.38 150.67 28.47 Favored 'General case' 0 C--N 1.313 -0.993 0 CA-C-N 116.559 -0.292 . . . . 0.0 110.707 -177.374 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 83.3 mt -105.6 115.17 46.83 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.937 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 177.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 82.2 mt -131.53 80.5 1.93 Allowed 'General case' 0 C--O 1.27 2.182 0 CA-C-O 121.945 0.879 . . . . 0.0 112.589 -174.638 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 165.73 119.63 0.49 Allowed Glycine 0 N--CA 1.441 -0.993 0 CA-C-N 114.935 -1.029 . . . . 0.0 111.5 178.678 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 83.9 p -89.81 -1.54 58.02 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.34 0.59 . . . . 0.0 110.173 178.519 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 23.8 mtp180 -109.12 138.4 45.52 Favored 'General case' 0 N--CA 1.435 -1.181 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 178.884 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 72.5 tt0 -73.0 -38.26 66.67 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-O 121.354 0.597 . . . . 0.0 111.326 -173.324 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 53.5 m-80 -110.6 28.75 8.37 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.343 -177.934 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' GLN . . . . . 0.511 HE21 ' HB3' ' A' ' 120' ' ' TYR . 50.8 tt0 -156.96 125.2 5.61 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.119 0.485 . . . . 0.0 110.467 -177.545 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' ASN . . . . . 0.524 ' HB3' ' OH ' ' A' ' 71' ' ' TYR . 91.6 m-20 -104.64 169.69 8.32 Favored 'General case' 0 C--O 1.251 1.136 0 CA-C-N 115.647 -0.706 . . . . 0.0 111.949 -174.319 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 26.4 m -83.73 151.8 3.89 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.433 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.918 177.886 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . 0.524 ' HB ' ' OG ' ' A' ' 40' ' ' SER . 33.8 m -123.45 -29.66 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 C-N-CA 120.909 -0.316 . . . . 0.0 111.49 177.416 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . 0.451 ' HB2' ' HB ' ' A' ' 119' ' ' THR . . . -140.56 135.34 31.72 Favored 'General case' 0 C--N 1.317 -0.828 0 C-N-CA 120.197 -0.601 . . . . 0.0 111.13 179.07 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.543 ' O ' ' HA ' ' A' ' 37' ' ' ASN . 88.6 mt -128.41 121.47 55.45 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.044 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 178.447 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 8.1 t30 -127.8 95.07 4.11 Favored 'General case' 0 C--N 1.325 -0.463 0 O-C-N 123.908 0.755 . . . . 0.0 109.48 -179.296 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.438 HG11 ' CD2' ' A' ' 128' ' ' PHE . 31.7 m -143.65 148.58 18.83 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 N-CA-C 112.672 0.619 . . . . 0.0 112.672 -175.293 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 69.8 tt0 -150.05 154.32 37.95 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.335 -0.848 . . . . 0.0 109.553 174.863 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 44.3 t -136.28 150.8 49.09 Favored 'General case' 0 C--N 1.31 -1.146 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.107 -178.846 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -97.2 1.79 60.92 Favored Glycine 0 N--CA 1.44 -1.069 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 174.479 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -98.56 -172.68 2.37 Favored 'General case' 0 CA--C 1.507 -0.703 0 N-CA-C 109.596 -0.52 . . . . 0.0 109.596 179.716 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 10.4 p-10 -92.47 32.76 1.17 Allowed 'General case' 0 C--N 1.312 -1.028 0 CA-C-O 121.435 0.636 . . . . 0.0 109.559 176.147 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . 0.573 ' HA3' ' ND2' ' A' ' 32' ' ' ASN . . . 94.81 9.24 58.72 Favored Glycine 0 N--CA 1.445 -0.719 0 CA-C-N 115.618 -0.719 . . . . 0.0 113.271 -179.347 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 112' ' ' GLN . . . . . 0.505 ' HA ' ' CD1' ' A' ' 132' ' ' LEU . 97.1 mt-30 -65.08 -50.69 65.16 Favored 'General case' 0 C--O 1.24 0.593 0 CA-C-O 120.96 0.409 . . . . 0.0 111.072 179.289 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 40.2 p -129.49 130.33 45.7 Favored 'General case' 0 N--CA 1.444 -0.751 0 CA-C-N 115.899 -0.591 . . . . 0.0 109.844 178.56 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 88.6 mt -108.85 125.44 51.98 Favored 'General case' 0 C--N 1.31 -1.149 0 N-CA-C 110.075 -0.343 . . . . 0.0 110.075 179.781 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 15.7 m120 -109.84 136.37 49.25 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.173 -178.768 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 167.33 -145.56 9.93 Favored Glycine 0 N--CA 1.439 -1.136 0 C-N-CA 119.074 -1.536 . . . . 0.0 113.584 176.408 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 26.9 p -139.17 161.58 37.05 Favored 'General case' 0 C--N 1.314 -0.951 0 C-N-CA 123.211 0.605 . . . . 0.0 110.699 -177.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 118' ' ' MET . . . . . 0.526 ' O ' ' HA ' ' A' ' 125' ' ' PRO . 18.4 ptp -140.28 148.59 41.66 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.303 -0.408 . . . . 0.0 109.968 178.776 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 119' ' ' THR . . . . . 0.451 ' HB ' ' HB2' ' A' ' 102' ' ' ALA . 27.7 m -128.78 130.53 47.14 Favored 'General case' 0 C--N 1.313 -0.998 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 177.973 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . 0.541 ' HB2' ' HB3' ' A' ' 123' ' ' GLU . 38.4 m-85 -96.56 173.08 7.52 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.006 0.431 . . . . 0.0 112.037 -179.945 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -55.51 -36.57 66.83 Favored 'General case' 0 CA--C 1.533 0.298 0 CA-C-N 115.396 -0.82 . . . . 0.0 112.859 -178.43 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -144.2 46.01 0.84 Allowed Glycine 0 CA--C 1.506 -0.522 0 C-N-CA 120.388 -0.91 . . . . 0.0 111.668 -179.321 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . 0.541 ' HB3' ' HB2' ' A' ' 120' ' ' TYR . 76.1 tt0 -151.62 144.66 24.55 Favored 'General case' 0 C--N 1.315 -0.894 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 -178.032 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -68.01 160.29 50.59 Favored Glycine 0 CA--C 1.518 0.246 0 C-N-CA 121.153 -0.546 . . . . 0.0 113.002 -177.512 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . 0.526 ' HA ' ' O ' ' A' ' 118' ' ' MET . 30.2 Cg_endo -63.15 136.65 57.21 Favored 'Trans proline' 0 C--N 1.348 0.537 0 C-N-CA 122.416 2.077 . . . . 0.0 111.994 179.701 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 44.0 pt -129.47 165.1 30.27 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.913 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.567 -179.133 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -73.09 132.44 16.89 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 121.053 -0.594 . . . . 0.0 112.145 -179.18 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . 0.438 ' CD2' HG11 ' A' ' 105' ' ' VAL . 49.9 t80 -114.92 131.29 56.93 Favored 'General case' 0 C--O 1.245 0.862 0 C-N-CA 122.937 0.495 . . . . 0.0 111.793 -177.798 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 62.5 tttm -133.13 97.35 3.97 Favored 'General case' 0 N--CA 1.441 -0.89 0 CA-C-N 115.249 -0.887 . . . . 0.0 109.687 175.658 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -91.81 130.84 10.49 Favored Glycine 0 CA--C 1.502 -0.738 0 N-CA-C 111.06 -0.816 . . . . 0.0 111.06 179.917 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 28.2 m -128.5 133.94 48.58 Favored 'General case' 0 C--N 1.311 -1.093 0 CA-C-N 117.282 0.541 . . . . 0.0 110.461 -178.376 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 132' ' ' LEU . . . . . 0.505 ' CD1' ' HA ' ' A' ' 112' ' ' GLN . 80.3 mt -57.12 134.34 55.79 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-O 121.001 0.429 . . . . 0.0 110.962 177.784 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 24.1 m . . . . . 0 C--O 1.251 1.152 0 CA-C-O 118.123 -0.941 . . . . 0.0 109.61 179.682 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.701 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' LEU . . . . . 0.513 HD11 HE21 ' A' ' 22' ' ' GLN . 3.3 tm? -98.23 132.53 43.66 Favored 'General case' 0 C--N 1.317 -0.805 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 -178.772 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . 0.449 ' CE1' ' HB ' ' A' ' 25' ' ' ILE . 96.9 m-85 -125.9 150.06 48.22 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-O 121.153 0.501 . . . . 0.0 111.256 -179.668 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 10.1 m-80 -99.0 136.56 38.79 Favored 'General case' 0 C--N 1.318 -0.791 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 174.728 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.457 HG22 ' CG ' ' A' ' 23' ' ' TRP . 53.6 t -115.87 129.83 71.57 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 N-CA-C 114.007 1.114 . . . . 0.0 114.007 -172.953 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . 0.456 ' HA ' ' HA ' ' A' ' 19' ' ' GLU . 78.4 mt-10 -114.27 134.33 55.02 Favored 'General case' 0 N--CA 1.437 -1.09 0 CA-C-N 113.999 -1.455 . . . . 0.0 107.97 176.038 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 11.6 m120 -116.07 136.15 53.28 Favored 'General case' 0 C--N 1.315 -0.918 0 CA-C-O 120.635 0.255 . . . . 0.0 110.517 -178.949 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . 0.516 ' HB2' ' CE3' ' A' ' 17' ' ' TRP . 58.6 tt0 -112.39 122.1 46.74 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.827 -178.166 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 15.0 p90 -139.47 141.87 37.39 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.912 -0.585 . . . . 0.0 109.654 175.079 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 127.62 2.21 6.33 Favored Glycine 0 N--CA 1.443 -0.862 0 C-N-CA 120.657 -0.782 . . . . 0.0 111.59 -179.234 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 82.03 -156.69 36.35 Favored Glycine 0 N--CA 1.445 -0.766 0 C-N-CA 121.161 -0.542 . . . . 0.0 113.892 178.776 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 8.1 m -54.45 137.54 42.27 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-N 115.011 -0.594 . . . . 0.0 111.8 179.659 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 21.0 m 64.08 18.92 11.52 Favored 'General case' 0 N--CA 1.469 0.511 0 N-CA-C 113.131 0.789 . . . . 0.0 113.131 177.616 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -79.93 140.28 54.04 Favored Pre-proline 0 C--N 1.322 -0.597 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 177.209 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 69.9 Cg_endo -71.13 158.73 54.22 Favored 'Trans proline' 0 C--O 1.238 0.505 0 C-N-CA 122.495 2.13 . . . . 0.0 112.287 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' TRP . . . . . 0.516 ' CE3' ' HB2' ' A' ' 9' ' ' GLN . 91.7 m95 -92.94 128.78 38.92 Favored 'General case' 0 C--N 1.314 -0.965 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 179.076 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 88.9 m-20 -116.37 117.12 29.07 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-N 116.7 -0.227 . . . . 0.0 110.691 -177.573 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.456 ' HA ' ' HA ' ' A' ' 7' ' ' GLU . 11.2 pt-20 -72.27 135.55 46.03 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 177.669 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -142.87 26.16 2.23 Favored Glycine 0 N--CA 1.44 -1.074 0 C-N-CA 119.375 -1.393 . . . . 0.0 113.266 179.302 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 149.85 -176.04 28.7 Favored Glycine 0 N--CA 1.447 -0.567 0 C-N-CA 119.531 -1.318 . . . . 0.0 113.583 -179.832 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . 0.513 HE21 HD11 ' A' ' 3' ' ' LEU . 4.4 pt20 -131.32 136.97 48.57 Favored 'General case' 0 C--N 1.325 -0.478 0 C-N-CA 122.603 0.361 . . . . 0.0 110.425 -178.728 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . 0.457 ' CG ' HG22 ' A' ' 6' ' ' VAL . 29.3 m0 -112.58 154.64 25.68 Favored 'General case' 0 CA--C 1.504 -0.826 0 N-CA-C 110.126 -0.324 . . . . 0.0 110.126 179.406 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 69.5 tt0 -117.89 114.16 22.82 Favored 'General case' 0 C--N 1.31 -1.111 0 C-N-CA 119.772 -0.771 . . . . 0.0 109.085 176.185 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.449 ' HB ' ' CE1' ' A' ' 4' ' ' TYR . 96.8 mt -127.0 135.76 62.74 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.598 -175.486 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 113.5 165.13 15.89 Favored Glycine 0 N--CA 1.438 -1.183 0 C-N-CA 120.667 -0.778 . . . . 0.0 112.721 176.838 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 58.5 m -134.63 -55.77 0.84 Allowed 'General case' 0 C--N 1.309 -1.163 0 N-CA-C 108.793 -0.817 . . . . 0.0 108.793 179.454 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 93.4 mtt-85 -80.36 137.09 36.51 Favored 'General case' 0 N--CA 1.448 -0.551 0 CA-C-N 115.506 -0.77 . . . . 0.0 109.164 176.403 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 24.8 m -89.03 -19.98 24.95 Favored 'General case' 0 C--N 1.314 -0.95 0 CA-C-O 121.257 0.551 . . . . 0.0 110.884 -179.379 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 17.3 m-20 -95.68 1.01 53.3 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.781 -0.645 . . . . 0.0 111.407 -178.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . 0.456 ' OE1' ' HB3' ' A' ' 53' ' ' TYR . 0.4 OUTLIER -141.65 112.41 7.21 Favored 'General case' 0 C--N 1.321 -0.67 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 178.966 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 2.7 t30 -95.2 161.2 14.2 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-O 120.958 0.409 . . . . 0.0 111.497 -176.088 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.406 ' HA ' ' HA ' ' A' ' 53' ' ' TYR . 59.6 t -98.77 134.58 37.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 C-N-CA 123.204 0.602 . . . . 0.0 110.151 -179.146 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 23.8 m -112.72 -15.22 10.4 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.545 0 N-CA-C 112.548 0.573 . . . . 0.0 112.548 -179.319 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.45 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -147.8 143.85 27.78 Favored 'General case' 0 C--O 1.239 0.52 0 C-N-CA 120.228 -0.589 . . . . 0.0 111.52 177.597 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 94.8 mt -141.84 124.96 15.06 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 -179.772 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' ASN . . . . . 0.4 HD21 ' HA ' ' A' ' 37' ' ' ASN . 1.0 OUTLIER -133.4 112.5 11.64 Favored 'General case' 0 C--N 1.311 -1.068 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 177.951 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.436 HG22 ' HB ' ' A' ' 103' ' ' ILE . 19.7 m -146.37 147.83 17.66 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.775 0 N-CA-C 112.202 0.445 . . . . 0.0 112.202 -174.388 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 69.2 tt0 -131.02 143.2 50.53 Favored 'General case' 0 CA--C 1.536 0.404 0 CA-C-N 115.692 -0.685 . . . . 0.0 109.629 176.768 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' SER . . . . . 0.415 ' HA ' ' O ' ' A' ' 46' ' ' THR . 22.1 p -71.13 147.64 48.2 Favored 'General case' 0 C--N 1.319 -0.754 0 N-CA-C 112.441 0.534 . . . . 0.0 112.441 179.633 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -97.87 -48.69 1.89 Allowed Glycine 0 N--CA 1.45 -0.403 0 N-CA-C 110.515 -1.034 . . . . 0.0 110.515 176.597 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 6.9 m-20 -97.26 -168.07 1.64 Allowed 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 175.783 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 28.3 m-20 -74.93 59.83 0.93 Allowed 'General case' 0 N--CA 1.469 0.501 0 CA-C-O 121.133 0.492 . . . . 0.0 111.947 -179.543 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 82.77 11.6 81.34 Favored Glycine 0 N--CA 1.452 -0.268 0 CA-C-N 115.976 -0.556 . . . . 0.0 112.75 177.477 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 63.1 tt0 -97.08 -30.51 13.0 Favored 'General case' 0 C--O 1.215 -0.715 0 C-N-CA 120.784 -0.366 . . . . 0.0 111.314 179.701 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' THR . . . . . 0.415 ' O ' ' HA ' ' A' ' 40' ' ' SER . 31.0 p -124.04 147.36 47.9 Favored 'General case' 0 C--N 1.308 -1.203 0 C-N-CA 120.818 -0.353 . . . . 0.0 110.801 -179.806 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' LEU . . . . . 0.439 ' HB2' ' HB1' ' A' ' 63' ' ' ALA . 94.1 mt -133.28 129.47 37.65 Favored 'General case' 0 C--N 1.318 -0.79 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 -179.7 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 51.3 m-80 -127.16 140.75 52.04 Favored 'General case' 0 C--N 1.311 -1.101 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 177.565 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 177.22 -157.75 22.8 Favored Glycine 0 N--CA 1.438 -1.197 0 C-N-CA 119.4 -1.381 . . . . 0.0 113.541 179.904 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 44.6 m -126.23 129.96 49.98 Favored 'General case' 0 N--CA 1.44 -0.973 0 CA-C-N 115.302 -0.449 . . . . 0.0 110.239 -177.272 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 19.0 ttm -110.78 141.93 43.43 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 109.69 -0.485 . . . . 0.0 109.69 179.089 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.45 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 36.2 m -126.29 122.38 35.33 Favored 'General case' 0 C--O 1.254 1.29 0 CA-C-O 120.956 0.408 . . . . 0.0 111.233 178.019 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . 0.517 ' HB2' ' HB2' ' A' ' 56' ' ' GLU . 78.6 m-85 -85.92 164.3 17.53 Favored 'General case' 0 C--O 1.231 0.127 0 CA-C-N 115.404 -0.816 . . . . 0.0 110.702 178.891 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -69.58 105.44 2.67 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.895 -179.515 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 86.44 8.43 77.61 Favored Glycine 0 CA--C 1.518 0.236 0 C-N-CA 121.013 -0.613 . . . . 0.0 112.943 176.711 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . 0.517 ' HB2' ' HB2' ' A' ' 53' ' ' TYR . 78.6 mm-40 -122.12 165.56 15.9 Favored 'General case' 0 C--N 1.315 -0.893 0 N-CA-C 110.012 -0.366 . . . . 0.0 110.012 -179.003 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -77.7 161.96 50.16 Favored Glycine 0 N--CA 1.446 -0.683 0 C-N-CA 120.663 -0.779 . . . . 0.0 112.086 178.51 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -72.73 145.87 42.03 Favored 'Trans proline' 0 C--O 1.241 0.645 0 C-N-CA 122.811 2.341 . . . . 0.0 112.716 179.835 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . 0.538 ' HB ' ' O ' ' A' ' 76' ' ' GLN . 49.7 pt -128.86 165.83 27.72 Favored 'Isoleucine or valine' 0 C--O 1.242 0.687 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.653 179.888 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -77.13 134.84 15.47 Favored Glycine 0 C--O 1.239 0.459 0 C-N-CA 120.897 -0.668 . . . . 0.0 111.819 -179.347 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 72.1 t80 -117.43 127.49 54.07 Favored 'General case' 0 C--O 1.237 0.443 0 C-N-CA 122.429 0.291 . . . . 0.0 111.24 -177.556 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 50.2 ttm-85 -130.29 127.75 40.14 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.016 -0.538 . . . . 0.0 109.86 176.699 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.439 ' HB1' ' HB2' ' A' ' 47' ' ' LEU . . . -132.05 139.87 48.69 Favored 'General case' 0 C--N 1.319 -0.741 0 C-N-CA 120.796 -0.362 . . . . 0.0 111.819 178.529 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 46.7 m -122.28 127.02 49.38 Favored 'General case' 0 CA--C 1.54 0.568 0 CA-C-N 115.879 -0.601 . . . . 0.0 110.005 178.201 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -74.5 119.77 19.15 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-O 121.053 0.454 . . . . 0.0 110.678 -178.118 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 91.7 mt -94.43 -25.14 17.04 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.669 -0.696 . . . . 0.0 109.962 178.368 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 134.57 157.5 8.14 Favored Glycine 0 N--CA 1.44 -1.044 0 CA-C-N 115.675 -0.693 . . . . 0.0 111.882 179.638 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 92.4 m-20 56.69 34.33 24.37 Favored 'General case' 0 N--CA 1.481 1.114 0 C-N-CA 122.463 0.305 . . . . 0.0 111.469 179.2 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . 0.534 ' ND2' ' HA3' ' A' ' 93' ' ' GLY . 21.8 m120 70.15 10.49 7.36 Favored 'General case' 0 N--CA 1.481 1.087 0 C-N-CA 123.522 0.729 . . . . 0.0 112.415 -179.407 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 55.8 m -87.72 122.31 31.22 Favored 'General case' 0 C--O 1.236 0.376 0 N-CA-C 110.015 -0.365 . . . . 0.0 110.015 177.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.555 ' OH ' ' HB3' ' A' ' 99' ' ' ASN . 70.8 m-85 -115.44 129.96 56.73 Favored 'General case' 0 C--N 1.311 -1.065 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.217 -179.643 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 52.2 tp10 -85.31 118.82 25.09 Favored 'General case' 0 N--CA 1.438 -1.064 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 174.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 68.0 t -106.98 132.75 53.52 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.23 0 N-CA-C 112.937 0.717 . . . . 0.0 112.937 -173.427 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -123.72 142.85 50.69 Favored 'General case' 0 N--CA 1.446 -0.645 0 N-CA-C 107.273 -1.381 . . . . 0.0 107.273 175.801 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 93.4 m-20 -134.71 161.24 35.71 Favored 'General case' 0 C--N 1.316 -0.851 0 C-N-CA 120.869 -0.332 . . . . 0.0 111.291 -174.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' GLN . . . . . 0.538 ' O ' ' HB ' ' A' ' 59' ' ' ILE . 2.9 pt20 -130.64 129.99 43.38 Favored 'General case' 0 C--O 1.239 0.543 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.159 177.006 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 6.6 p90 -133.96 151.19 51.38 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.91 -178.408 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 98.12 -1.96 59.45 Favored Glycine 0 N--CA 1.448 -0.54 0 C-N-CA 120.713 -0.756 . . . . 0.0 111.871 -179.614 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 140.99 164.62 9.99 Favored Glycine 0 N--CA 1.441 -1.031 0 C-N-CA 121.054 -0.593 . . . . 0.0 112.2 179.072 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -65.54 -33.0 74.89 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-O 121.248 0.546 . . . . 0.0 110.473 179.44 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 32.5 p -79.85 6.87 9.95 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.257 -0.883 . . . . 0.0 112.459 -178.055 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -83.89 146.64 49.56 Favored Pre-proline 0 C--N 1.316 -0.89 0 CA-C-N 116.698 -0.228 . . . . 0.0 110.527 179.668 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -67.92 173.73 8.8 Favored 'Trans proline' 0 C--N 1.345 0.353 0 C-N-CA 122.459 2.106 . . . . 0.0 111.604 178.855 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' TRP . . . . . . . . . . . . . 95.2 m95 -98.37 127.72 44.43 Favored 'General case' 0 N--CA 1.444 -0.751 0 CA-C-O 121.172 0.51 . . . . 0.0 110.248 -177.666 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 97.3 m-70 -115.7 149.69 38.0 Favored 'General case' 0 C--N 1.31 -1.116 0 CA-C-N 115.398 -0.819 . . . . 0.0 110.323 -177.629 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 10.0 m -61.53 130.25 45.06 Favored 'General case' 0 C--N 1.315 -0.925 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.833 -179.562 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -105.08 -52.68 0.82 Allowed Glycine 0 N--CA 1.439 -1.107 0 C-N-CA 120.913 -0.66 . . . . 0.0 111.634 179.43 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 155.68 -172.52 33.75 Favored Glycine 0 C--O 1.22 -0.753 0 C-N-CA 120.596 -0.811 . . . . 0.0 111.774 179.605 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 21.2 t-20 -110.28 112.08 23.8 Favored 'General case' 0 C--N 1.313 -1.009 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 179.512 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 27.4 m0 -102.4 149.8 23.99 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.993 -177.749 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 47.4 mm -107.17 114.02 45.04 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 177.247 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . 0.406 ' HB2' ' CE1' ' A' ' 71' ' ' TYR . 85.0 mt -124.25 89.25 3.05 Favored 'General case' 0 C--O 1.272 2.279 0 CA-C-O 121.725 0.774 . . . . 0.0 112.691 -175.796 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . 0.534 ' HA3' ' ND2' ' A' ' 69' ' ' ASN . . . 154.86 116.91 0.58 Allowed Glycine 0 N--CA 1.443 -0.876 0 CA-C-N 115.0 -1.0 . . . . 0.0 111.676 178.911 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' SER . . . . . 0.406 ' N ' ' HE1' ' A' ' 23' ' ' TRP . 76.8 p -86.0 -15.28 41.95 Favored 'General case' 0 CA--C 1.516 -0.355 0 CA-C-O 121.395 0.617 . . . . 0.0 109.913 178.849 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 58.4 mtt-85 -88.91 141.85 28.14 Favored 'General case' 0 N--CA 1.435 -1.185 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.004 -179.93 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 8.9 pt-20 -68.65 -33.11 73.43 Favored 'General case' 0 C--N 1.31 -1.117 0 CA-C-N 115.53 -0.759 . . . . 0.0 111.975 -175.376 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 31.3 p-10 -120.75 28.66 7.82 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 111.788 0.292 . . . . 0.0 111.788 -178.117 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' GLN . . . . . 0.458 ' OE1' ' HG2' ' A' ' 123' ' ' GLU . 0.0 OUTLIER -142.78 118.48 10.46 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 112.326 0.491 . . . . 0.0 112.326 -176.672 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' ASN . . . . . 0.555 ' HB3' ' OH ' ' A' ' 71' ' ' TYR . 93.2 m-20 -89.36 157.86 18.01 Favored 'General case' 0 C--O 1.262 1.755 0 CA-C-N 115.724 -0.671 . . . . 0.0 111.166 177.673 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . 0.443 HG21 ' CH2' ' A' ' 23' ' ' TRP . 85.9 t -84.35 134.14 27.66 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.594 0 CA-C-N 115.355 -0.839 . . . . 0.0 111.705 178.445 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 35.8 m -110.66 -29.03 2.49 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.397 0 CA-C-N 116.035 -0.529 . . . . 0.0 112.275 179.765 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . 0.422 ' HB2' ' HB ' ' A' ' 119' ' ' THR . . . -146.24 139.37 25.77 Favored 'General case' 0 C--N 1.323 -0.585 0 C-N-CA 120.2 -0.6 . . . . 0.0 111.144 179.056 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.436 ' HB ' HG22 ' A' ' 38' ' ' VAL . 94.9 mt -131.62 124.95 55.19 Favored 'Isoleucine or valine' 0 C--O 1.244 0.771 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.57 177.796 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 41.2 t30 -125.17 94.56 4.2 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 115.676 -0.693 . . . . 0.0 109.3 175.586 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 29.3 m -133.6 135.82 55.2 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 N-CA-C 112.859 0.689 . . . . 0.0 112.859 -176.538 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 75.3 tt0 -140.15 137.55 34.51 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.415 -0.811 . . . . 0.0 110.13 179.639 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 23.2 t -146.93 145.37 29.77 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 116.468 -0.333 . . . . 0.0 110.459 177.211 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -109.18 17.07 32.12 Favored Glycine 0 N--CA 1.447 -0.609 0 C-N-CA 121.11 -0.567 . . . . 0.0 112.435 -179.195 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 40.3 p-10 -91.91 -153.61 0.34 Allowed 'General case' 0 C--N 1.319 -0.753 0 CA-C-O 120.768 0.318 . . . . 0.0 110.158 179.098 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 37.1 t70 -88.94 12.86 14.19 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-O 121.167 0.508 . . . . 0.0 110.071 179.108 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 85.7 7.39 81.68 Favored Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 120.684 -0.769 . . . . 0.0 111.939 -177.173 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 36.5 tt0 -66.57 -38.78 87.79 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-O 121.109 0.481 . . . . 0.0 110.526 -179.671 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 113' ' ' THR . . . . . 0.419 ' HA ' ' O ' ' A' ' 130' ' ' GLY . 27.5 p -124.63 131.73 53.46 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-N 115.906 -0.588 . . . . 0.0 111.056 179.224 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -109.94 113.32 25.96 Favored 'General case' 0 C--N 1.315 -0.927 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 177.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 93.8 m-20 -117.23 147.5 42.46 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-O 121.016 0.436 . . . . 0.0 111.26 -177.941 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 159.57 -135.61 4.22 Favored Glycine 0 N--CA 1.434 -1.457 0 C-N-CA 120.458 -0.877 . . . . 0.0 112.906 177.717 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 20.8 p -134.04 157.97 44.76 Favored 'General case' 0 C--N 1.31 -1.143 0 C-N-CA 122.905 0.482 . . . . 0.0 110.316 -177.786 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 17.3 ptm -149.63 155.24 39.92 Favored 'General case' 0 C--N 1.312 -1.063 0 CA-C-N 116.498 -0.319 . . . . 0.0 110.391 -179.672 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 119' ' ' THR . . . . . 0.422 ' HB ' ' HB2' ' A' ' 102' ' ' ALA . 27.9 m -130.76 128.11 40.11 Favored 'General case' 0 C--O 1.249 1.055 0 CA-C-N 116.474 -0.33 . . . . 0.0 111.224 179.804 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 31.0 m-85 -89.85 166.02 13.77 Favored 'General case' 0 CA--C 1.507 -0.687 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.294 175.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . 0.419 ' HB3' HE22 ' A' ' 98' ' ' GLN . . . -66.47 45.38 0.03 OUTLIER 'General case' 0 CA--C 1.554 1.126 0 N-CA-C 114.043 1.127 . . . . 0.0 114.043 179.79 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 142.44 -25.63 2.31 Favored Glycine 0 C--N 1.334 0.429 0 C-N-CA 119.874 -1.155 . . . . 0.0 114.405 175.372 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . 0.458 ' HG2' ' OE1' ' A' ' 98' ' ' GLN . 69.4 mm-40 -67.33 -33.36 75.09 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 117.311 0.556 . . . . 0.0 112.424 -177.585 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 115.09 161.69 13.34 Favored Glycine 0 CA--C 1.519 0.334 0 C-N-CA 120.585 -0.817 . . . . 0.0 112.361 -179.542 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 20.8 Cg_exo -67.11 129.36 20.39 Favored 'Trans proline' 0 C--N 1.351 0.673 0 C-N-CA 122.782 2.321 . . . . 0.0 111.991 178.386 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 37.4 pt -135.44 161.73 38.71 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.691 179.592 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -69.8 139.25 31.17 Favored Glycine 0 C--O 1.239 0.453 0 C-N-CA 120.923 -0.656 . . . . 0.0 112.26 178.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 86.4 t80 -119.52 133.71 55.55 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 120.745 0.307 . . . . 0.0 111.233 -178.465 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 129' ' ' LYS . . . . . 0.408 ' HB3' ' HB2' ' A' ' 7' ' ' GLU . 63.6 tttm -140.99 118.12 11.27 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.911 -0.586 . . . . 0.0 109.519 176.718 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . 0.419 ' O ' ' HA ' ' A' ' 113' ' ' THR . . . -122.18 141.96 14.63 Favored Glycine 0 N--CA 1.449 -0.475 0 C-N-CA 120.735 -0.745 . . . . 0.0 111.941 -179.643 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 62.1 m -128.11 135.65 50.08 Favored 'General case' 0 C--N 1.317 -0.818 0 CA-C-N 116.619 0.21 . . . . 0.0 111.392 -179.585 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 3.4 tm? -57.79 138.26 55.77 Favored 'General case' 0 N--CA 1.467 0.392 0 C-N-CA 123.062 0.545 . . . . 0.0 110.391 179.723 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 24.0 m . . . . . 0 C--O 1.247 0.964 0 CA-C-O 118.503 -0.761 . . . . 0.0 110.322 -178.577 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.238 0.449 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' LEU . . . . . 0.513 HD13 ' NE2' ' A' ' 22' ' ' GLN . 3.1 tm? -90.76 128.68 36.77 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-O 120.855 0.359 . . . . 0.0 110.099 -179.914 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . 0.412 ' CD1' ' HB ' ' A' ' 25' ' ' ILE . 57.4 m-85 -119.65 143.07 47.91 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.142 178.1 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 12.9 m-80 -97.24 135.52 39.05 Favored 'General case' 0 C--N 1.309 -1.159 0 N-CA-C 108.394 -0.965 . . . . 0.0 108.394 175.689 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 53.5 t -111.36 126.65 68.76 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.862 0 CA-C-O 121.803 0.811 . . . . 0.0 112.627 -174.769 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . 0.42 ' HG2' ' HB3' ' A' ' 19' ' ' GLU . 63.6 mt-10 -118.82 133.18 56.02 Favored 'General case' 0 N--CA 1.438 -1.047 0 CA-C-N 114.684 -1.144 . . . . 0.0 108.5 176.665 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . 0.443 ' HA ' ' O ' ' A' ' 127' ' ' GLY . 13.0 m120 -117.89 139.76 50.67 Favored 'General case' 0 C--N 1.313 -1.004 0 CA-C-O 121.072 0.463 . . . . 0.0 111.424 -176.641 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . 0.423 ' HB2' ' CE3' ' A' ' 17' ' ' TRP . 28.1 tt0 -132.6 125.86 31.43 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.059 179.131 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 24.1 p90 -128.98 141.29 51.3 Favored 'General case' 0 C--N 1.316 -0.853 0 C-N-CA 120.607 -0.437 . . . . 0.0 111.265 -179.048 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 115.77 -77.72 0.27 Allowed Glycine 0 N--CA 1.442 -0.936 0 CA-C-N 115.562 -0.744 . . . . 0.0 111.794 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -170.34 173.62 44.3 Favored Glycine 0 N--CA 1.442 -0.953 0 C-N-CA 121.085 -0.579 . . . . 0.0 111.725 -179.579 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 26.2 t -59.25 -23.8 62.65 Favored 'General case' 0 CA--C 1.538 0.506 0 N-CA-C 111.881 0.326 . . . . 0.0 111.881 -179.729 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 23.5 p -65.23 -19.65 66.07 Favored 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 112.009 0.374 . . . . 0.0 112.009 177.823 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -93.09 146.91 32.84 Favored Pre-proline 0 N--CA 1.446 -0.671 0 N-CA-C 109.978 -0.379 . . . . 0.0 109.978 179.414 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_endo -79.41 173.27 13.39 Favored 'Trans proline' 0 CA--C 1.537 0.652 0 C-N-CA 122.723 2.282 . . . . 0.0 112.869 179.457 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' TRP . . . . . 0.423 ' CE3' ' HB2' ' A' ' 9' ' ' GLN . 95.5 m95 -87.14 131.24 34.22 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.938 -0.573 . . . . 0.0 109.795 178.741 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 46.5 m-80 -114.37 118.62 34.36 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.937 -178.395 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.42 ' HB3' ' HG2' ' A' ' 7' ' ' GLU . 10.9 pt-20 -82.7 124.75 30.51 Favored 'General case' 0 C--N 1.315 -0.897 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.499 179.236 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . 0.428 ' O ' ' HB2' ' A' ' 94' ' ' SER . . . -132.46 29.93 3.22 Favored Glycine 0 N--CA 1.442 -0.963 0 C-N-CA 120.069 -1.062 . . . . 0.0 112.838 -177.709 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 140.96 -175.12 22.36 Favored Glycine 0 N--CA 1.442 -0.907 0 C-N-CA 120.25 -0.976 . . . . 0.0 112.819 178.818 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . 0.513 ' NE2' HD13 ' A' ' 3' ' ' LEU . 18.5 pt20 -141.46 153.05 44.74 Favored 'General case' 0 C--N 1.313 -1.01 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 179.812 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . 0.424 ' HB3' ' O ' ' A' ' 91' ' ' ILE . 45.0 m0 -127.68 174.7 8.87 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.543 -0.299 . . . . 0.0 110.787 -176.086 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 79.6 tt0 -121.01 118.11 28.97 Favored 'General case' 0 CA--C 1.51 -0.57 0 C-N-CA 120.624 -0.43 . . . . 0.0 109.902 176.776 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.412 ' HB ' ' CD1' ' A' ' 4' ' ' TYR . 98.3 mt -131.53 140.14 49.01 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.774 0 CA-C-N 115.816 -0.629 . . . . 0.0 109.609 -178.762 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 86.15 66.64 1.39 Allowed Glycine 0 N--CA 1.443 -0.886 0 C-N-CA 120.34 -0.933 . . . . 0.0 112.544 178.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 19.2 p -59.78 -36.88 77.61 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 121.131 0.491 . . . . 0.0 110.239 177.744 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 93.5 mtt-85 -94.88 108.23 20.26 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 175.233 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 51.0 m -73.7 -7.87 53.76 Favored 'General case' 0 C--N 1.321 -0.671 0 N-CA-C 113.082 0.771 . . . . 0.0 113.082 -174.761 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 97.9 m-20 -76.81 -18.76 58.21 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.906 0.384 . . . . 0.0 110.996 179.854 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . 0.512 ' NE2' ' HA ' ' A' ' 31' ' ' GLN . 7.2 mm-40 -133.53 114.83 14.02 Favored 'General case' 0 CA--C 1.51 -0.561 0 N-CA-C 112.589 0.589 . . . . 0.0 112.589 -178.741 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . 0.537 ' ND2' ' HA3' ' A' ' 111' ' ' GLY . 2.6 t30 -82.21 142.43 32.16 Favored 'General case' 0 C--O 1.242 0.7 0 CA-C-N 116.011 -0.541 . . . . 0.0 110.043 179.369 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 47.0 t -92.37 129.75 42.51 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 CA-C-N 115.507 -0.77 . . . . 0.0 109.857 -178.331 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.43 ' HB ' ' O ' ' A' ' 107' ' ' SER . 30.5 m -110.13 -21.15 5.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 N-CA-C 112.38 0.511 . . . . 0.0 112.38 -179.925 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.451 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -144.85 143.13 30.46 Favored 'General case' 0 C--N 1.322 -0.605 0 C-N-CA 119.816 -0.753 . . . . 0.0 111.85 179.319 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.412 ' C ' HD21 ' A' ' 37' ' ' ASN . 91.5 mt -142.08 119.38 7.47 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 CA-C-N 115.48 -0.782 . . . . 0.0 109.061 179.802 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' ASN . . . . . 0.412 HD21 ' C ' ' A' ' 36' ' ' ILE . 0.9 OUTLIER -126.4 109.92 12.76 Favored 'General case' 0 C--N 1.306 -1.32 0 N-CA-C 108.389 -0.967 . . . . 0.0 108.389 176.506 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.445 HG13 ' CD2' ' A' ' 61' ' ' PHE . 29.5 m -148.26 153.42 11.54 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.63 0 N-CA-C 112.111 0.411 . . . . 0.0 112.111 -173.753 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 -146.35 148.34 32.26 Favored 'General case' 0 C--O 1.245 0.82 0 CA-C-N 115.431 -0.804 . . . . 0.0 109.299 174.778 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' SER . . . . . 0.461 ' HB3' ' CD2' ' A' ' 47' ' ' LEU . 37.1 p -80.49 151.54 29.18 Favored 'General case' 0 C--N 1.313 -1.014 0 CA-C-O 121.496 0.665 . . . . 0.0 112.511 -176.88 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -92.76 -13.26 56.99 Favored Glycine 0 N--CA 1.438 -1.168 0 N-CA-C 110.084 -1.206 . . . . 0.0 110.084 173.281 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 28.3 m-20 -137.33 -155.16 0.59 Allowed 'General case' 0 N--CA 1.468 0.445 0 C-N-CA 123.203 0.601 . . . . 0.0 109.403 -179.34 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -79.4 42.12 0.49 Allowed 'General case' 0 N--CA 1.47 0.572 0 CA-C-O 121.099 0.476 . . . . 0.0 110.725 178.117 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 91.43 3.82 68.84 Favored Glycine 0 C--O 1.22 -0.743 0 C-N-CA 121.025 -0.607 . . . . 0.0 112.881 -178.834 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 55.9 tp60 -63.97 -47.67 79.48 Favored 'General case' 0 N--CA 1.462 0.17 0 CA-C-O 120.903 0.382 . . . . 0.0 111.016 179.575 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 9.4 t -133.32 127.75 34.23 Favored 'General case' 0 C--N 1.312 -1.059 0 C-N-CA 120.72 -0.392 . . . . 0.0 110.113 177.551 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' LEU . . . . . 0.461 ' CD2' ' HB3' ' A' ' 40' ' ' SER . 64.9 mt -109.08 127.96 54.58 Favored 'General case' 0 N--CA 1.447 -0.618 0 N-CA-C 109.662 -0.496 . . . . 0.0 109.662 179.636 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 65.2 m-80 -121.97 147.1 46.47 Favored 'General case' 0 C--N 1.313 -0.982 0 N-CA-C 109.558 -0.534 . . . . 0.0 109.558 176.8 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 176.13 -154.4 16.88 Favored Glycine 0 N--CA 1.433 -1.557 0 C-N-CA 119.925 -1.131 . . . . 0.0 113.064 179.602 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 89.9 m -129.35 130.7 46.39 Favored 'General case' 0 N--CA 1.436 -1.159 0 C-N-CA 122.668 0.387 . . . . 0.0 111.13 -177.483 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 44.9 mtp -110.08 151.27 27.42 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.394 -0.367 . . . . 0.0 110.927 177.846 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.451 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 23.7 m -132.84 127.77 35.2 Favored 'General case' 0 C--N 1.315 -0.898 0 N-CA-C 110.185 -0.302 . . . . 0.0 110.185 176.009 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . 0.436 ' CD1' ' HB3' ' A' ' 31' ' ' GLN . 83.6 m-85 -92.48 163.21 13.91 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.867 178.721 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -61.31 103.36 0.29 Allowed 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.969 -178.553 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 94.77 -6.59 70.24 Favored Glycine 0 CA--C 1.51 -0.258 0 C-N-CA 120.863 -0.684 . . . . 0.0 113.267 177.975 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 69.8 mm-40 -104.82 -179.24 3.89 Favored 'General case' 0 C--N 1.311 -1.102 0 CA-C-O 120.709 0.29 . . . . 0.0 110.836 -178.347 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -99.06 173.73 26.86 Favored Glycine 0 N--CA 1.444 -0.796 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.33 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -68.66 139.38 44.08 Favored 'Trans proline' 0 CA--C 1.538 0.709 0 C-N-CA 122.818 2.345 . . . . 0.0 112.588 179.503 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 50.2 pt -131.93 167.17 27.0 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.079 178.372 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -78.53 139.09 21.92 Favored Glycine 0 N--CA 1.446 -0.677 0 N-CA-C 111.019 -0.832 . . . . 0.0 111.019 179.459 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.445 ' CD2' HG13 ' A' ' 38' ' ' VAL . 29.1 t80 -131.31 129.71 41.82 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 120.953 0.406 . . . . 0.0 111.583 -177.479 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 55.4 ttm-85 -127.11 130.06 49.13 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.514 -0.766 . . . . 0.0 110.493 178.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.426 ' HB2' ' HB3' ' A' ' 71' ' ' TYR . . . -129.27 132.32 47.16 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-O 120.594 0.235 . . . . 0.0 110.796 177.175 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 85.3 m -117.31 125.47 51.12 Favored 'General case' 0 C--N 1.316 -0.861 0 CA-C-O 120.996 0.427 . . . . 0.0 110.74 179.637 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . 0.484 ' HG ' ' N ' ' A' ' 67' ' ' GLY . 66.6 tp -71.52 132.89 45.36 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.759 -0.655 . . . . 0.0 112.544 -177.579 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -85.94 -16.15 39.33 Favored 'General case' 0 N--CA 1.471 0.577 0 CA-C-N 115.29 -0.868 . . . . 0.0 109.898 174.743 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.484 ' N ' ' HG ' ' A' ' 65' ' ' LEU . . . 103.7 7.61 41.68 Favored Glycine 0 N--CA 1.463 0.44 0 CA-C-N 115.527 -0.76 . . . . 0.0 112.7 177.471 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 29.7 p-10 -137.73 39.65 2.39 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-O 120.851 0.358 . . . . 0.0 110.592 -179.331 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 89.0 m-20 68.9 -1.72 1.96 Allowed 'General case' 0 N--CA 1.485 1.281 0 C-N-CA 123.528 0.731 . . . . 0.0 112.128 -178.558 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 15.3 m -91.82 132.23 36.59 Favored 'General case' 0 C--N 1.314 -0.948 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 177.456 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.442 ' CE1' ' HB2' ' A' ' 92' ' ' LEU . 79.1 m-85 -124.09 133.96 53.49 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.741 -179.25 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 79.9 tt0 -87.13 123.6 32.35 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 174.691 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 48.8 t -99.37 128.61 50.92 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 N-CA-C 112.826 0.676 . . . . 0.0 112.826 -175.656 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 75.4 mt-10 -127.19 121.81 32.34 Favored 'General case' 0 CA--C 1.535 0.378 0 CA-C-N 114.794 -1.094 . . . . 0.0 108.467 175.194 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' ASN . . . . . 0.423 ' OD1' ' HD1' ' A' ' 61' ' ' PHE . 96.4 m-20 -108.42 153.01 23.91 Favored 'General case' 0 C--O 1.236 0.393 0 N-CA-C 112.56 0.578 . . . . 0.0 112.56 -176.283 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 60.2 tt0 -127.72 125.55 40.19 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.358 -0.837 . . . . 0.0 109.389 -179.775 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 6.6 p90 -127.29 4.4 6.33 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 112.734 0.642 . . . . 0.0 112.734 -178.246 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -84.74 -1.88 88.87 Favored Glycine 0 CA--C 1.521 0.415 0 C-N-CA 120.561 -0.828 . . . . 0.0 111.954 178.242 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 106.14 -153.83 16.99 Favored Glycine 0 CA--C 1.497 -1.037 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 -179.717 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -62.43 -32.54 73.41 Favored 'General case' 0 CA--C 1.514 -0.422 0 CA-C-N 117.675 0.738 . . . . 0.0 109.217 173.827 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 47.7 m -84.78 -175.35 5.74 Favored 'General case' 0 N--CA 1.438 -1.04 0 CA-C-N 114.947 -1.024 . . . . 0.0 110.016 176.588 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 75.78 147.22 0.12 Allowed Pre-proline 0 N--CA 1.471 0.578 0 C-N-CA 123.997 0.919 . . . . 0.0 111.701 -179.445 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -73.76 169.19 22.95 Favored 'Trans proline' 0 C--O 1.238 0.508 0 C-N-CA 122.874 2.383 . . . . 0.0 111.807 178.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' TRP . . . . . . . . . . . . . 82.7 m95 -87.87 145.65 25.96 Favored 'General case' 0 N--CA 1.447 -0.589 0 N-CA-C 109.524 -0.547 . . . . 0.0 109.524 -179.911 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 94.3 m-70 -116.97 143.38 45.78 Favored 'General case' 0 C--N 1.317 -0.836 0 N-CA-C 110.033 -0.358 . . . . 0.0 110.033 -179.551 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 13.5 m -63.01 137.02 58.14 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-O 120.802 0.334 . . . . 0.0 110.904 -178.748 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -112.83 -48.92 0.6 Allowed Glycine 0 N--CA 1.447 -0.573 0 C-N-CA 121.228 -0.511 . . . . 0.0 112.371 -179.632 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 152.95 -167.95 31.75 Favored Glycine 0 C--O 1.214 -1.155 0 C-N-CA 120.257 -0.973 . . . . 0.0 112.121 179.201 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 16.1 m120 -111.99 118.88 36.67 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 117.082 0.441 . . . . 0.0 110.488 179.868 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 27.4 m0 -111.01 155.27 22.98 Favored 'General case' 0 C--N 1.321 -0.651 0 N-CA-C 110.25 -0.278 . . . . 0.0 110.25 -179.306 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . 0.424 ' O ' ' HB3' ' A' ' 23' ' ' TRP . 49.2 mm -110.93 116.61 52.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 N-CA-C 109.179 -0.674 . . . . 0.0 109.179 177.893 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . 0.442 ' HB2' ' CE1' ' A' ' 71' ' ' TYR . 77.9 mt -128.98 81.72 2.04 Favored 'General case' 0 C--O 1.272 2.267 0 CA-C-O 121.772 0.796 . . . . 0.0 112.069 -177.996 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 166.22 112.61 0.26 Allowed Glycine 0 N--CA 1.442 -0.92 0 CA-C-N 115.222 -0.899 . . . . 0.0 111.771 179.159 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' SER . . . . . 0.428 ' HB2' ' O ' ' A' ' 20' ' ' GLY . 77.4 p -86.01 -10.94 54.19 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 121.277 0.56 . . . . 0.0 110.761 179.887 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 98.6 mtt180 -111.44 154.24 24.96 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.556 -0.747 . . . . 0.0 109.413 -179.702 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -70.65 -53.19 16.75 Favored 'General case' 0 N--CA 1.472 0.669 0 N-CA-C 113.501 0.926 . . . . 0.0 113.501 -172.348 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 94.8 m-20 -115.0 36.47 3.86 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.75 0.31 . . . . 0.0 111.4 -176.769 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' GLN . . . . . . . . . . . . . 38.1 tp60 -103.47 -59.42 1.72 Allowed 'General case' 0 C--N 1.316 -0.853 0 C-N-CA 120.484 -0.486 . . . . 0.0 110.651 -178.681 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 88.8 m-20 74.62 133.72 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.599 0 O-C-N 123.894 0.746 . . . . 0.0 111.812 177.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . 0.409 HG23 ' CH2' ' A' ' 23' ' ' TRP . 73.6 t -80.35 133.24 29.96 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.489 0 C-N-CA 120.094 -0.642 . . . . 0.0 111.736 178.727 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 26.8 m -111.19 -31.93 2.24 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.487 0 N-CA-C 112.73 0.641 . . . . 0.0 112.73 -179.621 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -146.57 138.18 24.55 Favored 'General case' 0 C--N 1.324 -0.537 0 C-N-CA 119.809 -0.756 . . . . 0.0 111.625 179.721 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.423 ' HB ' HG22 ' A' ' 38' ' ' VAL . 96.1 mt -131.85 126.32 56.86 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.124 178.019 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 41.9 t30 -126.18 99.17 5.77 Favored 'General case' 0 C--N 1.314 -0.935 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 174.772 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.436 HG13 ' CD2' ' A' ' 128' ' ' PHE . 30.2 m -139.82 140.52 36.0 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.091 0 CA-C-N 115.85 -0.614 . . . . 0.0 111.78 -175.715 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 81.5 tt0 -144.2 145.58 32.16 Favored 'General case' 0 C--N 1.315 -0.924 0 CA-C-N 115.774 -0.648 . . . . 0.0 109.977 178.051 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 107' ' ' SER . . . . . 0.539 ' HB2' ' OD1' ' A' ' 109' ' ' ASP . 21.6 p -152.71 152.93 32.27 Favored 'General case' 0 C--N 1.312 -1.039 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.559 178.143 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -130.53 15.46 5.49 Favored Glycine 0 CA--C 1.505 -0.538 0 N-CA-C 111.105 -0.798 . . . . 0.0 111.105 178.888 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . 0.539 ' OD1' ' HB2' ' A' ' 107' ' ' SER . 10.4 p-10 -96.23 22.82 7.23 Favored 'General case' 0 C--N 1.316 -0.859 0 C-N-CA 123.167 0.587 . . . . 0.0 110.5 -179.521 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 110' ' ' ASP . . . . . 0.52 ' HB2' ' O ' ' A' ' 109' ' ' ASP . 4.2 m-20 81.94 10.42 0.76 Allowed 'General case' 0 N--CA 1.486 1.366 0 C-N-CA 124.131 0.972 . . . . 0.0 112.282 -179.944 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . 0.537 ' HA3' ' ND2' ' A' ' 32' ' ' ASN . . . 88.12 12.59 65.45 Favored Glycine 0 N--CA 1.446 -0.661 0 C-N-CA 119.999 -1.096 . . . . 0.0 113.718 176.402 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 98.2 mt-30 -71.74 -38.74 70.39 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 117.046 0.423 . . . . 0.0 110.591 179.178 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 12.7 p -131.18 109.94 10.79 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.928 175.952 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 6.1 mp -92.07 113.55 25.85 Favored 'General case' 0 C--N 1.319 -0.722 0 N-CA-C 109.767 -0.456 . . . . 0.0 109.767 179.713 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 54.3 m-80 -108.3 145.54 34.24 Favored 'General case' 0 C--N 1.311 -1.079 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.836 -178.431 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 166.33 -139.29 5.68 Favored Glycine 0 N--CA 1.433 -1.508 0 C-N-CA 120.121 -1.038 . . . . 0.0 112.996 177.881 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 41.2 p -137.72 160.9 37.96 Favored 'General case' 0 C--N 1.31 -1.145 0 C-N-CA 123.429 0.692 . . . . 0.0 109.924 -177.75 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 19.8 ptm -149.29 161.49 41.94 Favored 'General case' 0 C--N 1.311 -1.087 0 CA-C-O 120.729 0.299 . . . . 0.0 110.698 179.302 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 23.5 m -135.39 133.15 38.39 Favored 'General case' 0 C--O 1.246 0.892 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.473 -179.813 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 12.3 m-85 -99.81 158.81 15.53 Favored 'General case' 0 CA--C 1.515 -0.398 0 CA-C-N 115.946 -0.57 . . . . 0.0 109.798 176.618 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -61.07 122.66 15.54 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 120.608 0.242 . . . . 0.0 111.495 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 68.73 27.86 73.54 Favored Glycine 0 C--N 1.338 0.673 0 CA-C-N 115.969 -0.559 . . . . 0.0 113.243 179.847 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 80.4 tt0 -142.58 155.87 45.03 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 116.872 0.336 . . . . 0.0 110.389 -178.014 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -77.69 161.32 49.66 Favored Glycine 0 CA--C 1.521 0.441 0 C-N-CA 121.169 -0.539 . . . . 0.0 112.707 -178.907 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 23.1 Cg_exo -64.05 141.66 77.81 Favored 'Trans proline' 0 C--N 1.345 0.357 0 C-N-CA 122.802 2.334 . . . . 0.0 112.756 -179.564 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 35.9 pt -133.07 157.83 43.02 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.994 0 CA-C-N 115.402 -0.817 . . . . 0.0 109.763 178.321 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . 0.443 ' O ' ' HA ' ' A' ' 8' ' ' ASN . . . -70.32 139.5 30.78 Favored Glycine 0 C--O 1.235 0.209 0 C-N-CA 121.096 -0.574 . . . . 0.0 112.083 179.042 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . 0.436 ' CD2' HG13 ' A' ' 105' ' ' VAL . 73.0 t80 -119.05 133.53 55.75 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-O 120.887 0.375 . . . . 0.0 111.221 -177.109 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 62.7 tttm -136.19 105.42 6.0 Favored 'General case' 0 C--N 1.313 -0.986 0 CA-C-N 115.676 -0.693 . . . . 0.0 109.767 176.401 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -100.66 131.16 10.47 Favored Glycine 0 N--CA 1.439 -1.153 0 N-CA-C 110.696 -0.962 . . . . 0.0 110.696 178.917 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 28.5 m -122.24 130.53 53.26 Favored 'General case' 0 C--N 1.312 -1.039 0 N-CA-C 110.007 -0.368 . . . . 0.0 110.007 -179.139 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 132' ' ' LEU . . . . . 0.404 HD23 ' CZ ' ' A' ' 4' ' ' TYR . 3.3 tm? -67.11 135.21 53.25 Favored 'General case' 0 C--O 1.236 0.373 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.231 -178.022 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 26.6 m . . . . . 0 N--CA 1.435 -1.185 0 CA-C-O 118.18 -0.914 . . . . 0.0 109.569 -179.372 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.784 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -147.14 123.2 10.77 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 -177.783 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . 0.417 ' CD1' ' HB ' ' A' ' 25' ' ' ILE . 59.2 m-85 -118.24 141.41 48.54 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 112.351 0.5 . . . . 0.0 112.351 -178.134 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 49.3 m-80 -88.68 139.07 30.85 Favored 'General case' 0 C--N 1.316 -0.883 0 N-CA-C 107.763 -1.199 . . . . 0.0 107.763 174.858 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.454 HG22 ' CD1' ' A' ' 23' ' ' TRP . 87.3 t -99.38 115.54 40.4 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.02 0 CA-C-O 121.146 0.498 . . . . 0.0 112.323 -175.0 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . 0.449 ' HB2' ' HB3' ' A' ' 129' ' ' LYS . 42.4 mt-10 -113.99 119.53 37.52 Favored 'General case' 0 C--N 1.311 -1.088 0 CA-C-N 115.025 -0.989 . . . . 0.0 108.58 177.329 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 13.6 m120 -119.01 136.48 54.1 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 116.571 -0.286 . . . . 0.0 110.752 -177.504 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 58.9 tt0 -124.09 128.29 49.08 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-O 120.866 0.365 . . . . 0.0 110.839 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 14.6 p90 -141.49 148.02 38.78 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 116.153 -0.476 . . . . 0.0 109.993 177.043 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 100.89 2.1 55.08 Favored Glycine 0 N--CA 1.449 -0.47 0 C-N-CA 120.37 -0.919 . . . . 0.0 112.268 178.889 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 114.56 155.83 11.29 Favored Glycine 0 N--CA 1.441 -0.991 0 C-N-CA 120.903 -0.665 . . . . 0.0 112.442 179.543 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 7.6 t -59.1 -20.13 50.69 Favored 'General case' 0 CA--C 1.539 0.54 0 C-N-CA 122.746 0.418 . . . . 0.0 111.616 179.008 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 10.2 m -77.78 -10.01 59.32 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.765 0.317 . . . . 0.0 111.027 179.748 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -89.97 152.09 45.96 Favored Pre-proline 0 C--N 1.325 -0.494 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 179.467 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 78.9 Cg_endo -73.69 161.19 42.43 Favored 'Trans proline' 0 C--O 1.237 0.429 0 C-N-CA 122.625 2.217 . . . . 0.0 112.917 179.765 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 82.7 m95 -85.94 134.7 33.86 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 115.546 -0.752 . . . . 0.0 109.095 178.419 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 46.9 m-80 -113.54 141.68 46.87 Favored 'General case' 0 C--N 1.32 -0.701 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 -177.596 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 9.2 pt-20 -116.53 122.48 44.81 Favored 'General case' 0 C--N 1.308 -1.221 0 CA-C-O 120.734 0.302 . . . . 0.0 110.455 -178.929 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -137.23 31.64 2.51 Favored Glycine 0 N--CA 1.444 -0.793 0 C-N-CA 119.814 -1.184 . . . . 0.0 113.133 -177.255 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 162.68 179.68 37.41 Favored Glycine 0 N--CA 1.447 -0.58 0 C-N-CA 119.745 -1.217 . . . . 0.0 113.015 179.767 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 4.5 pt20 -136.99 137.03 39.02 Favored 'General case' 0 C--N 1.32 -0.714 0 N-CA-C 109.419 -0.586 . . . . 0.0 109.419 178.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . 0.454 ' CD1' HG22 ' A' ' 6' ' ' VAL . 38.7 m0 -109.31 151.62 26.34 Favored 'General case' 0 CA--C 1.502 -0.873 0 CA-C-O 120.866 0.365 . . . . 0.0 111.23 -178.513 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 79.1 tt0 -108.86 110.88 22.34 Favored 'General case' 0 N--CA 1.44 -0.926 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 177.689 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.417 ' HB ' ' CD1' ' A' ' 4' ' ' TYR . 89.8 mt -127.79 136.5 60.19 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.892 0 CA-C-N 115.395 -0.82 . . . . 0.0 109.803 -176.679 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 90.86 93.44 1.27 Allowed Glycine 0 N--CA 1.444 -0.795 0 C-N-CA 120.67 -0.776 . . . . 0.0 112.499 177.653 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 3.7 p -94.92 10.2 36.37 Favored 'General case' 0 C--N 1.311 -1.084 0 CA-C-O 121.432 0.634 . . . . 0.0 110.38 178.795 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 39.4 mmt180 -124.84 121.05 33.44 Favored 'General case' 0 N--CA 1.445 -0.682 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 -179.88 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 43.6 m -65.95 -38.85 89.67 Favored 'General case' 0 C--N 1.314 -0.948 0 N-CA-C 112.13 0.418 . . . . 0.0 112.13 -178.205 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 75.0 m-20 -75.05 -38.44 61.4 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 112.345 0.498 . . . . 0.0 112.345 -177.047 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . 0.476 ' NE2' ' HA ' ' A' ' 31' ' ' GLN . 9.7 mm-40 -114.49 117.65 31.57 Favored 'General case' 0 CA--C 1.5 -0.942 0 N-CA-C 113.708 1.003 . . . . 0.0 113.708 -176.854 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 4.1 t30 -96.13 160.76 14.27 Favored 'General case' 0 N--CA 1.438 -1.063 0 CA-C-N 114.923 -1.035 . . . . 0.0 108.992 177.017 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 62.5 t -94.06 131.51 40.76 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.491 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.182 -176.744 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 35.5 m -112.46 -11.08 11.96 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.655 0 N-CA-C 112.701 0.63 . . . . 0.0 112.701 178.31 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.467 ' HB1' ' HB ' ' A' ' 52' ' ' THR . . . -152.52 144.94 24.05 Favored 'General case' 0 CA--C 1.508 -0.66 0 C-N-CA 120.015 -0.674 . . . . 0.0 111.59 177.882 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 91.8 mt -143.97 117.74 3.38 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.373 0 N-CA-C 109.618 -0.512 . . . . 0.0 109.618 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' ASN . . . . . 0.532 ' HA ' ' O ' ' A' ' 103' ' ' ILE . 47.5 m-80 -133.63 112.27 11.3 Favored 'General case' 0 C--N 1.311 -1.078 0 N-CA-C 108.523 -0.918 . . . . 0.0 108.523 175.667 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.464 HG13 ' CD1' ' A' ' 61' ' ' PHE . 22.4 m -148.41 152.02 12.78 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 C-N-CA 120.92 -0.312 . . . . 0.0 111.655 -174.01 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 67.4 tt0 -136.13 142.47 44.24 Favored 'General case' 0 N--CA 1.443 -0.817 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 176.366 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 31.5 p -77.2 147.12 36.61 Favored 'General case' 0 C--N 1.314 -0.935 0 CA-C-O 121.033 0.444 . . . . 0.0 111.641 -177.912 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -94.78 -15.55 45.51 Favored Glycine 0 N--CA 1.451 -0.361 0 N-CA-C 110.512 -1.035 . . . . 0.0 110.512 175.512 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . 0.416 ' C ' ' H ' ' A' ' 44' ' ' GLY . 55.0 m-20 -139.28 -154.69 0.54 Allowed 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 109.257 -0.645 . . . . 0.0 109.257 179.457 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 20.9 m-20 -73.25 38.25 0.09 Allowed 'General case' 0 N--CA 1.476 0.846 0 C-N-CA 122.893 0.477 . . . . 0.0 111.487 -179.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . 0.416 ' H ' ' C ' ' A' ' 42' ' ' ASP . . . 92.74 -6.7 77.22 Favored Glycine 0 C--O 1.217 -0.95 0 C-N-CA 121.173 -0.537 . . . . 0.0 112.66 179.848 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 59.3 mt-30 -63.0 -39.9 96.14 Favored 'General case' 0 C--N 1.326 -0.416 0 N-CA-C 112.137 0.421 . . . . 0.0 112.137 -178.364 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' THR . . . . . 0.5 ' HA ' ' O ' ' A' ' 63' ' ' ALA . 5.2 t -128.18 115.4 18.32 Favored 'General case' 0 C--N 1.311 -1.065 0 CA-C-O 121.187 0.518 . . . . 0.0 110.801 177.812 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' LEU . . . . . 0.431 ' O ' ' HA ' ' A' ' 62' ' ' ARG . 79.5 mt -99.53 130.42 45.77 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.855 -0.612 . . . . 0.0 109.595 178.442 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 49.2 m-80 -130.11 143.17 50.64 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 116.488 -0.324 . . . . 0.0 110.469 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . 0.403 ' HA3' ' HA ' ' A' ' 38' ' ' VAL . . . 171.08 -150.79 14.32 Favored Glycine 0 N--CA 1.44 -1.086 0 C-N-CA 120.084 -1.055 . . . . 0.0 113.262 179.978 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 25.1 m -125.99 131.48 52.23 Favored 'General case' 0 C--N 1.317 -0.838 0 C-N-CA 122.965 0.506 . . . . 0.0 110.19 -177.199 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' MET . . . . . 0.447 ' SD ' ' HH2' ' A' ' 90' ' ' TRP . 62.5 ttp -125.53 150.27 47.57 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 -179.834 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.467 ' HB ' ' HB1' ' A' ' 35' ' ' ALA . 27.7 m -126.98 130.74 50.64 Favored 'General case' 0 C--O 1.243 0.723 0 CA-C-O 120.735 0.302 . . . . 0.0 111.316 -178.81 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . 0.421 ' HB3' ' OE1' ' A' ' 31' ' ' GLN . 47.0 m-85 -90.61 162.2 15.08 Favored 'General case' 0 C--O 1.233 0.218 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.323 177.247 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -60.42 107.84 0.73 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.799 -0.637 . . . . 0.0 112.634 -178.072 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 88.33 -0.27 83.26 Favored Glycine 0 N--CA 1.454 -0.138 0 CA-C-N 115.796 -0.638 . . . . 0.0 112.854 178.05 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 73.2 mm-40 -108.21 179.22 4.27 Favored 'General case' 0 C--N 1.314 -0.937 0 CA-C-O 120.705 0.288 . . . . 0.0 110.6 -178.744 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -97.71 176.71 31.25 Favored Glycine 0 N--CA 1.439 -1.144 0 C-N-CA 120.678 -0.773 . . . . 0.0 111.452 178.512 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo -67.13 139.5 50.81 Favored 'Trans proline' 0 CA--C 1.535 0.539 0 C-N-CA 122.501 2.134 . . . . 0.0 112.277 179.507 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 48.3 pt -133.01 166.73 28.56 Favored 'Isoleucine or valine' 0 C--O 1.24 0.554 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.137 178.243 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -75.22 138.59 23.66 Favored Glycine 0 CA--C 1.521 0.464 0 C-N-CA 120.724 -0.751 . . . . 0.0 111.957 -179.541 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.464 ' CD1' HG13 ' A' ' 38' ' ' VAL . 50.2 t80 -124.52 129.84 51.35 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 120.519 0.2 . . . . 0.0 110.916 -178.982 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . 0.431 ' HA ' ' O ' ' A' ' 47' ' ' LEU . 62.7 ttp85 -140.67 134.65 30.69 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.22 176.048 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.5 ' O ' ' HA ' ' A' ' 46' ' ' THR . . . -135.08 142.86 46.38 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.567 -0.288 . . . . 0.0 111.304 179.794 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 49.6 m -122.05 131.48 54.01 Favored 'General case' 0 CA--C 1.546 0.803 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.695 -179.608 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . 0.533 HD12 ' O ' ' A' ' 68' ' ' ASN . 55.9 tp -71.03 126.19 28.91 Favored 'General case' 0 CA--C 1.535 0.391 0 N-CA-C 113.1 0.778 . . . . 0.0 113.1 -176.9 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -73.4 -35.19 65.84 Favored 'General case' 0 N--CA 1.473 0.692 0 CA-C-N 115.204 -0.907 . . . . 0.0 111.751 176.349 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 133.05 2.67 3.73 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 111.052 -0.819 . . . . 0.0 111.052 -175.828 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' ASN . . . . . 0.533 ' O ' HD12 ' A' ' 65' ' ' LEU . 31.5 p-10 -131.41 -150.67 0.43 Allowed 'General case' 0 C--N 1.31 -1.147 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.42 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 85.6 m-20 -90.09 4.21 51.01 Favored 'General case' 0 C--N 1.323 -0.545 0 C-N-CA 120.407 -0.517 . . . . 0.0 110.33 179.58 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 24.0 m -101.27 144.56 29.98 Favored 'General case' 0 N--CA 1.448 -0.572 0 CA-C-O 121.362 0.601 . . . . 0.0 111.232 -178.833 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.41 ' HB3' ' HB2' ' A' ' 63' ' ' ALA . 96.3 m-85 -124.33 145.54 49.36 Favored 'General case' 0 C--N 1.312 -1.042 0 CA-C-N 115.463 -0.789 . . . . 0.0 110.617 179.557 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . 0.4 ' O ' ' HA ' ' A' ' 63' ' ' ALA . 79.5 tt0 -86.24 112.82 21.73 Favored 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 107.371 -1.344 . . . . 0.0 107.371 174.565 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 75.4 t -97.77 129.68 47.58 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.103 0 CA-C-O 121.4 0.619 . . . . 0.0 112.064 -175.311 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 45.8 mt-10 -128.05 124.76 37.87 Favored 'General case' 0 N--CA 1.438 -1.049 0 CA-C-N 114.891 -1.05 . . . . 0.0 108.748 177.474 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 14.7 m120 -104.04 147.74 27.04 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-O 121.057 0.456 . . . . 0.0 111.286 -177.478 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' GLN . . . . . 0.527 ' HB2' ' CE3' ' A' ' 84' ' ' TRP . 61.6 tt0 -115.1 119.61 37.02 Favored 'General case' 0 C--N 1.31 -1.11 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.672 -179.68 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 14.9 p90 -138.81 152.85 48.22 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 116.478 -0.328 . . . . 0.0 110.458 177.806 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 147.04 -122.64 1.62 Allowed Glycine 0 N--CA 1.444 -0.825 0 N-CA-C 110.119 -1.192 . . . . 0.0 110.119 -177.295 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . 0.528 ' O ' ' HB2' ' A' ' 80' ' ' ASP . . . -119.31 23.18 8.64 Favored Glycine 0 N--CA 1.444 -0.785 0 C-N-CA 120.291 -0.956 . . . . 0.0 111.115 178.228 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . 0.528 ' HB2' ' O ' ' A' ' 79' ' ' GLY . 12.8 m-20 92.24 -43.47 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.836 0 C-N-CA 124.96 1.304 . . . . 0.0 110.587 178.348 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 34.5 m -76.78 -2.46 33.26 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 121.312 0.577 . . . . 0.0 110.7 175.901 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -66.62 157.39 83.27 Favored Pre-proline 0 C--N 1.324 -0.519 0 CA-C-N 115.353 -0.84 . . . . 0.0 112.029 -178.447 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 75.6 Cg_endo -77.9 -172.86 1.6 Allowed 'Trans proline' 0 CA--C 1.537 0.644 0 C-N-CA 122.752 2.301 . . . . 0.0 112.453 179.102 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' TRP . . . . . 0.527 ' CE3' ' HB2' ' A' ' 76' ' ' GLN . 95.1 m95 -98.13 147.5 24.5 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.822 -178.564 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 94.4 m-70 -128.74 146.38 50.91 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.061 -0.518 . . . . 0.0 109.964 -179.662 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 28.8 p -65.21 136.56 56.78 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-O 121.04 0.448 . . . . 0.0 111.421 -178.735 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -108.27 -52.18 0.69 Allowed Glycine 0 N--CA 1.437 -1.269 0 C-N-CA 120.745 -0.74 . . . . 0.0 111.55 177.968 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 151.45 -166.72 30.74 Favored Glycine 0 CA--C 1.52 0.345 0 C-N-CA 120.918 -0.658 . . . . 0.0 112.045 -179.778 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 19.3 m120 -112.43 119.21 37.46 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 117.014 0.407 . . . . 0.0 110.195 -179.862 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' TRP . . . . . 0.447 ' HH2' ' SD ' ' A' ' 51' ' ' MET . 29.3 m0 -117.12 154.02 31.77 Favored 'General case' 0 N--CA 1.47 0.564 0 CA-C-N 116.467 -0.333 . . . . 0.0 111.123 -177.129 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 89.0 mt -108.6 119.19 57.73 Favored 'Isoleucine or valine' 0 C--O 1.242 0.707 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 176.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 86.7 mt -132.05 83.3 2.07 Favored 'General case' 0 C--O 1.267 1.981 0 N-CA-C 113.127 0.788 . . . . 0.0 113.127 -174.602 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 164.16 116.58 0.37 Allowed Glycine 0 C--O 1.225 -0.439 0 CA-C-N 115.083 -0.962 . . . . 0.0 111.31 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 75.2 p -90.33 -9.36 48.05 Favored 'General case' 0 N--CA 1.463 0.191 0 CA-C-N 117.217 0.509 . . . . 0.0 111.502 -179.58 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -100.38 145.6 27.99 Favored 'General case' 0 N--CA 1.444 -0.763 0 CA-C-O 120.981 0.419 . . . . 0.0 110.872 179.606 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -68.74 -36.77 78.8 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 115.653 -0.703 . . . . 0.0 112.738 -173.463 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 30.5 p-10 -121.6 28.97 7.41 Favored 'General case' 0 C--N 1.313 -1.009 0 CA-C-O 120.715 0.293 . . . . 0.0 111.513 -176.627 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' GLN . . . . . 0.547 ' NE2' ' HB2' ' A' ' 123' ' ' GLU . 53.9 tt0 -157.2 124.44 5.21 Favored 'General case' 0 C--N 1.319 -0.725 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 -177.299 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 96.9 m-20 -113.52 177.66 4.56 Favored 'General case' 0 C--O 1.245 0.819 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.674 -175.355 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . 0.447 HG12 ' CH2' ' A' ' 23' ' ' TRP . 21.2 m -80.41 141.06 15.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.75 -0.659 . . . . 0.0 112.193 -177.656 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 28.7 m -120.95 -26.45 2.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.726 176.425 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . 0.487 ' HB1' ' HB ' ' A' ' 119' ' ' THR . . . -147.26 138.56 23.89 Favored 'General case' 0 C--N 1.324 -0.512 0 C-N-CA 120.872 -0.331 . . . . 0.0 110.65 177.404 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.532 ' O ' ' HA ' ' A' ' 37' ' ' ASN . 87.7 mt -132.23 127.03 56.9 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.029 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 178.822 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 9.6 t30 -128.04 91.06 3.2 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.13 178.414 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 22.3 m -145.06 153.26 14.33 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.615 0 N-CA-C 113.895 1.072 . . . . 0.0 113.895 -176.453 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 91.4 mt-10 -138.95 163.1 33.22 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 114.223 -1.353 . . . . 0.0 108.132 173.896 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 32.7 t -108.2 -51.02 2.95 Favored 'General case' 0 C--N 1.311 -1.1 0 CA-C-O 120.797 0.332 . . . . 0.0 110.893 -179.616 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 84.66 -14.79 45.35 Favored Glycine 0 N--CA 1.446 -0.66 0 N-CA-C 111.101 -0.8 . . . . 0.0 111.101 -176.768 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . 0.457 ' HB3' ' H ' ' A' ' 110' ' ' ASP . 54.2 m-20 -117.25 -151.29 0.48 Allowed 'General case' 0 N--CA 1.45 -0.432 0 C-N-CA 123.074 0.55 . . . . 0.0 109.999 -179.414 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 110' ' ' ASP . . . . . 0.457 ' H ' ' HB3' ' A' ' 109' ' ' ASP . 12.5 p-10 -88.55 16.43 6.59 Favored 'General case' 0 C--N 1.322 -0.618 0 C-N-CA 122.628 0.371 . . . . 0.0 111.18 -178.881 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 96.29 9.68 56.63 Favored Glycine 0 N--CA 1.444 -0.828 0 C-N-CA 120.086 -1.054 . . . . 0.0 113.045 -178.339 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 112' ' ' GLN . . . . . 0.4 ' HA ' ' CD1' ' A' ' 132' ' ' LEU . 28.1 tt0 -64.3 -45.4 88.12 Favored 'General case' 0 C--O 1.239 0.521 0 CA-C-O 120.833 0.349 . . . . 0.0 111.235 179.934 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 113' ' ' THR . . . . . 0.494 ' HA ' ' O ' ' A' ' 130' ' ' GLY . 21.0 p -132.73 130.38 39.92 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.289 -179.831 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 114' ' ' LEU . . . . . 0.484 ' O ' ' HA ' ' A' ' 129' ' ' LYS . 4.3 mm? -105.86 130.5 53.81 Favored 'General case' 0 C--N 1.319 -0.739 0 N-CA-C 108.49 -0.93 . . . . 0.0 108.49 176.599 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 27.7 p30 -135.1 152.25 51.47 Favored 'General case' 0 C--N 1.316 -0.861 0 C-N-CA 120.191 -0.603 . . . . 0.0 112.274 -179.152 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 152.28 -129.38 2.77 Favored Glycine 0 N--CA 1.441 -1.025 0 CA-C-N 115.461 -0.79 . . . . 0.0 112.337 178.244 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 21.4 p -131.72 156.13 46.45 Favored 'General case' 0 C--N 1.316 -0.879 0 CA-C-O 121.012 0.434 . . . . 0.0 111.02 -178.163 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 118' ' ' MET . . . . . 0.553 ' HE3' ' CE2' ' A' ' 120' ' ' TYR . 19.5 ptm -140.64 149.74 42.67 Favored 'General case' 0 C--N 1.314 -0.963 0 CA-C-N 116.062 -0.517 . . . . 0.0 109.968 -178.6 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 119' ' ' THR . . . . . 0.487 ' HB ' ' HB1' ' A' ' 102' ' ' ALA . 23.3 m -131.23 129.46 41.64 Favored 'General case' 0 C--N 1.313 -1.016 0 CA-C-O 120.804 0.335 . . . . 0.0 111.019 -179.696 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . 0.553 ' CE2' ' HE3' ' A' ' 118' ' ' MET . 45.0 m-85 -101.47 161.18 13.82 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.947 178.66 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -59.84 121.83 12.72 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.094 179.779 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 66.03 24.26 71.62 Favored Glycine 0 C--N 1.336 0.536 0 C-N-CA 121.117 -0.564 . . . . 0.0 112.336 -179.214 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . 0.547 ' HB2' ' NE2' ' A' ' 98' ' ' GLN . 32.5 tp10 -127.95 164.87 21.37 Favored 'General case' 0 C--N 1.318 -0.78 0 N-CA-C 109.622 -0.51 . . . . 0.0 109.622 -177.083 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -93.49 159.66 24.18 Favored Glycine 0 N--CA 1.443 -0.837 0 N-CA-C 110.803 -0.919 . . . . 0.0 110.803 177.318 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . 0.403 ' HA ' ' O ' ' A' ' 118' ' ' MET . 37.8 Cg_endo -66.2 136.15 42.91 Favored 'Trans proline' 0 CA--C 1.53 0.286 0 C-N-CA 122.16 1.907 . . . . 0.0 112.233 179.67 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 41.7 pt -132.65 166.4 29.41 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.004 178.929 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -70.02 134.73 25.53 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.912 -0.661 . . . . 0.0 112.197 -179.7 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . 0.53 ' HB2' ' SD ' ' A' ' 118' ' ' MET . 25.4 t80 -124.84 134.75 52.61 Favored 'General case' 0 CA--C 1.513 -0.443 0 CA-C-O 121.173 0.511 . . . . 0.0 111.443 -179.45 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 129' ' ' LYS . . . . . 0.484 ' HA ' ' O ' ' A' ' 114' ' ' LEU . 62.3 tttm -140.86 123.64 16.21 Favored 'General case' 0 N--CA 1.435 -1.196 0 CA-C-N 115.073 -0.967 . . . . 0.0 109.494 178.591 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . 0.494 ' O ' ' HA ' ' A' ' 113' ' ' THR . . . -117.32 131.61 9.51 Favored Glycine 0 N--CA 1.444 -0.809 0 N-CA-C 110.973 -0.851 . . . . 0.0 110.973 178.948 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 32.1 m -125.32 133.88 52.44 Favored 'General case' 0 C--N 1.314 -0.973 0 CA-C-N 117.015 0.408 . . . . 0.0 110.709 -177.249 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 132' ' ' LEU . . . . . 0.4 ' CD1' ' HA ' ' A' ' 112' ' ' GLN . 78.3 mt -62.37 135.14 57.31 Favored 'General case' 0 C--O 1.238 0.473 0 CA-C-O 120.741 0.305 . . . . 0.0 110.779 177.283 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 8.6 t . . . . . 0 C--O 1.249 1.051 0 CA-C-O 118.368 -0.825 . . . . 0.0 110.34 178.391 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.468 0.474 0 N-CA-C 110.028 -0.36 . . . . 0.0 110.028 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' LEU . . . . . 0.597 HD11 HE21 ' A' ' 22' ' ' GLN . 1.4 tm? -97.42 132.41 43.15 Favored 'General case' 0 C--N 1.316 -0.85 0 N-CA-C 109.584 -0.525 . . . . 0.0 109.584 -177.817 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . 0.537 ' N ' HD12 ' A' ' 3' ' ' LEU . 89.8 m-85 -122.91 147.74 46.24 Favored 'General case' 0 C--O 1.236 0.351 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.649 -177.96 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' ASN . . . . . 0.536 ' O ' ' HA2' ' A' ' 130' ' ' GLY . 18.7 m120 -94.73 134.5 37.26 Favored 'General case' 0 CA--C 1.506 -0.715 0 N-CA-C 106.34 -1.726 . . . . 0.0 106.34 174.792 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 59.3 t -118.2 126.84 75.28 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.891 0 C-N-CA 119.492 -0.883 . . . . 0.0 113.031 -175.443 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . 0.521 ' HA ' ' HA ' ' A' ' 19' ' ' GLU . 98.4 mt-10 -115.06 139.72 49.64 Favored 'General case' 0 N--CA 1.439 -1.012 0 CA-C-N 114.477 -1.238 . . . . 0.0 108.792 176.326 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 12.1 m120 -119.35 144.05 47.07 Favored 'General case' 0 C--N 1.313 -1.013 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.309 -177.045 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 60.4 tt0 -121.68 114.89 21.78 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 174.605 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 45.8 p90 -129.16 139.08 52.06 Favored 'General case' 0 C--N 1.317 -0.832 0 C-N-CA 121.028 -0.269 . . . . 0.0 110.913 -178.309 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 102.09 11.77 35.92 Favored Glycine 0 N--CA 1.444 -0.783 0 C-N-CA 120.363 -0.922 . . . . 0.0 112.582 178.616 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 99.7 167.37 29.66 Favored Glycine 0 N--CA 1.444 -0.816 0 C-N-CA 120.446 -0.883 . . . . 0.0 113.28 -179.43 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 15.6 m -56.2 -25.61 47.76 Favored 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 123.158 0.583 . . . . 0.0 112.227 179.474 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 14.1 p -61.23 -21.04 63.49 Favored 'General case' 0 CA--C 1.542 0.671 0 N-CA-C 112.25 0.463 . . . . 0.0 112.25 177.268 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -90.84 142.93 28.05 Favored Pre-proline 0 C--N 1.321 -0.66 0 CA-C-O 120.541 0.21 . . . . 0.0 110.733 179.7 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 95.3 Cg_endo -78.37 170.51 18.36 Favored 'Trans proline' 0 C--O 1.238 0.518 0 C-N-CA 122.803 2.335 . . . . 0.0 112.241 179.692 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 96.4 m95 -86.97 124.88 33.65 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.118 -0.492 . . . . 0.0 109.905 -179.77 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 47.8 m-80 -123.26 126.19 46.46 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.991 -178.87 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.521 ' HA ' ' HA ' ' A' ' 7' ' ' GLU . 15.3 pt-20 -68.94 133.51 48.29 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 109.65 -0.5 . . . . 0.0 109.65 177.631 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -134.31 22.78 3.72 Favored Glycine 0 N--CA 1.443 -0.858 0 C-N-CA 119.566 -1.302 . . . . 0.0 112.876 -179.308 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . 0.505 ' HA3' ' HB2' ' A' ' 94' ' ' SER . . . 145.07 -170.9 26.38 Favored Glycine 0 N--CA 1.449 -0.472 0 C-N-CA 120.17 -1.014 . . . . 0.0 113.293 177.352 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . 0.597 HE21 HD11 ' A' ' 3' ' ' LEU . 4.3 pt20 -131.73 136.05 47.3 Favored 'General case' 0 C--N 1.324 -0.514 0 C-N-CA 122.604 0.362 . . . . 0.0 110.634 -178.337 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . 0.459 ' CH2' HG22 ' A' ' 100' ' ' VAL . 26.2 m0 -110.76 165.88 11.47 Favored 'General case' 0 N--CA 1.469 0.491 0 CA-C-O 120.668 0.27 . . . . 0.0 110.482 179.01 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 40.1 tt0 -128.87 116.56 19.62 Favored 'General case' 0 C--N 1.32 -0.68 0 C-N-CA 120.46 -0.496 . . . . 0.0 110.166 175.827 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.481 ' HB ' ' CE1' ' A' ' 4' ' ' TYR . 98.7 mt -130.18 137.49 56.26 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.764 0 CA-C-N 115.5 -0.773 . . . . 0.0 110.196 -177.567 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 93.37 102.32 1.59 Allowed Glycine 0 N--CA 1.446 -0.683 0 C-N-CA 120.775 -0.726 . . . . 0.0 111.892 179.451 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 4.2 p -101.57 12.17 37.71 Favored 'General case' 0 C--N 1.312 -1.036 0 CA-C-O 121.01 0.433 . . . . 0.0 111.293 -178.832 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 62.6 mtt-85 -130.64 130.32 43.79 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.053 -178.932 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 15.6 m -66.78 -36.64 82.87 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.094 0.473 . . . . 0.0 112.052 -179.145 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 64.8 m-20 -73.93 -43.24 58.96 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.965 -0.562 . . . . 0.0 112.387 -175.505 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 8.7 mm-40 -121.41 122.12 39.08 Favored 'General case' 0 CA--C 1.506 -0.727 0 N-CA-C 113.106 0.78 . . . . 0.0 113.106 -176.42 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . 0.423 ' ND2' ' HA3' ' A' ' 111' ' ' GLY . 62.3 t30 -104.39 172.72 6.64 Favored 'General case' 0 N--CA 1.442 -0.837 0 CA-C-N 114.893 -1.049 . . . . 0.0 109.499 178.201 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 59.0 t -106.86 133.68 50.73 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.164 0 N-CA-C 112.287 0.477 . . . . 0.0 112.287 -174.803 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 29.3 m -113.73 -18.0 7.9 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.609 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.947 178.01 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.533 ' HB2' ' HB ' ' A' ' 52' ' ' THR . . . -144.99 145.27 31.44 Favored 'General case' 0 CA--C 1.513 -0.459 0 C-N-CA 119.968 -0.693 . . . . 0.0 111.464 178.928 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 86.8 mt -144.67 126.71 9.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 -178.916 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' ASN . . . . . 0.497 ' HA ' ' O ' ' A' ' 103' ' ' ILE . 31.3 m-80 -136.64 109.12 7.39 Favored 'General case' 0 C--N 1.312 -1.038 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 176.888 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.454 HG11 ' CD1' ' A' ' 61' ' ' PHE . 25.3 m -151.07 157.59 5.38 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 C-N-CA 120.917 -0.313 . . . . 0.0 111.165 -172.833 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -142.71 150.71 40.48 Favored 'General case' 0 N--CA 1.447 -0.596 0 CA-C-N 115.8 -0.636 . . . . 0.0 109.925 177.253 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' SER . . . . . 0.445 ' OG ' ' HB ' ' A' ' 101' ' ' VAL . 35.1 p -79.97 153.59 28.8 Favored 'General case' 0 C--N 1.318 -0.79 0 N-CA-C 112.477 0.547 . . . . 0.0 112.477 -177.682 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -115.45 -68.31 0.44 Allowed Glycine 0 N--CA 1.434 -1.474 0 CA-C-N 115.114 -0.948 . . . . 0.0 110.848 175.151 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 22.5 m-20 -89.95 81.57 6.26 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 112.154 0.427 . . . . 0.0 112.154 -179.001 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 84.5 m-20 51.22 31.53 6.96 Favored 'General case' 0 N--CA 1.491 1.576 0 N-CA-C 113.424 0.898 . . . . 0.0 113.424 174.791 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 88.84 -14.58 59.87 Favored Glycine 0 C--O 1.223 -0.57 0 C-N-CA 120.116 -1.04 . . . . 0.0 113.139 179.229 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 61.3 mt-30 -70.11 -30.44 67.65 Favored 'General case' 0 CA--C 1.512 -0.503 0 CA-C-O 121.193 0.521 . . . . 0.0 110.749 178.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 31.9 m -119.37 130.61 55.42 Favored 'General case' 0 N--CA 1.434 -1.247 0 CA-C-N 115.476 -0.783 . . . . 0.0 108.9 -179.641 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 84.6 mt -124.81 133.96 52.93 Favored 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 108.892 -0.781 . . . . 0.0 108.892 -179.063 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 28.1 p30 -136.8 148.77 47.37 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-O 121.122 0.487 . . . . 0.0 111.146 178.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 164.28 -145.04 9.94 Favored Glycine 0 N--CA 1.445 -0.758 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.16 177.68 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' THR . . . . . 0.518 ' HA ' ' O ' ' A' ' 59' ' ' ILE . 19.6 p -129.56 141.81 50.89 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 120.904 0.383 . . . . 0.0 110.975 179.925 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' MET . . . . . 0.448 ' HE3' ' CZ ' ' A' ' 53' ' ' TYR . 15.6 tmm? -131.92 149.01 52.56 Favored 'General case' 0 C--N 1.317 -0.839 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 179.291 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.533 ' HB ' ' HB2' ' A' ' 35' ' ' ALA . 61.7 m -124.56 126.15 45.35 Favored 'General case' 0 C--O 1.252 1.197 0 N-CA-C 112.266 0.469 . . . . 0.0 112.266 -176.61 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . 0.448 ' CZ ' ' HE3' ' A' ' 51' ' ' MET . 59.8 m-85 -82.68 161.13 22.24 Favored 'General case' 0 C--O 1.236 0.353 0 CA-C-N 115.407 -0.815 . . . . 0.0 111.096 176.521 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -63.76 113.63 3.51 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.914 179.269 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 90.72 7.86 66.09 Favored Glycine 0 N--CA 1.443 -0.859 0 C-N-CA 120.877 -0.678 . . . . 0.0 112.62 179.556 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 81.2 mm-40 -126.72 -172.61 2.68 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.767 0.317 . . . . 0.0 111.447 179.479 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -111.92 -171.56 18.86 Favored Glycine 0 N--CA 1.443 -0.86 0 N-CA-C 111.409 -0.677 . . . . 0.0 111.409 178.615 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 96.1 Cg_endo -76.01 140.06 22.39 Favored 'Trans proline' 0 C--O 1.241 0.651 0 C-N-CA 122.488 2.126 . . . . 0.0 113.431 -178.853 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . 0.518 ' O ' ' HA ' ' A' ' 50' ' ' THR . 43.6 pt -132.17 173.12 15.24 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 CA-C-N 115.36 -0.836 . . . . 0.0 109.243 175.625 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -75.35 139.72 25.25 Favored Glycine 0 C--N 1.317 -0.502 0 N-CA-C 111.44 -0.664 . . . . 0.0 111.44 -177.725 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.454 ' CD1' HG11 ' A' ' 38' ' ' VAL . 49.2 t80 -128.34 128.43 44.55 Favored 'General case' 0 C--N 1.312 -1.049 0 CA-C-O 120.511 0.196 . . . . 0.0 110.964 -177.277 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 70.1 ttp85 -136.21 131.13 34.17 Favored 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 175.104 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.422 ' HB1' ' HB3' ' A' ' 71' ' ' TYR . . . -135.4 147.58 49.06 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-O 120.782 0.325 . . . . 0.0 111.3 -178.766 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 83.5 m -126.75 132.44 51.08 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.938 -0.573 . . . . 0.0 110.552 178.895 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 61.4 tp -71.97 123.87 23.68 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.093 0.473 . . . . 0.0 111.854 -178.255 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -66.58 -36.66 83.17 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.896 176.665 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 137.62 -6.69 3.57 Favored Glycine 0 CA--C 1.523 0.591 0 C-N-CA 120.298 -0.953 . . . . 0.0 113.011 -177.519 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 58.3 m-80 -144.14 61.35 1.35 Allowed 'General case' 0 N--CA 1.476 0.838 0 N-CA-C 111.879 0.325 . . . . 0.0 111.879 -178.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 90.6 m-20 59.65 5.73 0.73 Allowed 'General case' 0 N--CA 1.487 1.397 0 C-N-CA 123.169 0.587 . . . . 0.0 112.13 179.161 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 9.3 m -99.13 133.83 42.85 Favored 'General case' 0 N--CA 1.44 -0.965 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 179.193 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.43 ' OH ' ' HB3' ' A' ' 99' ' ' ASN . 65.6 m-85 -122.4 136.09 54.83 Favored 'General case' 0 C--N 1.307 -1.259 0 CA-C-O 120.83 0.348 . . . . 0.0 111.546 -178.373 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 43.1 tt0 -90.57 120.35 31.58 Favored 'General case' 0 C--N 1.316 -0.855 0 N-CA-C 107.743 -1.206 . . . . 0.0 107.743 174.785 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 77.5 t -104.85 133.29 49.44 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.201 0 N-CA-C 113.091 0.774 . . . . 0.0 113.091 -173.621 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.436 ' HG2' ' HA ' ' A' ' 86' ' ' SER . 49.7 mt-10 -127.58 126.21 41.69 Favored 'General case' 0 N--CA 1.445 -0.711 0 CA-C-N 114.482 -1.235 . . . . 0.0 108.103 174.631 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 94.7 m-20 -103.9 144.04 32.04 Favored 'General case' 0 C--O 1.241 0.622 0 CA-C-O 121.256 0.55 . . . . 0.0 111.689 -176.541 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' GLN . . . . . 0.557 ' HB2' ' CE3' ' A' ' 84' ' ' TRP . 55.6 tt0 -118.29 122.95 44.19 Favored 'General case' 0 C--N 1.309 -1.161 0 CA-C-N 115.449 -0.796 . . . . 0.0 109.482 -178.247 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 8.1 p90 -110.55 97.04 6.57 Favored 'General case' 0 C--N 1.311 -1.083 0 C-N-CA 119.378 -0.929 . . . . 0.0 110.994 176.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 156.86 -153.51 24.76 Favored Glycine 0 N--CA 1.433 -1.563 0 N-CA-C 108.339 -1.905 . . . . 0.0 108.339 -177.378 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -84.93 -148.99 10.32 Favored Glycine 0 N--CA 1.442 -0.908 0 C-N-CA 119.926 -1.13 . . . . 0.0 111.248 175.858 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 65.3 m-20 -88.77 -6.31 57.49 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 117.207 0.504 . . . . 0.0 110.894 -178.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 24.1 t -98.13 -4.8 34.94 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.152 -178.002 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -76.49 149.91 81.78 Favored Pre-proline 0 C--N 1.323 -0.56 0 CA-C-N 116.496 -0.32 . . . . 0.0 110.868 -178.399 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -68.23 158.4 57.66 Favored 'Trans proline' 0 C--O 1.238 0.479 0 C-N-CA 122.351 2.034 . . . . 0.0 111.793 178.491 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' TRP . . . . . 0.557 ' CE3' ' HB2' ' A' ' 76' ' ' GLN . 96.0 m95 -94.8 138.69 32.28 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.337 -178.608 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 74.7 m-70 -119.16 146.62 45.0 Favored 'General case' 0 C--N 1.32 -0.712 0 N-CA-C 109.549 -0.538 . . . . 0.0 109.549 179.845 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' SER . . . . . 0.436 ' HA ' ' HG2' ' A' ' 74' ' ' GLU . 10.8 p -71.08 139.99 50.55 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 121.192 0.52 . . . . 0.0 112.229 -176.756 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -115.41 -45.69 0.61 Allowed Glycine 0 N--CA 1.44 -1.099 0 C-N-CA 120.993 -0.622 . . . . 0.0 112.342 178.718 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 147.65 -162.28 28.67 Favored Glycine 0 C--O 1.225 -0.411 0 C-N-CA 120.279 -0.962 . . . . 0.0 112.655 179.445 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 17.9 m120 -115.11 124.55 51.83 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.842 0.321 . . . . 0.0 110.497 179.849 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 34.2 m0 -118.89 153.59 34.31 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.614 -178.581 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 46.9 mm -106.76 114.33 45.61 Favored 'Isoleucine or valine' 0 C--O 1.244 0.776 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 178.388 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 78.5 mt -128.07 77.72 1.78 Allowed 'General case' 0 C--O 1.256 1.445 0 CA-C-O 121.539 0.685 . . . . 0.0 111.559 -177.007 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 166.23 93.79 0.09 OUTLIER Glycine 0 N--CA 1.446 -0.689 0 CA-C-N 115.762 -0.654 . . . . 0.0 111.695 -179.649 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' SER . . . . . 0.505 ' HB2' ' HA3' ' A' ' 21' ' ' GLY . 43.8 p -92.28 -12.42 32.57 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-O 120.838 0.351 . . . . 0.0 111.816 -178.516 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 91.6 mtt180 -88.69 15.84 7.6 Favored 'General case' 0 C--N 1.317 -0.821 0 N-CA-C 114.141 1.163 . . . . 0.0 114.141 -176.339 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 77.9 tt0 69.44 -81.67 0.03 OUTLIER 'General case' 0 N--CA 1.472 0.671 0 N-CA-C 113.298 0.851 . . . . 0.0 113.298 172.86 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 61.6 m-80 -92.73 24.19 3.72 Favored 'General case' 0 N--CA 1.473 0.681 0 CA-C-O 121.006 0.432 . . . . 0.0 110.995 -176.429 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' GLN . . . . . 0.409 ' HG2' ' HB3' ' A' ' 120' ' ' TYR . 54.8 tt0 -145.51 116.3 7.73 Favored 'General case' 0 C--N 1.312 -1.022 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 -177.298 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' ASN . . . . . 0.43 ' HB3' ' OH ' ' A' ' 71' ' ' TYR . 50.3 m-80 -89.23 158.93 17.68 Favored 'General case' 0 C--O 1.248 0.983 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.731 -177.512 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . 0.459 HG22 ' CH2' ' A' ' 23' ' ' TRP . 98.0 t -80.57 130.04 36.56 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.206 0 C-N-CA 120.536 -0.466 . . . . 0.0 110.724 177.892 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . 0.445 ' HB ' ' OG ' ' A' ' 40' ' ' SER . 34.8 m -110.27 -17.15 8.5 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.59 0 N-CA-C 112.439 0.533 . . . . 0.0 112.439 -178.686 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . 0.472 ' HB2' ' HB ' ' A' ' 119' ' ' THR . . . -155.57 145.11 21.12 Favored 'General case' 0 CA--C 1.509 -0.61 0 C-N-CA 120.16 -0.616 . . . . 0.0 111.261 176.9 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.497 ' O ' ' HA ' ' A' ' 37' ' ' ASN . 83.0 mt -135.19 125.26 43.88 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 N-CA-C 110.102 -0.333 . . . . 0.0 110.102 179.457 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . 0.458 ' HB3' ' OG1' ' A' ' 117' ' ' THR . 7.5 t30 -127.8 94.18 3.88 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.872 -0.604 . . . . 0.0 109.829 175.91 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 30.0 m -137.86 138.67 43.8 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.661 0 N-CA-C 113.119 0.785 . . . . 0.0 113.119 -176.343 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -142.71 96.85 3.0 Favored 'General case' 0 CA--C 1.543 0.686 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.781 176.847 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 107' ' ' SER . . . . . 0.467 ' HB2' ' H ' ' A' ' 115' ' ' ASN . 58.9 m -167.14 166.15 15.16 Favored 'General case' 0 N--CA 1.484 1.264 0 CA-C-N 115.204 -0.907 . . . . 0.0 113.38 -177.963 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 107.07 127.55 5.79 Favored Glycine 0 N--CA 1.427 -1.965 0 C-N-CA 120.488 -0.863 . . . . 0.0 112.85 175.844 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 7.3 m-20 -77.93 -48.63 15.88 Favored 'General case' 0 C--N 1.317 -0.817 0 N-CA-C 107.063 -1.458 . . . . 0.0 107.063 176.247 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 -125.63 23.3 7.43 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 113.941 -1.481 . . . . 0.0 108.998 177.708 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . 0.423 ' HA3' ' ND2' ' A' ' 32' ' ' ASN . . . 81.83 17.56 69.96 Favored Glycine 0 C--O 1.22 -0.723 0 C-N-CA 120.457 -0.878 . . . . 0.0 111.823 -175.818 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 112' ' ' GLN . . . . . 0.467 ' HA ' ' CD1' ' A' ' 132' ' ' LEU . 98.4 mt-30 -65.59 -43.61 89.18 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.742 0.306 . . . . 0.0 111.656 -179.17 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 34.0 p -131.77 149.51 52.45 Favored 'General case' 0 N--CA 1.441 -0.876 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.4 179.546 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 97.5 mt -128.41 131.17 48.48 Favored 'General case' 0 C--N 1.316 -0.881 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.012 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . 0.467 ' H ' ' HB2' ' A' ' 107' ' ' SER . 54.5 m-80 -136.16 150.29 48.99 Favored 'General case' 0 C--O 1.245 0.841 0 CA-C-O 120.792 0.33 . . . . 0.0 110.667 -178.802 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 157.51 -128.54 2.15 Favored Glycine 0 N--CA 1.442 -0.935 0 CA-C-N 115.75 -0.659 . . . . 0.0 112.049 179.042 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 117' ' ' THR . . . . . 0.458 ' OG1' ' HB3' ' A' ' 104' ' ' ASN . 25.1 p -136.2 156.43 48.69 Favored 'General case' 0 C--N 1.312 -1.03 0 CA-C-O 121.03 0.443 . . . . 0.0 110.875 179.91 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 118' ' ' MET . . . . . 0.584 ' SD ' ' HE1' ' A' ' 120' ' ' TYR . 3.4 ptp -137.66 145.2 42.37 Favored 'General case' 0 C--N 1.314 -0.969 0 CA-C-N 115.94 -0.573 . . . . 0.0 109.966 -179.278 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 119' ' ' THR . . . . . 0.472 ' HB ' ' HB2' ' A' ' 102' ' ' ALA . 20.8 m -125.5 127.12 45.96 Favored 'General case' 0 C--O 1.247 0.936 0 N-CA-C 110.125 -0.324 . . . . 0.0 110.125 178.557 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . 0.584 ' HE1' ' SD ' ' A' ' 118' ' ' MET . 24.3 m-85 -107.15 155.04 20.31 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.987 179.04 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -58.44 127.87 34.31 Favored 'General case' 0 C--O 1.236 0.391 0 CA-C-O 121.131 0.491 . . . . 0.0 112.121 -178.649 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 81.64 7.71 87.79 Favored Glycine 0 C--O 1.227 -0.338 0 CA-C-N 115.618 -0.719 . . . . 0.0 113.406 177.863 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 85.9 tt0 -145.05 165.2 28.91 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 117.091 0.446 . . . . 0.0 110.493 -178.599 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -87.23 176.43 46.92 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.953 -0.642 . . . . 0.0 112.784 -178.448 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . 0.479 ' HA ' ' O ' ' A' ' 118' ' ' MET . 71.6 Cg_endo -72.48 140.01 32.46 Favored 'Trans proline' 0 CA--C 1.534 0.523 0 C-N-CA 122.817 2.345 . . . . 0.0 112.923 -179.685 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 43.6 pt -131.15 170.42 19.77 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.013 178.809 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -68.33 133.56 28.36 Favored Glycine 0 C--O 1.242 0.614 0 C-N-CA 120.929 -0.653 . . . . 0.0 112.987 -178.401 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 45.1 t80 -111.74 130.59 55.74 Favored 'General case' 0 C--O 1.236 0.378 0 C-N-CA 123.287 0.635 . . . . 0.0 110.602 -179.502 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 62.1 tttm -140.84 115.45 9.52 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 177.385 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . 0.536 ' HA2' ' O ' ' A' ' 5' ' ' ASN . . . -132.13 149.38 19.4 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.501 -0.857 . . . . 0.0 113.266 -178.132 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 80.8 m -141.29 143.09 33.88 Favored 'General case' 0 C--N 1.323 -0.564 0 C-N-CA 122.307 0.243 . . . . 0.0 111.079 179.256 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 132' ' ' LEU . . . . . 0.467 ' CD1' ' HA ' ' A' ' 112' ' ' GLN . 82.4 mt -53.9 136.33 40.94 Favored 'General case' 0 N--CA 1.475 0.793 0 O-C-N 123.548 0.53 . . . . 0.0 110.764 176.112 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 25.1 m . . . . . 0 C--O 1.255 1.368 0 CA-C-O 118.421 -0.799 . . . . 0.0 110.85 -179.034 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 0.622 0 N-CA-C 110.064 -0.347 . . . . 0.0 110.064 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 2.8 tm? -88.16 129.28 35.37 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 121.084 0.468 . . . . 0.0 110.093 -178.714 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . 0.49 ' CE1' ' HB ' ' A' ' 25' ' ' ILE . 35.2 m-85 -117.62 141.92 47.81 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.783 -0.644 . . . . 0.0 111.813 179.901 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 -98.21 139.61 33.74 Favored 'General case' 0 C--N 1.312 -1.037 0 N-CA-C 107.794 -1.188 . . . . 0.0 107.794 173.328 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 69.0 t -114.39 127.87 71.67 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.224 0 CA-C-O 121.222 0.534 . . . . 0.0 112.211 -174.059 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -122.55 138.76 54.47 Favored 'General case' 0 C--N 1.317 -0.84 0 N-CA-C 107.826 -1.176 . . . . 0.0 107.826 175.083 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 23.5 m120 -128.89 148.53 50.92 Favored 'General case' 0 C--N 1.313 -0.992 0 N-CA-C 112.454 0.538 . . . . 0.0 112.454 -177.319 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 51.0 tt0 -126.36 122.31 35.03 Favored 'General case' 0 C--N 1.32 -0.71 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 176.967 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 41.5 p90 -145.6 13.64 1.36 Allowed 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 114.033 1.123 . . . . 0.0 114.033 -176.376 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -110.36 21.27 24.42 Favored Glycine 0 N--CA 1.446 -0.671 0 C-N-CA 118.491 -1.814 . . . . 0.0 112.031 -177.302 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 107.72 175.9 22.36 Favored Glycine 0 N--CA 1.448 -0.56 0 C-N-CA 120.539 -0.839 . . . . 0.0 113.098 179.083 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 12.4 m -64.36 150.91 45.32 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 115.365 -0.417 . . . . 0.0 111.5 177.831 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 37.6 m 64.89 21.23 12.3 Favored 'General case' 0 N--CA 1.472 0.63 0 CA-C-N 115.706 -0.679 . . . . 0.0 111.509 -178.705 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -96.61 146.27 31.02 Favored Pre-proline 0 N--CA 1.448 -0.539 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.595 179.803 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_exo -71.86 159.23 51.07 Favored 'Trans proline' 0 N--CA 1.455 -0.741 0 C-N-CA 122.764 2.309 . . . . 0.0 112.302 178.502 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 80.6 m95 -90.21 131.4 36.06 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 115.658 -0.701 . . . . 0.0 109.285 178.852 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 38.8 m-80 -109.35 142.67 39.94 Favored 'General case' 0 C--N 1.308 -1.216 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 -178.854 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -69.04 125.59 27.14 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-O 121.612 0.72 . . . . 0.0 111.623 -178.299 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . 0.607 ' O ' ' HB3' ' A' ' 94' ' ' SER . . . -100.33 -17.66 23.8 Favored Glycine 0 N--CA 1.447 -0.567 0 CA-C-N 114.661 -1.154 . . . . 0.0 113.851 -176.515 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 137.14 -151.18 20.94 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.241 -0.981 . . . . 0.0 111.887 -177.566 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 4.6 pt20 -138.62 132.83 31.6 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 120.852 0.358 . . . . 0.0 111.264 -179.912 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . 0.416 ' CZ2' HG22 ' A' ' 100' ' ' VAL . 46.0 m0 -115.34 161.65 18.22 Favored 'General case' 0 CA--C 1.507 -0.691 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.372 178.548 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 81.7 tt0 -120.07 118.96 31.97 Favored 'General case' 0 C--N 1.314 -0.973 0 C-N-CA 119.986 -0.686 . . . . 0.0 109.649 174.313 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.49 ' HB ' ' CE1' ' A' ' 4' ' ' TYR . 97.8 mt -134.45 146.09 31.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 CA-C-N 114.99 -1.005 . . . . 0.0 109.457 -176.225 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 83.71 73.54 1.25 Allowed Glycine 0 CA--C 1.505 -0.56 0 C-N-CA 120.364 -0.922 . . . . 0.0 111.605 178.955 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 16.1 m -62.21 -43.31 99.11 Favored 'General case' 0 C--N 1.314 -0.961 0 CA-C-N 115.175 -0.513 . . . . 0.0 110.77 179.55 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 84.8 mtt85 -77.64 129.78 36.01 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.903 -0.589 . . . . 0.0 111.337 -179.709 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 15.6 m -66.7 -32.77 74.29 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.607 -0.724 . . . . 0.0 111.69 179.85 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 28.6 m-20 -97.62 16.78 19.45 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.524 -176.458 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 7.2 mm-40 -155.21 102.32 2.29 Favored 'General case' 0 CA--C 1.505 -0.781 0 CA-C-O 120.909 0.385 . . . . 0.0 111.646 -174.656 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 63.7 t30 -102.34 157.86 16.61 Favored 'General case' 0 N--CA 1.443 -0.814 0 CA-C-N 115.877 -0.602 . . . . 0.0 109.945 178.305 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 57.0 t -96.22 133.11 38.68 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.66 0 CA-C-N 115.255 -0.884 . . . . 0.0 110.841 -175.166 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 30.1 m -110.13 -17.22 8.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 N-CA-C 111.78 0.289 . . . . 0.0 111.78 179.787 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.461 ' HB2' ' HB ' ' A' ' 52' ' ' THR . . . -149.89 143.48 25.31 Favored 'General case' 0 C--O 1.236 0.358 0 C-N-CA 120.628 -0.429 . . . . 0.0 111.195 178.532 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.405 ' HB ' HG21 ' A' ' 105' ' ' VAL . 94.6 mt -140.72 123.32 15.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.036 -179.016 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -126.74 106.47 9.39 Favored 'General case' 0 C--N 1.319 -0.723 0 N-CA-C 108.672 -0.862 . . . . 0.0 108.672 173.896 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 23.9 m -147.67 151.1 13.9 Favored 'Isoleucine or valine' 0 C--O 1.237 0.423 0 C-N-CA 120.748 -0.381 . . . . 0.0 111.379 -174.881 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 78.7 tt0 -147.14 150.46 35.02 Favored 'General case' 0 C--N 1.319 -0.735 0 N-CA-C 108.609 -0.886 . . . . 0.0 108.609 175.612 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' SER . . . . . 0.433 ' HB2' HD21 ' A' ' 47' ' ' LEU . 8.4 t -90.91 143.46 26.69 Favored 'General case' 0 C--N 1.312 -1.027 0 CA-C-O 120.857 0.36 . . . . 0.0 111.436 -177.759 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -87.09 -15.49 62.59 Favored Glycine 0 CA--C 1.52 0.347 0 C-N-CA 120.51 -0.852 . . . . 0.0 111.132 175.892 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . 0.415 ' HB3' ' H ' ' A' ' 43' ' ' ASP . 15.7 m-20 -127.46 -156.01 0.73 Allowed 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.157 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . 0.415 ' H ' ' HB3' ' A' ' 42' ' ' ASP . 43.4 m-20 -76.72 38.72 0.2 Allowed 'General case' 0 N--CA 1.472 0.663 0 C-N-CA 122.576 0.351 . . . . 0.0 111.625 -179.316 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . 0.525 ' O ' ' HE2' ' A' ' 71' ' ' TYR . . . 96.04 -8.39 67.61 Favored Glycine 0 C--O 1.214 -1.095 0 C-N-CA 120.917 -0.658 . . . . 0.0 111.856 -179.527 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 56.2 mt-30 -64.06 -39.66 94.56 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 113.14 0.793 . . . . 0.0 113.14 -176.711 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 4.0 t -126.81 110.56 13.22 Favored 'General case' 0 C--N 1.313 -1.011 0 C-N-CA 120.077 -0.649 . . . . 0.0 110.985 178.57 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' LEU . . . . . 0.433 HD21 ' HB2' ' A' ' 40' ' ' SER . 74.0 mt -93.76 125.52 38.42 Favored 'General case' 0 N--CA 1.443 -0.78 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 176.079 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 13.4 m120 -125.08 141.21 52.26 Favored 'General case' 0 C--N 1.3 -1.547 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 -178.902 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 170.64 -152.99 20.1 Favored Glycine 0 N--CA 1.444 -0.813 0 C-N-CA 119.05 -1.548 . . . . 0.0 113.987 179.333 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 38.6 m -128.47 133.15 48.44 Favored 'General case' 0 N--CA 1.443 -0.808 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 -177.235 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 46.4 ttp -122.61 144.78 48.9 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 -178.344 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.461 ' HB ' ' HB2' ' A' ' 35' ' ' ALA . 32.5 m -125.06 126.69 45.77 Favored 'General case' 0 C--O 1.247 0.958 0 CA-C-O 120.73 0.3 . . . . 0.0 111.368 -179.11 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 62.1 m-85 -90.45 162.73 14.94 Favored 'General case' 0 C--O 1.234 0.248 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.95 177.947 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -66.49 131.44 46.05 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.375 178.734 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 74.0 2.08 61.02 Favored Glycine 0 CA--C 1.519 0.34 0 CA-C-N 115.981 -0.554 . . . . 0.0 113.21 179.209 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 75.2 mm-40 -121.74 -179.03 3.98 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 120.826 0.345 . . . . 0.0 110.764 -178.424 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -105.71 173.76 20.39 Favored Glycine 0 N--CA 1.442 -0.927 0 C-N-CA 121.029 -0.605 . . . . 0.0 111.811 179.215 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 26.3 Cg_exo -63.32 136.32 54.77 Favored 'Trans proline' 0 C--O 1.242 0.712 0 C-N-CA 122.892 2.394 . . . . 0.0 112.375 179.811 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . 0.507 ' HB ' ' O ' ' A' ' 76' ' ' GLN . 50.9 pt -130.79 167.2 26.47 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.577 -179.671 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -73.1 135.14 20.89 Favored Glycine 0 C--O 1.249 1.068 0 C-N-CA 120.842 -0.694 . . . . 0.0 112.122 179.776 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 58.1 t80 -127.51 126.9 43.07 Favored 'General case' 0 C--O 1.243 0.717 0 C-N-CA 122.647 0.379 . . . . 0.0 110.795 -177.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 62.1 ttp180 -135.82 131.85 35.91 Favored 'General case' 0 N--CA 1.463 0.205 0 N-CA-C 110.016 -0.364 . . . . 0.0 110.016 176.681 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -135.21 141.11 45.75 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.649 0.262 . . . . 0.0 111.703 -179.85 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 40.9 m -121.7 132.05 54.43 Favored 'General case' 0 CA--C 1.544 0.719 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.538 179.554 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 58.8 tp -71.56 114.27 9.47 Favored 'General case' 0 CA--C 1.522 -0.13 0 CA-C-O 121.202 0.525 . . . . 0.0 112.345 -178.412 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 68.1 mt -80.87 -31.38 35.33 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.553 -0.749 . . . . 0.0 109.803 175.566 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 123.72 164.73 12.09 Favored Glycine 0 N--CA 1.445 -0.711 0 N-CA-C 110.362 -1.095 . . . . 0.0 110.362 -177.6 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 94.0 m-20 61.11 36.03 18.43 Favored 'General case' 0 N--CA 1.477 0.896 0 CA-C-N 117.343 0.571 . . . . 0.0 110.917 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 95.0 m-20 63.78 18.88 11.43 Favored 'General case' 0 N--CA 1.477 0.878 0 CA-C-N 115.389 -0.823 . . . . 0.0 111.864 179.235 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 31.6 m -108.56 131.91 54.38 Favored 'General case' 0 N--CA 1.448 -0.565 0 CA-C-O 121.123 0.487 . . . . 0.0 110.926 -179.243 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.525 ' HE2' ' O ' ' A' ' 44' ' ' GLY . 95.6 m-85 -119.13 152.14 37.06 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.212 179.911 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 58.1 tt0 -108.0 127.57 53.88 Favored 'General case' 0 C--N 1.314 -0.946 0 N-CA-C 107.997 -1.112 . . . . 0.0 107.997 174.482 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 56.5 t -111.64 137.56 43.77 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.855 0 N-CA-C 113.77 1.026 . . . . 0.0 113.77 -171.147 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 50.1 mt-10 -123.98 149.49 45.93 Favored 'General case' 0 C--O 1.245 0.86 0 CA-C-N 114.832 -1.076 . . . . 0.0 108.303 175.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 14.3 m120 -131.65 156.54 45.66 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-O 120.561 0.22 . . . . 0.0 110.47 -175.98 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' GLN . . . . . 0.507 ' O ' ' HB ' ' A' ' 59' ' ' ILE . 1.7 pt20 -147.18 144.07 28.68 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.402 176.315 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 31.9 p90 -147.24 168.25 22.17 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.16 -177.467 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 79.54 70.35 1.33 Allowed Glycine 0 N--CA 1.441 -0.987 0 C-N-CA 121.078 -0.582 . . . . 0.0 114.109 176.316 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . 0.513 ' O ' ' HB3' ' A' ' 80' ' ' ASP . . . 106.22 -27.32 17.55 Favored Glycine 0 N--CA 1.445 -0.702 0 C-N-CA 120.296 -0.955 . . . . 0.0 113.827 175.733 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . 0.513 ' HB3' ' O ' ' A' ' 79' ' ' GLY . 19.3 t70 81.28 -28.63 0.12 Allowed 'General case' 0 N--CA 1.493 1.703 0 CA-C-O 121.328 0.585 . . . . 0.0 110.736 178.356 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 11.6 p -85.08 16.73 3.3 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-O 121.247 0.546 . . . . 0.0 110.629 174.221 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -89.33 165.45 25.97 Favored Pre-proline 0 CA--C 1.538 0.495 0 CA-C-N 115.599 -0.728 . . . . 0.0 111.073 -178.12 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 10.6 Cg_exo -70.47 166.88 27.02 Favored 'Trans proline' 0 C--N 1.357 0.979 0 C-N-CA 122.851 2.367 . . . . 0.0 111.746 178.481 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' TRP . . . . . . . . . . . . . 90.8 m95 -95.59 137.45 34.63 Favored 'General case' 0 N--CA 1.445 -0.691 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -178.489 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 85.4 m-70 -119.28 145.54 46.02 Favored 'General case' 0 C--N 1.313 -0.98 0 N-CA-C 109.669 -0.493 . . . . 0.0 109.669 -177.26 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 7.1 m -61.78 133.92 56.1 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 110.303 -0.258 . . . . 0.0 110.303 -179.239 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -108.77 -50.67 0.73 Allowed Glycine 0 N--CA 1.443 -0.856 0 C-N-CA 120.137 -1.03 . . . . 0.0 111.987 178.66 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 152.65 -167.7 31.55 Favored Glycine 0 C--O 1.221 -0.683 0 C-N-CA 120.699 -0.762 . . . . 0.0 111.865 179.55 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 19.8 m120 -103.66 145.5 29.97 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 116.901 0.35 . . . . 0.0 110.722 179.824 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' TRP . . . . . 0.48 ' CH2' HG21 ' A' ' 25' ' ' ILE . 12.4 m0 -132.88 142.54 48.98 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 -178.376 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 86.6 mt -109.25 116.41 52.02 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.962 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 177.958 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . 0.41 ' HB2' ' CE1' ' A' ' 71' ' ' TYR . 71.8 mt -134.81 75.89 1.6 Allowed 'General case' 0 C--O 1.263 1.789 0 CA-C-O 121.449 0.643 . . . . 0.0 111.668 -175.967 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . 0.422 ' O ' ' HB2' ' A' ' 94' ' ' SER . . . -148.93 -69.51 0.01 OUTLIER Glycine 0 N--CA 1.445 -0.763 0 C-N-CA 120.289 -0.958 . . . . 0.0 112.785 -179.931 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 94' ' ' SER . . . . . 0.607 ' HB3' ' O ' ' A' ' 20' ' ' GLY . 17.3 m 73.44 -34.95 0.3 Allowed 'General case' 0 N--CA 1.479 1.009 0 C-N-CA 123.478 0.711 . . . . 0.0 112.563 -178.593 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 82.6 mtp180 -101.02 153.95 19.11 Favored 'General case' 0 N--CA 1.439 -0.984 0 CA-C-O 120.868 0.366 . . . . 0.0 110.942 -179.179 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 44.5 tt0 -62.03 -54.37 42.4 Favored 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 113.51 0.93 . . . . 0.0 113.51 -172.87 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 47.4 m-80 -122.29 37.1 4.46 Favored 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 111.869 0.322 . . . . 0.0 111.869 -176.475 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' GLN . . . . . 0.527 HE21 ' CB ' ' A' ' 120' ' ' TYR . 39.6 tt0 -148.04 116.12 6.48 Favored 'General case' 0 C--N 1.316 -0.867 0 C-N-CA 120.543 -0.463 . . . . 0.0 110.354 -178.044 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 52.7 m-80 -96.69 164.85 12.41 Favored 'General case' 0 C--O 1.247 0.946 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.716 -175.427 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . 0.416 HG22 ' CZ2' ' A' ' 23' ' ' TRP . 86.7 t -87.36 137.11 21.58 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.735 0 CA-C-N 115.897 -0.592 . . . . 0.0 111.198 177.361 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . 0.43 ' CG1' ' HA ' ' A' ' 121' ' ' ALA . 34.3 m -119.87 -29.59 1.78 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.743 0 N-CA-C 112.971 0.73 . . . . 0.0 112.971 -178.426 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . 0.462 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -141.26 138.06 32.97 Favored 'General case' 0 C--N 1.323 -0.557 0 C-N-CA 120.048 -0.661 . . . . 0.0 111.445 179.537 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 93.3 mt -134.03 128.02 52.42 Favored 'Isoleucine or valine' 0 C--O 1.244 0.78 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.836 179.154 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 43.5 t30 -129.21 99.76 5.35 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 109.033 -0.728 . . . . 0.0 109.033 174.483 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.405 HG21 ' HB ' ' A' ' 36' ' ' ILE . 25.2 m -141.99 148.31 20.68 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 N-CA-C 112.572 0.582 . . . . 0.0 112.572 -176.416 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 37.9 tt0 -149.92 154.98 39.21 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 115.156 -0.929 . . . . 0.0 108.88 175.469 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 37.7 t -132.84 143.65 49.68 Favored 'General case' 0 C--N 1.311 -1.078 0 CA-C-O 121.132 0.491 . . . . 0.0 111.702 -177.997 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -84.78 -9.42 81.07 Favored Glycine 0 N--CA 1.441 -0.979 0 N-CA-C 110.166 -1.174 . . . . 0.0 110.166 174.922 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 78.3 m-20 -97.29 -171.28 2.17 Favored 'General case' 0 CA--C 1.507 -0.685 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 178.404 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 99.4 m-20 -89.65 39.53 0.96 Allowed 'General case' 0 C--N 1.308 -1.221 0 CA-C-O 121.373 0.606 . . . . 0.0 110.392 177.843 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 95.18 -2.65 65.94 Favored Glycine 0 N--CA 1.447 -0.598 0 CA-C-N 115.609 -0.723 . . . . 0.0 113.152 178.571 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 112' ' ' GLN . . . . . 0.461 ' HA ' HD22 ' A' ' 132' ' ' LEU . 98.4 mt-30 -64.14 -42.7 96.69 Favored 'General case' 0 C--O 1.245 0.839 0 N-CA-C 112.755 0.65 . . . . 0.0 112.755 -176.989 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 46.5 p -124.63 106.64 10.27 Favored 'General case' 0 N--CA 1.449 -0.521 0 CA-C-O 120.954 0.407 . . . . 0.0 110.279 176.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 98.3 mt -91.33 111.84 23.51 Favored 'General case' 0 C--N 1.316 -0.883 0 CA-C-O 120.642 0.258 . . . . 0.0 110.347 -179.344 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 57.1 m-80 -108.86 143.03 38.59 Favored 'General case' 0 C--N 1.313 -0.997 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.342 -179.955 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 163.56 -141.69 7.31 Favored Glycine 0 N--CA 1.435 -1.426 0 C-N-CA 119.655 -1.26 . . . . 0.0 113.162 177.599 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 33.8 p -134.85 158.12 45.05 Favored 'General case' 0 C--N 1.315 -0.907 0 C-N-CA 122.616 0.366 . . . . 0.0 110.504 -177.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 25.8 ptm -144.97 152.24 39.86 Favored 'General case' 0 C--N 1.314 -0.939 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.297 -179.766 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 119' ' ' THR . . . . . 0.462 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 32.9 m -129.74 129.34 44.03 Favored 'General case' 0 C--O 1.249 1.059 0 CA-C-N 116.387 -0.37 . . . . 0.0 110.694 179.682 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . 0.527 ' CB ' HE21 ' A' ' 98' ' ' GLN . 45.6 m-85 -85.34 170.48 12.71 Favored 'General case' 0 CA--C 1.517 -0.289 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.325 176.4 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . 0.43 ' HA ' ' CG1' ' A' ' 101' ' ' VAL . . . -53.21 -40.4 64.44 Favored 'General case' 0 N--CA 1.471 0.586 0 N-CA-C 113.167 0.803 . . . . 0.0 113.167 -178.13 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -151.81 87.88 0.14 Allowed Glycine 0 N--CA 1.447 -0.602 0 C-N-CA 119.579 -1.296 . . . . 0.0 112.821 -179.404 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 77.4 tt0 -169.8 -69.14 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.771 0.32 . . . . 0.0 110.842 179.436 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 153.44 161.87 10.65 Favored Glycine 0 N--CA 1.443 -0.841 0 C-N-CA 120.812 -0.708 . . . . 0.0 111.887 179.316 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 21.2 Cg_exo -66.96 136.57 41.75 Favored 'Trans proline' 0 C--O 1.24 0.582 0 C-N-CA 122.733 2.289 . . . . 0.0 111.73 178.865 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 43.1 pt -135.52 166.26 28.14 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.145 178.862 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -72.89 136.15 22.48 Favored Glycine 0 C--O 1.237 0.284 0 C-N-CA 120.712 -0.756 . . . . 0.0 111.786 -179.759 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 78.9 t80 -122.46 136.81 54.97 Favored 'General case' 0 C--O 1.24 0.569 0 CA-C-O 120.959 0.409 . . . . 0.0 111.651 -177.286 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 61.9 tttm -134.87 103.69 5.7 Favored 'General case' 0 N--CA 1.446 -0.668 0 CA-C-N 115.349 -0.841 . . . . 0.0 109.941 177.145 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -100.24 133.33 11.26 Favored Glycine 0 N--CA 1.443 -0.863 0 N-CA-C 111.183 -0.767 . . . . 0.0 111.183 177.733 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 38.7 m -129.84 137.56 50.51 Favored 'General case' 0 C--N 1.306 -1.286 0 CA-C-N 117.042 0.421 . . . . 0.0 111.187 -177.951 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 132' ' ' LEU . . . . . 0.461 HD22 ' HA ' ' A' ' 112' ' ' GLN . 2.9 mm? -59.76 137.78 57.96 Favored 'General case' 0 N--CA 1.473 0.708 0 CA-C-O 121.285 0.564 . . . . 0.0 111.727 178.752 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 14.4 m . . . . . 0 N--CA 1.435 -1.203 0 CA-C-N 115.528 -0.76 . . . . 0.0 110.174 178.283 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.51 -0.561 0 CA-C-O 120.694 0.283 . . . . 0.0 110.33 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 10.2 tt -99.77 131.83 45.5 Favored 'General case' 0 C--N 1.316 -0.889 0 CA-C-O 121.177 0.513 . . . . 0.0 110.486 -179.059 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 85.8 m-85 -120.81 142.64 49.42 Favored 'General case' 0 C--N 1.311 -1.083 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.201 178.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' ASN . . . . . 0.494 ' O ' ' HA2' ' A' ' 130' ' ' GLY . 88.9 m-20 -87.94 132.15 34.33 Favored 'General case' 0 C--N 1.308 -1.219 0 N-CA-C 107.501 -1.296 . . . . 0.0 107.501 176.786 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.593 HG22 ' CG ' ' A' ' 23' ' ' TRP . 54.2 t -113.88 128.66 70.7 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.99 0 CA-C-O 121.973 0.892 . . . . 0.0 113.191 -173.456 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . 0.416 ' HB2' ' HB3' ' A' ' 129' ' ' LYS . 27.0 mt-10 -120.82 131.75 54.62 Favored 'General case' 0 N--CA 1.43 -1.45 0 CA-C-N 113.631 -1.622 . . . . 0.0 107.755 179.785 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 10.9 m120 -119.9 145.32 46.8 Favored 'General case' 0 C--N 1.314 -0.939 0 CA-C-O 120.995 0.426 . . . . 0.0 111.9 -176.81 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 53.4 tt0 -122.66 110.29 15.34 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.57 -0.741 . . . . 0.0 109.138 179.554 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 3.1 p90 -128.68 -171.42 2.46 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 112.682 0.623 . . . . 0.0 112.682 -175.079 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 66.34 -90.84 0.15 Allowed Glycine 0 C--N 1.336 0.552 0 CA-C-N 114.955 -1.02 . . . . 0.0 114.938 176.084 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.511 ' C ' ' H ' ' A' ' 14' ' ' SER . . . -85.85 0.78 87.97 Favored Glycine 0 C--N 1.319 -0.376 0 C-N-CA 121.319 -0.467 . . . . 0.0 114.098 -173.52 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 13.3 t 59.17 -6.46 0.06 Allowed 'General case' 0 CA--C 1.562 1.434 0 C-N-CA 123.323 0.649 . . . . 0.0 112.662 -177.719 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' SER . . . . . 0.511 ' H ' ' C ' ' A' ' 12' ' ' GLY . 8.7 t -125.7 16.13 8.11 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-O 121.658 0.742 . . . . 0.0 109.358 -179.39 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -80.05 163.79 55.94 Favored Pre-proline 0 N--CA 1.445 -0.718 0 CA-C-N 114.877 -1.056 . . . . 0.0 110.122 -179.463 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 14.2 Cg_exo -69.71 169.6 18.47 Favored 'Trans proline' 0 N--CA 1.46 -0.488 0 C-N-CA 122.608 2.205 . . . . 0.0 111.757 177.967 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 98.5 m95 -80.92 121.71 26.34 Favored 'General case' 0 C--N 1.316 -0.868 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 -179.224 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 91.4 m-20 -106.56 114.19 28.16 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.573 -177.595 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -78.56 128.62 33.78 Favored 'General case' 0 C--N 1.319 -0.756 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 178.406 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -143.3 35.45 1.66 Allowed Glycine 0 N--CA 1.442 -0.961 0 C-N-CA 119.51 -1.329 . . . . 0.0 112.694 -179.713 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 137.62 -174.02 22.02 Favored Glycine 0 N--CA 1.443 -0.843 0 C-N-CA 120.034 -1.079 . . . . 0.0 112.782 178.185 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 88.1 mt-30 -132.0 149.21 52.49 Favored 'General case' 0 C--N 1.318 -0.788 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 -179.768 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . 0.593 ' CG ' HG22 ' A' ' 6' ' ' VAL . 38.5 m0 -119.07 153.24 35.08 Favored 'General case' 0 C--N 1.315 -0.913 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 177.947 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 89.1 mt-10 -111.59 113.69 26.26 Favored 'General case' 0 C--N 1.305 -1.345 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 175.946 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 81.8 mt -130.25 140.35 49.1 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-N 116.0 -0.546 . . . . 0.0 111.904 -172.381 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 91.79 125.17 3.4 Favored Glycine 0 N--CA 1.442 -0.945 0 N-CA-C 114.761 0.665 . . . . 0.0 114.761 172.294 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 3.8 p -88.35 12.61 13.66 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 109.278 -0.638 . . . . 0.0 109.278 173.939 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 62.6 ttp85 -24.74 108.91 0.03 OUTLIER 'General case' 0 N--CA 1.474 0.727 0 C-N-CA 125.477 1.511 . . . . 0.0 113.883 179.732 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 11.0 m -102.88 -62.36 1.29 Allowed 'General case' 0 N--CA 1.436 -1.14 0 CA-C-N 115.235 -0.893 . . . . 0.0 108.83 176.733 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 27.2 m-20 -124.4 5.85 8.36 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.46 178.17 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 1.4 mm-40 -149.53 136.36 19.53 Favored 'General case' 0 C--N 1.318 -0.761 0 CA-C-N 116.009 -0.542 . . . . 0.0 111.432 -177.864 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . 0.513 ' ND2' ' HA3' ' A' ' 111' ' ' GLY . 63.7 t30 -93.36 164.45 13.21 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.947 -0.569 . . . . 0.0 111.331 -179.126 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 57.8 t -96.27 130.37 45.03 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 CA-C-N 115.422 -0.808 . . . . 0.0 110.699 -176.912 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 23.7 m -114.07 -16.33 9.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 N-CA-C 112.218 0.451 . . . . 0.0 112.218 178.754 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -145.86 142.37 28.74 Favored 'General case' 0 CA--C 1.515 -0.384 0 C-N-CA 120.377 -0.529 . . . . 0.0 111.537 178.998 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.417 ' HB ' ' CG2' ' A' ' 105' ' ' VAL . 96.3 mt -142.57 127.46 16.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 N-CA-C 108.987 -0.746 . . . . 0.0 108.987 179.124 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' ASN . . . . . 0.434 ' HA ' ' O ' ' A' ' 103' ' ' ILE . 3.0 t-20 -138.0 113.09 9.2 Favored 'General case' 0 C--N 1.313 -0.991 0 N-CA-C 108.739 -0.837 . . . . 0.0 108.739 176.865 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.414 HG11 ' CD2' ' A' ' 61' ' ' PHE . 28.0 m -148.18 153.15 11.88 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.442 0 C-N-CA 120.918 -0.313 . . . . 0.0 111.19 -174.059 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 81.3 tt0 -139.17 145.37 39.26 Favored 'General case' 0 C--N 1.321 -0.639 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 176.714 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 12.9 t -77.04 139.93 40.19 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-O 120.883 0.373 . . . . 0.0 110.714 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -88.63 -7.07 72.29 Favored Glycine 0 N--CA 1.446 -0.672 0 C-N-CA 120.555 -0.831 . . . . 0.0 111.114 177.061 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 21.1 m-20 -141.83 -153.98 0.49 Allowed 'General case' 0 C--N 1.33 -0.242 0 C-N-CA 122.508 0.323 . . . . 0.0 110.257 -179.319 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 86.7 m-20 -78.28 44.07 0.48 Allowed 'General case' 0 N--CA 1.471 0.589 0 C-N-CA 122.664 0.386 . . . . 0.0 111.961 -178.468 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 87.49 -5.13 85.53 Favored Glycine 0 C--O 1.227 -0.335 0 C-N-CA 120.787 -0.721 . . . . 0.0 113.491 178.094 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 54.9 mt-30 -70.29 -38.89 75.1 Favored 'General case' 0 C--O 1.222 -0.362 0 N-CA-C 112.59 0.589 . . . . 0.0 112.59 179.604 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' THR . . . . . 0.602 ' HA ' ' O ' ' A' ' 63' ' ' ALA . 7.8 t -127.71 123.57 35.73 Favored 'General case' 0 C--N 1.32 -0.689 0 C-N-CA 120.426 -0.51 . . . . 0.0 111.293 -179.027 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 95.5 mt -103.15 124.81 49.29 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.037 177.912 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . 0.495 ' OD1' ' HG3' ' A' ' 62' ' ' ARG . 93.2 m-20 -119.61 142.11 48.7 Favored 'General case' 0 C--N 1.313 -0.985 0 CA-C-N 115.969 -0.559 . . . . 0.0 110.021 179.616 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 166.47 -146.48 10.97 Favored Glycine 0 CA--C 1.501 -0.822 0 C-N-CA 119.787 -1.197 . . . . 0.0 112.787 179.373 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 33.5 p -135.51 153.04 51.86 Favored 'General case' 0 N--CA 1.446 -0.629 0 CA-C-O 120.973 0.416 . . . . 0.0 111.066 -178.718 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' MET . . . . . 0.422 ' HE3' ' CZ ' ' A' ' 53' ' ' TYR . 16.6 tmm? -135.01 138.65 44.16 Favored 'General case' 0 C--N 1.317 -0.83 0 N-CA-C 109.276 -0.638 . . . . 0.0 109.276 178.148 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 29.4 m -125.24 129.26 49.71 Favored 'General case' 0 C--O 1.255 1.365 0 N-CA-C 112.527 0.566 . . . . 0.0 112.527 -175.564 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . 0.482 ' HB2' ' HB2' ' A' ' 56' ' ' GLU . 95.1 m-85 -85.29 165.73 17.07 Favored 'General case' 0 CA--C 1.532 0.251 0 CA-C-N 115.341 -0.845 . . . . 0.0 109.805 176.659 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -66.87 113.51 4.98 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 120.714 0.292 . . . . 0.0 111.707 -179.008 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 76.6 16.53 80.67 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.844 178.11 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . 0.482 ' HB2' ' HB2' ' A' ' 53' ' ' TYR . 73.0 mm-40 -121.71 177.67 5.16 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-O 120.769 0.319 . . . . 0.0 110.395 -179.397 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -93.38 153.48 21.37 Favored Glycine 0 N--CA 1.443 -0.857 0 C-N-CA 120.805 -0.712 . . . . 0.0 111.556 178.694 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -67.8 144.27 64.55 Favored 'Trans proline' 0 C--O 1.237 0.432 0 C-N-CA 122.555 2.17 . . . . 0.0 112.574 179.581 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 39.6 pt -125.86 162.69 28.74 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.818 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.284 178.644 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -71.24 145.1 38.74 Favored Glycine 0 N--CA 1.448 -0.537 0 C-N-CA 121.195 -0.526 . . . . 0.0 112.323 -177.559 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.414 ' CD2' HG11 ' A' ' 38' ' ' VAL . 69.4 t80 -130.93 126.94 37.42 Favored 'General case' 0 C--N 1.313 -1.02 0 C-N-CA 122.106 0.162 . . . . 0.0 110.972 -178.186 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . 0.495 ' HG3' ' OD1' ' A' ' 48' ' ' ASN . 29.0 ttp85 -135.32 128.31 31.51 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 108.798 -0.816 . . . . 0.0 108.798 174.643 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.602 ' O ' ' HA ' ' A' ' 46' ' ' THR . . . -132.87 141.76 48.58 Favored 'General case' 0 C--N 1.316 -0.857 0 C-N-CA 120.852 -0.339 . . . . 0.0 111.713 -178.378 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 31.7 m -124.06 128.97 50.1 Favored 'General case' 0 CA--C 1.539 0.527 0 CA-C-N 116.458 -0.337 . . . . 0.0 110.634 179.516 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 51.2 tp -74.73 127.6 33.53 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 112.279 0.474 . . . . 0.0 112.279 -177.514 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 10.7 mp -79.82 -24.36 41.41 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.969 177.094 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 113.64 -8.36 24.05 Favored Glycine 0 CA--C 1.521 0.465 0 C-N-CA 120.93 -0.653 . . . . 0.0 112.638 179.88 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 24.2 p-10 -115.41 30.12 7.56 Favored 'General case' 0 C--N 1.312 -1.054 0 CA-C-O 121.04 0.448 . . . . 0.0 110.445 179.937 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 87.3 m-20 76.48 -9.38 1.49 Allowed 'General case' 0 N--CA 1.485 1.278 0 C-N-CA 124.353 1.061 . . . . 0.0 111.048 -178.099 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' SER . . . . . 0.454 ' HG ' ' CD1' ' A' ' 91' ' ' ILE . 9.0 m -81.49 138.58 35.47 Favored 'General case' 0 N--CA 1.441 -0.884 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.433 177.828 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.448 ' HB3' ' HB1' ' A' ' 63' ' ' ALA . 43.8 m-85 -122.12 129.94 52.8 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-N 115.679 -0.691 . . . . 0.0 109.685 178.126 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 36.0 tt0 -83.45 119.02 24.14 Favored 'General case' 0 N--CA 1.44 -0.949 0 N-CA-C 107.774 -1.195 . . . . 0.0 107.774 174.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 53.0 t -108.08 133.62 52.41 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.307 0 N-CA-C 112.866 0.691 . . . . 0.0 112.866 -172.474 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 99.8 mt-10 -120.03 122.4 41.05 Favored 'General case' 0 N--CA 1.436 -1.158 0 CA-C-N 114.51 -1.223 . . . . 0.0 108.875 176.676 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 2.7 m-20 -96.29 140.57 30.78 Favored 'General case' 0 C--N 1.313 -1.018 0 CA-C-N 116.288 -0.415 . . . . 0.0 109.917 179.367 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' GLN . . . . . 0.494 ' HB2' ' CE3' ' A' ' 84' ' ' TRP . 61.3 tt0 -115.87 120.89 40.68 Favored 'General case' 0 C--N 1.307 -1.254 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 179.345 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 6.1 p90 -137.55 157.1 47.25 Favored 'General case' 0 C--N 1.312 -1.027 0 CA-C-O 120.723 0.297 . . . . 0.0 110.329 179.481 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 103.13 -13.84 55.51 Favored Glycine 0 N--CA 1.439 -1.115 0 C-N-CA 120.756 -0.735 . . . . 0.0 111.652 -179.838 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 131.51 170.64 12.67 Favored Glycine 0 N--CA 1.437 -1.246 0 C-N-CA 120.886 -0.673 . . . . 0.0 111.972 178.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 5.7 p-10 -65.73 -33.1 75.09 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 121.056 0.455 . . . . 0.0 111.127 179.864 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 40.6 m -78.45 -2.89 40.66 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 115.845 -0.616 . . . . 0.0 111.856 -178.565 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -89.61 146.11 34.99 Favored Pre-proline 0 C--N 1.325 -0.458 0 CA-C-N 116.6 -0.273 . . . . 0.0 110.341 178.606 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.82 177.09 5.98 Favored 'Trans proline' 0 CA--C 1.532 0.405 0 C-N-CA 122.738 2.292 . . . . 0.0 112.298 179.847 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' TRP . . . . . 0.494 ' CE3' ' HB2' ' A' ' 76' ' ' GLN . 98.5 m95 -85.89 143.09 28.41 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 109.716 -0.476 . . . . 0.0 109.716 -179.154 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 91.7 m-70 -119.61 146.11 45.83 Favored 'General case' 0 C--N 1.313 -1.021 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 -179.643 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 46.0 m -63.51 131.2 47.36 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-O 120.891 0.377 . . . . 0.0 110.898 -179.396 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -107.94 -55.2 0.61 Allowed Glycine 0 N--CA 1.441 -1.013 0 C-N-CA 120.842 -0.694 . . . . 0.0 111.694 179.536 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 157.42 -173.43 34.88 Favored Glycine 0 C--O 1.223 -0.546 0 C-N-CA 120.26 -0.971 . . . . 0.0 112.184 179.326 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 24.3 t-20 -109.7 113.26 25.88 Favored 'General case' 0 C--N 1.316 -0.879 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 178.919 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 21.0 m0 -105.96 153.14 22.41 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.432 -176.416 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . 0.454 ' CD1' ' HG ' ' A' ' 70' ' ' SER . 46.8 mm -107.22 113.54 43.8 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.799 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 177.259 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 82.8 mt -127.08 78.51 1.82 Allowed 'General case' 0 C--O 1.268 2.066 0 CA-C-O 122.045 0.926 . . . . 0.0 112.371 -176.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 162.71 104.87 0.19 Allowed Glycine 0 N--CA 1.444 -0.772 0 CA-C-N 114.741 -1.118 . . . . 0.0 110.752 -179.072 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 15.7 p -106.88 -13.12 15.31 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 120.889 0.376 . . . . 0.0 111.867 -178.0 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 85.2 mtp180 -85.47 16.2 3.96 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 121.248 0.547 . . . . 0.0 111.452 -179.202 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 46.9 tp10 65.36 -74.51 0.05 Allowed 'General case' 0 N--CA 1.472 0.646 0 CA-C-N 114.459 -1.246 . . . . 0.0 113.97 174.007 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 61.9 m-80 -91.97 26.85 2.3 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-O 120.765 0.317 . . . . 0.0 111.739 -175.077 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' GLN . . . . . . . . . . . . . 58.1 tt0 -150.05 116.62 5.81 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.801 0.334 . . . . 0.0 110.218 -177.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 83.6 m-20 -84.58 160.02 20.54 Favored 'General case' 0 C--O 1.245 0.819 0 CA-C-N 115.977 -0.556 . . . . 0.0 111.77 -176.895 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 79.5 t -82.36 132.43 31.43 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.664 0 C-N-CA 120.728 -0.389 . . . . 0.0 110.818 176.699 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 34.7 m -114.44 -23.76 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.601 0 N-CA-C 113.087 0.773 . . . . 0.0 113.087 -179.457 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . 0.425 ' HB2' ' HB ' ' A' ' 119' ' ' THR . . . -152.04 144.13 23.87 Favored 'General case' 0 CA--C 1.512 -0.49 0 C-N-CA 120.425 -0.51 . . . . 0.0 111.113 178.198 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.434 ' O ' ' HA ' ' A' ' 37' ' ' ASN . 84.6 mt -135.88 125.8 41.24 Favored 'Isoleucine or valine' 0 C--O 1.236 0.393 0 CA-C-O 120.582 0.23 . . . . 0.0 110.81 179.066 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 9.6 t30 -126.74 94.88 4.16 Favored 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 175.172 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.417 ' CG2' ' HB ' ' A' ' 36' ' ' ILE . 30.9 m -136.88 141.43 40.68 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.702 0 N-CA-C 113.633 0.975 . . . . 0.0 113.633 -174.191 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 74.6 tt0 -141.71 150.49 41.9 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 114.97 -1.014 . . . . 0.0 109.298 178.117 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 35.6 p -150.65 153.17 35.15 Favored 'General case' 0 N--CA 1.446 -0.671 0 CA-C-O 120.821 0.343 . . . . 0.0 111.219 177.545 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -123.19 5.59 9.47 Favored Glycine 0 N--CA 1.439 -1.124 0 N-CA-C 111.112 -0.795 . . . . 0.0 111.112 177.474 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -92.34 34.59 1.03 Allowed 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 121.196 0.522 . . . . 0.0 110.528 179.495 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 29.3 m-20 59.21 21.83 10.0 Favored 'General case' 0 N--CA 1.474 0.741 0 CA-C-N 115.284 -0.871 . . . . 0.0 112.507 176.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . 0.513 ' HA3' ' ND2' ' A' ' 32' ' ' ASN . . . 89.71 -0.14 79.5 Favored Glycine 0 N--CA 1.447 -0.582 0 C-N-CA 120.748 -0.739 . . . . 0.0 113.174 177.928 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 51.8 tt0 -65.62 -43.38 89.76 Favored 'General case' 0 C--O 1.235 0.335 0 CA-C-O 121.356 0.598 . . . . 0.0 110.282 178.725 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 6.4 p -128.72 125.99 39.11 Favored 'General case' 0 N--CA 1.434 -1.248 0 CA-C-N 115.428 -0.805 . . . . 0.0 109.97 176.665 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 42.4 tp -112.47 134.94 53.73 Favored 'General case' 0 C--N 1.306 -1.319 0 CA-C-N 115.899 -0.591 . . . . 0.0 109.596 -177.776 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 30.1 p30 -145.72 169.91 17.54 Favored 'General case' 0 C--N 1.32 -0.698 0 C-N-CA 119.779 -0.768 . . . . 0.0 112.301 179.92 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 147.36 -131.71 4.02 Favored Glycine 0 N--CA 1.434 -1.444 0 CA-C-N 115.127 -0.942 . . . . 0.0 111.204 179.283 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 21.9 p -133.2 159.23 40.79 Favored 'General case' 0 C--N 1.307 -1.246 0 CA-C-O 121.095 0.474 . . . . 0.0 110.72 179.923 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 4.5 ppp? -153.91 163.02 40.73 Favored 'General case' 0 C--N 1.306 -1.306 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 178.802 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 119' ' ' THR . . . . . 0.425 ' HB ' ' HB2' ' A' ' 102' ' ' ALA . 32.1 m -131.47 130.2 42.13 Favored 'General case' 0 C--N 1.307 -1.254 0 CA-C-O 120.791 0.329 . . . . 0.0 111.235 -179.79 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 11.5 m-85 -94.71 161.22 14.27 Favored 'General case' 0 N--CA 1.45 -0.473 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.075 177.095 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -65.6 128.19 34.93 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 120.89 0.376 . . . . 0.0 111.89 -179.098 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 76.23 19.17 78.72 Favored Glycine 0 N--CA 1.45 -0.396 0 CA-C-N 115.775 -0.648 . . . . 0.0 112.956 176.859 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 70.5 tt0 -147.22 161.08 41.65 Favored 'General case' 0 C--N 1.317 -0.832 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 -178.393 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -80.05 -179.49 52.54 Favored Glycine 0 N--CA 1.448 -0.508 0 C-N-CA 121.017 -0.611 . . . . 0.0 112.356 179.63 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -71.56 140.37 36.05 Favored 'Trans proline' 0 CA--C 1.532 0.392 0 C-N-CA 122.714 2.276 . . . . 0.0 112.959 -178.788 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 44.0 pt -132.68 165.99 30.64 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.13 178.805 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -73.15 142.6 31.91 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 121.017 -0.611 . . . . 0.0 112.458 -179.809 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 79.4 t80 -122.76 136.88 55.01 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-O 120.911 0.386 . . . . 0.0 111.272 -179.288 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 129' ' ' LYS . . . . . 0.416 ' HB3' ' HB2' ' A' ' 7' ' ' GLU . 63.2 tttm -142.0 125.95 17.21 Favored 'General case' 0 N--CA 1.447 -0.58 0 CA-C-N 115.649 -0.705 . . . . 0.0 109.154 175.668 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . 0.494 ' HA2' ' O ' ' A' ' 5' ' ' ASN . . . -127.24 135.74 8.96 Favored Glycine 0 N--CA 1.432 -1.581 0 N-CA-C 110.856 -0.898 . . . . 0.0 110.856 178.918 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 30.1 m -118.55 126.94 53.08 Favored 'General case' 0 C--N 1.305 -1.338 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 -178.581 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 66.1 tp -75.24 140.71 43.39 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.782 0.325 . . . . 0.0 111.154 -178.608 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 9.8 t . . . . . 0 C--O 1.248 1.022 0 CA-C-O 118.604 -0.712 . . . . 0.0 109.533 177.987 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.467 0.394 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' LEU . . . . . 0.448 HD12 HE21 ' A' ' 22' ' ' GLN . 3.3 tm? -90.72 128.08 36.54 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-O 121.046 0.45 . . . . 0.0 110.332 -178.331 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 47.2 m-85 -124.46 147.08 48.56 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.864 -0.607 . . . . 0.0 111.175 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 5.7 m-20 -100.97 137.83 38.82 Favored 'General case' 0 C--N 1.315 -0.931 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 175.502 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.441 HG22 ' CD2' ' A' ' 23' ' ' TRP . 68.1 t -116.02 128.26 73.36 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.774 0 CA-C-O 121.527 0.68 . . . . 0.0 112.745 -173.913 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . 0.42 ' HA ' ' HA ' ' A' ' 19' ' ' GLU . 65.4 mt-10 -118.66 138.36 52.66 Favored 'General case' 0 N--CA 1.437 -1.101 0 CA-C-N 114.681 -1.145 . . . . 0.0 108.423 176.713 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 11.9 m120 -127.44 147.16 50.29 Favored 'General case' 0 C--N 1.312 -1.037 0 CA-C-O 121.172 0.511 . . . . 0.0 111.896 -177.056 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 52.1 tt0 -123.38 117.24 24.75 Favored 'General case' 0 C--N 1.314 -0.955 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 178.118 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 7.6 p90 -137.93 9.44 2.81 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 114.313 1.227 . . . . 0.0 114.313 -174.84 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -93.24 31.51 6.3 Favored Glycine 0 CA--C 1.522 0.485 0 C-N-CA 118.748 -1.692 . . . . 0.0 114.353 -174.784 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.63 58.88 3.17 Favored Glycine 0 CA--C 1.525 0.67 0 C-N-CA 120.428 -0.891 . . . . 0.0 114.376 176.922 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 22.8 t 60.69 154.55 0.03 OUTLIER 'General case' 0 CA--C 1.553 1.083 0 N-CA-C 113.408 0.892 . . . . 0.0 113.408 177.325 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 49.3 m 63.3 14.42 7.82 Favored 'General case' 0 N--CA 1.472 0.671 0 CA-C-N 115.851 -0.613 . . . . 0.0 112.355 177.223 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -96.7 153.95 38.57 Favored Pre-proline 0 C--N 1.314 -0.939 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.189 -179.446 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -73.18 161.69 42.47 Favored 'Trans proline' 0 C--O 1.238 0.503 0 C-N-CA 122.634 2.223 . . . . 0.0 111.703 177.772 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' TRP . . . . . 0.402 ' HB3' ' HB3' ' A' ' 7' ' ' GLU . 92.6 m95 -85.18 129.46 34.8 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 109.664 -0.495 . . . . 0.0 109.664 179.51 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 27.6 m-80 -113.22 118.57 35.04 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.661 -178.053 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.42 ' HA ' ' HA ' ' A' ' 7' ' ' GLU . 11.5 pt-20 -75.48 129.94 38.09 Favored 'General case' 0 C--N 1.319 -0.718 0 N-CA-C 109.724 -0.473 . . . . 0.0 109.724 177.474 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -137.62 26.57 2.9 Favored Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 119.596 -1.288 . . . . 0.0 113.159 -178.661 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 147.86 179.26 23.72 Favored Glycine 0 N--CA 1.449 -0.433 0 C-N-CA 119.79 -1.195 . . . . 0.0 113.075 178.125 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . 0.448 HE21 HD12 ' A' ' 3' ' ' LEU . 4.4 pt20 -127.99 138.74 52.72 Favored 'General case' 0 C--N 1.322 -0.601 0 C-N-CA 122.69 0.396 . . . . 0.0 110.205 -179.93 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . 0.441 ' CD2' HG22 ' A' ' 6' ' ' VAL . 45.7 m0 -116.07 171.81 7.56 Favored 'General case' 0 C--O 1.242 0.661 0 CA-C-O 120.86 0.362 . . . . 0.0 111.226 -177.802 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 76.5 tt0 -119.13 110.73 17.4 Favored 'General case' 0 CA--C 1.513 -0.465 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 178.005 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 91.1 mt -133.01 143.97 37.9 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-N 115.401 -0.818 . . . . 0.0 109.579 -178.164 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 83.94 71.73 1.31 Allowed Glycine 0 CA--C 1.508 -0.351 0 C-N-CA 120.369 -0.92 . . . . 0.0 112.014 177.891 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 15.9 m -62.68 -45.62 91.97 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 120.823 0.344 . . . . 0.0 111.279 -179.313 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 83.0 mtm-85 -88.36 133.99 33.94 Favored 'General case' 0 CA--C 1.517 -0.322 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.057 178.797 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 18.8 p -87.16 -16.13 36.3 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.956 -0.565 . . . . 0.0 111.398 179.701 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 16.5 m-20 -71.31 -43.2 67.52 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-O 121.51 0.671 . . . . 0.0 110.161 179.933 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 14.1 mm100 -131.76 122.3 25.61 Favored 'General case' 0 C--N 1.312 -1.027 0 CA-C-N 114.915 -1.039 . . . . 0.0 110.046 -179.399 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . 0.498 ' ND2' ' HA3' ' A' ' 111' ' ' GLY . 59.4 t30 -108.15 172.36 6.88 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.324 -177.575 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 14.0 t -101.71 134.24 42.76 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.92 0 N-CA-C 111.877 0.325 . . . . 0.0 111.877 -172.031 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 33.6 m -113.77 -15.34 10.25 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.356 0 CA-C-O 121.017 0.437 . . . . 0.0 111.594 177.386 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.485 ' HB1' ' HB ' ' A' ' 52' ' ' THR . . . -147.48 142.67 27.19 Favored 'General case' 0 CA--C 1.506 -0.715 0 C-N-CA 120.269 -0.572 . . . . 0.0 111.181 178.199 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 85.9 mt -142.36 120.43 8.04 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 N-CA-C 109.155 -0.683 . . . . 0.0 109.155 -179.377 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' ASN . . . . . 0.457 ' HA ' ' O ' ' A' ' 103' ' ' ILE . 22.7 m-80 -132.37 109.81 10.12 Favored 'General case' 0 C--N 1.31 -1.151 0 N-CA-C 108.88 -0.785 . . . . 0.0 108.88 176.49 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.447 HG22 ' HB ' ' A' ' 103' ' ' ILE . 33.3 m -147.79 152.93 12.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 C-N-CA 120.996 -0.281 . . . . 0.0 111.254 -172.57 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 41.6 tt0 -142.45 147.27 35.84 Favored 'General case' 0 N--CA 1.446 -0.633 0 CA-C-N 115.845 -0.616 . . . . 0.0 109.433 176.755 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 19.9 p -70.42 144.38 51.53 Favored 'General case' 0 C--N 1.313 -1.005 0 CA-C-O 121.083 0.468 . . . . 0.0 111.652 -178.548 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -88.38 -59.18 1.67 Allowed Glycine 0 N--CA 1.441 -0.971 0 N-CA-C 110.366 -1.094 . . . . 0.0 110.366 177.174 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 43.9 m-20 -93.78 -147.11 0.25 Allowed 'General case' 0 C--N 1.32 -0.713 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 176.708 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 20.2 p-10 -78.99 40.66 0.41 Allowed 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.124 0.488 . . . . 0.0 111.949 -178.818 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 97.89 -22.39 41.07 Favored Glycine 0 C--O 1.219 -0.82 0 C-N-CA 120.753 -0.736 . . . . 0.0 113.736 177.351 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 56.3 mt-30 -64.34 -28.61 69.82 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 117.319 0.559 . . . . 0.0 112.111 -178.603 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 26.0 p -117.54 137.0 52.87 Favored 'General case' 0 C--N 1.312 -1.029 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.392 179.334 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 88.7 mt -127.51 128.91 46.47 Favored 'General case' 0 C--N 1.318 -0.793 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 62.7 m-80 -129.47 140.82 51.17 Favored 'General case' 0 C--N 1.318 -0.762 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 178.335 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 178.97 -156.89 19.8 Favored Glycine 0 N--CA 1.438 -1.196 0 C-N-CA 119.972 -1.108 . . . . 0.0 112.797 179.522 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 65.3 m -130.98 132.99 45.39 Favored 'General case' 0 C--N 1.312 -1.04 0 CA-C-O 120.843 0.354 . . . . 0.0 110.646 -179.536 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 46.9 mtp -115.66 148.28 39.88 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.722 177.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.485 ' HB ' ' HB1' ' A' ' 35' ' ' ALA . 33.0 m -126.4 125.33 42.01 Favored 'General case' 0 C--O 1.25 1.086 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.136 177.149 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . 0.422 ' HB2' ' HB2' ' A' ' 56' ' ' GLU . 50.8 m-85 -94.67 164.74 12.83 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.869 -179.43 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -65.14 95.97 0.19 Allowed 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.813 -0.63 . . . . 0.0 111.641 -179.47 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 98.81 4.67 56.82 Favored Glycine 0 C--N 1.318 -0.424 0 CA-C-N 115.613 -0.721 . . . . 0.0 112.434 177.153 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . 0.422 ' HB2' ' HB2' ' A' ' 53' ' ' TYR . 41.8 mt-10 -114.45 168.02 10.21 Favored 'General case' 0 C--N 1.314 -0.968 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 178.871 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -89.61 168.95 35.12 Favored Glycine 0 N--CA 1.437 -1.298 0 C-N-CA 120.541 -0.838 . . . . 0.0 111.413 178.756 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_exo -63.02 134.33 45.62 Favored 'Trans proline' 0 C--O 1.239 0.545 0 C-N-CA 122.345 2.03 . . . . 0.0 111.465 178.735 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 45.0 pt -130.54 166.7 27.47 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.846 179.675 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -73.6 142.49 31.23 Favored Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 121.074 -0.584 . . . . 0.0 112.338 -177.409 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 39.8 t80 -126.77 128.47 46.66 Favored 'General case' 0 C--N 1.317 -0.839 0 C-N-CA 122.451 0.3 . . . . 0.0 111.125 -179.067 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 69.5 ttp85 -136.5 132.25 35.04 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 174.348 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.464 ' HA ' ' O ' ' A' ' 72' ' ' GLU . . . -137.28 146.26 44.48 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 111.892 0.33 . . . . 0.0 111.892 179.837 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 60.1 m -121.32 131.3 54.12 Favored 'General case' 0 CA--C 1.546 0.793 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.38 179.176 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . 0.515 ' O ' ' HB3' ' A' ' 66' ' ' LEU . 59.9 tp -43.2 -51.81 5.89 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 115.513 1.672 . . . . 0.0 115.513 -176.493 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . 0.515 ' HB3' ' O ' ' A' ' 65' ' ' LEU . 3.2 tm? 75.64 -57.06 0.59 Allowed 'General case' 0 CA--C 1.549 0.935 0 CA-C-N 118.364 0.529 . . . . 0.0 110.641 177.949 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -141.35 -90.27 0.16 Allowed Glycine 0 C--N 1.333 0.398 0 C-N-CA 121.057 -0.592 . . . . 0.0 112.646 -179.405 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 9.0 p30 -160.94 133.03 5.89 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 179.705 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 94.3 m-20 57.19 24.27 9.62 Favored 'General case' 0 N--CA 1.478 0.968 0 CA-C-O 121.279 0.562 . . . . 0.0 111.172 -176.256 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 43.5 m -138.2 152.03 48.25 Favored 'General case' 0 N--CA 1.434 -1.229 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 179.336 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.519 ' OH ' ' HB3' ' A' ' 99' ' ' ASN . 97.3 m-85 -149.85 126.39 10.91 Favored 'General case' 0 C--N 1.31 -1.118 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 176.662 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . 0.464 ' O ' ' HA ' ' A' ' 63' ' ' ALA . 83.7 tt0 -82.81 127.53 33.55 Favored 'General case' 0 N--CA 1.439 -0.991 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 175.603 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 76.9 t -104.75 131.55 53.55 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.278 0 CA-C-N 115.352 -0.84 . . . . 0.0 112.585 -171.96 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.457 ' HG2' ' HA ' ' A' ' 86' ' ' SER . 48.1 mt-10 -129.76 126.65 38.67 Favored 'General case' 0 N--CA 1.44 -0.966 0 CA-C-N 114.275 -1.33 . . . . 0.0 107.523 175.059 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 97.0 m-20 -109.53 154.34 22.85 Favored 'General case' 0 C--N 1.314 -0.973 0 CA-C-O 121.042 0.449 . . . . 0.0 112.053 -176.132 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' GLN . . . . . 0.522 ' HB2' ' CE3' ' A' ' 84' ' ' TRP . 61.8 tt0 -118.47 124.52 47.82 Favored 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 115.527 -0.76 . . . . 0.0 110.608 -176.193 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 6.0 p90 -142.59 158.8 43.3 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.158 179.07 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 98.32 -12.42 63.41 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.628 -0.796 . . . . 0.0 112.697 179.931 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 134.26 169.59 12.05 Favored Glycine 0 N--CA 1.447 -0.621 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.192 179.64 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 6.5 p-10 -68.83 -30.42 68.96 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 120.71 0.291 . . . . 0.0 111.097 -179.812 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 23.6 t -71.96 -16.0 62.08 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.255 179.28 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -79.96 143.62 57.88 Favored Pre-proline 0 C--N 1.324 -0.512 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.029 -178.488 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_endo -72.3 -178.16 3.12 Favored 'Trans proline' 0 C--O 1.238 0.511 0 C-N-CA 122.881 2.387 . . . . 0.0 112.149 179.168 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' TRP . . . . . 0.522 ' CE3' ' HB2' ' A' ' 76' ' ' GLN . 88.3 m95 -94.39 142.4 27.47 Favored 'General case' 0 C--N 1.317 -0.829 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 -179.816 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 96.6 m-70 -116.51 142.14 47.26 Favored 'General case' 0 C--N 1.316 -0.889 0 N-CA-C 109.778 -0.452 . . . . 0.0 109.778 -178.542 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' SER . . . . . 0.457 ' HA ' ' HG2' ' A' ' 74' ' ' GLU . 20.8 t -65.39 132.56 49.28 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 120.874 0.368 . . . . 0.0 111.229 -176.374 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -110.75 -48.35 0.74 Allowed Glycine 0 N--CA 1.441 -1.03 0 C-N-CA 120.936 -0.65 . . . . 0.0 112.188 178.547 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 157.96 -171.74 35.02 Favored Glycine 0 C--O 1.217 -0.911 0 C-N-CA 120.57 -0.824 . . . . 0.0 111.84 -179.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 3.9 t30 -112.4 115.64 29.04 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 117.54 0.67 . . . . 0.0 110.251 179.699 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 35.1 m0 -97.88 148.71 23.16 Favored 'General case' 0 C--N 1.311 -1.092 0 CA-C-O 121.037 0.446 . . . . 0.0 111.622 -177.725 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . 0.402 ' O ' ' HB3' ' A' ' 23' ' ' TRP . 76.6 mt -108.49 118.18 55.54 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.057 0 N-CA-C 108.49 -0.93 . . . . 0.0 108.49 175.605 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 85.8 mt -134.53 83.39 2.03 Favored 'General case' 0 C--O 1.267 1.985 0 O-C-N 124.031 0.832 . . . . 0.0 112.057 -173.675 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 172.11 111.34 0.26 Allowed Glycine 0 N--CA 1.444 -0.769 0 CA-C-N 115.752 -0.658 . . . . 0.0 112.644 177.407 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 78.8 p -90.07 -7.88 52.79 Favored 'General case' 0 C--O 1.236 0.362 0 CA-C-O 121.45 0.643 . . . . 0.0 110.014 177.348 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 97.3 mtt180 -105.28 142.74 34.52 Favored 'General case' 0 N--CA 1.445 -0.692 0 CA-C-N 115.357 -0.838 . . . . 0.0 110.701 179.725 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -70.48 -34.68 72.65 Favored 'General case' 0 C--N 1.311 -1.08 0 CA-C-N 115.688 -0.687 . . . . 0.0 112.811 -175.193 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 27.2 p-10 -116.21 27.29 9.33 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 112.77 0.655 . . . . 0.0 112.77 -176.54 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' GLN . . . . . . . . . . . . . 72.1 mt-30 -148.82 125.76 11.27 Favored 'General case' 0 CA--C 1.511 -0.54 0 CA-C-O 121.12 0.486 . . . . 0.0 112.276 -179.855 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 99' ' ' ASN . . . . . 0.519 ' HB3' ' OH ' ' A' ' 71' ' ' TYR . 94.9 m-20 -96.17 152.87 18.15 Favored 'General case' 0 C--O 1.258 1.512 0 CA-C-N 114.985 -1.007 . . . . 0.0 109.889 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 57.5 t -73.9 134.91 28.64 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.561 0 CA-C-O 120.932 0.396 . . . . 0.0 111.057 178.424 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 23.3 m -120.08 -23.64 3.26 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.478 0 N-CA-C 112.649 0.611 . . . . 0.0 112.649 -178.848 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . 0.442 ' HB1' ' HB ' ' A' ' 119' ' ' THR . . . -148.05 139.58 23.69 Favored 'General case' 0 C--O 1.236 0.392 0 C-N-CA 120.342 -0.543 . . . . 0.0 111.85 179.433 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.457 ' O ' ' HA ' ' A' ' 37' ' ' ASN . 37.4 mm -134.02 130.0 54.74 Favored 'Isoleucine or valine' 0 C--O 1.239 0.53 0 CA-C-N 115.904 -0.589 . . . . 0.0 111.287 178.901 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 6.8 t30 -129.07 93.75 3.66 Favored 'General case' 0 CA--C 1.534 0.359 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.368 176.222 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 27.3 m -138.44 141.55 37.3 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.932 0 N-CA-C 113.033 0.753 . . . . 0.0 113.033 -176.561 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 85.6 tt0 -144.14 87.63 1.91 Allowed 'General case' 0 CA--C 1.534 0.358 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.676 176.447 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 107' ' ' SER . . . . . 0.464 ' HB2' ' H ' ' A' ' 115' ' ' ASN . 13.6 m -162.93 159.82 24.1 Favored 'General case' 0 C--N 1.312 -1.061 0 CA-C-N 114.667 -1.151 . . . . 0.0 111.206 -179.359 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 136.95 94.46 0.37 Allowed Glycine 0 N--CA 1.424 -2.139 0 C-N-CA 119.215 -1.469 . . . . 0.0 114.578 173.633 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 16.7 m-20 -75.68 100.47 4.67 Favored 'General case' 0 CA--C 1.502 -0.878 0 N-CA-C 105.875 -1.898 . . . . 0.0 105.875 171.918 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 70.5 m-20 62.27 24.35 14.48 Favored 'General case' 0 CA--C 1.534 0.344 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 -172.234 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . 0.498 ' HA3' ' ND2' ' A' ' 32' ' ' ASN . . . 77.91 22.85 67.98 Favored Glycine 0 CA--C 1.527 0.821 0 CA-C-N 115.217 -0.901 . . . . 0.0 113.539 179.928 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 52.8 tt0 -66.35 -43.49 85.9 Favored 'General case' 0 CA--C 1.541 0.597 0 N-CA-C 112.433 0.531 . . . . 0.0 112.433 -179.263 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 21.8 p -131.8 157.01 45.0 Favored 'General case' 0 C--N 1.325 -0.496 0 O-C-N 122.335 -0.228 . . . . 0.0 111.525 -177.629 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 114' ' ' LEU . . . . . 0.4 ' HA ' ' HB2' ' A' ' 107' ' ' SER . 96.4 mt -133.38 109.39 9.31 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 110.199 -0.297 . . . . 0.0 110.199 178.353 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . 0.464 ' H ' ' HB2' ' A' ' 107' ' ' SER . 93.3 m-20 -114.5 143.35 45.1 Favored 'General case' 0 C--O 1.252 1.207 0 CA-C-O 121.091 0.472 . . . . 0.0 111.018 -179.366 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 162.08 -135.11 3.74 Favored Glycine 0 N--CA 1.44 -1.043 0 CA-C-N 115.718 -0.674 . . . . 0.0 112.366 178.751 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 3.0 p -137.2 159.61 41.42 Favored 'General case' 0 C--N 1.311 -1.069 0 C-N-CA 122.629 0.372 . . . . 0.0 110.544 -179.241 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 23.2 ptm -146.3 160.29 42.21 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 116.501 -0.318 . . . . 0.0 110.614 -178.376 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 119' ' ' THR . . . . . 0.442 ' HB ' ' HB1' ' A' ' 102' ' ' ALA . 25.6 m -143.14 136.59 28.37 Favored 'General case' 0 C--O 1.253 1.242 0 CA-C-N 116.609 -0.269 . . . . 0.0 111.426 179.893 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 52.5 m-85 -100.69 164.65 11.77 Favored 'General case' 0 CA--C 1.508 -0.639 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.223 177.418 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -63.46 130.19 43.36 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.058 176.66 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 63.03 27.41 70.39 Favored Glycine 0 CA--C 1.521 0.463 0 C-N-CA 121.118 -0.563 . . . . 0.0 113.117 -179.131 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 9.9 tp10 -136.83 162.2 33.89 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -178.829 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -89.11 170.57 37.77 Favored Glycine 0 CA--C 1.522 0.479 0 C-N-CA 120.847 -0.692 . . . . 0.0 112.341 179.599 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -72.03 135.15 24.69 Favored 'Trans proline' 0 N--CA 1.46 -0.484 0 C-N-CA 122.369 2.046 . . . . 0.0 112.201 179.125 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 40.7 pt -130.83 161.56 40.56 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.269 179.673 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -72.42 134.91 21.62 Favored Glycine 0 C--O 1.238 0.391 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.119 -179.916 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 91.6 t80 -115.85 133.16 56.31 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.858 0.361 . . . . 0.0 110.99 -178.952 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 62.8 tttm -140.64 108.54 5.69 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 115.679 -0.691 . . . . 0.0 109.265 177.954 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -117.42 147.78 18.78 Favored Glycine 0 N--CA 1.44 -1.056 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.053 -179.35 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 5.4 t -137.16 142.84 42.2 Favored 'General case' 0 C--N 1.313 -1.002 0 CA-C-O 120.899 0.381 . . . . 0.0 111.231 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 63.2 tp -72.17 136.81 46.56 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.582 -0.736 . . . . 0.0 110.355 177.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 37.2 m . . . . . 0 C--N 1.307 -1.248 0 CA-C-O 118.802 -0.618 . . . . 0.0 110.407 -179.904 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.235 0.309 0 CA-C-O 120.655 0.264 . . . . 0.0 110.304 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' LEU . . . . . 0.467 HD23 HE21 ' A' ' 22' ' ' GLN . 9.2 tt -90.32 132.15 35.72 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-O 120.988 0.423 . . . . 0.0 110.197 179.593 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . 0.536 ' CD1' ' HB ' ' A' ' 25' ' ' ILE . 34.5 m-85 -116.43 137.97 51.73 Favored 'General case' 0 C--N 1.317 -0.841 0 CA-C-O 121.386 0.612 . . . . 0.0 111.32 -178.926 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' ASN . . . . . 0.544 ' HB2' ' OG1' ' A' ' 133' ' ' THR . 60.8 t30 -96.51 135.61 38.16 Favored 'General case' 0 C--N 1.305 -1.339 0 N-CA-C 107.176 -1.416 . . . . 0.0 107.176 177.226 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.412 ' O ' ' HA ' ' A' ' 19' ' ' GLU . 72.2 t -116.48 126.31 73.89 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 N-CA-C 113.176 0.806 . . . . 0.0 113.176 -172.419 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -118.71 137.42 53.35 Favored 'General case' 0 N--CA 1.439 -0.991 0 CA-C-N 114.479 -1.237 . . . . 0.0 107.962 175.911 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 13.4 m120 -128.79 151.64 49.35 Favored 'General case' 0 C--N 1.313 -1.007 0 N-CA-C 112.607 0.595 . . . . 0.0 112.607 -175.238 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 52.9 tt0 -122.33 110.33 15.53 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 107.527 -1.286 . . . . 0.0 107.527 175.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 40.2 p90 -134.47 4.91 3.43 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 114.556 1.317 . . . . 0.0 114.556 -172.875 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -119.32 18.99 10.08 Favored Glycine 0 N--CA 1.446 -0.65 0 C-N-CA 118.357 -1.878 . . . . 0.0 113.696 -176.11 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 152.02 -160.91 29.1 Favored Glycine 0 N--CA 1.446 -0.7 0 C-N-CA 119.541 -1.314 . . . . 0.0 112.907 179.097 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 36.6 p -102.5 -21.97 14.12 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-O 121.061 0.458 . . . . 0.0 110.462 -177.149 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 47.0 p -107.15 -1.3 22.07 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.607 -0.724 . . . . 0.0 110.423 -178.801 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -59.46 135.35 88.86 Favored Pre-proline 0 N--CA 1.453 -0.289 0 CA-C-N 115.616 -0.72 . . . . 0.0 111.068 -178.034 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -70.01 162.89 40.5 Favored 'Trans proline' 0 N--CA 1.459 -0.527 0 C-N-CA 122.653 2.235 . . . . 0.0 111.874 179.088 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 99.0 m95 -84.77 123.68 30.69 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 179.865 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 44.1 m-80 -118.68 128.46 54.54 Favored 'General case' 0 C--N 1.315 -0.898 0 N-CA-C 110.245 -0.28 . . . . 0.0 110.245 -178.869 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.412 ' HA ' ' O ' ' A' ' 6' ' ' VAL . 11.3 pt-20 -82.03 132.35 35.25 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 176.34 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -133.09 23.36 3.9 Favored Glycine 0 N--CA 1.438 -1.193 0 C-N-CA 120.028 -1.082 . . . . 0.0 112.114 -179.318 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 153.4 178.04 27.53 Favored Glycine 0 N--CA 1.439 -1.144 0 C-N-CA 120.644 -0.789 . . . . 0.0 111.969 -179.385 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . 0.467 HE21 HD23 ' A' ' 3' ' ' LEU . 4.1 pt20 -131.5 138.66 49.07 Favored 'General case' 0 C--N 1.313 -0.997 0 N-CA-C 110.012 -0.366 . . . . 0.0 110.012 -179.456 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 44.1 m0 -113.03 175.37 5.47 Favored 'General case' 0 CA--C 1.506 -0.74 0 CA-C-O 121.081 0.467 . . . . 0.0 110.693 -178.128 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 39.4 tt0 -129.68 115.15 16.91 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-N 116.098 -0.501 . . . . 0.0 109.812 178.062 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.536 ' HB ' ' CD1' ' A' ' 4' ' ' TYR . 93.8 mt -128.33 135.62 62.14 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.962 0 CA-C-N 115.574 -0.739 . . . . 0.0 109.561 -177.29 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 86.31 71.42 1.3 Allowed Glycine 0 N--CA 1.441 -1.01 0 C-N-CA 119.935 -1.126 . . . . 0.0 111.363 -179.781 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 32.1 t -59.79 -41.07 90.36 Favored 'General case' 0 C--N 1.318 -0.796 0 N-CA-C 109.526 -0.546 . . . . 0.0 109.526 179.413 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 97.1 mtt180 -99.35 133.54 43.5 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 176.064 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 2.4 p -86.22 2.37 47.29 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-O 121.011 0.434 . . . . 0.0 111.908 -177.832 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 -66.0 -34.28 77.73 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.407 178.74 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . 0.507 ' NE2' ' HA ' ' A' ' 31' ' ' GLN . 5.6 mm-40 -143.1 126.58 16.79 Favored 'General case' 0 CA--C 1.502 -0.871 0 N-CA-C 113.367 0.877 . . . . 0.0 113.367 -177.239 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . 0.433 ' HB3' ' HA3' ' A' ' 111' ' ' GLY . 95.9 m-20 -90.4 156.04 18.51 Favored 'General case' 0 N--CA 1.446 -0.639 0 CA-C-N 115.022 -0.99 . . . . 0.0 110.091 177.466 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 18.0 m -105.77 137.33 36.2 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.034 0 CA-C-N 115.727 -0.67 . . . . 0.0 112.672 -175.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 27.7 m -111.73 -20.59 6.13 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.2 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.908 177.535 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.48 ' HB1' ' HB ' ' A' ' 52' ' ' THR . . . -145.21 144.83 31.05 Favored 'General case' 0 C--N 1.321 -0.663 0 C-N-CA 119.94 -0.704 . . . . 0.0 111.533 178.68 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 91.6 mt -144.33 126.88 10.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 N-CA-C 108.709 -0.848 . . . . 0.0 108.709 -179.535 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' ASN . . . . . 0.541 ' HA ' ' O ' ' A' ' 103' ' ' ILE . 3.3 t-20 -140.22 114.31 9.04 Favored 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 179.097 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.568 HG13 ' CD2' ' A' ' 61' ' ' PHE . 16.5 m -151.96 158.77 4.28 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.931 0 CA-C-O 120.807 0.337 . . . . 0.0 111.834 -173.743 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 66.2 tt0 -139.19 147.96 42.5 Favored 'General case' 0 N--CA 1.451 -0.392 0 CA-C-N 115.229 -0.896 . . . . 0.0 109.299 174.836 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' SER . . . . . 0.426 ' OG ' ' HB ' ' A' ' 101' ' ' VAL . 95.2 p -82.31 166.05 19.84 Favored 'General case' 0 C--N 1.313 -0.984 0 CA-C-O 121.146 0.498 . . . . 0.0 111.911 -179.351 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -107.74 -52.41 0.71 Allowed Glycine 0 N--CA 1.442 -0.948 0 CA-C-N 115.528 -0.76 . . . . 0.0 111.344 175.1 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -131.14 102.12 5.87 Favored 'General case' 0 C--N 1.326 -0.431 0 C-N-CA 122.334 0.253 . . . . 0.0 111.262 -179.563 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 83.8 m-20 52.1 26.4 3.81 Favored 'General case' 0 N--CA 1.492 1.656 0 N-CA-C 113.732 1.012 . . . . 0.0 113.732 177.105 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 82.48 -6.5 68.57 Favored Glycine 0 C--N 1.312 -0.761 0 C-N-CA 120.333 -0.936 . . . . 0.0 113.396 178.184 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 28.3 mt-30 -64.95 -32.49 74.23 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 117.219 0.509 . . . . 0.0 110.842 -179.065 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 4.9 t -118.11 131.44 56.43 Favored 'General case' 0 C--N 1.307 -1.279 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 174.652 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 91.7 mt -126.26 134.37 51.2 Favored 'General case' 0 C--N 1.316 -0.861 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 -177.756 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 20.7 p30 -143.89 147.43 34.01 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-O 121.207 0.527 . . . . 0.0 111.511 179.569 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 164.4 -142.49 7.83 Favored Glycine 0 N--CA 1.442 -0.934 0 N-CA-C 111.389 -0.684 . . . . 0.0 111.389 179.873 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 40.2 p -132.98 150.39 52.16 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-O 121.028 0.442 . . . . 0.0 111.846 -178.938 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 32.2 mtp -124.17 152.68 42.56 Favored 'General case' 0 C--N 1.326 -0.415 0 C-N-CA 123.341 0.656 . . . . 0.0 109.603 176.348 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.48 ' HB ' ' HB1' ' A' ' 35' ' ' ALA . 24.1 m -130.37 123.6 30.27 Favored 'General case' 0 C--O 1.25 1.081 0 C-N-CA 121.141 -0.224 . . . . 0.0 110.435 176.313 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . 0.428 ' HB2' ' HB2' ' A' ' 56' ' ' GLU . 71.8 m-85 -85.57 164.33 17.83 Favored 'General case' 0 C--O 1.232 0.173 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.43 178.712 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -67.22 101.88 0.97 Allowed 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.499 -179.996 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 97.06 -0.85 60.61 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.731 -0.747 . . . . 0.0 113.229 177.674 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . 0.428 ' HB2' ' HB2' ' A' ' 53' ' ' TYR . 79.9 mm-40 -111.19 179.77 3.95 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 117.024 0.412 . . . . 0.0 110.739 -179.982 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -95.75 168.16 26.16 Favored Glycine 0 N--CA 1.443 -0.868 0 C-N-CA 120.845 -0.693 . . . . 0.0 111.944 178.922 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 23.5 Cg_exo -64.45 139.77 66.36 Favored 'Trans proline' 0 C--O 1.238 0.523 0 C-N-CA 122.657 2.238 . . . . 0.0 112.301 179.002 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . 0.426 ' HB ' ' O ' ' A' ' 76' ' ' GLN . 48.9 pt -131.74 168.4 24.05 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 CA-C-N 115.801 -0.636 . . . . 0.0 109.918 179.0 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -79.95 148.31 30.02 Favored Glycine 0 C--N 1.32 -0.351 0 C-N-CA 120.874 -0.679 . . . . 0.0 111.645 -179.816 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.568 ' CD2' HG13 ' A' ' 38' ' ' VAL . 2.6 t80 -136.88 130.83 32.3 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-O 120.819 0.342 . . . . 0.0 111.18 -178.538 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 57.3 ttp180 -135.62 134.81 39.66 Favored 'General case' 0 C--O 1.232 0.142 0 CA-C-N 115.833 -0.621 . . . . 0.0 109.934 176.784 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.418 ' HA ' ' O ' ' A' ' 72' ' ' GLU . . . -136.81 146.14 45.32 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 120.738 0.304 . . . . 0.0 111.484 179.797 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 65.0 m -125.27 131.25 53.13 Favored 'General case' 0 CA--C 1.537 0.461 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.055 178.952 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 61.1 tp -74.26 119.19 18.13 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.334 0.588 . . . . 0.0 112.311 -177.205 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 94.2 mt -90.1 -29.52 18.28 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.502 -0.772 . . . . 0.0 109.849 175.227 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 134.23 166.68 11.31 Favored Glycine 0 N--CA 1.447 -0.578 0 N-CA-C 110.962 -0.855 . . . . 0.0 110.962 -179.135 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 53.9 m-80 58.06 36.39 25.96 Favored 'General case' 0 N--CA 1.477 0.883 0 CA-C-N 117.21 0.505 . . . . 0.0 111.331 179.245 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 17.3 m120 63.59 14.08 7.8 Favored 'General case' 0 N--CA 1.479 0.987 0 CA-C-N 115.614 -0.721 . . . . 0.0 111.277 179.204 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 17.6 m -101.33 126.07 48.04 Favored 'General case' 0 C--O 1.239 0.552 0 CA-C-O 121.081 0.467 . . . . 0.0 111.156 -178.883 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 91.0 m-85 -114.52 141.98 47.01 Favored 'General case' 0 C--N 1.313 -0.997 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.494 -178.556 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . 0.418 ' O ' ' HA ' ' A' ' 63' ' ' ALA . 35.8 tt0 -90.39 120.16 31.28 Favored 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 108.35 -0.982 . . . . 0.0 108.35 175.574 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.416 HG11 ' CE1' ' A' ' 61' ' ' PHE . 54.2 t -103.67 132.83 49.19 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.013 0 N-CA-C 113.871 1.063 . . . . 0.0 113.871 -171.953 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 70.6 mt-10 -129.3 129.47 44.91 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 114.472 -1.24 . . . . 0.0 107.976 173.762 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 96.4 m-20 -109.12 145.48 35.63 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 121.279 0.562 . . . . 0.0 111.838 -177.781 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' GLN . . . . . 0.426 ' O ' ' HB ' ' A' ' 59' ' ' ILE . 10.4 tt0 -111.26 123.59 50.51 Favored 'General case' 0 C--N 1.316 -0.873 0 C-N-CA 124.032 0.933 . . . . 0.0 111.592 -177.125 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 10.0 p90 -140.27 155.61 46.79 Favored 'General case' 0 C--N 1.316 -0.89 0 N-CA-C 110.52 -0.178 . . . . 0.0 110.52 175.061 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 107.0 -9.71 39.92 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.852 -0.69 . . . . 0.0 112.279 -179.934 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 145.03 171.81 15.02 Favored Glycine 0 N--CA 1.447 -0.591 0 N-CA-C 111.581 -0.608 . . . . 0.0 111.581 178.912 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 1.8 p-10 -62.9 153.03 34.7 Favored 'General case' 0 C--O 1.241 0.609 0 CA-C-N 117.015 0.408 . . . . 0.0 110.31 178.081 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 16.3 m 65.42 -95.06 0.04 OUTLIER 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.717 -0.674 . . . . 0.0 109.497 -178.33 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 50.23 172.48 0.03 OUTLIER Pre-proline 0 CA--C 1.555 1.158 0 N-CA-C 113.533 0.938 . . . . 0.0 113.533 176.519 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_exo -69.91 144.97 54.87 Favored 'Trans proline' 0 N--CA 1.45 -1.062 0 C-N-CA 121.722 1.614 . . . . 0.0 110.161 172.255 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' TRP . . . . . . . . . . . . . 92.7 m95 -90.88 139.34 30.84 Favored 'General case' 0 C--N 1.313 -0.983 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 178.757 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 84.8 m-70 -111.5 138.63 47.77 Favored 'General case' 0 C--N 1.313 -1.005 0 N-CA-C 108.936 -0.764 . . . . 0.0 108.936 -178.822 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 10.5 m -66.85 135.62 54.17 Favored 'General case' 0 C--N 1.314 -0.957 0 CA-C-O 120.675 0.274 . . . . 0.0 110.922 -177.324 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -110.01 -44.59 1.01 Allowed Glycine 0 N--CA 1.443 -0.838 0 C-N-CA 120.832 -0.699 . . . . 0.0 111.742 179.376 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 143.74 -158.7 27.44 Favored Glycine 0 C--O 1.214 -1.151 0 C-N-CA 120.723 -0.751 . . . . 0.0 111.473 178.681 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 19.1 m120 -115.33 129.25 56.55 Favored 'General case' 0 C--N 1.315 -0.918 0 CA-C-N 117.303 0.551 . . . . 0.0 110.88 179.278 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 23.3 m0 -118.96 150.73 39.42 Favored 'General case' 0 N--CA 1.466 0.335 0 N-CA-C 109.981 -0.377 . . . . 0.0 109.981 179.777 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 92.1 mt -109.63 123.08 65.23 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 177.76 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 83.6 mt -134.3 84.85 2.14 Favored 'General case' 0 C--O 1.265 1.871 0 O-C-N 123.688 0.617 . . . . 0.0 112.473 -175.85 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 168.13 110.36 0.23 Allowed Glycine 0 C--O 1.218 -0.903 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.688 178.003 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 68.3 p -100.78 -9.43 21.73 Favored 'General case' 0 C--O 1.225 -0.232 0 CA-C-O 120.984 0.421 . . . . 0.0 111.116 178.379 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 92.2 mtt180 -96.69 3.79 52.23 Favored 'General case' 0 C--O 1.232 0.162 0 C-N-CA 120.574 -0.45 . . . . 0.0 111.921 179.32 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 66.6 tt0 72.83 -83.13 0.03 OUTLIER 'General case' 0 N--CA 1.467 0.401 0 C-N-CA 123.22 0.608 . . . . 0.0 112.377 173.067 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 63.4 m-80 -92.34 34.15 1.06 Allowed 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 120.831 0.348 . . . . 0.0 111.612 -174.802 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' GLN . . . . . . . . . . . . . 23.6 tp60 -120.08 -48.11 2.35 Favored 'General case' 0 C--N 1.316 -0.875 0 C-N-CA 120.59 -0.444 . . . . 0.0 110.284 -178.945 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 93.4 m-20 72.62 137.84 0.05 Allowed 'General case' 0 N--CA 1.485 1.308 0 O-C-N 123.735 0.647 . . . . 0.0 112.284 178.499 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 69.9 t -78.43 132.4 32.44 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.33 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.871 178.861 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . 0.426 ' HB ' ' OG ' ' A' ' 40' ' ' SER . 34.4 m -113.04 -27.64 2.68 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.517 0 N-CA-C 112.555 0.576 . . . . 0.0 112.555 -179.506 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . 0.436 ' HB1' ' HB ' ' A' ' 119' ' ' THR . . . -146.82 144.45 29.35 Favored 'General case' 0 C--N 1.322 -0.619 0 C-N-CA 119.96 -0.696 . . . . 0.0 111.546 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.541 ' O ' ' HA ' ' A' ' 37' ' ' ASN . 34.1 mm -133.98 128.05 52.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.62 179.193 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . 0.429 ' HB3' ' OG1' ' A' ' 117' ' ' THR . 43.4 t30 -131.27 92.08 3.13 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.292 175.714 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 29.4 m -138.12 144.26 31.11 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.566 0 N-CA-C 113.017 0.747 . . . . 0.0 113.017 -175.451 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 79.9 tt0 -148.19 101.39 3.26 Favored 'General case' 0 CA--C 1.538 0.501 0 CA-C-N 115.558 -0.746 . . . . 0.0 110.656 176.832 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 107' ' ' SER . . . . . 0.44 ' HB2' ' H ' ' A' ' 115' ' ' ASN . 69.5 m -166.69 165.82 16.27 Favored 'General case' 0 N--CA 1.475 0.821 0 CA-C-N 114.834 -1.075 . . . . 0.0 112.388 -178.909 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 116.41 117.19 2.98 Favored Glycine 0 N--CA 1.424 -2.156 0 C-N-CA 120.344 -0.932 . . . . 0.0 113.241 175.308 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 -67.38 -42.44 83.39 Favored 'General case' 0 C--N 1.319 -0.757 0 N-CA-C 107.997 -1.112 . . . . 0.0 107.997 175.639 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 30.3 t70 -142.38 33.43 1.48 Allowed 'General case' 0 C--O 1.213 -0.85 0 CA-C-N 114.428 -1.26 . . . . 0.0 108.228 175.432 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . 0.433 ' HA3' ' HB3' ' A' ' 32' ' ' ASN . . . 81.82 18.05 68.82 Favored Glycine 0 CA--C 1.523 0.538 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.656 -178.335 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 112' ' ' GLN . . . . . 0.434 ' HA ' ' CD1' ' A' ' 132' ' ' LEU . 98.1 mt-30 -66.66 -40.64 88.7 Favored 'General case' 0 C--O 1.244 0.794 0 CA-C-O 120.975 0.417 . . . . 0.0 111.71 -179.177 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 25.6 p -139.15 143.37 38.15 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.824 -0.626 . . . . 0.0 110.755 -178.391 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 114' ' ' LEU . . . . . 0.4 ' HA ' ' HB2' ' A' ' 107' ' ' SER . 4.4 mm? -119.4 123.35 43.89 Favored 'General case' 0 C--N 1.317 -0.814 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 176.539 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . 0.44 ' H ' ' HB2' ' A' ' 107' ' ' SER . 53.6 m-80 -128.66 149.6 50.6 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-O 120.851 0.358 . . . . 0.0 110.587 -178.503 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 155.48 -131.34 3.05 Favored Glycine 0 N--CA 1.438 -1.175 0 C-N-CA 120.634 -0.793 . . . . 0.0 112.343 177.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 117' ' ' THR . . . . . 0.429 ' OG1' ' HB3' ' A' ' 104' ' ' ASN . 23.9 p -130.25 155.37 46.39 Favored 'General case' 0 C--N 1.311 -1.089 0 CA-C-O 121.015 0.436 . . . . 0.0 110.848 -178.459 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 23.2 ptm -146.2 153.34 40.52 Favored 'General case' 0 C--N 1.313 -0.991 0 CA-C-N 115.949 -0.569 . . . . 0.0 109.67 -178.809 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 119' ' ' THR . . . . . 0.436 ' HB ' ' HB1' ' A' ' 102' ' ' ALA . 26.0 m -132.99 131.34 40.64 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-O 120.642 0.258 . . . . 0.0 111.422 -179.294 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 33.0 m-85 -95.75 163.49 13.15 Favored 'General case' 0 CA--C 1.509 -0.611 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.394 175.992 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -62.75 128.59 36.64 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.588 178.155 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 70.95 15.58 74.18 Favored Glycine 0 CA--C 1.524 0.596 0 CA-C-N 115.895 -0.593 . . . . 0.0 113.257 179.44 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -127.03 179.82 5.22 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 117.149 0.474 . . . . 0.0 111.335 -179.46 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -105.55 170.09 16.91 Favored Glycine 0 N--CA 1.445 -0.754 0 N-CA-C 111.502 -0.639 . . . . 0.0 111.502 178.533 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 22.9 Cg_exo -65.37 135.39 42.61 Favored 'Trans proline' 0 CA--C 1.534 0.511 0 C-N-CA 122.542 2.161 . . . . 0.0 112.375 -179.812 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 48.0 pt -131.21 165.09 32.49 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 116.06 -0.518 . . . . 0.0 109.941 177.931 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -73.76 132.78 16.25 Favored Glycine 0 CA--C 1.521 0.464 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.751 -179.169 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 91.6 t80 -114.8 132.96 56.3 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 120.634 0.254 . . . . 0.0 111.224 -179.526 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 63.0 tttm -137.49 101.83 4.61 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.029 176.927 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -106.37 133.51 11.66 Favored Glycine 0 N--CA 1.446 -0.645 0 C-N-CA 120.977 -0.63 . . . . 0.0 111.617 179.485 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 49.1 m -130.24 137.55 50.08 Favored 'General case' 0 C--N 1.311 -1.072 0 CA-C-N 116.638 0.219 . . . . 0.0 111.191 -179.334 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 132' ' ' LEU . . . . . 0.434 ' CD1' ' HA ' ' A' ' 112' ' ' GLN . 87.9 mt -57.7 134.93 56.64 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-O 120.858 0.361 . . . . 0.0 110.31 176.781 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 133' ' ' THR . . . . . 0.544 ' OG1' ' HB2' ' A' ' 5' ' ' ASN . 57.5 m . . . . . 0 C--O 1.251 1.182 0 CA-C-O 118.643 -0.694 . . . . 0.0 110.539 -179.086 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.692 0 N-CA-C 110.373 -0.232 . . . . 0.0 110.373 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' LEU . . . . . 0.538 HD11 HE21 ' A' ' 22' ' ' GLN . 2.8 tm? -99.85 131.41 45.85 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.357 -177.663 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . 0.595 ' CE1' ' HB ' ' A' ' 25' ' ' ILE . 85.1 m-85 -121.41 145.11 48.25 Favored 'General case' 0 C--O 1.238 0.476 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.866 -179.215 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 14.9 m120 -82.67 142.23 31.85 Favored 'General case' 0 N--CA 1.468 0.436 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 176.991 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.46 HG21 ' CD1' ' A' ' 23' ' ' TRP . 59.0 t -116.09 126.76 73.72 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 N-CA-C 113.464 0.913 . . . . 0.0 113.464 -176.159 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 92.0 mt-10 -128.09 132.43 49.01 Favored 'General case' 0 N--CA 1.445 -0.683 0 CA-C-N 114.634 -1.167 . . . . 0.0 108.088 175.001 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 12.8 m120 -124.59 145.74 49.43 Favored 'General case' 0 C--N 1.313 -0.986 0 CA-C-O 120.645 0.259 . . . . 0.0 110.696 -178.158 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 52.0 tt0 -119.65 118.24 30.43 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.808 0.337 . . . . 0.0 110.464 179.071 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' TRP . . . . . 0.5 ' CZ3' ' HB2' ' A' ' 18' ' ' ASN . 2.5 m-90 -79.2 140.79 37.6 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.332 179.711 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 89.33 -42.21 3.02 Favored Glycine 0 N--CA 1.444 -0.811 0 C-N-CA 120.579 -0.82 . . . . 0.0 112.05 -179.085 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.84 21.42 71.51 Favored Glycine 0 C--O 1.227 -0.327 0 C-N-CA 120.85 -0.691 . . . . 0.0 111.581 -179.707 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 20.9 p -168.2 133.82 1.86 Allowed 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.771 -0.214 . . . . 0.0 111.188 -178.024 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 63.6 p 46.85 44.73 14.66 Favored 'General case' 0 N--CA 1.475 0.824 0 C-N-CA 123.456 0.702 . . . . 0.0 112.638 176.79 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . 0.429 ' HA ' ' HD3' ' A' ' 16' ' ' PRO . . . -139.6 144.32 38.9 Favored Pre-proline 0 C--N 1.324 -0.517 0 C-N-CA 120.905 -0.318 . . . . 0.0 111.425 -178.158 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.429 ' HD3' ' HA ' ' A' ' 15' ' ' ALA . 11.4 Cg_exo -71.57 157.45 55.98 Favored 'Trans proline' 0 C--N 1.347 0.483 0 C-N-CA 123.033 2.489 . . . . 0.0 111.699 176.888 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 91.5 m95 -85.26 134.15 34.14 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 120.891 0.377 . . . . 0.0 110.343 179.57 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' ASN . . . . . 0.5 ' HB2' ' CZ3' ' A' ' 10' ' ' TRP . 90.7 m-20 -110.01 135.67 50.47 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.105 179.231 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 14.7 pt-20 -105.44 131.2 53.15 Favored 'General case' 0 C--N 1.314 -0.95 0 N-CA-C 109.241 -0.652 . . . . 0.0 109.241 -179.828 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -157.33 34.26 0.55 Allowed Glycine 0 N--CA 1.44 -1.045 0 C-N-CA 119.058 -1.544 . . . . 0.0 112.997 179.843 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 162.67 -179.02 38.21 Favored Glycine 0 N--CA 1.444 -0.777 0 C-N-CA 119.58 -1.295 . . . . 0.0 113.511 178.847 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . 0.538 HE21 HD11 ' A' ' 3' ' ' LEU . 3.3 pt20 -145.29 140.66 27.94 Favored 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 179.218 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . 0.46 ' CD1' HG21 ' A' ' 6' ' ' VAL . 48.0 m0 -114.74 155.97 25.7 Favored 'General case' 0 CA--C 1.505 -0.761 0 CA-C-O 120.715 0.293 . . . . 0.0 111.443 -176.213 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 77.8 tt0 -116.6 119.52 35.79 Favored 'General case' 0 C--N 1.321 -0.633 0 C-N-CA 120.445 -0.502 . . . . 0.0 110.221 177.881 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.595 ' HB ' ' CE1' ' A' ' 4' ' ' TYR . 97.7 mt -135.32 143.37 37.12 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.72 0 CA-C-N 114.998 -1.001 . . . . 0.0 109.464 -177.681 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 84.0 60.61 1.93 Allowed Glycine 0 C--O 1.225 -0.437 0 C-N-CA 120.18 -1.01 . . . . 0.0 112.398 178.629 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 15.4 m -58.15 -40.4 81.26 Favored 'General case' 0 C--N 1.317 -0.838 0 O-C-N 123.935 0.432 . . . . 0.0 111.618 179.759 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 79.9 ttt180 -61.29 -42.27 98.37 Favored 'General case' 0 CA--C 1.538 0.518 0 CA-C-N 116.588 -0.278 . . . . 0.0 111.558 178.803 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 20.1 m 75.99 -21.98 0.29 Allowed 'General case' 0 N--CA 1.482 1.17 0 C-N-CA 123.75 0.82 . . . . 0.0 113.201 179.073 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 58.3 m-20 -68.23 -11.71 59.77 Favored 'General case' 0 N--CA 1.483 1.189 0 CA-C-O 121.06 0.457 . . . . 0.0 111.414 178.243 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -152.71 136.09 15.87 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.133 -178.963 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . 0.561 ' ND2' ' HA3' ' A' ' 111' ' ' GLY . 2.5 t30 -93.45 150.81 20.16 Favored 'General case' 0 C--O 1.247 0.967 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.247 178.984 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 46.3 t -93.98 131.33 41.2 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 CA-C-N 115.697 -0.683 . . . . 0.0 109.62 -178.399 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 28.1 m -102.75 -32.43 3.11 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.686 0 C-N-CA 120.596 -0.442 . . . . 0.0 111.835 -179.595 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.485 ' HB1' ' HB ' ' A' ' 52' ' ' THR . . . -135.01 145.19 47.83 Favored 'General case' 0 CA--C 1.511 -0.537 0 C-N-CA 120.349 -0.54 . . . . 0.0 111.28 -179.201 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 93.9 mt -142.33 122.54 10.72 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 CA-C-N 115.744 -0.662 . . . . 0.0 109.553 -179.543 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 19.7 m120 -130.74 112.58 13.21 Favored 'General case' 0 C--N 1.316 -0.851 0 N-CA-C 108.246 -1.02 . . . . 0.0 108.246 176.07 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.444 HG23 ' HB ' ' A' ' 103' ' ' ILE . 27.3 m -147.41 150.57 14.49 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 C-N-CA 120.665 -0.414 . . . . 0.0 111.208 -175.146 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 74.6 tt0 -142.73 145.1 33.01 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 108.955 -0.758 . . . . 0.0 108.955 176.031 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' SER . . . . . 0.426 ' HA ' ' O ' ' A' ' 46' ' ' THR . 34.2 p -80.55 148.95 30.14 Favored 'General case' 0 C--N 1.312 -1.024 0 N-CA-C 112.203 0.446 . . . . 0.0 112.203 -176.327 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -95.06 -19.95 29.48 Favored Glycine 0 N--CA 1.449 -0.476 0 N-CA-C 111.012 -0.835 . . . . 0.0 111.012 176.831 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 15.7 m-20 -128.72 -156.56 0.76 Allowed 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 109.45 -0.574 . . . . 0.0 109.45 179.071 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 9.9 p-10 -77.23 46.89 0.52 Allowed 'General case' 0 N--CA 1.474 0.775 0 CA-C-O 121.314 0.578 . . . . 0.0 112.065 -179.11 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 88.22 -7.79 80.46 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 121.047 -0.597 . . . . 0.0 113.176 178.441 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 53.5 mt-30 -72.58 -34.83 67.71 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.964 0.382 . . . . 0.0 111.498 178.906 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' THR . . . . . 0.426 ' O ' ' HA ' ' A' ' 40' ' ' SER . 24.5 p -115.02 132.01 56.74 Favored 'General case' 0 C--N 1.314 -0.975 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.535 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 93.8 mt -124.3 127.97 48.44 Favored 'General case' 0 CA--C 1.509 -0.607 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 -179.475 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 9.0 m120 -129.39 137.05 50.7 Favored 'General case' 0 C--N 1.313 -1.011 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 -179.696 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 178.18 -157.22 21.1 Favored Glycine 0 N--CA 1.445 -0.72 0 C-N-CA 119.287 -1.435 . . . . 0.0 113.795 179.275 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 38.3 m -130.0 134.35 47.37 Favored 'General case' 0 CA--C 1.545 0.756 0 C-N-CA 123.087 0.555 . . . . 0.0 110.905 -178.562 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' MET . . . . . 0.401 ' SD ' ' HD1' ' A' ' 61' ' ' PHE . 48.0 mtp -110.2 155.32 22.14 Favored 'General case' 0 N--CA 1.468 0.459 0 C-N-CA 122.308 0.243 . . . . 0.0 110.815 177.151 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.485 ' HB ' ' HB1' ' A' ' 35' ' ' ALA . 25.5 m -133.78 126.29 30.3 Favored 'General case' 0 CA--C 1.542 0.641 0 CA-C-N 116.491 -0.322 . . . . 0.0 110.167 175.322 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . 0.446 ' HB2' ' HB2' ' A' ' 56' ' ' GLU . 65.5 m-85 -92.94 166.97 12.12 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 116.664 -0.244 . . . . 0.0 110.769 177.964 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -63.34 106.48 0.91 Allowed 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.473 -179.754 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 81.78 16.03 73.9 Favored Glycine 0 CA--C 1.52 0.358 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.788 178.857 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . 0.446 ' HB2' ' HB2' ' A' ' 53' ' ' TYR . 80.3 mm-40 -119.99 169.62 10.02 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 120.773 0.32 . . . . 0.0 110.807 -179.93 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -90.05 172.56 38.55 Favored Glycine 0 N--CA 1.444 -0.813 0 C-N-CA 120.99 -0.624 . . . . 0.0 112.303 179.925 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_exo -67.14 137.56 44.47 Favored 'Trans proline' 0 CA--C 1.535 0.56 0 C-N-CA 122.726 2.284 . . . . 0.0 112.026 179.16 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 45.0 pt -128.79 160.86 38.91 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.428 179.195 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -75.1 141.61 28.3 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.451 -178.919 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.401 ' HD1' ' SD ' ' A' ' 51' ' ' MET . 61.8 t80 -126.01 127.04 45.27 Favored 'General case' 0 C--N 1.32 -0.712 0 C-N-CA 122.401 0.28 . . . . 0.0 110.797 -179.792 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 29.3 ttp85 -136.97 129.04 29.44 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 175.801 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.44 ' HB1' ' HB3' ' A' ' 71' ' ' TYR . . . -136.88 146.4 45.51 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 112.304 0.483 . . . . 0.0 112.304 -177.622 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 55.9 m -122.7 128.18 50.23 Favored 'General case' 0 CA--C 1.542 0.668 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.222 178.303 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 2.3 tm? -73.47 121.52 20.68 Favored 'General case' 0 CA--C 1.538 0.493 0 CA-C-O 121.134 0.492 . . . . 0.0 111.054 -178.058 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 96.0 mt -75.04 -33.94 61.81 Favored 'General case' 0 CA--C 1.534 0.354 0 CA-C-N 115.638 -0.71 . . . . 0.0 111.907 179.799 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 126.12 -14.84 6.96 Favored Glycine 0 C--O 1.219 -0.812 0 C-N-CA 120.574 -0.822 . . . . 0.0 112.476 -178.262 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 28.9 p-10 -111.75 30.23 7.17 Favored 'General case' 0 C--N 1.316 -0.856 0 CA-C-O 120.824 0.345 . . . . 0.0 110.736 -179.078 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 96.1 m-20 69.03 6.47 5.66 Favored 'General case' 0 N--CA 1.483 1.187 0 C-N-CA 123.6 0.76 . . . . 0.0 111.499 -177.25 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 35.0 t -102.46 140.35 36.86 Favored 'General case' 0 N--CA 1.438 -1.069 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 177.178 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.44 ' HB3' ' HB1' ' A' ' 63' ' ' ALA . 66.8 m-85 -116.91 139.72 50.31 Favored 'General case' 0 C--N 1.303 -1.42 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.936 -178.296 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 39.5 tt0 -85.29 112.3 20.66 Favored 'General case' 0 C--N 1.309 -1.16 0 N-CA-C 106.759 -1.571 . . . . 0.0 106.759 173.673 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 70.5 t -109.41 135.83 47.17 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 N-CA-C 113.475 0.917 . . . . 0.0 113.475 -171.141 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -128.54 130.48 47.48 Favored 'General case' 0 N--CA 1.443 -0.811 0 CA-C-N 114.708 -1.133 . . . . 0.0 108.917 175.281 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 95.9 m-20 -108.9 150.11 28.17 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.748 -179.286 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 61.3 tt0 -115.49 120.36 39.24 Favored 'General case' 0 C--N 1.308 -1.232 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.435 -177.534 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 8.6 p90 -142.87 162.85 34.37 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 110.24 -0.281 . . . . 0.0 110.24 179.544 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 100.91 -9.02 58.07 Favored Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.768 -0.729 . . . . 0.0 111.97 179.781 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 137.59 159.61 8.26 Favored Glycine 0 N--CA 1.442 -0.917 0 N-CA-C 111.019 -0.832 . . . . 0.0 111.019 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 5.9 m-20 -60.41 -39.59 87.93 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 116.963 0.382 . . . . 0.0 111.687 -179.319 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 4.6 m -76.57 -4.93 45.42 Favored 'General case' 0 C--N 1.321 -0.671 0 N-CA-C 112.251 0.463 . . . . 0.0 112.251 -177.476 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -75.46 153.16 85.76 Favored Pre-proline 0 C--N 1.324 -0.538 0 CA-C-O 120.587 0.232 . . . . 0.0 111.196 -178.422 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 10.7 Cg_exo -72.34 178.48 6.06 Favored 'Trans proline' 0 C--N 1.35 0.642 0 C-N-CA 122.925 2.417 . . . . 0.0 112.017 178.646 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' TRP . . . . . . . . . . . . . 90.9 m95 -92.14 138.17 31.75 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 109.322 -0.622 . . . . 0.0 109.322 179.722 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 82.8 m-70 -112.59 144.61 41.79 Favored 'General case' 0 C--N 1.318 -0.791 0 N-CA-C 109.992 -0.373 . . . . 0.0 109.992 -177.685 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 19.5 p -64.36 116.4 6.03 Favored 'General case' 0 C--N 1.316 -0.89 0 CA-C-O 120.781 0.324 . . . . 0.0 111.457 -178.376 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -89.63 -46.41 4.3 Favored Glycine 0 N--CA 1.44 -1.088 0 C-N-CA 120.388 -0.911 . . . . 0.0 111.018 178.008 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 139.87 -157.86 25.48 Favored Glycine 0 N--CA 1.442 -0.909 0 C-N-CA 120.816 -0.707 . . . . 0.0 111.629 177.471 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 19.8 m120 -105.48 134.19 49.0 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 109.697 -0.483 . . . . 0.0 109.697 178.974 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 90' ' ' TRP . . . . . 0.482 ' CH2' HG21 ' A' ' 25' ' ' ILE . 13.8 m0 -124.04 146.13 48.77 Favored 'General case' 0 C--N 1.316 -0.862 0 CA-C-N 116.203 -0.453 . . . . 0.0 109.84 -178.548 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 91.6 mt -110.57 114.63 47.6 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.285 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 177.456 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 85.5 mt -133.56 79.98 1.85 Allowed 'General case' 0 C--O 1.269 2.113 0 CA-C-O 121.771 0.796 . . . . 0.0 112.312 -175.724 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 170.0 109.51 0.22 Allowed Glycine 0 N--CA 1.442 -0.966 0 CA-C-N 115.344 -0.844 . . . . 0.0 111.768 -179.498 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 19.1 m -96.67 30.27 2.68 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-O 120.902 0.382 . . . . 0.0 110.349 -179.882 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 95' ' ' ARG . . . . . 0.542 ' CB ' ' HB3' ' A' ' 98' ' ' GLN . 9.7 mmt180 -136.56 150.54 48.65 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-O 121.257 0.551 . . . . 0.0 112.317 -176.968 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 79.3 tt0 -55.99 -51.27 68.33 Favored 'General case' 0 CA--C 1.541 0.601 0 CA-C-N 114.731 -1.122 . . . . 0.0 112.602 -176.961 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 57.5 m-80 -134.63 42.69 2.81 Favored 'General case' 0 N--CA 1.471 0.609 0 CA-C-O 120.965 0.412 . . . . 0.0 109.99 -179.928 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' GLN . . . . . 0.594 ' NE2' ' HB2' ' A' ' 123' ' ' GLU . 52.8 tt0 -144.37 110.39 5.41 Favored 'General case' 0 C--N 1.315 -0.919 0 CA-C-O 121.147 0.499 . . . . 0.0 110.614 -175.952 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 99' ' ' ASN . . . . . 0.439 ' HB3' ' OH ' ' A' ' 71' ' ' TYR . 87.7 m-20 -91.06 168.37 11.69 Favored 'General case' 0 C--O 1.244 0.782 0 CA-C-N 115.293 -0.867 . . . . 0.0 111.111 -175.73 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 23.6 m -83.01 140.53 16.19 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.673 0 C-N-CA 120.011 -0.676 . . . . 0.0 110.244 173.443 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 29.7 m -115.55 -27.45 2.56 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.429 0 C-N-CA 120.608 -0.437 . . . . 0.0 112.062 178.14 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -147.87 142.06 26.12 Favored 'General case' 0 C--N 1.32 -0.677 0 C-N-CA 120.581 -0.447 . . . . 0.0 110.551 178.352 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.444 ' HB ' HG23 ' A' ' 38' ' ' VAL . 94.9 mt -138.4 125.75 27.83 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 N-CA-C 110.106 -0.331 . . . . 0.0 110.106 178.26 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 35.2 t30 -128.06 97.8 4.91 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.367 176.589 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.417 HG13 ' HD2' ' A' ' 128' ' ' PHE . 11.7 m -142.6 149.7 18.85 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 N-CA-C 113.185 0.809 . . . . 0.0 113.185 -176.454 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 41.9 tt0 -148.15 147.19 29.18 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.089 -0.959 . . . . 0.0 109.839 175.621 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 47.1 t -113.23 133.59 55.01 Favored 'General case' 0 N--CA 1.442 -0.874 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.355 -177.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -81.52 -5.07 90.22 Favored Glycine 0 N--CA 1.447 -0.568 0 N-CA-C 111.103 -0.799 . . . . 0.0 111.103 175.444 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . 0.402 ' C ' ' H ' ' A' ' 111' ' ' GLY . 62.8 m-20 -114.06 -166.46 1.1 Allowed 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 109.362 -0.607 . . . . 0.0 109.362 -179.95 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 25.6 m-20 -77.68 34.97 0.18 Allowed 'General case' 0 N--CA 1.472 0.66 0 CA-C-O 120.847 0.356 . . . . 0.0 111.123 178.931 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . 0.561 ' HA3' ' ND2' ' A' ' 32' ' ' ASN . . . 81.43 8.24 87.32 Favored Glycine 0 N--CA 1.445 -0.74 0 C-N-CA 120.888 -0.672 . . . . 0.0 112.405 -178.852 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 97.3 mt-30 -66.04 -44.22 85.26 Favored 'General case' 0 C--O 1.243 0.713 0 CA-C-O 121.056 0.455 . . . . 0.0 109.995 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 22.5 p -113.12 117.61 32.44 Favored 'General case' 0 N--CA 1.441 -0.888 0 CA-C-N 115.374 -0.83 . . . . 0.0 109.259 177.548 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 34.8 tp -111.84 121.88 46.25 Favored 'General case' 0 C--N 1.311 -1.08 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 -178.957 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 26.3 p30 -145.57 164.82 30.49 Favored 'General case' 0 C--O 1.251 1.134 0 C-N-CA 120.039 -0.664 . . . . 0.0 112.677 -178.609 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 149.75 -127.78 2.53 Favored Glycine 0 N--CA 1.439 -1.12 0 CA-C-N 114.655 -1.157 . . . . 0.0 111.127 -179.636 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 31.9 p -134.0 159.75 39.82 Favored 'General case' 0 C--N 1.314 -0.96 0 CA-C-O 120.851 0.358 . . . . 0.0 111.063 -178.9 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 4.2 ppp? -157.28 161.93 39.17 Favored 'General case' 0 C--N 1.313 -1.004 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 179.154 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 48.7 m -133.39 126.3 30.99 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-N 116.46 -0.336 . . . . 0.0 110.978 -179.894 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . 0.44 ' CB ' HE21 ' A' ' 98' ' ' GLN . 64.9 m-85 -88.13 162.98 16.43 Favored 'General case' 0 CA--C 1.521 -0.147 0 CA-C-N 116.196 -0.456 . . . . 0.0 109.789 174.285 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -55.76 -30.59 61.5 Favored 'General case' 0 N--CA 1.47 0.553 0 N-CA-C 113.602 0.964 . . . . 0.0 113.602 -176.627 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -140.65 26.62 2.52 Favored Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 119.636 -1.269 . . . . 0.0 112.67 -178.434 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . 0.594 ' HB2' ' NE2' ' A' ' 98' ' ' GLN . 23.5 tp10 -112.6 -50.71 2.88 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.988 0.423 . . . . 0.0 110.461 -177.578 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 116.5 -179.76 17.76 Favored Glycine 0 N--CA 1.441 -0.986 0 N-CA-C 111.122 -0.791 . . . . 0.0 111.122 -177.639 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 7.4 Cg_exo -73.81 112.8 3.62 Favored 'Trans proline' 0 N--CA 1.461 -0.392 0 C-N-CA 122.735 2.29 . . . . 0.0 112.021 179.651 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 39.2 pt -129.84 162.92 36.58 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.862 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.517 179.734 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -72.84 144.41 35.1 Favored Glycine 0 N--CA 1.448 -0.517 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.728 -179.496 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . 0.417 ' HD2' HG13 ' A' ' 105' ' ' VAL . 21.1 t80 -125.59 132.63 52.49 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 121.162 0.506 . . . . 0.0 110.732 178.733 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 62.6 tttm -137.42 123.46 20.3 Favored 'General case' 0 C--N 1.311 -1.073 0 CA-C-N 115.0 -1.0 . . . . 0.0 108.93 -179.829 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -139.23 141.72 12.1 Favored Glycine 0 N--CA 1.436 -1.302 0 C-N-CA 120.363 -0.922 . . . . 0.0 112.725 -179.335 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 35.3 m -121.35 133.11 55.1 Favored 'General case' 0 C--N 1.311 -1.107 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.355 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 60.2 tp -66.85 139.89 57.78 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 109.754 -0.462 . . . . 0.0 109.754 178.492 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 133' ' ' THR . . . . . 0.444 HG21 ' O ' ' A' ' 3' ' ' LEU . 13.4 t . . . . . 0 C--O 1.253 1.251 0 CA-C-O 118.53 -0.748 . . . . 0.0 110.251 -179.117 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.737 0 CA-C-O 120.668 0.271 . . . . 0.0 110.42 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' LEU . . . . . 0.451 HD11 HE21 ' A' ' 22' ' ' GLN . 1.7 tm? -95.16 129.89 42.09 Favored 'General case' 0 C--N 1.319 -0.739 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 178.598 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . 0.451 ' N ' HD12 ' A' ' 3' ' ' LEU . 78.8 m-85 -120.53 145.85 46.89 Favored 'General case' 0 C--O 1.24 0.597 0 CA-C-O 121.081 0.467 . . . . 0.0 112.158 -176.842 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' ASN . . . . . 0.61 ' O ' ' HA2' ' A' ' 130' ' ' GLY . 21.6 m120 -87.46 140.46 29.51 Favored 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 107.186 -1.413 . . . . 0.0 107.186 175.274 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.471 HG23 ' CD1' ' A' ' 23' ' ' TRP . 70.1 t -114.64 128.41 71.73 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 N-CA-C 113.641 0.978 . . . . 0.0 113.641 -174.274 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . 0.41 ' HB2' ' HB3' ' A' ' 129' ' ' LYS . 99.7 mt-10 -125.44 134.09 52.22 Favored 'General case' 0 N--CA 1.444 -0.759 0 CA-C-N 114.517 -1.219 . . . . 0.0 109.098 175.358 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 12.9 m120 -121.4 140.54 52.01 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-N 116.462 -0.336 . . . . 0.0 110.601 -178.929 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 60.8 tt0 -120.02 120.02 35.1 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.676 -178.972 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 19.6 p90 -135.72 143.18 45.21 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 110.131 -0.322 . . . . 0.0 110.131 178.708 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 106.83 8.53 31.93 Favored Glycine 0 N--CA 1.446 -0.646 0 C-N-CA 120.29 -0.957 . . . . 0.0 111.497 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 103.08 164.71 25.76 Favored Glycine 0 N--CA 1.442 -0.958 0 C-N-CA 121.344 -0.455 . . . . 0.0 112.281 178.502 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 68.8 m -59.07 -23.47 62.07 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 120.836 0.35 . . . . 0.0 111.722 178.766 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 38.8 m -73.52 -6.61 47.56 Favored 'General case' 0 CA--C 1.543 0.696 0 CA-C-O 120.7 0.286 . . . . 0.0 111.596 177.921 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . 0.413 ' HA ' ' HD3' ' A' ' 16' ' ' PRO . . . -95.07 145.56 29.75 Favored Pre-proline 0 C--N 1.328 -0.355 0 O-C-N 122.421 -0.174 . . . . 0.0 110.881 -179.814 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.413 ' HD3' ' HA ' ' A' ' 15' ' ' ALA . 8.2 Cg_exo -73.1 163.82 37.15 Favored 'Trans proline' 0 C--N 1.347 0.492 0 C-N-CA 123.042 2.494 . . . . 0.0 112.586 179.594 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' TRP . . . . . 0.508 ' CZ3' ' HB2' ' A' ' 129' ' ' LYS . 91.3 m95 -83.51 131.13 35.02 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 178.939 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 41.2 m-80 -109.54 141.71 41.62 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.524 -177.833 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 13.9 pt-20 -112.18 137.5 50.18 Favored 'General case' 0 C--N 1.313 -0.991 0 N-CA-C 110.016 -0.364 . . . . 0.0 110.016 179.05 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -154.2 32.45 0.72 Allowed Glycine 0 N--CA 1.443 -0.842 0 C-N-CA 119.76 -1.21 . . . . 0.0 112.641 179.045 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 156.25 -177.61 33.18 Favored Glycine 0 N--CA 1.447 -0.613 0 C-N-CA 119.658 -1.258 . . . . 0.0 113.3 -179.16 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . 0.451 HE21 HD11 ' A' ' 3' ' ' LEU . 4.4 pt20 -141.62 145.35 34.9 Favored 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 109.537 -0.542 . . . . 0.0 109.537 -179.828 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . 0.471 ' CD1' HG23 ' A' ' 6' ' ' VAL . 45.0 m0 -115.93 153.28 31.86 Favored 'General case' 0 C--O 1.24 0.591 0 CA-C-O 121.121 0.486 . . . . 0.0 111.895 -176.752 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 85.9 tt0 -112.17 114.47 27.29 Favored 'General case' 0 CA--C 1.508 -0.663 0 CA-C-N 115.512 -0.767 . . . . 0.0 109.072 177.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 96.8 mt -131.82 136.7 56.49 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-O 121.355 0.597 . . . . 0.0 112.27 -176.048 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 104.93 -26.52 22.05 Favored Glycine 0 N--CA 1.449 -0.454 0 CA-C-N 115.881 -0.6 . . . . 0.0 113.531 175.312 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 2.7 p 44.99 20.89 0.04 OUTLIER 'General case' 0 N--CA 1.486 1.335 0 C-N-CA 123.867 0.867 . . . . 0.0 112.991 -177.512 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 83.4 mtm180 -149.62 150.57 32.4 Favored 'General case' 0 C--O 1.241 0.626 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 -179.243 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 12.6 m -95.51 -15.42 22.9 Favored 'General case' 0 C--N 1.309 -1.159 0 CA-C-O 121.089 0.471 . . . . 0.0 110.268 177.828 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 23.3 m-20 -75.21 -35.5 61.5 Favored 'General case' 0 N--CA 1.468 0.475 0 CA-C-N 115.809 -0.632 . . . . 0.0 112.182 -177.052 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 5.0 mm-40 -132.49 128.23 36.93 Favored 'General case' 0 CA--C 1.509 -0.628 0 N-CA-C 113.876 1.065 . . . . 0.0 113.876 -175.34 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 3.4 m-20 -100.07 151.15 21.71 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 114.834 -1.075 . . . . 0.0 109.311 174.61 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 33.2 m -92.53 142.95 12.38 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.277 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.78 -179.818 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 27.7 m -111.4 -16.08 9.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 C-N-CA 120.931 -0.308 . . . . 0.0 111.744 178.772 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.468 ' HB2' ' HB ' ' A' ' 52' ' ' THR . . . -147.94 140.75 24.74 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 120.3 -0.56 . . . . 0.0 111.597 178.972 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.411 ' HB ' ' CG2' ' A' ' 105' ' ' VAL . 88.8 mt -142.84 121.29 7.7 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 178.607 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' ASN . . . . . 0.477 ' HA ' ' O ' ' A' ' 103' ' ' ILE . 4.8 t-20 -136.54 111.26 8.71 Favored 'General case' 0 C--N 1.307 -1.243 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 177.984 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.441 HG11 ' CD1' ' A' ' 61' ' ' PHE . 27.0 m -148.43 154.37 10.36 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-O 120.804 0.335 . . . . 0.0 111.626 -171.843 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 45.4 tt0 -136.34 143.37 44.07 Favored 'General case' 0 N--CA 1.447 -0.61 0 CA-C-N 115.624 -0.716 . . . . 0.0 109.371 176.644 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 88.4 p -72.83 155.04 40.33 Favored 'General case' 0 C--N 1.314 -0.961 0 CA-C-O 121.131 0.491 . . . . 0.0 111.846 -178.288 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -108.26 -45.0 1.11 Allowed Glycine 0 N--CA 1.438 -1.188 0 CA-C-N 115.596 -0.729 . . . . 0.0 111.924 177.86 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 30.7 t70 -129.3 95.28 3.99 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 111.564 0.209 . . . . 0.0 111.564 -178.772 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 52.15 31.53 9.17 Favored 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 113.594 0.961 . . . . 0.0 113.594 174.989 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 75.7 1.0 65.19 Favored Glycine 0 C--N 1.32 -0.359 0 C-N-CA 120.373 -0.918 . . . . 0.0 113.09 179.828 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 13.8 mm100 -78.48 -29.68 46.89 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-O 121.328 0.585 . . . . 0.0 109.743 178.857 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 32.1 p -121.74 144.26 48.9 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-N 115.709 -0.678 . . . . 0.0 109.912 176.738 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' LEU . . . . . 0.481 ' O ' ' HA ' ' A' ' 62' ' ' ARG . 93.3 mt -129.82 130.96 45.97 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 -178.185 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 94.0 m-20 -127.49 138.97 53.08 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 178.141 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 172.81 -153.04 17.68 Favored Glycine 0 N--CA 1.445 -0.732 0 C-N-CA 119.487 -1.339 . . . . 0.0 113.525 178.707 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 90.9 m -131.99 133.19 44.18 Favored 'General case' 0 C--N 1.317 -0.811 0 C-N-CA 122.704 0.402 . . . . 0.0 110.283 -178.904 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' MET . . . . . 0.501 ' HE2' ' CZ ' ' A' ' 53' ' ' TYR . 15.7 tmm? -126.32 147.58 49.7 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 116.531 -0.304 . . . . 0.0 110.34 -178.949 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.468 ' HB ' ' HB2' ' A' ' 35' ' ' ALA . 28.4 m -128.98 129.12 44.99 Favored 'General case' 0 C--O 1.252 1.234 0 CA-C-O 120.797 0.332 . . . . 0.0 111.826 -177.505 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . 0.501 ' CZ ' ' HE2' ' A' ' 51' ' ' MET . 94.3 m-85 -83.47 167.4 17.47 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 115.811 -0.632 . . . . 0.0 110.419 177.582 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -63.96 103.71 0.62 Allowed 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 112.402 0.519 . . . . 0.0 112.402 -179.012 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 85.84 4.51 84.8 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.937 -0.649 . . . . 0.0 113.261 177.717 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . 0.459 ' HB2' ' HB2' ' A' ' 53' ' ' TYR . 81.9 mm-40 -107.97 176.99 4.95 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-O 120.697 0.284 . . . . 0.0 110.665 -179.781 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -90.11 156.82 25.52 Favored Glycine 0 N--CA 1.44 -1.048 0 C-N-CA 120.879 -0.677 . . . . 0.0 112.16 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_exo -63.67 140.32 74.03 Favored 'Trans proline' 0 CA--C 1.533 0.449 0 C-N-CA 122.758 2.305 . . . . 0.0 112.116 178.697 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 46.4 pt -130.75 166.0 29.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-N 116.341 -0.391 . . . . 0.0 110.649 179.633 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -73.29 138.63 25.55 Favored Glycine 0 N--CA 1.45 -0.398 0 N-CA-C 111.243 -0.743 . . . . 0.0 111.243 179.856 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.441 ' CD1' HG11 ' A' ' 38' ' ' VAL . 52.4 t80 -124.86 130.03 51.58 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-O 120.673 0.273 . . . . 0.0 111.111 -177.148 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . 0.481 ' HA ' ' O ' ' A' ' 47' ' ' LEU . 68.2 ttp85 -140.29 132.67 28.41 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.068 175.041 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -136.64 148.17 47.29 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 120.754 0.311 . . . . 0.0 111.828 -178.074 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 56.3 m -127.18 132.53 50.46 Favored 'General case' 0 CA--C 1.541 0.628 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.513 178.836 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . 0.403 HD23 ' O ' ' A' ' 70' ' ' SER . 3.4 tm? -77.13 114.54 16.04 Favored 'General case' 0 C--N 1.325 -0.486 0 C-N-CA 122.633 0.373 . . . . 0.0 110.447 -179.133 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 10.5 mp -81.99 -32.16 30.75 Favored 'General case' 0 N--CA 1.468 0.455 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.915 178.824 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 164.8 173.58 33.58 Favored Glycine 0 CA--C 1.497 -1.045 0 N-CA-C 110.614 -0.995 . . . . 0.0 110.614 -177.577 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 16.2 t30 40.23 -96.32 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.134 0 C-N-CA 123.138 0.575 . . . . 0.0 111.777 -176.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 24.7 m120 -140.67 19.81 2.35 Favored 'General case' 0 N--CA 1.467 0.412 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 177.29 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' SER . . . . . 0.403 ' O ' HD23 ' A' ' 65' ' ' LEU . 40.7 t -94.54 122.98 37.69 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.308 -0.86 . . . . 0.0 111.256 -175.742 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.626 ' OH ' ' HB3' ' A' ' 99' ' ' ASN . 73.9 m-85 -116.25 137.61 52.0 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 115.817 -0.628 . . . . 0.0 110.515 -179.673 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 82.2 tt0 -92.38 125.4 37.02 Favored 'General case' 0 N--CA 1.439 -1.004 0 N-CA-C 107.476 -1.305 . . . . 0.0 107.476 172.081 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 65.5 t -105.04 130.67 55.8 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.5 0 CA-C-O 121.432 0.634 . . . . 0.0 111.973 -174.953 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 67.0 mt-10 -126.25 120.64 30.51 Favored 'General case' 0 N--CA 1.431 -1.381 0 CA-C-N 114.455 -1.248 . . . . 0.0 107.669 176.424 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 94.4 m-20 -109.55 155.73 21.03 Favored 'General case' 0 C--N 1.317 -0.831 0 CA-C-O 121.2 0.524 . . . . 0.0 111.968 -174.507 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' GLN . . . . . 0.438 ' HB2' ' CE3' ' A' ' 84' ' ' TRP . 61.4 tt0 -119.39 119.9 35.31 Favored 'General case' 0 C--N 1.31 -1.13 0 CA-C-N 115.494 -0.775 . . . . 0.0 109.933 -178.344 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 7.9 p90 -137.2 155.64 49.28 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.593 -0.276 . . . . 0.0 110.727 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 97.75 -10.27 64.39 Favored Glycine 0 N--CA 1.447 -0.615 0 N-CA-C 111.151 -0.779 . . . . 0.0 111.151 -178.652 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 139.35 159.56 8.04 Favored Glycine 0 N--CA 1.44 -1.045 0 N-CA-C 111.312 -0.715 . . . . 0.0 111.312 179.465 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 7.4 p-10 -74.55 -23.37 58.78 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-O 121.046 0.45 . . . . 0.0 111.0 -179.632 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 6.9 m -76.24 -7.89 55.87 Favored 'General case' 0 CA--C 1.542 0.654 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.622 177.346 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -83.86 158.45 62.09 Favored Pre-proline 0 C--N 1.326 -0.415 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.456 -179.407 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -72.84 177.84 7.15 Favored 'Trans proline' 0 C--O 1.237 0.471 0 C-N-CA 122.279 1.986 . . . . 0.0 111.636 177.498 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' TRP . . . . . 0.438 ' CE3' ' HB2' ' A' ' 76' ' ' GLN . 96.4 m95 -90.24 142.23 27.92 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 179.957 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 88.9 m-70 -117.87 146.98 43.51 Favored 'General case' 0 C--N 1.313 -0.986 0 N-CA-C 109.534 -0.543 . . . . 0.0 109.534 -178.71 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 18.8 p -62.87 136.85 58.07 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-O 120.561 0.22 . . . . 0.0 111.351 -179.831 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -111.89 -50.98 0.57 Allowed Glycine 0 N--CA 1.446 -0.637 0 C-N-CA 120.821 -0.704 . . . . 0.0 111.534 178.314 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 148.58 -164.47 29.08 Favored Glycine 0 C--O 1.219 -0.807 0 C-N-CA 120.603 -0.808 . . . . 0.0 111.879 178.308 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 27.9 t-20 -111.46 120.12 41.1 Favored 'General case' 0 C--N 1.317 -0.829 0 CA-C-N 116.988 0.394 . . . . 0.0 110.121 179.205 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 28.1 m0 -114.96 148.78 38.29 Favored 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 -178.472 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 79.9 mt -108.69 118.72 56.86 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.071 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 177.2 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 84.8 mt -131.81 87.38 2.44 Favored 'General case' 0 C--O 1.271 2.2 0 CA-C-O 121.939 0.876 . . . . 0.0 113.253 -174.292 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 160.61 117.04 0.44 Allowed Glycine 0 N--CA 1.446 -0.65 0 CA-C-N 115.162 -0.926 . . . . 0.0 111.829 178.502 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 70.7 p -91.32 -12.82 33.91 Favored 'General case' 0 C--O 1.223 -0.322 0 CA-C-N 117.216 0.508 . . . . 0.0 110.517 178.798 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 94.1 mtt-85 -89.17 138.56 31.32 Favored 'General case' 0 N--CA 1.444 -0.741 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.129 178.904 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -70.94 -34.65 71.68 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 115.673 -0.694 . . . . 0.0 111.408 -175.623 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 89.4 m-20 -112.91 25.89 11.0 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.019 -0.537 . . . . 0.0 111.372 -177.404 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 98' ' ' GLN . . . . . . . . . . . . . 2.0 tt0 -155.49 130.58 9.42 Favored 'General case' 0 C--N 1.333 -0.136 0 C-N-CA 120.323 -0.551 . . . . 0.0 112.244 -176.251 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 99' ' ' ASN . . . . . 0.626 ' HB3' ' OH ' ' A' ' 71' ' ' TYR . 95.2 m-20 -99.32 162.66 12.91 Favored 'General case' 0 C--O 1.253 1.251 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.487 178.867 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 33.3 m -78.3 147.15 7.21 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 C-N-CA 119.884 -0.726 . . . . 0.0 110.979 179.282 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 35.5 m -123.4 -36.93 1.18 Allowed 'Isoleucine or valine' 0 C--O 1.219 -0.502 0 C-N-CA 120.728 -0.389 . . . . 0.0 111.821 177.657 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -136.25 132.19 35.48 Favored 'General case' 0 CA--C 1.503 -0.837 0 C-N-CA 120.407 -0.517 . . . . 0.0 110.687 -179.398 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.477 ' O ' ' HA ' ' A' ' 37' ' ' ASN . 92.3 mt -132.52 124.36 51.37 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 CA-C-N 116.472 -0.331 . . . . 0.0 110.111 178.255 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 7.9 t30 -125.29 97.82 5.37 Favored 'General case' 0 C--N 1.32 -0.708 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 176.482 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.411 ' CG2' ' HB ' ' A' ' 36' ' ' ILE . 26.9 m -139.94 142.97 31.0 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.782 0 N-CA-C 113.134 0.79 . . . . 0.0 113.134 -175.511 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 44.4 tt0 -146.32 148.95 32.93 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.111 -0.949 . . . . 0.0 109.215 177.37 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 40.8 t -137.37 145.06 42.84 Favored 'General case' 0 C--N 1.313 -1.022 0 CA-C-O 121.087 0.47 . . . . 0.0 111.573 -178.809 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -94.92 5.45 68.99 Favored Glycine 0 N--CA 1.441 -0.986 0 N-CA-C 111.011 -0.836 . . . . 0.0 111.011 176.313 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 83.3 m-20 -93.03 178.59 5.7 Favored 'General case' 0 CA--C 1.508 -0.65 0 CA-C-O 121.154 0.502 . . . . 0.0 111.077 178.509 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 10.8 p-10 -90.38 19.13 5.41 Favored 'General case' 0 C--N 1.311 -1.095 0 CA-C-N 115.512 -0.767 . . . . 0.0 110.5 179.444 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 106.11 4.82 38.38 Favored Glycine 0 N--CA 1.443 -0.839 0 CA-C-N 115.64 -0.709 . . . . 0.0 111.906 -177.688 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 30.7 tt0 -65.13 -45.6 84.4 Favored 'General case' 0 C--O 1.237 0.44 0 CA-C-O 120.865 0.364 . . . . 0.0 110.324 177.715 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 70.3 p -133.53 157.6 45.25 Favored 'General case' 0 N--CA 1.447 -0.577 0 CA-C-N 116.216 -0.447 . . . . 0.0 109.808 177.767 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 49.2 tp -139.09 131.46 28.46 Favored 'General case' 0 C--N 1.315 -0.9 0 N-CA-C 109.087 -0.708 . . . . 0.0 109.087 178.818 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 6.8 p30 -147.99 167.27 25.34 Favored 'General case' 0 C--N 1.319 -0.743 0 C-N-CA 119.853 -0.739 . . . . 0.0 112.878 -179.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 155.79 -130.24 2.71 Favored Glycine 0 N--CA 1.442 -0.938 0 CA-C-N 114.951 -1.022 . . . . 0.0 111.738 -179.821 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 33.0 p -133.37 156.98 46.67 Favored 'General case' 0 C--N 1.318 -0.796 0 C-N-CA 122.671 0.388 . . . . 0.0 110.621 -178.818 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 23.7 ptm -152.48 167.47 28.69 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 120.897 0.38 . . . . 0.0 111.096 -179.571 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 48.4 m -151.63 139.98 20.43 Favored 'General case' 0 CA--C 1.547 0.862 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.991 -179.936 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . 0.433 ' C ' ' H ' ' A' ' 122' ' ' GLY . 67.8 m-85 -99.02 172.29 7.5 Favored 'General case' 0 N--CA 1.473 0.701 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.28 178.538 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -67.9 37.83 0.03 OUTLIER 'General case' 0 N--CA 1.487 1.421 0 C-N-CA 123.695 0.798 . . . . 0.0 113.104 -179.752 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . 0.433 ' H ' ' C ' ' A' ' 120' ' ' TYR . . . 153.44 42.67 0.02 OUTLIER Glycine 0 CA--C 1.5 -0.879 0 N-CA-C 110.08 -1.208 . . . . 0.0 110.08 179.805 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . 0.4 ' HB3' ' H ' ' A' ' 120' ' ' TYR . 47.3 tp10 -139.69 160.82 39.0 Favored 'General case' 0 C--N 1.315 -0.925 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 -175.705 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -90.2 175.29 41.13 Favored Glycine 0 N--CA 1.443 -0.895 0 N-CA-C 111.023 -0.831 . . . . 0.0 111.023 177.238 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 22.5 Cg_exo -63.35 119.91 7.15 Favored 'Trans proline' 0 N--CA 1.461 -0.41 0 C-N-CA 121.939 1.759 . . . . 0.0 111.2 178.262 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 42.5 pt -127.53 154.11 37.55 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 CA-C-O 120.656 0.265 . . . . 0.0 110.811 -179.897 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -72.31 143.65 34.69 Favored Glycine 0 N--CA 1.444 -0.809 0 C-N-CA 121.087 -0.578 . . . . 0.0 112.463 179.422 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 73.0 t80 -122.07 133.8 54.78 Favored 'General case' 0 C--N 1.315 -0.901 0 CA-C-O 120.689 0.281 . . . . 0.0 110.579 179.194 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 129' ' ' LYS . . . . . 0.508 ' HB2' ' CZ3' ' A' ' 17' ' ' TRP . 84.0 tttt -140.39 130.35 24.69 Favored 'General case' 0 N--CA 1.439 -0.998 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 177.539 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . 0.61 ' HA2' ' O ' ' A' ' 5' ' ' ASN . . . -134.4 141.22 12.5 Favored Glycine 0 N--CA 1.436 -1.325 0 C-N-CA 121.087 -0.578 . . . . 0.0 112.007 179.875 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 53.7 m -128.27 135.36 49.53 Favored 'General case' 0 C--N 1.314 -0.97 0 CA-C-O 120.481 0.182 . . . . 0.0 110.786 -179.473 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 54.8 tp -64.52 136.5 57.11 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 177.638 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 133' ' ' THR . . . . . 0.462 ' HB ' ' OD1' ' A' ' 5' ' ' ASN . 11.8 t . . . . . 0 C--O 1.252 1.221 0 CA-C-O 118.733 -0.651 . . . . 0.0 110.634 -179.251 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 0.414 ' O ' ' HB3' ' A' ' 3' ' ' LEU . . . . . . . . 0 N--CA 1.472 0.637 0 N-CA-C 110.014 -0.365 . . . . 0.0 110.014 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' LEU . . . . . 0.477 HD22 HE21 ' A' ' 22' ' ' GLN . 10.3 tt 87.41 150.74 0.06 Allowed 'General case' 0 N--CA 1.475 0.813 0 C-N-CA 124.289 1.036 . . . . 0.0 109.956 179.232 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . 0.4 ' N ' HD23 ' A' ' 3' ' ' LEU . 86.7 m-85 -132.45 154.13 50.18 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-O 120.951 0.405 . . . . 0.0 111.082 -175.007 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 92.7 m-20 -95.78 151.78 19.07 Favored 'General case' 0 C--N 1.314 -0.972 0 N-CA-C 107.702 -1.221 . . . . 0.0 107.702 177.664 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.465 HG21 ' CD1' ' A' ' 23' ' ' TRP . 78.5 t -111.9 121.84 65.13 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.184 0 CA-C-O 121.744 0.783 . . . . 0.0 111.73 -177.459 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 69.1 mt-10 -121.7 127.03 50.3 Favored 'General case' 0 C--N 1.311 -1.084 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 177.689 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 12.4 m120 -126.28 148.72 49.46 Favored 'General case' 0 C--N 1.312 -1.057 0 N-CA-C 112.527 0.566 . . . . 0.0 112.527 -174.036 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 54.2 tt0 -127.3 118.38 24.08 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 175.986 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 39.7 p90 -143.9 20.46 1.8 Allowed 'General case' 0 C--N 1.322 -0.613 0 C-N-CA 120.24 -0.584 . . . . 0.0 112.555 -175.293 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -96.53 24.15 31.93 Favored Glycine 0 N--CA 1.448 -0.532 0 C-N-CA 119.321 -1.418 . . . . 0.0 113.572 -177.43 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.55 -50.21 2.83 Favored Glycine 0 N--CA 1.466 0.683 0 CA-C-N 117.152 0.476 . . . . 0.0 114.268 178.261 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 22.6 t -172.63 153.23 2.74 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 -176.216 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 19.0 m 58.8 30.05 19.55 Favored 'General case' 0 CA--C 1.536 0.409 0 CA-C-O 121.322 0.582 . . . . 0.0 110.986 179.436 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -111.02 128.93 24.53 Favored Pre-proline 0 N--CA 1.443 -0.803 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.999 -178.053 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 97.8 Cg_endo -77.06 169.6 21.26 Favored 'Trans proline' 0 N--CA 1.456 -0.692 0 C-N-CA 122.697 2.265 . . . . 0.0 111.466 177.124 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 97.8 m95 -80.35 128.73 33.9 Favored 'General case' 0 C--N 1.314 -0.969 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 179.293 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 87.4 m-20 -116.28 127.6 54.86 Favored 'General case' 0 C--N 1.311 -1.099 0 N-CA-C 109.553 -0.536 . . . . 0.0 109.553 -177.854 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 10.7 pt-20 -83.43 127.68 33.89 Favored 'General case' 0 C--N 1.314 -0.948 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 178.453 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -137.38 19.82 3.38 Favored Glycine 0 C--O 1.225 -0.454 0 C-N-CA 120.43 -0.891 . . . . 0.0 112.812 -177.695 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 156.44 -173.01 34.27 Favored Glycine 0 N--CA 1.439 -1.163 0 C-N-CA 120.603 -0.808 . . . . 0.0 111.751 179.601 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . 0.477 HE21 HD22 ' A' ' 3' ' ' LEU . 17.6 pt20 -148.55 149.02 30.86 Favored 'General case' 0 C--N 1.311 -1.073 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 178.684 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . 0.465 ' CD1' HG21 ' A' ' 6' ' ' VAL . 48.0 m0 -118.62 150.69 39.27 Favored 'General case' 0 C--N 1.313 -1.001 0 CA-C-O 120.784 0.326 . . . . 0.0 110.473 -178.05 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 78.9 tt0 -106.13 115.14 29.71 Favored 'General case' 0 C--N 1.313 -0.983 0 C-N-CA 120.052 -0.659 . . . . 0.0 109.544 178.26 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 93.6 mt -139.19 149.47 23.17 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.891 0 CA-C-N 115.213 -0.903 . . . . 0.0 108.979 -175.85 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 90.26 83.38 1.37 Allowed Glycine 0 N--CA 1.446 -0.699 0 C-N-CA 120.482 -0.866 . . . . 0.0 112.808 179.474 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 11.6 p -94.97 13.51 24.73 Favored 'General case' 0 N--CA 1.449 -0.495 0 CA-C-O 120.969 0.414 . . . . 0.0 111.159 178.842 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 15.8 ptp180 -129.28 134.79 48.11 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 179.463 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 26.7 t -89.02 -21.92 23.24 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-O 121.121 0.486 . . . . 0.0 111.143 -179.031 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 51.8 m-20 -64.88 -36.23 83.68 Favored 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 112.746 0.647 . . . . 0.0 112.746 -177.91 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . 0.599 HE21 ' HA ' ' A' ' 31' ' ' GLN . 0.0 OUTLIER -135.74 134.47 39.08 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 111.938 0.348 . . . . 0.0 111.938 -175.095 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . 0.466 ' ND2' ' HA3' ' A' ' 111' ' ' GLY . 66.0 t30 -90.77 161.39 15.33 Favored 'General case' 0 C--O 1.24 0.572 0 CA-C-N 116.111 -0.495 . . . . 0.0 109.977 178.308 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 57.8 t -88.62 126.61 41.8 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.484 -176.756 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 30.7 m -111.46 -31.23 2.22 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.599 0 N-CA-C 113.236 0.828 . . . . 0.0 113.236 177.132 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.502 ' HB1' ' HB ' ' A' ' 52' ' ' THR . . . -151.41 148.81 28.55 Favored 'General case' 0 N--CA 1.469 0.515 0 C-N-CA 119.839 -0.744 . . . . 0.0 111.959 179.828 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 93.4 mt -141.92 126.87 17.23 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.15 -179.616 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' ASN . . . . . 0.4 ' HA ' ' O ' ' A' ' 103' ' ' ILE . 0.6 OUTLIER -133.66 112.36 11.36 Favored 'General case' 0 C--N 1.321 -0.65 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 174.168 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 21.7 m -150.88 153.92 9.38 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-O 120.749 0.309 . . . . 0.0 111.115 -175.607 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 42.2 tt0 -145.38 151.67 38.64 Favored 'General case' 0 C--N 1.318 -0.771 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 176.414 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 27.3 p -79.46 148.08 32.03 Favored 'General case' 0 C--N 1.31 -1.14 0 CA-C-O 121.089 0.471 . . . . 0.0 111.802 -178.792 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -97.19 -10.27 54.67 Favored Glycine 0 N--CA 1.447 -0.604 0 N-CA-C 110.03 -1.228 . . . . 0.0 110.03 175.347 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . 0.445 ' C ' ' H ' ' A' ' 44' ' ' GLY . 18.9 m-20 -137.7 -160.63 1.08 Allowed 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 114.464 -0.868 . . . . 0.0 108.766 179.505 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 17.9 m-20 -76.5 34.51 0.14 Allowed 'General case' 0 N--CA 1.481 1.086 0 CA-C-O 120.971 0.415 . . . . 0.0 110.999 178.53 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . 0.526 ' O ' ' HE2' ' A' ' 71' ' ' TYR . . . 103.11 -6.27 50.77 Favored Glycine 0 C--O 1.208 -1.484 0 N-CA-C 111.456 -0.658 . . . . 0.0 111.456 -178.827 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 59.7 tp60 -65.18 -40.13 93.83 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.233 0.54 . . . . 0.0 110.602 179.89 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 74.4 p -125.24 142.56 51.42 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.47 178.693 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' LEU . . . . . 0.434 ' HB2' ' HB3' ' A' ' 63' ' ' ALA . 92.3 mt -128.56 126.98 41.46 Favored 'General case' 0 C--N 1.322 -0.626 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 178.131 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 15.1 m120 -129.02 142.3 50.96 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 179.94 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 173.28 -155.51 22.64 Favored Glycine 0 N--CA 1.441 -0.998 0 C-N-CA 119.547 -1.311 . . . . 0.0 113.145 177.69 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 53.7 m -128.35 130.86 48.38 Favored 'General case' 0 C--N 1.311 -1.079 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 -179.452 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' MET . . . . . 0.563 ' SD ' ' HH2' ' A' ' 90' ' ' TRP . 23.5 ttt -116.22 145.61 42.98 Favored 'General case' 0 C--N 1.314 -0.964 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 -179.813 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.502 ' HB ' ' HB1' ' A' ' 35' ' ' ALA . 37.6 m -122.19 126.11 47.57 Favored 'General case' 0 C--O 1.246 0.887 0 CA-C-O 121.162 0.506 . . . . 0.0 111.601 -179.19 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 74.2 m-85 -103.58 158.63 16.23 Favored 'General case' 0 N--CA 1.445 -0.705 0 CA-C-N 115.339 -0.846 . . . . 0.0 109.338 176.739 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -61.42 137.69 58.25 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.229 -179.027 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 77.02 -60.34 3.48 Favored Glycine 0 CA--C 1.524 0.595 0 N-CA-C 114.647 0.619 . . . . 0.0 114.647 176.772 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -66.36 -40.71 89.93 Favored 'General case' 0 C--O 1.239 0.504 0 N-CA-C 113.218 0.822 . . . . 0.0 113.218 -175.272 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 111.63 -162.49 12.43 Favored Glycine 0 N--CA 1.446 -0.652 0 C-N-CA 120.0 -1.095 . . . . 0.0 112.944 178.595 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 97.8 Cg_endo -79.0 141.74 16.84 Favored 'Trans proline' 0 C--O 1.237 0.454 0 C-N-CA 123.126 2.551 . . . . 0.0 113.416 -179.636 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . 0.735 ' HB ' ' O ' ' A' ' 76' ' ' GLN . 48.7 pt -136.07 167.99 23.45 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 CA-C-N 115.712 -0.676 . . . . 0.0 109.905 176.974 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . 0.441 ' HA3' ' HB3' ' A' ' 76' ' ' GLN . . . -73.95 142.66 31.07 Favored Glycine 0 C--O 1.237 0.338 0 C-N-CA 120.332 -0.937 . . . . 0.0 111.357 -179.49 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 37.8 t80 -128.1 125.0 38.36 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-O 120.611 0.243 . . . . 0.0 111.001 -177.647 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . 0.438 HH21 ' CD ' ' A' ' 74' ' ' GLU . 19.5 ttp85 -135.12 130.63 35.77 Favored 'General case' 0 C--O 1.217 -0.612 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 175.352 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.434 ' HB3' ' HB2' ' A' ' 47' ' ' LEU . . . -137.44 146.2 44.06 Favored 'General case' 0 C--N 1.317 -0.828 0 C-N-CA 120.835 -0.346 . . . . 0.0 111.38 -179.597 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 63.4 m -125.11 134.71 52.36 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.069 179.074 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 55.6 tp -63.83 118.5 8.44 Favored 'General case' 0 CA--C 1.509 -0.617 0 CA-C-O 121.074 0.464 . . . . 0.0 110.998 -179.767 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 52.3 tp -67.53 -39.43 85.04 Favored 'General case' 0 N--CA 1.436 -1.146 0 CA-C-N 115.374 -0.83 . . . . 0.0 111.116 -179.956 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 178.68 -37.69 0.08 OUTLIER Glycine 0 N--CA 1.446 -0.652 0 C-N-CA 120.485 -0.864 . . . . 0.0 112.557 179.763 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 18.8 p-10 -173.73 114.05 0.21 Allowed 'General case' 0 C--N 1.326 -0.414 0 C-N-CA 122.405 0.282 . . . . 0.0 110.353 -178.611 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 96.1 m-20 68.19 -43.77 0.49 Allowed 'General case' 0 N--CA 1.484 1.273 0 C-N-CA 123.795 0.838 . . . . 0.0 113.114 -178.824 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 9.6 m -77.96 133.76 37.97 Favored 'General case' 0 C--N 1.315 -0.932 0 CA-C-O 121.113 0.482 . . . . 0.0 110.898 178.396 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.597 ' OH ' ' HB3' ' A' ' 99' ' ' ASN . 96.4 m-85 -126.41 148.74 49.57 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.037 178.586 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -95.54 117.25 30.09 Favored 'General case' 0 C--N 1.308 -1.235 0 N-CA-C 107.797 -1.186 . . . . 0.0 107.797 173.448 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 79.0 t -103.3 136.6 35.3 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.849 0 CA-C-O 121.244 0.545 . . . . 0.0 112.416 -173.635 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.443 ' HG2' ' HA ' ' A' ' 86' ' ' SER . 98.0 mt-10 -118.76 146.88 44.43 Favored 'General case' 0 N--CA 1.439 -1.025 0 CA-C-N 114.982 -1.008 . . . . 0.0 109.081 177.438 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 10.0 m120 -123.99 137.18 54.64 Favored 'General case' 0 C--N 1.315 -0.904 0 CA-C-O 121.226 0.536 . . . . 0.0 110.931 -177.095 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' GLN . . . . . 0.735 ' O ' ' HB ' ' A' ' 59' ' ' ILE . 30.4 tt0 -110.37 115.82 30.35 Favored 'General case' 0 C--N 1.309 -1.194 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.32 -179.875 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 6.1 p90 -129.28 44.62 2.94 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-O 121.423 0.63 . . . . 0.0 110.717 179.467 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -104.8 -68.95 0.75 Allowed Glycine 0 N--CA 1.443 -0.839 0 C-N-CA 120.647 -0.787 . . . . 0.0 111.183 -178.848 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 170.81 -67.18 0.15 Allowed Glycine 0 N--CA 1.446 -0.676 0 N-CA-C 110.686 -0.965 . . . . 0.0 110.686 178.354 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 37.0 t70 -139.08 117.27 11.84 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 177.654 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 32.3 t 76.76 -75.08 0.07 Allowed 'General case' 0 C--N 1.327 -0.396 0 O-C-N 123.876 0.735 . . . . 0.0 110.092 -178.436 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 63.99 161.6 0.12 Allowed Pre-proline 0 N--CA 1.477 0.901 0 N-CA-C 112.352 0.501 . . . . 0.0 112.352 177.141 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' PRO . . . . . 0.593 ' O ' ' HB2' ' A' ' 84' ' ' TRP . 51.7 Cg_exo -57.07 -41.83 70.47 Favored 'Trans proline' 0 C--N 1.355 0.892 0 C-N-CA 122.526 2.151 . . . . 0.0 112.859 177.612 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' TRP . . . . . 0.593 ' HB2' ' O ' ' A' ' 83' ' ' PRO . 74.0 m95 94.48 116.42 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.778 0 C-N-CA 124.747 1.219 . . . . 0.0 110.231 -178.725 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 92.7 m-70 -112.15 139.04 48.0 Favored 'General case' 0 CA--C 1.517 -0.324 0 CA-C-N 116.484 -0.326 . . . . 0.0 110.531 -176.845 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' SER . . . . . 0.443 ' HA ' ' HG2' ' A' ' 74' ' ' GLU . 13.1 m -70.61 141.3 51.76 Favored 'General case' 0 C--N 1.311 -1.092 0 CA-C-N 116.442 -0.345 . . . . 0.0 110.096 177.134 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -109.29 -34.06 2.59 Favored Glycine 0 N--CA 1.447 -0.578 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.852 -178.349 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 147.57 -160.56 28.33 Favored Glycine 0 N--CA 1.453 -0.211 0 C-N-CA 120.315 -0.945 . . . . 0.0 112.459 178.649 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 23.8 t-20 -118.67 124.61 47.8 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.433 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 90' ' ' TRP . . . . . 0.563 ' HH2' ' SD ' ' A' ' 51' ' ' MET . 36.2 m0 -118.24 152.88 34.87 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.129 -177.721 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 79.1 mt -107.25 116.71 51.5 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 N-CA-C 110.191 -0.299 . . . . 0.0 110.191 178.494 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 90.2 mt -126.57 76.46 1.63 Allowed 'General case' 0 C--O 1.256 1.406 0 CA-C-O 121.625 0.726 . . . . 0.0 111.036 -178.411 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -176.73 105.3 0.2 Allowed Glycine 0 N--CA 1.435 -1.374 0 CA-C-N 114.842 -1.072 . . . . 0.0 111.612 -179.551 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.4 p -86.2 -11.8 51.48 Favored 'General case' 0 C--N 1.313 -1.003 0 CA-C-O 121.265 0.555 . . . . 0.0 110.695 178.384 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 97.6 mtt180 -106.92 153.39 22.6 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.563 -0.744 . . . . 0.0 111.68 178.825 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -66.69 -43.14 85.19 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 115.207 -0.906 . . . . 0.0 112.388 -175.967 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 21.4 m120 -123.04 34.1 5.22 Favored 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 111.967 0.358 . . . . 0.0 111.967 -176.364 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 98' ' ' GLN . . . . . . . . . . . . . 9.6 tt0 -146.95 121.01 9.41 Favored 'General case' 0 C--N 1.32 -0.688 0 C-N-CA 120.278 -0.569 . . . . 0.0 110.549 -178.473 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 99' ' ' ASN . . . . . 0.597 ' HB3' ' OH ' ' A' ' 71' ' ' TYR . 90.2 m-20 -95.34 159.71 14.88 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.182 -176.45 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 79.1 t -81.46 133.72 28.65 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.637 0 CA-C-N 116.509 -0.314 . . . . 0.0 110.79 176.64 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 33.7 m -113.33 -26.83 2.88 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 N-CA-C 112.83 0.678 . . . . 0.0 112.83 -178.755 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . 0.465 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -146.91 140.12 25.42 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 119.696 -0.801 . . . . 0.0 112.095 178.65 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.4 ' O ' ' HA ' ' A' ' 37' ' ' ASN . 91.1 mt -133.22 124.64 49.73 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.929 -0.578 . . . . 0.0 111.073 178.25 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 40.2 t30 -128.78 97.45 4.67 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.317 174.703 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 28.6 m -143.48 148.37 19.18 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 N-CA-C 112.949 0.722 . . . . 0.0 112.949 -174.526 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 76.1 tt0 -142.66 138.04 30.38 Favored 'General case' 0 N--CA 1.437 -1.092 0 CA-C-N 115.072 -0.967 . . . . 0.0 108.544 175.248 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 107' ' ' SER . . . . . 0.414 ' HA ' ' HA ' ' A' ' 114' ' ' LEU . 44.8 t -74.87 -52.42 11.36 Favored 'General case' 0 C--N 1.306 -1.287 0 CA-C-N 116.09 -0.504 . . . . 0.0 111.382 -178.183 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 81.8 -9.26 57.01 Favored Glycine 0 N--CA 1.449 -0.457 0 N-CA-C 110.875 -0.89 . . . . 0.0 110.875 -176.366 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . 0.534 ' CG ' ' H ' ' A' ' 110' ' ' ASP . 19.4 t70 -125.07 -150.76 0.45 Allowed 'General case' 0 N--CA 1.445 -0.677 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 179.398 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 110' ' ' ASP . . . . . 0.534 ' H ' ' CG ' ' A' ' 109' ' ' ASP . 31.7 m-20 -89.86 12.88 15.99 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 120.845 0.355 . . . . 0.0 111.475 -179.426 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . 0.466 ' HA3' ' ND2' ' A' ' 32' ' ' ASN . . . 101.33 8.61 46.54 Favored Glycine 0 C--O 1.229 -0.217 0 C-N-CA 120.129 -1.034 . . . . 0.0 113.408 179.529 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 48.4 mt-30 -68.83 -42.37 77.27 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.487 0.66 . . . . 0.0 110.557 179.224 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 17.5 p -133.51 139.28 46.55 Favored 'General case' 0 C--N 1.317 -0.839 0 CA-C-N 115.32 -0.854 . . . . 0.0 110.837 179.104 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 114' ' ' LEU . . . . . 0.414 ' HA ' ' HA ' ' A' ' 107' ' ' SER . 9.1 mp -120.31 145.16 47.37 Favored 'General case' 0 C--N 1.316 -0.867 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 178.677 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 8.6 p30 -148.1 160.4 42.93 Favored 'General case' 0 C--N 1.314 -0.939 0 C-N-CA 120.617 -0.433 . . . . 0.0 110.939 178.486 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 153.35 -128.0 2.32 Favored Glycine 0 N--CA 1.436 -1.337 0 CA-C-N 115.683 -0.69 . . . . 0.0 111.673 179.875 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 22.1 p -135.24 158.83 43.36 Favored 'General case' 0 C--N 1.315 -0.9 0 CA-C-O 121.11 0.481 . . . . 0.0 111.055 -179.079 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 118' ' ' MET . . . . . 0.437 ' O ' ' HA ' ' A' ' 125' ' ' PRO . 4.7 ppp? -147.19 156.03 42.61 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 116.156 -0.474 . . . . 0.0 109.841 178.841 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 119' ' ' THR . . . . . 0.465 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 26.4 m -128.72 126.45 40.06 Favored 'General case' 0 C--O 1.254 1.292 0 CA-C-O 120.519 0.2 . . . . 0.0 111.115 179.91 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 70.0 m-85 -85.42 158.44 20.22 Favored 'General case' 0 C--O 1.233 0.196 0 CA-C-N 115.777 -0.647 . . . . 0.0 109.982 176.264 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -60.3 126.32 27.03 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 120.778 0.323 . . . . 0.0 110.796 177.631 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 65.03 30.81 78.95 Favored Glycine 0 CA--C 1.523 0.562 0 CA-C-N 115.964 -0.562 . . . . 0.0 114.113 178.715 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 77.2 tt0 -150.49 160.2 43.95 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 117.229 0.514 . . . . 0.0 110.218 -179.345 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -77.2 160.08 49.46 Favored Glycine 0 CA--C 1.522 0.53 0 C-N-CA 121.084 -0.579 . . . . 0.0 112.908 -178.947 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . 0.437 ' HA ' ' O ' ' A' ' 118' ' ' MET . 51.4 Cg_endo -68.21 142.78 56.63 Favored 'Trans proline' 0 CA--C 1.534 0.502 0 C-N-CA 122.993 2.462 . . . . 0.0 113.271 179.743 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 49.1 pt -131.6 169.42 21.8 Favored 'Isoleucine or valine' 0 C--O 1.24 0.581 0 CA-C-N 115.737 -0.665 . . . . 0.0 109.935 178.547 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -70.66 131.99 21.99 Favored Glycine 0 C--N 1.336 0.55 0 C-N-CA 120.677 -0.773 . . . . 0.0 111.981 -179.381 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 84.7 t80 -119.5 139.19 52.48 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 121.255 0.55 . . . . 0.0 111.583 -178.146 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 62.8 tttm -140.94 134.8 30.48 Favored 'General case' 0 N--CA 1.431 -1.379 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 176.85 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -135.15 144.75 16.78 Favored Glycine 0 N--CA 1.436 -1.355 0 C-N-CA 120.521 -0.847 . . . . 0.0 111.428 -179.502 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 56.2 m -123.81 130.55 52.79 Favored 'General case' 0 C--N 1.311 -1.084 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 -178.72 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 61.1 tp -70.67 136.22 48.9 Favored 'General case' 0 C--O 1.237 0.436 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 179.076 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 15.4 t . . . . . 0 C--O 1.251 1.149 0 CA-C-O 119.144 -0.455 . . . . 0.0 110.069 -177.65 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 0.57 ' O ' ' HG3' ' A' ' 24' ' ' GLU . . . . . . . . 0 N--CA 1.48 1.047 0 N-CA-C 110.022 -0.362 . . . . 0.0 110.022 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -91.97 128.23 37.74 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-O 121.019 0.437 . . . . 0.0 110.537 -175.743 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 11.8 m-85 -121.3 144.47 48.62 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.169 178.27 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 94.4 m-20 -94.66 140.13 30.29 Favored 'General case' 0 C--N 1.313 -0.99 0 N-CA-C 107.826 -1.176 . . . . 0.0 107.826 177.538 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 77.3 t -116.33 128.46 73.65 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.961 0 CA-C-O 121.274 0.559 . . . . 0.0 112.434 -175.629 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -125.09 138.75 54.18 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 176.691 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 65.3 m-80 -131.01 151.88 50.93 Favored 'General case' 0 C--N 1.316 -0.866 0 N-CA-C 112.653 0.612 . . . . 0.0 112.653 -177.526 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . 0.414 ' OE1' ' HA ' ' A' ' 13' ' ' SER . 35.7 tt0 -129.47 128.13 42.28 Favored 'General case' 0 C--O 1.238 0.498 0 CA-C-N 115.343 -0.844 . . . . 0.0 110.533 178.336 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 46.8 p90 -138.11 146.24 42.63 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 116.575 -0.284 . . . . 0.0 110.484 178.617 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 95.12 11.82 55.76 Favored Glycine 0 N--CA 1.444 -0.775 0 C-N-CA 120.545 -0.836 . . . . 0.0 111.759 179.207 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 104.88 157.38 23.27 Favored Glycine 0 N--CA 1.442 -0.919 0 C-N-CA 120.953 -0.642 . . . . 0.0 112.144 179.088 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' SER . . . . . 0.414 ' HA ' ' OE1' ' A' ' 9' ' ' GLN . 15.5 m -58.13 -21.16 45.42 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 112.128 0.418 . . . . 0.0 112.128 179.036 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 18.7 m -59.14 -33.73 71.23 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 120.806 0.336 . . . . 0.0 110.857 176.82 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -76.78 145.28 74.31 Favored Pre-proline 0 N--CA 1.45 -0.437 0 CA-C-N 116.009 -0.542 . . . . 0.0 111.132 -179.409 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 93.1 Cg_endo -73.26 163.19 38.62 Favored 'Trans proline' 0 C--O 1.236 0.375 0 C-N-CA 122.808 2.339 . . . . 0.0 112.266 -179.892 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 92.3 m95 -85.17 131.68 34.4 Favored 'General case' 0 C--N 1.319 -0.75 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 179.23 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 55.9 m-80 -124.1 144.94 49.59 Favored 'General case' 0 C--N 1.312 -1.029 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 -179.525 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -64.99 135.4 55.6 Favored 'General case' 0 C--N 1.311 -1.066 0 CA-C-O 121.598 0.713 . . . . 0.0 112.207 -177.274 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -112.2 34.82 4.98 Favored Glycine 0 CA--C 1.499 -0.912 0 CA-C-N 114.604 -1.18 . . . . 0.0 110.961 178.326 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 83.3 -156.85 34.24 Favored Glycine 0 N--CA 1.436 -1.353 0 N-CA-C 111.344 -0.702 . . . . 0.0 111.344 -177.387 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 13.6 pt20 -144.27 147.41 33.5 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-O 120.869 0.366 . . . . 0.0 110.246 178.204 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . 0.594 ' HB3' ' O ' ' A' ' 91' ' ' ILE . 54.4 m0 -128.33 -179.14 4.86 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.743 -173.893 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . 0.57 ' HG3' ' O ' ' A' ' 2' ' ' ALA . 82.6 tt0 -123.69 116.15 22.6 Favored 'General case' 0 CA--C 1.511 -0.534 0 CA-C-O 120.943 0.401 . . . . 0.0 110.522 176.446 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 95.3 mt -126.94 134.16 66.8 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.784 0 CA-C-N 115.448 -0.796 . . . . 0.0 110.767 -177.701 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 90.94 106.74 1.38 Allowed Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.973 -0.632 . . . . 0.0 113.911 176.526 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 19.8 m -69.1 -43.04 75.29 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.369 0.604 . . . . 0.0 110.02 175.419 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -71.0 137.96 49.52 Favored 'General case' 0 N--CA 1.451 -0.396 0 CA-C-N 115.292 -0.867 . . . . 0.0 110.663 179.77 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 19.8 m -102.86 -26.16 13.23 Favored 'General case' 0 C--N 1.315 -0.924 0 CA-C-O 121.054 0.454 . . . . 0.0 110.4 178.687 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 27.1 m-20 -91.09 -5.3 55.34 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.918 179.263 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . 0.441 HE21 ' HB3' ' A' ' 53' ' ' TYR . 57.6 tp60 -139.59 120.55 14.54 Favored 'General case' 0 C--N 1.31 -1.133 0 N-CA-C 109.35 -0.611 . . . . 0.0 109.35 -178.999 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 62.0 t30 -97.74 162.76 13.11 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-O 121.172 0.51 . . . . 0.0 112.083 -175.975 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 89.5 t -98.74 133.59 40.66 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.639 0 CA-C-N 115.217 -0.902 . . . . 0.0 109.991 179.965 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 21.0 m -107.05 -27.73 2.96 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.456 0 N-CA-C 111.981 0.364 . . . . 0.0 111.981 -179.38 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -139.56 143.63 37.44 Favored 'General case' 0 CA--C 1.509 -0.634 0 C-N-CA 120.109 -0.637 . . . . 0.0 111.632 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.421 ' HB ' ' CG2' ' A' ' 105' ' ' VAL . 94.2 mt -139.64 117.73 11.4 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.832 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 179.039 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 1.3 t-20 -129.02 108.25 10.24 Favored 'General case' 0 C--N 1.304 -1.388 0 N-CA-C 108.065 -1.087 . . . . 0.0 108.065 177.453 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 23.9 m -147.03 151.38 13.95 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.762 0 C-N-CA 120.448 -0.501 . . . . 0.0 111.339 -173.184 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 36.1 tt0 -141.1 145.56 35.95 Favored 'General case' 0 N--CA 1.437 -1.089 0 CA-C-N 115.512 -0.767 . . . . 0.0 109.001 176.433 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 30.9 t -72.26 142.6 48.93 Favored 'General case' 0 C--N 1.309 -1.176 0 CA-C-O 121.093 0.473 . . . . 0.0 111.338 -178.522 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -95.22 -25.12 14.79 Favored Glycine 0 N--CA 1.433 -1.553 0 C-N-CA 120.504 -0.855 . . . . 0.0 111.769 177.919 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 36.1 t70 -145.11 79.63 1.59 Allowed 'General case' 0 CA--C 1.536 0.405 0 N-CA-C 112.842 0.682 . . . . 0.0 112.842 -177.372 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 50.24 29.03 3.44 Favored 'General case' 0 N--CA 1.491 1.611 0 N-CA-C 114.564 1.32 . . . . 0.0 114.564 173.673 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . 0.443 ' HA2' HG13 ' A' ' 101' ' ' VAL . . . 99.44 -16.77 58.6 Favored Glycine 0 C--N 1.312 -0.791 0 C-N-CA 120.658 -0.782 . . . . 0.0 113.189 178.187 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 59.7 tp60 -66.42 -39.01 88.72 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-O 121.04 0.448 . . . . 0.0 110.77 -179.944 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 36.8 p -125.67 147.84 49.21 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.975 178.499 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 95.2 mt -128.36 128.15 43.99 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 109.524 -0.547 . . . . 0.0 109.524 179.254 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 13.8 m120 -128.44 141.1 51.51 Favored 'General case' 0 C--N 1.319 -0.723 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 178.398 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 175.45 -156.26 21.73 Favored Glycine 0 N--CA 1.442 -0.948 0 C-N-CA 119.411 -1.376 . . . . 0.0 113.503 178.444 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 70.4 m -128.95 131.46 47.5 Favored 'General case' 0 N--CA 1.44 -0.971 0 C-N-CA 122.839 0.456 . . . . 0.0 110.149 -178.43 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 14.7 tmm? -125.91 144.73 50.56 Favored 'General case' 0 C--N 1.316 -0.875 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 -179.265 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 33.6 m -126.26 130.06 50.13 Favored 'General case' 0 C--O 1.245 0.866 0 N-CA-C 112.054 0.39 . . . . 0.0 112.054 -176.57 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . 0.441 ' HB3' HE21 ' A' ' 31' ' ' GLN . 72.4 m-85 -87.15 161.8 17.87 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.946 177.176 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -63.54 106.91 1.02 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.989 -0.55 . . . . 0.0 112.069 -179.713 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 84.67 10.6 79.0 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.713 -0.756 . . . . 0.0 113.528 177.836 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 57.8 mt-10 -123.07 168.02 12.9 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 117.212 0.506 . . . . 0.0 110.793 178.26 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -79.86 155.48 38.97 Favored Glycine 0 N--CA 1.447 -0.599 0 C-N-CA 120.84 -0.695 . . . . 0.0 112.379 -179.884 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 32.9 Cg_endo -62.81 142.72 89.89 Favored 'Trans proline' 0 CA--C 1.534 0.503 0 C-N-CA 123.012 2.475 . . . . 0.0 112.546 -179.758 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . 0.563 ' HB ' ' O ' ' A' ' 76' ' ' GLN . 47.3 pt -128.25 167.35 23.55 Favored 'Isoleucine or valine' 0 C--O 1.239 0.501 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.736 -179.765 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -79.11 138.63 20.89 Favored Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 120.929 -0.653 . . . . 0.0 111.807 -179.702 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 60.9 t80 -118.62 123.59 45.36 Favored 'General case' 0 C--N 1.317 -0.827 0 C-N-CA 122.389 0.275 . . . . 0.0 110.799 -178.132 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 49.1 ttm-85 -126.81 128.22 46.22 Favored 'General case' 0 C--O 1.22 -0.452 0 N-CA-C 109.325 -0.62 . . . . 0.0 109.325 175.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.485 ' HB1' ' HB3' ' A' ' 71' ' ' TYR . . . -136.12 142.81 44.29 Favored 'General case' 0 C--N 1.32 -0.696 0 C-N-CA 120.231 -0.588 . . . . 0.0 112.094 178.574 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 57.3 m -118.7 127.45 53.58 Favored 'General case' 0 CA--C 1.54 0.573 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.084 178.249 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 2.4 tm? -72.74 118.31 15.51 Favored 'General case' 0 CA--C 1.544 0.749 0 CA-C-O 121.372 0.606 . . . . 0.0 112.156 -177.866 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 4.6 mm? -66.86 -38.22 85.94 Favored 'General case' 0 N--CA 1.475 0.792 0 CA-C-N 115.283 -0.871 . . . . 0.0 111.869 178.091 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 125.45 -6.14 8.07 Favored Glycine 0 C--O 1.227 -0.304 0 C-N-CA 120.593 -0.813 . . . . 0.0 112.521 -176.263 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 29.7 p-10 -125.83 38.19 4.2 Favored 'General case' 0 C--N 1.316 -0.889 0 CA-C-O 121.117 0.484 . . . . 0.0 110.507 -179.372 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 96.1 m-20 66.59 5.09 3.64 Favored 'General case' 0 N--CA 1.479 0.976 0 CA-C-N 115.469 -0.787 . . . . 0.0 111.882 -178.761 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 32.8 m -99.17 138.06 36.81 Favored 'General case' 0 N--CA 1.443 -0.785 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 177.367 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.58 ' OH ' ' HB3' ' A' ' 99' ' ' ASN . 91.5 m-85 -120.38 135.65 54.97 Favored 'General case' 0 C--N 1.306 -1.296 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.329 -179.28 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . 0.404 ' O ' ' HA ' ' A' ' 63' ' ' ALA . 71.6 tt0 -88.76 121.31 31.0 Favored 'General case' 0 C--N 1.311 -1.077 0 N-CA-C 107.964 -1.124 . . . . 0.0 107.964 175.286 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 75.3 t -107.67 137.05 40.85 Favored 'Isoleucine or valine' 0 C--O 1.247 0.957 0 N-CA-C 113.661 0.986 . . . . 0.0 113.661 -170.857 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -119.17 142.67 47.76 Favored 'General case' 0 N--CA 1.444 -0.739 0 CA-C-N 114.19 -1.368 . . . . 0.0 107.84 175.565 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 94.1 m-20 -118.06 135.31 54.27 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-O 120.825 0.345 . . . . 0.0 111.251 -175.699 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' GLN . . . . . 0.563 ' O ' ' HB ' ' A' ' 59' ' ' ILE . 17.3 tt0 -110.09 119.35 39.02 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.889 179.124 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 7.5 p90 -139.63 156.71 46.68 Favored 'General case' 0 C--N 1.326 -0.456 0 C-N-CA 120.856 -0.338 . . . . 0.0 111.358 177.013 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 105.81 -3.95 39.13 Favored Glycine 0 N--CA 1.449 -0.498 0 C-N-CA 121.198 -0.525 . . . . 0.0 112.177 179.666 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 139.63 171.57 12.35 Favored Glycine 0 CA--C 1.503 -0.694 0 N-CA-C 110.579 -1.008 . . . . 0.0 110.579 -179.602 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -68.07 155.16 40.15 Favored 'General case' 0 C--O 1.245 0.839 0 CA-C-N 117.527 0.664 . . . . 0.0 110.047 178.448 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 14.7 m 70.95 -95.2 0.03 OUTLIER 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.467 -0.788 . . . . 0.0 109.042 -176.601 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . 0.522 ' HB3' ' HD2' ' A' ' 83' ' ' PRO . . . 51.46 171.07 0.04 OUTLIER Pre-proline 0 CA--C 1.557 1.25 0 N-CA-C 113.31 0.855 . . . . 0.0 113.31 176.38 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' PRO . . . . . 0.522 ' HD2' ' HB3' ' A' ' 82' ' ' ALA . 63.6 Cg_endo -73.27 150.6 47.49 Favored 'Trans proline' 0 N--CA 1.452 -0.943 0 C-N-CA 121.591 1.527 . . . . 0.0 109.927 170.551 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' TRP . . . . . . . . . . . . . 82.2 m95 -95.69 137.99 33.98 Favored 'General case' 0 C--N 1.315 -0.924 0 C-N-CA 120.54 -0.464 . . . . 0.0 109.768 -179.91 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 84.4 m-70 -113.18 138.8 49.43 Favored 'General case' 0 C--N 1.314 -0.976 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 -177.775 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 13.4 p -65.15 131.25 46.04 Favored 'General case' 0 C--N 1.32 -0.688 0 C-N-CA 121.113 -0.235 . . . . 0.0 110.447 -179.779 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -105.36 -52.3 0.83 Allowed Glycine 0 N--CA 1.443 -0.836 0 C-N-CA 120.239 -0.981 . . . . 0.0 113.23 -179.187 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 154.59 -166.27 32.24 Favored Glycine 0 C--O 1.22 -0.747 0 C-N-CA 120.187 -1.006 . . . . 0.0 112.115 -178.108 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 20.5 t-20 -113.81 119.43 37.32 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 117.01 0.405 . . . . 0.0 110.709 -179.482 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 22.4 m0 -108.89 148.1 31.16 Favored 'General case' 0 C--O 1.217 -0.621 0 N-CA-C 109.492 -0.558 . . . . 0.0 109.492 -179.867 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . 0.594 ' O ' ' HB3' ' A' ' 23' ' ' TRP . 85.0 mt -107.7 119.56 57.51 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.072 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 178.903 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . 0.452 ' HB2' ' CE1' ' A' ' 71' ' ' TYR . 90.9 mt -134.08 78.95 1.79 Allowed 'General case' 0 C--O 1.267 1.984 0 CA-C-O 121.688 0.756 . . . . 0.0 111.6 -177.399 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 168.85 126.7 0.87 Allowed Glycine 0 N--CA 1.44 -1.08 0 CA-C-N 115.13 -0.941 . . . . 0.0 111.875 179.29 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 94' ' ' SER . . . . . 0.402 ' HB3' ' HE1' ' A' ' 23' ' ' TRP . 32.4 p -117.95 4.2 12.13 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-O 121.353 0.596 . . . . 0.0 110.651 178.379 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 62.3 mtt-85 -102.01 142.84 32.66 Favored 'General case' 0 N--CA 1.445 -0.702 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.521 178.903 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 -62.66 -37.61 87.09 Favored 'General case' 0 C--N 1.312 -1.029 0 CA-C-N 115.421 -0.809 . . . . 0.0 112.899 -176.143 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 29.0 p-10 -126.3 27.93 6.11 Favored 'General case' 0 C--N 1.316 -0.86 0 N-CA-C 111.827 0.306 . . . . 0.0 111.827 -176.333 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 98' ' ' GLN . . . . . 0.47 HE21 ' HB3' ' A' ' 121' ' ' ALA . 21.9 tp60 -146.19 126.56 14.01 Favored 'General case' 0 C--N 1.322 -0.615 0 C-N-CA 119.319 -0.953 . . . . 0.0 111.688 -175.471 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 99' ' ' ASN . . . . . 0.58 ' HB3' ' OH ' ' A' ' 71' ' ' TYR . 87.2 m-20 -97.24 154.28 17.5 Favored 'General case' 0 C--O 1.249 1.048 0 CA-C-N 115.452 -0.795 . . . . 0.0 110.572 -179.439 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 70.8 t -79.03 136.86 22.9 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.791 0 C-N-CA 120.85 -0.34 . . . . 0.0 110.79 177.84 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . 0.443 HG13 ' HA2' ' A' ' 44' ' ' GLY . 33.3 m -123.0 -35.52 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.714 0 N-CA-C 113.878 1.066 . . . . 0.0 113.878 -177.118 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -127.59 127.33 43.68 Favored 'General case' 0 C--N 1.319 -0.743 0 C-N-CA 120.153 -0.619 . . . . 0.0 111.386 -178.63 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 94.0 mt -131.18 122.09 50.57 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.091 177.927 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 7.6 t30 -124.79 95.4 4.5 Favored 'General case' 0 C--N 1.313 -1.001 0 N-CA-C 108.812 -0.81 . . . . 0.0 108.812 176.455 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.421 ' CG2' ' HB ' ' A' ' 36' ' ' ILE . 26.8 m -140.17 142.68 31.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 N-CA-C 112.682 0.623 . . . . 0.0 112.682 -175.612 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 -145.1 147.16 32.23 Favored 'General case' 0 N--CA 1.444 -0.759 0 CA-C-N 115.4 -0.818 . . . . 0.0 109.153 176.526 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 47.2 t -137.73 142.48 40.99 Favored 'General case' 0 C--N 1.308 -1.221 0 CA-C-O 120.797 0.332 . . . . 0.0 110.78 -178.589 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -108.01 -6.18 32.39 Favored Glycine 0 N--CA 1.44 -1.05 0 N-CA-C 110.796 -0.922 . . . . 0.0 110.796 175.766 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 68.3 m-20 -98.26 54.65 1.09 Allowed 'General case' 0 C--O 1.235 0.33 0 N-CA-C 112.643 0.609 . . . . 0.0 112.643 -177.582 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 28.7 t70 59.55 15.55 4.65 Favored 'General case' 0 N--CA 1.481 1.098 0 C-N-CA 123.3 0.64 . . . . 0.0 112.284 174.863 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 86.37 -3.85 86.66 Favored Glycine 0 N--CA 1.447 -0.625 0 C-N-CA 120.447 -0.882 . . . . 0.0 112.944 178.232 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 112' ' ' GLN . . . . . 0.415 ' O ' ' HA ' ' A' ' 131' ' ' THR . 97.6 mt-30 -64.21 -40.14 95.45 Favored 'General case' 0 CA--C 1.517 -0.29 0 CA-C-N 116.926 0.363 . . . . 0.0 111.622 -177.76 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 33.5 p -123.32 112.17 17.28 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 110.0 -0.37 . . . . 0.0 110.0 177.833 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 92.5 mt -90.93 126.95 36.21 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 116.464 -0.335 . . . . 0.0 110.477 -178.66 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 9.0 m120 -118.72 129.86 55.51 Favored 'General case' 0 C--O 1.241 0.651 0 CA-C-N 116.224 -0.444 . . . . 0.0 109.882 -178.812 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 172.21 -141.32 6.22 Favored Glycine 0 N--CA 1.445 -0.755 0 C-N-CA 119.741 -1.218 . . . . 0.0 113.608 178.098 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 16.9 p -137.29 159.32 42.27 Favored 'General case' 0 C--N 1.319 -0.726 0 C-N-CA 123.276 0.63 . . . . 0.0 110.781 -178.269 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 17.8 ptm -147.31 150.44 34.79 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 120.864 0.364 . . . . 0.0 110.898 -179.721 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 23.3 m -142.48 136.09 29.05 Favored 'General case' 0 C--O 1.252 1.194 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.064 178.053 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . 0.62 ' HB2' ' O ' ' A' ' 123' ' ' GLU . 37.1 m-85 -83.58 174.26 10.7 Favored 'General case' 0 C--O 1.225 -0.23 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.342 175.597 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . 0.47 ' HB3' HE21 ' A' ' 98' ' ' GLN . . . -51.22 -28.87 12.55 Favored 'General case' 0 N--CA 1.478 0.933 0 N-CA-C 114.058 1.133 . . . . 0.0 114.058 -175.951 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -165.54 26.84 0.18 Allowed Glycine 0 N--CA 1.447 -0.589 0 C-N-CA 119.29 -1.433 . . . . 0.0 112.742 179.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . 0.62 ' O ' ' HB2' ' A' ' 120' ' ' TYR . 13.3 pt-20 -165.97 145.59 6.25 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.132 0.491 . . . . 0.0 111.868 -178.51 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 71.87 67.92 1.74 Allowed Glycine 0 CA--C 1.531 1.084 0 N-CA-C 116.312 1.285 . . . . 0.0 116.312 173.075 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_exo -84.14 95.07 0.73 Allowed 'Trans proline' 0 N--CA 1.459 -0.53 0 C-N-CA 122.454 2.102 . . . . 0.0 108.374 170.561 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 19.6 pt -130.28 165.83 29.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 N-CA-C 113.234 0.828 . . . . 0.0 113.234 -170.762 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -70.44 135.99 25.96 Favored Glycine 0 C--N 1.339 0.703 0 CA-C-N 115.488 -0.778 . . . . 0.0 111.577 178.29 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 82.5 t80 -112.54 133.26 54.69 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 121.281 0.562 . . . . 0.0 111.754 -175.688 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 63.5 tttm -137.64 110.4 7.61 Favored 'General case' 0 C--N 1.314 -0.939 0 CA-C-N 115.241 -0.891 . . . . 0.0 108.933 177.089 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -117.56 153.82 17.02 Favored Glycine 0 N--CA 1.446 -0.685 0 C-N-CA 120.298 -0.953 . . . . 0.0 112.332 -178.363 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 131' ' ' THR . . . . . 0.415 ' HA ' ' O ' ' A' ' 112' ' ' GLN . 14.9 t -143.01 144.95 32.49 Favored 'General case' 0 C--N 1.311 -1.073 0 CA-C-O 121.149 0.5 . . . . 0.0 111.945 179.625 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 68.6 tp -80.91 127.16 32.24 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.342 -0.845 . . . . 0.0 110.219 178.337 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 9.1 t . . . . . 0 C--O 1.253 1.27 0 CA-C-O 118.957 -0.544 . . . . 0.0 110.496 -179.343 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.697 0 N-CA-C 109.995 -0.372 . . . . 0.0 109.995 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' LEU . . . . . 0.503 HD11 HE21 ' A' ' 22' ' ' GLN . 2.2 tm? -92.08 134.91 34.4 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 116.117 -0.492 . . . . 0.0 109.801 -178.031 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . 0.472 ' CE1' ' HB ' ' A' ' 25' ' ' ILE . 74.1 m-85 -123.36 146.54 47.87 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.515 -179.803 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' ASN . . . . . 0.414 ' O ' ' HA2' ' A' ' 130' ' ' GLY . 23.6 t-20 -96.45 140.9 30.42 Favored 'General case' 0 C--N 1.308 -1.211 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 176.627 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 69.9 t -122.77 129.53 75.1 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.916 0 N-CA-C 112.699 0.629 . . . . 0.0 112.699 -175.154 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 91.4 mt-10 -122.4 144.32 49.11 Favored 'General case' 0 C--N 1.32 -0.679 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 173.09 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 11.9 m120 -123.49 144.67 49.39 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-O 120.921 0.391 . . . . 0.0 111.493 -177.003 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . 0.577 ' HB2' ' CE3' ' A' ' 17' ' ' TRP . 57.9 tt0 -123.88 127.14 47.59 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.766 -179.853 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 8.7 p90 -136.09 139.22 42.83 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-N 116.193 -0.458 . . . . 0.0 109.865 176.915 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 105.34 8.0 36.41 Favored Glycine 0 N--CA 1.448 -0.529 0 C-N-CA 120.286 -0.959 . . . . 0.0 112.294 179.862 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 103.24 165.71 25.68 Favored Glycine 0 N--CA 1.445 -0.724 0 C-N-CA 120.402 -0.904 . . . . 0.0 113.427 177.954 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 15.6 m -54.81 -31.81 59.6 Favored 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 123.631 0.773 . . . . 0.0 112.321 179.013 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 33.6 t -64.25 -40.0 95.11 Favored 'General case' 0 C--O 1.242 0.701 0 CA-C-O 120.97 0.414 . . . . 0.0 110.604 -179.573 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -63.43 150.55 89.56 Favored Pre-proline 0 C--O 1.235 0.34 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.403 -179.118 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 88.8 Cg_endo -75.33 156.87 41.6 Favored 'Trans proline' 0 C--O 1.238 0.477 0 C-N-CA 122.888 2.392 . . . . 0.0 112.93 -179.476 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' TRP . . . . . 0.577 ' CE3' ' HB2' ' A' ' 9' ' ' GLN . 85.7 m95 -84.91 124.59 31.82 Favored 'General case' 0 N--CA 1.446 -0.627 0 N-CA-C 107.872 -1.159 . . . . 0.0 107.872 175.71 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 55.1 m-80 -103.68 137.13 42.15 Favored 'General case' 0 C--N 1.308 -1.228 0 N-CA-C 109.122 -0.695 . . . . 0.0 109.122 -179.177 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 18.5 pt-20 -63.78 128.79 37.38 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-O 121.625 0.726 . . . . 0.0 111.673 -178.277 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . 0.681 ' O ' ' HB2' ' A' ' 94' ' ' SER . . . -102.26 -25.28 7.92 Favored Glycine 0 N--CA 1.434 -1.467 0 CA-C-N 114.435 -1.257 . . . . 0.0 113.746 -174.851 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 139.07 -153.04 22.57 Favored Glycine 0 N--CA 1.443 -0.849 0 C-N-CA 119.684 -1.246 . . . . 0.0 112.071 -174.367 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . 0.503 HE21 HD11 ' A' ' 3' ' ' LEU . 4.1 pt20 -138.41 134.37 34.04 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 120.733 0.302 . . . . 0.0 110.707 -179.054 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . 0.434 ' HE1' ' HB3' ' A' ' 94' ' ' SER . 44.9 m0 -117.61 172.74 7.15 Favored 'General case' 0 N--CA 1.47 0.568 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.637 -179.021 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 79.2 tt0 -130.93 122.49 27.04 Favored 'General case' 0 CA--C 1.518 -0.286 0 C-N-CA 120.513 -0.475 . . . . 0.0 110.142 178.006 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.555 HG23 ' CZ3' ' A' ' 90' ' ' TRP . 99.1 mt -139.72 151.39 22.26 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.769 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.189 -176.146 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 84.62 25.91 40.68 Favored Glycine 0 C--N 1.336 0.559 0 C-N-CA 121.009 -0.615 . . . . 0.0 113.81 175.26 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 4.9 m -77.85 7.94 5.25 Favored 'General case' 0 CA--C 1.549 0.93 0 N-CA-C 112.471 0.545 . . . . 0.0 112.471 -179.06 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . 0.481 ' HA ' ' O ' ' A' ' 87' ' ' GLY . 70.7 ttt180 -64.16 -49.68 71.15 Favored 'General case' 0 N--CA 1.474 0.756 0 CA-C-O 121.14 0.495 . . . . 0.0 111.85 -177.977 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 59.2 m -161.47 25.41 0.13 Allowed 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 -179.795 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 27.4 m-20 61.35 94.38 0.04 OUTLIER 'General case' 0 C--O 1.236 0.388 0 CA-C-N 114.486 -1.234 . . . . 0.0 108.783 -175.894 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -160.93 143.42 12.6 Favored 'General case' 0 N--CA 1.443 -0.78 0 N-CA-C 107.455 -1.313 . . . . 0.0 107.455 -176.23 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . 0.492 ' HB3' ' HA3' ' A' ' 111' ' ' GLY . 3.8 m120 -83.37 134.71 34.88 Favored 'General case' 0 C--N 1.311 -1.089 0 CA-C-O 121.543 0.687 . . . . 0.0 112.589 -177.741 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.408 HG21 ' CE1' ' A' ' 53' ' ' TYR . 44.7 t -92.9 135.99 26.18 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.727 0 CA-C-N 114.768 -1.105 . . . . 0.0 110.153 -179.857 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 29.7 m -109.36 -18.6 7.41 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 C-N-CA 120.758 -0.377 . . . . 0.0 111.572 -179.671 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -149.92 139.1 21.22 Favored 'General case' 0 C--O 1.236 0.361 0 C-N-CA 120.787 -0.365 . . . . 0.0 111.48 178.666 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.429 ' HB ' ' CG2' ' A' ' 105' ' ' VAL . 86.8 mt -140.03 116.32 8.74 Favored 'Isoleucine or valine' 0 C--O 1.237 0.446 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 178.635 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 14.7 m120 -123.55 106.65 10.77 Favored 'General case' 0 C--N 1.311 -1.085 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 176.716 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 18.6 m -146.56 148.11 17.26 Favored 'Isoleucine or valine' 0 C--O 1.238 0.472 0 CA-C-O 120.742 0.306 . . . . 0.0 111.236 -174.764 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 83.0 tt0 -142.61 147.41 35.78 Favored 'General case' 0 C--N 1.319 -0.759 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 178.169 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 19.4 p -70.81 150.33 45.94 Favored 'General case' 0 C--N 1.319 -0.757 0 N-CA-C 112.985 0.735 . . . . 0.0 112.985 -176.248 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -103.55 -47.39 1.3 Allowed Glycine 0 N--CA 1.443 -0.879 0 N-CA-C 110.529 -1.029 . . . . 0.0 110.529 176.252 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 45.4 m-20 -102.11 -152.8 0.45 Allowed 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 109.57 -0.53 . . . . 0.0 109.57 177.065 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 19.0 m-20 -74.17 44.41 0.19 Allowed 'General case' 0 N--CA 1.486 1.367 0 N-CA-C 112.147 0.425 . . . . 0.0 112.147 -177.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 79.91 3.45 89.32 Favored Glycine 0 CA--C 1.506 -0.475 0 C-N-CA 120.881 -0.676 . . . . 0.0 112.056 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 61.1 mt-30 -83.43 -21.99 32.78 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-O 121.215 0.531 . . . . 0.0 110.081 178.464 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' THR . . . . . 0.503 ' HA ' ' O ' ' A' ' 63' ' ' ALA . 35.2 p -129.03 142.62 50.85 Favored 'General case' 0 C--N 1.315 -0.907 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.936 178.52 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 95.9 mt -128.62 133.18 48.22 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 109.103 -0.702 . . . . 0.0 109.103 179.915 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 14.0 m120 -126.5 139.4 53.25 Favored 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 -179.97 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 169.74 -150.51 15.13 Favored Glycine 0 N--CA 1.448 -0.538 0 C-N-CA 120.112 -1.042 . . . . 0.0 112.463 178.035 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 34.8 p -134.45 152.43 51.79 Favored 'General case' 0 C--N 1.317 -0.83 0 N-CA-C 110.031 -0.359 . . . . 0.0 110.031 179.676 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 11.0 tmm? -142.12 145.49 34.3 Favored 'General case' 0 C--N 1.315 -0.912 0 C-N-CA 121.124 -0.23 . . . . 0.0 110.85 -178.829 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 60.4 m -129.07 128.64 43.97 Favored 'General case' 0 C--O 1.248 1.014 0 CA-C-O 120.81 0.338 . . . . 0.0 111.904 -177.399 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . 0.464 ' HB2' ' HB2' ' A' ' 56' ' ' GLU . 78.7 m-85 -91.11 164.63 13.86 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 115.617 -0.72 . . . . 0.0 110.327 176.86 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -69.39 98.26 1.07 Allowed 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.189 179.017 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 103.9 2.16 45.78 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.946 -0.645 . . . . 0.0 112.793 177.779 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . 0.464 ' HB2' ' HB2' ' A' ' 53' ' ' TYR . 66.7 mm-40 -117.69 162.91 17.27 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 110.115 -0.328 . . . . 0.0 110.115 179.02 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -84.08 166.25 42.34 Favored Glycine 0 N--CA 1.441 -0.972 0 C-N-CA 120.282 -0.961 . . . . 0.0 111.784 179.114 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 23.1 Cg_exo -65.82 139.78 58.61 Favored 'Trans proline' 0 N--CA 1.462 -0.348 0 C-N-CA 122.459 2.106 . . . . 0.0 111.912 178.921 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 38.3 pt -128.88 161.29 38.36 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.792 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.386 178.85 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -74.8 134.48 17.41 Favored Glycine 0 N--CA 1.446 -0.669 0 N-CA-C 111.331 -0.707 . . . . 0.0 111.331 179.984 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 52.6 t80 -117.46 125.98 51.84 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-O 121.034 0.445 . . . . 0.0 111.562 -176.905 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 64.0 ttp85 -136.53 129.08 30.42 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.857 -0.61 . . . . 0.0 109.747 174.737 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.503 ' O ' ' HA ' ' A' ' 46' ' ' THR . . . -129.41 139.3 51.7 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 116.563 -0.289 . . . . 0.0 110.966 -177.748 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 40.6 m -122.29 128.72 51.41 Favored 'General case' 0 C--N 1.323 -0.544 0 O-C-N 123.512 0.507 . . . . 0.0 109.74 178.534 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 52.6 tp -75.58 119.28 19.42 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 112.388 0.514 . . . . 0.0 112.388 -177.082 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 84.6 mt -84.18 -27.61 27.94 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.453 -0.794 . . . . 0.0 109.438 174.847 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 129.81 158.86 9.59 Favored Glycine 0 N--CA 1.442 -0.901 0 CA-C-N 115.109 -0.95 . . . . 0.0 110.81 -178.861 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 93.0 m-20 60.89 37.29 18.55 Favored 'General case' 0 N--CA 1.476 0.86 0 CA-C-O 120.848 0.356 . . . . 0.0 111.242 178.969 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 16.8 m120 66.37 8.15 5.48 Favored 'General case' 0 N--CA 1.485 1.309 0 C-N-CA 123.244 0.618 . . . . 0.0 112.151 179.237 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 15.8 m -92.18 121.84 34.09 Favored 'General case' 0 N--CA 1.446 -0.666 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 178.703 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 64.8 m-85 -113.58 132.73 55.62 Favored 'General case' 0 C--N 1.312 -1.04 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.999 -178.942 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 63.2 tt0 -86.96 119.76 27.51 Favored 'General case' 0 N--CA 1.438 -1.035 0 N-CA-C 106.763 -1.569 . . . . 0.0 106.763 172.952 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 79.2 t -107.27 134.51 48.76 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 CA-C-O 121.182 0.515 . . . . 0.0 112.086 -172.824 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 87.6 mt-10 -127.37 129.61 47.9 Favored 'General case' 0 N--CA 1.438 -1.072 0 N-CA-C 107.703 -1.221 . . . . 0.0 107.703 176.363 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 48.9 m-80 -112.42 154.79 25.26 Favored 'General case' 0 C--N 1.314 -0.971 0 CA-C-O 120.967 0.413 . . . . 0.0 111.041 -176.68 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 63.1 tt0 -115.45 119.95 37.91 Favored 'General case' 0 C--N 1.311 -1.099 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.152 -178.695 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 12.4 p90 -143.67 161.86 37.44 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.804 179.388 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 100.4 -7.21 58.06 Favored Glycine 0 N--CA 1.446 -0.674 0 C-N-CA 120.858 -0.687 . . . . 0.0 111.924 179.648 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 136.2 160.28 8.74 Favored Glycine 0 N--CA 1.44 -1.081 0 N-CA-C 111.574 -0.611 . . . . 0.0 111.574 179.92 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 15.7 t70 -59.74 -41.78 91.69 Favored 'General case' 0 C--N 1.319 -0.737 0 C-N-CA 123.115 0.566 . . . . 0.0 112.085 179.626 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 50.6 p -76.71 -3.97 40.79 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 112.573 0.583 . . . . 0.0 112.573 -179.205 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -76.52 150.74 82.5 Favored Pre-proline 0 C--N 1.325 -0.46 0 CA-C-O 120.518 0.199 . . . . 0.0 110.945 -179.686 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -74.07 -178.55 3.95 Favored 'Trans proline' 0 C--O 1.239 0.54 0 C-N-CA 122.633 2.222 . . . . 0.0 112.083 179.212 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' TRP . . . . . . . . . . . . . 89.0 m95 -95.77 140.24 30.85 Favored 'General case' 0 N--CA 1.444 -0.729 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.352 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 89.5 m-70 -118.26 142.98 46.92 Favored 'General case' 0 C--N 1.31 -1.117 0 CA-C-N 116.273 -0.421 . . . . 0.0 109.949 179.878 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 11.8 p -62.85 134.26 55.97 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.843 0.354 . . . . 0.0 111.161 -178.366 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . 0.481 ' O ' ' HA ' ' A' ' 28' ' ' ARG . . . -107.89 -46.43 1.03 Allowed Glycine 0 N--CA 1.438 -1.167 0 C-N-CA 120.971 -0.633 . . . . 0.0 111.909 179.76 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 148.39 -168.0 29.08 Favored Glycine 0 C--O 1.225 -0.44 0 C-N-CA 120.031 -1.081 . . . . 0.0 112.733 178.24 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 24.9 t-20 -106.0 117.05 33.02 Favored 'General case' 0 C--N 1.321 -0.674 0 N-CA-C 110.054 -0.35 . . . . 0.0 110.054 -179.012 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 90' ' ' TRP . . . . . 0.555 ' CZ3' HG23 ' A' ' 25' ' ' ILE . 18.6 m0 -113.56 148.21 36.56 Favored 'General case' 0 C--N 1.317 -0.818 0 N-CA-C 109.284 -0.635 . . . . 0.0 109.284 179.887 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 85.6 mt -105.32 117.89 51.8 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.843 0 N-CA-C 109.547 -0.538 . . . . 0.0 109.547 179.064 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 86.0 mt -129.26 78.61 1.86 Allowed 'General case' 0 C--O 1.265 1.92 0 CA-C-O 121.863 0.839 . . . . 0.0 112.092 -177.76 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 170.05 124.45 0.74 Allowed Glycine 0 N--CA 1.441 -0.987 0 CA-C-N 114.757 -1.111 . . . . 0.0 110.722 178.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 94' ' ' SER . . . . . 0.681 ' HB2' ' O ' ' A' ' 20' ' ' GLY . 83.7 p -106.42 -7.61 17.53 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-O 120.898 0.38 . . . . 0.0 111.665 -179.55 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 95' ' ' ARG . . . . . 0.42 HH12 ' CD ' ' A' ' 123' ' ' GLU . 99.5 mtt180 -106.76 154.61 20.73 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 121.269 0.557 . . . . 0.0 112.091 178.871 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 26.8 tp10 -68.62 -38.83 80.89 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 114.965 -1.016 . . . . 0.0 111.061 -174.258 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 10.1 p30 -116.17 21.06 13.96 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.925 -177.076 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 98' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -136.75 115.82 12.42 Favored 'General case' 0 C--N 1.32 -0.697 0 C-N-CA 119.573 -0.851 . . . . 0.0 112.89 -176.46 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 90.4 m-20 -92.44 154.76 18.3 Favored 'General case' 0 C--O 1.249 1.057 0 CA-C-N 115.029 -0.987 . . . . 0.0 109.353 177.488 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . 0.41 HG22 ' CH2' ' A' ' 23' ' ' TRP . 85.2 t -79.75 130.8 35.49 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.555 0 C-N-CA 120.092 -0.643 . . . . 0.0 110.899 178.492 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 33.7 m -111.74 -19.18 7.08 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.438 0 N-CA-C 112.122 0.415 . . . . 0.0 112.122 -179.654 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . 0.477 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -152.12 140.07 20.08 Favored 'General case' 0 CA--C 1.511 -0.537 0 C-N-CA 119.899 -0.72 . . . . 0.0 111.588 176.975 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 95.4 mt -135.49 125.01 41.75 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.175 177.456 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 52.6 t30 -129.74 101.22 5.8 Favored 'General case' 0 C--N 1.315 -0.931 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 175.801 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.429 ' CG2' ' HB ' ' A' ' 36' ' ' ILE . 19.8 m -140.9 142.8 29.51 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.791 0 N-CA-C 113.195 0.813 . . . . 0.0 113.195 -175.547 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 99.9 mt-10 -141.58 151.25 43.02 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 114.911 -1.04 . . . . 0.0 108.615 176.507 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 36.5 t -130.12 146.94 51.81 Favored 'General case' 0 C--N 1.311 -1.106 0 CA-C-O 121.244 0.545 . . . . 0.0 111.871 -177.817 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -89.61 -10.98 64.63 Favored Glycine 0 N--CA 1.444 -0.792 0 N-CA-C 110.366 -1.094 . . . . 0.0 110.366 174.435 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 83.6 m-20 -94.16 -172.06 2.71 Favored 'General case' 0 CA--C 1.513 -0.48 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 178.28 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 13.5 p-10 -95.74 33.86 1.59 Allowed 'General case' 0 C--N 1.313 -0.988 0 CA-C-O 121.031 0.443 . . . . 0.0 109.986 176.884 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . 0.492 ' HA3' ' HB3' ' A' ' 32' ' ' ASN . . . 97.42 8.56 56.15 Favored Glycine 0 C--N 1.333 0.406 0 CA-C-N 115.825 -0.625 . . . . 0.0 113.803 179.13 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 28.3 tt0 -64.72 -40.88 96.08 Favored 'General case' 0 C--O 1.241 0.621 0 CA-C-O 121.537 0.684 . . . . 0.0 109.858 178.383 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 73.2 p -135.58 146.93 48.47 Favored 'General case' 0 N--CA 1.446 -0.651 0 CA-C-N 114.841 -1.072 . . . . 0.0 109.483 178.306 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 96.0 mt -119.97 126.47 50.93 Favored 'General case' 0 C--N 1.312 -1.06 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 178.951 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 14.2 m120 -122.99 143.57 49.84 Favored 'General case' 0 C--N 1.317 -0.835 0 N-CA-C 110.01 -0.367 . . . . 0.0 110.01 -178.963 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 161.19 -142.11 7.83 Favored Glycine 0 N--CA 1.448 -0.513 0 C-N-CA 119.747 -1.216 . . . . 0.0 113.303 177.3 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 23.6 p -131.47 156.95 44.75 Favored 'General case' 0 C--N 1.316 -0.849 0 C-N-CA 122.919 0.488 . . . . 0.0 110.819 -178.709 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 19.9 ptm -149.69 157.08 42.9 Favored 'General case' 0 C--N 1.314 -0.945 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.152 179.955 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 119' ' ' THR . . . . . 0.477 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 40.6 m -132.0 130.31 41.24 Favored 'General case' 0 C--O 1.245 0.841 0 CA-C-N 116.589 -0.278 . . . . 0.0 111.269 -179.176 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 11.7 m-85 -94.22 160.52 14.65 Favored 'General case' 0 N--CA 1.455 -0.197 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.883 176.616 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -38.7 -45.14 1.08 Allowed 'General case' 0 N--CA 1.482 1.161 0 N-CA-C 114.149 1.166 . . . . 0.0 114.149 -177.245 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -145.63 43.01 0.94 Allowed Glycine 0 CA--C 1.506 -0.514 0 C-N-CA 120.084 -1.055 . . . . 0.0 111.713 -178.972 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . 0.42 ' CD ' HH12 ' A' ' 95' ' ' ARG . 28.5 tp10 -116.13 -61.95 1.66 Allowed 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 121.199 0.523 . . . . 0.0 110.714 -177.712 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 134.26 -179.0 17.97 Favored Glycine 0 N--CA 1.443 -0.836 0 N-CA-C 111.264 -0.734 . . . . 0.0 111.264 -178.503 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 62.0 Cg_endo -81.46 117.15 3.04 Favored 'Trans proline' 0 N--CA 1.455 -0.738 0 C-N-CA 122.424 2.082 . . . . 0.0 112.182 179.508 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 38.0 pt -126.22 161.2 32.44 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.922 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.415 -179.894 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -72.5 138.67 26.55 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.949 -0.643 . . . . 0.0 112.609 -178.732 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 77.8 t80 -114.82 132.23 56.56 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-O 121.061 0.458 . . . . 0.0 110.994 -179.153 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 129' ' ' LYS . . . . . 0.45 ' HB2' ' CZ3' ' A' ' 17' ' ' TRP . 86.9 tttt -134.28 101.33 4.97 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.098 177.43 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . 0.414 ' HA2' ' O ' ' A' ' 5' ' ' ASN . . . -109.44 150.41 17.26 Favored Glycine 0 N--CA 1.435 -1.38 0 C-N-CA 120.326 -0.94 . . . . 0.0 112.0 179.3 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 6.0 t -146.39 148.77 32.68 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-O 120.718 0.294 . . . . 0.0 111.15 179.21 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 83.4 mt -63.51 132.93 52.87 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.059 -0.518 . . . . 0.0 110.107 175.796 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 6.9 p . . . . . 0 C--O 1.249 1.051 0 CA-C-O 118.511 -0.756 . . . . 0.0 110.702 178.873 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 0.595 ' O ' ' HG3' ' A' ' 24' ' ' GLU . . . . . . . . 0 N--CA 1.475 0.825 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' LEU . . . . . 0.441 HD12 ' N ' ' A' ' 4' ' ' TYR . 0.3 OUTLIER -90.94 130.58 36.86 Favored 'General case' 0 C--N 1.313 -0.994 0 CA-C-O 121.064 0.459 . . . . 0.0 109.88 -174.58 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . 0.441 ' N ' HD12 ' A' ' 3' ' ' LEU . 28.5 m-85 -116.99 137.39 52.25 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-N 115.854 -0.612 . . . . 0.0 111.24 -179.989 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 20.8 t-20 -87.12 131.73 34.06 Favored 'General case' 0 C--N 1.306 -1.317 0 N-CA-C 106.577 -1.638 . . . . 0.0 106.577 176.884 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.513 HG23 ' CG ' ' A' ' 23' ' ' TRP . 58.6 t -114.72 126.16 72.21 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.854 0 N-CA-C 113.204 0.816 . . . . 0.0 113.204 -172.969 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . 0.411 ' HG2' ' HB3' ' A' ' 19' ' ' GLU . 92.3 mt-10 -120.56 135.66 55.02 Favored 'General case' 0 N--CA 1.435 -1.195 0 CA-C-N 114.575 -1.193 . . . . 0.0 108.353 176.833 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 9.9 m120 -120.22 144.53 47.68 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-O 120.899 0.381 . . . . 0.0 111.858 -176.226 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . 0.558 ' OE1' ' HA ' ' A' ' 13' ' ' SER . 36.4 tt0 -129.2 122.01 28.85 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.557 -0.747 . . . . 0.0 109.869 178.754 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 17.5 p90 -120.94 140.93 51.17 Favored 'General case' 0 C--N 1.314 -0.945 0 CA-C-O 121.337 0.589 . . . . 0.0 111.695 -179.845 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 107.24 -69.95 0.21 Allowed Glycine 0 N--CA 1.441 -1.009 0 CA-C-N 115.429 -0.805 . . . . 0.0 111.576 179.287 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -165.09 166.78 38.41 Favored Glycine 0 N--CA 1.442 -0.929 0 N-CA-C 111.612 -0.595 . . . . 0.0 111.612 179.467 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' SER . . . . . 0.558 ' HA ' ' OE1' ' A' ' 9' ' ' GLN . 11.5 p -60.04 -20.42 57.85 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 112.9 0.704 . . . . 0.0 112.9 -179.246 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 8.1 m -78.58 -5.59 53.23 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 120.642 0.258 . . . . 0.0 111.541 179.7 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -86.68 146.7 41.98 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 120.745 0.307 . . . . 0.0 111.359 -178.943 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -65.74 149.37 87.02 Favored 'Trans proline' 0 C--O 1.235 0.331 0 C-N-CA 122.823 2.349 . . . . 0.0 112.094 179.102 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 96.9 m95 -82.88 132.27 35.16 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 178.27 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 89.1 m-20 -120.67 122.84 41.33 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.43 -178.504 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.411 ' HB3' ' HG2' ' A' ' 7' ' ' GLU . 5.1 pt-20 -90.32 127.76 36.25 Favored 'General case' 0 C--N 1.313 -0.986 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 178.111 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -139.14 29.43 2.53 Favored Glycine 0 N--CA 1.445 -0.747 0 C-N-CA 119.761 -1.209 . . . . 0.0 112.611 -178.07 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 157.21 174.88 27.48 Favored Glycine 0 N--CA 1.438 -1.224 0 C-N-CA 120.381 -0.914 . . . . 0.0 112.458 179.829 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 4.4 pt20 -134.56 139.33 45.32 Favored 'General case' 0 C--N 1.314 -0.946 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 179.643 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' TRP . . . . . 0.527 ' HB3' ' O ' ' A' ' 91' ' ' ILE . 38.8 m0 -116.72 178.44 4.34 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.404 -176.715 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . 0.595 ' HG3' ' O ' ' A' ' 2' ' ' ALA . 76.9 tt0 -131.58 121.48 24.46 Favored 'General case' 0 N--CA 1.441 -0.879 0 C-N-CA 120.371 -0.531 . . . . 0.0 110.447 174.899 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 91.3 mt -127.59 131.99 69.57 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.955 0 CA-C-N 115.349 -0.841 . . . . 0.0 109.479 -178.668 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 91.13 121.28 2.49 Favored Glycine 0 N--CA 1.441 -0.99 0 C-N-CA 120.474 -0.869 . . . . 0.0 112.356 179.637 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' SER . . . . . 0.492 ' CB ' ' HA3' ' A' ' 88' ' ' GLY . 6.3 m -119.44 11.54 12.18 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-O 121.277 0.56 . . . . 0.0 109.819 179.957 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 63.1 mtt-85 -141.07 141.84 34.22 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.391 -0.822 . . . . 0.0 109.21 -176.485 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 37.3 p -92.09 2.5 56.54 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-O 121.145 0.498 . . . . 0.0 111.344 -178.523 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 37.0 m-20 -62.31 -38.1 88.11 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.585 -0.734 . . . . 0.0 111.509 -178.839 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 1.3 tm0? -167.35 151.36 6.63 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.937 -177.276 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . 0.453 ' HB3' ' HA3' ' A' ' 111' ' ' GLY . 15.6 m120 -96.91 173.14 7.44 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.679 0.752 . . . . 0.0 111.239 179.375 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 17.2 t -102.85 134.22 44.47 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.256 0 CA-C-N 115.202 -0.908 . . . . 0.0 112.51 -175.144 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 27.0 m -121.11 -28.14 1.87 Allowed 'Isoleucine or valine' 0 C--O 1.255 1.352 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.602 174.946 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.582 ' HA ' ' O ' ' A' ' 105' ' ' VAL . . . -140.31 140.33 35.63 Favored 'General case' 0 N--CA 1.442 -0.837 0 CA-C-O 121.38 0.609 . . . . 0.0 111.986 -178.706 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 93.7 mt -146.41 129.57 9.27 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 177.608 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -127.92 109.14 11.3 Favored 'General case' 0 C--N 1.311 -1.088 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 175.087 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . 0.475 HG11 ' CD1' ' A' ' 61' ' ' PHE . 19.4 m -147.47 149.49 15.47 Favored 'Isoleucine or valine' 0 C--O 1.242 0.685 0 C-N-CA 120.874 -0.33 . . . . 0.0 111.343 -174.906 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 77.6 tt0 -138.82 144.9 39.51 Favored 'General case' 0 N--CA 1.443 -0.813 0 CA-C-N 115.72 -0.673 . . . . 0.0 109.279 178.043 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 37.0 p -69.76 140.87 53.47 Favored 'General case' 0 C--N 1.317 -0.817 0 N-CA-C 112.533 0.568 . . . . 0.0 112.533 -176.862 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -86.83 -62.39 1.53 Allowed Glycine 0 CA--C 1.502 -0.771 0 N-CA-C 109.113 -1.595 . . . . 0.0 109.113 174.628 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 51.0 m-20 -88.36 -169.2 2.46 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 173.988 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 70.9 m-20 -77.11 57.98 1.48 Allowed 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 112.462 0.542 . . . . 0.0 112.462 -177.946 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 97.02 -20.32 51.31 Favored Glycine 0 C--O 1.218 -0.857 0 C-N-CA 121.068 -0.587 . . . . 0.0 113.419 175.542 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 56.0 mt-30 -64.99 -34.07 77.55 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 112.89 0.7 . . . . 0.0 112.89 -177.754 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' THR . . . . . 0.52 ' HA ' ' O ' ' A' ' 63' ' ' ALA . 14.8 t -136.14 131.64 34.98 Favored 'General case' 0 N--CA 1.438 -1.049 0 C-N-CA 120.387 -0.525 . . . . 0.0 111.239 178.622 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' LEU . . . . . 0.406 ' O ' ' HA ' ' A' ' 62' ' ' ARG . 80.1 mt -111.01 133.03 53.72 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.837 -0.619 . . . . 0.0 109.508 179.384 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 64.0 m-80 -125.27 146.21 49.65 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-O 120.703 0.287 . . . . 0.0 110.706 179.238 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 163.34 -140.52 6.54 Favored Glycine 0 N--CA 1.439 -1.15 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.497 178.4 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 24.5 p -133.41 150.75 51.78 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 120.908 0.385 . . . . 0.0 111.21 -179.292 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 18.4 ttt -124.82 137.0 54.32 Favored 'General case' 0 C--N 1.32 -0.68 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 179.78 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.543 ' HB ' ' HB2' ' A' ' 35' ' ' ALA . 60.6 m -124.89 122.55 37.68 Favored 'General case' 0 C--O 1.259 1.592 0 CA-C-O 121.17 0.509 . . . . 0.0 111.799 -178.303 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' TYR . . . . . 0.401 ' HB2' ' HB2' ' A' ' 56' ' ' GLU . 98.1 m-85 -84.66 166.0 17.44 Favored 'General case' 0 CA--C 1.52 -0.201 0 CA-C-N 115.372 -0.831 . . . . 0.0 109.835 178.512 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -67.94 110.69 3.99 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 120.952 0.406 . . . . 0.0 111.125 179.836 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 83.41 16.84 67.87 Favored Glycine 0 CA--C 1.522 0.493 0 C-N-CA 120.667 -0.778 . . . . 0.0 113.711 179.401 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' GLU . . . . . 0.401 ' HB2' ' HB2' ' A' ' 53' ' ' TYR . 98.1 mt-10 -132.01 163.24 28.83 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 117.339 0.569 . . . . 0.0 111.135 178.962 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -81.08 156.42 37.79 Favored Glycine 0 N--CA 1.447 -0.612 0 CA-C-N 115.955 -0.566 . . . . 0.0 112.603 -179.273 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 21.8 Cg_exo -64.62 142.56 77.86 Favored 'Trans proline' 0 C--N 1.347 0.467 0 C-N-CA 122.924 2.416 . . . . 0.0 112.81 -179.295 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 44.7 pt -125.91 167.66 19.98 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.872 0 CA-C-N 115.527 -0.76 . . . . 0.0 109.332 177.272 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -70.37 137.63 27.97 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.19 -1.005 . . . . 0.0 111.674 -178.952 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.475 ' CD1' HG11 ' A' ' 38' ' ' VAL . 50.2 t80 -127.71 128.42 45.37 Favored 'General case' 0 C--N 1.317 -0.847 0 CA-C-O 120.757 0.313 . . . . 0.0 110.831 -177.887 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . 0.406 ' HA ' ' O ' ' A' ' 47' ' ' LEU . 63.7 ttp85 -138.77 132.72 31.13 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.181 175.276 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.52 ' O ' ' HA ' ' A' ' 46' ' ' THR . . . -127.74 137.02 52.31 Favored 'General case' 0 C--N 1.311 -1.09 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.653 179.658 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 61.2 m -123.55 132.41 53.89 Favored 'General case' 0 C--N 1.315 -0.913 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 178.776 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . 0.646 HD21 ' O ' ' A' ' 68' ' ' ASN . 3.7 mt -60.5 128.17 35.33 Favored 'General case' 0 CA--C 1.501 -0.911 0 N-CA-C 113.928 1.085 . . . . 0.0 113.928 -178.13 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . 0.58 HD12 ' ND2' ' A' ' 89' ' ' ASN . 96.1 mt -76.43 -34.72 58.77 Favored 'General case' 0 N--CA 1.431 -1.394 0 N-CA-C 107.27 -1.381 . . . . 0.0 107.27 169.004 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -166.91 -72.66 0.03 OUTLIER Glycine 0 N--CA 1.433 -1.564 0 C-N-CA 120.405 -0.903 . . . . 0.0 115.013 -179.504 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' ASN . . . . . 0.646 ' O ' HD21 ' A' ' 65' ' ' LEU . 17.0 m120 -125.3 -77.34 0.59 Allowed 'General case' 0 C--O 1.214 -0.782 0 CA-C-N 118.212 1.006 . . . . 0.0 110.202 -175.85 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 12.2 m120 -100.94 -6.31 24.77 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 120.898 0.38 . . . . 0.0 110.643 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 8.3 m -95.37 121.13 36.72 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.698 -178.134 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' TYR . . . . . 0.402 ' CE2' ' HG ' ' A' ' 65' ' ' LEU . 96.0 m-85 -115.9 150.21 37.44 Favored 'General case' 0 C--N 1.314 -0.937 0 CA-C-N 116.323 -0.399 . . . . 0.0 111.181 -178.657 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 70.4 tt0 -105.72 125.53 51.09 Favored 'General case' 0 C--N 1.31 -1.125 0 N-CA-C 107.451 -1.315 . . . . 0.0 107.451 173.499 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 65.3 t -104.8 132.27 51.9 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.388 0 CA-C-O 121.544 0.687 . . . . 0.0 112.471 -174.172 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 47.5 mt-10 -127.35 123.54 36.52 Favored 'General case' 0 N--CA 1.436 -1.161 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 176.631 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 97.5 m-20 -110.83 153.43 25.41 Favored 'General case' 0 C--N 1.317 -0.819 0 CA-C-O 121.229 0.538 . . . . 0.0 111.934 -176.018 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' GLN . . . . . 0.485 ' HB2' ' CE3' ' A' ' 84' ' ' TRP . 60.0 tt0 -113.98 116.43 29.21 Favored 'General case' 0 C--N 1.312 -1.05 0 CA-C-N 115.607 -0.724 . . . . 0.0 109.933 -178.589 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 13.4 p90 -142.72 160.59 40.01 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.157 179.446 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 94.68 -3.66 68.29 Favored Glycine 0 N--CA 1.449 -0.473 0 C-N-CA 120.599 -0.81 . . . . 0.0 112.073 -179.532 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 135.21 152.44 6.49 Favored Glycine 0 N--CA 1.446 -0.65 0 N-CA-C 111.469 -0.652 . . . . 0.0 111.469 179.38 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 25.7 t70 -62.71 -36.82 84.22 Favored 'General case' 0 N--CA 1.468 0.453 0 CA-C-O 120.869 0.366 . . . . 0.0 111.932 -179.71 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 29.3 p -69.65 -15.78 63.25 Favored 'General case' 0 C--N 1.316 -0.86 0 N-CA-C 112.125 0.417 . . . . 0.0 112.125 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -75.87 142.71 73.43 Favored Pre-proline 0 C--O 1.234 0.267 0 CA-C-N 116.478 -0.328 . . . . 0.0 110.884 -179.512 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 96.7 Cg_endo -73.59 156.25 49.5 Favored 'Trans proline' 0 N--CA 1.462 -0.353 0 C-N-CA 122.712 2.274 . . . . 0.0 111.819 178.731 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' TRP . . . . . 0.485 ' CE3' ' HB2' ' A' ' 76' ' ' GLN . 81.7 m95 -60.98 138.31 58.18 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.305 0.574 . . . . 0.0 111.543 179.615 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 99.1 m-70 -113.03 144.65 42.24 Favored 'General case' 0 C--N 1.311 -1.096 0 CA-C-N 115.213 -0.903 . . . . 0.0 109.208 178.344 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 12.9 p -61.46 125.75 24.9 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-O 121.192 0.52 . . . . 0.0 111.941 -177.293 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -96.42 -48.85 2.11 Favored Glycine 0 N--CA 1.441 -1.032 0 CA-C-N 115.595 -0.73 . . . . 0.0 111.532 179.747 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . 0.492 ' HA3' ' CB ' ' A' ' 27' ' ' SER . . . 149.86 -167.17 29.92 Favored Glycine 0 C--O 1.216 -1.027 0 N-CA-C 111.326 -0.71 . . . . 0.0 111.326 178.405 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 89' ' ' ASN . . . . . 0.58 ' ND2' HD12 ' A' ' 66' ' ' LEU . 22.7 m120 -108.53 140.84 41.3 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 117.379 0.59 . . . . 0.0 110.867 179.35 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 90' ' ' TRP . . . . . 0.441 ' HD1' ' C ' ' A' ' 89' ' ' ASN . 29.4 m0 -133.69 160.62 36.99 Favored 'General case' 0 N--CA 1.465 0.298 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 -177.16 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . 0.527 ' O ' ' HB3' ' A' ' 23' ' ' TRP . 96.9 mt -121.19 121.6 65.31 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.035 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 175.806 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 83.7 mt -134.63 82.93 1.99 Allowed 'General case' 0 C--O 1.267 1.979 0 N-CA-C 112.765 0.654 . . . . 0.0 112.765 -175.414 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 164.64 118.5 0.44 Allowed Glycine 0 N--CA 1.448 -0.536 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.81 177.954 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 43.1 m -90.64 -0.14 57.58 Favored 'General case' 0 N--CA 1.463 0.211 0 CA-C-O 121.11 0.481 . . . . 0.0 110.64 177.922 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -120.02 152.16 37.91 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 178.788 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 78.1 tt0 -66.06 -65.44 0.68 Allowed 'General case' 0 C--N 1.32 -0.71 0 N-CA-C 112.6 0.593 . . . . 0.0 112.6 -174.86 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 93.5 m-20 -107.15 36.9 2.52 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 116.271 -0.422 . . . . 0.0 112.026 -175.409 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 98' ' ' GLN . . . . . . . . . . . . . 14.5 tp60 -108.67 -62.33 1.48 Allowed 'General case' 0 C--N 1.316 -0.885 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 179.646 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 91.7 m-20 71.87 149.98 0.1 Allowed 'General case' 0 C--O 1.248 1.013 0 CA-C-N 115.225 -0.898 . . . . 0.0 112.942 178.258 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 76.6 t -81.66 132.14 32.19 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.335 0 CA-C-N 115.44 -0.8 . . . . 0.0 111.191 178.279 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 26.8 m -114.49 -21.57 5.3 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.185 0 CA-C-N 116.004 -0.544 . . . . 0.0 112.356 179.571 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . 0.417 ' HB2' ' HB ' ' A' ' 119' ' ' THR . . . -150.09 141.44 23.27 Favored 'General case' 0 C--N 1.326 -0.444 0 C-N-CA 120.161 -0.615 . . . . 0.0 111.596 178.601 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.426 ' HB ' HG23 ' A' ' 38' ' ' VAL . 32.2 mm -134.61 127.21 49.33 Favored 'Isoleucine or valine' 0 C--O 1.244 0.766 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.863 178.429 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 50.4 t30 -131.76 97.38 4.18 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.782 -0.645 . . . . 0.0 109.867 175.277 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.582 ' O ' ' HA ' ' A' ' 35' ' ' ALA . 15.5 m -130.51 135.06 61.28 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.029 0 CA-C-N 115.775 -0.648 . . . . 0.0 111.162 -176.926 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 52.8 mt-10 -139.1 27.45 2.37 Favored 'General case' 0 N--CA 1.486 1.371 0 CA-C-O 121.526 0.679 . . . . 0.0 110.953 -178.841 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 107' ' ' SER . . . . . 0.569 ' HB2' ' HB2' ' A' ' 115' ' ' ASN . 53.7 m -139.1 147.34 41.85 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 114.259 1.207 . . . . 0.0 114.259 -175.1 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 148.71 122.06 1.2 Allowed Glycine 0 N--CA 1.436 -1.341 0 CA-C-N 114.624 -1.171 . . . . 0.0 111.84 178.268 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -83.29 107.67 15.98 Favored 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 178.657 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 59.58 18.13 6.77 Favored 'General case' 0 N--CA 1.481 1.084 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.275 -177.446 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . 0.453 ' HA3' ' HB3' ' A' ' 32' ' ' ASN . . . 80.06 15.39 78.96 Favored Glycine 0 N--CA 1.442 -0.913 0 CA-C-N 115.818 -0.628 . . . . 0.0 112.838 179.006 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 52.2 tt0 -64.15 -37.52 87.74 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-O 121.799 0.809 . . . . 0.0 109.138 177.607 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 60.5 p -133.93 164.25 27.71 Favored 'General case' 0 N--CA 1.431 -1.422 0 CA-C-N 114.56 -1.2 . . . . 0.0 108.724 177.354 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 114' ' ' LEU . . . . . 0.402 ' HA ' ' O ' ' A' ' 107' ' ' SER . 33.8 tp -134.84 114.69 12.84 Favored 'General case' 0 C--N 1.301 -1.519 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 176.937 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 115' ' ' ASN . . . . . 0.569 ' HB2' ' HB2' ' A' ' 107' ' ' SER . 0.8 OUTLIER -116.9 143.7 45.39 Favored 'General case' 0 C--O 1.263 1.81 0 C-N-CA 120.117 -0.633 . . . . 0.0 111.577 -176.31 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 165.02 -138.31 5.18 Favored Glycine 0 N--CA 1.437 -1.298 0 CA-C-N 115.164 -0.925 . . . . 0.0 112.25 177.208 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 29.8 p -130.51 155.48 46.4 Favored 'General case' 0 C--N 1.307 -1.265 0 C-N-CA 122.792 0.437 . . . . 0.0 109.986 -179.221 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 118' ' ' MET . . . . . 0.405 ' HE1' ' HB2' ' A' ' 118' ' ' MET . 18.0 ptm -146.94 153.32 39.95 Favored 'General case' 0 C--N 1.309 -1.194 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.465 -179.065 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 119' ' ' THR . . . . . 0.417 ' HB ' ' HB2' ' A' ' 102' ' ' ALA . 25.9 m -132.83 129.8 38.97 Favored 'General case' 0 C--O 1.248 1.0 0 CA-C-N 116.487 -0.324 . . . . 0.0 111.368 -179.811 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . 0.464 ' HB2' ' HB3' ' A' ' 123' ' ' GLU . 57.2 m-85 -94.1 159.16 15.27 Favored 'General case' 0 CA--C 1.516 -0.35 0 CA-C-N 115.746 -0.661 . . . . 0.0 109.58 175.298 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -66.27 134.39 52.56 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 109.662 -0.496 . . . . 0.0 109.662 176.284 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 64.95 22.44 68.6 Favored Glycine 0 CA--C 1.523 0.532 0 C-N-CA 120.815 -0.707 . . . . 0.0 113.113 -179.856 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . 0.464 ' HB3' ' HB2' ' A' ' 120' ' ' TYR . 39.3 tp10 -137.87 161.86 35.51 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 -178.172 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -89.06 156.51 26.28 Favored Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.284 -0.96 . . . . 0.0 111.84 178.617 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_exo -60.6 134.28 53.52 Favored 'Trans proline' 0 C--N 1.349 0.6 0 C-N-CA 122.394 2.062 . . . . 0.0 111.707 178.743 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 39.7 pt -131.57 165.44 31.71 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.812 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.51 -178.91 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -73.87 139.23 25.91 Favored Glycine 0 N--CA 1.445 -0.726 0 C-N-CA 121.206 -0.521 . . . . 0.0 112.003 179.717 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 92.2 t80 -117.35 132.63 56.56 Favored 'General case' 0 C--O 1.244 0.794 0 CA-C-O 120.974 0.416 . . . . 0.0 111.083 -178.697 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 61.7 tttm -135.48 102.37 5.11 Favored 'General case' 0 N--CA 1.442 -0.865 0 CA-C-N 115.567 -0.742 . . . . 0.0 109.694 177.867 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -100.58 140.7 15.04 Favored Glycine 0 CA--C 1.503 -0.67 0 N-CA-C 110.793 -0.923 . . . . 0.0 110.793 178.25 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 45.5 m -136.69 133.4 36.12 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-N 117.224 0.512 . . . . 0.0 111.059 179.881 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 78.8 mt -60.71 129.91 43.86 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-O 120.907 0.384 . . . . 0.0 110.363 177.21 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 133' ' ' THR . . . . . 0.408 HG22 HD13 ' A' ' 3' ' ' LEU . 5.3 t . . . . . 0 C--O 1.247 0.958 0 CA-C-O 118.244 -0.884 . . . . 0.0 110.13 -179.037 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.72 0 N-CA-C 110.246 -0.279 . . . . 0.0 110.246 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 2.3 tm? -91.43 128.32 37.21 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 -177.918 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . 0.442 ' CE2' ' HB ' ' A' ' 25' ' ' ILE . 83.1 m-85 -119.31 146.77 45.0 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-O 120.991 0.424 . . . . 0.0 111.645 -179.632 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 49.0 m-80 -97.31 138.74 34.32 Favored 'General case' 0 C--N 1.315 -0.932 0 N-CA-C 107.213 -1.403 . . . . 0.0 107.213 175.89 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 69.7 t -115.95 126.7 73.57 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.878 0 N-CA-C 113.108 0.781 . . . . 0.0 113.108 -175.17 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 94.4 mt-10 -120.72 135.66 55.07 Favored 'General case' 0 N--CA 1.443 -0.811 0 CA-C-N 114.817 -1.083 . . . . 0.0 108.21 175.21 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 12.7 m120 -125.44 148.43 48.82 Favored 'General case' 0 C--N 1.313 -0.994 0 CA-C-O 121.042 0.449 . . . . 0.0 111.738 -176.665 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 58.0 tt0 -125.92 119.38 27.61 Favored 'General case' 0 C--N 1.316 -0.857 0 N-CA-C 107.471 -1.307 . . . . 0.0 107.471 177.143 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 39.3 p90 -142.04 9.74 1.92 Allowed 'General case' 0 C--N 1.319 -0.721 0 N-CA-C 114.404 1.261 . . . . 0.0 114.404 -174.814 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -120.96 18.15 9.1 Favored Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 118.351 -1.881 . . . . 0.0 112.075 -176.767 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 110.83 159.58 16.47 Favored Glycine 0 N--CA 1.443 -0.879 0 C-N-CA 120.859 -0.686 . . . . 0.0 112.203 -179.761 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 41.3 m -56.18 -33.23 65.07 Favored 'General case' 0 C--N 1.323 -0.57 0 C-N-CA 122.74 0.416 . . . . 0.0 111.967 178.855 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 20.3 m -68.21 -14.18 62.79 Favored 'General case' 0 CA--C 1.539 0.535 0 CA-C-N 116.582 -0.281 . . . . 0.0 111.499 178.454 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -96.86 138.66 21.34 Favored Pre-proline 0 C--N 1.323 -0.549 0 N-CA-C 110.013 -0.366 . . . . 0.0 110.013 178.597 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_endo -77.9 -171.78 1.29 Allowed 'Trans proline' 0 CA--C 1.534 0.52 0 C-N-CA 122.954 2.436 . . . . 0.0 113.01 -178.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 96.9 m95 -91.34 136.06 33.37 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.103 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 90.8 m-20 -119.71 122.14 40.78 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.103 -179.288 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 75.3 tt0 -78.23 132.03 37.37 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 115.924 -0.58 . . . . 0.0 109.64 178.07 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.44 ' O ' ' HB2' ' A' ' 94' ' ' SER . . . -137.1 29.8 2.69 Favored Glycine 0 N--CA 1.447 -0.612 0 C-N-CA 119.565 -1.303 . . . . 0.0 113.547 -178.919 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 137.33 179.43 16.85 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.023 -1.084 . . . . 0.0 113.333 178.564 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 98.9 mt-30 -123.02 147.56 46.53 Favored 'General case' 0 C--N 1.327 -0.384 0 C-N-CA 122.796 0.438 . . . . 0.0 110.099 179.351 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . 0.41 ' HE1' ' HB3' ' A' ' 94' ' ' SER . 45.5 m0 -121.83 171.81 8.62 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 178.813 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -127.23 117.41 22.25 Favored 'General case' 0 C--N 1.317 -0.829 0 C-N-CA 120.635 -0.426 . . . . 0.0 110.144 175.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.442 ' HB ' ' CE2' ' A' ' 4' ' ' TYR . 99.1 mt -133.98 144.49 35.39 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 CA-C-N 115.559 -0.746 . . . . 0.0 109.677 -177.827 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . 0.43 ' C ' ' H ' ' A' ' 28' ' ' ARG . . . 81.57 35.64 22.1 Favored Glycine 0 CA--C 1.506 -0.487 0 C-N-CA 120.231 -0.985 . . . . 0.0 111.921 179.536 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 11.4 m -74.05 21.62 0.09 Allowed 'General case' 0 C--N 1.317 -0.823 0 N-CA-C 111.9 0.333 . . . . 0.0 111.9 179.83 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . 0.482 ' NH1' ' HG3' ' A' ' 31' ' ' GLN . 54.4 ttt180 -92.61 10.46 30.36 Favored 'General case' 0 CA--C 1.544 0.748 0 CA-C-O 121.686 0.755 . . . . 0.0 109.075 178.807 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 29.3 m 72.57 -79.67 0.04 OUTLIER 'General case' 0 CA--C 1.541 0.619 0 CA-C-N 114.802 -1.09 . . . . 0.0 113.288 176.135 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 28.4 m-20 -88.98 2.68 53.57 Favored 'General case' 0 N--CA 1.473 0.683 0 N-CA-C 113.106 0.78 . . . . 0.0 113.106 -175.222 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . 0.482 ' HG3' ' NH1' ' A' ' 28' ' ' ARG . 8.4 mm-40 -122.47 117.18 25.34 Favored 'General case' 0 C--N 1.309 -1.167 0 N-CA-C 113.394 0.887 . . . . 0.0 113.394 -178.869 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . 0.57 ' OD1' ' HA3' ' A' ' 111' ' ' GLY . 28.2 t-20 -92.39 145.16 24.68 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 114.932 -1.031 . . . . 0.0 110.376 177.163 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.419 HG23 ' CH2' ' A' ' 90' ' ' TRP . 53.3 t -97.62 131.95 43.42 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.148 0 CA-C-N 115.586 -0.734 . . . . 0.0 111.089 -178.814 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 29.1 m -109.36 -19.15 7.04 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.155 0 N-CA-C 112.361 0.504 . . . . 0.0 112.361 -179.597 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.4 ' HB2' ' HB ' ' A' ' 52' ' ' THR . . . -148.3 143.4 26.89 Favored 'General case' 0 CA--C 1.515 -0.383 0 C-N-CA 120.403 -0.519 . . . . 0.0 111.228 179.078 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.406 ' HB ' HG21 ' A' ' 105' ' ' VAL . 90.9 mt -142.68 122.04 9.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.215 -178.99 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 11.7 m120 -127.7 106.78 9.37 Favored 'General case' 0 C--N 1.313 -0.989 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 175.141 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.492 HG11 ' CD1' ' A' ' 61' ' ' PHE . 29.2 m -149.17 154.53 9.44 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 C-N-CA 120.79 -0.364 . . . . 0.0 111.463 -173.693 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 73.8 tt0 -147.61 152.42 37.87 Favored 'General case' 0 N--CA 1.442 -0.844 0 N-CA-C 109.284 -0.635 . . . . 0.0 109.284 176.471 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 33.2 p -83.25 130.33 35.07 Favored 'General case' 0 C--N 1.312 -1.028 0 CA-C-N 116.498 -0.319 . . . . 0.0 111.78 -177.541 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -71.58 -43.41 52.65 Favored Glycine 0 N--CA 1.445 -0.712 0 N-CA-C 110.197 -1.161 . . . . 0.0 110.197 174.681 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . 0.417 ' HB3' ' H ' ' A' ' 43' ' ' ASP . 57.2 m-20 -104.71 -152.91 0.47 Allowed 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 114.898 -0.651 . . . . 0.0 109.764 178.338 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . 0.417 ' H ' ' HB3' ' A' ' 42' ' ' ASP . 6.4 m-20 -74.81 40.27 0.14 Allowed 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 123.683 0.793 . . . . 0.0 111.308 -179.907 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.413 ' O ' ' HE2' ' A' ' 71' ' ' TYR . . . 92.92 -6.83 76.83 Favored Glycine 0 C--O 1.217 -0.924 0 C-N-CA 121.032 -0.604 . . . . 0.0 112.419 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 57.5 mt-30 -65.08 -38.84 92.05 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 112.736 0.643 . . . . 0.0 112.736 -178.086 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 5.4 t -126.06 110.84 14.01 Favored 'General case' 0 C--N 1.306 -1.285 0 CA-C-O 121.135 0.493 . . . . 0.0 110.515 179.806 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . 0.402 ' O ' ' HA ' ' A' ' 62' ' ' ARG . 79.4 mt -96.72 127.61 42.87 Favored 'General case' 0 C--N 1.316 -0.885 0 N-CA-C 108.936 -0.764 . . . . 0.0 108.936 177.354 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 24.7 p30 -135.28 152.84 51.89 Favored 'General case' 0 C--N 1.308 -1.204 0 CA-C-O 121.008 0.432 . . . . 0.0 110.966 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 162.53 -144.15 9.39 Favored Glycine 0 N--CA 1.438 -1.17 0 C-N-CA 120.447 -0.882 . . . . 0.0 112.683 179.258 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 61.6 m -127.91 130.9 49.26 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-O 120.94 0.4 . . . . 0.0 110.126 -178.013 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' MET . . . . . 0.553 ' HE1' ' CE2' ' A' ' 53' ' ' TYR . 15.0 tmm? -130.39 148.19 52.18 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-N 116.491 -0.322 . . . . 0.0 110.203 -178.414 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.4 ' HB ' ' HB2' ' A' ' 35' ' ' ALA . 30.5 m -126.21 128.2 46.86 Favored 'General case' 0 C--O 1.249 1.076 0 CA-C-O 120.909 0.385 . . . . 0.0 111.967 -176.849 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . 0.553 ' CE2' ' HE1' ' A' ' 51' ' ' MET . 52.1 m-85 -88.15 163.21 16.3 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-N 115.676 -0.693 . . . . 0.0 110.768 177.186 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -65.05 127.45 31.68 Favored 'General case' 0 C--O 1.24 0.571 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.078 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 76.45 3.64 78.19 Favored Glycine 0 N--CA 1.446 -0.67 0 CA-C-N 115.9 -0.591 . . . . 0.0 112.766 179.032 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 78.7 mm-40 -120.3 178.89 4.48 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-O 120.828 0.347 . . . . 0.0 111.075 -177.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -101.98 174.17 24.08 Favored Glycine 0 N--CA 1.437 -1.241 0 N-CA-C 111.157 -0.777 . . . . 0.0 111.157 178.507 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_endo -66.68 137.71 46.79 Favored 'Trans proline' 0 CA--C 1.531 0.359 0 C-N-CA 122.217 1.944 . . . . 0.0 112.538 179.709 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 44.2 pt -133.61 171.73 17.52 Favored 'Isoleucine or valine' 0 C--O 1.241 0.644 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.356 179.084 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -74.67 138.11 23.44 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.684 -0.77 . . . . 0.0 111.974 -178.835 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.492 ' CD1' HG11 ' A' ' 38' ' ' VAL . 55.4 t80 -127.01 129.57 48.33 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-O 120.488 0.185 . . . . 0.0 110.91 -178.94 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . 0.402 ' HA ' ' O ' ' A' ' 47' ' ' LEU . 59.9 ttp85 -141.74 133.05 26.51 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.305 -0.407 . . . . 0.0 109.96 175.978 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.451 ' HB1' ' HB3' ' A' ' 71' ' ' TYR . . . -133.53 139.85 46.86 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.67 -0.241 . . . . 0.0 111.373 -179.969 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 25.2 m -113.67 127.53 56.08 Favored 'General case' 0 CA--C 1.539 0.555 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.482 -179.286 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 58.0 tp -72.44 125.52 27.61 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 112.422 0.527 . . . . 0.0 112.422 -178.276 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 86.9 mt -76.28 -25.78 55.24 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.671 -0.695 . . . . 0.0 110.541 176.249 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 118.27 0.3 16.47 Favored Glycine 0 C--N 1.337 0.596 0 C-N-CA 120.808 -0.711 . . . . 0.0 113.175 178.761 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 29.0 p-10 -135.03 37.59 3.01 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-O 120.919 0.39 . . . . 0.0 111.008 -178.171 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 97.1 m-20 69.29 4.31 4.55 Favored 'General case' 0 N--CA 1.488 1.431 0 C-N-CA 123.417 0.687 . . . . 0.0 111.735 -177.708 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 16.3 t -95.43 126.07 40.48 Favored 'General case' 0 N--CA 1.435 -1.198 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 177.486 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.451 ' HB3' ' HB1' ' A' ' 63' ' ' ALA . 95.7 m-85 -116.98 129.31 55.95 Favored 'General case' 0 C--N 1.309 -1.172 0 CA-C-N 116.411 -0.359 . . . . 0.0 111.405 -178.023 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -81.52 116.25 21.21 Favored 'General case' 0 C--N 1.315 -0.907 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 175.144 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 54.2 t -102.53 132.96 47.52 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.198 0 N-CA-C 113.215 0.82 . . . . 0.0 113.215 -173.235 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 49.2 mt-10 -127.37 145.78 50.69 Favored 'General case' 0 N--CA 1.44 -0.933 0 CA-C-N 114.267 -1.333 . . . . 0.0 108.666 177.919 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 13.5 m120 -123.77 149.5 45.55 Favored 'General case' 0 C--N 1.316 -0.848 0 N-CA-C 110.246 -0.279 . . . . 0.0 110.246 -176.216 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' GLN . . . . . 0.428 ' HB2' ' CE3' ' A' ' 84' ' ' TRP . 63.1 tt0 -121.83 124.9 45.25 Favored 'General case' 0 C--N 1.315 -0.908 0 CA-C-N 116.464 -0.335 . . . . 0.0 110.385 179.724 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 8.3 p90 -144.05 162.73 35.49 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.876 -0.602 . . . . 0.0 109.628 179.063 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 101.17 -13.04 58.8 Favored Glycine 0 C--N 1.316 -0.583 0 C-N-CA 120.898 -0.667 . . . . 0.0 112.766 179.821 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 125.22 174.87 14.06 Favored Glycine 0 N--CA 1.444 -0.769 0 C-N-CA 120.505 -0.855 . . . . 0.0 112.367 178.626 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 7.5 p-10 -63.43 -34.59 78.08 Favored 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 112.303 0.483 . . . . 0.0 112.303 -179.581 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 73.1 p -78.95 -6.54 56.5 Favored 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 111.965 0.358 . . . . 0.0 111.965 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -85.34 146.18 44.21 Favored Pre-proline 0 C--N 1.322 -0.624 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.796 -179.95 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 84.5 Cg_endo -80.37 -175.09 2.52 Favored 'Trans proline' 0 C--O 1.236 0.404 0 C-N-CA 122.777 2.318 . . . . 0.0 112.768 -179.408 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' TRP . . . . . 0.428 ' CE3' ' HB2' ' A' ' 76' ' ' GLN . 90.5 m95 -94.9 144.87 25.32 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.793 -0.64 . . . . 0.0 109.979 179.412 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 87.9 m-70 -124.52 142.26 51.47 Favored 'General case' 0 C--N 1.316 -0.859 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 179.225 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 22.6 p -61.78 133.87 56.04 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-O 120.911 0.386 . . . . 0.0 111.5 -179.11 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -106.27 -46.26 1.17 Allowed Glycine 0 N--CA 1.445 -0.739 0 C-N-CA 120.667 -0.778 . . . . 0.0 111.639 178.859 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 156.25 -171.74 34.03 Favored Glycine 0 C--O 1.221 -0.685 0 C-N-CA 120.777 -0.725 . . . . 0.0 111.463 178.906 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 7.4 t30 -110.29 118.23 35.77 Favored 'General case' 0 C--N 1.312 -1.047 0 CA-C-N 117.147 0.474 . . . . 0.0 110.178 179.08 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' TRP . . . . . 0.419 ' CH2' HG23 ' A' ' 33' ' ' VAL . 28.6 m0 -107.63 150.16 27.22 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.574 -0.284 . . . . 0.0 110.399 -178.294 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 49.8 mm -107.72 114.61 46.8 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 N-CA-C 109.217 -0.66 . . . . 0.0 109.217 178.109 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 90.0 mt -127.15 79.94 1.92 Allowed 'General case' 0 C--O 1.265 1.893 0 CA-C-O 121.819 0.818 . . . . 0.0 111.814 -177.83 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 169.15 99.69 0.13 Allowed Glycine 0 N--CA 1.438 -1.201 0 CA-C-N 115.113 -0.949 . . . . 0.0 111.969 179.325 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' SER . . . . . 0.44 ' HB2' ' O ' ' A' ' 20' ' ' GLY . 71.6 p -86.19 -7.87 58.23 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 121.308 0.575 . . . . 0.0 110.148 178.604 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -103.68 146.35 28.72 Favored 'General case' 0 N--CA 1.438 -1.055 0 CA-C-N 115.475 -0.784 . . . . 0.0 109.289 179.878 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 -90.24 -19.8 23.72 Favored 'General case' 0 C--N 1.31 -1.138 0 N-CA-C 112.187 0.44 . . . . 0.0 112.187 -172.677 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 28.3 p-10 -117.7 14.52 14.4 Favored 'General case' 0 C--N 1.313 -0.988 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.107 -178.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' GLN . . . . . . . . . . . . . 56.7 tt0 -154.55 123.25 6.18 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 120.834 0.35 . . . . 0.0 110.18 -176.656 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 1.6 m-20 -98.48 162.59 13.07 Favored 'General case' 0 C--O 1.242 0.691 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.064 -175.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 54.3 t -77.55 133.75 29.95 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.579 0 C-N-CA 120.84 -0.344 . . . . 0.0 111.283 178.114 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 35.9 m -116.43 -34.63 1.88 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.503 0 N-CA-C 113.205 0.817 . . . . 0.0 113.205 -179.036 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . 0.455 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -142.73 138.91 30.85 Favored 'General case' 0 CA--C 1.512 -0.489 0 C-N-CA 120.019 -0.672 . . . . 0.0 111.486 179.523 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 40.4 mm -131.77 125.15 55.11 Favored 'Isoleucine or valine' 0 C--O 1.244 0.79 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.287 179.614 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 45.5 t30 -123.84 95.9 4.75 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.628 -0.714 . . . . 0.0 109.311 174.229 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.406 HG21 ' HB ' ' A' ' 36' ' ' ILE . 29.9 m -136.85 138.78 45.71 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.926 0 N-CA-C 112.516 0.562 . . . . 0.0 112.516 -176.442 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -138.36 136.86 36.77 Favored 'General case' 0 C--N 1.309 -1.182 0 CA-C-N 115.132 -0.94 . . . . 0.0 108.481 177.238 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 39.3 t -118.39 129.23 55.3 Favored 'General case' 0 C--N 1.302 -1.496 0 C-N-CA 120.85 -0.34 . . . . 0.0 110.663 -179.549 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -86.45 -6.86 80.23 Favored Glycine 0 N--CA 1.441 -1.001 0 N-CA-C 110.359 -1.096 . . . . 0.0 110.359 175.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . 0.513 ' CG ' ' H ' ' A' ' 110' ' ' ASP . 11.1 t70 -93.88 -164.27 1.15 Allowed 'General case' 0 N--CA 1.445 -0.699 0 CA-C-N 115.286 -0.457 . . . . 0.0 110.025 179.656 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . 0.513 ' H ' ' CG ' ' A' ' 109' ' ' ASP . 16.2 m-20 -95.49 19.49 10.89 Favored 'General case' 0 C--N 1.318 -0.784 0 C-N-CA 122.989 0.516 . . . . 0.0 110.682 -178.016 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . 0.57 ' HA3' ' OD1' ' A' ' 32' ' ' ASN . . . 101.73 2.22 52.71 Favored Glycine 0 N--CA 1.443 -0.861 0 C-N-CA 120.605 -0.807 . . . . 0.0 112.545 -179.79 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 35.4 tt0 -64.1 -41.64 97.2 Favored 'General case' 0 C--O 1.226 -0.163 0 CA-C-O 120.984 0.421 . . . . 0.0 110.275 179.417 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 8.6 p -132.24 147.74 52.42 Favored 'General case' 0 N--CA 1.441 -0.878 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.436 177.746 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 92.8 mt -114.76 125.77 54.08 Favored 'General case' 0 C--N 1.319 -0.752 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 179.159 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 18.4 m120 -118.55 137.54 53.16 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-N 116.515 -0.312 . . . . 0.0 111.098 -177.633 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 161.62 -139.91 6.29 Favored Glycine 0 N--CA 1.442 -0.934 0 C-N-CA 119.633 -1.27 . . . . 0.0 113.424 176.299 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 27.2 p -138.05 159.97 40.6 Favored 'General case' 0 C--N 1.312 -1.06 0 C-N-CA 123.037 0.535 . . . . 0.0 110.031 -178.703 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' MET . . . . . 0.402 ' HE1' ' HB2' ' A' ' 118' ' ' MET . 20.5 ptm -146.35 163.0 36.94 Favored 'General case' 0 C--N 1.31 -1.138 0 C-N-CA 121.027 -0.269 . . . . 0.0 111.071 -177.749 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' THR . . . . . 0.455 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 25.8 m -136.68 127.51 27.39 Favored 'General case' 0 C--O 1.251 1.175 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.177 178.727 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . 0.522 ' HB2' ' OE1' ' A' ' 123' ' ' GLU . 6.9 m-85 -94.67 162.7 13.67 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.215 -0.448 . . . . 0.0 109.946 174.705 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -58.79 119.17 6.66 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.695 0.283 . . . . 0.0 111.26 179.813 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 74.03 23.96 74.93 Favored Glycine 0 CA--C 1.52 0.376 0 C-N-CA 120.892 -0.67 . . . . 0.0 112.868 -179.792 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . 0.522 ' OE1' ' HB2' ' A' ' 120' ' ' TYR . 40.0 tt0 -130.2 158.38 39.9 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.769 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -89.14 162.89 31.31 Favored Glycine 0 N--CA 1.444 -0.791 0 N-CA-C 110.902 -0.879 . . . . 0.0 110.902 177.326 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_exo -58.43 131.54 43.38 Favored 'Trans proline' 0 CA--C 1.532 0.394 0 C-N-CA 122.261 1.974 . . . . 0.0 112.471 -179.237 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 43.1 pt -127.87 163.67 31.04 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.18 179.724 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -71.04 133.68 22.67 Favored Glycine 0 C--O 1.242 0.608 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.224 -178.89 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 87.7 t80 -118.02 133.87 55.51 Favored 'General case' 0 C--O 1.245 0.841 0 CA-C-O 121.091 0.472 . . . . 0.0 111.366 -178.083 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 76.5 tttt -137.74 111.0 7.88 Favored 'General case' 0 N--CA 1.44 -0.938 0 CA-C-N 115.165 -0.925 . . . . 0.0 108.887 178.026 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -112.16 143.65 17.56 Favored Glycine 0 C--N 1.311 -0.86 0 C-N-CA 120.377 -0.916 . . . . 0.0 111.843 179.885 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 41.3 m -130.36 130.45 44.42 Favored 'General case' 0 C--N 1.313 -0.998 0 CA-C-N 117.074 0.437 . . . . 0.0 110.401 179.203 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 64.8 tp -65.87 141.06 58.39 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.759 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 18.3 m . . . . . 0 C--O 1.251 1.132 0 CA-C-O 118.484 -0.77 . . . . 0.0 109.504 178.745 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 0.532 ' HB3' ' O ' ' A' ' 25' ' ' ILE . . . . . . . . 0 N--CA 1.474 0.775 0 N-CA-C 110.308 -0.256 . . . . 0.0 110.308 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . 0.43 HD12 HE21 ' A' ' 22' ' ' GLN . 0.9 OUTLIER -151.91 128.04 10.46 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 -178.474 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . 0.408 ' N ' HD13 ' A' ' 3' ' ' LEU . 61.7 m-85 -123.52 147.31 47.37 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 112.917 0.71 . . . . 0.0 112.917 -178.293 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 27.4 t-20 -97.92 129.72 44.83 Favored 'General case' 0 C--N 1.316 -0.864 0 N-CA-C 106.677 -1.601 . . . . 0.0 106.677 174.705 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 65.1 t -116.91 129.48 73.37 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.046 0 CA-C-O 121.437 0.637 . . . . 0.0 112.635 -173.818 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 -114.2 139.74 49.13 Favored 'General case' 0 C--O 1.249 1.032 0 CA-C-N 114.974 -1.012 . . . . 0.0 108.346 176.874 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 10.2 m120 -114.16 140.74 48.28 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 116.453 -0.34 . . . . 0.0 110.94 -176.699 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . 0.596 ' OE1' ' HA ' ' A' ' 13' ' ' SER . 36.6 tt0 -127.64 125.56 40.39 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 120.948 0.404 . . . . 0.0 111.289 177.784 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 22.8 p90 -137.29 144.75 42.81 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 116.042 -0.526 . . . . 0.0 109.83 177.192 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 99.52 9.64 49.75 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 120.568 -0.825 . . . . 0.0 111.98 179.039 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 111.17 154.95 13.4 Favored Glycine 0 N--CA 1.444 -0.773 0 C-N-CA 120.959 -0.638 . . . . 0.0 112.325 179.527 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' SER . . . . . 0.596 ' HA ' ' OE1' ' A' ' 9' ' ' GLN . 69.9 m -65.98 -14.76 62.19 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 112.883 0.697 . . . . 0.0 112.883 -179.627 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 46.9 m -84.21 -7.93 59.21 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 121.059 0.457 . . . . 0.0 110.481 177.132 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -84.84 150.16 55.25 Favored Pre-proline 0 N--CA 1.449 -0.478 0 CA-C-N 115.924 -0.58 . . . . 0.0 109.773 178.79 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -67.33 152.35 79.27 Favored 'Trans proline' 0 C--O 1.236 0.409 0 C-N-CA 122.458 2.105 . . . . 0.0 113.046 -178.231 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 90.8 m95 -83.78 130.46 34.94 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 115.52 -0.764 . . . . 0.0 109.056 178.422 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' ASN . . . . . 0.512 ' N ' HD21 ' A' ' 18' ' ' ASN . 0.8 OUTLIER -107.51 132.48 53.19 Favored 'General case' 0 C--N 1.313 -1.016 0 N-CA-C 107.524 -1.287 . . . . 0.0 107.524 179.168 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 71.8 tt0 -66.42 128.02 34.57 Favored 'General case' 0 C--N 1.308 -1.221 0 CA-C-O 121.58 0.705 . . . . 0.0 110.634 -176.793 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -100.96 -4.48 54.28 Favored Glycine 0 N--CA 1.435 -1.396 0 CA-C-N 115.026 -0.988 . . . . 0.0 113.345 -175.113 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 115.01 -153.52 17.58 Favored Glycine 0 N--CA 1.443 -0.851 0 C-N-CA 120.306 -0.95 . . . . 0.0 111.943 -178.142 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . 0.43 HE21 HD12 ' A' ' 3' ' ' LEU . 4.4 pt20 -132.52 139.41 47.88 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-O 120.701 0.286 . . . . 0.0 110.553 -179.812 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 38.4 m0 -117.29 161.44 19.49 Favored 'General case' 0 CA--C 1.508 -0.665 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.887 -178.517 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 73.4 tt0 -112.47 107.05 15.68 Favored 'General case' 0 N--CA 1.443 -0.825 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 175.11 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.532 ' O ' ' HB3' ' A' ' 2' ' ' ALA . 92.4 mt -123.22 132.07 72.06 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.843 0 CA-C-N 115.922 -0.581 . . . . 0.0 109.872 -177.36 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 90.85 116.33 1.9 Allowed Glycine 0 N--CA 1.446 -0.641 0 C-N-CA 120.33 -0.938 . . . . 0.0 112.432 178.707 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' SER . . . . . 0.455 ' OG ' ' HA3' ' A' ' 88' ' ' GLY . 13.2 t -112.56 14.96 20.23 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-O 121.071 0.463 . . . . 0.0 110.201 -179.848 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 75.7 mtp180 -127.64 138.69 52.91 Favored 'General case' 0 CA--C 1.513 -0.449 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.375 -179.426 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 19.4 m -93.01 -27.27 17.1 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.783 179.407 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 11.8 p-10 -77.32 -38.62 50.09 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.45 -177.618 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . 0.486 HE21 ' HA ' ' A' ' 31' ' ' GLN . 0.0 OUTLIER -130.21 121.41 26.15 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.302 179.709 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . 0.547 ' ND2' ' HA3' ' A' ' 111' ' ' GLY . 65.6 t30 -95.3 169.02 10.37 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 178.792 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 58.8 t -96.44 131.25 43.7 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.991 0 CA-C-N 116.568 -0.287 . . . . 0.0 110.934 -177.5 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 28.4 m -111.39 -20.25 6.38 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.163 0 N-CA-C 112.19 0.441 . . . . 0.0 112.19 179.002 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.452 ' HB2' ' HB ' ' A' ' 52' ' ' THR . . . -147.86 145.57 28.74 Favored 'General case' 0 CA--C 1.514 -0.435 0 C-N-CA 120.296 -0.562 . . . . 0.0 111.512 179.992 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 92.0 mt -144.87 127.95 11.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.042 -0.526 . . . . 0.0 109.893 -179.539 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . 0.429 ' HA ' ' O ' ' A' ' 103' ' ' ILE . 0.6 OUTLIER -133.17 112.11 11.46 Favored 'General case' 0 C--N 1.317 -0.81 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 174.967 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.499 HG13 ' CD2' ' A' ' 61' ' ' PHE . 15.5 m -147.67 150.21 14.72 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.804 0 N-CA-C 112.207 0.447 . . . . 0.0 112.207 -174.871 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 70.5 tt0 -133.22 143.11 48.93 Favored 'General case' 0 N--CA 1.442 -0.851 0 CA-C-N 114.976 -1.011 . . . . 0.0 108.703 176.485 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 21.2 p -73.75 146.34 44.43 Favored 'General case' 0 C--N 1.31 -1.128 0 CA-C-O 120.728 0.299 . . . . 0.0 111.216 178.591 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -92.11 -42.48 4.64 Favored Glycine 0 N--CA 1.447 -0.576 0 N-CA-C 109.687 -1.365 . . . . 0.0 109.687 175.333 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 23.0 m-20 -102.27 -161.36 0.84 Allowed 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 114.711 -0.745 . . . . 0.0 109.116 176.042 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 29.4 p-10 -84.12 47.79 1.38 Allowed 'General case' 0 C--N 1.315 -0.895 0 CA-C-O 121.325 0.583 . . . . 0.0 110.874 179.484 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 99.53 -14.4 60.72 Favored Glycine 0 C--O 1.22 -0.778 0 CA-C-N 115.923 -0.581 . . . . 0.0 112.665 -179.411 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 58.5 tp60 -64.87 -39.39 93.47 Favored 'General case' 0 CA--C 1.534 0.362 0 CA-C-O 120.803 0.335 . . . . 0.0 111.328 -179.162 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 61.3 p -128.45 142.87 50.96 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.604 -0.271 . . . . 0.0 110.742 179.07 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 86.0 mt -126.68 133.83 50.85 Favored 'General case' 0 C--O 1.236 0.369 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 179.168 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -136.22 147.91 47.83 Favored 'General case' 0 C--N 1.32 -0.692 0 C-N-CA 120.905 -0.318 . . . . 0.0 110.951 179.981 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 165.67 -144.17 9.02 Favored Glycine 0 N--CA 1.442 -0.922 0 C-N-CA 120.497 -0.858 . . . . 0.0 112.104 177.909 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 9.4 t -133.53 145.51 50.2 Favored 'General case' 0 N--CA 1.435 -1.177 0 CA-C-O 121.103 0.477 . . . . 0.0 110.558 -179.211 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' MET . . . . . 0.472 ' HE3' ' CZ ' ' A' ' 53' ' ' TYR . 14.6 tmm? -133.32 147.19 51.85 Favored 'General case' 0 C--N 1.314 -0.96 0 CA-C-N 115.918 -0.583 . . . . 0.0 109.685 -179.952 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.452 ' HB ' ' HB2' ' A' ' 35' ' ' ALA . 28.7 m -125.96 128.01 46.84 Favored 'General case' 0 C--O 1.249 1.054 0 N-CA-C 112.045 0.387 . . . . 0.0 112.045 -176.812 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . 0.472 ' CZ ' ' HE3' ' A' ' 51' ' ' MET . 86.0 m-85 -86.27 162.29 18.34 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.565 176.781 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -64.29 122.09 15.84 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.886 178.479 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.59 5.84 89.19 Favored Glycine 0 CA--C 1.517 0.198 0 C-N-CA 120.958 -0.639 . . . . 0.0 112.499 179.925 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 69.6 mm-40 -119.55 179.14 4.31 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 120.742 0.306 . . . . 0.0 110.874 -178.608 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -106.77 169.2 14.96 Favored Glycine 0 N--CA 1.44 -1.078 0 N-CA-C 111.237 -0.745 . . . . 0.0 111.237 178.881 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_exo -62.34 137.36 64.97 Favored 'Trans proline' 0 C--O 1.235 0.359 0 C-N-CA 122.583 2.189 . . . . 0.0 112.239 179.102 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . 0.468 ' HB ' ' O ' ' A' ' 76' ' ' GLN . 48.6 pt -130.32 170.98 18.3 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 CA-C-N 115.984 -0.553 . . . . 0.0 109.813 178.387 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -75.57 136.27 19.76 Favored Glycine 0 N--CA 1.446 -0.671 0 C-N-CA 120.2 -1.0 . . . . 0.0 110.889 -179.346 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.499 ' CD2' HG13 ' A' ' 38' ' ' VAL . 7.5 t80 -131.22 125.15 32.16 Favored 'General case' 0 C--N 1.31 -1.152 0 CA-C-O 120.958 0.409 . . . . 0.0 111.457 -178.046 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 61.9 ttp180 -130.03 130.99 45.66 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.608 -0.724 . . . . 0.0 110.338 178.039 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -130.99 138.98 49.93 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.782 179.382 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 63.6 m -121.16 130.18 53.6 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.392 179.838 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 61.7 tp -68.16 121.68 16.7 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 121.064 0.459 . . . . 0.0 111.365 -178.459 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 96.1 mt -71.32 -34.24 70.39 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.613 178.242 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 133.5 -12.16 4.91 Favored Glycine 0 CA--C 1.521 0.445 0 C-N-CA 120.485 -0.865 . . . . 0.0 113.31 -179.742 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 20.7 m120 -130.89 50.84 2.19 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-O 120.981 0.42 . . . . 0.0 111.4 -178.038 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 86.7 m-20 65.03 1.54 1.52 Allowed 'General case' 0 N--CA 1.486 1.336 0 C-N-CA 123.845 0.858 . . . . 0.0 111.98 178.835 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 25.7 t -102.62 138.19 39.84 Favored 'General case' 0 N--CA 1.436 -1.146 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 179.108 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.439 ' CE1' ' HB2' ' A' ' 92' ' ' LEU . 84.7 m-85 -118.1 140.87 49.14 Favored 'General case' 0 C--N 1.307 -1.263 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.742 -178.534 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -91.24 123.88 35.03 Favored 'General case' 0 N--CA 1.438 -1.063 0 N-CA-C 107.657 -1.238 . . . . 0.0 107.657 173.746 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 45.3 t -105.32 134.04 47.92 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.246 0 N-CA-C 113.413 0.894 . . . . 0.0 113.413 -173.057 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 84.7 mt-10 -129.25 126.27 38.72 Favored 'General case' 0 N--CA 1.438 -1.042 0 CA-C-N 114.367 -1.288 . . . . 0.0 107.69 176.369 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 92.8 m-20 -109.22 146.69 33.79 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-O 121.021 0.439 . . . . 0.0 111.789 -175.582 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' GLN . . . . . 0.468 ' O ' ' HB ' ' A' ' 59' ' ' ILE . 58.4 tt0 -114.47 121.26 42.99 Favored 'General case' 0 C--N 1.312 -1.061 0 CA-C-N 115.707 -0.678 . . . . 0.0 109.645 -179.955 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 5.8 p90 -140.46 159.47 42.12 Favored 'General case' 0 C--N 1.318 -0.79 0 C-N-CA 120.874 -0.33 . . . . 0.0 110.578 179.246 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 95.35 -7.16 68.83 Favored Glycine 0 N--CA 1.447 -0.575 0 C-N-CA 120.834 -0.698 . . . . 0.0 111.846 -179.704 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 146.58 154.93 6.33 Favored Glycine 0 N--CA 1.445 -0.725 0 N-CA-C 111.684 -0.566 . . . . 0.0 111.684 178.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -72.28 -25.56 61.64 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-O 120.965 0.412 . . . . 0.0 111.198 -179.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 4.6 m -82.47 -11.7 58.33 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.412 177.72 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -72.63 155.3 91.09 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.445 -177.236 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -69.38 169.02 19.38 Favored 'Trans proline' 0 C--N 1.347 0.485 0 C-N-CA 122.721 2.281 . . . . 0.0 112.141 178.342 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' TRP . . . . . 0.467 ' CE3' ' HB2' ' A' ' 76' ' ' GLN . 91.8 m95 -87.49 143.29 27.29 Favored 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 -178.409 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 85.8 m-70 -118.61 157.77 26.75 Favored 'General case' 0 C--N 1.313 -0.996 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 -179.705 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 48.3 m -63.81 143.74 57.61 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-O 120.837 0.351 . . . . 0.0 111.023 179.787 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -117.18 -58.91 0.3 Allowed Glycine 0 N--CA 1.439 -1.164 0 N-CA-C 110.931 -0.867 . . . . 0.0 110.931 178.556 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.455 ' HA3' ' OG ' ' A' ' 27' ' ' SER . . . 149.38 -167.68 29.66 Favored Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 120.929 -0.653 . . . . 0.0 111.929 177.067 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' ASN . . . . . 0.417 ' C ' ' HD1' ' A' ' 90' ' ' TRP . 11.2 m120 -102.48 132.68 48.37 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-O 120.679 0.276 . . . . 0.0 110.624 178.747 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' TRP . . . . . 0.417 ' HD1' ' C ' ' A' ' 89' ' ' ASN . 12.5 m0 -130.63 151.58 50.93 Favored 'General case' 0 C--N 1.319 -0.744 0 N-CA-C 108.472 -0.936 . . . . 0.0 108.472 -179.222 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 95.8 mt -117.26 115.52 49.05 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.153 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 176.643 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . 0.439 ' HB2' ' CE1' ' A' ' 71' ' ' TYR . 88.8 mt -125.6 74.14 1.38 Allowed 'General case' 0 C--O 1.247 0.962 0 CA-C-O 121.683 0.754 . . . . 0.0 110.215 -177.577 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 167.72 87.39 0.07 OUTLIER Glycine 0 N--CA 1.431 -1.648 0 CA-C-N 114.892 -1.049 . . . . 0.0 110.73 -177.888 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 22.5 p -91.63 -5.68 53.46 Favored 'General case' 0 C--N 1.31 -1.116 0 CA-C-O 121.176 0.512 . . . . 0.0 110.586 -179.243 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' ARG . . . . . 0.401 HH11 ' HD3' ' A' ' 95' ' ' ARG . 61.7 mtt-85 -94.2 150.0 20.72 Favored 'General case' 0 N--CA 1.442 -0.849 0 CA-C-N 115.64 -0.709 . . . . 0.0 109.676 179.127 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 77.3 tt0 -70.06 -42.76 72.39 Favored 'General case' 0 C--N 1.315 -0.925 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.669 -174.048 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 94.4 m-20 -113.46 18.13 17.9 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.905 -176.871 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' GLN . . . . . . . . . . . . . 2.3 mt-30 -141.53 117.92 10.82 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 113.18 0.807 . . . . 0.0 113.18 -176.118 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 35.8 m-80 -98.25 166.44 11.4 Favored 'General case' 0 C--O 1.245 0.852 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.204 175.138 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 97.1 t -85.18 134.07 27.93 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.611 -179.063 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 27.9 m -115.23 -31.43 1.97 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-N 115.785 -0.643 . . . . 0.0 112.626 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . 0.491 ' HB2' ' HB ' ' A' ' 119' ' ' THR . . . -144.22 139.08 28.48 Favored 'General case' 0 CA--C 1.514 -0.409 0 C-N-CA 120.097 -0.641 . . . . 0.0 111.631 179.306 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.429 ' O ' ' HA ' ' A' ' 37' ' ' ASN . 92.0 mt -132.75 128.38 57.15 Favored 'Isoleucine or valine' 0 C--O 1.238 0.497 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.177 179.743 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 40.7 t30 -128.42 98.16 4.96 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.674 -0.694 . . . . 0.0 109.435 173.544 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 28.3 m -138.0 140.93 39.74 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 N-CA-C 112.331 0.493 . . . . 0.0 112.331 -176.634 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 42.4 tt0 -141.11 138.52 33.56 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.658 -0.701 . . . . 0.0 109.965 178.078 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 46.4 t -143.85 141.71 30.47 Favored 'General case' 0 N--CA 1.446 -0.634 0 CA-C-O 120.894 0.378 . . . . 0.0 111.24 179.18 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -106.81 6.22 37.6 Favored Glycine 0 N--CA 1.443 -0.873 0 N-CA-C 110.624 -0.991 . . . . 0.0 110.624 176.187 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 23.1 m-20 -95.78 14.33 23.62 Favored 'General case' 0 CA--C 1.516 -0.344 0 C-N-CA 123.004 0.522 . . . . 0.0 111.324 -178.176 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 85.7 m-20 63.59 23.38 13.56 Favored 'General case' 0 N--CA 1.47 0.561 0 CA-C-N 115.632 -0.713 . . . . 0.0 112.319 178.173 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . 0.547 ' HA3' ' ND2' ' A' ' 32' ' ' ASN . . . 103.45 5.21 46.05 Favored Glycine 0 N--CA 1.446 -0.653 0 C-N-CA 120.008 -1.092 . . . . 0.0 114.249 176.651 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 54.2 tt0 -62.63 -49.53 74.81 Favored 'General case' 0 C--O 1.249 1.059 0 CA-C-O 121.583 0.706 . . . . 0.0 109.891 177.612 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 14.4 p -136.12 133.17 36.99 Favored 'General case' 0 N--CA 1.442 -0.846 0 CA-C-N 115.034 -0.985 . . . . 0.0 109.555 177.163 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -107.38 122.76 47.24 Favored 'General case' 0 C--N 1.314 -0.97 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 178.787 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 88.9 m-20 -119.54 143.72 47.45 Favored 'General case' 0 C--N 1.311 -1.082 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.121 -179.063 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 160.87 -138.09 5.3 Favored Glycine 0 N--CA 1.442 -0.915 0 C-N-CA 120.216 -0.992 . . . . 0.0 112.685 177.568 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 2.1 p -131.68 153.34 50.1 Favored 'General case' 0 C--N 1.314 -0.978 0 CA-C-O 121.086 0.47 . . . . 0.0 110.789 -179.592 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 118' ' ' MET . . . . . 0.62 ' SD ' ' HD1' ' A' ' 128' ' ' PHE . 21.7 ptm -139.56 147.81 41.7 Favored 'General case' 0 C--N 1.314 -0.962 0 CA-C-N 115.813 -0.63 . . . . 0.0 109.993 -176.764 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 119' ' ' THR . . . . . 0.491 ' HB ' ' HB2' ' A' ' 102' ' ' ALA . 29.1 m -131.75 125.61 32.4 Favored 'General case' 0 C--O 1.249 1.063 0 C-N-CA 120.99 -0.284 . . . . 0.0 111.096 179.095 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . 0.538 ' CE2' ' HE3' ' A' ' 118' ' ' MET . 63.1 m-85 -94.11 163.7 13.36 Favored 'General case' 0 CA--C 1.513 -0.476 0 CA-C-N 116.159 -0.473 . . . . 0.0 109.969 175.52 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -53.51 -33.81 55.8 Favored 'General case' 0 N--CA 1.47 0.545 0 N-CA-C 113.503 0.927 . . . . 0.0 113.503 -176.544 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -138.0 25.31 2.93 Favored Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 119.596 -1.288 . . . . 0.0 112.776 -178.017 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 36.1 tp10 -111.28 -53.06 2.74 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-O 121.29 0.567 . . . . 0.0 110.326 -177.926 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 115.01 177.43 18.8 Favored Glycine 0 N--CA 1.439 -1.154 0 CA-C-N 115.541 -0.754 . . . . 0.0 111.452 -178.308 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 13.5 Cg_exo -71.16 117.13 5.0 Favored 'Trans proline' 0 N--CA 1.458 -0.561 0 C-N-CA 122.8 2.333 . . . . 0.0 112.051 179.053 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 36.7 pt -130.16 165.96 29.01 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.946 0 CA-C-N 115.93 -0.577 . . . . 0.0 109.891 178.388 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -70.26 135.72 26.0 Favored Glycine 0 C--O 1.241 0.532 0 C-N-CA 120.871 -0.68 . . . . 0.0 112.531 -178.5 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . 0.62 ' HD1' ' SD ' ' A' ' 118' ' ' MET . 72.8 t80 -112.5 132.3 55.15 Favored 'General case' 0 C--O 1.249 1.031 0 CA-C-O 120.832 0.349 . . . . 0.0 111.054 -178.793 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 61.0 tttm -137.59 108.9 6.85 Favored 'General case' 0 N--CA 1.447 -0.587 0 CA-C-N 115.599 -0.728 . . . . 0.0 109.213 175.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -114.03 137.12 13.85 Favored Glycine 0 N--CA 1.446 -0.648 0 C-N-CA 120.522 -0.847 . . . . 0.0 111.818 179.244 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 55.8 m -132.34 140.64 48.62 Favored 'General case' 0 C--N 1.308 -1.21 0 CA-C-N 116.645 0.223 . . . . 0.0 110.605 -179.241 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 88.1 mt -56.99 130.03 44.29 Favored 'General case' 0 N--CA 1.472 0.663 0 O-C-N 123.17 0.294 . . . . 0.0 110.939 177.5 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 14.8 p . . . . . 0 C--O 1.252 1.212 0 CA-C-O 118.145 -0.931 . . . . 0.0 110.326 178.313 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 0.581 0 N-CA-C 109.713 -0.477 . . . . 0.0 109.713 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . 0.469 HD11 ' NE2' ' A' ' 22' ' ' GLN . 3.0 tm? -94.81 127.12 40.59 Favored 'General case' 0 C--N 1.317 -0.823 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 -177.153 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 40.5 m-85 -117.16 136.66 52.87 Favored 'General case' 0 C--N 1.312 -1.023 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.305 178.444 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . 0.481 ' O ' ' HA2' ' A' ' 130' ' ' GLY . 0.9 OUTLIER -85.06 132.23 34.35 Favored 'General case' 0 CA--C 1.499 -0.989 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 175.378 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.506 HG23 ' CG ' ' A' ' 23' ' ' TRP . 53.2 t -114.35 128.13 71.51 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.115 0 N-CA-C 113.182 0.808 . . . . 0.0 113.182 -173.847 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 71.6 mt-10 -124.05 135.9 53.89 Favored 'General case' 0 N--CA 1.436 -1.143 0 CA-C-N 114.577 -1.192 . . . . 0.0 108.469 177.542 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 10.8 m120 -121.1 145.11 48.15 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 120.884 0.373 . . . . 0.0 111.415 -175.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . 0.427 ' NE2' ' HA ' ' A' ' 13' ' ' SER . 52.1 tt0 -124.97 123.39 39.77 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.717 178.264 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 40.1 p90 -133.44 142.56 48.37 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 116.653 -0.249 . . . . 0.0 110.922 179.264 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 105.16 10.31 32.22 Favored Glycine 0 CA--C 1.52 0.345 0 C-N-CA 120.327 -0.94 . . . . 0.0 112.945 177.164 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.36 171.51 33.52 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.574 -0.822 . . . . 0.0 112.887 179.56 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' SER . . . . . 0.427 ' HA ' ' NE2' ' A' ' 9' ' ' GLN . 16.4 m -57.8 -26.31 61.78 Favored 'General case' 0 CA--C 1.536 0.426 0 C-N-CA 122.993 0.517 . . . . 0.0 112.061 179.311 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 14.8 m -59.24 -24.76 63.46 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 122.62 0.368 . . . . 0.0 111.695 177.5 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -91.37 144.27 29.47 Favored Pre-proline 0 C--N 1.324 -0.51 0 CA-C-N 116.75 -0.204 . . . . 0.0 110.577 179.515 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -81.13 -176.05 2.95 Favored 'Trans proline' 0 C--O 1.239 0.538 0 C-N-CA 122.657 2.238 . . . . 0.0 112.32 179.397 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 99.1 m95 -87.22 128.8 35.14 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.213 -0.449 . . . . 0.0 109.908 179.64 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 34.0 m-80 -113.65 110.74 20.69 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.384 -177.093 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 73.1 tt0 -73.35 121.29 20.2 Favored 'General case' 0 C--N 1.317 -0.837 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 177.084 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -134.68 32.59 2.59 Favored Glycine 0 N--CA 1.447 -0.624 0 C-N-CA 119.792 -1.194 . . . . 0.0 112.967 -178.634 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 136.99 -167.22 24.71 Favored Glycine 0 N--CA 1.444 -0.821 0 C-N-CA 120.103 -1.046 . . . . 0.0 112.817 178.104 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . 0.469 ' NE2' HD11 ' A' ' 3' ' ' LEU . 10.9 pt20 -147.84 153.9 39.75 Favored 'General case' 0 C--N 1.316 -0.879 0 C-N-CA 122.236 0.214 . . . . 0.0 110.543 -179.715 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . 0.506 ' CG ' HG23 ' A' ' 6' ' ' VAL . 38.4 m0 -126.82 177.04 6.84 Favored 'General case' 0 N--CA 1.47 0.531 0 CA-C-N 116.343 -0.389 . . . . 0.0 110.347 -175.623 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . 0.402 ' HB3' HG12 ' A' ' 91' ' ' ILE . 83.7 tt0 -124.61 114.44 19.38 Favored 'General case' 0 CA--C 1.505 -0.768 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.031 174.74 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 98.2 mt -124.38 132.83 70.77 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.878 0 CA-C-N 115.446 -0.797 . . . . 0.0 109.632 -178.294 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 87.75 55.21 2.33 Favored Glycine 0 N--CA 1.447 -0.606 0 C-N-CA 120.077 -1.059 . . . . 0.0 112.45 178.283 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 36.1 t -61.57 -38.14 86.43 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.575 0.226 . . . . 0.0 110.558 178.993 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 70.4 ttt180 -49.98 -42.61 49.27 Favored 'General case' 0 CA--C 1.542 0.656 0 CA-C-N 116.199 -0.455 . . . . 0.0 112.174 179.501 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 14.9 m 74.16 -42.13 0.5 Allowed 'General case' 0 N--CA 1.48 1.052 0 N-CA-C 114.36 1.244 . . . . 0.0 114.36 175.6 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 3.9 p-10 -74.98 -4.33 37.59 Favored 'General case' 0 N--CA 1.487 1.411 0 CA-C-N 118.378 0.535 . . . . 0.0 111.782 -178.237 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 1.1 tm0? -150.71 119.7 6.68 Favored 'General case' 0 C--N 1.314 -0.968 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.755 178.525 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . 0.646 ' OD1' ' HA3' ' A' ' 111' ' ' GLY . 27.0 t-20 -85.59 145.74 27.21 Favored 'General case' 0 CA--C 1.534 0.357 0 CA-C-O 121.667 0.746 . . . . 0.0 111.97 -179.696 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 15.4 t -97.14 130.07 46.29 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.12 0 CA-C-N 115.085 -0.961 . . . . 0.0 110.531 -177.698 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 17.2 m -101.3 -24.52 4.05 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 N-CA-C 112.002 0.371 . . . . 0.0 112.002 -179.599 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.502 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -141.25 146.13 36.45 Favored 'General case' 0 C--N 1.323 -0.551 0 C-N-CA 120.273 -0.571 . . . . 0.0 111.12 179.327 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.425 ' HB ' ' CG2' ' A' ' 105' ' ' VAL . 98.2 mt -142.84 125.53 13.47 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.325 -177.427 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -130.81 113.36 13.98 Favored 'General case' 0 C--N 1.316 -0.869 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 174.898 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.47 HG22 ' HB ' ' A' ' 103' ' ' ILE . 28.7 m -144.73 145.64 20.95 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 C-N-CA 120.89 -0.324 . . . . 0.0 111.214 -175.785 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 79.6 tt0 -141.03 146.22 36.93 Favored 'General case' 0 N--CA 1.45 -0.453 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.163 178.263 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' SER . . . . . 0.551 ' OG ' ' HB ' ' A' ' 101' ' ' VAL . 26.0 p -81.89 144.86 30.69 Favored 'General case' 0 C--N 1.316 -0.864 0 N-CA-C 111.875 0.324 . . . . 0.0 111.875 -179.11 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -91.23 -21.62 34.75 Favored Glycine 0 N--CA 1.449 -0.454 0 N-CA-C 110.744 -0.942 . . . . 0.0 110.744 175.206 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . 0.444 ' C ' ' H ' ' A' ' 44' ' ' GLY . 28.2 m-20 -132.91 -150.2 0.4 Allowed 'General case' 0 CA--C 1.514 -0.415 0 N-CA-C 108.917 -0.772 . . . . 0.0 108.917 179.373 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -75.81 34.89 0.12 Allowed 'General case' 0 N--CA 1.471 0.614 0 C-N-CA 122.768 0.427 . . . . 0.0 110.818 178.517 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.444 ' H ' ' C ' ' A' ' 42' ' ' ASP . . . 90.85 1.81 72.88 Favored Glycine 0 N--CA 1.442 -0.951 0 C-N-CA 121.057 -0.592 . . . . 0.0 112.655 -178.669 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 60.5 tp60 -62.89 -44.81 95.09 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-O 120.971 0.415 . . . . 0.0 110.547 -179.433 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 4.3 t -129.97 122.6 28.8 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.185 176.404 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 81.8 mt -102.48 132.8 48.28 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 116.139 -0.482 . . . . 0.0 109.777 178.782 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 13.0 m120 -121.34 133.39 55.11 Favored 'General case' 0 C--N 1.314 -0.964 0 N-CA-C 108.963 -0.755 . . . . 0.0 108.963 177.38 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . 0.403 ' HA3' ' HA ' ' A' ' 38' ' ' VAL . . . -173.2 -162.72 25.69 Favored Glycine 0 N--CA 1.436 -1.321 0 C-N-CA 119.367 -1.397 . . . . 0.0 113.243 179.876 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 90.4 m -131.65 130.48 42.16 Favored 'General case' 0 C--N 1.309 -1.176 0 C-N-CA 122.692 0.397 . . . . 0.0 111.4 -179.701 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 43.8 mtp -106.24 145.08 32.04 Favored 'General case' 0 N--CA 1.469 0.49 0 C-N-CA 122.689 0.396 . . . . 0.0 110.161 177.042 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.502 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 36.2 m -123.92 122.35 37.74 Favored 'General case' 0 C--O 1.249 1.076 0 CA-C-O 120.636 0.255 . . . . 0.0 110.64 177.727 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 24.0 m-85 -82.44 161.38 22.46 Favored 'General case' 0 N--CA 1.462 0.142 0 CA-C-N 115.654 -0.703 . . . . 0.0 111.491 -179.468 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -65.46 109.37 2.3 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.932 -0.576 . . . . 0.0 111.661 -179.545 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 83.32 14.93 72.94 Favored Glycine 0 N--CA 1.446 -0.649 0 C-N-CA 120.836 -0.697 . . . . 0.0 113.392 178.371 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 51.1 mt-10 -137.07 167.78 20.87 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.974 0.387 . . . . 0.0 111.513 -178.993 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -78.18 163.1 50.34 Favored Glycine 0 N--CA 1.448 -0.507 0 CA-C-N 115.87 -0.604 . . . . 0.0 113.36 -177.301 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_exo -67.5 142.85 60.78 Favored 'Trans proline' 0 CA--C 1.54 0.781 0 C-N-CA 123.188 2.592 . . . . 0.0 112.749 179.778 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . 0.506 ' HB ' ' O ' ' A' ' 76' ' ' GLN . 47.5 pt -127.14 166.0 24.71 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.329 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.818 -179.422 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -73.83 144.09 33.3 Favored Glycine 0 CA--C 1.517 0.217 0 C-N-CA 121.078 -0.582 . . . . 0.0 112.502 -177.852 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 41.5 t80 -130.45 127.8 39.99 Favored 'General case' 0 C--O 1.238 0.499 0 CA-C-O 120.829 0.347 . . . . 0.0 111.091 -178.791 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 67.3 ttp85 -136.32 127.58 28.21 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 175.585 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -135.07 146.91 49.38 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 120.565 0.221 . . . . 0.0 111.548 -178.175 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 64.3 m -124.54 129.41 50.55 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.598 178.875 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . 0.448 ' HB2' ' CE2' ' A' ' 71' ' ' TYR . 56.6 tp -74.58 130.21 39.15 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.879 -178.847 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . 0.415 ' HB2' ' OD1' ' A' ' 68' ' ' ASN . 85.8 mt -84.52 -17.83 37.69 Favored 'General case' 0 CA--C 1.536 0.429 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.077 177.094 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.432 ' N ' ' HG ' ' A' ' 65' ' ' LEU . . . 105.58 -8.99 44.32 Favored Glycine 0 C--O 1.222 -0.638 0 CA-C-N 115.761 -0.654 . . . . 0.0 112.198 178.49 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' ASN . . . . . 0.415 ' OD1' ' HB2' ' A' ' 66' ' ' LEU . 29.7 p-10 -110.85 34.72 3.84 Favored 'General case' 0 C--N 1.316 -0.858 0 CA-C-O 120.921 0.391 . . . . 0.0 110.749 -179.742 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . 0.481 HD22 ' HA ' ' A' ' 96' ' ' GLU . 90.8 m-20 66.83 7.99 5.67 Favored 'General case' 0 N--CA 1.484 1.225 0 CA-C-N 115.599 -0.728 . . . . 0.0 111.11 -179.399 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 7.3 m -107.94 133.35 52.4 Favored 'General case' 0 N--CA 1.436 -1.143 0 CA-C-N 115.685 -0.689 . . . . 0.0 109.932 -179.796 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.483 ' CE1' ' HB2' ' A' ' 92' ' ' LEU . 86.4 m-85 -114.8 134.99 54.68 Favored 'General case' 0 C--N 1.308 -1.205 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.654 -179.712 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 71.8 tt0 -86.95 119.98 27.73 Favored 'General case' 0 N--CA 1.442 -0.831 0 N-CA-C 106.967 -1.494 . . . . 0.0 106.967 173.39 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 63.1 t -108.71 134.13 51.61 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.073 0 N-CA-C 112.943 0.72 . . . . 0.0 112.943 -172.835 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 49.1 mt-10 -131.45 131.91 43.91 Favored 'General case' 0 N--CA 1.441 -0.912 0 CA-C-N 114.6 -1.182 . . . . 0.0 107.93 175.943 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 95.1 m-20 -119.28 160.62 21.87 Favored 'General case' 0 C--N 1.309 -1.18 0 CA-C-O 121.371 0.605 . . . . 0.0 112.257 -175.207 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' GLN . . . . . 0.506 ' O ' ' HB ' ' A' ' 59' ' ' ILE . 59.8 tt0 -118.95 114.26 22.28 Favored 'General case' 0 C--N 1.312 -1.025 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.569 -179.17 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 3.3 p90 -134.83 35.71 3.11 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 120.941 0.401 . . . . 0.0 111.416 -176.615 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -133.49 -6.9 2.56 Favored Glycine 0 C--N 1.318 -0.433 0 C-N-CA 120.225 -0.988 . . . . 0.0 112.742 -178.32 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 127.47 160.43 10.47 Favored Glycine 0 N--CA 1.445 -0.745 0 N-CA-C 109.805 -1.318 . . . . 0.0 109.805 -178.076 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 19.6 m-20 -58.97 -39.98 83.39 Favored 'General case' 0 N--CA 1.474 0.749 0 CA-C-N 117.72 0.76 . . . . 0.0 112.245 -177.114 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 4.7 p -81.24 -5.66 58.01 Favored 'General case' 0 C--N 1.316 -0.85 0 N-CA-C 112.436 0.532 . . . . 0.0 112.436 -177.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -83.93 149.21 55.87 Favored Pre-proline 0 C--N 1.321 -0.67 0 CA-C-N 116.755 -0.202 . . . . 0.0 110.995 -178.644 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_exo -67.33 161.31 43.73 Favored 'Trans proline' 0 C--N 1.346 0.443 0 C-N-CA 122.796 2.331 . . . . 0.0 111.939 178.242 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' TRP . . . . . . . . . . . . . 79.2 m95 -80.99 147.12 30.36 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.04 -179.496 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 89.9 m-70 -118.48 147.38 43.68 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.075 179.638 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 13.0 m -62.32 134.47 56.52 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-O 121.224 0.535 . . . . 0.0 111.565 -178.073 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -105.45 -48.5 1.04 Allowed Glycine 0 N--CA 1.441 -0.982 0 CA-C-N 115.451 -0.795 . . . . 0.0 111.463 179.082 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 144.92 -163.79 27.96 Favored Glycine 0 N--CA 1.442 -0.911 0 C-N-CA 120.544 -0.836 . . . . 0.0 112.251 177.535 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 16.5 m120 -104.72 127.16 52.41 Favored 'General case' 0 C--N 1.316 -0.858 0 CA-C-O 120.812 0.339 . . . . 0.0 110.341 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 12.4 m0 -119.7 144.45 47.2 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 179.825 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . 0.48 ' O ' ' HB3' ' A' ' 23' ' ' TRP . 45.5 mm -108.38 113.36 43.72 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.933 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.027 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . 0.483 ' HB2' ' CE1' ' A' ' 71' ' ' TYR . 77.9 mt -129.23 81.53 2.03 Favored 'General case' 0 C--O 1.261 1.699 0 CA-C-O 121.47 0.653 . . . . 0.0 111.894 -177.437 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 165.56 99.55 0.14 Allowed Glycine 0 N--CA 1.445 -0.751 0 CA-C-N 115.417 -0.811 . . . . 0.0 111.292 -179.813 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 3.2 p -101.69 -12.54 18.31 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 117.036 0.418 . . . . 0.0 111.844 -177.826 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' ARG . . . . . 0.404 HH12 ' CD ' ' A' ' 123' ' ' GLU . 96.6 mtt180 -83.49 -5.0 59.03 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.438 -0.346 . . . . 0.0 111.339 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . 0.481 ' HA ' HD22 ' A' ' 69' ' ' ASN . 72.3 tt0 71.29 -55.84 0.64 Allowed 'General case' 0 N--CA 1.47 0.553 0 C-N-CA 123.502 0.721 . . . . 0.0 112.724 177.113 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 44.7 m-80 -96.18 14.93 22.36 Favored 'General case' 0 C--N 1.315 -0.919 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.341 -175.309 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' GLN . . . . . 0.463 ' HG2' ' HB3' ' A' ' 120' ' ' TYR . 59.2 tt0 -152.36 115.43 4.66 Favored 'General case' 0 C--N 1.316 -0.883 0 CA-C-O 120.992 0.425 . . . . 0.0 109.944 -177.731 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 76.5 m-20 -78.71 160.97 27.2 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.581 -0.736 . . . . 0.0 111.421 -176.376 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 90.6 t -87.97 133.04 31.58 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.496 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.205 175.252 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . 0.551 ' HB ' ' OG ' ' A' ' 40' ' ' SER . 35.3 m -116.03 -28.02 2.39 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 N-CA-C 113.345 0.869 . . . . 0.0 113.345 -176.41 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . 0.428 ' HB2' ' HB ' ' A' ' 119' ' ' THR . . . -146.94 137.66 23.77 Favored 'General case' 0 C--N 1.325 -0.483 0 C-N-CA 120.341 -0.544 . . . . 0.0 111.285 179.237 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.47 ' HB ' HG22 ' A' ' 38' ' ' VAL . 91.5 mt -133.85 127.91 52.88 Favored 'Isoleucine or valine' 0 C--O 1.242 0.699 0 CA-C-N 116.354 -0.384 . . . . 0.0 110.608 179.011 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . 0.453 ' C ' HD21 ' A' ' 104' ' ' ASN . 0.2 OUTLIER -126.31 99.48 5.88 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 175.258 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.425 ' CG2' ' HB ' ' A' ' 36' ' ' ILE . 19.5 m -137.92 141.11 39.5 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 N-CA-C 112.546 0.573 . . . . 0.0 112.546 -176.925 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 70.4 tt0 -142.14 138.02 31.32 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.705 -0.679 . . . . 0.0 109.583 177.466 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 28.8 t -140.7 142.24 34.89 Favored 'General case' 0 N--CA 1.448 -0.529 0 CA-C-O 121.038 0.447 . . . . 0.0 111.801 -178.682 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -107.97 9.99 37.17 Favored Glycine 0 N--CA 1.443 -0.846 0 N-CA-C 110.759 -0.936 . . . . 0.0 110.759 175.361 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 20.5 m-20 -91.64 14.03 16.3 Favored 'General case' 0 N--CA 1.466 0.348 0 C-N-CA 122.909 0.484 . . . . 0.0 110.401 -177.829 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 12.4 m-20 63.37 30.88 15.45 Favored 'General case' 0 N--CA 1.471 0.612 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.741 -177.554 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . 0.646 ' HA3' ' OD1' ' A' ' 32' ' ' ASN . . . 89.03 7.11 70.79 Favored Glycine 0 N--CA 1.449 -0.456 0 CA-C-N 115.654 -0.703 . . . . 0.0 114.273 175.271 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 52.9 tt0 -65.21 -47.85 75.45 Favored 'General case' 0 C--O 1.237 0.438 0 CA-C-N 117.438 0.619 . . . . 0.0 110.198 177.67 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' THR . . . . . 0.437 ' HA ' ' O ' ' A' ' 130' ' ' GLY . 2.0 p -134.18 118.3 17.5 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-N 115.492 -0.776 . . . . 0.0 111.037 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -95.33 122.29 37.89 Favored 'General case' 0 C--N 1.319 -0.754 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.273 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 93.4 m-20 -123.42 148.6 45.98 Favored 'General case' 0 C--N 1.312 -1.036 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.703 -178.71 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 160.66 -135.29 3.95 Favored Glycine 0 N--CA 1.438 -1.184 0 C-N-CA 120.362 -0.923 . . . . 0.0 112.775 177.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 25.8 p -133.28 156.77 46.97 Favored 'General case' 0 C--N 1.316 -0.885 0 C-N-CA 122.858 0.463 . . . . 0.0 109.962 -178.532 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 11.3 ptm -151.4 157.61 42.64 Favored 'General case' 0 C--N 1.312 -1.046 0 CA-C-O 120.614 0.245 . . . . 0.0 110.822 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 119' ' ' THR . . . . . 0.428 ' HB ' ' HB2' ' A' ' 102' ' ' ALA . 38.0 m -132.51 131.02 41.18 Favored 'General case' 0 C--O 1.249 1.079 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.041 179.717 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . 0.463 ' HB3' ' HG2' ' A' ' 98' ' ' GLN . 78.3 m-85 -93.72 166.89 11.99 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.934 -0.575 . . . . 0.0 109.961 176.644 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -63.22 118.29 7.76 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.675 -0.239 . . . . 0.0 110.731 178.837 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 68.2 34.63 81.2 Favored Glycine 0 C--N 1.333 0.395 0 C-N-CA 120.819 -0.705 . . . . 0.0 111.613 -178.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . 0.404 ' CD ' HH12 ' A' ' 95' ' ' ARG . 31.6 tp10 -132.61 163.24 29.34 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 -176.723 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -94.41 159.21 23.2 Favored Glycine 0 N--CA 1.442 -0.947 0 N-CA-C 110.553 -1.019 . . . . 0.0 110.553 176.24 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_endo -62.52 132.78 39.58 Favored 'Trans proline' 0 C--O 1.237 0.464 0 C-N-CA 122.177 1.918 . . . . 0.0 111.885 -179.782 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 40.9 pt -132.79 166.19 30.1 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 CA-C-N 115.932 -0.577 . . . . 0.0 110.464 -179.742 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -70.61 141.49 33.6 Favored Glycine 0 C--O 1.242 0.615 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.176 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 82.7 t80 -123.67 135.57 53.98 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-O 120.824 0.345 . . . . 0.0 111.188 -178.725 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 62.4 tttm -139.3 118.93 13.06 Favored 'General case' 0 N--CA 1.445 -0.713 0 CA-C-N 115.497 -0.774 . . . . 0.0 109.313 177.178 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . 0.481 ' HA2' ' O ' ' A' ' 5' ' ' ASN . . . -125.26 137.94 10.67 Favored Glycine 0 N--CA 1.445 -0.737 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.054 179.67 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 59.4 m -123.63 129.69 51.53 Favored 'General case' 0 C--N 1.313 -0.98 0 CA-C-N 116.853 0.327 . . . . 0.0 110.817 -179.303 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -67.45 117.7 9.78 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-O 121.186 0.517 . . . . 0.0 111.429 -178.163 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 15.0 m . . . . . 0 C--O 1.25 1.1 0 CA-C-N 115.707 -0.678 . . . . 0.0 110.612 176.229 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.807 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . 0.405 HD11 ' NE2' ' A' ' 22' ' ' GLN . 2.2 tm? -89.99 126.71 35.85 Favored 'General case' 0 C--N 1.315 -0.917 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -178.987 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . 0.463 ' CE1' ' HB ' ' A' ' 25' ' ' ILE . 58.0 m-85 -114.53 141.46 47.7 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.225 -178.796 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 23.4 t-20 -93.72 137.85 32.55 Favored 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 106.719 -1.586 . . . . 0.0 106.719 174.918 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.433 HG22 ' CG ' ' A' ' 23' ' ' TRP . 59.0 t -114.48 128.31 71.58 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.894 0 N-CA-C 113.287 0.847 . . . . 0.0 113.287 -173.679 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -118.31 133.05 56.22 Favored 'General case' 0 C--O 1.245 0.833 0 CA-C-N 114.748 -1.114 . . . . 0.0 109.283 176.907 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 12.0 m120 -110.32 135.38 51.15 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.076 -177.411 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . 0.425 ' OE1' ' HA ' ' A' ' 13' ' ' SER . 36.0 tt0 -120.45 114.23 21.48 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 120.988 0.423 . . . . 0.0 110.448 175.713 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 2.4 p90 -112.12 175.66 5.34 Favored 'General case' 0 C--N 1.311 -1.097 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.487 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 69.87 -71.34 0.56 Allowed Glycine 0 CA--C 1.529 0.948 0 CA-C-N 115.706 -0.679 . . . . 0.0 112.956 -176.847 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -165.08 168.3 39.16 Favored Glycine 0 N--CA 1.446 -0.684 0 C-N-CA 121.014 -0.612 . . . . 0.0 112.304 -178.458 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' SER . . . . . 0.425 ' HA ' ' OE1' ' A' ' 9' ' ' GLN . 28.2 t -62.85 -19.55 64.23 Favored 'General case' 0 CA--C 1.54 0.563 0 N-CA-C 112.329 0.492 . . . . 0.0 112.329 -178.669 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 30.4 p -77.47 -6.83 54.92 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.873 0.368 . . . . 0.0 111.76 179.411 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -86.69 149.36 48.35 Favored Pre-proline 0 C--N 1.323 -0.584 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.548 179.131 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_endo -69.14 162.43 41.8 Favored 'Trans proline' 0 C--O 1.237 0.458 0 C-N-CA 122.529 2.153 . . . . 0.0 112.086 179.071 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 98.3 m95 -85.65 124.26 31.98 Favored 'General case' 0 C--N 1.317 -0.837 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 179.695 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 92.4 m-20 -111.44 113.42 25.86 Favored 'General case' 0 C--N 1.309 -1.154 0 CA-C-N 116.332 -0.394 . . . . 0.0 111.059 -175.89 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 80.6 tt0 -71.97 122.43 20.84 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-N 115.826 -0.625 . . . . 0.0 109.611 179.864 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -137.69 25.6 2.95 Favored Glycine 0 N--CA 1.446 -0.679 0 C-N-CA 120.29 -0.957 . . . . 0.0 112.559 -177.93 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . 0.402 ' HA3' ' HB3' ' A' ' 94' ' ' SER . . . 156.63 -172.39 34.33 Favored Glycine 0 N--CA 1.433 -1.524 0 C-N-CA 119.961 -1.114 . . . . 0.0 112.651 179.205 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . 0.405 ' NE2' HD11 ' A' ' 3' ' ' LEU . 19.6 pt20 -150.34 145.43 26.13 Favored 'General case' 0 C--N 1.31 -1.11 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 179.299 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . 0.433 ' CG ' HG22 ' A' ' 6' ' ' VAL . 43.7 m0 -122.47 159.45 27.61 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.749 -177.172 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 79.3 tt0 -118.05 119.71 35.59 Favored 'General case' 0 C--N 1.306 -1.316 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 176.079 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.463 ' HB ' ' CE1' ' A' ' 4' ' ' TYR . 98.9 mt -127.87 135.14 63.76 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-N 115.432 -0.804 . . . . 0.0 109.934 -175.011 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 89.07 71.83 1.27 Allowed Glycine 0 N--CA 1.435 -1.427 0 C-N-CA 119.718 -1.229 . . . . 0.0 111.944 -179.878 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' SER . . . . . 0.448 ' OG ' ' HA3' ' A' ' 88' ' ' GLY . 7.5 t -59.44 -39.38 83.39 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 176.829 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 73.3 ttt180 -82.22 113.03 19.77 Favored 'General case' 0 N--CA 1.439 -1.013 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 174.599 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 30.8 m -78.3 -13.71 59.73 Favored 'General case' 0 C--N 1.315 -0.892 0 CA-C-O 120.965 0.412 . . . . 0.0 111.777 -174.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 23.2 t70 -72.0 -33.43 68.09 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.403 0.62 . . . . 0.0 110.987 178.865 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . 0.556 HE21 ' HA ' ' A' ' 31' ' ' GLN . 0.0 OUTLIER -126.17 120.62 30.57 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.63 -0.713 . . . . 0.0 111.012 -177.369 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . 0.541 ' ND2' ' HA3' ' A' ' 111' ' ' GLY . 64.2 t30 -95.04 154.41 17.19 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.532 -0.304 . . . . 0.0 110.235 178.943 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.425 ' HA ' ' HA ' ' A' ' 53' ' ' TYR . 62.0 t -96.22 133.53 37.15 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.541 -176.457 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 28.4 m -113.49 -14.54 10.83 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.151 0 N-CA-C 112.299 0.481 . . . . 0.0 112.299 178.891 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.472 ' HB1' ' HB ' ' A' ' 52' ' ' THR . . . -147.49 138.96 23.86 Favored 'General case' 0 C--N 1.323 -0.565 0 C-N-CA 120.391 -0.524 . . . . 0.0 111.487 179.552 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 88.8 mt -141.42 123.3 13.97 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-N 116.058 -0.519 . . . . 0.0 109.912 -179.6 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -128.97 109.39 11.19 Favored 'General case' 0 C--N 1.309 -1.188 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 174.055 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 18.4 m -146.49 148.13 17.28 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 C-N-CA 120.674 -0.41 . . . . 0.0 112.012 -174.356 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 66.7 tt0 -138.42 140.54 39.36 Favored 'General case' 0 C--N 1.315 -0.899 0 CA-C-N 115.214 -0.903 . . . . 0.0 108.619 176.293 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' SER . . . . . 0.431 ' HA ' ' O ' ' A' ' 46' ' ' THR . 94.7 p -81.55 153.8 26.58 Favored 'General case' 0 C--N 1.308 -1.216 0 CA-C-O 120.921 0.391 . . . . 0.0 111.946 -176.84 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -97.43 -57.14 1.07 Allowed Glycine 0 N--CA 1.435 -1.393 0 CA-C-N 115.765 -0.652 . . . . 0.0 111.767 176.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -113.54 98.4 7.04 Favored 'General case' 0 CA--C 1.533 0.315 0 N-CA-C 111.924 0.342 . . . . 0.0 111.924 -178.477 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 14.1 m-20 47.76 34.53 3.88 Favored 'General case' 0 N--CA 1.492 1.667 0 N-CA-C 114.454 1.279 . . . . 0.0 114.454 175.222 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.416 ' HA2' ' CB ' ' A' ' 40' ' ' SER . . . 80.11 0.65 86.45 Favored Glycine 0 C--N 1.319 -0.41 0 C-N-CA 120.438 -0.887 . . . . 0.0 113.793 178.196 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 59.9 mt-30 -77.4 -30.45 53.59 Favored 'General case' 0 CA--C 1.513 -0.458 0 CA-C-N 117.398 0.599 . . . . 0.0 111.331 178.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' THR . . . . . 0.431 ' O ' ' HA ' ' A' ' 40' ' ' SER . 5.1 p -122.83 107.02 11.42 Favored 'General case' 0 C--N 1.308 -1.229 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.999 -179.472 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . 0.493 ' O ' ' HA ' ' A' ' 62' ' ' ARG . 90.8 mt -89.91 129.16 36.3 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 177.534 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 15.4 m120 -126.65 136.99 53.23 Favored 'General case' 0 C--N 1.318 -0.804 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 171.03 -153.32 20.47 Favored Glycine 0 N--CA 1.443 -0.857 0 C-N-CA 118.876 -1.63 . . . . 0.0 114.057 178.813 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 52.4 m -127.43 131.92 50.16 Favored 'General case' 0 C--N 1.315 -0.899 0 C-N-CA 123.14 0.576 . . . . 0.0 109.455 -178.002 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' MET . . . . . 0.437 ' HE3' ' CZ ' ' A' ' 53' ' ' TYR . 15.5 tmm? -128.52 139.8 52.13 Favored 'General case' 0 C--N 1.315 -0.927 0 C-N-CA 121.31 -0.156 . . . . 0.0 110.65 -178.842 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.472 ' HB ' ' HB1' ' A' ' 35' ' ' ALA . 33.8 m -124.24 128.73 49.61 Favored 'General case' 0 C--O 1.253 1.286 0 CA-C-O 121.135 0.493 . . . . 0.0 111.773 -176.718 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . 0.437 ' CZ ' ' HE3' ' A' ' 51' ' ' MET . 78.4 m-85 -84.76 163.73 18.96 Favored 'General case' 0 N--CA 1.462 0.147 0 CA-C-N 115.532 -0.758 . . . . 0.0 110.951 177.958 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -58.06 109.14 0.69 Allowed 'General case' 0 N--CA 1.469 0.478 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.957 -179.228 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 72.81 18.45 78.87 Favored Glycine 0 C--O 1.225 -0.414 0 C-N-CA 121.133 -0.556 . . . . 0.0 113.054 178.007 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . 0.402 ' HB2' ' HB2' ' A' ' 53' ' ' TYR . 70.2 mm-40 -117.76 174.19 6.32 Favored 'General case' 0 C--N 1.317 -0.817 0 N-CA-C 110.197 -0.297 . . . . 0.0 110.197 -179.062 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -86.71 157.03 29.5 Favored Glycine 0 N--CA 1.444 -0.827 0 C-N-CA 120.685 -0.769 . . . . 0.0 111.733 178.418 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -67.86 141.23 53.19 Favored 'Trans proline' 0 C--O 1.234 0.286 0 C-N-CA 122.64 2.227 . . . . 0.0 111.986 179.497 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . 0.43 HD13 ' HB3' ' A' ' 75' ' ' ASN . 39.6 pt -131.33 165.53 31.33 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.852 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.678 179.92 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -72.83 136.84 23.43 Favored Glycine 0 N--CA 1.447 -0.598 0 C-N-CA 120.889 -0.672 . . . . 0.0 111.499 -179.634 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 47.9 t80 -121.48 124.85 45.43 Favored 'General case' 0 C--N 1.313 -0.999 0 CA-C-O 120.722 0.296 . . . . 0.0 110.943 -178.462 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . 0.493 ' HA ' ' O ' ' A' ' 47' ' ' LEU . 62.0 ttp180 -135.65 129.59 33.03 Favored 'General case' 0 N--CA 1.445 -0.691 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 173.824 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -127.65 136.72 52.0 Favored 'General case' 0 C--N 1.311 -1.077 0 CA-C-O 120.667 0.27 . . . . 0.0 110.584 -179.836 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 28.2 m -114.16 124.68 52.66 Favored 'General case' 0 N--CA 1.435 -1.199 0 CA-C-N 116.035 -0.53 . . . . 0.0 109.861 177.914 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . 0.532 HD12 ' O ' ' A' ' 67' ' ' GLY . 2.7 tm? -63.25 129.24 39.43 Favored 'General case' 0 C--N 1.31 -1.151 0 CA-C-N 115.604 -0.725 . . . . 0.0 110.945 -179.34 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 96.5 mt -95.74 -40.42 9.37 Favored 'General case' 0 C--O 1.225 -0.199 0 CA-C-O 121.103 0.478 . . . . 0.0 111.094 178.505 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.532 ' O ' HD12 ' A' ' 65' ' ' LEU . . . -140.27 -79.93 0.06 OUTLIER Glycine 0 CA--C 1.499 -0.964 0 N-CA-C 110.766 -0.933 . . . . 0.0 110.766 -178.3 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 65.1 m-80 -146.01 -71.32 0.25 Allowed 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 107.527 -1.286 . . . . 0.0 107.527 174.389 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 84.4 m-20 -67.77 -39.87 84.06 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.652 -0.704 . . . . 0.0 111.458 176.501 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 23.3 t -81.48 130.45 35.05 Favored 'General case' 0 CA--C 1.538 0.492 0 N-CA-C 113.025 0.75 . . . . 0.0 113.025 -174.334 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.436 ' OH ' ' HB3' ' A' ' 99' ' ' ASN . 56.9 m-85 -127.66 145.21 50.96 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.106 -0.952 . . . . 0.0 109.919 177.08 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -105.43 125.19 50.7 Favored 'General case' 0 C--N 1.312 -1.053 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 174.401 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 62.2 t -111.03 137.74 42.21 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.162 0 N-CA-C 113.225 0.824 . . . . 0.0 113.225 -171.914 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 63.9 mt-10 -126.53 129.74 49.22 Favored 'General case' 0 N--CA 1.442 -0.871 0 CA-C-N 114.578 -1.192 . . . . 0.0 108.257 176.344 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' ASN . . . . . 0.43 ' HB3' HD13 ' A' ' 59' ' ' ILE . 12.1 m120 -110.12 151.51 27.16 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-O 121.167 0.508 . . . . 0.0 111.693 -178.033 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' GLN . . . . . 0.447 ' HB2' ' CE3' ' A' ' 84' ' ' TRP . 62.3 tt0 -117.19 121.04 40.11 Favored 'General case' 0 C--N 1.311 -1.071 0 CA-C-N 115.359 -0.837 . . . . 0.0 110.113 -178.725 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 4.7 p90 -142.7 161.78 37.18 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.855 -179.241 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 99.83 -12.22 60.91 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 121.026 -0.607 . . . . 0.0 112.437 178.715 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 140.53 160.1 8.18 Favored Glycine 0 N--CA 1.441 -1.029 0 N-CA-C 111.087 -0.805 . . . . 0.0 111.087 179.388 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 24.7 m-20 -62.75 -35.04 78.49 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-O 120.828 0.347 . . . . 0.0 111.617 -179.319 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 5.1 m -72.53 -12.9 61.26 Favored 'General case' 0 CA--C 1.54 0.592 0 CA-C-N 116.228 -0.442 . . . . 0.0 112.003 -179.709 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -75.96 147.83 80.99 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-O 120.518 0.199 . . . . 0.0 111.217 -178.424 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -72.14 -178.44 3.23 Favored 'Trans proline' 0 C--O 1.24 0.602 0 C-N-CA 122.733 2.289 . . . . 0.0 112.289 178.762 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' TRP . . . . . 0.447 ' CE3' ' HB2' ' A' ' 76' ' ' GLN . 92.3 m95 -91.64 139.66 30.47 Favored 'General case' 0 C--N 1.319 -0.718 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 -179.358 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 93.7 m-70 -115.48 148.46 39.43 Favored 'General case' 0 C--N 1.315 -0.922 0 N-CA-C 109.689 -0.486 . . . . 0.0 109.689 -179.32 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 13.2 p -64.59 135.36 55.89 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-O 120.778 0.323 . . . . 0.0 110.856 -178.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -110.37 -52.36 0.6 Allowed Glycine 0 N--CA 1.442 -0.906 0 C-N-CA 120.52 -0.848 . . . . 0.0 111.958 -179.549 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.448 ' HA3' ' OG ' ' A' ' 27' ' ' SER . . . 147.72 -162.87 28.77 Favored Glycine 0 N--CA 1.444 -0.824 0 C-N-CA 120.212 -0.994 . . . . 0.0 112.822 179.698 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 17.1 m120 -104.08 134.9 46.57 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 120.832 0.349 . . . . 0.0 110.953 -178.557 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 11.8 m0 -127.38 150.8 49.45 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.929 -0.578 . . . . 0.0 109.714 179.002 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 50.1 mm -113.93 110.03 30.67 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.927 0 N-CA-C 109.021 -0.733 . . . . 0.0 109.021 177.729 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . 0.401 ' O ' HG12 ' A' ' 100' ' ' VAL . 78.0 mt -132.84 75.8 1.65 Allowed 'General case' 0 C--O 1.26 1.649 0 CA-C-O 121.893 0.854 . . . . 0.0 111.835 -177.325 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . 0.409 ' O ' ' HB2' ' A' ' 94' ' ' SER . . . -150.15 -91.64 0.09 OUTLIER Glycine 0 N--CA 1.448 -0.504 0 CA-C-N 115.399 -0.819 . . . . 0.0 112.9 -178.901 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' SER . . . . . 0.409 ' HB2' ' O ' ' A' ' 93' ' ' GLY . 69.6 m 78.29 8.56 2.26 Favored 'General case' 0 N--CA 1.482 1.13 0 C-N-CA 124.092 0.957 . . . . 0.0 112.181 -177.378 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' ARG . . . . . 0.477 ' HB2' ' O ' ' A' ' 98' ' ' GLN . 95.9 mtt180 -137.6 145.03 42.29 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 116.083 -0.508 . . . . 0.0 109.725 177.557 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 78.1 tt0 -70.44 -45.64 65.44 Favored 'General case' 0 C--N 1.315 -0.906 0 N-CA-C 112.622 0.601 . . . . 0.0 112.622 -172.729 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 7.2 p30 -117.41 20.89 13.4 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.26 0.552 . . . . 0.0 111.207 -179.269 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' GLN . . . . . 0.477 ' O ' ' HB2' ' A' ' 95' ' ' ARG . 90.5 mt-30 -139.78 115.63 10.22 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-N 115.658 -0.701 . . . . 0.0 111.12 179.635 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' ASN . . . . . 0.436 ' HB3' ' OH ' ' A' ' 71' ' ' TYR . 85.2 m-20 -108.49 176.19 5.2 Favored 'General case' 0 C--N 1.306 -1.309 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 179.575 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . 0.401 HG12 ' O ' ' A' ' 92' ' ' LEU . 33.6 m -78.22 133.69 29.78 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.668 0 C-N-CA 119.565 -0.854 . . . . 0.0 111.352 179.348 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 35.4 m -113.92 -31.09 2.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.165 177.243 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . 0.484 ' HB1' ' HB ' ' A' ' 119' ' ' THR . . . -148.18 133.32 18.32 Favored 'General case' 0 CA--C 1.511 -0.546 0 C-N-CA 120.688 -0.405 . . . . 0.0 110.475 178.003 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 89.6 mt -130.16 125.1 59.39 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.785 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.961 179.78 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 10.0 t30 -126.19 100.38 6.29 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.704 -0.68 . . . . 0.0 109.574 175.631 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 27.7 m -141.46 140.96 30.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-N 115.983 -0.553 . . . . 0.0 112.326 -176.121 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 61.5 mt-10 -143.66 149.53 37.39 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.2 -0.909 . . . . 0.0 109.606 177.111 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 46.3 t -128.66 144.62 51.2 Favored 'General case' 0 C--N 1.313 -0.994 0 CA-C-O 120.966 0.412 . . . . 0.0 111.508 -178.842 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -91.63 -4.46 67.76 Favored Glycine 0 N--CA 1.439 -1.16 0 N-CA-C 110.656 -0.978 . . . . 0.0 110.656 175.161 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 35.4 m-20 -98.28 -167.62 1.53 Allowed 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 -179.528 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . 0.408 ' OD1' ' HG3' ' A' ' 112' ' ' GLN . 7.3 p-10 -93.86 21.22 6.79 Favored 'General case' 0 C--N 1.311 -1.082 0 CA-C-O 121.291 0.567 . . . . 0.0 109.864 178.041 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . 0.541 ' HA3' ' ND2' ' A' ' 32' ' ' ASN . . . 105.34 9.77 32.99 Favored Glycine 0 C--O 1.22 -0.753 0 C-N-CA 120.761 -0.733 . . . . 0.0 113.466 -178.525 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' GLN . . . . . 0.408 ' HG3' ' OD1' ' A' ' 110' ' ' ASP . 98.3 mt-30 -64.72 -43.8 92.26 Favored 'General case' 0 C--O 1.242 0.66 0 CA-C-N 117.439 0.62 . . . . 0.0 110.681 178.89 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 81.8 p -136.48 145.76 45.52 Favored 'General case' 0 N--CA 1.444 -0.758 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.937 176.445 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 88.8 mt -116.54 129.75 56.36 Favored 'General case' 0 C--N 1.315 -0.922 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 179.312 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 15.3 m120 -120.5 142.87 48.9 Favored 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 110.318 -0.253 . . . . 0.0 110.318 -178.916 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 163.77 -141.19 6.94 Favored Glycine 0 N--CA 1.444 -0.8 0 C-N-CA 119.385 -1.388 . . . . 0.0 113.426 176.586 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 3.0 p -130.91 151.02 51.79 Favored 'General case' 0 C--N 1.311 -1.1 0 C-N-CA 123.056 0.542 . . . . 0.0 110.209 -178.295 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 118' ' ' MET . . . . . 0.628 ' SD ' ' HD1' ' A' ' 128' ' ' PHE . 20.0 ptm -136.96 144.5 43.42 Favored 'General case' 0 C--N 1.31 -1.128 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.253 -177.792 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 119' ' ' THR . . . . . 0.484 ' HB ' ' HB1' ' A' ' 102' ' ' ALA . 24.5 m -128.8 126.47 39.95 Favored 'General case' 0 C--O 1.252 1.22 0 CA-C-O 120.737 0.303 . . . . 0.0 110.535 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . 0.543 ' CE2' ' HE3' ' A' ' 118' ' ' MET . 42.1 m-85 -98.39 162.62 13.07 Favored 'General case' 0 CA--C 1.509 -0.631 0 CA-C-N 115.616 -0.72 . . . . 0.0 111.167 179.563 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -59.17 114.91 2.85 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 115.489 -0.778 . . . . 0.0 111.169 176.842 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 78.04 17.49 78.26 Favored Glycine 0 N--CA 1.451 -0.354 0 CA-C-N 115.787 -0.642 . . . . 0.0 114.014 177.759 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 69.2 tt0 -142.26 144.02 33.12 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 117.47 0.635 . . . . 0.0 110.566 179.837 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -69.03 163.77 50.48 Favored Glycine 0 CA--C 1.522 0.53 0 CA-C-N 116.141 -0.481 . . . . 0.0 113.246 -177.436 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . 0.469 ' HA ' ' O ' ' A' ' 118' ' ' MET . 23.7 Cg_exo -63.46 138.72 66.88 Favored 'Trans proline' 0 C--N 1.347 0.492 0 C-N-CA 122.784 2.322 . . . . 0.0 112.887 -178.752 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 41.0 pt -131.04 167.75 25.4 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.806 0 CA-C-N 115.532 -0.758 . . . . 0.0 109.675 177.467 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -69.0 136.96 29.31 Favored Glycine 0 C--O 1.236 0.281 0 C-N-CA 120.994 -0.622 . . . . 0.0 112.354 -178.754 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . 0.628 ' HD1' ' SD ' ' A' ' 118' ' ' MET . 82.4 t80 -118.59 133.8 55.59 Favored 'General case' 0 C--O 1.249 1.072 0 CA-C-O 120.963 0.411 . . . . 0.0 111.526 -178.564 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 64.1 tttm -136.52 111.44 8.86 Favored 'General case' 0 N--CA 1.442 -0.861 0 CA-C-N 115.562 -0.745 . . . . 0.0 109.782 175.678 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -104.87 133.01 11.35 Favored Glycine 0 N--CA 1.441 -0.997 0 N-CA-C 110.94 -0.864 . . . . 0.0 110.94 178.314 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 25.7 m -128.97 132.9 47.63 Favored 'General case' 0 C--N 1.311 -1.102 0 CA-C-N 116.944 0.372 . . . . 0.0 110.092 -178.754 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 74.0 mt -59.81 130.52 47.19 Favored 'General case' 0 N--CA 1.467 0.396 0 C-N-CA 120.301 -0.559 . . . . 0.0 110.799 177.726 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 52.8 m . . . . . 0 C--O 1.247 0.929 0 CA-C-O 118.512 -0.756 . . . . 0.0 110.734 -179.196 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.741 0 CA-C-O 120.897 0.38 . . . . 0.0 110.749 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . 0.496 HD12 HE21 ' A' ' 22' ' ' GLN . 3.2 tm? -92.68 130.39 38.32 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.064 179.313 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 81.4 m-85 -119.27 144.9 46.53 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.954 -0.566 . . . . 0.0 111.777 -179.242 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . 0.5 ' O ' ' HA2' ' A' ' 130' ' ' GLY . 11.5 t-20 -96.32 136.03 37.36 Favored 'General case' 0 C--N 1.313 -0.988 0 N-CA-C 107.706 -1.22 . . . . 0.0 107.706 179.269 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 78.7 t -116.56 127.11 74.25 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 CA-C-O 121.529 0.681 . . . . 0.0 112.703 -174.59 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.424 ' HB2' ' HB3' ' A' ' 129' ' ' LYS . 45.4 mt-10 -116.58 138.8 51.14 Favored 'General case' 0 N--CA 1.44 -0.926 0 CA-C-N 114.949 -1.023 . . . . 0.0 108.286 175.275 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 10.6 m120 -116.29 139.3 50.52 Favored 'General case' 0 C--N 1.306 -1.32 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.545 -178.442 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . 0.491 ' HB2' ' CE3' ' A' ' 17' ' ' TRP . 54.4 tt0 -129.36 124.3 33.9 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.703 -0.68 . . . . 0.0 109.767 179.33 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 20.1 p90 -122.99 136.84 55.01 Favored 'General case' 0 C--N 1.307 -1.262 0 CA-C-O 120.849 0.357 . . . . 0.0 111.222 179.213 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 111.17 -75.49 0.21 Allowed Glycine 0 N--CA 1.445 -0.752 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.851 -179.653 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -162.34 163.65 35.13 Favored Glycine 0 N--CA 1.449 -0.438 0 N-CA-C 111.617 -0.593 . . . . 0.0 111.617 179.725 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' SER . . . . . 0.406 ' HA ' ' NE2' ' A' ' 9' ' ' GLN . 12.1 m -64.07 -19.06 64.97 Favored 'General case' 0 CA--C 1.536 0.44 0 N-CA-C 112.279 0.474 . . . . 0.0 112.279 -179.002 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 35.3 p -72.42 -18.22 61.73 Favored 'General case' 0 CA--C 1.539 0.536 0 CA-C-O 120.988 0.423 . . . . 0.0 111.231 178.799 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -80.66 155.0 73.73 Favored Pre-proline 0 CA--C 1.533 0.317 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.695 -179.755 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 66.6 Cg_endo -72.11 158.68 51.7 Favored 'Trans proline' 0 C--O 1.236 0.393 0 C-N-CA 122.47 2.113 . . . . 0.0 112.783 178.701 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . 0.491 ' CE3' ' HB2' ' A' ' 9' ' ' GLN . 94.4 m95 -89.22 138.6 31.28 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.408 179.624 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 90.5 m-20 -124.08 129.9 51.64 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 109.141 -0.689 . . . . 0.0 109.141 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 42.6 tt0 -61.37 128.04 34.43 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-O 120.962 0.41 . . . . 0.0 111.299 -178.305 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -108.7 -0.63 32.38 Favored Glycine 0 N--CA 1.448 -0.52 0 CA-C-N 115.469 -0.787 . . . . 0.0 112.805 -178.821 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 130.27 -150.11 19.09 Favored Glycine 0 N--CA 1.443 -0.881 0 C-N-CA 120.335 -0.936 . . . . 0.0 112.249 -179.83 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . 0.496 HE21 HD12 ' A' ' 3' ' ' LEU . 4.2 pt20 -145.5 138.02 25.83 Favored 'General case' 0 C--N 1.319 -0.738 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.771 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 45.3 m0 -117.14 155.23 29.69 Favored 'General case' 0 C--N 1.318 -0.761 0 CA-C-O 120.89 0.376 . . . . 0.0 111.159 -178.429 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -109.11 112.64 24.93 Favored 'General case' 0 C--N 1.317 -0.812 0 N-CA-C 109.511 -0.551 . . . . 0.0 109.511 177.481 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 95.8 mt -130.7 136.82 57.47 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.585 0 CA-C-N 115.203 -0.908 . . . . 0.0 109.762 -178.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 91.55 106.81 1.49 Allowed Glycine 0 N--CA 1.442 -0.911 0 C-N-CA 120.208 -0.996 . . . . 0.0 111.966 -179.383 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 13.9 m -111.86 13.58 20.95 Favored 'General case' 0 C--N 1.31 -1.136 0 CA-C-O 121.208 0.528 . . . . 0.0 110.311 -178.699 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 94.7 mtt-85 -137.44 128.17 27.03 Favored 'General case' 0 N--CA 1.445 -0.72 0 CA-C-N 116.004 -0.544 . . . . 0.0 109.967 -177.069 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 34.5 t -76.77 -17.43 59.05 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-O 121.207 0.527 . . . . 0.0 110.215 179.353 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 15.8 m-20 -75.0 -47.56 28.52 Favored 'General case' 0 C--O 1.224 -0.275 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.904 -178.033 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 14.3 mm100 -128.71 123.19 32.45 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.603 -0.726 . . . . 0.0 111.234 -176.575 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . 0.659 ' ND2' ' HA3' ' A' ' 111' ' ' GLY . 62.5 t30 -101.18 161.74 13.39 Favored 'General case' 0 C--N 1.319 -0.751 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 178.348 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 46.6 t -94.69 130.73 43.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-O 120.572 0.225 . . . . 0.0 111.409 -173.771 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 28.7 m -110.59 -18.57 7.5 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.276 0 CA-C-N 116.464 -0.335 . . . . 0.0 111.731 179.224 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.451 ' HB2' ' HB ' ' A' ' 52' ' ' THR . . . -154.6 149.67 26.88 Favored 'General case' 0 C--O 1.237 0.416 0 C-N-CA 120.563 -0.455 . . . . 0.0 111.685 178.682 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.476 ' HB ' ' CG2' ' A' ' 105' ' ' VAL . 89.9 mt -144.09 123.63 7.84 Favored 'Isoleucine or valine' 0 C--O 1.235 0.308 0 CA-C-N 115.97 -0.559 . . . . 0.0 109.64 -179.743 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 13.4 m120 -124.82 106.58 10.14 Favored 'General case' 0 C--N 1.313 -1.012 0 N-CA-C 107.767 -1.197 . . . . 0.0 107.767 175.844 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 36.0 m -147.68 149.56 15.32 Favored 'Isoleucine or valine' 0 C--O 1.237 0.436 0 C-N-CA 120.146 -0.622 . . . . 0.0 111.957 -172.757 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 66.7 mt-10 -142.55 149.1 38.63 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.299 -0.864 . . . . 0.0 109.325 175.337 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 20.5 p -73.97 142.62 45.84 Favored 'General case' 0 C--N 1.307 -1.25 0 N-CA-C 112.104 0.409 . . . . 0.0 112.104 -177.444 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -88.62 -42.56 5.73 Favored Glycine 0 N--CA 1.443 -0.841 0 N-CA-C 109.148 -1.581 . . . . 0.0 109.148 174.755 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 48.8 m-20 -105.18 -161.55 0.82 Allowed 'General case' 0 C--N 1.317 -0.836 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 175.045 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -76.17 47.98 0.48 Allowed 'General case' 0 N--CA 1.474 0.766 0 N-CA-C 112.303 0.483 . . . . 0.0 112.303 -178.361 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 91.64 -8.55 78.51 Favored Glycine 0 C--O 1.222 -0.649 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.223 178.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 56.1 mt-30 -70.23 -36.23 74.39 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.99 0.424 . . . . 0.0 110.713 178.356 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 22.0 p -122.58 139.4 53.95 Favored 'General case' 0 C--N 1.311 -1.106 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.207 179.66 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 91.2 mt -125.94 127.05 45.36 Favored 'General case' 0 C--N 1.315 -0.932 0 N-CA-C 108.509 -0.923 . . . . 0.0 108.509 179.865 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 88.9 m-20 -125.3 138.07 54.08 Favored 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 109.376 -0.602 . . . . 0.0 109.376 -179.352 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 173.25 -151.23 13.26 Favored Glycine 0 N--CA 1.443 -0.873 0 C-N-CA 120.078 -1.058 . . . . 0.0 112.558 178.853 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' THR . . . . . 0.402 ' HA ' ' O ' ' A' ' 59' ' ' ILE . 33.6 p -132.49 146.87 52.25 Favored 'General case' 0 N--CA 1.443 -0.8 0 CA-C-O 121.003 0.43 . . . . 0.0 110.921 179.692 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 40.7 mtp -121.12 156.49 32.18 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.74 177.18 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.451 ' HB ' ' HB2' ' A' ' 35' ' ' ALA . 26.8 m -132.1 126.35 33.53 Favored 'General case' 0 C--O 1.247 0.965 0 N-CA-C 110.04 -0.356 . . . . 0.0 110.04 175.657 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 72.2 m-85 -98.19 162.64 13.1 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.272 178.607 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -63.6 125.21 23.51 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.577 178.541 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 74.56 12.94 82.27 Favored Glycine 0 N--CA 1.447 -0.608 0 C-N-CA 120.948 -0.644 . . . . 0.0 112.851 -179.705 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 73.8 mm-40 -127.41 177.31 6.82 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 110.137 -0.32 . . . . 0.0 110.137 -179.373 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -109.13 -179.9 21.19 Favored Glycine 0 N--CA 1.445 -0.724 0 C-N-CA 120.879 -0.677 . . . . 0.0 111.614 178.805 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_exo -63.76 137.64 59.6 Favored 'Trans proline' 0 C--N 1.349 0.555 0 C-N-CA 122.504 2.136 . . . . 0.0 112.222 178.88 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . 0.54 ' HB ' ' O ' ' A' ' 76' ' ' GLN . 45.4 pt -132.36 166.11 30.15 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 CA-C-N 115.706 -0.679 . . . . 0.0 109.713 179.316 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -75.73 145.96 33.34 Favored Glycine 0 C--N 1.321 -0.299 0 C-N-CA 120.703 -0.761 . . . . 0.0 111.886 -179.47 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 31.6 t80 -132.12 130.54 41.33 Favored 'General case' 0 C--N 1.317 -0.839 0 C-N-CA 122.477 0.311 . . . . 0.0 111.398 -178.831 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 59.3 ttp180 -138.71 130.49 27.81 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 174.015 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -134.87 146.66 49.43 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 120.704 0.288 . . . . 0.0 111.148 -179.648 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 48.9 m -128.33 136.26 50.71 Favored 'General case' 0 CA--C 1.544 0.724 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.748 179.065 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . 0.408 HD11 ' O ' ' A' ' 68' ' ' ASN . 59.8 tp -69.34 127.8 34.31 Favored 'General case' 0 CA--C 1.535 0.376 0 N-CA-C 112.274 0.472 . . . . 0.0 112.274 -178.539 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -91.18 -41.3 11.08 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-N 115.972 -0.558 . . . . 0.0 112.482 178.702 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -151.8 -68.34 0.01 OUTLIER Glycine 0 CA--C 1.499 -0.922 0 C-N-CA 119.63 -1.272 . . . . 0.0 113.244 -175.835 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' ASN . . . . . 0.408 ' O ' HD11 ' A' ' 65' ' ' LEU . 20.2 m120 -133.49 -81.07 0.47 Allowed 'General case' 0 C--O 1.209 -1.036 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 -178.706 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . 0.482 ' OD1' ' HA3' ' A' ' 93' ' ' GLY . 90.7 m-20 -98.72 -5.73 30.89 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 120.77 0.319 . . . . 0.0 110.486 179.43 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 8.7 m -88.66 123.56 33.23 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 121.291 0.567 . . . . 0.0 112.017 -176.647 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 60.2 m-85 -121.88 145.53 48.0 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.659 178.805 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 71.8 tt0 -100.26 122.56 43.26 Favored 'General case' 0 C--N 1.316 -0.869 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 173.007 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 66.5 t -103.98 132.46 50.4 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.016 0 CA-C-N 115.687 -0.688 . . . . 0.0 111.767 -175.156 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 99.6 mt-10 -127.34 125.75 41.33 Favored 'General case' 0 N--CA 1.446 -0.655 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 177.141 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 95.1 m-20 -111.61 155.57 23.16 Favored 'General case' 0 C--N 1.312 -1.065 0 CA-C-O 121.473 0.654 . . . . 0.0 112.427 -177.204 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' GLN . . . . . 0.54 ' O ' ' HB ' ' A' ' 59' ' ' ILE . 33.8 tt0 -117.69 121.65 41.42 Favored 'General case' 0 C--N 1.311 -1.07 0 CA-C-N 114.878 -1.055 . . . . 0.0 110.285 -177.291 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -107.45 107.84 18.89 Favored 'General case' 0 C--N 1.323 -0.548 0 C-N-CA 120.221 -0.592 . . . . 0.0 110.305 176.834 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 174.04 -158.83 27.86 Favored Glycine 0 N--CA 1.439 -1.146 0 N-CA-C 110.586 -1.006 . . . . 0.0 110.586 -178.655 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -96.41 -42.61 3.39 Favored Glycine 0 N--CA 1.441 -1.008 0 C-N-CA 120.113 -1.042 . . . . 0.0 111.496 178.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 20.9 t70 -176.3 150.31 0.91 Allowed 'General case' 0 C--O 1.236 0.374 0 C-N-CA 122.56 0.344 . . . . 0.0 110.223 179.641 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 23.2 t 52.79 33.25 13.74 Favored 'General case' 0 CA--C 1.549 0.935 0 C-N-CA 123.057 0.543 . . . . 0.0 112.357 177.257 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -91.59 165.22 21.46 Favored Pre-proline 0 CA--C 1.544 0.746 0 CA-C-N 116.463 -0.335 . . . . 0.0 110.752 -179.392 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 26.9 Cg_exo -62.66 152.57 77.32 Favored 'Trans proline' 0 C--N 1.354 0.856 0 C-N-CA 122.703 2.269 . . . . 0.0 112.521 178.703 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' TRP . . . . . . . . . . . . . 96.2 m95 -98.61 143.12 29.35 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.544 -177.586 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 80.1 m-70 -129.83 141.1 50.88 Favored 'General case' 0 C--N 1.318 -0.761 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 179.298 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 42.1 m -61.38 133.89 56.32 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-O 121.216 0.531 . . . . 0.0 111.42 -178.038 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -105.23 -43.3 1.63 Allowed Glycine 0 N--CA 1.438 -1.198 0 N-CA-C 111.561 -0.616 . . . . 0.0 111.561 178.296 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 153.65 -170.03 32.37 Favored Glycine 0 C--O 1.223 -0.535 0 C-N-CA 120.456 -0.878 . . . . 0.0 112.259 178.349 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 20.2 m120 -110.6 123.11 49.36 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.465 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 44.1 m0 -114.41 152.81 30.95 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-O 121.016 0.436 . . . . 0.0 111.704 -177.363 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . 0.438 ' HA ' ' O ' ' A' ' 69' ' ' ASN . 82.8 mt -108.02 112.29 39.6 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.751 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 176.785 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 70.0 mt -135.15 73.08 1.46 Allowed 'General case' 0 C--O 1.266 1.972 0 CA-C-O 121.692 0.758 . . . . 0.0 111.835 -175.592 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . 0.482 ' HA3' ' OD1' ' A' ' 69' ' ' ASN . . . -153.67 -78.85 0.02 OUTLIER Glycine 0 N--CA 1.447 -0.615 0 C-N-CA 120.228 -0.987 . . . . 0.0 113.278 -178.096 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 57.5 m 69.94 10.29 7.4 Favored 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 123.268 0.627 . . . . 0.0 111.869 -177.784 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' ARG . . . . . 0.71 ' HB2' ' O ' ' A' ' 98' ' ' GLN . 16.8 mmt180 -127.12 141.39 51.77 Favored 'General case' 0 N--CA 1.443 -0.783 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 177.308 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 16.6 pt-20 -67.38 -40.45 85.71 Favored 'General case' 0 C--N 1.311 -1.097 0 N-CA-C 112.96 0.726 . . . . 0.0 112.96 -176.298 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 91.8 m-20 -127.58 28.91 5.58 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 111.912 0.338 . . . . 0.0 111.912 -176.35 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' GLN . . . . . 0.71 ' O ' ' HB2' ' A' ' 95' ' ' ARG . 46.0 tt0 -155.64 132.52 10.61 Favored 'General case' 0 C--N 1.32 -0.688 0 C-N-CA 120.625 -0.43 . . . . 0.0 110.078 -177.946 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 91.3 m-20 -115.3 179.49 3.95 Favored 'General case' 0 C--O 1.26 1.638 0 C-N-CA 120.717 -0.393 . . . . 0.0 111.957 -177.909 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 22.5 m -81.06 143.33 12.48 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.427 0 CA-C-N 115.673 -0.694 . . . . 0.0 111.132 178.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 31.2 m -121.51 -36.43 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.694 178.223 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . 0.452 ' HB2' ' HB ' ' A' ' 119' ' ' THR . . . -133.4 130.41 38.7 Favored 'General case' 0 CA--C 1.51 -0.572 0 C-N-CA 119.943 -0.703 . . . . 0.0 111.153 178.76 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 96.5 mt -133.29 122.55 45.17 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.934 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.656 178.862 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 12.0 t30 -126.67 99.27 5.71 Favored 'General case' 0 C--N 1.316 -0.882 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 176.804 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.476 ' CG2' ' HB ' ' A' ' 36' ' ' ILE . 17.8 m -135.21 135.86 51.91 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.146 0 CA-C-N 115.513 -0.767 . . . . 0.0 112.429 -174.787 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 60.2 mt-10 -141.17 142.58 34.02 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.597 -0.728 . . . . 0.0 110.256 179.85 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 35.5 t -140.33 148.65 41.67 Favored 'General case' 0 C--N 1.315 -0.913 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.878 179.366 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -96.29 1.11 62.26 Favored Glycine 0 N--CA 1.444 -0.785 0 N-CA-C 110.769 -0.932 . . . . 0.0 110.769 176.234 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 84.6 m-20 -88.93 179.13 6.25 Favored 'General case' 0 CA--C 1.511 -0.539 0 CA-C-O 120.872 0.368 . . . . 0.0 110.601 -179.635 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 7.8 p-10 -88.83 16.41 6.91 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-O 121.568 0.699 . . . . 0.0 109.602 177.577 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . 0.659 ' HA3' ' ND2' ' A' ' 32' ' ' ASN . . . 113.25 7.82 20.45 Favored Glycine 0 N--CA 1.438 -1.232 0 CA-C-N 115.384 -0.826 . . . . 0.0 112.516 -177.526 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 98.6 mt-30 -62.71 -47.91 81.56 Favored 'General case' 0 C--O 1.238 0.45 0 CA-C-O 120.759 0.314 . . . . 0.0 110.363 178.783 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 70.7 p -130.44 155.39 46.5 Favored 'General case' 0 N--CA 1.444 -0.748 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 176.151 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 40.1 tp -136.39 108.38 7.16 Favored 'General case' 0 C--N 1.314 -0.946 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 178.352 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 89.0 m-20 -119.84 155.14 33.2 Favored 'General case' 0 C--N 1.316 -0.882 0 C-N-CA 120.597 -0.441 . . . . 0.0 111.737 -175.484 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 162.34 -136.15 4.21 Favored Glycine 0 N--CA 1.438 -1.176 0 C-N-CA 120.543 -0.837 . . . . 0.0 112.737 178.016 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 26.6 p -130.89 153.28 49.31 Favored 'General case' 0 C--N 1.312 -1.032 0 C-N-CA 122.752 0.421 . . . . 0.0 110.469 -178.343 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 25.6 ptm -143.57 146.23 33.15 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.074 179.899 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 119' ' ' THR . . . . . 0.452 ' HB ' ' HB2' ' A' ' 102' ' ' ALA . 36.7 m -129.8 126.6 38.49 Favored 'General case' 0 C--N 1.305 -1.358 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.533 179.294 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 67.0 m-85 -81.18 164.43 22.34 Favored 'General case' 0 CA--C 1.508 -0.645 0 O-C-N 123.716 0.635 . . . . 0.0 109.502 176.172 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -51.54 -31.63 24.96 Favored 'General case' 0 CA--C 1.54 0.586 0 N-CA-C 113.37 0.878 . . . . 0.0 113.37 -178.827 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -155.84 15.93 0.45 Allowed Glycine 0 CA--C 1.519 0.287 0 C-N-CA 119.189 -1.481 . . . . 0.0 114.263 -178.246 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 82.9 tt0 -100.19 -23.74 14.75 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 117.619 0.709 . . . . 0.0 111.327 -179.894 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 115.03 179.67 18.54 Favored Glycine 0 N--CA 1.448 -0.507 0 C-N-CA 120.235 -0.983 . . . . 0.0 112.935 178.039 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -90.39 122.06 0.91 Allowed 'Trans proline' 0 N--CA 1.449 -1.102 0 C-N-CA 123.767 2.978 . . . . 0.0 112.408 179.749 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 41.2 pt -128.53 163.12 33.8 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.803 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.58 179.487 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -70.08 137.01 27.58 Favored Glycine 0 C--O 1.244 0.728 0 CA-C-N 116.188 -0.46 . . . . 0.0 112.165 179.37 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 83.7 t80 -115.25 133.97 55.56 Favored 'General case' 0 C--N 1.316 -0.853 0 C-N-CA 122.51 0.324 . . . . 0.0 110.678 -178.966 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 129' ' ' LYS . . . . . 0.424 ' HB3' ' HB2' ' A' ' 7' ' ' GLU . 86.3 tttt -137.45 114.99 11.17 Favored 'General case' 0 N--CA 1.437 -1.09 0 N-CA-C 109.301 -0.629 . . . . 0.0 109.301 176.53 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . 0.5 ' HA2' ' O ' ' A' ' 5' ' ' ASN . . . -115.13 136.02 12.78 Favored Glycine 0 N--CA 1.433 -1.561 0 N-CA-C 111.157 -0.777 . . . . 0.0 111.157 177.837 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 52.5 m -128.7 136.72 50.99 Favored 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -179.905 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 58.3 tp -59.89 126.03 25.96 Favored 'General case' 0 C--N 1.327 -0.379 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 178.538 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 24.5 m . . . . . 0 N--CA 1.439 -1.024 0 CA-C-O 118.745 -0.645 . . . . 0.0 110.776 -178.275 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 0.603 ' O ' ' HG3' ' A' ' 24' ' ' GLU . . . . . . . . 0 N--CA 1.479 1.004 0 N-CA-C 110.144 -0.317 . . . . 0.0 110.144 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . 0.463 HD13 HE21 ' A' ' 22' ' ' GLN . 3.0 tm? -87.3 132.21 34.0 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-O 121.271 0.558 . . . . 0.0 110.713 -175.504 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . 0.423 ' N ' HD11 ' A' ' 3' ' ' LEU . 20.0 m-85 -115.45 134.78 54.76 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 115.486 -0.779 . . . . 0.0 111.392 178.542 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 46.6 t-20 -92.9 117.37 29.97 Favored 'General case' 0 C--N 1.309 -1.158 0 N-CA-C 106.992 -1.484 . . . . 0.0 106.992 176.814 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.437 HG13 HD22 ' A' ' 8' ' ' ASN . 58.5 t -102.04 104.89 17.08 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.146 0 CA-C-O 121.146 0.498 . . . . 0.0 112.307 -174.067 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -94.3 137.62 33.24 Favored 'General case' 0 C--N 1.312 -1.028 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 175.931 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . 0.437 HD22 HG13 ' A' ' 6' ' ' VAL . 63.2 m-80 -132.69 159.17 40.41 Favored 'General case' 0 C--N 1.314 -0.972 0 CA-C-O 121.627 0.727 . . . . 0.0 112.784 -175.075 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 36.4 tt0 -124.02 106.29 10.27 Favored 'General case' 0 C--N 1.309 -1.166 0 N-CA-C 106.828 -1.545 . . . . 0.0 106.828 173.118 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 1.4 p90 -125.68 0.21 7.45 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 114.056 1.132 . . . . 0.0 114.056 -173.289 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -116.3 21.4 11.9 Favored Glycine 0 N--CA 1.446 -0.647 0 C-N-CA 119.014 -1.565 . . . . 0.0 112.296 -177.74 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 122.14 157.21 9.91 Favored Glycine 0 N--CA 1.441 -1.01 0 C-N-CA 120.8 -0.714 . . . . 0.0 111.99 -179.726 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 21.3 p -59.46 -31.88 69.73 Favored 'General case' 0 C--N 1.317 -0.822 0 C-N-CA 123.018 0.527 . . . . 0.0 112.41 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 17.1 p -81.41 -7.56 59.6 Favored 'General case' 0 C--N 1.32 -0.703 0 N-CA-C 112.26 0.467 . . . . 0.0 112.26 179.449 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -78.99 142.11 59.59 Favored Pre-proline 0 C--N 1.328 -0.353 0 CA-C-O 120.801 0.334 . . . . 0.0 111.255 -178.674 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 64.2 Cg_endo -70.8 165.37 32.38 Favored 'Trans proline' 0 C--O 1.237 0.47 0 C-N-CA 123.084 2.523 . . . . 0.0 112.54 -179.81 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 93.5 m95 -81.69 137.81 35.35 Favored 'General case' 0 N--CA 1.452 -0.354 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.357 -178.731 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 3.1 p30 -145.32 137.78 25.9 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.99 -179.827 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 8.3 pt-20 -93.16 141.37 28.49 Favored 'General case' 0 C--N 1.317 -0.833 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 178.098 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -132.71 26.98 3.57 Favored Glycine 0 N--CA 1.442 -0.956 0 C-N-CA 120.45 -0.881 . . . . 0.0 111.21 179.726 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 154.76 169.34 19.29 Favored Glycine 0 N--CA 1.437 -1.263 0 C-N-CA 120.991 -0.623 . . . . 0.0 111.846 -179.475 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . 0.463 HE21 HD13 ' A' ' 3' ' ' LEU . 4.4 pt20 -122.0 132.8 54.71 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-O 120.835 0.35 . . . . 0.0 110.339 179.913 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 40.4 m0 -113.21 172.83 6.71 Favored 'General case' 0 CA--C 1.506 -0.718 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.165 -176.409 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . 0.603 ' HG3' ' O ' ' A' ' 2' ' ' ALA . 33.5 tt0 -131.23 114.66 15.34 Favored 'General case' 0 C--N 1.317 -0.837 0 N-CA-C 108.815 -0.809 . . . . 0.0 108.815 173.572 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.405 HG22 HD11 ' A' ' 36' ' ' ILE . 97.7 mt -105.54 -36.81 3.8 Favored 'Isoleucine or valine' 0 C--O 1.199 -1.6 0 CA-C-N 115.138 -0.937 . . . . 0.0 113.156 -173.053 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -109.07 126.98 8.32 Favored Glycine 0 C--N 1.307 -1.078 0 C-N-CA 119.888 -1.149 . . . . 0.0 112.387 -179.858 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 59.6 p -117.19 8.16 13.17 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 111.875 0.324 . . . . 0.0 111.875 -179.883 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 69.1 ttt180 -122.09 135.5 54.81 Favored 'General case' 0 N--CA 1.446 -0.629 0 CA-C-O 121.162 0.506 . . . . 0.0 111.904 -177.153 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 47.9 t -77.35 149.36 35.26 Favored 'General case' 0 N--CA 1.442 -0.846 0 CA-C-N 115.294 -0.866 . . . . 0.0 109.908 176.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.459 ' O ' ' HG2' ' A' ' 31' ' ' GLN . 8.9 m-20 59.62 22.71 11.42 Favored 'General case' 0 N--CA 1.479 0.99 0 C-N-CA 123.032 0.533 . . . . 0.0 111.433 176.902 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . 0.459 ' HG2' ' O ' ' A' ' 30' ' ' ASP . 4.5 mm-40 -163.06 91.26 0.71 Allowed 'General case' 0 CA--C 1.501 -0.91 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.241 -178.058 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . 0.573 ' ND2' ' HA3' ' A' ' 111' ' ' GLY . 63.6 t30 -94.69 162.02 13.95 Favored 'General case' 0 C--N 1.309 -1.174 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.239 -179.01 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 72.6 t -95.57 129.52 45.57 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.201 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.89 -176.51 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 33.0 m -110.39 -13.06 11.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 N-CA-C 112.187 0.439 . . . . 0.0 112.187 179.154 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.464 ' O ' ' HG2' ' A' ' 51' ' ' MET . . . -156.34 149.36 24.13 Favored 'General case' 0 CA--C 1.517 -0.304 0 C-N-CA 120.464 -0.494 . . . . 0.0 111.851 178.685 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.405 HD11 HG22 ' A' ' 25' ' ' ILE . 88.2 mt -148.54 119.18 1.29 Allowed 'Isoleucine or valine' 0 CA--C 1.513 -0.46 0 N-CA-C 107.935 -1.135 . . . . 0.0 107.935 178.565 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . 0.543 ' HA ' ' O ' ' A' ' 103' ' ' ILE . 57.5 m-80 -140.05 74.91 1.48 Allowed 'General case' 0 C--N 1.301 -1.534 0 C-N-CA 120.706 -0.398 . . . . 0.0 110.759 -179.375 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.576 HG13 ' CD1' ' A' ' 61' ' ' PHE . 17.1 m -120.18 171.32 8.74 Favored 'Isoleucine or valine' 0 C--O 1.235 0.319 0 N-CA-C 112.49 0.552 . . . . 0.0 112.49 178.541 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 75.3 tt0 -140.34 153.23 46.33 Favored 'General case' 0 N--CA 1.447 -0.593 0 CA-C-N 115.234 -0.893 . . . . 0.0 109.731 179.213 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' SER . . . . . 0.524 ' OG ' ' HB ' ' A' ' 101' ' ' VAL . 34.6 p -76.95 157.72 31.11 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-O 121.297 0.57 . . . . 0.0 112.487 -177.595 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -105.99 -49.46 0.94 Allowed Glycine 0 N--CA 1.438 -1.224 0 N-CA-C 110.177 -1.169 . . . . 0.0 110.177 174.427 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 18.9 m-20 -102.24 -149.68 0.39 Allowed 'General case' 0 C--N 1.325 -0.48 0 C-N-CA 122.889 0.476 . . . . 0.0 110.502 179.013 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 11.9 m-20 -71.96 38.19 0.07 Allowed 'General case' 0 N--CA 1.484 1.268 0 C-N-CA 123.747 0.819 . . . . 0.0 112.261 -177.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 83.69 2.93 89.81 Favored Glycine 0 C--N 1.316 -0.532 0 C-N-CA 120.669 -0.776 . . . . 0.0 111.571 -178.738 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . 0.436 ' HA ' ' HB3' ' A' ' 65' ' ' LEU . 62.3 mt-30 -80.5 -28.59 37.44 Favored 'General case' 0 C--O 1.218 -0.559 0 CA-C-O 120.981 0.419 . . . . 0.0 110.66 178.218 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' THR . . . . . 0.422 ' O ' ' HA ' ' A' ' 40' ' ' SER . 22.6 p -118.54 132.49 56.21 Favored 'General case' 0 C--N 1.306 -1.298 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.637 179.877 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 90.5 mt -126.46 132.64 51.4 Favored 'General case' 0 C--N 1.319 -0.759 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 179.754 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.405 ' HA ' ' O ' ' A' ' 61' ' ' PHE . 9.4 p30 -142.65 147.61 36.05 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-O 120.789 0.328 . . . . 0.0 110.585 179.234 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 158.68 -135.05 4.05 Favored Glycine 0 C--N 1.312 -0.786 0 C-N-CA 120.601 -0.809 . . . . 0.0 111.885 178.656 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 24.7 p -130.8 149.23 52.54 Favored 'General case' 0 N--CA 1.452 -0.347 0 CA-C-O 121.175 0.512 . . . . 0.0 111.812 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' MET . . . . . 0.541 ' HE1' ' CZ ' ' A' ' 53' ' ' TYR . 18.4 tmm? -142.45 148.47 37.81 Favored 'General case' 0 C--N 1.316 -0.853 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 177.399 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.422 ' HB ' ' HB2' ' A' ' 35' ' ' ALA . 66.1 m -129.53 127.64 41.17 Favored 'General case' 0 C--O 1.246 0.919 0 N-CA-C 112.385 0.513 . . . . 0.0 112.385 -177.04 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . 0.541 ' CZ ' ' HE1' ' A' ' 51' ' ' MET . 64.9 m-85 -87.99 161.76 17.22 Favored 'General case' 0 CA--C 1.515 -0.369 0 CA-C-N 115.507 -0.769 . . . . 0.0 109.458 174.46 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -66.71 129.99 41.7 Favored 'General case' 0 C--N 1.315 -0.918 0 N-CA-C 110.04 -0.356 . . . . 0.0 110.04 178.158 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 90.45 -19.99 40.53 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.869 -0.681 . . . . 0.0 113.081 179.228 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 81.5 mm-40 -107.56 170.17 8.14 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 120.736 0.303 . . . . 0.0 110.767 -178.589 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -95.46 -157.89 32.35 Favored Glycine 0 N--CA 1.446 -0.664 0 C-N-CA 120.943 -0.646 . . . . 0.0 112.354 179.52 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_endo -64.3 138.46 60.93 Favored 'Trans proline' 0 C--N 1.345 0.38 0 C-N-CA 122.462 2.108 . . . . 0.0 112.099 179.743 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 98.3 mt -132.89 142.5 42.14 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.026 0 CA-C-N 115.578 -0.737 . . . . 0.0 109.771 -179.12 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -73.82 128.27 10.97 Favored Glycine 0 N--CA 1.443 -0.898 0 N-CA-C 110.579 -1.009 . . . . 0.0 110.579 179.058 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.576 ' CD1' HG13 ' A' ' 38' ' ' VAL . 47.5 t80 -114.41 128.08 56.16 Favored 'General case' 0 C--N 1.311 -1.08 0 CA-C-O 120.594 0.235 . . . . 0.0 110.903 -176.177 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 64.9 ttp85 -135.49 129.61 33.39 Favored 'General case' 0 N--CA 1.448 -0.536 0 CA-C-N 116.016 -0.538 . . . . 0.0 109.986 176.024 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -138.94 149.66 45.02 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 120.773 0.321 . . . . 0.0 111.754 -178.517 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 27.6 m -125.35 131.5 52.98 Favored 'General case' 0 CA--C 1.54 0.596 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.359 179.204 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . 0.436 ' HB3' ' HA ' ' A' ' 45' ' ' GLN . 3.0 tm? -80.2 113.29 18.26 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 120.981 0.419 . . . . 0.0 110.503 -178.495 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 94.6 mt -88.4 -18.96 27.24 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.498 177.799 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 125.34 167.66 12.59 Favored Glycine 0 N--CA 1.442 -0.959 0 C-N-CA 121.02 -0.609 . . . . 0.0 111.596 179.765 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 94.8 m-20 56.47 36.66 27.91 Favored 'General case' 0 N--CA 1.473 0.721 0 C-N-CA 122.56 0.344 . . . . 0.0 111.707 178.279 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 16.3 m120 66.36 9.66 6.62 Favored 'General case' 0 N--CA 1.48 1.031 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.363 179.644 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 35.1 m -97.88 123.55 41.9 Favored 'General case' 0 C--O 1.24 0.562 0 CA-C-O 121.37 0.605 . . . . 0.0 111.586 -177.537 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.524 ' OH ' ' HB3' ' A' ' 99' ' ' ASN . 59.4 m-85 -112.98 138.51 49.75 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 115.468 -0.787 . . . . 0.0 110.83 -179.613 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 42.5 tt0 -92.52 116.64 29.17 Favored 'General case' 0 N--CA 1.439 -0.976 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 174.786 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 78.2 t -105.03 133.15 50.05 Favored 'Isoleucine or valine' 0 C--O 1.248 1.019 0 N-CA-C 112.75 0.648 . . . . 0.0 112.75 -173.615 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 68.7 mt-10 -133.33 134.42 43.78 Favored 'General case' 0 C--O 1.244 0.772 0 N-CA-C 107.899 -1.148 . . . . 0.0 107.899 175.253 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 92.8 m-20 -119.46 154.43 33.76 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 112.911 0.708 . . . . 0.0 112.911 -173.797 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 35.9 tt0 -132.52 127.76 35.87 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.07 -0.968 . . . . 0.0 108.999 179.389 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 37.9 p90 -137.58 157.47 46.44 Favored 'General case' 0 C--N 1.317 -0.835 0 C-N-CA 119.973 -0.691 . . . . 0.0 111.997 -177.046 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 81.19 12.13 82.69 Favored Glycine 0 N--CA 1.453 -0.216 0 CA-C-N 115.4 -0.818 . . . . 0.0 112.465 179.513 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 124.48 175.67 14.4 Favored Glycine 0 N--CA 1.445 -0.709 0 N-CA-C 111.259 -0.736 . . . . 0.0 111.259 -179.582 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 -89.74 -5.19 57.23 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 121.114 0.483 . . . . 0.0 110.373 -179.194 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 33.2 m -79.04 -12.96 60.03 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.413 179.367 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -90.8 128.69 47.21 Favored Pre-proline 0 C--N 1.321 -0.641 0 CA-C-N 116.54 -0.3 . . . . 0.0 110.484 -179.532 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 30.1 Cg_endo -63.21 136.2 54.59 Favored 'Trans proline' 0 N--CA 1.463 -0.289 0 C-N-CA 122.157 1.904 . . . . 0.0 111.736 179.735 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' TRP . . . . . . . . . . . . . 87.0 m95 -51.1 138.67 19.53 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-O 121.302 0.572 . . . . 0.0 112.261 178.667 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 96.1 m-70 -115.11 147.14 40.59 Favored 'General case' 0 C--N 1.314 -0.949 0 CA-C-N 115.325 -0.852 . . . . 0.0 109.299 179.361 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 6.3 m -58.37 148.59 27.26 Favored 'General case' 0 C--N 1.316 -0.851 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.629 179.004 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -124.32 -54.44 0.18 Allowed Glycine 0 N--CA 1.44 -1.065 0 N-CA-C 110.552 -1.019 . . . . 0.0 110.552 -179.591 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 149.48 -165.95 29.58 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.605 -0.807 . . . . 0.0 112.353 176.788 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 14.5 m120 -110.66 118.45 36.22 Favored 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 109.346 -0.613 . . . . 0.0 109.346 178.362 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 32.8 m0 -110.38 150.67 28.47 Favored 'General case' 0 C--N 1.313 -0.993 0 CA-C-N 116.559 -0.292 . . . . 0.0 110.707 -177.374 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 83.3 mt -105.6 115.17 46.83 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.937 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 177.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 82.2 mt -131.53 80.5 1.93 Allowed 'General case' 0 C--O 1.27 2.182 0 CA-C-O 121.945 0.879 . . . . 0.0 112.589 -174.638 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 165.73 119.63 0.49 Allowed Glycine 0 N--CA 1.441 -0.993 0 CA-C-N 114.935 -1.029 . . . . 0.0 111.5 178.678 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 83.9 p -89.81 -1.54 58.02 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.34 0.59 . . . . 0.0 110.173 178.519 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 23.8 mtp180 -109.12 138.4 45.52 Favored 'General case' 0 N--CA 1.435 -1.181 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 178.884 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 72.5 tt0 -73.0 -38.26 66.67 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-O 121.354 0.597 . . . . 0.0 111.326 -173.324 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 53.5 m-80 -110.6 28.75 8.37 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.343 -177.934 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' GLN . . . . . 0.511 HE21 ' HB3' ' A' ' 120' ' ' TYR . 50.8 tt0 -156.96 125.2 5.61 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.119 0.485 . . . . 0.0 110.467 -177.545 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' ASN . . . . . 0.524 ' HB3' ' OH ' ' A' ' 71' ' ' TYR . 91.6 m-20 -104.64 169.69 8.32 Favored 'General case' 0 C--O 1.251 1.136 0 CA-C-N 115.647 -0.706 . . . . 0.0 111.949 -174.319 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 26.4 m -83.73 151.8 3.89 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.433 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.918 177.886 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . 0.524 ' HB ' ' OG ' ' A' ' 40' ' ' SER . 33.8 m -123.45 -29.66 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 C-N-CA 120.909 -0.316 . . . . 0.0 111.49 177.416 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . 0.451 ' HB2' ' HB ' ' A' ' 119' ' ' THR . . . -140.56 135.34 31.72 Favored 'General case' 0 C--N 1.317 -0.828 0 C-N-CA 120.197 -0.601 . . . . 0.0 111.13 179.07 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.543 ' O ' ' HA ' ' A' ' 37' ' ' ASN . 88.6 mt -128.41 121.47 55.45 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.044 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 178.447 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 8.1 t30 -127.8 95.07 4.11 Favored 'General case' 0 C--N 1.325 -0.463 0 O-C-N 123.908 0.755 . . . . 0.0 109.48 -179.296 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.438 HG11 ' CD2' ' A' ' 128' ' ' PHE . 31.7 m -143.65 148.58 18.83 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 N-CA-C 112.672 0.619 . . . . 0.0 112.672 -175.293 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 69.8 tt0 -150.05 154.32 37.95 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.335 -0.848 . . . . 0.0 109.553 174.863 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 44.3 t -136.28 150.8 49.09 Favored 'General case' 0 C--N 1.31 -1.146 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.107 -178.846 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -97.2 1.79 60.92 Favored Glycine 0 N--CA 1.44 -1.069 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 174.479 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -98.56 -172.68 2.37 Favored 'General case' 0 CA--C 1.507 -0.703 0 N-CA-C 109.596 -0.52 . . . . 0.0 109.596 179.716 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 10.4 p-10 -92.47 32.76 1.17 Allowed 'General case' 0 C--N 1.312 -1.028 0 CA-C-O 121.435 0.636 . . . . 0.0 109.559 176.147 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . 0.573 ' HA3' ' ND2' ' A' ' 32' ' ' ASN . . . 94.81 9.24 58.72 Favored Glycine 0 N--CA 1.445 -0.719 0 CA-C-N 115.618 -0.719 . . . . 0.0 113.271 -179.347 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' GLN . . . . . 0.505 ' HA ' ' CD1' ' A' ' 132' ' ' LEU . 97.1 mt-30 -65.08 -50.69 65.16 Favored 'General case' 0 C--O 1.24 0.593 0 CA-C-O 120.96 0.409 . . . . 0.0 111.072 179.289 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 40.2 p -129.49 130.33 45.7 Favored 'General case' 0 N--CA 1.444 -0.751 0 CA-C-N 115.899 -0.591 . . . . 0.0 109.844 178.56 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 88.6 mt -108.85 125.44 51.98 Favored 'General case' 0 C--N 1.31 -1.149 0 N-CA-C 110.075 -0.343 . . . . 0.0 110.075 179.781 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 15.7 m120 -109.84 136.37 49.25 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.173 -178.768 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 167.33 -145.56 9.93 Favored Glycine 0 N--CA 1.439 -1.136 0 C-N-CA 119.074 -1.536 . . . . 0.0 113.584 176.408 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 26.9 p -139.17 161.58 37.05 Favored 'General case' 0 C--N 1.314 -0.951 0 C-N-CA 123.211 0.605 . . . . 0.0 110.699 -177.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 118' ' ' MET . . . . . 0.526 ' O ' ' HA ' ' A' ' 125' ' ' PRO . 18.4 ptp -140.28 148.59 41.66 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.303 -0.408 . . . . 0.0 109.968 178.776 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 119' ' ' THR . . . . . 0.451 ' HB ' ' HB2' ' A' ' 102' ' ' ALA . 27.7 m -128.78 130.53 47.14 Favored 'General case' 0 C--N 1.313 -0.998 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 177.973 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . 0.541 ' HB2' ' HB3' ' A' ' 123' ' ' GLU . 38.4 m-85 -96.56 173.08 7.52 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.006 0.431 . . . . 0.0 112.037 -179.945 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -55.51 -36.57 66.83 Favored 'General case' 0 CA--C 1.533 0.298 0 CA-C-N 115.396 -0.82 . . . . 0.0 112.859 -178.43 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -144.2 46.01 0.84 Allowed Glycine 0 CA--C 1.506 -0.522 0 C-N-CA 120.388 -0.91 . . . . 0.0 111.668 -179.321 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . 0.541 ' HB3' ' HB2' ' A' ' 120' ' ' TYR . 76.1 tt0 -151.62 144.66 24.55 Favored 'General case' 0 C--N 1.315 -0.894 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 -178.032 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -68.01 160.29 50.59 Favored Glycine 0 CA--C 1.518 0.246 0 C-N-CA 121.153 -0.546 . . . . 0.0 113.002 -177.512 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . 0.526 ' HA ' ' O ' ' A' ' 118' ' ' MET . 30.2 Cg_endo -63.15 136.65 57.21 Favored 'Trans proline' 0 C--N 1.348 0.537 0 C-N-CA 122.416 2.077 . . . . 0.0 111.994 179.701 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 44.0 pt -129.47 165.1 30.27 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.913 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.567 -179.133 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -73.09 132.44 16.89 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 121.053 -0.594 . . . . 0.0 112.145 -179.18 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . 0.438 ' CD2' HG11 ' A' ' 105' ' ' VAL . 49.9 t80 -114.92 131.29 56.93 Favored 'General case' 0 C--O 1.245 0.862 0 C-N-CA 122.937 0.495 . . . . 0.0 111.793 -177.798 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 62.5 tttm -133.13 97.35 3.97 Favored 'General case' 0 N--CA 1.441 -0.89 0 CA-C-N 115.249 -0.887 . . . . 0.0 109.687 175.658 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -91.81 130.84 10.49 Favored Glycine 0 CA--C 1.502 -0.738 0 N-CA-C 111.06 -0.816 . . . . 0.0 111.06 179.917 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 28.2 m -128.5 133.94 48.58 Favored 'General case' 0 C--N 1.311 -1.093 0 CA-C-N 117.282 0.541 . . . . 0.0 110.461 -178.376 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 132' ' ' LEU . . . . . 0.505 ' CD1' ' HA ' ' A' ' 112' ' ' GLN . 80.3 mt -57.12 134.34 55.79 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-O 121.001 0.429 . . . . 0.0 110.962 177.784 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 24.1 m . . . . . 0 C--O 1.251 1.152 0 CA-C-O 118.123 -0.941 . . . . 0.0 109.61 179.682 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.701 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . 0.513 HD11 HE21 ' A' ' 22' ' ' GLN . 3.3 tm? -98.23 132.53 43.66 Favored 'General case' 0 C--N 1.317 -0.805 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 -178.772 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . 0.449 ' CE1' ' HB ' ' A' ' 25' ' ' ILE . 96.9 m-85 -125.9 150.06 48.22 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-O 121.153 0.501 . . . . 0.0 111.256 -179.668 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 10.1 m-80 -99.0 136.56 38.79 Favored 'General case' 0 C--N 1.318 -0.791 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 174.728 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.457 HG22 ' CG ' ' A' ' 23' ' ' TRP . 53.6 t -115.87 129.83 71.57 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 N-CA-C 114.007 1.114 . . . . 0.0 114.007 -172.953 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.456 ' HA ' ' HA ' ' A' ' 19' ' ' GLU . 78.4 mt-10 -114.27 134.33 55.02 Favored 'General case' 0 N--CA 1.437 -1.09 0 CA-C-N 113.999 -1.455 . . . . 0.0 107.97 176.038 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 11.6 m120 -116.07 136.15 53.28 Favored 'General case' 0 C--N 1.315 -0.918 0 CA-C-O 120.635 0.255 . . . . 0.0 110.517 -178.949 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . 0.516 ' HB2' ' CE3' ' A' ' 17' ' ' TRP . 58.6 tt0 -112.39 122.1 46.74 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.827 -178.166 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 15.0 p90 -139.47 141.87 37.39 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.912 -0.585 . . . . 0.0 109.654 175.079 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 127.62 2.21 6.33 Favored Glycine 0 N--CA 1.443 -0.862 0 C-N-CA 120.657 -0.782 . . . . 0.0 111.59 -179.234 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 82.03 -156.69 36.35 Favored Glycine 0 N--CA 1.445 -0.766 0 C-N-CA 121.161 -0.542 . . . . 0.0 113.892 178.776 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 8.1 m -54.45 137.54 42.27 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-N 115.011 -0.594 . . . . 0.0 111.8 179.659 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 21.0 m 64.08 18.92 11.52 Favored 'General case' 0 N--CA 1.469 0.511 0 N-CA-C 113.131 0.789 . . . . 0.0 113.131 177.616 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -79.93 140.28 54.04 Favored Pre-proline 0 C--N 1.322 -0.597 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 177.209 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 69.9 Cg_endo -71.13 158.73 54.22 Favored 'Trans proline' 0 C--O 1.238 0.505 0 C-N-CA 122.495 2.13 . . . . 0.0 112.287 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . 0.516 ' CE3' ' HB2' ' A' ' 9' ' ' GLN . 91.7 m95 -92.94 128.78 38.92 Favored 'General case' 0 C--N 1.314 -0.965 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 179.076 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 88.9 m-20 -116.37 117.12 29.07 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-N 116.7 -0.227 . . . . 0.0 110.691 -177.573 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.456 ' HA ' ' HA ' ' A' ' 7' ' ' GLU . 11.2 pt-20 -72.27 135.55 46.03 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 177.669 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -142.87 26.16 2.23 Favored Glycine 0 N--CA 1.44 -1.074 0 C-N-CA 119.375 -1.393 . . . . 0.0 113.266 179.302 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 149.85 -176.04 28.7 Favored Glycine 0 N--CA 1.447 -0.567 0 C-N-CA 119.531 -1.318 . . . . 0.0 113.583 -179.832 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . 0.513 HE21 HD11 ' A' ' 3' ' ' LEU . 4.4 pt20 -131.32 136.97 48.57 Favored 'General case' 0 C--N 1.325 -0.478 0 C-N-CA 122.603 0.361 . . . . 0.0 110.425 -178.728 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . 0.457 ' CG ' HG22 ' A' ' 6' ' ' VAL . 29.3 m0 -112.58 154.64 25.68 Favored 'General case' 0 CA--C 1.504 -0.826 0 N-CA-C 110.126 -0.324 . . . . 0.0 110.126 179.406 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 69.5 tt0 -117.89 114.16 22.82 Favored 'General case' 0 C--N 1.31 -1.111 0 C-N-CA 119.772 -0.771 . . . . 0.0 109.085 176.185 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.449 ' HB ' ' CE1' ' A' ' 4' ' ' TYR . 96.8 mt -127.0 135.76 62.74 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.598 -175.486 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 113.5 165.13 15.89 Favored Glycine 0 N--CA 1.438 -1.183 0 C-N-CA 120.667 -0.778 . . . . 0.0 112.721 176.838 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 58.5 m -134.63 -55.77 0.84 Allowed 'General case' 0 C--N 1.309 -1.163 0 N-CA-C 108.793 -0.817 . . . . 0.0 108.793 179.454 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 93.4 mtt-85 -80.36 137.09 36.51 Favored 'General case' 0 N--CA 1.448 -0.551 0 CA-C-N 115.506 -0.77 . . . . 0.0 109.164 176.403 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 24.8 m -89.03 -19.98 24.95 Favored 'General case' 0 C--N 1.314 -0.95 0 CA-C-O 121.257 0.551 . . . . 0.0 110.884 -179.379 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 17.3 m-20 -95.68 1.01 53.3 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.781 -0.645 . . . . 0.0 111.407 -178.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . 0.456 ' OE1' ' HB3' ' A' ' 53' ' ' TYR . 0.4 OUTLIER -141.65 112.41 7.21 Favored 'General case' 0 C--N 1.321 -0.67 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 178.966 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 2.7 t30 -95.2 161.2 14.2 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-O 120.958 0.409 . . . . 0.0 111.497 -176.088 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.406 ' HA ' ' HA ' ' A' ' 53' ' ' TYR . 59.6 t -98.77 134.58 37.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 C-N-CA 123.204 0.602 . . . . 0.0 110.151 -179.146 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 23.8 m -112.72 -15.22 10.4 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.545 0 N-CA-C 112.548 0.573 . . . . 0.0 112.548 -179.319 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.45 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -147.8 143.85 27.78 Favored 'General case' 0 C--O 1.239 0.52 0 C-N-CA 120.228 -0.589 . . . . 0.0 111.52 177.597 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 94.8 mt -141.84 124.96 15.06 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 -179.772 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . 0.4 HD21 ' HA ' ' A' ' 37' ' ' ASN . 1.0 OUTLIER -133.4 112.5 11.64 Favored 'General case' 0 C--N 1.311 -1.068 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 177.951 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.436 HG22 ' HB ' ' A' ' 103' ' ' ILE . 19.7 m -146.37 147.83 17.66 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.775 0 N-CA-C 112.202 0.445 . . . . 0.0 112.202 -174.388 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 69.2 tt0 -131.02 143.2 50.53 Favored 'General case' 0 CA--C 1.536 0.404 0 CA-C-N 115.692 -0.685 . . . . 0.0 109.629 176.768 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' SER . . . . . 0.415 ' HA ' ' O ' ' A' ' 46' ' ' THR . 22.1 p -71.13 147.64 48.2 Favored 'General case' 0 C--N 1.319 -0.754 0 N-CA-C 112.441 0.534 . . . . 0.0 112.441 179.633 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -97.87 -48.69 1.89 Allowed Glycine 0 N--CA 1.45 -0.403 0 N-CA-C 110.515 -1.034 . . . . 0.0 110.515 176.597 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 6.9 m-20 -97.26 -168.07 1.64 Allowed 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 175.783 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 28.3 m-20 -74.93 59.83 0.93 Allowed 'General case' 0 N--CA 1.469 0.501 0 CA-C-O 121.133 0.492 . . . . 0.0 111.947 -179.543 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 82.77 11.6 81.34 Favored Glycine 0 N--CA 1.452 -0.268 0 CA-C-N 115.976 -0.556 . . . . 0.0 112.75 177.477 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 63.1 tt0 -97.08 -30.51 13.0 Favored 'General case' 0 C--O 1.215 -0.715 0 C-N-CA 120.784 -0.366 . . . . 0.0 111.314 179.701 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' THR . . . . . 0.415 ' O ' ' HA ' ' A' ' 40' ' ' SER . 31.0 p -124.04 147.36 47.9 Favored 'General case' 0 C--N 1.308 -1.203 0 C-N-CA 120.818 -0.353 . . . . 0.0 110.801 -179.806 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . 0.439 ' HB2' ' HB1' ' A' ' 63' ' ' ALA . 94.1 mt -133.28 129.47 37.65 Favored 'General case' 0 C--N 1.318 -0.79 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 -179.7 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 51.3 m-80 -127.16 140.75 52.04 Favored 'General case' 0 C--N 1.311 -1.101 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 177.565 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 177.22 -157.75 22.8 Favored Glycine 0 N--CA 1.438 -1.197 0 C-N-CA 119.4 -1.381 . . . . 0.0 113.541 179.904 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 44.6 m -126.23 129.96 49.98 Favored 'General case' 0 N--CA 1.44 -0.973 0 CA-C-N 115.302 -0.449 . . . . 0.0 110.239 -177.272 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 19.0 ttm -110.78 141.93 43.43 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 109.69 -0.485 . . . . 0.0 109.69 179.089 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.45 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 36.2 m -126.29 122.38 35.33 Favored 'General case' 0 C--O 1.254 1.29 0 CA-C-O 120.956 0.408 . . . . 0.0 111.233 178.019 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . 0.517 ' HB2' ' HB2' ' A' ' 56' ' ' GLU . 78.6 m-85 -85.92 164.3 17.53 Favored 'General case' 0 C--O 1.231 0.127 0 CA-C-N 115.404 -0.816 . . . . 0.0 110.702 178.891 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -69.58 105.44 2.67 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.895 -179.515 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 86.44 8.43 77.61 Favored Glycine 0 CA--C 1.518 0.236 0 C-N-CA 121.013 -0.613 . . . . 0.0 112.943 176.711 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . 0.517 ' HB2' ' HB2' ' A' ' 53' ' ' TYR . 78.6 mm-40 -122.12 165.56 15.9 Favored 'General case' 0 C--N 1.315 -0.893 0 N-CA-C 110.012 -0.366 . . . . 0.0 110.012 -179.003 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -77.7 161.96 50.16 Favored Glycine 0 N--CA 1.446 -0.683 0 C-N-CA 120.663 -0.779 . . . . 0.0 112.086 178.51 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -72.73 145.87 42.03 Favored 'Trans proline' 0 C--O 1.241 0.645 0 C-N-CA 122.811 2.341 . . . . 0.0 112.716 179.835 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . 0.538 ' HB ' ' O ' ' A' ' 76' ' ' GLN . 49.7 pt -128.86 165.83 27.72 Favored 'Isoleucine or valine' 0 C--O 1.242 0.687 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.653 179.888 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -77.13 134.84 15.47 Favored Glycine 0 C--O 1.239 0.459 0 C-N-CA 120.897 -0.668 . . . . 0.0 111.819 -179.347 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 72.1 t80 -117.43 127.49 54.07 Favored 'General case' 0 C--O 1.237 0.443 0 C-N-CA 122.429 0.291 . . . . 0.0 111.24 -177.556 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 50.2 ttm-85 -130.29 127.75 40.14 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.016 -0.538 . . . . 0.0 109.86 176.699 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.439 ' HB1' ' HB2' ' A' ' 47' ' ' LEU . . . -132.05 139.87 48.69 Favored 'General case' 0 C--N 1.319 -0.741 0 C-N-CA 120.796 -0.362 . . . . 0.0 111.819 178.529 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 46.7 m -122.28 127.02 49.38 Favored 'General case' 0 CA--C 1.54 0.568 0 CA-C-N 115.879 -0.601 . . . . 0.0 110.005 178.201 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -74.5 119.77 19.15 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-O 121.053 0.454 . . . . 0.0 110.678 -178.118 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 91.7 mt -94.43 -25.14 17.04 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.669 -0.696 . . . . 0.0 109.962 178.368 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 134.57 157.5 8.14 Favored Glycine 0 N--CA 1.44 -1.044 0 CA-C-N 115.675 -0.693 . . . . 0.0 111.882 179.638 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 92.4 m-20 56.69 34.33 24.37 Favored 'General case' 0 N--CA 1.481 1.114 0 C-N-CA 122.463 0.305 . . . . 0.0 111.469 179.2 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . 0.534 ' ND2' ' HA3' ' A' ' 93' ' ' GLY . 21.8 m120 70.15 10.49 7.36 Favored 'General case' 0 N--CA 1.481 1.087 0 C-N-CA 123.522 0.729 . . . . 0.0 112.415 -179.407 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 55.8 m -87.72 122.31 31.22 Favored 'General case' 0 C--O 1.236 0.376 0 N-CA-C 110.015 -0.365 . . . . 0.0 110.015 177.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.555 ' OH ' ' HB3' ' A' ' 99' ' ' ASN . 70.8 m-85 -115.44 129.96 56.73 Favored 'General case' 0 C--N 1.311 -1.065 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.217 -179.643 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 52.2 tp10 -85.31 118.82 25.09 Favored 'General case' 0 N--CA 1.438 -1.064 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 174.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 68.0 t -106.98 132.75 53.52 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.23 0 N-CA-C 112.937 0.717 . . . . 0.0 112.937 -173.427 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -123.72 142.85 50.69 Favored 'General case' 0 N--CA 1.446 -0.645 0 N-CA-C 107.273 -1.381 . . . . 0.0 107.273 175.801 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 93.4 m-20 -134.71 161.24 35.71 Favored 'General case' 0 C--N 1.316 -0.851 0 C-N-CA 120.869 -0.332 . . . . 0.0 111.291 -174.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' GLN . . . . . 0.538 ' O ' ' HB ' ' A' ' 59' ' ' ILE . 2.9 pt20 -130.64 129.99 43.38 Favored 'General case' 0 C--O 1.239 0.543 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.159 177.006 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 6.6 p90 -133.96 151.19 51.38 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.91 -178.408 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 98.12 -1.96 59.45 Favored Glycine 0 N--CA 1.448 -0.54 0 C-N-CA 120.713 -0.756 . . . . 0.0 111.871 -179.614 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 140.99 164.62 9.99 Favored Glycine 0 N--CA 1.441 -1.031 0 C-N-CA 121.054 -0.593 . . . . 0.0 112.2 179.072 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -65.54 -33.0 74.89 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-O 121.248 0.546 . . . . 0.0 110.473 179.44 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 32.5 p -79.85 6.87 9.95 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.257 -0.883 . . . . 0.0 112.459 -178.055 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -83.89 146.64 49.56 Favored Pre-proline 0 C--N 1.316 -0.89 0 CA-C-N 116.698 -0.228 . . . . 0.0 110.527 179.668 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -67.92 173.73 8.8 Favored 'Trans proline' 0 C--N 1.345 0.353 0 C-N-CA 122.459 2.106 . . . . 0.0 111.604 178.855 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' TRP . . . . . . . . . . . . . 95.2 m95 -98.37 127.72 44.43 Favored 'General case' 0 N--CA 1.444 -0.751 0 CA-C-O 121.172 0.51 . . . . 0.0 110.248 -177.666 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 97.3 m-70 -115.7 149.69 38.0 Favored 'General case' 0 C--N 1.31 -1.116 0 CA-C-N 115.398 -0.819 . . . . 0.0 110.323 -177.629 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 10.0 m -61.53 130.25 45.06 Favored 'General case' 0 C--N 1.315 -0.925 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.833 -179.562 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -105.08 -52.68 0.82 Allowed Glycine 0 N--CA 1.439 -1.107 0 C-N-CA 120.913 -0.66 . . . . 0.0 111.634 179.43 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 155.68 -172.52 33.75 Favored Glycine 0 C--O 1.22 -0.753 0 C-N-CA 120.596 -0.811 . . . . 0.0 111.774 179.605 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 21.2 t-20 -110.28 112.08 23.8 Favored 'General case' 0 C--N 1.313 -1.009 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 179.512 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 27.4 m0 -102.4 149.8 23.99 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.993 -177.749 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 47.4 mm -107.17 114.02 45.04 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 177.247 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . 0.406 ' HB2' ' CE1' ' A' ' 71' ' ' TYR . 85.0 mt -124.25 89.25 3.05 Favored 'General case' 0 C--O 1.272 2.279 0 CA-C-O 121.725 0.774 . . . . 0.0 112.691 -175.796 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . 0.534 ' HA3' ' ND2' ' A' ' 69' ' ' ASN . . . 154.86 116.91 0.58 Allowed Glycine 0 N--CA 1.443 -0.876 0 CA-C-N 115.0 -1.0 . . . . 0.0 111.676 178.911 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' SER . . . . . 0.406 ' N ' ' HE1' ' A' ' 23' ' ' TRP . 76.8 p -86.0 -15.28 41.95 Favored 'General case' 0 CA--C 1.516 -0.355 0 CA-C-O 121.395 0.617 . . . . 0.0 109.913 178.849 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 58.4 mtt-85 -88.91 141.85 28.14 Favored 'General case' 0 N--CA 1.435 -1.185 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.004 -179.93 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 8.9 pt-20 -68.65 -33.11 73.43 Favored 'General case' 0 C--N 1.31 -1.117 0 CA-C-N 115.53 -0.759 . . . . 0.0 111.975 -175.376 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 31.3 p-10 -120.75 28.66 7.82 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 111.788 0.292 . . . . 0.0 111.788 -178.117 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' GLN . . . . . 0.458 ' OE1' ' HG2' ' A' ' 123' ' ' GLU . 0.0 OUTLIER -142.78 118.48 10.46 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 112.326 0.491 . . . . 0.0 112.326 -176.672 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' ASN . . . . . 0.555 ' HB3' ' OH ' ' A' ' 71' ' ' TYR . 93.2 m-20 -89.36 157.86 18.01 Favored 'General case' 0 C--O 1.262 1.755 0 CA-C-N 115.724 -0.671 . . . . 0.0 111.166 177.673 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . 0.443 HG21 ' CH2' ' A' ' 23' ' ' TRP . 85.9 t -84.35 134.14 27.66 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.594 0 CA-C-N 115.355 -0.839 . . . . 0.0 111.705 178.445 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 35.8 m -110.66 -29.03 2.49 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.397 0 CA-C-N 116.035 -0.529 . . . . 0.0 112.275 179.765 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . 0.422 ' HB2' ' HB ' ' A' ' 119' ' ' THR . . . -146.24 139.37 25.77 Favored 'General case' 0 C--N 1.323 -0.585 0 C-N-CA 120.2 -0.6 . . . . 0.0 111.144 179.056 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.436 ' HB ' HG22 ' A' ' 38' ' ' VAL . 94.9 mt -131.62 124.95 55.19 Favored 'Isoleucine or valine' 0 C--O 1.244 0.771 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.57 177.796 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 41.2 t30 -125.17 94.56 4.2 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 115.676 -0.693 . . . . 0.0 109.3 175.586 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 29.3 m -133.6 135.82 55.2 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 N-CA-C 112.859 0.689 . . . . 0.0 112.859 -176.538 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 75.3 tt0 -140.15 137.55 34.51 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.415 -0.811 . . . . 0.0 110.13 179.639 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 23.2 t -146.93 145.37 29.77 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 116.468 -0.333 . . . . 0.0 110.459 177.211 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -109.18 17.07 32.12 Favored Glycine 0 N--CA 1.447 -0.609 0 C-N-CA 121.11 -0.567 . . . . 0.0 112.435 -179.195 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 40.3 p-10 -91.91 -153.61 0.34 Allowed 'General case' 0 C--N 1.319 -0.753 0 CA-C-O 120.768 0.318 . . . . 0.0 110.158 179.098 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 37.1 t70 -88.94 12.86 14.19 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-O 121.167 0.508 . . . . 0.0 110.071 179.108 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 85.7 7.39 81.68 Favored Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 120.684 -0.769 . . . . 0.0 111.939 -177.173 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 36.5 tt0 -66.57 -38.78 87.79 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-O 121.109 0.481 . . . . 0.0 110.526 -179.671 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' THR . . . . . 0.419 ' HA ' ' O ' ' A' ' 130' ' ' GLY . 27.5 p -124.63 131.73 53.46 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-N 115.906 -0.588 . . . . 0.0 111.056 179.224 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -109.94 113.32 25.96 Favored 'General case' 0 C--N 1.315 -0.927 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 177.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 93.8 m-20 -117.23 147.5 42.46 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-O 121.016 0.436 . . . . 0.0 111.26 -177.941 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 159.57 -135.61 4.22 Favored Glycine 0 N--CA 1.434 -1.457 0 C-N-CA 120.458 -0.877 . . . . 0.0 112.906 177.717 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 20.8 p -134.04 157.97 44.76 Favored 'General case' 0 C--N 1.31 -1.143 0 C-N-CA 122.905 0.482 . . . . 0.0 110.316 -177.786 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 17.3 ptm -149.63 155.24 39.92 Favored 'General case' 0 C--N 1.312 -1.063 0 CA-C-N 116.498 -0.319 . . . . 0.0 110.391 -179.672 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 119' ' ' THR . . . . . 0.422 ' HB ' ' HB2' ' A' ' 102' ' ' ALA . 27.9 m -130.76 128.11 40.11 Favored 'General case' 0 C--O 1.249 1.055 0 CA-C-N 116.474 -0.33 . . . . 0.0 111.224 179.804 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 31.0 m-85 -89.85 166.02 13.77 Favored 'General case' 0 CA--C 1.507 -0.687 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.294 175.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . 0.419 ' HB3' HE22 ' A' ' 98' ' ' GLN . . . -66.47 45.38 0.03 OUTLIER 'General case' 0 CA--C 1.554 1.126 0 N-CA-C 114.043 1.127 . . . . 0.0 114.043 179.79 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 142.44 -25.63 2.31 Favored Glycine 0 C--N 1.334 0.429 0 C-N-CA 119.874 -1.155 . . . . 0.0 114.405 175.372 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . 0.458 ' HG2' ' OE1' ' A' ' 98' ' ' GLN . 69.4 mm-40 -67.33 -33.36 75.09 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 117.311 0.556 . . . . 0.0 112.424 -177.585 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 115.09 161.69 13.34 Favored Glycine 0 CA--C 1.519 0.334 0 C-N-CA 120.585 -0.817 . . . . 0.0 112.361 -179.542 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 20.8 Cg_exo -67.11 129.36 20.39 Favored 'Trans proline' 0 C--N 1.351 0.673 0 C-N-CA 122.782 2.321 . . . . 0.0 111.991 178.386 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 37.4 pt -135.44 161.73 38.71 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.691 179.592 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -69.8 139.25 31.17 Favored Glycine 0 C--O 1.239 0.453 0 C-N-CA 120.923 -0.656 . . . . 0.0 112.26 178.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 86.4 t80 -119.52 133.71 55.55 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 120.745 0.307 . . . . 0.0 111.233 -178.465 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 129' ' ' LYS . . . . . 0.408 ' HB3' ' HB2' ' A' ' 7' ' ' GLU . 63.6 tttm -140.99 118.12 11.27 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.911 -0.586 . . . . 0.0 109.519 176.718 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . 0.419 ' O ' ' HA ' ' A' ' 113' ' ' THR . . . -122.18 141.96 14.63 Favored Glycine 0 N--CA 1.449 -0.475 0 C-N-CA 120.735 -0.745 . . . . 0.0 111.941 -179.643 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 62.1 m -128.11 135.65 50.08 Favored 'General case' 0 C--N 1.317 -0.818 0 CA-C-N 116.619 0.21 . . . . 0.0 111.392 -179.585 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 3.4 tm? -57.79 138.26 55.77 Favored 'General case' 0 N--CA 1.467 0.392 0 C-N-CA 123.062 0.545 . . . . 0.0 110.391 179.723 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 24.0 m . . . . . 0 C--O 1.247 0.964 0 CA-C-O 118.503 -0.761 . . . . 0.0 110.322 -178.577 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.238 0.449 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . 0.513 HD13 ' NE2' ' A' ' 22' ' ' GLN . 3.1 tm? -90.76 128.68 36.77 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-O 120.855 0.359 . . . . 0.0 110.099 -179.914 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . 0.412 ' CD1' ' HB ' ' A' ' 25' ' ' ILE . 57.4 m-85 -119.65 143.07 47.91 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.142 178.1 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 12.9 m-80 -97.24 135.52 39.05 Favored 'General case' 0 C--N 1.309 -1.159 0 N-CA-C 108.394 -0.965 . . . . 0.0 108.394 175.689 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 53.5 t -111.36 126.65 68.76 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.862 0 CA-C-O 121.803 0.811 . . . . 0.0 112.627 -174.769 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.42 ' HG2' ' HB3' ' A' ' 19' ' ' GLU . 63.6 mt-10 -118.82 133.18 56.02 Favored 'General case' 0 N--CA 1.438 -1.047 0 CA-C-N 114.684 -1.144 . . . . 0.0 108.5 176.665 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . 0.443 ' HA ' ' O ' ' A' ' 127' ' ' GLY . 13.0 m120 -117.89 139.76 50.67 Favored 'General case' 0 C--N 1.313 -1.004 0 CA-C-O 121.072 0.463 . . . . 0.0 111.424 -176.641 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . 0.423 ' HB2' ' CE3' ' A' ' 17' ' ' TRP . 28.1 tt0 -132.6 125.86 31.43 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.059 179.131 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 24.1 p90 -128.98 141.29 51.3 Favored 'General case' 0 C--N 1.316 -0.853 0 C-N-CA 120.607 -0.437 . . . . 0.0 111.265 -179.048 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 115.77 -77.72 0.27 Allowed Glycine 0 N--CA 1.442 -0.936 0 CA-C-N 115.562 -0.744 . . . . 0.0 111.794 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -170.34 173.62 44.3 Favored Glycine 0 N--CA 1.442 -0.953 0 C-N-CA 121.085 -0.579 . . . . 0.0 111.725 -179.579 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 26.2 t -59.25 -23.8 62.65 Favored 'General case' 0 CA--C 1.538 0.506 0 N-CA-C 111.881 0.326 . . . . 0.0 111.881 -179.729 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 23.5 p -65.23 -19.65 66.07 Favored 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 112.009 0.374 . . . . 0.0 112.009 177.823 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -93.09 146.91 32.84 Favored Pre-proline 0 N--CA 1.446 -0.671 0 N-CA-C 109.978 -0.379 . . . . 0.0 109.978 179.414 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_endo -79.41 173.27 13.39 Favored 'Trans proline' 0 CA--C 1.537 0.652 0 C-N-CA 122.723 2.282 . . . . 0.0 112.869 179.457 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . 0.423 ' CE3' ' HB2' ' A' ' 9' ' ' GLN . 95.5 m95 -87.14 131.24 34.22 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.938 -0.573 . . . . 0.0 109.795 178.741 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 46.5 m-80 -114.37 118.62 34.36 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.937 -178.395 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.42 ' HB3' ' HG2' ' A' ' 7' ' ' GLU . 10.9 pt-20 -82.7 124.75 30.51 Favored 'General case' 0 C--N 1.315 -0.897 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.499 179.236 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.428 ' O ' ' HB2' ' A' ' 94' ' ' SER . . . -132.46 29.93 3.22 Favored Glycine 0 N--CA 1.442 -0.963 0 C-N-CA 120.069 -1.062 . . . . 0.0 112.838 -177.709 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 140.96 -175.12 22.36 Favored Glycine 0 N--CA 1.442 -0.907 0 C-N-CA 120.25 -0.976 . . . . 0.0 112.819 178.818 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . 0.513 ' NE2' HD13 ' A' ' 3' ' ' LEU . 18.5 pt20 -141.46 153.05 44.74 Favored 'General case' 0 C--N 1.313 -1.01 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 179.812 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . 0.424 ' HB3' ' O ' ' A' ' 91' ' ' ILE . 45.0 m0 -127.68 174.7 8.87 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.543 -0.299 . . . . 0.0 110.787 -176.086 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 79.6 tt0 -121.01 118.11 28.97 Favored 'General case' 0 CA--C 1.51 -0.57 0 C-N-CA 120.624 -0.43 . . . . 0.0 109.902 176.776 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.412 ' HB ' ' CD1' ' A' ' 4' ' ' TYR . 98.3 mt -131.53 140.14 49.01 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.774 0 CA-C-N 115.816 -0.629 . . . . 0.0 109.609 -178.762 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 86.15 66.64 1.39 Allowed Glycine 0 N--CA 1.443 -0.886 0 C-N-CA 120.34 -0.933 . . . . 0.0 112.544 178.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 19.2 p -59.78 -36.88 77.61 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 121.131 0.491 . . . . 0.0 110.239 177.744 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 93.5 mtt-85 -94.88 108.23 20.26 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 175.233 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 51.0 m -73.7 -7.87 53.76 Favored 'General case' 0 C--N 1.321 -0.671 0 N-CA-C 113.082 0.771 . . . . 0.0 113.082 -174.761 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 97.9 m-20 -76.81 -18.76 58.21 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.906 0.384 . . . . 0.0 110.996 179.854 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . 0.512 ' NE2' ' HA ' ' A' ' 31' ' ' GLN . 7.2 mm-40 -133.53 114.83 14.02 Favored 'General case' 0 CA--C 1.51 -0.561 0 N-CA-C 112.589 0.589 . . . . 0.0 112.589 -178.741 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . 0.537 ' ND2' ' HA3' ' A' ' 111' ' ' GLY . 2.6 t30 -82.21 142.43 32.16 Favored 'General case' 0 C--O 1.242 0.7 0 CA-C-N 116.011 -0.541 . . . . 0.0 110.043 179.369 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 47.0 t -92.37 129.75 42.51 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 CA-C-N 115.507 -0.77 . . . . 0.0 109.857 -178.331 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.43 ' HB ' ' O ' ' A' ' 107' ' ' SER . 30.5 m -110.13 -21.15 5.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 N-CA-C 112.38 0.511 . . . . 0.0 112.38 -179.925 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.451 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -144.85 143.13 30.46 Favored 'General case' 0 C--N 1.322 -0.605 0 C-N-CA 119.816 -0.753 . . . . 0.0 111.85 179.319 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.412 ' C ' HD21 ' A' ' 37' ' ' ASN . 91.5 mt -142.08 119.38 7.47 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 CA-C-N 115.48 -0.782 . . . . 0.0 109.061 179.802 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . 0.412 HD21 ' C ' ' A' ' 36' ' ' ILE . 0.9 OUTLIER -126.4 109.92 12.76 Favored 'General case' 0 C--N 1.306 -1.32 0 N-CA-C 108.389 -0.967 . . . . 0.0 108.389 176.506 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.445 HG13 ' CD2' ' A' ' 61' ' ' PHE . 29.5 m -148.26 153.42 11.54 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.63 0 N-CA-C 112.111 0.411 . . . . 0.0 112.111 -173.753 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 -146.35 148.34 32.26 Favored 'General case' 0 C--O 1.245 0.82 0 CA-C-N 115.431 -0.804 . . . . 0.0 109.299 174.778 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' SER . . . . . 0.461 ' HB3' ' CD2' ' A' ' 47' ' ' LEU . 37.1 p -80.49 151.54 29.18 Favored 'General case' 0 C--N 1.313 -1.014 0 CA-C-O 121.496 0.665 . . . . 0.0 112.511 -176.88 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -92.76 -13.26 56.99 Favored Glycine 0 N--CA 1.438 -1.168 0 N-CA-C 110.084 -1.206 . . . . 0.0 110.084 173.281 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 28.3 m-20 -137.33 -155.16 0.59 Allowed 'General case' 0 N--CA 1.468 0.445 0 C-N-CA 123.203 0.601 . . . . 0.0 109.403 -179.34 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -79.4 42.12 0.49 Allowed 'General case' 0 N--CA 1.47 0.572 0 CA-C-O 121.099 0.476 . . . . 0.0 110.725 178.117 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 91.43 3.82 68.84 Favored Glycine 0 C--O 1.22 -0.743 0 C-N-CA 121.025 -0.607 . . . . 0.0 112.881 -178.834 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 55.9 tp60 -63.97 -47.67 79.48 Favored 'General case' 0 N--CA 1.462 0.17 0 CA-C-O 120.903 0.382 . . . . 0.0 111.016 179.575 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 9.4 t -133.32 127.75 34.23 Favored 'General case' 0 C--N 1.312 -1.059 0 C-N-CA 120.72 -0.392 . . . . 0.0 110.113 177.551 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . 0.461 ' CD2' ' HB3' ' A' ' 40' ' ' SER . 64.9 mt -109.08 127.96 54.58 Favored 'General case' 0 N--CA 1.447 -0.618 0 N-CA-C 109.662 -0.496 . . . . 0.0 109.662 179.636 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 65.2 m-80 -121.97 147.1 46.47 Favored 'General case' 0 C--N 1.313 -0.982 0 N-CA-C 109.558 -0.534 . . . . 0.0 109.558 176.8 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 176.13 -154.4 16.88 Favored Glycine 0 N--CA 1.433 -1.557 0 C-N-CA 119.925 -1.131 . . . . 0.0 113.064 179.602 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 89.9 m -129.35 130.7 46.39 Favored 'General case' 0 N--CA 1.436 -1.159 0 C-N-CA 122.668 0.387 . . . . 0.0 111.13 -177.483 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 44.9 mtp -110.08 151.27 27.42 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.394 -0.367 . . . . 0.0 110.927 177.846 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.451 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 23.7 m -132.84 127.77 35.2 Favored 'General case' 0 C--N 1.315 -0.898 0 N-CA-C 110.185 -0.302 . . . . 0.0 110.185 176.009 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . 0.436 ' CD1' ' HB3' ' A' ' 31' ' ' GLN . 83.6 m-85 -92.48 163.21 13.91 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.867 178.721 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -61.31 103.36 0.29 Allowed 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.969 -178.553 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 94.77 -6.59 70.24 Favored Glycine 0 CA--C 1.51 -0.258 0 C-N-CA 120.863 -0.684 . . . . 0.0 113.267 177.975 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 69.8 mm-40 -104.82 -179.24 3.89 Favored 'General case' 0 C--N 1.311 -1.102 0 CA-C-O 120.709 0.29 . . . . 0.0 110.836 -178.347 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -99.06 173.73 26.86 Favored Glycine 0 N--CA 1.444 -0.796 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.33 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -68.66 139.38 44.08 Favored 'Trans proline' 0 CA--C 1.538 0.709 0 C-N-CA 122.818 2.345 . . . . 0.0 112.588 179.503 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 50.2 pt -131.93 167.17 27.0 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.079 178.372 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -78.53 139.09 21.92 Favored Glycine 0 N--CA 1.446 -0.677 0 N-CA-C 111.019 -0.832 . . . . 0.0 111.019 179.459 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.445 ' CD2' HG13 ' A' ' 38' ' ' VAL . 29.1 t80 -131.31 129.71 41.82 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 120.953 0.406 . . . . 0.0 111.583 -177.479 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 55.4 ttm-85 -127.11 130.06 49.13 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.514 -0.766 . . . . 0.0 110.493 178.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.426 ' HB2' ' HB3' ' A' ' 71' ' ' TYR . . . -129.27 132.32 47.16 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-O 120.594 0.235 . . . . 0.0 110.796 177.175 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 85.3 m -117.31 125.47 51.12 Favored 'General case' 0 C--N 1.316 -0.861 0 CA-C-O 120.996 0.427 . . . . 0.0 110.74 179.637 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . 0.484 ' HG ' ' N ' ' A' ' 67' ' ' GLY . 66.6 tp -71.52 132.89 45.36 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.759 -0.655 . . . . 0.0 112.544 -177.579 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -85.94 -16.15 39.33 Favored 'General case' 0 N--CA 1.471 0.577 0 CA-C-N 115.29 -0.868 . . . . 0.0 109.898 174.743 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.484 ' N ' ' HG ' ' A' ' 65' ' ' LEU . . . 103.7 7.61 41.68 Favored Glycine 0 N--CA 1.463 0.44 0 CA-C-N 115.527 -0.76 . . . . 0.0 112.7 177.471 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 29.7 p-10 -137.73 39.65 2.39 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-O 120.851 0.358 . . . . 0.0 110.592 -179.331 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 89.0 m-20 68.9 -1.72 1.96 Allowed 'General case' 0 N--CA 1.485 1.281 0 C-N-CA 123.528 0.731 . . . . 0.0 112.128 -178.558 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 15.3 m -91.82 132.23 36.59 Favored 'General case' 0 C--N 1.314 -0.948 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 177.456 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.442 ' CE1' ' HB2' ' A' ' 92' ' ' LEU . 79.1 m-85 -124.09 133.96 53.49 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.741 -179.25 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 79.9 tt0 -87.13 123.6 32.35 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 174.691 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 48.8 t -99.37 128.61 50.92 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 N-CA-C 112.826 0.676 . . . . 0.0 112.826 -175.656 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 75.4 mt-10 -127.19 121.81 32.34 Favored 'General case' 0 CA--C 1.535 0.378 0 CA-C-N 114.794 -1.094 . . . . 0.0 108.467 175.194 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' ASN . . . . . 0.423 ' OD1' ' HD1' ' A' ' 61' ' ' PHE . 96.4 m-20 -108.42 153.01 23.91 Favored 'General case' 0 C--O 1.236 0.393 0 N-CA-C 112.56 0.578 . . . . 0.0 112.56 -176.283 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 60.2 tt0 -127.72 125.55 40.19 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.358 -0.837 . . . . 0.0 109.389 -179.775 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 6.6 p90 -127.29 4.4 6.33 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 112.734 0.642 . . . . 0.0 112.734 -178.246 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -84.74 -1.88 88.87 Favored Glycine 0 CA--C 1.521 0.415 0 C-N-CA 120.561 -0.828 . . . . 0.0 111.954 178.242 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 106.14 -153.83 16.99 Favored Glycine 0 CA--C 1.497 -1.037 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 -179.717 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -62.43 -32.54 73.41 Favored 'General case' 0 CA--C 1.514 -0.422 0 CA-C-N 117.675 0.738 . . . . 0.0 109.217 173.827 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 47.7 m -84.78 -175.35 5.74 Favored 'General case' 0 N--CA 1.438 -1.04 0 CA-C-N 114.947 -1.024 . . . . 0.0 110.016 176.588 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 75.78 147.22 0.12 Allowed Pre-proline 0 N--CA 1.471 0.578 0 C-N-CA 123.997 0.919 . . . . 0.0 111.701 -179.445 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -73.76 169.19 22.95 Favored 'Trans proline' 0 C--O 1.238 0.508 0 C-N-CA 122.874 2.383 . . . . 0.0 111.807 178.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' TRP . . . . . . . . . . . . . 82.7 m95 -87.87 145.65 25.96 Favored 'General case' 0 N--CA 1.447 -0.589 0 N-CA-C 109.524 -0.547 . . . . 0.0 109.524 -179.911 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 94.3 m-70 -116.97 143.38 45.78 Favored 'General case' 0 C--N 1.317 -0.836 0 N-CA-C 110.033 -0.358 . . . . 0.0 110.033 -179.551 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 13.5 m -63.01 137.02 58.14 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-O 120.802 0.334 . . . . 0.0 110.904 -178.748 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -112.83 -48.92 0.6 Allowed Glycine 0 N--CA 1.447 -0.573 0 C-N-CA 121.228 -0.511 . . . . 0.0 112.371 -179.632 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 152.95 -167.95 31.75 Favored Glycine 0 C--O 1.214 -1.155 0 C-N-CA 120.257 -0.973 . . . . 0.0 112.121 179.201 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 16.1 m120 -111.99 118.88 36.67 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 117.082 0.441 . . . . 0.0 110.488 179.868 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 27.4 m0 -111.01 155.27 22.98 Favored 'General case' 0 C--N 1.321 -0.651 0 N-CA-C 110.25 -0.278 . . . . 0.0 110.25 -179.306 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . 0.424 ' O ' ' HB3' ' A' ' 23' ' ' TRP . 49.2 mm -110.93 116.61 52.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 N-CA-C 109.179 -0.674 . . . . 0.0 109.179 177.893 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . 0.442 ' HB2' ' CE1' ' A' ' 71' ' ' TYR . 77.9 mt -128.98 81.72 2.04 Favored 'General case' 0 C--O 1.272 2.267 0 CA-C-O 121.772 0.796 . . . . 0.0 112.069 -177.996 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 166.22 112.61 0.26 Allowed Glycine 0 N--CA 1.442 -0.92 0 CA-C-N 115.222 -0.899 . . . . 0.0 111.771 179.159 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' SER . . . . . 0.428 ' HB2' ' O ' ' A' ' 20' ' ' GLY . 77.4 p -86.01 -10.94 54.19 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 121.277 0.56 . . . . 0.0 110.761 179.887 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 98.6 mtt180 -111.44 154.24 24.96 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.556 -0.747 . . . . 0.0 109.413 -179.702 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -70.65 -53.19 16.75 Favored 'General case' 0 N--CA 1.472 0.669 0 N-CA-C 113.501 0.926 . . . . 0.0 113.501 -172.348 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 94.8 m-20 -115.0 36.47 3.86 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.75 0.31 . . . . 0.0 111.4 -176.769 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' GLN . . . . . . . . . . . . . 38.1 tp60 -103.47 -59.42 1.72 Allowed 'General case' 0 C--N 1.316 -0.853 0 C-N-CA 120.484 -0.486 . . . . 0.0 110.651 -178.681 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 88.8 m-20 74.62 133.72 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.599 0 O-C-N 123.894 0.746 . . . . 0.0 111.812 177.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . 0.409 HG23 ' CH2' ' A' ' 23' ' ' TRP . 73.6 t -80.35 133.24 29.96 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.489 0 C-N-CA 120.094 -0.642 . . . . 0.0 111.736 178.727 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 26.8 m -111.19 -31.93 2.24 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.487 0 N-CA-C 112.73 0.641 . . . . 0.0 112.73 -179.621 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -146.57 138.18 24.55 Favored 'General case' 0 C--N 1.324 -0.537 0 C-N-CA 119.809 -0.756 . . . . 0.0 111.625 179.721 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.423 ' HB ' HG22 ' A' ' 38' ' ' VAL . 96.1 mt -131.85 126.32 56.86 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.124 178.019 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 41.9 t30 -126.18 99.17 5.77 Favored 'General case' 0 C--N 1.314 -0.935 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 174.772 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.436 HG13 ' CD2' ' A' ' 128' ' ' PHE . 30.2 m -139.82 140.52 36.0 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.091 0 CA-C-N 115.85 -0.614 . . . . 0.0 111.78 -175.715 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 81.5 tt0 -144.2 145.58 32.16 Favored 'General case' 0 C--N 1.315 -0.924 0 CA-C-N 115.774 -0.648 . . . . 0.0 109.977 178.051 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' SER . . . . . 0.539 ' HB2' ' OD1' ' A' ' 109' ' ' ASP . 21.6 p -152.71 152.93 32.27 Favored 'General case' 0 C--N 1.312 -1.039 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.559 178.143 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -130.53 15.46 5.49 Favored Glycine 0 CA--C 1.505 -0.538 0 N-CA-C 111.105 -0.798 . . . . 0.0 111.105 178.888 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . 0.539 ' OD1' ' HB2' ' A' ' 107' ' ' SER . 10.4 p-10 -96.23 22.82 7.23 Favored 'General case' 0 C--N 1.316 -0.859 0 C-N-CA 123.167 0.587 . . . . 0.0 110.5 -179.521 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . 0.52 ' HB2' ' O ' ' A' ' 109' ' ' ASP . 4.2 m-20 81.94 10.42 0.76 Allowed 'General case' 0 N--CA 1.486 1.366 0 C-N-CA 124.131 0.972 . . . . 0.0 112.282 -179.944 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . 0.537 ' HA3' ' ND2' ' A' ' 32' ' ' ASN . . . 88.12 12.59 65.45 Favored Glycine 0 N--CA 1.446 -0.661 0 C-N-CA 119.999 -1.096 . . . . 0.0 113.718 176.402 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 98.2 mt-30 -71.74 -38.74 70.39 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 117.046 0.423 . . . . 0.0 110.591 179.178 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 12.7 p -131.18 109.94 10.79 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.928 175.952 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 6.1 mp -92.07 113.55 25.85 Favored 'General case' 0 C--N 1.319 -0.722 0 N-CA-C 109.767 -0.456 . . . . 0.0 109.767 179.713 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 54.3 m-80 -108.3 145.54 34.24 Favored 'General case' 0 C--N 1.311 -1.079 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.836 -178.431 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 166.33 -139.29 5.68 Favored Glycine 0 N--CA 1.433 -1.508 0 C-N-CA 120.121 -1.038 . . . . 0.0 112.996 177.881 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 41.2 p -137.72 160.9 37.96 Favored 'General case' 0 C--N 1.31 -1.145 0 C-N-CA 123.429 0.692 . . . . 0.0 109.924 -177.75 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 19.8 ptm -149.29 161.49 41.94 Favored 'General case' 0 C--N 1.311 -1.087 0 CA-C-O 120.729 0.299 . . . . 0.0 110.698 179.302 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 23.5 m -135.39 133.15 38.39 Favored 'General case' 0 C--O 1.246 0.892 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.473 -179.813 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 12.3 m-85 -99.81 158.81 15.53 Favored 'General case' 0 CA--C 1.515 -0.398 0 CA-C-N 115.946 -0.57 . . . . 0.0 109.798 176.618 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -61.07 122.66 15.54 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 120.608 0.242 . . . . 0.0 111.495 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 68.73 27.86 73.54 Favored Glycine 0 C--N 1.338 0.673 0 CA-C-N 115.969 -0.559 . . . . 0.0 113.243 179.847 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 80.4 tt0 -142.58 155.87 45.03 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 116.872 0.336 . . . . 0.0 110.389 -178.014 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -77.69 161.32 49.66 Favored Glycine 0 CA--C 1.521 0.441 0 C-N-CA 121.169 -0.539 . . . . 0.0 112.707 -178.907 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 23.1 Cg_exo -64.05 141.66 77.81 Favored 'Trans proline' 0 C--N 1.345 0.357 0 C-N-CA 122.802 2.334 . . . . 0.0 112.756 -179.564 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 35.9 pt -133.07 157.83 43.02 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.994 0 CA-C-N 115.402 -0.817 . . . . 0.0 109.763 178.321 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . 0.443 ' O ' ' HA ' ' A' ' 8' ' ' ASN . . . -70.32 139.5 30.78 Favored Glycine 0 C--O 1.235 0.209 0 C-N-CA 121.096 -0.574 . . . . 0.0 112.083 179.042 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . 0.436 ' CD2' HG13 ' A' ' 105' ' ' VAL . 73.0 t80 -119.05 133.53 55.75 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-O 120.887 0.375 . . . . 0.0 111.221 -177.109 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 62.7 tttm -136.19 105.42 6.0 Favored 'General case' 0 C--N 1.313 -0.986 0 CA-C-N 115.676 -0.693 . . . . 0.0 109.767 176.401 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -100.66 131.16 10.47 Favored Glycine 0 N--CA 1.439 -1.153 0 N-CA-C 110.696 -0.962 . . . . 0.0 110.696 178.917 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 28.5 m -122.24 130.53 53.26 Favored 'General case' 0 C--N 1.312 -1.039 0 N-CA-C 110.007 -0.368 . . . . 0.0 110.007 -179.139 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 132' ' ' LEU . . . . . 0.404 HD23 ' CZ ' ' A' ' 4' ' ' TYR . 3.3 tm? -67.11 135.21 53.25 Favored 'General case' 0 C--O 1.236 0.373 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.231 -178.022 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 26.6 m . . . . . 0 N--CA 1.435 -1.185 0 CA-C-O 118.18 -0.914 . . . . 0.0 109.569 -179.372 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.784 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -147.14 123.2 10.77 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 -177.783 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . 0.417 ' CD1' ' HB ' ' A' ' 25' ' ' ILE . 59.2 m-85 -118.24 141.41 48.54 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 112.351 0.5 . . . . 0.0 112.351 -178.134 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 49.3 m-80 -88.68 139.07 30.85 Favored 'General case' 0 C--N 1.316 -0.883 0 N-CA-C 107.763 -1.199 . . . . 0.0 107.763 174.858 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.454 HG22 ' CD1' ' A' ' 23' ' ' TRP . 87.3 t -99.38 115.54 40.4 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.02 0 CA-C-O 121.146 0.498 . . . . 0.0 112.323 -175.0 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.449 ' HB2' ' HB3' ' A' ' 129' ' ' LYS . 42.4 mt-10 -113.99 119.53 37.52 Favored 'General case' 0 C--N 1.311 -1.088 0 CA-C-N 115.025 -0.989 . . . . 0.0 108.58 177.329 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 13.6 m120 -119.01 136.48 54.1 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 116.571 -0.286 . . . . 0.0 110.752 -177.504 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 58.9 tt0 -124.09 128.29 49.08 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-O 120.866 0.365 . . . . 0.0 110.839 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 14.6 p90 -141.49 148.02 38.78 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 116.153 -0.476 . . . . 0.0 109.993 177.043 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 100.89 2.1 55.08 Favored Glycine 0 N--CA 1.449 -0.47 0 C-N-CA 120.37 -0.919 . . . . 0.0 112.268 178.889 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 114.56 155.83 11.29 Favored Glycine 0 N--CA 1.441 -0.991 0 C-N-CA 120.903 -0.665 . . . . 0.0 112.442 179.543 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 7.6 t -59.1 -20.13 50.69 Favored 'General case' 0 CA--C 1.539 0.54 0 C-N-CA 122.746 0.418 . . . . 0.0 111.616 179.008 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 10.2 m -77.78 -10.01 59.32 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.765 0.317 . . . . 0.0 111.027 179.748 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -89.97 152.09 45.96 Favored Pre-proline 0 C--N 1.325 -0.494 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 179.467 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 78.9 Cg_endo -73.69 161.19 42.43 Favored 'Trans proline' 0 C--O 1.237 0.429 0 C-N-CA 122.625 2.217 . . . . 0.0 112.917 179.765 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 82.7 m95 -85.94 134.7 33.86 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 115.546 -0.752 . . . . 0.0 109.095 178.419 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 46.9 m-80 -113.54 141.68 46.87 Favored 'General case' 0 C--N 1.32 -0.701 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 -177.596 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 9.2 pt-20 -116.53 122.48 44.81 Favored 'General case' 0 C--N 1.308 -1.221 0 CA-C-O 120.734 0.302 . . . . 0.0 110.455 -178.929 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -137.23 31.64 2.51 Favored Glycine 0 N--CA 1.444 -0.793 0 C-N-CA 119.814 -1.184 . . . . 0.0 113.133 -177.255 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 162.68 179.68 37.41 Favored Glycine 0 N--CA 1.447 -0.58 0 C-N-CA 119.745 -1.217 . . . . 0.0 113.015 179.767 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 4.5 pt20 -136.99 137.03 39.02 Favored 'General case' 0 C--N 1.32 -0.714 0 N-CA-C 109.419 -0.586 . . . . 0.0 109.419 178.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . 0.454 ' CD1' HG22 ' A' ' 6' ' ' VAL . 38.7 m0 -109.31 151.62 26.34 Favored 'General case' 0 CA--C 1.502 -0.873 0 CA-C-O 120.866 0.365 . . . . 0.0 111.23 -178.513 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 79.1 tt0 -108.86 110.88 22.34 Favored 'General case' 0 N--CA 1.44 -0.926 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 177.689 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.417 ' HB ' ' CD1' ' A' ' 4' ' ' TYR . 89.8 mt -127.79 136.5 60.19 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.892 0 CA-C-N 115.395 -0.82 . . . . 0.0 109.803 -176.679 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 90.86 93.44 1.27 Allowed Glycine 0 N--CA 1.444 -0.795 0 C-N-CA 120.67 -0.776 . . . . 0.0 112.499 177.653 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 3.7 p -94.92 10.2 36.37 Favored 'General case' 0 C--N 1.311 -1.084 0 CA-C-O 121.432 0.634 . . . . 0.0 110.38 178.795 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 39.4 mmt180 -124.84 121.05 33.44 Favored 'General case' 0 N--CA 1.445 -0.682 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 -179.88 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 43.6 m -65.95 -38.85 89.67 Favored 'General case' 0 C--N 1.314 -0.948 0 N-CA-C 112.13 0.418 . . . . 0.0 112.13 -178.205 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 75.0 m-20 -75.05 -38.44 61.4 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 112.345 0.498 . . . . 0.0 112.345 -177.047 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . 0.476 ' NE2' ' HA ' ' A' ' 31' ' ' GLN . 9.7 mm-40 -114.49 117.65 31.57 Favored 'General case' 0 CA--C 1.5 -0.942 0 N-CA-C 113.708 1.003 . . . . 0.0 113.708 -176.854 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 4.1 t30 -96.13 160.76 14.27 Favored 'General case' 0 N--CA 1.438 -1.063 0 CA-C-N 114.923 -1.035 . . . . 0.0 108.992 177.017 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 62.5 t -94.06 131.51 40.76 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.491 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.182 -176.744 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 35.5 m -112.46 -11.08 11.96 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.655 0 N-CA-C 112.701 0.63 . . . . 0.0 112.701 178.31 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.467 ' HB1' ' HB ' ' A' ' 52' ' ' THR . . . -152.52 144.94 24.05 Favored 'General case' 0 CA--C 1.508 -0.66 0 C-N-CA 120.015 -0.674 . . . . 0.0 111.59 177.882 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 91.8 mt -143.97 117.74 3.38 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.373 0 N-CA-C 109.618 -0.512 . . . . 0.0 109.618 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . 0.532 ' HA ' ' O ' ' A' ' 103' ' ' ILE . 47.5 m-80 -133.63 112.27 11.3 Favored 'General case' 0 C--N 1.311 -1.078 0 N-CA-C 108.523 -0.918 . . . . 0.0 108.523 175.667 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.464 HG13 ' CD1' ' A' ' 61' ' ' PHE . 22.4 m -148.41 152.02 12.78 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 C-N-CA 120.92 -0.312 . . . . 0.0 111.655 -174.01 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 67.4 tt0 -136.13 142.47 44.24 Favored 'General case' 0 N--CA 1.443 -0.817 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 176.366 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 31.5 p -77.2 147.12 36.61 Favored 'General case' 0 C--N 1.314 -0.935 0 CA-C-O 121.033 0.444 . . . . 0.0 111.641 -177.912 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -94.78 -15.55 45.51 Favored Glycine 0 N--CA 1.451 -0.361 0 N-CA-C 110.512 -1.035 . . . . 0.0 110.512 175.512 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . 0.416 ' C ' ' H ' ' A' ' 44' ' ' GLY . 55.0 m-20 -139.28 -154.69 0.54 Allowed 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 109.257 -0.645 . . . . 0.0 109.257 179.457 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 20.9 m-20 -73.25 38.25 0.09 Allowed 'General case' 0 N--CA 1.476 0.846 0 C-N-CA 122.893 0.477 . . . . 0.0 111.487 -179.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.416 ' H ' ' C ' ' A' ' 42' ' ' ASP . . . 92.74 -6.7 77.22 Favored Glycine 0 C--O 1.217 -0.95 0 C-N-CA 121.173 -0.537 . . . . 0.0 112.66 179.848 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 59.3 mt-30 -63.0 -39.9 96.14 Favored 'General case' 0 C--N 1.326 -0.416 0 N-CA-C 112.137 0.421 . . . . 0.0 112.137 -178.364 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' THR . . . . . 0.5 ' HA ' ' O ' ' A' ' 63' ' ' ALA . 5.2 t -128.18 115.4 18.32 Favored 'General case' 0 C--N 1.311 -1.065 0 CA-C-O 121.187 0.518 . . . . 0.0 110.801 177.812 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . 0.431 ' O ' ' HA ' ' A' ' 62' ' ' ARG . 79.5 mt -99.53 130.42 45.77 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.855 -0.612 . . . . 0.0 109.595 178.442 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 49.2 m-80 -130.11 143.17 50.64 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 116.488 -0.324 . . . . 0.0 110.469 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . 0.403 ' HA3' ' HA ' ' A' ' 38' ' ' VAL . . . 171.08 -150.79 14.32 Favored Glycine 0 N--CA 1.44 -1.086 0 C-N-CA 120.084 -1.055 . . . . 0.0 113.262 179.978 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 25.1 m -125.99 131.48 52.23 Favored 'General case' 0 C--N 1.317 -0.838 0 C-N-CA 122.965 0.506 . . . . 0.0 110.19 -177.199 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' MET . . . . . 0.447 ' SD ' ' HH2' ' A' ' 90' ' ' TRP . 62.5 ttp -125.53 150.27 47.57 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 -179.834 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.467 ' HB ' ' HB1' ' A' ' 35' ' ' ALA . 27.7 m -126.98 130.74 50.64 Favored 'General case' 0 C--O 1.243 0.723 0 CA-C-O 120.735 0.302 . . . . 0.0 111.316 -178.81 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . 0.421 ' HB3' ' OE1' ' A' ' 31' ' ' GLN . 47.0 m-85 -90.61 162.2 15.08 Favored 'General case' 0 C--O 1.233 0.218 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.323 177.247 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -60.42 107.84 0.73 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.799 -0.637 . . . . 0.0 112.634 -178.072 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 88.33 -0.27 83.26 Favored Glycine 0 N--CA 1.454 -0.138 0 CA-C-N 115.796 -0.638 . . . . 0.0 112.854 178.05 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 73.2 mm-40 -108.21 179.22 4.27 Favored 'General case' 0 C--N 1.314 -0.937 0 CA-C-O 120.705 0.288 . . . . 0.0 110.6 -178.744 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -97.71 176.71 31.25 Favored Glycine 0 N--CA 1.439 -1.144 0 C-N-CA 120.678 -0.773 . . . . 0.0 111.452 178.512 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo -67.13 139.5 50.81 Favored 'Trans proline' 0 CA--C 1.535 0.539 0 C-N-CA 122.501 2.134 . . . . 0.0 112.277 179.507 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 48.3 pt -133.01 166.73 28.56 Favored 'Isoleucine or valine' 0 C--O 1.24 0.554 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.137 178.243 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -75.22 138.59 23.66 Favored Glycine 0 CA--C 1.521 0.464 0 C-N-CA 120.724 -0.751 . . . . 0.0 111.957 -179.541 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.464 ' CD1' HG13 ' A' ' 38' ' ' VAL . 50.2 t80 -124.52 129.84 51.35 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 120.519 0.2 . . . . 0.0 110.916 -178.982 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . 0.431 ' HA ' ' O ' ' A' ' 47' ' ' LEU . 62.7 ttp85 -140.67 134.65 30.69 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.22 176.048 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.5 ' O ' ' HA ' ' A' ' 46' ' ' THR . . . -135.08 142.86 46.38 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.567 -0.288 . . . . 0.0 111.304 179.794 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 49.6 m -122.05 131.48 54.01 Favored 'General case' 0 CA--C 1.546 0.803 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.695 -179.608 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . 0.533 HD12 ' O ' ' A' ' 68' ' ' ASN . 55.9 tp -71.03 126.19 28.91 Favored 'General case' 0 CA--C 1.535 0.391 0 N-CA-C 113.1 0.778 . . . . 0.0 113.1 -176.9 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -73.4 -35.19 65.84 Favored 'General case' 0 N--CA 1.473 0.692 0 CA-C-N 115.204 -0.907 . . . . 0.0 111.751 176.349 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 133.05 2.67 3.73 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 111.052 -0.819 . . . . 0.0 111.052 -175.828 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' ASN . . . . . 0.533 ' O ' HD12 ' A' ' 65' ' ' LEU . 31.5 p-10 -131.41 -150.67 0.43 Allowed 'General case' 0 C--N 1.31 -1.147 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.42 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 85.6 m-20 -90.09 4.21 51.01 Favored 'General case' 0 C--N 1.323 -0.545 0 C-N-CA 120.407 -0.517 . . . . 0.0 110.33 179.58 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 24.0 m -101.27 144.56 29.98 Favored 'General case' 0 N--CA 1.448 -0.572 0 CA-C-O 121.362 0.601 . . . . 0.0 111.232 -178.833 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.41 ' HB3' ' HB2' ' A' ' 63' ' ' ALA . 96.3 m-85 -124.33 145.54 49.36 Favored 'General case' 0 C--N 1.312 -1.042 0 CA-C-N 115.463 -0.789 . . . . 0.0 110.617 179.557 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . 0.4 ' O ' ' HA ' ' A' ' 63' ' ' ALA . 79.5 tt0 -86.24 112.82 21.73 Favored 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 107.371 -1.344 . . . . 0.0 107.371 174.565 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 75.4 t -97.77 129.68 47.58 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.103 0 CA-C-O 121.4 0.619 . . . . 0.0 112.064 -175.311 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 45.8 mt-10 -128.05 124.76 37.87 Favored 'General case' 0 N--CA 1.438 -1.049 0 CA-C-N 114.891 -1.05 . . . . 0.0 108.748 177.474 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 14.7 m120 -104.04 147.74 27.04 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-O 121.057 0.456 . . . . 0.0 111.286 -177.478 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' GLN . . . . . 0.527 ' HB2' ' CE3' ' A' ' 84' ' ' TRP . 61.6 tt0 -115.1 119.61 37.02 Favored 'General case' 0 C--N 1.31 -1.11 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.672 -179.68 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 14.9 p90 -138.81 152.85 48.22 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 116.478 -0.328 . . . . 0.0 110.458 177.806 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 147.04 -122.64 1.62 Allowed Glycine 0 N--CA 1.444 -0.825 0 N-CA-C 110.119 -1.192 . . . . 0.0 110.119 -177.295 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . 0.528 ' O ' ' HB2' ' A' ' 80' ' ' ASP . . . -119.31 23.18 8.64 Favored Glycine 0 N--CA 1.444 -0.785 0 C-N-CA 120.291 -0.956 . . . . 0.0 111.115 178.228 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . 0.528 ' HB2' ' O ' ' A' ' 79' ' ' GLY . 12.8 m-20 92.24 -43.47 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.836 0 C-N-CA 124.96 1.304 . . . . 0.0 110.587 178.348 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 34.5 m -76.78 -2.46 33.26 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 121.312 0.577 . . . . 0.0 110.7 175.901 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -66.62 157.39 83.27 Favored Pre-proline 0 C--N 1.324 -0.519 0 CA-C-N 115.353 -0.84 . . . . 0.0 112.029 -178.447 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 75.6 Cg_endo -77.9 -172.86 1.6 Allowed 'Trans proline' 0 CA--C 1.537 0.644 0 C-N-CA 122.752 2.301 . . . . 0.0 112.453 179.102 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' TRP . . . . . 0.527 ' CE3' ' HB2' ' A' ' 76' ' ' GLN . 95.1 m95 -98.13 147.5 24.5 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.822 -178.564 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 94.4 m-70 -128.74 146.38 50.91 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.061 -0.518 . . . . 0.0 109.964 -179.662 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 28.8 p -65.21 136.56 56.78 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-O 121.04 0.448 . . . . 0.0 111.421 -178.735 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -108.27 -52.18 0.69 Allowed Glycine 0 N--CA 1.437 -1.269 0 C-N-CA 120.745 -0.74 . . . . 0.0 111.55 177.968 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 151.45 -166.72 30.74 Favored Glycine 0 CA--C 1.52 0.345 0 C-N-CA 120.918 -0.658 . . . . 0.0 112.045 -179.778 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 19.3 m120 -112.43 119.21 37.46 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 117.014 0.407 . . . . 0.0 110.195 -179.862 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' TRP . . . . . 0.447 ' HH2' ' SD ' ' A' ' 51' ' ' MET . 29.3 m0 -117.12 154.02 31.77 Favored 'General case' 0 N--CA 1.47 0.564 0 CA-C-N 116.467 -0.333 . . . . 0.0 111.123 -177.129 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 89.0 mt -108.6 119.19 57.73 Favored 'Isoleucine or valine' 0 C--O 1.242 0.707 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 176.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 86.7 mt -132.05 83.3 2.07 Favored 'General case' 0 C--O 1.267 1.981 0 N-CA-C 113.127 0.788 . . . . 0.0 113.127 -174.602 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 164.16 116.58 0.37 Allowed Glycine 0 C--O 1.225 -0.439 0 CA-C-N 115.083 -0.962 . . . . 0.0 111.31 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 75.2 p -90.33 -9.36 48.05 Favored 'General case' 0 N--CA 1.463 0.191 0 CA-C-N 117.217 0.509 . . . . 0.0 111.502 -179.58 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -100.38 145.6 27.99 Favored 'General case' 0 N--CA 1.444 -0.763 0 CA-C-O 120.981 0.419 . . . . 0.0 110.872 179.606 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -68.74 -36.77 78.8 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 115.653 -0.703 . . . . 0.0 112.738 -173.463 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 30.5 p-10 -121.6 28.97 7.41 Favored 'General case' 0 C--N 1.313 -1.009 0 CA-C-O 120.715 0.293 . . . . 0.0 111.513 -176.627 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' GLN . . . . . 0.547 ' NE2' ' HB2' ' A' ' 123' ' ' GLU . 53.9 tt0 -157.2 124.44 5.21 Favored 'General case' 0 C--N 1.319 -0.725 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 -177.299 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 96.9 m-20 -113.52 177.66 4.56 Favored 'General case' 0 C--O 1.245 0.819 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.674 -175.355 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . 0.447 HG12 ' CH2' ' A' ' 23' ' ' TRP . 21.2 m -80.41 141.06 15.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.75 -0.659 . . . . 0.0 112.193 -177.656 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 28.7 m -120.95 -26.45 2.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.726 176.425 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . 0.487 ' HB1' ' HB ' ' A' ' 119' ' ' THR . . . -147.26 138.56 23.89 Favored 'General case' 0 C--N 1.324 -0.512 0 C-N-CA 120.872 -0.331 . . . . 0.0 110.65 177.404 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.532 ' O ' ' HA ' ' A' ' 37' ' ' ASN . 87.7 mt -132.23 127.03 56.9 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.029 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 178.822 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 9.6 t30 -128.04 91.06 3.2 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.13 178.414 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 22.3 m -145.06 153.26 14.33 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.615 0 N-CA-C 113.895 1.072 . . . . 0.0 113.895 -176.453 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 91.4 mt-10 -138.95 163.1 33.22 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 114.223 -1.353 . . . . 0.0 108.132 173.896 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 32.7 t -108.2 -51.02 2.95 Favored 'General case' 0 C--N 1.311 -1.1 0 CA-C-O 120.797 0.332 . . . . 0.0 110.893 -179.616 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 84.66 -14.79 45.35 Favored Glycine 0 N--CA 1.446 -0.66 0 N-CA-C 111.101 -0.8 . . . . 0.0 111.101 -176.768 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . 0.457 ' HB3' ' H ' ' A' ' 110' ' ' ASP . 54.2 m-20 -117.25 -151.29 0.48 Allowed 'General case' 0 N--CA 1.45 -0.432 0 C-N-CA 123.074 0.55 . . . . 0.0 109.999 -179.414 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . 0.457 ' H ' ' HB3' ' A' ' 109' ' ' ASP . 12.5 p-10 -88.55 16.43 6.59 Favored 'General case' 0 C--N 1.322 -0.618 0 C-N-CA 122.628 0.371 . . . . 0.0 111.18 -178.881 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 96.29 9.68 56.63 Favored Glycine 0 N--CA 1.444 -0.828 0 C-N-CA 120.086 -1.054 . . . . 0.0 113.045 -178.339 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' GLN . . . . . 0.4 ' HA ' ' CD1' ' A' ' 132' ' ' LEU . 28.1 tt0 -64.3 -45.4 88.12 Favored 'General case' 0 C--O 1.239 0.521 0 CA-C-O 120.833 0.349 . . . . 0.0 111.235 179.934 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' THR . . . . . 0.494 ' HA ' ' O ' ' A' ' 130' ' ' GLY . 21.0 p -132.73 130.38 39.92 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.289 -179.831 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' LEU . . . . . 0.484 ' O ' ' HA ' ' A' ' 129' ' ' LYS . 4.3 mm? -105.86 130.5 53.81 Favored 'General case' 0 C--N 1.319 -0.739 0 N-CA-C 108.49 -0.93 . . . . 0.0 108.49 176.599 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 27.7 p30 -135.1 152.25 51.47 Favored 'General case' 0 C--N 1.316 -0.861 0 C-N-CA 120.191 -0.603 . . . . 0.0 112.274 -179.152 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 152.28 -129.38 2.77 Favored Glycine 0 N--CA 1.441 -1.025 0 CA-C-N 115.461 -0.79 . . . . 0.0 112.337 178.244 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 21.4 p -131.72 156.13 46.45 Favored 'General case' 0 C--N 1.316 -0.879 0 CA-C-O 121.012 0.434 . . . . 0.0 111.02 -178.163 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 118' ' ' MET . . . . . 0.553 ' HE3' ' CE2' ' A' ' 120' ' ' TYR . 19.5 ptm -140.64 149.74 42.67 Favored 'General case' 0 C--N 1.314 -0.963 0 CA-C-N 116.062 -0.517 . . . . 0.0 109.968 -178.6 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 119' ' ' THR . . . . . 0.487 ' HB ' ' HB1' ' A' ' 102' ' ' ALA . 23.3 m -131.23 129.46 41.64 Favored 'General case' 0 C--N 1.313 -1.016 0 CA-C-O 120.804 0.335 . . . . 0.0 111.019 -179.696 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . 0.553 ' CE2' ' HE3' ' A' ' 118' ' ' MET . 45.0 m-85 -101.47 161.18 13.82 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.947 178.66 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -59.84 121.83 12.72 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.094 179.779 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 66.03 24.26 71.62 Favored Glycine 0 C--N 1.336 0.536 0 C-N-CA 121.117 -0.564 . . . . 0.0 112.336 -179.214 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . 0.547 ' HB2' ' NE2' ' A' ' 98' ' ' GLN . 32.5 tp10 -127.95 164.87 21.37 Favored 'General case' 0 C--N 1.318 -0.78 0 N-CA-C 109.622 -0.51 . . . . 0.0 109.622 -177.083 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -93.49 159.66 24.18 Favored Glycine 0 N--CA 1.443 -0.837 0 N-CA-C 110.803 -0.919 . . . . 0.0 110.803 177.318 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . 0.403 ' HA ' ' O ' ' A' ' 118' ' ' MET . 37.8 Cg_endo -66.2 136.15 42.91 Favored 'Trans proline' 0 CA--C 1.53 0.286 0 C-N-CA 122.16 1.907 . . . . 0.0 112.233 179.67 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 41.7 pt -132.65 166.4 29.41 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.004 178.929 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -70.02 134.73 25.53 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.912 -0.661 . . . . 0.0 112.197 -179.7 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . 0.53 ' HB2' ' SD ' ' A' ' 118' ' ' MET . 25.4 t80 -124.84 134.75 52.61 Favored 'General case' 0 CA--C 1.513 -0.443 0 CA-C-O 121.173 0.511 . . . . 0.0 111.443 -179.45 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 129' ' ' LYS . . . . . 0.484 ' HA ' ' O ' ' A' ' 114' ' ' LEU . 62.3 tttm -140.86 123.64 16.21 Favored 'General case' 0 N--CA 1.435 -1.196 0 CA-C-N 115.073 -0.967 . . . . 0.0 109.494 178.591 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . 0.494 ' O ' ' HA ' ' A' ' 113' ' ' THR . . . -117.32 131.61 9.51 Favored Glycine 0 N--CA 1.444 -0.809 0 N-CA-C 110.973 -0.851 . . . . 0.0 110.973 178.948 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 32.1 m -125.32 133.88 52.44 Favored 'General case' 0 C--N 1.314 -0.973 0 CA-C-N 117.015 0.408 . . . . 0.0 110.709 -177.249 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 132' ' ' LEU . . . . . 0.4 ' CD1' ' HA ' ' A' ' 112' ' ' GLN . 78.3 mt -62.37 135.14 57.31 Favored 'General case' 0 C--O 1.238 0.473 0 CA-C-O 120.741 0.305 . . . . 0.0 110.779 177.283 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 8.6 t . . . . . 0 C--O 1.249 1.051 0 CA-C-O 118.368 -0.825 . . . . 0.0 110.34 178.391 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.468 0.474 0 N-CA-C 110.028 -0.36 . . . . 0.0 110.028 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . 0.597 HD11 HE21 ' A' ' 22' ' ' GLN . 1.4 tm? -97.42 132.41 43.15 Favored 'General case' 0 C--N 1.316 -0.85 0 N-CA-C 109.584 -0.525 . . . . 0.0 109.584 -177.817 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . 0.537 ' N ' HD12 ' A' ' 3' ' ' LEU . 89.8 m-85 -122.91 147.74 46.24 Favored 'General case' 0 C--O 1.236 0.351 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.649 -177.96 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . 0.536 ' O ' ' HA2' ' A' ' 130' ' ' GLY . 18.7 m120 -94.73 134.5 37.26 Favored 'General case' 0 CA--C 1.506 -0.715 0 N-CA-C 106.34 -1.726 . . . . 0.0 106.34 174.792 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 59.3 t -118.2 126.84 75.28 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.891 0 C-N-CA 119.492 -0.883 . . . . 0.0 113.031 -175.443 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.521 ' HA ' ' HA ' ' A' ' 19' ' ' GLU . 98.4 mt-10 -115.06 139.72 49.64 Favored 'General case' 0 N--CA 1.439 -1.012 0 CA-C-N 114.477 -1.238 . . . . 0.0 108.792 176.326 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 12.1 m120 -119.35 144.05 47.07 Favored 'General case' 0 C--N 1.313 -1.013 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.309 -177.045 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 60.4 tt0 -121.68 114.89 21.78 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 174.605 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 45.8 p90 -129.16 139.08 52.06 Favored 'General case' 0 C--N 1.317 -0.832 0 C-N-CA 121.028 -0.269 . . . . 0.0 110.913 -178.309 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 102.09 11.77 35.92 Favored Glycine 0 N--CA 1.444 -0.783 0 C-N-CA 120.363 -0.922 . . . . 0.0 112.582 178.616 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 99.7 167.37 29.66 Favored Glycine 0 N--CA 1.444 -0.816 0 C-N-CA 120.446 -0.883 . . . . 0.0 113.28 -179.43 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 15.6 m -56.2 -25.61 47.76 Favored 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 123.158 0.583 . . . . 0.0 112.227 179.474 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 14.1 p -61.23 -21.04 63.49 Favored 'General case' 0 CA--C 1.542 0.671 0 N-CA-C 112.25 0.463 . . . . 0.0 112.25 177.268 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -90.84 142.93 28.05 Favored Pre-proline 0 C--N 1.321 -0.66 0 CA-C-O 120.541 0.21 . . . . 0.0 110.733 179.7 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 95.3 Cg_endo -78.37 170.51 18.36 Favored 'Trans proline' 0 C--O 1.238 0.518 0 C-N-CA 122.803 2.335 . . . . 0.0 112.241 179.692 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 96.4 m95 -86.97 124.88 33.65 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.118 -0.492 . . . . 0.0 109.905 -179.77 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 47.8 m-80 -123.26 126.19 46.46 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.991 -178.87 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.521 ' HA ' ' HA ' ' A' ' 7' ' ' GLU . 15.3 pt-20 -68.94 133.51 48.29 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 109.65 -0.5 . . . . 0.0 109.65 177.631 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -134.31 22.78 3.72 Favored Glycine 0 N--CA 1.443 -0.858 0 C-N-CA 119.566 -1.302 . . . . 0.0 112.876 -179.308 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . 0.505 ' HA3' ' HB2' ' A' ' 94' ' ' SER . . . 145.07 -170.9 26.38 Favored Glycine 0 N--CA 1.449 -0.472 0 C-N-CA 120.17 -1.014 . . . . 0.0 113.293 177.352 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . 0.597 HE21 HD11 ' A' ' 3' ' ' LEU . 4.3 pt20 -131.73 136.05 47.3 Favored 'General case' 0 C--N 1.324 -0.514 0 C-N-CA 122.604 0.362 . . . . 0.0 110.634 -178.337 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . 0.459 ' CH2' HG22 ' A' ' 100' ' ' VAL . 26.2 m0 -110.76 165.88 11.47 Favored 'General case' 0 N--CA 1.469 0.491 0 CA-C-O 120.668 0.27 . . . . 0.0 110.482 179.01 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 40.1 tt0 -128.87 116.56 19.62 Favored 'General case' 0 C--N 1.32 -0.68 0 C-N-CA 120.46 -0.496 . . . . 0.0 110.166 175.827 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.481 ' HB ' ' CE1' ' A' ' 4' ' ' TYR . 98.7 mt -130.18 137.49 56.26 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.764 0 CA-C-N 115.5 -0.773 . . . . 0.0 110.196 -177.567 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 93.37 102.32 1.59 Allowed Glycine 0 N--CA 1.446 -0.683 0 C-N-CA 120.775 -0.726 . . . . 0.0 111.892 179.451 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 4.2 p -101.57 12.17 37.71 Favored 'General case' 0 C--N 1.312 -1.036 0 CA-C-O 121.01 0.433 . . . . 0.0 111.293 -178.832 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 62.6 mtt-85 -130.64 130.32 43.79 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.053 -178.932 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 15.6 m -66.78 -36.64 82.87 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.094 0.473 . . . . 0.0 112.052 -179.145 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 64.8 m-20 -73.93 -43.24 58.96 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.965 -0.562 . . . . 0.0 112.387 -175.505 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 8.7 mm-40 -121.41 122.12 39.08 Favored 'General case' 0 CA--C 1.506 -0.727 0 N-CA-C 113.106 0.78 . . . . 0.0 113.106 -176.42 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . 0.423 ' ND2' ' HA3' ' A' ' 111' ' ' GLY . 62.3 t30 -104.39 172.72 6.64 Favored 'General case' 0 N--CA 1.442 -0.837 0 CA-C-N 114.893 -1.049 . . . . 0.0 109.499 178.201 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 59.0 t -106.86 133.68 50.73 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.164 0 N-CA-C 112.287 0.477 . . . . 0.0 112.287 -174.803 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 29.3 m -113.73 -18.0 7.9 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.609 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.947 178.01 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.533 ' HB2' ' HB ' ' A' ' 52' ' ' THR . . . -144.99 145.27 31.44 Favored 'General case' 0 CA--C 1.513 -0.459 0 C-N-CA 119.968 -0.693 . . . . 0.0 111.464 178.928 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 86.8 mt -144.67 126.71 9.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 -178.916 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . 0.497 ' HA ' ' O ' ' A' ' 103' ' ' ILE . 31.3 m-80 -136.64 109.12 7.39 Favored 'General case' 0 C--N 1.312 -1.038 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 176.888 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.454 HG11 ' CD1' ' A' ' 61' ' ' PHE . 25.3 m -151.07 157.59 5.38 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 C-N-CA 120.917 -0.313 . . . . 0.0 111.165 -172.833 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -142.71 150.71 40.48 Favored 'General case' 0 N--CA 1.447 -0.596 0 CA-C-N 115.8 -0.636 . . . . 0.0 109.925 177.253 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' SER . . . . . 0.445 ' OG ' ' HB ' ' A' ' 101' ' ' VAL . 35.1 p -79.97 153.59 28.8 Favored 'General case' 0 C--N 1.318 -0.79 0 N-CA-C 112.477 0.547 . . . . 0.0 112.477 -177.682 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -115.45 -68.31 0.44 Allowed Glycine 0 N--CA 1.434 -1.474 0 CA-C-N 115.114 -0.948 . . . . 0.0 110.848 175.151 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 22.5 m-20 -89.95 81.57 6.26 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 112.154 0.427 . . . . 0.0 112.154 -179.001 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 84.5 m-20 51.22 31.53 6.96 Favored 'General case' 0 N--CA 1.491 1.576 0 N-CA-C 113.424 0.898 . . . . 0.0 113.424 174.791 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 88.84 -14.58 59.87 Favored Glycine 0 C--O 1.223 -0.57 0 C-N-CA 120.116 -1.04 . . . . 0.0 113.139 179.229 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 61.3 mt-30 -70.11 -30.44 67.65 Favored 'General case' 0 CA--C 1.512 -0.503 0 CA-C-O 121.193 0.521 . . . . 0.0 110.749 178.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 31.9 m -119.37 130.61 55.42 Favored 'General case' 0 N--CA 1.434 -1.247 0 CA-C-N 115.476 -0.783 . . . . 0.0 108.9 -179.641 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 84.6 mt -124.81 133.96 52.93 Favored 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 108.892 -0.781 . . . . 0.0 108.892 -179.063 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 28.1 p30 -136.8 148.77 47.37 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-O 121.122 0.487 . . . . 0.0 111.146 178.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 164.28 -145.04 9.94 Favored Glycine 0 N--CA 1.445 -0.758 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.16 177.68 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' THR . . . . . 0.518 ' HA ' ' O ' ' A' ' 59' ' ' ILE . 19.6 p -129.56 141.81 50.89 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 120.904 0.383 . . . . 0.0 110.975 179.925 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' MET . . . . . 0.448 ' HE3' ' CZ ' ' A' ' 53' ' ' TYR . 15.6 tmm? -131.92 149.01 52.56 Favored 'General case' 0 C--N 1.317 -0.839 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 179.291 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.533 ' HB ' ' HB2' ' A' ' 35' ' ' ALA . 61.7 m -124.56 126.15 45.35 Favored 'General case' 0 C--O 1.252 1.197 0 N-CA-C 112.266 0.469 . . . . 0.0 112.266 -176.61 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . 0.448 ' CZ ' ' HE3' ' A' ' 51' ' ' MET . 59.8 m-85 -82.68 161.13 22.24 Favored 'General case' 0 C--O 1.236 0.353 0 CA-C-N 115.407 -0.815 . . . . 0.0 111.096 176.521 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -63.76 113.63 3.51 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.914 179.269 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 90.72 7.86 66.09 Favored Glycine 0 N--CA 1.443 -0.859 0 C-N-CA 120.877 -0.678 . . . . 0.0 112.62 179.556 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 81.2 mm-40 -126.72 -172.61 2.68 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.767 0.317 . . . . 0.0 111.447 179.479 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -111.92 -171.56 18.86 Favored Glycine 0 N--CA 1.443 -0.86 0 N-CA-C 111.409 -0.677 . . . . 0.0 111.409 178.615 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 96.1 Cg_endo -76.01 140.06 22.39 Favored 'Trans proline' 0 C--O 1.241 0.651 0 C-N-CA 122.488 2.126 . . . . 0.0 113.431 -178.853 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . 0.518 ' O ' ' HA ' ' A' ' 50' ' ' THR . 43.6 pt -132.17 173.12 15.24 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 CA-C-N 115.36 -0.836 . . . . 0.0 109.243 175.625 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -75.35 139.72 25.25 Favored Glycine 0 C--N 1.317 -0.502 0 N-CA-C 111.44 -0.664 . . . . 0.0 111.44 -177.725 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.454 ' CD1' HG11 ' A' ' 38' ' ' VAL . 49.2 t80 -128.34 128.43 44.55 Favored 'General case' 0 C--N 1.312 -1.049 0 CA-C-O 120.511 0.196 . . . . 0.0 110.964 -177.277 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 70.1 ttp85 -136.21 131.13 34.17 Favored 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 175.104 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.422 ' HB1' ' HB3' ' A' ' 71' ' ' TYR . . . -135.4 147.58 49.06 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-O 120.782 0.325 . . . . 0.0 111.3 -178.766 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 83.5 m -126.75 132.44 51.08 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.938 -0.573 . . . . 0.0 110.552 178.895 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 61.4 tp -71.97 123.87 23.68 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.093 0.473 . . . . 0.0 111.854 -178.255 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -66.58 -36.66 83.17 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.896 176.665 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 137.62 -6.69 3.57 Favored Glycine 0 CA--C 1.523 0.591 0 C-N-CA 120.298 -0.953 . . . . 0.0 113.011 -177.519 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 58.3 m-80 -144.14 61.35 1.35 Allowed 'General case' 0 N--CA 1.476 0.838 0 N-CA-C 111.879 0.325 . . . . 0.0 111.879 -178.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 90.6 m-20 59.65 5.73 0.73 Allowed 'General case' 0 N--CA 1.487 1.397 0 C-N-CA 123.169 0.587 . . . . 0.0 112.13 179.161 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 9.3 m -99.13 133.83 42.85 Favored 'General case' 0 N--CA 1.44 -0.965 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 179.193 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.43 ' OH ' ' HB3' ' A' ' 99' ' ' ASN . 65.6 m-85 -122.4 136.09 54.83 Favored 'General case' 0 C--N 1.307 -1.259 0 CA-C-O 120.83 0.348 . . . . 0.0 111.546 -178.373 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 43.1 tt0 -90.57 120.35 31.58 Favored 'General case' 0 C--N 1.316 -0.855 0 N-CA-C 107.743 -1.206 . . . . 0.0 107.743 174.785 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 77.5 t -104.85 133.29 49.44 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.201 0 N-CA-C 113.091 0.774 . . . . 0.0 113.091 -173.621 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.436 ' HG2' ' HA ' ' A' ' 86' ' ' SER . 49.7 mt-10 -127.58 126.21 41.69 Favored 'General case' 0 N--CA 1.445 -0.711 0 CA-C-N 114.482 -1.235 . . . . 0.0 108.103 174.631 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 94.7 m-20 -103.9 144.04 32.04 Favored 'General case' 0 C--O 1.241 0.622 0 CA-C-O 121.256 0.55 . . . . 0.0 111.689 -176.541 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' GLN . . . . . 0.557 ' HB2' ' CE3' ' A' ' 84' ' ' TRP . 55.6 tt0 -118.29 122.95 44.19 Favored 'General case' 0 C--N 1.309 -1.161 0 CA-C-N 115.449 -0.796 . . . . 0.0 109.482 -178.247 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 8.1 p90 -110.55 97.04 6.57 Favored 'General case' 0 C--N 1.311 -1.083 0 C-N-CA 119.378 -0.929 . . . . 0.0 110.994 176.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 156.86 -153.51 24.76 Favored Glycine 0 N--CA 1.433 -1.563 0 N-CA-C 108.339 -1.905 . . . . 0.0 108.339 -177.378 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -84.93 -148.99 10.32 Favored Glycine 0 N--CA 1.442 -0.908 0 C-N-CA 119.926 -1.13 . . . . 0.0 111.248 175.858 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 65.3 m-20 -88.77 -6.31 57.49 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 117.207 0.504 . . . . 0.0 110.894 -178.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 24.1 t -98.13 -4.8 34.94 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.152 -178.002 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -76.49 149.91 81.78 Favored Pre-proline 0 C--N 1.323 -0.56 0 CA-C-N 116.496 -0.32 . . . . 0.0 110.868 -178.399 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -68.23 158.4 57.66 Favored 'Trans proline' 0 C--O 1.238 0.479 0 C-N-CA 122.351 2.034 . . . . 0.0 111.793 178.491 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' TRP . . . . . 0.557 ' CE3' ' HB2' ' A' ' 76' ' ' GLN . 96.0 m95 -94.8 138.69 32.28 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.337 -178.608 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 74.7 m-70 -119.16 146.62 45.0 Favored 'General case' 0 C--N 1.32 -0.712 0 N-CA-C 109.549 -0.538 . . . . 0.0 109.549 179.845 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' SER . . . . . 0.436 ' HA ' ' HG2' ' A' ' 74' ' ' GLU . 10.8 p -71.08 139.99 50.55 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 121.192 0.52 . . . . 0.0 112.229 -176.756 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -115.41 -45.69 0.61 Allowed Glycine 0 N--CA 1.44 -1.099 0 C-N-CA 120.993 -0.622 . . . . 0.0 112.342 178.718 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 147.65 -162.28 28.67 Favored Glycine 0 C--O 1.225 -0.411 0 C-N-CA 120.279 -0.962 . . . . 0.0 112.655 179.445 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 17.9 m120 -115.11 124.55 51.83 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.842 0.321 . . . . 0.0 110.497 179.849 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 34.2 m0 -118.89 153.59 34.31 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.614 -178.581 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 46.9 mm -106.76 114.33 45.61 Favored 'Isoleucine or valine' 0 C--O 1.244 0.776 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 178.388 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 78.5 mt -128.07 77.72 1.78 Allowed 'General case' 0 C--O 1.256 1.445 0 CA-C-O 121.539 0.685 . . . . 0.0 111.559 -177.007 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 166.23 93.79 0.09 OUTLIER Glycine 0 N--CA 1.446 -0.689 0 CA-C-N 115.762 -0.654 . . . . 0.0 111.695 -179.649 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' SER . . . . . 0.505 ' HB2' ' HA3' ' A' ' 21' ' ' GLY . 43.8 p -92.28 -12.42 32.57 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-O 120.838 0.351 . . . . 0.0 111.816 -178.516 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 91.6 mtt180 -88.69 15.84 7.6 Favored 'General case' 0 C--N 1.317 -0.821 0 N-CA-C 114.141 1.163 . . . . 0.0 114.141 -176.339 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 77.9 tt0 69.44 -81.67 0.03 OUTLIER 'General case' 0 N--CA 1.472 0.671 0 N-CA-C 113.298 0.851 . . . . 0.0 113.298 172.86 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 61.6 m-80 -92.73 24.19 3.72 Favored 'General case' 0 N--CA 1.473 0.681 0 CA-C-O 121.006 0.432 . . . . 0.0 110.995 -176.429 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' GLN . . . . . 0.409 ' HG2' ' HB3' ' A' ' 120' ' ' TYR . 54.8 tt0 -145.51 116.3 7.73 Favored 'General case' 0 C--N 1.312 -1.022 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 -177.298 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' ASN . . . . . 0.43 ' HB3' ' OH ' ' A' ' 71' ' ' TYR . 50.3 m-80 -89.23 158.93 17.68 Favored 'General case' 0 C--O 1.248 0.983 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.731 -177.512 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . 0.459 HG22 ' CH2' ' A' ' 23' ' ' TRP . 98.0 t -80.57 130.04 36.56 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.206 0 C-N-CA 120.536 -0.466 . . . . 0.0 110.724 177.892 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . 0.445 ' HB ' ' OG ' ' A' ' 40' ' ' SER . 34.8 m -110.27 -17.15 8.5 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.59 0 N-CA-C 112.439 0.533 . . . . 0.0 112.439 -178.686 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . 0.472 ' HB2' ' HB ' ' A' ' 119' ' ' THR . . . -155.57 145.11 21.12 Favored 'General case' 0 CA--C 1.509 -0.61 0 C-N-CA 120.16 -0.616 . . . . 0.0 111.261 176.9 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.497 ' O ' ' HA ' ' A' ' 37' ' ' ASN . 83.0 mt -135.19 125.26 43.88 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 N-CA-C 110.102 -0.333 . . . . 0.0 110.102 179.457 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . 0.458 ' HB3' ' OG1' ' A' ' 117' ' ' THR . 7.5 t30 -127.8 94.18 3.88 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.872 -0.604 . . . . 0.0 109.829 175.91 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 30.0 m -137.86 138.67 43.8 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.661 0 N-CA-C 113.119 0.785 . . . . 0.0 113.119 -176.343 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -142.71 96.85 3.0 Favored 'General case' 0 CA--C 1.543 0.686 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.781 176.847 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' SER . . . . . 0.467 ' HB2' ' H ' ' A' ' 115' ' ' ASN . 58.9 m -167.14 166.15 15.16 Favored 'General case' 0 N--CA 1.484 1.264 0 CA-C-N 115.204 -0.907 . . . . 0.0 113.38 -177.963 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 107.07 127.55 5.79 Favored Glycine 0 N--CA 1.427 -1.965 0 C-N-CA 120.488 -0.863 . . . . 0.0 112.85 175.844 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 7.3 m-20 -77.93 -48.63 15.88 Favored 'General case' 0 C--N 1.317 -0.817 0 N-CA-C 107.063 -1.458 . . . . 0.0 107.063 176.247 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 -125.63 23.3 7.43 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 113.941 -1.481 . . . . 0.0 108.998 177.708 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . 0.423 ' HA3' ' ND2' ' A' ' 32' ' ' ASN . . . 81.83 17.56 69.96 Favored Glycine 0 C--O 1.22 -0.723 0 C-N-CA 120.457 -0.878 . . . . 0.0 111.823 -175.818 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' GLN . . . . . 0.467 ' HA ' ' CD1' ' A' ' 132' ' ' LEU . 98.4 mt-30 -65.59 -43.61 89.18 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.742 0.306 . . . . 0.0 111.656 -179.17 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 34.0 p -131.77 149.51 52.45 Favored 'General case' 0 N--CA 1.441 -0.876 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.4 179.546 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 97.5 mt -128.41 131.17 48.48 Favored 'General case' 0 C--N 1.316 -0.881 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.012 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . 0.467 ' H ' ' HB2' ' A' ' 107' ' ' SER . 54.5 m-80 -136.16 150.29 48.99 Favored 'General case' 0 C--O 1.245 0.841 0 CA-C-O 120.792 0.33 . . . . 0.0 110.667 -178.802 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 157.51 -128.54 2.15 Favored Glycine 0 N--CA 1.442 -0.935 0 CA-C-N 115.75 -0.659 . . . . 0.0 112.049 179.042 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 117' ' ' THR . . . . . 0.458 ' OG1' ' HB3' ' A' ' 104' ' ' ASN . 25.1 p -136.2 156.43 48.69 Favored 'General case' 0 C--N 1.312 -1.03 0 CA-C-O 121.03 0.443 . . . . 0.0 110.875 179.91 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 118' ' ' MET . . . . . 0.584 ' SD ' ' HE1' ' A' ' 120' ' ' TYR . 3.4 ptp -137.66 145.2 42.37 Favored 'General case' 0 C--N 1.314 -0.969 0 CA-C-N 115.94 -0.573 . . . . 0.0 109.966 -179.278 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 119' ' ' THR . . . . . 0.472 ' HB ' ' HB2' ' A' ' 102' ' ' ALA . 20.8 m -125.5 127.12 45.96 Favored 'General case' 0 C--O 1.247 0.936 0 N-CA-C 110.125 -0.324 . . . . 0.0 110.125 178.557 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . 0.584 ' HE1' ' SD ' ' A' ' 118' ' ' MET . 24.3 m-85 -107.15 155.04 20.31 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.987 179.04 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -58.44 127.87 34.31 Favored 'General case' 0 C--O 1.236 0.391 0 CA-C-O 121.131 0.491 . . . . 0.0 112.121 -178.649 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 81.64 7.71 87.79 Favored Glycine 0 C--O 1.227 -0.338 0 CA-C-N 115.618 -0.719 . . . . 0.0 113.406 177.863 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 85.9 tt0 -145.05 165.2 28.91 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 117.091 0.446 . . . . 0.0 110.493 -178.599 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -87.23 176.43 46.92 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.953 -0.642 . . . . 0.0 112.784 -178.448 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . 0.479 ' HA ' ' O ' ' A' ' 118' ' ' MET . 71.6 Cg_endo -72.48 140.01 32.46 Favored 'Trans proline' 0 CA--C 1.534 0.523 0 C-N-CA 122.817 2.345 . . . . 0.0 112.923 -179.685 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 43.6 pt -131.15 170.42 19.77 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.013 178.809 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -68.33 133.56 28.36 Favored Glycine 0 C--O 1.242 0.614 0 C-N-CA 120.929 -0.653 . . . . 0.0 112.987 -178.401 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 45.1 t80 -111.74 130.59 55.74 Favored 'General case' 0 C--O 1.236 0.378 0 C-N-CA 123.287 0.635 . . . . 0.0 110.602 -179.502 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 62.1 tttm -140.84 115.45 9.52 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 177.385 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . 0.536 ' HA2' ' O ' ' A' ' 5' ' ' ASN . . . -132.13 149.38 19.4 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.501 -0.857 . . . . 0.0 113.266 -178.132 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 80.8 m -141.29 143.09 33.88 Favored 'General case' 0 C--N 1.323 -0.564 0 C-N-CA 122.307 0.243 . . . . 0.0 111.079 179.256 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 132' ' ' LEU . . . . . 0.467 ' CD1' ' HA ' ' A' ' 112' ' ' GLN . 82.4 mt -53.9 136.33 40.94 Favored 'General case' 0 N--CA 1.475 0.793 0 O-C-N 123.548 0.53 . . . . 0.0 110.764 176.112 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 25.1 m . . . . . 0 C--O 1.255 1.368 0 CA-C-O 118.421 -0.799 . . . . 0.0 110.85 -179.034 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 0.622 0 N-CA-C 110.064 -0.347 . . . . 0.0 110.064 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 2.8 tm? -88.16 129.28 35.37 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 121.084 0.468 . . . . 0.0 110.093 -178.714 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . 0.49 ' CE1' ' HB ' ' A' ' 25' ' ' ILE . 35.2 m-85 -117.62 141.92 47.81 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.783 -0.644 . . . . 0.0 111.813 179.901 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 -98.21 139.61 33.74 Favored 'General case' 0 C--N 1.312 -1.037 0 N-CA-C 107.794 -1.188 . . . . 0.0 107.794 173.328 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 69.0 t -114.39 127.87 71.67 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.224 0 CA-C-O 121.222 0.534 . . . . 0.0 112.211 -174.059 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -122.55 138.76 54.47 Favored 'General case' 0 C--N 1.317 -0.84 0 N-CA-C 107.826 -1.176 . . . . 0.0 107.826 175.083 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 23.5 m120 -128.89 148.53 50.92 Favored 'General case' 0 C--N 1.313 -0.992 0 N-CA-C 112.454 0.538 . . . . 0.0 112.454 -177.319 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 51.0 tt0 -126.36 122.31 35.03 Favored 'General case' 0 C--N 1.32 -0.71 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 176.967 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 41.5 p90 -145.6 13.64 1.36 Allowed 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 114.033 1.123 . . . . 0.0 114.033 -176.376 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -110.36 21.27 24.42 Favored Glycine 0 N--CA 1.446 -0.671 0 C-N-CA 118.491 -1.814 . . . . 0.0 112.031 -177.302 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 107.72 175.9 22.36 Favored Glycine 0 N--CA 1.448 -0.56 0 C-N-CA 120.539 -0.839 . . . . 0.0 113.098 179.083 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 12.4 m -64.36 150.91 45.32 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 115.365 -0.417 . . . . 0.0 111.5 177.831 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 37.6 m 64.89 21.23 12.3 Favored 'General case' 0 N--CA 1.472 0.63 0 CA-C-N 115.706 -0.679 . . . . 0.0 111.509 -178.705 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -96.61 146.27 31.02 Favored Pre-proline 0 N--CA 1.448 -0.539 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.595 179.803 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_exo -71.86 159.23 51.07 Favored 'Trans proline' 0 N--CA 1.455 -0.741 0 C-N-CA 122.764 2.309 . . . . 0.0 112.302 178.502 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 80.6 m95 -90.21 131.4 36.06 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 115.658 -0.701 . . . . 0.0 109.285 178.852 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 38.8 m-80 -109.35 142.67 39.94 Favored 'General case' 0 C--N 1.308 -1.216 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 -178.854 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -69.04 125.59 27.14 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-O 121.612 0.72 . . . . 0.0 111.623 -178.299 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.607 ' O ' ' HB3' ' A' ' 94' ' ' SER . . . -100.33 -17.66 23.8 Favored Glycine 0 N--CA 1.447 -0.567 0 CA-C-N 114.661 -1.154 . . . . 0.0 113.851 -176.515 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 137.14 -151.18 20.94 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.241 -0.981 . . . . 0.0 111.887 -177.566 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 4.6 pt20 -138.62 132.83 31.6 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 120.852 0.358 . . . . 0.0 111.264 -179.912 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . 0.416 ' CZ2' HG22 ' A' ' 100' ' ' VAL . 46.0 m0 -115.34 161.65 18.22 Favored 'General case' 0 CA--C 1.507 -0.691 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.372 178.548 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 81.7 tt0 -120.07 118.96 31.97 Favored 'General case' 0 C--N 1.314 -0.973 0 C-N-CA 119.986 -0.686 . . . . 0.0 109.649 174.313 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.49 ' HB ' ' CE1' ' A' ' 4' ' ' TYR . 97.8 mt -134.45 146.09 31.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 CA-C-N 114.99 -1.005 . . . . 0.0 109.457 -176.225 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 83.71 73.54 1.25 Allowed Glycine 0 CA--C 1.505 -0.56 0 C-N-CA 120.364 -0.922 . . . . 0.0 111.605 178.955 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 16.1 m -62.21 -43.31 99.11 Favored 'General case' 0 C--N 1.314 -0.961 0 CA-C-N 115.175 -0.513 . . . . 0.0 110.77 179.55 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 84.8 mtt85 -77.64 129.78 36.01 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.903 -0.589 . . . . 0.0 111.337 -179.709 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 15.6 m -66.7 -32.77 74.29 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.607 -0.724 . . . . 0.0 111.69 179.85 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 28.6 m-20 -97.62 16.78 19.45 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.524 -176.458 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 7.2 mm-40 -155.21 102.32 2.29 Favored 'General case' 0 CA--C 1.505 -0.781 0 CA-C-O 120.909 0.385 . . . . 0.0 111.646 -174.656 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 63.7 t30 -102.34 157.86 16.61 Favored 'General case' 0 N--CA 1.443 -0.814 0 CA-C-N 115.877 -0.602 . . . . 0.0 109.945 178.305 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 57.0 t -96.22 133.11 38.68 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.66 0 CA-C-N 115.255 -0.884 . . . . 0.0 110.841 -175.166 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 30.1 m -110.13 -17.22 8.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 N-CA-C 111.78 0.289 . . . . 0.0 111.78 179.787 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.461 ' HB2' ' HB ' ' A' ' 52' ' ' THR . . . -149.89 143.48 25.31 Favored 'General case' 0 C--O 1.236 0.358 0 C-N-CA 120.628 -0.429 . . . . 0.0 111.195 178.532 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.405 ' HB ' HG21 ' A' ' 105' ' ' VAL . 94.6 mt -140.72 123.32 15.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.036 -179.016 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -126.74 106.47 9.39 Favored 'General case' 0 C--N 1.319 -0.723 0 N-CA-C 108.672 -0.862 . . . . 0.0 108.672 173.896 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 23.9 m -147.67 151.1 13.9 Favored 'Isoleucine or valine' 0 C--O 1.237 0.423 0 C-N-CA 120.748 -0.381 . . . . 0.0 111.379 -174.881 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 78.7 tt0 -147.14 150.46 35.02 Favored 'General case' 0 C--N 1.319 -0.735 0 N-CA-C 108.609 -0.886 . . . . 0.0 108.609 175.612 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' SER . . . . . 0.433 ' HB2' HD21 ' A' ' 47' ' ' LEU . 8.4 t -90.91 143.46 26.69 Favored 'General case' 0 C--N 1.312 -1.027 0 CA-C-O 120.857 0.36 . . . . 0.0 111.436 -177.759 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -87.09 -15.49 62.59 Favored Glycine 0 CA--C 1.52 0.347 0 C-N-CA 120.51 -0.852 . . . . 0.0 111.132 175.892 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . 0.415 ' HB3' ' H ' ' A' ' 43' ' ' ASP . 15.7 m-20 -127.46 -156.01 0.73 Allowed 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.157 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . 0.415 ' H ' ' HB3' ' A' ' 42' ' ' ASP . 43.4 m-20 -76.72 38.72 0.2 Allowed 'General case' 0 N--CA 1.472 0.663 0 C-N-CA 122.576 0.351 . . . . 0.0 111.625 -179.316 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.525 ' O ' ' HE2' ' A' ' 71' ' ' TYR . . . 96.04 -8.39 67.61 Favored Glycine 0 C--O 1.214 -1.095 0 C-N-CA 120.917 -0.658 . . . . 0.0 111.856 -179.527 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 56.2 mt-30 -64.06 -39.66 94.56 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 113.14 0.793 . . . . 0.0 113.14 -176.711 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 4.0 t -126.81 110.56 13.22 Favored 'General case' 0 C--N 1.313 -1.011 0 C-N-CA 120.077 -0.649 . . . . 0.0 110.985 178.57 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . 0.433 HD21 ' HB2' ' A' ' 40' ' ' SER . 74.0 mt -93.76 125.52 38.42 Favored 'General case' 0 N--CA 1.443 -0.78 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 176.079 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 13.4 m120 -125.08 141.21 52.26 Favored 'General case' 0 C--N 1.3 -1.547 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 -178.902 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 170.64 -152.99 20.1 Favored Glycine 0 N--CA 1.444 -0.813 0 C-N-CA 119.05 -1.548 . . . . 0.0 113.987 179.333 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 38.6 m -128.47 133.15 48.44 Favored 'General case' 0 N--CA 1.443 -0.808 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 -177.235 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 46.4 ttp -122.61 144.78 48.9 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 -178.344 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.461 ' HB ' ' HB2' ' A' ' 35' ' ' ALA . 32.5 m -125.06 126.69 45.77 Favored 'General case' 0 C--O 1.247 0.958 0 CA-C-O 120.73 0.3 . . . . 0.0 111.368 -179.11 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 62.1 m-85 -90.45 162.73 14.94 Favored 'General case' 0 C--O 1.234 0.248 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.95 177.947 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -66.49 131.44 46.05 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.375 178.734 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 74.0 2.08 61.02 Favored Glycine 0 CA--C 1.519 0.34 0 CA-C-N 115.981 -0.554 . . . . 0.0 113.21 179.209 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 75.2 mm-40 -121.74 -179.03 3.98 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 120.826 0.345 . . . . 0.0 110.764 -178.424 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -105.71 173.76 20.39 Favored Glycine 0 N--CA 1.442 -0.927 0 C-N-CA 121.029 -0.605 . . . . 0.0 111.811 179.215 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 26.3 Cg_exo -63.32 136.32 54.77 Favored 'Trans proline' 0 C--O 1.242 0.712 0 C-N-CA 122.892 2.394 . . . . 0.0 112.375 179.811 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . 0.507 ' HB ' ' O ' ' A' ' 76' ' ' GLN . 50.9 pt -130.79 167.2 26.47 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.577 -179.671 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -73.1 135.14 20.89 Favored Glycine 0 C--O 1.249 1.068 0 C-N-CA 120.842 -0.694 . . . . 0.0 112.122 179.776 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 58.1 t80 -127.51 126.9 43.07 Favored 'General case' 0 C--O 1.243 0.717 0 C-N-CA 122.647 0.379 . . . . 0.0 110.795 -177.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 62.1 ttp180 -135.82 131.85 35.91 Favored 'General case' 0 N--CA 1.463 0.205 0 N-CA-C 110.016 -0.364 . . . . 0.0 110.016 176.681 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -135.21 141.11 45.75 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.649 0.262 . . . . 0.0 111.703 -179.85 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 40.9 m -121.7 132.05 54.43 Favored 'General case' 0 CA--C 1.544 0.719 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.538 179.554 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 58.8 tp -71.56 114.27 9.47 Favored 'General case' 0 CA--C 1.522 -0.13 0 CA-C-O 121.202 0.525 . . . . 0.0 112.345 -178.412 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 68.1 mt -80.87 -31.38 35.33 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.553 -0.749 . . . . 0.0 109.803 175.566 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 123.72 164.73 12.09 Favored Glycine 0 N--CA 1.445 -0.711 0 N-CA-C 110.362 -1.095 . . . . 0.0 110.362 -177.6 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 94.0 m-20 61.11 36.03 18.43 Favored 'General case' 0 N--CA 1.477 0.896 0 CA-C-N 117.343 0.571 . . . . 0.0 110.917 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 95.0 m-20 63.78 18.88 11.43 Favored 'General case' 0 N--CA 1.477 0.878 0 CA-C-N 115.389 -0.823 . . . . 0.0 111.864 179.235 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 31.6 m -108.56 131.91 54.38 Favored 'General case' 0 N--CA 1.448 -0.565 0 CA-C-O 121.123 0.487 . . . . 0.0 110.926 -179.243 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.525 ' HE2' ' O ' ' A' ' 44' ' ' GLY . 95.6 m-85 -119.13 152.14 37.06 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.212 179.911 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 58.1 tt0 -108.0 127.57 53.88 Favored 'General case' 0 C--N 1.314 -0.946 0 N-CA-C 107.997 -1.112 . . . . 0.0 107.997 174.482 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 56.5 t -111.64 137.56 43.77 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.855 0 N-CA-C 113.77 1.026 . . . . 0.0 113.77 -171.147 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 50.1 mt-10 -123.98 149.49 45.93 Favored 'General case' 0 C--O 1.245 0.86 0 CA-C-N 114.832 -1.076 . . . . 0.0 108.303 175.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 14.3 m120 -131.65 156.54 45.66 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-O 120.561 0.22 . . . . 0.0 110.47 -175.98 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' GLN . . . . . 0.507 ' O ' ' HB ' ' A' ' 59' ' ' ILE . 1.7 pt20 -147.18 144.07 28.68 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.402 176.315 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 31.9 p90 -147.24 168.25 22.17 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.16 -177.467 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 79.54 70.35 1.33 Allowed Glycine 0 N--CA 1.441 -0.987 0 C-N-CA 121.078 -0.582 . . . . 0.0 114.109 176.316 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . 0.513 ' O ' ' HB3' ' A' ' 80' ' ' ASP . . . 106.22 -27.32 17.55 Favored Glycine 0 N--CA 1.445 -0.702 0 C-N-CA 120.296 -0.955 . . . . 0.0 113.827 175.733 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . 0.513 ' HB3' ' O ' ' A' ' 79' ' ' GLY . 19.3 t70 81.28 -28.63 0.12 Allowed 'General case' 0 N--CA 1.493 1.703 0 CA-C-O 121.328 0.585 . . . . 0.0 110.736 178.356 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 11.6 p -85.08 16.73 3.3 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-O 121.247 0.546 . . . . 0.0 110.629 174.221 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -89.33 165.45 25.97 Favored Pre-proline 0 CA--C 1.538 0.495 0 CA-C-N 115.599 -0.728 . . . . 0.0 111.073 -178.12 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 10.6 Cg_exo -70.47 166.88 27.02 Favored 'Trans proline' 0 C--N 1.357 0.979 0 C-N-CA 122.851 2.367 . . . . 0.0 111.746 178.481 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' TRP . . . . . . . . . . . . . 90.8 m95 -95.59 137.45 34.63 Favored 'General case' 0 N--CA 1.445 -0.691 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -178.489 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 85.4 m-70 -119.28 145.54 46.02 Favored 'General case' 0 C--N 1.313 -0.98 0 N-CA-C 109.669 -0.493 . . . . 0.0 109.669 -177.26 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 7.1 m -61.78 133.92 56.1 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 110.303 -0.258 . . . . 0.0 110.303 -179.239 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -108.77 -50.67 0.73 Allowed Glycine 0 N--CA 1.443 -0.856 0 C-N-CA 120.137 -1.03 . . . . 0.0 111.987 178.66 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 152.65 -167.7 31.55 Favored Glycine 0 C--O 1.221 -0.683 0 C-N-CA 120.699 -0.762 . . . . 0.0 111.865 179.55 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 19.8 m120 -103.66 145.5 29.97 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 116.901 0.35 . . . . 0.0 110.722 179.824 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' TRP . . . . . 0.48 ' CH2' HG21 ' A' ' 25' ' ' ILE . 12.4 m0 -132.88 142.54 48.98 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 -178.376 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 86.6 mt -109.25 116.41 52.02 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.962 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 177.958 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . 0.41 ' HB2' ' CE1' ' A' ' 71' ' ' TYR . 71.8 mt -134.81 75.89 1.6 Allowed 'General case' 0 C--O 1.263 1.789 0 CA-C-O 121.449 0.643 . . . . 0.0 111.668 -175.967 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . 0.422 ' O ' ' HB2' ' A' ' 94' ' ' SER . . . -148.93 -69.51 0.01 OUTLIER Glycine 0 N--CA 1.445 -0.763 0 C-N-CA 120.289 -0.958 . . . . 0.0 112.785 -179.931 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' SER . . . . . 0.607 ' HB3' ' O ' ' A' ' 20' ' ' GLY . 17.3 m 73.44 -34.95 0.3 Allowed 'General case' 0 N--CA 1.479 1.009 0 C-N-CA 123.478 0.711 . . . . 0.0 112.563 -178.593 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 82.6 mtp180 -101.02 153.95 19.11 Favored 'General case' 0 N--CA 1.439 -0.984 0 CA-C-O 120.868 0.366 . . . . 0.0 110.942 -179.179 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 44.5 tt0 -62.03 -54.37 42.4 Favored 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 113.51 0.93 . . . . 0.0 113.51 -172.87 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 47.4 m-80 -122.29 37.1 4.46 Favored 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 111.869 0.322 . . . . 0.0 111.869 -176.475 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' GLN . . . . . 0.527 HE21 ' CB ' ' A' ' 120' ' ' TYR . 39.6 tt0 -148.04 116.12 6.48 Favored 'General case' 0 C--N 1.316 -0.867 0 C-N-CA 120.543 -0.463 . . . . 0.0 110.354 -178.044 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 52.7 m-80 -96.69 164.85 12.41 Favored 'General case' 0 C--O 1.247 0.946 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.716 -175.427 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . 0.416 HG22 ' CZ2' ' A' ' 23' ' ' TRP . 86.7 t -87.36 137.11 21.58 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.735 0 CA-C-N 115.897 -0.592 . . . . 0.0 111.198 177.361 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . 0.43 ' CG1' ' HA ' ' A' ' 121' ' ' ALA . 34.3 m -119.87 -29.59 1.78 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.743 0 N-CA-C 112.971 0.73 . . . . 0.0 112.971 -178.426 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . 0.462 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -141.26 138.06 32.97 Favored 'General case' 0 C--N 1.323 -0.557 0 C-N-CA 120.048 -0.661 . . . . 0.0 111.445 179.537 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 93.3 mt -134.03 128.02 52.42 Favored 'Isoleucine or valine' 0 C--O 1.244 0.78 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.836 179.154 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 43.5 t30 -129.21 99.76 5.35 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 109.033 -0.728 . . . . 0.0 109.033 174.483 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.405 HG21 ' HB ' ' A' ' 36' ' ' ILE . 25.2 m -141.99 148.31 20.68 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 N-CA-C 112.572 0.582 . . . . 0.0 112.572 -176.416 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 37.9 tt0 -149.92 154.98 39.21 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 115.156 -0.929 . . . . 0.0 108.88 175.469 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 37.7 t -132.84 143.65 49.68 Favored 'General case' 0 C--N 1.311 -1.078 0 CA-C-O 121.132 0.491 . . . . 0.0 111.702 -177.997 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -84.78 -9.42 81.07 Favored Glycine 0 N--CA 1.441 -0.979 0 N-CA-C 110.166 -1.174 . . . . 0.0 110.166 174.922 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 78.3 m-20 -97.29 -171.28 2.17 Favored 'General case' 0 CA--C 1.507 -0.685 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 178.404 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 99.4 m-20 -89.65 39.53 0.96 Allowed 'General case' 0 C--N 1.308 -1.221 0 CA-C-O 121.373 0.606 . . . . 0.0 110.392 177.843 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 95.18 -2.65 65.94 Favored Glycine 0 N--CA 1.447 -0.598 0 CA-C-N 115.609 -0.723 . . . . 0.0 113.152 178.571 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 112' ' ' GLN . . . . . 0.461 ' HA ' HD22 ' A' ' 132' ' ' LEU . 98.4 mt-30 -64.14 -42.7 96.69 Favored 'General case' 0 C--O 1.245 0.839 0 N-CA-C 112.755 0.65 . . . . 0.0 112.755 -176.989 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 46.5 p -124.63 106.64 10.27 Favored 'General case' 0 N--CA 1.449 -0.521 0 CA-C-O 120.954 0.407 . . . . 0.0 110.279 176.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 98.3 mt -91.33 111.84 23.51 Favored 'General case' 0 C--N 1.316 -0.883 0 CA-C-O 120.642 0.258 . . . . 0.0 110.347 -179.344 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 57.1 m-80 -108.86 143.03 38.59 Favored 'General case' 0 C--N 1.313 -0.997 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.342 -179.955 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 163.56 -141.69 7.31 Favored Glycine 0 N--CA 1.435 -1.426 0 C-N-CA 119.655 -1.26 . . . . 0.0 113.162 177.599 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 33.8 p -134.85 158.12 45.05 Favored 'General case' 0 C--N 1.315 -0.907 0 C-N-CA 122.616 0.366 . . . . 0.0 110.504 -177.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 25.8 ptm -144.97 152.24 39.86 Favored 'General case' 0 C--N 1.314 -0.939 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.297 -179.766 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 119' ' ' THR . . . . . 0.462 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 32.9 m -129.74 129.34 44.03 Favored 'General case' 0 C--O 1.249 1.059 0 CA-C-N 116.387 -0.37 . . . . 0.0 110.694 179.682 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . 0.527 ' CB ' HE21 ' A' ' 98' ' ' GLN . 45.6 m-85 -85.34 170.48 12.71 Favored 'General case' 0 CA--C 1.517 -0.289 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.325 176.4 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . 0.43 ' HA ' ' CG1' ' A' ' 101' ' ' VAL . . . -53.21 -40.4 64.44 Favored 'General case' 0 N--CA 1.471 0.586 0 N-CA-C 113.167 0.803 . . . . 0.0 113.167 -178.13 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -151.81 87.88 0.14 Allowed Glycine 0 N--CA 1.447 -0.602 0 C-N-CA 119.579 -1.296 . . . . 0.0 112.821 -179.404 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 77.4 tt0 -169.8 -69.14 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.771 0.32 . . . . 0.0 110.842 179.436 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 153.44 161.87 10.65 Favored Glycine 0 N--CA 1.443 -0.841 0 C-N-CA 120.812 -0.708 . . . . 0.0 111.887 179.316 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 21.2 Cg_exo -66.96 136.57 41.75 Favored 'Trans proline' 0 C--O 1.24 0.582 0 C-N-CA 122.733 2.289 . . . . 0.0 111.73 178.865 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 43.1 pt -135.52 166.26 28.14 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.145 178.862 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -72.89 136.15 22.48 Favored Glycine 0 C--O 1.237 0.284 0 C-N-CA 120.712 -0.756 . . . . 0.0 111.786 -179.759 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 78.9 t80 -122.46 136.81 54.97 Favored 'General case' 0 C--O 1.24 0.569 0 CA-C-O 120.959 0.409 . . . . 0.0 111.651 -177.286 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 61.9 tttm -134.87 103.69 5.7 Favored 'General case' 0 N--CA 1.446 -0.668 0 CA-C-N 115.349 -0.841 . . . . 0.0 109.941 177.145 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -100.24 133.33 11.26 Favored Glycine 0 N--CA 1.443 -0.863 0 N-CA-C 111.183 -0.767 . . . . 0.0 111.183 177.733 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 38.7 m -129.84 137.56 50.51 Favored 'General case' 0 C--N 1.306 -1.286 0 CA-C-N 117.042 0.421 . . . . 0.0 111.187 -177.951 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 132' ' ' LEU . . . . . 0.461 HD22 ' HA ' ' A' ' 112' ' ' GLN . 2.9 mm? -59.76 137.78 57.96 Favored 'General case' 0 N--CA 1.473 0.708 0 CA-C-O 121.285 0.564 . . . . 0.0 111.727 178.752 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 14.4 m . . . . . 0 N--CA 1.435 -1.203 0 CA-C-N 115.528 -0.76 . . . . 0.0 110.174 178.283 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.51 -0.561 0 CA-C-O 120.694 0.283 . . . . 0.0 110.33 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 10.2 tt -99.77 131.83 45.5 Favored 'General case' 0 C--N 1.316 -0.889 0 CA-C-O 121.177 0.513 . . . . 0.0 110.486 -179.059 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 85.8 m-85 -120.81 142.64 49.42 Favored 'General case' 0 C--N 1.311 -1.083 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.201 178.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . 0.494 ' O ' ' HA2' ' A' ' 130' ' ' GLY . 88.9 m-20 -87.94 132.15 34.33 Favored 'General case' 0 C--N 1.308 -1.219 0 N-CA-C 107.501 -1.296 . . . . 0.0 107.501 176.786 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.593 HG22 ' CG ' ' A' ' 23' ' ' TRP . 54.2 t -113.88 128.66 70.7 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.99 0 CA-C-O 121.973 0.892 . . . . 0.0 113.191 -173.456 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.416 ' HB2' ' HB3' ' A' ' 129' ' ' LYS . 27.0 mt-10 -120.82 131.75 54.62 Favored 'General case' 0 N--CA 1.43 -1.45 0 CA-C-N 113.631 -1.622 . . . . 0.0 107.755 179.785 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 10.9 m120 -119.9 145.32 46.8 Favored 'General case' 0 C--N 1.314 -0.939 0 CA-C-O 120.995 0.426 . . . . 0.0 111.9 -176.81 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 53.4 tt0 -122.66 110.29 15.34 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.57 -0.741 . . . . 0.0 109.138 179.554 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 3.1 p90 -128.68 -171.42 2.46 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 112.682 0.623 . . . . 0.0 112.682 -175.079 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 66.34 -90.84 0.15 Allowed Glycine 0 C--N 1.336 0.552 0 CA-C-N 114.955 -1.02 . . . . 0.0 114.938 176.084 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.511 ' C ' ' H ' ' A' ' 14' ' ' SER . . . -85.85 0.78 87.97 Favored Glycine 0 C--N 1.319 -0.376 0 C-N-CA 121.319 -0.467 . . . . 0.0 114.098 -173.52 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 13.3 t 59.17 -6.46 0.06 Allowed 'General case' 0 CA--C 1.562 1.434 0 C-N-CA 123.323 0.649 . . . . 0.0 112.662 -177.719 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' SER . . . . . 0.511 ' H ' ' C ' ' A' ' 12' ' ' GLY . 8.7 t -125.7 16.13 8.11 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-O 121.658 0.742 . . . . 0.0 109.358 -179.39 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -80.05 163.79 55.94 Favored Pre-proline 0 N--CA 1.445 -0.718 0 CA-C-N 114.877 -1.056 . . . . 0.0 110.122 -179.463 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 14.2 Cg_exo -69.71 169.6 18.47 Favored 'Trans proline' 0 N--CA 1.46 -0.488 0 C-N-CA 122.608 2.205 . . . . 0.0 111.757 177.967 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 98.5 m95 -80.92 121.71 26.34 Favored 'General case' 0 C--N 1.316 -0.868 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 -179.224 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 91.4 m-20 -106.56 114.19 28.16 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.573 -177.595 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -78.56 128.62 33.78 Favored 'General case' 0 C--N 1.319 -0.756 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 178.406 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -143.3 35.45 1.66 Allowed Glycine 0 N--CA 1.442 -0.961 0 C-N-CA 119.51 -1.329 . . . . 0.0 112.694 -179.713 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 137.62 -174.02 22.02 Favored Glycine 0 N--CA 1.443 -0.843 0 C-N-CA 120.034 -1.079 . . . . 0.0 112.782 178.185 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 88.1 mt-30 -132.0 149.21 52.49 Favored 'General case' 0 C--N 1.318 -0.788 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 -179.768 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . 0.593 ' CG ' HG22 ' A' ' 6' ' ' VAL . 38.5 m0 -119.07 153.24 35.08 Favored 'General case' 0 C--N 1.315 -0.913 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 177.947 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 89.1 mt-10 -111.59 113.69 26.26 Favored 'General case' 0 C--N 1.305 -1.345 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 175.946 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 81.8 mt -130.25 140.35 49.1 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-N 116.0 -0.546 . . . . 0.0 111.904 -172.381 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 91.79 125.17 3.4 Favored Glycine 0 N--CA 1.442 -0.945 0 N-CA-C 114.761 0.665 . . . . 0.0 114.761 172.294 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 3.8 p -88.35 12.61 13.66 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 109.278 -0.638 . . . . 0.0 109.278 173.939 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 62.6 ttp85 -24.74 108.91 0.03 OUTLIER 'General case' 0 N--CA 1.474 0.727 0 C-N-CA 125.477 1.511 . . . . 0.0 113.883 179.732 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 11.0 m -102.88 -62.36 1.29 Allowed 'General case' 0 N--CA 1.436 -1.14 0 CA-C-N 115.235 -0.893 . . . . 0.0 108.83 176.733 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 27.2 m-20 -124.4 5.85 8.36 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.46 178.17 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 1.4 mm-40 -149.53 136.36 19.53 Favored 'General case' 0 C--N 1.318 -0.761 0 CA-C-N 116.009 -0.542 . . . . 0.0 111.432 -177.864 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . 0.513 ' ND2' ' HA3' ' A' ' 111' ' ' GLY . 63.7 t30 -93.36 164.45 13.21 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.947 -0.569 . . . . 0.0 111.331 -179.126 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 57.8 t -96.27 130.37 45.03 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 CA-C-N 115.422 -0.808 . . . . 0.0 110.699 -176.912 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 23.7 m -114.07 -16.33 9.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 N-CA-C 112.218 0.451 . . . . 0.0 112.218 178.754 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -145.86 142.37 28.74 Favored 'General case' 0 CA--C 1.515 -0.384 0 C-N-CA 120.377 -0.529 . . . . 0.0 111.537 178.998 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.417 ' HB ' ' CG2' ' A' ' 105' ' ' VAL . 96.3 mt -142.57 127.46 16.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 N-CA-C 108.987 -0.746 . . . . 0.0 108.987 179.124 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . 0.434 ' HA ' ' O ' ' A' ' 103' ' ' ILE . 3.0 t-20 -138.0 113.09 9.2 Favored 'General case' 0 C--N 1.313 -0.991 0 N-CA-C 108.739 -0.837 . . . . 0.0 108.739 176.865 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.414 HG11 ' CD2' ' A' ' 61' ' ' PHE . 28.0 m -148.18 153.15 11.88 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.442 0 C-N-CA 120.918 -0.313 . . . . 0.0 111.19 -174.059 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 81.3 tt0 -139.17 145.37 39.26 Favored 'General case' 0 C--N 1.321 -0.639 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 176.714 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 12.9 t -77.04 139.93 40.19 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-O 120.883 0.373 . . . . 0.0 110.714 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -88.63 -7.07 72.29 Favored Glycine 0 N--CA 1.446 -0.672 0 C-N-CA 120.555 -0.831 . . . . 0.0 111.114 177.061 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 21.1 m-20 -141.83 -153.98 0.49 Allowed 'General case' 0 C--N 1.33 -0.242 0 C-N-CA 122.508 0.323 . . . . 0.0 110.257 -179.319 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 86.7 m-20 -78.28 44.07 0.48 Allowed 'General case' 0 N--CA 1.471 0.589 0 C-N-CA 122.664 0.386 . . . . 0.0 111.961 -178.468 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 87.49 -5.13 85.53 Favored Glycine 0 C--O 1.227 -0.335 0 C-N-CA 120.787 -0.721 . . . . 0.0 113.491 178.094 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 54.9 mt-30 -70.29 -38.89 75.1 Favored 'General case' 0 C--O 1.222 -0.362 0 N-CA-C 112.59 0.589 . . . . 0.0 112.59 179.604 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' THR . . . . . 0.602 ' HA ' ' O ' ' A' ' 63' ' ' ALA . 7.8 t -127.71 123.57 35.73 Favored 'General case' 0 C--N 1.32 -0.689 0 C-N-CA 120.426 -0.51 . . . . 0.0 111.293 -179.027 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 95.5 mt -103.15 124.81 49.29 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.037 177.912 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . 0.495 ' OD1' ' HG3' ' A' ' 62' ' ' ARG . 93.2 m-20 -119.61 142.11 48.7 Favored 'General case' 0 C--N 1.313 -0.985 0 CA-C-N 115.969 -0.559 . . . . 0.0 110.021 179.616 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 166.47 -146.48 10.97 Favored Glycine 0 CA--C 1.501 -0.822 0 C-N-CA 119.787 -1.197 . . . . 0.0 112.787 179.373 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 33.5 p -135.51 153.04 51.86 Favored 'General case' 0 N--CA 1.446 -0.629 0 CA-C-O 120.973 0.416 . . . . 0.0 111.066 -178.718 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' MET . . . . . 0.422 ' HE3' ' CZ ' ' A' ' 53' ' ' TYR . 16.6 tmm? -135.01 138.65 44.16 Favored 'General case' 0 C--N 1.317 -0.83 0 N-CA-C 109.276 -0.638 . . . . 0.0 109.276 178.148 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 29.4 m -125.24 129.26 49.71 Favored 'General case' 0 C--O 1.255 1.365 0 N-CA-C 112.527 0.566 . . . . 0.0 112.527 -175.564 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . 0.482 ' HB2' ' HB2' ' A' ' 56' ' ' GLU . 95.1 m-85 -85.29 165.73 17.07 Favored 'General case' 0 CA--C 1.532 0.251 0 CA-C-N 115.341 -0.845 . . . . 0.0 109.805 176.659 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -66.87 113.51 4.98 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 120.714 0.292 . . . . 0.0 111.707 -179.008 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 76.6 16.53 80.67 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.844 178.11 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . 0.482 ' HB2' ' HB2' ' A' ' 53' ' ' TYR . 73.0 mm-40 -121.71 177.67 5.16 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-O 120.769 0.319 . . . . 0.0 110.395 -179.397 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -93.38 153.48 21.37 Favored Glycine 0 N--CA 1.443 -0.857 0 C-N-CA 120.805 -0.712 . . . . 0.0 111.556 178.694 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -67.8 144.27 64.55 Favored 'Trans proline' 0 C--O 1.237 0.432 0 C-N-CA 122.555 2.17 . . . . 0.0 112.574 179.581 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 39.6 pt -125.86 162.69 28.74 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.818 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.284 178.644 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -71.24 145.1 38.74 Favored Glycine 0 N--CA 1.448 -0.537 0 C-N-CA 121.195 -0.526 . . . . 0.0 112.323 -177.559 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.414 ' CD2' HG11 ' A' ' 38' ' ' VAL . 69.4 t80 -130.93 126.94 37.42 Favored 'General case' 0 C--N 1.313 -1.02 0 C-N-CA 122.106 0.162 . . . . 0.0 110.972 -178.186 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . 0.495 ' HG3' ' OD1' ' A' ' 48' ' ' ASN . 29.0 ttp85 -135.32 128.31 31.51 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 108.798 -0.816 . . . . 0.0 108.798 174.643 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.602 ' O ' ' HA ' ' A' ' 46' ' ' THR . . . -132.87 141.76 48.58 Favored 'General case' 0 C--N 1.316 -0.857 0 C-N-CA 120.852 -0.339 . . . . 0.0 111.713 -178.378 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 31.7 m -124.06 128.97 50.1 Favored 'General case' 0 CA--C 1.539 0.527 0 CA-C-N 116.458 -0.337 . . . . 0.0 110.634 179.516 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 51.2 tp -74.73 127.6 33.53 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 112.279 0.474 . . . . 0.0 112.279 -177.514 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 10.7 mp -79.82 -24.36 41.41 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.969 177.094 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 113.64 -8.36 24.05 Favored Glycine 0 CA--C 1.521 0.465 0 C-N-CA 120.93 -0.653 . . . . 0.0 112.638 179.88 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 24.2 p-10 -115.41 30.12 7.56 Favored 'General case' 0 C--N 1.312 -1.054 0 CA-C-O 121.04 0.448 . . . . 0.0 110.445 179.937 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 87.3 m-20 76.48 -9.38 1.49 Allowed 'General case' 0 N--CA 1.485 1.278 0 C-N-CA 124.353 1.061 . . . . 0.0 111.048 -178.099 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' SER . . . . . 0.454 ' HG ' ' CD1' ' A' ' 91' ' ' ILE . 9.0 m -81.49 138.58 35.47 Favored 'General case' 0 N--CA 1.441 -0.884 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.433 177.828 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.448 ' HB3' ' HB1' ' A' ' 63' ' ' ALA . 43.8 m-85 -122.12 129.94 52.8 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-N 115.679 -0.691 . . . . 0.0 109.685 178.126 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 36.0 tt0 -83.45 119.02 24.14 Favored 'General case' 0 N--CA 1.44 -0.949 0 N-CA-C 107.774 -1.195 . . . . 0.0 107.774 174.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 53.0 t -108.08 133.62 52.41 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.307 0 N-CA-C 112.866 0.691 . . . . 0.0 112.866 -172.474 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 99.8 mt-10 -120.03 122.4 41.05 Favored 'General case' 0 N--CA 1.436 -1.158 0 CA-C-N 114.51 -1.223 . . . . 0.0 108.875 176.676 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 2.7 m-20 -96.29 140.57 30.78 Favored 'General case' 0 C--N 1.313 -1.018 0 CA-C-N 116.288 -0.415 . . . . 0.0 109.917 179.367 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' GLN . . . . . 0.494 ' HB2' ' CE3' ' A' ' 84' ' ' TRP . 61.3 tt0 -115.87 120.89 40.68 Favored 'General case' 0 C--N 1.307 -1.254 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 179.345 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 6.1 p90 -137.55 157.1 47.25 Favored 'General case' 0 C--N 1.312 -1.027 0 CA-C-O 120.723 0.297 . . . . 0.0 110.329 179.481 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 103.13 -13.84 55.51 Favored Glycine 0 N--CA 1.439 -1.115 0 C-N-CA 120.756 -0.735 . . . . 0.0 111.652 -179.838 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 131.51 170.64 12.67 Favored Glycine 0 N--CA 1.437 -1.246 0 C-N-CA 120.886 -0.673 . . . . 0.0 111.972 178.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 5.7 p-10 -65.73 -33.1 75.09 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 121.056 0.455 . . . . 0.0 111.127 179.864 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 40.6 m -78.45 -2.89 40.66 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 115.845 -0.616 . . . . 0.0 111.856 -178.565 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -89.61 146.11 34.99 Favored Pre-proline 0 C--N 1.325 -0.458 0 CA-C-N 116.6 -0.273 . . . . 0.0 110.341 178.606 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.82 177.09 5.98 Favored 'Trans proline' 0 CA--C 1.532 0.405 0 C-N-CA 122.738 2.292 . . . . 0.0 112.298 179.847 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' TRP . . . . . 0.494 ' CE3' ' HB2' ' A' ' 76' ' ' GLN . 98.5 m95 -85.89 143.09 28.41 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 109.716 -0.476 . . . . 0.0 109.716 -179.154 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 91.7 m-70 -119.61 146.11 45.83 Favored 'General case' 0 C--N 1.313 -1.021 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 -179.643 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 46.0 m -63.51 131.2 47.36 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-O 120.891 0.377 . . . . 0.0 110.898 -179.396 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -107.94 -55.2 0.61 Allowed Glycine 0 N--CA 1.441 -1.013 0 C-N-CA 120.842 -0.694 . . . . 0.0 111.694 179.536 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 157.42 -173.43 34.88 Favored Glycine 0 C--O 1.223 -0.546 0 C-N-CA 120.26 -0.971 . . . . 0.0 112.184 179.326 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 24.3 t-20 -109.7 113.26 25.88 Favored 'General case' 0 C--N 1.316 -0.879 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 178.919 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 21.0 m0 -105.96 153.14 22.41 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.432 -176.416 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . 0.454 ' CD1' ' HG ' ' A' ' 70' ' ' SER . 46.8 mm -107.22 113.54 43.8 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.799 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 177.259 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 82.8 mt -127.08 78.51 1.82 Allowed 'General case' 0 C--O 1.268 2.066 0 CA-C-O 122.045 0.926 . . . . 0.0 112.371 -176.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 162.71 104.87 0.19 Allowed Glycine 0 N--CA 1.444 -0.772 0 CA-C-N 114.741 -1.118 . . . . 0.0 110.752 -179.072 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 15.7 p -106.88 -13.12 15.31 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 120.889 0.376 . . . . 0.0 111.867 -178.0 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 85.2 mtp180 -85.47 16.2 3.96 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 121.248 0.547 . . . . 0.0 111.452 -179.202 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 46.9 tp10 65.36 -74.51 0.05 Allowed 'General case' 0 N--CA 1.472 0.646 0 CA-C-N 114.459 -1.246 . . . . 0.0 113.97 174.007 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 61.9 m-80 -91.97 26.85 2.3 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-O 120.765 0.317 . . . . 0.0 111.739 -175.077 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' GLN . . . . . . . . . . . . . 58.1 tt0 -150.05 116.62 5.81 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.801 0.334 . . . . 0.0 110.218 -177.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 83.6 m-20 -84.58 160.02 20.54 Favored 'General case' 0 C--O 1.245 0.819 0 CA-C-N 115.977 -0.556 . . . . 0.0 111.77 -176.895 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 79.5 t -82.36 132.43 31.43 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.664 0 C-N-CA 120.728 -0.389 . . . . 0.0 110.818 176.699 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 34.7 m -114.44 -23.76 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.601 0 N-CA-C 113.087 0.773 . . . . 0.0 113.087 -179.457 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . 0.425 ' HB2' ' HB ' ' A' ' 119' ' ' THR . . . -152.04 144.13 23.87 Favored 'General case' 0 CA--C 1.512 -0.49 0 C-N-CA 120.425 -0.51 . . . . 0.0 111.113 178.198 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.434 ' O ' ' HA ' ' A' ' 37' ' ' ASN . 84.6 mt -135.88 125.8 41.24 Favored 'Isoleucine or valine' 0 C--O 1.236 0.393 0 CA-C-O 120.582 0.23 . . . . 0.0 110.81 179.066 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 9.6 t30 -126.74 94.88 4.16 Favored 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 175.172 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.417 ' CG2' ' HB ' ' A' ' 36' ' ' ILE . 30.9 m -136.88 141.43 40.68 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.702 0 N-CA-C 113.633 0.975 . . . . 0.0 113.633 -174.191 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 74.6 tt0 -141.71 150.49 41.9 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 114.97 -1.014 . . . . 0.0 109.298 178.117 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 35.6 p -150.65 153.17 35.15 Favored 'General case' 0 N--CA 1.446 -0.671 0 CA-C-O 120.821 0.343 . . . . 0.0 111.219 177.545 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -123.19 5.59 9.47 Favored Glycine 0 N--CA 1.439 -1.124 0 N-CA-C 111.112 -0.795 . . . . 0.0 111.112 177.474 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -92.34 34.59 1.03 Allowed 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 121.196 0.522 . . . . 0.0 110.528 179.495 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 29.3 m-20 59.21 21.83 10.0 Favored 'General case' 0 N--CA 1.474 0.741 0 CA-C-N 115.284 -0.871 . . . . 0.0 112.507 176.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . 0.513 ' HA3' ' ND2' ' A' ' 32' ' ' ASN . . . 89.71 -0.14 79.5 Favored Glycine 0 N--CA 1.447 -0.582 0 C-N-CA 120.748 -0.739 . . . . 0.0 113.174 177.928 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 51.8 tt0 -65.62 -43.38 89.76 Favored 'General case' 0 C--O 1.235 0.335 0 CA-C-O 121.356 0.598 . . . . 0.0 110.282 178.725 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 6.4 p -128.72 125.99 39.11 Favored 'General case' 0 N--CA 1.434 -1.248 0 CA-C-N 115.428 -0.805 . . . . 0.0 109.97 176.665 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 42.4 tp -112.47 134.94 53.73 Favored 'General case' 0 C--N 1.306 -1.319 0 CA-C-N 115.899 -0.591 . . . . 0.0 109.596 -177.776 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 30.1 p30 -145.72 169.91 17.54 Favored 'General case' 0 C--N 1.32 -0.698 0 C-N-CA 119.779 -0.768 . . . . 0.0 112.301 179.92 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 147.36 -131.71 4.02 Favored Glycine 0 N--CA 1.434 -1.444 0 CA-C-N 115.127 -0.942 . . . . 0.0 111.204 179.283 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 21.9 p -133.2 159.23 40.79 Favored 'General case' 0 C--N 1.307 -1.246 0 CA-C-O 121.095 0.474 . . . . 0.0 110.72 179.923 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 4.5 ppp? -153.91 163.02 40.73 Favored 'General case' 0 C--N 1.306 -1.306 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 178.802 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 119' ' ' THR . . . . . 0.425 ' HB ' ' HB2' ' A' ' 102' ' ' ALA . 32.1 m -131.47 130.2 42.13 Favored 'General case' 0 C--N 1.307 -1.254 0 CA-C-O 120.791 0.329 . . . . 0.0 111.235 -179.79 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 11.5 m-85 -94.71 161.22 14.27 Favored 'General case' 0 N--CA 1.45 -0.473 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.075 177.095 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -65.6 128.19 34.93 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 120.89 0.376 . . . . 0.0 111.89 -179.098 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 76.23 19.17 78.72 Favored Glycine 0 N--CA 1.45 -0.396 0 CA-C-N 115.775 -0.648 . . . . 0.0 112.956 176.859 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 70.5 tt0 -147.22 161.08 41.65 Favored 'General case' 0 C--N 1.317 -0.832 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 -178.393 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -80.05 -179.49 52.54 Favored Glycine 0 N--CA 1.448 -0.508 0 C-N-CA 121.017 -0.611 . . . . 0.0 112.356 179.63 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -71.56 140.37 36.05 Favored 'Trans proline' 0 CA--C 1.532 0.392 0 C-N-CA 122.714 2.276 . . . . 0.0 112.959 -178.788 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 44.0 pt -132.68 165.99 30.64 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.13 178.805 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -73.15 142.6 31.91 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 121.017 -0.611 . . . . 0.0 112.458 -179.809 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 79.4 t80 -122.76 136.88 55.01 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-O 120.911 0.386 . . . . 0.0 111.272 -179.288 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 129' ' ' LYS . . . . . 0.416 ' HB3' ' HB2' ' A' ' 7' ' ' GLU . 63.2 tttm -142.0 125.95 17.21 Favored 'General case' 0 N--CA 1.447 -0.58 0 CA-C-N 115.649 -0.705 . . . . 0.0 109.154 175.668 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . 0.494 ' HA2' ' O ' ' A' ' 5' ' ' ASN . . . -127.24 135.74 8.96 Favored Glycine 0 N--CA 1.432 -1.581 0 N-CA-C 110.856 -0.898 . . . . 0.0 110.856 178.918 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 30.1 m -118.55 126.94 53.08 Favored 'General case' 0 C--N 1.305 -1.338 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 -178.581 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 66.1 tp -75.24 140.71 43.39 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.782 0.325 . . . . 0.0 111.154 -178.608 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 9.8 t . . . . . 0 C--O 1.248 1.022 0 CA-C-O 118.604 -0.712 . . . . 0.0 109.533 177.987 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.467 0.394 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . 0.448 HD12 HE21 ' A' ' 22' ' ' GLN . 3.3 tm? -90.72 128.08 36.54 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-O 121.046 0.45 . . . . 0.0 110.332 -178.331 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 47.2 m-85 -124.46 147.08 48.56 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.864 -0.607 . . . . 0.0 111.175 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 5.7 m-20 -100.97 137.83 38.82 Favored 'General case' 0 C--N 1.315 -0.931 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 175.502 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.441 HG22 ' CD2' ' A' ' 23' ' ' TRP . 68.1 t -116.02 128.26 73.36 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.774 0 CA-C-O 121.527 0.68 . . . . 0.0 112.745 -173.913 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.42 ' HA ' ' HA ' ' A' ' 19' ' ' GLU . 65.4 mt-10 -118.66 138.36 52.66 Favored 'General case' 0 N--CA 1.437 -1.101 0 CA-C-N 114.681 -1.145 . . . . 0.0 108.423 176.713 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 11.9 m120 -127.44 147.16 50.29 Favored 'General case' 0 C--N 1.312 -1.037 0 CA-C-O 121.172 0.511 . . . . 0.0 111.896 -177.056 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 52.1 tt0 -123.38 117.24 24.75 Favored 'General case' 0 C--N 1.314 -0.955 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 178.118 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 7.6 p90 -137.93 9.44 2.81 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 114.313 1.227 . . . . 0.0 114.313 -174.84 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -93.24 31.51 6.3 Favored Glycine 0 CA--C 1.522 0.485 0 C-N-CA 118.748 -1.692 . . . . 0.0 114.353 -174.784 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.63 58.88 3.17 Favored Glycine 0 CA--C 1.525 0.67 0 C-N-CA 120.428 -0.891 . . . . 0.0 114.376 176.922 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 22.8 t 60.69 154.55 0.03 OUTLIER 'General case' 0 CA--C 1.553 1.083 0 N-CA-C 113.408 0.892 . . . . 0.0 113.408 177.325 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 49.3 m 63.3 14.42 7.82 Favored 'General case' 0 N--CA 1.472 0.671 0 CA-C-N 115.851 -0.613 . . . . 0.0 112.355 177.223 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -96.7 153.95 38.57 Favored Pre-proline 0 C--N 1.314 -0.939 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.189 -179.446 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -73.18 161.69 42.47 Favored 'Trans proline' 0 C--O 1.238 0.503 0 C-N-CA 122.634 2.223 . . . . 0.0 111.703 177.772 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . 0.402 ' HB3' ' HB3' ' A' ' 7' ' ' GLU . 92.6 m95 -85.18 129.46 34.8 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 109.664 -0.495 . . . . 0.0 109.664 179.51 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 27.6 m-80 -113.22 118.57 35.04 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.661 -178.053 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.42 ' HA ' ' HA ' ' A' ' 7' ' ' GLU . 11.5 pt-20 -75.48 129.94 38.09 Favored 'General case' 0 C--N 1.319 -0.718 0 N-CA-C 109.724 -0.473 . . . . 0.0 109.724 177.474 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -137.62 26.57 2.9 Favored Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 119.596 -1.288 . . . . 0.0 113.159 -178.661 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 147.86 179.26 23.72 Favored Glycine 0 N--CA 1.449 -0.433 0 C-N-CA 119.79 -1.195 . . . . 0.0 113.075 178.125 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . 0.448 HE21 HD12 ' A' ' 3' ' ' LEU . 4.4 pt20 -127.99 138.74 52.72 Favored 'General case' 0 C--N 1.322 -0.601 0 C-N-CA 122.69 0.396 . . . . 0.0 110.205 -179.93 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . 0.441 ' CD2' HG22 ' A' ' 6' ' ' VAL . 45.7 m0 -116.07 171.81 7.56 Favored 'General case' 0 C--O 1.242 0.661 0 CA-C-O 120.86 0.362 . . . . 0.0 111.226 -177.802 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 76.5 tt0 -119.13 110.73 17.4 Favored 'General case' 0 CA--C 1.513 -0.465 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 178.005 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 91.1 mt -133.01 143.97 37.9 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-N 115.401 -0.818 . . . . 0.0 109.579 -178.164 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 83.94 71.73 1.31 Allowed Glycine 0 CA--C 1.508 -0.351 0 C-N-CA 120.369 -0.92 . . . . 0.0 112.014 177.891 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 15.9 m -62.68 -45.62 91.97 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 120.823 0.344 . . . . 0.0 111.279 -179.313 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 83.0 mtm-85 -88.36 133.99 33.94 Favored 'General case' 0 CA--C 1.517 -0.322 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.057 178.797 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 18.8 p -87.16 -16.13 36.3 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.956 -0.565 . . . . 0.0 111.398 179.701 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 16.5 m-20 -71.31 -43.2 67.52 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-O 121.51 0.671 . . . . 0.0 110.161 179.933 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 14.1 mm100 -131.76 122.3 25.61 Favored 'General case' 0 C--N 1.312 -1.027 0 CA-C-N 114.915 -1.039 . . . . 0.0 110.046 -179.399 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . 0.498 ' ND2' ' HA3' ' A' ' 111' ' ' GLY . 59.4 t30 -108.15 172.36 6.88 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.324 -177.575 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 14.0 t -101.71 134.24 42.76 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.92 0 N-CA-C 111.877 0.325 . . . . 0.0 111.877 -172.031 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 33.6 m -113.77 -15.34 10.25 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.356 0 CA-C-O 121.017 0.437 . . . . 0.0 111.594 177.386 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.485 ' HB1' ' HB ' ' A' ' 52' ' ' THR . . . -147.48 142.67 27.19 Favored 'General case' 0 CA--C 1.506 -0.715 0 C-N-CA 120.269 -0.572 . . . . 0.0 111.181 178.199 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 85.9 mt -142.36 120.43 8.04 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 N-CA-C 109.155 -0.683 . . . . 0.0 109.155 -179.377 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . 0.457 ' HA ' ' O ' ' A' ' 103' ' ' ILE . 22.7 m-80 -132.37 109.81 10.12 Favored 'General case' 0 C--N 1.31 -1.151 0 N-CA-C 108.88 -0.785 . . . . 0.0 108.88 176.49 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.447 HG22 ' HB ' ' A' ' 103' ' ' ILE . 33.3 m -147.79 152.93 12.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 C-N-CA 120.996 -0.281 . . . . 0.0 111.254 -172.57 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 41.6 tt0 -142.45 147.27 35.84 Favored 'General case' 0 N--CA 1.446 -0.633 0 CA-C-N 115.845 -0.616 . . . . 0.0 109.433 176.755 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 19.9 p -70.42 144.38 51.53 Favored 'General case' 0 C--N 1.313 -1.005 0 CA-C-O 121.083 0.468 . . . . 0.0 111.652 -178.548 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -88.38 -59.18 1.67 Allowed Glycine 0 N--CA 1.441 -0.971 0 N-CA-C 110.366 -1.094 . . . . 0.0 110.366 177.174 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 43.9 m-20 -93.78 -147.11 0.25 Allowed 'General case' 0 C--N 1.32 -0.713 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 176.708 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 20.2 p-10 -78.99 40.66 0.41 Allowed 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.124 0.488 . . . . 0.0 111.949 -178.818 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 97.89 -22.39 41.07 Favored Glycine 0 C--O 1.219 -0.82 0 C-N-CA 120.753 -0.736 . . . . 0.0 113.736 177.351 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 56.3 mt-30 -64.34 -28.61 69.82 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 117.319 0.559 . . . . 0.0 112.111 -178.603 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 26.0 p -117.54 137.0 52.87 Favored 'General case' 0 C--N 1.312 -1.029 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.392 179.334 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 88.7 mt -127.51 128.91 46.47 Favored 'General case' 0 C--N 1.318 -0.793 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 62.7 m-80 -129.47 140.82 51.17 Favored 'General case' 0 C--N 1.318 -0.762 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 178.335 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 178.97 -156.89 19.8 Favored Glycine 0 N--CA 1.438 -1.196 0 C-N-CA 119.972 -1.108 . . . . 0.0 112.797 179.522 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 65.3 m -130.98 132.99 45.39 Favored 'General case' 0 C--N 1.312 -1.04 0 CA-C-O 120.843 0.354 . . . . 0.0 110.646 -179.536 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 46.9 mtp -115.66 148.28 39.88 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.722 177.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.485 ' HB ' ' HB1' ' A' ' 35' ' ' ALA . 33.0 m -126.4 125.33 42.01 Favored 'General case' 0 C--O 1.25 1.086 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.136 177.149 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . 0.422 ' HB2' ' HB2' ' A' ' 56' ' ' GLU . 50.8 m-85 -94.67 164.74 12.83 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.869 -179.43 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -65.14 95.97 0.19 Allowed 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.813 -0.63 . . . . 0.0 111.641 -179.47 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 98.81 4.67 56.82 Favored Glycine 0 C--N 1.318 -0.424 0 CA-C-N 115.613 -0.721 . . . . 0.0 112.434 177.153 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . 0.422 ' HB2' ' HB2' ' A' ' 53' ' ' TYR . 41.8 mt-10 -114.45 168.02 10.21 Favored 'General case' 0 C--N 1.314 -0.968 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 178.871 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -89.61 168.95 35.12 Favored Glycine 0 N--CA 1.437 -1.298 0 C-N-CA 120.541 -0.838 . . . . 0.0 111.413 178.756 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_exo -63.02 134.33 45.62 Favored 'Trans proline' 0 C--O 1.239 0.545 0 C-N-CA 122.345 2.03 . . . . 0.0 111.465 178.735 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 45.0 pt -130.54 166.7 27.47 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.846 179.675 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -73.6 142.49 31.23 Favored Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 121.074 -0.584 . . . . 0.0 112.338 -177.409 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 39.8 t80 -126.77 128.47 46.66 Favored 'General case' 0 C--N 1.317 -0.839 0 C-N-CA 122.451 0.3 . . . . 0.0 111.125 -179.067 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 69.5 ttp85 -136.5 132.25 35.04 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 174.348 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.464 ' HA ' ' O ' ' A' ' 72' ' ' GLU . . . -137.28 146.26 44.48 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 111.892 0.33 . . . . 0.0 111.892 179.837 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 60.1 m -121.32 131.3 54.12 Favored 'General case' 0 CA--C 1.546 0.793 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.38 179.176 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . 0.515 ' O ' ' HB3' ' A' ' 66' ' ' LEU . 59.9 tp -43.2 -51.81 5.89 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 115.513 1.672 . . . . 0.0 115.513 -176.493 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . 0.515 ' HB3' ' O ' ' A' ' 65' ' ' LEU . 3.2 tm? 75.64 -57.06 0.59 Allowed 'General case' 0 CA--C 1.549 0.935 0 CA-C-N 118.364 0.529 . . . . 0.0 110.641 177.949 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -141.35 -90.27 0.16 Allowed Glycine 0 C--N 1.333 0.398 0 C-N-CA 121.057 -0.592 . . . . 0.0 112.646 -179.405 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 9.0 p30 -160.94 133.03 5.89 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 179.705 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 94.3 m-20 57.19 24.27 9.62 Favored 'General case' 0 N--CA 1.478 0.968 0 CA-C-O 121.279 0.562 . . . . 0.0 111.172 -176.256 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 43.5 m -138.2 152.03 48.25 Favored 'General case' 0 N--CA 1.434 -1.229 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 179.336 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.519 ' OH ' ' HB3' ' A' ' 99' ' ' ASN . 97.3 m-85 -149.85 126.39 10.91 Favored 'General case' 0 C--N 1.31 -1.118 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 176.662 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . 0.464 ' O ' ' HA ' ' A' ' 63' ' ' ALA . 83.7 tt0 -82.81 127.53 33.55 Favored 'General case' 0 N--CA 1.439 -0.991 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 175.603 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 76.9 t -104.75 131.55 53.55 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.278 0 CA-C-N 115.352 -0.84 . . . . 0.0 112.585 -171.96 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.457 ' HG2' ' HA ' ' A' ' 86' ' ' SER . 48.1 mt-10 -129.76 126.65 38.67 Favored 'General case' 0 N--CA 1.44 -0.966 0 CA-C-N 114.275 -1.33 . . . . 0.0 107.523 175.059 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 97.0 m-20 -109.53 154.34 22.85 Favored 'General case' 0 C--N 1.314 -0.973 0 CA-C-O 121.042 0.449 . . . . 0.0 112.053 -176.132 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' GLN . . . . . 0.522 ' HB2' ' CE3' ' A' ' 84' ' ' TRP . 61.8 tt0 -118.47 124.52 47.82 Favored 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 115.527 -0.76 . . . . 0.0 110.608 -176.193 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 6.0 p90 -142.59 158.8 43.3 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.158 179.07 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 98.32 -12.42 63.41 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.628 -0.796 . . . . 0.0 112.697 179.931 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 134.26 169.59 12.05 Favored Glycine 0 N--CA 1.447 -0.621 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.192 179.64 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 6.5 p-10 -68.83 -30.42 68.96 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 120.71 0.291 . . . . 0.0 111.097 -179.812 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 23.6 t -71.96 -16.0 62.08 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.255 179.28 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -79.96 143.62 57.88 Favored Pre-proline 0 C--N 1.324 -0.512 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.029 -178.488 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_endo -72.3 -178.16 3.12 Favored 'Trans proline' 0 C--O 1.238 0.511 0 C-N-CA 122.881 2.387 . . . . 0.0 112.149 179.168 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' TRP . . . . . 0.522 ' CE3' ' HB2' ' A' ' 76' ' ' GLN . 88.3 m95 -94.39 142.4 27.47 Favored 'General case' 0 C--N 1.317 -0.829 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 -179.816 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 96.6 m-70 -116.51 142.14 47.26 Favored 'General case' 0 C--N 1.316 -0.889 0 N-CA-C 109.778 -0.452 . . . . 0.0 109.778 -178.542 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' SER . . . . . 0.457 ' HA ' ' HG2' ' A' ' 74' ' ' GLU . 20.8 t -65.39 132.56 49.28 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 120.874 0.368 . . . . 0.0 111.229 -176.374 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -110.75 -48.35 0.74 Allowed Glycine 0 N--CA 1.441 -1.03 0 C-N-CA 120.936 -0.65 . . . . 0.0 112.188 178.547 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 157.96 -171.74 35.02 Favored Glycine 0 C--O 1.217 -0.911 0 C-N-CA 120.57 -0.824 . . . . 0.0 111.84 -179.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 3.9 t30 -112.4 115.64 29.04 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 117.54 0.67 . . . . 0.0 110.251 179.699 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 35.1 m0 -97.88 148.71 23.16 Favored 'General case' 0 C--N 1.311 -1.092 0 CA-C-O 121.037 0.446 . . . . 0.0 111.622 -177.725 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . 0.402 ' O ' ' HB3' ' A' ' 23' ' ' TRP . 76.6 mt -108.49 118.18 55.54 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.057 0 N-CA-C 108.49 -0.93 . . . . 0.0 108.49 175.605 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 85.8 mt -134.53 83.39 2.03 Favored 'General case' 0 C--O 1.267 1.985 0 O-C-N 124.031 0.832 . . . . 0.0 112.057 -173.675 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 172.11 111.34 0.26 Allowed Glycine 0 N--CA 1.444 -0.769 0 CA-C-N 115.752 -0.658 . . . . 0.0 112.644 177.407 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 78.8 p -90.07 -7.88 52.79 Favored 'General case' 0 C--O 1.236 0.362 0 CA-C-O 121.45 0.643 . . . . 0.0 110.014 177.348 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 97.3 mtt180 -105.28 142.74 34.52 Favored 'General case' 0 N--CA 1.445 -0.692 0 CA-C-N 115.357 -0.838 . . . . 0.0 110.701 179.725 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -70.48 -34.68 72.65 Favored 'General case' 0 C--N 1.311 -1.08 0 CA-C-N 115.688 -0.687 . . . . 0.0 112.811 -175.193 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 27.2 p-10 -116.21 27.29 9.33 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 112.77 0.655 . . . . 0.0 112.77 -176.54 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' GLN . . . . . . . . . . . . . 72.1 mt-30 -148.82 125.76 11.27 Favored 'General case' 0 CA--C 1.511 -0.54 0 CA-C-O 121.12 0.486 . . . . 0.0 112.276 -179.855 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' ASN . . . . . 0.519 ' HB3' ' OH ' ' A' ' 71' ' ' TYR . 94.9 m-20 -96.17 152.87 18.15 Favored 'General case' 0 C--O 1.258 1.512 0 CA-C-N 114.985 -1.007 . . . . 0.0 109.889 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 57.5 t -73.9 134.91 28.64 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.561 0 CA-C-O 120.932 0.396 . . . . 0.0 111.057 178.424 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 23.3 m -120.08 -23.64 3.26 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.478 0 N-CA-C 112.649 0.611 . . . . 0.0 112.649 -178.848 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . 0.442 ' HB1' ' HB ' ' A' ' 119' ' ' THR . . . -148.05 139.58 23.69 Favored 'General case' 0 C--O 1.236 0.392 0 C-N-CA 120.342 -0.543 . . . . 0.0 111.85 179.433 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.457 ' O ' ' HA ' ' A' ' 37' ' ' ASN . 37.4 mm -134.02 130.0 54.74 Favored 'Isoleucine or valine' 0 C--O 1.239 0.53 0 CA-C-N 115.904 -0.589 . . . . 0.0 111.287 178.901 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 6.8 t30 -129.07 93.75 3.66 Favored 'General case' 0 CA--C 1.534 0.359 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.368 176.222 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 27.3 m -138.44 141.55 37.3 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.932 0 N-CA-C 113.033 0.753 . . . . 0.0 113.033 -176.561 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 85.6 tt0 -144.14 87.63 1.91 Allowed 'General case' 0 CA--C 1.534 0.358 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.676 176.447 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' SER . . . . . 0.464 ' HB2' ' H ' ' A' ' 115' ' ' ASN . 13.6 m -162.93 159.82 24.1 Favored 'General case' 0 C--N 1.312 -1.061 0 CA-C-N 114.667 -1.151 . . . . 0.0 111.206 -179.359 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 136.95 94.46 0.37 Allowed Glycine 0 N--CA 1.424 -2.139 0 C-N-CA 119.215 -1.469 . . . . 0.0 114.578 173.633 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 16.7 m-20 -75.68 100.47 4.67 Favored 'General case' 0 CA--C 1.502 -0.878 0 N-CA-C 105.875 -1.898 . . . . 0.0 105.875 171.918 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 70.5 m-20 62.27 24.35 14.48 Favored 'General case' 0 CA--C 1.534 0.344 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 -172.234 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . 0.498 ' HA3' ' ND2' ' A' ' 32' ' ' ASN . . . 77.91 22.85 67.98 Favored Glycine 0 CA--C 1.527 0.821 0 CA-C-N 115.217 -0.901 . . . . 0.0 113.539 179.928 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 52.8 tt0 -66.35 -43.49 85.9 Favored 'General case' 0 CA--C 1.541 0.597 0 N-CA-C 112.433 0.531 . . . . 0.0 112.433 -179.263 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 21.8 p -131.8 157.01 45.0 Favored 'General case' 0 C--N 1.325 -0.496 0 O-C-N 122.335 -0.228 . . . . 0.0 111.525 -177.629 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 114' ' ' LEU . . . . . 0.4 ' HA ' ' HB2' ' A' ' 107' ' ' SER . 96.4 mt -133.38 109.39 9.31 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 110.199 -0.297 . . . . 0.0 110.199 178.353 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . 0.464 ' H ' ' HB2' ' A' ' 107' ' ' SER . 93.3 m-20 -114.5 143.35 45.1 Favored 'General case' 0 C--O 1.252 1.207 0 CA-C-O 121.091 0.472 . . . . 0.0 111.018 -179.366 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 162.08 -135.11 3.74 Favored Glycine 0 N--CA 1.44 -1.043 0 CA-C-N 115.718 -0.674 . . . . 0.0 112.366 178.751 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 3.0 p -137.2 159.61 41.42 Favored 'General case' 0 C--N 1.311 -1.069 0 C-N-CA 122.629 0.372 . . . . 0.0 110.544 -179.241 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 23.2 ptm -146.3 160.29 42.21 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 116.501 -0.318 . . . . 0.0 110.614 -178.376 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 119' ' ' THR . . . . . 0.442 ' HB ' ' HB1' ' A' ' 102' ' ' ALA . 25.6 m -143.14 136.59 28.37 Favored 'General case' 0 C--O 1.253 1.242 0 CA-C-N 116.609 -0.269 . . . . 0.0 111.426 179.893 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 52.5 m-85 -100.69 164.65 11.77 Favored 'General case' 0 CA--C 1.508 -0.639 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.223 177.418 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -63.46 130.19 43.36 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.058 176.66 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 63.03 27.41 70.39 Favored Glycine 0 CA--C 1.521 0.463 0 C-N-CA 121.118 -0.563 . . . . 0.0 113.117 -179.131 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 9.9 tp10 -136.83 162.2 33.89 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -178.829 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -89.11 170.57 37.77 Favored Glycine 0 CA--C 1.522 0.479 0 C-N-CA 120.847 -0.692 . . . . 0.0 112.341 179.599 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -72.03 135.15 24.69 Favored 'Trans proline' 0 N--CA 1.46 -0.484 0 C-N-CA 122.369 2.046 . . . . 0.0 112.201 179.125 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 40.7 pt -130.83 161.56 40.56 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.269 179.673 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -72.42 134.91 21.62 Favored Glycine 0 C--O 1.238 0.391 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.119 -179.916 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 91.6 t80 -115.85 133.16 56.31 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.858 0.361 . . . . 0.0 110.99 -178.952 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 62.8 tttm -140.64 108.54 5.69 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 115.679 -0.691 . . . . 0.0 109.265 177.954 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -117.42 147.78 18.78 Favored Glycine 0 N--CA 1.44 -1.056 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.053 -179.35 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 5.4 t -137.16 142.84 42.2 Favored 'General case' 0 C--N 1.313 -1.002 0 CA-C-O 120.899 0.381 . . . . 0.0 111.231 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 63.2 tp -72.17 136.81 46.56 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.582 -0.736 . . . . 0.0 110.355 177.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 37.2 m . . . . . 0 C--N 1.307 -1.248 0 CA-C-O 118.802 -0.618 . . . . 0.0 110.407 -179.904 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.235 0.309 0 CA-C-O 120.655 0.264 . . . . 0.0 110.304 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . 0.467 HD23 HE21 ' A' ' 22' ' ' GLN . 9.2 tt -90.32 132.15 35.72 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-O 120.988 0.423 . . . . 0.0 110.197 179.593 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . 0.536 ' CD1' ' HB ' ' A' ' 25' ' ' ILE . 34.5 m-85 -116.43 137.97 51.73 Favored 'General case' 0 C--N 1.317 -0.841 0 CA-C-O 121.386 0.612 . . . . 0.0 111.32 -178.926 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . 0.544 ' HB2' ' OG1' ' A' ' 133' ' ' THR . 60.8 t30 -96.51 135.61 38.16 Favored 'General case' 0 C--N 1.305 -1.339 0 N-CA-C 107.176 -1.416 . . . . 0.0 107.176 177.226 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.412 ' O ' ' HA ' ' A' ' 19' ' ' GLU . 72.2 t -116.48 126.31 73.89 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 N-CA-C 113.176 0.806 . . . . 0.0 113.176 -172.419 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -118.71 137.42 53.35 Favored 'General case' 0 N--CA 1.439 -0.991 0 CA-C-N 114.479 -1.237 . . . . 0.0 107.962 175.911 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 13.4 m120 -128.79 151.64 49.35 Favored 'General case' 0 C--N 1.313 -1.007 0 N-CA-C 112.607 0.595 . . . . 0.0 112.607 -175.238 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 52.9 tt0 -122.33 110.33 15.53 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 107.527 -1.286 . . . . 0.0 107.527 175.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 40.2 p90 -134.47 4.91 3.43 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 114.556 1.317 . . . . 0.0 114.556 -172.875 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -119.32 18.99 10.08 Favored Glycine 0 N--CA 1.446 -0.65 0 C-N-CA 118.357 -1.878 . . . . 0.0 113.696 -176.11 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 152.02 -160.91 29.1 Favored Glycine 0 N--CA 1.446 -0.7 0 C-N-CA 119.541 -1.314 . . . . 0.0 112.907 179.097 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 36.6 p -102.5 -21.97 14.12 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-O 121.061 0.458 . . . . 0.0 110.462 -177.149 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 47.0 p -107.15 -1.3 22.07 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.607 -0.724 . . . . 0.0 110.423 -178.801 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -59.46 135.35 88.86 Favored Pre-proline 0 N--CA 1.453 -0.289 0 CA-C-N 115.616 -0.72 . . . . 0.0 111.068 -178.034 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -70.01 162.89 40.5 Favored 'Trans proline' 0 N--CA 1.459 -0.527 0 C-N-CA 122.653 2.235 . . . . 0.0 111.874 179.088 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 99.0 m95 -84.77 123.68 30.69 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 179.865 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 44.1 m-80 -118.68 128.46 54.54 Favored 'General case' 0 C--N 1.315 -0.898 0 N-CA-C 110.245 -0.28 . . . . 0.0 110.245 -178.869 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.412 ' HA ' ' O ' ' A' ' 6' ' ' VAL . 11.3 pt-20 -82.03 132.35 35.25 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 176.34 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -133.09 23.36 3.9 Favored Glycine 0 N--CA 1.438 -1.193 0 C-N-CA 120.028 -1.082 . . . . 0.0 112.114 -179.318 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 153.4 178.04 27.53 Favored Glycine 0 N--CA 1.439 -1.144 0 C-N-CA 120.644 -0.789 . . . . 0.0 111.969 -179.385 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . 0.467 HE21 HD23 ' A' ' 3' ' ' LEU . 4.1 pt20 -131.5 138.66 49.07 Favored 'General case' 0 C--N 1.313 -0.997 0 N-CA-C 110.012 -0.366 . . . . 0.0 110.012 -179.456 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 44.1 m0 -113.03 175.37 5.47 Favored 'General case' 0 CA--C 1.506 -0.74 0 CA-C-O 121.081 0.467 . . . . 0.0 110.693 -178.128 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 39.4 tt0 -129.68 115.15 16.91 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-N 116.098 -0.501 . . . . 0.0 109.812 178.062 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.536 ' HB ' ' CD1' ' A' ' 4' ' ' TYR . 93.8 mt -128.33 135.62 62.14 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.962 0 CA-C-N 115.574 -0.739 . . . . 0.0 109.561 -177.29 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 86.31 71.42 1.3 Allowed Glycine 0 N--CA 1.441 -1.01 0 C-N-CA 119.935 -1.126 . . . . 0.0 111.363 -179.781 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 32.1 t -59.79 -41.07 90.36 Favored 'General case' 0 C--N 1.318 -0.796 0 N-CA-C 109.526 -0.546 . . . . 0.0 109.526 179.413 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 97.1 mtt180 -99.35 133.54 43.5 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 176.064 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 2.4 p -86.22 2.37 47.29 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-O 121.011 0.434 . . . . 0.0 111.908 -177.832 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 -66.0 -34.28 77.73 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.407 178.74 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . 0.507 ' NE2' ' HA ' ' A' ' 31' ' ' GLN . 5.6 mm-40 -143.1 126.58 16.79 Favored 'General case' 0 CA--C 1.502 -0.871 0 N-CA-C 113.367 0.877 . . . . 0.0 113.367 -177.239 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . 0.433 ' HB3' ' HA3' ' A' ' 111' ' ' GLY . 95.9 m-20 -90.4 156.04 18.51 Favored 'General case' 0 N--CA 1.446 -0.639 0 CA-C-N 115.022 -0.99 . . . . 0.0 110.091 177.466 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 18.0 m -105.77 137.33 36.2 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.034 0 CA-C-N 115.727 -0.67 . . . . 0.0 112.672 -175.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 27.7 m -111.73 -20.59 6.13 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.2 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.908 177.535 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.48 ' HB1' ' HB ' ' A' ' 52' ' ' THR . . . -145.21 144.83 31.05 Favored 'General case' 0 C--N 1.321 -0.663 0 C-N-CA 119.94 -0.704 . . . . 0.0 111.533 178.68 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 91.6 mt -144.33 126.88 10.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 N-CA-C 108.709 -0.848 . . . . 0.0 108.709 -179.535 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . 0.541 ' HA ' ' O ' ' A' ' 103' ' ' ILE . 3.3 t-20 -140.22 114.31 9.04 Favored 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 179.097 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.568 HG13 ' CD2' ' A' ' 61' ' ' PHE . 16.5 m -151.96 158.77 4.28 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.931 0 CA-C-O 120.807 0.337 . . . . 0.0 111.834 -173.743 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 66.2 tt0 -139.19 147.96 42.5 Favored 'General case' 0 N--CA 1.451 -0.392 0 CA-C-N 115.229 -0.896 . . . . 0.0 109.299 174.836 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' SER . . . . . 0.426 ' OG ' ' HB ' ' A' ' 101' ' ' VAL . 95.2 p -82.31 166.05 19.84 Favored 'General case' 0 C--N 1.313 -0.984 0 CA-C-O 121.146 0.498 . . . . 0.0 111.911 -179.351 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -107.74 -52.41 0.71 Allowed Glycine 0 N--CA 1.442 -0.948 0 CA-C-N 115.528 -0.76 . . . . 0.0 111.344 175.1 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -131.14 102.12 5.87 Favored 'General case' 0 C--N 1.326 -0.431 0 C-N-CA 122.334 0.253 . . . . 0.0 111.262 -179.563 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 83.8 m-20 52.1 26.4 3.81 Favored 'General case' 0 N--CA 1.492 1.656 0 N-CA-C 113.732 1.012 . . . . 0.0 113.732 177.105 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 82.48 -6.5 68.57 Favored Glycine 0 C--N 1.312 -0.761 0 C-N-CA 120.333 -0.936 . . . . 0.0 113.396 178.184 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 28.3 mt-30 -64.95 -32.49 74.23 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 117.219 0.509 . . . . 0.0 110.842 -179.065 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 4.9 t -118.11 131.44 56.43 Favored 'General case' 0 C--N 1.307 -1.279 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 174.652 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 91.7 mt -126.26 134.37 51.2 Favored 'General case' 0 C--N 1.316 -0.861 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 -177.756 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 20.7 p30 -143.89 147.43 34.01 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-O 121.207 0.527 . . . . 0.0 111.511 179.569 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 164.4 -142.49 7.83 Favored Glycine 0 N--CA 1.442 -0.934 0 N-CA-C 111.389 -0.684 . . . . 0.0 111.389 179.873 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 40.2 p -132.98 150.39 52.16 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-O 121.028 0.442 . . . . 0.0 111.846 -178.938 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 32.2 mtp -124.17 152.68 42.56 Favored 'General case' 0 C--N 1.326 -0.415 0 C-N-CA 123.341 0.656 . . . . 0.0 109.603 176.348 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.48 ' HB ' ' HB1' ' A' ' 35' ' ' ALA . 24.1 m -130.37 123.6 30.27 Favored 'General case' 0 C--O 1.25 1.081 0 C-N-CA 121.141 -0.224 . . . . 0.0 110.435 176.313 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . 0.428 ' HB2' ' HB2' ' A' ' 56' ' ' GLU . 71.8 m-85 -85.57 164.33 17.83 Favored 'General case' 0 C--O 1.232 0.173 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.43 178.712 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -67.22 101.88 0.97 Allowed 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.499 -179.996 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 97.06 -0.85 60.61 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.731 -0.747 . . . . 0.0 113.229 177.674 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . 0.428 ' HB2' ' HB2' ' A' ' 53' ' ' TYR . 79.9 mm-40 -111.19 179.77 3.95 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 117.024 0.412 . . . . 0.0 110.739 -179.982 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -95.75 168.16 26.16 Favored Glycine 0 N--CA 1.443 -0.868 0 C-N-CA 120.845 -0.693 . . . . 0.0 111.944 178.922 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 23.5 Cg_exo -64.45 139.77 66.36 Favored 'Trans proline' 0 C--O 1.238 0.523 0 C-N-CA 122.657 2.238 . . . . 0.0 112.301 179.002 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . 0.426 ' HB ' ' O ' ' A' ' 76' ' ' GLN . 48.9 pt -131.74 168.4 24.05 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 CA-C-N 115.801 -0.636 . . . . 0.0 109.918 179.0 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -79.95 148.31 30.02 Favored Glycine 0 C--N 1.32 -0.351 0 C-N-CA 120.874 -0.679 . . . . 0.0 111.645 -179.816 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.568 ' CD2' HG13 ' A' ' 38' ' ' VAL . 2.6 t80 -136.88 130.83 32.3 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-O 120.819 0.342 . . . . 0.0 111.18 -178.538 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 57.3 ttp180 -135.62 134.81 39.66 Favored 'General case' 0 C--O 1.232 0.142 0 CA-C-N 115.833 -0.621 . . . . 0.0 109.934 176.784 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.418 ' HA ' ' O ' ' A' ' 72' ' ' GLU . . . -136.81 146.14 45.32 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 120.738 0.304 . . . . 0.0 111.484 179.797 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 65.0 m -125.27 131.25 53.13 Favored 'General case' 0 CA--C 1.537 0.461 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.055 178.952 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 61.1 tp -74.26 119.19 18.13 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.334 0.588 . . . . 0.0 112.311 -177.205 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 94.2 mt -90.1 -29.52 18.28 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.502 -0.772 . . . . 0.0 109.849 175.227 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 134.23 166.68 11.31 Favored Glycine 0 N--CA 1.447 -0.578 0 N-CA-C 110.962 -0.855 . . . . 0.0 110.962 -179.135 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 53.9 m-80 58.06 36.39 25.96 Favored 'General case' 0 N--CA 1.477 0.883 0 CA-C-N 117.21 0.505 . . . . 0.0 111.331 179.245 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 17.3 m120 63.59 14.08 7.8 Favored 'General case' 0 N--CA 1.479 0.987 0 CA-C-N 115.614 -0.721 . . . . 0.0 111.277 179.204 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 17.6 m -101.33 126.07 48.04 Favored 'General case' 0 C--O 1.239 0.552 0 CA-C-O 121.081 0.467 . . . . 0.0 111.156 -178.883 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 91.0 m-85 -114.52 141.98 47.01 Favored 'General case' 0 C--N 1.313 -0.997 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.494 -178.556 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . 0.418 ' O ' ' HA ' ' A' ' 63' ' ' ALA . 35.8 tt0 -90.39 120.16 31.28 Favored 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 108.35 -0.982 . . . . 0.0 108.35 175.574 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.416 HG11 ' CE1' ' A' ' 61' ' ' PHE . 54.2 t -103.67 132.83 49.19 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.013 0 N-CA-C 113.871 1.063 . . . . 0.0 113.871 -171.953 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 70.6 mt-10 -129.3 129.47 44.91 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 114.472 -1.24 . . . . 0.0 107.976 173.762 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 96.4 m-20 -109.12 145.48 35.63 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 121.279 0.562 . . . . 0.0 111.838 -177.781 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' GLN . . . . . 0.426 ' O ' ' HB ' ' A' ' 59' ' ' ILE . 10.4 tt0 -111.26 123.59 50.51 Favored 'General case' 0 C--N 1.316 -0.873 0 C-N-CA 124.032 0.933 . . . . 0.0 111.592 -177.125 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 10.0 p90 -140.27 155.61 46.79 Favored 'General case' 0 C--N 1.316 -0.89 0 N-CA-C 110.52 -0.178 . . . . 0.0 110.52 175.061 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 107.0 -9.71 39.92 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.852 -0.69 . . . . 0.0 112.279 -179.934 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 145.03 171.81 15.02 Favored Glycine 0 N--CA 1.447 -0.591 0 N-CA-C 111.581 -0.608 . . . . 0.0 111.581 178.912 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 1.8 p-10 -62.9 153.03 34.7 Favored 'General case' 0 C--O 1.241 0.609 0 CA-C-N 117.015 0.408 . . . . 0.0 110.31 178.081 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 16.3 m 65.42 -95.06 0.04 OUTLIER 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.717 -0.674 . . . . 0.0 109.497 -178.33 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 50.23 172.48 0.03 OUTLIER Pre-proline 0 CA--C 1.555 1.158 0 N-CA-C 113.533 0.938 . . . . 0.0 113.533 176.519 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_exo -69.91 144.97 54.87 Favored 'Trans proline' 0 N--CA 1.45 -1.062 0 C-N-CA 121.722 1.614 . . . . 0.0 110.161 172.255 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' TRP . . . . . . . . . . . . . 92.7 m95 -90.88 139.34 30.84 Favored 'General case' 0 C--N 1.313 -0.983 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 178.757 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 84.8 m-70 -111.5 138.63 47.77 Favored 'General case' 0 C--N 1.313 -1.005 0 N-CA-C 108.936 -0.764 . . . . 0.0 108.936 -178.822 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 10.5 m -66.85 135.62 54.17 Favored 'General case' 0 C--N 1.314 -0.957 0 CA-C-O 120.675 0.274 . . . . 0.0 110.922 -177.324 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -110.01 -44.59 1.01 Allowed Glycine 0 N--CA 1.443 -0.838 0 C-N-CA 120.832 -0.699 . . . . 0.0 111.742 179.376 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 143.74 -158.7 27.44 Favored Glycine 0 C--O 1.214 -1.151 0 C-N-CA 120.723 -0.751 . . . . 0.0 111.473 178.681 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 19.1 m120 -115.33 129.25 56.55 Favored 'General case' 0 C--N 1.315 -0.918 0 CA-C-N 117.303 0.551 . . . . 0.0 110.88 179.278 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 23.3 m0 -118.96 150.73 39.42 Favored 'General case' 0 N--CA 1.466 0.335 0 N-CA-C 109.981 -0.377 . . . . 0.0 109.981 179.777 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 92.1 mt -109.63 123.08 65.23 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 177.76 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 83.6 mt -134.3 84.85 2.14 Favored 'General case' 0 C--O 1.265 1.871 0 O-C-N 123.688 0.617 . . . . 0.0 112.473 -175.85 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 168.13 110.36 0.23 Allowed Glycine 0 C--O 1.218 -0.903 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.688 178.003 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 68.3 p -100.78 -9.43 21.73 Favored 'General case' 0 C--O 1.225 -0.232 0 CA-C-O 120.984 0.421 . . . . 0.0 111.116 178.379 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 92.2 mtt180 -96.69 3.79 52.23 Favored 'General case' 0 C--O 1.232 0.162 0 C-N-CA 120.574 -0.45 . . . . 0.0 111.921 179.32 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 66.6 tt0 72.83 -83.13 0.03 OUTLIER 'General case' 0 N--CA 1.467 0.401 0 C-N-CA 123.22 0.608 . . . . 0.0 112.377 173.067 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 63.4 m-80 -92.34 34.15 1.06 Allowed 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 120.831 0.348 . . . . 0.0 111.612 -174.802 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' GLN . . . . . . . . . . . . . 23.6 tp60 -120.08 -48.11 2.35 Favored 'General case' 0 C--N 1.316 -0.875 0 C-N-CA 120.59 -0.444 . . . . 0.0 110.284 -178.945 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 93.4 m-20 72.62 137.84 0.05 Allowed 'General case' 0 N--CA 1.485 1.308 0 O-C-N 123.735 0.647 . . . . 0.0 112.284 178.499 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 69.9 t -78.43 132.4 32.44 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.33 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.871 178.861 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . 0.426 ' HB ' ' OG ' ' A' ' 40' ' ' SER . 34.4 m -113.04 -27.64 2.68 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.517 0 N-CA-C 112.555 0.576 . . . . 0.0 112.555 -179.506 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . 0.436 ' HB1' ' HB ' ' A' ' 119' ' ' THR . . . -146.82 144.45 29.35 Favored 'General case' 0 C--N 1.322 -0.619 0 C-N-CA 119.96 -0.696 . . . . 0.0 111.546 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.541 ' O ' ' HA ' ' A' ' 37' ' ' ASN . 34.1 mm -133.98 128.05 52.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.62 179.193 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . 0.429 ' HB3' ' OG1' ' A' ' 117' ' ' THR . 43.4 t30 -131.27 92.08 3.13 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.292 175.714 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 29.4 m -138.12 144.26 31.11 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.566 0 N-CA-C 113.017 0.747 . . . . 0.0 113.017 -175.451 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 79.9 tt0 -148.19 101.39 3.26 Favored 'General case' 0 CA--C 1.538 0.501 0 CA-C-N 115.558 -0.746 . . . . 0.0 110.656 176.832 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' SER . . . . . 0.44 ' HB2' ' H ' ' A' ' 115' ' ' ASN . 69.5 m -166.69 165.82 16.27 Favored 'General case' 0 N--CA 1.475 0.821 0 CA-C-N 114.834 -1.075 . . . . 0.0 112.388 -178.909 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 116.41 117.19 2.98 Favored Glycine 0 N--CA 1.424 -2.156 0 C-N-CA 120.344 -0.932 . . . . 0.0 113.241 175.308 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 -67.38 -42.44 83.39 Favored 'General case' 0 C--N 1.319 -0.757 0 N-CA-C 107.997 -1.112 . . . . 0.0 107.997 175.639 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 30.3 t70 -142.38 33.43 1.48 Allowed 'General case' 0 C--O 1.213 -0.85 0 CA-C-N 114.428 -1.26 . . . . 0.0 108.228 175.432 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . 0.433 ' HA3' ' HB3' ' A' ' 32' ' ' ASN . . . 81.82 18.05 68.82 Favored Glycine 0 CA--C 1.523 0.538 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.656 -178.335 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 112' ' ' GLN . . . . . 0.434 ' HA ' ' CD1' ' A' ' 132' ' ' LEU . 98.1 mt-30 -66.66 -40.64 88.7 Favored 'General case' 0 C--O 1.244 0.794 0 CA-C-O 120.975 0.417 . . . . 0.0 111.71 -179.177 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 25.6 p -139.15 143.37 38.15 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.824 -0.626 . . . . 0.0 110.755 -178.391 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 114' ' ' LEU . . . . . 0.4 ' HA ' ' HB2' ' A' ' 107' ' ' SER . 4.4 mm? -119.4 123.35 43.89 Favored 'General case' 0 C--N 1.317 -0.814 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 176.539 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . 0.44 ' H ' ' HB2' ' A' ' 107' ' ' SER . 53.6 m-80 -128.66 149.6 50.6 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-O 120.851 0.358 . . . . 0.0 110.587 -178.503 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 155.48 -131.34 3.05 Favored Glycine 0 N--CA 1.438 -1.175 0 C-N-CA 120.634 -0.793 . . . . 0.0 112.343 177.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 117' ' ' THR . . . . . 0.429 ' OG1' ' HB3' ' A' ' 104' ' ' ASN . 23.9 p -130.25 155.37 46.39 Favored 'General case' 0 C--N 1.311 -1.089 0 CA-C-O 121.015 0.436 . . . . 0.0 110.848 -178.459 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 23.2 ptm -146.2 153.34 40.52 Favored 'General case' 0 C--N 1.313 -0.991 0 CA-C-N 115.949 -0.569 . . . . 0.0 109.67 -178.809 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 119' ' ' THR . . . . . 0.436 ' HB ' ' HB1' ' A' ' 102' ' ' ALA . 26.0 m -132.99 131.34 40.64 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-O 120.642 0.258 . . . . 0.0 111.422 -179.294 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 33.0 m-85 -95.75 163.49 13.15 Favored 'General case' 0 CA--C 1.509 -0.611 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.394 175.992 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -62.75 128.59 36.64 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.588 178.155 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 70.95 15.58 74.18 Favored Glycine 0 CA--C 1.524 0.596 0 CA-C-N 115.895 -0.593 . . . . 0.0 113.257 179.44 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -127.03 179.82 5.22 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 117.149 0.474 . . . . 0.0 111.335 -179.46 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -105.55 170.09 16.91 Favored Glycine 0 N--CA 1.445 -0.754 0 N-CA-C 111.502 -0.639 . . . . 0.0 111.502 178.533 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 22.9 Cg_exo -65.37 135.39 42.61 Favored 'Trans proline' 0 CA--C 1.534 0.511 0 C-N-CA 122.542 2.161 . . . . 0.0 112.375 -179.812 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 48.0 pt -131.21 165.09 32.49 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 116.06 -0.518 . . . . 0.0 109.941 177.931 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -73.76 132.78 16.25 Favored Glycine 0 CA--C 1.521 0.464 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.751 -179.169 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 91.6 t80 -114.8 132.96 56.3 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 120.634 0.254 . . . . 0.0 111.224 -179.526 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 63.0 tttm -137.49 101.83 4.61 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.029 176.927 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -106.37 133.51 11.66 Favored Glycine 0 N--CA 1.446 -0.645 0 C-N-CA 120.977 -0.63 . . . . 0.0 111.617 179.485 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 49.1 m -130.24 137.55 50.08 Favored 'General case' 0 C--N 1.311 -1.072 0 CA-C-N 116.638 0.219 . . . . 0.0 111.191 -179.334 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 132' ' ' LEU . . . . . 0.434 ' CD1' ' HA ' ' A' ' 112' ' ' GLN . 87.9 mt -57.7 134.93 56.64 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-O 120.858 0.361 . . . . 0.0 110.31 176.781 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 133' ' ' THR . . . . . 0.544 ' OG1' ' HB2' ' A' ' 5' ' ' ASN . 57.5 m . . . . . 0 C--O 1.251 1.182 0 CA-C-O 118.643 -0.694 . . . . 0.0 110.539 -179.086 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.692 0 N-CA-C 110.373 -0.232 . . . . 0.0 110.373 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . 0.538 HD11 HE21 ' A' ' 22' ' ' GLN . 2.8 tm? -99.85 131.41 45.85 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.357 -177.663 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . 0.595 ' CE1' ' HB ' ' A' ' 25' ' ' ILE . 85.1 m-85 -121.41 145.11 48.25 Favored 'General case' 0 C--O 1.238 0.476 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.866 -179.215 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 14.9 m120 -82.67 142.23 31.85 Favored 'General case' 0 N--CA 1.468 0.436 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 176.991 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.46 HG21 ' CD1' ' A' ' 23' ' ' TRP . 59.0 t -116.09 126.76 73.72 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 N-CA-C 113.464 0.913 . . . . 0.0 113.464 -176.159 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 92.0 mt-10 -128.09 132.43 49.01 Favored 'General case' 0 N--CA 1.445 -0.683 0 CA-C-N 114.634 -1.167 . . . . 0.0 108.088 175.001 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 12.8 m120 -124.59 145.74 49.43 Favored 'General case' 0 C--N 1.313 -0.986 0 CA-C-O 120.645 0.259 . . . . 0.0 110.696 -178.158 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 52.0 tt0 -119.65 118.24 30.43 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.808 0.337 . . . . 0.0 110.464 179.071 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' TRP . . . . . 0.5 ' CZ3' ' HB2' ' A' ' 18' ' ' ASN . 2.5 m-90 -79.2 140.79 37.6 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.332 179.711 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 89.33 -42.21 3.02 Favored Glycine 0 N--CA 1.444 -0.811 0 C-N-CA 120.579 -0.82 . . . . 0.0 112.05 -179.085 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.84 21.42 71.51 Favored Glycine 0 C--O 1.227 -0.327 0 C-N-CA 120.85 -0.691 . . . . 0.0 111.581 -179.707 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 20.9 p -168.2 133.82 1.86 Allowed 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.771 -0.214 . . . . 0.0 111.188 -178.024 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 63.6 p 46.85 44.73 14.66 Favored 'General case' 0 N--CA 1.475 0.824 0 C-N-CA 123.456 0.702 . . . . 0.0 112.638 176.79 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.429 ' HA ' ' HD3' ' A' ' 16' ' ' PRO . . . -139.6 144.32 38.9 Favored Pre-proline 0 C--N 1.324 -0.517 0 C-N-CA 120.905 -0.318 . . . . 0.0 111.425 -178.158 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.429 ' HD3' ' HA ' ' A' ' 15' ' ' ALA . 11.4 Cg_exo -71.57 157.45 55.98 Favored 'Trans proline' 0 C--N 1.347 0.483 0 C-N-CA 123.033 2.489 . . . . 0.0 111.699 176.888 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 91.5 m95 -85.26 134.15 34.14 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 120.891 0.377 . . . . 0.0 110.343 179.57 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' ASN . . . . . 0.5 ' HB2' ' CZ3' ' A' ' 10' ' ' TRP . 90.7 m-20 -110.01 135.67 50.47 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.105 179.231 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 14.7 pt-20 -105.44 131.2 53.15 Favored 'General case' 0 C--N 1.314 -0.95 0 N-CA-C 109.241 -0.652 . . . . 0.0 109.241 -179.828 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -157.33 34.26 0.55 Allowed Glycine 0 N--CA 1.44 -1.045 0 C-N-CA 119.058 -1.544 . . . . 0.0 112.997 179.843 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 162.67 -179.02 38.21 Favored Glycine 0 N--CA 1.444 -0.777 0 C-N-CA 119.58 -1.295 . . . . 0.0 113.511 178.847 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . 0.538 HE21 HD11 ' A' ' 3' ' ' LEU . 3.3 pt20 -145.29 140.66 27.94 Favored 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 179.218 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . 0.46 ' CD1' HG21 ' A' ' 6' ' ' VAL . 48.0 m0 -114.74 155.97 25.7 Favored 'General case' 0 CA--C 1.505 -0.761 0 CA-C-O 120.715 0.293 . . . . 0.0 111.443 -176.213 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 77.8 tt0 -116.6 119.52 35.79 Favored 'General case' 0 C--N 1.321 -0.633 0 C-N-CA 120.445 -0.502 . . . . 0.0 110.221 177.881 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.595 ' HB ' ' CE1' ' A' ' 4' ' ' TYR . 97.7 mt -135.32 143.37 37.12 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.72 0 CA-C-N 114.998 -1.001 . . . . 0.0 109.464 -177.681 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 84.0 60.61 1.93 Allowed Glycine 0 C--O 1.225 -0.437 0 C-N-CA 120.18 -1.01 . . . . 0.0 112.398 178.629 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 15.4 m -58.15 -40.4 81.26 Favored 'General case' 0 C--N 1.317 -0.838 0 O-C-N 123.935 0.432 . . . . 0.0 111.618 179.759 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 79.9 ttt180 -61.29 -42.27 98.37 Favored 'General case' 0 CA--C 1.538 0.518 0 CA-C-N 116.588 -0.278 . . . . 0.0 111.558 178.803 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 20.1 m 75.99 -21.98 0.29 Allowed 'General case' 0 N--CA 1.482 1.17 0 C-N-CA 123.75 0.82 . . . . 0.0 113.201 179.073 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 58.3 m-20 -68.23 -11.71 59.77 Favored 'General case' 0 N--CA 1.483 1.189 0 CA-C-O 121.06 0.457 . . . . 0.0 111.414 178.243 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -152.71 136.09 15.87 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.133 -178.963 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . 0.561 ' ND2' ' HA3' ' A' ' 111' ' ' GLY . 2.5 t30 -93.45 150.81 20.16 Favored 'General case' 0 C--O 1.247 0.967 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.247 178.984 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 46.3 t -93.98 131.33 41.2 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 CA-C-N 115.697 -0.683 . . . . 0.0 109.62 -178.399 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 28.1 m -102.75 -32.43 3.11 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.686 0 C-N-CA 120.596 -0.442 . . . . 0.0 111.835 -179.595 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.485 ' HB1' ' HB ' ' A' ' 52' ' ' THR . . . -135.01 145.19 47.83 Favored 'General case' 0 CA--C 1.511 -0.537 0 C-N-CA 120.349 -0.54 . . . . 0.0 111.28 -179.201 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 93.9 mt -142.33 122.54 10.72 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 CA-C-N 115.744 -0.662 . . . . 0.0 109.553 -179.543 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 19.7 m120 -130.74 112.58 13.21 Favored 'General case' 0 C--N 1.316 -0.851 0 N-CA-C 108.246 -1.02 . . . . 0.0 108.246 176.07 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.444 HG23 ' HB ' ' A' ' 103' ' ' ILE . 27.3 m -147.41 150.57 14.49 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 C-N-CA 120.665 -0.414 . . . . 0.0 111.208 -175.146 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 74.6 tt0 -142.73 145.1 33.01 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 108.955 -0.758 . . . . 0.0 108.955 176.031 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' SER . . . . . 0.426 ' HA ' ' O ' ' A' ' 46' ' ' THR . 34.2 p -80.55 148.95 30.14 Favored 'General case' 0 C--N 1.312 -1.024 0 N-CA-C 112.203 0.446 . . . . 0.0 112.203 -176.327 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -95.06 -19.95 29.48 Favored Glycine 0 N--CA 1.449 -0.476 0 N-CA-C 111.012 -0.835 . . . . 0.0 111.012 176.831 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 15.7 m-20 -128.72 -156.56 0.76 Allowed 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 109.45 -0.574 . . . . 0.0 109.45 179.071 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 9.9 p-10 -77.23 46.89 0.52 Allowed 'General case' 0 N--CA 1.474 0.775 0 CA-C-O 121.314 0.578 . . . . 0.0 112.065 -179.11 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 88.22 -7.79 80.46 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 121.047 -0.597 . . . . 0.0 113.176 178.441 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 53.5 mt-30 -72.58 -34.83 67.71 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.964 0.382 . . . . 0.0 111.498 178.906 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' THR . . . . . 0.426 ' O ' ' HA ' ' A' ' 40' ' ' SER . 24.5 p -115.02 132.01 56.74 Favored 'General case' 0 C--N 1.314 -0.975 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.535 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 93.8 mt -124.3 127.97 48.44 Favored 'General case' 0 CA--C 1.509 -0.607 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 -179.475 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 9.0 m120 -129.39 137.05 50.7 Favored 'General case' 0 C--N 1.313 -1.011 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 -179.696 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 178.18 -157.22 21.1 Favored Glycine 0 N--CA 1.445 -0.72 0 C-N-CA 119.287 -1.435 . . . . 0.0 113.795 179.275 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 38.3 m -130.0 134.35 47.37 Favored 'General case' 0 CA--C 1.545 0.756 0 C-N-CA 123.087 0.555 . . . . 0.0 110.905 -178.562 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' MET . . . . . 0.401 ' SD ' ' HD1' ' A' ' 61' ' ' PHE . 48.0 mtp -110.2 155.32 22.14 Favored 'General case' 0 N--CA 1.468 0.459 0 C-N-CA 122.308 0.243 . . . . 0.0 110.815 177.151 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.485 ' HB ' ' HB1' ' A' ' 35' ' ' ALA . 25.5 m -133.78 126.29 30.3 Favored 'General case' 0 CA--C 1.542 0.641 0 CA-C-N 116.491 -0.322 . . . . 0.0 110.167 175.322 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . 0.446 ' HB2' ' HB2' ' A' ' 56' ' ' GLU . 65.5 m-85 -92.94 166.97 12.12 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 116.664 -0.244 . . . . 0.0 110.769 177.964 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -63.34 106.48 0.91 Allowed 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.473 -179.754 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 81.78 16.03 73.9 Favored Glycine 0 CA--C 1.52 0.358 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.788 178.857 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . 0.446 ' HB2' ' HB2' ' A' ' 53' ' ' TYR . 80.3 mm-40 -119.99 169.62 10.02 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 120.773 0.32 . . . . 0.0 110.807 -179.93 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -90.05 172.56 38.55 Favored Glycine 0 N--CA 1.444 -0.813 0 C-N-CA 120.99 -0.624 . . . . 0.0 112.303 179.925 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_exo -67.14 137.56 44.47 Favored 'Trans proline' 0 CA--C 1.535 0.56 0 C-N-CA 122.726 2.284 . . . . 0.0 112.026 179.16 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 45.0 pt -128.79 160.86 38.91 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.428 179.195 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -75.1 141.61 28.3 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.451 -178.919 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.401 ' HD1' ' SD ' ' A' ' 51' ' ' MET . 61.8 t80 -126.01 127.04 45.27 Favored 'General case' 0 C--N 1.32 -0.712 0 C-N-CA 122.401 0.28 . . . . 0.0 110.797 -179.792 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 29.3 ttp85 -136.97 129.04 29.44 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 175.801 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.44 ' HB1' ' HB3' ' A' ' 71' ' ' TYR . . . -136.88 146.4 45.51 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 112.304 0.483 . . . . 0.0 112.304 -177.622 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 55.9 m -122.7 128.18 50.23 Favored 'General case' 0 CA--C 1.542 0.668 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.222 178.303 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 2.3 tm? -73.47 121.52 20.68 Favored 'General case' 0 CA--C 1.538 0.493 0 CA-C-O 121.134 0.492 . . . . 0.0 111.054 -178.058 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 96.0 mt -75.04 -33.94 61.81 Favored 'General case' 0 CA--C 1.534 0.354 0 CA-C-N 115.638 -0.71 . . . . 0.0 111.907 179.799 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 126.12 -14.84 6.96 Favored Glycine 0 C--O 1.219 -0.812 0 C-N-CA 120.574 -0.822 . . . . 0.0 112.476 -178.262 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 28.9 p-10 -111.75 30.23 7.17 Favored 'General case' 0 C--N 1.316 -0.856 0 CA-C-O 120.824 0.345 . . . . 0.0 110.736 -179.078 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 96.1 m-20 69.03 6.47 5.66 Favored 'General case' 0 N--CA 1.483 1.187 0 C-N-CA 123.6 0.76 . . . . 0.0 111.499 -177.25 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 35.0 t -102.46 140.35 36.86 Favored 'General case' 0 N--CA 1.438 -1.069 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 177.178 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.44 ' HB3' ' HB1' ' A' ' 63' ' ' ALA . 66.8 m-85 -116.91 139.72 50.31 Favored 'General case' 0 C--N 1.303 -1.42 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.936 -178.296 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 39.5 tt0 -85.29 112.3 20.66 Favored 'General case' 0 C--N 1.309 -1.16 0 N-CA-C 106.759 -1.571 . . . . 0.0 106.759 173.673 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 70.5 t -109.41 135.83 47.17 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 N-CA-C 113.475 0.917 . . . . 0.0 113.475 -171.141 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -128.54 130.48 47.48 Favored 'General case' 0 N--CA 1.443 -0.811 0 CA-C-N 114.708 -1.133 . . . . 0.0 108.917 175.281 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 95.9 m-20 -108.9 150.11 28.17 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.748 -179.286 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 61.3 tt0 -115.49 120.36 39.24 Favored 'General case' 0 C--N 1.308 -1.232 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.435 -177.534 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 8.6 p90 -142.87 162.85 34.37 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 110.24 -0.281 . . . . 0.0 110.24 179.544 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 100.91 -9.02 58.07 Favored Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.768 -0.729 . . . . 0.0 111.97 179.781 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 137.59 159.61 8.26 Favored Glycine 0 N--CA 1.442 -0.917 0 N-CA-C 111.019 -0.832 . . . . 0.0 111.019 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 5.9 m-20 -60.41 -39.59 87.93 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 116.963 0.382 . . . . 0.0 111.687 -179.319 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 4.6 m -76.57 -4.93 45.42 Favored 'General case' 0 C--N 1.321 -0.671 0 N-CA-C 112.251 0.463 . . . . 0.0 112.251 -177.476 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -75.46 153.16 85.76 Favored Pre-proline 0 C--N 1.324 -0.538 0 CA-C-O 120.587 0.232 . . . . 0.0 111.196 -178.422 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 10.7 Cg_exo -72.34 178.48 6.06 Favored 'Trans proline' 0 C--N 1.35 0.642 0 C-N-CA 122.925 2.417 . . . . 0.0 112.017 178.646 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' TRP . . . . . . . . . . . . . 90.9 m95 -92.14 138.17 31.75 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 109.322 -0.622 . . . . 0.0 109.322 179.722 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 82.8 m-70 -112.59 144.61 41.79 Favored 'General case' 0 C--N 1.318 -0.791 0 N-CA-C 109.992 -0.373 . . . . 0.0 109.992 -177.685 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 19.5 p -64.36 116.4 6.03 Favored 'General case' 0 C--N 1.316 -0.89 0 CA-C-O 120.781 0.324 . . . . 0.0 111.457 -178.376 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -89.63 -46.41 4.3 Favored Glycine 0 N--CA 1.44 -1.088 0 C-N-CA 120.388 -0.911 . . . . 0.0 111.018 178.008 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 139.87 -157.86 25.48 Favored Glycine 0 N--CA 1.442 -0.909 0 C-N-CA 120.816 -0.707 . . . . 0.0 111.629 177.471 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 19.8 m120 -105.48 134.19 49.0 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 109.697 -0.483 . . . . 0.0 109.697 178.974 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' TRP . . . . . 0.482 ' CH2' HG21 ' A' ' 25' ' ' ILE . 13.8 m0 -124.04 146.13 48.77 Favored 'General case' 0 C--N 1.316 -0.862 0 CA-C-N 116.203 -0.453 . . . . 0.0 109.84 -178.548 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 91.6 mt -110.57 114.63 47.6 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.285 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 177.456 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 85.5 mt -133.56 79.98 1.85 Allowed 'General case' 0 C--O 1.269 2.113 0 CA-C-O 121.771 0.796 . . . . 0.0 112.312 -175.724 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 170.0 109.51 0.22 Allowed Glycine 0 N--CA 1.442 -0.966 0 CA-C-N 115.344 -0.844 . . . . 0.0 111.768 -179.498 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 19.1 m -96.67 30.27 2.68 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-O 120.902 0.382 . . . . 0.0 110.349 -179.882 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' ARG . . . . . 0.542 ' CB ' ' HB3' ' A' ' 98' ' ' GLN . 9.7 mmt180 -136.56 150.54 48.65 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-O 121.257 0.551 . . . . 0.0 112.317 -176.968 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 79.3 tt0 -55.99 -51.27 68.33 Favored 'General case' 0 CA--C 1.541 0.601 0 CA-C-N 114.731 -1.122 . . . . 0.0 112.602 -176.961 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 57.5 m-80 -134.63 42.69 2.81 Favored 'General case' 0 N--CA 1.471 0.609 0 CA-C-O 120.965 0.412 . . . . 0.0 109.99 -179.928 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' GLN . . . . . 0.594 ' NE2' ' HB2' ' A' ' 123' ' ' GLU . 52.8 tt0 -144.37 110.39 5.41 Favored 'General case' 0 C--N 1.315 -0.919 0 CA-C-O 121.147 0.499 . . . . 0.0 110.614 -175.952 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' ASN . . . . . 0.439 ' HB3' ' OH ' ' A' ' 71' ' ' TYR . 87.7 m-20 -91.06 168.37 11.69 Favored 'General case' 0 C--O 1.244 0.782 0 CA-C-N 115.293 -0.867 . . . . 0.0 111.111 -175.73 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 23.6 m -83.01 140.53 16.19 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.673 0 C-N-CA 120.011 -0.676 . . . . 0.0 110.244 173.443 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 29.7 m -115.55 -27.45 2.56 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.429 0 C-N-CA 120.608 -0.437 . . . . 0.0 112.062 178.14 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -147.87 142.06 26.12 Favored 'General case' 0 C--N 1.32 -0.677 0 C-N-CA 120.581 -0.447 . . . . 0.0 110.551 178.352 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.444 ' HB ' HG23 ' A' ' 38' ' ' VAL . 94.9 mt -138.4 125.75 27.83 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 N-CA-C 110.106 -0.331 . . . . 0.0 110.106 178.26 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 35.2 t30 -128.06 97.8 4.91 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.367 176.589 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.417 HG13 ' HD2' ' A' ' 128' ' ' PHE . 11.7 m -142.6 149.7 18.85 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 N-CA-C 113.185 0.809 . . . . 0.0 113.185 -176.454 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 41.9 tt0 -148.15 147.19 29.18 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.089 -0.959 . . . . 0.0 109.839 175.621 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 47.1 t -113.23 133.59 55.01 Favored 'General case' 0 N--CA 1.442 -0.874 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.355 -177.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -81.52 -5.07 90.22 Favored Glycine 0 N--CA 1.447 -0.568 0 N-CA-C 111.103 -0.799 . . . . 0.0 111.103 175.444 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . 0.402 ' C ' ' H ' ' A' ' 111' ' ' GLY . 62.8 m-20 -114.06 -166.46 1.1 Allowed 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 109.362 -0.607 . . . . 0.0 109.362 -179.95 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 25.6 m-20 -77.68 34.97 0.18 Allowed 'General case' 0 N--CA 1.472 0.66 0 CA-C-O 120.847 0.356 . . . . 0.0 111.123 178.931 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . 0.561 ' HA3' ' ND2' ' A' ' 32' ' ' ASN . . . 81.43 8.24 87.32 Favored Glycine 0 N--CA 1.445 -0.74 0 C-N-CA 120.888 -0.672 . . . . 0.0 112.405 -178.852 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 97.3 mt-30 -66.04 -44.22 85.26 Favored 'General case' 0 C--O 1.243 0.713 0 CA-C-O 121.056 0.455 . . . . 0.0 109.995 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 22.5 p -113.12 117.61 32.44 Favored 'General case' 0 N--CA 1.441 -0.888 0 CA-C-N 115.374 -0.83 . . . . 0.0 109.259 177.548 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 34.8 tp -111.84 121.88 46.25 Favored 'General case' 0 C--N 1.311 -1.08 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 -178.957 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 26.3 p30 -145.57 164.82 30.49 Favored 'General case' 0 C--O 1.251 1.134 0 C-N-CA 120.039 -0.664 . . . . 0.0 112.677 -178.609 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 149.75 -127.78 2.53 Favored Glycine 0 N--CA 1.439 -1.12 0 CA-C-N 114.655 -1.157 . . . . 0.0 111.127 -179.636 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 31.9 p -134.0 159.75 39.82 Favored 'General case' 0 C--N 1.314 -0.96 0 CA-C-O 120.851 0.358 . . . . 0.0 111.063 -178.9 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 4.2 ppp? -157.28 161.93 39.17 Favored 'General case' 0 C--N 1.313 -1.004 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 179.154 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 48.7 m -133.39 126.3 30.99 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-N 116.46 -0.336 . . . . 0.0 110.978 -179.894 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . 0.44 ' CB ' HE21 ' A' ' 98' ' ' GLN . 64.9 m-85 -88.13 162.98 16.43 Favored 'General case' 0 CA--C 1.521 -0.147 0 CA-C-N 116.196 -0.456 . . . . 0.0 109.789 174.285 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -55.76 -30.59 61.5 Favored 'General case' 0 N--CA 1.47 0.553 0 N-CA-C 113.602 0.964 . . . . 0.0 113.602 -176.627 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -140.65 26.62 2.52 Favored Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 119.636 -1.269 . . . . 0.0 112.67 -178.434 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . 0.594 ' HB2' ' NE2' ' A' ' 98' ' ' GLN . 23.5 tp10 -112.6 -50.71 2.88 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.988 0.423 . . . . 0.0 110.461 -177.578 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 116.5 -179.76 17.76 Favored Glycine 0 N--CA 1.441 -0.986 0 N-CA-C 111.122 -0.791 . . . . 0.0 111.122 -177.639 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 7.4 Cg_exo -73.81 112.8 3.62 Favored 'Trans proline' 0 N--CA 1.461 -0.392 0 C-N-CA 122.735 2.29 . . . . 0.0 112.021 179.651 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 39.2 pt -129.84 162.92 36.58 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.862 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.517 179.734 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -72.84 144.41 35.1 Favored Glycine 0 N--CA 1.448 -0.517 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.728 -179.496 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . 0.417 ' HD2' HG13 ' A' ' 105' ' ' VAL . 21.1 t80 -125.59 132.63 52.49 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 121.162 0.506 . . . . 0.0 110.732 178.733 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 62.6 tttm -137.42 123.46 20.3 Favored 'General case' 0 C--N 1.311 -1.073 0 CA-C-N 115.0 -1.0 . . . . 0.0 108.93 -179.829 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -139.23 141.72 12.1 Favored Glycine 0 N--CA 1.436 -1.302 0 C-N-CA 120.363 -0.922 . . . . 0.0 112.725 -179.335 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 35.3 m -121.35 133.11 55.1 Favored 'General case' 0 C--N 1.311 -1.107 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.355 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 60.2 tp -66.85 139.89 57.78 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 109.754 -0.462 . . . . 0.0 109.754 178.492 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 133' ' ' THR . . . . . 0.444 HG21 ' O ' ' A' ' 3' ' ' LEU . 13.4 t . . . . . 0 C--O 1.253 1.251 0 CA-C-O 118.53 -0.748 . . . . 0.0 110.251 -179.117 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.737 0 CA-C-O 120.668 0.271 . . . . 0.0 110.42 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . 0.451 HD11 HE21 ' A' ' 22' ' ' GLN . 1.7 tm? -95.16 129.89 42.09 Favored 'General case' 0 C--N 1.319 -0.739 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 178.598 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . 0.451 ' N ' HD12 ' A' ' 3' ' ' LEU . 78.8 m-85 -120.53 145.85 46.89 Favored 'General case' 0 C--O 1.24 0.597 0 CA-C-O 121.081 0.467 . . . . 0.0 112.158 -176.842 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . 0.61 ' O ' ' HA2' ' A' ' 130' ' ' GLY . 21.6 m120 -87.46 140.46 29.51 Favored 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 107.186 -1.413 . . . . 0.0 107.186 175.274 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.471 HG23 ' CD1' ' A' ' 23' ' ' TRP . 70.1 t -114.64 128.41 71.73 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 N-CA-C 113.641 0.978 . . . . 0.0 113.641 -174.274 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.41 ' HB2' ' HB3' ' A' ' 129' ' ' LYS . 99.7 mt-10 -125.44 134.09 52.22 Favored 'General case' 0 N--CA 1.444 -0.759 0 CA-C-N 114.517 -1.219 . . . . 0.0 109.098 175.358 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 12.9 m120 -121.4 140.54 52.01 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-N 116.462 -0.336 . . . . 0.0 110.601 -178.929 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 60.8 tt0 -120.02 120.02 35.1 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.676 -178.972 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 19.6 p90 -135.72 143.18 45.21 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 110.131 -0.322 . . . . 0.0 110.131 178.708 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 106.83 8.53 31.93 Favored Glycine 0 N--CA 1.446 -0.646 0 C-N-CA 120.29 -0.957 . . . . 0.0 111.497 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 103.08 164.71 25.76 Favored Glycine 0 N--CA 1.442 -0.958 0 C-N-CA 121.344 -0.455 . . . . 0.0 112.281 178.502 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 68.8 m -59.07 -23.47 62.07 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 120.836 0.35 . . . . 0.0 111.722 178.766 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 38.8 m -73.52 -6.61 47.56 Favored 'General case' 0 CA--C 1.543 0.696 0 CA-C-O 120.7 0.286 . . . . 0.0 111.596 177.921 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.413 ' HA ' ' HD3' ' A' ' 16' ' ' PRO . . . -95.07 145.56 29.75 Favored Pre-proline 0 C--N 1.328 -0.355 0 O-C-N 122.421 -0.174 . . . . 0.0 110.881 -179.814 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.413 ' HD3' ' HA ' ' A' ' 15' ' ' ALA . 8.2 Cg_exo -73.1 163.82 37.15 Favored 'Trans proline' 0 C--N 1.347 0.492 0 C-N-CA 123.042 2.494 . . . . 0.0 112.586 179.594 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . 0.508 ' CZ3' ' HB2' ' A' ' 129' ' ' LYS . 91.3 m95 -83.51 131.13 35.02 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 178.939 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 41.2 m-80 -109.54 141.71 41.62 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.524 -177.833 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 13.9 pt-20 -112.18 137.5 50.18 Favored 'General case' 0 C--N 1.313 -0.991 0 N-CA-C 110.016 -0.364 . . . . 0.0 110.016 179.05 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -154.2 32.45 0.72 Allowed Glycine 0 N--CA 1.443 -0.842 0 C-N-CA 119.76 -1.21 . . . . 0.0 112.641 179.045 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 156.25 -177.61 33.18 Favored Glycine 0 N--CA 1.447 -0.613 0 C-N-CA 119.658 -1.258 . . . . 0.0 113.3 -179.16 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . 0.451 HE21 HD11 ' A' ' 3' ' ' LEU . 4.4 pt20 -141.62 145.35 34.9 Favored 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 109.537 -0.542 . . . . 0.0 109.537 -179.828 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . 0.471 ' CD1' HG23 ' A' ' 6' ' ' VAL . 45.0 m0 -115.93 153.28 31.86 Favored 'General case' 0 C--O 1.24 0.591 0 CA-C-O 121.121 0.486 . . . . 0.0 111.895 -176.752 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 85.9 tt0 -112.17 114.47 27.29 Favored 'General case' 0 CA--C 1.508 -0.663 0 CA-C-N 115.512 -0.767 . . . . 0.0 109.072 177.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 96.8 mt -131.82 136.7 56.49 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-O 121.355 0.597 . . . . 0.0 112.27 -176.048 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 104.93 -26.52 22.05 Favored Glycine 0 N--CA 1.449 -0.454 0 CA-C-N 115.881 -0.6 . . . . 0.0 113.531 175.312 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 2.7 p 44.99 20.89 0.04 OUTLIER 'General case' 0 N--CA 1.486 1.335 0 C-N-CA 123.867 0.867 . . . . 0.0 112.991 -177.512 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 83.4 mtm180 -149.62 150.57 32.4 Favored 'General case' 0 C--O 1.241 0.626 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 -179.243 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 12.6 m -95.51 -15.42 22.9 Favored 'General case' 0 C--N 1.309 -1.159 0 CA-C-O 121.089 0.471 . . . . 0.0 110.268 177.828 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 23.3 m-20 -75.21 -35.5 61.5 Favored 'General case' 0 N--CA 1.468 0.475 0 CA-C-N 115.809 -0.632 . . . . 0.0 112.182 -177.052 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 5.0 mm-40 -132.49 128.23 36.93 Favored 'General case' 0 CA--C 1.509 -0.628 0 N-CA-C 113.876 1.065 . . . . 0.0 113.876 -175.34 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 3.4 m-20 -100.07 151.15 21.71 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 114.834 -1.075 . . . . 0.0 109.311 174.61 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 33.2 m -92.53 142.95 12.38 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.277 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.78 -179.818 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 27.7 m -111.4 -16.08 9.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 C-N-CA 120.931 -0.308 . . . . 0.0 111.744 178.772 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.468 ' HB2' ' HB ' ' A' ' 52' ' ' THR . . . -147.94 140.75 24.74 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 120.3 -0.56 . . . . 0.0 111.597 178.972 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.411 ' HB ' ' CG2' ' A' ' 105' ' ' VAL . 88.8 mt -142.84 121.29 7.7 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 178.607 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . 0.477 ' HA ' ' O ' ' A' ' 103' ' ' ILE . 4.8 t-20 -136.54 111.26 8.71 Favored 'General case' 0 C--N 1.307 -1.243 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 177.984 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.441 HG11 ' CD1' ' A' ' 61' ' ' PHE . 27.0 m -148.43 154.37 10.36 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-O 120.804 0.335 . . . . 0.0 111.626 -171.843 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 45.4 tt0 -136.34 143.37 44.07 Favored 'General case' 0 N--CA 1.447 -0.61 0 CA-C-N 115.624 -0.716 . . . . 0.0 109.371 176.644 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 88.4 p -72.83 155.04 40.33 Favored 'General case' 0 C--N 1.314 -0.961 0 CA-C-O 121.131 0.491 . . . . 0.0 111.846 -178.288 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -108.26 -45.0 1.11 Allowed Glycine 0 N--CA 1.438 -1.188 0 CA-C-N 115.596 -0.729 . . . . 0.0 111.924 177.86 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 30.7 t70 -129.3 95.28 3.99 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 111.564 0.209 . . . . 0.0 111.564 -178.772 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 52.15 31.53 9.17 Favored 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 113.594 0.961 . . . . 0.0 113.594 174.989 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 75.7 1.0 65.19 Favored Glycine 0 C--N 1.32 -0.359 0 C-N-CA 120.373 -0.918 . . . . 0.0 113.09 179.828 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 13.8 mm100 -78.48 -29.68 46.89 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-O 121.328 0.585 . . . . 0.0 109.743 178.857 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 32.1 p -121.74 144.26 48.9 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-N 115.709 -0.678 . . . . 0.0 109.912 176.738 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . 0.481 ' O ' ' HA ' ' A' ' 62' ' ' ARG . 93.3 mt -129.82 130.96 45.97 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 -178.185 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 94.0 m-20 -127.49 138.97 53.08 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 178.141 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 172.81 -153.04 17.68 Favored Glycine 0 N--CA 1.445 -0.732 0 C-N-CA 119.487 -1.339 . . . . 0.0 113.525 178.707 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 90.9 m -131.99 133.19 44.18 Favored 'General case' 0 C--N 1.317 -0.811 0 C-N-CA 122.704 0.402 . . . . 0.0 110.283 -178.904 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' MET . . . . . 0.501 ' HE2' ' CZ ' ' A' ' 53' ' ' TYR . 15.7 tmm? -126.32 147.58 49.7 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 116.531 -0.304 . . . . 0.0 110.34 -178.949 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.468 ' HB ' ' HB2' ' A' ' 35' ' ' ALA . 28.4 m -128.98 129.12 44.99 Favored 'General case' 0 C--O 1.252 1.234 0 CA-C-O 120.797 0.332 . . . . 0.0 111.826 -177.505 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . 0.501 ' CZ ' ' HE2' ' A' ' 51' ' ' MET . 94.3 m-85 -83.47 167.4 17.47 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 115.811 -0.632 . . . . 0.0 110.419 177.582 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -63.96 103.71 0.62 Allowed 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 112.402 0.519 . . . . 0.0 112.402 -179.012 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 85.84 4.51 84.8 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.937 -0.649 . . . . 0.0 113.261 177.717 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . 0.459 ' HB2' ' HB2' ' A' ' 53' ' ' TYR . 81.9 mm-40 -107.97 176.99 4.95 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-O 120.697 0.284 . . . . 0.0 110.665 -179.781 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -90.11 156.82 25.52 Favored Glycine 0 N--CA 1.44 -1.048 0 C-N-CA 120.879 -0.677 . . . . 0.0 112.16 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_exo -63.67 140.32 74.03 Favored 'Trans proline' 0 CA--C 1.533 0.449 0 C-N-CA 122.758 2.305 . . . . 0.0 112.116 178.697 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 46.4 pt -130.75 166.0 29.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-N 116.341 -0.391 . . . . 0.0 110.649 179.633 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -73.29 138.63 25.55 Favored Glycine 0 N--CA 1.45 -0.398 0 N-CA-C 111.243 -0.743 . . . . 0.0 111.243 179.856 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.441 ' CD1' HG11 ' A' ' 38' ' ' VAL . 52.4 t80 -124.86 130.03 51.58 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-O 120.673 0.273 . . . . 0.0 111.111 -177.148 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . 0.481 ' HA ' ' O ' ' A' ' 47' ' ' LEU . 68.2 ttp85 -140.29 132.67 28.41 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.068 175.041 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -136.64 148.17 47.29 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 120.754 0.311 . . . . 0.0 111.828 -178.074 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 56.3 m -127.18 132.53 50.46 Favored 'General case' 0 CA--C 1.541 0.628 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.513 178.836 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . 0.403 HD23 ' O ' ' A' ' 70' ' ' SER . 3.4 tm? -77.13 114.54 16.04 Favored 'General case' 0 C--N 1.325 -0.486 0 C-N-CA 122.633 0.373 . . . . 0.0 110.447 -179.133 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 10.5 mp -81.99 -32.16 30.75 Favored 'General case' 0 N--CA 1.468 0.455 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.915 178.824 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 164.8 173.58 33.58 Favored Glycine 0 CA--C 1.497 -1.045 0 N-CA-C 110.614 -0.995 . . . . 0.0 110.614 -177.577 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 16.2 t30 40.23 -96.32 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.134 0 C-N-CA 123.138 0.575 . . . . 0.0 111.777 -176.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 24.7 m120 -140.67 19.81 2.35 Favored 'General case' 0 N--CA 1.467 0.412 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 177.29 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' SER . . . . . 0.403 ' O ' HD23 ' A' ' 65' ' ' LEU . 40.7 t -94.54 122.98 37.69 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.308 -0.86 . . . . 0.0 111.256 -175.742 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.626 ' OH ' ' HB3' ' A' ' 99' ' ' ASN . 73.9 m-85 -116.25 137.61 52.0 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 115.817 -0.628 . . . . 0.0 110.515 -179.673 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 82.2 tt0 -92.38 125.4 37.02 Favored 'General case' 0 N--CA 1.439 -1.004 0 N-CA-C 107.476 -1.305 . . . . 0.0 107.476 172.081 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 65.5 t -105.04 130.67 55.8 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.5 0 CA-C-O 121.432 0.634 . . . . 0.0 111.973 -174.953 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 67.0 mt-10 -126.25 120.64 30.51 Favored 'General case' 0 N--CA 1.431 -1.381 0 CA-C-N 114.455 -1.248 . . . . 0.0 107.669 176.424 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 94.4 m-20 -109.55 155.73 21.03 Favored 'General case' 0 C--N 1.317 -0.831 0 CA-C-O 121.2 0.524 . . . . 0.0 111.968 -174.507 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' GLN . . . . . 0.438 ' HB2' ' CE3' ' A' ' 84' ' ' TRP . 61.4 tt0 -119.39 119.9 35.31 Favored 'General case' 0 C--N 1.31 -1.13 0 CA-C-N 115.494 -0.775 . . . . 0.0 109.933 -178.344 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 7.9 p90 -137.2 155.64 49.28 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.593 -0.276 . . . . 0.0 110.727 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 97.75 -10.27 64.39 Favored Glycine 0 N--CA 1.447 -0.615 0 N-CA-C 111.151 -0.779 . . . . 0.0 111.151 -178.652 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 139.35 159.56 8.04 Favored Glycine 0 N--CA 1.44 -1.045 0 N-CA-C 111.312 -0.715 . . . . 0.0 111.312 179.465 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 7.4 p-10 -74.55 -23.37 58.78 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-O 121.046 0.45 . . . . 0.0 111.0 -179.632 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 6.9 m -76.24 -7.89 55.87 Favored 'General case' 0 CA--C 1.542 0.654 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.622 177.346 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -83.86 158.45 62.09 Favored Pre-proline 0 C--N 1.326 -0.415 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.456 -179.407 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -72.84 177.84 7.15 Favored 'Trans proline' 0 C--O 1.237 0.471 0 C-N-CA 122.279 1.986 . . . . 0.0 111.636 177.498 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' TRP . . . . . 0.438 ' CE3' ' HB2' ' A' ' 76' ' ' GLN . 96.4 m95 -90.24 142.23 27.92 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 179.957 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 88.9 m-70 -117.87 146.98 43.51 Favored 'General case' 0 C--N 1.313 -0.986 0 N-CA-C 109.534 -0.543 . . . . 0.0 109.534 -178.71 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 18.8 p -62.87 136.85 58.07 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-O 120.561 0.22 . . . . 0.0 111.351 -179.831 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -111.89 -50.98 0.57 Allowed Glycine 0 N--CA 1.446 -0.637 0 C-N-CA 120.821 -0.704 . . . . 0.0 111.534 178.314 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 148.58 -164.47 29.08 Favored Glycine 0 C--O 1.219 -0.807 0 C-N-CA 120.603 -0.808 . . . . 0.0 111.879 178.308 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 27.9 t-20 -111.46 120.12 41.1 Favored 'General case' 0 C--N 1.317 -0.829 0 CA-C-N 116.988 0.394 . . . . 0.0 110.121 179.205 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 28.1 m0 -114.96 148.78 38.29 Favored 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 -178.472 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 79.9 mt -108.69 118.72 56.86 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.071 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 177.2 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 84.8 mt -131.81 87.38 2.44 Favored 'General case' 0 C--O 1.271 2.2 0 CA-C-O 121.939 0.876 . . . . 0.0 113.253 -174.292 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 160.61 117.04 0.44 Allowed Glycine 0 N--CA 1.446 -0.65 0 CA-C-N 115.162 -0.926 . . . . 0.0 111.829 178.502 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 70.7 p -91.32 -12.82 33.91 Favored 'General case' 0 C--O 1.223 -0.322 0 CA-C-N 117.216 0.508 . . . . 0.0 110.517 178.798 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 94.1 mtt-85 -89.17 138.56 31.32 Favored 'General case' 0 N--CA 1.444 -0.741 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.129 178.904 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -70.94 -34.65 71.68 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 115.673 -0.694 . . . . 0.0 111.408 -175.623 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 89.4 m-20 -112.91 25.89 11.0 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.019 -0.537 . . . . 0.0 111.372 -177.404 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' GLN . . . . . . . . . . . . . 2.0 tt0 -155.49 130.58 9.42 Favored 'General case' 0 C--N 1.333 -0.136 0 C-N-CA 120.323 -0.551 . . . . 0.0 112.244 -176.251 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' ASN . . . . . 0.626 ' HB3' ' OH ' ' A' ' 71' ' ' TYR . 95.2 m-20 -99.32 162.66 12.91 Favored 'General case' 0 C--O 1.253 1.251 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.487 178.867 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 33.3 m -78.3 147.15 7.21 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 C-N-CA 119.884 -0.726 . . . . 0.0 110.979 179.282 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 35.5 m -123.4 -36.93 1.18 Allowed 'Isoleucine or valine' 0 C--O 1.219 -0.502 0 C-N-CA 120.728 -0.389 . . . . 0.0 111.821 177.657 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -136.25 132.19 35.48 Favored 'General case' 0 CA--C 1.503 -0.837 0 C-N-CA 120.407 -0.517 . . . . 0.0 110.687 -179.398 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.477 ' O ' ' HA ' ' A' ' 37' ' ' ASN . 92.3 mt -132.52 124.36 51.37 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 CA-C-N 116.472 -0.331 . . . . 0.0 110.111 178.255 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 7.9 t30 -125.29 97.82 5.37 Favored 'General case' 0 C--N 1.32 -0.708 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 176.482 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.411 ' CG2' ' HB ' ' A' ' 36' ' ' ILE . 26.9 m -139.94 142.97 31.0 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.782 0 N-CA-C 113.134 0.79 . . . . 0.0 113.134 -175.511 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 44.4 tt0 -146.32 148.95 32.93 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.111 -0.949 . . . . 0.0 109.215 177.37 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 40.8 t -137.37 145.06 42.84 Favored 'General case' 0 C--N 1.313 -1.022 0 CA-C-O 121.087 0.47 . . . . 0.0 111.573 -178.809 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -94.92 5.45 68.99 Favored Glycine 0 N--CA 1.441 -0.986 0 N-CA-C 111.011 -0.836 . . . . 0.0 111.011 176.313 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 83.3 m-20 -93.03 178.59 5.7 Favored 'General case' 0 CA--C 1.508 -0.65 0 CA-C-O 121.154 0.502 . . . . 0.0 111.077 178.509 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 10.8 p-10 -90.38 19.13 5.41 Favored 'General case' 0 C--N 1.311 -1.095 0 CA-C-N 115.512 -0.767 . . . . 0.0 110.5 179.444 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 106.11 4.82 38.38 Favored Glycine 0 N--CA 1.443 -0.839 0 CA-C-N 115.64 -0.709 . . . . 0.0 111.906 -177.688 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 30.7 tt0 -65.13 -45.6 84.4 Favored 'General case' 0 C--O 1.237 0.44 0 CA-C-O 120.865 0.364 . . . . 0.0 110.324 177.715 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 70.3 p -133.53 157.6 45.25 Favored 'General case' 0 N--CA 1.447 -0.577 0 CA-C-N 116.216 -0.447 . . . . 0.0 109.808 177.767 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 49.2 tp -139.09 131.46 28.46 Favored 'General case' 0 C--N 1.315 -0.9 0 N-CA-C 109.087 -0.708 . . . . 0.0 109.087 178.818 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 6.8 p30 -147.99 167.27 25.34 Favored 'General case' 0 C--N 1.319 -0.743 0 C-N-CA 119.853 -0.739 . . . . 0.0 112.878 -179.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 155.79 -130.24 2.71 Favored Glycine 0 N--CA 1.442 -0.938 0 CA-C-N 114.951 -1.022 . . . . 0.0 111.738 -179.821 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 33.0 p -133.37 156.98 46.67 Favored 'General case' 0 C--N 1.318 -0.796 0 C-N-CA 122.671 0.388 . . . . 0.0 110.621 -178.818 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 23.7 ptm -152.48 167.47 28.69 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 120.897 0.38 . . . . 0.0 111.096 -179.571 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 48.4 m -151.63 139.98 20.43 Favored 'General case' 0 CA--C 1.547 0.862 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.991 -179.936 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . 0.433 ' C ' ' H ' ' A' ' 122' ' ' GLY . 67.8 m-85 -99.02 172.29 7.5 Favored 'General case' 0 N--CA 1.473 0.701 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.28 178.538 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -67.9 37.83 0.03 OUTLIER 'General case' 0 N--CA 1.487 1.421 0 C-N-CA 123.695 0.798 . . . . 0.0 113.104 -179.752 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . 0.433 ' H ' ' C ' ' A' ' 120' ' ' TYR . . . 153.44 42.67 0.02 OUTLIER Glycine 0 CA--C 1.5 -0.879 0 N-CA-C 110.08 -1.208 . . . . 0.0 110.08 179.805 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . 0.4 ' HB3' ' H ' ' A' ' 120' ' ' TYR . 47.3 tp10 -139.69 160.82 39.0 Favored 'General case' 0 C--N 1.315 -0.925 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 -175.705 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -90.2 175.29 41.13 Favored Glycine 0 N--CA 1.443 -0.895 0 N-CA-C 111.023 -0.831 . . . . 0.0 111.023 177.238 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 22.5 Cg_exo -63.35 119.91 7.15 Favored 'Trans proline' 0 N--CA 1.461 -0.41 0 C-N-CA 121.939 1.759 . . . . 0.0 111.2 178.262 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 42.5 pt -127.53 154.11 37.55 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 CA-C-O 120.656 0.265 . . . . 0.0 110.811 -179.897 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -72.31 143.65 34.69 Favored Glycine 0 N--CA 1.444 -0.809 0 C-N-CA 121.087 -0.578 . . . . 0.0 112.463 179.422 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 73.0 t80 -122.07 133.8 54.78 Favored 'General case' 0 C--N 1.315 -0.901 0 CA-C-O 120.689 0.281 . . . . 0.0 110.579 179.194 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 129' ' ' LYS . . . . . 0.508 ' HB2' ' CZ3' ' A' ' 17' ' ' TRP . 84.0 tttt -140.39 130.35 24.69 Favored 'General case' 0 N--CA 1.439 -0.998 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 177.539 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . 0.61 ' HA2' ' O ' ' A' ' 5' ' ' ASN . . . -134.4 141.22 12.5 Favored Glycine 0 N--CA 1.436 -1.325 0 C-N-CA 121.087 -0.578 . . . . 0.0 112.007 179.875 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 53.7 m -128.27 135.36 49.53 Favored 'General case' 0 C--N 1.314 -0.97 0 CA-C-O 120.481 0.182 . . . . 0.0 110.786 -179.473 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 54.8 tp -64.52 136.5 57.11 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 177.638 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 133' ' ' THR . . . . . 0.462 ' HB ' ' OD1' ' A' ' 5' ' ' ASN . 11.8 t . . . . . 0 C--O 1.252 1.221 0 CA-C-O 118.733 -0.651 . . . . 0.0 110.634 -179.251 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 0.414 ' O ' ' HB3' ' A' ' 3' ' ' LEU . . . . . . . . 0 N--CA 1.472 0.637 0 N-CA-C 110.014 -0.365 . . . . 0.0 110.014 . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . 0.477 HD22 HE21 ' A' ' 22' ' ' GLN . 10.3 tt 87.41 150.74 0.06 Allowed 'General case' 0 N--CA 1.475 0.813 0 C-N-CA 124.289 1.036 . . . . 0.0 109.956 179.232 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . 0.4 ' N ' HD23 ' A' ' 3' ' ' LEU . 86.7 m-85 -132.45 154.13 50.18 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-O 120.951 0.405 . . . . 0.0 111.082 -175.007 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 92.7 m-20 -95.78 151.78 19.07 Favored 'General case' 0 C--N 1.314 -0.972 0 N-CA-C 107.702 -1.221 . . . . 0.0 107.702 177.664 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.465 HG21 ' CD1' ' A' ' 23' ' ' TRP . 78.5 t -111.9 121.84 65.13 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.184 0 CA-C-O 121.744 0.783 . . . . 0.0 111.73 -177.459 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 69.1 mt-10 -121.7 127.03 50.3 Favored 'General case' 0 C--N 1.311 -1.084 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 177.689 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 12.4 m120 -126.28 148.72 49.46 Favored 'General case' 0 C--N 1.312 -1.057 0 N-CA-C 112.527 0.566 . . . . 0.0 112.527 -174.036 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 54.2 tt0 -127.3 118.38 24.08 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 175.986 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 39.7 p90 -143.9 20.46 1.8 Allowed 'General case' 0 C--N 1.322 -0.613 0 C-N-CA 120.24 -0.584 . . . . 0.0 112.555 -175.293 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -96.53 24.15 31.93 Favored Glycine 0 N--CA 1.448 -0.532 0 C-N-CA 119.321 -1.418 . . . . 0.0 113.572 -177.43 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.55 -50.21 2.83 Favored Glycine 0 N--CA 1.466 0.683 0 CA-C-N 117.152 0.476 . . . . 0.0 114.268 178.261 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 22.6 t -172.63 153.23 2.74 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 -176.216 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 19.0 m 58.8 30.05 19.55 Favored 'General case' 0 CA--C 1.536 0.409 0 CA-C-O 121.322 0.582 . . . . 0.0 110.986 179.436 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -111.02 128.93 24.53 Favored Pre-proline 0 N--CA 1.443 -0.803 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.999 -178.053 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 97.8 Cg_endo -77.06 169.6 21.26 Favored 'Trans proline' 0 N--CA 1.456 -0.692 0 C-N-CA 122.697 2.265 . . . . 0.0 111.466 177.124 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 97.8 m95 -80.35 128.73 33.9 Favored 'General case' 0 C--N 1.314 -0.969 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 179.293 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 87.4 m-20 -116.28 127.6 54.86 Favored 'General case' 0 C--N 1.311 -1.099 0 N-CA-C 109.553 -0.536 . . . . 0.0 109.553 -177.854 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 10.7 pt-20 -83.43 127.68 33.89 Favored 'General case' 0 C--N 1.314 -0.948 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 178.453 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -137.38 19.82 3.38 Favored Glycine 0 C--O 1.225 -0.454 0 C-N-CA 120.43 -0.891 . . . . 0.0 112.812 -177.695 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 156.44 -173.01 34.27 Favored Glycine 0 N--CA 1.439 -1.163 0 C-N-CA 120.603 -0.808 . . . . 0.0 111.751 179.601 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . 0.477 HE21 HD22 ' A' ' 3' ' ' LEU . 17.6 pt20 -148.55 149.02 30.86 Favored 'General case' 0 C--N 1.311 -1.073 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 178.684 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . 0.465 ' CD1' HG21 ' A' ' 6' ' ' VAL . 48.0 m0 -118.62 150.69 39.27 Favored 'General case' 0 C--N 1.313 -1.001 0 CA-C-O 120.784 0.326 . . . . 0.0 110.473 -178.05 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 78.9 tt0 -106.13 115.14 29.71 Favored 'General case' 0 C--N 1.313 -0.983 0 C-N-CA 120.052 -0.659 . . . . 0.0 109.544 178.26 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 93.6 mt -139.19 149.47 23.17 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.891 0 CA-C-N 115.213 -0.903 . . . . 0.0 108.979 -175.85 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 90.26 83.38 1.37 Allowed Glycine 0 N--CA 1.446 -0.699 0 C-N-CA 120.482 -0.866 . . . . 0.0 112.808 179.474 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 11.6 p -94.97 13.51 24.73 Favored 'General case' 0 N--CA 1.449 -0.495 0 CA-C-O 120.969 0.414 . . . . 0.0 111.159 178.842 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 15.8 ptp180 -129.28 134.79 48.11 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 179.463 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 26.7 t -89.02 -21.92 23.24 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-O 121.121 0.486 . . . . 0.0 111.143 -179.031 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 51.8 m-20 -64.88 -36.23 83.68 Favored 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 112.746 0.647 . . . . 0.0 112.746 -177.91 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . 0.599 HE21 ' HA ' ' A' ' 31' ' ' GLN . 0.0 OUTLIER -135.74 134.47 39.08 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 111.938 0.348 . . . . 0.0 111.938 -175.095 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . 0.466 ' ND2' ' HA3' ' A' ' 111' ' ' GLY . 66.0 t30 -90.77 161.39 15.33 Favored 'General case' 0 C--O 1.24 0.572 0 CA-C-N 116.111 -0.495 . . . . 0.0 109.977 178.308 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 57.8 t -88.62 126.61 41.8 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.484 -176.756 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 30.7 m -111.46 -31.23 2.22 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.599 0 N-CA-C 113.236 0.828 . . . . 0.0 113.236 177.132 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.502 ' HB1' ' HB ' ' A' ' 52' ' ' THR . . . -151.41 148.81 28.55 Favored 'General case' 0 N--CA 1.469 0.515 0 C-N-CA 119.839 -0.744 . . . . 0.0 111.959 179.828 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 93.4 mt -141.92 126.87 17.23 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.15 -179.616 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . 0.4 ' HA ' ' O ' ' A' ' 103' ' ' ILE . 0.6 OUTLIER -133.66 112.36 11.36 Favored 'General case' 0 C--N 1.321 -0.65 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 174.168 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 21.7 m -150.88 153.92 9.38 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-O 120.749 0.309 . . . . 0.0 111.115 -175.607 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 42.2 tt0 -145.38 151.67 38.64 Favored 'General case' 0 C--N 1.318 -0.771 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 176.414 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 27.3 p -79.46 148.08 32.03 Favored 'General case' 0 C--N 1.31 -1.14 0 CA-C-O 121.089 0.471 . . . . 0.0 111.802 -178.792 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -97.19 -10.27 54.67 Favored Glycine 0 N--CA 1.447 -0.604 0 N-CA-C 110.03 -1.228 . . . . 0.0 110.03 175.347 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . 0.445 ' C ' ' H ' ' A' ' 44' ' ' GLY . 18.9 m-20 -137.7 -160.63 1.08 Allowed 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 114.464 -0.868 . . . . 0.0 108.766 179.505 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 17.9 m-20 -76.5 34.51 0.14 Allowed 'General case' 0 N--CA 1.481 1.086 0 CA-C-O 120.971 0.415 . . . . 0.0 110.999 178.53 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.526 ' O ' ' HE2' ' A' ' 71' ' ' TYR . . . 103.11 -6.27 50.77 Favored Glycine 0 C--O 1.208 -1.484 0 N-CA-C 111.456 -0.658 . . . . 0.0 111.456 -178.827 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 59.7 tp60 -65.18 -40.13 93.83 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.233 0.54 . . . . 0.0 110.602 179.89 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 74.4 p -125.24 142.56 51.42 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.47 178.693 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . 0.434 ' HB2' ' HB3' ' A' ' 63' ' ' ALA . 92.3 mt -128.56 126.98 41.46 Favored 'General case' 0 C--N 1.322 -0.626 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 178.131 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 15.1 m120 -129.02 142.3 50.96 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 179.94 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 173.28 -155.51 22.64 Favored Glycine 0 N--CA 1.441 -0.998 0 C-N-CA 119.547 -1.311 . . . . 0.0 113.145 177.69 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 53.7 m -128.35 130.86 48.38 Favored 'General case' 0 C--N 1.311 -1.079 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 -179.452 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' MET . . . . . 0.563 ' SD ' ' HH2' ' A' ' 90' ' ' TRP . 23.5 ttt -116.22 145.61 42.98 Favored 'General case' 0 C--N 1.314 -0.964 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 -179.813 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.502 ' HB ' ' HB1' ' A' ' 35' ' ' ALA . 37.6 m -122.19 126.11 47.57 Favored 'General case' 0 C--O 1.246 0.887 0 CA-C-O 121.162 0.506 . . . . 0.0 111.601 -179.19 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 74.2 m-85 -103.58 158.63 16.23 Favored 'General case' 0 N--CA 1.445 -0.705 0 CA-C-N 115.339 -0.846 . . . . 0.0 109.338 176.739 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -61.42 137.69 58.25 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.229 -179.027 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 77.02 -60.34 3.48 Favored Glycine 0 CA--C 1.524 0.595 0 N-CA-C 114.647 0.619 . . . . 0.0 114.647 176.772 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -66.36 -40.71 89.93 Favored 'General case' 0 C--O 1.239 0.504 0 N-CA-C 113.218 0.822 . . . . 0.0 113.218 -175.272 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 111.63 -162.49 12.43 Favored Glycine 0 N--CA 1.446 -0.652 0 C-N-CA 120.0 -1.095 . . . . 0.0 112.944 178.595 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 97.8 Cg_endo -79.0 141.74 16.84 Favored 'Trans proline' 0 C--O 1.237 0.454 0 C-N-CA 123.126 2.551 . . . . 0.0 113.416 -179.636 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . 0.735 ' HB ' ' O ' ' A' ' 76' ' ' GLN . 48.7 pt -136.07 167.99 23.45 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 CA-C-N 115.712 -0.676 . . . . 0.0 109.905 176.974 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . 0.441 ' HA3' ' HB3' ' A' ' 76' ' ' GLN . . . -73.95 142.66 31.07 Favored Glycine 0 C--O 1.237 0.338 0 C-N-CA 120.332 -0.937 . . . . 0.0 111.357 -179.49 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 37.8 t80 -128.1 125.0 38.36 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-O 120.611 0.243 . . . . 0.0 111.001 -177.647 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . 0.438 HH21 ' CD ' ' A' ' 74' ' ' GLU . 19.5 ttp85 -135.12 130.63 35.77 Favored 'General case' 0 C--O 1.217 -0.612 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 175.352 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.434 ' HB3' ' HB2' ' A' ' 47' ' ' LEU . . . -137.44 146.2 44.06 Favored 'General case' 0 C--N 1.317 -0.828 0 C-N-CA 120.835 -0.346 . . . . 0.0 111.38 -179.597 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 63.4 m -125.11 134.71 52.36 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.069 179.074 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 55.6 tp -63.83 118.5 8.44 Favored 'General case' 0 CA--C 1.509 -0.617 0 CA-C-O 121.074 0.464 . . . . 0.0 110.998 -179.767 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 52.3 tp -67.53 -39.43 85.04 Favored 'General case' 0 N--CA 1.436 -1.146 0 CA-C-N 115.374 -0.83 . . . . 0.0 111.116 -179.956 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 178.68 -37.69 0.08 OUTLIER Glycine 0 N--CA 1.446 -0.652 0 C-N-CA 120.485 -0.864 . . . . 0.0 112.557 179.763 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 18.8 p-10 -173.73 114.05 0.21 Allowed 'General case' 0 C--N 1.326 -0.414 0 C-N-CA 122.405 0.282 . . . . 0.0 110.353 -178.611 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 96.1 m-20 68.19 -43.77 0.49 Allowed 'General case' 0 N--CA 1.484 1.273 0 C-N-CA 123.795 0.838 . . . . 0.0 113.114 -178.824 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 9.6 m -77.96 133.76 37.97 Favored 'General case' 0 C--N 1.315 -0.932 0 CA-C-O 121.113 0.482 . . . . 0.0 110.898 178.396 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.597 ' OH ' ' HB3' ' A' ' 99' ' ' ASN . 96.4 m-85 -126.41 148.74 49.57 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.037 178.586 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -95.54 117.25 30.09 Favored 'General case' 0 C--N 1.308 -1.235 0 N-CA-C 107.797 -1.186 . . . . 0.0 107.797 173.448 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 79.0 t -103.3 136.6 35.3 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.849 0 CA-C-O 121.244 0.545 . . . . 0.0 112.416 -173.635 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.443 ' HG2' ' HA ' ' A' ' 86' ' ' SER . 98.0 mt-10 -118.76 146.88 44.43 Favored 'General case' 0 N--CA 1.439 -1.025 0 CA-C-N 114.982 -1.008 . . . . 0.0 109.081 177.438 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 10.0 m120 -123.99 137.18 54.64 Favored 'General case' 0 C--N 1.315 -0.904 0 CA-C-O 121.226 0.536 . . . . 0.0 110.931 -177.095 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' GLN . . . . . 0.735 ' O ' ' HB ' ' A' ' 59' ' ' ILE . 30.4 tt0 -110.37 115.82 30.35 Favored 'General case' 0 C--N 1.309 -1.194 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.32 -179.875 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 6.1 p90 -129.28 44.62 2.94 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-O 121.423 0.63 . . . . 0.0 110.717 179.467 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -104.8 -68.95 0.75 Allowed Glycine 0 N--CA 1.443 -0.839 0 C-N-CA 120.647 -0.787 . . . . 0.0 111.183 -178.848 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 170.81 -67.18 0.15 Allowed Glycine 0 N--CA 1.446 -0.676 0 N-CA-C 110.686 -0.965 . . . . 0.0 110.686 178.354 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 37.0 t70 -139.08 117.27 11.84 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 177.654 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 32.3 t 76.76 -75.08 0.07 Allowed 'General case' 0 C--N 1.327 -0.396 0 O-C-N 123.876 0.735 . . . . 0.0 110.092 -178.436 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 63.99 161.6 0.12 Allowed Pre-proline 0 N--CA 1.477 0.901 0 N-CA-C 112.352 0.501 . . . . 0.0 112.352 177.141 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . 0.593 ' O ' ' HB2' ' A' ' 84' ' ' TRP . 51.7 Cg_exo -57.07 -41.83 70.47 Favored 'Trans proline' 0 C--N 1.355 0.892 0 C-N-CA 122.526 2.151 . . . . 0.0 112.859 177.612 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' TRP . . . . . 0.593 ' HB2' ' O ' ' A' ' 83' ' ' PRO . 74.0 m95 94.48 116.42 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.778 0 C-N-CA 124.747 1.219 . . . . 0.0 110.231 -178.725 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 92.7 m-70 -112.15 139.04 48.0 Favored 'General case' 0 CA--C 1.517 -0.324 0 CA-C-N 116.484 -0.326 . . . . 0.0 110.531 -176.845 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' SER . . . . . 0.443 ' HA ' ' HG2' ' A' ' 74' ' ' GLU . 13.1 m -70.61 141.3 51.76 Favored 'General case' 0 C--N 1.311 -1.092 0 CA-C-N 116.442 -0.345 . . . . 0.0 110.096 177.134 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -109.29 -34.06 2.59 Favored Glycine 0 N--CA 1.447 -0.578 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.852 -178.349 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 147.57 -160.56 28.33 Favored Glycine 0 N--CA 1.453 -0.211 0 C-N-CA 120.315 -0.945 . . . . 0.0 112.459 178.649 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 23.8 t-20 -118.67 124.61 47.8 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.433 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' TRP . . . . . 0.563 ' HH2' ' SD ' ' A' ' 51' ' ' MET . 36.2 m0 -118.24 152.88 34.87 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.129 -177.721 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 79.1 mt -107.25 116.71 51.5 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 N-CA-C 110.191 -0.299 . . . . 0.0 110.191 178.494 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 90.2 mt -126.57 76.46 1.63 Allowed 'General case' 0 C--O 1.256 1.406 0 CA-C-O 121.625 0.726 . . . . 0.0 111.036 -178.411 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -176.73 105.3 0.2 Allowed Glycine 0 N--CA 1.435 -1.374 0 CA-C-N 114.842 -1.072 . . . . 0.0 111.612 -179.551 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.4 p -86.2 -11.8 51.48 Favored 'General case' 0 C--N 1.313 -1.003 0 CA-C-O 121.265 0.555 . . . . 0.0 110.695 178.384 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 97.6 mtt180 -106.92 153.39 22.6 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.563 -0.744 . . . . 0.0 111.68 178.825 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -66.69 -43.14 85.19 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 115.207 -0.906 . . . . 0.0 112.388 -175.967 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 21.4 m120 -123.04 34.1 5.22 Favored 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 111.967 0.358 . . . . 0.0 111.967 -176.364 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' GLN . . . . . . . . . . . . . 9.6 tt0 -146.95 121.01 9.41 Favored 'General case' 0 C--N 1.32 -0.688 0 C-N-CA 120.278 -0.569 . . . . 0.0 110.549 -178.473 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' ASN . . . . . 0.597 ' HB3' ' OH ' ' A' ' 71' ' ' TYR . 90.2 m-20 -95.34 159.71 14.88 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.182 -176.45 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 79.1 t -81.46 133.72 28.65 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.637 0 CA-C-N 116.509 -0.314 . . . . 0.0 110.79 176.64 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 33.7 m -113.33 -26.83 2.88 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 N-CA-C 112.83 0.678 . . . . 0.0 112.83 -178.755 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . 0.465 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -146.91 140.12 25.42 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 119.696 -0.801 . . . . 0.0 112.095 178.65 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.4 ' O ' ' HA ' ' A' ' 37' ' ' ASN . 91.1 mt -133.22 124.64 49.73 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.929 -0.578 . . . . 0.0 111.073 178.25 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 40.2 t30 -128.78 97.45 4.67 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.317 174.703 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 28.6 m -143.48 148.37 19.18 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 N-CA-C 112.949 0.722 . . . . 0.0 112.949 -174.526 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 76.1 tt0 -142.66 138.04 30.38 Favored 'General case' 0 N--CA 1.437 -1.092 0 CA-C-N 115.072 -0.967 . . . . 0.0 108.544 175.248 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 107' ' ' SER . . . . . 0.414 ' HA ' ' HA ' ' A' ' 114' ' ' LEU . 44.8 t -74.87 -52.42 11.36 Favored 'General case' 0 C--N 1.306 -1.287 0 CA-C-N 116.09 -0.504 . . . . 0.0 111.382 -178.183 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 81.8 -9.26 57.01 Favored Glycine 0 N--CA 1.449 -0.457 0 N-CA-C 110.875 -0.89 . . . . 0.0 110.875 -176.366 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . 0.534 ' CG ' ' H ' ' A' ' 110' ' ' ASP . 19.4 t70 -125.07 -150.76 0.45 Allowed 'General case' 0 N--CA 1.445 -0.677 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 179.398 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . 0.534 ' H ' ' CG ' ' A' ' 109' ' ' ASP . 31.7 m-20 -89.86 12.88 15.99 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 120.845 0.355 . . . . 0.0 111.475 -179.426 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . 0.466 ' HA3' ' ND2' ' A' ' 32' ' ' ASN . . . 101.33 8.61 46.54 Favored Glycine 0 C--O 1.229 -0.217 0 C-N-CA 120.129 -1.034 . . . . 0.0 113.408 179.529 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 48.4 mt-30 -68.83 -42.37 77.27 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.487 0.66 . . . . 0.0 110.557 179.224 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 17.5 p -133.51 139.28 46.55 Favored 'General case' 0 C--N 1.317 -0.839 0 CA-C-N 115.32 -0.854 . . . . 0.0 110.837 179.104 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 114' ' ' LEU . . . . . 0.414 ' HA ' ' HA ' ' A' ' 107' ' ' SER . 9.1 mp -120.31 145.16 47.37 Favored 'General case' 0 C--N 1.316 -0.867 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 178.677 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 8.6 p30 -148.1 160.4 42.93 Favored 'General case' 0 C--N 1.314 -0.939 0 C-N-CA 120.617 -0.433 . . . . 0.0 110.939 178.486 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 153.35 -128.0 2.32 Favored Glycine 0 N--CA 1.436 -1.337 0 CA-C-N 115.683 -0.69 . . . . 0.0 111.673 179.875 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 22.1 p -135.24 158.83 43.36 Favored 'General case' 0 C--N 1.315 -0.9 0 CA-C-O 121.11 0.481 . . . . 0.0 111.055 -179.079 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 118' ' ' MET . . . . . 0.437 ' O ' ' HA ' ' A' ' 125' ' ' PRO . 4.7 ppp? -147.19 156.03 42.61 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 116.156 -0.474 . . . . 0.0 109.841 178.841 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 119' ' ' THR . . . . . 0.465 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 26.4 m -128.72 126.45 40.06 Favored 'General case' 0 C--O 1.254 1.292 0 CA-C-O 120.519 0.2 . . . . 0.0 111.115 179.91 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 70.0 m-85 -85.42 158.44 20.22 Favored 'General case' 0 C--O 1.233 0.196 0 CA-C-N 115.777 -0.647 . . . . 0.0 109.982 176.264 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -60.3 126.32 27.03 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 120.778 0.323 . . . . 0.0 110.796 177.631 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 65.03 30.81 78.95 Favored Glycine 0 CA--C 1.523 0.562 0 CA-C-N 115.964 -0.562 . . . . 0.0 114.113 178.715 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 77.2 tt0 -150.49 160.2 43.95 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 117.229 0.514 . . . . 0.0 110.218 -179.345 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -77.2 160.08 49.46 Favored Glycine 0 CA--C 1.522 0.53 0 C-N-CA 121.084 -0.579 . . . . 0.0 112.908 -178.947 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . 0.437 ' HA ' ' O ' ' A' ' 118' ' ' MET . 51.4 Cg_endo -68.21 142.78 56.63 Favored 'Trans proline' 0 CA--C 1.534 0.502 0 C-N-CA 122.993 2.462 . . . . 0.0 113.271 179.743 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 49.1 pt -131.6 169.42 21.8 Favored 'Isoleucine or valine' 0 C--O 1.24 0.581 0 CA-C-N 115.737 -0.665 . . . . 0.0 109.935 178.547 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -70.66 131.99 21.99 Favored Glycine 0 C--N 1.336 0.55 0 C-N-CA 120.677 -0.773 . . . . 0.0 111.981 -179.381 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 84.7 t80 -119.5 139.19 52.48 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 121.255 0.55 . . . . 0.0 111.583 -178.146 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 62.8 tttm -140.94 134.8 30.48 Favored 'General case' 0 N--CA 1.431 -1.379 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 176.85 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -135.15 144.75 16.78 Favored Glycine 0 N--CA 1.436 -1.355 0 C-N-CA 120.521 -0.847 . . . . 0.0 111.428 -179.502 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 56.2 m -123.81 130.55 52.79 Favored 'General case' 0 C--N 1.311 -1.084 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 -178.72 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 61.1 tp -70.67 136.22 48.9 Favored 'General case' 0 C--O 1.237 0.436 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 179.076 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 15.4 t . . . . . 0 C--O 1.251 1.149 0 CA-C-O 119.144 -0.455 . . . . 0.0 110.069 -177.65 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 0.57 ' O ' ' HG3' ' A' ' 24' ' ' GLU . . . . . . . . 0 N--CA 1.48 1.047 0 N-CA-C 110.022 -0.362 . . . . 0.0 110.022 . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -91.97 128.23 37.74 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-O 121.019 0.437 . . . . 0.0 110.537 -175.743 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 11.8 m-85 -121.3 144.47 48.62 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.169 178.27 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 94.4 m-20 -94.66 140.13 30.29 Favored 'General case' 0 C--N 1.313 -0.99 0 N-CA-C 107.826 -1.176 . . . . 0.0 107.826 177.538 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 77.3 t -116.33 128.46 73.65 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.961 0 CA-C-O 121.274 0.559 . . . . 0.0 112.434 -175.629 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -125.09 138.75 54.18 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 176.691 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 65.3 m-80 -131.01 151.88 50.93 Favored 'General case' 0 C--N 1.316 -0.866 0 N-CA-C 112.653 0.612 . . . . 0.0 112.653 -177.526 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . 0.414 ' OE1' ' HA ' ' A' ' 13' ' ' SER . 35.7 tt0 -129.47 128.13 42.28 Favored 'General case' 0 C--O 1.238 0.498 0 CA-C-N 115.343 -0.844 . . . . 0.0 110.533 178.336 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 46.8 p90 -138.11 146.24 42.63 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 116.575 -0.284 . . . . 0.0 110.484 178.617 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 95.12 11.82 55.76 Favored Glycine 0 N--CA 1.444 -0.775 0 C-N-CA 120.545 -0.836 . . . . 0.0 111.759 179.207 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 104.88 157.38 23.27 Favored Glycine 0 N--CA 1.442 -0.919 0 C-N-CA 120.953 -0.642 . . . . 0.0 112.144 179.088 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' SER . . . . . 0.414 ' HA ' ' OE1' ' A' ' 9' ' ' GLN . 15.5 m -58.13 -21.16 45.42 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 112.128 0.418 . . . . 0.0 112.128 179.036 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 18.7 m -59.14 -33.73 71.23 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 120.806 0.336 . . . . 0.0 110.857 176.82 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -76.78 145.28 74.31 Favored Pre-proline 0 N--CA 1.45 -0.437 0 CA-C-N 116.009 -0.542 . . . . 0.0 111.132 -179.409 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 93.1 Cg_endo -73.26 163.19 38.62 Favored 'Trans proline' 0 C--O 1.236 0.375 0 C-N-CA 122.808 2.339 . . . . 0.0 112.266 -179.892 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 92.3 m95 -85.17 131.68 34.4 Favored 'General case' 0 C--N 1.319 -0.75 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 179.23 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 55.9 m-80 -124.1 144.94 49.59 Favored 'General case' 0 C--N 1.312 -1.029 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 -179.525 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -64.99 135.4 55.6 Favored 'General case' 0 C--N 1.311 -1.066 0 CA-C-O 121.598 0.713 . . . . 0.0 112.207 -177.274 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -112.2 34.82 4.98 Favored Glycine 0 CA--C 1.499 -0.912 0 CA-C-N 114.604 -1.18 . . . . 0.0 110.961 178.326 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 83.3 -156.85 34.24 Favored Glycine 0 N--CA 1.436 -1.353 0 N-CA-C 111.344 -0.702 . . . . 0.0 111.344 -177.387 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 13.6 pt20 -144.27 147.41 33.5 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-O 120.869 0.366 . . . . 0.0 110.246 178.204 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . 0.594 ' HB3' ' O ' ' A' ' 91' ' ' ILE . 54.4 m0 -128.33 -179.14 4.86 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.743 -173.893 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . 0.57 ' HG3' ' O ' ' A' ' 2' ' ' ALA . 82.6 tt0 -123.69 116.15 22.6 Favored 'General case' 0 CA--C 1.511 -0.534 0 CA-C-O 120.943 0.401 . . . . 0.0 110.522 176.446 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 95.3 mt -126.94 134.16 66.8 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.784 0 CA-C-N 115.448 -0.796 . . . . 0.0 110.767 -177.701 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 90.94 106.74 1.38 Allowed Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.973 -0.632 . . . . 0.0 113.911 176.526 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 19.8 m -69.1 -43.04 75.29 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.369 0.604 . . . . 0.0 110.02 175.419 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -71.0 137.96 49.52 Favored 'General case' 0 N--CA 1.451 -0.396 0 CA-C-N 115.292 -0.867 . . . . 0.0 110.663 179.77 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 19.8 m -102.86 -26.16 13.23 Favored 'General case' 0 C--N 1.315 -0.924 0 CA-C-O 121.054 0.454 . . . . 0.0 110.4 178.687 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 27.1 m-20 -91.09 -5.3 55.34 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.918 179.263 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . 0.441 HE21 ' HB3' ' A' ' 53' ' ' TYR . 57.6 tp60 -139.59 120.55 14.54 Favored 'General case' 0 C--N 1.31 -1.133 0 N-CA-C 109.35 -0.611 . . . . 0.0 109.35 -178.999 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 62.0 t30 -97.74 162.76 13.11 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-O 121.172 0.51 . . . . 0.0 112.083 -175.975 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 89.5 t -98.74 133.59 40.66 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.639 0 CA-C-N 115.217 -0.902 . . . . 0.0 109.991 179.965 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 21.0 m -107.05 -27.73 2.96 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.456 0 N-CA-C 111.981 0.364 . . . . 0.0 111.981 -179.38 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -139.56 143.63 37.44 Favored 'General case' 0 CA--C 1.509 -0.634 0 C-N-CA 120.109 -0.637 . . . . 0.0 111.632 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.421 ' HB ' ' CG2' ' A' ' 105' ' ' VAL . 94.2 mt -139.64 117.73 11.4 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.832 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 179.039 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 1.3 t-20 -129.02 108.25 10.24 Favored 'General case' 0 C--N 1.304 -1.388 0 N-CA-C 108.065 -1.087 . . . . 0.0 108.065 177.453 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 23.9 m -147.03 151.38 13.95 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.762 0 C-N-CA 120.448 -0.501 . . . . 0.0 111.339 -173.184 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 36.1 tt0 -141.1 145.56 35.95 Favored 'General case' 0 N--CA 1.437 -1.089 0 CA-C-N 115.512 -0.767 . . . . 0.0 109.001 176.433 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 30.9 t -72.26 142.6 48.93 Favored 'General case' 0 C--N 1.309 -1.176 0 CA-C-O 121.093 0.473 . . . . 0.0 111.338 -178.522 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -95.22 -25.12 14.79 Favored Glycine 0 N--CA 1.433 -1.553 0 C-N-CA 120.504 -0.855 . . . . 0.0 111.769 177.919 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 36.1 t70 -145.11 79.63 1.59 Allowed 'General case' 0 CA--C 1.536 0.405 0 N-CA-C 112.842 0.682 . . . . 0.0 112.842 -177.372 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 50.24 29.03 3.44 Favored 'General case' 0 N--CA 1.491 1.611 0 N-CA-C 114.564 1.32 . . . . 0.0 114.564 173.673 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.443 ' HA2' HG13 ' A' ' 101' ' ' VAL . . . 99.44 -16.77 58.6 Favored Glycine 0 C--N 1.312 -0.791 0 C-N-CA 120.658 -0.782 . . . . 0.0 113.189 178.187 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 59.7 tp60 -66.42 -39.01 88.72 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-O 121.04 0.448 . . . . 0.0 110.77 -179.944 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 36.8 p -125.67 147.84 49.21 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.975 178.499 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 95.2 mt -128.36 128.15 43.99 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 109.524 -0.547 . . . . 0.0 109.524 179.254 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 13.8 m120 -128.44 141.1 51.51 Favored 'General case' 0 C--N 1.319 -0.723 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 178.398 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 175.45 -156.26 21.73 Favored Glycine 0 N--CA 1.442 -0.948 0 C-N-CA 119.411 -1.376 . . . . 0.0 113.503 178.444 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 70.4 m -128.95 131.46 47.5 Favored 'General case' 0 N--CA 1.44 -0.971 0 C-N-CA 122.839 0.456 . . . . 0.0 110.149 -178.43 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 14.7 tmm? -125.91 144.73 50.56 Favored 'General case' 0 C--N 1.316 -0.875 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 -179.265 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 33.6 m -126.26 130.06 50.13 Favored 'General case' 0 C--O 1.245 0.866 0 N-CA-C 112.054 0.39 . . . . 0.0 112.054 -176.57 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . 0.441 ' HB3' HE21 ' A' ' 31' ' ' GLN . 72.4 m-85 -87.15 161.8 17.87 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.946 177.176 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -63.54 106.91 1.02 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.989 -0.55 . . . . 0.0 112.069 -179.713 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 84.67 10.6 79.0 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.713 -0.756 . . . . 0.0 113.528 177.836 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 57.8 mt-10 -123.07 168.02 12.9 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 117.212 0.506 . . . . 0.0 110.793 178.26 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -79.86 155.48 38.97 Favored Glycine 0 N--CA 1.447 -0.599 0 C-N-CA 120.84 -0.695 . . . . 0.0 112.379 -179.884 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 32.9 Cg_endo -62.81 142.72 89.89 Favored 'Trans proline' 0 CA--C 1.534 0.503 0 C-N-CA 123.012 2.475 . . . . 0.0 112.546 -179.758 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . 0.563 ' HB ' ' O ' ' A' ' 76' ' ' GLN . 47.3 pt -128.25 167.35 23.55 Favored 'Isoleucine or valine' 0 C--O 1.239 0.501 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.736 -179.765 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -79.11 138.63 20.89 Favored Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 120.929 -0.653 . . . . 0.0 111.807 -179.702 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 60.9 t80 -118.62 123.59 45.36 Favored 'General case' 0 C--N 1.317 -0.827 0 C-N-CA 122.389 0.275 . . . . 0.0 110.799 -178.132 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 49.1 ttm-85 -126.81 128.22 46.22 Favored 'General case' 0 C--O 1.22 -0.452 0 N-CA-C 109.325 -0.62 . . . . 0.0 109.325 175.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.485 ' HB1' ' HB3' ' A' ' 71' ' ' TYR . . . -136.12 142.81 44.29 Favored 'General case' 0 C--N 1.32 -0.696 0 C-N-CA 120.231 -0.588 . . . . 0.0 112.094 178.574 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 57.3 m -118.7 127.45 53.58 Favored 'General case' 0 CA--C 1.54 0.573 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.084 178.249 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 2.4 tm? -72.74 118.31 15.51 Favored 'General case' 0 CA--C 1.544 0.749 0 CA-C-O 121.372 0.606 . . . . 0.0 112.156 -177.866 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 4.6 mm? -66.86 -38.22 85.94 Favored 'General case' 0 N--CA 1.475 0.792 0 CA-C-N 115.283 -0.871 . . . . 0.0 111.869 178.091 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 125.45 -6.14 8.07 Favored Glycine 0 C--O 1.227 -0.304 0 C-N-CA 120.593 -0.813 . . . . 0.0 112.521 -176.263 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 29.7 p-10 -125.83 38.19 4.2 Favored 'General case' 0 C--N 1.316 -0.889 0 CA-C-O 121.117 0.484 . . . . 0.0 110.507 -179.372 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 96.1 m-20 66.59 5.09 3.64 Favored 'General case' 0 N--CA 1.479 0.976 0 CA-C-N 115.469 -0.787 . . . . 0.0 111.882 -178.761 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 32.8 m -99.17 138.06 36.81 Favored 'General case' 0 N--CA 1.443 -0.785 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 177.367 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.58 ' OH ' ' HB3' ' A' ' 99' ' ' ASN . 91.5 m-85 -120.38 135.65 54.97 Favored 'General case' 0 C--N 1.306 -1.296 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.329 -179.28 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . 0.404 ' O ' ' HA ' ' A' ' 63' ' ' ALA . 71.6 tt0 -88.76 121.31 31.0 Favored 'General case' 0 C--N 1.311 -1.077 0 N-CA-C 107.964 -1.124 . . . . 0.0 107.964 175.286 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 75.3 t -107.67 137.05 40.85 Favored 'Isoleucine or valine' 0 C--O 1.247 0.957 0 N-CA-C 113.661 0.986 . . . . 0.0 113.661 -170.857 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -119.17 142.67 47.76 Favored 'General case' 0 N--CA 1.444 -0.739 0 CA-C-N 114.19 -1.368 . . . . 0.0 107.84 175.565 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 94.1 m-20 -118.06 135.31 54.27 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-O 120.825 0.345 . . . . 0.0 111.251 -175.699 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' GLN . . . . . 0.563 ' O ' ' HB ' ' A' ' 59' ' ' ILE . 17.3 tt0 -110.09 119.35 39.02 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.889 179.124 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 7.5 p90 -139.63 156.71 46.68 Favored 'General case' 0 C--N 1.326 -0.456 0 C-N-CA 120.856 -0.338 . . . . 0.0 111.358 177.013 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 105.81 -3.95 39.13 Favored Glycine 0 N--CA 1.449 -0.498 0 C-N-CA 121.198 -0.525 . . . . 0.0 112.177 179.666 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 139.63 171.57 12.35 Favored Glycine 0 CA--C 1.503 -0.694 0 N-CA-C 110.579 -1.008 . . . . 0.0 110.579 -179.602 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -68.07 155.16 40.15 Favored 'General case' 0 C--O 1.245 0.839 0 CA-C-N 117.527 0.664 . . . . 0.0 110.047 178.448 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 14.7 m 70.95 -95.2 0.03 OUTLIER 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.467 -0.788 . . . . 0.0 109.042 -176.601 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . 0.522 ' HB3' ' HD2' ' A' ' 83' ' ' PRO . . . 51.46 171.07 0.04 OUTLIER Pre-proline 0 CA--C 1.557 1.25 0 N-CA-C 113.31 0.855 . . . . 0.0 113.31 176.38 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . 0.522 ' HD2' ' HB3' ' A' ' 82' ' ' ALA . 63.6 Cg_endo -73.27 150.6 47.49 Favored 'Trans proline' 0 N--CA 1.452 -0.943 0 C-N-CA 121.591 1.527 . . . . 0.0 109.927 170.551 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' TRP . . . . . . . . . . . . . 82.2 m95 -95.69 137.99 33.98 Favored 'General case' 0 C--N 1.315 -0.924 0 C-N-CA 120.54 -0.464 . . . . 0.0 109.768 -179.91 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 84.4 m-70 -113.18 138.8 49.43 Favored 'General case' 0 C--N 1.314 -0.976 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 -177.775 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 13.4 p -65.15 131.25 46.04 Favored 'General case' 0 C--N 1.32 -0.688 0 C-N-CA 121.113 -0.235 . . . . 0.0 110.447 -179.779 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -105.36 -52.3 0.83 Allowed Glycine 0 N--CA 1.443 -0.836 0 C-N-CA 120.239 -0.981 . . . . 0.0 113.23 -179.187 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 154.59 -166.27 32.24 Favored Glycine 0 C--O 1.22 -0.747 0 C-N-CA 120.187 -1.006 . . . . 0.0 112.115 -178.108 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 20.5 t-20 -113.81 119.43 37.32 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 117.01 0.405 . . . . 0.0 110.709 -179.482 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 22.4 m0 -108.89 148.1 31.16 Favored 'General case' 0 C--O 1.217 -0.621 0 N-CA-C 109.492 -0.558 . . . . 0.0 109.492 -179.867 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . 0.594 ' O ' ' HB3' ' A' ' 23' ' ' TRP . 85.0 mt -107.7 119.56 57.51 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.072 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 178.903 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . 0.452 ' HB2' ' CE1' ' A' ' 71' ' ' TYR . 90.9 mt -134.08 78.95 1.79 Allowed 'General case' 0 C--O 1.267 1.984 0 CA-C-O 121.688 0.756 . . . . 0.0 111.6 -177.399 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 168.85 126.7 0.87 Allowed Glycine 0 N--CA 1.44 -1.08 0 CA-C-N 115.13 -0.941 . . . . 0.0 111.875 179.29 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' SER . . . . . 0.402 ' HB3' ' HE1' ' A' ' 23' ' ' TRP . 32.4 p -117.95 4.2 12.13 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-O 121.353 0.596 . . . . 0.0 110.651 178.379 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 62.3 mtt-85 -102.01 142.84 32.66 Favored 'General case' 0 N--CA 1.445 -0.702 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.521 178.903 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 -62.66 -37.61 87.09 Favored 'General case' 0 C--N 1.312 -1.029 0 CA-C-N 115.421 -0.809 . . . . 0.0 112.899 -176.143 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 29.0 p-10 -126.3 27.93 6.11 Favored 'General case' 0 C--N 1.316 -0.86 0 N-CA-C 111.827 0.306 . . . . 0.0 111.827 -176.333 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' GLN . . . . . 0.47 HE21 ' HB3' ' A' ' 121' ' ' ALA . 21.9 tp60 -146.19 126.56 14.01 Favored 'General case' 0 C--N 1.322 -0.615 0 C-N-CA 119.319 -0.953 . . . . 0.0 111.688 -175.471 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' ASN . . . . . 0.58 ' HB3' ' OH ' ' A' ' 71' ' ' TYR . 87.2 m-20 -97.24 154.28 17.5 Favored 'General case' 0 C--O 1.249 1.048 0 CA-C-N 115.452 -0.795 . . . . 0.0 110.572 -179.439 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 70.8 t -79.03 136.86 22.9 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.791 0 C-N-CA 120.85 -0.34 . . . . 0.0 110.79 177.84 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . 0.443 HG13 ' HA2' ' A' ' 44' ' ' GLY . 33.3 m -123.0 -35.52 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.714 0 N-CA-C 113.878 1.066 . . . . 0.0 113.878 -177.118 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -127.59 127.33 43.68 Favored 'General case' 0 C--N 1.319 -0.743 0 C-N-CA 120.153 -0.619 . . . . 0.0 111.386 -178.63 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 94.0 mt -131.18 122.09 50.57 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.091 177.927 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 7.6 t30 -124.79 95.4 4.5 Favored 'General case' 0 C--N 1.313 -1.001 0 N-CA-C 108.812 -0.81 . . . . 0.0 108.812 176.455 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.421 ' CG2' ' HB ' ' A' ' 36' ' ' ILE . 26.8 m -140.17 142.68 31.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 N-CA-C 112.682 0.623 . . . . 0.0 112.682 -175.612 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 -145.1 147.16 32.23 Favored 'General case' 0 N--CA 1.444 -0.759 0 CA-C-N 115.4 -0.818 . . . . 0.0 109.153 176.526 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 47.2 t -137.73 142.48 40.99 Favored 'General case' 0 C--N 1.308 -1.221 0 CA-C-O 120.797 0.332 . . . . 0.0 110.78 -178.589 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -108.01 -6.18 32.39 Favored Glycine 0 N--CA 1.44 -1.05 0 N-CA-C 110.796 -0.922 . . . . 0.0 110.796 175.766 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 68.3 m-20 -98.26 54.65 1.09 Allowed 'General case' 0 C--O 1.235 0.33 0 N-CA-C 112.643 0.609 . . . . 0.0 112.643 -177.582 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 28.7 t70 59.55 15.55 4.65 Favored 'General case' 0 N--CA 1.481 1.098 0 C-N-CA 123.3 0.64 . . . . 0.0 112.284 174.863 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 86.37 -3.85 86.66 Favored Glycine 0 N--CA 1.447 -0.625 0 C-N-CA 120.447 -0.882 . . . . 0.0 112.944 178.232 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 112' ' ' GLN . . . . . 0.415 ' O ' ' HA ' ' A' ' 131' ' ' THR . 97.6 mt-30 -64.21 -40.14 95.45 Favored 'General case' 0 CA--C 1.517 -0.29 0 CA-C-N 116.926 0.363 . . . . 0.0 111.622 -177.76 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 33.5 p -123.32 112.17 17.28 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 110.0 -0.37 . . . . 0.0 110.0 177.833 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 92.5 mt -90.93 126.95 36.21 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 116.464 -0.335 . . . . 0.0 110.477 -178.66 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 9.0 m120 -118.72 129.86 55.51 Favored 'General case' 0 C--O 1.241 0.651 0 CA-C-N 116.224 -0.444 . . . . 0.0 109.882 -178.812 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 172.21 -141.32 6.22 Favored Glycine 0 N--CA 1.445 -0.755 0 C-N-CA 119.741 -1.218 . . . . 0.0 113.608 178.098 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 16.9 p -137.29 159.32 42.27 Favored 'General case' 0 C--N 1.319 -0.726 0 C-N-CA 123.276 0.63 . . . . 0.0 110.781 -178.269 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 17.8 ptm -147.31 150.44 34.79 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 120.864 0.364 . . . . 0.0 110.898 -179.721 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 23.3 m -142.48 136.09 29.05 Favored 'General case' 0 C--O 1.252 1.194 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.064 178.053 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . 0.62 ' HB2' ' O ' ' A' ' 123' ' ' GLU . 37.1 m-85 -83.58 174.26 10.7 Favored 'General case' 0 C--O 1.225 -0.23 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.342 175.597 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . 0.47 ' HB3' HE21 ' A' ' 98' ' ' GLN . . . -51.22 -28.87 12.55 Favored 'General case' 0 N--CA 1.478 0.933 0 N-CA-C 114.058 1.133 . . . . 0.0 114.058 -175.951 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -165.54 26.84 0.18 Allowed Glycine 0 N--CA 1.447 -0.589 0 C-N-CA 119.29 -1.433 . . . . 0.0 112.742 179.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . 0.62 ' O ' ' HB2' ' A' ' 120' ' ' TYR . 13.3 pt-20 -165.97 145.59 6.25 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.132 0.491 . . . . 0.0 111.868 -178.51 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 71.87 67.92 1.74 Allowed Glycine 0 CA--C 1.531 1.084 0 N-CA-C 116.312 1.285 . . . . 0.0 116.312 173.075 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_exo -84.14 95.07 0.73 Allowed 'Trans proline' 0 N--CA 1.459 -0.53 0 C-N-CA 122.454 2.102 . . . . 0.0 108.374 170.561 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 19.6 pt -130.28 165.83 29.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 N-CA-C 113.234 0.828 . . . . 0.0 113.234 -170.762 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -70.44 135.99 25.96 Favored Glycine 0 C--N 1.339 0.703 0 CA-C-N 115.488 -0.778 . . . . 0.0 111.577 178.29 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 82.5 t80 -112.54 133.26 54.69 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 121.281 0.562 . . . . 0.0 111.754 -175.688 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 63.5 tttm -137.64 110.4 7.61 Favored 'General case' 0 C--N 1.314 -0.939 0 CA-C-N 115.241 -0.891 . . . . 0.0 108.933 177.089 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -117.56 153.82 17.02 Favored Glycine 0 N--CA 1.446 -0.685 0 C-N-CA 120.298 -0.953 . . . . 0.0 112.332 -178.363 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 131' ' ' THR . . . . . 0.415 ' HA ' ' O ' ' A' ' 112' ' ' GLN . 14.9 t -143.01 144.95 32.49 Favored 'General case' 0 C--N 1.311 -1.073 0 CA-C-O 121.149 0.5 . . . . 0.0 111.945 179.625 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 68.6 tp -80.91 127.16 32.24 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.342 -0.845 . . . . 0.0 110.219 178.337 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 9.1 t . . . . . 0 C--O 1.253 1.27 0 CA-C-O 118.957 -0.544 . . . . 0.0 110.496 -179.343 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.697 0 N-CA-C 109.995 -0.372 . . . . 0.0 109.995 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . 0.503 HD11 HE21 ' A' ' 22' ' ' GLN . 2.2 tm? -92.08 134.91 34.4 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 116.117 -0.492 . . . . 0.0 109.801 -178.031 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . 0.472 ' CE1' ' HB ' ' A' ' 25' ' ' ILE . 74.1 m-85 -123.36 146.54 47.87 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.515 -179.803 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . 0.414 ' O ' ' HA2' ' A' ' 130' ' ' GLY . 23.6 t-20 -96.45 140.9 30.42 Favored 'General case' 0 C--N 1.308 -1.211 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 176.627 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 69.9 t -122.77 129.53 75.1 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.916 0 N-CA-C 112.699 0.629 . . . . 0.0 112.699 -175.154 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 91.4 mt-10 -122.4 144.32 49.11 Favored 'General case' 0 C--N 1.32 -0.679 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 173.09 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 11.9 m120 -123.49 144.67 49.39 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-O 120.921 0.391 . . . . 0.0 111.493 -177.003 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . 0.577 ' HB2' ' CE3' ' A' ' 17' ' ' TRP . 57.9 tt0 -123.88 127.14 47.59 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.766 -179.853 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 8.7 p90 -136.09 139.22 42.83 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-N 116.193 -0.458 . . . . 0.0 109.865 176.915 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 105.34 8.0 36.41 Favored Glycine 0 N--CA 1.448 -0.529 0 C-N-CA 120.286 -0.959 . . . . 0.0 112.294 179.862 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 103.24 165.71 25.68 Favored Glycine 0 N--CA 1.445 -0.724 0 C-N-CA 120.402 -0.904 . . . . 0.0 113.427 177.954 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 15.6 m -54.81 -31.81 59.6 Favored 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 123.631 0.773 . . . . 0.0 112.321 179.013 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 33.6 t -64.25 -40.0 95.11 Favored 'General case' 0 C--O 1.242 0.701 0 CA-C-O 120.97 0.414 . . . . 0.0 110.604 -179.573 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -63.43 150.55 89.56 Favored Pre-proline 0 C--O 1.235 0.34 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.403 -179.118 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 88.8 Cg_endo -75.33 156.87 41.6 Favored 'Trans proline' 0 C--O 1.238 0.477 0 C-N-CA 122.888 2.392 . . . . 0.0 112.93 -179.476 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . 0.577 ' CE3' ' HB2' ' A' ' 9' ' ' GLN . 85.7 m95 -84.91 124.59 31.82 Favored 'General case' 0 N--CA 1.446 -0.627 0 N-CA-C 107.872 -1.159 . . . . 0.0 107.872 175.71 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 55.1 m-80 -103.68 137.13 42.15 Favored 'General case' 0 C--N 1.308 -1.228 0 N-CA-C 109.122 -0.695 . . . . 0.0 109.122 -179.177 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 18.5 pt-20 -63.78 128.79 37.38 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-O 121.625 0.726 . . . . 0.0 111.673 -178.277 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.681 ' O ' ' HB2' ' A' ' 94' ' ' SER . . . -102.26 -25.28 7.92 Favored Glycine 0 N--CA 1.434 -1.467 0 CA-C-N 114.435 -1.257 . . . . 0.0 113.746 -174.851 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 139.07 -153.04 22.57 Favored Glycine 0 N--CA 1.443 -0.849 0 C-N-CA 119.684 -1.246 . . . . 0.0 112.071 -174.367 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . 0.503 HE21 HD11 ' A' ' 3' ' ' LEU . 4.1 pt20 -138.41 134.37 34.04 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 120.733 0.302 . . . . 0.0 110.707 -179.054 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . 0.434 ' HE1' ' HB3' ' A' ' 94' ' ' SER . 44.9 m0 -117.61 172.74 7.15 Favored 'General case' 0 N--CA 1.47 0.568 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.637 -179.021 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 79.2 tt0 -130.93 122.49 27.04 Favored 'General case' 0 CA--C 1.518 -0.286 0 C-N-CA 120.513 -0.475 . . . . 0.0 110.142 178.006 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.555 HG23 ' CZ3' ' A' ' 90' ' ' TRP . 99.1 mt -139.72 151.39 22.26 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.769 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.189 -176.146 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 84.62 25.91 40.68 Favored Glycine 0 C--N 1.336 0.559 0 C-N-CA 121.009 -0.615 . . . . 0.0 113.81 175.26 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 4.9 m -77.85 7.94 5.25 Favored 'General case' 0 CA--C 1.549 0.93 0 N-CA-C 112.471 0.545 . . . . 0.0 112.471 -179.06 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . 0.481 ' HA ' ' O ' ' A' ' 87' ' ' GLY . 70.7 ttt180 -64.16 -49.68 71.15 Favored 'General case' 0 N--CA 1.474 0.756 0 CA-C-O 121.14 0.495 . . . . 0.0 111.85 -177.977 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 59.2 m -161.47 25.41 0.13 Allowed 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 -179.795 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 27.4 m-20 61.35 94.38 0.04 OUTLIER 'General case' 0 C--O 1.236 0.388 0 CA-C-N 114.486 -1.234 . . . . 0.0 108.783 -175.894 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -160.93 143.42 12.6 Favored 'General case' 0 N--CA 1.443 -0.78 0 N-CA-C 107.455 -1.313 . . . . 0.0 107.455 -176.23 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . 0.492 ' HB3' ' HA3' ' A' ' 111' ' ' GLY . 3.8 m120 -83.37 134.71 34.88 Favored 'General case' 0 C--N 1.311 -1.089 0 CA-C-O 121.543 0.687 . . . . 0.0 112.589 -177.741 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.408 HG21 ' CE1' ' A' ' 53' ' ' TYR . 44.7 t -92.9 135.99 26.18 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.727 0 CA-C-N 114.768 -1.105 . . . . 0.0 110.153 -179.857 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 29.7 m -109.36 -18.6 7.41 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 C-N-CA 120.758 -0.377 . . . . 0.0 111.572 -179.671 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -149.92 139.1 21.22 Favored 'General case' 0 C--O 1.236 0.361 0 C-N-CA 120.787 -0.365 . . . . 0.0 111.48 178.666 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.429 ' HB ' ' CG2' ' A' ' 105' ' ' VAL . 86.8 mt -140.03 116.32 8.74 Favored 'Isoleucine or valine' 0 C--O 1.237 0.446 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 178.635 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 14.7 m120 -123.55 106.65 10.77 Favored 'General case' 0 C--N 1.311 -1.085 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 176.716 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 18.6 m -146.56 148.11 17.26 Favored 'Isoleucine or valine' 0 C--O 1.238 0.472 0 CA-C-O 120.742 0.306 . . . . 0.0 111.236 -174.764 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 83.0 tt0 -142.61 147.41 35.78 Favored 'General case' 0 C--N 1.319 -0.759 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 178.169 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 19.4 p -70.81 150.33 45.94 Favored 'General case' 0 C--N 1.319 -0.757 0 N-CA-C 112.985 0.735 . . . . 0.0 112.985 -176.248 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -103.55 -47.39 1.3 Allowed Glycine 0 N--CA 1.443 -0.879 0 N-CA-C 110.529 -1.029 . . . . 0.0 110.529 176.252 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 45.4 m-20 -102.11 -152.8 0.45 Allowed 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 109.57 -0.53 . . . . 0.0 109.57 177.065 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 19.0 m-20 -74.17 44.41 0.19 Allowed 'General case' 0 N--CA 1.486 1.367 0 N-CA-C 112.147 0.425 . . . . 0.0 112.147 -177.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 79.91 3.45 89.32 Favored Glycine 0 CA--C 1.506 -0.475 0 C-N-CA 120.881 -0.676 . . . . 0.0 112.056 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 61.1 mt-30 -83.43 -21.99 32.78 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-O 121.215 0.531 . . . . 0.0 110.081 178.464 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' THR . . . . . 0.503 ' HA ' ' O ' ' A' ' 63' ' ' ALA . 35.2 p -129.03 142.62 50.85 Favored 'General case' 0 C--N 1.315 -0.907 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.936 178.52 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 95.9 mt -128.62 133.18 48.22 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 109.103 -0.702 . . . . 0.0 109.103 179.915 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 14.0 m120 -126.5 139.4 53.25 Favored 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 -179.97 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 169.74 -150.51 15.13 Favored Glycine 0 N--CA 1.448 -0.538 0 C-N-CA 120.112 -1.042 . . . . 0.0 112.463 178.035 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 34.8 p -134.45 152.43 51.79 Favored 'General case' 0 C--N 1.317 -0.83 0 N-CA-C 110.031 -0.359 . . . . 0.0 110.031 179.676 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 11.0 tmm? -142.12 145.49 34.3 Favored 'General case' 0 C--N 1.315 -0.912 0 C-N-CA 121.124 -0.23 . . . . 0.0 110.85 -178.829 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 60.4 m -129.07 128.64 43.97 Favored 'General case' 0 C--O 1.248 1.014 0 CA-C-O 120.81 0.338 . . . . 0.0 111.904 -177.399 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . 0.464 ' HB2' ' HB2' ' A' ' 56' ' ' GLU . 78.7 m-85 -91.11 164.63 13.86 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 115.617 -0.72 . . . . 0.0 110.327 176.86 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -69.39 98.26 1.07 Allowed 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.189 179.017 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 103.9 2.16 45.78 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.946 -0.645 . . . . 0.0 112.793 177.779 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . 0.464 ' HB2' ' HB2' ' A' ' 53' ' ' TYR . 66.7 mm-40 -117.69 162.91 17.27 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 110.115 -0.328 . . . . 0.0 110.115 179.02 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -84.08 166.25 42.34 Favored Glycine 0 N--CA 1.441 -0.972 0 C-N-CA 120.282 -0.961 . . . . 0.0 111.784 179.114 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 23.1 Cg_exo -65.82 139.78 58.61 Favored 'Trans proline' 0 N--CA 1.462 -0.348 0 C-N-CA 122.459 2.106 . . . . 0.0 111.912 178.921 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 38.3 pt -128.88 161.29 38.36 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.792 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.386 178.85 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -74.8 134.48 17.41 Favored Glycine 0 N--CA 1.446 -0.669 0 N-CA-C 111.331 -0.707 . . . . 0.0 111.331 179.984 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 52.6 t80 -117.46 125.98 51.84 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-O 121.034 0.445 . . . . 0.0 111.562 -176.905 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 64.0 ttp85 -136.53 129.08 30.42 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.857 -0.61 . . . . 0.0 109.747 174.737 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.503 ' O ' ' HA ' ' A' ' 46' ' ' THR . . . -129.41 139.3 51.7 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 116.563 -0.289 . . . . 0.0 110.966 -177.748 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 40.6 m -122.29 128.72 51.41 Favored 'General case' 0 C--N 1.323 -0.544 0 O-C-N 123.512 0.507 . . . . 0.0 109.74 178.534 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 52.6 tp -75.58 119.28 19.42 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 112.388 0.514 . . . . 0.0 112.388 -177.082 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 84.6 mt -84.18 -27.61 27.94 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.453 -0.794 . . . . 0.0 109.438 174.847 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 129.81 158.86 9.59 Favored Glycine 0 N--CA 1.442 -0.901 0 CA-C-N 115.109 -0.95 . . . . 0.0 110.81 -178.861 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 93.0 m-20 60.89 37.29 18.55 Favored 'General case' 0 N--CA 1.476 0.86 0 CA-C-O 120.848 0.356 . . . . 0.0 111.242 178.969 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 16.8 m120 66.37 8.15 5.48 Favored 'General case' 0 N--CA 1.485 1.309 0 C-N-CA 123.244 0.618 . . . . 0.0 112.151 179.237 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 15.8 m -92.18 121.84 34.09 Favored 'General case' 0 N--CA 1.446 -0.666 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 178.703 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 64.8 m-85 -113.58 132.73 55.62 Favored 'General case' 0 C--N 1.312 -1.04 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.999 -178.942 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 63.2 tt0 -86.96 119.76 27.51 Favored 'General case' 0 N--CA 1.438 -1.035 0 N-CA-C 106.763 -1.569 . . . . 0.0 106.763 172.952 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 79.2 t -107.27 134.51 48.76 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 CA-C-O 121.182 0.515 . . . . 0.0 112.086 -172.824 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 87.6 mt-10 -127.37 129.61 47.9 Favored 'General case' 0 N--CA 1.438 -1.072 0 N-CA-C 107.703 -1.221 . . . . 0.0 107.703 176.363 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 48.9 m-80 -112.42 154.79 25.26 Favored 'General case' 0 C--N 1.314 -0.971 0 CA-C-O 120.967 0.413 . . . . 0.0 111.041 -176.68 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 63.1 tt0 -115.45 119.95 37.91 Favored 'General case' 0 C--N 1.311 -1.099 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.152 -178.695 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 12.4 p90 -143.67 161.86 37.44 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.804 179.388 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 100.4 -7.21 58.06 Favored Glycine 0 N--CA 1.446 -0.674 0 C-N-CA 120.858 -0.687 . . . . 0.0 111.924 179.648 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 136.2 160.28 8.74 Favored Glycine 0 N--CA 1.44 -1.081 0 N-CA-C 111.574 -0.611 . . . . 0.0 111.574 179.92 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 15.7 t70 -59.74 -41.78 91.69 Favored 'General case' 0 C--N 1.319 -0.737 0 C-N-CA 123.115 0.566 . . . . 0.0 112.085 179.626 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 50.6 p -76.71 -3.97 40.79 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 112.573 0.583 . . . . 0.0 112.573 -179.205 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -76.52 150.74 82.5 Favored Pre-proline 0 C--N 1.325 -0.46 0 CA-C-O 120.518 0.199 . . . . 0.0 110.945 -179.686 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -74.07 -178.55 3.95 Favored 'Trans proline' 0 C--O 1.239 0.54 0 C-N-CA 122.633 2.222 . . . . 0.0 112.083 179.212 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' TRP . . . . . . . . . . . . . 89.0 m95 -95.77 140.24 30.85 Favored 'General case' 0 N--CA 1.444 -0.729 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.352 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 89.5 m-70 -118.26 142.98 46.92 Favored 'General case' 0 C--N 1.31 -1.117 0 CA-C-N 116.273 -0.421 . . . . 0.0 109.949 179.878 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 11.8 p -62.85 134.26 55.97 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.843 0.354 . . . . 0.0 111.161 -178.366 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . 0.481 ' O ' ' HA ' ' A' ' 28' ' ' ARG . . . -107.89 -46.43 1.03 Allowed Glycine 0 N--CA 1.438 -1.167 0 C-N-CA 120.971 -0.633 . . . . 0.0 111.909 179.76 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 148.39 -168.0 29.08 Favored Glycine 0 C--O 1.225 -0.44 0 C-N-CA 120.031 -1.081 . . . . 0.0 112.733 178.24 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 24.9 t-20 -106.0 117.05 33.02 Favored 'General case' 0 C--N 1.321 -0.674 0 N-CA-C 110.054 -0.35 . . . . 0.0 110.054 -179.012 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' TRP . . . . . 0.555 ' CZ3' HG23 ' A' ' 25' ' ' ILE . 18.6 m0 -113.56 148.21 36.56 Favored 'General case' 0 C--N 1.317 -0.818 0 N-CA-C 109.284 -0.635 . . . . 0.0 109.284 179.887 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 85.6 mt -105.32 117.89 51.8 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.843 0 N-CA-C 109.547 -0.538 . . . . 0.0 109.547 179.064 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 86.0 mt -129.26 78.61 1.86 Allowed 'General case' 0 C--O 1.265 1.92 0 CA-C-O 121.863 0.839 . . . . 0.0 112.092 -177.76 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 170.05 124.45 0.74 Allowed Glycine 0 N--CA 1.441 -0.987 0 CA-C-N 114.757 -1.111 . . . . 0.0 110.722 178.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' SER . . . . . 0.681 ' HB2' ' O ' ' A' ' 20' ' ' GLY . 83.7 p -106.42 -7.61 17.53 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-O 120.898 0.38 . . . . 0.0 111.665 -179.55 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' ARG . . . . . 0.42 HH12 ' CD ' ' A' ' 123' ' ' GLU . 99.5 mtt180 -106.76 154.61 20.73 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 121.269 0.557 . . . . 0.0 112.091 178.871 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 26.8 tp10 -68.62 -38.83 80.89 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 114.965 -1.016 . . . . 0.0 111.061 -174.258 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 10.1 p30 -116.17 21.06 13.96 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.925 -177.076 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -136.75 115.82 12.42 Favored 'General case' 0 C--N 1.32 -0.697 0 C-N-CA 119.573 -0.851 . . . . 0.0 112.89 -176.46 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 90.4 m-20 -92.44 154.76 18.3 Favored 'General case' 0 C--O 1.249 1.057 0 CA-C-N 115.029 -0.987 . . . . 0.0 109.353 177.488 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . 0.41 HG22 ' CH2' ' A' ' 23' ' ' TRP . 85.2 t -79.75 130.8 35.49 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.555 0 C-N-CA 120.092 -0.643 . . . . 0.0 110.899 178.492 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 33.7 m -111.74 -19.18 7.08 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.438 0 N-CA-C 112.122 0.415 . . . . 0.0 112.122 -179.654 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . 0.477 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -152.12 140.07 20.08 Favored 'General case' 0 CA--C 1.511 -0.537 0 C-N-CA 119.899 -0.72 . . . . 0.0 111.588 176.975 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 95.4 mt -135.49 125.01 41.75 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.175 177.456 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 52.6 t30 -129.74 101.22 5.8 Favored 'General case' 0 C--N 1.315 -0.931 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 175.801 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.429 ' CG2' ' HB ' ' A' ' 36' ' ' ILE . 19.8 m -140.9 142.8 29.51 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.791 0 N-CA-C 113.195 0.813 . . . . 0.0 113.195 -175.547 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 99.9 mt-10 -141.58 151.25 43.02 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 114.911 -1.04 . . . . 0.0 108.615 176.507 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 36.5 t -130.12 146.94 51.81 Favored 'General case' 0 C--N 1.311 -1.106 0 CA-C-O 121.244 0.545 . . . . 0.0 111.871 -177.817 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -89.61 -10.98 64.63 Favored Glycine 0 N--CA 1.444 -0.792 0 N-CA-C 110.366 -1.094 . . . . 0.0 110.366 174.435 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 83.6 m-20 -94.16 -172.06 2.71 Favored 'General case' 0 CA--C 1.513 -0.48 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 178.28 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 13.5 p-10 -95.74 33.86 1.59 Allowed 'General case' 0 C--N 1.313 -0.988 0 CA-C-O 121.031 0.443 . . . . 0.0 109.986 176.884 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . 0.492 ' HA3' ' HB3' ' A' ' 32' ' ' ASN . . . 97.42 8.56 56.15 Favored Glycine 0 C--N 1.333 0.406 0 CA-C-N 115.825 -0.625 . . . . 0.0 113.803 179.13 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 28.3 tt0 -64.72 -40.88 96.08 Favored 'General case' 0 C--O 1.241 0.621 0 CA-C-O 121.537 0.684 . . . . 0.0 109.858 178.383 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 73.2 p -135.58 146.93 48.47 Favored 'General case' 0 N--CA 1.446 -0.651 0 CA-C-N 114.841 -1.072 . . . . 0.0 109.483 178.306 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 96.0 mt -119.97 126.47 50.93 Favored 'General case' 0 C--N 1.312 -1.06 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 178.951 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 14.2 m120 -122.99 143.57 49.84 Favored 'General case' 0 C--N 1.317 -0.835 0 N-CA-C 110.01 -0.367 . . . . 0.0 110.01 -178.963 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 161.19 -142.11 7.83 Favored Glycine 0 N--CA 1.448 -0.513 0 C-N-CA 119.747 -1.216 . . . . 0.0 113.303 177.3 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 23.6 p -131.47 156.95 44.75 Favored 'General case' 0 C--N 1.316 -0.849 0 C-N-CA 122.919 0.488 . . . . 0.0 110.819 -178.709 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 19.9 ptm -149.69 157.08 42.9 Favored 'General case' 0 C--N 1.314 -0.945 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.152 179.955 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 119' ' ' THR . . . . . 0.477 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 40.6 m -132.0 130.31 41.24 Favored 'General case' 0 C--O 1.245 0.841 0 CA-C-N 116.589 -0.278 . . . . 0.0 111.269 -179.176 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 11.7 m-85 -94.22 160.52 14.65 Favored 'General case' 0 N--CA 1.455 -0.197 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.883 176.616 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -38.7 -45.14 1.08 Allowed 'General case' 0 N--CA 1.482 1.161 0 N-CA-C 114.149 1.166 . . . . 0.0 114.149 -177.245 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -145.63 43.01 0.94 Allowed Glycine 0 CA--C 1.506 -0.514 0 C-N-CA 120.084 -1.055 . . . . 0.0 111.713 -178.972 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . 0.42 ' CD ' HH12 ' A' ' 95' ' ' ARG . 28.5 tp10 -116.13 -61.95 1.66 Allowed 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 121.199 0.523 . . . . 0.0 110.714 -177.712 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 134.26 -179.0 17.97 Favored Glycine 0 N--CA 1.443 -0.836 0 N-CA-C 111.264 -0.734 . . . . 0.0 111.264 -178.503 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 62.0 Cg_endo -81.46 117.15 3.04 Favored 'Trans proline' 0 N--CA 1.455 -0.738 0 C-N-CA 122.424 2.082 . . . . 0.0 112.182 179.508 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 38.0 pt -126.22 161.2 32.44 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.922 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.415 -179.894 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -72.5 138.67 26.55 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.949 -0.643 . . . . 0.0 112.609 -178.732 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 77.8 t80 -114.82 132.23 56.56 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-O 121.061 0.458 . . . . 0.0 110.994 -179.153 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 129' ' ' LYS . . . . . 0.45 ' HB2' ' CZ3' ' A' ' 17' ' ' TRP . 86.9 tttt -134.28 101.33 4.97 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.098 177.43 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . 0.414 ' HA2' ' O ' ' A' ' 5' ' ' ASN . . . -109.44 150.41 17.26 Favored Glycine 0 N--CA 1.435 -1.38 0 C-N-CA 120.326 -0.94 . . . . 0.0 112.0 179.3 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 6.0 t -146.39 148.77 32.68 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-O 120.718 0.294 . . . . 0.0 111.15 179.21 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 83.4 mt -63.51 132.93 52.87 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.059 -0.518 . . . . 0.0 110.107 175.796 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 6.9 p . . . . . 0 C--O 1.249 1.051 0 CA-C-O 118.511 -0.756 . . . . 0.0 110.702 178.873 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 0.595 ' O ' ' HG3' ' A' ' 24' ' ' GLU . . . . . . . . 0 N--CA 1.475 0.825 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . 0.441 HD12 ' N ' ' A' ' 4' ' ' TYR . 0.3 OUTLIER -90.94 130.58 36.86 Favored 'General case' 0 C--N 1.313 -0.994 0 CA-C-O 121.064 0.459 . . . . 0.0 109.88 -174.58 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . 0.441 ' N ' HD12 ' A' ' 3' ' ' LEU . 28.5 m-85 -116.99 137.39 52.25 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-N 115.854 -0.612 . . . . 0.0 111.24 -179.989 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 20.8 t-20 -87.12 131.73 34.06 Favored 'General case' 0 C--N 1.306 -1.317 0 N-CA-C 106.577 -1.638 . . . . 0.0 106.577 176.884 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.513 HG23 ' CG ' ' A' ' 23' ' ' TRP . 58.6 t -114.72 126.16 72.21 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.854 0 N-CA-C 113.204 0.816 . . . . 0.0 113.204 -172.969 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.411 ' HG2' ' HB3' ' A' ' 19' ' ' GLU . 92.3 mt-10 -120.56 135.66 55.02 Favored 'General case' 0 N--CA 1.435 -1.195 0 CA-C-N 114.575 -1.193 . . . . 0.0 108.353 176.833 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 9.9 m120 -120.22 144.53 47.68 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-O 120.899 0.381 . . . . 0.0 111.858 -176.226 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . 0.558 ' OE1' ' HA ' ' A' ' 13' ' ' SER . 36.4 tt0 -129.2 122.01 28.85 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.557 -0.747 . . . . 0.0 109.869 178.754 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 17.5 p90 -120.94 140.93 51.17 Favored 'General case' 0 C--N 1.314 -0.945 0 CA-C-O 121.337 0.589 . . . . 0.0 111.695 -179.845 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 107.24 -69.95 0.21 Allowed Glycine 0 N--CA 1.441 -1.009 0 CA-C-N 115.429 -0.805 . . . . 0.0 111.576 179.287 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -165.09 166.78 38.41 Favored Glycine 0 N--CA 1.442 -0.929 0 N-CA-C 111.612 -0.595 . . . . 0.0 111.612 179.467 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' SER . . . . . 0.558 ' HA ' ' OE1' ' A' ' 9' ' ' GLN . 11.5 p -60.04 -20.42 57.85 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 112.9 0.704 . . . . 0.0 112.9 -179.246 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 8.1 m -78.58 -5.59 53.23 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 120.642 0.258 . . . . 0.0 111.541 179.7 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -86.68 146.7 41.98 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 120.745 0.307 . . . . 0.0 111.359 -178.943 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -65.74 149.37 87.02 Favored 'Trans proline' 0 C--O 1.235 0.331 0 C-N-CA 122.823 2.349 . . . . 0.0 112.094 179.102 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 96.9 m95 -82.88 132.27 35.16 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 178.27 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 89.1 m-20 -120.67 122.84 41.33 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.43 -178.504 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.411 ' HB3' ' HG2' ' A' ' 7' ' ' GLU . 5.1 pt-20 -90.32 127.76 36.25 Favored 'General case' 0 C--N 1.313 -0.986 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 178.111 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -139.14 29.43 2.53 Favored Glycine 0 N--CA 1.445 -0.747 0 C-N-CA 119.761 -1.209 . . . . 0.0 112.611 -178.07 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 157.21 174.88 27.48 Favored Glycine 0 N--CA 1.438 -1.224 0 C-N-CA 120.381 -0.914 . . . . 0.0 112.458 179.829 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 4.4 pt20 -134.56 139.33 45.32 Favored 'General case' 0 C--N 1.314 -0.946 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 179.643 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' TRP . . . . . 0.527 ' HB3' ' O ' ' A' ' 91' ' ' ILE . 38.8 m0 -116.72 178.44 4.34 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.404 -176.715 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . 0.595 ' HG3' ' O ' ' A' ' 2' ' ' ALA . 76.9 tt0 -131.58 121.48 24.46 Favored 'General case' 0 N--CA 1.441 -0.879 0 C-N-CA 120.371 -0.531 . . . . 0.0 110.447 174.899 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 91.3 mt -127.59 131.99 69.57 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.955 0 CA-C-N 115.349 -0.841 . . . . 0.0 109.479 -178.668 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 91.13 121.28 2.49 Favored Glycine 0 N--CA 1.441 -0.99 0 C-N-CA 120.474 -0.869 . . . . 0.0 112.356 179.637 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' SER . . . . . 0.492 ' CB ' ' HA3' ' A' ' 88' ' ' GLY . 6.3 m -119.44 11.54 12.18 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-O 121.277 0.56 . . . . 0.0 109.819 179.957 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 63.1 mtt-85 -141.07 141.84 34.22 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.391 -0.822 . . . . 0.0 109.21 -176.485 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 37.3 p -92.09 2.5 56.54 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-O 121.145 0.498 . . . . 0.0 111.344 -178.523 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 37.0 m-20 -62.31 -38.1 88.11 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.585 -0.734 . . . . 0.0 111.509 -178.839 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 1.3 tm0? -167.35 151.36 6.63 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.937 -177.276 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . 0.453 ' HB3' ' HA3' ' A' ' 111' ' ' GLY . 15.6 m120 -96.91 173.14 7.44 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.679 0.752 . . . . 0.0 111.239 179.375 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 17.2 t -102.85 134.22 44.47 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.256 0 CA-C-N 115.202 -0.908 . . . . 0.0 112.51 -175.144 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 27.0 m -121.11 -28.14 1.87 Allowed 'Isoleucine or valine' 0 C--O 1.255 1.352 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.602 174.946 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.582 ' HA ' ' O ' ' A' ' 105' ' ' VAL . . . -140.31 140.33 35.63 Favored 'General case' 0 N--CA 1.442 -0.837 0 CA-C-O 121.38 0.609 . . . . 0.0 111.986 -178.706 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 93.7 mt -146.41 129.57 9.27 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 177.608 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -127.92 109.14 11.3 Favored 'General case' 0 C--N 1.311 -1.088 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 175.087 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . 0.475 HG11 ' CD1' ' A' ' 61' ' ' PHE . 19.4 m -147.47 149.49 15.47 Favored 'Isoleucine or valine' 0 C--O 1.242 0.685 0 C-N-CA 120.874 -0.33 . . . . 0.0 111.343 -174.906 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 77.6 tt0 -138.82 144.9 39.51 Favored 'General case' 0 N--CA 1.443 -0.813 0 CA-C-N 115.72 -0.673 . . . . 0.0 109.279 178.043 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 37.0 p -69.76 140.87 53.47 Favored 'General case' 0 C--N 1.317 -0.817 0 N-CA-C 112.533 0.568 . . . . 0.0 112.533 -176.862 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -86.83 -62.39 1.53 Allowed Glycine 0 CA--C 1.502 -0.771 0 N-CA-C 109.113 -1.595 . . . . 0.0 109.113 174.628 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 51.0 m-20 -88.36 -169.2 2.46 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 173.988 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 70.9 m-20 -77.11 57.98 1.48 Allowed 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 112.462 0.542 . . . . 0.0 112.462 -177.946 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 97.02 -20.32 51.31 Favored Glycine 0 C--O 1.218 -0.857 0 C-N-CA 121.068 -0.587 . . . . 0.0 113.419 175.542 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 56.0 mt-30 -64.99 -34.07 77.55 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 112.89 0.7 . . . . 0.0 112.89 -177.754 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' THR . . . . . 0.52 ' HA ' ' O ' ' A' ' 63' ' ' ALA . 14.8 t -136.14 131.64 34.98 Favored 'General case' 0 N--CA 1.438 -1.049 0 C-N-CA 120.387 -0.525 . . . . 0.0 111.239 178.622 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' LEU . . . . . 0.406 ' O ' ' HA ' ' A' ' 62' ' ' ARG . 80.1 mt -111.01 133.03 53.72 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.837 -0.619 . . . . 0.0 109.508 179.384 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 64.0 m-80 -125.27 146.21 49.65 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-O 120.703 0.287 . . . . 0.0 110.706 179.238 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 163.34 -140.52 6.54 Favored Glycine 0 N--CA 1.439 -1.15 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.497 178.4 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 24.5 p -133.41 150.75 51.78 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 120.908 0.385 . . . . 0.0 111.21 -179.292 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 18.4 ttt -124.82 137.0 54.32 Favored 'General case' 0 C--N 1.32 -0.68 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 179.78 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.543 ' HB ' ' HB2' ' A' ' 35' ' ' ALA . 60.6 m -124.89 122.55 37.68 Favored 'General case' 0 C--O 1.259 1.592 0 CA-C-O 121.17 0.509 . . . . 0.0 111.799 -178.303 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' TYR . . . . . 0.401 ' HB2' ' HB2' ' A' ' 56' ' ' GLU . 98.1 m-85 -84.66 166.0 17.44 Favored 'General case' 0 CA--C 1.52 -0.201 0 CA-C-N 115.372 -0.831 . . . . 0.0 109.835 178.512 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -67.94 110.69 3.99 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 120.952 0.406 . . . . 0.0 111.125 179.836 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 83.41 16.84 67.87 Favored Glycine 0 CA--C 1.522 0.493 0 C-N-CA 120.667 -0.778 . . . . 0.0 113.711 179.401 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' GLU . . . . . 0.401 ' HB2' ' HB2' ' A' ' 53' ' ' TYR . 98.1 mt-10 -132.01 163.24 28.83 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 117.339 0.569 . . . . 0.0 111.135 178.962 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -81.08 156.42 37.79 Favored Glycine 0 N--CA 1.447 -0.612 0 CA-C-N 115.955 -0.566 . . . . 0.0 112.603 -179.273 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 21.8 Cg_exo -64.62 142.56 77.86 Favored 'Trans proline' 0 C--N 1.347 0.467 0 C-N-CA 122.924 2.416 . . . . 0.0 112.81 -179.295 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 44.7 pt -125.91 167.66 19.98 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.872 0 CA-C-N 115.527 -0.76 . . . . 0.0 109.332 177.272 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -70.37 137.63 27.97 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.19 -1.005 . . . . 0.0 111.674 -178.952 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.475 ' CD1' HG11 ' A' ' 38' ' ' VAL . 50.2 t80 -127.71 128.42 45.37 Favored 'General case' 0 C--N 1.317 -0.847 0 CA-C-O 120.757 0.313 . . . . 0.0 110.831 -177.887 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . 0.406 ' HA ' ' O ' ' A' ' 47' ' ' LEU . 63.7 ttp85 -138.77 132.72 31.13 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.181 175.276 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.52 ' O ' ' HA ' ' A' ' 46' ' ' THR . . . -127.74 137.02 52.31 Favored 'General case' 0 C--N 1.311 -1.09 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.653 179.658 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 61.2 m -123.55 132.41 53.89 Favored 'General case' 0 C--N 1.315 -0.913 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 178.776 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . 0.646 HD21 ' O ' ' A' ' 68' ' ' ASN . 3.7 mt -60.5 128.17 35.33 Favored 'General case' 0 CA--C 1.501 -0.911 0 N-CA-C 113.928 1.085 . . . . 0.0 113.928 -178.13 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . 0.58 HD12 ' ND2' ' A' ' 89' ' ' ASN . 96.1 mt -76.43 -34.72 58.77 Favored 'General case' 0 N--CA 1.431 -1.394 0 N-CA-C 107.27 -1.381 . . . . 0.0 107.27 169.004 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -166.91 -72.66 0.03 OUTLIER Glycine 0 N--CA 1.433 -1.564 0 C-N-CA 120.405 -0.903 . . . . 0.0 115.013 -179.504 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' ASN . . . . . 0.646 ' O ' HD21 ' A' ' 65' ' ' LEU . 17.0 m120 -125.3 -77.34 0.59 Allowed 'General case' 0 C--O 1.214 -0.782 0 CA-C-N 118.212 1.006 . . . . 0.0 110.202 -175.85 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 12.2 m120 -100.94 -6.31 24.77 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 120.898 0.38 . . . . 0.0 110.643 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 8.3 m -95.37 121.13 36.72 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.698 -178.134 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' TYR . . . . . 0.402 ' CE2' ' HG ' ' A' ' 65' ' ' LEU . 96.0 m-85 -115.9 150.21 37.44 Favored 'General case' 0 C--N 1.314 -0.937 0 CA-C-N 116.323 -0.399 . . . . 0.0 111.181 -178.657 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 70.4 tt0 -105.72 125.53 51.09 Favored 'General case' 0 C--N 1.31 -1.125 0 N-CA-C 107.451 -1.315 . . . . 0.0 107.451 173.499 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 65.3 t -104.8 132.27 51.9 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.388 0 CA-C-O 121.544 0.687 . . . . 0.0 112.471 -174.172 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 47.5 mt-10 -127.35 123.54 36.52 Favored 'General case' 0 N--CA 1.436 -1.161 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 176.631 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 97.5 m-20 -110.83 153.43 25.41 Favored 'General case' 0 C--N 1.317 -0.819 0 CA-C-O 121.229 0.538 . . . . 0.0 111.934 -176.018 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' GLN . . . . . 0.485 ' HB2' ' CE3' ' A' ' 84' ' ' TRP . 60.0 tt0 -113.98 116.43 29.21 Favored 'General case' 0 C--N 1.312 -1.05 0 CA-C-N 115.607 -0.724 . . . . 0.0 109.933 -178.589 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 13.4 p90 -142.72 160.59 40.01 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.157 179.446 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 94.68 -3.66 68.29 Favored Glycine 0 N--CA 1.449 -0.473 0 C-N-CA 120.599 -0.81 . . . . 0.0 112.073 -179.532 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 135.21 152.44 6.49 Favored Glycine 0 N--CA 1.446 -0.65 0 N-CA-C 111.469 -0.652 . . . . 0.0 111.469 179.38 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 25.7 t70 -62.71 -36.82 84.22 Favored 'General case' 0 N--CA 1.468 0.453 0 CA-C-O 120.869 0.366 . . . . 0.0 111.932 -179.71 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 29.3 p -69.65 -15.78 63.25 Favored 'General case' 0 C--N 1.316 -0.86 0 N-CA-C 112.125 0.417 . . . . 0.0 112.125 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -75.87 142.71 73.43 Favored Pre-proline 0 C--O 1.234 0.267 0 CA-C-N 116.478 -0.328 . . . . 0.0 110.884 -179.512 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 96.7 Cg_endo -73.59 156.25 49.5 Favored 'Trans proline' 0 N--CA 1.462 -0.353 0 C-N-CA 122.712 2.274 . . . . 0.0 111.819 178.731 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' TRP . . . . . 0.485 ' CE3' ' HB2' ' A' ' 76' ' ' GLN . 81.7 m95 -60.98 138.31 58.18 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.305 0.574 . . . . 0.0 111.543 179.615 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 99.1 m-70 -113.03 144.65 42.24 Favored 'General case' 0 C--N 1.311 -1.096 0 CA-C-N 115.213 -0.903 . . . . 0.0 109.208 178.344 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 12.9 p -61.46 125.75 24.9 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-O 121.192 0.52 . . . . 0.0 111.941 -177.293 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -96.42 -48.85 2.11 Favored Glycine 0 N--CA 1.441 -1.032 0 CA-C-N 115.595 -0.73 . . . . 0.0 111.532 179.747 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . 0.492 ' HA3' ' CB ' ' A' ' 27' ' ' SER . . . 149.86 -167.17 29.92 Favored Glycine 0 C--O 1.216 -1.027 0 N-CA-C 111.326 -0.71 . . . . 0.0 111.326 178.405 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' ASN . . . . . 0.58 ' ND2' HD12 ' A' ' 66' ' ' LEU . 22.7 m120 -108.53 140.84 41.3 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 117.379 0.59 . . . . 0.0 110.867 179.35 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' TRP . . . . . 0.441 ' HD1' ' C ' ' A' ' 89' ' ' ASN . 29.4 m0 -133.69 160.62 36.99 Favored 'General case' 0 N--CA 1.465 0.298 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 -177.16 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . 0.527 ' O ' ' HB3' ' A' ' 23' ' ' TRP . 96.9 mt -121.19 121.6 65.31 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.035 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 175.806 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 83.7 mt -134.63 82.93 1.99 Allowed 'General case' 0 C--O 1.267 1.979 0 N-CA-C 112.765 0.654 . . . . 0.0 112.765 -175.414 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 164.64 118.5 0.44 Allowed Glycine 0 N--CA 1.448 -0.536 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.81 177.954 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 43.1 m -90.64 -0.14 57.58 Favored 'General case' 0 N--CA 1.463 0.211 0 CA-C-O 121.11 0.481 . . . . 0.0 110.64 177.922 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -120.02 152.16 37.91 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 178.788 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 78.1 tt0 -66.06 -65.44 0.68 Allowed 'General case' 0 C--N 1.32 -0.71 0 N-CA-C 112.6 0.593 . . . . 0.0 112.6 -174.86 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 93.5 m-20 -107.15 36.9 2.52 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 116.271 -0.422 . . . . 0.0 112.026 -175.409 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' GLN . . . . . . . . . . . . . 14.5 tp60 -108.67 -62.33 1.48 Allowed 'General case' 0 C--N 1.316 -0.885 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 179.646 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 91.7 m-20 71.87 149.98 0.1 Allowed 'General case' 0 C--O 1.248 1.013 0 CA-C-N 115.225 -0.898 . . . . 0.0 112.942 178.258 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 76.6 t -81.66 132.14 32.19 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.335 0 CA-C-N 115.44 -0.8 . . . . 0.0 111.191 178.279 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 26.8 m -114.49 -21.57 5.3 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.185 0 CA-C-N 116.004 -0.544 . . . . 0.0 112.356 179.571 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . 0.417 ' HB2' ' HB ' ' A' ' 119' ' ' THR . . . -150.09 141.44 23.27 Favored 'General case' 0 C--N 1.326 -0.444 0 C-N-CA 120.161 -0.615 . . . . 0.0 111.596 178.601 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.426 ' HB ' HG23 ' A' ' 38' ' ' VAL . 32.2 mm -134.61 127.21 49.33 Favored 'Isoleucine or valine' 0 C--O 1.244 0.766 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.863 178.429 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 50.4 t30 -131.76 97.38 4.18 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.782 -0.645 . . . . 0.0 109.867 175.277 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.582 ' O ' ' HA ' ' A' ' 35' ' ' ALA . 15.5 m -130.51 135.06 61.28 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.029 0 CA-C-N 115.775 -0.648 . . . . 0.0 111.162 -176.926 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 52.8 mt-10 -139.1 27.45 2.37 Favored 'General case' 0 N--CA 1.486 1.371 0 CA-C-O 121.526 0.679 . . . . 0.0 110.953 -178.841 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 107' ' ' SER . . . . . 0.569 ' HB2' ' HB2' ' A' ' 115' ' ' ASN . 53.7 m -139.1 147.34 41.85 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 114.259 1.207 . . . . 0.0 114.259 -175.1 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 148.71 122.06 1.2 Allowed Glycine 0 N--CA 1.436 -1.341 0 CA-C-N 114.624 -1.171 . . . . 0.0 111.84 178.268 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -83.29 107.67 15.98 Favored 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 178.657 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 59.58 18.13 6.77 Favored 'General case' 0 N--CA 1.481 1.084 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.275 -177.446 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . 0.453 ' HA3' ' HB3' ' A' ' 32' ' ' ASN . . . 80.06 15.39 78.96 Favored Glycine 0 N--CA 1.442 -0.913 0 CA-C-N 115.818 -0.628 . . . . 0.0 112.838 179.006 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 52.2 tt0 -64.15 -37.52 87.74 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-O 121.799 0.809 . . . . 0.0 109.138 177.607 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 60.5 p -133.93 164.25 27.71 Favored 'General case' 0 N--CA 1.431 -1.422 0 CA-C-N 114.56 -1.2 . . . . 0.0 108.724 177.354 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 114' ' ' LEU . . . . . 0.402 ' HA ' ' O ' ' A' ' 107' ' ' SER . 33.8 tp -134.84 114.69 12.84 Favored 'General case' 0 C--N 1.301 -1.519 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 176.937 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 115' ' ' ASN . . . . . 0.569 ' HB2' ' HB2' ' A' ' 107' ' ' SER . 0.8 OUTLIER -116.9 143.7 45.39 Favored 'General case' 0 C--O 1.263 1.81 0 C-N-CA 120.117 -0.633 . . . . 0.0 111.577 -176.31 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 165.02 -138.31 5.18 Favored Glycine 0 N--CA 1.437 -1.298 0 CA-C-N 115.164 -0.925 . . . . 0.0 112.25 177.208 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 29.8 p -130.51 155.48 46.4 Favored 'General case' 0 C--N 1.307 -1.265 0 C-N-CA 122.792 0.437 . . . . 0.0 109.986 -179.221 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 118' ' ' MET . . . . . 0.405 ' HE1' ' HB2' ' A' ' 118' ' ' MET . 18.0 ptm -146.94 153.32 39.95 Favored 'General case' 0 C--N 1.309 -1.194 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.465 -179.065 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 119' ' ' THR . . . . . 0.417 ' HB ' ' HB2' ' A' ' 102' ' ' ALA . 25.9 m -132.83 129.8 38.97 Favored 'General case' 0 C--O 1.248 1.0 0 CA-C-N 116.487 -0.324 . . . . 0.0 111.368 -179.811 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . 0.464 ' HB2' ' HB3' ' A' ' 123' ' ' GLU . 57.2 m-85 -94.1 159.16 15.27 Favored 'General case' 0 CA--C 1.516 -0.35 0 CA-C-N 115.746 -0.661 . . . . 0.0 109.58 175.298 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -66.27 134.39 52.56 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 109.662 -0.496 . . . . 0.0 109.662 176.284 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 64.95 22.44 68.6 Favored Glycine 0 CA--C 1.523 0.532 0 C-N-CA 120.815 -0.707 . . . . 0.0 113.113 -179.856 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . 0.464 ' HB3' ' HB2' ' A' ' 120' ' ' TYR . 39.3 tp10 -137.87 161.86 35.51 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 -178.172 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -89.06 156.51 26.28 Favored Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.284 -0.96 . . . . 0.0 111.84 178.617 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_exo -60.6 134.28 53.52 Favored 'Trans proline' 0 C--N 1.349 0.6 0 C-N-CA 122.394 2.062 . . . . 0.0 111.707 178.743 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 39.7 pt -131.57 165.44 31.71 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.812 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.51 -178.91 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -73.87 139.23 25.91 Favored Glycine 0 N--CA 1.445 -0.726 0 C-N-CA 121.206 -0.521 . . . . 0.0 112.003 179.717 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 92.2 t80 -117.35 132.63 56.56 Favored 'General case' 0 C--O 1.244 0.794 0 CA-C-O 120.974 0.416 . . . . 0.0 111.083 -178.697 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 61.7 tttm -135.48 102.37 5.11 Favored 'General case' 0 N--CA 1.442 -0.865 0 CA-C-N 115.567 -0.742 . . . . 0.0 109.694 177.867 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -100.58 140.7 15.04 Favored Glycine 0 CA--C 1.503 -0.67 0 N-CA-C 110.793 -0.923 . . . . 0.0 110.793 178.25 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 45.5 m -136.69 133.4 36.12 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-N 117.224 0.512 . . . . 0.0 111.059 179.881 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 78.8 mt -60.71 129.91 43.86 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-O 120.907 0.384 . . . . 0.0 110.363 177.21 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 133' ' ' THR . . . . . 0.408 HG22 HD13 ' A' ' 3' ' ' LEU . 5.3 t . . . . . 0 C--O 1.247 0.958 0 CA-C-O 118.244 -0.884 . . . . 0.0 110.13 -179.037 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.72 0 N-CA-C 110.246 -0.279 . . . . 0.0 110.246 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 3' ' ' LEU . . . . . 0.412 HD13 ' N ' ' A' ' 4' ' ' TYR . 2.3 tm? -91.43 128.32 37.21 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 -177.918 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 4' ' ' TYR . . . . . 0.453 ' CE2' ' HB ' ' A' ' 25' ' ' ILE . 83.1 m-85 -119.31 146.77 45.0 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-O 120.991 0.424 . . . . 0.0 111.645 -179.632 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 49.0 m-80 -97.31 138.74 34.32 Favored 'General case' 0 C--N 1.315 -0.932 0 N-CA-C 107.213 -1.403 . . . . 0.0 107.213 175.89 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 69.7 t -115.95 126.7 73.57 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.878 0 N-CA-C 113.108 0.781 . . . . 0.0 113.108 -175.17 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 94.4 mt-10 -120.72 135.66 55.07 Favored 'General case' 0 N--CA 1.443 -0.811 0 CA-C-N 114.817 -1.083 . . . . 0.0 108.21 175.21 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 91.6 m-20 -125.44 148.43 48.82 Favored 'General case' 0 C--N 1.313 -0.994 0 CA-C-O 121.042 0.449 . . . . 0.0 111.738 -176.665 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 58.0 tt0 -125.92 119.38 27.61 Favored 'General case' 0 C--N 1.316 -0.857 0 N-CA-C 107.471 -1.307 . . . . 0.0 107.471 177.143 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 39.3 p90 -142.04 9.74 1.92 Allowed 'General case' 0 C--N 1.319 -0.721 0 N-CA-C 114.404 1.261 . . . . 0.0 114.404 -174.814 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -120.96 18.15 9.1 Favored Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 118.351 -1.881 . . . . 0.0 112.075 -176.767 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 110.83 159.58 16.47 Favored Glycine 0 N--CA 1.443 -0.879 0 C-N-CA 120.859 -0.686 . . . . 0.0 112.203 -179.761 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 41.3 m -56.18 -33.23 65.07 Favored 'General case' 0 C--N 1.323 -0.57 0 C-N-CA 122.74 0.416 . . . . 0.0 111.967 178.855 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 20.3 m -68.21 -14.18 62.79 Favored 'General case' 0 CA--C 1.539 0.535 0 CA-C-N 116.582 -0.281 . . . . 0.0 111.499 178.454 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -96.86 138.66 21.34 Favored Pre-proline 0 C--N 1.323 -0.549 0 N-CA-C 110.013 -0.366 . . . . 0.0 110.013 178.597 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_endo -77.9 -171.78 1.29 Allowed 'Trans proline' 0 CA--C 1.534 0.52 0 C-N-CA 122.954 2.436 . . . . 0.0 113.01 -178.966 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 96.9 m95 -91.34 136.06 33.37 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.103 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 90.8 m-20 -119.71 122.14 40.78 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.103 -179.288 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 75.3 tt0 -78.23 132.03 37.37 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 115.924 -0.58 . . . . 0.0 109.64 178.07 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.441 ' O ' ' HB2' ' A' ' 94' ' ' SER . . . -137.1 29.8 2.69 Favored Glycine 0 N--CA 1.447 -0.612 0 C-N-CA 119.565 -1.303 . . . . 0.0 113.547 -178.919 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 137.33 179.43 16.85 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.023 -1.084 . . . . 0.0 113.333 178.564 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 98.9 mt-30 -123.02 147.56 46.53 Favored 'General case' 0 C--N 1.327 -0.384 0 C-N-CA 122.796 0.438 . . . . 0.0 110.099 179.351 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' TRP . . . . . 0.424 ' HE1' ' HB3' ' A' ' 94' ' ' SER . 45.5 m0 -121.83 171.81 8.62 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 178.813 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -127.23 117.41 22.25 Favored 'General case' 0 C--N 1.317 -0.829 0 C-N-CA 120.635 -0.426 . . . . 0.0 110.144 175.97 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.453 ' HB ' ' CE2' ' A' ' 4' ' ' TYR . 99.1 mt -133.98 144.49 35.39 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 CA-C-N 115.559 -0.746 . . . . 0.0 109.677 -177.827 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 81.57 35.64 22.1 Favored Glycine 0 CA--C 1.506 -0.487 0 C-N-CA 120.231 -0.985 . . . . 0.0 111.921 179.536 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 11.4 m -74.05 21.62 0.09 Allowed 'General case' 0 C--N 1.317 -0.823 0 N-CA-C 111.9 0.333 . . . . 0.0 111.9 179.83 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' ARG . . . . . 0.481 ' NH1' ' HG3' ' A' ' 31' ' ' GLN . 54.4 ttt180 -92.61 10.46 30.36 Favored 'General case' 0 CA--C 1.544 0.748 0 CA-C-O 121.686 0.755 . . . . 0.0 109.075 178.807 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 29.3 m 72.57 -79.67 0.04 OUTLIER 'General case' 0 CA--C 1.541 0.619 0 CA-C-N 114.802 -1.09 . . . . 0.0 113.288 176.135 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 28.4 m-20 -88.98 2.68 53.57 Favored 'General case' 0 N--CA 1.473 0.683 0 N-CA-C 113.106 0.78 . . . . 0.0 113.106 -175.222 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' GLN . . . . . 0.481 ' HG3' ' NH1' ' A' ' 28' ' ' ARG . 8.4 mm-40 -122.47 117.18 25.34 Favored 'General case' 0 C--N 1.309 -1.167 0 N-CA-C 113.394 0.887 . . . . 0.0 113.394 -178.869 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 32' ' ' ASN . . . . . 0.587 ' OD1' ' HA3' ' A' ' 111' ' ' GLY . 28.2 t-20 -92.39 145.16 24.68 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 114.932 -1.031 . . . . 0.0 110.376 177.163 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.438 HG21 ' CH2' ' A' ' 90' ' ' TRP . 53.3 t -97.62 131.95 43.42 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.148 0 CA-C-N 115.586 -0.734 . . . . 0.0 111.089 -178.814 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 29.1 m -109.36 -19.15 7.04 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.155 0 N-CA-C 112.361 0.504 . . . . 0.0 112.361 -179.597 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' ALA . . . . . 0.479 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -148.3 143.4 26.89 Favored 'General case' 0 CA--C 1.515 -0.383 0 C-N-CA 120.403 -0.519 . . . . 0.0 111.228 179.078 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.434 ' HB ' HG22 ' A' ' 105' ' ' VAL . 90.9 mt -142.68 122.04 9.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.215 -178.99 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 93.0 m-20 -127.7 106.78 9.37 Favored 'General case' 0 C--N 1.313 -0.989 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 175.141 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.506 HG11 ' CD1' ' A' ' 61' ' ' PHE . 29.2 m -149.17 154.53 9.44 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 C-N-CA 120.79 -0.364 . . . . 0.0 111.463 -173.693 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 73.8 tt0 -147.61 152.42 37.87 Favored 'General case' 0 N--CA 1.442 -0.844 0 N-CA-C 109.284 -0.635 . . . . 0.0 109.284 176.471 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 33.2 p -83.25 130.33 35.07 Favored 'General case' 0 C--N 1.312 -1.028 0 CA-C-N 116.498 -0.319 . . . . 0.0 111.78 -177.541 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -71.58 -43.41 52.65 Favored Glycine 0 N--CA 1.445 -0.712 0 N-CA-C 110.197 -1.161 . . . . 0.0 110.197 174.681 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 57.2 m-20 -104.71 -152.91 0.47 Allowed 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 114.898 -0.651 . . . . 0.0 109.764 178.338 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -74.81 40.27 0.14 Allowed 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 123.683 0.793 . . . . 0.0 111.308 -179.907 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.413 ' O ' ' HE2' ' A' ' 71' ' ' TYR . . . 92.92 -6.83 76.83 Favored Glycine 0 C--O 1.217 -0.924 0 C-N-CA 121.032 -0.604 . . . . 0.0 112.419 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 57.5 mt-30 -65.08 -38.84 92.05 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 112.736 0.643 . . . . 0.0 112.736 -178.086 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 5.4 t -126.06 110.84 14.01 Favored 'General case' 0 C--N 1.306 -1.285 0 CA-C-O 121.135 0.493 . . . . 0.0 110.515 179.806 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 47' ' ' LEU . . . . . 0.412 ' O ' ' HA ' ' A' ' 62' ' ' ARG . 79.4 mt -96.72 127.61 42.87 Favored 'General case' 0 C--N 1.316 -0.885 0 N-CA-C 108.936 -0.764 . . . . 0.0 108.936 177.354 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 24.7 p30 -135.28 152.84 51.89 Favored 'General case' 0 C--N 1.308 -1.204 0 CA-C-O 121.008 0.432 . . . . 0.0 110.966 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 162.53 -144.15 9.39 Favored Glycine 0 N--CA 1.438 -1.17 0 C-N-CA 120.447 -0.882 . . . . 0.0 112.683 179.258 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 61.6 m -127.91 130.9 49.26 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-O 120.94 0.4 . . . . 0.0 110.126 -178.013 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 51' ' ' MET . . . . . 0.509 ' HE2' ' HD2' ' A' ' 61' ' ' PHE . 15.0 tmm? -130.39 148.19 52.18 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-N 116.491 -0.322 . . . . 0.0 110.203 -178.414 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.479 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 30.5 m -126.21 128.2 46.86 Favored 'General case' 0 C--O 1.249 1.076 0 CA-C-O 120.909 0.385 . . . . 0.0 111.967 -176.849 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 53' ' ' TYR . . . . . 0.444 ' CD1' ' HB3' ' A' ' 31' ' ' GLN . 52.1 m-85 -88.15 163.21 16.3 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-N 115.676 -0.693 . . . . 0.0 110.768 177.186 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -65.05 127.45 31.68 Favored 'General case' 0 C--O 1.24 0.571 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.078 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 76.45 3.64 78.19 Favored Glycine 0 N--CA 1.446 -0.67 0 CA-C-N 115.9 -0.591 . . . . 0.0 112.766 179.032 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 78.7 mm-40 -120.3 178.89 4.48 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-O 120.828 0.347 . . . . 0.0 111.075 -177.912 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -101.98 174.17 24.08 Favored Glycine 0 N--CA 1.437 -1.241 0 N-CA-C 111.157 -0.777 . . . . 0.0 111.157 178.507 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_endo -66.68 137.71 46.79 Favored 'Trans proline' 0 CA--C 1.531 0.359 0 C-N-CA 122.217 1.944 . . . . 0.0 112.538 179.709 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 44.2 pt -133.61 171.73 17.52 Favored 'Isoleucine or valine' 0 C--O 1.241 0.644 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.356 179.084 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -74.67 138.11 23.44 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.684 -0.77 . . . . 0.0 111.974 -178.835 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.509 ' HD2' ' HE2' ' A' ' 51' ' ' MET . 55.4 t80 -127.01 129.57 48.33 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-O 120.488 0.185 . . . . 0.0 110.91 -178.94 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 62' ' ' ARG . . . . . 0.412 ' HA ' ' O ' ' A' ' 47' ' ' LEU . 59.9 ttp85 -141.74 133.05 26.51 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.305 -0.407 . . . . 0.0 109.96 175.978 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.536 ' HB1' ' HB3' ' A' ' 71' ' ' TYR . . . -133.53 139.85 46.86 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.67 -0.241 . . . . 0.0 111.373 -179.969 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 25.2 m -113.67 127.53 56.08 Favored 'General case' 0 CA--C 1.539 0.555 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.482 -179.286 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 58.0 tp -72.44 125.52 27.61 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 112.422 0.527 . . . . 0.0 112.422 -178.276 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 86.9 mt -76.28 -25.78 55.24 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.671 -0.695 . . . . 0.0 110.541 176.249 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 118.27 0.3 16.47 Favored Glycine 0 C--N 1.337 0.596 0 C-N-CA 120.808 -0.711 . . . . 0.0 113.175 178.761 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 29.0 p-10 -135.03 37.59 3.01 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-O 120.919 0.39 . . . . 0.0 111.008 -178.171 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 97.1 m-20 69.29 4.31 4.55 Favored 'General case' 0 N--CA 1.488 1.431 0 C-N-CA 123.417 0.687 . . . . 0.0 111.735 -177.708 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 16.3 t -95.43 126.07 40.48 Favored 'General case' 0 N--CA 1.435 -1.198 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 177.486 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.536 ' HB3' ' HB1' ' A' ' 63' ' ' ALA . 95.7 m-85 -116.98 129.31 55.95 Favored 'General case' 0 C--N 1.309 -1.172 0 CA-C-N 116.411 -0.359 . . . . 0.0 111.405 -178.023 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -81.52 116.25 21.21 Favored 'General case' 0 C--N 1.315 -0.907 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 175.144 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 54.2 t -102.53 132.96 47.52 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.198 0 N-CA-C 113.215 0.82 . . . . 0.0 113.215 -173.235 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 49.2 mt-10 -127.37 145.78 50.69 Favored 'General case' 0 N--CA 1.44 -0.933 0 CA-C-N 114.267 -1.333 . . . . 0.0 108.666 177.919 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 13.5 m120 -123.77 149.5 45.55 Favored 'General case' 0 C--N 1.316 -0.848 0 N-CA-C 110.246 -0.279 . . . . 0.0 110.246 -176.216 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 76' ' ' GLN . . . . . 0.444 ' HB2' ' CE3' ' A' ' 84' ' ' TRP . 63.1 tt0 -121.83 124.9 45.25 Favored 'General case' 0 C--N 1.315 -0.908 0 CA-C-N 116.464 -0.335 . . . . 0.0 110.385 179.724 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 8.3 p90 -144.05 162.73 35.49 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.876 -0.602 . . . . 0.0 109.628 179.063 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 101.17 -13.04 58.8 Favored Glycine 0 C--N 1.316 -0.583 0 C-N-CA 120.898 -0.667 . . . . 0.0 112.766 179.821 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 125.22 174.87 14.06 Favored Glycine 0 N--CA 1.444 -0.769 0 C-N-CA 120.505 -0.855 . . . . 0.0 112.367 178.626 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 7.5 p-10 -63.43 -34.59 78.08 Favored 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 112.303 0.483 . . . . 0.0 112.303 -179.581 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 73.1 p -78.95 -6.54 56.5 Favored 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 111.965 0.358 . . . . 0.0 111.965 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -85.34 146.18 44.21 Favored Pre-proline 0 C--N 1.322 -0.624 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.796 -179.95 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 84.5 Cg_endo -80.37 -175.09 2.52 Favored 'Trans proline' 0 C--O 1.236 0.404 0 C-N-CA 122.777 2.318 . . . . 0.0 112.768 -179.408 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 84' ' ' TRP . . . . . 0.444 ' CE3' ' HB2' ' A' ' 76' ' ' GLN . 90.5 m95 -94.9 144.87 25.32 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.793 -0.64 . . . . 0.0 109.979 179.412 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 87.9 m-70 -124.52 142.26 51.47 Favored 'General case' 0 C--N 1.316 -0.859 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 179.225 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 22.6 p -61.78 133.87 56.04 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-O 120.911 0.386 . . . . 0.0 111.5 -179.11 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -106.27 -46.26 1.17 Allowed Glycine 0 N--CA 1.445 -0.739 0 C-N-CA 120.667 -0.778 . . . . 0.0 111.639 178.859 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 156.25 -171.74 34.03 Favored Glycine 0 C--O 1.221 -0.685 0 C-N-CA 120.777 -0.725 . . . . 0.0 111.463 178.906 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 7.4 t30 -110.29 118.23 35.77 Favored 'General case' 0 C--N 1.312 -1.047 0 CA-C-N 117.147 0.474 . . . . 0.0 110.178 179.08 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 90' ' ' TRP . . . . . 0.438 ' CH2' HG21 ' A' ' 33' ' ' VAL . 28.6 m0 -107.63 150.16 27.22 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.574 -0.284 . . . . 0.0 110.399 -178.294 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 49.8 mm -107.72 114.61 46.8 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 N-CA-C 109.217 -0.66 . . . . 0.0 109.217 178.109 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 90.0 mt -127.15 79.94 1.92 Allowed 'General case' 0 C--O 1.265 1.893 0 CA-C-O 121.819 0.818 . . . . 0.0 111.814 -177.83 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 169.15 99.69 0.13 Allowed Glycine 0 N--CA 1.438 -1.201 0 CA-C-N 115.113 -0.949 . . . . 0.0 111.969 179.325 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 94' ' ' SER . . . . . 0.441 ' HB2' ' O ' ' A' ' 20' ' ' GLY . 71.6 p -86.19 -7.87 58.23 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 121.308 0.575 . . . . 0.0 110.148 178.604 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -103.68 146.35 28.72 Favored 'General case' 0 N--CA 1.438 -1.055 0 CA-C-N 115.475 -0.784 . . . . 0.0 109.289 179.878 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 -90.24 -19.8 23.72 Favored 'General case' 0 C--N 1.31 -1.138 0 N-CA-C 112.187 0.44 . . . . 0.0 112.187 -172.677 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 28.3 p-10 -117.7 14.52 14.4 Favored 'General case' 0 C--N 1.313 -0.988 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.107 -178.935 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 98' ' ' GLN . . . . . . . . . . . . . 56.7 tt0 -154.55 123.25 6.18 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 120.834 0.35 . . . . 0.0 110.18 -176.656 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 1.6 m-20 -98.48 162.59 13.07 Favored 'General case' 0 C--O 1.242 0.691 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.064 -175.951 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 54.3 t -77.55 133.75 29.95 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.579 0 C-N-CA 120.84 -0.344 . . . . 0.0 111.283 178.114 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 35.9 m -116.43 -34.63 1.88 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.503 0 N-CA-C 113.205 0.817 . . . . 0.0 113.205 -179.036 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 102' ' ' ALA . . . . . 0.587 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -142.73 138.91 30.85 Favored 'General case' 0 CA--C 1.512 -0.489 0 C-N-CA 120.019 -0.672 . . . . 0.0 111.486 179.523 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 40.4 mm -131.77 125.15 55.11 Favored 'Isoleucine or valine' 0 C--O 1.244 0.79 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.287 179.614 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 2.8 t-20 -123.84 95.9 4.75 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.628 -0.714 . . . . 0.0 109.311 174.229 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.434 HG22 ' HB ' ' A' ' 36' ' ' ILE . 29.9 m -136.85 138.78 45.71 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.926 0 N-CA-C 112.516 0.562 . . . . 0.0 112.516 -176.442 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -138.36 136.86 36.77 Favored 'General case' 0 C--N 1.309 -1.182 0 CA-C-N 115.132 -0.94 . . . . 0.0 108.481 177.238 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 39.3 t -118.39 129.23 55.3 Favored 'General case' 0 C--N 1.302 -1.496 0 C-N-CA 120.85 -0.34 . . . . 0.0 110.663 -179.549 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -86.45 -6.86 80.23 Favored Glycine 0 N--CA 1.441 -1.001 0 N-CA-C 110.359 -1.096 . . . . 0.0 110.359 175.937 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 109' ' ' ASP . . . . . 0.484 ' CG ' ' H ' ' A' ' 110' ' ' ASP . 11.1 t70 -93.88 -164.27 1.15 Allowed 'General case' 0 N--CA 1.445 -0.699 0 CA-C-N 115.286 -0.457 . . . . 0.0 110.025 179.656 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 110' ' ' ASP . . . . . 0.484 ' H ' ' CG ' ' A' ' 109' ' ' ASP . 16.2 m-20 -95.49 19.49 10.89 Favored 'General case' 0 C--N 1.318 -0.784 0 C-N-CA 122.989 0.516 . . . . 0.0 110.682 -178.016 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 111' ' ' GLY . . . . . 0.587 ' HA3' ' OD1' ' A' ' 32' ' ' ASN . . . 101.73 2.22 52.71 Favored Glycine 0 N--CA 1.443 -0.861 0 C-N-CA 120.605 -0.807 . . . . 0.0 112.545 -179.79 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 35.4 tt0 -64.1 -41.64 97.2 Favored 'General case' 0 C--O 1.226 -0.163 0 CA-C-O 120.984 0.421 . . . . 0.0 110.275 179.417 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 8.6 p -132.24 147.74 52.42 Favored 'General case' 0 N--CA 1.441 -0.878 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.436 177.746 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 92.8 mt -114.76 125.77 54.08 Favored 'General case' 0 C--N 1.319 -0.752 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 179.159 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 18.4 m120 -118.55 137.54 53.16 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-N 116.515 -0.312 . . . . 0.0 111.098 -177.633 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 161.62 -139.91 6.29 Favored Glycine 0 N--CA 1.442 -0.934 0 C-N-CA 119.633 -1.27 . . . . 0.0 113.424 176.299 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 27.2 p -138.05 159.97 40.6 Favored 'General case' 0 C--N 1.312 -1.06 0 C-N-CA 123.037 0.535 . . . . 0.0 110.031 -178.703 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 20.5 ptm -146.35 163.0 36.94 Favored 'General case' 0 C--N 1.31 -1.138 0 C-N-CA 121.027 -0.269 . . . . 0.0 111.071 -177.749 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 119' ' ' THR . . . . . 0.587 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 25.8 m -136.68 127.51 27.39 Favored 'General case' 0 C--O 1.251 1.175 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.177 178.727 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 120' ' ' TYR . . . . . 0.52 ' HB2' ' OE1' ' A' ' 123' ' ' GLU . 6.9 m-85 -94.67 162.7 13.67 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.215 -0.448 . . . . 0.0 109.946 174.705 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -58.79 119.17 6.66 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.695 0.283 . . . . 0.0 111.26 179.813 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 74.03 23.96 74.93 Favored Glycine 0 CA--C 1.52 0.376 0 C-N-CA 120.892 -0.67 . . . . 0.0 112.868 -179.792 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 123' ' ' GLU . . . . . 0.52 ' OE1' ' HB2' ' A' ' 120' ' ' TYR . 40.0 tt0 -130.2 158.38 39.9 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.769 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -89.14 162.89 31.31 Favored Glycine 0 N--CA 1.444 -0.791 0 N-CA-C 110.902 -0.879 . . . . 0.0 110.902 177.326 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_exo -58.43 131.54 43.38 Favored 'Trans proline' 0 CA--C 1.532 0.394 0 C-N-CA 122.261 1.974 . . . . 0.0 112.471 -179.237 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 43.1 pt -127.87 163.67 31.04 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.18 179.724 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -71.04 133.68 22.67 Favored Glycine 0 C--O 1.242 0.608 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.224 -178.89 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 87.7 t80 -118.02 133.87 55.51 Favored 'General case' 0 C--O 1.245 0.841 0 CA-C-O 121.091 0.472 . . . . 0.0 111.366 -178.083 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 76.5 tttt -137.74 111.0 7.88 Favored 'General case' 0 N--CA 1.44 -0.938 0 CA-C-N 115.165 -0.925 . . . . 0.0 108.887 178.026 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -112.16 143.65 17.56 Favored Glycine 0 C--N 1.311 -0.86 0 C-N-CA 120.377 -0.916 . . . . 0.0 111.843 179.885 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 41.3 m -130.36 130.45 44.42 Favored 'General case' 0 C--N 1.313 -0.998 0 CA-C-N 117.074 0.437 . . . . 0.0 110.401 179.203 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 64.8 tp -65.87 141.06 58.39 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.759 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 18.3 m . . . . . 0 C--O 1.251 1.132 0 CA-C-O 118.484 -0.77 . . . . 0.0 109.504 178.745 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 0.549 ' HB3' ' O ' ' A' ' 25' ' ' ILE . . . . . . . . 0 N--CA 1.474 0.775 0 N-CA-C 110.308 -0.256 . . . . 0.0 110.308 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 3' ' ' LEU . . . . . 0.401 HD13 ' N ' ' A' ' 4' ' ' TYR . 0.9 OUTLIER -151.91 128.04 10.46 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 -178.474 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 4' ' ' TYR . . . . . 0.401 ' N ' HD13 ' A' ' 3' ' ' LEU . 61.7 m-85 -123.52 147.31 47.37 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 112.917 0.71 . . . . 0.0 112.917 -178.293 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 27.4 t-20 -97.92 129.72 44.83 Favored 'General case' 0 C--N 1.316 -0.864 0 N-CA-C 106.677 -1.601 . . . . 0.0 106.677 174.705 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 65.1 t -116.91 129.48 73.37 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.046 0 CA-C-O 121.437 0.637 . . . . 0.0 112.635 -173.818 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 -114.2 139.74 49.13 Favored 'General case' 0 C--O 1.249 1.032 0 CA-C-N 114.974 -1.012 . . . . 0.0 108.346 176.874 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 10.2 m120 -114.16 140.74 48.28 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 116.453 -0.34 . . . . 0.0 110.94 -176.699 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' GLN . . . . . 0.593 ' OE1' ' HA ' ' A' ' 13' ' ' SER . 36.6 tt0 -127.64 125.56 40.39 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 120.948 0.404 . . . . 0.0 111.289 177.784 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 22.8 p90 -137.29 144.75 42.81 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 116.042 -0.526 . . . . 0.0 109.83 177.192 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 99.52 9.64 49.75 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 120.568 -0.825 . . . . 0.0 111.98 179.039 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 111.17 154.95 13.4 Favored Glycine 0 N--CA 1.444 -0.773 0 C-N-CA 120.959 -0.638 . . . . 0.0 112.325 179.527 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' SER . . . . . 0.593 ' HA ' ' OE1' ' A' ' 9' ' ' GLN . 69.9 m -65.98 -14.76 62.19 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 112.883 0.697 . . . . 0.0 112.883 -179.627 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 46.9 m -84.21 -7.93 59.21 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 121.059 0.457 . . . . 0.0 110.481 177.132 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -84.84 150.16 55.25 Favored Pre-proline 0 N--CA 1.449 -0.478 0 CA-C-N 115.924 -0.58 . . . . 0.0 109.773 178.79 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -67.33 152.35 79.27 Favored 'Trans proline' 0 C--O 1.236 0.409 0 C-N-CA 122.458 2.105 . . . . 0.0 113.046 -178.231 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' TRP . . . . . 0.414 ' CE3' ' HB2' ' A' ' 9' ' ' GLN . 90.8 m95 -83.78 130.46 34.94 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 115.52 -0.764 . . . . 0.0 109.056 178.422 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 2.9 m-20 -107.51 132.48 53.19 Favored 'General case' 0 C--N 1.313 -1.016 0 N-CA-C 107.524 -1.287 . . . . 0.0 107.524 179.168 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 71.8 tt0 -66.42 128.02 34.57 Favored 'General case' 0 C--N 1.308 -1.221 0 CA-C-O 121.58 0.705 . . . . 0.0 110.634 -176.793 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -100.96 -4.48 54.28 Favored Glycine 0 N--CA 1.435 -1.396 0 CA-C-N 115.026 -0.988 . . . . 0.0 113.345 -175.113 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 115.01 -153.52 17.58 Favored Glycine 0 N--CA 1.443 -0.851 0 C-N-CA 120.306 -0.95 . . . . 0.0 111.943 -178.142 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 28.6 pt20 -132.52 139.41 47.88 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-O 120.701 0.286 . . . . 0.0 110.553 -179.812 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' TRP . . . . . 0.458 ' CZ2' ' HE3' ' A' ' 118' ' ' MET . 38.4 m0 -117.29 161.44 19.49 Favored 'General case' 0 CA--C 1.508 -0.665 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.887 -178.517 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 24' ' ' GLU . . . . . 0.412 ' HB3' ' H ' ' A' ' 91' ' ' ILE . 73.4 tt0 -112.47 107.05 15.68 Favored 'General case' 0 N--CA 1.443 -0.825 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 175.11 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.549 ' O ' ' HB3' ' A' ' 2' ' ' ALA . 92.4 mt -123.22 132.07 72.06 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.843 0 CA-C-N 115.922 -0.581 . . . . 0.0 109.872 -177.36 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 90.85 116.33 1.9 Allowed Glycine 0 N--CA 1.446 -0.641 0 C-N-CA 120.33 -0.938 . . . . 0.0 112.432 178.707 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' SER . . . . . 0.472 ' OG ' ' HA3' ' A' ' 88' ' ' GLY . 13.2 t -112.56 14.96 20.23 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-O 121.071 0.463 . . . . 0.0 110.201 -179.848 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 75.7 mtp180 -127.64 138.69 52.91 Favored 'General case' 0 CA--C 1.513 -0.449 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.375 -179.426 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 19.4 m -93.01 -27.27 17.1 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.783 179.407 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 11.8 p-10 -77.32 -38.62 50.09 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.45 -177.618 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 22.1 mm-40 -130.21 121.41 26.15 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.302 179.709 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' ASN . . . . . 0.559 ' ND2' ' HA3' ' A' ' 111' ' ' GLY . 65.6 t30 -95.3 169.02 10.37 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 178.792 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 58.8 t -96.44 131.25 43.7 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.991 0 CA-C-N 116.568 -0.287 . . . . 0.0 110.934 -177.5 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 28.4 m -111.39 -20.25 6.38 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.163 0 N-CA-C 112.19 0.441 . . . . 0.0 112.19 179.002 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' ALA . . . . . 0.532 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -147.86 145.57 28.74 Favored 'General case' 0 CA--C 1.514 -0.435 0 C-N-CA 120.296 -0.562 . . . . 0.0 111.512 179.992 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.403 ' HB ' HG22 ' A' ' 105' ' ' VAL . 92.0 mt -144.87 127.95 11.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.042 -0.526 . . . . 0.0 109.893 -179.539 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 37' ' ' ASN . . . . . 0.421 ' HA ' ' O ' ' A' ' 103' ' ' ILE . 0.6 OUTLIER -133.17 112.11 11.46 Favored 'General case' 0 C--N 1.317 -0.81 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 174.967 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.512 HG11 ' CD2' ' A' ' 61' ' ' PHE . 15.5 m -147.67 150.21 14.72 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.804 0 N-CA-C 112.207 0.447 . . . . 0.0 112.207 -174.871 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 70.5 tt0 -133.22 143.11 48.93 Favored 'General case' 0 N--CA 1.442 -0.851 0 CA-C-N 114.976 -1.011 . . . . 0.0 108.703 176.485 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 21.2 p -73.75 146.34 44.43 Favored 'General case' 0 C--N 1.31 -1.128 0 CA-C-O 120.728 0.299 . . . . 0.0 111.216 178.591 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -92.11 -42.48 4.64 Favored Glycine 0 N--CA 1.447 -0.576 0 N-CA-C 109.687 -1.365 . . . . 0.0 109.687 175.333 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 23.0 m-20 -102.27 -161.36 0.84 Allowed 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 114.711 -0.745 . . . . 0.0 109.116 176.042 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 29.4 p-10 -84.12 47.79 1.38 Allowed 'General case' 0 C--N 1.315 -0.895 0 CA-C-O 121.325 0.583 . . . . 0.0 110.874 179.484 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 99.53 -14.4 60.72 Favored Glycine 0 C--O 1.22 -0.778 0 CA-C-N 115.923 -0.581 . . . . 0.0 112.665 -179.411 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 58.5 tp60 -64.87 -39.39 93.47 Favored 'General case' 0 CA--C 1.534 0.362 0 CA-C-O 120.803 0.335 . . . . 0.0 111.328 -179.162 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 61.3 p -128.45 142.87 50.96 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.604 -0.271 . . . . 0.0 110.742 179.07 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 86.0 mt -126.68 133.83 50.85 Favored 'General case' 0 C--O 1.236 0.369 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 179.168 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -136.22 147.91 47.83 Favored 'General case' 0 C--N 1.32 -0.692 0 C-N-CA 120.905 -0.318 . . . . 0.0 110.951 179.981 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 165.67 -144.17 9.02 Favored Glycine 0 N--CA 1.442 -0.922 0 C-N-CA 120.497 -0.858 . . . . 0.0 112.104 177.909 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 9.4 t -133.53 145.51 50.2 Favored 'General case' 0 N--CA 1.435 -1.177 0 CA-C-O 121.103 0.477 . . . . 0.0 110.558 -179.211 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 14.6 tmm? -133.32 147.19 51.85 Favored 'General case' 0 C--N 1.314 -0.96 0 CA-C-N 115.918 -0.583 . . . . 0.0 109.685 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.532 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 28.7 m -125.96 128.01 46.84 Favored 'General case' 0 C--O 1.249 1.054 0 N-CA-C 112.045 0.387 . . . . 0.0 112.045 -176.812 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 53' ' ' TYR . . . . . 0.429 ' HB2' ' HB2' ' A' ' 56' ' ' GLU . 86.0 m-85 -86.27 162.29 18.34 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.565 176.781 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -64.29 122.09 15.84 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.886 178.479 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.59 5.84 89.19 Favored Glycine 0 CA--C 1.517 0.198 0 C-N-CA 120.958 -0.639 . . . . 0.0 112.499 179.925 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 56' ' ' GLU . . . . . 0.429 ' HB2' ' HB2' ' A' ' 53' ' ' TYR . 69.6 mm-40 -119.55 179.14 4.31 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 120.742 0.306 . . . . 0.0 110.874 -178.608 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -106.77 169.2 14.96 Favored Glycine 0 N--CA 1.44 -1.078 0 N-CA-C 111.237 -0.745 . . . . 0.0 111.237 178.881 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_exo -62.34 137.36 64.97 Favored 'Trans proline' 0 C--O 1.235 0.359 0 C-N-CA 122.583 2.189 . . . . 0.0 112.239 179.102 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 59' ' ' ILE . . . . . 0.475 ' HB ' ' O ' ' A' ' 76' ' ' GLN . 48.6 pt -130.32 170.98 18.3 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 CA-C-N 115.984 -0.553 . . . . 0.0 109.813 178.387 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -75.57 136.27 19.76 Favored Glycine 0 N--CA 1.446 -0.671 0 C-N-CA 120.2 -1.0 . . . . 0.0 110.889 -179.346 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.512 ' CD2' HG11 ' A' ' 38' ' ' VAL . 7.5 t80 -131.22 125.15 32.16 Favored 'General case' 0 C--N 1.31 -1.152 0 CA-C-O 120.958 0.409 . . . . 0.0 111.457 -178.046 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 61.9 ttp180 -130.03 130.99 45.66 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.608 -0.724 . . . . 0.0 110.338 178.039 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.409 ' HB1' ' HB3' ' A' ' 71' ' ' TYR . . . -130.99 138.98 49.93 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.782 179.382 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 63.6 m -121.16 130.18 53.6 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.392 179.838 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 61.7 tp -68.16 121.68 16.7 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 121.064 0.459 . . . . 0.0 111.365 -178.459 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 96.1 mt -71.32 -34.24 70.39 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.613 178.242 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 133.5 -12.16 4.91 Favored Glycine 0 CA--C 1.521 0.445 0 C-N-CA 120.485 -0.865 . . . . 0.0 113.31 -179.742 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 20.7 m120 -130.89 50.84 2.19 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-O 120.981 0.42 . . . . 0.0 111.4 -178.038 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 86.7 m-20 65.03 1.54 1.52 Allowed 'General case' 0 N--CA 1.486 1.336 0 C-N-CA 123.845 0.858 . . . . 0.0 111.98 178.835 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 25.7 t -102.62 138.19 39.84 Favored 'General case' 0 N--CA 1.436 -1.146 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 179.108 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.447 ' CE1' ' HB2' ' A' ' 92' ' ' LEU . 84.7 m-85 -118.1 140.87 49.14 Favored 'General case' 0 C--N 1.307 -1.263 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.742 -178.534 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -91.24 123.88 35.03 Favored 'General case' 0 N--CA 1.438 -1.063 0 N-CA-C 107.657 -1.238 . . . . 0.0 107.657 173.746 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.439 HG13 ' HE1' ' A' ' 61' ' ' PHE . 45.3 t -105.32 134.04 47.92 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.246 0 N-CA-C 113.413 0.894 . . . . 0.0 113.413 -173.057 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 84.7 mt-10 -129.25 126.27 38.72 Favored 'General case' 0 N--CA 1.438 -1.042 0 CA-C-N 114.367 -1.288 . . . . 0.0 107.69 176.369 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 92.8 m-20 -109.22 146.69 33.79 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-O 121.021 0.439 . . . . 0.0 111.789 -175.582 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 76' ' ' GLN . . . . . 0.479 ' HB2' ' CE3' ' A' ' 84' ' ' TRP . 58.4 tt0 -114.47 121.26 42.99 Favored 'General case' 0 C--N 1.312 -1.061 0 CA-C-N 115.707 -0.678 . . . . 0.0 109.645 -179.955 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 5.8 p90 -140.46 159.47 42.12 Favored 'General case' 0 C--N 1.318 -0.79 0 C-N-CA 120.874 -0.33 . . . . 0.0 110.578 179.246 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 95.35 -7.16 68.83 Favored Glycine 0 N--CA 1.447 -0.575 0 C-N-CA 120.834 -0.698 . . . . 0.0 111.846 -179.704 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 146.58 154.93 6.33 Favored Glycine 0 N--CA 1.445 -0.725 0 N-CA-C 111.684 -0.566 . . . . 0.0 111.684 178.999 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -72.28 -25.56 61.64 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-O 120.965 0.412 . . . . 0.0 111.198 -179.987 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 4.6 m -82.47 -11.7 58.33 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.412 177.72 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -72.63 155.3 91.09 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.445 -177.236 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -69.38 169.02 19.38 Favored 'Trans proline' 0 C--N 1.347 0.485 0 C-N-CA 122.721 2.281 . . . . 0.0 112.141 178.342 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 84' ' ' TRP . . . . . 0.479 ' CE3' ' HB2' ' A' ' 76' ' ' GLN . 91.8 m95 -87.49 143.29 27.29 Favored 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 -178.409 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 85.8 m-70 -118.61 157.77 26.75 Favored 'General case' 0 C--N 1.313 -0.996 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 -179.705 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 48.3 m -63.81 143.74 57.61 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-O 120.837 0.351 . . . . 0.0 111.023 179.787 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -117.18 -58.91 0.3 Allowed Glycine 0 N--CA 1.439 -1.164 0 N-CA-C 110.931 -0.867 . . . . 0.0 110.931 178.556 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.472 ' HA3' ' OG ' ' A' ' 27' ' ' SER . . . 149.38 -167.68 29.66 Favored Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 120.929 -0.653 . . . . 0.0 111.929 177.067 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 89' ' ' ASN . . . . . 0.407 ' C ' ' HD1' ' A' ' 90' ' ' TRP . 90.5 m-20 -102.48 132.68 48.37 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-O 120.679 0.276 . . . . 0.0 110.624 178.747 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 90' ' ' TRP . . . . . 0.407 ' HD1' ' C ' ' A' ' 89' ' ' ASN . 12.5 m0 -130.63 151.58 50.93 Favored 'General case' 0 C--N 1.319 -0.744 0 N-CA-C 108.472 -0.936 . . . . 0.0 108.472 -179.222 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 91' ' ' ILE . . . . . 0.412 ' H ' ' HB3' ' A' ' 24' ' ' GLU . 95.8 mt -117.26 115.52 49.05 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.153 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 176.643 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 92' ' ' LEU . . . . . 0.447 ' HB2' ' CE1' ' A' ' 71' ' ' TYR . 88.8 mt -125.6 74.14 1.38 Allowed 'General case' 0 C--O 1.247 0.962 0 CA-C-O 121.683 0.754 . . . . 0.0 110.215 -177.577 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 167.72 87.39 0.07 OUTLIER Glycine 0 N--CA 1.431 -1.648 0 CA-C-N 114.892 -1.049 . . . . 0.0 110.73 -177.888 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 22.5 p -91.63 -5.68 53.46 Favored 'General case' 0 C--N 1.31 -1.116 0 CA-C-O 121.176 0.512 . . . . 0.0 110.586 -179.243 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 95' ' ' ARG . . . . . 0.427 HH11 ' HD3' ' A' ' 95' ' ' ARG . 61.7 mtt-85 -94.2 150.0 20.72 Favored 'General case' 0 N--CA 1.442 -0.849 0 CA-C-N 115.64 -0.709 . . . . 0.0 109.676 179.127 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 77.3 tt0 -70.06 -42.76 72.39 Favored 'General case' 0 C--N 1.315 -0.925 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.669 -174.048 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 94.4 m-20 -113.46 18.13 17.9 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.905 -176.871 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 98' ' ' GLN . . . . . . . . . . . . . 2.3 mt-30 -141.53 117.92 10.82 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 113.18 0.807 . . . . 0.0 113.18 -176.118 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 35.8 m-80 -98.25 166.44 11.4 Favored 'General case' 0 C--O 1.245 0.852 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.204 175.138 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 97.1 t -85.18 134.07 27.93 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.611 -179.063 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 27.9 m -115.23 -31.43 1.97 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-N 115.785 -0.643 . . . . 0.0 112.626 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 102' ' ' ALA . . . . . 0.601 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -144.22 139.08 28.48 Favored 'General case' 0 CA--C 1.514 -0.409 0 C-N-CA 120.097 -0.641 . . . . 0.0 111.631 179.306 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.445 ' HB ' HG22 ' A' ' 38' ' ' VAL . 92.0 mt -132.75 128.38 57.15 Favored 'Isoleucine or valine' 0 C--O 1.238 0.497 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.177 179.743 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 40.7 t30 -128.42 98.16 4.96 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.674 -0.694 . . . . 0.0 109.435 173.544 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.403 HG22 ' HB ' ' A' ' 36' ' ' ILE . 28.3 m -138.0 140.93 39.74 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 N-CA-C 112.331 0.493 . . . . 0.0 112.331 -176.634 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 42.4 tt0 -141.11 138.52 33.56 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.658 -0.701 . . . . 0.0 109.965 178.078 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 46.4 t -143.85 141.71 30.47 Favored 'General case' 0 N--CA 1.446 -0.634 0 CA-C-O 120.894 0.378 . . . . 0.0 111.24 179.18 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -106.81 6.22 37.6 Favored Glycine 0 N--CA 1.443 -0.873 0 N-CA-C 110.624 -0.991 . . . . 0.0 110.624 176.187 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 23.1 m-20 -95.78 14.33 23.62 Favored 'General case' 0 CA--C 1.516 -0.344 0 C-N-CA 123.004 0.522 . . . . 0.0 111.324 -178.176 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 85.7 m-20 63.59 23.38 13.56 Favored 'General case' 0 N--CA 1.47 0.561 0 CA-C-N 115.632 -0.713 . . . . 0.0 112.319 178.173 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 111' ' ' GLY . . . . . 0.559 ' HA3' ' ND2' ' A' ' 32' ' ' ASN . . . 103.45 5.21 46.05 Favored Glycine 0 N--CA 1.446 -0.653 0 C-N-CA 120.008 -1.092 . . . . 0.0 114.249 176.651 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 54.2 tt0 -62.63 -49.53 74.81 Favored 'General case' 0 C--O 1.249 1.059 0 CA-C-O 121.583 0.706 . . . . 0.0 109.891 177.612 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 14.4 p -136.12 133.17 36.99 Favored 'General case' 0 N--CA 1.442 -0.846 0 CA-C-N 115.034 -0.985 . . . . 0.0 109.555 177.163 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -107.38 122.76 47.24 Favored 'General case' 0 C--N 1.314 -0.97 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 178.787 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 88.9 m-20 -119.54 143.72 47.45 Favored 'General case' 0 C--N 1.311 -1.082 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.121 -179.063 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 160.87 -138.09 5.3 Favored Glycine 0 N--CA 1.442 -0.915 0 C-N-CA 120.216 -0.992 . . . . 0.0 112.685 177.568 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 2.1 p -131.68 153.34 50.1 Favored 'General case' 0 C--N 1.314 -0.978 0 CA-C-O 121.086 0.47 . . . . 0.0 110.789 -179.592 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 118' ' ' MET . . . . . 0.619 ' SD ' ' HD1' ' A' ' 128' ' ' PHE . 21.7 ptm -139.56 147.81 41.7 Favored 'General case' 0 C--N 1.314 -0.962 0 CA-C-N 115.813 -0.63 . . . . 0.0 109.993 -176.764 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 119' ' ' THR . . . . . 0.601 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 29.1 m -131.75 125.61 32.4 Favored 'General case' 0 C--O 1.249 1.063 0 C-N-CA 120.99 -0.284 . . . . 0.0 111.096 179.095 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 120' ' ' TYR . . . . . 0.4 ' HB2' ' HB3' ' A' ' 123' ' ' GLU . 63.1 m-85 -94.11 163.7 13.36 Favored 'General case' 0 CA--C 1.513 -0.476 0 CA-C-N 116.159 -0.473 . . . . 0.0 109.969 175.52 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -53.51 -33.81 55.8 Favored 'General case' 0 N--CA 1.47 0.545 0 N-CA-C 113.503 0.927 . . . . 0.0 113.503 -176.544 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -138.0 25.31 2.93 Favored Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 119.596 -1.288 . . . . 0.0 112.776 -178.017 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 123' ' ' GLU . . . . . 0.4 ' HB3' ' HB2' ' A' ' 120' ' ' TYR . 36.1 tp10 -111.28 -53.06 2.74 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-O 121.29 0.567 . . . . 0.0 110.326 -177.926 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 115.01 177.43 18.8 Favored Glycine 0 N--CA 1.439 -1.154 0 CA-C-N 115.541 -0.754 . . . . 0.0 111.452 -178.308 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 13.5 Cg_exo -71.16 117.13 5.0 Favored 'Trans proline' 0 N--CA 1.458 -0.561 0 C-N-CA 122.8 2.333 . . . . 0.0 112.051 179.053 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 36.7 pt -130.16 165.96 29.01 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.946 0 CA-C-N 115.93 -0.577 . . . . 0.0 109.891 178.388 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -70.26 135.72 26.0 Favored Glycine 0 C--O 1.241 0.532 0 C-N-CA 120.871 -0.68 . . . . 0.0 112.531 -178.5 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 128' ' ' PHE . . . . . 0.619 ' HD1' ' SD ' ' A' ' 118' ' ' MET . 72.8 t80 -112.5 132.3 55.15 Favored 'General case' 0 C--O 1.249 1.031 0 CA-C-O 120.832 0.349 . . . . 0.0 111.054 -178.793 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 129' ' ' LYS . . . . . 0.402 ' HB2' ' CZ3' ' A' ' 17' ' ' TRP . 61.0 tttm -137.59 108.9 6.85 Favored 'General case' 0 N--CA 1.447 -0.587 0 CA-C-N 115.599 -0.728 . . . . 0.0 109.213 175.976 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -114.03 137.12 13.85 Favored Glycine 0 N--CA 1.446 -0.648 0 C-N-CA 120.522 -0.847 . . . . 0.0 111.818 179.244 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 55.8 m -132.34 140.64 48.62 Favored 'General case' 0 C--N 1.308 -1.21 0 CA-C-N 116.645 0.223 . . . . 0.0 110.605 -179.241 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 88.1 mt -56.99 130.03 44.29 Favored 'General case' 0 N--CA 1.472 0.663 0 O-C-N 123.17 0.294 . . . . 0.0 110.939 177.5 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 14.8 p . . . . . 0 C--O 1.252 1.212 0 CA-C-O 118.145 -0.931 . . . . 0.0 110.326 178.313 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 0.406 ' O ' ' HG3' ' A' ' 24' ' ' GLU . . . . . . . . 0 N--CA 1.471 0.581 0 N-CA-C 109.713 -0.477 . . . . 0.0 109.713 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 3.0 tm? -94.81 127.12 40.59 Favored 'General case' 0 C--N 1.317 -0.823 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 -177.153 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 40.5 m-85 -117.16 136.66 52.87 Favored 'General case' 0 C--N 1.312 -1.023 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.305 178.444 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 5' ' ' ASN . . . . . 0.487 ' O ' ' HA2' ' A' ' 130' ' ' GLY . 5.9 m-20 -85.06 132.23 34.35 Favored 'General case' 0 CA--C 1.499 -0.989 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 175.378 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.509 HG21 ' CG ' ' A' ' 23' ' ' TRP . 53.2 t -114.35 128.13 71.51 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.115 0 N-CA-C 113.182 0.808 . . . . 0.0 113.182 -173.847 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 71.6 mt-10 -124.05 135.9 53.89 Favored 'General case' 0 N--CA 1.436 -1.143 0 CA-C-N 114.577 -1.192 . . . . 0.0 108.469 177.542 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' ASN . . . . . 0.438 ' HB3' HD12 ' A' ' 126' ' ' ILE . 10.8 m120 -121.1 145.11 48.15 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 120.884 0.373 . . . . 0.0 111.415 -175.935 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 9' ' ' GLN . . . . . 0.465 HE22 ' HA ' ' A' ' 13' ' ' SER . 52.1 tt0 -124.97 123.39 39.77 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.717 178.264 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 40.1 p90 -133.44 142.56 48.37 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 116.653 -0.249 . . . . 0.0 110.922 179.264 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 105.16 10.31 32.22 Favored Glycine 0 CA--C 1.52 0.345 0 C-N-CA 120.327 -0.94 . . . . 0.0 112.945 177.164 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.36 171.51 33.52 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.574 -0.822 . . . . 0.0 112.887 179.56 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' SER . . . . . 0.465 ' HA ' HE22 ' A' ' 9' ' ' GLN . 16.4 m -57.8 -26.31 61.78 Favored 'General case' 0 CA--C 1.536 0.426 0 C-N-CA 122.993 0.517 . . . . 0.0 112.061 179.311 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 14.8 m -59.24 -24.76 63.46 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 122.62 0.368 . . . . 0.0 111.695 177.5 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -91.37 144.27 29.47 Favored Pre-proline 0 C--N 1.324 -0.51 0 CA-C-N 116.75 -0.204 . . . . 0.0 110.577 179.515 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -81.13 -176.05 2.95 Favored 'Trans proline' 0 C--O 1.239 0.538 0 C-N-CA 122.657 2.238 . . . . 0.0 112.32 179.397 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 99.1 m95 -87.22 128.8 35.14 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.213 -0.449 . . . . 0.0 109.908 179.64 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 34.0 m-80 -113.65 110.74 20.69 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.384 -177.093 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 73.1 tt0 -73.35 121.29 20.2 Favored 'General case' 0 C--N 1.317 -0.837 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 177.084 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -134.68 32.59 2.59 Favored Glycine 0 N--CA 1.447 -0.624 0 C-N-CA 119.792 -1.194 . . . . 0.0 112.967 -178.634 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' GLY . . . . . 0.419 ' HA3' ' HB2' ' A' ' 94' ' ' SER . . . 136.99 -167.22 24.71 Favored Glycine 0 N--CA 1.444 -0.821 0 C-N-CA 120.103 -1.046 . . . . 0.0 112.817 178.104 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 7.1 pt20 -147.84 153.9 39.75 Favored 'General case' 0 C--N 1.316 -0.879 0 C-N-CA 122.236 0.214 . . . . 0.0 110.543 -179.715 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' TRP . . . . . 0.509 ' CG ' HG21 ' A' ' 6' ' ' VAL . 38.4 m0 -126.82 177.04 6.84 Favored 'General case' 0 N--CA 1.47 0.531 0 CA-C-N 116.343 -0.389 . . . . 0.0 110.347 -175.623 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' GLU . . . . . 0.459 ' HB3' HG12 ' A' ' 91' ' ' ILE . 83.7 tt0 -124.61 114.44 19.38 Favored 'General case' 0 CA--C 1.505 -0.768 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.031 174.74 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 98.2 mt -124.38 132.83 70.77 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.878 0 CA-C-N 115.446 -0.797 . . . . 0.0 109.632 -178.294 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 87.75 55.21 2.33 Favored Glycine 0 N--CA 1.447 -0.606 0 C-N-CA 120.077 -1.059 . . . . 0.0 112.45 178.283 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 36.1 t -61.57 -38.14 86.43 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.575 0.226 . . . . 0.0 110.558 178.993 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 70.4 ttt180 -49.98 -42.61 49.27 Favored 'General case' 0 CA--C 1.542 0.656 0 CA-C-N 116.199 -0.455 . . . . 0.0 112.174 179.501 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 14.9 m 74.16 -42.13 0.5 Allowed 'General case' 0 N--CA 1.48 1.052 0 N-CA-C 114.36 1.244 . . . . 0.0 114.36 175.6 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 3.9 p-10 -74.98 -4.33 37.59 Favored 'General case' 0 N--CA 1.487 1.411 0 CA-C-N 118.378 0.535 . . . . 0.0 111.782 -178.237 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 1.1 tm0? -150.71 119.7 6.68 Favored 'General case' 0 C--N 1.314 -0.968 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.755 178.525 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 32' ' ' ASN . . . . . 0.658 ' OD1' ' HA3' ' A' ' 111' ' ' GLY . 27.0 t-20 -85.59 145.74 27.21 Favored 'General case' 0 CA--C 1.534 0.357 0 CA-C-O 121.667 0.746 . . . . 0.0 111.97 -179.696 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 15.4 t -97.14 130.07 46.29 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.12 0 CA-C-N 115.085 -0.961 . . . . 0.0 110.531 -177.698 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 17.2 m -101.3 -24.52 4.05 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 N-CA-C 112.002 0.371 . . . . 0.0 112.002 -179.599 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' ALA . . . . . 0.572 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -141.25 146.13 36.45 Favored 'General case' 0 C--N 1.323 -0.551 0 C-N-CA 120.273 -0.571 . . . . 0.0 111.12 179.327 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.438 ' HB ' ' CG2' ' A' ' 105' ' ' VAL . 98.2 mt -142.84 125.53 13.47 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.325 -177.427 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -130.81 113.36 13.98 Favored 'General case' 0 C--N 1.316 -0.869 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 174.898 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.505 HG22 ' HB ' ' A' ' 103' ' ' ILE . 28.7 m -144.73 145.64 20.95 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 C-N-CA 120.89 -0.324 . . . . 0.0 111.214 -175.785 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 79.6 tt0 -141.03 146.22 36.93 Favored 'General case' 0 N--CA 1.45 -0.453 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.163 178.263 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 40' ' ' SER . . . . . 0.557 ' OG ' ' HB ' ' A' ' 101' ' ' VAL . 26.0 p -81.89 144.86 30.69 Favored 'General case' 0 C--N 1.316 -0.864 0 N-CA-C 111.875 0.324 . . . . 0.0 111.875 -179.11 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -91.23 -21.62 34.75 Favored Glycine 0 N--CA 1.449 -0.454 0 N-CA-C 110.744 -0.942 . . . . 0.0 110.744 175.206 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 42' ' ' ASP . . . . . 0.4 ' C ' ' H ' ' A' ' 44' ' ' GLY . 28.2 m-20 -132.91 -150.2 0.4 Allowed 'General case' 0 CA--C 1.514 -0.415 0 N-CA-C 108.917 -0.772 . . . . 0.0 108.917 179.373 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -75.81 34.89 0.12 Allowed 'General case' 0 N--CA 1.471 0.614 0 C-N-CA 122.768 0.427 . . . . 0.0 110.818 178.517 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.42 ' O ' ' HE2' ' A' ' 71' ' ' TYR . . . 90.85 1.81 72.88 Favored Glycine 0 N--CA 1.442 -0.951 0 C-N-CA 121.057 -0.592 . . . . 0.0 112.655 -178.669 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 60.5 tp60 -62.89 -44.81 95.09 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-O 120.971 0.415 . . . . 0.0 110.547 -179.433 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 4.3 t -129.97 122.6 28.8 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.185 176.404 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 81.8 mt -102.48 132.8 48.28 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 116.139 -0.482 . . . . 0.0 109.777 178.782 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 86.1 m-20 -121.34 133.39 55.11 Favored 'General case' 0 C--N 1.314 -0.964 0 N-CA-C 108.963 -0.755 . . . . 0.0 108.963 177.38 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 49' ' ' GLY . . . . . 0.438 ' HA3' ' HA ' ' A' ' 38' ' ' VAL . . . -173.2 -162.72 25.69 Favored Glycine 0 N--CA 1.436 -1.321 0 C-N-CA 119.367 -1.397 . . . . 0.0 113.243 179.876 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 90.4 m -131.65 130.48 42.16 Favored 'General case' 0 C--N 1.309 -1.176 0 C-N-CA 122.692 0.397 . . . . 0.0 111.4 -179.701 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 43.8 mtp -106.24 145.08 32.04 Favored 'General case' 0 N--CA 1.469 0.49 0 C-N-CA 122.689 0.396 . . . . 0.0 110.161 177.042 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.572 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 36.2 m -123.92 122.35 37.74 Favored 'General case' 0 C--O 1.249 1.076 0 CA-C-O 120.636 0.255 . . . . 0.0 110.64 177.727 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 24.0 m-85 -82.44 161.38 22.46 Favored 'General case' 0 N--CA 1.462 0.142 0 CA-C-N 115.654 -0.703 . . . . 0.0 111.491 -179.468 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -65.46 109.37 2.3 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.932 -0.576 . . . . 0.0 111.661 -179.545 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 83.32 14.93 72.94 Favored Glycine 0 N--CA 1.446 -0.649 0 C-N-CA 120.836 -0.697 . . . . 0.0 113.392 178.371 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 51.1 mt-10 -137.07 167.78 20.87 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.974 0.387 . . . . 0.0 111.513 -178.993 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -78.18 163.1 50.34 Favored Glycine 0 N--CA 1.448 -0.507 0 CA-C-N 115.87 -0.604 . . . . 0.0 113.36 -177.301 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_exo -67.5 142.85 60.78 Favored 'Trans proline' 0 CA--C 1.54 0.781 0 C-N-CA 123.188 2.592 . . . . 0.0 112.749 179.778 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 59' ' ' ILE . . . . . 0.512 ' HB ' ' O ' ' A' ' 76' ' ' GLN . 47.5 pt -127.14 166.0 24.71 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.329 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.818 -179.422 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -73.83 144.09 33.3 Favored Glycine 0 CA--C 1.517 0.217 0 C-N-CA 121.078 -0.582 . . . . 0.0 112.502 -177.852 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 41.5 t80 -130.45 127.8 39.99 Favored 'General case' 0 C--O 1.238 0.499 0 CA-C-O 120.829 0.347 . . . . 0.0 111.091 -178.791 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 67.3 ttp85 -136.32 127.58 28.21 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 175.585 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.436 ' HB2' HG22 ' A' ' 73' ' ' VAL . . . -135.07 146.91 49.38 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 120.565 0.221 . . . . 0.0 111.548 -178.175 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 64.3 m -124.54 129.41 50.55 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.598 178.875 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 65' ' ' LEU . . . . . 0.467 ' HG ' ' H ' ' A' ' 67' ' ' GLY . 56.6 tp -74.58 130.21 39.15 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.879 -178.847 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 66' ' ' LEU . . . . . 0.427 ' HB2' ' OD1' ' A' ' 68' ' ' ASN . 85.8 mt -84.52 -17.83 37.69 Favored 'General case' 0 CA--C 1.536 0.429 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.077 177.094 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.467 ' H ' ' HG ' ' A' ' 65' ' ' LEU . . . 105.58 -8.99 44.32 Favored Glycine 0 C--O 1.222 -0.638 0 CA-C-N 115.761 -0.654 . . . . 0.0 112.198 178.49 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 68' ' ' ASN . . . . . 0.427 ' OD1' ' HB2' ' A' ' 66' ' ' LEU . 29.7 p-10 -110.85 34.72 3.84 Favored 'General case' 0 C--N 1.316 -0.858 0 CA-C-O 120.921 0.391 . . . . 0.0 110.749 -179.742 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 15.8 m120 66.83 7.99 5.67 Favored 'General case' 0 N--CA 1.484 1.225 0 CA-C-N 115.599 -0.728 . . . . 0.0 111.11 -179.399 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 7.3 m -107.94 133.35 52.4 Favored 'General case' 0 N--CA 1.436 -1.143 0 CA-C-N 115.685 -0.689 . . . . 0.0 109.932 -179.796 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.494 ' CE1' ' HB2' ' A' ' 92' ' ' LEU . 86.4 m-85 -114.8 134.99 54.68 Favored 'General case' 0 C--N 1.308 -1.205 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.654 -179.712 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 71.8 tt0 -86.95 119.98 27.73 Favored 'General case' 0 N--CA 1.442 -0.831 0 N-CA-C 106.967 -1.494 . . . . 0.0 106.967 173.39 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.436 HG22 ' HB2' ' A' ' 63' ' ' ALA . 63.1 t -108.71 134.13 51.61 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.073 0 N-CA-C 112.943 0.72 . . . . 0.0 112.943 -172.835 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.405 ' HG2' ' HA ' ' A' ' 86' ' ' SER . 49.1 mt-10 -131.45 131.91 43.91 Favored 'General case' 0 N--CA 1.441 -0.912 0 CA-C-N 114.6 -1.182 . . . . 0.0 107.93 175.943 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 95.1 m-20 -119.28 160.62 21.87 Favored 'General case' 0 C--N 1.309 -1.18 0 CA-C-O 121.371 0.605 . . . . 0.0 112.257 -175.207 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 76' ' ' GLN . . . . . 0.512 ' O ' ' HB ' ' A' ' 59' ' ' ILE . 59.8 tt0 -118.95 114.26 22.28 Favored 'General case' 0 C--N 1.312 -1.025 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.569 -179.17 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 3.3 p90 -134.83 35.71 3.11 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 120.941 0.401 . . . . 0.0 111.416 -176.615 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -133.49 -6.9 2.56 Favored Glycine 0 C--N 1.318 -0.433 0 C-N-CA 120.225 -0.988 . . . . 0.0 112.742 -178.32 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 127.47 160.43 10.47 Favored Glycine 0 N--CA 1.445 -0.745 0 N-CA-C 109.805 -1.318 . . . . 0.0 109.805 -178.076 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 19.6 m-20 -58.97 -39.98 83.39 Favored 'General case' 0 N--CA 1.474 0.749 0 CA-C-N 117.72 0.76 . . . . 0.0 112.245 -177.114 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 4.7 p -81.24 -5.66 58.01 Favored 'General case' 0 C--N 1.316 -0.85 0 N-CA-C 112.436 0.532 . . . . 0.0 112.436 -177.974 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 82' ' ' ALA . . . . . 0.441 ' HA ' ' HD3' ' A' ' 83' ' ' PRO . . . -83.93 149.21 55.87 Favored Pre-proline 0 C--N 1.321 -0.67 0 CA-C-N 116.755 -0.202 . . . . 0.0 110.995 -178.644 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 83' ' ' PRO . . . . . 0.441 ' HD3' ' HA ' ' A' ' 82' ' ' ALA . 17.7 Cg_exo -67.33 161.31 43.73 Favored 'Trans proline' 0 C--N 1.346 0.443 0 C-N-CA 122.796 2.331 . . . . 0.0 111.939 178.242 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 84' ' ' TRP . . . . . . . . . . . . . 79.2 m95 -80.99 147.12 30.36 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.04 -179.496 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 89.9 m-70 -118.48 147.38 43.68 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.075 179.638 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 86' ' ' SER . . . . . 0.405 ' HA ' ' HG2' ' A' ' 74' ' ' GLU . 13.0 m -62.32 134.47 56.52 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-O 121.224 0.535 . . . . 0.0 111.565 -178.073 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -105.45 -48.5 1.04 Allowed Glycine 0 N--CA 1.441 -0.982 0 CA-C-N 115.451 -0.795 . . . . 0.0 111.463 179.082 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 144.92 -163.79 27.96 Favored Glycine 0 N--CA 1.442 -0.911 0 C-N-CA 120.544 -0.836 . . . . 0.0 112.251 177.535 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 16.5 m120 -104.72 127.16 52.41 Favored 'General case' 0 C--N 1.316 -0.858 0 CA-C-O 120.812 0.339 . . . . 0.0 110.341 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 12.4 m0 -119.7 144.45 47.2 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 179.825 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 91' ' ' ILE . . . . . 0.482 ' O ' ' HB3' ' A' ' 23' ' ' TRP . 45.5 mm -108.38 113.36 43.72 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.933 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.027 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 92' ' ' LEU . . . . . 0.494 ' HB2' ' CE1' ' A' ' 71' ' ' TYR . 77.9 mt -129.23 81.53 2.03 Favored 'General case' 0 C--O 1.261 1.699 0 CA-C-O 121.47 0.653 . . . . 0.0 111.894 -177.437 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 165.56 99.55 0.14 Allowed Glycine 0 N--CA 1.445 -0.751 0 CA-C-N 115.417 -0.811 . . . . 0.0 111.292 -179.813 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 94' ' ' SER . . . . . 0.419 ' HB2' ' HA3' ' A' ' 21' ' ' GLY . 3.2 p -101.69 -12.54 18.31 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 117.036 0.418 . . . . 0.0 111.844 -177.826 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 95' ' ' ARG . . . . . 0.404 HH12 ' CD ' ' A' ' 123' ' ' GLU . 96.6 mtt180 -83.49 -5.0 59.03 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.438 -0.346 . . . . 0.0 111.339 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 72.3 tt0 71.29 -55.84 0.64 Allowed 'General case' 0 N--CA 1.47 0.553 0 C-N-CA 123.502 0.721 . . . . 0.0 112.724 177.113 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 44.7 m-80 -96.18 14.93 22.36 Favored 'General case' 0 C--N 1.315 -0.919 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.341 -175.309 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 98' ' ' GLN . . . . . 0.478 ' HG2' ' HB3' ' A' ' 120' ' ' TYR . 59.2 tt0 -152.36 115.43 4.66 Favored 'General case' 0 C--N 1.316 -0.883 0 CA-C-O 120.992 0.425 . . . . 0.0 109.944 -177.731 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 76.5 m-20 -78.71 160.97 27.2 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.581 -0.736 . . . . 0.0 111.421 -176.376 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 90.6 t -87.97 133.04 31.58 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.496 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.205 175.252 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 101' ' ' VAL . . . . . 0.557 ' HB ' ' OG ' ' A' ' 40' ' ' SER . 35.3 m -116.03 -28.02 2.39 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 N-CA-C 113.345 0.869 . . . . 0.0 113.345 -176.41 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 102' ' ' ALA . . . . . 0.504 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -146.94 137.66 23.77 Favored 'General case' 0 C--N 1.325 -0.483 0 C-N-CA 120.341 -0.544 . . . . 0.0 111.285 179.237 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.505 ' HB ' HG22 ' A' ' 38' ' ' VAL . 91.5 mt -133.85 127.91 52.88 Favored 'Isoleucine or valine' 0 C--O 1.242 0.699 0 CA-C-N 116.354 -0.384 . . . . 0.0 110.608 179.011 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 48.9 t-20 -126.31 99.48 5.88 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 175.258 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.438 ' CG2' ' HB ' ' A' ' 36' ' ' ILE . 19.5 m -137.92 141.11 39.5 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 N-CA-C 112.546 0.573 . . . . 0.0 112.546 -176.925 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 70.4 tt0 -142.14 138.02 31.32 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.705 -0.679 . . . . 0.0 109.583 177.466 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 28.8 t -140.7 142.24 34.89 Favored 'General case' 0 N--CA 1.448 -0.529 0 CA-C-O 121.038 0.447 . . . . 0.0 111.801 -178.682 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -107.97 9.99 37.17 Favored Glycine 0 N--CA 1.443 -0.846 0 N-CA-C 110.759 -0.936 . . . . 0.0 110.759 175.361 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 20.5 m-20 -91.64 14.03 16.3 Favored 'General case' 0 N--CA 1.466 0.348 0 C-N-CA 122.909 0.484 . . . . 0.0 110.401 -177.829 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 12.4 m-20 63.37 30.88 15.45 Favored 'General case' 0 N--CA 1.471 0.612 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.741 -177.554 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 111' ' ' GLY . . . . . 0.658 ' HA3' ' OD1' ' A' ' 32' ' ' ASN . . . 89.03 7.11 70.79 Favored Glycine 0 N--CA 1.449 -0.456 0 CA-C-N 115.654 -0.703 . . . . 0.0 114.273 175.271 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 52.9 tt0 -65.21 -47.85 75.45 Favored 'General case' 0 C--O 1.237 0.438 0 CA-C-N 117.438 0.619 . . . . 0.0 110.198 177.67 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 113' ' ' THR . . . . . 0.438 ' HA ' ' O ' ' A' ' 130' ' ' GLY . 2.0 p -134.18 118.3 17.5 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-N 115.492 -0.776 . . . . 0.0 111.037 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -95.33 122.29 37.89 Favored 'General case' 0 C--N 1.319 -0.754 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.273 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 93.4 m-20 -123.42 148.6 45.98 Favored 'General case' 0 C--N 1.312 -1.036 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.703 -178.71 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 160.66 -135.29 3.95 Favored Glycine 0 N--CA 1.438 -1.184 0 C-N-CA 120.362 -0.923 . . . . 0.0 112.775 177.986 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 25.8 p -133.28 156.77 46.97 Favored 'General case' 0 C--N 1.316 -0.885 0 C-N-CA 122.858 0.463 . . . . 0.0 109.962 -178.532 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 11.3 ptm -151.4 157.61 42.64 Favored 'General case' 0 C--N 1.312 -1.046 0 CA-C-O 120.614 0.245 . . . . 0.0 110.822 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 119' ' ' THR . . . . . 0.504 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 38.0 m -132.51 131.02 41.18 Favored 'General case' 0 C--O 1.249 1.079 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.041 179.717 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 120' ' ' TYR . . . . . 0.478 ' HB3' ' HG2' ' A' ' 98' ' ' GLN . 78.3 m-85 -93.72 166.89 11.99 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.934 -0.575 . . . . 0.0 109.961 176.644 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -63.22 118.29 7.76 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.675 -0.239 . . . . 0.0 110.731 178.837 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 68.2 34.63 81.2 Favored Glycine 0 C--N 1.333 0.395 0 C-N-CA 120.819 -0.705 . . . . 0.0 111.613 -178.997 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 123' ' ' GLU . . . . . 0.427 ' CB ' ' HB2' ' A' ' 120' ' ' TYR . 31.6 tp10 -132.61 163.24 29.34 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 -176.723 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -94.41 159.21 23.2 Favored Glycine 0 N--CA 1.442 -0.947 0 N-CA-C 110.553 -1.019 . . . . 0.0 110.553 176.24 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_endo -62.52 132.78 39.58 Favored 'Trans proline' 0 C--O 1.237 0.464 0 C-N-CA 122.177 1.918 . . . . 0.0 111.885 -179.782 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 126' ' ' ILE . . . . . 0.438 HD12 ' HB3' ' A' ' 8' ' ' ASN . 40.9 pt -132.79 166.19 30.1 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 CA-C-N 115.932 -0.577 . . . . 0.0 110.464 -179.742 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -70.61 141.49 33.6 Favored Glycine 0 C--O 1.242 0.615 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.176 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 82.7 t80 -123.67 135.57 53.98 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-O 120.824 0.345 . . . . 0.0 111.188 -178.725 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 62.4 tttm -139.3 118.93 13.06 Favored 'General case' 0 N--CA 1.445 -0.713 0 CA-C-N 115.497 -0.774 . . . . 0.0 109.313 177.178 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 130' ' ' GLY . . . . . 0.487 ' HA2' ' O ' ' A' ' 5' ' ' ASN . . . -125.26 137.94 10.67 Favored Glycine 0 N--CA 1.445 -0.737 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.054 179.67 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 59.4 m -123.63 129.69 51.53 Favored 'General case' 0 C--N 1.313 -0.98 0 CA-C-N 116.853 0.327 . . . . 0.0 110.817 -179.303 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -67.45 117.7 9.78 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-O 121.186 0.517 . . . . 0.0 111.429 -178.163 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 15.0 m . . . . . 0 C--O 1.25 1.1 0 CA-C-N 115.707 -0.678 . . . . 0.0 110.612 176.229 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.807 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 2.2 tm? -89.99 126.71 35.85 Favored 'General case' 0 C--N 1.315 -0.917 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -178.987 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 4' ' ' TYR . . . . . 0.474 ' CE1' ' HB ' ' A' ' 25' ' ' ILE . 58.0 m-85 -114.53 141.46 47.7 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.225 -178.796 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 23.4 t-20 -93.72 137.85 32.55 Favored 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 106.719 -1.586 . . . . 0.0 106.719 174.918 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.435 HG21 ' CG ' ' A' ' 23' ' ' TRP . 59.0 t -114.48 128.31 71.58 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.894 0 N-CA-C 113.287 0.847 . . . . 0.0 113.287 -173.679 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -118.31 133.05 56.22 Favored 'General case' 0 C--O 1.245 0.833 0 CA-C-N 114.748 -1.114 . . . . 0.0 109.283 176.907 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 70.8 m-20 -110.32 135.38 51.15 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.076 -177.411 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' GLN . . . . . 0.434 ' OE1' ' HA ' ' A' ' 13' ' ' SER . 36.0 tt0 -120.45 114.23 21.48 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 120.988 0.423 . . . . 0.0 110.448 175.713 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 2.4 p90 -112.12 175.66 5.34 Favored 'General case' 0 C--N 1.311 -1.097 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.487 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 69.87 -71.34 0.56 Allowed Glycine 0 CA--C 1.529 0.948 0 CA-C-N 115.706 -0.679 . . . . 0.0 112.956 -176.847 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -165.08 168.3 39.16 Favored Glycine 0 N--CA 1.446 -0.684 0 C-N-CA 121.014 -0.612 . . . . 0.0 112.304 -178.458 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' SER . . . . . 0.434 ' HA ' ' OE1' ' A' ' 9' ' ' GLN . 28.2 t -62.85 -19.55 64.23 Favored 'General case' 0 CA--C 1.54 0.563 0 N-CA-C 112.329 0.492 . . . . 0.0 112.329 -178.669 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 30.4 p -77.47 -6.83 54.92 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.873 0.368 . . . . 0.0 111.76 179.411 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -86.69 149.36 48.35 Favored Pre-proline 0 C--N 1.323 -0.584 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.548 179.131 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_endo -69.14 162.43 41.8 Favored 'Trans proline' 0 C--O 1.237 0.458 0 C-N-CA 122.529 2.153 . . . . 0.0 112.086 179.071 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 98.3 m95 -85.65 124.26 31.98 Favored 'General case' 0 C--N 1.317 -0.837 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 179.695 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 92.4 m-20 -111.44 113.42 25.86 Favored 'General case' 0 C--N 1.309 -1.154 0 CA-C-N 116.332 -0.394 . . . . 0.0 111.059 -175.89 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 80.6 tt0 -71.97 122.43 20.84 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-N 115.826 -0.625 . . . . 0.0 109.611 179.864 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -137.69 25.6 2.95 Favored Glycine 0 N--CA 1.446 -0.679 0 C-N-CA 120.29 -0.957 . . . . 0.0 112.559 -177.93 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' GLY . . . . . 0.414 ' HA3' ' HB3' ' A' ' 94' ' ' SER . . . 156.63 -172.39 34.33 Favored Glycine 0 N--CA 1.433 -1.524 0 C-N-CA 119.961 -1.114 . . . . 0.0 112.651 179.205 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 13.2 pt20 -150.34 145.43 26.13 Favored 'General case' 0 C--N 1.31 -1.11 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 179.299 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' TRP . . . . . 0.435 ' CG ' HG21 ' A' ' 6' ' ' VAL . 43.7 m0 -122.47 159.45 27.61 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.749 -177.172 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 24' ' ' GLU . . . . . 0.409 ' H ' ' HB ' ' A' ' 91' ' ' ILE . 79.3 tt0 -118.05 119.71 35.59 Favored 'General case' 0 C--N 1.306 -1.316 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 176.079 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.474 ' HB ' ' CE1' ' A' ' 4' ' ' TYR . 98.9 mt -127.87 135.14 63.76 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-N 115.432 -0.804 . . . . 0.0 109.934 -175.011 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 89.07 71.83 1.27 Allowed Glycine 0 N--CA 1.435 -1.427 0 C-N-CA 119.718 -1.229 . . . . 0.0 111.944 -179.878 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' SER . . . . . 0.457 ' OG ' ' HA3' ' A' ' 88' ' ' GLY . 7.5 t -59.44 -39.38 83.39 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 176.829 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 73.3 ttt180 -82.22 113.03 19.77 Favored 'General case' 0 N--CA 1.439 -1.013 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 174.599 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 30.8 m -78.3 -13.71 59.73 Favored 'General case' 0 C--N 1.315 -0.892 0 CA-C-O 120.965 0.412 . . . . 0.0 111.777 -174.963 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 23.2 t70 -72.0 -33.43 68.09 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.403 0.62 . . . . 0.0 110.987 178.865 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 22.2 mm-40 -126.17 120.62 30.57 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.63 -0.713 . . . . 0.0 111.012 -177.369 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' ASN . . . . . 0.546 ' ND2' ' HA3' ' A' ' 111' ' ' GLY . 64.2 t30 -95.04 154.41 17.19 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.532 -0.304 . . . . 0.0 110.235 178.943 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.451 ' HA ' ' HA ' ' A' ' 53' ' ' TYR . 62.0 t -96.22 133.53 37.15 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.541 -176.457 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 28.4 m -113.49 -14.54 10.83 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.151 0 N-CA-C 112.299 0.481 . . . . 0.0 112.299 178.891 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' ALA . . . . . 0.513 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -147.49 138.96 23.86 Favored 'General case' 0 C--N 1.323 -0.565 0 C-N-CA 120.391 -0.524 . . . . 0.0 111.487 179.552 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.417 ' HB ' HG22 ' A' ' 105' ' ' VAL . 88.8 mt -141.42 123.3 13.97 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-N 116.058 -0.519 . . . . 0.0 109.912 -179.6 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -128.97 109.39 11.19 Favored 'General case' 0 C--N 1.309 -1.188 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 174.055 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.441 HG11 ' CD1' ' A' ' 61' ' ' PHE . 18.4 m -146.49 148.13 17.28 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 C-N-CA 120.674 -0.41 . . . . 0.0 112.012 -174.356 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 66.7 tt0 -138.42 140.54 39.36 Favored 'General case' 0 C--N 1.315 -0.899 0 CA-C-N 115.214 -0.903 . . . . 0.0 108.619 176.293 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' SER . . . . . 0.431 ' HA ' ' O ' ' A' ' 46' ' ' THR . 94.7 p -81.55 153.8 26.58 Favored 'General case' 0 C--N 1.308 -1.216 0 CA-C-O 120.921 0.391 . . . . 0.0 111.946 -176.84 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -97.43 -57.14 1.07 Allowed Glycine 0 N--CA 1.435 -1.393 0 CA-C-N 115.765 -0.652 . . . . 0.0 111.767 176.934 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -113.54 98.4 7.04 Favored 'General case' 0 CA--C 1.533 0.315 0 N-CA-C 111.924 0.342 . . . . 0.0 111.924 -178.477 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 14.1 m-20 47.76 34.53 3.88 Favored 'General case' 0 N--CA 1.492 1.667 0 N-CA-C 114.454 1.279 . . . . 0.0 114.454 175.222 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.418 ' HA2' ' CB ' ' A' ' 40' ' ' SER . . . 80.11 0.65 86.45 Favored Glycine 0 C--N 1.319 -0.41 0 C-N-CA 120.438 -0.887 . . . . 0.0 113.793 178.196 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 59.9 mt-30 -77.4 -30.45 53.59 Favored 'General case' 0 CA--C 1.513 -0.458 0 CA-C-N 117.398 0.599 . . . . 0.0 111.331 178.999 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 46' ' ' THR . . . . . 0.431 ' O ' ' HA ' ' A' ' 40' ' ' SER . 5.1 p -122.83 107.02 11.42 Favored 'General case' 0 C--N 1.308 -1.229 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.999 -179.472 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 47' ' ' LEU . . . . . 0.512 ' HB2' ' HB3' ' A' ' 63' ' ' ALA . 90.8 mt -89.91 129.16 36.3 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 177.534 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 15.4 m120 -126.65 136.99 53.23 Favored 'General case' 0 C--N 1.318 -0.804 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 171.03 -153.32 20.47 Favored Glycine 0 N--CA 1.443 -0.857 0 C-N-CA 118.876 -1.63 . . . . 0.0 114.057 178.813 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 52.4 m -127.43 131.92 50.16 Favored 'General case' 0 C--N 1.315 -0.899 0 C-N-CA 123.14 0.576 . . . . 0.0 109.455 -178.002 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 51' ' ' MET . . . . . 0.534 ' HE3' HD11 ' A' ' 59' ' ' ILE . 15.5 tmm? -128.52 139.8 52.13 Favored 'General case' 0 C--N 1.315 -0.927 0 C-N-CA 121.31 -0.156 . . . . 0.0 110.65 -178.842 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.513 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 33.8 m -124.24 128.73 49.61 Favored 'General case' 0 C--O 1.253 1.286 0 CA-C-O 121.135 0.493 . . . . 0.0 111.773 -176.718 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 53' ' ' TYR . . . . . 0.451 ' HA ' ' HA ' ' A' ' 33' ' ' VAL . 78.4 m-85 -84.76 163.73 18.96 Favored 'General case' 0 N--CA 1.462 0.147 0 CA-C-N 115.532 -0.758 . . . . 0.0 110.951 177.958 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -58.06 109.14 0.69 Allowed 'General case' 0 N--CA 1.469 0.478 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.957 -179.228 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 72.81 18.45 78.87 Favored Glycine 0 C--O 1.225 -0.414 0 C-N-CA 121.133 -0.556 . . . . 0.0 113.054 178.007 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 56' ' ' GLU . . . . . 0.432 ' HB2' ' HB2' ' A' ' 53' ' ' TYR . 70.2 mm-40 -117.76 174.19 6.32 Favored 'General case' 0 C--N 1.317 -0.817 0 N-CA-C 110.197 -0.297 . . . . 0.0 110.197 -179.062 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -86.71 157.03 29.5 Favored Glycine 0 N--CA 1.444 -0.827 0 C-N-CA 120.685 -0.769 . . . . 0.0 111.733 178.418 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -67.86 141.23 53.19 Favored 'Trans proline' 0 C--O 1.234 0.286 0 C-N-CA 122.64 2.227 . . . . 0.0 111.986 179.497 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 59' ' ' ILE . . . . . 0.534 HD11 ' HE3' ' A' ' 51' ' ' MET . 39.6 pt -131.33 165.53 31.33 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.852 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.678 179.92 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -72.83 136.84 23.43 Favored Glycine 0 N--CA 1.447 -0.598 0 C-N-CA 120.889 -0.672 . . . . 0.0 111.499 -179.634 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.441 ' CD1' HG11 ' A' ' 38' ' ' VAL . 47.9 t80 -121.48 124.85 45.43 Favored 'General case' 0 C--N 1.313 -0.999 0 CA-C-O 120.722 0.296 . . . . 0.0 110.943 -178.462 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 62' ' ' ARG . . . . . 0.494 ' HA ' ' O ' ' A' ' 47' ' ' LEU . 62.0 ttp180 -135.65 129.59 33.03 Favored 'General case' 0 N--CA 1.445 -0.691 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 173.824 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.512 ' HB3' ' HB2' ' A' ' 47' ' ' LEU . . . -127.65 136.72 52.0 Favored 'General case' 0 C--N 1.311 -1.077 0 CA-C-O 120.667 0.27 . . . . 0.0 110.584 -179.836 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 28.2 m -114.16 124.68 52.66 Favored 'General case' 0 N--CA 1.435 -1.199 0 CA-C-N 116.035 -0.53 . . . . 0.0 109.861 177.914 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 65' ' ' LEU . . . . . 0.538 HD11 ' O ' ' A' ' 67' ' ' GLY . 2.7 tm? -63.25 129.24 39.43 Favored 'General case' 0 C--N 1.31 -1.151 0 CA-C-N 115.604 -0.725 . . . . 0.0 110.945 -179.34 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 96.5 mt -95.74 -40.42 9.37 Favored 'General case' 0 C--O 1.225 -0.199 0 CA-C-O 121.103 0.478 . . . . 0.0 111.094 178.505 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.538 ' O ' HD11 ' A' ' 65' ' ' LEU . . . -140.27 -79.93 0.06 OUTLIER Glycine 0 CA--C 1.499 -0.964 0 N-CA-C 110.766 -0.933 . . . . 0.0 110.766 -178.3 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 65.1 m-80 -146.01 -71.32 0.25 Allowed 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 107.527 -1.286 . . . . 0.0 107.527 174.389 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 69' ' ' ASN . . . . . 0.422 ' HB3' HG23 ' A' ' 91' ' ' ILE . 84.4 m-20 -67.77 -39.87 84.06 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.652 -0.704 . . . . 0.0 111.458 176.501 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 23.3 t -81.48 130.45 35.05 Favored 'General case' 0 CA--C 1.538 0.492 0 N-CA-C 113.025 0.75 . . . . 0.0 113.025 -174.334 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.452 ' OH ' ' HB3' ' A' ' 99' ' ' ASN . 56.9 m-85 -127.66 145.21 50.96 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.106 -0.952 . . . . 0.0 109.919 177.08 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -105.43 125.19 50.7 Favored 'General case' 0 C--N 1.312 -1.053 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 174.401 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.456 HG22 ' HB2' ' A' ' 63' ' ' ALA . 62.2 t -111.03 137.74 42.21 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.162 0 N-CA-C 113.225 0.824 . . . . 0.0 113.225 -171.914 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 63.9 mt-10 -126.53 129.74 49.22 Favored 'General case' 0 N--CA 1.442 -0.871 0 CA-C-N 114.578 -1.192 . . . . 0.0 108.257 176.344 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 75' ' ' ASN . . . . . 0.509 ' HB3' HD12 ' A' ' 59' ' ' ILE . 89.5 m-20 -110.12 151.51 27.16 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-O 121.167 0.508 . . . . 0.0 111.693 -178.033 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 76' ' ' GLN . . . . . 0.463 ' HB2' ' CE3' ' A' ' 84' ' ' TRP . 62.3 tt0 -117.19 121.04 40.11 Favored 'General case' 0 C--N 1.311 -1.071 0 CA-C-N 115.359 -0.837 . . . . 0.0 110.113 -178.725 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 4.7 p90 -142.7 161.78 37.18 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.855 -179.241 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 99.83 -12.22 60.91 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 121.026 -0.607 . . . . 0.0 112.437 178.715 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 140.53 160.1 8.18 Favored Glycine 0 N--CA 1.441 -1.029 0 N-CA-C 111.087 -0.805 . . . . 0.0 111.087 179.388 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 24.7 m-20 -62.75 -35.04 78.49 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-O 120.828 0.347 . . . . 0.0 111.617 -179.319 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 5.1 m -72.53 -12.9 61.26 Favored 'General case' 0 CA--C 1.54 0.592 0 CA-C-N 116.228 -0.442 . . . . 0.0 112.003 -179.709 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -75.96 147.83 80.99 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-O 120.518 0.199 . . . . 0.0 111.217 -178.424 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -72.14 -178.44 3.23 Favored 'Trans proline' 0 C--O 1.24 0.602 0 C-N-CA 122.733 2.289 . . . . 0.0 112.289 178.762 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 84' ' ' TRP . . . . . 0.463 ' CE3' ' HB2' ' A' ' 76' ' ' GLN . 92.3 m95 -91.64 139.66 30.47 Favored 'General case' 0 C--N 1.319 -0.718 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 -179.358 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 93.7 m-70 -115.48 148.46 39.43 Favored 'General case' 0 C--N 1.315 -0.922 0 N-CA-C 109.689 -0.486 . . . . 0.0 109.689 -179.32 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 13.2 p -64.59 135.36 55.89 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-O 120.778 0.323 . . . . 0.0 110.856 -178.94 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -110.37 -52.36 0.6 Allowed Glycine 0 N--CA 1.442 -0.906 0 C-N-CA 120.52 -0.848 . . . . 0.0 111.958 -179.549 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.457 ' HA3' ' OG ' ' A' ' 27' ' ' SER . . . 147.72 -162.87 28.77 Favored Glycine 0 N--CA 1.444 -0.824 0 C-N-CA 120.212 -0.994 . . . . 0.0 112.822 179.698 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 17.1 m120 -104.08 134.9 46.57 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 120.832 0.349 . . . . 0.0 110.953 -178.557 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 11.8 m0 -127.38 150.8 49.45 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.929 -0.578 . . . . 0.0 109.714 179.002 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 91' ' ' ILE . . . . . 0.422 HG23 ' HB3' ' A' ' 69' ' ' ASN . 50.1 mm -113.93 110.03 30.67 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.927 0 N-CA-C 109.021 -0.733 . . . . 0.0 109.021 177.729 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 92' ' ' LEU . . . . . 0.41 ' O ' HG13 ' A' ' 100' ' ' VAL . 78.0 mt -132.84 75.8 1.65 Allowed 'General case' 0 C--O 1.26 1.649 0 CA-C-O 121.893 0.854 . . . . 0.0 111.835 -177.325 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 93' ' ' GLY . . . . . 0.4 ' O ' ' HB2' ' A' ' 94' ' ' SER . . . -150.15 -91.64 0.09 OUTLIER Glycine 0 N--CA 1.448 -0.504 0 CA-C-N 115.399 -0.819 . . . . 0.0 112.9 -178.901 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 94' ' ' SER . . . . . 0.414 ' HB3' ' HA3' ' A' ' 21' ' ' GLY . 69.6 m 78.29 8.56 2.26 Favored 'General case' 0 N--CA 1.482 1.13 0 C-N-CA 124.092 0.957 . . . . 0.0 112.181 -177.378 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 95' ' ' ARG . . . . . 0.492 ' HB2' ' O ' ' A' ' 98' ' ' GLN . 95.9 mtt180 -137.6 145.03 42.29 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 116.083 -0.508 . . . . 0.0 109.725 177.557 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 78.1 tt0 -70.44 -45.64 65.44 Favored 'General case' 0 C--N 1.315 -0.906 0 N-CA-C 112.622 0.601 . . . . 0.0 112.622 -172.729 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 7.2 p30 -117.41 20.89 13.4 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.26 0.552 . . . . 0.0 111.207 -179.269 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 98' ' ' GLN . . . . . 0.492 ' O ' ' HB2' ' A' ' 95' ' ' ARG . 90.5 mt-30 -139.78 115.63 10.22 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-N 115.658 -0.701 . . . . 0.0 111.12 179.635 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 99' ' ' ASN . . . . . 0.452 ' HB3' ' OH ' ' A' ' 71' ' ' TYR . 85.2 m-20 -108.49 176.19 5.2 Favored 'General case' 0 C--N 1.306 -1.309 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 179.575 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.41 HG13 ' O ' ' A' ' 92' ' ' LEU . 33.6 m -78.22 133.69 29.78 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.668 0 C-N-CA 119.565 -0.854 . . . . 0.0 111.352 179.348 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 35.4 m -113.92 -31.09 2.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.165 177.243 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 102' ' ' ALA . . . . . 0.573 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -148.18 133.32 18.32 Favored 'General case' 0 CA--C 1.511 -0.546 0 C-N-CA 120.688 -0.405 . . . . 0.0 110.475 178.003 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 89.6 mt -130.16 125.1 59.39 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.785 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.961 179.78 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 10.0 t30 -126.19 100.38 6.29 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.704 -0.68 . . . . 0.0 109.574 175.631 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.417 HG22 ' HB ' ' A' ' 36' ' ' ILE . 27.7 m -141.46 140.96 30.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-N 115.983 -0.553 . . . . 0.0 112.326 -176.121 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 61.5 mt-10 -143.66 149.53 37.39 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.2 -0.909 . . . . 0.0 109.606 177.111 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 107' ' ' SER . . . . . 0.409 ' HB2' HD23 ' A' ' 114' ' ' LEU . 46.3 t -128.66 144.62 51.2 Favored 'General case' 0 C--N 1.313 -0.994 0 CA-C-O 120.966 0.412 . . . . 0.0 111.508 -178.842 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -91.63 -4.46 67.76 Favored Glycine 0 N--CA 1.439 -1.16 0 N-CA-C 110.656 -0.978 . . . . 0.0 110.656 175.161 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 35.4 m-20 -98.28 -167.62 1.53 Allowed 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 -179.528 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 110' ' ' ASP . . . . . 0.42 ' OD1' ' HG3' ' A' ' 112' ' ' GLN . 7.3 p-10 -93.86 21.22 6.79 Favored 'General case' 0 C--N 1.311 -1.082 0 CA-C-O 121.291 0.567 . . . . 0.0 109.864 178.041 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 111' ' ' GLY . . . . . 0.546 ' HA3' ' ND2' ' A' ' 32' ' ' ASN . . . 105.34 9.77 32.99 Favored Glycine 0 C--O 1.22 -0.753 0 C-N-CA 120.761 -0.733 . . . . 0.0 113.466 -178.525 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 112' ' ' GLN . . . . . 0.431 ' HA ' HD12 ' A' ' 132' ' ' LEU . 98.3 mt-30 -64.72 -43.8 92.26 Favored 'General case' 0 C--O 1.242 0.66 0 CA-C-N 117.439 0.62 . . . . 0.0 110.681 178.89 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 81.8 p -136.48 145.76 45.52 Favored 'General case' 0 N--CA 1.444 -0.758 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.937 176.445 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 114' ' ' LEU . . . . . 0.409 HD23 ' HB2' ' A' ' 107' ' ' SER . 88.8 mt -116.54 129.75 56.36 Favored 'General case' 0 C--N 1.315 -0.922 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 179.312 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 84.5 m-20 -120.5 142.87 48.9 Favored 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 110.318 -0.253 . . . . 0.0 110.318 -178.916 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 163.77 -141.19 6.94 Favored Glycine 0 N--CA 1.444 -0.8 0 C-N-CA 119.385 -1.388 . . . . 0.0 113.426 176.586 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 3.0 p -130.91 151.02 51.79 Favored 'General case' 0 C--N 1.311 -1.1 0 C-N-CA 123.056 0.542 . . . . 0.0 110.209 -178.295 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 118' ' ' MET . . . . . 0.624 ' SD ' ' HD1' ' A' ' 128' ' ' PHE . 20.0 ptm -136.96 144.5 43.42 Favored 'General case' 0 C--N 1.31 -1.128 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.253 -177.792 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 119' ' ' THR . . . . . 0.573 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 24.5 m -128.8 126.47 39.95 Favored 'General case' 0 C--O 1.252 1.22 0 CA-C-O 120.737 0.303 . . . . 0.0 110.535 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 42.1 m-85 -98.39 162.62 13.07 Favored 'General case' 0 CA--C 1.509 -0.631 0 CA-C-N 115.616 -0.72 . . . . 0.0 111.167 179.563 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -59.17 114.91 2.85 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 115.489 -0.778 . . . . 0.0 111.169 176.842 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 78.04 17.49 78.26 Favored Glycine 0 N--CA 1.451 -0.354 0 CA-C-N 115.787 -0.642 . . . . 0.0 114.014 177.759 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 69.2 tt0 -142.26 144.02 33.12 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 117.47 0.635 . . . . 0.0 110.566 179.837 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -69.03 163.77 50.48 Favored Glycine 0 CA--C 1.522 0.53 0 CA-C-N 116.141 -0.481 . . . . 0.0 113.246 -177.436 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 125' ' ' PRO . . . . . 0.492 ' HA ' ' O ' ' A' ' 118' ' ' MET . 23.7 Cg_exo -63.46 138.72 66.88 Favored 'Trans proline' 0 C--N 1.347 0.492 0 C-N-CA 122.784 2.322 . . . . 0.0 112.887 -178.752 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 41.0 pt -131.04 167.75 25.4 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.806 0 CA-C-N 115.532 -0.758 . . . . 0.0 109.675 177.467 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -69.0 136.96 29.31 Favored Glycine 0 C--O 1.236 0.281 0 C-N-CA 120.994 -0.622 . . . . 0.0 112.354 -178.754 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 128' ' ' PHE . . . . . 0.624 ' HD1' ' SD ' ' A' ' 118' ' ' MET . 82.4 t80 -118.59 133.8 55.59 Favored 'General case' 0 C--O 1.249 1.072 0 CA-C-O 120.963 0.411 . . . . 0.0 111.526 -178.564 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 64.1 tttm -136.52 111.44 8.86 Favored 'General case' 0 N--CA 1.442 -0.861 0 CA-C-N 115.562 -0.745 . . . . 0.0 109.782 175.678 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -104.87 133.01 11.35 Favored Glycine 0 N--CA 1.441 -0.997 0 N-CA-C 110.94 -0.864 . . . . 0.0 110.94 178.314 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 25.7 m -128.97 132.9 47.63 Favored 'General case' 0 C--N 1.311 -1.102 0 CA-C-N 116.944 0.372 . . . . 0.0 110.092 -178.754 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 132' ' ' LEU . . . . . 0.431 HD12 ' HA ' ' A' ' 112' ' ' GLN . 74.0 mt -59.81 130.52 47.19 Favored 'General case' 0 N--CA 1.467 0.396 0 C-N-CA 120.301 -0.559 . . . . 0.0 110.799 177.726 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 52.8 m . . . . . 0 C--O 1.247 0.929 0 CA-C-O 118.512 -0.756 . . . . 0.0 110.734 -179.196 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.741 0 CA-C-O 120.897 0.38 . . . . 0.0 110.749 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 3.2 tm? -92.68 130.39 38.32 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.064 179.313 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 81.4 m-85 -119.27 144.9 46.53 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.954 -0.566 . . . . 0.0 111.777 -179.242 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 5' ' ' ASN . . . . . 0.512 ' O ' ' HA2' ' A' ' 130' ' ' GLY . 11.5 t-20 -96.32 136.03 37.36 Favored 'General case' 0 C--N 1.313 -0.988 0 N-CA-C 107.706 -1.22 . . . . 0.0 107.706 179.269 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 78.7 t -116.56 127.11 74.25 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 CA-C-O 121.529 0.681 . . . . 0.0 112.703 -174.59 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.448 ' HB2' ' HB3' ' A' ' 129' ' ' LYS . 45.4 mt-10 -116.58 138.8 51.14 Favored 'General case' 0 N--CA 1.44 -0.926 0 CA-C-N 114.949 -1.023 . . . . 0.0 108.286 175.275 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 90.7 m-20 -116.29 139.3 50.52 Favored 'General case' 0 C--N 1.306 -1.32 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.545 -178.442 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' GLN . . . . . 0.506 ' HB2' ' CE3' ' A' ' 17' ' ' TRP . 54.4 tt0 -129.36 124.3 33.9 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.703 -0.68 . . . . 0.0 109.767 179.33 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 20.1 p90 -122.99 136.84 55.01 Favored 'General case' 0 C--N 1.307 -1.262 0 CA-C-O 120.849 0.357 . . . . 0.0 111.222 179.213 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 111.17 -75.49 0.21 Allowed Glycine 0 N--CA 1.445 -0.752 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.851 -179.653 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -162.34 163.65 35.13 Favored Glycine 0 N--CA 1.449 -0.438 0 N-CA-C 111.617 -0.593 . . . . 0.0 111.617 179.725 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' SER . . . . . 0.434 ' HA ' ' NE2' ' A' ' 9' ' ' GLN . 12.1 m -64.07 -19.06 64.97 Favored 'General case' 0 CA--C 1.536 0.44 0 N-CA-C 112.279 0.474 . . . . 0.0 112.279 -179.002 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 35.3 p -72.42 -18.22 61.73 Favored 'General case' 0 CA--C 1.539 0.536 0 CA-C-O 120.988 0.423 . . . . 0.0 111.231 178.799 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -80.66 155.0 73.73 Favored Pre-proline 0 CA--C 1.533 0.317 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.695 -179.755 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 66.6 Cg_endo -72.11 158.68 51.7 Favored 'Trans proline' 0 C--O 1.236 0.393 0 C-N-CA 122.47 2.113 . . . . 0.0 112.783 178.701 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' TRP . . . . . 0.506 ' CE3' ' HB2' ' A' ' 9' ' ' GLN . 94.4 m95 -89.22 138.6 31.28 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.408 179.624 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 90.5 m-20 -124.08 129.9 51.64 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 109.141 -0.689 . . . . 0.0 109.141 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 42.6 tt0 -61.37 128.04 34.43 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-O 120.962 0.41 . . . . 0.0 111.299 -178.305 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -108.7 -0.63 32.38 Favored Glycine 0 N--CA 1.448 -0.52 0 CA-C-N 115.469 -0.787 . . . . 0.0 112.805 -178.821 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 130.27 -150.11 19.09 Favored Glycine 0 N--CA 1.443 -0.881 0 C-N-CA 120.335 -0.936 . . . . 0.0 112.249 -179.83 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 23.5 pt20 -145.5 138.02 25.83 Favored 'General case' 0 C--N 1.319 -0.738 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.771 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 45.3 m0 -117.14 155.23 29.69 Favored 'General case' 0 C--N 1.318 -0.761 0 CA-C-O 120.89 0.376 . . . . 0.0 111.159 -178.429 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -109.11 112.64 24.93 Favored 'General case' 0 C--N 1.317 -0.812 0 N-CA-C 109.511 -0.551 . . . . 0.0 109.511 177.481 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 95.8 mt -130.7 136.82 57.47 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.585 0 CA-C-N 115.203 -0.908 . . . . 0.0 109.762 -178.955 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 91.55 106.81 1.49 Allowed Glycine 0 N--CA 1.442 -0.911 0 C-N-CA 120.208 -0.996 . . . . 0.0 111.966 -179.383 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 13.9 m -111.86 13.58 20.95 Favored 'General case' 0 C--N 1.31 -1.136 0 CA-C-O 121.208 0.528 . . . . 0.0 110.311 -178.699 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 94.7 mtt-85 -137.44 128.17 27.03 Favored 'General case' 0 N--CA 1.445 -0.72 0 CA-C-N 116.004 -0.544 . . . . 0.0 109.967 -177.069 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 34.5 t -76.77 -17.43 59.05 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-O 121.207 0.527 . . . . 0.0 110.215 179.353 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 15.8 m-20 -75.0 -47.56 28.52 Favored 'General case' 0 C--O 1.224 -0.275 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.904 -178.033 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 84.9 mm-40 -128.71 123.19 32.45 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.603 -0.726 . . . . 0.0 111.234 -176.575 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' ASN . . . . . 0.663 ' ND2' ' HA3' ' A' ' 111' ' ' GLY . 62.5 t30 -101.18 161.74 13.39 Favored 'General case' 0 C--N 1.319 -0.751 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 178.348 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 46.6 t -94.69 130.73 43.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-O 120.572 0.225 . . . . 0.0 111.409 -173.771 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 28.7 m -110.59 -18.57 7.5 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.276 0 CA-C-N 116.464 -0.335 . . . . 0.0 111.731 179.224 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' ALA . . . . . 0.533 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -154.6 149.67 26.88 Favored 'General case' 0 C--O 1.237 0.416 0 C-N-CA 120.563 -0.455 . . . . 0.0 111.685 178.682 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.495 ' HB ' ' CG2' ' A' ' 105' ' ' VAL . 89.9 mt -144.09 123.63 7.84 Favored 'Isoleucine or valine' 0 C--O 1.235 0.308 0 CA-C-N 115.97 -0.559 . . . . 0.0 109.64 -179.743 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 88.9 m-20 -124.82 106.58 10.14 Favored 'General case' 0 C--N 1.313 -1.012 0 N-CA-C 107.767 -1.197 . . . . 0.0 107.767 175.844 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 36.0 m -147.68 149.56 15.32 Favored 'Isoleucine or valine' 0 C--O 1.237 0.436 0 C-N-CA 120.146 -0.622 . . . . 0.0 111.957 -172.757 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 66.7 mt-10 -142.55 149.1 38.63 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.299 -0.864 . . . . 0.0 109.325 175.337 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 20.5 p -73.97 142.62 45.84 Favored 'General case' 0 C--N 1.307 -1.25 0 N-CA-C 112.104 0.409 . . . . 0.0 112.104 -177.444 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -88.62 -42.56 5.73 Favored Glycine 0 N--CA 1.443 -0.841 0 N-CA-C 109.148 -1.581 . . . . 0.0 109.148 174.755 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 48.8 m-20 -105.18 -161.55 0.82 Allowed 'General case' 0 C--N 1.317 -0.836 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 175.045 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -76.17 47.98 0.48 Allowed 'General case' 0 N--CA 1.474 0.766 0 N-CA-C 112.303 0.483 . . . . 0.0 112.303 -178.361 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 91.64 -8.55 78.51 Favored Glycine 0 C--O 1.222 -0.649 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.223 178.969 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 56.1 mt-30 -70.23 -36.23 74.39 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.99 0.424 . . . . 0.0 110.713 178.356 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 22.0 p -122.58 139.4 53.95 Favored 'General case' 0 C--N 1.311 -1.106 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.207 179.66 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 47' ' ' LEU . . . . . 0.435 ' HB2' ' HB3' ' A' ' 63' ' ' ALA . 91.2 mt -125.94 127.05 45.36 Favored 'General case' 0 C--N 1.315 -0.932 0 N-CA-C 108.509 -0.923 . . . . 0.0 108.509 179.865 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 88.9 m-20 -125.3 138.07 54.08 Favored 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 109.376 -0.602 . . . . 0.0 109.376 -179.352 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 173.25 -151.23 13.26 Favored Glycine 0 N--CA 1.443 -0.873 0 C-N-CA 120.078 -1.058 . . . . 0.0 112.558 178.853 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 33.6 p -132.49 146.87 52.25 Favored 'General case' 0 N--CA 1.443 -0.8 0 CA-C-O 121.003 0.43 . . . . 0.0 110.921 179.692 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 40.7 mtp -121.12 156.49 32.18 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.74 177.18 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.533 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 26.8 m -132.1 126.35 33.53 Favored 'General case' 0 C--O 1.247 0.965 0 N-CA-C 110.04 -0.356 . . . . 0.0 110.04 175.657 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 72.2 m-85 -98.19 162.64 13.1 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.272 178.607 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -63.6 125.21 23.51 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.577 178.541 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 74.56 12.94 82.27 Favored Glycine 0 N--CA 1.447 -0.608 0 C-N-CA 120.948 -0.644 . . . . 0.0 112.851 -179.705 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 73.8 mm-40 -127.41 177.31 6.82 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 110.137 -0.32 . . . . 0.0 110.137 -179.373 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -109.13 -179.9 21.19 Favored Glycine 0 N--CA 1.445 -0.724 0 C-N-CA 120.879 -0.677 . . . . 0.0 111.614 178.805 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_exo -63.76 137.64 59.6 Favored 'Trans proline' 0 C--N 1.349 0.555 0 C-N-CA 122.504 2.136 . . . . 0.0 112.222 178.88 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 59' ' ' ILE . . . . . 0.545 ' HB ' ' O ' ' A' ' 76' ' ' GLN . 45.4 pt -132.36 166.11 30.15 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 CA-C-N 115.706 -0.679 . . . . 0.0 109.713 179.316 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -75.73 145.96 33.34 Favored Glycine 0 C--N 1.321 -0.299 0 C-N-CA 120.703 -0.761 . . . . 0.0 111.886 -179.47 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 31.6 t80 -132.12 130.54 41.33 Favored 'General case' 0 C--N 1.317 -0.839 0 C-N-CA 122.477 0.311 . . . . 0.0 111.398 -178.831 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 59.3 ttp180 -138.71 130.49 27.81 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 174.015 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.435 ' HB3' ' HB2' ' A' ' 47' ' ' LEU . . . -134.87 146.66 49.43 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 120.704 0.288 . . . . 0.0 111.148 -179.648 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 48.9 m -128.33 136.26 50.71 Favored 'General case' 0 CA--C 1.544 0.724 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.748 179.065 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 65' ' ' LEU . . . . . 0.401 HD11 ' O ' ' A' ' 68' ' ' ASN . 59.8 tp -69.34 127.8 34.31 Favored 'General case' 0 CA--C 1.535 0.376 0 N-CA-C 112.274 0.472 . . . . 0.0 112.274 -178.539 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 66' ' ' LEU . . . . . 0.434 HD21 ' HB2' ' A' ' 72' ' ' GLU . 4.3 mm? -91.18 -41.3 11.08 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-N 115.972 -0.558 . . . . 0.0 112.482 178.702 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -151.8 -68.34 0.01 OUTLIER Glycine 0 CA--C 1.499 -0.922 0 C-N-CA 119.63 -1.272 . . . . 0.0 113.244 -175.835 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 68' ' ' ASN . . . . . 0.401 ' O ' HD11 ' A' ' 65' ' ' LEU . 20.2 m120 -133.49 -81.07 0.47 Allowed 'General case' 0 C--O 1.209 -1.036 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 -178.706 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 69' ' ' ASN . . . . . 0.484 ' OD1' ' HA3' ' A' ' 93' ' ' GLY . 90.7 m-20 -98.72 -5.73 30.89 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 120.77 0.319 . . . . 0.0 110.486 179.43 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 8.7 m -88.66 123.56 33.23 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 121.291 0.567 . . . . 0.0 112.017 -176.647 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 60.2 m-85 -121.88 145.53 48.0 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.659 178.805 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 72' ' ' GLU . . . . . 0.434 ' HB2' HD21 ' A' ' 66' ' ' LEU . 71.8 tt0 -100.26 122.56 43.26 Favored 'General case' 0 C--N 1.316 -0.869 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 173.007 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 66.5 t -103.98 132.46 50.4 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.016 0 CA-C-N 115.687 -0.688 . . . . 0.0 111.767 -175.156 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 99.6 mt-10 -127.34 125.75 41.33 Favored 'General case' 0 N--CA 1.446 -0.655 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 177.141 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 75' ' ' ASN . . . . . 0.445 ' HB3' HD12 ' A' ' 59' ' ' ILE . 95.1 m-20 -111.61 155.57 23.16 Favored 'General case' 0 C--N 1.312 -1.065 0 CA-C-O 121.473 0.654 . . . . 0.0 112.427 -177.204 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 76' ' ' GLN . . . . . 0.545 ' O ' ' HB ' ' A' ' 59' ' ' ILE . 33.8 tt0 -117.69 121.65 41.42 Favored 'General case' 0 C--N 1.311 -1.07 0 CA-C-N 114.878 -1.055 . . . . 0.0 110.285 -177.291 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -107.45 107.84 18.89 Favored 'General case' 0 C--N 1.323 -0.548 0 C-N-CA 120.221 -0.592 . . . . 0.0 110.305 176.834 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 174.04 -158.83 27.86 Favored Glycine 0 N--CA 1.439 -1.146 0 N-CA-C 110.586 -1.006 . . . . 0.0 110.586 -178.655 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -96.41 -42.61 3.39 Favored Glycine 0 N--CA 1.441 -1.008 0 C-N-CA 120.113 -1.042 . . . . 0.0 111.496 178.991 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 20.9 t70 -176.3 150.31 0.91 Allowed 'General case' 0 C--O 1.236 0.374 0 C-N-CA 122.56 0.344 . . . . 0.0 110.223 179.641 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 23.2 t 52.79 33.25 13.74 Favored 'General case' 0 CA--C 1.549 0.935 0 C-N-CA 123.057 0.543 . . . . 0.0 112.357 177.257 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -91.59 165.22 21.46 Favored Pre-proline 0 CA--C 1.544 0.746 0 CA-C-N 116.463 -0.335 . . . . 0.0 110.752 -179.392 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 26.9 Cg_exo -62.66 152.57 77.32 Favored 'Trans proline' 0 C--N 1.354 0.856 0 C-N-CA 122.703 2.269 . . . . 0.0 112.521 178.703 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 84' ' ' TRP . . . . . . . . . . . . . 96.2 m95 -98.61 143.12 29.35 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.544 -177.586 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 80.1 m-70 -129.83 141.1 50.88 Favored 'General case' 0 C--N 1.318 -0.761 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 179.298 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 42.1 m -61.38 133.89 56.32 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-O 121.216 0.531 . . . . 0.0 111.42 -178.038 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -105.23 -43.3 1.63 Allowed Glycine 0 N--CA 1.438 -1.198 0 N-CA-C 111.561 -0.616 . . . . 0.0 111.561 178.296 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 153.65 -170.03 32.37 Favored Glycine 0 C--O 1.223 -0.535 0 C-N-CA 120.456 -0.878 . . . . 0.0 112.259 178.349 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 20.2 m120 -110.6 123.11 49.36 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.465 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 44.1 m0 -114.41 152.81 30.95 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-O 121.016 0.436 . . . . 0.0 111.704 -177.363 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 91' ' ' ILE . . . . . 0.435 ' HA ' ' O ' ' A' ' 69' ' ' ASN . 82.8 mt -108.02 112.29 39.6 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.751 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 176.785 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 92' ' ' LEU . . . . . 0.436 ' HB3' HG21 ' A' ' 100' ' ' VAL . 70.0 mt -135.15 73.08 1.46 Allowed 'General case' 0 C--O 1.266 1.972 0 CA-C-O 121.692 0.758 . . . . 0.0 111.835 -175.592 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 93' ' ' GLY . . . . . 0.484 ' HA3' ' OD1' ' A' ' 69' ' ' ASN . . . -153.67 -78.85 0.02 OUTLIER Glycine 0 N--CA 1.447 -0.615 0 C-N-CA 120.228 -0.987 . . . . 0.0 113.278 -178.096 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 57.5 m 69.94 10.29 7.4 Favored 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 123.268 0.627 . . . . 0.0 111.869 -177.784 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 95' ' ' ARG . . . . . 0.721 ' HB2' ' O ' ' A' ' 98' ' ' GLN . 16.8 mmt180 -127.12 141.39 51.77 Favored 'General case' 0 N--CA 1.443 -0.783 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 177.308 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 16.6 pt-20 -67.38 -40.45 85.71 Favored 'General case' 0 C--N 1.311 -1.097 0 N-CA-C 112.96 0.726 . . . . 0.0 112.96 -176.298 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 91.8 m-20 -127.58 28.91 5.58 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 111.912 0.338 . . . . 0.0 111.912 -176.35 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 98' ' ' GLN . . . . . 0.721 ' O ' ' HB2' ' A' ' 95' ' ' ARG . 7.9 tt0 -155.64 132.52 10.61 Favored 'General case' 0 C--N 1.32 -0.688 0 C-N-CA 120.625 -0.43 . . . . 0.0 110.078 -177.946 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 91.3 m-20 -115.3 179.49 3.95 Favored 'General case' 0 C--O 1.26 1.638 0 C-N-CA 120.717 -0.393 . . . . 0.0 111.957 -177.909 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.436 HG21 ' HB3' ' A' ' 92' ' ' LEU . 22.5 m -81.06 143.33 12.48 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.427 0 CA-C-N 115.673 -0.694 . . . . 0.0 111.132 178.945 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 31.2 m -121.51 -36.43 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.694 178.223 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 102' ' ' ALA . . . . . 0.611 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -133.4 130.41 38.7 Favored 'General case' 0 CA--C 1.51 -0.572 0 C-N-CA 119.943 -0.703 . . . . 0.0 111.153 178.76 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 96.5 mt -133.29 122.55 45.17 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.934 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.656 178.862 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 12.0 t30 -126.67 99.27 5.71 Favored 'General case' 0 C--N 1.316 -0.882 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 176.804 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.495 ' CG2' ' HB ' ' A' ' 36' ' ' ILE . 17.8 m -135.21 135.86 51.91 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.146 0 CA-C-N 115.513 -0.767 . . . . 0.0 112.429 -174.787 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 60.2 mt-10 -141.17 142.58 34.02 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.597 -0.728 . . . . 0.0 110.256 179.85 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 35.5 t -140.33 148.65 41.67 Favored 'General case' 0 C--N 1.315 -0.913 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.878 179.366 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -96.29 1.11 62.26 Favored Glycine 0 N--CA 1.444 -0.785 0 N-CA-C 110.769 -0.932 . . . . 0.0 110.769 176.234 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 84.6 m-20 -88.93 179.13 6.25 Favored 'General case' 0 CA--C 1.511 -0.539 0 CA-C-O 120.872 0.368 . . . . 0.0 110.601 -179.635 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 7.8 p-10 -88.83 16.41 6.91 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-O 121.568 0.699 . . . . 0.0 109.602 177.577 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 111' ' ' GLY . . . . . 0.663 ' HA3' ' ND2' ' A' ' 32' ' ' ASN . . . 113.25 7.82 20.45 Favored Glycine 0 N--CA 1.438 -1.232 0 CA-C-N 115.384 -0.826 . . . . 0.0 112.516 -177.526 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 98.6 mt-30 -62.71 -47.91 81.56 Favored 'General case' 0 C--O 1.238 0.45 0 CA-C-O 120.759 0.314 . . . . 0.0 110.363 178.783 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 70.7 p -130.44 155.39 46.5 Favored 'General case' 0 N--CA 1.444 -0.748 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 176.151 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 40.1 tp -136.39 108.38 7.16 Favored 'General case' 0 C--N 1.314 -0.946 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 178.352 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 89.0 m-20 -119.84 155.14 33.2 Favored 'General case' 0 C--N 1.316 -0.882 0 C-N-CA 120.597 -0.441 . . . . 0.0 111.737 -175.484 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 162.34 -136.15 4.21 Favored Glycine 0 N--CA 1.438 -1.176 0 C-N-CA 120.543 -0.837 . . . . 0.0 112.737 178.016 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 26.6 p -130.89 153.28 49.31 Favored 'General case' 0 C--N 1.312 -1.032 0 C-N-CA 122.752 0.421 . . . . 0.0 110.469 -178.343 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 25.6 ptm -143.57 146.23 33.15 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.074 179.899 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 119' ' ' THR . . . . . 0.611 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 36.7 m -129.8 126.6 38.49 Favored 'General case' 0 C--N 1.305 -1.358 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.533 179.294 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 67.0 m-85 -81.18 164.43 22.34 Favored 'General case' 0 CA--C 1.508 -0.645 0 O-C-N 123.716 0.635 . . . . 0.0 109.502 176.172 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -51.54 -31.63 24.96 Favored 'General case' 0 CA--C 1.54 0.586 0 N-CA-C 113.37 0.878 . . . . 0.0 113.37 -178.827 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -155.84 15.93 0.45 Allowed Glycine 0 CA--C 1.519 0.287 0 C-N-CA 119.189 -1.481 . . . . 0.0 114.263 -178.246 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 82.9 tt0 -100.19 -23.74 14.75 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 117.619 0.709 . . . . 0.0 111.327 -179.894 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 115.03 179.67 18.54 Favored Glycine 0 N--CA 1.448 -0.507 0 C-N-CA 120.235 -0.983 . . . . 0.0 112.935 178.039 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -90.39 122.06 0.91 Allowed 'Trans proline' 0 N--CA 1.449 -1.102 0 C-N-CA 123.767 2.978 . . . . 0.0 112.408 179.749 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 41.2 pt -128.53 163.12 33.8 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.803 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.58 179.487 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -70.08 137.01 27.58 Favored Glycine 0 C--O 1.244 0.728 0 CA-C-N 116.188 -0.46 . . . . 0.0 112.165 179.37 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 83.7 t80 -115.25 133.97 55.56 Favored 'General case' 0 C--N 1.316 -0.853 0 C-N-CA 122.51 0.324 . . . . 0.0 110.678 -178.966 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 129' ' ' LYS . . . . . 0.448 ' HB3' ' HB2' ' A' ' 7' ' ' GLU . 86.3 tttt -137.45 114.99 11.17 Favored 'General case' 0 N--CA 1.437 -1.09 0 N-CA-C 109.301 -0.629 . . . . 0.0 109.301 176.53 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 130' ' ' GLY . . . . . 0.512 ' HA2' ' O ' ' A' ' 5' ' ' ASN . . . -115.13 136.02 12.78 Favored Glycine 0 N--CA 1.433 -1.561 0 N-CA-C 111.157 -0.777 . . . . 0.0 111.157 177.837 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 52.5 m -128.7 136.72 50.99 Favored 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -179.905 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 58.3 tp -59.89 126.03 25.96 Favored 'General case' 0 C--N 1.327 -0.379 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 178.538 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 24.5 m . . . . . 0 N--CA 1.439 -1.024 0 CA-C-O 118.745 -0.645 . . . . 0.0 110.776 -178.275 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 0.609 ' O ' ' HG3' ' A' ' 24' ' ' GLU . . . . . . . . 0 N--CA 1.479 1.004 0 N-CA-C 110.144 -0.317 . . . . 0.0 110.144 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 3' ' ' LEU . . . . . 0.427 HD13 ' N ' ' A' ' 4' ' ' TYR . 3.0 tm? -87.3 132.21 34.0 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-O 121.271 0.558 . . . . 0.0 110.713 -175.504 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 4' ' ' TYR . . . . . 0.427 ' N ' HD13 ' A' ' 3' ' ' LEU . 20.0 m-85 -115.45 134.78 54.76 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 115.486 -0.779 . . . . 0.0 111.392 178.542 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 46.6 t-20 -92.9 117.37 29.97 Favored 'General case' 0 C--N 1.309 -1.158 0 N-CA-C 106.992 -1.484 . . . . 0.0 106.992 176.814 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.469 HG12 HD21 ' A' ' 8' ' ' ASN . 58.5 t -102.04 104.89 17.08 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.146 0 CA-C-O 121.146 0.498 . . . . 0.0 112.307 -174.067 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -94.3 137.62 33.24 Favored 'General case' 0 C--N 1.312 -1.028 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 175.931 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' ASN . . . . . 0.469 HD21 HG12 ' A' ' 6' ' ' VAL . 63.2 m-80 -132.69 159.17 40.41 Favored 'General case' 0 C--N 1.314 -0.972 0 CA-C-O 121.627 0.727 . . . . 0.0 112.784 -175.075 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 36.4 tt0 -124.02 106.29 10.27 Favored 'General case' 0 C--N 1.309 -1.166 0 N-CA-C 106.828 -1.545 . . . . 0.0 106.828 173.118 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 1.4 p90 -125.68 0.21 7.45 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 114.056 1.132 . . . . 0.0 114.056 -173.289 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -116.3 21.4 11.9 Favored Glycine 0 N--CA 1.446 -0.647 0 C-N-CA 119.014 -1.565 . . . . 0.0 112.296 -177.74 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 122.14 157.21 9.91 Favored Glycine 0 N--CA 1.441 -1.01 0 C-N-CA 120.8 -0.714 . . . . 0.0 111.99 -179.726 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 21.3 p -59.46 -31.88 69.73 Favored 'General case' 0 C--N 1.317 -0.822 0 C-N-CA 123.018 0.527 . . . . 0.0 112.41 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 17.1 p -81.41 -7.56 59.6 Favored 'General case' 0 C--N 1.32 -0.703 0 N-CA-C 112.26 0.467 . . . . 0.0 112.26 179.449 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -78.99 142.11 59.59 Favored Pre-proline 0 C--N 1.328 -0.353 0 CA-C-O 120.801 0.334 . . . . 0.0 111.255 -178.674 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 64.2 Cg_endo -70.8 165.37 32.38 Favored 'Trans proline' 0 C--O 1.237 0.47 0 C-N-CA 123.084 2.523 . . . . 0.0 112.54 -179.81 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 93.5 m95 -81.69 137.81 35.35 Favored 'General case' 0 N--CA 1.452 -0.354 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.357 -178.731 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 3.1 p30 -145.32 137.78 25.9 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.99 -179.827 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 8.3 pt-20 -93.16 141.37 28.49 Favored 'General case' 0 C--N 1.317 -0.833 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 178.098 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -132.71 26.98 3.57 Favored Glycine 0 N--CA 1.442 -0.956 0 C-N-CA 120.45 -0.881 . . . . 0.0 111.21 179.726 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 154.76 169.34 19.29 Favored Glycine 0 N--CA 1.437 -1.263 0 C-N-CA 120.991 -0.623 . . . . 0.0 111.846 -179.475 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 21.7 pt20 -122.0 132.8 54.71 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-O 120.835 0.35 . . . . 0.0 110.339 179.913 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 40.4 m0 -113.21 172.83 6.71 Favored 'General case' 0 CA--C 1.506 -0.718 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.165 -176.409 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' GLU . . . . . 0.609 ' HG3' ' O ' ' A' ' 2' ' ' ALA . 33.5 tt0 -131.23 114.66 15.34 Favored 'General case' 0 C--N 1.317 -0.837 0 N-CA-C 108.815 -0.809 . . . . 0.0 108.815 173.572 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.44 HG23 HD11 ' A' ' 36' ' ' ILE . 97.7 mt -105.54 -36.81 3.8 Favored 'Isoleucine or valine' 0 C--O 1.199 -1.6 0 CA-C-N 115.138 -0.937 . . . . 0.0 113.156 -173.053 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -109.07 126.98 8.32 Favored Glycine 0 C--N 1.307 -1.078 0 C-N-CA 119.888 -1.149 . . . . 0.0 112.387 -179.858 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 59.6 p -117.19 8.16 13.17 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 111.875 0.324 . . . . 0.0 111.875 -179.883 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 69.1 ttt180 -122.09 135.5 54.81 Favored 'General case' 0 N--CA 1.446 -0.629 0 CA-C-O 121.162 0.506 . . . . 0.0 111.904 -177.153 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 47.9 t -77.35 149.36 35.26 Favored 'General case' 0 N--CA 1.442 -0.846 0 CA-C-N 115.294 -0.866 . . . . 0.0 109.908 176.972 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.453 ' O ' ' HG2' ' A' ' 31' ' ' GLN . 8.9 m-20 59.62 22.71 11.42 Favored 'General case' 0 N--CA 1.479 0.99 0 C-N-CA 123.032 0.533 . . . . 0.0 111.433 176.902 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 31' ' ' GLN . . . . . 0.453 ' HG2' ' O ' ' A' ' 30' ' ' ASP . 4.5 mm-40 -163.06 91.26 0.71 Allowed 'General case' 0 CA--C 1.501 -0.91 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.241 -178.058 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 32' ' ' ASN . . . . . 0.573 ' ND2' ' HA3' ' A' ' 111' ' ' GLY . 63.6 t30 -94.69 162.02 13.95 Favored 'General case' 0 C--N 1.309 -1.174 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.239 -179.01 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 72.6 t -95.57 129.52 45.57 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.201 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.89 -176.51 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 33.0 m -110.39 -13.06 11.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 N-CA-C 112.187 0.439 . . . . 0.0 112.187 179.154 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' ALA . . . . . 0.518 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -156.34 149.36 24.13 Favored 'General case' 0 CA--C 1.517 -0.304 0 C-N-CA 120.464 -0.494 . . . . 0.0 111.851 178.685 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.44 HD11 HG23 ' A' ' 25' ' ' ILE . 88.2 mt -148.54 119.18 1.29 Allowed 'Isoleucine or valine' 0 CA--C 1.513 -0.46 0 N-CA-C 107.935 -1.135 . . . . 0.0 107.935 178.565 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 37' ' ' ASN . . . . . 0.545 ' HA ' ' O ' ' A' ' 103' ' ' ILE . 57.5 m-80 -140.05 74.91 1.48 Allowed 'General case' 0 C--N 1.301 -1.534 0 C-N-CA 120.706 -0.398 . . . . 0.0 110.759 -179.375 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.576 HG11 ' CD1' ' A' ' 61' ' ' PHE . 17.1 m -120.18 171.32 8.74 Favored 'Isoleucine or valine' 0 C--O 1.235 0.319 0 N-CA-C 112.49 0.552 . . . . 0.0 112.49 178.541 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 75.3 tt0 -140.34 153.23 46.33 Favored 'General case' 0 N--CA 1.447 -0.593 0 CA-C-N 115.234 -0.893 . . . . 0.0 109.731 179.213 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 40' ' ' SER . . . . . 0.527 ' OG ' ' HB ' ' A' ' 101' ' ' VAL . 34.6 p -76.95 157.72 31.11 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-O 121.297 0.57 . . . . 0.0 112.487 -177.595 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -105.99 -49.46 0.94 Allowed Glycine 0 N--CA 1.438 -1.224 0 N-CA-C 110.177 -1.169 . . . . 0.0 110.177 174.427 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 18.9 m-20 -102.24 -149.68 0.39 Allowed 'General case' 0 C--N 1.325 -0.48 0 C-N-CA 122.889 0.476 . . . . 0.0 110.502 179.013 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 11.9 m-20 -71.96 38.19 0.07 Allowed 'General case' 0 N--CA 1.484 1.268 0 C-N-CA 123.747 0.819 . . . . 0.0 112.261 -177.988 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 83.69 2.93 89.81 Favored Glycine 0 C--N 1.316 -0.532 0 C-N-CA 120.669 -0.776 . . . . 0.0 111.571 -178.738 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 45' ' ' GLN . . . . . 0.476 ' HA ' ' HB3' ' A' ' 65' ' ' LEU . 62.3 mt-30 -80.5 -28.59 37.44 Favored 'General case' 0 C--O 1.218 -0.559 0 CA-C-O 120.981 0.419 . . . . 0.0 110.66 178.218 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 46' ' ' THR . . . . . 0.409 ' O ' ' HA ' ' A' ' 40' ' ' SER . 22.6 p -118.54 132.49 56.21 Favored 'General case' 0 C--N 1.306 -1.298 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.637 179.877 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 90.5 mt -126.46 132.64 51.4 Favored 'General case' 0 C--N 1.319 -0.759 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 179.754 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.411 ' HA ' ' O ' ' A' ' 61' ' ' PHE . 9.4 p30 -142.65 147.61 36.05 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-O 120.789 0.328 . . . . 0.0 110.585 179.234 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 158.68 -135.05 4.05 Favored Glycine 0 C--N 1.312 -0.786 0 C-N-CA 120.601 -0.809 . . . . 0.0 111.885 178.656 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 24.7 p -130.8 149.23 52.54 Favored 'General case' 0 N--CA 1.452 -0.347 0 CA-C-O 121.175 0.512 . . . . 0.0 111.812 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 51' ' ' MET . . . . . 0.462 ' HG2' ' O ' ' A' ' 35' ' ' ALA . 18.4 tmm? -142.45 148.47 37.81 Favored 'General case' 0 C--N 1.316 -0.853 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 177.399 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.518 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 66.1 m -129.53 127.64 41.17 Favored 'General case' 0 C--O 1.246 0.919 0 N-CA-C 112.385 0.513 . . . . 0.0 112.385 -177.04 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 64.9 m-85 -87.99 161.76 17.22 Favored 'General case' 0 CA--C 1.515 -0.369 0 CA-C-N 115.507 -0.769 . . . . 0.0 109.458 174.46 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -66.71 129.99 41.7 Favored 'General case' 0 C--N 1.315 -0.918 0 N-CA-C 110.04 -0.356 . . . . 0.0 110.04 178.158 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 90.45 -19.99 40.53 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.869 -0.681 . . . . 0.0 113.081 179.228 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 81.5 mm-40 -107.56 170.17 8.14 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 120.736 0.303 . . . . 0.0 110.767 -178.589 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -95.46 -157.89 32.35 Favored Glycine 0 N--CA 1.446 -0.664 0 C-N-CA 120.943 -0.646 . . . . 0.0 112.354 179.52 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_endo -64.3 138.46 60.93 Favored 'Trans proline' 0 C--N 1.345 0.38 0 C-N-CA 122.462 2.108 . . . . 0.0 112.099 179.743 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 59' ' ' ILE . . . . . 0.455 HG23 ' HB3' ' A' ' 77' ' ' TRP . 98.3 mt -132.89 142.5 42.14 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.026 0 CA-C-N 115.578 -0.737 . . . . 0.0 109.771 -179.12 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -73.82 128.27 10.97 Favored Glycine 0 N--CA 1.443 -0.898 0 N-CA-C 110.579 -1.009 . . . . 0.0 110.579 179.058 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.576 ' CD1' HG11 ' A' ' 38' ' ' VAL . 47.5 t80 -114.41 128.08 56.16 Favored 'General case' 0 C--N 1.311 -1.08 0 CA-C-O 120.594 0.235 . . . . 0.0 110.903 -176.177 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 64.9 ttp85 -135.49 129.61 33.39 Favored 'General case' 0 N--CA 1.448 -0.536 0 CA-C-N 116.016 -0.538 . . . . 0.0 109.986 176.024 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -138.94 149.66 45.02 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 120.773 0.321 . . . . 0.0 111.754 -178.517 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 27.6 m -125.35 131.5 52.98 Favored 'General case' 0 CA--C 1.54 0.596 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.359 179.204 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 65' ' ' LEU . . . . . 0.476 ' HB3' ' HA ' ' A' ' 45' ' ' GLN . 3.0 tm? -80.2 113.29 18.26 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 120.981 0.419 . . . . 0.0 110.503 -178.495 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 94.6 mt -88.4 -18.96 27.24 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.498 177.799 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 125.34 167.66 12.59 Favored Glycine 0 N--CA 1.442 -0.959 0 C-N-CA 121.02 -0.609 . . . . 0.0 111.596 179.765 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 94.8 m-20 56.47 36.66 27.91 Favored 'General case' 0 N--CA 1.473 0.721 0 C-N-CA 122.56 0.344 . . . . 0.0 111.707 178.279 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 16.3 m120 66.36 9.66 6.62 Favored 'General case' 0 N--CA 1.48 1.031 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.363 179.644 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 35.1 m -97.88 123.55 41.9 Favored 'General case' 0 C--O 1.24 0.562 0 CA-C-O 121.37 0.605 . . . . 0.0 111.586 -177.537 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.534 ' OH ' ' HB3' ' A' ' 99' ' ' ASN . 59.4 m-85 -112.98 138.51 49.75 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 115.468 -0.787 . . . . 0.0 110.83 -179.613 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 42.5 tt0 -92.52 116.64 29.17 Favored 'General case' 0 N--CA 1.439 -0.976 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 174.786 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 78.2 t -105.03 133.15 50.05 Favored 'Isoleucine or valine' 0 C--O 1.248 1.019 0 N-CA-C 112.75 0.648 . . . . 0.0 112.75 -173.615 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 68.7 mt-10 -133.33 134.42 43.78 Favored 'General case' 0 C--O 1.244 0.772 0 N-CA-C 107.899 -1.148 . . . . 0.0 107.899 175.253 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 92.8 m-20 -119.46 154.43 33.76 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 112.911 0.708 . . . . 0.0 112.911 -173.797 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 35.9 tt0 -132.52 127.76 35.87 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.07 -0.968 . . . . 0.0 108.999 179.389 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 77' ' ' TRP . . . . . 0.455 ' HB3' HG23 ' A' ' 59' ' ' ILE . 37.9 p90 -137.58 157.47 46.44 Favored 'General case' 0 C--N 1.317 -0.835 0 C-N-CA 119.973 -0.691 . . . . 0.0 111.997 -177.046 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 81.19 12.13 82.69 Favored Glycine 0 N--CA 1.453 -0.216 0 CA-C-N 115.4 -0.818 . . . . 0.0 112.465 179.513 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 124.48 175.67 14.4 Favored Glycine 0 N--CA 1.445 -0.709 0 N-CA-C 111.259 -0.736 . . . . 0.0 111.259 -179.582 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 -89.74 -5.19 57.23 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 121.114 0.483 . . . . 0.0 110.373 -179.194 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 33.2 m -79.04 -12.96 60.03 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.413 179.367 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -90.8 128.69 47.21 Favored Pre-proline 0 C--N 1.321 -0.641 0 CA-C-N 116.54 -0.3 . . . . 0.0 110.484 -179.532 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 30.1 Cg_endo -63.21 136.2 54.59 Favored 'Trans proline' 0 N--CA 1.463 -0.289 0 C-N-CA 122.157 1.904 . . . . 0.0 111.736 179.735 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 84' ' ' TRP . . . . . . . . . . . . . 87.0 m95 -51.1 138.67 19.53 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-O 121.302 0.572 . . . . 0.0 112.261 178.667 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 96.1 m-70 -115.11 147.14 40.59 Favored 'General case' 0 C--N 1.314 -0.949 0 CA-C-N 115.325 -0.852 . . . . 0.0 109.299 179.361 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 6.3 m -58.37 148.59 27.26 Favored 'General case' 0 C--N 1.316 -0.851 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.629 179.004 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -124.32 -54.44 0.18 Allowed Glycine 0 N--CA 1.44 -1.065 0 N-CA-C 110.552 -1.019 . . . . 0.0 110.552 -179.591 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 149.48 -165.95 29.58 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.605 -0.807 . . . . 0.0 112.353 176.788 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 92.4 m-20 -110.66 118.45 36.22 Favored 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 109.346 -0.613 . . . . 0.0 109.346 178.362 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 32.8 m0 -110.38 150.67 28.47 Favored 'General case' 0 C--N 1.313 -0.993 0 CA-C-N 116.559 -0.292 . . . . 0.0 110.707 -177.374 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 83.3 mt -105.6 115.17 46.83 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.937 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 177.965 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 92' ' ' LEU . . . . . 0.51 ' HB3' HG21 ' A' ' 100' ' ' VAL . 82.2 mt -131.53 80.5 1.93 Allowed 'General case' 0 C--O 1.27 2.182 0 CA-C-O 121.945 0.879 . . . . 0.0 112.589 -174.638 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 165.73 119.63 0.49 Allowed Glycine 0 N--CA 1.441 -0.993 0 CA-C-N 114.935 -1.029 . . . . 0.0 111.5 178.678 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 83.9 p -89.81 -1.54 58.02 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.34 0.59 . . . . 0.0 110.173 178.519 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 23.8 mtp180 -109.12 138.4 45.52 Favored 'General case' 0 N--CA 1.435 -1.181 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 178.884 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 72.5 tt0 -73.0 -38.26 66.67 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-O 121.354 0.597 . . . . 0.0 111.326 -173.324 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 53.5 m-80 -110.6 28.75 8.37 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.343 -177.934 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 98' ' ' GLN . . . . . . . . . . . . . 8.6 tt0 -156.96 125.2 5.61 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.119 0.485 . . . . 0.0 110.467 -177.545 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 99' ' ' ASN . . . . . 0.534 ' HB3' ' OH ' ' A' ' 71' ' ' TYR . 91.6 m-20 -104.64 169.69 8.32 Favored 'General case' 0 C--O 1.251 1.136 0 CA-C-N 115.647 -0.706 . . . . 0.0 111.949 -174.319 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.51 HG21 ' HB3' ' A' ' 92' ' ' LEU . 26.4 m -83.73 151.8 3.89 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.433 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.918 177.886 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 101' ' ' VAL . . . . . 0.527 ' HB ' ' OG ' ' A' ' 40' ' ' SER . 33.8 m -123.45 -29.66 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 C-N-CA 120.909 -0.316 . . . . 0.0 111.49 177.416 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 102' ' ' ALA . . . . . 0.585 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -140.56 135.34 31.72 Favored 'General case' 0 C--N 1.317 -0.828 0 C-N-CA 120.197 -0.601 . . . . 0.0 111.13 179.07 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.545 ' O ' ' HA ' ' A' ' 37' ' ' ASN . 88.6 mt -128.41 121.47 55.45 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.044 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 178.447 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 8.1 t30 -127.8 95.07 4.11 Favored 'General case' 0 C--N 1.325 -0.463 0 O-C-N 123.908 0.755 . . . . 0.0 109.48 -179.296 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.484 HG11 ' CD2' ' A' ' 128' ' ' PHE . 31.7 m -143.65 148.58 18.83 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 N-CA-C 112.672 0.619 . . . . 0.0 112.672 -175.293 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 69.8 tt0 -150.05 154.32 37.95 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.335 -0.848 . . . . 0.0 109.553 174.863 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 44.3 t -136.28 150.8 49.09 Favored 'General case' 0 C--N 1.31 -1.146 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.107 -178.846 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -97.2 1.79 60.92 Favored Glycine 0 N--CA 1.44 -1.069 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 174.479 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -98.56 -172.68 2.37 Favored 'General case' 0 CA--C 1.507 -0.703 0 N-CA-C 109.596 -0.52 . . . . 0.0 109.596 179.716 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 10.4 p-10 -92.47 32.76 1.17 Allowed 'General case' 0 C--N 1.312 -1.028 0 CA-C-O 121.435 0.636 . . . . 0.0 109.559 176.147 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 111' ' ' GLY . . . . . 0.573 ' HA3' ' ND2' ' A' ' 32' ' ' ASN . . . 94.81 9.24 58.72 Favored Glycine 0 N--CA 1.445 -0.719 0 CA-C-N 115.618 -0.719 . . . . 0.0 113.271 -179.347 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 112' ' ' GLN . . . . . 0.519 ' HA ' ' CD1' ' A' ' 132' ' ' LEU . 97.1 mt-30 -65.08 -50.69 65.16 Favored 'General case' 0 C--O 1.24 0.593 0 CA-C-O 120.96 0.409 . . . . 0.0 111.072 179.289 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 40.2 p -129.49 130.33 45.7 Favored 'General case' 0 N--CA 1.444 -0.751 0 CA-C-N 115.899 -0.591 . . . . 0.0 109.844 178.56 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 88.6 mt -108.85 125.44 51.98 Favored 'General case' 0 C--N 1.31 -1.149 0 N-CA-C 110.075 -0.343 . . . . 0.0 110.075 179.781 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 15.7 m120 -109.84 136.37 49.25 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.173 -178.768 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 116' ' ' GLY . . . . . 0.435 ' HA3' HG12 ' A' ' 105' ' ' VAL . . . 167.33 -145.56 9.93 Favored Glycine 0 N--CA 1.439 -1.136 0 C-N-CA 119.074 -1.536 . . . . 0.0 113.584 176.408 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 26.9 p -139.17 161.58 37.05 Favored 'General case' 0 C--N 1.314 -0.951 0 C-N-CA 123.211 0.605 . . . . 0.0 110.699 -177.987 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 118' ' ' MET . . . . . 0.55 ' O ' ' HA ' ' A' ' 125' ' ' PRO . 18.4 ptp -140.28 148.59 41.66 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.303 -0.408 . . . . 0.0 109.968 178.776 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 119' ' ' THR . . . . . 0.585 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 27.7 m -128.78 130.53 47.14 Favored 'General case' 0 C--N 1.313 -0.998 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 177.973 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 120' ' ' TYR . . . . . 0.586 ' HB2' ' HB3' ' A' ' 123' ' ' GLU . 38.4 m-85 -96.56 173.08 7.52 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.006 0.431 . . . . 0.0 112.037 -179.945 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 121' ' ' ALA . . . . . 0.416 ' HA ' HG11 ' A' ' 101' ' ' VAL . . . -55.51 -36.57 66.83 Favored 'General case' 0 CA--C 1.533 0.298 0 CA-C-N 115.396 -0.82 . . . . 0.0 112.859 -178.43 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -144.2 46.01 0.84 Allowed Glycine 0 CA--C 1.506 -0.522 0 C-N-CA 120.388 -0.91 . . . . 0.0 111.668 -179.321 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 123' ' ' GLU . . . . . 0.586 ' HB3' ' HB2' ' A' ' 120' ' ' TYR . 76.1 tt0 -151.62 144.66 24.55 Favored 'General case' 0 C--N 1.315 -0.894 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 -178.032 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -68.01 160.29 50.59 Favored Glycine 0 CA--C 1.518 0.246 0 C-N-CA 121.153 -0.546 . . . . 0.0 113.002 -177.512 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 125' ' ' PRO . . . . . 0.55 ' HA ' ' O ' ' A' ' 118' ' ' MET . 30.2 Cg_endo -63.15 136.65 57.21 Favored 'Trans proline' 0 C--N 1.348 0.537 0 C-N-CA 122.416 2.077 . . . . 0.0 111.994 179.701 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 44.0 pt -129.47 165.1 30.27 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.913 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.567 -179.133 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -73.09 132.44 16.89 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 121.053 -0.594 . . . . 0.0 112.145 -179.18 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 128' ' ' PHE . . . . . 0.484 ' CD2' HG11 ' A' ' 105' ' ' VAL . 49.9 t80 -114.92 131.29 56.93 Favored 'General case' 0 C--O 1.245 0.862 0 C-N-CA 122.937 0.495 . . . . 0.0 111.793 -177.798 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 62.5 tttm -133.13 97.35 3.97 Favored 'General case' 0 N--CA 1.441 -0.89 0 CA-C-N 115.249 -0.887 . . . . 0.0 109.687 175.658 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -91.81 130.84 10.49 Favored Glycine 0 CA--C 1.502 -0.738 0 N-CA-C 111.06 -0.816 . . . . 0.0 111.06 179.917 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 28.2 m -128.5 133.94 48.58 Favored 'General case' 0 C--N 1.311 -1.093 0 CA-C-N 117.282 0.541 . . . . 0.0 110.461 -178.376 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 132' ' ' LEU . . . . . 0.519 ' CD1' ' HA ' ' A' ' 112' ' ' GLN . 80.3 mt -57.12 134.34 55.79 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-O 121.001 0.429 . . . . 0.0 110.962 177.784 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 24.1 m . . . . . 0 C--O 1.251 1.152 0 CA-C-O 118.123 -0.941 . . . . 0.0 109.61 179.682 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.701 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 3.3 tm? -98.23 132.53 43.66 Favored 'General case' 0 C--N 1.317 -0.805 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 -178.772 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 4' ' ' TYR . . . . . 0.459 ' CE1' ' HB ' ' A' ' 25' ' ' ILE . 96.9 m-85 -125.9 150.06 48.22 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-O 121.153 0.501 . . . . 0.0 111.256 -179.668 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 10.1 m-80 -99.0 136.56 38.79 Favored 'General case' 0 C--N 1.318 -0.791 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 174.728 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.461 HG21 ' CG ' ' A' ' 23' ' ' TRP . 53.6 t -115.87 129.83 71.57 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 N-CA-C 114.007 1.114 . . . . 0.0 114.007 -172.953 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.477 ' HA ' ' HA ' ' A' ' 19' ' ' GLU . 78.4 mt-10 -114.27 134.33 55.02 Favored 'General case' 0 N--CA 1.437 -1.09 0 CA-C-N 113.999 -1.455 . . . . 0.0 107.97 176.038 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 86.1 m-20 -116.07 136.15 53.28 Favored 'General case' 0 C--N 1.315 -0.918 0 CA-C-O 120.635 0.255 . . . . 0.0 110.517 -178.949 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' GLN . . . . . 0.53 ' HB2' ' CE3' ' A' ' 17' ' ' TRP . 58.6 tt0 -112.39 122.1 46.74 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.827 -178.166 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 15.0 p90 -139.47 141.87 37.39 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.912 -0.585 . . . . 0.0 109.654 175.079 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 127.62 2.21 6.33 Favored Glycine 0 N--CA 1.443 -0.862 0 C-N-CA 120.657 -0.782 . . . . 0.0 111.59 -179.234 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 82.03 -156.69 36.35 Favored Glycine 0 N--CA 1.445 -0.766 0 C-N-CA 121.161 -0.542 . . . . 0.0 113.892 178.776 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 8.1 m -54.45 137.54 42.27 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-N 115.011 -0.594 . . . . 0.0 111.8 179.659 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 21.0 m 64.08 18.92 11.52 Favored 'General case' 0 N--CA 1.469 0.511 0 N-CA-C 113.131 0.789 . . . . 0.0 113.131 177.616 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -79.93 140.28 54.04 Favored Pre-proline 0 C--N 1.322 -0.597 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 177.209 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 69.9 Cg_endo -71.13 158.73 54.22 Favored 'Trans proline' 0 C--O 1.238 0.505 0 C-N-CA 122.495 2.13 . . . . 0.0 112.287 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' TRP . . . . . 0.53 ' CE3' ' HB2' ' A' ' 9' ' ' GLN . 91.7 m95 -92.94 128.78 38.92 Favored 'General case' 0 C--N 1.314 -0.965 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 179.076 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 88.9 m-20 -116.37 117.12 29.07 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-N 116.7 -0.227 . . . . 0.0 110.691 -177.573 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.477 ' HA ' ' HA ' ' A' ' 7' ' ' GLU . 11.2 pt-20 -72.27 135.55 46.03 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 177.669 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -142.87 26.16 2.23 Favored Glycine 0 N--CA 1.44 -1.074 0 C-N-CA 119.375 -1.393 . . . . 0.0 113.266 179.302 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 149.85 -176.04 28.7 Favored Glycine 0 N--CA 1.447 -0.567 0 C-N-CA 119.531 -1.318 . . . . 0.0 113.583 -179.832 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 27.6 pt20 -131.32 136.97 48.57 Favored 'General case' 0 C--N 1.325 -0.478 0 C-N-CA 122.603 0.361 . . . . 0.0 110.425 -178.728 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' TRP . . . . . 0.461 ' CG ' HG21 ' A' ' 6' ' ' VAL . 29.3 m0 -112.58 154.64 25.68 Favored 'General case' 0 CA--C 1.504 -0.826 0 N-CA-C 110.126 -0.324 . . . . 0.0 110.126 179.406 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 69.5 tt0 -117.89 114.16 22.82 Favored 'General case' 0 C--N 1.31 -1.111 0 C-N-CA 119.772 -0.771 . . . . 0.0 109.085 176.185 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.459 ' HB ' ' CE1' ' A' ' 4' ' ' TYR . 96.8 mt -127.0 135.76 62.74 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.598 -175.486 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 113.5 165.13 15.89 Favored Glycine 0 N--CA 1.438 -1.183 0 C-N-CA 120.667 -0.778 . . . . 0.0 112.721 176.838 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 58.5 m -134.63 -55.77 0.84 Allowed 'General case' 0 C--N 1.309 -1.163 0 N-CA-C 108.793 -0.817 . . . . 0.0 108.793 179.454 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 93.4 mtt-85 -80.36 137.09 36.51 Favored 'General case' 0 N--CA 1.448 -0.551 0 CA-C-N 115.506 -0.77 . . . . 0.0 109.164 176.403 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 24.8 m -89.03 -19.98 24.95 Favored 'General case' 0 C--N 1.314 -0.95 0 CA-C-O 121.257 0.551 . . . . 0.0 110.884 -179.379 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 17.3 m-20 -95.68 1.01 53.3 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.781 -0.645 . . . . 0.0 111.407 -178.948 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' GLN . . . . . 0.46 ' OE1' ' HB3' ' A' ' 53' ' ' TYR . 0.4 OUTLIER -141.65 112.41 7.21 Favored 'General case' 0 C--N 1.321 -0.67 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 178.966 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 4.5 t-20 -95.2 161.2 14.2 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-O 120.958 0.409 . . . . 0.0 111.497 -176.088 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.432 ' HA ' ' HA ' ' A' ' 53' ' ' TYR . 59.6 t -98.77 134.58 37.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 C-N-CA 123.204 0.602 . . . . 0.0 110.151 -179.146 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.405 HG13 ' HB2' ' A' ' 54' ' ' ALA . 23.8 m -112.72 -15.22 10.4 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.545 0 N-CA-C 112.548 0.573 . . . . 0.0 112.548 -179.319 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 35' ' ' ALA . . . . . 0.509 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -147.8 143.85 27.78 Favored 'General case' 0 C--O 1.239 0.52 0 C-N-CA 120.228 -0.589 . . . . 0.0 111.52 177.597 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.41 ' HB ' ' CG2' ' A' ' 105' ' ' VAL . 94.8 mt -141.84 124.96 15.06 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 -179.772 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 16.8 t30 -133.4 112.5 11.64 Favored 'General case' 0 C--N 1.311 -1.068 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 177.951 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.469 HG22 ' HB ' ' A' ' 103' ' ' ILE . 19.7 m -146.37 147.83 17.66 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.775 0 N-CA-C 112.202 0.445 . . . . 0.0 112.202 -174.388 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 69.2 tt0 -131.02 143.2 50.53 Favored 'General case' 0 CA--C 1.536 0.404 0 CA-C-N 115.692 -0.685 . . . . 0.0 109.629 176.768 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' SER . . . . . 0.416 ' HA ' ' O ' ' A' ' 46' ' ' THR . 22.1 p -71.13 147.64 48.2 Favored 'General case' 0 C--N 1.319 -0.754 0 N-CA-C 112.441 0.534 . . . . 0.0 112.441 179.633 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -97.87 -48.69 1.89 Allowed Glycine 0 N--CA 1.45 -0.403 0 N-CA-C 110.515 -1.034 . . . . 0.0 110.515 176.597 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 6.9 m-20 -97.26 -168.07 1.64 Allowed 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 175.783 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 28.3 m-20 -74.93 59.83 0.93 Allowed 'General case' 0 N--CA 1.469 0.501 0 CA-C-O 121.133 0.492 . . . . 0.0 111.947 -179.543 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 82.77 11.6 81.34 Favored Glycine 0 N--CA 1.452 -0.268 0 CA-C-N 115.976 -0.556 . . . . 0.0 112.75 177.477 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 63.1 tt0 -97.08 -30.51 13.0 Favored 'General case' 0 C--O 1.215 -0.715 0 C-N-CA 120.784 -0.366 . . . . 0.0 111.314 179.701 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 46' ' ' THR . . . . . 0.416 ' O ' ' HA ' ' A' ' 40' ' ' SER . 31.0 p -124.04 147.36 47.9 Favored 'General case' 0 C--N 1.308 -1.203 0 C-N-CA 120.818 -0.353 . . . . 0.0 110.801 -179.806 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 47' ' ' LEU . . . . . 0.526 ' HB2' ' HB3' ' A' ' 63' ' ' ALA . 94.1 mt -133.28 129.47 37.65 Favored 'General case' 0 C--N 1.318 -0.79 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 -179.7 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 51.3 m-80 -127.16 140.75 52.04 Favored 'General case' 0 C--N 1.311 -1.101 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 177.565 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 49' ' ' GLY . . . . . 0.433 ' HA3' HG12 ' A' ' 38' ' ' VAL . . . 177.22 -157.75 22.8 Favored Glycine 0 N--CA 1.438 -1.197 0 C-N-CA 119.4 -1.381 . . . . 0.0 113.541 179.904 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 44.6 m -126.23 129.96 49.98 Favored 'General case' 0 N--CA 1.44 -0.973 0 CA-C-N 115.302 -0.449 . . . . 0.0 110.239 -177.272 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 19.0 ttm -110.78 141.93 43.43 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 109.69 -0.485 . . . . 0.0 109.69 179.089 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.509 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 36.2 m -126.29 122.38 35.33 Favored 'General case' 0 C--O 1.254 1.29 0 CA-C-O 120.956 0.408 . . . . 0.0 111.233 178.019 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 53' ' ' TYR . . . . . 0.561 ' HB2' ' HB2' ' A' ' 56' ' ' GLU . 78.6 m-85 -85.92 164.3 17.53 Favored 'General case' 0 C--O 1.231 0.127 0 CA-C-N 115.404 -0.816 . . . . 0.0 110.702 178.891 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 54' ' ' ALA . . . . . 0.405 ' HB2' HG13 ' A' ' 34' ' ' VAL . . . -69.58 105.44 2.67 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.895 -179.515 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 86.44 8.43 77.61 Favored Glycine 0 CA--C 1.518 0.236 0 C-N-CA 121.013 -0.613 . . . . 0.0 112.943 176.711 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 56' ' ' GLU . . . . . 0.561 ' HB2' ' HB2' ' A' ' 53' ' ' TYR . 78.6 mm-40 -122.12 165.56 15.9 Favored 'General case' 0 C--N 1.315 -0.893 0 N-CA-C 110.012 -0.366 . . . . 0.0 110.012 -179.003 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -77.7 161.96 50.16 Favored Glycine 0 N--CA 1.446 -0.683 0 C-N-CA 120.663 -0.779 . . . . 0.0 112.086 178.51 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -72.73 145.87 42.03 Favored 'Trans proline' 0 C--O 1.241 0.645 0 C-N-CA 122.811 2.341 . . . . 0.0 112.716 179.835 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 59' ' ' ILE . . . . . 0.542 ' HB ' ' O ' ' A' ' 76' ' ' GLN . 49.7 pt -128.86 165.83 27.72 Favored 'Isoleucine or valine' 0 C--O 1.242 0.687 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.653 179.888 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -77.13 134.84 15.47 Favored Glycine 0 C--O 1.239 0.459 0 C-N-CA 120.897 -0.668 . . . . 0.0 111.819 -179.347 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.429 ' CD2' HG11 ' A' ' 38' ' ' VAL . 72.1 t80 -117.43 127.49 54.07 Favored 'General case' 0 C--O 1.237 0.443 0 C-N-CA 122.429 0.291 . . . . 0.0 111.24 -177.556 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 50.2 ttm-85 -130.29 127.75 40.14 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.016 -0.538 . . . . 0.0 109.86 176.699 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.526 ' HB3' ' HB2' ' A' ' 47' ' ' LEU . . . -132.05 139.87 48.69 Favored 'General case' 0 C--N 1.319 -0.741 0 C-N-CA 120.796 -0.362 . . . . 0.0 111.819 178.529 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 46.7 m -122.28 127.02 49.38 Favored 'General case' 0 CA--C 1.54 0.568 0 CA-C-N 115.879 -0.601 . . . . 0.0 110.005 178.201 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -74.5 119.77 19.15 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-O 121.053 0.454 . . . . 0.0 110.678 -178.118 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 91.7 mt -94.43 -25.14 17.04 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.669 -0.696 . . . . 0.0 109.962 178.368 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 134.57 157.5 8.14 Favored Glycine 0 N--CA 1.44 -1.044 0 CA-C-N 115.675 -0.693 . . . . 0.0 111.882 179.638 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 92.4 m-20 56.69 34.33 24.37 Favored 'General case' 0 N--CA 1.481 1.114 0 C-N-CA 122.463 0.305 . . . . 0.0 111.469 179.2 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 49.1 m-80 70.15 10.49 7.36 Favored 'General case' 0 N--CA 1.481 1.087 0 C-N-CA 123.522 0.729 . . . . 0.0 112.415 -179.407 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 55.8 m -87.72 122.31 31.22 Favored 'General case' 0 C--O 1.236 0.376 0 N-CA-C 110.015 -0.365 . . . . 0.0 110.015 177.959 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.562 ' OH ' ' HB3' ' A' ' 99' ' ' ASN . 70.8 m-85 -115.44 129.96 56.73 Favored 'General case' 0 C--N 1.311 -1.065 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.217 -179.643 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 52.2 tp10 -85.31 118.82 25.09 Favored 'General case' 0 N--CA 1.438 -1.064 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 174.992 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 68.0 t -106.98 132.75 53.52 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.23 0 N-CA-C 112.937 0.717 . . . . 0.0 112.937 -173.427 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -123.72 142.85 50.69 Favored 'General case' 0 N--CA 1.446 -0.645 0 N-CA-C 107.273 -1.381 . . . . 0.0 107.273 175.801 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 93.4 m-20 -134.71 161.24 35.71 Favored 'General case' 0 C--N 1.316 -0.851 0 C-N-CA 120.869 -0.332 . . . . 0.0 111.291 -174.964 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 76' ' ' GLN . . . . . 0.542 ' O ' ' HB ' ' A' ' 59' ' ' ILE . 2.9 pt20 -130.64 129.99 43.38 Favored 'General case' 0 C--O 1.239 0.543 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.159 177.006 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 6.6 p90 -133.96 151.19 51.38 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.91 -178.408 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 98.12 -1.96 59.45 Favored Glycine 0 N--CA 1.448 -0.54 0 C-N-CA 120.713 -0.756 . . . . 0.0 111.871 -179.614 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 140.99 164.62 9.99 Favored Glycine 0 N--CA 1.441 -1.031 0 C-N-CA 121.054 -0.593 . . . . 0.0 112.2 179.072 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -65.54 -33.0 74.89 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-O 121.248 0.546 . . . . 0.0 110.473 179.44 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 32.5 p -79.85 6.87 9.95 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.257 -0.883 . . . . 0.0 112.459 -178.055 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -83.89 146.64 49.56 Favored Pre-proline 0 C--N 1.316 -0.89 0 CA-C-N 116.698 -0.228 . . . . 0.0 110.527 179.668 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -67.92 173.73 8.8 Favored 'Trans proline' 0 C--N 1.345 0.353 0 C-N-CA 122.459 2.106 . . . . 0.0 111.604 178.855 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 84' ' ' TRP . . . . . . . . . . . . . 95.2 m95 -98.37 127.72 44.43 Favored 'General case' 0 N--CA 1.444 -0.751 0 CA-C-O 121.172 0.51 . . . . 0.0 110.248 -177.666 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 97.3 m-70 -115.7 149.69 38.0 Favored 'General case' 0 C--N 1.31 -1.116 0 CA-C-N 115.398 -0.819 . . . . 0.0 110.323 -177.629 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 10.0 m -61.53 130.25 45.06 Favored 'General case' 0 C--N 1.315 -0.925 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.833 -179.562 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -105.08 -52.68 0.82 Allowed Glycine 0 N--CA 1.439 -1.107 0 C-N-CA 120.913 -0.66 . . . . 0.0 111.634 179.43 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 155.68 -172.52 33.75 Favored Glycine 0 C--O 1.22 -0.753 0 C-N-CA 120.596 -0.811 . . . . 0.0 111.774 179.605 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 21.2 t-20 -110.28 112.08 23.8 Favored 'General case' 0 C--N 1.313 -1.009 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 179.512 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 27.4 m0 -102.4 149.8 23.99 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.993 -177.749 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 47.4 mm -107.17 114.02 45.04 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 177.247 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 92' ' ' LEU . . . . . 0.414 ' HB2' ' CE1' ' A' ' 71' ' ' TYR . 85.0 mt -124.25 89.25 3.05 Favored 'General case' 0 C--O 1.272 2.279 0 CA-C-O 121.725 0.774 . . . . 0.0 112.691 -175.796 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 154.86 116.91 0.58 Allowed Glycine 0 N--CA 1.443 -0.876 0 CA-C-N 115.0 -1.0 . . . . 0.0 111.676 178.911 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 94' ' ' SER . . . . . 0.436 ' N ' ' HE1' ' A' ' 23' ' ' TRP . 76.8 p -86.0 -15.28 41.95 Favored 'General case' 0 CA--C 1.516 -0.355 0 CA-C-O 121.395 0.617 . . . . 0.0 109.913 178.849 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 58.4 mtt-85 -88.91 141.85 28.14 Favored 'General case' 0 N--CA 1.435 -1.185 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.004 -179.93 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 8.9 pt-20 -68.65 -33.11 73.43 Favored 'General case' 0 C--N 1.31 -1.117 0 CA-C-N 115.53 -0.759 . . . . 0.0 111.975 -175.376 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 31.3 p-10 -120.75 28.66 7.82 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 111.788 0.292 . . . . 0.0 111.788 -178.117 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 98' ' ' GLN . . . . . 0.704 HE21 ' HG2' ' A' ' 123' ' ' GLU . 2.3 mm-40 -142.78 118.48 10.46 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 112.326 0.491 . . . . 0.0 112.326 -176.672 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 99' ' ' ASN . . . . . 0.562 ' HB3' ' OH ' ' A' ' 71' ' ' TYR . 93.2 m-20 -89.36 157.86 18.01 Favored 'General case' 0 C--O 1.262 1.755 0 CA-C-N 115.724 -0.671 . . . . 0.0 111.166 177.673 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.445 HG21 ' CH2' ' A' ' 23' ' ' TRP . 85.9 t -84.35 134.14 27.66 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.594 0 CA-C-N 115.355 -0.839 . . . . 0.0 111.705 178.445 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 35.8 m -110.66 -29.03 2.49 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.397 0 CA-C-N 116.035 -0.529 . . . . 0.0 112.275 179.765 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 102' ' ' ALA . . . . . 0.516 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -146.24 139.37 25.77 Favored 'General case' 0 C--N 1.323 -0.585 0 C-N-CA 120.2 -0.6 . . . . 0.0 111.144 179.056 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.469 ' HB ' HG22 ' A' ' 38' ' ' VAL . 94.9 mt -131.62 124.95 55.19 Favored 'Isoleucine or valine' 0 C--O 1.244 0.771 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.57 177.796 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 41.2 t30 -125.17 94.56 4.2 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 115.676 -0.693 . . . . 0.0 109.3 175.586 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.41 ' CG2' ' HB ' ' A' ' 36' ' ' ILE . 29.3 m -133.6 135.82 55.2 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 N-CA-C 112.859 0.689 . . . . 0.0 112.859 -176.538 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 75.3 tt0 -140.15 137.55 34.51 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.415 -0.811 . . . . 0.0 110.13 179.639 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 23.2 t -146.93 145.37 29.77 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 116.468 -0.333 . . . . 0.0 110.459 177.211 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -109.18 17.07 32.12 Favored Glycine 0 N--CA 1.447 -0.609 0 C-N-CA 121.11 -0.567 . . . . 0.0 112.435 -179.195 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 40.3 p-10 -91.91 -153.61 0.34 Allowed 'General case' 0 C--N 1.319 -0.753 0 CA-C-O 120.768 0.318 . . . . 0.0 110.158 179.098 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 37.1 t70 -88.94 12.86 14.19 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-O 121.167 0.508 . . . . 0.0 110.071 179.108 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 85.7 7.39 81.68 Favored Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 120.684 -0.769 . . . . 0.0 111.939 -177.173 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 36.5 tt0 -66.57 -38.78 87.79 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-O 121.109 0.481 . . . . 0.0 110.526 -179.671 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 113' ' ' THR . . . . . 0.418 ' HA ' ' O ' ' A' ' 130' ' ' GLY . 27.5 p -124.63 131.73 53.46 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-N 115.906 -0.588 . . . . 0.0 111.056 179.224 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -109.94 113.32 25.96 Favored 'General case' 0 C--N 1.315 -0.927 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 177.999 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 93.8 m-20 -117.23 147.5 42.46 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-O 121.016 0.436 . . . . 0.0 111.26 -177.941 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 159.57 -135.61 4.22 Favored Glycine 0 N--CA 1.434 -1.457 0 C-N-CA 120.458 -0.877 . . . . 0.0 112.906 177.717 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 20.8 p -134.04 157.97 44.76 Favored 'General case' 0 C--N 1.31 -1.143 0 C-N-CA 122.905 0.482 . . . . 0.0 110.316 -177.786 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 118' ' ' MET . . . . . 0.41 ' HE1' ' CZ ' ' A' ' 120' ' ' TYR . 17.3 ptm -149.63 155.24 39.92 Favored 'General case' 0 C--N 1.312 -1.063 0 CA-C-N 116.498 -0.319 . . . . 0.0 110.391 -179.672 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 119' ' ' THR . . . . . 0.516 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 27.9 m -130.76 128.11 40.11 Favored 'General case' 0 C--O 1.249 1.055 0 CA-C-N 116.474 -0.33 . . . . 0.0 111.224 179.804 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 120' ' ' TYR . . . . . 0.41 ' CZ ' ' HE1' ' A' ' 118' ' ' MET . 31.0 m-85 -89.85 166.02 13.77 Favored 'General case' 0 CA--C 1.507 -0.687 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.294 175.975 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -66.47 45.38 0.03 OUTLIER 'General case' 0 CA--C 1.554 1.126 0 N-CA-C 114.043 1.127 . . . . 0.0 114.043 179.79 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 142.44 -25.63 2.31 Favored Glycine 0 C--N 1.334 0.429 0 C-N-CA 119.874 -1.155 . . . . 0.0 114.405 175.372 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 123' ' ' GLU . . . . . 0.704 ' HG2' HE21 ' A' ' 98' ' ' GLN . 69.4 mm-40 -67.33 -33.36 75.09 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 117.311 0.556 . . . . 0.0 112.424 -177.585 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 115.09 161.69 13.34 Favored Glycine 0 CA--C 1.519 0.334 0 C-N-CA 120.585 -0.817 . . . . 0.0 112.361 -179.542 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 20.8 Cg_exo -67.11 129.36 20.39 Favored 'Trans proline' 0 C--N 1.351 0.673 0 C-N-CA 122.782 2.321 . . . . 0.0 111.991 178.386 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 37.4 pt -135.44 161.73 38.71 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.691 179.592 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -69.8 139.25 31.17 Favored Glycine 0 C--O 1.239 0.453 0 C-N-CA 120.923 -0.656 . . . . 0.0 112.26 178.948 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 86.4 t80 -119.52 133.71 55.55 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 120.745 0.307 . . . . 0.0 111.233 -178.465 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 129' ' ' LYS . . . . . 0.427 ' HB3' ' HB2' ' A' ' 7' ' ' GLU . 63.6 tttm -140.99 118.12 11.27 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.911 -0.586 . . . . 0.0 109.519 176.718 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 130' ' ' GLY . . . . . 0.418 ' O ' ' HA ' ' A' ' 113' ' ' THR . . . -122.18 141.96 14.63 Favored Glycine 0 N--CA 1.449 -0.475 0 C-N-CA 120.735 -0.745 . . . . 0.0 111.941 -179.643 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 62.1 m -128.11 135.65 50.08 Favored 'General case' 0 C--N 1.317 -0.818 0 CA-C-N 116.619 0.21 . . . . 0.0 111.392 -179.585 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 132' ' ' LEU . . . . . 0.401 HD13 ' N ' ' A' ' 133' ' ' THR . 3.4 tm? -57.79 138.26 55.77 Favored 'General case' 0 N--CA 1.467 0.392 0 C-N-CA 123.062 0.545 . . . . 0.0 110.391 179.723 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 133' ' ' THR . . . . . 0.401 ' N ' HD13 ' A' ' 132' ' ' LEU . 24.0 m . . . . . 0 C--O 1.247 0.964 0 CA-C-O 118.503 -0.761 . . . . 0.0 110.322 -178.577 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.238 0.449 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -90.76 128.68 36.77 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-O 120.855 0.359 . . . . 0.0 110.099 -179.914 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 4' ' ' TYR . . . . . 0.424 ' CD1' ' HB ' ' A' ' 25' ' ' ILE . 57.4 m-85 -119.65 143.07 47.91 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.142 178.1 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 12.9 m-80 -97.24 135.52 39.05 Favored 'General case' 0 C--N 1.309 -1.159 0 N-CA-C 108.394 -0.965 . . . . 0.0 108.394 175.689 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 53.5 t -111.36 126.65 68.76 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.862 0 CA-C-O 121.803 0.811 . . . . 0.0 112.627 -174.769 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.452 ' HG2' ' HB3' ' A' ' 19' ' ' GLU . 63.6 mt-10 -118.82 133.18 56.02 Favored 'General case' 0 N--CA 1.438 -1.047 0 CA-C-N 114.684 -1.144 . . . . 0.0 108.5 176.665 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 8' ' ' ASN . . . . . 0.45 ' HA ' ' O ' ' A' ' 127' ' ' GLY . 89.3 m-20 -117.89 139.76 50.67 Favored 'General case' 0 C--N 1.313 -1.004 0 CA-C-O 121.072 0.463 . . . . 0.0 111.424 -176.641 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 9' ' ' GLN . . . . . 0.445 ' HB2' ' CE3' ' A' ' 17' ' ' TRP . 28.1 tt0 -132.6 125.86 31.43 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.059 179.131 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 24.1 p90 -128.98 141.29 51.3 Favored 'General case' 0 C--N 1.316 -0.853 0 C-N-CA 120.607 -0.437 . . . . 0.0 111.265 -179.048 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 115.77 -77.72 0.27 Allowed Glycine 0 N--CA 1.442 -0.936 0 CA-C-N 115.562 -0.744 . . . . 0.0 111.794 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -170.34 173.62 44.3 Favored Glycine 0 N--CA 1.442 -0.953 0 C-N-CA 121.085 -0.579 . . . . 0.0 111.725 -179.579 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 26.2 t -59.25 -23.8 62.65 Favored 'General case' 0 CA--C 1.538 0.506 0 N-CA-C 111.881 0.326 . . . . 0.0 111.881 -179.729 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 23.5 p -65.23 -19.65 66.07 Favored 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 112.009 0.374 . . . . 0.0 112.009 177.823 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -93.09 146.91 32.84 Favored Pre-proline 0 N--CA 1.446 -0.671 0 N-CA-C 109.978 -0.379 . . . . 0.0 109.978 179.414 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_endo -79.41 173.27 13.39 Favored 'Trans proline' 0 CA--C 1.537 0.652 0 C-N-CA 122.723 2.282 . . . . 0.0 112.869 179.457 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' TRP . . . . . 0.445 ' CE3' ' HB2' ' A' ' 9' ' ' GLN . 95.5 m95 -87.14 131.24 34.22 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.938 -0.573 . . . . 0.0 109.795 178.741 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 46.5 m-80 -114.37 118.62 34.36 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.937 -178.395 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.452 ' HB3' ' HG2' ' A' ' 7' ' ' GLU . 10.9 pt-20 -82.7 124.75 30.51 Favored 'General case' 0 C--N 1.315 -0.897 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.499 179.236 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.439 ' O ' ' HB2' ' A' ' 94' ' ' SER . . . -132.46 29.93 3.22 Favored Glycine 0 N--CA 1.442 -0.963 0 C-N-CA 120.069 -1.062 . . . . 0.0 112.838 -177.709 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 140.96 -175.12 22.36 Favored Glycine 0 N--CA 1.442 -0.907 0 C-N-CA 120.25 -0.976 . . . . 0.0 112.819 178.818 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' GLN . . . . . 0.404 ' O ' ' HD1' ' A' ' 23' ' ' TRP . 12.4 pt20 -141.46 153.05 44.74 Favored 'General case' 0 C--N 1.313 -1.01 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 179.812 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' TRP . . . . . 0.425 ' HB3' ' O ' ' A' ' 91' ' ' ILE . 45.0 m0 -127.68 174.7 8.87 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.543 -0.299 . . . . 0.0 110.787 -176.086 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 79.6 tt0 -121.01 118.11 28.97 Favored 'General case' 0 CA--C 1.51 -0.57 0 C-N-CA 120.624 -0.43 . . . . 0.0 109.902 176.776 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.424 ' HB ' ' CD1' ' A' ' 4' ' ' TYR . 98.3 mt -131.53 140.14 49.01 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.774 0 CA-C-N 115.816 -0.629 . . . . 0.0 109.609 -178.762 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 86.15 66.64 1.39 Allowed Glycine 0 N--CA 1.443 -0.886 0 C-N-CA 120.34 -0.933 . . . . 0.0 112.544 178.982 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 19.2 p -59.78 -36.88 77.61 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 121.131 0.491 . . . . 0.0 110.239 177.744 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 93.5 mtt-85 -94.88 108.23 20.26 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 175.233 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 51.0 m -73.7 -7.87 53.76 Favored 'General case' 0 C--N 1.321 -0.671 0 N-CA-C 113.082 0.771 . . . . 0.0 113.082 -174.761 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 97.9 m-20 -76.81 -18.76 58.21 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.906 0.384 . . . . 0.0 110.996 179.854 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' GLN . . . . . 0.452 ' HB3' ' CD1' ' A' ' 53' ' ' TYR . 7.4 mm100 -133.53 114.83 14.02 Favored 'General case' 0 CA--C 1.51 -0.561 0 N-CA-C 112.589 0.589 . . . . 0.0 112.589 -178.741 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 2.7 t-20 -82.21 142.43 32.16 Favored 'General case' 0 C--O 1.242 0.7 0 CA-C-N 116.011 -0.541 . . . . 0.0 110.043 179.369 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 47.0 t -92.37 129.75 42.51 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 CA-C-N 115.507 -0.77 . . . . 0.0 109.857 -178.331 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.442 ' HB ' ' O ' ' A' ' 107' ' ' SER . 30.5 m -110.13 -21.15 5.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 N-CA-C 112.38 0.511 . . . . 0.0 112.38 -179.925 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 35' ' ' ALA . . . . . 0.627 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -144.85 143.13 30.46 Favored 'General case' 0 C--N 1.322 -0.605 0 C-N-CA 119.816 -0.753 . . . . 0.0 111.85 179.319 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.403 ' HB ' ' CG2' ' A' ' 105' ' ' VAL . 91.5 mt -142.08 119.38 7.47 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 CA-C-N 115.48 -0.782 . . . . 0.0 109.061 179.802 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 7.8 m-20 -126.4 109.92 12.76 Favored 'General case' 0 C--N 1.306 -1.32 0 N-CA-C 108.389 -0.967 . . . . 0.0 108.389 176.506 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.551 HG12 ' HA3' ' A' ' 49' ' ' GLY . 29.5 m -148.26 153.42 11.54 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.63 0 N-CA-C 112.111 0.411 . . . . 0.0 112.111 -173.753 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 -146.35 148.34 32.26 Favored 'General case' 0 C--O 1.245 0.82 0 CA-C-N 115.431 -0.804 . . . . 0.0 109.299 174.778 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 40' ' ' SER . . . . . 0.474 ' HB3' ' CD2' ' A' ' 47' ' ' LEU . 37.1 p -80.49 151.54 29.18 Favored 'General case' 0 C--N 1.313 -1.014 0 CA-C-O 121.496 0.665 . . . . 0.0 112.511 -176.88 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -92.76 -13.26 56.99 Favored Glycine 0 N--CA 1.438 -1.168 0 N-CA-C 110.084 -1.206 . . . . 0.0 110.084 173.281 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 28.3 m-20 -137.33 -155.16 0.59 Allowed 'General case' 0 N--CA 1.468 0.445 0 C-N-CA 123.203 0.601 . . . . 0.0 109.403 -179.34 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -79.4 42.12 0.49 Allowed 'General case' 0 N--CA 1.47 0.572 0 CA-C-O 121.099 0.476 . . . . 0.0 110.725 178.117 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 91.43 3.82 68.84 Favored Glycine 0 C--O 1.22 -0.743 0 C-N-CA 121.025 -0.607 . . . . 0.0 112.881 -178.834 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 55.9 tp60 -63.97 -47.67 79.48 Favored 'General case' 0 N--CA 1.462 0.17 0 CA-C-O 120.903 0.382 . . . . 0.0 111.016 179.575 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 9.4 t -133.32 127.75 34.23 Favored 'General case' 0 C--N 1.312 -1.059 0 C-N-CA 120.72 -0.392 . . . . 0.0 110.113 177.551 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 47' ' ' LEU . . . . . 0.474 ' CD2' ' HB3' ' A' ' 40' ' ' SER . 64.9 mt -109.08 127.96 54.58 Favored 'General case' 0 N--CA 1.447 -0.618 0 N-CA-C 109.662 -0.496 . . . . 0.0 109.662 179.636 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 65.2 m-80 -121.97 147.1 46.47 Favored 'General case' 0 C--N 1.313 -0.982 0 N-CA-C 109.558 -0.534 . . . . 0.0 109.558 176.8 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 49' ' ' GLY . . . . . 0.551 ' HA3' HG12 ' A' ' 38' ' ' VAL . . . 176.13 -154.4 16.88 Favored Glycine 0 N--CA 1.433 -1.557 0 C-N-CA 119.925 -1.131 . . . . 0.0 113.064 179.602 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 89.9 m -129.35 130.7 46.39 Favored 'General case' 0 N--CA 1.436 -1.159 0 C-N-CA 122.668 0.387 . . . . 0.0 111.13 -177.483 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 44.9 mtp -110.08 151.27 27.42 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.394 -0.367 . . . . 0.0 110.927 177.846 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.627 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 23.7 m -132.84 127.77 35.2 Favored 'General case' 0 C--N 1.315 -0.898 0 N-CA-C 110.185 -0.302 . . . . 0.0 110.185 176.009 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 53' ' ' TYR . . . . . 0.452 ' CD1' ' HB3' ' A' ' 31' ' ' GLN . 83.6 m-85 -92.48 163.21 13.91 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.867 178.721 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -61.31 103.36 0.29 Allowed 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.969 -178.553 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 94.77 -6.59 70.24 Favored Glycine 0 CA--C 1.51 -0.258 0 C-N-CA 120.863 -0.684 . . . . 0.0 113.267 177.975 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 69.8 mm-40 -104.82 -179.24 3.89 Favored 'General case' 0 C--N 1.311 -1.102 0 CA-C-O 120.709 0.29 . . . . 0.0 110.836 -178.347 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -99.06 173.73 26.86 Favored Glycine 0 N--CA 1.444 -0.796 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.33 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -68.66 139.38 44.08 Favored 'Trans proline' 0 CA--C 1.538 0.709 0 C-N-CA 122.818 2.345 . . . . 0.0 112.588 179.503 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 50.2 pt -131.93 167.17 27.0 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.079 178.372 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -78.53 139.09 21.92 Favored Glycine 0 N--CA 1.446 -0.677 0 N-CA-C 111.019 -0.832 . . . . 0.0 111.019 179.459 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.547 ' CD2' HG11 ' A' ' 38' ' ' VAL . 29.1 t80 -131.31 129.71 41.82 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 120.953 0.406 . . . . 0.0 111.583 -177.479 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 55.4 ttm-85 -127.11 130.06 49.13 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.514 -0.766 . . . . 0.0 110.493 178.951 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.455 ' HB1' ' HB3' ' A' ' 71' ' ' TYR . . . -129.27 132.32 47.16 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-O 120.594 0.235 . . . . 0.0 110.796 177.175 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 85.3 m -117.31 125.47 51.12 Favored 'General case' 0 C--N 1.316 -0.861 0 CA-C-O 120.996 0.427 . . . . 0.0 110.74 179.637 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 65' ' ' LEU . . . . . 0.507 ' HG ' ' H ' ' A' ' 67' ' ' GLY . 66.6 tp -71.52 132.89 45.36 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.759 -0.655 . . . . 0.0 112.544 -177.579 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -85.94 -16.15 39.33 Favored 'General case' 0 N--CA 1.471 0.577 0 CA-C-N 115.29 -0.868 . . . . 0.0 109.898 174.743 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.507 ' H ' ' HG ' ' A' ' 65' ' ' LEU . . . 103.7 7.61 41.68 Favored Glycine 0 N--CA 1.463 0.44 0 CA-C-N 115.527 -0.76 . . . . 0.0 112.7 177.471 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 29.7 p-10 -137.73 39.65 2.39 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-O 120.851 0.358 . . . . 0.0 110.592 -179.331 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 89.0 m-20 68.9 -1.72 1.96 Allowed 'General case' 0 N--CA 1.485 1.281 0 C-N-CA 123.528 0.731 . . . . 0.0 112.128 -178.558 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 15.3 m -91.82 132.23 36.59 Favored 'General case' 0 C--N 1.314 -0.948 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 177.456 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.455 ' HB3' ' HB1' ' A' ' 63' ' ' ALA . 79.1 m-85 -124.09 133.96 53.49 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.741 -179.25 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 79.9 tt0 -87.13 123.6 32.35 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 174.691 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.481 HG13 ' CE1' ' A' ' 61' ' ' PHE . 48.8 t -99.37 128.61 50.92 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 N-CA-C 112.826 0.676 . . . . 0.0 112.826 -175.656 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 75.4 mt-10 -127.19 121.81 32.34 Favored 'General case' 0 CA--C 1.535 0.378 0 CA-C-N 114.794 -1.094 . . . . 0.0 108.467 175.194 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 75' ' ' ASN . . . . . 0.421 ' OD1' ' HD1' ' A' ' 61' ' ' PHE . 96.4 m-20 -108.42 153.01 23.91 Favored 'General case' 0 C--O 1.236 0.393 0 N-CA-C 112.56 0.578 . . . . 0.0 112.56 -176.283 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 60.2 tt0 -127.72 125.55 40.19 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.358 -0.837 . . . . 0.0 109.389 -179.775 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 6.6 p90 -127.29 4.4 6.33 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 112.734 0.642 . . . . 0.0 112.734 -178.246 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -84.74 -1.88 88.87 Favored Glycine 0 CA--C 1.521 0.415 0 C-N-CA 120.561 -0.828 . . . . 0.0 111.954 178.242 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 106.14 -153.83 16.99 Favored Glycine 0 CA--C 1.497 -1.037 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 -179.717 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -62.43 -32.54 73.41 Favored 'General case' 0 CA--C 1.514 -0.422 0 CA-C-N 117.675 0.738 . . . . 0.0 109.217 173.827 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 47.7 m -84.78 -175.35 5.74 Favored 'General case' 0 N--CA 1.438 -1.04 0 CA-C-N 114.947 -1.024 . . . . 0.0 110.016 176.588 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 75.78 147.22 0.12 Allowed Pre-proline 0 N--CA 1.471 0.578 0 C-N-CA 123.997 0.919 . . . . 0.0 111.701 -179.445 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -73.76 169.19 22.95 Favored 'Trans proline' 0 C--O 1.238 0.508 0 C-N-CA 122.874 2.383 . . . . 0.0 111.807 178.999 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 84' ' ' TRP . . . . . . . . . . . . . 82.7 m95 -87.87 145.65 25.96 Favored 'General case' 0 N--CA 1.447 -0.589 0 N-CA-C 109.524 -0.547 . . . . 0.0 109.524 -179.911 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 94.3 m-70 -116.97 143.38 45.78 Favored 'General case' 0 C--N 1.317 -0.836 0 N-CA-C 110.033 -0.358 . . . . 0.0 110.033 -179.551 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 13.5 m -63.01 137.02 58.14 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-O 120.802 0.334 . . . . 0.0 110.904 -178.748 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -112.83 -48.92 0.6 Allowed Glycine 0 N--CA 1.447 -0.573 0 C-N-CA 121.228 -0.511 . . . . 0.0 112.371 -179.632 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 152.95 -167.95 31.75 Favored Glycine 0 C--O 1.214 -1.155 0 C-N-CA 120.257 -0.973 . . . . 0.0 112.121 179.201 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 16.1 m120 -111.99 118.88 36.67 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 117.082 0.441 . . . . 0.0 110.488 179.868 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 27.4 m0 -111.01 155.27 22.98 Favored 'General case' 0 C--N 1.321 -0.651 0 N-CA-C 110.25 -0.278 . . . . 0.0 110.25 -179.306 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 91' ' ' ILE . . . . . 0.425 ' O ' ' HB3' ' A' ' 23' ' ' TRP . 49.2 mm -110.93 116.61 52.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 N-CA-C 109.179 -0.674 . . . . 0.0 109.179 177.893 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 92' ' ' LEU . . . . . 0.45 ' HB2' ' CE1' ' A' ' 71' ' ' TYR . 77.9 mt -128.98 81.72 2.04 Favored 'General case' 0 C--O 1.272 2.267 0 CA-C-O 121.772 0.796 . . . . 0.0 112.069 -177.996 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 166.22 112.61 0.26 Allowed Glycine 0 N--CA 1.442 -0.92 0 CA-C-N 115.222 -0.899 . . . . 0.0 111.771 179.159 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 94' ' ' SER . . . . . 0.439 ' HB2' ' O ' ' A' ' 20' ' ' GLY . 77.4 p -86.01 -10.94 54.19 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 121.277 0.56 . . . . 0.0 110.761 179.887 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 98.6 mtt180 -111.44 154.24 24.96 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.556 -0.747 . . . . 0.0 109.413 -179.702 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -70.65 -53.19 16.75 Favored 'General case' 0 N--CA 1.472 0.669 0 N-CA-C 113.501 0.926 . . . . 0.0 113.501 -172.348 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 94.8 m-20 -115.0 36.47 3.86 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.75 0.31 . . . . 0.0 111.4 -176.769 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 98' ' ' GLN . . . . . 0.418 ' HG3' ' HB3' ' A' ' 120' ' ' TYR . 38.1 tp60 -103.47 -59.42 1.72 Allowed 'General case' 0 C--N 1.316 -0.853 0 C-N-CA 120.484 -0.486 . . . . 0.0 110.651 -178.681 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 88.8 m-20 74.62 133.72 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.599 0 O-C-N 123.894 0.746 . . . . 0.0 111.812 177.994 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.41 HG21 ' CH2' ' A' ' 23' ' ' TRP . 73.6 t -80.35 133.24 29.96 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.489 0 C-N-CA 120.094 -0.642 . . . . 0.0 111.736 178.727 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 26.8 m -111.19 -31.93 2.24 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.487 0 N-CA-C 112.73 0.641 . . . . 0.0 112.73 -179.621 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 102' ' ' ALA . . . . . 0.543 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -146.57 138.18 24.55 Favored 'General case' 0 C--N 1.324 -0.537 0 C-N-CA 119.809 -0.756 . . . . 0.0 111.625 179.721 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.446 ' HB ' HG22 ' A' ' 38' ' ' VAL . 96.1 mt -131.85 126.32 56.86 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.124 178.019 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 41.9 t30 -126.18 99.17 5.77 Favored 'General case' 0 C--N 1.314 -0.935 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 174.772 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.494 HG11 ' CD2' ' A' ' 128' ' ' PHE . 30.2 m -139.82 140.52 36.0 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.091 0 CA-C-N 115.85 -0.614 . . . . 0.0 111.78 -175.715 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 81.5 tt0 -144.2 145.58 32.16 Favored 'General case' 0 C--N 1.315 -0.924 0 CA-C-N 115.774 -0.648 . . . . 0.0 109.977 178.051 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 107' ' ' SER . . . . . 0.558 ' HB2' ' OD1' ' A' ' 109' ' ' ASP . 21.6 p -152.71 152.93 32.27 Favored 'General case' 0 C--N 1.312 -1.039 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.559 178.143 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -130.53 15.46 5.49 Favored Glycine 0 CA--C 1.505 -0.538 0 N-CA-C 111.105 -0.798 . . . . 0.0 111.105 178.888 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 109' ' ' ASP . . . . . 0.558 ' OD1' ' HB2' ' A' ' 107' ' ' SER . 10.4 p-10 -96.23 22.82 7.23 Favored 'General case' 0 C--N 1.316 -0.859 0 C-N-CA 123.167 0.587 . . . . 0.0 110.5 -179.521 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 110' ' ' ASP . . . . . 0.516 ' HB2' ' O ' ' A' ' 109' ' ' ASP . 4.2 m-20 81.94 10.42 0.76 Allowed 'General case' 0 N--CA 1.486 1.366 0 C-N-CA 124.131 0.972 . . . . 0.0 112.282 -179.944 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 88.12 12.59 65.45 Favored Glycine 0 N--CA 1.446 -0.661 0 C-N-CA 119.999 -1.096 . . . . 0.0 113.718 176.402 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 98.2 mt-30 -71.74 -38.74 70.39 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 117.046 0.423 . . . . 0.0 110.591 179.178 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 12.7 p -131.18 109.94 10.79 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.928 175.952 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 6.1 mp -92.07 113.55 25.85 Favored 'General case' 0 C--N 1.319 -0.722 0 N-CA-C 109.767 -0.456 . . . . 0.0 109.767 179.713 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 54.3 m-80 -108.3 145.54 34.24 Favored 'General case' 0 C--N 1.311 -1.079 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.836 -178.431 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 166.33 -139.29 5.68 Favored Glycine 0 N--CA 1.433 -1.508 0 C-N-CA 120.121 -1.038 . . . . 0.0 112.996 177.881 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 41.2 p -137.72 160.9 37.96 Favored 'General case' 0 C--N 1.31 -1.145 0 C-N-CA 123.429 0.692 . . . . 0.0 109.924 -177.75 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 19.8 ptm -149.29 161.49 41.94 Favored 'General case' 0 C--N 1.311 -1.087 0 CA-C-O 120.729 0.299 . . . . 0.0 110.698 179.302 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 119' ' ' THR . . . . . 0.543 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 23.5 m -135.39 133.15 38.39 Favored 'General case' 0 C--O 1.246 0.892 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.473 -179.813 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 120' ' ' TYR . . . . . 0.418 ' HB3' ' HG3' ' A' ' 98' ' ' GLN . 12.3 m-85 -99.81 158.81 15.53 Favored 'General case' 0 CA--C 1.515 -0.398 0 CA-C-N 115.946 -0.57 . . . . 0.0 109.798 176.618 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -61.07 122.66 15.54 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 120.608 0.242 . . . . 0.0 111.495 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 68.73 27.86 73.54 Favored Glycine 0 C--N 1.338 0.673 0 CA-C-N 115.969 -0.559 . . . . 0.0 113.243 179.847 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 80.4 tt0 -142.58 155.87 45.03 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 116.872 0.336 . . . . 0.0 110.389 -178.014 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -77.69 161.32 49.66 Favored Glycine 0 CA--C 1.521 0.441 0 C-N-CA 121.169 -0.539 . . . . 0.0 112.707 -178.907 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 23.1 Cg_exo -64.05 141.66 77.81 Favored 'Trans proline' 0 C--N 1.345 0.357 0 C-N-CA 122.802 2.334 . . . . 0.0 112.756 -179.564 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 35.9 pt -133.07 157.83 43.02 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.994 0 CA-C-N 115.402 -0.817 . . . . 0.0 109.763 178.321 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 127' ' ' GLY . . . . . 0.45 ' O ' ' HA ' ' A' ' 8' ' ' ASN . . . -70.32 139.5 30.78 Favored Glycine 0 C--O 1.235 0.209 0 C-N-CA 121.096 -0.574 . . . . 0.0 112.083 179.042 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 128' ' ' PHE . . . . . 0.494 ' CD2' HG11 ' A' ' 105' ' ' VAL . 73.0 t80 -119.05 133.53 55.75 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-O 120.887 0.375 . . . . 0.0 111.221 -177.109 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 62.7 tttm -136.19 105.42 6.0 Favored 'General case' 0 C--N 1.313 -0.986 0 CA-C-N 115.676 -0.693 . . . . 0.0 109.767 176.401 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -100.66 131.16 10.47 Favored Glycine 0 N--CA 1.439 -1.153 0 N-CA-C 110.696 -0.962 . . . . 0.0 110.696 178.917 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 28.5 m -122.24 130.53 53.26 Favored 'General case' 0 C--N 1.312 -1.039 0 N-CA-C 110.007 -0.368 . . . . 0.0 110.007 -179.139 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 132' ' ' LEU . . . . . 0.406 HD23 ' CZ ' ' A' ' 4' ' ' TYR . 3.3 tm? -67.11 135.21 53.25 Favored 'General case' 0 C--O 1.236 0.373 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.231 -178.022 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 26.6 m . . . . . 0 N--CA 1.435 -1.185 0 CA-C-O 118.18 -0.914 . . . . 0.0 109.569 -179.372 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.784 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -147.14 123.2 10.77 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 -177.783 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 4' ' ' TYR . . . . . 0.427 ' CD1' ' HB ' ' A' ' 25' ' ' ILE . 59.2 m-85 -118.24 141.41 48.54 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 112.351 0.5 . . . . 0.0 112.351 -178.134 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 49.3 m-80 -88.68 139.07 30.85 Favored 'General case' 0 C--N 1.316 -0.883 0 N-CA-C 107.763 -1.199 . . . . 0.0 107.763 174.858 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.464 HG21 ' CD1' ' A' ' 23' ' ' TRP . 87.3 t -99.38 115.54 40.4 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.02 0 CA-C-O 121.146 0.498 . . . . 0.0 112.323 -175.0 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.494 ' HB2' ' HB3' ' A' ' 129' ' ' LYS . 42.4 mt-10 -113.99 119.53 37.52 Favored 'General case' 0 C--N 1.311 -1.088 0 CA-C-N 115.025 -0.989 . . . . 0.0 108.58 177.329 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 84.7 m-20 -119.01 136.48 54.1 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 116.571 -0.286 . . . . 0.0 110.752 -177.504 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 58.9 tt0 -124.09 128.29 49.08 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-O 120.866 0.365 . . . . 0.0 110.839 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 14.6 p90 -141.49 148.02 38.78 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 116.153 -0.476 . . . . 0.0 109.993 177.043 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 100.89 2.1 55.08 Favored Glycine 0 N--CA 1.449 -0.47 0 C-N-CA 120.37 -0.919 . . . . 0.0 112.268 178.889 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 114.56 155.83 11.29 Favored Glycine 0 N--CA 1.441 -0.991 0 C-N-CA 120.903 -0.665 . . . . 0.0 112.442 179.543 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 7.6 t -59.1 -20.13 50.69 Favored 'General case' 0 CA--C 1.539 0.54 0 C-N-CA 122.746 0.418 . . . . 0.0 111.616 179.008 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 10.2 m -77.78 -10.01 59.32 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.765 0.317 . . . . 0.0 111.027 179.748 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -89.97 152.09 45.96 Favored Pre-proline 0 C--N 1.325 -0.494 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 179.467 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 78.9 Cg_endo -73.69 161.19 42.43 Favored 'Trans proline' 0 C--O 1.237 0.429 0 C-N-CA 122.625 2.217 . . . . 0.0 112.917 179.765 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 82.7 m95 -85.94 134.7 33.86 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 115.546 -0.752 . . . . 0.0 109.095 178.419 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 46.9 m-80 -113.54 141.68 46.87 Favored 'General case' 0 C--N 1.32 -0.701 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 -177.596 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.405 ' HA ' ' O ' ' A' ' 6' ' ' VAL . 9.2 pt-20 -116.53 122.48 44.81 Favored 'General case' 0 C--N 1.308 -1.221 0 CA-C-O 120.734 0.302 . . . . 0.0 110.455 -178.929 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -137.23 31.64 2.51 Favored Glycine 0 N--CA 1.444 -0.793 0 C-N-CA 119.814 -1.184 . . . . 0.0 113.133 -177.255 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 162.68 179.68 37.41 Favored Glycine 0 N--CA 1.447 -0.58 0 C-N-CA 119.745 -1.217 . . . . 0.0 113.015 179.767 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 26.7 pt20 -136.99 137.03 39.02 Favored 'General case' 0 C--N 1.32 -0.714 0 N-CA-C 109.419 -0.586 . . . . 0.0 109.419 178.905 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' TRP . . . . . 0.464 ' CD1' HG21 ' A' ' 6' ' ' VAL . 38.7 m0 -109.31 151.62 26.34 Favored 'General case' 0 CA--C 1.502 -0.873 0 CA-C-O 120.866 0.365 . . . . 0.0 111.23 -178.513 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 79.1 tt0 -108.86 110.88 22.34 Favored 'General case' 0 N--CA 1.44 -0.926 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 177.689 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.427 ' HB ' ' CD1' ' A' ' 4' ' ' TYR . 89.8 mt -127.79 136.5 60.19 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.892 0 CA-C-N 115.395 -0.82 . . . . 0.0 109.803 -176.679 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 90.86 93.44 1.27 Allowed Glycine 0 N--CA 1.444 -0.795 0 C-N-CA 120.67 -0.776 . . . . 0.0 112.499 177.653 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 3.7 p -94.92 10.2 36.37 Favored 'General case' 0 C--N 1.311 -1.084 0 CA-C-O 121.432 0.634 . . . . 0.0 110.38 178.795 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 39.4 mmt180 -124.84 121.05 33.44 Favored 'General case' 0 N--CA 1.445 -0.682 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 -179.88 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 43.6 m -65.95 -38.85 89.67 Favored 'General case' 0 C--N 1.314 -0.948 0 N-CA-C 112.13 0.418 . . . . 0.0 112.13 -178.205 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 75.0 m-20 -75.05 -38.44 61.4 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 112.345 0.498 . . . . 0.0 112.345 -177.047 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' GLN . . . . . 0.465 ' HA ' ' NE2' ' A' ' 31' ' ' GLN . 9.7 mm-40 -114.49 117.65 31.57 Favored 'General case' 0 CA--C 1.5 -0.942 0 N-CA-C 113.708 1.003 . . . . 0.0 113.708 -176.854 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 4.1 t30 -96.13 160.76 14.27 Favored 'General case' 0 N--CA 1.438 -1.063 0 CA-C-N 114.923 -1.035 . . . . 0.0 108.992 177.017 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 62.5 t -94.06 131.51 40.76 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.491 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.182 -176.744 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 35.5 m -112.46 -11.08 11.96 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.655 0 N-CA-C 112.701 0.63 . . . . 0.0 112.701 178.31 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' ALA . . . . . 0.649 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -152.52 144.94 24.05 Favored 'General case' 0 CA--C 1.508 -0.66 0 C-N-CA 120.015 -0.674 . . . . 0.0 111.59 177.882 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 91.8 mt -143.97 117.74 3.38 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.373 0 N-CA-C 109.618 -0.512 . . . . 0.0 109.618 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 37' ' ' ASN . . . . . 0.526 ' HA ' ' O ' ' A' ' 103' ' ' ILE . 47.5 m-80 -133.63 112.27 11.3 Favored 'General case' 0 C--N 1.311 -1.078 0 N-CA-C 108.523 -0.918 . . . . 0.0 108.523 175.667 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.49 HG11 ' CD1' ' A' ' 61' ' ' PHE . 22.4 m -148.41 152.02 12.78 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 C-N-CA 120.92 -0.312 . . . . 0.0 111.655 -174.01 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 67.4 tt0 -136.13 142.47 44.24 Favored 'General case' 0 N--CA 1.443 -0.817 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 176.366 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 31.5 p -77.2 147.12 36.61 Favored 'General case' 0 C--N 1.314 -0.935 0 CA-C-O 121.033 0.444 . . . . 0.0 111.641 -177.912 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -94.78 -15.55 45.51 Favored Glycine 0 N--CA 1.451 -0.361 0 N-CA-C 110.512 -1.035 . . . . 0.0 110.512 175.512 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 42' ' ' ASP . . . . . 0.403 ' HB3' ' H ' ' A' ' 43' ' ' ASP . 55.0 m-20 -139.28 -154.69 0.54 Allowed 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 109.257 -0.645 . . . . 0.0 109.257 179.457 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 43' ' ' ASP . . . . . 0.403 ' H ' ' HB3' ' A' ' 42' ' ' ASP . 20.9 m-20 -73.25 38.25 0.09 Allowed 'General case' 0 N--CA 1.476 0.846 0 C-N-CA 122.893 0.477 . . . . 0.0 111.487 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 92.74 -6.7 77.22 Favored Glycine 0 C--O 1.217 -0.95 0 C-N-CA 121.173 -0.537 . . . . 0.0 112.66 179.848 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 59.3 mt-30 -63.0 -39.9 96.14 Favored 'General case' 0 C--N 1.326 -0.416 0 N-CA-C 112.137 0.421 . . . . 0.0 112.137 -178.364 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' THR . . . . . 0.506 ' HA ' ' O ' ' A' ' 63' ' ' ALA . 5.2 t -128.18 115.4 18.32 Favored 'General case' 0 C--N 1.311 -1.065 0 CA-C-O 121.187 0.518 . . . . 0.0 110.801 177.812 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 47' ' ' LEU . . . . . 0.44 ' O ' ' HA ' ' A' ' 62' ' ' ARG . 79.5 mt -99.53 130.42 45.77 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.855 -0.612 . . . . 0.0 109.595 178.442 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 49.2 m-80 -130.11 143.17 50.64 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 116.488 -0.324 . . . . 0.0 110.469 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 49' ' ' GLY . . . . . 0.431 ' HA3' ' HA ' ' A' ' 38' ' ' VAL . . . 171.08 -150.79 14.32 Favored Glycine 0 N--CA 1.44 -1.086 0 C-N-CA 120.084 -1.055 . . . . 0.0 113.262 179.978 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 25.1 m -125.99 131.48 52.23 Favored 'General case' 0 C--N 1.317 -0.838 0 C-N-CA 122.965 0.506 . . . . 0.0 110.19 -177.199 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 51' ' ' MET . . . . . 0.44 ' SD ' ' HH2' ' A' ' 90' ' ' TRP . 62.5 ttp -125.53 150.27 47.57 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 -179.834 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.649 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 27.7 m -126.98 130.74 50.64 Favored 'General case' 0 C--O 1.243 0.723 0 CA-C-O 120.735 0.302 . . . . 0.0 111.316 -178.81 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 53' ' ' TYR . . . . . 0.437 ' HB3' ' OE1' ' A' ' 31' ' ' GLN . 47.0 m-85 -90.61 162.2 15.08 Favored 'General case' 0 C--O 1.233 0.218 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.323 177.247 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -60.42 107.84 0.73 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.799 -0.637 . . . . 0.0 112.634 -178.072 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 88.33 -0.27 83.26 Favored Glycine 0 N--CA 1.454 -0.138 0 CA-C-N 115.796 -0.638 . . . . 0.0 112.854 178.05 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 73.2 mm-40 -108.21 179.22 4.27 Favored 'General case' 0 C--N 1.314 -0.937 0 CA-C-O 120.705 0.288 . . . . 0.0 110.6 -178.744 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -97.71 176.71 31.25 Favored Glycine 0 N--CA 1.439 -1.144 0 C-N-CA 120.678 -0.773 . . . . 0.0 111.452 178.512 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo -67.13 139.5 50.81 Favored 'Trans proline' 0 CA--C 1.535 0.539 0 C-N-CA 122.501 2.134 . . . . 0.0 112.277 179.507 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 48.3 pt -133.01 166.73 28.56 Favored 'Isoleucine or valine' 0 C--O 1.24 0.554 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.137 178.243 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -75.22 138.59 23.66 Favored Glycine 0 CA--C 1.521 0.464 0 C-N-CA 120.724 -0.751 . . . . 0.0 111.957 -179.541 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.49 ' CD1' HG11 ' A' ' 38' ' ' VAL . 50.2 t80 -124.52 129.84 51.35 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 120.519 0.2 . . . . 0.0 110.916 -178.982 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 62' ' ' ARG . . . . . 0.44 ' HA ' ' O ' ' A' ' 47' ' ' LEU . 62.7 ttp85 -140.67 134.65 30.69 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.22 176.048 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.506 ' O ' ' HA ' ' A' ' 46' ' ' THR . . . -135.08 142.86 46.38 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.567 -0.288 . . . . 0.0 111.304 179.794 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 49.6 m -122.05 131.48 54.01 Favored 'General case' 0 CA--C 1.546 0.803 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.695 -179.608 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 65' ' ' LEU . . . . . 0.543 HD11 ' O ' ' A' ' 68' ' ' ASN . 55.9 tp -71.03 126.19 28.91 Favored 'General case' 0 CA--C 1.535 0.391 0 N-CA-C 113.1 0.778 . . . . 0.0 113.1 -176.9 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 66' ' ' LEU . . . . . 0.405 HD13 ' HA ' ' A' ' 66' ' ' LEU . 3.9 mm? -73.4 -35.19 65.84 Favored 'General case' 0 N--CA 1.473 0.692 0 CA-C-N 115.204 -0.907 . . . . 0.0 111.751 176.349 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 133.05 2.67 3.73 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 111.052 -0.819 . . . . 0.0 111.052 -175.828 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 68' ' ' ASN . . . . . 0.543 ' O ' HD11 ' A' ' 65' ' ' LEU . 31.5 p-10 -131.41 -150.67 0.43 Allowed 'General case' 0 C--N 1.31 -1.147 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.42 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 85.6 m-20 -90.09 4.21 51.01 Favored 'General case' 0 C--N 1.323 -0.545 0 C-N-CA 120.407 -0.517 . . . . 0.0 110.33 179.58 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 24.0 m -101.27 144.56 29.98 Favored 'General case' 0 N--CA 1.448 -0.572 0 CA-C-O 121.362 0.601 . . . . 0.0 111.232 -178.833 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.5 ' HB3' ' HB1' ' A' ' 63' ' ' ALA . 96.3 m-85 -124.33 145.54 49.36 Favored 'General case' 0 C--N 1.312 -1.042 0 CA-C-N 115.463 -0.789 . . . . 0.0 110.617 179.557 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 72' ' ' GLU . . . . . 0.414 ' O ' ' HA ' ' A' ' 63' ' ' ALA . 79.5 tt0 -86.24 112.82 21.73 Favored 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 107.371 -1.344 . . . . 0.0 107.371 174.565 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 75.4 t -97.77 129.68 47.58 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.103 0 CA-C-O 121.4 0.619 . . . . 0.0 112.064 -175.311 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 45.8 mt-10 -128.05 124.76 37.87 Favored 'General case' 0 N--CA 1.438 -1.049 0 CA-C-N 114.891 -1.05 . . . . 0.0 108.748 177.474 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 90.4 m-20 -104.04 147.74 27.04 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-O 121.057 0.456 . . . . 0.0 111.286 -177.478 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 76' ' ' GLN . . . . . 0.539 ' HB2' ' CE3' ' A' ' 84' ' ' TRP . 61.6 tt0 -115.1 119.61 37.02 Favored 'General case' 0 C--N 1.31 -1.11 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.672 -179.68 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 14.9 p90 -138.81 152.85 48.22 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 116.478 -0.328 . . . . 0.0 110.458 177.806 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 147.04 -122.64 1.62 Allowed Glycine 0 N--CA 1.444 -0.825 0 N-CA-C 110.119 -1.192 . . . . 0.0 110.119 -177.295 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.523 ' O ' ' HB2' ' A' ' 80' ' ' ASP . . . -119.31 23.18 8.64 Favored Glycine 0 N--CA 1.444 -0.785 0 C-N-CA 120.291 -0.956 . . . . 0.0 111.115 178.228 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 80' ' ' ASP . . . . . 0.523 ' HB2' ' O ' ' A' ' 79' ' ' GLY . 12.8 m-20 92.24 -43.47 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.836 0 C-N-CA 124.96 1.304 . . . . 0.0 110.587 178.348 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 34.5 m -76.78 -2.46 33.26 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 121.312 0.577 . . . . 0.0 110.7 175.901 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -66.62 157.39 83.27 Favored Pre-proline 0 C--N 1.324 -0.519 0 CA-C-N 115.353 -0.84 . . . . 0.0 112.029 -178.447 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 75.6 Cg_endo -77.9 -172.86 1.6 Allowed 'Trans proline' 0 CA--C 1.537 0.644 0 C-N-CA 122.752 2.301 . . . . 0.0 112.453 179.102 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 84' ' ' TRP . . . . . 0.539 ' CE3' ' HB2' ' A' ' 76' ' ' GLN . 95.1 m95 -98.13 147.5 24.5 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.822 -178.564 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 94.4 m-70 -128.74 146.38 50.91 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.061 -0.518 . . . . 0.0 109.964 -179.662 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 28.8 p -65.21 136.56 56.78 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-O 121.04 0.448 . . . . 0.0 111.421 -178.735 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -108.27 -52.18 0.69 Allowed Glycine 0 N--CA 1.437 -1.269 0 C-N-CA 120.745 -0.74 . . . . 0.0 111.55 177.968 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 151.45 -166.72 30.74 Favored Glycine 0 CA--C 1.52 0.345 0 C-N-CA 120.918 -0.658 . . . . 0.0 112.045 -179.778 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 19.3 m120 -112.43 119.21 37.46 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 117.014 0.407 . . . . 0.0 110.195 -179.862 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 90' ' ' TRP . . . . . 0.44 ' HH2' ' SD ' ' A' ' 51' ' ' MET . 29.3 m0 -117.12 154.02 31.77 Favored 'General case' 0 N--CA 1.47 0.564 0 CA-C-N 116.467 -0.333 . . . . 0.0 111.123 -177.129 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 89.0 mt -108.6 119.19 57.73 Favored 'Isoleucine or valine' 0 C--O 1.242 0.707 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 176.991 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 92' ' ' LEU . . . . . 0.426 ' HB3' HG21 ' A' ' 100' ' ' VAL . 86.7 mt -132.05 83.3 2.07 Favored 'General case' 0 C--O 1.267 1.981 0 N-CA-C 113.127 0.788 . . . . 0.0 113.127 -174.602 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 164.16 116.58 0.37 Allowed Glycine 0 C--O 1.225 -0.439 0 CA-C-N 115.083 -0.962 . . . . 0.0 111.31 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 75.2 p -90.33 -9.36 48.05 Favored 'General case' 0 N--CA 1.463 0.191 0 CA-C-N 117.217 0.509 . . . . 0.0 111.502 -179.58 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -100.38 145.6 27.99 Favored 'General case' 0 N--CA 1.444 -0.763 0 CA-C-O 120.981 0.419 . . . . 0.0 110.872 179.606 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -68.74 -36.77 78.8 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 115.653 -0.703 . . . . 0.0 112.738 -173.463 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 30.5 p-10 -121.6 28.97 7.41 Favored 'General case' 0 C--N 1.313 -1.009 0 CA-C-O 120.715 0.293 . . . . 0.0 111.513 -176.627 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 98' ' ' GLN . . . . . 0.554 ' NE2' ' HB2' ' A' ' 123' ' ' GLU . 53.9 tt0 -157.2 124.44 5.21 Favored 'General case' 0 C--N 1.319 -0.725 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 -177.299 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 96.9 m-20 -113.52 177.66 4.56 Favored 'General case' 0 C--O 1.245 0.819 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.674 -175.355 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.461 HG11 ' CH2' ' A' ' 23' ' ' TRP . 21.2 m -80.41 141.06 15.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.75 -0.659 . . . . 0.0 112.193 -177.656 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 28.7 m -120.95 -26.45 2.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.726 176.425 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 102' ' ' ALA . . . . . 0.639 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -147.26 138.56 23.89 Favored 'General case' 0 C--N 1.324 -0.512 0 C-N-CA 120.872 -0.331 . . . . 0.0 110.65 177.404 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.526 ' O ' ' HA ' ' A' ' 37' ' ' ASN . 87.7 mt -132.23 127.03 56.9 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.029 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 178.822 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 9.6 t30 -128.04 91.06 3.2 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.13 178.414 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.501 HG11 ' HD2' ' A' ' 128' ' ' PHE . 22.3 m -145.06 153.26 14.33 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.615 0 N-CA-C 113.895 1.072 . . . . 0.0 113.895 -176.453 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 91.4 mt-10 -138.95 163.1 33.22 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 114.223 -1.353 . . . . 0.0 108.132 173.896 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 32.7 t -108.2 -51.02 2.95 Favored 'General case' 0 C--N 1.311 -1.1 0 CA-C-O 120.797 0.332 . . . . 0.0 110.893 -179.616 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 84.66 -14.79 45.35 Favored Glycine 0 N--CA 1.446 -0.66 0 N-CA-C 111.101 -0.8 . . . . 0.0 111.101 -176.768 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 109' ' ' ASP . . . . . 0.416 ' HB3' ' H ' ' A' ' 110' ' ' ASP . 54.2 m-20 -117.25 -151.29 0.48 Allowed 'General case' 0 N--CA 1.45 -0.432 0 C-N-CA 123.074 0.55 . . . . 0.0 109.999 -179.414 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 110' ' ' ASP . . . . . 0.416 ' H ' ' HB3' ' A' ' 109' ' ' ASP . 12.5 p-10 -88.55 16.43 6.59 Favored 'General case' 0 C--N 1.322 -0.618 0 C-N-CA 122.628 0.371 . . . . 0.0 111.18 -178.881 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 96.29 9.68 56.63 Favored Glycine 0 N--CA 1.444 -0.828 0 C-N-CA 120.086 -1.054 . . . . 0.0 113.045 -178.339 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 112' ' ' GLN . . . . . 0.475 ' HA ' HD12 ' A' ' 132' ' ' LEU . 28.1 tt0 -64.3 -45.4 88.12 Favored 'General case' 0 C--O 1.239 0.521 0 CA-C-O 120.833 0.349 . . . . 0.0 111.235 179.934 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 113' ' ' THR . . . . . 0.489 ' HA ' ' O ' ' A' ' 130' ' ' GLY . 21.0 p -132.73 130.38 39.92 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.289 -179.831 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 114' ' ' LEU . . . . . 0.507 ' O ' ' HA ' ' A' ' 129' ' ' LYS . 4.3 mm? -105.86 130.5 53.81 Favored 'General case' 0 C--N 1.319 -0.739 0 N-CA-C 108.49 -0.93 . . . . 0.0 108.49 176.599 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 27.7 p30 -135.1 152.25 51.47 Favored 'General case' 0 C--N 1.316 -0.861 0 C-N-CA 120.191 -0.603 . . . . 0.0 112.274 -179.152 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 152.28 -129.38 2.77 Favored Glycine 0 N--CA 1.441 -1.025 0 CA-C-N 115.461 -0.79 . . . . 0.0 112.337 178.244 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 21.4 p -131.72 156.13 46.45 Favored 'General case' 0 C--N 1.316 -0.879 0 CA-C-O 121.012 0.434 . . . . 0.0 111.02 -178.163 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 118' ' ' MET . . . . . 0.521 ' SD ' ' HB2' ' A' ' 128' ' ' PHE . 19.5 ptm -140.64 149.74 42.67 Favored 'General case' 0 C--N 1.314 -0.963 0 CA-C-N 116.062 -0.517 . . . . 0.0 109.968 -178.6 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 119' ' ' THR . . . . . 0.639 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 23.3 m -131.23 129.46 41.64 Favored 'General case' 0 C--N 1.313 -1.016 0 CA-C-O 120.804 0.335 . . . . 0.0 111.019 -179.696 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 120' ' ' TYR . . . . . 0.466 ' HB3' ' HG2' ' A' ' 98' ' ' GLN . 45.0 m-85 -101.47 161.18 13.82 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.947 178.66 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -59.84 121.83 12.72 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.094 179.779 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 66.03 24.26 71.62 Favored Glycine 0 C--N 1.336 0.536 0 C-N-CA 121.117 -0.564 . . . . 0.0 112.336 -179.214 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 123' ' ' GLU . . . . . 0.554 ' HB2' ' NE2' ' A' ' 98' ' ' GLN . 32.5 tp10 -127.95 164.87 21.37 Favored 'General case' 0 C--N 1.318 -0.78 0 N-CA-C 109.622 -0.51 . . . . 0.0 109.622 -177.083 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -93.49 159.66 24.18 Favored Glycine 0 N--CA 1.443 -0.837 0 N-CA-C 110.803 -0.919 . . . . 0.0 110.803 177.318 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 125' ' ' PRO . . . . . 0.438 ' HA ' ' O ' ' A' ' 118' ' ' MET . 37.8 Cg_endo -66.2 136.15 42.91 Favored 'Trans proline' 0 CA--C 1.53 0.286 0 C-N-CA 122.16 1.907 . . . . 0.0 112.233 179.67 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 41.7 pt -132.65 166.4 29.41 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.004 178.929 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -70.02 134.73 25.53 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.912 -0.661 . . . . 0.0 112.197 -179.7 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 128' ' ' PHE . . . . . 0.521 ' HB2' ' SD ' ' A' ' 118' ' ' MET . 25.4 t80 -124.84 134.75 52.61 Favored 'General case' 0 CA--C 1.513 -0.443 0 CA-C-O 121.173 0.511 . . . . 0.0 111.443 -179.45 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 129' ' ' LYS . . . . . 0.507 ' HA ' ' O ' ' A' ' 114' ' ' LEU . 62.3 tttm -140.86 123.64 16.21 Favored 'General case' 0 N--CA 1.435 -1.196 0 CA-C-N 115.073 -0.967 . . . . 0.0 109.494 178.591 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 130' ' ' GLY . . . . . 0.489 ' O ' ' HA ' ' A' ' 113' ' ' THR . . . -117.32 131.61 9.51 Favored Glycine 0 N--CA 1.444 -0.809 0 N-CA-C 110.973 -0.851 . . . . 0.0 110.973 178.948 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 32.1 m -125.32 133.88 52.44 Favored 'General case' 0 C--N 1.314 -0.973 0 CA-C-N 117.015 0.408 . . . . 0.0 110.709 -177.249 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 132' ' ' LEU . . . . . 0.475 HD12 ' HA ' ' A' ' 112' ' ' GLN . 78.3 mt -62.37 135.14 57.31 Favored 'General case' 0 C--O 1.238 0.473 0 CA-C-O 120.741 0.305 . . . . 0.0 110.779 177.283 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 8.6 t . . . . . 0 C--O 1.249 1.051 0 CA-C-O 118.368 -0.825 . . . . 0.0 110.34 178.391 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.468 0.474 0 N-CA-C 110.028 -0.36 . . . . 0.0 110.028 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 3' ' ' LEU . . . . . 0.525 HD13 ' N ' ' A' ' 4' ' ' TYR . 1.4 tm? -97.42 132.41 43.15 Favored 'General case' 0 C--N 1.316 -0.85 0 N-CA-C 109.584 -0.525 . . . . 0.0 109.584 -177.817 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 4' ' ' TYR . . . . . 0.525 ' N ' HD13 ' A' ' 3' ' ' LEU . 89.8 m-85 -122.91 147.74 46.24 Favored 'General case' 0 C--O 1.236 0.351 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.649 -177.96 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 5' ' ' ASN . . . . . 0.55 ' O ' ' HA2' ' A' ' 130' ' ' GLY . 18.7 m120 -94.73 134.5 37.26 Favored 'General case' 0 CA--C 1.506 -0.715 0 N-CA-C 106.34 -1.726 . . . . 0.0 106.34 174.792 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.402 HG21 ' CG ' ' A' ' 23' ' ' TRP . 59.3 t -118.2 126.84 75.28 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.891 0 C-N-CA 119.492 -0.883 . . . . 0.0 113.031 -175.443 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.547 ' HA ' ' HA ' ' A' ' 19' ' ' GLU . 98.4 mt-10 -115.06 139.72 49.64 Favored 'General case' 0 N--CA 1.439 -1.012 0 CA-C-N 114.477 -1.238 . . . . 0.0 108.792 176.326 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 8' ' ' ASN . . . . . 0.433 ' HB3' HD12 ' A' ' 126' ' ' ILE . 81.4 m-20 -119.35 144.05 47.07 Favored 'General case' 0 C--N 1.313 -1.013 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.309 -177.045 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 60.4 tt0 -121.68 114.89 21.78 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 174.605 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 45.8 p90 -129.16 139.08 52.06 Favored 'General case' 0 C--N 1.317 -0.832 0 C-N-CA 121.028 -0.269 . . . . 0.0 110.913 -178.309 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 102.09 11.77 35.92 Favored Glycine 0 N--CA 1.444 -0.783 0 C-N-CA 120.363 -0.922 . . . . 0.0 112.582 178.616 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 99.7 167.37 29.66 Favored Glycine 0 N--CA 1.444 -0.816 0 C-N-CA 120.446 -0.883 . . . . 0.0 113.28 -179.43 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 15.6 m -56.2 -25.61 47.76 Favored 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 123.158 0.583 . . . . 0.0 112.227 179.474 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 14.1 p -61.23 -21.04 63.49 Favored 'General case' 0 CA--C 1.542 0.671 0 N-CA-C 112.25 0.463 . . . . 0.0 112.25 177.268 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -90.84 142.93 28.05 Favored Pre-proline 0 C--N 1.321 -0.66 0 CA-C-O 120.541 0.21 . . . . 0.0 110.733 179.7 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 95.3 Cg_endo -78.37 170.51 18.36 Favored 'Trans proline' 0 C--O 1.238 0.518 0 C-N-CA 122.803 2.335 . . . . 0.0 112.241 179.692 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 96.4 m95 -86.97 124.88 33.65 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.118 -0.492 . . . . 0.0 109.905 -179.77 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 47.8 m-80 -123.26 126.19 46.46 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.991 -178.87 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.547 ' HA ' ' HA ' ' A' ' 7' ' ' GLU . 15.3 pt-20 -68.94 133.51 48.29 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 109.65 -0.5 . . . . 0.0 109.65 177.631 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -134.31 22.78 3.72 Favored Glycine 0 N--CA 1.443 -0.858 0 C-N-CA 119.566 -1.302 . . . . 0.0 112.876 -179.308 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' GLY . . . . . 0.549 ' HA3' ' HB2' ' A' ' 94' ' ' SER . . . 145.07 -170.9 26.38 Favored Glycine 0 N--CA 1.449 -0.472 0 C-N-CA 120.17 -1.014 . . . . 0.0 113.293 177.352 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 25.5 pt20 -131.73 136.05 47.3 Favored 'General case' 0 C--N 1.324 -0.514 0 C-N-CA 122.604 0.362 . . . . 0.0 110.634 -178.337 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' TRP . . . . . 0.469 ' CH2' HG21 ' A' ' 100' ' ' VAL . 26.2 m0 -110.76 165.88 11.47 Favored 'General case' 0 N--CA 1.469 0.491 0 CA-C-O 120.668 0.27 . . . . 0.0 110.482 179.01 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 40.1 tt0 -128.87 116.56 19.62 Favored 'General case' 0 C--N 1.32 -0.68 0 C-N-CA 120.46 -0.496 . . . . 0.0 110.166 175.827 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.49 ' HB ' ' CE1' ' A' ' 4' ' ' TYR . 98.7 mt -130.18 137.49 56.26 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.764 0 CA-C-N 115.5 -0.773 . . . . 0.0 110.196 -177.567 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 93.37 102.32 1.59 Allowed Glycine 0 N--CA 1.446 -0.683 0 C-N-CA 120.775 -0.726 . . . . 0.0 111.892 179.451 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 4.2 p -101.57 12.17 37.71 Favored 'General case' 0 C--N 1.312 -1.036 0 CA-C-O 121.01 0.433 . . . . 0.0 111.293 -178.832 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' ARG . . . . . 0.401 HH11 ' HD3' ' A' ' 28' ' ' ARG . 62.6 mtt-85 -130.64 130.32 43.79 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.053 -178.932 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 15.6 m -66.78 -36.64 82.87 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.094 0.473 . . . . 0.0 112.052 -179.145 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 64.8 m-20 -73.93 -43.24 58.96 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.965 -0.562 . . . . 0.0 112.387 -175.505 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 8.9 mm100 -121.41 122.12 39.08 Favored 'General case' 0 CA--C 1.506 -0.727 0 N-CA-C 113.106 0.78 . . . . 0.0 113.106 -176.42 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' ASN . . . . . 0.418 ' ND2' ' HA3' ' A' ' 111' ' ' GLY . 62.3 t30 -104.39 172.72 6.64 Favored 'General case' 0 N--CA 1.442 -0.837 0 CA-C-N 114.893 -1.049 . . . . 0.0 109.499 178.201 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 59.0 t -106.86 133.68 50.73 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.164 0 N-CA-C 112.287 0.477 . . . . 0.0 112.287 -174.803 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 29.3 m -113.73 -18.0 7.9 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.609 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.947 178.01 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' ALA . . . . . 0.706 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -144.99 145.27 31.44 Favored 'General case' 0 CA--C 1.513 -0.459 0 C-N-CA 119.968 -0.693 . . . . 0.0 111.464 178.928 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 86.8 mt -144.67 126.71 9.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 -178.916 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 37' ' ' ASN . . . . . 0.487 ' HA ' ' O ' ' A' ' 103' ' ' ILE . 31.3 m-80 -136.64 109.12 7.39 Favored 'General case' 0 C--N 1.312 -1.038 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 176.888 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.467 HG11 ' CD1' ' A' ' 61' ' ' PHE . 25.3 m -151.07 157.59 5.38 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 C-N-CA 120.917 -0.313 . . . . 0.0 111.165 -172.833 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -142.71 150.71 40.48 Favored 'General case' 0 N--CA 1.447 -0.596 0 CA-C-N 115.8 -0.636 . . . . 0.0 109.925 177.253 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' SER . . . . . 0.447 ' OG ' ' HB ' ' A' ' 101' ' ' VAL . 35.1 p -79.97 153.59 28.8 Favored 'General case' 0 C--N 1.318 -0.79 0 N-CA-C 112.477 0.547 . . . . 0.0 112.477 -177.682 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -115.45 -68.31 0.44 Allowed Glycine 0 N--CA 1.434 -1.474 0 CA-C-N 115.114 -0.948 . . . . 0.0 110.848 175.151 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 22.5 m-20 -89.95 81.57 6.26 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 112.154 0.427 . . . . 0.0 112.154 -179.001 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 84.5 m-20 51.22 31.53 6.96 Favored 'General case' 0 N--CA 1.491 1.576 0 N-CA-C 113.424 0.898 . . . . 0.0 113.424 174.791 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 88.84 -14.58 59.87 Favored Glycine 0 C--O 1.223 -0.57 0 C-N-CA 120.116 -1.04 . . . . 0.0 113.139 179.229 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 61.3 mt-30 -70.11 -30.44 67.65 Favored 'General case' 0 CA--C 1.512 -0.503 0 CA-C-O 121.193 0.521 . . . . 0.0 110.749 178.99 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 31.9 m -119.37 130.61 55.42 Favored 'General case' 0 N--CA 1.434 -1.247 0 CA-C-N 115.476 -0.783 . . . . 0.0 108.9 -179.641 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 84.6 mt -124.81 133.96 52.93 Favored 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 108.892 -0.781 . . . . 0.0 108.892 -179.063 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 28.1 p30 -136.8 148.77 47.37 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-O 121.122 0.487 . . . . 0.0 111.146 178.997 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 164.28 -145.04 9.94 Favored Glycine 0 N--CA 1.445 -0.758 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.16 177.68 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 50' ' ' THR . . . . . 0.516 ' HA ' ' O ' ' A' ' 59' ' ' ILE . 19.6 p -129.56 141.81 50.89 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 120.904 0.383 . . . . 0.0 110.975 179.925 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 15.6 tmm? -131.92 149.01 52.56 Favored 'General case' 0 C--N 1.317 -0.839 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 179.291 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.706 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 61.7 m -124.56 126.15 45.35 Favored 'General case' 0 C--O 1.252 1.197 0 N-CA-C 112.266 0.469 . . . . 0.0 112.266 -176.61 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 59.8 m-85 -82.68 161.13 22.24 Favored 'General case' 0 C--O 1.236 0.353 0 CA-C-N 115.407 -0.815 . . . . 0.0 111.096 176.521 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -63.76 113.63 3.51 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.914 179.269 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 90.72 7.86 66.09 Favored Glycine 0 N--CA 1.443 -0.859 0 C-N-CA 120.877 -0.678 . . . . 0.0 112.62 179.556 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 81.2 mm-40 -126.72 -172.61 2.68 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.767 0.317 . . . . 0.0 111.447 179.479 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -111.92 -171.56 18.86 Favored Glycine 0 N--CA 1.443 -0.86 0 N-CA-C 111.409 -0.677 . . . . 0.0 111.409 178.615 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 96.1 Cg_endo -76.01 140.06 22.39 Favored 'Trans proline' 0 C--O 1.241 0.651 0 C-N-CA 122.488 2.126 . . . . 0.0 113.431 -178.853 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 59' ' ' ILE . . . . . 0.516 ' O ' ' HA ' ' A' ' 50' ' ' THR . 43.6 pt -132.17 173.12 15.24 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 CA-C-N 115.36 -0.836 . . . . 0.0 109.243 175.625 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -75.35 139.72 25.25 Favored Glycine 0 C--N 1.317 -0.502 0 N-CA-C 111.44 -0.664 . . . . 0.0 111.44 -177.725 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.467 ' CD1' HG11 ' A' ' 38' ' ' VAL . 49.2 t80 -128.34 128.43 44.55 Favored 'General case' 0 C--N 1.312 -1.049 0 CA-C-O 120.511 0.196 . . . . 0.0 110.964 -177.277 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 70.1 ttp85 -136.21 131.13 34.17 Favored 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 175.104 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.487 ' HB1' ' HB3' ' A' ' 71' ' ' TYR . . . -135.4 147.58 49.06 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-O 120.782 0.325 . . . . 0.0 111.3 -178.766 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 83.5 m -126.75 132.44 51.08 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.938 -0.573 . . . . 0.0 110.552 178.895 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 61.4 tp -71.97 123.87 23.68 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.093 0.473 . . . . 0.0 111.854 -178.255 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -66.58 -36.66 83.17 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.896 176.665 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 137.62 -6.69 3.57 Favored Glycine 0 CA--C 1.523 0.591 0 C-N-CA 120.298 -0.953 . . . . 0.0 113.011 -177.519 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 58.3 m-80 -144.14 61.35 1.35 Allowed 'General case' 0 N--CA 1.476 0.838 0 N-CA-C 111.879 0.325 . . . . 0.0 111.879 -178.95 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 90.6 m-20 59.65 5.73 0.73 Allowed 'General case' 0 N--CA 1.487 1.397 0 C-N-CA 123.169 0.587 . . . . 0.0 112.13 179.161 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 9.3 m -99.13 133.83 42.85 Favored 'General case' 0 N--CA 1.44 -0.965 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 179.193 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.487 ' HB3' ' HB1' ' A' ' 63' ' ' ALA . 65.6 m-85 -122.4 136.09 54.83 Favored 'General case' 0 C--N 1.307 -1.259 0 CA-C-O 120.83 0.348 . . . . 0.0 111.546 -178.373 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 43.1 tt0 -90.57 120.35 31.58 Favored 'General case' 0 C--N 1.316 -0.855 0 N-CA-C 107.743 -1.206 . . . . 0.0 107.743 174.785 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 77.5 t -104.85 133.29 49.44 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.201 0 N-CA-C 113.091 0.774 . . . . 0.0 113.091 -173.621 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.45 ' HG2' ' HA ' ' A' ' 86' ' ' SER . 49.7 mt-10 -127.58 126.21 41.69 Favored 'General case' 0 N--CA 1.445 -0.711 0 CA-C-N 114.482 -1.235 . . . . 0.0 108.103 174.631 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 94.7 m-20 -103.9 144.04 32.04 Favored 'General case' 0 C--O 1.241 0.622 0 CA-C-O 121.256 0.55 . . . . 0.0 111.689 -176.541 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 76' ' ' GLN . . . . . 0.57 ' HB2' ' CE3' ' A' ' 84' ' ' TRP . 55.6 tt0 -118.29 122.95 44.19 Favored 'General case' 0 C--N 1.309 -1.161 0 CA-C-N 115.449 -0.796 . . . . 0.0 109.482 -178.247 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 8.1 p90 -110.55 97.04 6.57 Favored 'General case' 0 C--N 1.311 -1.083 0 C-N-CA 119.378 -0.929 . . . . 0.0 110.994 176.974 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 156.86 -153.51 24.76 Favored Glycine 0 N--CA 1.433 -1.563 0 N-CA-C 108.339 -1.905 . . . . 0.0 108.339 -177.378 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -84.93 -148.99 10.32 Favored Glycine 0 N--CA 1.442 -0.908 0 C-N-CA 119.926 -1.13 . . . . 0.0 111.248 175.858 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 65.3 m-20 -88.77 -6.31 57.49 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 117.207 0.504 . . . . 0.0 110.894 -178.969 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 24.1 t -98.13 -4.8 34.94 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.152 -178.002 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -76.49 149.91 81.78 Favored Pre-proline 0 C--N 1.323 -0.56 0 CA-C-N 116.496 -0.32 . . . . 0.0 110.868 -178.399 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -68.23 158.4 57.66 Favored 'Trans proline' 0 C--O 1.238 0.479 0 C-N-CA 122.351 2.034 . . . . 0.0 111.793 178.491 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 84' ' ' TRP . . . . . 0.57 ' CE3' ' HB2' ' A' ' 76' ' ' GLN . 96.0 m95 -94.8 138.69 32.28 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.337 -178.608 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 74.7 m-70 -119.16 146.62 45.0 Favored 'General case' 0 C--N 1.32 -0.712 0 N-CA-C 109.549 -0.538 . . . . 0.0 109.549 179.845 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 86' ' ' SER . . . . . 0.45 ' HA ' ' HG2' ' A' ' 74' ' ' GLU . 10.8 p -71.08 139.99 50.55 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 121.192 0.52 . . . . 0.0 112.229 -176.756 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -115.41 -45.69 0.61 Allowed Glycine 0 N--CA 1.44 -1.099 0 C-N-CA 120.993 -0.622 . . . . 0.0 112.342 178.718 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 147.65 -162.28 28.67 Favored Glycine 0 C--O 1.225 -0.411 0 C-N-CA 120.279 -0.962 . . . . 0.0 112.655 179.445 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 17.9 m120 -115.11 124.55 51.83 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.842 0.321 . . . . 0.0 110.497 179.849 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 34.2 m0 -118.89 153.59 34.31 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.614 -178.581 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 46.9 mm -106.76 114.33 45.61 Favored 'Isoleucine or valine' 0 C--O 1.244 0.776 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 178.388 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 78.5 mt -128.07 77.72 1.78 Allowed 'General case' 0 C--O 1.256 1.445 0 CA-C-O 121.539 0.685 . . . . 0.0 111.559 -177.007 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 166.23 93.79 0.09 OUTLIER Glycine 0 N--CA 1.446 -0.689 0 CA-C-N 115.762 -0.654 . . . . 0.0 111.695 -179.649 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 94' ' ' SER . . . . . 0.549 ' HB2' ' HA3' ' A' ' 21' ' ' GLY . 43.8 p -92.28 -12.42 32.57 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-O 120.838 0.351 . . . . 0.0 111.816 -178.516 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 91.6 mtt180 -88.69 15.84 7.6 Favored 'General case' 0 C--N 1.317 -0.821 0 N-CA-C 114.141 1.163 . . . . 0.0 114.141 -176.339 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 77.9 tt0 69.44 -81.67 0.03 OUTLIER 'General case' 0 N--CA 1.472 0.671 0 N-CA-C 113.298 0.851 . . . . 0.0 113.298 172.86 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 61.6 m-80 -92.73 24.19 3.72 Favored 'General case' 0 N--CA 1.473 0.681 0 CA-C-O 121.006 0.432 . . . . 0.0 110.995 -176.429 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 98' ' ' GLN . . . . . 0.414 ' HG2' ' HB3' ' A' ' 120' ' ' TYR . 54.8 tt0 -145.51 116.3 7.73 Favored 'General case' 0 C--N 1.312 -1.022 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 -177.298 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 99' ' ' ASN . . . . . 0.442 ' HB3' ' OH ' ' A' ' 71' ' ' TYR . 50.3 m-80 -89.23 158.93 17.68 Favored 'General case' 0 C--O 1.248 0.983 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.731 -177.512 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.469 HG21 ' CH2' ' A' ' 23' ' ' TRP . 98.0 t -80.57 130.04 36.56 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.206 0 C-N-CA 120.536 -0.466 . . . . 0.0 110.724 177.892 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 101' ' ' VAL . . . . . 0.447 ' HB ' ' OG ' ' A' ' 40' ' ' SER . 34.8 m -110.27 -17.15 8.5 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.59 0 N-CA-C 112.439 0.533 . . . . 0.0 112.439 -178.686 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 102' ' ' ALA . . . . . 0.713 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -155.57 145.11 21.12 Favored 'General case' 0 CA--C 1.509 -0.61 0 C-N-CA 120.16 -0.616 . . . . 0.0 111.261 176.9 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.487 ' O ' ' HA ' ' A' ' 37' ' ' ASN . 83.0 mt -135.19 125.26 43.88 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 N-CA-C 110.102 -0.333 . . . . 0.0 110.102 179.457 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 104' ' ' ASN . . . . . 0.466 ' HB3' ' OG1' ' A' ' 117' ' ' THR . 7.5 t30 -127.8 94.18 3.88 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.872 -0.604 . . . . 0.0 109.829 175.91 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 30.0 m -137.86 138.67 43.8 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.661 0 N-CA-C 113.119 0.785 . . . . 0.0 113.119 -176.343 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -142.71 96.85 3.0 Favored 'General case' 0 CA--C 1.543 0.686 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.781 176.847 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 107' ' ' SER . . . . . 0.466 ' HB2' ' H ' ' A' ' 115' ' ' ASN . 58.9 m -167.14 166.15 15.16 Favored 'General case' 0 N--CA 1.484 1.264 0 CA-C-N 115.204 -0.907 . . . . 0.0 113.38 -177.963 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 107.07 127.55 5.79 Favored Glycine 0 N--CA 1.427 -1.965 0 C-N-CA 120.488 -0.863 . . . . 0.0 112.85 175.844 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 7.3 m-20 -77.93 -48.63 15.88 Favored 'General case' 0 C--N 1.317 -0.817 0 N-CA-C 107.063 -1.458 . . . . 0.0 107.063 176.247 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 -125.63 23.3 7.43 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 113.941 -1.481 . . . . 0.0 108.998 177.708 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 111' ' ' GLY . . . . . 0.418 ' HA3' ' ND2' ' A' ' 32' ' ' ASN . . . 81.83 17.56 69.96 Favored Glycine 0 C--O 1.22 -0.723 0 C-N-CA 120.457 -0.878 . . . . 0.0 111.823 -175.818 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 112' ' ' GLN . . . . . 0.477 ' HA ' ' CD1' ' A' ' 132' ' ' LEU . 98.4 mt-30 -65.59 -43.61 89.18 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.742 0.306 . . . . 0.0 111.656 -179.17 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 34.0 p -131.77 149.51 52.45 Favored 'General case' 0 N--CA 1.441 -0.876 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.4 179.546 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 114' ' ' LEU . . . . . 0.424 ' HA ' ' HB2' ' A' ' 107' ' ' SER . 97.5 mt -128.41 131.17 48.48 Favored 'General case' 0 C--N 1.316 -0.881 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.012 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 115' ' ' ASN . . . . . 0.466 ' H ' ' HB2' ' A' ' 107' ' ' SER . 54.5 m-80 -136.16 150.29 48.99 Favored 'General case' 0 C--O 1.245 0.841 0 CA-C-O 120.792 0.33 . . . . 0.0 110.667 -178.802 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 157.51 -128.54 2.15 Favored Glycine 0 N--CA 1.442 -0.935 0 CA-C-N 115.75 -0.659 . . . . 0.0 112.049 179.042 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 117' ' ' THR . . . . . 0.466 ' OG1' ' HB3' ' A' ' 104' ' ' ASN . 25.1 p -136.2 156.43 48.69 Favored 'General case' 0 C--N 1.312 -1.03 0 CA-C-O 121.03 0.443 . . . . 0.0 110.875 179.91 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 118' ' ' MET . . . . . 0.583 ' SD ' ' HE1' ' A' ' 120' ' ' TYR . 3.4 ptp -137.66 145.2 42.37 Favored 'General case' 0 C--N 1.314 -0.969 0 CA-C-N 115.94 -0.573 . . . . 0.0 109.966 -179.278 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 119' ' ' THR . . . . . 0.713 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 20.8 m -125.5 127.12 45.96 Favored 'General case' 0 C--O 1.247 0.936 0 N-CA-C 110.125 -0.324 . . . . 0.0 110.125 178.557 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 120' ' ' TYR . . . . . 0.583 ' HE1' ' SD ' ' A' ' 118' ' ' MET . 24.3 m-85 -107.15 155.04 20.31 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.987 179.04 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -58.44 127.87 34.31 Favored 'General case' 0 C--O 1.236 0.391 0 CA-C-O 121.131 0.491 . . . . 0.0 112.121 -178.649 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 81.64 7.71 87.79 Favored Glycine 0 C--O 1.227 -0.338 0 CA-C-N 115.618 -0.719 . . . . 0.0 113.406 177.863 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 85.9 tt0 -145.05 165.2 28.91 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 117.091 0.446 . . . . 0.0 110.493 -178.599 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -87.23 176.43 46.92 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.953 -0.642 . . . . 0.0 112.784 -178.448 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 125' ' ' PRO . . . . . 0.511 ' HA ' ' O ' ' A' ' 118' ' ' MET . 71.6 Cg_endo -72.48 140.01 32.46 Favored 'Trans proline' 0 CA--C 1.534 0.523 0 C-N-CA 122.817 2.345 . . . . 0.0 112.923 -179.685 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 126' ' ' ILE . . . . . 0.433 HD12 ' HB3' ' A' ' 8' ' ' ASN . 43.6 pt -131.15 170.42 19.77 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.013 178.809 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -68.33 133.56 28.36 Favored Glycine 0 C--O 1.242 0.614 0 C-N-CA 120.929 -0.653 . . . . 0.0 112.987 -178.401 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 45.1 t80 -111.74 130.59 55.74 Favored 'General case' 0 C--O 1.236 0.378 0 C-N-CA 123.287 0.635 . . . . 0.0 110.602 -179.502 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 62.1 tttm -140.84 115.45 9.52 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 177.385 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 130' ' ' GLY . . . . . 0.55 ' HA2' ' O ' ' A' ' 5' ' ' ASN . . . -132.13 149.38 19.4 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.501 -0.857 . . . . 0.0 113.266 -178.132 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 80.8 m -141.29 143.09 33.88 Favored 'General case' 0 C--N 1.323 -0.564 0 C-N-CA 122.307 0.243 . . . . 0.0 111.079 179.256 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 132' ' ' LEU . . . . . 0.477 ' CD1' ' HA ' ' A' ' 112' ' ' GLN . 82.4 mt -53.9 136.33 40.94 Favored 'General case' 0 N--CA 1.475 0.793 0 O-C-N 123.548 0.53 . . . . 0.0 110.764 176.112 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 25.1 m . . . . . 0 C--O 1.255 1.368 0 CA-C-O 118.421 -0.799 . . . . 0.0 110.85 -179.034 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 0.622 0 N-CA-C 110.064 -0.347 . . . . 0.0 110.064 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 3' ' ' LEU . . . . . 0.433 HD12 ' HB ' ' A' ' 133' ' ' THR . 2.8 tm? -88.16 129.28 35.37 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 121.084 0.468 . . . . 0.0 110.093 -178.714 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 4' ' ' TYR . . . . . 0.501 ' CE1' ' HB ' ' A' ' 25' ' ' ILE . 35.2 m-85 -117.62 141.92 47.81 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.783 -0.644 . . . . 0.0 111.813 179.901 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 -98.21 139.61 33.74 Favored 'General case' 0 C--N 1.312 -1.037 0 N-CA-C 107.794 -1.188 . . . . 0.0 107.794 173.328 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 69.0 t -114.39 127.87 71.67 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.224 0 CA-C-O 121.222 0.534 . . . . 0.0 112.211 -174.059 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -122.55 138.76 54.47 Favored 'General case' 0 C--N 1.317 -0.84 0 N-CA-C 107.826 -1.176 . . . . 0.0 107.826 175.083 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 23.5 m120 -128.89 148.53 50.92 Favored 'General case' 0 C--N 1.313 -0.992 0 N-CA-C 112.454 0.538 . . . . 0.0 112.454 -177.319 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 51.0 tt0 -126.36 122.31 35.03 Favored 'General case' 0 C--N 1.32 -0.71 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 176.967 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 41.5 p90 -145.6 13.64 1.36 Allowed 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 114.033 1.123 . . . . 0.0 114.033 -176.376 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -110.36 21.27 24.42 Favored Glycine 0 N--CA 1.446 -0.671 0 C-N-CA 118.491 -1.814 . . . . 0.0 112.031 -177.302 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 107.72 175.9 22.36 Favored Glycine 0 N--CA 1.448 -0.56 0 C-N-CA 120.539 -0.839 . . . . 0.0 113.098 179.083 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 12.4 m -64.36 150.91 45.32 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 115.365 -0.417 . . . . 0.0 111.5 177.831 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 37.6 m 64.89 21.23 12.3 Favored 'General case' 0 N--CA 1.472 0.63 0 CA-C-N 115.706 -0.679 . . . . 0.0 111.509 -178.705 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' ALA . . . . . 0.432 ' HA ' ' HD3' ' A' ' 16' ' ' PRO . . . -96.61 146.27 31.02 Favored Pre-proline 0 N--CA 1.448 -0.539 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.595 179.803 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.432 ' HD3' ' HA ' ' A' ' 15' ' ' ALA . 11.2 Cg_exo -71.86 159.23 51.07 Favored 'Trans proline' 0 N--CA 1.455 -0.741 0 C-N-CA 122.764 2.309 . . . . 0.0 112.302 178.502 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 80.6 m95 -90.21 131.4 36.06 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 115.658 -0.701 . . . . 0.0 109.285 178.852 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 38.8 m-80 -109.35 142.67 39.94 Favored 'General case' 0 C--N 1.308 -1.216 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 -178.854 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -69.04 125.59 27.14 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-O 121.612 0.72 . . . . 0.0 111.623 -178.299 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.614 ' O ' ' HB3' ' A' ' 94' ' ' SER . . . -100.33 -17.66 23.8 Favored Glycine 0 N--CA 1.447 -0.567 0 CA-C-N 114.661 -1.154 . . . . 0.0 113.851 -176.515 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 137.14 -151.18 20.94 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.241 -0.981 . . . . 0.0 111.887 -177.566 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 29.5 pt20 -138.62 132.83 31.6 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 120.852 0.358 . . . . 0.0 111.264 -179.912 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' TRP . . . . . 0.417 ' CZ2' HG21 ' A' ' 100' ' ' VAL . 46.0 m0 -115.34 161.65 18.22 Favored 'General case' 0 CA--C 1.507 -0.691 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.372 178.548 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 81.7 tt0 -120.07 118.96 31.97 Favored 'General case' 0 C--N 1.314 -0.973 0 C-N-CA 119.986 -0.686 . . . . 0.0 109.649 174.313 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.501 ' HB ' ' CE1' ' A' ' 4' ' ' TYR . 97.8 mt -134.45 146.09 31.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 CA-C-N 114.99 -1.005 . . . . 0.0 109.457 -176.225 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 83.71 73.54 1.25 Allowed Glycine 0 CA--C 1.505 -0.56 0 C-N-CA 120.364 -0.922 . . . . 0.0 111.605 178.955 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 16.1 m -62.21 -43.31 99.11 Favored 'General case' 0 C--N 1.314 -0.961 0 CA-C-N 115.175 -0.513 . . . . 0.0 110.77 179.55 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 84.8 mtt85 -77.64 129.78 36.01 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.903 -0.589 . . . . 0.0 111.337 -179.709 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 15.6 m -66.7 -32.77 74.29 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.607 -0.724 . . . . 0.0 111.69 179.85 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 28.6 m-20 -97.62 16.78 19.45 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.524 -176.458 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 7.2 mm-40 -155.21 102.32 2.29 Favored 'General case' 0 CA--C 1.505 -0.781 0 CA-C-O 120.909 0.385 . . . . 0.0 111.646 -174.656 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 63.7 t30 -102.34 157.86 16.61 Favored 'General case' 0 N--CA 1.443 -0.814 0 CA-C-N 115.877 -0.602 . . . . 0.0 109.945 178.305 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 57.0 t -96.22 133.11 38.68 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.66 0 CA-C-N 115.255 -0.884 . . . . 0.0 110.841 -175.166 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 30.1 m -110.13 -17.22 8.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 N-CA-C 111.78 0.289 . . . . 0.0 111.78 179.787 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 35' ' ' ALA . . . . . 0.548 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -149.89 143.48 25.31 Favored 'General case' 0 C--O 1.236 0.358 0 C-N-CA 120.628 -0.429 . . . . 0.0 111.195 178.532 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.446 ' HB ' HG22 ' A' ' 105' ' ' VAL . 94.6 mt -140.72 123.32 15.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.036 -179.016 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -126.74 106.47 9.39 Favored 'General case' 0 C--N 1.319 -0.723 0 N-CA-C 108.672 -0.862 . . . . 0.0 108.672 173.896 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 23.9 m -147.67 151.1 13.9 Favored 'Isoleucine or valine' 0 C--O 1.237 0.423 0 C-N-CA 120.748 -0.381 . . . . 0.0 111.379 -174.881 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 78.7 tt0 -147.14 150.46 35.02 Favored 'General case' 0 C--N 1.319 -0.735 0 N-CA-C 108.609 -0.886 . . . . 0.0 108.609 175.612 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 40' ' ' SER . . . . . 0.456 ' HB2' HD23 ' A' ' 47' ' ' LEU . 8.4 t -90.91 143.46 26.69 Favored 'General case' 0 C--N 1.312 -1.027 0 CA-C-O 120.857 0.36 . . . . 0.0 111.436 -177.759 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -87.09 -15.49 62.59 Favored Glycine 0 CA--C 1.52 0.347 0 C-N-CA 120.51 -0.852 . . . . 0.0 111.132 175.892 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 42' ' ' ASP . . . . . 0.405 ' HB3' ' H ' ' A' ' 43' ' ' ASP . 15.7 m-20 -127.46 -156.01 0.73 Allowed 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.157 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 43' ' ' ASP . . . . . 0.405 ' H ' ' HB3' ' A' ' 42' ' ' ASP . 43.4 m-20 -76.72 38.72 0.2 Allowed 'General case' 0 N--CA 1.472 0.663 0 C-N-CA 122.576 0.351 . . . . 0.0 111.625 -179.316 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.524 ' O ' ' HE2' ' A' ' 71' ' ' TYR . . . 96.04 -8.39 67.61 Favored Glycine 0 C--O 1.214 -1.095 0 C-N-CA 120.917 -0.658 . . . . 0.0 111.856 -179.527 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 56.2 mt-30 -64.06 -39.66 94.56 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 113.14 0.793 . . . . 0.0 113.14 -176.711 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 4.0 t -126.81 110.56 13.22 Favored 'General case' 0 C--N 1.313 -1.011 0 C-N-CA 120.077 -0.649 . . . . 0.0 110.985 178.57 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 47' ' ' LEU . . . . . 0.456 HD23 ' HB2' ' A' ' 40' ' ' SER . 74.0 mt -93.76 125.52 38.42 Favored 'General case' 0 N--CA 1.443 -0.78 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 176.079 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 13.4 m120 -125.08 141.21 52.26 Favored 'General case' 0 C--N 1.3 -1.547 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 -178.902 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 170.64 -152.99 20.1 Favored Glycine 0 N--CA 1.444 -0.813 0 C-N-CA 119.05 -1.548 . . . . 0.0 113.987 179.333 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 38.6 m -128.47 133.15 48.44 Favored 'General case' 0 N--CA 1.443 -0.808 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 -177.235 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 46.4 ttp -122.61 144.78 48.9 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 -178.344 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.548 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 32.5 m -125.06 126.69 45.77 Favored 'General case' 0 C--O 1.247 0.958 0 CA-C-O 120.73 0.3 . . . . 0.0 111.368 -179.11 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 62.1 m-85 -90.45 162.73 14.94 Favored 'General case' 0 C--O 1.234 0.248 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.95 177.947 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -66.49 131.44 46.05 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.375 178.734 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 74.0 2.08 61.02 Favored Glycine 0 CA--C 1.519 0.34 0 CA-C-N 115.981 -0.554 . . . . 0.0 113.21 179.209 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 75.2 mm-40 -121.74 -179.03 3.98 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 120.826 0.345 . . . . 0.0 110.764 -178.424 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -105.71 173.76 20.39 Favored Glycine 0 N--CA 1.442 -0.927 0 C-N-CA 121.029 -0.605 . . . . 0.0 111.811 179.215 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 26.3 Cg_exo -63.32 136.32 54.77 Favored 'Trans proline' 0 C--O 1.242 0.712 0 C-N-CA 122.892 2.394 . . . . 0.0 112.375 179.811 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 59' ' ' ILE . . . . . 0.512 ' HB ' ' O ' ' A' ' 76' ' ' GLN . 50.9 pt -130.79 167.2 26.47 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.577 -179.671 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -73.1 135.14 20.89 Favored Glycine 0 C--O 1.249 1.068 0 C-N-CA 120.842 -0.694 . . . . 0.0 112.122 179.776 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 58.1 t80 -127.51 126.9 43.07 Favored 'General case' 0 C--O 1.243 0.717 0 C-N-CA 122.647 0.379 . . . . 0.0 110.795 -177.982 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 62.1 ttp180 -135.82 131.85 35.91 Favored 'General case' 0 N--CA 1.463 0.205 0 N-CA-C 110.016 -0.364 . . . . 0.0 110.016 176.681 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.453 ' HB2' HG22 ' A' ' 73' ' ' VAL . . . -135.21 141.11 45.75 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.649 0.262 . . . . 0.0 111.703 -179.85 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 40.9 m -121.7 132.05 54.43 Favored 'General case' 0 CA--C 1.544 0.719 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.538 179.554 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 58.8 tp -71.56 114.27 9.47 Favored 'General case' 0 CA--C 1.522 -0.13 0 CA-C-O 121.202 0.525 . . . . 0.0 112.345 -178.412 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 68.1 mt -80.87 -31.38 35.33 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.553 -0.749 . . . . 0.0 109.803 175.566 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 123.72 164.73 12.09 Favored Glycine 0 N--CA 1.445 -0.711 0 N-CA-C 110.362 -1.095 . . . . 0.0 110.362 -177.6 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 94.0 m-20 61.11 36.03 18.43 Favored 'General case' 0 N--CA 1.477 0.896 0 CA-C-N 117.343 0.571 . . . . 0.0 110.917 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 95.0 m-20 63.78 18.88 11.43 Favored 'General case' 0 N--CA 1.477 0.878 0 CA-C-N 115.389 -0.823 . . . . 0.0 111.864 179.235 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 31.6 m -108.56 131.91 54.38 Favored 'General case' 0 N--CA 1.448 -0.565 0 CA-C-O 121.123 0.487 . . . . 0.0 110.926 -179.243 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.524 ' HE2' ' O ' ' A' ' 44' ' ' GLY . 95.6 m-85 -119.13 152.14 37.06 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.212 179.911 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 58.1 tt0 -108.0 127.57 53.88 Favored 'General case' 0 C--N 1.314 -0.946 0 N-CA-C 107.997 -1.112 . . . . 0.0 107.997 174.482 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.453 HG22 ' HB2' ' A' ' 63' ' ' ALA . 56.5 t -111.64 137.56 43.77 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.855 0 N-CA-C 113.77 1.026 . . . . 0.0 113.77 -171.147 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 50.1 mt-10 -123.98 149.49 45.93 Favored 'General case' 0 C--O 1.245 0.86 0 CA-C-N 114.832 -1.076 . . . . 0.0 108.303 175.95 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 14.3 m120 -131.65 156.54 45.66 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-O 120.561 0.22 . . . . 0.0 110.47 -175.98 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 76' ' ' GLN . . . . . 0.512 ' O ' ' HB ' ' A' ' 59' ' ' ILE . 1.7 pt20 -147.18 144.07 28.68 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.402 176.315 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 31.9 p90 -147.24 168.25 22.17 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.16 -177.467 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 79.54 70.35 1.33 Allowed Glycine 0 N--CA 1.441 -0.987 0 C-N-CA 121.078 -0.582 . . . . 0.0 114.109 176.316 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.522 ' O ' ' HB3' ' A' ' 80' ' ' ASP . . . 106.22 -27.32 17.55 Favored Glycine 0 N--CA 1.445 -0.702 0 C-N-CA 120.296 -0.955 . . . . 0.0 113.827 175.733 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 80' ' ' ASP . . . . . 0.522 ' HB3' ' O ' ' A' ' 79' ' ' GLY . 19.3 t70 81.28 -28.63 0.12 Allowed 'General case' 0 N--CA 1.493 1.703 0 CA-C-O 121.328 0.585 . . . . 0.0 110.736 178.356 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 11.6 p -85.08 16.73 3.3 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-O 121.247 0.546 . . . . 0.0 110.629 174.221 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -89.33 165.45 25.97 Favored Pre-proline 0 CA--C 1.538 0.495 0 CA-C-N 115.599 -0.728 . . . . 0.0 111.073 -178.12 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 10.6 Cg_exo -70.47 166.88 27.02 Favored 'Trans proline' 0 C--N 1.357 0.979 0 C-N-CA 122.851 2.367 . . . . 0.0 111.746 178.481 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 84' ' ' TRP . . . . . . . . . . . . . 90.8 m95 -95.59 137.45 34.63 Favored 'General case' 0 N--CA 1.445 -0.691 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -178.489 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 85.4 m-70 -119.28 145.54 46.02 Favored 'General case' 0 C--N 1.313 -0.98 0 N-CA-C 109.669 -0.493 . . . . 0.0 109.669 -177.26 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 7.1 m -61.78 133.92 56.1 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 110.303 -0.258 . . . . 0.0 110.303 -179.239 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -108.77 -50.67 0.73 Allowed Glycine 0 N--CA 1.443 -0.856 0 C-N-CA 120.137 -1.03 . . . . 0.0 111.987 178.66 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 152.65 -167.7 31.55 Favored Glycine 0 C--O 1.221 -0.683 0 C-N-CA 120.699 -0.762 . . . . 0.0 111.865 179.55 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 19.8 m120 -103.66 145.5 29.97 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 116.901 0.35 . . . . 0.0 110.722 179.824 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 90' ' ' TRP . . . . . 0.49 ' CH2' HG23 ' A' ' 25' ' ' ILE . 12.4 m0 -132.88 142.54 48.98 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 -178.376 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 86.6 mt -109.25 116.41 52.02 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.962 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 177.958 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 92' ' ' LEU . . . . . 0.422 ' HB2' ' CE1' ' A' ' 71' ' ' TYR . 71.8 mt -134.81 75.89 1.6 Allowed 'General case' 0 C--O 1.263 1.789 0 CA-C-O 121.449 0.643 . . . . 0.0 111.668 -175.967 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 93' ' ' GLY . . . . . 0.423 ' O ' ' HB2' ' A' ' 94' ' ' SER . . . -148.93 -69.51 0.01 OUTLIER Glycine 0 N--CA 1.445 -0.763 0 C-N-CA 120.289 -0.958 . . . . 0.0 112.785 -179.931 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 94' ' ' SER . . . . . 0.614 ' HB3' ' O ' ' A' ' 20' ' ' GLY . 17.3 m 73.44 -34.95 0.3 Allowed 'General case' 0 N--CA 1.479 1.009 0 C-N-CA 123.478 0.711 . . . . 0.0 112.563 -178.593 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 82.6 mtp180 -101.02 153.95 19.11 Favored 'General case' 0 N--CA 1.439 -0.984 0 CA-C-O 120.868 0.366 . . . . 0.0 110.942 -179.179 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 44.5 tt0 -62.03 -54.37 42.4 Favored 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 113.51 0.93 . . . . 0.0 113.51 -172.87 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 16.4 m120 -122.29 37.1 4.46 Favored 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 111.869 0.322 . . . . 0.0 111.869 -176.475 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 98' ' ' GLN . . . . . . . . . . . . . 6.6 tt0 -148.04 116.12 6.48 Favored 'General case' 0 C--N 1.316 -0.867 0 C-N-CA 120.543 -0.463 . . . . 0.0 110.354 -178.044 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 52.7 m-80 -96.69 164.85 12.41 Favored 'General case' 0 C--O 1.247 0.946 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.716 -175.427 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.417 HG21 ' CZ2' ' A' ' 23' ' ' TRP . 86.7 t -87.36 137.11 21.58 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.735 0 CA-C-N 115.897 -0.592 . . . . 0.0 111.198 177.361 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 101' ' ' VAL . . . . . 0.475 HG11 ' HA ' ' A' ' 121' ' ' ALA . 34.3 m -119.87 -29.59 1.78 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.743 0 N-CA-C 112.971 0.73 . . . . 0.0 112.971 -178.426 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 102' ' ' ALA . . . . . 0.629 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -141.26 138.06 32.97 Favored 'General case' 0 C--N 1.323 -0.557 0 C-N-CA 120.048 -0.661 . . . . 0.0 111.445 179.537 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 93.3 mt -134.03 128.02 52.42 Favored 'Isoleucine or valine' 0 C--O 1.244 0.78 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.836 179.154 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 43.5 t30 -129.21 99.76 5.35 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 109.033 -0.728 . . . . 0.0 109.033 174.483 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.446 HG22 ' HB ' ' A' ' 36' ' ' ILE . 25.2 m -141.99 148.31 20.68 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 N-CA-C 112.572 0.582 . . . . 0.0 112.572 -176.416 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 37.9 tt0 -149.92 154.98 39.21 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 115.156 -0.929 . . . . 0.0 108.88 175.469 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 107' ' ' SER . . . . . 0.406 ' HB2' HD23 ' A' ' 114' ' ' LEU . 37.7 t -132.84 143.65 49.68 Favored 'General case' 0 C--N 1.311 -1.078 0 CA-C-O 121.132 0.491 . . . . 0.0 111.702 -177.997 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -84.78 -9.42 81.07 Favored Glycine 0 N--CA 1.441 -0.979 0 N-CA-C 110.166 -1.174 . . . . 0.0 110.166 174.922 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 78.3 m-20 -97.29 -171.28 2.17 Favored 'General case' 0 CA--C 1.507 -0.685 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 178.404 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 99.4 m-20 -89.65 39.53 0.96 Allowed 'General case' 0 C--N 1.308 -1.221 0 CA-C-O 121.373 0.606 . . . . 0.0 110.392 177.843 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 95.18 -2.65 65.94 Favored Glycine 0 N--CA 1.447 -0.598 0 CA-C-N 115.609 -0.723 . . . . 0.0 113.152 178.571 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 112' ' ' GLN . . . . . 0.664 ' HA ' HD23 ' A' ' 132' ' ' LEU . 98.4 mt-30 -64.14 -42.7 96.69 Favored 'General case' 0 C--O 1.245 0.839 0 N-CA-C 112.755 0.65 . . . . 0.0 112.755 -176.989 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 46.5 p -124.63 106.64 10.27 Favored 'General case' 0 N--CA 1.449 -0.521 0 CA-C-O 120.954 0.407 . . . . 0.0 110.279 176.996 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 114' ' ' LEU . . . . . 0.406 HD23 ' HB2' ' A' ' 107' ' ' SER . 98.3 mt -91.33 111.84 23.51 Favored 'General case' 0 C--N 1.316 -0.883 0 CA-C-O 120.642 0.258 . . . . 0.0 110.347 -179.344 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 57.1 m-80 -108.86 143.03 38.59 Favored 'General case' 0 C--N 1.313 -0.997 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.342 -179.955 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 163.56 -141.69 7.31 Favored Glycine 0 N--CA 1.435 -1.426 0 C-N-CA 119.655 -1.26 . . . . 0.0 113.162 177.599 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 33.8 p -134.85 158.12 45.05 Favored 'General case' 0 C--N 1.315 -0.907 0 C-N-CA 122.616 0.366 . . . . 0.0 110.504 -177.99 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 25.8 ptm -144.97 152.24 39.86 Favored 'General case' 0 C--N 1.314 -0.939 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.297 -179.766 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 119' ' ' THR . . . . . 0.629 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 32.9 m -129.74 129.34 44.03 Favored 'General case' 0 C--O 1.249 1.059 0 CA-C-N 116.387 -0.37 . . . . 0.0 110.694 179.682 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 45.6 m-85 -85.34 170.48 12.71 Favored 'General case' 0 CA--C 1.517 -0.289 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.325 176.4 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 121' ' ' ALA . . . . . 0.475 ' HA ' HG11 ' A' ' 101' ' ' VAL . . . -53.21 -40.4 64.44 Favored 'General case' 0 N--CA 1.471 0.586 0 N-CA-C 113.167 0.803 . . . . 0.0 113.167 -178.13 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -151.81 87.88 0.14 Allowed Glycine 0 N--CA 1.447 -0.602 0 C-N-CA 119.579 -1.296 . . . . 0.0 112.821 -179.404 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 77.4 tt0 -169.8 -69.14 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.771 0.32 . . . . 0.0 110.842 179.436 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 153.44 161.87 10.65 Favored Glycine 0 N--CA 1.443 -0.841 0 C-N-CA 120.812 -0.708 . . . . 0.0 111.887 179.316 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 21.2 Cg_exo -66.96 136.57 41.75 Favored 'Trans proline' 0 C--O 1.24 0.582 0 C-N-CA 122.733 2.289 . . . . 0.0 111.73 178.865 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 43.1 pt -135.52 166.26 28.14 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.145 178.862 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -72.89 136.15 22.48 Favored Glycine 0 C--O 1.237 0.284 0 C-N-CA 120.712 -0.756 . . . . 0.0 111.786 -179.759 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 78.9 t80 -122.46 136.81 54.97 Favored 'General case' 0 C--O 1.24 0.569 0 CA-C-O 120.959 0.409 . . . . 0.0 111.651 -177.286 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 61.9 tttm -134.87 103.69 5.7 Favored 'General case' 0 N--CA 1.446 -0.668 0 CA-C-N 115.349 -0.841 . . . . 0.0 109.941 177.145 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -100.24 133.33 11.26 Favored Glycine 0 N--CA 1.443 -0.863 0 N-CA-C 111.183 -0.767 . . . . 0.0 111.183 177.733 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 38.7 m -129.84 137.56 50.51 Favored 'General case' 0 C--N 1.306 -1.286 0 CA-C-N 117.042 0.421 . . . . 0.0 111.187 -177.951 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 132' ' ' LEU . . . . . 0.664 HD23 ' HA ' ' A' ' 112' ' ' GLN . 2.9 mm? -59.76 137.78 57.96 Favored 'General case' 0 N--CA 1.473 0.708 0 CA-C-O 121.285 0.564 . . . . 0.0 111.727 178.752 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 133' ' ' THR . . . . . 0.433 ' HB ' HD12 ' A' ' 3' ' ' LEU . 14.4 m . . . . . 0 N--CA 1.435 -1.203 0 CA-C-N 115.528 -0.76 . . . . 0.0 110.174 178.283 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.51 -0.561 0 CA-C-O 120.694 0.283 . . . . 0.0 110.33 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 10.2 tt -99.77 131.83 45.5 Favored 'General case' 0 C--N 1.316 -0.889 0 CA-C-O 121.177 0.513 . . . . 0.0 110.486 -179.059 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 85.8 m-85 -120.81 142.64 49.42 Favored 'General case' 0 C--N 1.311 -1.083 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.201 178.964 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 5' ' ' ASN . . . . . 0.503 ' O ' ' HA2' ' A' ' 130' ' ' GLY . 88.9 m-20 -87.94 132.15 34.33 Favored 'General case' 0 C--N 1.308 -1.219 0 N-CA-C 107.501 -1.296 . . . . 0.0 107.501 176.786 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.6 HG21 ' CG ' ' A' ' 23' ' ' TRP . 54.2 t -113.88 128.66 70.7 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.99 0 CA-C-O 121.973 0.892 . . . . 0.0 113.191 -173.456 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.437 ' HB2' ' HB3' ' A' ' 129' ' ' LYS . 27.0 mt-10 -120.82 131.75 54.62 Favored 'General case' 0 N--CA 1.43 -1.45 0 CA-C-N 113.631 -1.622 . . . . 0.0 107.755 179.785 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 88.9 m-20 -119.9 145.32 46.8 Favored 'General case' 0 C--N 1.314 -0.939 0 CA-C-O 120.995 0.426 . . . . 0.0 111.9 -176.81 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 53.4 tt0 -122.66 110.29 15.34 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.57 -0.741 . . . . 0.0 109.138 179.554 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 3.1 p90 -128.68 -171.42 2.46 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 112.682 0.623 . . . . 0.0 112.682 -175.079 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 66.34 -90.84 0.15 Allowed Glycine 0 C--N 1.336 0.552 0 CA-C-N 114.955 -1.02 . . . . 0.0 114.938 176.084 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.466 ' C ' ' H ' ' A' ' 14' ' ' SER . . . -85.85 0.78 87.97 Favored Glycine 0 C--N 1.319 -0.376 0 C-N-CA 121.319 -0.467 . . . . 0.0 114.098 -173.52 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 13.3 t 59.17 -6.46 0.06 Allowed 'General case' 0 CA--C 1.562 1.434 0 C-N-CA 123.323 0.649 . . . . 0.0 112.662 -177.719 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' SER . . . . . 0.466 ' H ' ' C ' ' A' ' 12' ' ' GLY . 8.7 t -125.7 16.13 8.11 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-O 121.658 0.742 . . . . 0.0 109.358 -179.39 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -80.05 163.79 55.94 Favored Pre-proline 0 N--CA 1.445 -0.718 0 CA-C-N 114.877 -1.056 . . . . 0.0 110.122 -179.463 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 14.2 Cg_exo -69.71 169.6 18.47 Favored 'Trans proline' 0 N--CA 1.46 -0.488 0 C-N-CA 122.608 2.205 . . . . 0.0 111.757 177.967 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 98.5 m95 -80.92 121.71 26.34 Favored 'General case' 0 C--N 1.316 -0.868 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 -179.224 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 91.4 m-20 -106.56 114.19 28.16 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.573 -177.595 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -78.56 128.62 33.78 Favored 'General case' 0 C--N 1.319 -0.756 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 178.406 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -143.3 35.45 1.66 Allowed Glycine 0 N--CA 1.442 -0.961 0 C-N-CA 119.51 -1.329 . . . . 0.0 112.694 -179.713 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 137.62 -174.02 22.02 Favored Glycine 0 N--CA 1.443 -0.843 0 C-N-CA 120.034 -1.079 . . . . 0.0 112.782 178.185 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 88.1 mt-30 -132.0 149.21 52.49 Favored 'General case' 0 C--N 1.318 -0.788 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 -179.768 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' TRP . . . . . 0.6 ' CG ' HG21 ' A' ' 6' ' ' VAL . 38.5 m0 -119.07 153.24 35.08 Favored 'General case' 0 C--N 1.315 -0.913 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 177.947 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 24' ' ' GLU . . . . . 0.443 ' H ' ' HB ' ' A' ' 91' ' ' ILE . 89.1 mt-10 -111.59 113.69 26.26 Favored 'General case' 0 C--N 1.305 -1.345 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 175.946 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 81.8 mt -130.25 140.35 49.1 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-N 116.0 -0.546 . . . . 0.0 111.904 -172.381 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 91.79 125.17 3.4 Favored Glycine 0 N--CA 1.442 -0.945 0 N-CA-C 114.761 0.665 . . . . 0.0 114.761 172.294 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 3.8 p -88.35 12.61 13.66 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 109.278 -0.638 . . . . 0.0 109.278 173.939 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 62.6 ttp85 -24.74 108.91 0.03 OUTLIER 'General case' 0 N--CA 1.474 0.727 0 C-N-CA 125.477 1.511 . . . . 0.0 113.883 179.732 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 11.0 m -102.88 -62.36 1.29 Allowed 'General case' 0 N--CA 1.436 -1.14 0 CA-C-N 115.235 -0.893 . . . . 0.0 108.83 176.733 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 27.2 m-20 -124.4 5.85 8.36 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.46 178.17 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 1.4 mm-40 -149.53 136.36 19.53 Favored 'General case' 0 C--N 1.318 -0.761 0 CA-C-N 116.009 -0.542 . . . . 0.0 111.432 -177.864 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 32' ' ' ASN . . . . . 0.516 ' ND2' ' HA3' ' A' ' 111' ' ' GLY . 63.7 t30 -93.36 164.45 13.21 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.947 -0.569 . . . . 0.0 111.331 -179.126 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.411 ' HA ' ' HA ' ' A' ' 53' ' ' TYR . 57.8 t -96.27 130.37 45.03 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 CA-C-N 115.422 -0.808 . . . . 0.0 110.699 -176.912 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 23.7 m -114.07 -16.33 9.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 N-CA-C 112.218 0.451 . . . . 0.0 112.218 178.754 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 35' ' ' ALA . . . . . 0.403 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -145.86 142.37 28.74 Favored 'General case' 0 CA--C 1.515 -0.384 0 C-N-CA 120.377 -0.529 . . . . 0.0 111.537 178.998 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.435 ' HB ' ' CG2' ' A' ' 105' ' ' VAL . 96.3 mt -142.57 127.46 16.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 N-CA-C 108.987 -0.746 . . . . 0.0 108.987 179.124 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 37' ' ' ASN . . . . . 0.435 ' HA ' ' O ' ' A' ' 103' ' ' ILE . 3.1 t30 -138.0 113.09 9.2 Favored 'General case' 0 C--N 1.313 -0.991 0 N-CA-C 108.739 -0.837 . . . . 0.0 108.739 176.865 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.45 HG11 ' CD2' ' A' ' 61' ' ' PHE . 28.0 m -148.18 153.15 11.88 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.442 0 C-N-CA 120.918 -0.313 . . . . 0.0 111.19 -174.059 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 81.3 tt0 -139.17 145.37 39.26 Favored 'General case' 0 C--N 1.321 -0.639 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 176.714 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 12.9 t -77.04 139.93 40.19 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-O 120.883 0.373 . . . . 0.0 110.714 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -88.63 -7.07 72.29 Favored Glycine 0 N--CA 1.446 -0.672 0 C-N-CA 120.555 -0.831 . . . . 0.0 111.114 177.061 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 42' ' ' ASP . . . . . 0.442 ' HB3' ' H ' ' A' ' 43' ' ' ASP . 21.1 m-20 -141.83 -153.98 0.49 Allowed 'General case' 0 C--N 1.33 -0.242 0 C-N-CA 122.508 0.323 . . . . 0.0 110.257 -179.319 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 43' ' ' ASP . . . . . 0.442 ' H ' ' HB3' ' A' ' 42' ' ' ASP . 86.7 m-20 -78.28 44.07 0.48 Allowed 'General case' 0 N--CA 1.471 0.589 0 C-N-CA 122.664 0.386 . . . . 0.0 111.961 -178.468 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 87.49 -5.13 85.53 Favored Glycine 0 C--O 1.227 -0.335 0 C-N-CA 120.787 -0.721 . . . . 0.0 113.491 178.094 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 54.9 mt-30 -70.29 -38.89 75.1 Favored 'General case' 0 C--O 1.222 -0.362 0 N-CA-C 112.59 0.589 . . . . 0.0 112.59 179.604 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 46' ' ' THR . . . . . 0.606 ' HA ' ' O ' ' A' ' 63' ' ' ALA . 7.8 t -127.71 123.57 35.73 Favored 'General case' 0 C--N 1.32 -0.689 0 C-N-CA 120.426 -0.51 . . . . 0.0 111.293 -179.027 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 95.5 mt -103.15 124.81 49.29 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.037 177.912 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 48' ' ' ASN . . . . . 0.503 ' OD1' ' HG3' ' A' ' 62' ' ' ARG . 93.2 m-20 -119.61 142.11 48.7 Favored 'General case' 0 C--N 1.313 -0.985 0 CA-C-N 115.969 -0.559 . . . . 0.0 110.021 179.616 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 166.47 -146.48 10.97 Favored Glycine 0 CA--C 1.501 -0.822 0 C-N-CA 119.787 -1.197 . . . . 0.0 112.787 179.373 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 33.5 p -135.51 153.04 51.86 Favored 'General case' 0 N--CA 1.446 -0.629 0 CA-C-O 120.973 0.416 . . . . 0.0 111.066 -178.718 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 51' ' ' MET . . . . . 0.415 ' HE1' ' CZ ' ' A' ' 53' ' ' TYR . 16.6 tmm? -135.01 138.65 44.16 Favored 'General case' 0 C--N 1.317 -0.83 0 N-CA-C 109.276 -0.638 . . . . 0.0 109.276 178.148 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.403 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 29.4 m -125.24 129.26 49.71 Favored 'General case' 0 C--O 1.255 1.365 0 N-CA-C 112.527 0.566 . . . . 0.0 112.527 -175.564 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 53' ' ' TYR . . . . . 0.51 ' HB2' ' HB2' ' A' ' 56' ' ' GLU . 95.1 m-85 -85.29 165.73 17.07 Favored 'General case' 0 CA--C 1.532 0.251 0 CA-C-N 115.341 -0.845 . . . . 0.0 109.805 176.659 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -66.87 113.51 4.98 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 120.714 0.292 . . . . 0.0 111.707 -179.008 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 76.6 16.53 80.67 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.844 178.11 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 56' ' ' GLU . . . . . 0.51 ' HB2' ' HB2' ' A' ' 53' ' ' TYR . 73.0 mm-40 -121.71 177.67 5.16 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-O 120.769 0.319 . . . . 0.0 110.395 -179.397 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -93.38 153.48 21.37 Favored Glycine 0 N--CA 1.443 -0.857 0 C-N-CA 120.805 -0.712 . . . . 0.0 111.556 178.694 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -67.8 144.27 64.55 Favored 'Trans proline' 0 C--O 1.237 0.432 0 C-N-CA 122.555 2.17 . . . . 0.0 112.574 179.581 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 39.6 pt -125.86 162.69 28.74 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.818 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.284 178.644 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -71.24 145.1 38.74 Favored Glycine 0 N--CA 1.448 -0.537 0 C-N-CA 121.195 -0.526 . . . . 0.0 112.323 -177.559 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.45 ' CD2' HG11 ' A' ' 38' ' ' VAL . 69.4 t80 -130.93 126.94 37.42 Favored 'General case' 0 C--N 1.313 -1.02 0 C-N-CA 122.106 0.162 . . . . 0.0 110.972 -178.186 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 62' ' ' ARG . . . . . 0.503 ' HG3' ' OD1' ' A' ' 48' ' ' ASN . 29.0 ttp85 -135.32 128.31 31.51 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 108.798 -0.816 . . . . 0.0 108.798 174.643 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.606 ' O ' ' HA ' ' A' ' 46' ' ' THR . . . -132.87 141.76 48.58 Favored 'General case' 0 C--N 1.316 -0.857 0 C-N-CA 120.852 -0.339 . . . . 0.0 111.713 -178.378 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 31.7 m -124.06 128.97 50.1 Favored 'General case' 0 CA--C 1.539 0.527 0 CA-C-N 116.458 -0.337 . . . . 0.0 110.634 179.516 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 51.2 tp -74.73 127.6 33.53 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 112.279 0.474 . . . . 0.0 112.279 -177.514 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 10.7 mp -79.82 -24.36 41.41 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.969 177.094 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 113.64 -8.36 24.05 Favored Glycine 0 CA--C 1.521 0.465 0 C-N-CA 120.93 -0.653 . . . . 0.0 112.638 179.88 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 24.2 p-10 -115.41 30.12 7.56 Favored 'General case' 0 C--N 1.312 -1.054 0 CA-C-O 121.04 0.448 . . . . 0.0 110.445 179.937 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 87.3 m-20 76.48 -9.38 1.49 Allowed 'General case' 0 N--CA 1.485 1.278 0 C-N-CA 124.353 1.061 . . . . 0.0 111.048 -178.099 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 9.0 m -81.49 138.58 35.47 Favored 'General case' 0 N--CA 1.441 -0.884 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.433 177.828 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.524 ' HB3' ' HB1' ' A' ' 63' ' ' ALA . 43.8 m-85 -122.12 129.94 52.8 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-N 115.679 -0.691 . . . . 0.0 109.685 178.126 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 72' ' ' GLU . . . . . 0.41 ' O ' ' HA ' ' A' ' 63' ' ' ALA . 36.0 tt0 -83.45 119.02 24.14 Favored 'General case' 0 N--CA 1.44 -0.949 0 N-CA-C 107.774 -1.195 . . . . 0.0 107.774 174.99 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.449 HG22 ' HB2' ' A' ' 63' ' ' ALA . 53.0 t -108.08 133.62 52.41 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.307 0 N-CA-C 112.866 0.691 . . . . 0.0 112.866 -172.474 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 99.8 mt-10 -120.03 122.4 41.05 Favored 'General case' 0 N--CA 1.436 -1.158 0 CA-C-N 114.51 -1.223 . . . . 0.0 108.875 176.676 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 2.7 m-20 -96.29 140.57 30.78 Favored 'General case' 0 C--N 1.313 -1.018 0 CA-C-N 116.288 -0.415 . . . . 0.0 109.917 179.367 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 76' ' ' GLN . . . . . 0.508 ' HB2' ' CE3' ' A' ' 84' ' ' TRP . 61.3 tt0 -115.87 120.89 40.68 Favored 'General case' 0 C--N 1.307 -1.254 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 179.345 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 6.1 p90 -137.55 157.1 47.25 Favored 'General case' 0 C--N 1.312 -1.027 0 CA-C-O 120.723 0.297 . . . . 0.0 110.329 179.481 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 103.13 -13.84 55.51 Favored Glycine 0 N--CA 1.439 -1.115 0 C-N-CA 120.756 -0.735 . . . . 0.0 111.652 -179.838 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 131.51 170.64 12.67 Favored Glycine 0 N--CA 1.437 -1.246 0 C-N-CA 120.886 -0.673 . . . . 0.0 111.972 178.97 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 5.7 p-10 -65.73 -33.1 75.09 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 121.056 0.455 . . . . 0.0 111.127 179.864 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 40.6 m -78.45 -2.89 40.66 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 115.845 -0.616 . . . . 0.0 111.856 -178.565 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -89.61 146.11 34.99 Favored Pre-proline 0 C--N 1.325 -0.458 0 CA-C-N 116.6 -0.273 . . . . 0.0 110.341 178.606 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.82 177.09 5.98 Favored 'Trans proline' 0 CA--C 1.532 0.405 0 C-N-CA 122.738 2.292 . . . . 0.0 112.298 179.847 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 84' ' ' TRP . . . . . 0.508 ' CE3' ' HB2' ' A' ' 76' ' ' GLN . 98.5 m95 -85.89 143.09 28.41 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 109.716 -0.476 . . . . 0.0 109.716 -179.154 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 91.7 m-70 -119.61 146.11 45.83 Favored 'General case' 0 C--N 1.313 -1.021 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 -179.643 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 46.0 m -63.51 131.2 47.36 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-O 120.891 0.377 . . . . 0.0 110.898 -179.396 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -107.94 -55.2 0.61 Allowed Glycine 0 N--CA 1.441 -1.013 0 C-N-CA 120.842 -0.694 . . . . 0.0 111.694 179.536 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 157.42 -173.43 34.88 Favored Glycine 0 C--O 1.223 -0.546 0 C-N-CA 120.26 -0.971 . . . . 0.0 112.184 179.326 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 24.3 t-20 -109.7 113.26 25.88 Favored 'General case' 0 C--N 1.316 -0.879 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 178.919 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 21.0 m0 -105.96 153.14 22.41 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.432 -176.416 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 91' ' ' ILE . . . . . 0.443 ' HB ' ' H ' ' A' ' 24' ' ' GLU . 46.8 mm -107.22 113.54 43.8 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.799 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 177.259 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 82.8 mt -127.08 78.51 1.82 Allowed 'General case' 0 C--O 1.268 2.066 0 CA-C-O 122.045 0.926 . . . . 0.0 112.371 -176.973 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 162.71 104.87 0.19 Allowed Glycine 0 N--CA 1.444 -0.772 0 CA-C-N 114.741 -1.118 . . . . 0.0 110.752 -179.072 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 15.7 p -106.88 -13.12 15.31 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 120.889 0.376 . . . . 0.0 111.867 -178.0 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 85.2 mtp180 -85.47 16.2 3.96 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 121.248 0.547 . . . . 0.0 111.452 -179.202 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 46.9 tp10 65.36 -74.51 0.05 Allowed 'General case' 0 N--CA 1.472 0.646 0 CA-C-N 114.459 -1.246 . . . . 0.0 113.97 174.007 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 61.9 m-80 -91.97 26.85 2.3 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-O 120.765 0.317 . . . . 0.0 111.739 -175.077 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 98' ' ' GLN . . . . . . . . . . . . . 58.1 tt0 -150.05 116.62 5.81 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.801 0.334 . . . . 0.0 110.218 -177.969 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 83.6 m-20 -84.58 160.02 20.54 Favored 'General case' 0 C--O 1.245 0.819 0 CA-C-N 115.977 -0.556 . . . . 0.0 111.77 -176.895 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 79.5 t -82.36 132.43 31.43 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.664 0 C-N-CA 120.728 -0.389 . . . . 0.0 110.818 176.699 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 34.7 m -114.44 -23.76 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.601 0 N-CA-C 113.087 0.773 . . . . 0.0 113.087 -179.457 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 102' ' ' ALA . . . . . 0.549 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -152.04 144.13 23.87 Favored 'General case' 0 CA--C 1.512 -0.49 0 C-N-CA 120.425 -0.51 . . . . 0.0 111.113 178.198 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.442 ' HB ' HG22 ' A' ' 38' ' ' VAL . 84.6 mt -135.88 125.8 41.24 Favored 'Isoleucine or valine' 0 C--O 1.236 0.393 0 CA-C-O 120.582 0.23 . . . . 0.0 110.81 179.066 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 27.2 t-20 -126.74 94.88 4.16 Favored 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 175.172 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.435 ' CG2' ' HB ' ' A' ' 36' ' ' ILE . 30.9 m -136.88 141.43 40.68 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.702 0 N-CA-C 113.633 0.975 . . . . 0.0 113.633 -174.191 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 74.6 tt0 -141.71 150.49 41.9 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 114.97 -1.014 . . . . 0.0 109.298 178.117 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 107' ' ' SER . . . . . 0.415 ' HB3' ' HA ' ' A' ' 114' ' ' LEU . 35.6 p -150.65 153.17 35.15 Favored 'General case' 0 N--CA 1.446 -0.671 0 CA-C-O 120.821 0.343 . . . . 0.0 111.219 177.545 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -123.19 5.59 9.47 Favored Glycine 0 N--CA 1.439 -1.124 0 N-CA-C 111.112 -0.795 . . . . 0.0 111.112 177.474 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -92.34 34.59 1.03 Allowed 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 121.196 0.522 . . . . 0.0 110.528 179.495 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 29.3 m-20 59.21 21.83 10.0 Favored 'General case' 0 N--CA 1.474 0.741 0 CA-C-N 115.284 -0.871 . . . . 0.0 112.507 176.997 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 111' ' ' GLY . . . . . 0.516 ' HA3' ' ND2' ' A' ' 32' ' ' ASN . . . 89.71 -0.14 79.5 Favored Glycine 0 N--CA 1.447 -0.582 0 C-N-CA 120.748 -0.739 . . . . 0.0 113.174 177.928 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 51.8 tt0 -65.62 -43.38 89.76 Favored 'General case' 0 C--O 1.235 0.335 0 CA-C-O 121.356 0.598 . . . . 0.0 110.282 178.725 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 6.4 p -128.72 125.99 39.11 Favored 'General case' 0 N--CA 1.434 -1.248 0 CA-C-N 115.428 -0.805 . . . . 0.0 109.97 176.665 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 114' ' ' LEU . . . . . 0.415 ' HA ' ' HB3' ' A' ' 107' ' ' SER . 42.4 tp -112.47 134.94 53.73 Favored 'General case' 0 C--N 1.306 -1.319 0 CA-C-N 115.899 -0.591 . . . . 0.0 109.596 -177.776 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 30.1 p30 -145.72 169.91 17.54 Favored 'General case' 0 C--N 1.32 -0.698 0 C-N-CA 119.779 -0.768 . . . . 0.0 112.301 179.92 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 147.36 -131.71 4.02 Favored Glycine 0 N--CA 1.434 -1.444 0 CA-C-N 115.127 -0.942 . . . . 0.0 111.204 179.283 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 21.9 p -133.2 159.23 40.79 Favored 'General case' 0 C--N 1.307 -1.246 0 CA-C-O 121.095 0.474 . . . . 0.0 110.72 179.923 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 118' ' ' MET . . . . . 0.404 ' HE2' ' HB2' ' A' ' 118' ' ' MET . 4.5 ppp? -153.91 163.02 40.73 Favored 'General case' 0 C--N 1.306 -1.306 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 178.802 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 119' ' ' THR . . . . . 0.549 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 32.1 m -131.47 130.2 42.13 Favored 'General case' 0 C--N 1.307 -1.254 0 CA-C-O 120.791 0.329 . . . . 0.0 111.235 -179.79 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 11.5 m-85 -94.71 161.22 14.27 Favored 'General case' 0 N--CA 1.45 -0.473 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.075 177.095 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -65.6 128.19 34.93 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 120.89 0.376 . . . . 0.0 111.89 -179.098 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 76.23 19.17 78.72 Favored Glycine 0 N--CA 1.45 -0.396 0 CA-C-N 115.775 -0.648 . . . . 0.0 112.956 176.859 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 70.5 tt0 -147.22 161.08 41.65 Favored 'General case' 0 C--N 1.317 -0.832 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 -178.393 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -80.05 -179.49 52.54 Favored Glycine 0 N--CA 1.448 -0.508 0 C-N-CA 121.017 -0.611 . . . . 0.0 112.356 179.63 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -71.56 140.37 36.05 Favored 'Trans proline' 0 CA--C 1.532 0.392 0 C-N-CA 122.714 2.276 . . . . 0.0 112.959 -178.788 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 44.0 pt -132.68 165.99 30.64 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.13 178.805 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -73.15 142.6 31.91 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 121.017 -0.611 . . . . 0.0 112.458 -179.809 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 79.4 t80 -122.76 136.88 55.01 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-O 120.911 0.386 . . . . 0.0 111.272 -179.288 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 129' ' ' LYS . . . . . 0.437 ' HB3' ' HB2' ' A' ' 7' ' ' GLU . 63.2 tttm -142.0 125.95 17.21 Favored 'General case' 0 N--CA 1.447 -0.58 0 CA-C-N 115.649 -0.705 . . . . 0.0 109.154 175.668 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 130' ' ' GLY . . . . . 0.503 ' HA2' ' O ' ' A' ' 5' ' ' ASN . . . -127.24 135.74 8.96 Favored Glycine 0 N--CA 1.432 -1.581 0 N-CA-C 110.856 -0.898 . . . . 0.0 110.856 178.918 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 30.1 m -118.55 126.94 53.08 Favored 'General case' 0 C--N 1.305 -1.338 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 -178.581 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 66.1 tp -75.24 140.71 43.39 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.782 0.325 . . . . 0.0 111.154 -178.608 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 9.8 t . . . . . 0 C--O 1.248 1.022 0 CA-C-O 118.604 -0.712 . . . . 0.0 109.533 177.987 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.467 0.394 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 3.3 tm? -90.72 128.08 36.54 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-O 121.046 0.45 . . . . 0.0 110.332 -178.331 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 47.2 m-85 -124.46 147.08 48.56 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.864 -0.607 . . . . 0.0 111.175 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 5.7 m-20 -100.97 137.83 38.82 Favored 'General case' 0 C--N 1.315 -0.931 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 175.502 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.452 HG21 ' CD2' ' A' ' 23' ' ' TRP . 68.1 t -116.02 128.26 73.36 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.774 0 CA-C-O 121.527 0.68 . . . . 0.0 112.745 -173.913 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.453 ' HB3' ' HB3' ' A' ' 17' ' ' TRP . 65.4 mt-10 -118.66 138.36 52.66 Favored 'General case' 0 N--CA 1.437 -1.101 0 CA-C-N 114.681 -1.145 . . . . 0.0 108.423 176.713 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 89.7 m-20 -127.44 147.16 50.29 Favored 'General case' 0 C--N 1.312 -1.037 0 CA-C-O 121.172 0.511 . . . . 0.0 111.896 -177.056 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 52.1 tt0 -123.38 117.24 24.75 Favored 'General case' 0 C--N 1.314 -0.955 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 178.118 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 7.6 p90 -137.93 9.44 2.81 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 114.313 1.227 . . . . 0.0 114.313 -174.84 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -93.24 31.51 6.3 Favored Glycine 0 CA--C 1.522 0.485 0 C-N-CA 118.748 -1.692 . . . . 0.0 114.353 -174.784 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.63 58.88 3.17 Favored Glycine 0 CA--C 1.525 0.67 0 C-N-CA 120.428 -0.891 . . . . 0.0 114.376 176.922 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 22.8 t 60.69 154.55 0.03 OUTLIER 'General case' 0 CA--C 1.553 1.083 0 N-CA-C 113.408 0.892 . . . . 0.0 113.408 177.325 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 49.3 m 63.3 14.42 7.82 Favored 'General case' 0 N--CA 1.472 0.671 0 CA-C-N 115.851 -0.613 . . . . 0.0 112.355 177.223 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -96.7 153.95 38.57 Favored Pre-proline 0 C--N 1.314 -0.939 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.189 -179.446 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -73.18 161.69 42.47 Favored 'Trans proline' 0 C--O 1.238 0.503 0 C-N-CA 122.634 2.223 . . . . 0.0 111.703 177.772 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' TRP . . . . . 0.453 ' HB3' ' HB3' ' A' ' 7' ' ' GLU . 92.6 m95 -85.18 129.46 34.8 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 109.664 -0.495 . . . . 0.0 109.664 179.51 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 27.6 m-80 -113.22 118.57 35.04 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.661 -178.053 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.434 ' HA ' ' HA ' ' A' ' 7' ' ' GLU . 11.5 pt-20 -75.48 129.94 38.09 Favored 'General case' 0 C--N 1.319 -0.718 0 N-CA-C 109.724 -0.473 . . . . 0.0 109.724 177.474 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -137.62 26.57 2.9 Favored Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 119.596 -1.288 . . . . 0.0 113.159 -178.661 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 147.86 179.26 23.72 Favored Glycine 0 N--CA 1.449 -0.433 0 C-N-CA 119.79 -1.195 . . . . 0.0 113.075 178.125 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 25.8 pt20 -127.99 138.74 52.72 Favored 'General case' 0 C--N 1.322 -0.601 0 C-N-CA 122.69 0.396 . . . . 0.0 110.205 -179.93 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' TRP . . . . . 0.452 ' CD2' HG21 ' A' ' 6' ' ' VAL . 45.7 m0 -116.07 171.81 7.56 Favored 'General case' 0 C--O 1.242 0.661 0 CA-C-O 120.86 0.362 . . . . 0.0 111.226 -177.802 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 76.5 tt0 -119.13 110.73 17.4 Favored 'General case' 0 CA--C 1.513 -0.465 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 178.005 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 91.1 mt -133.01 143.97 37.9 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-N 115.401 -0.818 . . . . 0.0 109.579 -178.164 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 83.94 71.73 1.31 Allowed Glycine 0 CA--C 1.508 -0.351 0 C-N-CA 120.369 -0.92 . . . . 0.0 112.014 177.891 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 15.9 m -62.68 -45.62 91.97 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 120.823 0.344 . . . . 0.0 111.279 -179.313 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 83.0 mtm-85 -88.36 133.99 33.94 Favored 'General case' 0 CA--C 1.517 -0.322 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.057 178.797 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 18.8 p -87.16 -16.13 36.3 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.956 -0.565 . . . . 0.0 111.398 179.701 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 16.5 m-20 -71.31 -43.2 67.52 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-O 121.51 0.671 . . . . 0.0 110.161 179.933 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 14.1 mm100 -131.76 122.3 25.61 Favored 'General case' 0 C--N 1.312 -1.027 0 CA-C-N 114.915 -1.039 . . . . 0.0 110.046 -179.399 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 32' ' ' ASN . . . . . 0.506 ' ND2' ' HA3' ' A' ' 111' ' ' GLY . 59.4 t30 -108.15 172.36 6.88 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.324 -177.575 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 14.0 t -101.71 134.24 42.76 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.92 0 N-CA-C 111.877 0.325 . . . . 0.0 111.877 -172.031 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 33.6 m -113.77 -15.34 10.25 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.356 0 CA-C-O 121.017 0.437 . . . . 0.0 111.594 177.386 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 35' ' ' ALA . . . . . 0.647 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -147.48 142.67 27.19 Favored 'General case' 0 CA--C 1.506 -0.715 0 C-N-CA 120.269 -0.572 . . . . 0.0 111.181 178.199 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.402 ' HB ' HG22 ' A' ' 105' ' ' VAL . 85.9 mt -142.36 120.43 8.04 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 N-CA-C 109.155 -0.683 . . . . 0.0 109.155 -179.377 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 37' ' ' ASN . . . . . 0.452 ' HA ' ' O ' ' A' ' 103' ' ' ILE . 22.7 m-80 -132.37 109.81 10.12 Favored 'General case' 0 C--N 1.31 -1.151 0 N-CA-C 108.88 -0.785 . . . . 0.0 108.88 176.49 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.488 HG22 ' HB ' ' A' ' 103' ' ' ILE . 33.3 m -147.79 152.93 12.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 C-N-CA 120.996 -0.281 . . . . 0.0 111.254 -172.57 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 41.6 tt0 -142.45 147.27 35.84 Favored 'General case' 0 N--CA 1.446 -0.633 0 CA-C-N 115.845 -0.616 . . . . 0.0 109.433 176.755 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 19.9 p -70.42 144.38 51.53 Favored 'General case' 0 C--N 1.313 -1.005 0 CA-C-O 121.083 0.468 . . . . 0.0 111.652 -178.548 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -88.38 -59.18 1.67 Allowed Glycine 0 N--CA 1.441 -0.971 0 N-CA-C 110.366 -1.094 . . . . 0.0 110.366 177.174 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 43.9 m-20 -93.78 -147.11 0.25 Allowed 'General case' 0 C--N 1.32 -0.713 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 176.708 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 20.2 p-10 -78.99 40.66 0.41 Allowed 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.124 0.488 . . . . 0.0 111.949 -178.818 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 97.89 -22.39 41.07 Favored Glycine 0 C--O 1.219 -0.82 0 C-N-CA 120.753 -0.736 . . . . 0.0 113.736 177.351 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 56.3 mt-30 -64.34 -28.61 69.82 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 117.319 0.559 . . . . 0.0 112.111 -178.603 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 26.0 p -117.54 137.0 52.87 Favored 'General case' 0 C--N 1.312 -1.029 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.392 179.334 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 88.7 mt -127.51 128.91 46.47 Favored 'General case' 0 C--N 1.318 -0.793 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 62.7 m-80 -129.47 140.82 51.17 Favored 'General case' 0 C--N 1.318 -0.762 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 178.335 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 178.97 -156.89 19.8 Favored Glycine 0 N--CA 1.438 -1.196 0 C-N-CA 119.972 -1.108 . . . . 0.0 112.797 179.522 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 65.3 m -130.98 132.99 45.39 Favored 'General case' 0 C--N 1.312 -1.04 0 CA-C-O 120.843 0.354 . . . . 0.0 110.646 -179.536 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 46.9 mtp -115.66 148.28 39.88 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.722 177.983 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.647 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 33.0 m -126.4 125.33 42.01 Favored 'General case' 0 C--O 1.25 1.086 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.136 177.149 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 53' ' ' TYR . . . . . 0.441 ' HB2' ' HB2' ' A' ' 56' ' ' GLU . 50.8 m-85 -94.67 164.74 12.83 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.869 -179.43 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -65.14 95.97 0.19 Allowed 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.813 -0.63 . . . . 0.0 111.641 -179.47 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 98.81 4.67 56.82 Favored Glycine 0 C--N 1.318 -0.424 0 CA-C-N 115.613 -0.721 . . . . 0.0 112.434 177.153 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 56' ' ' GLU . . . . . 0.441 ' HB2' ' HB2' ' A' ' 53' ' ' TYR . 41.8 mt-10 -114.45 168.02 10.21 Favored 'General case' 0 C--N 1.314 -0.968 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 178.871 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -89.61 168.95 35.12 Favored Glycine 0 N--CA 1.437 -1.298 0 C-N-CA 120.541 -0.838 . . . . 0.0 111.413 178.756 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_exo -63.02 134.33 45.62 Favored 'Trans proline' 0 C--O 1.239 0.545 0 C-N-CA 122.345 2.03 . . . . 0.0 111.465 178.735 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 45.0 pt -130.54 166.7 27.47 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.846 179.675 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -73.6 142.49 31.23 Favored Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 121.074 -0.584 . . . . 0.0 112.338 -177.409 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 39.8 t80 -126.77 128.47 46.66 Favored 'General case' 0 C--N 1.317 -0.839 0 C-N-CA 122.451 0.3 . . . . 0.0 111.125 -179.067 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 69.5 ttp85 -136.5 132.25 35.04 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 174.348 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.654 ' HB1' ' HB3' ' A' ' 71' ' ' TYR . . . -137.28 146.26 44.48 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 111.892 0.33 . . . . 0.0 111.892 179.837 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 60.1 m -121.32 131.3 54.12 Favored 'General case' 0 CA--C 1.546 0.793 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.38 179.176 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 65' ' ' LEU . . . . . 0.511 ' O ' ' HB3' ' A' ' 66' ' ' LEU . 59.9 tp -43.2 -51.81 5.89 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 115.513 1.672 . . . . 0.0 115.513 -176.493 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 66' ' ' LEU . . . . . 0.511 ' HB3' ' O ' ' A' ' 65' ' ' LEU . 3.2 tm? 75.64 -57.06 0.59 Allowed 'General case' 0 CA--C 1.549 0.935 0 CA-C-N 118.364 0.529 . . . . 0.0 110.641 177.949 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -141.35 -90.27 0.16 Allowed Glycine 0 C--N 1.333 0.398 0 C-N-CA 121.057 -0.592 . . . . 0.0 112.646 -179.405 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 9.0 p30 -160.94 133.03 5.89 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 179.705 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 94.3 m-20 57.19 24.27 9.62 Favored 'General case' 0 N--CA 1.478 0.968 0 CA-C-O 121.279 0.562 . . . . 0.0 111.172 -176.256 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 43.5 m -138.2 152.03 48.25 Favored 'General case' 0 N--CA 1.434 -1.229 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 179.336 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.654 ' HB3' ' HB1' ' A' ' 63' ' ' ALA . 97.3 m-85 -149.85 126.39 10.91 Favored 'General case' 0 C--N 1.31 -1.118 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 176.662 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 72' ' ' GLU . . . . . 0.468 ' O ' ' HA ' ' A' ' 63' ' ' ALA . 83.7 tt0 -82.81 127.53 33.55 Favored 'General case' 0 N--CA 1.439 -0.991 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 175.603 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 76.9 t -104.75 131.55 53.55 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.278 0 CA-C-N 115.352 -0.84 . . . . 0.0 112.585 -171.96 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.469 ' HG2' ' HA ' ' A' ' 86' ' ' SER . 48.1 mt-10 -129.76 126.65 38.67 Favored 'General case' 0 N--CA 1.44 -0.966 0 CA-C-N 114.275 -1.33 . . . . 0.0 107.523 175.059 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 97.0 m-20 -109.53 154.34 22.85 Favored 'General case' 0 C--N 1.314 -0.973 0 CA-C-O 121.042 0.449 . . . . 0.0 112.053 -176.132 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 76' ' ' GLN . . . . . 0.537 ' HB2' ' CE3' ' A' ' 84' ' ' TRP . 61.8 tt0 -118.47 124.52 47.82 Favored 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 115.527 -0.76 . . . . 0.0 110.608 -176.193 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 6.0 p90 -142.59 158.8 43.3 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.158 179.07 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 98.32 -12.42 63.41 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.628 -0.796 . . . . 0.0 112.697 179.931 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 134.26 169.59 12.05 Favored Glycine 0 N--CA 1.447 -0.621 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.192 179.64 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 6.5 p-10 -68.83 -30.42 68.96 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 120.71 0.291 . . . . 0.0 111.097 -179.812 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 23.6 t -71.96 -16.0 62.08 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.255 179.28 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -79.96 143.62 57.88 Favored Pre-proline 0 C--N 1.324 -0.512 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.029 -178.488 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_endo -72.3 -178.16 3.12 Favored 'Trans proline' 0 C--O 1.238 0.511 0 C-N-CA 122.881 2.387 . . . . 0.0 112.149 179.168 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 84' ' ' TRP . . . . . 0.537 ' CE3' ' HB2' ' A' ' 76' ' ' GLN . 88.3 m95 -94.39 142.4 27.47 Favored 'General case' 0 C--N 1.317 -0.829 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 -179.816 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 96.6 m-70 -116.51 142.14 47.26 Favored 'General case' 0 C--N 1.316 -0.889 0 N-CA-C 109.778 -0.452 . . . . 0.0 109.778 -178.542 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 86' ' ' SER . . . . . 0.469 ' HA ' ' HG2' ' A' ' 74' ' ' GLU . 20.8 t -65.39 132.56 49.28 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 120.874 0.368 . . . . 0.0 111.229 -176.374 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -110.75 -48.35 0.74 Allowed Glycine 0 N--CA 1.441 -1.03 0 C-N-CA 120.936 -0.65 . . . . 0.0 112.188 178.547 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 157.96 -171.74 35.02 Favored Glycine 0 C--O 1.217 -0.911 0 C-N-CA 120.57 -0.824 . . . . 0.0 111.84 -179.943 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 8.1 t-20 -112.4 115.64 29.04 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 117.54 0.67 . . . . 0.0 110.251 179.699 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 35.1 m0 -97.88 148.71 23.16 Favored 'General case' 0 C--N 1.311 -1.092 0 CA-C-O 121.037 0.446 . . . . 0.0 111.622 -177.725 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 91' ' ' ILE . . . . . 0.401 ' O ' ' HB3' ' A' ' 23' ' ' TRP . 76.6 mt -108.49 118.18 55.54 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.057 0 N-CA-C 108.49 -0.93 . . . . 0.0 108.49 175.605 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 85.8 mt -134.53 83.39 2.03 Favored 'General case' 0 C--O 1.267 1.985 0 O-C-N 124.031 0.832 . . . . 0.0 112.057 -173.675 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 172.11 111.34 0.26 Allowed Glycine 0 N--CA 1.444 -0.769 0 CA-C-N 115.752 -0.658 . . . . 0.0 112.644 177.407 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 78.8 p -90.07 -7.88 52.79 Favored 'General case' 0 C--O 1.236 0.362 0 CA-C-O 121.45 0.643 . . . . 0.0 110.014 177.348 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 97.3 mtt180 -105.28 142.74 34.52 Favored 'General case' 0 N--CA 1.445 -0.692 0 CA-C-N 115.357 -0.838 . . . . 0.0 110.701 179.725 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -70.48 -34.68 72.65 Favored 'General case' 0 C--N 1.311 -1.08 0 CA-C-N 115.688 -0.687 . . . . 0.0 112.811 -175.193 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 27.2 p-10 -116.21 27.29 9.33 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 112.77 0.655 . . . . 0.0 112.77 -176.54 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 98' ' ' GLN . . . . . . . . . . . . . 72.1 mt-30 -148.82 125.76 11.27 Favored 'General case' 0 CA--C 1.511 -0.54 0 CA-C-O 121.12 0.486 . . . . 0.0 112.276 -179.855 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 99' ' ' ASN . . . . . 0.531 ' HB3' ' OH ' ' A' ' 71' ' ' TYR . 94.9 m-20 -96.17 152.87 18.15 Favored 'General case' 0 C--O 1.258 1.512 0 CA-C-N 114.985 -1.007 . . . . 0.0 109.889 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 57.5 t -73.9 134.91 28.64 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.561 0 CA-C-O 120.932 0.396 . . . . 0.0 111.057 178.424 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 23.3 m -120.08 -23.64 3.26 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.478 0 N-CA-C 112.649 0.611 . . . . 0.0 112.649 -178.848 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 102' ' ' ALA . . . . . 0.511 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -148.05 139.58 23.69 Favored 'General case' 0 C--O 1.236 0.392 0 C-N-CA 120.342 -0.543 . . . . 0.0 111.85 179.433 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.488 ' HB ' HG22 ' A' ' 38' ' ' VAL . 37.4 mm -134.02 130.0 54.74 Favored 'Isoleucine or valine' 0 C--O 1.239 0.53 0 CA-C-N 115.904 -0.589 . . . . 0.0 111.287 178.901 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 6.8 t30 -129.07 93.75 3.66 Favored 'General case' 0 CA--C 1.534 0.359 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.368 176.222 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.402 HG22 ' HB ' ' A' ' 36' ' ' ILE . 27.3 m -138.44 141.55 37.3 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.932 0 N-CA-C 113.033 0.753 . . . . 0.0 113.033 -176.561 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 85.6 tt0 -144.14 87.63 1.91 Allowed 'General case' 0 CA--C 1.534 0.358 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.676 176.447 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 107' ' ' SER . . . . . 0.464 ' HB2' ' H ' ' A' ' 115' ' ' ASN . 13.6 m -162.93 159.82 24.1 Favored 'General case' 0 C--N 1.312 -1.061 0 CA-C-N 114.667 -1.151 . . . . 0.0 111.206 -179.359 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 136.95 94.46 0.37 Allowed Glycine 0 N--CA 1.424 -2.139 0 C-N-CA 119.215 -1.469 . . . . 0.0 114.578 173.633 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 16.7 m-20 -75.68 100.47 4.67 Favored 'General case' 0 CA--C 1.502 -0.878 0 N-CA-C 105.875 -1.898 . . . . 0.0 105.875 171.918 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 70.5 m-20 62.27 24.35 14.48 Favored 'General case' 0 CA--C 1.534 0.344 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 -172.234 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 111' ' ' GLY . . . . . 0.506 ' HA3' ' ND2' ' A' ' 32' ' ' ASN . . . 77.91 22.85 67.98 Favored Glycine 0 CA--C 1.527 0.821 0 CA-C-N 115.217 -0.901 . . . . 0.0 113.539 179.928 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 52.8 tt0 -66.35 -43.49 85.9 Favored 'General case' 0 CA--C 1.541 0.597 0 N-CA-C 112.433 0.531 . . . . 0.0 112.433 -179.263 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 21.8 p -131.8 157.01 45.0 Favored 'General case' 0 C--N 1.325 -0.496 0 O-C-N 122.335 -0.228 . . . . 0.0 111.525 -177.629 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 114' ' ' LEU . . . . . 0.423 ' HA ' ' HB2' ' A' ' 107' ' ' SER . 96.4 mt -133.38 109.39 9.31 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 110.199 -0.297 . . . . 0.0 110.199 178.353 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 115' ' ' ASN . . . . . 0.464 ' H ' ' HB2' ' A' ' 107' ' ' SER . 93.3 m-20 -114.5 143.35 45.1 Favored 'General case' 0 C--O 1.252 1.207 0 CA-C-O 121.091 0.472 . . . . 0.0 111.018 -179.366 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 162.08 -135.11 3.74 Favored Glycine 0 N--CA 1.44 -1.043 0 CA-C-N 115.718 -0.674 . . . . 0.0 112.366 178.751 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 3.0 p -137.2 159.61 41.42 Favored 'General case' 0 C--N 1.311 -1.069 0 C-N-CA 122.629 0.372 . . . . 0.0 110.544 -179.241 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 23.2 ptm -146.3 160.29 42.21 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 116.501 -0.318 . . . . 0.0 110.614 -178.376 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 119' ' ' THR . . . . . 0.511 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 25.6 m -143.14 136.59 28.37 Favored 'General case' 0 C--O 1.253 1.242 0 CA-C-N 116.609 -0.269 . . . . 0.0 111.426 179.893 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 120' ' ' TYR . . . . . 0.415 ' HB2' ' HB3' ' A' ' 123' ' ' GLU . 52.5 m-85 -100.69 164.65 11.77 Favored 'General case' 0 CA--C 1.508 -0.639 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.223 177.418 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -63.46 130.19 43.36 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.058 176.66 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 63.03 27.41 70.39 Favored Glycine 0 CA--C 1.521 0.463 0 C-N-CA 121.118 -0.563 . . . . 0.0 113.117 -179.131 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 123' ' ' GLU . . . . . 0.415 ' HB3' ' HB2' ' A' ' 120' ' ' TYR . 9.9 tp10 -136.83 162.2 33.89 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -178.829 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -89.11 170.57 37.77 Favored Glycine 0 CA--C 1.522 0.479 0 C-N-CA 120.847 -0.692 . . . . 0.0 112.341 179.599 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -72.03 135.15 24.69 Favored 'Trans proline' 0 N--CA 1.46 -0.484 0 C-N-CA 122.369 2.046 . . . . 0.0 112.201 179.125 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 40.7 pt -130.83 161.56 40.56 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.269 179.673 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -72.42 134.91 21.62 Favored Glycine 0 C--O 1.238 0.391 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.119 -179.916 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 91.6 t80 -115.85 133.16 56.31 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.858 0.361 . . . . 0.0 110.99 -178.952 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 62.8 tttm -140.64 108.54 5.69 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 115.679 -0.691 . . . . 0.0 109.265 177.954 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -117.42 147.78 18.78 Favored Glycine 0 N--CA 1.44 -1.056 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.053 -179.35 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 5.4 t -137.16 142.84 42.2 Favored 'General case' 0 C--N 1.313 -1.002 0 CA-C-O 120.899 0.381 . . . . 0.0 111.231 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 63.2 tp -72.17 136.81 46.56 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.582 -0.736 . . . . 0.0 110.355 177.961 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 37.2 m . . . . . 0 C--N 1.307 -1.248 0 CA-C-O 118.802 -0.618 . . . . 0.0 110.407 -179.904 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.235 0.309 0 CA-C-O 120.655 0.264 . . . . 0.0 110.304 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 9.2 tt -90.32 132.15 35.72 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-O 120.988 0.423 . . . . 0.0 110.197 179.593 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 4' ' ' TYR . . . . . 0.548 ' CD1' ' HB ' ' A' ' 25' ' ' ILE . 34.5 m-85 -116.43 137.97 51.73 Favored 'General case' 0 C--N 1.317 -0.841 0 CA-C-O 121.386 0.612 . . . . 0.0 111.32 -178.926 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 5' ' ' ASN . . . . . 0.561 ' HB2' ' OG1' ' A' ' 133' ' ' THR . 60.8 t30 -96.51 135.61 38.16 Favored 'General case' 0 C--N 1.305 -1.339 0 N-CA-C 107.176 -1.416 . . . . 0.0 107.176 177.226 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.438 ' O ' ' HA ' ' A' ' 19' ' ' GLU . 72.2 t -116.48 126.31 73.89 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 N-CA-C 113.176 0.806 . . . . 0.0 113.176 -172.419 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -118.71 137.42 53.35 Favored 'General case' 0 N--CA 1.439 -0.991 0 CA-C-N 114.479 -1.237 . . . . 0.0 107.962 175.911 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 91.1 m-20 -128.79 151.64 49.35 Favored 'General case' 0 C--N 1.313 -1.007 0 N-CA-C 112.607 0.595 . . . . 0.0 112.607 -175.238 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 52.9 tt0 -122.33 110.33 15.53 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 107.527 -1.286 . . . . 0.0 107.527 175.988 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 40.2 p90 -134.47 4.91 3.43 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 114.556 1.317 . . . . 0.0 114.556 -172.875 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -119.32 18.99 10.08 Favored Glycine 0 N--CA 1.446 -0.65 0 C-N-CA 118.357 -1.878 . . . . 0.0 113.696 -176.11 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 152.02 -160.91 29.1 Favored Glycine 0 N--CA 1.446 -0.7 0 C-N-CA 119.541 -1.314 . . . . 0.0 112.907 179.097 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 36.6 p -102.5 -21.97 14.12 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-O 121.061 0.458 . . . . 0.0 110.462 -177.149 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 47.0 p -107.15 -1.3 22.07 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.607 -0.724 . . . . 0.0 110.423 -178.801 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -59.46 135.35 88.86 Favored Pre-proline 0 N--CA 1.453 -0.289 0 CA-C-N 115.616 -0.72 . . . . 0.0 111.068 -178.034 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -70.01 162.89 40.5 Favored 'Trans proline' 0 N--CA 1.459 -0.527 0 C-N-CA 122.653 2.235 . . . . 0.0 111.874 179.088 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 99.0 m95 -84.77 123.68 30.69 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 179.865 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 44.1 m-80 -118.68 128.46 54.54 Favored 'General case' 0 C--N 1.315 -0.898 0 N-CA-C 110.245 -0.28 . . . . 0.0 110.245 -178.869 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.438 ' HA ' ' O ' ' A' ' 6' ' ' VAL . 11.3 pt-20 -82.03 132.35 35.25 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 176.34 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -133.09 23.36 3.9 Favored Glycine 0 N--CA 1.438 -1.193 0 C-N-CA 120.028 -1.082 . . . . 0.0 112.114 -179.318 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 153.4 178.04 27.53 Favored Glycine 0 N--CA 1.439 -1.144 0 C-N-CA 120.644 -0.789 . . . . 0.0 111.969 -179.385 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 27.3 pt20 -131.5 138.66 49.07 Favored 'General case' 0 C--N 1.313 -0.997 0 N-CA-C 110.012 -0.366 . . . . 0.0 110.012 -179.456 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 44.1 m0 -113.03 175.37 5.47 Favored 'General case' 0 CA--C 1.506 -0.74 0 CA-C-O 121.081 0.467 . . . . 0.0 110.693 -178.128 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 39.4 tt0 -129.68 115.15 16.91 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-N 116.098 -0.501 . . . . 0.0 109.812 178.062 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.548 ' HB ' ' CD1' ' A' ' 4' ' ' TYR . 93.8 mt -128.33 135.62 62.14 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.962 0 CA-C-N 115.574 -0.739 . . . . 0.0 109.561 -177.29 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 86.31 71.42 1.3 Allowed Glycine 0 N--CA 1.441 -1.01 0 C-N-CA 119.935 -1.126 . . . . 0.0 111.363 -179.781 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 32.1 t -59.79 -41.07 90.36 Favored 'General case' 0 C--N 1.318 -0.796 0 N-CA-C 109.526 -0.546 . . . . 0.0 109.526 179.413 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 97.1 mtt180 -99.35 133.54 43.5 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 176.064 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 2.4 p -86.22 2.37 47.29 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-O 121.011 0.434 . . . . 0.0 111.908 -177.832 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 -66.0 -34.28 77.73 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.407 178.74 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 31' ' ' GLN . . . . . 0.498 ' HA ' ' NE2' ' A' ' 31' ' ' GLN . 5.6 mm-40 -143.1 126.58 16.79 Favored 'General case' 0 CA--C 1.502 -0.871 0 N-CA-C 113.367 0.877 . . . . 0.0 113.367 -177.239 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 32' ' ' ASN . . . . . 0.461 ' HB3' ' HA3' ' A' ' 111' ' ' GLY . 95.9 m-20 -90.4 156.04 18.51 Favored 'General case' 0 N--CA 1.446 -0.639 0 CA-C-N 115.022 -0.99 . . . . 0.0 110.091 177.466 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 18.0 m -105.77 137.33 36.2 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.034 0 CA-C-N 115.727 -0.67 . . . . 0.0 112.672 -175.979 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 27.7 m -111.73 -20.59 6.13 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.2 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.908 177.535 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 35' ' ' ALA . . . . . 0.628 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -145.21 144.83 31.05 Favored 'General case' 0 C--N 1.321 -0.663 0 C-N-CA 119.94 -0.704 . . . . 0.0 111.533 178.68 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 91.6 mt -144.33 126.88 10.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 N-CA-C 108.709 -0.848 . . . . 0.0 108.709 -179.535 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 37' ' ' ASN . . . . . 0.551 ' HA ' ' O ' ' A' ' 103' ' ' ILE . 3.3 t-20 -140.22 114.31 9.04 Favored 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 179.097 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.582 HG11 ' CD2' ' A' ' 61' ' ' PHE . 16.5 m -151.96 158.77 4.28 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.931 0 CA-C-O 120.807 0.337 . . . . 0.0 111.834 -173.743 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 66.2 tt0 -139.19 147.96 42.5 Favored 'General case' 0 N--CA 1.451 -0.392 0 CA-C-N 115.229 -0.896 . . . . 0.0 109.299 174.836 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 40' ' ' SER . . . . . 0.426 ' OG ' ' HB ' ' A' ' 101' ' ' VAL . 95.2 p -82.31 166.05 19.84 Favored 'General case' 0 C--N 1.313 -0.984 0 CA-C-O 121.146 0.498 . . . . 0.0 111.911 -179.351 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -107.74 -52.41 0.71 Allowed Glycine 0 N--CA 1.442 -0.948 0 CA-C-N 115.528 -0.76 . . . . 0.0 111.344 175.1 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -131.14 102.12 5.87 Favored 'General case' 0 C--N 1.326 -0.431 0 C-N-CA 122.334 0.253 . . . . 0.0 111.262 -179.563 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 83.8 m-20 52.1 26.4 3.81 Favored 'General case' 0 N--CA 1.492 1.656 0 N-CA-C 113.732 1.012 . . . . 0.0 113.732 177.105 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 82.48 -6.5 68.57 Favored Glycine 0 C--N 1.312 -0.761 0 C-N-CA 120.333 -0.936 . . . . 0.0 113.396 178.184 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 81.3 mt-30 -64.95 -32.49 74.23 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 117.219 0.509 . . . . 0.0 110.842 -179.065 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 4.9 t -118.11 131.44 56.43 Favored 'General case' 0 C--N 1.307 -1.279 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 174.652 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 47' ' ' LEU . . . . . 0.432 ' HB2' ' HB3' ' A' ' 63' ' ' ALA . 91.7 mt -126.26 134.37 51.2 Favored 'General case' 0 C--N 1.316 -0.861 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 -177.756 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 20.7 p30 -143.89 147.43 34.01 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-O 121.207 0.527 . . . . 0.0 111.511 179.569 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 164.4 -142.49 7.83 Favored Glycine 0 N--CA 1.442 -0.934 0 N-CA-C 111.389 -0.684 . . . . 0.0 111.389 179.873 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 40.2 p -132.98 150.39 52.16 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-O 121.028 0.442 . . . . 0.0 111.846 -178.938 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 32.2 mtp -124.17 152.68 42.56 Favored 'General case' 0 C--N 1.326 -0.415 0 C-N-CA 123.341 0.656 . . . . 0.0 109.603 176.348 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.628 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 24.1 m -130.37 123.6 30.27 Favored 'General case' 0 C--O 1.25 1.081 0 C-N-CA 121.141 -0.224 . . . . 0.0 110.435 176.313 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 53' ' ' TYR . . . . . 0.456 ' HB2' ' HB2' ' A' ' 56' ' ' GLU . 71.8 m-85 -85.57 164.33 17.83 Favored 'General case' 0 C--O 1.232 0.173 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.43 178.712 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -67.22 101.88 0.97 Allowed 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.499 -179.996 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 97.06 -0.85 60.61 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.731 -0.747 . . . . 0.0 113.229 177.674 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 56' ' ' GLU . . . . . 0.456 ' HB2' ' HB2' ' A' ' 53' ' ' TYR . 79.9 mm-40 -111.19 179.77 3.95 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 117.024 0.412 . . . . 0.0 110.739 -179.982 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -95.75 168.16 26.16 Favored Glycine 0 N--CA 1.443 -0.868 0 C-N-CA 120.845 -0.693 . . . . 0.0 111.944 178.922 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 23.5 Cg_exo -64.45 139.77 66.36 Favored 'Trans proline' 0 C--O 1.238 0.523 0 C-N-CA 122.657 2.238 . . . . 0.0 112.301 179.002 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 59' ' ' ILE . . . . . 0.433 ' HB ' ' O ' ' A' ' 76' ' ' GLN . 48.9 pt -131.74 168.4 24.05 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 CA-C-N 115.801 -0.636 . . . . 0.0 109.918 179.0 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -79.95 148.31 30.02 Favored Glycine 0 C--N 1.32 -0.351 0 C-N-CA 120.874 -0.679 . . . . 0.0 111.645 -179.816 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.582 ' CD2' HG11 ' A' ' 38' ' ' VAL . 2.6 t80 -136.88 130.83 32.3 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-O 120.819 0.342 . . . . 0.0 111.18 -178.538 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 57.3 ttp180 -135.62 134.81 39.66 Favored 'General case' 0 C--O 1.232 0.142 0 CA-C-N 115.833 -0.621 . . . . 0.0 109.934 176.784 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.522 ' HB1' ' HB3' ' A' ' 71' ' ' TYR . . . -136.81 146.14 45.32 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 120.738 0.304 . . . . 0.0 111.484 179.797 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 65.0 m -125.27 131.25 53.13 Favored 'General case' 0 CA--C 1.537 0.461 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.055 178.952 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 61.1 tp -74.26 119.19 18.13 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.334 0.588 . . . . 0.0 112.311 -177.205 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 94.2 mt -90.1 -29.52 18.28 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.502 -0.772 . . . . 0.0 109.849 175.227 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 134.23 166.68 11.31 Favored Glycine 0 N--CA 1.447 -0.578 0 N-CA-C 110.962 -0.855 . . . . 0.0 110.962 -179.135 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 53.9 m-80 58.06 36.39 25.96 Favored 'General case' 0 N--CA 1.477 0.883 0 CA-C-N 117.21 0.505 . . . . 0.0 111.331 179.245 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 17.3 m120 63.59 14.08 7.8 Favored 'General case' 0 N--CA 1.479 0.987 0 CA-C-N 115.614 -0.721 . . . . 0.0 111.277 179.204 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 17.6 m -101.33 126.07 48.04 Favored 'General case' 0 C--O 1.239 0.552 0 CA-C-O 121.081 0.467 . . . . 0.0 111.156 -178.883 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.522 ' HB3' ' HB1' ' A' ' 63' ' ' ALA . 91.0 m-85 -114.52 141.98 47.01 Favored 'General case' 0 C--N 1.313 -0.997 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.494 -178.556 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 72' ' ' GLU . . . . . 0.429 ' O ' ' HA ' ' A' ' 63' ' ' ALA . 35.8 tt0 -90.39 120.16 31.28 Favored 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 108.35 -0.982 . . . . 0.0 108.35 175.574 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.492 HG13 ' CE1' ' A' ' 61' ' ' PHE . 54.2 t -103.67 132.83 49.19 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.013 0 N-CA-C 113.871 1.063 . . . . 0.0 113.871 -171.953 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 70.6 mt-10 -129.3 129.47 44.91 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 114.472 -1.24 . . . . 0.0 107.976 173.762 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 96.4 m-20 -109.12 145.48 35.63 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 121.279 0.562 . . . . 0.0 111.838 -177.781 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 76' ' ' GLN . . . . . 0.433 ' O ' ' HB ' ' A' ' 59' ' ' ILE . 10.4 tt0 -111.26 123.59 50.51 Favored 'General case' 0 C--N 1.316 -0.873 0 C-N-CA 124.032 0.933 . . . . 0.0 111.592 -177.125 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 10.0 p90 -140.27 155.61 46.79 Favored 'General case' 0 C--N 1.316 -0.89 0 N-CA-C 110.52 -0.178 . . . . 0.0 110.52 175.061 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 107.0 -9.71 39.92 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.852 -0.69 . . . . 0.0 112.279 -179.934 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 145.03 171.81 15.02 Favored Glycine 0 N--CA 1.447 -0.591 0 N-CA-C 111.581 -0.608 . . . . 0.0 111.581 178.912 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 1.8 p-10 -62.9 153.03 34.7 Favored 'General case' 0 C--O 1.241 0.609 0 CA-C-N 117.015 0.408 . . . . 0.0 110.31 178.081 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 16.3 m 65.42 -95.06 0.04 OUTLIER 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.717 -0.674 . . . . 0.0 109.497 -178.33 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 50.23 172.48 0.03 OUTLIER Pre-proline 0 CA--C 1.555 1.158 0 N-CA-C 113.533 0.938 . . . . 0.0 113.533 176.519 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_exo -69.91 144.97 54.87 Favored 'Trans proline' 0 N--CA 1.45 -1.062 0 C-N-CA 121.722 1.614 . . . . 0.0 110.161 172.255 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 84' ' ' TRP . . . . . . . . . . . . . 92.7 m95 -90.88 139.34 30.84 Favored 'General case' 0 C--N 1.313 -0.983 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 178.757 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 84.8 m-70 -111.5 138.63 47.77 Favored 'General case' 0 C--N 1.313 -1.005 0 N-CA-C 108.936 -0.764 . . . . 0.0 108.936 -178.822 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 10.5 m -66.85 135.62 54.17 Favored 'General case' 0 C--N 1.314 -0.957 0 CA-C-O 120.675 0.274 . . . . 0.0 110.922 -177.324 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -110.01 -44.59 1.01 Allowed Glycine 0 N--CA 1.443 -0.838 0 C-N-CA 120.832 -0.699 . . . . 0.0 111.742 179.376 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 143.74 -158.7 27.44 Favored Glycine 0 C--O 1.214 -1.151 0 C-N-CA 120.723 -0.751 . . . . 0.0 111.473 178.681 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 19.1 m120 -115.33 129.25 56.55 Favored 'General case' 0 C--N 1.315 -0.918 0 CA-C-N 117.303 0.551 . . . . 0.0 110.88 179.278 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 23.3 m0 -118.96 150.73 39.42 Favored 'General case' 0 N--CA 1.466 0.335 0 N-CA-C 109.981 -0.377 . . . . 0.0 109.981 179.777 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 92.1 mt -109.63 123.08 65.23 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 177.76 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 83.6 mt -134.3 84.85 2.14 Favored 'General case' 0 C--O 1.265 1.871 0 O-C-N 123.688 0.617 . . . . 0.0 112.473 -175.85 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 168.13 110.36 0.23 Allowed Glycine 0 C--O 1.218 -0.903 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.688 178.003 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 68.3 p -100.78 -9.43 21.73 Favored 'General case' 0 C--O 1.225 -0.232 0 CA-C-O 120.984 0.421 . . . . 0.0 111.116 178.379 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 92.2 mtt180 -96.69 3.79 52.23 Favored 'General case' 0 C--O 1.232 0.162 0 C-N-CA 120.574 -0.45 . . . . 0.0 111.921 179.32 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 66.6 tt0 72.83 -83.13 0.03 OUTLIER 'General case' 0 N--CA 1.467 0.401 0 C-N-CA 123.22 0.608 . . . . 0.0 112.377 173.067 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 63.4 m-80 -92.34 34.15 1.06 Allowed 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 120.831 0.348 . . . . 0.0 111.612 -174.802 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 98' ' ' GLN . . . . . . . . . . . . . 23.6 tp60 -120.08 -48.11 2.35 Favored 'General case' 0 C--N 1.316 -0.875 0 C-N-CA 120.59 -0.444 . . . . 0.0 110.284 -178.945 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 93.4 m-20 72.62 137.84 0.05 Allowed 'General case' 0 N--CA 1.485 1.308 0 O-C-N 123.735 0.647 . . . . 0.0 112.284 178.499 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 69.9 t -78.43 132.4 32.44 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.33 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.871 178.861 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 101' ' ' VAL . . . . . 0.426 ' HB ' ' OG ' ' A' ' 40' ' ' SER . 34.4 m -113.04 -27.64 2.68 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.517 0 N-CA-C 112.555 0.576 . . . . 0.0 112.555 -179.506 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 102' ' ' ALA . . . . . 0.56 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -146.82 144.45 29.35 Favored 'General case' 0 C--N 1.322 -0.619 0 C-N-CA 119.96 -0.696 . . . . 0.0 111.546 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.551 ' O ' ' HA ' ' A' ' 37' ' ' ASN . 34.1 mm -133.98 128.05 52.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.62 179.193 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 104' ' ' ASN . . . . . 0.43 ' HB3' ' OG1' ' A' ' 117' ' ' THR . 43.4 t30 -131.27 92.08 3.13 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.292 175.714 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 29.4 m -138.12 144.26 31.11 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.566 0 N-CA-C 113.017 0.747 . . . . 0.0 113.017 -175.451 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 79.9 tt0 -148.19 101.39 3.26 Favored 'General case' 0 CA--C 1.538 0.501 0 CA-C-N 115.558 -0.746 . . . . 0.0 110.656 176.832 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 107' ' ' SER . . . . . 0.418 ' HB2' ' H ' ' A' ' 115' ' ' ASN . 69.5 m -166.69 165.82 16.27 Favored 'General case' 0 N--CA 1.475 0.821 0 CA-C-N 114.834 -1.075 . . . . 0.0 112.388 -178.909 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 116.41 117.19 2.98 Favored Glycine 0 N--CA 1.424 -2.156 0 C-N-CA 120.344 -0.932 . . . . 0.0 113.241 175.308 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 -67.38 -42.44 83.39 Favored 'General case' 0 C--N 1.319 -0.757 0 N-CA-C 107.997 -1.112 . . . . 0.0 107.997 175.639 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 30.3 t70 -142.38 33.43 1.48 Allowed 'General case' 0 C--O 1.213 -0.85 0 CA-C-N 114.428 -1.26 . . . . 0.0 108.228 175.432 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 111' ' ' GLY . . . . . 0.461 ' HA3' ' HB3' ' A' ' 32' ' ' ASN . . . 81.82 18.05 68.82 Favored Glycine 0 CA--C 1.523 0.538 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.656 -178.335 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 112' ' ' GLN . . . . . 0.446 ' HA ' ' CD1' ' A' ' 132' ' ' LEU . 98.1 mt-30 -66.66 -40.64 88.7 Favored 'General case' 0 C--O 1.244 0.794 0 CA-C-O 120.975 0.417 . . . . 0.0 111.71 -179.177 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 25.6 p -139.15 143.37 38.15 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.824 -0.626 . . . . 0.0 110.755 -178.391 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -119.4 123.35 43.89 Favored 'General case' 0 C--N 1.317 -0.814 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 176.539 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 115' ' ' ASN . . . . . 0.418 ' H ' ' HB2' ' A' ' 107' ' ' SER . 53.6 m-80 -128.66 149.6 50.6 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-O 120.851 0.358 . . . . 0.0 110.587 -178.503 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 155.48 -131.34 3.05 Favored Glycine 0 N--CA 1.438 -1.175 0 C-N-CA 120.634 -0.793 . . . . 0.0 112.343 177.971 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 117' ' ' THR . . . . . 0.43 ' OG1' ' HB3' ' A' ' 104' ' ' ASN . 23.9 p -130.25 155.37 46.39 Favored 'General case' 0 C--N 1.311 -1.089 0 CA-C-O 121.015 0.436 . . . . 0.0 110.848 -178.459 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 23.2 ptm -146.2 153.34 40.52 Favored 'General case' 0 C--N 1.313 -0.991 0 CA-C-N 115.949 -0.569 . . . . 0.0 109.67 -178.809 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 119' ' ' THR . . . . . 0.56 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 26.0 m -132.99 131.34 40.64 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-O 120.642 0.258 . . . . 0.0 111.422 -179.294 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 33.0 m-85 -95.75 163.49 13.15 Favored 'General case' 0 CA--C 1.509 -0.611 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.394 175.992 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -62.75 128.59 36.64 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.588 178.155 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 70.95 15.58 74.18 Favored Glycine 0 CA--C 1.524 0.596 0 CA-C-N 115.895 -0.593 . . . . 0.0 113.257 179.44 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -127.03 179.82 5.22 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 117.149 0.474 . . . . 0.0 111.335 -179.46 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -105.55 170.09 16.91 Favored Glycine 0 N--CA 1.445 -0.754 0 N-CA-C 111.502 -0.639 . . . . 0.0 111.502 178.533 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 22.9 Cg_exo -65.37 135.39 42.61 Favored 'Trans proline' 0 CA--C 1.534 0.511 0 C-N-CA 122.542 2.161 . . . . 0.0 112.375 -179.812 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 48.0 pt -131.21 165.09 32.49 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 116.06 -0.518 . . . . 0.0 109.941 177.931 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -73.76 132.78 16.25 Favored Glycine 0 CA--C 1.521 0.464 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.751 -179.169 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 91.6 t80 -114.8 132.96 56.3 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 120.634 0.254 . . . . 0.0 111.224 -179.526 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 63.0 tttm -137.49 101.83 4.61 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.029 176.927 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -106.37 133.51 11.66 Favored Glycine 0 N--CA 1.446 -0.645 0 C-N-CA 120.977 -0.63 . . . . 0.0 111.617 179.485 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 49.1 m -130.24 137.55 50.08 Favored 'General case' 0 C--N 1.311 -1.072 0 CA-C-N 116.638 0.219 . . . . 0.0 111.191 -179.334 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 132' ' ' LEU . . . . . 0.446 ' CD1' ' HA ' ' A' ' 112' ' ' GLN . 87.9 mt -57.7 134.93 56.64 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-O 120.858 0.361 . . . . 0.0 110.31 176.781 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 133' ' ' THR . . . . . 0.561 ' OG1' ' HB2' ' A' ' 5' ' ' ASN . 57.5 m . . . . . 0 C--O 1.251 1.182 0 CA-C-O 118.643 -0.694 . . . . 0.0 110.539 -179.086 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.692 0 N-CA-C 110.373 -0.232 . . . . 0.0 110.373 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 3' ' ' LEU . . . . . 0.458 HD13 ' N ' ' A' ' 4' ' ' TYR . 2.8 tm? -99.85 131.41 45.85 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.357 -177.663 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 4' ' ' TYR . . . . . 0.607 ' CE1' ' HB ' ' A' ' 25' ' ' ILE . 85.1 m-85 -121.41 145.11 48.25 Favored 'General case' 0 C--O 1.238 0.476 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.866 -179.215 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 93.3 m-20 -82.67 142.23 31.85 Favored 'General case' 0 N--CA 1.468 0.436 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 176.991 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.46 HG21 ' CD1' ' A' ' 23' ' ' TRP . 59.0 t -116.09 126.76 73.72 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 N-CA-C 113.464 0.913 . . . . 0.0 113.464 -176.159 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 92.0 mt-10 -128.09 132.43 49.01 Favored 'General case' 0 N--CA 1.445 -0.683 0 CA-C-N 114.634 -1.167 . . . . 0.0 108.088 175.001 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 92.5 m-20 -124.59 145.74 49.43 Favored 'General case' 0 C--N 1.313 -0.986 0 CA-C-O 120.645 0.259 . . . . 0.0 110.696 -178.158 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 52.0 tt0 -119.65 118.24 30.43 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.808 0.337 . . . . 0.0 110.464 179.071 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' TRP . . . . . 0.507 ' CZ3' ' HB2' ' A' ' 18' ' ' ASN . 2.5 m-90 -79.2 140.79 37.6 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.332 179.711 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 89.33 -42.21 3.02 Favored Glycine 0 N--CA 1.444 -0.811 0 C-N-CA 120.579 -0.82 . . . . 0.0 112.05 -179.085 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.84 21.42 71.51 Favored Glycine 0 C--O 1.227 -0.327 0 C-N-CA 120.85 -0.691 . . . . 0.0 111.581 -179.707 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 20.9 p -168.2 133.82 1.86 Allowed 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.771 -0.214 . . . . 0.0 111.188 -178.024 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 63.6 p 46.85 44.73 14.66 Favored 'General case' 0 N--CA 1.475 0.824 0 C-N-CA 123.456 0.702 . . . . 0.0 112.638 176.79 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' ALA . . . . . 0.467 ' HA ' ' HD3' ' A' ' 16' ' ' PRO . . . -139.6 144.32 38.9 Favored Pre-proline 0 C--N 1.324 -0.517 0 C-N-CA 120.905 -0.318 . . . . 0.0 111.425 -178.158 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.467 ' HD3' ' HA ' ' A' ' 15' ' ' ALA . 11.4 Cg_exo -71.57 157.45 55.98 Favored 'Trans proline' 0 C--N 1.347 0.483 0 C-N-CA 123.033 2.489 . . . . 0.0 111.699 176.888 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 91.5 m95 -85.26 134.15 34.14 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 120.891 0.377 . . . . 0.0 110.343 179.57 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' ASN . . . . . 0.507 ' HB2' ' CZ3' ' A' ' 10' ' ' TRP . 90.7 m-20 -110.01 135.67 50.47 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.105 179.231 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 14.7 pt-20 -105.44 131.2 53.15 Favored 'General case' 0 C--N 1.314 -0.95 0 N-CA-C 109.241 -0.652 . . . . 0.0 109.241 -179.828 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -157.33 34.26 0.55 Allowed Glycine 0 N--CA 1.44 -1.045 0 C-N-CA 119.058 -1.544 . . . . 0.0 112.997 179.843 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 162.67 -179.02 38.21 Favored Glycine 0 N--CA 1.444 -0.777 0 C-N-CA 119.58 -1.295 . . . . 0.0 113.511 178.847 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 13.7 pt20 -145.29 140.66 27.94 Favored 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 179.218 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' TRP . . . . . 0.46 ' CD1' HG21 ' A' ' 6' ' ' VAL . 48.0 m0 -114.74 155.97 25.7 Favored 'General case' 0 CA--C 1.505 -0.761 0 CA-C-O 120.715 0.293 . . . . 0.0 111.443 -176.213 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 77.8 tt0 -116.6 119.52 35.79 Favored 'General case' 0 C--N 1.321 -0.633 0 C-N-CA 120.445 -0.502 . . . . 0.0 110.221 177.881 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.607 ' HB ' ' CE1' ' A' ' 4' ' ' TYR . 97.7 mt -135.32 143.37 37.12 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.72 0 CA-C-N 114.998 -1.001 . . . . 0.0 109.464 -177.681 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 84.0 60.61 1.93 Allowed Glycine 0 C--O 1.225 -0.437 0 C-N-CA 120.18 -1.01 . . . . 0.0 112.398 178.629 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 15.4 m -58.15 -40.4 81.26 Favored 'General case' 0 C--N 1.317 -0.838 0 O-C-N 123.935 0.432 . . . . 0.0 111.618 179.759 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 79.9 ttt180 -61.29 -42.27 98.37 Favored 'General case' 0 CA--C 1.538 0.518 0 CA-C-N 116.588 -0.278 . . . . 0.0 111.558 178.803 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 20.1 m 75.99 -21.98 0.29 Allowed 'General case' 0 N--CA 1.482 1.17 0 C-N-CA 123.75 0.82 . . . . 0.0 113.201 179.073 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 58.3 m-20 -68.23 -11.71 59.77 Favored 'General case' 0 N--CA 1.483 1.189 0 CA-C-O 121.06 0.457 . . . . 0.0 111.414 178.243 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -152.71 136.09 15.87 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.133 -178.963 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 32' ' ' ASN . . . . . 0.564 ' ND2' ' HA3' ' A' ' 111' ' ' GLY . 2.5 t30 -93.45 150.81 20.16 Favored 'General case' 0 C--O 1.247 0.967 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.247 178.984 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 46.3 t -93.98 131.33 41.2 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 CA-C-N 115.697 -0.683 . . . . 0.0 109.62 -178.399 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 28.1 m -102.75 -32.43 3.11 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.686 0 C-N-CA 120.596 -0.442 . . . . 0.0 111.835 -179.595 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 35' ' ' ALA . . . . . 0.641 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -135.01 145.19 47.83 Favored 'General case' 0 CA--C 1.511 -0.537 0 C-N-CA 120.349 -0.54 . . . . 0.0 111.28 -179.201 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 93.9 mt -142.33 122.54 10.72 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 CA-C-N 115.744 -0.662 . . . . 0.0 109.553 -179.543 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 19.7 m120 -130.74 112.58 13.21 Favored 'General case' 0 C--N 1.316 -0.851 0 N-CA-C 108.246 -1.02 . . . . 0.0 108.246 176.07 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.489 HG22 ' HB ' ' A' ' 103' ' ' ILE . 27.3 m -147.41 150.57 14.49 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 C-N-CA 120.665 -0.414 . . . . 0.0 111.208 -175.146 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 74.6 tt0 -142.73 145.1 33.01 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 108.955 -0.758 . . . . 0.0 108.955 176.031 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 40' ' ' SER . . . . . 0.412 ' HA ' ' O ' ' A' ' 46' ' ' THR . 34.2 p -80.55 148.95 30.14 Favored 'General case' 0 C--N 1.312 -1.024 0 N-CA-C 112.203 0.446 . . . . 0.0 112.203 -176.327 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -95.06 -19.95 29.48 Favored Glycine 0 N--CA 1.449 -0.476 0 N-CA-C 111.012 -0.835 . . . . 0.0 111.012 176.831 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 15.7 m-20 -128.72 -156.56 0.76 Allowed 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 109.45 -0.574 . . . . 0.0 109.45 179.071 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 9.9 p-10 -77.23 46.89 0.52 Allowed 'General case' 0 N--CA 1.474 0.775 0 CA-C-O 121.314 0.578 . . . . 0.0 112.065 -179.11 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 88.22 -7.79 80.46 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 121.047 -0.597 . . . . 0.0 113.176 178.441 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 53.5 mt-30 -72.58 -34.83 67.71 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.964 0.382 . . . . 0.0 111.498 178.906 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 46' ' ' THR . . . . . 0.412 ' O ' ' HA ' ' A' ' 40' ' ' SER . 24.5 p -115.02 132.01 56.74 Favored 'General case' 0 C--N 1.314 -0.975 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.535 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 47' ' ' LEU . . . . . 0.513 ' HB2' ' HB3' ' A' ' 63' ' ' ALA . 93.8 mt -124.3 127.97 48.44 Favored 'General case' 0 CA--C 1.509 -0.607 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 -179.475 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 9.0 m120 -129.39 137.05 50.7 Favored 'General case' 0 C--N 1.313 -1.011 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 -179.696 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 49' ' ' GLY . . . . . 0.435 ' HA3' ' HA ' ' A' ' 38' ' ' VAL . . . 178.18 -157.22 21.1 Favored Glycine 0 N--CA 1.445 -0.72 0 C-N-CA 119.287 -1.435 . . . . 0.0 113.795 179.275 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 38.3 m -130.0 134.35 47.37 Favored 'General case' 0 CA--C 1.545 0.756 0 C-N-CA 123.087 0.555 . . . . 0.0 110.905 -178.562 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 48.0 mtp -110.2 155.32 22.14 Favored 'General case' 0 N--CA 1.468 0.459 0 C-N-CA 122.308 0.243 . . . . 0.0 110.815 177.151 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.641 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 25.5 m -133.78 126.29 30.3 Favored 'General case' 0 CA--C 1.542 0.641 0 CA-C-N 116.491 -0.322 . . . . 0.0 110.167 175.322 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 53' ' ' TYR . . . . . 0.483 ' HB2' ' HB2' ' A' ' 56' ' ' GLU . 65.5 m-85 -92.94 166.97 12.12 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 116.664 -0.244 . . . . 0.0 110.769 177.964 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -63.34 106.48 0.91 Allowed 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.473 -179.754 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 81.78 16.03 73.9 Favored Glycine 0 CA--C 1.52 0.358 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.788 178.857 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 56' ' ' GLU . . . . . 0.483 ' HB2' ' HB2' ' A' ' 53' ' ' TYR . 80.3 mm-40 -119.99 169.62 10.02 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 120.773 0.32 . . . . 0.0 110.807 -179.93 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -90.05 172.56 38.55 Favored Glycine 0 N--CA 1.444 -0.813 0 C-N-CA 120.99 -0.624 . . . . 0.0 112.303 179.925 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_exo -67.14 137.56 44.47 Favored 'Trans proline' 0 CA--C 1.535 0.56 0 C-N-CA 122.726 2.284 . . . . 0.0 112.026 179.16 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 59' ' ' ILE . . . . . 0.414 HD12 ' HB3' ' A' ' 75' ' ' ASN . 45.0 pt -128.79 160.86 38.91 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.428 179.195 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -75.1 141.61 28.3 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.451 -178.919 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 61.8 t80 -126.01 127.04 45.27 Favored 'General case' 0 C--N 1.32 -0.712 0 C-N-CA 122.401 0.28 . . . . 0.0 110.797 -179.792 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 29.3 ttp85 -136.97 129.04 29.44 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 175.801 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.545 ' HB1' ' HB3' ' A' ' 71' ' ' TYR . . . -136.88 146.4 45.51 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 112.304 0.483 . . . . 0.0 112.304 -177.622 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 55.9 m -122.7 128.18 50.23 Favored 'General case' 0 CA--C 1.542 0.668 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.222 178.303 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 2.3 tm? -73.47 121.52 20.68 Favored 'General case' 0 CA--C 1.538 0.493 0 CA-C-O 121.134 0.492 . . . . 0.0 111.054 -178.058 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 96.0 mt -75.04 -33.94 61.81 Favored 'General case' 0 CA--C 1.534 0.354 0 CA-C-N 115.638 -0.71 . . . . 0.0 111.907 179.799 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 126.12 -14.84 6.96 Favored Glycine 0 C--O 1.219 -0.812 0 C-N-CA 120.574 -0.822 . . . . 0.0 112.476 -178.262 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 28.9 p-10 -111.75 30.23 7.17 Favored 'General case' 0 C--N 1.316 -0.856 0 CA-C-O 120.824 0.345 . . . . 0.0 110.736 -179.078 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 96.1 m-20 69.03 6.47 5.66 Favored 'General case' 0 N--CA 1.483 1.187 0 C-N-CA 123.6 0.76 . . . . 0.0 111.499 -177.25 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 35.0 t -102.46 140.35 36.86 Favored 'General case' 0 N--CA 1.438 -1.069 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 177.178 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.545 ' HB3' ' HB1' ' A' ' 63' ' ' ALA . 66.8 m-85 -116.91 139.72 50.31 Favored 'General case' 0 C--N 1.303 -1.42 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.936 -178.296 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 39.5 tt0 -85.29 112.3 20.66 Favored 'General case' 0 C--N 1.309 -1.16 0 N-CA-C 106.759 -1.571 . . . . 0.0 106.759 173.673 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.521 HG22 ' HB2' ' A' ' 63' ' ' ALA . 70.5 t -109.41 135.83 47.17 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 N-CA-C 113.475 0.917 . . . . 0.0 113.475 -171.141 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -128.54 130.48 47.48 Favored 'General case' 0 N--CA 1.443 -0.811 0 CA-C-N 114.708 -1.133 . . . . 0.0 108.917 175.281 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 75' ' ' ASN . . . . . 0.414 ' HB3' HD12 ' A' ' 59' ' ' ILE . 95.9 m-20 -108.9 150.11 28.17 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.748 -179.286 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 76' ' ' GLN . . . . . 0.41 ' HB2' ' CE3' ' A' ' 84' ' ' TRP . 61.3 tt0 -115.49 120.36 39.24 Favored 'General case' 0 C--N 1.308 -1.232 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.435 -177.534 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 8.6 p90 -142.87 162.85 34.37 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 110.24 -0.281 . . . . 0.0 110.24 179.544 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 100.91 -9.02 58.07 Favored Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.768 -0.729 . . . . 0.0 111.97 179.781 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 137.59 159.61 8.26 Favored Glycine 0 N--CA 1.442 -0.917 0 N-CA-C 111.019 -0.832 . . . . 0.0 111.019 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 5.9 m-20 -60.41 -39.59 87.93 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 116.963 0.382 . . . . 0.0 111.687 -179.319 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 4.6 m -76.57 -4.93 45.42 Favored 'General case' 0 C--N 1.321 -0.671 0 N-CA-C 112.251 0.463 . . . . 0.0 112.251 -177.476 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -75.46 153.16 85.76 Favored Pre-proline 0 C--N 1.324 -0.538 0 CA-C-O 120.587 0.232 . . . . 0.0 111.196 -178.422 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 10.7 Cg_exo -72.34 178.48 6.06 Favored 'Trans proline' 0 C--N 1.35 0.642 0 C-N-CA 122.925 2.417 . . . . 0.0 112.017 178.646 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 84' ' ' TRP . . . . . 0.41 ' CE3' ' HB2' ' A' ' 76' ' ' GLN . 90.9 m95 -92.14 138.17 31.75 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 109.322 -0.622 . . . . 0.0 109.322 179.722 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 82.8 m-70 -112.59 144.61 41.79 Favored 'General case' 0 C--N 1.318 -0.791 0 N-CA-C 109.992 -0.373 . . . . 0.0 109.992 -177.685 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 19.5 p -64.36 116.4 6.03 Favored 'General case' 0 C--N 1.316 -0.89 0 CA-C-O 120.781 0.324 . . . . 0.0 111.457 -178.376 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -89.63 -46.41 4.3 Favored Glycine 0 N--CA 1.44 -1.088 0 C-N-CA 120.388 -0.911 . . . . 0.0 111.018 178.008 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 139.87 -157.86 25.48 Favored Glycine 0 N--CA 1.442 -0.909 0 C-N-CA 120.816 -0.707 . . . . 0.0 111.629 177.471 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 19.8 m120 -105.48 134.19 49.0 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 109.697 -0.483 . . . . 0.0 109.697 178.974 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 90' ' ' TRP . . . . . 0.489 ' CH2' HG23 ' A' ' 25' ' ' ILE . 13.8 m0 -124.04 146.13 48.77 Favored 'General case' 0 C--N 1.316 -0.862 0 CA-C-N 116.203 -0.453 . . . . 0.0 109.84 -178.548 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 91.6 mt -110.57 114.63 47.6 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.285 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 177.456 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 92' ' ' LEU . . . . . 0.483 ' HB3' HG21 ' A' ' 100' ' ' VAL . 85.5 mt -133.56 79.98 1.85 Allowed 'General case' 0 C--O 1.269 2.113 0 CA-C-O 121.771 0.796 . . . . 0.0 112.312 -175.724 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 170.0 109.51 0.22 Allowed Glycine 0 N--CA 1.442 -0.966 0 CA-C-N 115.344 -0.844 . . . . 0.0 111.768 -179.498 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 19.1 m -96.67 30.27 2.68 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-O 120.902 0.382 . . . . 0.0 110.349 -179.882 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 95' ' ' ARG . . . . . 0.556 ' CB ' ' HB3' ' A' ' 98' ' ' GLN . 9.7 mmt180 -136.56 150.54 48.65 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-O 121.257 0.551 . . . . 0.0 112.317 -176.968 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 79.3 tt0 -55.99 -51.27 68.33 Favored 'General case' 0 CA--C 1.541 0.601 0 CA-C-N 114.731 -1.122 . . . . 0.0 112.602 -176.961 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 27.2 m120 -134.63 42.69 2.81 Favored 'General case' 0 N--CA 1.471 0.609 0 CA-C-O 120.965 0.412 . . . . 0.0 109.99 -179.928 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 98' ' ' GLN . . . . . 0.556 ' HB3' ' CB ' ' A' ' 95' ' ' ARG . 8.3 tt0 -144.37 110.39 5.41 Favored 'General case' 0 C--N 1.315 -0.919 0 CA-C-O 121.147 0.499 . . . . 0.0 110.614 -175.952 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 99' ' ' ASN . . . . . 0.445 ' HB3' ' OH ' ' A' ' 71' ' ' TYR . 87.7 m-20 -91.06 168.37 11.69 Favored 'General case' 0 C--O 1.244 0.782 0 CA-C-N 115.293 -0.867 . . . . 0.0 111.111 -175.73 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.483 HG21 ' HB3' ' A' ' 92' ' ' LEU . 23.6 m -83.01 140.53 16.19 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.673 0 C-N-CA 120.011 -0.676 . . . . 0.0 110.244 173.443 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 29.7 m -115.55 -27.45 2.56 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.429 0 C-N-CA 120.608 -0.437 . . . . 0.0 112.062 178.14 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 102' ' ' ALA . . . . . 0.448 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -147.87 142.06 26.12 Favored 'General case' 0 C--N 1.32 -0.677 0 C-N-CA 120.581 -0.447 . . . . 0.0 110.551 178.352 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.489 ' HB ' HG22 ' A' ' 38' ' ' VAL . 94.9 mt -138.4 125.75 27.83 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 N-CA-C 110.106 -0.331 . . . . 0.0 110.106 178.26 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 35.2 t30 -128.06 97.8 4.91 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.367 176.589 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.653 HG11 ' HD2' ' A' ' 128' ' ' PHE . 11.7 m -142.6 149.7 18.85 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 N-CA-C 113.185 0.809 . . . . 0.0 113.185 -176.454 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 41.9 tt0 -148.15 147.19 29.18 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.089 -0.959 . . . . 0.0 109.839 175.621 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 47.1 t -113.23 133.59 55.01 Favored 'General case' 0 N--CA 1.442 -0.874 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.355 -177.994 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -81.52 -5.07 90.22 Favored Glycine 0 N--CA 1.447 -0.568 0 N-CA-C 111.103 -0.799 . . . . 0.0 111.103 175.444 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 62.8 m-20 -114.06 -166.46 1.1 Allowed 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 109.362 -0.607 . . . . 0.0 109.362 -179.95 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 25.6 m-20 -77.68 34.97 0.18 Allowed 'General case' 0 N--CA 1.472 0.66 0 CA-C-O 120.847 0.356 . . . . 0.0 111.123 178.931 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 111' ' ' GLY . . . . . 0.564 ' HA3' ' ND2' ' A' ' 32' ' ' ASN . . . 81.43 8.24 87.32 Favored Glycine 0 N--CA 1.445 -0.74 0 C-N-CA 120.888 -0.672 . . . . 0.0 112.405 -178.852 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 97.3 mt-30 -66.04 -44.22 85.26 Favored 'General case' 0 C--O 1.243 0.713 0 CA-C-O 121.056 0.455 . . . . 0.0 109.995 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 22.5 p -113.12 117.61 32.44 Favored 'General case' 0 N--CA 1.441 -0.888 0 CA-C-N 115.374 -0.83 . . . . 0.0 109.259 177.548 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 34.8 tp -111.84 121.88 46.25 Favored 'General case' 0 C--N 1.311 -1.08 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 -178.957 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 26.3 p30 -145.57 164.82 30.49 Favored 'General case' 0 C--O 1.251 1.134 0 C-N-CA 120.039 -0.664 . . . . 0.0 112.677 -178.609 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 149.75 -127.78 2.53 Favored Glycine 0 N--CA 1.439 -1.12 0 CA-C-N 114.655 -1.157 . . . . 0.0 111.127 -179.636 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 31.9 p -134.0 159.75 39.82 Favored 'General case' 0 C--N 1.314 -0.96 0 CA-C-O 120.851 0.358 . . . . 0.0 111.063 -178.9 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 4.2 ppp? -157.28 161.93 39.17 Favored 'General case' 0 C--N 1.313 -1.004 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 179.154 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 119' ' ' THR . . . . . 0.448 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 48.7 m -133.39 126.3 30.99 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-N 116.46 -0.336 . . . . 0.0 110.978 -179.894 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 120' ' ' TYR . . . . . 0.426 ' HB2' ' CB ' ' A' ' 123' ' ' GLU . 64.9 m-85 -88.13 162.98 16.43 Favored 'General case' 0 CA--C 1.521 -0.147 0 CA-C-N 116.196 -0.456 . . . . 0.0 109.789 174.285 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -55.76 -30.59 61.5 Favored 'General case' 0 N--CA 1.47 0.553 0 N-CA-C 113.602 0.964 . . . . 0.0 113.602 -176.627 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -140.65 26.62 2.52 Favored Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 119.636 -1.269 . . . . 0.0 112.67 -178.434 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 123' ' ' GLU . . . . . 0.467 ' HB2' ' OE1' ' A' ' 98' ' ' GLN . 23.5 tp10 -112.6 -50.71 2.88 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.988 0.423 . . . . 0.0 110.461 -177.578 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 116.5 -179.76 17.76 Favored Glycine 0 N--CA 1.441 -0.986 0 N-CA-C 111.122 -0.791 . . . . 0.0 111.122 -177.639 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 7.4 Cg_exo -73.81 112.8 3.62 Favored 'Trans proline' 0 N--CA 1.461 -0.392 0 C-N-CA 122.735 2.29 . . . . 0.0 112.021 179.651 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 39.2 pt -129.84 162.92 36.58 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.862 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.517 179.734 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -72.84 144.41 35.1 Favored Glycine 0 N--CA 1.448 -0.517 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.728 -179.496 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 128' ' ' PHE . . . . . 0.653 ' HD2' HG11 ' A' ' 105' ' ' VAL . 21.1 t80 -125.59 132.63 52.49 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 121.162 0.506 . . . . 0.0 110.732 178.733 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 62.6 tttm -137.42 123.46 20.3 Favored 'General case' 0 C--N 1.311 -1.073 0 CA-C-N 115.0 -1.0 . . . . 0.0 108.93 -179.829 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -139.23 141.72 12.1 Favored Glycine 0 N--CA 1.436 -1.302 0 C-N-CA 120.363 -0.922 . . . . 0.0 112.725 -179.335 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 35.3 m -121.35 133.11 55.1 Favored 'General case' 0 C--N 1.311 -1.107 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.355 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 60.2 tp -66.85 139.89 57.78 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 109.754 -0.462 . . . . 0.0 109.754 178.492 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 133' ' ' THR . . . . . 0.455 HG22 ' O ' ' A' ' 3' ' ' LEU . 13.4 t . . . . . 0 C--O 1.253 1.251 0 CA-C-O 118.53 -0.748 . . . . 0.0 110.251 -179.117 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.737 0 CA-C-O 120.668 0.271 . . . . 0.0 110.42 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 3' ' ' LEU . . . . . 0.45 HD13 ' N ' ' A' ' 4' ' ' TYR . 1.7 tm? -95.16 129.89 42.09 Favored 'General case' 0 C--N 1.319 -0.739 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 178.598 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 4' ' ' TYR . . . . . 0.45 ' N ' HD13 ' A' ' 3' ' ' LEU . 78.8 m-85 -120.53 145.85 46.89 Favored 'General case' 0 C--O 1.24 0.597 0 CA-C-O 121.081 0.467 . . . . 0.0 112.158 -176.842 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 5' ' ' ASN . . . . . 0.627 ' O ' ' HA2' ' A' ' 130' ' ' GLY . 21.6 m120 -87.46 140.46 29.51 Favored 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 107.186 -1.413 . . . . 0.0 107.186 175.274 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.49 HG21 ' CD1' ' A' ' 23' ' ' TRP . 70.1 t -114.64 128.41 71.73 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 N-CA-C 113.641 0.978 . . . . 0.0 113.641 -174.274 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.436 ' HB2' ' HB3' ' A' ' 129' ' ' LYS . 99.7 mt-10 -125.44 134.09 52.22 Favored 'General case' 0 N--CA 1.444 -0.759 0 CA-C-N 114.517 -1.219 . . . . 0.0 109.098 175.358 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 91.5 m-20 -121.4 140.54 52.01 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-N 116.462 -0.336 . . . . 0.0 110.601 -178.929 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 60.8 tt0 -120.02 120.02 35.1 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.676 -178.972 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 19.6 p90 -135.72 143.18 45.21 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 110.131 -0.322 . . . . 0.0 110.131 178.708 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 106.83 8.53 31.93 Favored Glycine 0 N--CA 1.446 -0.646 0 C-N-CA 120.29 -0.957 . . . . 0.0 111.497 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 103.08 164.71 25.76 Favored Glycine 0 N--CA 1.442 -0.958 0 C-N-CA 121.344 -0.455 . . . . 0.0 112.281 178.502 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 68.8 m -59.07 -23.47 62.07 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 120.836 0.35 . . . . 0.0 111.722 178.766 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 38.8 m -73.52 -6.61 47.56 Favored 'General case' 0 CA--C 1.543 0.696 0 CA-C-O 120.7 0.286 . . . . 0.0 111.596 177.921 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' ALA . . . . . 0.457 ' HA ' ' HD3' ' A' ' 16' ' ' PRO . . . -95.07 145.56 29.75 Favored Pre-proline 0 C--N 1.328 -0.355 0 O-C-N 122.421 -0.174 . . . . 0.0 110.881 -179.814 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.457 ' HD3' ' HA ' ' A' ' 15' ' ' ALA . 8.2 Cg_exo -73.1 163.82 37.15 Favored 'Trans proline' 0 C--N 1.347 0.492 0 C-N-CA 123.042 2.494 . . . . 0.0 112.586 179.594 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 17' ' ' TRP . . . . . 0.53 ' CZ3' ' HB2' ' A' ' 129' ' ' LYS . 91.3 m95 -83.51 131.13 35.02 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 178.939 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 41.2 m-80 -109.54 141.71 41.62 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.524 -177.833 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 13.9 pt-20 -112.18 137.5 50.18 Favored 'General case' 0 C--N 1.313 -0.991 0 N-CA-C 110.016 -0.364 . . . . 0.0 110.016 179.05 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -154.2 32.45 0.72 Allowed Glycine 0 N--CA 1.443 -0.842 0 C-N-CA 119.76 -1.21 . . . . 0.0 112.641 179.045 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 156.25 -177.61 33.18 Favored Glycine 0 N--CA 1.447 -0.613 0 C-N-CA 119.658 -1.258 . . . . 0.0 113.3 -179.16 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 25.3 pt20 -141.62 145.35 34.9 Favored 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 109.537 -0.542 . . . . 0.0 109.537 -179.828 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' TRP . . . . . 0.49 ' CD1' HG21 ' A' ' 6' ' ' VAL . 45.0 m0 -115.93 153.28 31.86 Favored 'General case' 0 C--O 1.24 0.591 0 CA-C-O 121.121 0.486 . . . . 0.0 111.895 -176.752 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 85.9 tt0 -112.17 114.47 27.29 Favored 'General case' 0 CA--C 1.508 -0.663 0 CA-C-N 115.512 -0.767 . . . . 0.0 109.072 177.998 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 96.8 mt -131.82 136.7 56.49 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-O 121.355 0.597 . . . . 0.0 112.27 -176.048 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 104.93 -26.52 22.05 Favored Glycine 0 N--CA 1.449 -0.454 0 CA-C-N 115.881 -0.6 . . . . 0.0 113.531 175.312 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 2.7 p 44.99 20.89 0.04 OUTLIER 'General case' 0 N--CA 1.486 1.335 0 C-N-CA 123.867 0.867 . . . . 0.0 112.991 -177.512 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 83.4 mtm180 -149.62 150.57 32.4 Favored 'General case' 0 C--O 1.241 0.626 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 -179.243 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 12.6 m -95.51 -15.42 22.9 Favored 'General case' 0 C--N 1.309 -1.159 0 CA-C-O 121.089 0.471 . . . . 0.0 110.268 177.828 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 23.3 m-20 -75.21 -35.5 61.5 Favored 'General case' 0 N--CA 1.468 0.475 0 CA-C-N 115.809 -0.632 . . . . 0.0 112.182 -177.052 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 5.0 mm-40 -132.49 128.23 36.93 Favored 'General case' 0 CA--C 1.509 -0.628 0 N-CA-C 113.876 1.065 . . . . 0.0 113.876 -175.34 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 3.4 m-20 -100.07 151.15 21.71 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 114.834 -1.075 . . . . 0.0 109.311 174.61 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.433 HG21 HD11 ' A' ' 36' ' ' ILE . 33.2 m -92.53 142.95 12.38 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.277 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.78 -179.818 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 27.7 m -111.4 -16.08 9.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 C-N-CA 120.931 -0.308 . . . . 0.0 111.744 178.772 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 35' ' ' ALA . . . . . 0.549 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -147.94 140.75 24.74 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 120.3 -0.56 . . . . 0.0 111.597 178.972 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.433 HD11 HG21 ' A' ' 33' ' ' VAL . 88.8 mt -142.84 121.29 7.7 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 178.607 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 37' ' ' ASN . . . . . 0.485 ' HA ' ' O ' ' A' ' 103' ' ' ILE . 4.8 t-20 -136.54 111.26 8.71 Favored 'General case' 0 C--N 1.307 -1.243 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 177.984 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.462 HG11 ' CD1' ' A' ' 61' ' ' PHE . 27.0 m -148.43 154.37 10.36 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-O 120.804 0.335 . . . . 0.0 111.626 -171.843 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 45.4 tt0 -136.34 143.37 44.07 Favored 'General case' 0 N--CA 1.447 -0.61 0 CA-C-N 115.624 -0.716 . . . . 0.0 109.371 176.644 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 88.4 p -72.83 155.04 40.33 Favored 'General case' 0 C--N 1.314 -0.961 0 CA-C-O 121.131 0.491 . . . . 0.0 111.846 -178.288 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -108.26 -45.0 1.11 Allowed Glycine 0 N--CA 1.438 -1.188 0 CA-C-N 115.596 -0.729 . . . . 0.0 111.924 177.86 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 30.7 t70 -129.3 95.28 3.99 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 111.564 0.209 . . . . 0.0 111.564 -178.772 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 52.15 31.53 9.17 Favored 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 113.594 0.961 . . . . 0.0 113.594 174.989 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 75.7 1.0 65.19 Favored Glycine 0 C--N 1.32 -0.359 0 C-N-CA 120.373 -0.918 . . . . 0.0 113.09 179.828 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 23.4 mm-40 -78.48 -29.68 46.89 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-O 121.328 0.585 . . . . 0.0 109.743 178.857 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 32.1 p -121.74 144.26 48.9 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-N 115.709 -0.678 . . . . 0.0 109.912 176.738 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 47' ' ' LEU . . . . . 0.492 ' O ' ' HA ' ' A' ' 62' ' ' ARG . 93.3 mt -129.82 130.96 45.97 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 -178.185 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 94.0 m-20 -127.49 138.97 53.08 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 178.141 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 49' ' ' GLY . . . . . 0.401 ' HA3' ' HA ' ' A' ' 38' ' ' VAL . . . 172.81 -153.04 17.68 Favored Glycine 0 N--CA 1.445 -0.732 0 C-N-CA 119.487 -1.339 . . . . 0.0 113.525 178.707 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 90.9 m -131.99 133.19 44.18 Favored 'General case' 0 C--N 1.317 -0.811 0 C-N-CA 122.704 0.402 . . . . 0.0 110.283 -178.904 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 51' ' ' MET . . . . . 0.566 ' HE3' HD11 ' A' ' 59' ' ' ILE . 15.7 tmm? -126.32 147.58 49.7 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 116.531 -0.304 . . . . 0.0 110.34 -178.949 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.549 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 28.4 m -128.98 129.12 44.99 Favored 'General case' 0 C--O 1.252 1.234 0 CA-C-O 120.797 0.332 . . . . 0.0 111.826 -177.505 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 53' ' ' TYR . . . . . 0.49 ' HB2' ' HB2' ' A' ' 56' ' ' GLU . 94.3 m-85 -83.47 167.4 17.47 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 115.811 -0.632 . . . . 0.0 110.419 177.582 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -63.96 103.71 0.62 Allowed 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 112.402 0.519 . . . . 0.0 112.402 -179.012 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 85.84 4.51 84.8 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.937 -0.649 . . . . 0.0 113.261 177.717 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 56' ' ' GLU . . . . . 0.49 ' HB2' ' HB2' ' A' ' 53' ' ' TYR . 81.9 mm-40 -107.97 176.99 4.95 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-O 120.697 0.284 . . . . 0.0 110.665 -179.781 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -90.11 156.82 25.52 Favored Glycine 0 N--CA 1.44 -1.048 0 C-N-CA 120.879 -0.677 . . . . 0.0 112.16 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_exo -63.67 140.32 74.03 Favored 'Trans proline' 0 CA--C 1.533 0.449 0 C-N-CA 122.758 2.305 . . . . 0.0 112.116 178.697 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 59' ' ' ILE . . . . . 0.566 HD11 ' HE3' ' A' ' 51' ' ' MET . 46.4 pt -130.75 166.0 29.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-N 116.341 -0.391 . . . . 0.0 110.649 179.633 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -73.29 138.63 25.55 Favored Glycine 0 N--CA 1.45 -0.398 0 N-CA-C 111.243 -0.743 . . . . 0.0 111.243 179.856 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.462 ' CD1' HG11 ' A' ' 38' ' ' VAL . 52.4 t80 -124.86 130.03 51.58 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-O 120.673 0.273 . . . . 0.0 111.111 -177.148 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 62' ' ' ARG . . . . . 0.492 ' HA ' ' O ' ' A' ' 47' ' ' LEU . 68.2 ttp85 -140.29 132.67 28.41 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.068 175.041 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.403 ' HB3' ' HB2' ' A' ' 47' ' ' LEU . . . -136.64 148.17 47.29 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 120.754 0.311 . . . . 0.0 111.828 -178.074 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 56.3 m -127.18 132.53 50.46 Favored 'General case' 0 CA--C 1.541 0.628 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.513 178.836 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 65' ' ' LEU . . . . . 0.419 HD22 ' O ' ' A' ' 70' ' ' SER . 3.4 tm? -77.13 114.54 16.04 Favored 'General case' 0 C--N 1.325 -0.486 0 C-N-CA 122.633 0.373 . . . . 0.0 110.447 -179.133 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 10.5 mp -81.99 -32.16 30.75 Favored 'General case' 0 N--CA 1.468 0.455 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.915 178.824 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 164.8 173.58 33.58 Favored Glycine 0 CA--C 1.497 -1.045 0 N-CA-C 110.614 -0.995 . . . . 0.0 110.614 -177.577 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 24.3 t-20 40.23 -96.32 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.134 0 C-N-CA 123.138 0.575 . . . . 0.0 111.777 -176.947 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 56.7 m-80 -140.67 19.81 2.35 Favored 'General case' 0 N--CA 1.467 0.412 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 177.29 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 70' ' ' SER . . . . . 0.419 ' O ' HD22 ' A' ' 65' ' ' LEU . 40.7 t -94.54 122.98 37.69 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.308 -0.86 . . . . 0.0 111.256 -175.742 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.634 ' OH ' ' HB3' ' A' ' 99' ' ' ASN . 73.9 m-85 -116.25 137.61 52.0 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 115.817 -0.628 . . . . 0.0 110.515 -179.673 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 82.2 tt0 -92.38 125.4 37.02 Favored 'General case' 0 N--CA 1.439 -1.004 0 N-CA-C 107.476 -1.305 . . . . 0.0 107.476 172.081 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 65.5 t -105.04 130.67 55.8 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.5 0 CA-C-O 121.432 0.634 . . . . 0.0 111.973 -174.953 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 67.0 mt-10 -126.25 120.64 30.51 Favored 'General case' 0 N--CA 1.431 -1.381 0 CA-C-N 114.455 -1.248 . . . . 0.0 107.669 176.424 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 94.4 m-20 -109.55 155.73 21.03 Favored 'General case' 0 C--N 1.317 -0.831 0 CA-C-O 121.2 0.524 . . . . 0.0 111.968 -174.507 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 76' ' ' GLN . . . . . 0.45 ' HB2' ' CE3' ' A' ' 84' ' ' TRP . 61.4 tt0 -119.39 119.9 35.31 Favored 'General case' 0 C--N 1.31 -1.13 0 CA-C-N 115.494 -0.775 . . . . 0.0 109.933 -178.344 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 7.9 p90 -137.2 155.64 49.28 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.593 -0.276 . . . . 0.0 110.727 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 97.75 -10.27 64.39 Favored Glycine 0 N--CA 1.447 -0.615 0 N-CA-C 111.151 -0.779 . . . . 0.0 111.151 -178.652 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 139.35 159.56 8.04 Favored Glycine 0 N--CA 1.44 -1.045 0 N-CA-C 111.312 -0.715 . . . . 0.0 111.312 179.465 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 7.4 p-10 -74.55 -23.37 58.78 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-O 121.046 0.45 . . . . 0.0 111.0 -179.632 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 6.9 m -76.24 -7.89 55.87 Favored 'General case' 0 CA--C 1.542 0.654 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.622 177.346 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -83.86 158.45 62.09 Favored Pre-proline 0 C--N 1.326 -0.415 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.456 -179.407 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -72.84 177.84 7.15 Favored 'Trans proline' 0 C--O 1.237 0.471 0 C-N-CA 122.279 1.986 . . . . 0.0 111.636 177.498 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 84' ' ' TRP . . . . . 0.45 ' CE3' ' HB2' ' A' ' 76' ' ' GLN . 96.4 m95 -90.24 142.23 27.92 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 179.957 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 88.9 m-70 -117.87 146.98 43.51 Favored 'General case' 0 C--N 1.313 -0.986 0 N-CA-C 109.534 -0.543 . . . . 0.0 109.534 -178.71 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 18.8 p -62.87 136.85 58.07 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-O 120.561 0.22 . . . . 0.0 111.351 -179.831 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -111.89 -50.98 0.57 Allowed Glycine 0 N--CA 1.446 -0.637 0 C-N-CA 120.821 -0.704 . . . . 0.0 111.534 178.314 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 148.58 -164.47 29.08 Favored Glycine 0 C--O 1.219 -0.807 0 C-N-CA 120.603 -0.808 . . . . 0.0 111.879 178.308 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 27.9 t-20 -111.46 120.12 41.1 Favored 'General case' 0 C--N 1.317 -0.829 0 CA-C-N 116.988 0.394 . . . . 0.0 110.121 179.205 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 28.1 m0 -114.96 148.78 38.29 Favored 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 -178.472 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 79.9 mt -108.69 118.72 56.86 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.071 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 177.2 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 92' ' ' LEU . . . . . 0.485 ' HB3' HG21 ' A' ' 100' ' ' VAL . 84.8 mt -131.81 87.38 2.44 Favored 'General case' 0 C--O 1.271 2.2 0 CA-C-O 121.939 0.876 . . . . 0.0 113.253 -174.292 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 160.61 117.04 0.44 Allowed Glycine 0 N--CA 1.446 -0.65 0 CA-C-N 115.162 -0.926 . . . . 0.0 111.829 178.502 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 70.7 p -91.32 -12.82 33.91 Favored 'General case' 0 C--O 1.223 -0.322 0 CA-C-N 117.216 0.508 . . . . 0.0 110.517 178.798 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 94.1 mtt-85 -89.17 138.56 31.32 Favored 'General case' 0 N--CA 1.444 -0.741 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.129 178.904 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -70.94 -34.65 71.68 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 115.673 -0.694 . . . . 0.0 111.408 -175.623 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 89.4 m-20 -112.91 25.89 11.0 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.019 -0.537 . . . . 0.0 111.372 -177.404 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 98' ' ' GLN . . . . . . . . . . . . . 2.0 tt0 -155.49 130.58 9.42 Favored 'General case' 0 C--N 1.333 -0.136 0 C-N-CA 120.323 -0.551 . . . . 0.0 112.244 -176.251 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 99' ' ' ASN . . . . . 0.634 ' HB3' ' OH ' ' A' ' 71' ' ' TYR . 12.0 m120 -99.32 162.66 12.91 Favored 'General case' 0 C--O 1.253 1.251 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.487 178.867 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.485 HG21 ' HB3' ' A' ' 92' ' ' LEU . 33.3 m -78.3 147.15 7.21 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 C-N-CA 119.884 -0.726 . . . . 0.0 110.979 179.282 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 35.5 m -123.4 -36.93 1.18 Allowed 'Isoleucine or valine' 0 C--O 1.219 -0.502 0 C-N-CA 120.728 -0.389 . . . . 0.0 111.821 177.657 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -136.25 132.19 35.48 Favored 'General case' 0 CA--C 1.503 -0.837 0 C-N-CA 120.407 -0.517 . . . . 0.0 110.687 -179.398 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.485 ' O ' ' HA ' ' A' ' 37' ' ' ASN . 92.3 mt -132.52 124.36 51.37 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 CA-C-N 116.472 -0.331 . . . . 0.0 110.111 178.255 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 7.9 t30 -125.29 97.82 5.37 Favored 'General case' 0 C--N 1.32 -0.708 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 176.482 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.429 ' CG2' ' HB ' ' A' ' 36' ' ' ILE . 26.9 m -139.94 142.97 31.0 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.782 0 N-CA-C 113.134 0.79 . . . . 0.0 113.134 -175.511 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 44.4 tt0 -146.32 148.95 32.93 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.111 -0.949 . . . . 0.0 109.215 177.37 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 40.8 t -137.37 145.06 42.84 Favored 'General case' 0 C--N 1.313 -1.022 0 CA-C-O 121.087 0.47 . . . . 0.0 111.573 -178.809 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -94.92 5.45 68.99 Favored Glycine 0 N--CA 1.441 -0.986 0 N-CA-C 111.011 -0.836 . . . . 0.0 111.011 176.313 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 83.3 m-20 -93.03 178.59 5.7 Favored 'General case' 0 CA--C 1.508 -0.65 0 CA-C-O 121.154 0.502 . . . . 0.0 111.077 178.509 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 10.8 p-10 -90.38 19.13 5.41 Favored 'General case' 0 C--N 1.311 -1.095 0 CA-C-N 115.512 -0.767 . . . . 0.0 110.5 179.444 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 106.11 4.82 38.38 Favored Glycine 0 N--CA 1.443 -0.839 0 CA-C-N 115.64 -0.709 . . . . 0.0 111.906 -177.688 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 30.7 tt0 -65.13 -45.6 84.4 Favored 'General case' 0 C--O 1.237 0.44 0 CA-C-O 120.865 0.364 . . . . 0.0 110.324 177.715 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 70.3 p -133.53 157.6 45.25 Favored 'General case' 0 N--CA 1.447 -0.577 0 CA-C-N 116.216 -0.447 . . . . 0.0 109.808 177.767 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 49.2 tp -139.09 131.46 28.46 Favored 'General case' 0 C--N 1.315 -0.9 0 N-CA-C 109.087 -0.708 . . . . 0.0 109.087 178.818 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 6.8 p30 -147.99 167.27 25.34 Favored 'General case' 0 C--N 1.319 -0.743 0 C-N-CA 119.853 -0.739 . . . . 0.0 112.878 -179.985 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 155.79 -130.24 2.71 Favored Glycine 0 N--CA 1.442 -0.938 0 CA-C-N 114.951 -1.022 . . . . 0.0 111.738 -179.821 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 33.0 p -133.37 156.98 46.67 Favored 'General case' 0 C--N 1.318 -0.796 0 C-N-CA 122.671 0.388 . . . . 0.0 110.621 -178.818 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 23.7 ptm -152.48 167.47 28.69 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 120.897 0.38 . . . . 0.0 111.096 -179.571 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 48.4 m -151.63 139.98 20.43 Favored 'General case' 0 CA--C 1.547 0.862 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.991 -179.936 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 120' ' ' TYR . . . . . 0.495 ' H ' ' HB3' ' A' ' 123' ' ' GLU . 67.8 m-85 -99.02 172.29 7.5 Favored 'General case' 0 N--CA 1.473 0.701 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.28 178.538 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -67.9 37.83 0.03 OUTLIER 'General case' 0 N--CA 1.487 1.421 0 C-N-CA 123.695 0.798 . . . . 0.0 113.104 -179.752 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 153.44 42.67 0.02 OUTLIER Glycine 0 CA--C 1.5 -0.879 0 N-CA-C 110.08 -1.208 . . . . 0.0 110.08 179.805 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 123' ' ' GLU . . . . . 0.495 ' HB3' ' H ' ' A' ' 120' ' ' TYR . 47.3 tp10 -139.69 160.82 39.0 Favored 'General case' 0 C--N 1.315 -0.925 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 -175.705 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -90.2 175.29 41.13 Favored Glycine 0 N--CA 1.443 -0.895 0 N-CA-C 111.023 -0.831 . . . . 0.0 111.023 177.238 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 22.5 Cg_exo -63.35 119.91 7.15 Favored 'Trans proline' 0 N--CA 1.461 -0.41 0 C-N-CA 121.939 1.759 . . . . 0.0 111.2 178.262 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 42.5 pt -127.53 154.11 37.55 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 CA-C-O 120.656 0.265 . . . . 0.0 110.811 -179.897 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -72.31 143.65 34.69 Favored Glycine 0 N--CA 1.444 -0.809 0 C-N-CA 121.087 -0.578 . . . . 0.0 112.463 179.422 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 128' ' ' PHE . . . . . 0.424 ' CD2' HG11 ' A' ' 105' ' ' VAL . 73.0 t80 -122.07 133.8 54.78 Favored 'General case' 0 C--N 1.315 -0.901 0 CA-C-O 120.689 0.281 . . . . 0.0 110.579 179.194 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 129' ' ' LYS . . . . . 0.53 ' HB2' ' CZ3' ' A' ' 17' ' ' TRP . 84.0 tttt -140.39 130.35 24.69 Favored 'General case' 0 N--CA 1.439 -0.998 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 177.539 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 130' ' ' GLY . . . . . 0.627 ' HA2' ' O ' ' A' ' 5' ' ' ASN . . . -134.4 141.22 12.5 Favored Glycine 0 N--CA 1.436 -1.325 0 C-N-CA 121.087 -0.578 . . . . 0.0 112.007 179.875 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 53.7 m -128.27 135.36 49.53 Favored 'General case' 0 C--N 1.314 -0.97 0 CA-C-O 120.481 0.182 . . . . 0.0 110.786 -179.473 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 54.8 tp -64.52 136.5 57.11 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 177.638 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 133' ' ' THR . . . . . 0.469 ' HB ' ' OD1' ' A' ' 5' ' ' ASN . 11.8 t . . . . . 0 C--O 1.252 1.221 0 CA-C-O 118.733 -0.651 . . . . 0.0 110.634 -179.251 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 0.419 ' O ' ' HB3' ' A' ' 3' ' ' LEU . . . . . . . . 0 N--CA 1.472 0.637 0 N-CA-C 110.014 -0.365 . . . . 0.0 110.014 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 3' ' ' LEU . . . . . 0.43 HD23 ' N ' ' A' ' 4' ' ' TYR . 10.3 tt 87.41 150.74 0.06 Allowed 'General case' 0 N--CA 1.475 0.813 0 C-N-CA 124.289 1.036 . . . . 0.0 109.956 179.232 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 4' ' ' TYR . . . . . 0.43 ' N ' HD23 ' A' ' 3' ' ' LEU . 86.7 m-85 -132.45 154.13 50.18 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-O 120.951 0.405 . . . . 0.0 111.082 -175.007 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 5' ' ' ASN . . . . . 0.405 ' O ' ' HA2' ' A' ' 130' ' ' GLY . 92.7 m-20 -95.78 151.78 19.07 Favored 'General case' 0 C--N 1.314 -0.972 0 N-CA-C 107.702 -1.221 . . . . 0.0 107.702 177.664 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.47 HG21 ' CD1' ' A' ' 23' ' ' TRP . 78.5 t -111.9 121.84 65.13 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.184 0 CA-C-O 121.744 0.783 . . . . 0.0 111.73 -177.459 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.4 ' HB2' ' HB3' ' A' ' 129' ' ' LYS . 69.1 mt-10 -121.7 127.03 50.3 Favored 'General case' 0 C--N 1.311 -1.084 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 177.689 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 93.5 m-20 -126.28 148.72 49.46 Favored 'General case' 0 C--N 1.312 -1.057 0 N-CA-C 112.527 0.566 . . . . 0.0 112.527 -174.036 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 54.2 tt0 -127.3 118.38 24.08 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 175.986 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 39.7 p90 -143.9 20.46 1.8 Allowed 'General case' 0 C--N 1.322 -0.613 0 C-N-CA 120.24 -0.584 . . . . 0.0 112.555 -175.293 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -96.53 24.15 31.93 Favored Glycine 0 N--CA 1.448 -0.532 0 C-N-CA 119.321 -1.418 . . . . 0.0 113.572 -177.43 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.55 -50.21 2.83 Favored Glycine 0 N--CA 1.466 0.683 0 CA-C-N 117.152 0.476 . . . . 0.0 114.268 178.261 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 22.6 t -172.63 153.23 2.74 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 -176.216 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 19.0 m 58.8 30.05 19.55 Favored 'General case' 0 CA--C 1.536 0.409 0 CA-C-O 121.322 0.582 . . . . 0.0 110.986 179.436 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -111.02 128.93 24.53 Favored Pre-proline 0 N--CA 1.443 -0.803 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.999 -178.053 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 97.8 Cg_endo -77.06 169.6 21.26 Favored 'Trans proline' 0 N--CA 1.456 -0.692 0 C-N-CA 122.697 2.265 . . . . 0.0 111.466 177.124 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 97.8 m95 -80.35 128.73 33.9 Favored 'General case' 0 C--N 1.314 -0.969 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 179.293 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 87.4 m-20 -116.28 127.6 54.86 Favored 'General case' 0 C--N 1.311 -1.099 0 N-CA-C 109.553 -0.536 . . . . 0.0 109.553 -177.854 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 10.7 pt-20 -83.43 127.68 33.89 Favored 'General case' 0 C--N 1.314 -0.948 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 178.453 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -137.38 19.82 3.38 Favored Glycine 0 C--O 1.225 -0.454 0 C-N-CA 120.43 -0.891 . . . . 0.0 112.812 -177.695 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 156.44 -173.01 34.27 Favored Glycine 0 N--CA 1.439 -1.163 0 C-N-CA 120.603 -0.808 . . . . 0.0 111.751 179.601 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 10.2 pt20 -148.55 149.02 30.86 Favored 'General case' 0 C--N 1.311 -1.073 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 178.684 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 23' ' ' TRP . . . . . 0.47 ' CD1' HG21 ' A' ' 6' ' ' VAL . 48.0 m0 -118.62 150.69 39.27 Favored 'General case' 0 C--N 1.313 -1.001 0 CA-C-O 120.784 0.326 . . . . 0.0 110.473 -178.05 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 78.9 tt0 -106.13 115.14 29.71 Favored 'General case' 0 C--N 1.313 -0.983 0 C-N-CA 120.052 -0.659 . . . . 0.0 109.544 178.26 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 93.6 mt -139.19 149.47 23.17 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.891 0 CA-C-N 115.213 -0.903 . . . . 0.0 108.979 -175.85 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 90.26 83.38 1.37 Allowed Glycine 0 N--CA 1.446 -0.699 0 C-N-CA 120.482 -0.866 . . . . 0.0 112.808 179.474 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 11.6 p -94.97 13.51 24.73 Favored 'General case' 0 N--CA 1.449 -0.495 0 CA-C-O 120.969 0.414 . . . . 0.0 111.159 178.842 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 15.8 ptp180 -129.28 134.79 48.11 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 179.463 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 26.7 t -89.02 -21.92 23.24 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-O 121.121 0.486 . . . . 0.0 111.143 -179.031 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 51.8 m-20 -64.88 -36.23 83.68 Favored 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 112.746 0.647 . . . . 0.0 112.746 -177.91 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 24.4 mm-40 -135.74 134.47 39.08 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 111.938 0.348 . . . . 0.0 111.938 -175.095 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 32' ' ' ASN . . . . . 0.454 ' ND2' ' HA3' ' A' ' 111' ' ' GLY . 66.0 t30 -90.77 161.39 15.33 Favored 'General case' 0 C--O 1.24 0.572 0 CA-C-N 116.111 -0.495 . . . . 0.0 109.977 178.308 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 57.8 t -88.62 126.61 41.8 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.484 -176.756 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 30.7 m -111.46 -31.23 2.22 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.599 0 N-CA-C 113.236 0.828 . . . . 0.0 113.236 177.132 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 35' ' ' ALA . . . . . 0.618 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -151.41 148.81 28.55 Favored 'General case' 0 N--CA 1.469 0.515 0 C-N-CA 119.839 -0.744 . . . . 0.0 111.959 179.828 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.401 HG12 ' HG3' ' A' ' 51' ' ' MET . 93.4 mt -141.92 126.87 17.23 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.15 -179.616 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -133.66 112.36 11.36 Favored 'General case' 0 C--N 1.321 -0.65 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 174.168 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.412 HG22 ' HB ' ' A' ' 103' ' ' ILE . 21.7 m -150.88 153.92 9.38 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-O 120.749 0.309 . . . . 0.0 111.115 -175.607 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 42.2 tt0 -145.38 151.67 38.64 Favored 'General case' 0 C--N 1.318 -0.771 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 176.414 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 27.3 p -79.46 148.08 32.03 Favored 'General case' 0 C--N 1.31 -1.14 0 CA-C-O 121.089 0.471 . . . . 0.0 111.802 -178.792 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -97.19 -10.27 54.67 Favored Glycine 0 N--CA 1.447 -0.604 0 N-CA-C 110.03 -1.228 . . . . 0.0 110.03 175.347 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 42' ' ' ASP . . . . . 0.404 ' C ' ' H ' ' A' ' 44' ' ' GLY . 18.9 m-20 -137.7 -160.63 1.08 Allowed 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 114.464 -0.868 . . . . 0.0 108.766 179.505 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 17.9 m-20 -76.5 34.51 0.14 Allowed 'General case' 0 N--CA 1.481 1.086 0 CA-C-O 120.971 0.415 . . . . 0.0 110.999 178.53 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.529 ' O ' ' HE2' ' A' ' 71' ' ' TYR . . . 103.11 -6.27 50.77 Favored Glycine 0 C--O 1.208 -1.484 0 N-CA-C 111.456 -0.658 . . . . 0.0 111.456 -178.827 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 59.7 tp60 -65.18 -40.13 93.83 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.233 0.54 . . . . 0.0 110.602 179.89 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 74.4 p -125.24 142.56 51.42 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.47 178.693 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 47' ' ' LEU . . . . . 0.494 ' HB2' ' HB3' ' A' ' 63' ' ' ALA . 92.3 mt -128.56 126.98 41.46 Favored 'General case' 0 C--N 1.322 -0.626 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 178.131 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 87.0 m-20 -129.02 142.3 50.96 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 179.94 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 173.28 -155.51 22.64 Favored Glycine 0 N--CA 1.441 -0.998 0 C-N-CA 119.547 -1.311 . . . . 0.0 113.145 177.69 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 53.7 m -128.35 130.86 48.38 Favored 'General case' 0 C--N 1.311 -1.079 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 -179.452 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 51' ' ' MET . . . . . 0.558 ' SD ' ' HH2' ' A' ' 90' ' ' TRP . 23.5 ttt -116.22 145.61 42.98 Favored 'General case' 0 C--N 1.314 -0.964 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 -179.813 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.618 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 37.6 m -122.19 126.11 47.57 Favored 'General case' 0 C--O 1.246 0.887 0 CA-C-O 121.162 0.506 . . . . 0.0 111.601 -179.19 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 74.2 m-85 -103.58 158.63 16.23 Favored 'General case' 0 N--CA 1.445 -0.705 0 CA-C-N 115.339 -0.846 . . . . 0.0 109.338 176.739 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -61.42 137.69 58.25 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.229 -179.027 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 77.02 -60.34 3.48 Favored Glycine 0 CA--C 1.524 0.595 0 N-CA-C 114.647 0.619 . . . . 0.0 114.647 176.772 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -66.36 -40.71 89.93 Favored 'General case' 0 C--O 1.239 0.504 0 N-CA-C 113.218 0.822 . . . . 0.0 113.218 -175.272 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 111.63 -162.49 12.43 Favored Glycine 0 N--CA 1.446 -0.652 0 C-N-CA 120.0 -1.095 . . . . 0.0 112.944 178.595 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 97.8 Cg_endo -79.0 141.74 16.84 Favored 'Trans proline' 0 C--O 1.237 0.454 0 C-N-CA 123.126 2.551 . . . . 0.0 113.416 -179.636 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 59' ' ' ILE . . . . . 0.739 ' HB ' ' O ' ' A' ' 76' ' ' GLN . 48.7 pt -136.07 167.99 23.45 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 CA-C-N 115.712 -0.676 . . . . 0.0 109.905 176.974 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 60' ' ' GLY . . . . . 0.456 ' HA3' ' HB3' ' A' ' 76' ' ' GLN . . . -73.95 142.66 31.07 Favored Glycine 0 C--O 1.237 0.338 0 C-N-CA 120.332 -0.937 . . . . 0.0 111.357 -179.49 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 37.8 t80 -128.1 125.0 38.36 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-O 120.611 0.243 . . . . 0.0 111.001 -177.647 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 62' ' ' ARG . . . . . 0.448 HH21 ' CD ' ' A' ' 74' ' ' GLU . 19.5 ttp85 -135.12 130.63 35.77 Favored 'General case' 0 C--O 1.217 -0.612 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 175.352 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.494 ' HB3' ' HB2' ' A' ' 47' ' ' LEU . . . -137.44 146.2 44.06 Favored 'General case' 0 C--N 1.317 -0.828 0 C-N-CA 120.835 -0.346 . . . . 0.0 111.38 -179.597 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 63.4 m -125.11 134.71 52.36 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.069 179.074 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 55.6 tp -63.83 118.5 8.44 Favored 'General case' 0 CA--C 1.509 -0.617 0 CA-C-O 121.074 0.464 . . . . 0.0 110.998 -179.767 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 52.3 tp -67.53 -39.43 85.04 Favored 'General case' 0 N--CA 1.436 -1.146 0 CA-C-N 115.374 -0.83 . . . . 0.0 111.116 -179.956 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 178.68 -37.69 0.08 OUTLIER Glycine 0 N--CA 1.446 -0.652 0 C-N-CA 120.485 -0.864 . . . . 0.0 112.557 179.763 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 18.8 p-10 -173.73 114.05 0.21 Allowed 'General case' 0 C--N 1.326 -0.414 0 C-N-CA 122.405 0.282 . . . . 0.0 110.353 -178.611 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 69' ' ' ASN . . . . . 0.405 ' OD1' ' HA3' ' A' ' 93' ' ' GLY . 96.1 m-20 68.19 -43.77 0.49 Allowed 'General case' 0 N--CA 1.484 1.273 0 C-N-CA 123.795 0.838 . . . . 0.0 113.114 -178.824 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 9.6 m -77.96 133.76 37.97 Favored 'General case' 0 C--N 1.315 -0.932 0 CA-C-O 121.113 0.482 . . . . 0.0 110.898 178.396 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.607 ' OH ' ' HB3' ' A' ' 99' ' ' ASN . 96.4 m-85 -126.41 148.74 49.57 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.037 178.586 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -95.54 117.25 30.09 Favored 'General case' 0 C--N 1.308 -1.235 0 N-CA-C 107.797 -1.186 . . . . 0.0 107.797 173.448 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 79.0 t -103.3 136.6 35.3 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.849 0 CA-C-O 121.244 0.545 . . . . 0.0 112.416 -173.635 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.465 ' HG2' ' HA ' ' A' ' 86' ' ' SER . 98.0 mt-10 -118.76 146.88 44.43 Favored 'General case' 0 N--CA 1.439 -1.025 0 CA-C-N 114.982 -1.008 . . . . 0.0 109.081 177.438 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 75' ' ' ASN . . . . . 0.439 ' HB3' HD12 ' A' ' 59' ' ' ILE . 10.0 m120 -123.99 137.18 54.64 Favored 'General case' 0 C--N 1.315 -0.904 0 CA-C-O 121.226 0.536 . . . . 0.0 110.931 -177.095 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 76' ' ' GLN . . . . . 0.739 ' O ' ' HB ' ' A' ' 59' ' ' ILE . 30.4 tt0 -110.37 115.82 30.35 Favored 'General case' 0 C--N 1.309 -1.194 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.32 -179.875 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 6.1 p90 -129.28 44.62 2.94 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-O 121.423 0.63 . . . . 0.0 110.717 179.467 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -104.8 -68.95 0.75 Allowed Glycine 0 N--CA 1.443 -0.839 0 C-N-CA 120.647 -0.787 . . . . 0.0 111.183 -178.848 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 170.81 -67.18 0.15 Allowed Glycine 0 N--CA 1.446 -0.676 0 N-CA-C 110.686 -0.965 . . . . 0.0 110.686 178.354 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 37.0 t70 -139.08 117.27 11.84 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 177.654 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 32.3 t 76.76 -75.08 0.07 Allowed 'General case' 0 C--N 1.327 -0.396 0 O-C-N 123.876 0.735 . . . . 0.0 110.092 -178.436 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 63.99 161.6 0.12 Allowed Pre-proline 0 N--CA 1.477 0.901 0 N-CA-C 112.352 0.501 . . . . 0.0 112.352 177.141 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 83' ' ' PRO . . . . . 0.593 ' O ' ' HB2' ' A' ' 84' ' ' TRP . 51.7 Cg_exo -57.07 -41.83 70.47 Favored 'Trans proline' 0 C--N 1.355 0.892 0 C-N-CA 122.526 2.151 . . . . 0.0 112.859 177.612 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 84' ' ' TRP . . . . . 0.593 ' HB2' ' O ' ' A' ' 83' ' ' PRO . 74.0 m95 94.48 116.42 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.778 0 C-N-CA 124.747 1.219 . . . . 0.0 110.231 -178.725 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 92.7 m-70 -112.15 139.04 48.0 Favored 'General case' 0 CA--C 1.517 -0.324 0 CA-C-N 116.484 -0.326 . . . . 0.0 110.531 -176.845 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 86' ' ' SER . . . . . 0.465 ' HA ' ' HG2' ' A' ' 74' ' ' GLU . 13.1 m -70.61 141.3 51.76 Favored 'General case' 0 C--N 1.311 -1.092 0 CA-C-N 116.442 -0.345 . . . . 0.0 110.096 177.134 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -109.29 -34.06 2.59 Favored Glycine 0 N--CA 1.447 -0.578 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.852 -178.349 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 147.57 -160.56 28.33 Favored Glycine 0 N--CA 1.453 -0.211 0 C-N-CA 120.315 -0.945 . . . . 0.0 112.459 178.649 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 23.8 t-20 -118.67 124.61 47.8 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.433 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 90' ' ' TRP . . . . . 0.558 ' HH2' ' SD ' ' A' ' 51' ' ' MET . 36.2 m0 -118.24 152.88 34.87 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.129 -177.721 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 79.1 mt -107.25 116.71 51.5 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 N-CA-C 110.191 -0.299 . . . . 0.0 110.191 178.494 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 92' ' ' LEU . . . . . 0.402 ' HB2' ' CE1' ' A' ' 71' ' ' TYR . 90.2 mt -126.57 76.46 1.63 Allowed 'General case' 0 C--O 1.256 1.406 0 CA-C-O 121.625 0.726 . . . . 0.0 111.036 -178.411 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 93' ' ' GLY . . . . . 0.405 ' HA3' ' OD1' ' A' ' 69' ' ' ASN . . . -176.73 105.3 0.2 Allowed Glycine 0 N--CA 1.435 -1.374 0 CA-C-N 114.842 -1.072 . . . . 0.0 111.612 -179.551 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.4 p -86.2 -11.8 51.48 Favored 'General case' 0 C--N 1.313 -1.003 0 CA-C-O 121.265 0.555 . . . . 0.0 110.695 178.384 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 97.6 mtt180 -106.92 153.39 22.6 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.563 -0.744 . . . . 0.0 111.68 178.825 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -66.69 -43.14 85.19 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 115.207 -0.906 . . . . 0.0 112.388 -175.967 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 21.4 m120 -123.04 34.1 5.22 Favored 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 111.967 0.358 . . . . 0.0 111.967 -176.364 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 98' ' ' GLN . . . . . . . . . . . . . 9.6 tt0 -146.95 121.01 9.41 Favored 'General case' 0 C--N 1.32 -0.688 0 C-N-CA 120.278 -0.569 . . . . 0.0 110.549 -178.473 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 99' ' ' ASN . . . . . 0.607 ' HB3' ' OH ' ' A' ' 71' ' ' TYR . 90.2 m-20 -95.34 159.71 14.88 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.182 -176.45 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 79.1 t -81.46 133.72 28.65 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.637 0 CA-C-N 116.509 -0.314 . . . . 0.0 110.79 176.64 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 33.7 m -113.33 -26.83 2.88 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 N-CA-C 112.83 0.678 . . . . 0.0 112.83 -178.755 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 102' ' ' ALA . . . . . 0.648 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -146.91 140.12 25.42 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 119.696 -0.801 . . . . 0.0 112.095 178.65 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.412 ' HB ' HG22 ' A' ' 38' ' ' VAL . 91.1 mt -133.22 124.64 49.73 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.929 -0.578 . . . . 0.0 111.073 178.25 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 40.2 t30 -128.78 97.45 4.67 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.317 174.703 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 28.6 m -143.48 148.37 19.18 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 N-CA-C 112.949 0.722 . . . . 0.0 112.949 -174.526 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 76.1 tt0 -142.66 138.04 30.38 Favored 'General case' 0 N--CA 1.437 -1.092 0 CA-C-N 115.072 -0.967 . . . . 0.0 108.544 175.248 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 107' ' ' SER . . . . . 0.437 ' HA ' ' HA ' ' A' ' 114' ' ' LEU . 44.8 t -74.87 -52.42 11.36 Favored 'General case' 0 C--N 1.306 -1.287 0 CA-C-N 116.09 -0.504 . . . . 0.0 111.382 -178.183 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 81.8 -9.26 57.01 Favored Glycine 0 N--CA 1.449 -0.457 0 N-CA-C 110.875 -0.89 . . . . 0.0 110.875 -176.366 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 109' ' ' ASP . . . . . 0.495 ' CG ' ' H ' ' A' ' 110' ' ' ASP . 19.4 t70 -125.07 -150.76 0.45 Allowed 'General case' 0 N--CA 1.445 -0.677 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 179.398 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 110' ' ' ASP . . . . . 0.495 ' H ' ' CG ' ' A' ' 109' ' ' ASP . 31.7 m-20 -89.86 12.88 15.99 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 120.845 0.355 . . . . 0.0 111.475 -179.426 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 111' ' ' GLY . . . . . 0.454 ' HA3' ' ND2' ' A' ' 32' ' ' ASN . . . 101.33 8.61 46.54 Favored Glycine 0 C--O 1.229 -0.217 0 C-N-CA 120.129 -1.034 . . . . 0.0 113.408 179.529 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 48.4 mt-30 -68.83 -42.37 77.27 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.487 0.66 . . . . 0.0 110.557 179.224 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 17.5 p -133.51 139.28 46.55 Favored 'General case' 0 C--N 1.317 -0.839 0 CA-C-N 115.32 -0.854 . . . . 0.0 110.837 179.104 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 114' ' ' LEU . . . . . 0.437 ' HA ' ' HA ' ' A' ' 107' ' ' SER . 9.1 mp -120.31 145.16 47.37 Favored 'General case' 0 C--N 1.316 -0.867 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 178.677 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 8.6 p30 -148.1 160.4 42.93 Favored 'General case' 0 C--N 1.314 -0.939 0 C-N-CA 120.617 -0.433 . . . . 0.0 110.939 178.486 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 153.35 -128.0 2.32 Favored Glycine 0 N--CA 1.436 -1.337 0 CA-C-N 115.683 -0.69 . . . . 0.0 111.673 179.875 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 22.1 p -135.24 158.83 43.36 Favored 'General case' 0 C--N 1.315 -0.9 0 CA-C-O 121.11 0.481 . . . . 0.0 111.055 -179.079 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 118' ' ' MET . . . . . 0.442 ' O ' ' HA ' ' A' ' 125' ' ' PRO . 4.7 ppp? -147.19 156.03 42.61 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 116.156 -0.474 . . . . 0.0 109.841 178.841 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 119' ' ' THR . . . . . 0.648 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 26.4 m -128.72 126.45 40.06 Favored 'General case' 0 C--O 1.254 1.292 0 CA-C-O 120.519 0.2 . . . . 0.0 111.115 179.91 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 70.0 m-85 -85.42 158.44 20.22 Favored 'General case' 0 C--O 1.233 0.196 0 CA-C-N 115.777 -0.647 . . . . 0.0 109.982 176.264 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -60.3 126.32 27.03 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 120.778 0.323 . . . . 0.0 110.796 177.631 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 65.03 30.81 78.95 Favored Glycine 0 CA--C 1.523 0.562 0 CA-C-N 115.964 -0.562 . . . . 0.0 114.113 178.715 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 77.2 tt0 -150.49 160.2 43.95 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 117.229 0.514 . . . . 0.0 110.218 -179.345 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -77.2 160.08 49.46 Favored Glycine 0 CA--C 1.522 0.53 0 C-N-CA 121.084 -0.579 . . . . 0.0 112.908 -178.947 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 125' ' ' PRO . . . . . 0.442 ' HA ' ' O ' ' A' ' 118' ' ' MET . 51.4 Cg_endo -68.21 142.78 56.63 Favored 'Trans proline' 0 CA--C 1.534 0.502 0 C-N-CA 122.993 2.462 . . . . 0.0 113.271 179.743 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 49.1 pt -131.6 169.42 21.8 Favored 'Isoleucine or valine' 0 C--O 1.24 0.581 0 CA-C-N 115.737 -0.665 . . . . 0.0 109.935 178.547 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -70.66 131.99 21.99 Favored Glycine 0 C--N 1.336 0.55 0 C-N-CA 120.677 -0.773 . . . . 0.0 111.981 -179.381 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 84.7 t80 -119.5 139.19 52.48 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 121.255 0.55 . . . . 0.0 111.583 -178.146 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 129' ' ' LYS . . . . . 0.4 ' HB3' ' HB2' ' A' ' 7' ' ' GLU . 62.8 tttm -140.94 134.8 30.48 Favored 'General case' 0 N--CA 1.431 -1.379 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 176.85 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 130' ' ' GLY . . . . . 0.405 ' HA2' ' O ' ' A' ' 5' ' ' ASN . . . -135.15 144.75 16.78 Favored Glycine 0 N--CA 1.436 -1.355 0 C-N-CA 120.521 -0.847 . . . . 0.0 111.428 -179.502 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 56.2 m -123.81 130.55 52.79 Favored 'General case' 0 C--N 1.311 -1.084 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 -178.72 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 61.1 tp -70.67 136.22 48.9 Favored 'General case' 0 C--O 1.237 0.436 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 179.076 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 15.4 t . . . . . 0 C--O 1.251 1.149 0 CA-C-O 119.144 -0.455 . . . . 0.0 110.069 -177.65 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 0.578 ' O ' ' HG3' ' A' ' 24' ' ' GLU . . . . . . . . 0 N--CA 1.48 1.047 0 N-CA-C 110.022 -0.362 . . . . 0.0 110.022 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -91.97 128.23 37.74 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-O 121.019 0.437 . . . . 0.0 110.537 -175.743 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 11.8 m-85 -121.3 144.47 48.62 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.169 178.27 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 94.4 m-20 -94.66 140.13 30.29 Favored 'General case' 0 C--N 1.313 -0.99 0 N-CA-C 107.826 -1.176 . . . . 0.0 107.826 177.538 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 77.3 t -116.33 128.46 73.65 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.961 0 CA-C-O 121.274 0.559 . . . . 0.0 112.434 -175.629 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -125.09 138.75 54.18 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 176.691 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 8' ' ' ASN . . . . . 0.438 ' HB3' HD12 ' A' ' 126' ' ' ILE . 27.0 m120 -131.01 151.88 50.93 Favored 'General case' 0 C--N 1.316 -0.866 0 N-CA-C 112.653 0.612 . . . . 0.0 112.653 -177.526 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 9' ' ' GLN . . . . . 0.413 ' OE1' ' HA ' ' A' ' 13' ' ' SER . 35.7 tt0 -129.47 128.13 42.28 Favored 'General case' 0 C--O 1.238 0.498 0 CA-C-N 115.343 -0.844 . . . . 0.0 110.533 178.336 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 46.8 p90 -138.11 146.24 42.63 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 116.575 -0.284 . . . . 0.0 110.484 178.617 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 95.12 11.82 55.76 Favored Glycine 0 N--CA 1.444 -0.775 0 C-N-CA 120.545 -0.836 . . . . 0.0 111.759 179.207 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 104.88 157.38 23.27 Favored Glycine 0 N--CA 1.442 -0.919 0 C-N-CA 120.953 -0.642 . . . . 0.0 112.144 179.088 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' SER . . . . . 0.413 ' HA ' ' OE1' ' A' ' 9' ' ' GLN . 15.5 m -58.13 -21.16 45.42 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 112.128 0.418 . . . . 0.0 112.128 179.036 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 18.7 m -59.14 -33.73 71.23 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 120.806 0.336 . . . . 0.0 110.857 176.82 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -76.78 145.28 74.31 Favored Pre-proline 0 N--CA 1.45 -0.437 0 CA-C-N 116.009 -0.542 . . . . 0.0 111.132 -179.409 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 93.1 Cg_endo -73.26 163.19 38.62 Favored 'Trans proline' 0 C--O 1.236 0.375 0 C-N-CA 122.808 2.339 . . . . 0.0 112.266 -179.892 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 92.3 m95 -85.17 131.68 34.4 Favored 'General case' 0 C--N 1.319 -0.75 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 179.23 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 55.9 m-80 -124.1 144.94 49.59 Favored 'General case' 0 C--N 1.312 -1.029 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 -179.525 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -64.99 135.4 55.6 Favored 'General case' 0 C--N 1.311 -1.066 0 CA-C-O 121.598 0.713 . . . . 0.0 112.207 -177.274 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -112.2 34.82 4.98 Favored Glycine 0 CA--C 1.499 -0.912 0 CA-C-N 114.604 -1.18 . . . . 0.0 110.961 178.326 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 83.3 -156.85 34.24 Favored Glycine 0 N--CA 1.436 -1.353 0 N-CA-C 111.344 -0.702 . . . . 0.0 111.344 -177.387 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 9.2 pt20 -144.27 147.41 33.5 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-O 120.869 0.366 . . . . 0.0 110.246 178.204 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 23' ' ' TRP . . . . . 0.598 ' HB3' ' O ' ' A' ' 91' ' ' ILE . 54.4 m0 -128.33 -179.14 4.86 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.743 -173.893 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 24' ' ' GLU . . . . . 0.578 ' HG3' ' O ' ' A' ' 2' ' ' ALA . 82.6 tt0 -123.69 116.15 22.6 Favored 'General case' 0 CA--C 1.511 -0.534 0 CA-C-O 120.943 0.401 . . . . 0.0 110.522 176.446 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 95.3 mt -126.94 134.16 66.8 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.784 0 CA-C-N 115.448 -0.796 . . . . 0.0 110.767 -177.701 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 90.94 106.74 1.38 Allowed Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.973 -0.632 . . . . 0.0 113.911 176.526 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 19.8 m -69.1 -43.04 75.29 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.369 0.604 . . . . 0.0 110.02 175.419 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -71.0 137.96 49.52 Favored 'General case' 0 N--CA 1.451 -0.396 0 CA-C-N 115.292 -0.867 . . . . 0.0 110.663 179.77 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 19.8 m -102.86 -26.16 13.23 Favored 'General case' 0 C--N 1.315 -0.924 0 CA-C-O 121.054 0.454 . . . . 0.0 110.4 178.687 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 27.1 m-20 -91.09 -5.3 55.34 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.918 179.263 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 8.6 tp-100 -139.59 120.55 14.54 Favored 'General case' 0 C--N 1.31 -1.133 0 N-CA-C 109.35 -0.611 . . . . 0.0 109.35 -178.999 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 62.0 t30 -97.74 162.76 13.11 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-O 121.172 0.51 . . . . 0.0 112.083 -175.975 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.412 ' HA ' ' HA ' ' A' ' 53' ' ' TYR . 89.5 t -98.74 133.59 40.66 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.639 0 CA-C-N 115.217 -0.902 . . . . 0.0 109.991 179.965 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 21.0 m -107.05 -27.73 2.96 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.456 0 N-CA-C 111.981 0.364 . . . . 0.0 111.981 -179.38 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 35' ' ' ALA . . . . . 0.42 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -139.56 143.63 37.44 Favored 'General case' 0 CA--C 1.509 -0.634 0 C-N-CA 120.109 -0.637 . . . . 0.0 111.632 179.989 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.435 ' HB ' ' CG2' ' A' ' 105' ' ' VAL . 94.2 mt -139.64 117.73 11.4 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.832 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 179.039 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 23.0 t30 -129.02 108.25 10.24 Favored 'General case' 0 C--N 1.304 -1.388 0 N-CA-C 108.065 -1.087 . . . . 0.0 108.065 177.453 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.434 HG22 ' HB ' ' A' ' 103' ' ' ILE . 23.9 m -147.03 151.38 13.95 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.762 0 C-N-CA 120.448 -0.501 . . . . 0.0 111.339 -173.184 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 36.1 tt0 -141.1 145.56 35.95 Favored 'General case' 0 N--CA 1.437 -1.089 0 CA-C-N 115.512 -0.767 . . . . 0.0 109.001 176.433 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 30.9 t -72.26 142.6 48.93 Favored 'General case' 0 C--N 1.309 -1.176 0 CA-C-O 121.093 0.473 . . . . 0.0 111.338 -178.522 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -95.22 -25.12 14.79 Favored Glycine 0 N--CA 1.433 -1.553 0 C-N-CA 120.504 -0.855 . . . . 0.0 111.769 177.919 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 36.1 t70 -145.11 79.63 1.59 Allowed 'General case' 0 CA--C 1.536 0.405 0 N-CA-C 112.842 0.682 . . . . 0.0 112.842 -177.372 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 50.24 29.03 3.44 Favored 'General case' 0 N--CA 1.491 1.611 0 N-CA-C 114.564 1.32 . . . . 0.0 114.564 173.673 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.502 ' HA2' HG12 ' A' ' 101' ' ' VAL . . . 99.44 -16.77 58.6 Favored Glycine 0 C--N 1.312 -0.791 0 C-N-CA 120.658 -0.782 . . . . 0.0 113.189 178.187 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 59.7 tp60 -66.42 -39.01 88.72 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-O 121.04 0.448 . . . . 0.0 110.77 -179.944 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 36.8 p -125.67 147.84 49.21 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.975 178.499 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 47' ' ' LEU . . . . . 0.551 ' HB2' ' HB3' ' A' ' 63' ' ' ALA . 95.2 mt -128.36 128.15 43.99 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 109.524 -0.547 . . . . 0.0 109.524 179.254 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 83.4 m-20 -128.44 141.1 51.51 Favored 'General case' 0 C--N 1.319 -0.723 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 178.398 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 175.45 -156.26 21.73 Favored Glycine 0 N--CA 1.442 -0.948 0 C-N-CA 119.411 -1.376 . . . . 0.0 113.503 178.444 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 70.4 m -128.95 131.46 47.5 Favored 'General case' 0 N--CA 1.44 -0.971 0 C-N-CA 122.839 0.456 . . . . 0.0 110.149 -178.43 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 51' ' ' MET . . . . . 0.403 ' HE1' ' CZ ' ' A' ' 53' ' ' TYR . 14.7 tmm? -125.91 144.73 50.56 Favored 'General case' 0 C--N 1.316 -0.875 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 -179.265 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.42 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 33.6 m -126.26 130.06 50.13 Favored 'General case' 0 C--O 1.245 0.866 0 N-CA-C 112.054 0.39 . . . . 0.0 112.054 -176.57 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 53' ' ' TYR . . . . . 0.412 ' HA ' ' HA ' ' A' ' 33' ' ' VAL . 72.4 m-85 -87.15 161.8 17.87 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.946 177.176 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -63.54 106.91 1.02 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.989 -0.55 . . . . 0.0 112.069 -179.713 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 84.67 10.6 79.0 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.713 -0.756 . . . . 0.0 113.528 177.836 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 57.8 mt-10 -123.07 168.02 12.9 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 117.212 0.506 . . . . 0.0 110.793 178.26 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -79.86 155.48 38.97 Favored Glycine 0 N--CA 1.447 -0.599 0 C-N-CA 120.84 -0.695 . . . . 0.0 112.379 -179.884 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 32.9 Cg_endo -62.81 142.72 89.89 Favored 'Trans proline' 0 CA--C 1.534 0.503 0 C-N-CA 123.012 2.475 . . . . 0.0 112.546 -179.758 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 59' ' ' ILE . . . . . 0.566 ' HB ' ' O ' ' A' ' 76' ' ' GLN . 47.3 pt -128.25 167.35 23.55 Favored 'Isoleucine or valine' 0 C--O 1.239 0.501 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.736 -179.765 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -79.11 138.63 20.89 Favored Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 120.929 -0.653 . . . . 0.0 111.807 -179.702 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 60.9 t80 -118.62 123.59 45.36 Favored 'General case' 0 C--N 1.317 -0.827 0 C-N-CA 122.389 0.275 . . . . 0.0 110.799 -178.132 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 49.1 ttm-85 -126.81 128.22 46.22 Favored 'General case' 0 C--O 1.22 -0.452 0 N-CA-C 109.325 -0.62 . . . . 0.0 109.325 175.997 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.65 ' HB1' ' HB3' ' A' ' 71' ' ' TYR . . . -136.12 142.81 44.29 Favored 'General case' 0 C--N 1.32 -0.696 0 C-N-CA 120.231 -0.588 . . . . 0.0 112.094 178.574 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 57.3 m -118.7 127.45 53.58 Favored 'General case' 0 CA--C 1.54 0.573 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.084 178.249 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 65' ' ' LEU . . . . . 0.403 HD13 ' N ' ' A' ' 67' ' ' GLY . 2.4 tm? -72.74 118.31 15.51 Favored 'General case' 0 CA--C 1.544 0.749 0 CA-C-O 121.372 0.606 . . . . 0.0 112.156 -177.866 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 4.6 mm? -66.86 -38.22 85.94 Favored 'General case' 0 N--CA 1.475 0.792 0 CA-C-N 115.283 -0.871 . . . . 0.0 111.869 178.091 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.403 ' N ' HD13 ' A' ' 65' ' ' LEU . . . 125.45 -6.14 8.07 Favored Glycine 0 C--O 1.227 -0.304 0 C-N-CA 120.593 -0.813 . . . . 0.0 112.521 -176.263 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 29.7 p-10 -125.83 38.19 4.2 Favored 'General case' 0 C--N 1.316 -0.889 0 CA-C-O 121.117 0.484 . . . . 0.0 110.507 -179.372 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 96.1 m-20 66.59 5.09 3.64 Favored 'General case' 0 N--CA 1.479 0.976 0 CA-C-N 115.469 -0.787 . . . . 0.0 111.882 -178.761 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 32.8 m -99.17 138.06 36.81 Favored 'General case' 0 N--CA 1.443 -0.785 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 177.367 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.65 ' HB3' ' HB1' ' A' ' 63' ' ' ALA . 91.5 m-85 -120.38 135.65 54.97 Favored 'General case' 0 C--N 1.306 -1.296 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.329 -179.28 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 72' ' ' GLU . . . . . 0.417 ' O ' ' HA ' ' A' ' 63' ' ' ALA . 71.6 tt0 -88.76 121.31 31.0 Favored 'General case' 0 C--N 1.311 -1.077 0 N-CA-C 107.964 -1.124 . . . . 0.0 107.964 175.286 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.469 HG22 ' HB2' ' A' ' 63' ' ' ALA . 75.3 t -107.67 137.05 40.85 Favored 'Isoleucine or valine' 0 C--O 1.247 0.957 0 N-CA-C 113.661 0.986 . . . . 0.0 113.661 -170.857 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -119.17 142.67 47.76 Favored 'General case' 0 N--CA 1.444 -0.739 0 CA-C-N 114.19 -1.368 . . . . 0.0 107.84 175.565 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 94.1 m-20 -118.06 135.31 54.27 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-O 120.825 0.345 . . . . 0.0 111.251 -175.699 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 76' ' ' GLN . . . . . 0.566 ' O ' ' HB ' ' A' ' 59' ' ' ILE . 17.3 tt0 -110.09 119.35 39.02 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.889 179.124 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 7.5 p90 -139.63 156.71 46.68 Favored 'General case' 0 C--N 1.326 -0.456 0 C-N-CA 120.856 -0.338 . . . . 0.0 111.358 177.013 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 105.81 -3.95 39.13 Favored Glycine 0 N--CA 1.449 -0.498 0 C-N-CA 121.198 -0.525 . . . . 0.0 112.177 179.666 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 139.63 171.57 12.35 Favored Glycine 0 CA--C 1.503 -0.694 0 N-CA-C 110.579 -1.008 . . . . 0.0 110.579 -179.602 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -68.07 155.16 40.15 Favored 'General case' 0 C--O 1.245 0.839 0 CA-C-N 117.527 0.664 . . . . 0.0 110.047 178.448 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 14.7 m 70.95 -95.2 0.03 OUTLIER 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.467 -0.788 . . . . 0.0 109.042 -176.601 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 82' ' ' ALA . . . . . 0.547 ' HB1' ' HD2' ' A' ' 83' ' ' PRO . . . 51.46 171.07 0.04 OUTLIER Pre-proline 0 CA--C 1.557 1.25 0 N-CA-C 113.31 0.855 . . . . 0.0 113.31 176.38 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 83' ' ' PRO . . . . . 0.547 ' HD2' ' HB1' ' A' ' 82' ' ' ALA . 63.6 Cg_endo -73.27 150.6 47.49 Favored 'Trans proline' 0 N--CA 1.452 -0.943 0 C-N-CA 121.591 1.527 . . . . 0.0 109.927 170.551 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 84' ' ' TRP . . . . . . . . . . . . . 82.2 m95 -95.69 137.99 33.98 Favored 'General case' 0 C--N 1.315 -0.924 0 C-N-CA 120.54 -0.464 . . . . 0.0 109.768 -179.91 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 84.4 m-70 -113.18 138.8 49.43 Favored 'General case' 0 C--N 1.314 -0.976 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 -177.775 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 13.4 p -65.15 131.25 46.04 Favored 'General case' 0 C--N 1.32 -0.688 0 C-N-CA 121.113 -0.235 . . . . 0.0 110.447 -179.779 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -105.36 -52.3 0.83 Allowed Glycine 0 N--CA 1.443 -0.836 0 C-N-CA 120.239 -0.981 . . . . 0.0 113.23 -179.187 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 154.59 -166.27 32.24 Favored Glycine 0 C--O 1.22 -0.747 0 C-N-CA 120.187 -1.006 . . . . 0.0 112.115 -178.108 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 20.5 t-20 -113.81 119.43 37.32 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 117.01 0.405 . . . . 0.0 110.709 -179.482 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 22.4 m0 -108.89 148.1 31.16 Favored 'General case' 0 C--O 1.217 -0.621 0 N-CA-C 109.492 -0.558 . . . . 0.0 109.492 -179.867 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 91' ' ' ILE . . . . . 0.598 ' O ' ' HB3' ' A' ' 23' ' ' TRP . 85.0 mt -107.7 119.56 57.51 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.072 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 178.903 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 92' ' ' LEU . . . . . 0.463 ' HB2' ' CE1' ' A' ' 71' ' ' TYR . 90.9 mt -134.08 78.95 1.79 Allowed 'General case' 0 C--O 1.267 1.984 0 CA-C-O 121.688 0.756 . . . . 0.0 111.6 -177.399 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 168.85 126.7 0.87 Allowed Glycine 0 N--CA 1.44 -1.08 0 CA-C-N 115.13 -0.941 . . . . 0.0 111.875 179.29 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 94' ' ' SER . . . . . 0.425 ' HB3' ' HE1' ' A' ' 23' ' ' TRP . 32.4 p -117.95 4.2 12.13 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-O 121.353 0.596 . . . . 0.0 110.651 178.379 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 62.3 mtt-85 -102.01 142.84 32.66 Favored 'General case' 0 N--CA 1.445 -0.702 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.521 178.903 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 -62.66 -37.61 87.09 Favored 'General case' 0 C--N 1.312 -1.029 0 CA-C-N 115.421 -0.809 . . . . 0.0 112.899 -176.143 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 29.0 p-10 -126.3 27.93 6.11 Favored 'General case' 0 C--N 1.316 -0.86 0 N-CA-C 111.827 0.306 . . . . 0.0 111.827 -176.333 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 98' ' ' GLN . . . . . . . . . . . . . 4.4 tp-100 -146.19 126.56 14.01 Favored 'General case' 0 C--N 1.322 -0.615 0 C-N-CA 119.319 -0.953 . . . . 0.0 111.688 -175.471 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 99' ' ' ASN . . . . . 0.591 ' HB3' ' OH ' ' A' ' 71' ' ' TYR . 87.2 m-20 -97.24 154.28 17.5 Favored 'General case' 0 C--O 1.249 1.048 0 CA-C-N 115.452 -0.795 . . . . 0.0 110.572 -179.439 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 70.8 t -79.03 136.86 22.9 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.791 0 C-N-CA 120.85 -0.34 . . . . 0.0 110.79 177.84 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 101' ' ' VAL . . . . . 0.502 HG12 ' HA2' ' A' ' 44' ' ' GLY . 33.3 m -123.0 -35.52 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.714 0 N-CA-C 113.878 1.066 . . . . 0.0 113.878 -177.118 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 102' ' ' ALA . . . . . 0.43 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -127.59 127.33 43.68 Favored 'General case' 0 C--N 1.319 -0.743 0 C-N-CA 120.153 -0.619 . . . . 0.0 111.386 -178.63 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.434 ' HB ' HG22 ' A' ' 38' ' ' VAL . 94.0 mt -131.18 122.09 50.57 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.091 177.927 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 23.6 t-20 -124.79 95.4 4.5 Favored 'General case' 0 C--N 1.313 -1.001 0 N-CA-C 108.812 -0.81 . . . . 0.0 108.812 176.455 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.435 ' CG2' ' HB ' ' A' ' 36' ' ' ILE . 26.8 m -140.17 142.68 31.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 N-CA-C 112.682 0.623 . . . . 0.0 112.682 -175.612 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 -145.1 147.16 32.23 Favored 'General case' 0 N--CA 1.444 -0.759 0 CA-C-N 115.4 -0.818 . . . . 0.0 109.153 176.526 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 47.2 t -137.73 142.48 40.99 Favored 'General case' 0 C--N 1.308 -1.221 0 CA-C-O 120.797 0.332 . . . . 0.0 110.78 -178.589 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -108.01 -6.18 32.39 Favored Glycine 0 N--CA 1.44 -1.05 0 N-CA-C 110.796 -0.922 . . . . 0.0 110.796 175.766 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 68.3 m-20 -98.26 54.65 1.09 Allowed 'General case' 0 C--O 1.235 0.33 0 N-CA-C 112.643 0.609 . . . . 0.0 112.643 -177.582 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 28.7 t70 59.55 15.55 4.65 Favored 'General case' 0 N--CA 1.481 1.098 0 C-N-CA 123.3 0.64 . . . . 0.0 112.284 174.863 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 86.37 -3.85 86.66 Favored Glycine 0 N--CA 1.447 -0.625 0 C-N-CA 120.447 -0.882 . . . . 0.0 112.944 178.232 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 112' ' ' GLN . . . . . 0.42 ' O ' ' HA ' ' A' ' 131' ' ' THR . 97.6 mt-30 -64.21 -40.14 95.45 Favored 'General case' 0 CA--C 1.517 -0.29 0 CA-C-N 116.926 0.363 . . . . 0.0 111.622 -177.76 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 33.5 p -123.32 112.17 17.28 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 110.0 -0.37 . . . . 0.0 110.0 177.833 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 92.5 mt -90.93 126.95 36.21 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 116.464 -0.335 . . . . 0.0 110.477 -178.66 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 9.0 m120 -118.72 129.86 55.51 Favored 'General case' 0 C--O 1.241 0.651 0 CA-C-N 116.224 -0.444 . . . . 0.0 109.882 -178.812 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 172.21 -141.32 6.22 Favored Glycine 0 N--CA 1.445 -0.755 0 C-N-CA 119.741 -1.218 . . . . 0.0 113.608 178.098 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 16.9 p -137.29 159.32 42.27 Favored 'General case' 0 C--N 1.319 -0.726 0 C-N-CA 123.276 0.63 . . . . 0.0 110.781 -178.269 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 17.8 ptm -147.31 150.44 34.79 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 120.864 0.364 . . . . 0.0 110.898 -179.721 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 119' ' ' THR . . . . . 0.43 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 23.3 m -142.48 136.09 29.05 Favored 'General case' 0 C--O 1.252 1.194 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.064 178.053 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 120' ' ' TYR . . . . . 0.628 ' HB2' ' O ' ' A' ' 123' ' ' GLU . 37.1 m-85 -83.58 174.26 10.7 Favored 'General case' 0 C--O 1.225 -0.23 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.342 175.597 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 121' ' ' ALA . . . . . 0.496 ' HA ' HG11 ' A' ' 101' ' ' VAL . . . -51.22 -28.87 12.55 Favored 'General case' 0 N--CA 1.478 0.933 0 N-CA-C 114.058 1.133 . . . . 0.0 114.058 -175.951 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -165.54 26.84 0.18 Allowed Glycine 0 N--CA 1.447 -0.589 0 C-N-CA 119.29 -1.433 . . . . 0.0 112.742 179.986 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 123' ' ' GLU . . . . . 0.628 ' O ' ' HB2' ' A' ' 120' ' ' TYR . 13.3 pt-20 -165.97 145.59 6.25 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.132 0.491 . . . . 0.0 111.868 -178.51 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 71.87 67.92 1.74 Allowed Glycine 0 CA--C 1.531 1.084 0 N-CA-C 116.312 1.285 . . . . 0.0 116.312 173.075 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_exo -84.14 95.07 0.73 Allowed 'Trans proline' 0 N--CA 1.459 -0.53 0 C-N-CA 122.454 2.102 . . . . 0.0 108.374 170.561 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 126' ' ' ILE . . . . . 0.438 HD12 ' HB3' ' A' ' 8' ' ' ASN . 19.6 pt -130.28 165.83 29.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 N-CA-C 113.234 0.828 . . . . 0.0 113.234 -170.762 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -70.44 135.99 25.96 Favored Glycine 0 C--N 1.339 0.703 0 CA-C-N 115.488 -0.778 . . . . 0.0 111.577 178.29 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 82.5 t80 -112.54 133.26 54.69 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 121.281 0.562 . . . . 0.0 111.754 -175.688 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 63.5 tttm -137.64 110.4 7.61 Favored 'General case' 0 C--N 1.314 -0.939 0 CA-C-N 115.241 -0.891 . . . . 0.0 108.933 177.089 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -117.56 153.82 17.02 Favored Glycine 0 N--CA 1.446 -0.685 0 C-N-CA 120.298 -0.953 . . . . 0.0 112.332 -178.363 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 131' ' ' THR . . . . . 0.42 ' HA ' ' O ' ' A' ' 112' ' ' GLN . 14.9 t -143.01 144.95 32.49 Favored 'General case' 0 C--N 1.311 -1.073 0 CA-C-O 121.149 0.5 . . . . 0.0 111.945 179.625 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 68.6 tp -80.91 127.16 32.24 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.342 -0.845 . . . . 0.0 110.219 178.337 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 9.1 t . . . . . 0 C--O 1.253 1.27 0 CA-C-O 118.957 -0.544 . . . . 0.0 110.496 -179.343 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.697 0 N-CA-C 109.995 -0.372 . . . . 0.0 109.995 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 3' ' ' LEU . . . . . 0.473 HD13 ' N ' ' A' ' 4' ' ' TYR . 2.2 tm? -92.08 134.91 34.4 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 116.117 -0.492 . . . . 0.0 109.801 -178.031 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 4' ' ' TYR . . . . . 0.485 ' CE1' ' HB ' ' A' ' 25' ' ' ILE . 74.1 m-85 -123.36 146.54 47.87 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.515 -179.803 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 5' ' ' ASN . . . . . 0.428 ' O ' ' HA2' ' A' ' 130' ' ' GLY . 23.6 t-20 -96.45 140.9 30.42 Favored 'General case' 0 C--N 1.308 -1.211 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 176.627 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 69.9 t -122.77 129.53 75.1 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.916 0 N-CA-C 112.699 0.629 . . . . 0.0 112.699 -175.154 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 91.4 mt-10 -122.4 144.32 49.11 Favored 'General case' 0 C--N 1.32 -0.679 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 173.09 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 86.4 m-20 -123.49 144.67 49.39 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-O 120.921 0.391 . . . . 0.0 111.493 -177.003 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 9' ' ' GLN . . . . . 0.595 ' HB2' ' CE3' ' A' ' 17' ' ' TRP . 57.9 tt0 -123.88 127.14 47.59 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.766 -179.853 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 8.7 p90 -136.09 139.22 42.83 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-N 116.193 -0.458 . . . . 0.0 109.865 176.915 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 105.34 8.0 36.41 Favored Glycine 0 N--CA 1.448 -0.529 0 C-N-CA 120.286 -0.959 . . . . 0.0 112.294 179.862 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 103.24 165.71 25.68 Favored Glycine 0 N--CA 1.445 -0.724 0 C-N-CA 120.402 -0.904 . . . . 0.0 113.427 177.954 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 15.6 m -54.81 -31.81 59.6 Favored 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 123.631 0.773 . . . . 0.0 112.321 179.013 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 33.6 t -64.25 -40.0 95.11 Favored 'General case' 0 C--O 1.242 0.701 0 CA-C-O 120.97 0.414 . . . . 0.0 110.604 -179.573 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -63.43 150.55 89.56 Favored Pre-proline 0 C--O 1.235 0.34 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.403 -179.118 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 88.8 Cg_endo -75.33 156.87 41.6 Favored 'Trans proline' 0 C--O 1.238 0.477 0 C-N-CA 122.888 2.392 . . . . 0.0 112.93 -179.476 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' TRP . . . . . 0.595 ' CE3' ' HB2' ' A' ' 9' ' ' GLN . 85.7 m95 -84.91 124.59 31.82 Favored 'General case' 0 N--CA 1.446 -0.627 0 N-CA-C 107.872 -1.159 . . . . 0.0 107.872 175.71 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 55.1 m-80 -103.68 137.13 42.15 Favored 'General case' 0 C--N 1.308 -1.228 0 N-CA-C 109.122 -0.695 . . . . 0.0 109.122 -179.177 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 18.5 pt-20 -63.78 128.79 37.38 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-O 121.625 0.726 . . . . 0.0 111.673 -178.277 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.681 ' O ' ' HB2' ' A' ' 94' ' ' SER . . . -102.26 -25.28 7.92 Favored Glycine 0 N--CA 1.434 -1.467 0 CA-C-N 114.435 -1.257 . . . . 0.0 113.746 -174.851 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 139.07 -153.04 22.57 Favored Glycine 0 N--CA 1.443 -0.849 0 C-N-CA 119.684 -1.246 . . . . 0.0 112.071 -174.367 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 20.3 pt20 -138.41 134.37 34.04 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 120.733 0.302 . . . . 0.0 110.707 -179.054 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 23' ' ' TRP . . . . . 0.471 ' HE1' ' HB3' ' A' ' 94' ' ' SER . 44.9 m0 -117.61 172.74 7.15 Favored 'General case' 0 N--CA 1.47 0.568 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.637 -179.021 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 79.2 tt0 -130.93 122.49 27.04 Favored 'General case' 0 CA--C 1.518 -0.286 0 C-N-CA 120.513 -0.475 . . . . 0.0 110.142 178.006 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.571 HG23 ' CZ3' ' A' ' 90' ' ' TRP . 99.1 mt -139.72 151.39 22.26 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.769 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.189 -176.146 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 84.62 25.91 40.68 Favored Glycine 0 C--N 1.336 0.559 0 C-N-CA 121.009 -0.615 . . . . 0.0 113.81 175.26 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 4.9 m -77.85 7.94 5.25 Favored 'General case' 0 CA--C 1.549 0.93 0 N-CA-C 112.471 0.545 . . . . 0.0 112.471 -179.06 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 28' ' ' ARG . . . . . 0.499 ' HA ' ' O ' ' A' ' 87' ' ' GLY . 70.7 ttt180 -64.16 -49.68 71.15 Favored 'General case' 0 N--CA 1.474 0.756 0 CA-C-O 121.14 0.495 . . . . 0.0 111.85 -177.977 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 59.2 m -161.47 25.41 0.13 Allowed 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 -179.795 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 27.4 m-20 61.35 94.38 0.04 OUTLIER 'General case' 0 C--O 1.236 0.388 0 CA-C-N 114.486 -1.234 . . . . 0.0 108.783 -175.894 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -160.93 143.42 12.6 Favored 'General case' 0 N--CA 1.443 -0.78 0 N-CA-C 107.455 -1.313 . . . . 0.0 107.455 -176.23 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 32' ' ' ASN . . . . . 0.515 ' HB3' ' HA3' ' A' ' 111' ' ' GLY . 61.1 m-20 -83.37 134.71 34.88 Favored 'General case' 0 C--N 1.311 -1.089 0 CA-C-O 121.543 0.687 . . . . 0.0 112.589 -177.741 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.422 ' HA ' ' HA ' ' A' ' 53' ' ' TYR . 44.7 t -92.9 135.99 26.18 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.727 0 CA-C-N 114.768 -1.105 . . . . 0.0 110.153 -179.857 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 29.7 m -109.36 -18.6 7.41 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 C-N-CA 120.758 -0.377 . . . . 0.0 111.572 -179.671 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -149.92 139.1 21.22 Favored 'General case' 0 C--O 1.236 0.361 0 C-N-CA 120.787 -0.365 . . . . 0.0 111.48 178.666 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.449 ' HB ' ' CG2' ' A' ' 105' ' ' VAL . 86.8 mt -140.03 116.32 8.74 Favored 'Isoleucine or valine' 0 C--O 1.237 0.446 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 178.635 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 88.2 m-20 -123.55 106.65 10.77 Favored 'General case' 0 C--N 1.311 -1.085 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 176.716 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.413 ' CG2' ' HB ' ' A' ' 103' ' ' ILE . 18.6 m -146.56 148.11 17.26 Favored 'Isoleucine or valine' 0 C--O 1.238 0.472 0 CA-C-O 120.742 0.306 . . . . 0.0 111.236 -174.764 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 83.0 tt0 -142.61 147.41 35.78 Favored 'General case' 0 C--N 1.319 -0.759 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 178.169 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 19.4 p -70.81 150.33 45.94 Favored 'General case' 0 C--N 1.319 -0.757 0 N-CA-C 112.985 0.735 . . . . 0.0 112.985 -176.248 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -103.55 -47.39 1.3 Allowed Glycine 0 N--CA 1.443 -0.879 0 N-CA-C 110.529 -1.029 . . . . 0.0 110.529 176.252 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 45.4 m-20 -102.11 -152.8 0.45 Allowed 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 109.57 -0.53 . . . . 0.0 109.57 177.065 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 19.0 m-20 -74.17 44.41 0.19 Allowed 'General case' 0 N--CA 1.486 1.367 0 N-CA-C 112.147 0.425 . . . . 0.0 112.147 -177.927 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 79.91 3.45 89.32 Favored Glycine 0 CA--C 1.506 -0.475 0 C-N-CA 120.881 -0.676 . . . . 0.0 112.056 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 61.1 mt-30 -83.43 -21.99 32.78 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-O 121.215 0.531 . . . . 0.0 110.081 178.464 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 46' ' ' THR . . . . . 0.502 ' HA ' ' O ' ' A' ' 63' ' ' ALA . 35.2 p -129.03 142.62 50.85 Favored 'General case' 0 C--N 1.315 -0.907 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.936 178.52 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 47' ' ' LEU . . . . . 0.405 ' O ' ' HA ' ' A' ' 62' ' ' ARG . 95.9 mt -128.62 133.18 48.22 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 109.103 -0.702 . . . . 0.0 109.103 179.915 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 89.9 m-20 -126.5 139.4 53.25 Favored 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 -179.97 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 169.74 -150.51 15.13 Favored Glycine 0 N--CA 1.448 -0.538 0 C-N-CA 120.112 -1.042 . . . . 0.0 112.463 178.035 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 34.8 p -134.45 152.43 51.79 Favored 'General case' 0 C--N 1.317 -0.83 0 N-CA-C 110.031 -0.359 . . . . 0.0 110.031 179.676 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 11.0 tmm? -142.12 145.49 34.3 Favored 'General case' 0 C--N 1.315 -0.912 0 C-N-CA 121.124 -0.23 . . . . 0.0 110.85 -178.829 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 60.4 m -129.07 128.64 43.97 Favored 'General case' 0 C--O 1.248 1.014 0 CA-C-O 120.81 0.338 . . . . 0.0 111.904 -177.399 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 53' ' ' TYR . . . . . 0.494 ' HB2' ' HB2' ' A' ' 56' ' ' GLU . 78.7 m-85 -91.11 164.63 13.86 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 115.617 -0.72 . . . . 0.0 110.327 176.86 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -69.39 98.26 1.07 Allowed 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.189 179.017 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 103.9 2.16 45.78 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.946 -0.645 . . . . 0.0 112.793 177.779 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 56' ' ' GLU . . . . . 0.494 ' HB2' ' HB2' ' A' ' 53' ' ' TYR . 66.7 mm-40 -117.69 162.91 17.27 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 110.115 -0.328 . . . . 0.0 110.115 179.02 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -84.08 166.25 42.34 Favored Glycine 0 N--CA 1.441 -0.972 0 C-N-CA 120.282 -0.961 . . . . 0.0 111.784 179.114 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 23.1 Cg_exo -65.82 139.78 58.61 Favored 'Trans proline' 0 N--CA 1.462 -0.348 0 C-N-CA 122.459 2.106 . . . . 0.0 111.912 178.921 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 38.3 pt -128.88 161.29 38.36 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.792 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.386 178.85 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -74.8 134.48 17.41 Favored Glycine 0 N--CA 1.446 -0.669 0 N-CA-C 111.331 -0.707 . . . . 0.0 111.331 179.984 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 52.6 t80 -117.46 125.98 51.84 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-O 121.034 0.445 . . . . 0.0 111.562 -176.905 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 62' ' ' ARG . . . . . 0.405 ' HA ' ' O ' ' A' ' 47' ' ' LEU . 64.0 ttp85 -136.53 129.08 30.42 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.857 -0.61 . . . . 0.0 109.747 174.737 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.502 ' O ' ' HA ' ' A' ' 46' ' ' THR . . . -129.41 139.3 51.7 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 116.563 -0.289 . . . . 0.0 110.966 -177.748 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 40.6 m -122.29 128.72 51.41 Favored 'General case' 0 C--N 1.323 -0.544 0 O-C-N 123.512 0.507 . . . . 0.0 109.74 178.534 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 52.6 tp -75.58 119.28 19.42 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 112.388 0.514 . . . . 0.0 112.388 -177.082 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 84.6 mt -84.18 -27.61 27.94 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.453 -0.794 . . . . 0.0 109.438 174.847 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 129.81 158.86 9.59 Favored Glycine 0 N--CA 1.442 -0.901 0 CA-C-N 115.109 -0.95 . . . . 0.0 110.81 -178.861 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 93.0 m-20 60.89 37.29 18.55 Favored 'General case' 0 N--CA 1.476 0.86 0 CA-C-O 120.848 0.356 . . . . 0.0 111.242 178.969 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 91.6 m-20 66.37 8.15 5.48 Favored 'General case' 0 N--CA 1.485 1.309 0 C-N-CA 123.244 0.618 . . . . 0.0 112.151 179.237 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 15.8 m -92.18 121.84 34.09 Favored 'General case' 0 N--CA 1.446 -0.666 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 178.703 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 64.8 m-85 -113.58 132.73 55.62 Favored 'General case' 0 C--N 1.312 -1.04 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.999 -178.942 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 63.2 tt0 -86.96 119.76 27.51 Favored 'General case' 0 N--CA 1.438 -1.035 0 N-CA-C 106.763 -1.569 . . . . 0.0 106.763 172.952 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 79.2 t -107.27 134.51 48.76 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 CA-C-O 121.182 0.515 . . . . 0.0 112.086 -172.824 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 87.6 mt-10 -127.37 129.61 47.9 Favored 'General case' 0 N--CA 1.438 -1.072 0 N-CA-C 107.703 -1.221 . . . . 0.0 107.703 176.363 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 48.9 m-80 -112.42 154.79 25.26 Favored 'General case' 0 C--N 1.314 -0.971 0 CA-C-O 120.967 0.413 . . . . 0.0 111.041 -176.68 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 63.1 tt0 -115.45 119.95 37.91 Favored 'General case' 0 C--N 1.311 -1.099 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.152 -178.695 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 12.4 p90 -143.67 161.86 37.44 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.804 179.388 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 100.4 -7.21 58.06 Favored Glycine 0 N--CA 1.446 -0.674 0 C-N-CA 120.858 -0.687 . . . . 0.0 111.924 179.648 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 136.2 160.28 8.74 Favored Glycine 0 N--CA 1.44 -1.081 0 N-CA-C 111.574 -0.611 . . . . 0.0 111.574 179.92 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 15.7 t70 -59.74 -41.78 91.69 Favored 'General case' 0 C--N 1.319 -0.737 0 C-N-CA 123.115 0.566 . . . . 0.0 112.085 179.626 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 50.6 p -76.71 -3.97 40.79 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 112.573 0.583 . . . . 0.0 112.573 -179.205 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -76.52 150.74 82.5 Favored Pre-proline 0 C--N 1.325 -0.46 0 CA-C-O 120.518 0.199 . . . . 0.0 110.945 -179.686 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -74.07 -178.55 3.95 Favored 'Trans proline' 0 C--O 1.239 0.54 0 C-N-CA 122.633 2.222 . . . . 0.0 112.083 179.212 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 84' ' ' TRP . . . . . . . . . . . . . 89.0 m95 -95.77 140.24 30.85 Favored 'General case' 0 N--CA 1.444 -0.729 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.352 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 89.5 m-70 -118.26 142.98 46.92 Favored 'General case' 0 C--N 1.31 -1.117 0 CA-C-N 116.273 -0.421 . . . . 0.0 109.949 179.878 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 11.8 p -62.85 134.26 55.97 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.843 0.354 . . . . 0.0 111.161 -178.366 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 87' ' ' GLY . . . . . 0.499 ' O ' ' HA ' ' A' ' 28' ' ' ARG . . . -107.89 -46.43 1.03 Allowed Glycine 0 N--CA 1.438 -1.167 0 C-N-CA 120.971 -0.633 . . . . 0.0 111.909 179.76 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 148.39 -168.0 29.08 Favored Glycine 0 C--O 1.225 -0.44 0 C-N-CA 120.031 -1.081 . . . . 0.0 112.733 178.24 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 24.9 t-20 -106.0 117.05 33.02 Favored 'General case' 0 C--N 1.321 -0.674 0 N-CA-C 110.054 -0.35 . . . . 0.0 110.054 -179.012 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 90' ' ' TRP . . . . . 0.571 ' CZ3' HG23 ' A' ' 25' ' ' ILE . 18.6 m0 -113.56 148.21 36.56 Favored 'General case' 0 C--N 1.317 -0.818 0 N-CA-C 109.284 -0.635 . . . . 0.0 109.284 179.887 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 85.6 mt -105.32 117.89 51.8 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.843 0 N-CA-C 109.547 -0.538 . . . . 0.0 109.547 179.064 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 86.0 mt -129.26 78.61 1.86 Allowed 'General case' 0 C--O 1.265 1.92 0 CA-C-O 121.863 0.839 . . . . 0.0 112.092 -177.76 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 170.05 124.45 0.74 Allowed Glycine 0 N--CA 1.441 -0.987 0 CA-C-N 114.757 -1.111 . . . . 0.0 110.722 178.996 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 94' ' ' SER . . . . . 0.681 ' HB2' ' O ' ' A' ' 20' ' ' GLY . 83.7 p -106.42 -7.61 17.53 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-O 120.898 0.38 . . . . 0.0 111.665 -179.55 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 95' ' ' ARG . . . . . 0.424 HH12 ' CD ' ' A' ' 123' ' ' GLU . 99.5 mtt180 -106.76 154.61 20.73 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 121.269 0.557 . . . . 0.0 112.091 178.871 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 26.8 tp10 -68.62 -38.83 80.89 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 114.965 -1.016 . . . . 0.0 111.061 -174.258 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 10.1 p30 -116.17 21.06 13.96 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.925 -177.076 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 98' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -136.75 115.82 12.42 Favored 'General case' 0 C--N 1.32 -0.697 0 C-N-CA 119.573 -0.851 . . . . 0.0 112.89 -176.46 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 14.3 m120 -92.44 154.76 18.3 Favored 'General case' 0 C--O 1.249 1.057 0 CA-C-N 115.029 -0.987 . . . . 0.0 109.353 177.488 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.427 HG21 ' CH2' ' A' ' 23' ' ' TRP . 85.2 t -79.75 130.8 35.49 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.555 0 C-N-CA 120.092 -0.643 . . . . 0.0 110.899 178.492 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 101' ' ' VAL . . . . . 0.433 HG11 ' HA ' ' A' ' 121' ' ' ALA . 33.7 m -111.74 -19.18 7.08 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.438 0 N-CA-C 112.122 0.415 . . . . 0.0 112.122 -179.654 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 102' ' ' ALA . . . . . 0.639 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -152.12 140.07 20.08 Favored 'General case' 0 CA--C 1.511 -0.537 0 C-N-CA 119.899 -0.72 . . . . 0.0 111.588 176.975 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.413 ' HB ' ' CG2' ' A' ' 38' ' ' VAL . 95.4 mt -135.49 125.01 41.75 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.175 177.456 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 52.6 t30 -129.74 101.22 5.8 Favored 'General case' 0 C--N 1.315 -0.931 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 175.801 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.449 ' CG2' ' HB ' ' A' ' 36' ' ' ILE . 19.8 m -140.9 142.8 29.51 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.791 0 N-CA-C 113.195 0.813 . . . . 0.0 113.195 -175.547 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 99.9 mt-10 -141.58 151.25 43.02 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 114.911 -1.04 . . . . 0.0 108.615 176.507 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 36.5 t -130.12 146.94 51.81 Favored 'General case' 0 C--N 1.311 -1.106 0 CA-C-O 121.244 0.545 . . . . 0.0 111.871 -177.817 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -89.61 -10.98 64.63 Favored Glycine 0 N--CA 1.444 -0.792 0 N-CA-C 110.366 -1.094 . . . . 0.0 110.366 174.435 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 83.6 m-20 -94.16 -172.06 2.71 Favored 'General case' 0 CA--C 1.513 -0.48 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 178.28 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 13.5 p-10 -95.74 33.86 1.59 Allowed 'General case' 0 C--N 1.313 -0.988 0 CA-C-O 121.031 0.443 . . . . 0.0 109.986 176.884 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 111' ' ' GLY . . . . . 0.515 ' HA3' ' HB3' ' A' ' 32' ' ' ASN . . . 97.42 8.56 56.15 Favored Glycine 0 C--N 1.333 0.406 0 CA-C-N 115.825 -0.625 . . . . 0.0 113.803 179.13 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 28.3 tt0 -64.72 -40.88 96.08 Favored 'General case' 0 C--O 1.241 0.621 0 CA-C-O 121.537 0.684 . . . . 0.0 109.858 178.383 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 73.2 p -135.58 146.93 48.47 Favored 'General case' 0 N--CA 1.446 -0.651 0 CA-C-N 114.841 -1.072 . . . . 0.0 109.483 178.306 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 96.0 mt -119.97 126.47 50.93 Favored 'General case' 0 C--N 1.312 -1.06 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 178.951 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 86.5 m-20 -122.99 143.57 49.84 Favored 'General case' 0 C--N 1.317 -0.835 0 N-CA-C 110.01 -0.367 . . . . 0.0 110.01 -178.963 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 161.19 -142.11 7.83 Favored Glycine 0 N--CA 1.448 -0.513 0 C-N-CA 119.747 -1.216 . . . . 0.0 113.303 177.3 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 23.6 p -131.47 156.95 44.75 Favored 'General case' 0 C--N 1.316 -0.849 0 C-N-CA 122.919 0.488 . . . . 0.0 110.819 -178.709 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 19.9 ptm -149.69 157.08 42.9 Favored 'General case' 0 C--N 1.314 -0.945 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.152 179.955 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 119' ' ' THR . . . . . 0.639 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 40.6 m -132.0 130.31 41.24 Favored 'General case' 0 C--O 1.245 0.841 0 CA-C-N 116.589 -0.278 . . . . 0.0 111.269 -179.176 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 11.7 m-85 -94.22 160.52 14.65 Favored 'General case' 0 N--CA 1.455 -0.197 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.883 176.616 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 121' ' ' ALA . . . . . 0.433 ' HA ' HG11 ' A' ' 101' ' ' VAL . . . -38.7 -45.14 1.08 Allowed 'General case' 0 N--CA 1.482 1.161 0 N-CA-C 114.149 1.166 . . . . 0.0 114.149 -177.245 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -145.63 43.01 0.94 Allowed Glycine 0 CA--C 1.506 -0.514 0 C-N-CA 120.084 -1.055 . . . . 0.0 111.713 -178.972 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 123' ' ' GLU . . . . . 0.424 ' CD ' HH12 ' A' ' 95' ' ' ARG . 28.5 tp10 -116.13 -61.95 1.66 Allowed 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 121.199 0.523 . . . . 0.0 110.714 -177.712 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 134.26 -179.0 17.97 Favored Glycine 0 N--CA 1.443 -0.836 0 N-CA-C 111.264 -0.734 . . . . 0.0 111.264 -178.503 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 62.0 Cg_endo -81.46 117.15 3.04 Favored 'Trans proline' 0 N--CA 1.455 -0.738 0 C-N-CA 122.424 2.082 . . . . 0.0 112.182 179.508 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 38.0 pt -126.22 161.2 32.44 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.922 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.415 -179.894 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -72.5 138.67 26.55 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.949 -0.643 . . . . 0.0 112.609 -178.732 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 77.8 t80 -114.82 132.23 56.56 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-O 121.061 0.458 . . . . 0.0 110.994 -179.153 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 129' ' ' LYS . . . . . 0.47 ' HB2' ' CZ3' ' A' ' 17' ' ' TRP . 86.9 tttt -134.28 101.33 4.97 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.098 177.43 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 130' ' ' GLY . . . . . 0.428 ' HA2' ' O ' ' A' ' 5' ' ' ASN . . . -109.44 150.41 17.26 Favored Glycine 0 N--CA 1.435 -1.38 0 C-N-CA 120.326 -0.94 . . . . 0.0 112.0 179.3 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 6.0 t -146.39 148.77 32.68 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-O 120.718 0.294 . . . . 0.0 111.15 179.21 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 83.4 mt -63.51 132.93 52.87 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.059 -0.518 . . . . 0.0 110.107 175.796 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 6.9 p . . . . . 0 C--O 1.249 1.051 0 CA-C-O 118.511 -0.756 . . . . 0.0 110.702 178.873 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 0.606 ' O ' ' HG3' ' A' ' 24' ' ' GLU . . . . . . . . 0 N--CA 1.475 0.825 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 3' ' ' LEU . . . . . 0.46 HD12 HG21 ' A' ' 133' ' ' THR . 0.3 OUTLIER -90.94 130.58 36.86 Favored 'General case' 0 C--N 1.313 -0.994 0 CA-C-O 121.064 0.459 . . . . 0.0 109.88 -174.58 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 4' ' ' TYR . . . . . 0.435 ' N ' HD13 ' A' ' 3' ' ' LEU . 28.5 m-85 -116.99 137.39 52.25 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-N 115.854 -0.612 . . . . 0.0 111.24 -179.989 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 20.8 t-20 -87.12 131.73 34.06 Favored 'General case' 0 C--N 1.306 -1.317 0 N-CA-C 106.577 -1.638 . . . . 0.0 106.577 176.884 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.522 HG21 ' CG ' ' A' ' 23' ' ' TRP . 58.6 t -114.72 126.16 72.21 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.854 0 N-CA-C 113.204 0.816 . . . . 0.0 113.204 -172.969 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.452 ' HG2' ' HB3' ' A' ' 19' ' ' GLU . 92.3 mt-10 -120.56 135.66 55.02 Favored 'General case' 0 N--CA 1.435 -1.195 0 CA-C-N 114.575 -1.193 . . . . 0.0 108.353 176.833 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 87.8 m-20 -120.22 144.53 47.68 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-O 120.899 0.381 . . . . 0.0 111.858 -176.226 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 9' ' ' GLN . . . . . 0.56 ' OE1' ' HA ' ' A' ' 13' ' ' SER . 36.4 tt0 -129.2 122.01 28.85 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.557 -0.747 . . . . 0.0 109.869 178.754 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 17.5 p90 -120.94 140.93 51.17 Favored 'General case' 0 C--N 1.314 -0.945 0 CA-C-O 121.337 0.589 . . . . 0.0 111.695 -179.845 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 107.24 -69.95 0.21 Allowed Glycine 0 N--CA 1.441 -1.009 0 CA-C-N 115.429 -0.805 . . . . 0.0 111.576 179.287 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -165.09 166.78 38.41 Favored Glycine 0 N--CA 1.442 -0.929 0 N-CA-C 111.612 -0.595 . . . . 0.0 111.612 179.467 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' SER . . . . . 0.56 ' HA ' ' OE1' ' A' ' 9' ' ' GLN . 11.5 p -60.04 -20.42 57.85 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 112.9 0.704 . . . . 0.0 112.9 -179.246 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 8.1 m -78.58 -5.59 53.23 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 120.642 0.258 . . . . 0.0 111.541 179.7 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -86.68 146.7 41.98 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 120.745 0.307 . . . . 0.0 111.359 -178.943 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -65.74 149.37 87.02 Favored 'Trans proline' 0 C--O 1.235 0.331 0 C-N-CA 122.823 2.349 . . . . 0.0 112.094 179.102 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 96.9 m95 -82.88 132.27 35.16 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 178.27 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 89.1 m-20 -120.67 122.84 41.33 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.43 -178.504 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.452 ' HB3' ' HG2' ' A' ' 7' ' ' GLU . 5.1 pt-20 -90.32 127.76 36.25 Favored 'General case' 0 C--N 1.313 -0.986 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 178.111 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -139.14 29.43 2.53 Favored Glycine 0 N--CA 1.445 -0.747 0 C-N-CA 119.761 -1.209 . . . . 0.0 112.611 -178.07 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 157.21 174.88 27.48 Favored Glycine 0 N--CA 1.438 -1.224 0 C-N-CA 120.381 -0.914 . . . . 0.0 112.458 179.829 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 28.6 pt20 -134.56 139.33 45.32 Favored 'General case' 0 C--N 1.314 -0.946 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 179.643 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 23' ' ' TRP . . . . . 0.53 ' HB3' ' O ' ' A' ' 91' ' ' ILE . 38.8 m0 -116.72 178.44 4.34 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.404 -176.715 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 24' ' ' GLU . . . . . 0.606 ' HG3' ' O ' ' A' ' 2' ' ' ALA . 76.9 tt0 -131.58 121.48 24.46 Favored 'General case' 0 N--CA 1.441 -0.879 0 C-N-CA 120.371 -0.531 . . . . 0.0 110.447 174.899 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 91.3 mt -127.59 131.99 69.57 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.955 0 CA-C-N 115.349 -0.841 . . . . 0.0 109.479 -178.668 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 91.13 121.28 2.49 Favored Glycine 0 N--CA 1.441 -0.99 0 C-N-CA 120.474 -0.869 . . . . 0.0 112.356 179.637 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' SER . . . . . 0.499 ' CB ' ' HA3' ' A' ' 88' ' ' GLY . 6.3 m -119.44 11.54 12.18 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-O 121.277 0.56 . . . . 0.0 109.819 179.957 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 63.1 mtt-85 -141.07 141.84 34.22 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.391 -0.822 . . . . 0.0 109.21 -176.485 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 37.3 p -92.09 2.5 56.54 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-O 121.145 0.498 . . . . 0.0 111.344 -178.523 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 37.0 m-20 -62.31 -38.1 88.11 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.585 -0.734 . . . . 0.0 111.509 -178.839 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 1.3 tm0? -167.35 151.36 6.63 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.937 -177.276 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 32' ' ' ASN . . . . . 0.501 ' HB3' ' HA3' ' A' ' 111' ' ' GLY . 15.6 m120 -96.91 173.14 7.44 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.679 0.752 . . . . 0.0 111.239 179.375 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.474 HG11 HD11 ' A' ' 36' ' ' ILE . 17.2 t -102.85 134.22 44.47 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.256 0 CA-C-N 115.202 -0.908 . . . . 0.0 112.51 -175.144 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.44 HG13 ' HB2' ' A' ' 54' ' ' ALA . 27.0 m -121.11 -28.14 1.87 Allowed 'Isoleucine or valine' 0 C--O 1.255 1.352 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.602 174.946 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 35' ' ' ALA . . . . . 0.674 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -140.31 140.33 35.63 Favored 'General case' 0 N--CA 1.442 -0.837 0 CA-C-O 121.38 0.609 . . . . 0.0 111.986 -178.706 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.474 HD11 HG11 ' A' ' 33' ' ' VAL . 93.7 mt -146.41 129.57 9.27 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 177.608 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -127.92 109.14 11.3 Favored 'General case' 0 C--N 1.311 -1.088 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 175.087 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.495 HG11 ' CD1' ' A' ' 61' ' ' PHE . 19.4 m -147.47 149.49 15.47 Favored 'Isoleucine or valine' 0 C--O 1.242 0.685 0 C-N-CA 120.874 -0.33 . . . . 0.0 111.343 -174.906 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 77.6 tt0 -138.82 144.9 39.51 Favored 'General case' 0 N--CA 1.443 -0.813 0 CA-C-N 115.72 -0.673 . . . . 0.0 109.279 178.043 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 37.0 p -69.76 140.87 53.47 Favored 'General case' 0 C--N 1.317 -0.817 0 N-CA-C 112.533 0.568 . . . . 0.0 112.533 -176.862 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -86.83 -62.39 1.53 Allowed Glycine 0 CA--C 1.502 -0.771 0 N-CA-C 109.113 -1.595 . . . . 0.0 109.113 174.628 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 51.0 m-20 -88.36 -169.2 2.46 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 173.988 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 70.9 m-20 -77.11 57.98 1.48 Allowed 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 112.462 0.542 . . . . 0.0 112.462 -177.946 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 97.02 -20.32 51.31 Favored Glycine 0 C--O 1.218 -0.857 0 C-N-CA 121.068 -0.587 . . . . 0.0 113.419 175.542 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 56.0 mt-30 -64.99 -34.07 77.55 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 112.89 0.7 . . . . 0.0 112.89 -177.754 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 46' ' ' THR . . . . . 0.525 ' HA ' ' O ' ' A' ' 63' ' ' ALA . 14.8 t -136.14 131.64 34.98 Favored 'General case' 0 N--CA 1.438 -1.049 0 C-N-CA 120.387 -0.525 . . . . 0.0 111.239 178.622 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 47' ' ' LEU . . . . . 0.414 ' O ' ' HA ' ' A' ' 62' ' ' ARG . 80.1 mt -111.01 133.03 53.72 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.837 -0.619 . . . . 0.0 109.508 179.384 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 64.0 m-80 -125.27 146.21 49.65 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-O 120.703 0.287 . . . . 0.0 110.706 179.238 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 163.34 -140.52 6.54 Favored Glycine 0 N--CA 1.439 -1.15 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.497 178.4 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 24.5 p -133.41 150.75 51.78 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 120.908 0.385 . . . . 0.0 111.21 -179.292 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 18.4 ttt -124.82 137.0 54.32 Favored 'General case' 0 C--N 1.32 -0.68 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 179.78 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.674 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 60.6 m -124.89 122.55 37.68 Favored 'General case' 0 C--O 1.259 1.592 0 CA-C-O 121.17 0.509 . . . . 0.0 111.799 -178.303 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 53' ' ' TYR . . . . . 0.428 ' HB2' ' HB2' ' A' ' 56' ' ' GLU . 98.1 m-85 -84.66 166.0 17.44 Favored 'General case' 0 CA--C 1.52 -0.201 0 CA-C-N 115.372 -0.831 . . . . 0.0 109.835 178.512 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 54' ' ' ALA . . . . . 0.44 ' HB2' HG13 ' A' ' 34' ' ' VAL . . . -67.94 110.69 3.99 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 120.952 0.406 . . . . 0.0 111.125 179.836 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 83.41 16.84 67.87 Favored Glycine 0 CA--C 1.522 0.493 0 C-N-CA 120.667 -0.778 . . . . 0.0 113.711 179.401 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 56' ' ' GLU . . . . . 0.428 ' HB2' ' HB2' ' A' ' 53' ' ' TYR . 98.1 mt-10 -132.01 163.24 28.83 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 117.339 0.569 . . . . 0.0 111.135 178.962 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -81.08 156.42 37.79 Favored Glycine 0 N--CA 1.447 -0.612 0 CA-C-N 115.955 -0.566 . . . . 0.0 112.603 -179.273 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 21.8 Cg_exo -64.62 142.56 77.86 Favored 'Trans proline' 0 C--N 1.347 0.467 0 C-N-CA 122.924 2.416 . . . . 0.0 112.81 -179.295 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 44.7 pt -125.91 167.66 19.98 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.872 0 CA-C-N 115.527 -0.76 . . . . 0.0 109.332 177.272 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -70.37 137.63 27.97 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.19 -1.005 . . . . 0.0 111.674 -178.952 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.495 ' CD1' HG11 ' A' ' 38' ' ' VAL . 50.2 t80 -127.71 128.42 45.37 Favored 'General case' 0 C--N 1.317 -0.847 0 CA-C-O 120.757 0.313 . . . . 0.0 110.831 -177.887 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 62' ' ' ARG . . . . . 0.414 ' HA ' ' O ' ' A' ' 47' ' ' LEU . 63.7 ttp85 -138.77 132.72 31.13 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.181 175.276 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.525 ' O ' ' HA ' ' A' ' 46' ' ' THR . . . -127.74 137.02 52.31 Favored 'General case' 0 C--N 1.311 -1.09 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.653 179.658 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 61.2 m -123.55 132.41 53.89 Favored 'General case' 0 C--N 1.315 -0.913 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 178.776 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 65' ' ' LEU . . . . . 0.622 HD21 ' O ' ' A' ' 68' ' ' ASN . 3.7 mt -60.5 128.17 35.33 Favored 'General case' 0 CA--C 1.501 -0.911 0 N-CA-C 113.928 1.085 . . . . 0.0 113.928 -178.13 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 66' ' ' LEU . . . . . 0.445 HD11 ' OD1' ' A' ' 89' ' ' ASN . 96.1 mt -76.43 -34.72 58.77 Favored 'General case' 0 N--CA 1.431 -1.394 0 N-CA-C 107.27 -1.381 . . . . 0.0 107.27 169.004 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -166.91 -72.66 0.03 OUTLIER Glycine 0 N--CA 1.433 -1.564 0 C-N-CA 120.405 -0.903 . . . . 0.0 115.013 -179.504 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 68' ' ' ASN . . . . . 0.622 ' O ' HD21 ' A' ' 65' ' ' LEU . 17.0 m120 -125.3 -77.34 0.59 Allowed 'General case' 0 C--O 1.214 -0.782 0 CA-C-N 118.212 1.006 . . . . 0.0 110.202 -175.85 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 12.2 m120 -100.94 -6.31 24.77 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 120.898 0.38 . . . . 0.0 110.643 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 8.3 m -95.37 121.13 36.72 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.698 -178.134 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 71' ' ' TYR . . . . . 0.416 ' CE2' ' HG ' ' A' ' 65' ' ' LEU . 96.0 m-85 -115.9 150.21 37.44 Favored 'General case' 0 C--N 1.314 -0.937 0 CA-C-N 116.323 -0.399 . . . . 0.0 111.181 -178.657 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 70.4 tt0 -105.72 125.53 51.09 Favored 'General case' 0 C--N 1.31 -1.125 0 N-CA-C 107.451 -1.315 . . . . 0.0 107.451 173.499 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 65.3 t -104.8 132.27 51.9 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.388 0 CA-C-O 121.544 0.687 . . . . 0.0 112.471 -174.172 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 47.5 mt-10 -127.35 123.54 36.52 Favored 'General case' 0 N--CA 1.436 -1.161 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 176.631 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 97.5 m-20 -110.83 153.43 25.41 Favored 'General case' 0 C--N 1.317 -0.819 0 CA-C-O 121.229 0.538 . . . . 0.0 111.934 -176.018 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 76' ' ' GLN . . . . . 0.498 ' HB2' ' CE3' ' A' ' 84' ' ' TRP . 60.0 tt0 -113.98 116.43 29.21 Favored 'General case' 0 C--N 1.312 -1.05 0 CA-C-N 115.607 -0.724 . . . . 0.0 109.933 -178.589 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 13.4 p90 -142.72 160.59 40.01 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.157 179.446 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 94.68 -3.66 68.29 Favored Glycine 0 N--CA 1.449 -0.473 0 C-N-CA 120.599 -0.81 . . . . 0.0 112.073 -179.532 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 135.21 152.44 6.49 Favored Glycine 0 N--CA 1.446 -0.65 0 N-CA-C 111.469 -0.652 . . . . 0.0 111.469 179.38 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 25.7 t70 -62.71 -36.82 84.22 Favored 'General case' 0 N--CA 1.468 0.453 0 CA-C-O 120.869 0.366 . . . . 0.0 111.932 -179.71 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 29.3 p -69.65 -15.78 63.25 Favored 'General case' 0 C--N 1.316 -0.86 0 N-CA-C 112.125 0.417 . . . . 0.0 112.125 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -75.87 142.71 73.43 Favored Pre-proline 0 C--O 1.234 0.267 0 CA-C-N 116.478 -0.328 . . . . 0.0 110.884 -179.512 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 96.7 Cg_endo -73.59 156.25 49.5 Favored 'Trans proline' 0 N--CA 1.462 -0.353 0 C-N-CA 122.712 2.274 . . . . 0.0 111.819 178.731 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 84' ' ' TRP . . . . . 0.498 ' CE3' ' HB2' ' A' ' 76' ' ' GLN . 81.7 m95 -60.98 138.31 58.18 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.305 0.574 . . . . 0.0 111.543 179.615 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 99.1 m-70 -113.03 144.65 42.24 Favored 'General case' 0 C--N 1.311 -1.096 0 CA-C-N 115.213 -0.903 . . . . 0.0 109.208 178.344 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 12.9 p -61.46 125.75 24.9 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-O 121.192 0.52 . . . . 0.0 111.941 -177.293 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -96.42 -48.85 2.11 Favored Glycine 0 N--CA 1.441 -1.032 0 CA-C-N 115.595 -0.73 . . . . 0.0 111.532 179.747 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 88' ' ' GLY . . . . . 0.499 ' HA3' ' CB ' ' A' ' 27' ' ' SER . . . 149.86 -167.17 29.92 Favored Glycine 0 C--O 1.216 -1.027 0 N-CA-C 111.326 -0.71 . . . . 0.0 111.326 178.405 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 89' ' ' ASN . . . . . 0.445 ' OD1' HD11 ' A' ' 66' ' ' LEU . 56.7 m-80 -108.53 140.84 41.3 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 117.379 0.59 . . . . 0.0 110.867 179.35 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 90' ' ' TRP . . . . . 0.435 ' HD1' ' C ' ' A' ' 89' ' ' ASN . 29.4 m0 -133.69 160.62 36.99 Favored 'General case' 0 N--CA 1.465 0.298 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 -177.16 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 91' ' ' ILE . . . . . 0.53 ' O ' ' HB3' ' A' ' 23' ' ' TRP . 96.9 mt -121.19 121.6 65.31 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.035 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 175.806 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 83.7 mt -134.63 82.93 1.99 Allowed 'General case' 0 C--O 1.267 1.979 0 N-CA-C 112.765 0.654 . . . . 0.0 112.765 -175.414 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 164.64 118.5 0.44 Allowed Glycine 0 N--CA 1.448 -0.536 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.81 177.954 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 43.1 m -90.64 -0.14 57.58 Favored 'General case' 0 N--CA 1.463 0.211 0 CA-C-O 121.11 0.481 . . . . 0.0 110.64 177.922 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -120.02 152.16 37.91 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 178.788 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 78.1 tt0 -66.06 -65.44 0.68 Allowed 'General case' 0 C--N 1.32 -0.71 0 N-CA-C 112.6 0.593 . . . . 0.0 112.6 -174.86 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 93.5 m-20 -107.15 36.9 2.52 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 116.271 -0.422 . . . . 0.0 112.026 -175.409 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 98' ' ' GLN . . . . . 0.403 ' CG ' ' HB3' ' A' ' 120' ' ' TYR . 14.5 tp60 -108.67 -62.33 1.48 Allowed 'General case' 0 C--N 1.316 -0.885 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 179.646 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 91.7 m-20 71.87 149.98 0.1 Allowed 'General case' 0 C--O 1.248 1.013 0 CA-C-N 115.225 -0.898 . . . . 0.0 112.942 178.258 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 76.6 t -81.66 132.14 32.19 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.335 0 CA-C-N 115.44 -0.8 . . . . 0.0 111.191 178.279 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 26.8 m -114.49 -21.57 5.3 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.185 0 CA-C-N 116.004 -0.544 . . . . 0.0 112.356 179.571 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 102' ' ' ALA . . . . . 0.522 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -150.09 141.44 23.27 Favored 'General case' 0 C--N 1.326 -0.444 0 C-N-CA 120.161 -0.615 . . . . 0.0 111.596 178.601 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.463 ' HB ' HG22 ' A' ' 38' ' ' VAL . 32.2 mm -134.61 127.21 49.33 Favored 'Isoleucine or valine' 0 C--O 1.244 0.766 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.863 178.429 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 50.4 t30 -131.76 97.38 4.18 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.782 -0.645 . . . . 0.0 109.867 175.277 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.59 ' O ' ' HA ' ' A' ' 35' ' ' ALA . 15.5 m -130.51 135.06 61.28 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.029 0 CA-C-N 115.775 -0.648 . . . . 0.0 111.162 -176.926 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 52.8 mt-10 -139.1 27.45 2.37 Favored 'General case' 0 N--CA 1.486 1.371 0 CA-C-O 121.526 0.679 . . . . 0.0 110.953 -178.841 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 107' ' ' SER . . . . . 0.633 ' HB2' ' HB2' ' A' ' 115' ' ' ASN . 53.7 m -139.1 147.34 41.85 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 114.259 1.207 . . . . 0.0 114.259 -175.1 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 148.71 122.06 1.2 Allowed Glycine 0 N--CA 1.436 -1.341 0 CA-C-N 114.624 -1.171 . . . . 0.0 111.84 178.268 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -83.29 107.67 15.98 Favored 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 178.657 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 59.58 18.13 6.77 Favored 'General case' 0 N--CA 1.481 1.084 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.275 -177.446 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 111' ' ' GLY . . . . . 0.501 ' HA3' ' HB3' ' A' ' 32' ' ' ASN . . . 80.06 15.39 78.96 Favored Glycine 0 N--CA 1.442 -0.913 0 CA-C-N 115.818 -0.628 . . . . 0.0 112.838 179.006 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 112' ' ' GLN . . . . . 0.525 ' HA ' HD12 ' A' ' 132' ' ' LEU . 52.2 tt0 -64.15 -37.52 87.74 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-O 121.799 0.809 . . . . 0.0 109.138 177.607 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 60.5 p -133.93 164.25 27.71 Favored 'General case' 0 N--CA 1.431 -1.422 0 CA-C-N 114.56 -1.2 . . . . 0.0 108.724 177.354 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 114' ' ' LEU . . . . . 0.41 ' HA ' ' O ' ' A' ' 107' ' ' SER . 33.8 tp -134.84 114.69 12.84 Favored 'General case' 0 C--N 1.301 -1.519 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 176.937 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 115' ' ' ASN . . . . . 0.633 ' HB2' ' HB2' ' A' ' 107' ' ' SER . 1.4 m-20 -116.9 143.7 45.39 Favored 'General case' 0 C--O 1.263 1.81 0 C-N-CA 120.117 -0.633 . . . . 0.0 111.577 -176.31 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 165.02 -138.31 5.18 Favored Glycine 0 N--CA 1.437 -1.298 0 CA-C-N 115.164 -0.925 . . . . 0.0 112.25 177.208 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 29.8 p -130.51 155.48 46.4 Favored 'General case' 0 C--N 1.307 -1.265 0 C-N-CA 122.792 0.437 . . . . 0.0 109.986 -179.221 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 118' ' ' MET . . . . . 0.404 ' HE3' ' HB2' ' A' ' 118' ' ' MET . 18.0 ptm -146.94 153.32 39.95 Favored 'General case' 0 C--N 1.309 -1.194 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.465 -179.065 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 119' ' ' THR . . . . . 0.522 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 25.9 m -132.83 129.8 38.97 Favored 'General case' 0 C--O 1.248 1.0 0 CA-C-N 116.487 -0.324 . . . . 0.0 111.368 -179.811 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 120' ' ' TYR . . . . . 0.518 ' HB2' ' HB3' ' A' ' 123' ' ' GLU . 57.2 m-85 -94.1 159.16 15.27 Favored 'General case' 0 CA--C 1.516 -0.35 0 CA-C-N 115.746 -0.661 . . . . 0.0 109.58 175.298 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -66.27 134.39 52.56 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 109.662 -0.496 . . . . 0.0 109.662 176.284 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 64.95 22.44 68.6 Favored Glycine 0 CA--C 1.523 0.532 0 C-N-CA 120.815 -0.707 . . . . 0.0 113.113 -179.856 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 123' ' ' GLU . . . . . 0.518 ' HB3' ' HB2' ' A' ' 120' ' ' TYR . 39.3 tp10 -137.87 161.86 35.51 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 -178.172 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -89.06 156.51 26.28 Favored Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.284 -0.96 . . . . 0.0 111.84 178.617 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_exo -60.6 134.28 53.52 Favored 'Trans proline' 0 C--N 1.349 0.6 0 C-N-CA 122.394 2.062 . . . . 0.0 111.707 178.743 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 39.7 pt -131.57 165.44 31.71 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.812 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.51 -178.91 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -73.87 139.23 25.91 Favored Glycine 0 N--CA 1.445 -0.726 0 C-N-CA 121.206 -0.521 . . . . 0.0 112.003 179.717 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 92.2 t80 -117.35 132.63 56.56 Favored 'General case' 0 C--O 1.244 0.794 0 CA-C-O 120.974 0.416 . . . . 0.0 111.083 -178.697 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 61.7 tttm -135.48 102.37 5.11 Favored 'General case' 0 N--CA 1.442 -0.865 0 CA-C-N 115.567 -0.742 . . . . 0.0 109.694 177.867 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -100.58 140.7 15.04 Favored Glycine 0 CA--C 1.503 -0.67 0 N-CA-C 110.793 -0.923 . . . . 0.0 110.793 178.25 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 45.5 m -136.69 133.4 36.12 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-N 117.224 0.512 . . . . 0.0 111.059 179.881 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 132' ' ' LEU . . . . . 0.525 HD12 ' HA ' ' A' ' 112' ' ' GLN . 78.8 mt -60.71 129.91 43.86 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-O 120.907 0.384 . . . . 0.0 110.363 177.21 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 133' ' ' THR . . . . . 0.46 HG21 HD12 ' A' ' 3' ' ' LEU . 5.3 t . . . . . 0 C--O 1.247 0.958 0 CA-C-O 118.244 -0.884 . . . . 0.0 110.13 -179.037 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.72 0 N-CA-C 110.246 -0.279 . . . . 0.0 110.246 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 3' ' ' LEU . . . . . 0.412 HD13 ' N ' ' A' ' 4' ' ' TYR . 2.3 tm? -91.43 128.32 37.21 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 -177.918 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' TYR . . . . . 0.453 ' CE2' ' HB ' ' A' ' 25' ' ' ILE . 83.1 m-85 -119.31 146.77 45.0 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-O 120.991 0.424 . . . . 0.0 111.645 -179.632 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 49.0 m-80 -97.31 138.74 34.32 Favored 'General case' 0 C--N 1.315 -0.932 0 N-CA-C 107.213 -1.403 . . . . 0.0 107.213 175.89 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 69.7 t -115.95 126.7 73.57 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.878 0 N-CA-C 113.108 0.781 . . . . 0.0 113.108 -175.17 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 94.4 mt-10 -120.72 135.66 55.07 Favored 'General case' 0 N--CA 1.443 -0.811 0 CA-C-N 114.817 -1.083 . . . . 0.0 108.21 175.21 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 91.6 m-20 -125.44 148.43 48.82 Favored 'General case' 0 C--N 1.313 -0.994 0 CA-C-O 121.042 0.449 . . . . 0.0 111.738 -176.665 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 58.0 tt0 -125.92 119.38 27.61 Favored 'General case' 0 C--N 1.316 -0.857 0 N-CA-C 107.471 -1.307 . . . . 0.0 107.471 177.143 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 39.3 p90 -142.04 9.74 1.92 Allowed 'General case' 0 C--N 1.319 -0.721 0 N-CA-C 114.404 1.261 . . . . 0.0 114.404 -174.814 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -120.96 18.15 9.1 Favored Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 118.351 -1.881 . . . . 0.0 112.075 -176.767 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 110.83 159.58 16.47 Favored Glycine 0 N--CA 1.443 -0.879 0 C-N-CA 120.859 -0.686 . . . . 0.0 112.203 -179.761 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 41.3 m -56.18 -33.23 65.07 Favored 'General case' 0 C--N 1.323 -0.57 0 C-N-CA 122.74 0.416 . . . . 0.0 111.967 178.855 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 20.3 m -68.21 -14.18 62.79 Favored 'General case' 0 CA--C 1.539 0.535 0 CA-C-N 116.582 -0.281 . . . . 0.0 111.499 178.454 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -96.86 138.66 21.34 Favored Pre-proline 0 C--N 1.323 -0.549 0 N-CA-C 110.013 -0.366 . . . . 0.0 110.013 178.597 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_endo -77.9 -171.78 1.29 Allowed 'Trans proline' 0 CA--C 1.534 0.52 0 C-N-CA 122.954 2.436 . . . . 0.0 113.01 -178.966 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 96.9 m95 -91.34 136.06 33.37 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.103 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 90.8 m-20 -119.71 122.14 40.78 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.103 -179.288 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 75.3 tt0 -78.23 132.03 37.37 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 115.924 -0.58 . . . . 0.0 109.64 178.07 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.441 ' O ' ' HB2' ' A' ' 94' ' ' SER . . . -137.1 29.8 2.69 Favored Glycine 0 N--CA 1.447 -0.612 0 C-N-CA 119.565 -1.303 . . . . 0.0 113.547 -178.919 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 137.33 179.43 16.85 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.023 -1.084 . . . . 0.0 113.333 178.564 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 98.9 mt-30 -123.02 147.56 46.53 Favored 'General case' 0 C--N 1.327 -0.384 0 C-N-CA 122.796 0.438 . . . . 0.0 110.099 179.351 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' TRP . . . . . 0.424 ' HE1' ' HB3' ' A' ' 94' ' ' SER . 45.5 m0 -121.83 171.81 8.62 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 178.813 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -127.23 117.41 22.25 Favored 'General case' 0 C--N 1.317 -0.829 0 C-N-CA 120.635 -0.426 . . . . 0.0 110.144 175.97 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.453 ' HB ' ' CE2' ' A' ' 4' ' ' TYR . 99.1 mt -133.98 144.49 35.39 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 CA-C-N 115.559 -0.746 . . . . 0.0 109.677 -177.827 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 81.57 35.64 22.1 Favored Glycine 0 CA--C 1.506 -0.487 0 C-N-CA 120.231 -0.985 . . . . 0.0 111.921 179.536 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 11.4 m -74.05 21.62 0.09 Allowed 'General case' 0 C--N 1.317 -0.823 0 N-CA-C 111.9 0.333 . . . . 0.0 111.9 179.83 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' ARG . . . . . 0.481 ' NH1' ' HG3' ' A' ' 31' ' ' GLN . 54.4 ttt180 -92.61 10.46 30.36 Favored 'General case' 0 CA--C 1.544 0.748 0 CA-C-O 121.686 0.755 . . . . 0.0 109.075 178.807 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 29.3 m 72.57 -79.67 0.04 OUTLIER 'General case' 0 CA--C 1.541 0.619 0 CA-C-N 114.802 -1.09 . . . . 0.0 113.288 176.135 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 28.4 m-20 -88.98 2.68 53.57 Favored 'General case' 0 N--CA 1.473 0.683 0 N-CA-C 113.106 0.78 . . . . 0.0 113.106 -175.222 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' GLN . . . . . 0.481 ' HG3' ' NH1' ' A' ' 28' ' ' ARG . 8.4 mm-40 -122.47 117.18 25.34 Favored 'General case' 0 C--N 1.309 -1.167 0 N-CA-C 113.394 0.887 . . . . 0.0 113.394 -178.869 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' ASN . . . . . 0.587 ' OD1' ' HA3' ' A' ' 111' ' ' GLY . 28.2 t-20 -92.39 145.16 24.68 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 114.932 -1.031 . . . . 0.0 110.376 177.163 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.438 HG21 ' CH2' ' A' ' 90' ' ' TRP . 53.3 t -97.62 131.95 43.42 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.148 0 CA-C-N 115.586 -0.734 . . . . 0.0 111.089 -178.814 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 29.1 m -109.36 -19.15 7.04 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.155 0 N-CA-C 112.361 0.504 . . . . 0.0 112.361 -179.597 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.479 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -148.3 143.4 26.89 Favored 'General case' 0 CA--C 1.515 -0.383 0 C-N-CA 120.403 -0.519 . . . . 0.0 111.228 179.078 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.434 ' HB ' HG22 ' A' ' 105' ' ' VAL . 90.9 mt -142.68 122.04 9.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.215 -178.99 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 93.0 m-20 -127.7 106.78 9.37 Favored 'General case' 0 C--N 1.313 -0.989 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 175.141 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.506 HG11 ' CD1' ' A' ' 61' ' ' PHE . 29.2 m -149.17 154.53 9.44 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 C-N-CA 120.79 -0.364 . . . . 0.0 111.463 -173.693 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 73.8 tt0 -147.61 152.42 37.87 Favored 'General case' 0 N--CA 1.442 -0.844 0 N-CA-C 109.284 -0.635 . . . . 0.0 109.284 176.471 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 33.2 p -83.25 130.33 35.07 Favored 'General case' 0 C--N 1.312 -1.028 0 CA-C-N 116.498 -0.319 . . . . 0.0 111.78 -177.541 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -71.58 -43.41 52.65 Favored Glycine 0 N--CA 1.445 -0.712 0 N-CA-C 110.197 -1.161 . . . . 0.0 110.197 174.681 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 57.2 m-20 -104.71 -152.91 0.47 Allowed 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 114.898 -0.651 . . . . 0.0 109.764 178.338 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -74.81 40.27 0.14 Allowed 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 123.683 0.793 . . . . 0.0 111.308 -179.907 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.413 ' O ' ' HE2' ' A' ' 71' ' ' TYR . . . 92.92 -6.83 76.83 Favored Glycine 0 C--O 1.217 -0.924 0 C-N-CA 121.032 -0.604 . . . . 0.0 112.419 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 57.5 mt-30 -65.08 -38.84 92.05 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 112.736 0.643 . . . . 0.0 112.736 -178.086 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 5.4 t -126.06 110.84 14.01 Favored 'General case' 0 C--N 1.306 -1.285 0 CA-C-O 121.135 0.493 . . . . 0.0 110.515 179.806 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' LEU . . . . . 0.412 ' O ' ' HA ' ' A' ' 62' ' ' ARG . 79.4 mt -96.72 127.61 42.87 Favored 'General case' 0 C--N 1.316 -0.885 0 N-CA-C 108.936 -0.764 . . . . 0.0 108.936 177.354 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 24.7 p30 -135.28 152.84 51.89 Favored 'General case' 0 C--N 1.308 -1.204 0 CA-C-O 121.008 0.432 . . . . 0.0 110.966 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 162.53 -144.15 9.39 Favored Glycine 0 N--CA 1.438 -1.17 0 C-N-CA 120.447 -0.882 . . . . 0.0 112.683 179.258 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 61.6 m -127.91 130.9 49.26 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-O 120.94 0.4 . . . . 0.0 110.126 -178.013 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' MET . . . . . 0.509 ' HE2' ' HD2' ' A' ' 61' ' ' PHE . 15.0 tmm? -130.39 148.19 52.18 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-N 116.491 -0.322 . . . . 0.0 110.203 -178.414 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.479 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 30.5 m -126.21 128.2 46.86 Favored 'General case' 0 C--O 1.249 1.076 0 CA-C-O 120.909 0.385 . . . . 0.0 111.967 -176.849 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 53' ' ' TYR . . . . . 0.444 ' CD1' ' HB3' ' A' ' 31' ' ' GLN . 52.1 m-85 -88.15 163.21 16.3 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-N 115.676 -0.693 . . . . 0.0 110.768 177.186 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -65.05 127.45 31.68 Favored 'General case' 0 C--O 1.24 0.571 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.078 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 76.45 3.64 78.19 Favored Glycine 0 N--CA 1.446 -0.67 0 CA-C-N 115.9 -0.591 . . . . 0.0 112.766 179.032 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 78.7 mm-40 -120.3 178.89 4.48 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-O 120.828 0.347 . . . . 0.0 111.075 -177.912 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -101.98 174.17 24.08 Favored Glycine 0 N--CA 1.437 -1.241 0 N-CA-C 111.157 -0.777 . . . . 0.0 111.157 178.507 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_endo -66.68 137.71 46.79 Favored 'Trans proline' 0 CA--C 1.531 0.359 0 C-N-CA 122.217 1.944 . . . . 0.0 112.538 179.709 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 44.2 pt -133.61 171.73 17.52 Favored 'Isoleucine or valine' 0 C--O 1.241 0.644 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.356 179.084 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -74.67 138.11 23.44 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.684 -0.77 . . . . 0.0 111.974 -178.835 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.509 ' HD2' ' HE2' ' A' ' 51' ' ' MET . 55.4 t80 -127.01 129.57 48.33 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-O 120.488 0.185 . . . . 0.0 110.91 -178.94 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 62' ' ' ARG . . . . . 0.412 ' HA ' ' O ' ' A' ' 47' ' ' LEU . 59.9 ttp85 -141.74 133.05 26.51 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.305 -0.407 . . . . 0.0 109.96 175.978 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.536 ' HB1' ' HB3' ' A' ' 71' ' ' TYR . . . -133.53 139.85 46.86 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.67 -0.241 . . . . 0.0 111.373 -179.969 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 25.2 m -113.67 127.53 56.08 Favored 'General case' 0 CA--C 1.539 0.555 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.482 -179.286 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 58.0 tp -72.44 125.52 27.61 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 112.422 0.527 . . . . 0.0 112.422 -178.276 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 86.9 mt -76.28 -25.78 55.24 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.671 -0.695 . . . . 0.0 110.541 176.249 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 118.27 0.3 16.47 Favored Glycine 0 C--N 1.337 0.596 0 C-N-CA 120.808 -0.711 . . . . 0.0 113.175 178.761 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 29.0 p-10 -135.03 37.59 3.01 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-O 120.919 0.39 . . . . 0.0 111.008 -178.171 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 97.1 m-20 69.29 4.31 4.55 Favored 'General case' 0 N--CA 1.488 1.431 0 C-N-CA 123.417 0.687 . . . . 0.0 111.735 -177.708 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 16.3 t -95.43 126.07 40.48 Favored 'General case' 0 N--CA 1.435 -1.198 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 177.486 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.536 ' HB3' ' HB1' ' A' ' 63' ' ' ALA . 95.7 m-85 -116.98 129.31 55.95 Favored 'General case' 0 C--N 1.309 -1.172 0 CA-C-N 116.411 -0.359 . . . . 0.0 111.405 -178.023 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -81.52 116.25 21.21 Favored 'General case' 0 C--N 1.315 -0.907 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 175.144 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 54.2 t -102.53 132.96 47.52 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.198 0 N-CA-C 113.215 0.82 . . . . 0.0 113.215 -173.235 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 49.2 mt-10 -127.37 145.78 50.69 Favored 'General case' 0 N--CA 1.44 -0.933 0 CA-C-N 114.267 -1.333 . . . . 0.0 108.666 177.919 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 13.5 m120 -123.77 149.5 45.55 Favored 'General case' 0 C--N 1.316 -0.848 0 N-CA-C 110.246 -0.279 . . . . 0.0 110.246 -176.216 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' GLN . . . . . 0.444 ' HB2' ' CE3' ' A' ' 84' ' ' TRP . 63.1 tt0 -121.83 124.9 45.25 Favored 'General case' 0 C--N 1.315 -0.908 0 CA-C-N 116.464 -0.335 . . . . 0.0 110.385 179.724 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 8.3 p90 -144.05 162.73 35.49 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.876 -0.602 . . . . 0.0 109.628 179.063 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 101.17 -13.04 58.8 Favored Glycine 0 C--N 1.316 -0.583 0 C-N-CA 120.898 -0.667 . . . . 0.0 112.766 179.821 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 125.22 174.87 14.06 Favored Glycine 0 N--CA 1.444 -0.769 0 C-N-CA 120.505 -0.855 . . . . 0.0 112.367 178.626 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 7.5 p-10 -63.43 -34.59 78.08 Favored 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 112.303 0.483 . . . . 0.0 112.303 -179.581 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 73.1 p -78.95 -6.54 56.5 Favored 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 111.965 0.358 . . . . 0.0 111.965 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -85.34 146.18 44.21 Favored Pre-proline 0 C--N 1.322 -0.624 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.796 -179.95 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 84.5 Cg_endo -80.37 -175.09 2.52 Favored 'Trans proline' 0 C--O 1.236 0.404 0 C-N-CA 122.777 2.318 . . . . 0.0 112.768 -179.408 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 84' ' ' TRP . . . . . 0.444 ' CE3' ' HB2' ' A' ' 76' ' ' GLN . 90.5 m95 -94.9 144.87 25.32 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.793 -0.64 . . . . 0.0 109.979 179.412 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 87.9 m-70 -124.52 142.26 51.47 Favored 'General case' 0 C--N 1.316 -0.859 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 179.225 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 22.6 p -61.78 133.87 56.04 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-O 120.911 0.386 . . . . 0.0 111.5 -179.11 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -106.27 -46.26 1.17 Allowed Glycine 0 N--CA 1.445 -0.739 0 C-N-CA 120.667 -0.778 . . . . 0.0 111.639 178.859 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 156.25 -171.74 34.03 Favored Glycine 0 C--O 1.221 -0.685 0 C-N-CA 120.777 -0.725 . . . . 0.0 111.463 178.906 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 7.4 t30 -110.29 118.23 35.77 Favored 'General case' 0 C--N 1.312 -1.047 0 CA-C-N 117.147 0.474 . . . . 0.0 110.178 179.08 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' TRP . . . . . 0.438 ' CH2' HG21 ' A' ' 33' ' ' VAL . 28.6 m0 -107.63 150.16 27.22 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.574 -0.284 . . . . 0.0 110.399 -178.294 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 49.8 mm -107.72 114.61 46.8 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 N-CA-C 109.217 -0.66 . . . . 0.0 109.217 178.109 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 90.0 mt -127.15 79.94 1.92 Allowed 'General case' 0 C--O 1.265 1.893 0 CA-C-O 121.819 0.818 . . . . 0.0 111.814 -177.83 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 169.15 99.69 0.13 Allowed Glycine 0 N--CA 1.438 -1.201 0 CA-C-N 115.113 -0.949 . . . . 0.0 111.969 179.325 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 94' ' ' SER . . . . . 0.441 ' HB2' ' O ' ' A' ' 20' ' ' GLY . 71.6 p -86.19 -7.87 58.23 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 121.308 0.575 . . . . 0.0 110.148 178.604 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -103.68 146.35 28.72 Favored 'General case' 0 N--CA 1.438 -1.055 0 CA-C-N 115.475 -0.784 . . . . 0.0 109.289 179.878 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 -90.24 -19.8 23.72 Favored 'General case' 0 C--N 1.31 -1.138 0 N-CA-C 112.187 0.44 . . . . 0.0 112.187 -172.677 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 28.3 p-10 -117.7 14.52 14.4 Favored 'General case' 0 C--N 1.313 -0.988 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.107 -178.935 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 98' ' ' GLN . . . . . . . . . . . . . 56.7 tt0 -154.55 123.25 6.18 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 120.834 0.35 . . . . 0.0 110.18 -176.656 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 1.6 m-20 -98.48 162.59 13.07 Favored 'General case' 0 C--O 1.242 0.691 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.064 -175.951 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 54.3 t -77.55 133.75 29.95 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.579 0 C-N-CA 120.84 -0.344 . . . . 0.0 111.283 178.114 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 35.9 m -116.43 -34.63 1.88 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.503 0 N-CA-C 113.205 0.817 . . . . 0.0 113.205 -179.036 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 102' ' ' ALA . . . . . 0.587 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -142.73 138.91 30.85 Favored 'General case' 0 CA--C 1.512 -0.489 0 C-N-CA 120.019 -0.672 . . . . 0.0 111.486 179.523 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 40.4 mm -131.77 125.15 55.11 Favored 'Isoleucine or valine' 0 C--O 1.244 0.79 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.287 179.614 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 2.8 t-20 -123.84 95.9 4.75 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.628 -0.714 . . . . 0.0 109.311 174.229 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.434 HG22 ' HB ' ' A' ' 36' ' ' ILE . 29.9 m -136.85 138.78 45.71 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.926 0 N-CA-C 112.516 0.562 . . . . 0.0 112.516 -176.442 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -138.36 136.86 36.77 Favored 'General case' 0 C--N 1.309 -1.182 0 CA-C-N 115.132 -0.94 . . . . 0.0 108.481 177.238 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 39.3 t -118.39 129.23 55.3 Favored 'General case' 0 C--N 1.302 -1.496 0 C-N-CA 120.85 -0.34 . . . . 0.0 110.663 -179.549 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -86.45 -6.86 80.23 Favored Glycine 0 N--CA 1.441 -1.001 0 N-CA-C 110.359 -1.096 . . . . 0.0 110.359 175.937 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 109' ' ' ASP . . . . . 0.484 ' CG ' ' H ' ' A' ' 110' ' ' ASP . 11.1 t70 -93.88 -164.27 1.15 Allowed 'General case' 0 N--CA 1.445 -0.699 0 CA-C-N 115.286 -0.457 . . . . 0.0 110.025 179.656 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 110' ' ' ASP . . . . . 0.484 ' H ' ' CG ' ' A' ' 109' ' ' ASP . 16.2 m-20 -95.49 19.49 10.89 Favored 'General case' 0 C--N 1.318 -0.784 0 C-N-CA 122.989 0.516 . . . . 0.0 110.682 -178.016 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 111' ' ' GLY . . . . . 0.587 ' HA3' ' OD1' ' A' ' 32' ' ' ASN . . . 101.73 2.22 52.71 Favored Glycine 0 N--CA 1.443 -0.861 0 C-N-CA 120.605 -0.807 . . . . 0.0 112.545 -179.79 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 35.4 tt0 -64.1 -41.64 97.2 Favored 'General case' 0 C--O 1.226 -0.163 0 CA-C-O 120.984 0.421 . . . . 0.0 110.275 179.417 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 8.6 p -132.24 147.74 52.42 Favored 'General case' 0 N--CA 1.441 -0.878 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.436 177.746 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 92.8 mt -114.76 125.77 54.08 Favored 'General case' 0 C--N 1.319 -0.752 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 179.159 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 18.4 m120 -118.55 137.54 53.16 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-N 116.515 -0.312 . . . . 0.0 111.098 -177.633 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 161.62 -139.91 6.29 Favored Glycine 0 N--CA 1.442 -0.934 0 C-N-CA 119.633 -1.27 . . . . 0.0 113.424 176.299 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 27.2 p -138.05 159.97 40.6 Favored 'General case' 0 C--N 1.312 -1.06 0 C-N-CA 123.037 0.535 . . . . 0.0 110.031 -178.703 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 20.5 ptm -146.35 163.0 36.94 Favored 'General case' 0 C--N 1.31 -1.138 0 C-N-CA 121.027 -0.269 . . . . 0.0 111.071 -177.749 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 119' ' ' THR . . . . . 0.587 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 25.8 m -136.68 127.51 27.39 Favored 'General case' 0 C--O 1.251 1.175 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.177 178.727 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 120' ' ' TYR . . . . . 0.52 ' HB2' ' OE1' ' A' ' 123' ' ' GLU . 6.9 m-85 -94.67 162.7 13.67 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.215 -0.448 . . . . 0.0 109.946 174.705 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -58.79 119.17 6.66 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.695 0.283 . . . . 0.0 111.26 179.813 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 74.03 23.96 74.93 Favored Glycine 0 CA--C 1.52 0.376 0 C-N-CA 120.892 -0.67 . . . . 0.0 112.868 -179.792 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 123' ' ' GLU . . . . . 0.52 ' OE1' ' HB2' ' A' ' 120' ' ' TYR . 40.0 tt0 -130.2 158.38 39.9 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.769 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -89.14 162.89 31.31 Favored Glycine 0 N--CA 1.444 -0.791 0 N-CA-C 110.902 -0.879 . . . . 0.0 110.902 177.326 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_exo -58.43 131.54 43.38 Favored 'Trans proline' 0 CA--C 1.532 0.394 0 C-N-CA 122.261 1.974 . . . . 0.0 112.471 -179.237 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 43.1 pt -127.87 163.67 31.04 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.18 179.724 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -71.04 133.68 22.67 Favored Glycine 0 C--O 1.242 0.608 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.224 -178.89 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 87.7 t80 -118.02 133.87 55.51 Favored 'General case' 0 C--O 1.245 0.841 0 CA-C-O 121.091 0.472 . . . . 0.0 111.366 -178.083 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 76.5 tttt -137.74 111.0 7.88 Favored 'General case' 0 N--CA 1.44 -0.938 0 CA-C-N 115.165 -0.925 . . . . 0.0 108.887 178.026 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -112.16 143.65 17.56 Favored Glycine 0 C--N 1.311 -0.86 0 C-N-CA 120.377 -0.916 . . . . 0.0 111.843 179.885 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 41.3 m -130.36 130.45 44.42 Favored 'General case' 0 C--N 1.313 -0.998 0 CA-C-N 117.074 0.437 . . . . 0.0 110.401 179.203 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 64.8 tp -65.87 141.06 58.39 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.759 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 18.3 m . . . . . 0 C--O 1.251 1.132 0 CA-C-O 118.484 -0.77 . . . . 0.0 109.504 178.745 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.549 ' HB3' ' O ' ' A' ' 25' ' ' ILE . . . . . . . . 0 N--CA 1.474 0.775 0 N-CA-C 110.308 -0.256 . . . . 0.0 110.308 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' LEU . . . . . 0.401 HD13 ' N ' ' A' ' 4' ' ' TYR . 0.9 OUTLIER -151.91 128.04 10.46 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 -178.474 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 4' ' ' TYR . . . . . 0.401 ' N ' HD13 ' A' ' 3' ' ' LEU . 61.7 m-85 -123.52 147.31 47.37 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 112.917 0.71 . . . . 0.0 112.917 -178.293 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 27.4 t-20 -97.92 129.72 44.83 Favored 'General case' 0 C--N 1.316 -0.864 0 N-CA-C 106.677 -1.601 . . . . 0.0 106.677 174.705 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 65.1 t -116.91 129.48 73.37 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.046 0 CA-C-O 121.437 0.637 . . . . 0.0 112.635 -173.818 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 -114.2 139.74 49.13 Favored 'General case' 0 C--O 1.249 1.032 0 CA-C-N 114.974 -1.012 . . . . 0.0 108.346 176.874 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 10.2 m120 -114.16 140.74 48.28 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 116.453 -0.34 . . . . 0.0 110.94 -176.699 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' GLN . . . . . 0.593 ' OE1' ' HA ' ' A' ' 13' ' ' SER . 36.6 tt0 -127.64 125.56 40.39 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 120.948 0.404 . . . . 0.0 111.289 177.784 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 22.8 p90 -137.29 144.75 42.81 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 116.042 -0.526 . . . . 0.0 109.83 177.192 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 99.52 9.64 49.75 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 120.568 -0.825 . . . . 0.0 111.98 179.039 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 111.17 154.95 13.4 Favored Glycine 0 N--CA 1.444 -0.773 0 C-N-CA 120.959 -0.638 . . . . 0.0 112.325 179.527 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' SER . . . . . 0.593 ' HA ' ' OE1' ' A' ' 9' ' ' GLN . 69.9 m -65.98 -14.76 62.19 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 112.883 0.697 . . . . 0.0 112.883 -179.627 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 46.9 m -84.21 -7.93 59.21 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 121.059 0.457 . . . . 0.0 110.481 177.132 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -84.84 150.16 55.25 Favored Pre-proline 0 N--CA 1.449 -0.478 0 CA-C-N 115.924 -0.58 . . . . 0.0 109.773 178.79 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -67.33 152.35 79.27 Favored 'Trans proline' 0 C--O 1.236 0.409 0 C-N-CA 122.458 2.105 . . . . 0.0 113.046 -178.231 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' TRP . . . . . 0.414 ' CE3' ' HB2' ' A' ' 9' ' ' GLN . 90.8 m95 -83.78 130.46 34.94 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 115.52 -0.764 . . . . 0.0 109.056 178.422 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 2.9 m-20 -107.51 132.48 53.19 Favored 'General case' 0 C--N 1.313 -1.016 0 N-CA-C 107.524 -1.287 . . . . 0.0 107.524 179.168 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 71.8 tt0 -66.42 128.02 34.57 Favored 'General case' 0 C--N 1.308 -1.221 0 CA-C-O 121.58 0.705 . . . . 0.0 110.634 -176.793 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -100.96 -4.48 54.28 Favored Glycine 0 N--CA 1.435 -1.396 0 CA-C-N 115.026 -0.988 . . . . 0.0 113.345 -175.113 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 115.01 -153.52 17.58 Favored Glycine 0 N--CA 1.443 -0.851 0 C-N-CA 120.306 -0.95 . . . . 0.0 111.943 -178.142 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 28.6 pt20 -132.52 139.41 47.88 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-O 120.701 0.286 . . . . 0.0 110.553 -179.812 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' TRP . . . . . 0.458 ' CZ2' ' HE3' ' A' ' 118' ' ' MET . 38.4 m0 -117.29 161.44 19.49 Favored 'General case' 0 CA--C 1.508 -0.665 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.887 -178.517 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.412 ' HB3' ' H ' ' A' ' 91' ' ' ILE . 73.4 tt0 -112.47 107.05 15.68 Favored 'General case' 0 N--CA 1.443 -0.825 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 175.11 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.549 ' O ' ' HB3' ' A' ' 2' ' ' ALA . 92.4 mt -123.22 132.07 72.06 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.843 0 CA-C-N 115.922 -0.581 . . . . 0.0 109.872 -177.36 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 90.85 116.33 1.9 Allowed Glycine 0 N--CA 1.446 -0.641 0 C-N-CA 120.33 -0.938 . . . . 0.0 112.432 178.707 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' SER . . . . . 0.472 ' OG ' ' HA3' ' A' ' 88' ' ' GLY . 13.2 t -112.56 14.96 20.23 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-O 121.071 0.463 . . . . 0.0 110.201 -179.848 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 75.7 mtp180 -127.64 138.69 52.91 Favored 'General case' 0 CA--C 1.513 -0.449 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.375 -179.426 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 19.4 m -93.01 -27.27 17.1 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.783 179.407 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 11.8 p-10 -77.32 -38.62 50.09 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.45 -177.618 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 22.1 mm-40 -130.21 121.41 26.15 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.302 179.709 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' ASN . . . . . 0.559 ' ND2' ' HA3' ' A' ' 111' ' ' GLY . 65.6 t30 -95.3 169.02 10.37 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 178.792 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 58.8 t -96.44 131.25 43.7 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.991 0 CA-C-N 116.568 -0.287 . . . . 0.0 110.934 -177.5 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 28.4 m -111.39 -20.25 6.38 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.163 0 N-CA-C 112.19 0.441 . . . . 0.0 112.19 179.002 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.532 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -147.86 145.57 28.74 Favored 'General case' 0 CA--C 1.514 -0.435 0 C-N-CA 120.296 -0.562 . . . . 0.0 111.512 179.992 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.403 ' HB ' HG22 ' A' ' 105' ' ' VAL . 92.0 mt -144.87 127.95 11.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.042 -0.526 . . . . 0.0 109.893 -179.539 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 37' ' ' ASN . . . . . 0.421 ' HA ' ' O ' ' A' ' 103' ' ' ILE . 0.6 OUTLIER -133.17 112.11 11.46 Favored 'General case' 0 C--N 1.317 -0.81 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 174.967 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.512 HG11 ' CD2' ' A' ' 61' ' ' PHE . 15.5 m -147.67 150.21 14.72 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.804 0 N-CA-C 112.207 0.447 . . . . 0.0 112.207 -174.871 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 70.5 tt0 -133.22 143.11 48.93 Favored 'General case' 0 N--CA 1.442 -0.851 0 CA-C-N 114.976 -1.011 . . . . 0.0 108.703 176.485 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 21.2 p -73.75 146.34 44.43 Favored 'General case' 0 C--N 1.31 -1.128 0 CA-C-O 120.728 0.299 . . . . 0.0 111.216 178.591 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -92.11 -42.48 4.64 Favored Glycine 0 N--CA 1.447 -0.576 0 N-CA-C 109.687 -1.365 . . . . 0.0 109.687 175.333 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 23.0 m-20 -102.27 -161.36 0.84 Allowed 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 114.711 -0.745 . . . . 0.0 109.116 176.042 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 29.4 p-10 -84.12 47.79 1.38 Allowed 'General case' 0 C--N 1.315 -0.895 0 CA-C-O 121.325 0.583 . . . . 0.0 110.874 179.484 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 99.53 -14.4 60.72 Favored Glycine 0 C--O 1.22 -0.778 0 CA-C-N 115.923 -0.581 . . . . 0.0 112.665 -179.411 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 58.5 tp60 -64.87 -39.39 93.47 Favored 'General case' 0 CA--C 1.534 0.362 0 CA-C-O 120.803 0.335 . . . . 0.0 111.328 -179.162 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 61.3 p -128.45 142.87 50.96 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.604 -0.271 . . . . 0.0 110.742 179.07 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 86.0 mt -126.68 133.83 50.85 Favored 'General case' 0 C--O 1.236 0.369 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 179.168 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -136.22 147.91 47.83 Favored 'General case' 0 C--N 1.32 -0.692 0 C-N-CA 120.905 -0.318 . . . . 0.0 110.951 179.981 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 165.67 -144.17 9.02 Favored Glycine 0 N--CA 1.442 -0.922 0 C-N-CA 120.497 -0.858 . . . . 0.0 112.104 177.909 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 9.4 t -133.53 145.51 50.2 Favored 'General case' 0 N--CA 1.435 -1.177 0 CA-C-O 121.103 0.477 . . . . 0.0 110.558 -179.211 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 14.6 tmm? -133.32 147.19 51.85 Favored 'General case' 0 C--N 1.314 -0.96 0 CA-C-N 115.918 -0.583 . . . . 0.0 109.685 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.532 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 28.7 m -125.96 128.01 46.84 Favored 'General case' 0 C--O 1.249 1.054 0 N-CA-C 112.045 0.387 . . . . 0.0 112.045 -176.812 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 53' ' ' TYR . . . . . 0.429 ' HB2' ' HB2' ' A' ' 56' ' ' GLU . 86.0 m-85 -86.27 162.29 18.34 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.565 176.781 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -64.29 122.09 15.84 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.886 178.479 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.59 5.84 89.19 Favored Glycine 0 CA--C 1.517 0.198 0 C-N-CA 120.958 -0.639 . . . . 0.0 112.499 179.925 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' GLU . . . . . 0.429 ' HB2' ' HB2' ' A' ' 53' ' ' TYR . 69.6 mm-40 -119.55 179.14 4.31 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 120.742 0.306 . . . . 0.0 110.874 -178.608 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -106.77 169.2 14.96 Favored Glycine 0 N--CA 1.44 -1.078 0 N-CA-C 111.237 -0.745 . . . . 0.0 111.237 178.881 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_exo -62.34 137.36 64.97 Favored 'Trans proline' 0 C--O 1.235 0.359 0 C-N-CA 122.583 2.189 . . . . 0.0 112.239 179.102 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' ILE . . . . . 0.475 ' HB ' ' O ' ' A' ' 76' ' ' GLN . 48.6 pt -130.32 170.98 18.3 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 CA-C-N 115.984 -0.553 . . . . 0.0 109.813 178.387 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -75.57 136.27 19.76 Favored Glycine 0 N--CA 1.446 -0.671 0 C-N-CA 120.2 -1.0 . . . . 0.0 110.889 -179.346 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.512 ' CD2' HG11 ' A' ' 38' ' ' VAL . 7.5 t80 -131.22 125.15 32.16 Favored 'General case' 0 C--N 1.31 -1.152 0 CA-C-O 120.958 0.409 . . . . 0.0 111.457 -178.046 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 61.9 ttp180 -130.03 130.99 45.66 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.608 -0.724 . . . . 0.0 110.338 178.039 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.409 ' HB1' ' HB3' ' A' ' 71' ' ' TYR . . . -130.99 138.98 49.93 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.782 179.382 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 63.6 m -121.16 130.18 53.6 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.392 179.838 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 61.7 tp -68.16 121.68 16.7 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 121.064 0.459 . . . . 0.0 111.365 -178.459 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 96.1 mt -71.32 -34.24 70.39 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.613 178.242 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 133.5 -12.16 4.91 Favored Glycine 0 CA--C 1.521 0.445 0 C-N-CA 120.485 -0.865 . . . . 0.0 113.31 -179.742 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 20.7 m120 -130.89 50.84 2.19 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-O 120.981 0.42 . . . . 0.0 111.4 -178.038 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 86.7 m-20 65.03 1.54 1.52 Allowed 'General case' 0 N--CA 1.486 1.336 0 C-N-CA 123.845 0.858 . . . . 0.0 111.98 178.835 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 25.7 t -102.62 138.19 39.84 Favored 'General case' 0 N--CA 1.436 -1.146 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 179.108 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.447 ' CE1' ' HB2' ' A' ' 92' ' ' LEU . 84.7 m-85 -118.1 140.87 49.14 Favored 'General case' 0 C--N 1.307 -1.263 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.742 -178.534 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -91.24 123.88 35.03 Favored 'General case' 0 N--CA 1.438 -1.063 0 N-CA-C 107.657 -1.238 . . . . 0.0 107.657 173.746 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.439 HG13 ' HE1' ' A' ' 61' ' ' PHE . 45.3 t -105.32 134.04 47.92 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.246 0 N-CA-C 113.413 0.894 . . . . 0.0 113.413 -173.057 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 84.7 mt-10 -129.25 126.27 38.72 Favored 'General case' 0 N--CA 1.438 -1.042 0 CA-C-N 114.367 -1.288 . . . . 0.0 107.69 176.369 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 92.8 m-20 -109.22 146.69 33.79 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-O 121.021 0.439 . . . . 0.0 111.789 -175.582 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 76' ' ' GLN . . . . . 0.479 ' HB2' ' CE3' ' A' ' 84' ' ' TRP . 58.4 tt0 -114.47 121.26 42.99 Favored 'General case' 0 C--N 1.312 -1.061 0 CA-C-N 115.707 -0.678 . . . . 0.0 109.645 -179.955 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 5.8 p90 -140.46 159.47 42.12 Favored 'General case' 0 C--N 1.318 -0.79 0 C-N-CA 120.874 -0.33 . . . . 0.0 110.578 179.246 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 95.35 -7.16 68.83 Favored Glycine 0 N--CA 1.447 -0.575 0 C-N-CA 120.834 -0.698 . . . . 0.0 111.846 -179.704 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 146.58 154.93 6.33 Favored Glycine 0 N--CA 1.445 -0.725 0 N-CA-C 111.684 -0.566 . . . . 0.0 111.684 178.999 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -72.28 -25.56 61.64 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-O 120.965 0.412 . . . . 0.0 111.198 -179.987 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 4.6 m -82.47 -11.7 58.33 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.412 177.72 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -72.63 155.3 91.09 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.445 -177.236 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -69.38 169.02 19.38 Favored 'Trans proline' 0 C--N 1.347 0.485 0 C-N-CA 122.721 2.281 . . . . 0.0 112.141 178.342 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 84' ' ' TRP . . . . . 0.479 ' CE3' ' HB2' ' A' ' 76' ' ' GLN . 91.8 m95 -87.49 143.29 27.29 Favored 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 -178.409 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 85.8 m-70 -118.61 157.77 26.75 Favored 'General case' 0 C--N 1.313 -0.996 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 -179.705 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 48.3 m -63.81 143.74 57.61 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-O 120.837 0.351 . . . . 0.0 111.023 179.787 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -117.18 -58.91 0.3 Allowed Glycine 0 N--CA 1.439 -1.164 0 N-CA-C 110.931 -0.867 . . . . 0.0 110.931 178.556 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.472 ' HA3' ' OG ' ' A' ' 27' ' ' SER . . . 149.38 -167.68 29.66 Favored Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 120.929 -0.653 . . . . 0.0 111.929 177.067 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 89' ' ' ASN . . . . . 0.407 ' C ' ' HD1' ' A' ' 90' ' ' TRP . 90.5 m-20 -102.48 132.68 48.37 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-O 120.679 0.276 . . . . 0.0 110.624 178.747 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 90' ' ' TRP . . . . . 0.407 ' HD1' ' C ' ' A' ' 89' ' ' ASN . 12.5 m0 -130.63 151.58 50.93 Favored 'General case' 0 C--N 1.319 -0.744 0 N-CA-C 108.472 -0.936 . . . . 0.0 108.472 -179.222 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.412 ' H ' ' HB3' ' A' ' 24' ' ' GLU . 95.8 mt -117.26 115.52 49.05 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.153 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 176.643 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 92' ' ' LEU . . . . . 0.447 ' HB2' ' CE1' ' A' ' 71' ' ' TYR . 88.8 mt -125.6 74.14 1.38 Allowed 'General case' 0 C--O 1.247 0.962 0 CA-C-O 121.683 0.754 . . . . 0.0 110.215 -177.577 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 167.72 87.39 0.07 OUTLIER Glycine 0 N--CA 1.431 -1.648 0 CA-C-N 114.892 -1.049 . . . . 0.0 110.73 -177.888 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 22.5 p -91.63 -5.68 53.46 Favored 'General case' 0 C--N 1.31 -1.116 0 CA-C-O 121.176 0.512 . . . . 0.0 110.586 -179.243 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 95' ' ' ARG . . . . . 0.427 HH11 ' HD3' ' A' ' 95' ' ' ARG . 61.7 mtt-85 -94.2 150.0 20.72 Favored 'General case' 0 N--CA 1.442 -0.849 0 CA-C-N 115.64 -0.709 . . . . 0.0 109.676 179.127 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 77.3 tt0 -70.06 -42.76 72.39 Favored 'General case' 0 C--N 1.315 -0.925 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.669 -174.048 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 94.4 m-20 -113.46 18.13 17.9 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.905 -176.871 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 98' ' ' GLN . . . . . . . . . . . . . 2.3 mt-30 -141.53 117.92 10.82 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 113.18 0.807 . . . . 0.0 113.18 -176.118 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 35.8 m-80 -98.25 166.44 11.4 Favored 'General case' 0 C--O 1.245 0.852 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.204 175.138 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 97.1 t -85.18 134.07 27.93 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.611 -179.063 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 27.9 m -115.23 -31.43 1.97 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-N 115.785 -0.643 . . . . 0.0 112.626 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 102' ' ' ALA . . . . . 0.601 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -144.22 139.08 28.48 Favored 'General case' 0 CA--C 1.514 -0.409 0 C-N-CA 120.097 -0.641 . . . . 0.0 111.631 179.306 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.445 ' HB ' HG22 ' A' ' 38' ' ' VAL . 92.0 mt -132.75 128.38 57.15 Favored 'Isoleucine or valine' 0 C--O 1.238 0.497 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.177 179.743 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 40.7 t30 -128.42 98.16 4.96 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.674 -0.694 . . . . 0.0 109.435 173.544 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.403 HG22 ' HB ' ' A' ' 36' ' ' ILE . 28.3 m -138.0 140.93 39.74 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 N-CA-C 112.331 0.493 . . . . 0.0 112.331 -176.634 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 42.4 tt0 -141.11 138.52 33.56 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.658 -0.701 . . . . 0.0 109.965 178.078 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 46.4 t -143.85 141.71 30.47 Favored 'General case' 0 N--CA 1.446 -0.634 0 CA-C-O 120.894 0.378 . . . . 0.0 111.24 179.18 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -106.81 6.22 37.6 Favored Glycine 0 N--CA 1.443 -0.873 0 N-CA-C 110.624 -0.991 . . . . 0.0 110.624 176.187 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 23.1 m-20 -95.78 14.33 23.62 Favored 'General case' 0 CA--C 1.516 -0.344 0 C-N-CA 123.004 0.522 . . . . 0.0 111.324 -178.176 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 85.7 m-20 63.59 23.38 13.56 Favored 'General case' 0 N--CA 1.47 0.561 0 CA-C-N 115.632 -0.713 . . . . 0.0 112.319 178.173 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 111' ' ' GLY . . . . . 0.559 ' HA3' ' ND2' ' A' ' 32' ' ' ASN . . . 103.45 5.21 46.05 Favored Glycine 0 N--CA 1.446 -0.653 0 C-N-CA 120.008 -1.092 . . . . 0.0 114.249 176.651 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 54.2 tt0 -62.63 -49.53 74.81 Favored 'General case' 0 C--O 1.249 1.059 0 CA-C-O 121.583 0.706 . . . . 0.0 109.891 177.612 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 14.4 p -136.12 133.17 36.99 Favored 'General case' 0 N--CA 1.442 -0.846 0 CA-C-N 115.034 -0.985 . . . . 0.0 109.555 177.163 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -107.38 122.76 47.24 Favored 'General case' 0 C--N 1.314 -0.97 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 178.787 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 88.9 m-20 -119.54 143.72 47.45 Favored 'General case' 0 C--N 1.311 -1.082 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.121 -179.063 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 160.87 -138.09 5.3 Favored Glycine 0 N--CA 1.442 -0.915 0 C-N-CA 120.216 -0.992 . . . . 0.0 112.685 177.568 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 2.1 p -131.68 153.34 50.1 Favored 'General case' 0 C--N 1.314 -0.978 0 CA-C-O 121.086 0.47 . . . . 0.0 110.789 -179.592 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 118' ' ' MET . . . . . 0.619 ' SD ' ' HD1' ' A' ' 128' ' ' PHE . 21.7 ptm -139.56 147.81 41.7 Favored 'General case' 0 C--N 1.314 -0.962 0 CA-C-N 115.813 -0.63 . . . . 0.0 109.993 -176.764 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 119' ' ' THR . . . . . 0.601 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 29.1 m -131.75 125.61 32.4 Favored 'General case' 0 C--O 1.249 1.063 0 C-N-CA 120.99 -0.284 . . . . 0.0 111.096 179.095 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 120' ' ' TYR . . . . . 0.4 ' HB2' ' HB3' ' A' ' 123' ' ' GLU . 63.1 m-85 -94.11 163.7 13.36 Favored 'General case' 0 CA--C 1.513 -0.476 0 CA-C-N 116.159 -0.473 . . . . 0.0 109.969 175.52 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -53.51 -33.81 55.8 Favored 'General case' 0 N--CA 1.47 0.545 0 N-CA-C 113.503 0.927 . . . . 0.0 113.503 -176.544 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -138.0 25.31 2.93 Favored Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 119.596 -1.288 . . . . 0.0 112.776 -178.017 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 123' ' ' GLU . . . . . 0.4 ' HB3' ' HB2' ' A' ' 120' ' ' TYR . 36.1 tp10 -111.28 -53.06 2.74 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-O 121.29 0.567 . . . . 0.0 110.326 -177.926 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 115.01 177.43 18.8 Favored Glycine 0 N--CA 1.439 -1.154 0 CA-C-N 115.541 -0.754 . . . . 0.0 111.452 -178.308 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 13.5 Cg_exo -71.16 117.13 5.0 Favored 'Trans proline' 0 N--CA 1.458 -0.561 0 C-N-CA 122.8 2.333 . . . . 0.0 112.051 179.053 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 36.7 pt -130.16 165.96 29.01 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.946 0 CA-C-N 115.93 -0.577 . . . . 0.0 109.891 178.388 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -70.26 135.72 26.0 Favored Glycine 0 C--O 1.241 0.532 0 C-N-CA 120.871 -0.68 . . . . 0.0 112.531 -178.5 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 128' ' ' PHE . . . . . 0.619 ' HD1' ' SD ' ' A' ' 118' ' ' MET . 72.8 t80 -112.5 132.3 55.15 Favored 'General case' 0 C--O 1.249 1.031 0 CA-C-O 120.832 0.349 . . . . 0.0 111.054 -178.793 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 129' ' ' LYS . . . . . 0.402 ' HB2' ' CZ3' ' A' ' 17' ' ' TRP . 61.0 tttm -137.59 108.9 6.85 Favored 'General case' 0 N--CA 1.447 -0.587 0 CA-C-N 115.599 -0.728 . . . . 0.0 109.213 175.976 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -114.03 137.12 13.85 Favored Glycine 0 N--CA 1.446 -0.648 0 C-N-CA 120.522 -0.847 . . . . 0.0 111.818 179.244 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 55.8 m -132.34 140.64 48.62 Favored 'General case' 0 C--N 1.308 -1.21 0 CA-C-N 116.645 0.223 . . . . 0.0 110.605 -179.241 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 88.1 mt -56.99 130.03 44.29 Favored 'General case' 0 N--CA 1.472 0.663 0 O-C-N 123.17 0.294 . . . . 0.0 110.939 177.5 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 14.8 p . . . . . 0 C--O 1.252 1.212 0 CA-C-O 118.145 -0.931 . . . . 0.0 110.326 178.313 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.406 ' O ' ' HG3' ' A' ' 24' ' ' GLU . . . . . . . . 0 N--CA 1.471 0.581 0 N-CA-C 109.713 -0.477 . . . . 0.0 109.713 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 3.0 tm? -94.81 127.12 40.59 Favored 'General case' 0 C--N 1.317 -0.823 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 -177.153 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 40.5 m-85 -117.16 136.66 52.87 Favored 'General case' 0 C--N 1.312 -1.023 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.305 178.444 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' ASN . . . . . 0.487 ' O ' ' HA2' ' A' ' 130' ' ' GLY . 5.9 m-20 -85.06 132.23 34.35 Favored 'General case' 0 CA--C 1.499 -0.989 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 175.378 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.509 HG21 ' CG ' ' A' ' 23' ' ' TRP . 53.2 t -114.35 128.13 71.51 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.115 0 N-CA-C 113.182 0.808 . . . . 0.0 113.182 -173.847 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 71.6 mt-10 -124.05 135.9 53.89 Favored 'General case' 0 N--CA 1.436 -1.143 0 CA-C-N 114.577 -1.192 . . . . 0.0 108.469 177.542 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' ASN . . . . . 0.438 ' HB3' HD12 ' A' ' 126' ' ' ILE . 10.8 m120 -121.1 145.11 48.15 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 120.884 0.373 . . . . 0.0 111.415 -175.935 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' GLN . . . . . 0.465 HE22 ' HA ' ' A' ' 13' ' ' SER . 52.1 tt0 -124.97 123.39 39.77 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.717 178.264 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 40.1 p90 -133.44 142.56 48.37 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 116.653 -0.249 . . . . 0.0 110.922 179.264 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 105.16 10.31 32.22 Favored Glycine 0 CA--C 1.52 0.345 0 C-N-CA 120.327 -0.94 . . . . 0.0 112.945 177.164 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.36 171.51 33.52 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.574 -0.822 . . . . 0.0 112.887 179.56 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' SER . . . . . 0.465 ' HA ' HE22 ' A' ' 9' ' ' GLN . 16.4 m -57.8 -26.31 61.78 Favored 'General case' 0 CA--C 1.536 0.426 0 C-N-CA 122.993 0.517 . . . . 0.0 112.061 179.311 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 14.8 m -59.24 -24.76 63.46 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 122.62 0.368 . . . . 0.0 111.695 177.5 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -91.37 144.27 29.47 Favored Pre-proline 0 C--N 1.324 -0.51 0 CA-C-N 116.75 -0.204 . . . . 0.0 110.577 179.515 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -81.13 -176.05 2.95 Favored 'Trans proline' 0 C--O 1.239 0.538 0 C-N-CA 122.657 2.238 . . . . 0.0 112.32 179.397 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 99.1 m95 -87.22 128.8 35.14 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.213 -0.449 . . . . 0.0 109.908 179.64 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 34.0 m-80 -113.65 110.74 20.69 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.384 -177.093 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 73.1 tt0 -73.35 121.29 20.2 Favored 'General case' 0 C--N 1.317 -0.837 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 177.084 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -134.68 32.59 2.59 Favored Glycine 0 N--CA 1.447 -0.624 0 C-N-CA 119.792 -1.194 . . . . 0.0 112.967 -178.634 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' GLY . . . . . 0.419 ' HA3' ' HB2' ' A' ' 94' ' ' SER . . . 136.99 -167.22 24.71 Favored Glycine 0 N--CA 1.444 -0.821 0 C-N-CA 120.103 -1.046 . . . . 0.0 112.817 178.104 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 7.1 pt20 -147.84 153.9 39.75 Favored 'General case' 0 C--N 1.316 -0.879 0 C-N-CA 122.236 0.214 . . . . 0.0 110.543 -179.715 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' TRP . . . . . 0.509 ' CG ' HG21 ' A' ' 6' ' ' VAL . 38.4 m0 -126.82 177.04 6.84 Favored 'General case' 0 N--CA 1.47 0.531 0 CA-C-N 116.343 -0.389 . . . . 0.0 110.347 -175.623 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.459 ' HB3' HG12 ' A' ' 91' ' ' ILE . 83.7 tt0 -124.61 114.44 19.38 Favored 'General case' 0 CA--C 1.505 -0.768 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.031 174.74 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 98.2 mt -124.38 132.83 70.77 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.878 0 CA-C-N 115.446 -0.797 . . . . 0.0 109.632 -178.294 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 87.75 55.21 2.33 Favored Glycine 0 N--CA 1.447 -0.606 0 C-N-CA 120.077 -1.059 . . . . 0.0 112.45 178.283 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 36.1 t -61.57 -38.14 86.43 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.575 0.226 . . . . 0.0 110.558 178.993 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 70.4 ttt180 -49.98 -42.61 49.27 Favored 'General case' 0 CA--C 1.542 0.656 0 CA-C-N 116.199 -0.455 . . . . 0.0 112.174 179.501 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 14.9 m 74.16 -42.13 0.5 Allowed 'General case' 0 N--CA 1.48 1.052 0 N-CA-C 114.36 1.244 . . . . 0.0 114.36 175.6 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 3.9 p-10 -74.98 -4.33 37.59 Favored 'General case' 0 N--CA 1.487 1.411 0 CA-C-N 118.378 0.535 . . . . 0.0 111.782 -178.237 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 1.1 tm0? -150.71 119.7 6.68 Favored 'General case' 0 C--N 1.314 -0.968 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.755 178.525 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' ASN . . . . . 0.658 ' OD1' ' HA3' ' A' ' 111' ' ' GLY . 27.0 t-20 -85.59 145.74 27.21 Favored 'General case' 0 CA--C 1.534 0.357 0 CA-C-O 121.667 0.746 . . . . 0.0 111.97 -179.696 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 15.4 t -97.14 130.07 46.29 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.12 0 CA-C-N 115.085 -0.961 . . . . 0.0 110.531 -177.698 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 17.2 m -101.3 -24.52 4.05 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 N-CA-C 112.002 0.371 . . . . 0.0 112.002 -179.599 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.572 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -141.25 146.13 36.45 Favored 'General case' 0 C--N 1.323 -0.551 0 C-N-CA 120.273 -0.571 . . . . 0.0 111.12 179.327 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.438 ' HB ' ' CG2' ' A' ' 105' ' ' VAL . 98.2 mt -142.84 125.53 13.47 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.325 -177.427 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -130.81 113.36 13.98 Favored 'General case' 0 C--N 1.316 -0.869 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 174.898 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.505 HG22 ' HB ' ' A' ' 103' ' ' ILE . 28.7 m -144.73 145.64 20.95 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 C-N-CA 120.89 -0.324 . . . . 0.0 111.214 -175.785 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 79.6 tt0 -141.03 146.22 36.93 Favored 'General case' 0 N--CA 1.45 -0.453 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.163 178.263 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' SER . . . . . 0.557 ' OG ' ' HB ' ' A' ' 101' ' ' VAL . 26.0 p -81.89 144.86 30.69 Favored 'General case' 0 C--N 1.316 -0.864 0 N-CA-C 111.875 0.324 . . . . 0.0 111.875 -179.11 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -91.23 -21.62 34.75 Favored Glycine 0 N--CA 1.449 -0.454 0 N-CA-C 110.744 -0.942 . . . . 0.0 110.744 175.206 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' ASP . . . . . 0.4 ' C ' ' H ' ' A' ' 44' ' ' GLY . 28.2 m-20 -132.91 -150.2 0.4 Allowed 'General case' 0 CA--C 1.514 -0.415 0 N-CA-C 108.917 -0.772 . . . . 0.0 108.917 179.373 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -75.81 34.89 0.12 Allowed 'General case' 0 N--CA 1.471 0.614 0 C-N-CA 122.768 0.427 . . . . 0.0 110.818 178.517 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.42 ' O ' ' HE2' ' A' ' 71' ' ' TYR . . . 90.85 1.81 72.88 Favored Glycine 0 N--CA 1.442 -0.951 0 C-N-CA 121.057 -0.592 . . . . 0.0 112.655 -178.669 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 60.5 tp60 -62.89 -44.81 95.09 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-O 120.971 0.415 . . . . 0.0 110.547 -179.433 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 4.3 t -129.97 122.6 28.8 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.185 176.404 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 81.8 mt -102.48 132.8 48.28 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 116.139 -0.482 . . . . 0.0 109.777 178.782 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 86.1 m-20 -121.34 133.39 55.11 Favored 'General case' 0 C--N 1.314 -0.964 0 N-CA-C 108.963 -0.755 . . . . 0.0 108.963 177.38 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.438 ' HA3' ' HA ' ' A' ' 38' ' ' VAL . . . -173.2 -162.72 25.69 Favored Glycine 0 N--CA 1.436 -1.321 0 C-N-CA 119.367 -1.397 . . . . 0.0 113.243 179.876 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 90.4 m -131.65 130.48 42.16 Favored 'General case' 0 C--N 1.309 -1.176 0 C-N-CA 122.692 0.397 . . . . 0.0 111.4 -179.701 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 43.8 mtp -106.24 145.08 32.04 Favored 'General case' 0 N--CA 1.469 0.49 0 C-N-CA 122.689 0.396 . . . . 0.0 110.161 177.042 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.572 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 36.2 m -123.92 122.35 37.74 Favored 'General case' 0 C--O 1.249 1.076 0 CA-C-O 120.636 0.255 . . . . 0.0 110.64 177.727 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 24.0 m-85 -82.44 161.38 22.46 Favored 'General case' 0 N--CA 1.462 0.142 0 CA-C-N 115.654 -0.703 . . . . 0.0 111.491 -179.468 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -65.46 109.37 2.3 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.932 -0.576 . . . . 0.0 111.661 -179.545 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 83.32 14.93 72.94 Favored Glycine 0 N--CA 1.446 -0.649 0 C-N-CA 120.836 -0.697 . . . . 0.0 113.392 178.371 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 51.1 mt-10 -137.07 167.78 20.87 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.974 0.387 . . . . 0.0 111.513 -178.993 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -78.18 163.1 50.34 Favored Glycine 0 N--CA 1.448 -0.507 0 CA-C-N 115.87 -0.604 . . . . 0.0 113.36 -177.301 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_exo -67.5 142.85 60.78 Favored 'Trans proline' 0 CA--C 1.54 0.781 0 C-N-CA 123.188 2.592 . . . . 0.0 112.749 179.778 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' ILE . . . . . 0.512 ' HB ' ' O ' ' A' ' 76' ' ' GLN . 47.5 pt -127.14 166.0 24.71 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.329 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.818 -179.422 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -73.83 144.09 33.3 Favored Glycine 0 CA--C 1.517 0.217 0 C-N-CA 121.078 -0.582 . . . . 0.0 112.502 -177.852 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 41.5 t80 -130.45 127.8 39.99 Favored 'General case' 0 C--O 1.238 0.499 0 CA-C-O 120.829 0.347 . . . . 0.0 111.091 -178.791 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 67.3 ttp85 -136.32 127.58 28.21 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 175.585 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.436 ' HB2' HG22 ' A' ' 73' ' ' VAL . . . -135.07 146.91 49.38 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 120.565 0.221 . . . . 0.0 111.548 -178.175 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 64.3 m -124.54 129.41 50.55 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.598 178.875 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' LEU . . . . . 0.467 ' HG ' ' H ' ' A' ' 67' ' ' GLY . 56.6 tp -74.58 130.21 39.15 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.879 -178.847 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.427 ' HB2' ' OD1' ' A' ' 68' ' ' ASN . 85.8 mt -84.52 -17.83 37.69 Favored 'General case' 0 CA--C 1.536 0.429 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.077 177.094 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.467 ' H ' ' HG ' ' A' ' 65' ' ' LEU . . . 105.58 -8.99 44.32 Favored Glycine 0 C--O 1.222 -0.638 0 CA-C-N 115.761 -0.654 . . . . 0.0 112.198 178.49 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 68' ' ' ASN . . . . . 0.427 ' OD1' ' HB2' ' A' ' 66' ' ' LEU . 29.7 p-10 -110.85 34.72 3.84 Favored 'General case' 0 C--N 1.316 -0.858 0 CA-C-O 120.921 0.391 . . . . 0.0 110.749 -179.742 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 15.8 m120 66.83 7.99 5.67 Favored 'General case' 0 N--CA 1.484 1.225 0 CA-C-N 115.599 -0.728 . . . . 0.0 111.11 -179.399 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 7.3 m -107.94 133.35 52.4 Favored 'General case' 0 N--CA 1.436 -1.143 0 CA-C-N 115.685 -0.689 . . . . 0.0 109.932 -179.796 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.494 ' CE1' ' HB2' ' A' ' 92' ' ' LEU . 86.4 m-85 -114.8 134.99 54.68 Favored 'General case' 0 C--N 1.308 -1.205 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.654 -179.712 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 71.8 tt0 -86.95 119.98 27.73 Favored 'General case' 0 N--CA 1.442 -0.831 0 N-CA-C 106.967 -1.494 . . . . 0.0 106.967 173.39 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.436 HG22 ' HB2' ' A' ' 63' ' ' ALA . 63.1 t -108.71 134.13 51.61 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.073 0 N-CA-C 112.943 0.72 . . . . 0.0 112.943 -172.835 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.405 ' HG2' ' HA ' ' A' ' 86' ' ' SER . 49.1 mt-10 -131.45 131.91 43.91 Favored 'General case' 0 N--CA 1.441 -0.912 0 CA-C-N 114.6 -1.182 . . . . 0.0 107.93 175.943 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 95.1 m-20 -119.28 160.62 21.87 Favored 'General case' 0 C--N 1.309 -1.18 0 CA-C-O 121.371 0.605 . . . . 0.0 112.257 -175.207 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 76' ' ' GLN . . . . . 0.512 ' O ' ' HB ' ' A' ' 59' ' ' ILE . 59.8 tt0 -118.95 114.26 22.28 Favored 'General case' 0 C--N 1.312 -1.025 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.569 -179.17 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 3.3 p90 -134.83 35.71 3.11 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 120.941 0.401 . . . . 0.0 111.416 -176.615 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -133.49 -6.9 2.56 Favored Glycine 0 C--N 1.318 -0.433 0 C-N-CA 120.225 -0.988 . . . . 0.0 112.742 -178.32 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 127.47 160.43 10.47 Favored Glycine 0 N--CA 1.445 -0.745 0 N-CA-C 109.805 -1.318 . . . . 0.0 109.805 -178.076 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 19.6 m-20 -58.97 -39.98 83.39 Favored 'General case' 0 N--CA 1.474 0.749 0 CA-C-N 117.72 0.76 . . . . 0.0 112.245 -177.114 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 4.7 p -81.24 -5.66 58.01 Favored 'General case' 0 C--N 1.316 -0.85 0 N-CA-C 112.436 0.532 . . . . 0.0 112.436 -177.974 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 82' ' ' ALA . . . . . 0.441 ' HA ' ' HD3' ' A' ' 83' ' ' PRO . . . -83.93 149.21 55.87 Favored Pre-proline 0 C--N 1.321 -0.67 0 CA-C-N 116.755 -0.202 . . . . 0.0 110.995 -178.644 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 83' ' ' PRO . . . . . 0.441 ' HD3' ' HA ' ' A' ' 82' ' ' ALA . 17.7 Cg_exo -67.33 161.31 43.73 Favored 'Trans proline' 0 C--N 1.346 0.443 0 C-N-CA 122.796 2.331 . . . . 0.0 111.939 178.242 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 84' ' ' TRP . . . . . . . . . . . . . 79.2 m95 -80.99 147.12 30.36 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.04 -179.496 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 89.9 m-70 -118.48 147.38 43.68 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.075 179.638 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 86' ' ' SER . . . . . 0.405 ' HA ' ' HG2' ' A' ' 74' ' ' GLU . 13.0 m -62.32 134.47 56.52 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-O 121.224 0.535 . . . . 0.0 111.565 -178.073 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -105.45 -48.5 1.04 Allowed Glycine 0 N--CA 1.441 -0.982 0 CA-C-N 115.451 -0.795 . . . . 0.0 111.463 179.082 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 144.92 -163.79 27.96 Favored Glycine 0 N--CA 1.442 -0.911 0 C-N-CA 120.544 -0.836 . . . . 0.0 112.251 177.535 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 16.5 m120 -104.72 127.16 52.41 Favored 'General case' 0 C--N 1.316 -0.858 0 CA-C-O 120.812 0.339 . . . . 0.0 110.341 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 12.4 m0 -119.7 144.45 47.2 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 179.825 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.482 ' O ' ' HB3' ' A' ' 23' ' ' TRP . 45.5 mm -108.38 113.36 43.72 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.933 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.027 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 92' ' ' LEU . . . . . 0.494 ' HB2' ' CE1' ' A' ' 71' ' ' TYR . 77.9 mt -129.23 81.53 2.03 Favored 'General case' 0 C--O 1.261 1.699 0 CA-C-O 121.47 0.653 . . . . 0.0 111.894 -177.437 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 165.56 99.55 0.14 Allowed Glycine 0 N--CA 1.445 -0.751 0 CA-C-N 115.417 -0.811 . . . . 0.0 111.292 -179.813 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 94' ' ' SER . . . . . 0.419 ' HB2' ' HA3' ' A' ' 21' ' ' GLY . 3.2 p -101.69 -12.54 18.31 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 117.036 0.418 . . . . 0.0 111.844 -177.826 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 95' ' ' ARG . . . . . 0.404 HH12 ' CD ' ' A' ' 123' ' ' GLU . 96.6 mtt180 -83.49 -5.0 59.03 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.438 -0.346 . . . . 0.0 111.339 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 72.3 tt0 71.29 -55.84 0.64 Allowed 'General case' 0 N--CA 1.47 0.553 0 C-N-CA 123.502 0.721 . . . . 0.0 112.724 177.113 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 44.7 m-80 -96.18 14.93 22.36 Favored 'General case' 0 C--N 1.315 -0.919 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.341 -175.309 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 98' ' ' GLN . . . . . 0.478 ' HG2' ' HB3' ' A' ' 120' ' ' TYR . 59.2 tt0 -152.36 115.43 4.66 Favored 'General case' 0 C--N 1.316 -0.883 0 CA-C-O 120.992 0.425 . . . . 0.0 109.944 -177.731 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 76.5 m-20 -78.71 160.97 27.2 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.581 -0.736 . . . . 0.0 111.421 -176.376 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 90.6 t -87.97 133.04 31.58 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.496 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.205 175.252 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 0.557 ' HB ' ' OG ' ' A' ' 40' ' ' SER . 35.3 m -116.03 -28.02 2.39 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 N-CA-C 113.345 0.869 . . . . 0.0 113.345 -176.41 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 102' ' ' ALA . . . . . 0.504 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -146.94 137.66 23.77 Favored 'General case' 0 C--N 1.325 -0.483 0 C-N-CA 120.341 -0.544 . . . . 0.0 111.285 179.237 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.505 ' HB ' HG22 ' A' ' 38' ' ' VAL . 91.5 mt -133.85 127.91 52.88 Favored 'Isoleucine or valine' 0 C--O 1.242 0.699 0 CA-C-N 116.354 -0.384 . . . . 0.0 110.608 179.011 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 48.9 t-20 -126.31 99.48 5.88 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 175.258 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.438 ' CG2' ' HB ' ' A' ' 36' ' ' ILE . 19.5 m -137.92 141.11 39.5 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 N-CA-C 112.546 0.573 . . . . 0.0 112.546 -176.925 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 70.4 tt0 -142.14 138.02 31.32 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.705 -0.679 . . . . 0.0 109.583 177.466 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 28.8 t -140.7 142.24 34.89 Favored 'General case' 0 N--CA 1.448 -0.529 0 CA-C-O 121.038 0.447 . . . . 0.0 111.801 -178.682 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -107.97 9.99 37.17 Favored Glycine 0 N--CA 1.443 -0.846 0 N-CA-C 110.759 -0.936 . . . . 0.0 110.759 175.361 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 20.5 m-20 -91.64 14.03 16.3 Favored 'General case' 0 N--CA 1.466 0.348 0 C-N-CA 122.909 0.484 . . . . 0.0 110.401 -177.829 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 12.4 m-20 63.37 30.88 15.45 Favored 'General case' 0 N--CA 1.471 0.612 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.741 -177.554 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 111' ' ' GLY . . . . . 0.658 ' HA3' ' OD1' ' A' ' 32' ' ' ASN . . . 89.03 7.11 70.79 Favored Glycine 0 N--CA 1.449 -0.456 0 CA-C-N 115.654 -0.703 . . . . 0.0 114.273 175.271 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 52.9 tt0 -65.21 -47.85 75.45 Favored 'General case' 0 C--O 1.237 0.438 0 CA-C-N 117.438 0.619 . . . . 0.0 110.198 177.67 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 113' ' ' THR . . . . . 0.438 ' HA ' ' O ' ' A' ' 130' ' ' GLY . 2.0 p -134.18 118.3 17.5 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-N 115.492 -0.776 . . . . 0.0 111.037 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -95.33 122.29 37.89 Favored 'General case' 0 C--N 1.319 -0.754 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.273 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 93.4 m-20 -123.42 148.6 45.98 Favored 'General case' 0 C--N 1.312 -1.036 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.703 -178.71 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 160.66 -135.29 3.95 Favored Glycine 0 N--CA 1.438 -1.184 0 C-N-CA 120.362 -0.923 . . . . 0.0 112.775 177.986 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 25.8 p -133.28 156.77 46.97 Favored 'General case' 0 C--N 1.316 -0.885 0 C-N-CA 122.858 0.463 . . . . 0.0 109.962 -178.532 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 11.3 ptm -151.4 157.61 42.64 Favored 'General case' 0 C--N 1.312 -1.046 0 CA-C-O 120.614 0.245 . . . . 0.0 110.822 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 119' ' ' THR . . . . . 0.504 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 38.0 m -132.51 131.02 41.18 Favored 'General case' 0 C--O 1.249 1.079 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.041 179.717 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 120' ' ' TYR . . . . . 0.478 ' HB3' ' HG2' ' A' ' 98' ' ' GLN . 78.3 m-85 -93.72 166.89 11.99 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.934 -0.575 . . . . 0.0 109.961 176.644 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -63.22 118.29 7.76 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.675 -0.239 . . . . 0.0 110.731 178.837 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 68.2 34.63 81.2 Favored Glycine 0 C--N 1.333 0.395 0 C-N-CA 120.819 -0.705 . . . . 0.0 111.613 -178.997 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 123' ' ' GLU . . . . . 0.427 ' CB ' ' HB2' ' A' ' 120' ' ' TYR . 31.6 tp10 -132.61 163.24 29.34 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 -176.723 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -94.41 159.21 23.2 Favored Glycine 0 N--CA 1.442 -0.947 0 N-CA-C 110.553 -1.019 . . . . 0.0 110.553 176.24 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_endo -62.52 132.78 39.58 Favored 'Trans proline' 0 C--O 1.237 0.464 0 C-N-CA 122.177 1.918 . . . . 0.0 111.885 -179.782 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 126' ' ' ILE . . . . . 0.438 HD12 ' HB3' ' A' ' 8' ' ' ASN . 40.9 pt -132.79 166.19 30.1 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 CA-C-N 115.932 -0.577 . . . . 0.0 110.464 -179.742 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -70.61 141.49 33.6 Favored Glycine 0 C--O 1.242 0.615 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.176 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 82.7 t80 -123.67 135.57 53.98 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-O 120.824 0.345 . . . . 0.0 111.188 -178.725 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 62.4 tttm -139.3 118.93 13.06 Favored 'General case' 0 N--CA 1.445 -0.713 0 CA-C-N 115.497 -0.774 . . . . 0.0 109.313 177.178 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 130' ' ' GLY . . . . . 0.487 ' HA2' ' O ' ' A' ' 5' ' ' ASN . . . -125.26 137.94 10.67 Favored Glycine 0 N--CA 1.445 -0.737 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.054 179.67 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 59.4 m -123.63 129.69 51.53 Favored 'General case' 0 C--N 1.313 -0.98 0 CA-C-N 116.853 0.327 . . . . 0.0 110.817 -179.303 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -67.45 117.7 9.78 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-O 121.186 0.517 . . . . 0.0 111.429 -178.163 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 15.0 m . . . . . 0 C--O 1.25 1.1 0 CA-C-N 115.707 -0.678 . . . . 0.0 110.612 176.229 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.807 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 2.2 tm? -89.99 126.71 35.85 Favored 'General case' 0 C--N 1.315 -0.917 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -178.987 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' TYR . . . . . 0.474 ' CE1' ' HB ' ' A' ' 25' ' ' ILE . 58.0 m-85 -114.53 141.46 47.7 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.225 -178.796 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 23.4 t-20 -93.72 137.85 32.55 Favored 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 106.719 -1.586 . . . . 0.0 106.719 174.918 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.435 HG21 ' CG ' ' A' ' 23' ' ' TRP . 59.0 t -114.48 128.31 71.58 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.894 0 N-CA-C 113.287 0.847 . . . . 0.0 113.287 -173.679 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -118.31 133.05 56.22 Favored 'General case' 0 C--O 1.245 0.833 0 CA-C-N 114.748 -1.114 . . . . 0.0 109.283 176.907 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 70.8 m-20 -110.32 135.38 51.15 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.076 -177.411 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' GLN . . . . . 0.434 ' OE1' ' HA ' ' A' ' 13' ' ' SER . 36.0 tt0 -120.45 114.23 21.48 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 120.988 0.423 . . . . 0.0 110.448 175.713 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 2.4 p90 -112.12 175.66 5.34 Favored 'General case' 0 C--N 1.311 -1.097 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.487 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 69.87 -71.34 0.56 Allowed Glycine 0 CA--C 1.529 0.948 0 CA-C-N 115.706 -0.679 . . . . 0.0 112.956 -176.847 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -165.08 168.3 39.16 Favored Glycine 0 N--CA 1.446 -0.684 0 C-N-CA 121.014 -0.612 . . . . 0.0 112.304 -178.458 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' SER . . . . . 0.434 ' HA ' ' OE1' ' A' ' 9' ' ' GLN . 28.2 t -62.85 -19.55 64.23 Favored 'General case' 0 CA--C 1.54 0.563 0 N-CA-C 112.329 0.492 . . . . 0.0 112.329 -178.669 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 30.4 p -77.47 -6.83 54.92 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.873 0.368 . . . . 0.0 111.76 179.411 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -86.69 149.36 48.35 Favored Pre-proline 0 C--N 1.323 -0.584 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.548 179.131 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_endo -69.14 162.43 41.8 Favored 'Trans proline' 0 C--O 1.237 0.458 0 C-N-CA 122.529 2.153 . . . . 0.0 112.086 179.071 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 98.3 m95 -85.65 124.26 31.98 Favored 'General case' 0 C--N 1.317 -0.837 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 179.695 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 92.4 m-20 -111.44 113.42 25.86 Favored 'General case' 0 C--N 1.309 -1.154 0 CA-C-N 116.332 -0.394 . . . . 0.0 111.059 -175.89 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 80.6 tt0 -71.97 122.43 20.84 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-N 115.826 -0.625 . . . . 0.0 109.611 179.864 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -137.69 25.6 2.95 Favored Glycine 0 N--CA 1.446 -0.679 0 C-N-CA 120.29 -0.957 . . . . 0.0 112.559 -177.93 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' GLY . . . . . 0.414 ' HA3' ' HB3' ' A' ' 94' ' ' SER . . . 156.63 -172.39 34.33 Favored Glycine 0 N--CA 1.433 -1.524 0 C-N-CA 119.961 -1.114 . . . . 0.0 112.651 179.205 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 13.2 pt20 -150.34 145.43 26.13 Favored 'General case' 0 C--N 1.31 -1.11 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 179.299 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' TRP . . . . . 0.435 ' CG ' HG21 ' A' ' 6' ' ' VAL . 43.7 m0 -122.47 159.45 27.61 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.749 -177.172 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.409 ' H ' ' HB ' ' A' ' 91' ' ' ILE . 79.3 tt0 -118.05 119.71 35.59 Favored 'General case' 0 C--N 1.306 -1.316 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 176.079 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.474 ' HB ' ' CE1' ' A' ' 4' ' ' TYR . 98.9 mt -127.87 135.14 63.76 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-N 115.432 -0.804 . . . . 0.0 109.934 -175.011 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 89.07 71.83 1.27 Allowed Glycine 0 N--CA 1.435 -1.427 0 C-N-CA 119.718 -1.229 . . . . 0.0 111.944 -179.878 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' SER . . . . . 0.457 ' OG ' ' HA3' ' A' ' 88' ' ' GLY . 7.5 t -59.44 -39.38 83.39 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 176.829 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 73.3 ttt180 -82.22 113.03 19.77 Favored 'General case' 0 N--CA 1.439 -1.013 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 174.599 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 30.8 m -78.3 -13.71 59.73 Favored 'General case' 0 C--N 1.315 -0.892 0 CA-C-O 120.965 0.412 . . . . 0.0 111.777 -174.963 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 23.2 t70 -72.0 -33.43 68.09 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.403 0.62 . . . . 0.0 110.987 178.865 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 22.2 mm-40 -126.17 120.62 30.57 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.63 -0.713 . . . . 0.0 111.012 -177.369 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' ASN . . . . . 0.546 ' ND2' ' HA3' ' A' ' 111' ' ' GLY . 64.2 t30 -95.04 154.41 17.19 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.532 -0.304 . . . . 0.0 110.235 178.943 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.451 ' HA ' ' HA ' ' A' ' 53' ' ' TYR . 62.0 t -96.22 133.53 37.15 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.541 -176.457 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 28.4 m -113.49 -14.54 10.83 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.151 0 N-CA-C 112.299 0.481 . . . . 0.0 112.299 178.891 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.513 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -147.49 138.96 23.86 Favored 'General case' 0 C--N 1.323 -0.565 0 C-N-CA 120.391 -0.524 . . . . 0.0 111.487 179.552 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.417 ' HB ' HG22 ' A' ' 105' ' ' VAL . 88.8 mt -141.42 123.3 13.97 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-N 116.058 -0.519 . . . . 0.0 109.912 -179.6 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -128.97 109.39 11.19 Favored 'General case' 0 C--N 1.309 -1.188 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 174.055 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.441 HG11 ' CD1' ' A' ' 61' ' ' PHE . 18.4 m -146.49 148.13 17.28 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 C-N-CA 120.674 -0.41 . . . . 0.0 112.012 -174.356 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 66.7 tt0 -138.42 140.54 39.36 Favored 'General case' 0 C--N 1.315 -0.899 0 CA-C-N 115.214 -0.903 . . . . 0.0 108.619 176.293 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' SER . . . . . 0.431 ' HA ' ' O ' ' A' ' 46' ' ' THR . 94.7 p -81.55 153.8 26.58 Favored 'General case' 0 C--N 1.308 -1.216 0 CA-C-O 120.921 0.391 . . . . 0.0 111.946 -176.84 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -97.43 -57.14 1.07 Allowed Glycine 0 N--CA 1.435 -1.393 0 CA-C-N 115.765 -0.652 . . . . 0.0 111.767 176.934 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -113.54 98.4 7.04 Favored 'General case' 0 CA--C 1.533 0.315 0 N-CA-C 111.924 0.342 . . . . 0.0 111.924 -178.477 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 14.1 m-20 47.76 34.53 3.88 Favored 'General case' 0 N--CA 1.492 1.667 0 N-CA-C 114.454 1.279 . . . . 0.0 114.454 175.222 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.418 ' HA2' ' CB ' ' A' ' 40' ' ' SER . . . 80.11 0.65 86.45 Favored Glycine 0 C--N 1.319 -0.41 0 C-N-CA 120.438 -0.887 . . . . 0.0 113.793 178.196 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 59.9 mt-30 -77.4 -30.45 53.59 Favored 'General case' 0 CA--C 1.513 -0.458 0 CA-C-N 117.398 0.599 . . . . 0.0 111.331 178.999 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' THR . . . . . 0.431 ' O ' ' HA ' ' A' ' 40' ' ' SER . 5.1 p -122.83 107.02 11.42 Favored 'General case' 0 C--N 1.308 -1.229 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.999 -179.472 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 47' ' ' LEU . . . . . 0.512 ' HB2' ' HB3' ' A' ' 63' ' ' ALA . 90.8 mt -89.91 129.16 36.3 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 177.534 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 15.4 m120 -126.65 136.99 53.23 Favored 'General case' 0 C--N 1.318 -0.804 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 171.03 -153.32 20.47 Favored Glycine 0 N--CA 1.443 -0.857 0 C-N-CA 118.876 -1.63 . . . . 0.0 114.057 178.813 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 52.4 m -127.43 131.92 50.16 Favored 'General case' 0 C--N 1.315 -0.899 0 C-N-CA 123.14 0.576 . . . . 0.0 109.455 -178.002 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' MET . . . . . 0.534 ' HE3' HD11 ' A' ' 59' ' ' ILE . 15.5 tmm? -128.52 139.8 52.13 Favored 'General case' 0 C--N 1.315 -0.927 0 C-N-CA 121.31 -0.156 . . . . 0.0 110.65 -178.842 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.513 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 33.8 m -124.24 128.73 49.61 Favored 'General case' 0 C--O 1.253 1.286 0 CA-C-O 121.135 0.493 . . . . 0.0 111.773 -176.718 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 53' ' ' TYR . . . . . 0.451 ' HA ' ' HA ' ' A' ' 33' ' ' VAL . 78.4 m-85 -84.76 163.73 18.96 Favored 'General case' 0 N--CA 1.462 0.147 0 CA-C-N 115.532 -0.758 . . . . 0.0 110.951 177.958 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -58.06 109.14 0.69 Allowed 'General case' 0 N--CA 1.469 0.478 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.957 -179.228 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 72.81 18.45 78.87 Favored Glycine 0 C--O 1.225 -0.414 0 C-N-CA 121.133 -0.556 . . . . 0.0 113.054 178.007 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' GLU . . . . . 0.432 ' HB2' ' HB2' ' A' ' 53' ' ' TYR . 70.2 mm-40 -117.76 174.19 6.32 Favored 'General case' 0 C--N 1.317 -0.817 0 N-CA-C 110.197 -0.297 . . . . 0.0 110.197 -179.062 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -86.71 157.03 29.5 Favored Glycine 0 N--CA 1.444 -0.827 0 C-N-CA 120.685 -0.769 . . . . 0.0 111.733 178.418 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -67.86 141.23 53.19 Favored 'Trans proline' 0 C--O 1.234 0.286 0 C-N-CA 122.64 2.227 . . . . 0.0 111.986 179.497 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' ILE . . . . . 0.534 HD11 ' HE3' ' A' ' 51' ' ' MET . 39.6 pt -131.33 165.53 31.33 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.852 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.678 179.92 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -72.83 136.84 23.43 Favored Glycine 0 N--CA 1.447 -0.598 0 C-N-CA 120.889 -0.672 . . . . 0.0 111.499 -179.634 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.441 ' CD1' HG11 ' A' ' 38' ' ' VAL . 47.9 t80 -121.48 124.85 45.43 Favored 'General case' 0 C--N 1.313 -0.999 0 CA-C-O 120.722 0.296 . . . . 0.0 110.943 -178.462 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 62' ' ' ARG . . . . . 0.494 ' HA ' ' O ' ' A' ' 47' ' ' LEU . 62.0 ttp180 -135.65 129.59 33.03 Favored 'General case' 0 N--CA 1.445 -0.691 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 173.824 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.512 ' HB3' ' HB2' ' A' ' 47' ' ' LEU . . . -127.65 136.72 52.0 Favored 'General case' 0 C--N 1.311 -1.077 0 CA-C-O 120.667 0.27 . . . . 0.0 110.584 -179.836 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 28.2 m -114.16 124.68 52.66 Favored 'General case' 0 N--CA 1.435 -1.199 0 CA-C-N 116.035 -0.53 . . . . 0.0 109.861 177.914 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 65' ' ' LEU . . . . . 0.538 HD11 ' O ' ' A' ' 67' ' ' GLY . 2.7 tm? -63.25 129.24 39.43 Favored 'General case' 0 C--N 1.31 -1.151 0 CA-C-N 115.604 -0.725 . . . . 0.0 110.945 -179.34 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 96.5 mt -95.74 -40.42 9.37 Favored 'General case' 0 C--O 1.225 -0.199 0 CA-C-O 121.103 0.478 . . . . 0.0 111.094 178.505 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.538 ' O ' HD11 ' A' ' 65' ' ' LEU . . . -140.27 -79.93 0.06 OUTLIER Glycine 0 CA--C 1.499 -0.964 0 N-CA-C 110.766 -0.933 . . . . 0.0 110.766 -178.3 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 65.1 m-80 -146.01 -71.32 0.25 Allowed 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 107.527 -1.286 . . . . 0.0 107.527 174.389 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 69' ' ' ASN . . . . . 0.422 ' HB3' HG23 ' A' ' 91' ' ' ILE . 84.4 m-20 -67.77 -39.87 84.06 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.652 -0.704 . . . . 0.0 111.458 176.501 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 23.3 t -81.48 130.45 35.05 Favored 'General case' 0 CA--C 1.538 0.492 0 N-CA-C 113.025 0.75 . . . . 0.0 113.025 -174.334 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.452 ' OH ' ' HB3' ' A' ' 99' ' ' ASN . 56.9 m-85 -127.66 145.21 50.96 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.106 -0.952 . . . . 0.0 109.919 177.08 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -105.43 125.19 50.7 Favored 'General case' 0 C--N 1.312 -1.053 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 174.401 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.456 HG22 ' HB2' ' A' ' 63' ' ' ALA . 62.2 t -111.03 137.74 42.21 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.162 0 N-CA-C 113.225 0.824 . . . . 0.0 113.225 -171.914 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 63.9 mt-10 -126.53 129.74 49.22 Favored 'General case' 0 N--CA 1.442 -0.871 0 CA-C-N 114.578 -1.192 . . . . 0.0 108.257 176.344 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' ASN . . . . . 0.509 ' HB3' HD12 ' A' ' 59' ' ' ILE . 89.5 m-20 -110.12 151.51 27.16 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-O 121.167 0.508 . . . . 0.0 111.693 -178.033 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 76' ' ' GLN . . . . . 0.463 ' HB2' ' CE3' ' A' ' 84' ' ' TRP . 62.3 tt0 -117.19 121.04 40.11 Favored 'General case' 0 C--N 1.311 -1.071 0 CA-C-N 115.359 -0.837 . . . . 0.0 110.113 -178.725 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 4.7 p90 -142.7 161.78 37.18 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.855 -179.241 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 99.83 -12.22 60.91 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 121.026 -0.607 . . . . 0.0 112.437 178.715 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 140.53 160.1 8.18 Favored Glycine 0 N--CA 1.441 -1.029 0 N-CA-C 111.087 -0.805 . . . . 0.0 111.087 179.388 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 24.7 m-20 -62.75 -35.04 78.49 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-O 120.828 0.347 . . . . 0.0 111.617 -179.319 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 5.1 m -72.53 -12.9 61.26 Favored 'General case' 0 CA--C 1.54 0.592 0 CA-C-N 116.228 -0.442 . . . . 0.0 112.003 -179.709 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -75.96 147.83 80.99 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-O 120.518 0.199 . . . . 0.0 111.217 -178.424 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -72.14 -178.44 3.23 Favored 'Trans proline' 0 C--O 1.24 0.602 0 C-N-CA 122.733 2.289 . . . . 0.0 112.289 178.762 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 84' ' ' TRP . . . . . 0.463 ' CE3' ' HB2' ' A' ' 76' ' ' GLN . 92.3 m95 -91.64 139.66 30.47 Favored 'General case' 0 C--N 1.319 -0.718 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 -179.358 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 93.7 m-70 -115.48 148.46 39.43 Favored 'General case' 0 C--N 1.315 -0.922 0 N-CA-C 109.689 -0.486 . . . . 0.0 109.689 -179.32 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 13.2 p -64.59 135.36 55.89 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-O 120.778 0.323 . . . . 0.0 110.856 -178.94 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -110.37 -52.36 0.6 Allowed Glycine 0 N--CA 1.442 -0.906 0 C-N-CA 120.52 -0.848 . . . . 0.0 111.958 -179.549 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.457 ' HA3' ' OG ' ' A' ' 27' ' ' SER . . . 147.72 -162.87 28.77 Favored Glycine 0 N--CA 1.444 -0.824 0 C-N-CA 120.212 -0.994 . . . . 0.0 112.822 179.698 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 17.1 m120 -104.08 134.9 46.57 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 120.832 0.349 . . . . 0.0 110.953 -178.557 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 11.8 m0 -127.38 150.8 49.45 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.929 -0.578 . . . . 0.0 109.714 179.002 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.422 HG23 ' HB3' ' A' ' 69' ' ' ASN . 50.1 mm -113.93 110.03 30.67 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.927 0 N-CA-C 109.021 -0.733 . . . . 0.0 109.021 177.729 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 92' ' ' LEU . . . . . 0.41 ' O ' HG13 ' A' ' 100' ' ' VAL . 78.0 mt -132.84 75.8 1.65 Allowed 'General case' 0 C--O 1.26 1.649 0 CA-C-O 121.893 0.854 . . . . 0.0 111.835 -177.325 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 93' ' ' GLY . . . . . 0.4 ' O ' ' HB2' ' A' ' 94' ' ' SER . . . -150.15 -91.64 0.09 OUTLIER Glycine 0 N--CA 1.448 -0.504 0 CA-C-N 115.399 -0.819 . . . . 0.0 112.9 -178.901 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 94' ' ' SER . . . . . 0.414 ' HB3' ' HA3' ' A' ' 21' ' ' GLY . 69.6 m 78.29 8.56 2.26 Favored 'General case' 0 N--CA 1.482 1.13 0 C-N-CA 124.092 0.957 . . . . 0.0 112.181 -177.378 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 95' ' ' ARG . . . . . 0.492 ' HB2' ' O ' ' A' ' 98' ' ' GLN . 95.9 mtt180 -137.6 145.03 42.29 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 116.083 -0.508 . . . . 0.0 109.725 177.557 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 78.1 tt0 -70.44 -45.64 65.44 Favored 'General case' 0 C--N 1.315 -0.906 0 N-CA-C 112.622 0.601 . . . . 0.0 112.622 -172.729 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 7.2 p30 -117.41 20.89 13.4 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.26 0.552 . . . . 0.0 111.207 -179.269 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 98' ' ' GLN . . . . . 0.492 ' O ' ' HB2' ' A' ' 95' ' ' ARG . 90.5 mt-30 -139.78 115.63 10.22 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-N 115.658 -0.701 . . . . 0.0 111.12 179.635 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 99' ' ' ASN . . . . . 0.452 ' HB3' ' OH ' ' A' ' 71' ' ' TYR . 85.2 m-20 -108.49 176.19 5.2 Favored 'General case' 0 C--N 1.306 -1.309 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 179.575 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.41 HG13 ' O ' ' A' ' 92' ' ' LEU . 33.6 m -78.22 133.69 29.78 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.668 0 C-N-CA 119.565 -0.854 . . . . 0.0 111.352 179.348 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 35.4 m -113.92 -31.09 2.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.165 177.243 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 102' ' ' ALA . . . . . 0.573 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -148.18 133.32 18.32 Favored 'General case' 0 CA--C 1.511 -0.546 0 C-N-CA 120.688 -0.405 . . . . 0.0 110.475 178.003 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 89.6 mt -130.16 125.1 59.39 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.785 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.961 179.78 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 10.0 t30 -126.19 100.38 6.29 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.704 -0.68 . . . . 0.0 109.574 175.631 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.417 HG22 ' HB ' ' A' ' 36' ' ' ILE . 27.7 m -141.46 140.96 30.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-N 115.983 -0.553 . . . . 0.0 112.326 -176.121 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 61.5 mt-10 -143.66 149.53 37.39 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.2 -0.909 . . . . 0.0 109.606 177.111 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 107' ' ' SER . . . . . 0.409 ' HB2' HD23 ' A' ' 114' ' ' LEU . 46.3 t -128.66 144.62 51.2 Favored 'General case' 0 C--N 1.313 -0.994 0 CA-C-O 120.966 0.412 . . . . 0.0 111.508 -178.842 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -91.63 -4.46 67.76 Favored Glycine 0 N--CA 1.439 -1.16 0 N-CA-C 110.656 -0.978 . . . . 0.0 110.656 175.161 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 35.4 m-20 -98.28 -167.62 1.53 Allowed 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 -179.528 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 110' ' ' ASP . . . . . 0.42 ' OD1' ' HG3' ' A' ' 112' ' ' GLN . 7.3 p-10 -93.86 21.22 6.79 Favored 'General case' 0 C--N 1.311 -1.082 0 CA-C-O 121.291 0.567 . . . . 0.0 109.864 178.041 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 111' ' ' GLY . . . . . 0.546 ' HA3' ' ND2' ' A' ' 32' ' ' ASN . . . 105.34 9.77 32.99 Favored Glycine 0 C--O 1.22 -0.753 0 C-N-CA 120.761 -0.733 . . . . 0.0 113.466 -178.525 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 112' ' ' GLN . . . . . 0.431 ' HA ' HD12 ' A' ' 132' ' ' LEU . 98.3 mt-30 -64.72 -43.8 92.26 Favored 'General case' 0 C--O 1.242 0.66 0 CA-C-N 117.439 0.62 . . . . 0.0 110.681 178.89 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 81.8 p -136.48 145.76 45.52 Favored 'General case' 0 N--CA 1.444 -0.758 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.937 176.445 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 114' ' ' LEU . . . . . 0.409 HD23 ' HB2' ' A' ' 107' ' ' SER . 88.8 mt -116.54 129.75 56.36 Favored 'General case' 0 C--N 1.315 -0.922 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 179.312 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 84.5 m-20 -120.5 142.87 48.9 Favored 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 110.318 -0.253 . . . . 0.0 110.318 -178.916 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 163.77 -141.19 6.94 Favored Glycine 0 N--CA 1.444 -0.8 0 C-N-CA 119.385 -1.388 . . . . 0.0 113.426 176.586 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 3.0 p -130.91 151.02 51.79 Favored 'General case' 0 C--N 1.311 -1.1 0 C-N-CA 123.056 0.542 . . . . 0.0 110.209 -178.295 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 118' ' ' MET . . . . . 0.624 ' SD ' ' HD1' ' A' ' 128' ' ' PHE . 20.0 ptm -136.96 144.5 43.42 Favored 'General case' 0 C--N 1.31 -1.128 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.253 -177.792 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 119' ' ' THR . . . . . 0.573 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 24.5 m -128.8 126.47 39.95 Favored 'General case' 0 C--O 1.252 1.22 0 CA-C-O 120.737 0.303 . . . . 0.0 110.535 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 42.1 m-85 -98.39 162.62 13.07 Favored 'General case' 0 CA--C 1.509 -0.631 0 CA-C-N 115.616 -0.72 . . . . 0.0 111.167 179.563 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -59.17 114.91 2.85 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 115.489 -0.778 . . . . 0.0 111.169 176.842 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 78.04 17.49 78.26 Favored Glycine 0 N--CA 1.451 -0.354 0 CA-C-N 115.787 -0.642 . . . . 0.0 114.014 177.759 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 69.2 tt0 -142.26 144.02 33.12 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 117.47 0.635 . . . . 0.0 110.566 179.837 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -69.03 163.77 50.48 Favored Glycine 0 CA--C 1.522 0.53 0 CA-C-N 116.141 -0.481 . . . . 0.0 113.246 -177.436 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 125' ' ' PRO . . . . . 0.492 ' HA ' ' O ' ' A' ' 118' ' ' MET . 23.7 Cg_exo -63.46 138.72 66.88 Favored 'Trans proline' 0 C--N 1.347 0.492 0 C-N-CA 122.784 2.322 . . . . 0.0 112.887 -178.752 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 41.0 pt -131.04 167.75 25.4 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.806 0 CA-C-N 115.532 -0.758 . . . . 0.0 109.675 177.467 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -69.0 136.96 29.31 Favored Glycine 0 C--O 1.236 0.281 0 C-N-CA 120.994 -0.622 . . . . 0.0 112.354 -178.754 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 128' ' ' PHE . . . . . 0.624 ' HD1' ' SD ' ' A' ' 118' ' ' MET . 82.4 t80 -118.59 133.8 55.59 Favored 'General case' 0 C--O 1.249 1.072 0 CA-C-O 120.963 0.411 . . . . 0.0 111.526 -178.564 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 64.1 tttm -136.52 111.44 8.86 Favored 'General case' 0 N--CA 1.442 -0.861 0 CA-C-N 115.562 -0.745 . . . . 0.0 109.782 175.678 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -104.87 133.01 11.35 Favored Glycine 0 N--CA 1.441 -0.997 0 N-CA-C 110.94 -0.864 . . . . 0.0 110.94 178.314 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 25.7 m -128.97 132.9 47.63 Favored 'General case' 0 C--N 1.311 -1.102 0 CA-C-N 116.944 0.372 . . . . 0.0 110.092 -178.754 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 132' ' ' LEU . . . . . 0.431 HD12 ' HA ' ' A' ' 112' ' ' GLN . 74.0 mt -59.81 130.52 47.19 Favored 'General case' 0 N--CA 1.467 0.396 0 C-N-CA 120.301 -0.559 . . . . 0.0 110.799 177.726 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 52.8 m . . . . . 0 C--O 1.247 0.929 0 CA-C-O 118.512 -0.756 . . . . 0.0 110.734 -179.196 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.741 0 CA-C-O 120.897 0.38 . . . . 0.0 110.749 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 3.2 tm? -92.68 130.39 38.32 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.064 179.313 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 81.4 m-85 -119.27 144.9 46.53 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.954 -0.566 . . . . 0.0 111.777 -179.242 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' ASN . . . . . 0.512 ' O ' ' HA2' ' A' ' 130' ' ' GLY . 11.5 t-20 -96.32 136.03 37.36 Favored 'General case' 0 C--N 1.313 -0.988 0 N-CA-C 107.706 -1.22 . . . . 0.0 107.706 179.269 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 78.7 t -116.56 127.11 74.25 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 CA-C-O 121.529 0.681 . . . . 0.0 112.703 -174.59 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.448 ' HB2' ' HB3' ' A' ' 129' ' ' LYS . 45.4 mt-10 -116.58 138.8 51.14 Favored 'General case' 0 N--CA 1.44 -0.926 0 CA-C-N 114.949 -1.023 . . . . 0.0 108.286 175.275 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 90.7 m-20 -116.29 139.3 50.52 Favored 'General case' 0 C--N 1.306 -1.32 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.545 -178.442 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' GLN . . . . . 0.506 ' HB2' ' CE3' ' A' ' 17' ' ' TRP . 54.4 tt0 -129.36 124.3 33.9 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.703 -0.68 . . . . 0.0 109.767 179.33 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 20.1 p90 -122.99 136.84 55.01 Favored 'General case' 0 C--N 1.307 -1.262 0 CA-C-O 120.849 0.357 . . . . 0.0 111.222 179.213 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 111.17 -75.49 0.21 Allowed Glycine 0 N--CA 1.445 -0.752 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.851 -179.653 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -162.34 163.65 35.13 Favored Glycine 0 N--CA 1.449 -0.438 0 N-CA-C 111.617 -0.593 . . . . 0.0 111.617 179.725 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' SER . . . . . 0.434 ' HA ' ' NE2' ' A' ' 9' ' ' GLN . 12.1 m -64.07 -19.06 64.97 Favored 'General case' 0 CA--C 1.536 0.44 0 N-CA-C 112.279 0.474 . . . . 0.0 112.279 -179.002 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 35.3 p -72.42 -18.22 61.73 Favored 'General case' 0 CA--C 1.539 0.536 0 CA-C-O 120.988 0.423 . . . . 0.0 111.231 178.799 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -80.66 155.0 73.73 Favored Pre-proline 0 CA--C 1.533 0.317 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.695 -179.755 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 66.6 Cg_endo -72.11 158.68 51.7 Favored 'Trans proline' 0 C--O 1.236 0.393 0 C-N-CA 122.47 2.113 . . . . 0.0 112.783 178.701 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' TRP . . . . . 0.506 ' CE3' ' HB2' ' A' ' 9' ' ' GLN . 94.4 m95 -89.22 138.6 31.28 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.408 179.624 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 90.5 m-20 -124.08 129.9 51.64 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 109.141 -0.689 . . . . 0.0 109.141 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 42.6 tt0 -61.37 128.04 34.43 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-O 120.962 0.41 . . . . 0.0 111.299 -178.305 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -108.7 -0.63 32.38 Favored Glycine 0 N--CA 1.448 -0.52 0 CA-C-N 115.469 -0.787 . . . . 0.0 112.805 -178.821 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 130.27 -150.11 19.09 Favored Glycine 0 N--CA 1.443 -0.881 0 C-N-CA 120.335 -0.936 . . . . 0.0 112.249 -179.83 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 23.5 pt20 -145.5 138.02 25.83 Favored 'General case' 0 C--N 1.319 -0.738 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.771 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 45.3 m0 -117.14 155.23 29.69 Favored 'General case' 0 C--N 1.318 -0.761 0 CA-C-O 120.89 0.376 . . . . 0.0 111.159 -178.429 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -109.11 112.64 24.93 Favored 'General case' 0 C--N 1.317 -0.812 0 N-CA-C 109.511 -0.551 . . . . 0.0 109.511 177.481 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 95.8 mt -130.7 136.82 57.47 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.585 0 CA-C-N 115.203 -0.908 . . . . 0.0 109.762 -178.955 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 91.55 106.81 1.49 Allowed Glycine 0 N--CA 1.442 -0.911 0 C-N-CA 120.208 -0.996 . . . . 0.0 111.966 -179.383 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 13.9 m -111.86 13.58 20.95 Favored 'General case' 0 C--N 1.31 -1.136 0 CA-C-O 121.208 0.528 . . . . 0.0 110.311 -178.699 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 94.7 mtt-85 -137.44 128.17 27.03 Favored 'General case' 0 N--CA 1.445 -0.72 0 CA-C-N 116.004 -0.544 . . . . 0.0 109.967 -177.069 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 34.5 t -76.77 -17.43 59.05 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-O 121.207 0.527 . . . . 0.0 110.215 179.353 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 15.8 m-20 -75.0 -47.56 28.52 Favored 'General case' 0 C--O 1.224 -0.275 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.904 -178.033 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 84.9 mm-40 -128.71 123.19 32.45 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.603 -0.726 . . . . 0.0 111.234 -176.575 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' ASN . . . . . 0.663 ' ND2' ' HA3' ' A' ' 111' ' ' GLY . 62.5 t30 -101.18 161.74 13.39 Favored 'General case' 0 C--N 1.319 -0.751 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 178.348 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 46.6 t -94.69 130.73 43.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-O 120.572 0.225 . . . . 0.0 111.409 -173.771 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 28.7 m -110.59 -18.57 7.5 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.276 0 CA-C-N 116.464 -0.335 . . . . 0.0 111.731 179.224 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.533 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -154.6 149.67 26.88 Favored 'General case' 0 C--O 1.237 0.416 0 C-N-CA 120.563 -0.455 . . . . 0.0 111.685 178.682 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.495 ' HB ' ' CG2' ' A' ' 105' ' ' VAL . 89.9 mt -144.09 123.63 7.84 Favored 'Isoleucine or valine' 0 C--O 1.235 0.308 0 CA-C-N 115.97 -0.559 . . . . 0.0 109.64 -179.743 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 88.9 m-20 -124.82 106.58 10.14 Favored 'General case' 0 C--N 1.313 -1.012 0 N-CA-C 107.767 -1.197 . . . . 0.0 107.767 175.844 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 36.0 m -147.68 149.56 15.32 Favored 'Isoleucine or valine' 0 C--O 1.237 0.436 0 C-N-CA 120.146 -0.622 . . . . 0.0 111.957 -172.757 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 66.7 mt-10 -142.55 149.1 38.63 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.299 -0.864 . . . . 0.0 109.325 175.337 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 20.5 p -73.97 142.62 45.84 Favored 'General case' 0 C--N 1.307 -1.25 0 N-CA-C 112.104 0.409 . . . . 0.0 112.104 -177.444 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -88.62 -42.56 5.73 Favored Glycine 0 N--CA 1.443 -0.841 0 N-CA-C 109.148 -1.581 . . . . 0.0 109.148 174.755 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 48.8 m-20 -105.18 -161.55 0.82 Allowed 'General case' 0 C--N 1.317 -0.836 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 175.045 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -76.17 47.98 0.48 Allowed 'General case' 0 N--CA 1.474 0.766 0 N-CA-C 112.303 0.483 . . . . 0.0 112.303 -178.361 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 91.64 -8.55 78.51 Favored Glycine 0 C--O 1.222 -0.649 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.223 178.969 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 56.1 mt-30 -70.23 -36.23 74.39 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.99 0.424 . . . . 0.0 110.713 178.356 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 22.0 p -122.58 139.4 53.95 Favored 'General case' 0 C--N 1.311 -1.106 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.207 179.66 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' LEU . . . . . 0.435 ' HB2' ' HB3' ' A' ' 63' ' ' ALA . 91.2 mt -125.94 127.05 45.36 Favored 'General case' 0 C--N 1.315 -0.932 0 N-CA-C 108.509 -0.923 . . . . 0.0 108.509 179.865 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 88.9 m-20 -125.3 138.07 54.08 Favored 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 109.376 -0.602 . . . . 0.0 109.376 -179.352 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 173.25 -151.23 13.26 Favored Glycine 0 N--CA 1.443 -0.873 0 C-N-CA 120.078 -1.058 . . . . 0.0 112.558 178.853 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 33.6 p -132.49 146.87 52.25 Favored 'General case' 0 N--CA 1.443 -0.8 0 CA-C-O 121.003 0.43 . . . . 0.0 110.921 179.692 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 40.7 mtp -121.12 156.49 32.18 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.74 177.18 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.533 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 26.8 m -132.1 126.35 33.53 Favored 'General case' 0 C--O 1.247 0.965 0 N-CA-C 110.04 -0.356 . . . . 0.0 110.04 175.657 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 72.2 m-85 -98.19 162.64 13.1 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.272 178.607 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -63.6 125.21 23.51 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.577 178.541 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 74.56 12.94 82.27 Favored Glycine 0 N--CA 1.447 -0.608 0 C-N-CA 120.948 -0.644 . . . . 0.0 112.851 -179.705 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 73.8 mm-40 -127.41 177.31 6.82 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 110.137 -0.32 . . . . 0.0 110.137 -179.373 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -109.13 -179.9 21.19 Favored Glycine 0 N--CA 1.445 -0.724 0 C-N-CA 120.879 -0.677 . . . . 0.0 111.614 178.805 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_exo -63.76 137.64 59.6 Favored 'Trans proline' 0 C--N 1.349 0.555 0 C-N-CA 122.504 2.136 . . . . 0.0 112.222 178.88 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' ILE . . . . . 0.545 ' HB ' ' O ' ' A' ' 76' ' ' GLN . 45.4 pt -132.36 166.11 30.15 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 CA-C-N 115.706 -0.679 . . . . 0.0 109.713 179.316 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -75.73 145.96 33.34 Favored Glycine 0 C--N 1.321 -0.299 0 C-N-CA 120.703 -0.761 . . . . 0.0 111.886 -179.47 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 31.6 t80 -132.12 130.54 41.33 Favored 'General case' 0 C--N 1.317 -0.839 0 C-N-CA 122.477 0.311 . . . . 0.0 111.398 -178.831 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 59.3 ttp180 -138.71 130.49 27.81 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 174.015 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.435 ' HB3' ' HB2' ' A' ' 47' ' ' LEU . . . -134.87 146.66 49.43 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 120.704 0.288 . . . . 0.0 111.148 -179.648 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 48.9 m -128.33 136.26 50.71 Favored 'General case' 0 CA--C 1.544 0.724 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.748 179.065 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 65' ' ' LEU . . . . . 0.401 HD11 ' O ' ' A' ' 68' ' ' ASN . 59.8 tp -69.34 127.8 34.31 Favored 'General case' 0 CA--C 1.535 0.376 0 N-CA-C 112.274 0.472 . . . . 0.0 112.274 -178.539 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.434 HD21 ' HB2' ' A' ' 72' ' ' GLU . 4.3 mm? -91.18 -41.3 11.08 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-N 115.972 -0.558 . . . . 0.0 112.482 178.702 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -151.8 -68.34 0.01 OUTLIER Glycine 0 CA--C 1.499 -0.922 0 C-N-CA 119.63 -1.272 . . . . 0.0 113.244 -175.835 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 68' ' ' ASN . . . . . 0.401 ' O ' HD11 ' A' ' 65' ' ' LEU . 20.2 m120 -133.49 -81.07 0.47 Allowed 'General case' 0 C--O 1.209 -1.036 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 -178.706 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 69' ' ' ASN . . . . . 0.484 ' OD1' ' HA3' ' A' ' 93' ' ' GLY . 90.7 m-20 -98.72 -5.73 30.89 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 120.77 0.319 . . . . 0.0 110.486 179.43 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 8.7 m -88.66 123.56 33.23 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 121.291 0.567 . . . . 0.0 112.017 -176.647 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 60.2 m-85 -121.88 145.53 48.0 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.659 178.805 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 72' ' ' GLU . . . . . 0.434 ' HB2' HD21 ' A' ' 66' ' ' LEU . 71.8 tt0 -100.26 122.56 43.26 Favored 'General case' 0 C--N 1.316 -0.869 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 173.007 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 66.5 t -103.98 132.46 50.4 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.016 0 CA-C-N 115.687 -0.688 . . . . 0.0 111.767 -175.156 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 99.6 mt-10 -127.34 125.75 41.33 Favored 'General case' 0 N--CA 1.446 -0.655 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 177.141 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 75' ' ' ASN . . . . . 0.445 ' HB3' HD12 ' A' ' 59' ' ' ILE . 95.1 m-20 -111.61 155.57 23.16 Favored 'General case' 0 C--N 1.312 -1.065 0 CA-C-O 121.473 0.654 . . . . 0.0 112.427 -177.204 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 76' ' ' GLN . . . . . 0.545 ' O ' ' HB ' ' A' ' 59' ' ' ILE . 33.8 tt0 -117.69 121.65 41.42 Favored 'General case' 0 C--N 1.311 -1.07 0 CA-C-N 114.878 -1.055 . . . . 0.0 110.285 -177.291 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -107.45 107.84 18.89 Favored 'General case' 0 C--N 1.323 -0.548 0 C-N-CA 120.221 -0.592 . . . . 0.0 110.305 176.834 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 174.04 -158.83 27.86 Favored Glycine 0 N--CA 1.439 -1.146 0 N-CA-C 110.586 -1.006 . . . . 0.0 110.586 -178.655 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -96.41 -42.61 3.39 Favored Glycine 0 N--CA 1.441 -1.008 0 C-N-CA 120.113 -1.042 . . . . 0.0 111.496 178.991 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 20.9 t70 -176.3 150.31 0.91 Allowed 'General case' 0 C--O 1.236 0.374 0 C-N-CA 122.56 0.344 . . . . 0.0 110.223 179.641 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 23.2 t 52.79 33.25 13.74 Favored 'General case' 0 CA--C 1.549 0.935 0 C-N-CA 123.057 0.543 . . . . 0.0 112.357 177.257 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -91.59 165.22 21.46 Favored Pre-proline 0 CA--C 1.544 0.746 0 CA-C-N 116.463 -0.335 . . . . 0.0 110.752 -179.392 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 26.9 Cg_exo -62.66 152.57 77.32 Favored 'Trans proline' 0 C--N 1.354 0.856 0 C-N-CA 122.703 2.269 . . . . 0.0 112.521 178.703 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 84' ' ' TRP . . . . . . . . . . . . . 96.2 m95 -98.61 143.12 29.35 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.544 -177.586 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 80.1 m-70 -129.83 141.1 50.88 Favored 'General case' 0 C--N 1.318 -0.761 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 179.298 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 42.1 m -61.38 133.89 56.32 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-O 121.216 0.531 . . . . 0.0 111.42 -178.038 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -105.23 -43.3 1.63 Allowed Glycine 0 N--CA 1.438 -1.198 0 N-CA-C 111.561 -0.616 . . . . 0.0 111.561 178.296 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 153.65 -170.03 32.37 Favored Glycine 0 C--O 1.223 -0.535 0 C-N-CA 120.456 -0.878 . . . . 0.0 112.259 178.349 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 20.2 m120 -110.6 123.11 49.36 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.465 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 44.1 m0 -114.41 152.81 30.95 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-O 121.016 0.436 . . . . 0.0 111.704 -177.363 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.435 ' HA ' ' O ' ' A' ' 69' ' ' ASN . 82.8 mt -108.02 112.29 39.6 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.751 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 176.785 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 92' ' ' LEU . . . . . 0.436 ' HB3' HG21 ' A' ' 100' ' ' VAL . 70.0 mt -135.15 73.08 1.46 Allowed 'General case' 0 C--O 1.266 1.972 0 CA-C-O 121.692 0.758 . . . . 0.0 111.835 -175.592 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 93' ' ' GLY . . . . . 0.484 ' HA3' ' OD1' ' A' ' 69' ' ' ASN . . . -153.67 -78.85 0.02 OUTLIER Glycine 0 N--CA 1.447 -0.615 0 C-N-CA 120.228 -0.987 . . . . 0.0 113.278 -178.096 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 57.5 m 69.94 10.29 7.4 Favored 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 123.268 0.627 . . . . 0.0 111.869 -177.784 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 95' ' ' ARG . . . . . 0.721 ' HB2' ' O ' ' A' ' 98' ' ' GLN . 16.8 mmt180 -127.12 141.39 51.77 Favored 'General case' 0 N--CA 1.443 -0.783 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 177.308 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 16.6 pt-20 -67.38 -40.45 85.71 Favored 'General case' 0 C--N 1.311 -1.097 0 N-CA-C 112.96 0.726 . . . . 0.0 112.96 -176.298 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 91.8 m-20 -127.58 28.91 5.58 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 111.912 0.338 . . . . 0.0 111.912 -176.35 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 98' ' ' GLN . . . . . 0.721 ' O ' ' HB2' ' A' ' 95' ' ' ARG . 7.9 tt0 -155.64 132.52 10.61 Favored 'General case' 0 C--N 1.32 -0.688 0 C-N-CA 120.625 -0.43 . . . . 0.0 110.078 -177.946 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 91.3 m-20 -115.3 179.49 3.95 Favored 'General case' 0 C--O 1.26 1.638 0 C-N-CA 120.717 -0.393 . . . . 0.0 111.957 -177.909 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.436 HG21 ' HB3' ' A' ' 92' ' ' LEU . 22.5 m -81.06 143.33 12.48 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.427 0 CA-C-N 115.673 -0.694 . . . . 0.0 111.132 178.945 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 31.2 m -121.51 -36.43 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.694 178.223 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 102' ' ' ALA . . . . . 0.611 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -133.4 130.41 38.7 Favored 'General case' 0 CA--C 1.51 -0.572 0 C-N-CA 119.943 -0.703 . . . . 0.0 111.153 178.76 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 96.5 mt -133.29 122.55 45.17 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.934 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.656 178.862 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 12.0 t30 -126.67 99.27 5.71 Favored 'General case' 0 C--N 1.316 -0.882 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 176.804 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.495 ' CG2' ' HB ' ' A' ' 36' ' ' ILE . 17.8 m -135.21 135.86 51.91 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.146 0 CA-C-N 115.513 -0.767 . . . . 0.0 112.429 -174.787 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 60.2 mt-10 -141.17 142.58 34.02 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.597 -0.728 . . . . 0.0 110.256 179.85 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 35.5 t -140.33 148.65 41.67 Favored 'General case' 0 C--N 1.315 -0.913 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.878 179.366 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -96.29 1.11 62.26 Favored Glycine 0 N--CA 1.444 -0.785 0 N-CA-C 110.769 -0.932 . . . . 0.0 110.769 176.234 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 84.6 m-20 -88.93 179.13 6.25 Favored 'General case' 0 CA--C 1.511 -0.539 0 CA-C-O 120.872 0.368 . . . . 0.0 110.601 -179.635 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 7.8 p-10 -88.83 16.41 6.91 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-O 121.568 0.699 . . . . 0.0 109.602 177.577 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 111' ' ' GLY . . . . . 0.663 ' HA3' ' ND2' ' A' ' 32' ' ' ASN . . . 113.25 7.82 20.45 Favored Glycine 0 N--CA 1.438 -1.232 0 CA-C-N 115.384 -0.826 . . . . 0.0 112.516 -177.526 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 98.6 mt-30 -62.71 -47.91 81.56 Favored 'General case' 0 C--O 1.238 0.45 0 CA-C-O 120.759 0.314 . . . . 0.0 110.363 178.783 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 70.7 p -130.44 155.39 46.5 Favored 'General case' 0 N--CA 1.444 -0.748 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 176.151 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 40.1 tp -136.39 108.38 7.16 Favored 'General case' 0 C--N 1.314 -0.946 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 178.352 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 89.0 m-20 -119.84 155.14 33.2 Favored 'General case' 0 C--N 1.316 -0.882 0 C-N-CA 120.597 -0.441 . . . . 0.0 111.737 -175.484 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 162.34 -136.15 4.21 Favored Glycine 0 N--CA 1.438 -1.176 0 C-N-CA 120.543 -0.837 . . . . 0.0 112.737 178.016 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 26.6 p -130.89 153.28 49.31 Favored 'General case' 0 C--N 1.312 -1.032 0 C-N-CA 122.752 0.421 . . . . 0.0 110.469 -178.343 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 25.6 ptm -143.57 146.23 33.15 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.074 179.899 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 119' ' ' THR . . . . . 0.611 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 36.7 m -129.8 126.6 38.49 Favored 'General case' 0 C--N 1.305 -1.358 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.533 179.294 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 67.0 m-85 -81.18 164.43 22.34 Favored 'General case' 0 CA--C 1.508 -0.645 0 O-C-N 123.716 0.635 . . . . 0.0 109.502 176.172 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -51.54 -31.63 24.96 Favored 'General case' 0 CA--C 1.54 0.586 0 N-CA-C 113.37 0.878 . . . . 0.0 113.37 -178.827 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -155.84 15.93 0.45 Allowed Glycine 0 CA--C 1.519 0.287 0 C-N-CA 119.189 -1.481 . . . . 0.0 114.263 -178.246 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 82.9 tt0 -100.19 -23.74 14.75 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 117.619 0.709 . . . . 0.0 111.327 -179.894 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 115.03 179.67 18.54 Favored Glycine 0 N--CA 1.448 -0.507 0 C-N-CA 120.235 -0.983 . . . . 0.0 112.935 178.039 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -90.39 122.06 0.91 Allowed 'Trans proline' 0 N--CA 1.449 -1.102 0 C-N-CA 123.767 2.978 . . . . 0.0 112.408 179.749 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 41.2 pt -128.53 163.12 33.8 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.803 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.58 179.487 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -70.08 137.01 27.58 Favored Glycine 0 C--O 1.244 0.728 0 CA-C-N 116.188 -0.46 . . . . 0.0 112.165 179.37 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 83.7 t80 -115.25 133.97 55.56 Favored 'General case' 0 C--N 1.316 -0.853 0 C-N-CA 122.51 0.324 . . . . 0.0 110.678 -178.966 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 129' ' ' LYS . . . . . 0.448 ' HB3' ' HB2' ' A' ' 7' ' ' GLU . 86.3 tttt -137.45 114.99 11.17 Favored 'General case' 0 N--CA 1.437 -1.09 0 N-CA-C 109.301 -0.629 . . . . 0.0 109.301 176.53 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 130' ' ' GLY . . . . . 0.512 ' HA2' ' O ' ' A' ' 5' ' ' ASN . . . -115.13 136.02 12.78 Favored Glycine 0 N--CA 1.433 -1.561 0 N-CA-C 111.157 -0.777 . . . . 0.0 111.157 177.837 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 52.5 m -128.7 136.72 50.99 Favored 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -179.905 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 58.3 tp -59.89 126.03 25.96 Favored 'General case' 0 C--N 1.327 -0.379 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 178.538 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 24.5 m . . . . . 0 N--CA 1.439 -1.024 0 CA-C-O 118.745 -0.645 . . . . 0.0 110.776 -178.275 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.609 ' O ' ' HG3' ' A' ' 24' ' ' GLU . . . . . . . . 0 N--CA 1.479 1.004 0 N-CA-C 110.144 -0.317 . . . . 0.0 110.144 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' LEU . . . . . 0.427 HD13 ' N ' ' A' ' 4' ' ' TYR . 3.0 tm? -87.3 132.21 34.0 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-O 121.271 0.558 . . . . 0.0 110.713 -175.504 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 4' ' ' TYR . . . . . 0.427 ' N ' HD13 ' A' ' 3' ' ' LEU . 20.0 m-85 -115.45 134.78 54.76 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 115.486 -0.779 . . . . 0.0 111.392 178.542 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 46.6 t-20 -92.9 117.37 29.97 Favored 'General case' 0 C--N 1.309 -1.158 0 N-CA-C 106.992 -1.484 . . . . 0.0 106.992 176.814 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.469 HG12 HD21 ' A' ' 8' ' ' ASN . 58.5 t -102.04 104.89 17.08 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.146 0 CA-C-O 121.146 0.498 . . . . 0.0 112.307 -174.067 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -94.3 137.62 33.24 Favored 'General case' 0 C--N 1.312 -1.028 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 175.931 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' ASN . . . . . 0.469 HD21 HG12 ' A' ' 6' ' ' VAL . 63.2 m-80 -132.69 159.17 40.41 Favored 'General case' 0 C--N 1.314 -0.972 0 CA-C-O 121.627 0.727 . . . . 0.0 112.784 -175.075 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 36.4 tt0 -124.02 106.29 10.27 Favored 'General case' 0 C--N 1.309 -1.166 0 N-CA-C 106.828 -1.545 . . . . 0.0 106.828 173.118 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 1.4 p90 -125.68 0.21 7.45 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 114.056 1.132 . . . . 0.0 114.056 -173.289 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -116.3 21.4 11.9 Favored Glycine 0 N--CA 1.446 -0.647 0 C-N-CA 119.014 -1.565 . . . . 0.0 112.296 -177.74 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 122.14 157.21 9.91 Favored Glycine 0 N--CA 1.441 -1.01 0 C-N-CA 120.8 -0.714 . . . . 0.0 111.99 -179.726 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 21.3 p -59.46 -31.88 69.73 Favored 'General case' 0 C--N 1.317 -0.822 0 C-N-CA 123.018 0.527 . . . . 0.0 112.41 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 17.1 p -81.41 -7.56 59.6 Favored 'General case' 0 C--N 1.32 -0.703 0 N-CA-C 112.26 0.467 . . . . 0.0 112.26 179.449 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -78.99 142.11 59.59 Favored Pre-proline 0 C--N 1.328 -0.353 0 CA-C-O 120.801 0.334 . . . . 0.0 111.255 -178.674 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 64.2 Cg_endo -70.8 165.37 32.38 Favored 'Trans proline' 0 C--O 1.237 0.47 0 C-N-CA 123.084 2.523 . . . . 0.0 112.54 -179.81 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 93.5 m95 -81.69 137.81 35.35 Favored 'General case' 0 N--CA 1.452 -0.354 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.357 -178.731 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 3.1 p30 -145.32 137.78 25.9 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.99 -179.827 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 8.3 pt-20 -93.16 141.37 28.49 Favored 'General case' 0 C--N 1.317 -0.833 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 178.098 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -132.71 26.98 3.57 Favored Glycine 0 N--CA 1.442 -0.956 0 C-N-CA 120.45 -0.881 . . . . 0.0 111.21 179.726 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 154.76 169.34 19.29 Favored Glycine 0 N--CA 1.437 -1.263 0 C-N-CA 120.991 -0.623 . . . . 0.0 111.846 -179.475 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 21.7 pt20 -122.0 132.8 54.71 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-O 120.835 0.35 . . . . 0.0 110.339 179.913 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 40.4 m0 -113.21 172.83 6.71 Favored 'General case' 0 CA--C 1.506 -0.718 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.165 -176.409 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.609 ' HG3' ' O ' ' A' ' 2' ' ' ALA . 33.5 tt0 -131.23 114.66 15.34 Favored 'General case' 0 C--N 1.317 -0.837 0 N-CA-C 108.815 -0.809 . . . . 0.0 108.815 173.572 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.44 HG23 HD11 ' A' ' 36' ' ' ILE . 97.7 mt -105.54 -36.81 3.8 Favored 'Isoleucine or valine' 0 C--O 1.199 -1.6 0 CA-C-N 115.138 -0.937 . . . . 0.0 113.156 -173.053 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -109.07 126.98 8.32 Favored Glycine 0 C--N 1.307 -1.078 0 C-N-CA 119.888 -1.149 . . . . 0.0 112.387 -179.858 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 59.6 p -117.19 8.16 13.17 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 111.875 0.324 . . . . 0.0 111.875 -179.883 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 69.1 ttt180 -122.09 135.5 54.81 Favored 'General case' 0 N--CA 1.446 -0.629 0 CA-C-O 121.162 0.506 . . . . 0.0 111.904 -177.153 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 47.9 t -77.35 149.36 35.26 Favored 'General case' 0 N--CA 1.442 -0.846 0 CA-C-N 115.294 -0.866 . . . . 0.0 109.908 176.972 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.453 ' O ' ' HG2' ' A' ' 31' ' ' GLN . 8.9 m-20 59.62 22.71 11.42 Favored 'General case' 0 N--CA 1.479 0.99 0 C-N-CA 123.032 0.533 . . . . 0.0 111.433 176.902 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 31' ' ' GLN . . . . . 0.453 ' HG2' ' O ' ' A' ' 30' ' ' ASP . 4.5 mm-40 -163.06 91.26 0.71 Allowed 'General case' 0 CA--C 1.501 -0.91 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.241 -178.058 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 32' ' ' ASN . . . . . 0.573 ' ND2' ' HA3' ' A' ' 111' ' ' GLY . 63.6 t30 -94.69 162.02 13.95 Favored 'General case' 0 C--N 1.309 -1.174 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.239 -179.01 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 72.6 t -95.57 129.52 45.57 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.201 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.89 -176.51 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 33.0 m -110.39 -13.06 11.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 N-CA-C 112.187 0.439 . . . . 0.0 112.187 179.154 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.518 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -156.34 149.36 24.13 Favored 'General case' 0 CA--C 1.517 -0.304 0 C-N-CA 120.464 -0.494 . . . . 0.0 111.851 178.685 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.44 HD11 HG23 ' A' ' 25' ' ' ILE . 88.2 mt -148.54 119.18 1.29 Allowed 'Isoleucine or valine' 0 CA--C 1.513 -0.46 0 N-CA-C 107.935 -1.135 . . . . 0.0 107.935 178.565 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 37' ' ' ASN . . . . . 0.545 ' HA ' ' O ' ' A' ' 103' ' ' ILE . 57.5 m-80 -140.05 74.91 1.48 Allowed 'General case' 0 C--N 1.301 -1.534 0 C-N-CA 120.706 -0.398 . . . . 0.0 110.759 -179.375 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.576 HG11 ' CD1' ' A' ' 61' ' ' PHE . 17.1 m -120.18 171.32 8.74 Favored 'Isoleucine or valine' 0 C--O 1.235 0.319 0 N-CA-C 112.49 0.552 . . . . 0.0 112.49 178.541 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 75.3 tt0 -140.34 153.23 46.33 Favored 'General case' 0 N--CA 1.447 -0.593 0 CA-C-N 115.234 -0.893 . . . . 0.0 109.731 179.213 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' SER . . . . . 0.527 ' OG ' ' HB ' ' A' ' 101' ' ' VAL . 34.6 p -76.95 157.72 31.11 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-O 121.297 0.57 . . . . 0.0 112.487 -177.595 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -105.99 -49.46 0.94 Allowed Glycine 0 N--CA 1.438 -1.224 0 N-CA-C 110.177 -1.169 . . . . 0.0 110.177 174.427 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 18.9 m-20 -102.24 -149.68 0.39 Allowed 'General case' 0 C--N 1.325 -0.48 0 C-N-CA 122.889 0.476 . . . . 0.0 110.502 179.013 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 11.9 m-20 -71.96 38.19 0.07 Allowed 'General case' 0 N--CA 1.484 1.268 0 C-N-CA 123.747 0.819 . . . . 0.0 112.261 -177.988 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 83.69 2.93 89.81 Favored Glycine 0 C--N 1.316 -0.532 0 C-N-CA 120.669 -0.776 . . . . 0.0 111.571 -178.738 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' GLN . . . . . 0.476 ' HA ' ' HB3' ' A' ' 65' ' ' LEU . 62.3 mt-30 -80.5 -28.59 37.44 Favored 'General case' 0 C--O 1.218 -0.559 0 CA-C-O 120.981 0.419 . . . . 0.0 110.66 178.218 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 46' ' ' THR . . . . . 0.409 ' O ' ' HA ' ' A' ' 40' ' ' SER . 22.6 p -118.54 132.49 56.21 Favored 'General case' 0 C--N 1.306 -1.298 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.637 179.877 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 90.5 mt -126.46 132.64 51.4 Favored 'General case' 0 C--N 1.319 -0.759 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 179.754 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.411 ' HA ' ' O ' ' A' ' 61' ' ' PHE . 9.4 p30 -142.65 147.61 36.05 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-O 120.789 0.328 . . . . 0.0 110.585 179.234 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 158.68 -135.05 4.05 Favored Glycine 0 C--N 1.312 -0.786 0 C-N-CA 120.601 -0.809 . . . . 0.0 111.885 178.656 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 24.7 p -130.8 149.23 52.54 Favored 'General case' 0 N--CA 1.452 -0.347 0 CA-C-O 121.175 0.512 . . . . 0.0 111.812 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' MET . . . . . 0.462 ' HG2' ' O ' ' A' ' 35' ' ' ALA . 18.4 tmm? -142.45 148.47 37.81 Favored 'General case' 0 C--N 1.316 -0.853 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 177.399 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.518 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 66.1 m -129.53 127.64 41.17 Favored 'General case' 0 C--O 1.246 0.919 0 N-CA-C 112.385 0.513 . . . . 0.0 112.385 -177.04 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 64.9 m-85 -87.99 161.76 17.22 Favored 'General case' 0 CA--C 1.515 -0.369 0 CA-C-N 115.507 -0.769 . . . . 0.0 109.458 174.46 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -66.71 129.99 41.7 Favored 'General case' 0 C--N 1.315 -0.918 0 N-CA-C 110.04 -0.356 . . . . 0.0 110.04 178.158 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 90.45 -19.99 40.53 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.869 -0.681 . . . . 0.0 113.081 179.228 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 81.5 mm-40 -107.56 170.17 8.14 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 120.736 0.303 . . . . 0.0 110.767 -178.589 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -95.46 -157.89 32.35 Favored Glycine 0 N--CA 1.446 -0.664 0 C-N-CA 120.943 -0.646 . . . . 0.0 112.354 179.52 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_endo -64.3 138.46 60.93 Favored 'Trans proline' 0 C--N 1.345 0.38 0 C-N-CA 122.462 2.108 . . . . 0.0 112.099 179.743 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' ILE . . . . . 0.455 HG23 ' HB3' ' A' ' 77' ' ' TRP . 98.3 mt -132.89 142.5 42.14 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.026 0 CA-C-N 115.578 -0.737 . . . . 0.0 109.771 -179.12 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -73.82 128.27 10.97 Favored Glycine 0 N--CA 1.443 -0.898 0 N-CA-C 110.579 -1.009 . . . . 0.0 110.579 179.058 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.576 ' CD1' HG11 ' A' ' 38' ' ' VAL . 47.5 t80 -114.41 128.08 56.16 Favored 'General case' 0 C--N 1.311 -1.08 0 CA-C-O 120.594 0.235 . . . . 0.0 110.903 -176.177 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 64.9 ttp85 -135.49 129.61 33.39 Favored 'General case' 0 N--CA 1.448 -0.536 0 CA-C-N 116.016 -0.538 . . . . 0.0 109.986 176.024 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -138.94 149.66 45.02 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 120.773 0.321 . . . . 0.0 111.754 -178.517 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 27.6 m -125.35 131.5 52.98 Favored 'General case' 0 CA--C 1.54 0.596 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.359 179.204 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 65' ' ' LEU . . . . . 0.476 ' HB3' ' HA ' ' A' ' 45' ' ' GLN . 3.0 tm? -80.2 113.29 18.26 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 120.981 0.419 . . . . 0.0 110.503 -178.495 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 94.6 mt -88.4 -18.96 27.24 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.498 177.799 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 125.34 167.66 12.59 Favored Glycine 0 N--CA 1.442 -0.959 0 C-N-CA 121.02 -0.609 . . . . 0.0 111.596 179.765 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 94.8 m-20 56.47 36.66 27.91 Favored 'General case' 0 N--CA 1.473 0.721 0 C-N-CA 122.56 0.344 . . . . 0.0 111.707 178.279 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 16.3 m120 66.36 9.66 6.62 Favored 'General case' 0 N--CA 1.48 1.031 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.363 179.644 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 35.1 m -97.88 123.55 41.9 Favored 'General case' 0 C--O 1.24 0.562 0 CA-C-O 121.37 0.605 . . . . 0.0 111.586 -177.537 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.534 ' OH ' ' HB3' ' A' ' 99' ' ' ASN . 59.4 m-85 -112.98 138.51 49.75 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 115.468 -0.787 . . . . 0.0 110.83 -179.613 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 42.5 tt0 -92.52 116.64 29.17 Favored 'General case' 0 N--CA 1.439 -0.976 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 174.786 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 78.2 t -105.03 133.15 50.05 Favored 'Isoleucine or valine' 0 C--O 1.248 1.019 0 N-CA-C 112.75 0.648 . . . . 0.0 112.75 -173.615 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 68.7 mt-10 -133.33 134.42 43.78 Favored 'General case' 0 C--O 1.244 0.772 0 N-CA-C 107.899 -1.148 . . . . 0.0 107.899 175.253 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 92.8 m-20 -119.46 154.43 33.76 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 112.911 0.708 . . . . 0.0 112.911 -173.797 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 35.9 tt0 -132.52 127.76 35.87 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.07 -0.968 . . . . 0.0 108.999 179.389 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 77' ' ' TRP . . . . . 0.455 ' HB3' HG23 ' A' ' 59' ' ' ILE . 37.9 p90 -137.58 157.47 46.44 Favored 'General case' 0 C--N 1.317 -0.835 0 C-N-CA 119.973 -0.691 . . . . 0.0 111.997 -177.046 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 81.19 12.13 82.69 Favored Glycine 0 N--CA 1.453 -0.216 0 CA-C-N 115.4 -0.818 . . . . 0.0 112.465 179.513 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 124.48 175.67 14.4 Favored Glycine 0 N--CA 1.445 -0.709 0 N-CA-C 111.259 -0.736 . . . . 0.0 111.259 -179.582 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 -89.74 -5.19 57.23 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 121.114 0.483 . . . . 0.0 110.373 -179.194 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 33.2 m -79.04 -12.96 60.03 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.413 179.367 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -90.8 128.69 47.21 Favored Pre-proline 0 C--N 1.321 -0.641 0 CA-C-N 116.54 -0.3 . . . . 0.0 110.484 -179.532 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 30.1 Cg_endo -63.21 136.2 54.59 Favored 'Trans proline' 0 N--CA 1.463 -0.289 0 C-N-CA 122.157 1.904 . . . . 0.0 111.736 179.735 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 84' ' ' TRP . . . . . . . . . . . . . 87.0 m95 -51.1 138.67 19.53 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-O 121.302 0.572 . . . . 0.0 112.261 178.667 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 96.1 m-70 -115.11 147.14 40.59 Favored 'General case' 0 C--N 1.314 -0.949 0 CA-C-N 115.325 -0.852 . . . . 0.0 109.299 179.361 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 6.3 m -58.37 148.59 27.26 Favored 'General case' 0 C--N 1.316 -0.851 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.629 179.004 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -124.32 -54.44 0.18 Allowed Glycine 0 N--CA 1.44 -1.065 0 N-CA-C 110.552 -1.019 . . . . 0.0 110.552 -179.591 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 149.48 -165.95 29.58 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.605 -0.807 . . . . 0.0 112.353 176.788 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 92.4 m-20 -110.66 118.45 36.22 Favored 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 109.346 -0.613 . . . . 0.0 109.346 178.362 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 32.8 m0 -110.38 150.67 28.47 Favored 'General case' 0 C--N 1.313 -0.993 0 CA-C-N 116.559 -0.292 . . . . 0.0 110.707 -177.374 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 83.3 mt -105.6 115.17 46.83 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.937 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 177.965 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 92' ' ' LEU . . . . . 0.51 ' HB3' HG21 ' A' ' 100' ' ' VAL . 82.2 mt -131.53 80.5 1.93 Allowed 'General case' 0 C--O 1.27 2.182 0 CA-C-O 121.945 0.879 . . . . 0.0 112.589 -174.638 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 165.73 119.63 0.49 Allowed Glycine 0 N--CA 1.441 -0.993 0 CA-C-N 114.935 -1.029 . . . . 0.0 111.5 178.678 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 83.9 p -89.81 -1.54 58.02 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.34 0.59 . . . . 0.0 110.173 178.519 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 23.8 mtp180 -109.12 138.4 45.52 Favored 'General case' 0 N--CA 1.435 -1.181 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 178.884 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 72.5 tt0 -73.0 -38.26 66.67 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-O 121.354 0.597 . . . . 0.0 111.326 -173.324 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 53.5 m-80 -110.6 28.75 8.37 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.343 -177.934 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 98' ' ' GLN . . . . . . . . . . . . . 8.6 tt0 -156.96 125.2 5.61 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.119 0.485 . . . . 0.0 110.467 -177.545 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 99' ' ' ASN . . . . . 0.534 ' HB3' ' OH ' ' A' ' 71' ' ' TYR . 91.6 m-20 -104.64 169.69 8.32 Favored 'General case' 0 C--O 1.251 1.136 0 CA-C-N 115.647 -0.706 . . . . 0.0 111.949 -174.319 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.51 HG21 ' HB3' ' A' ' 92' ' ' LEU . 26.4 m -83.73 151.8 3.89 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.433 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.918 177.886 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 0.527 ' HB ' ' OG ' ' A' ' 40' ' ' SER . 33.8 m -123.45 -29.66 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 C-N-CA 120.909 -0.316 . . . . 0.0 111.49 177.416 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 102' ' ' ALA . . . . . 0.585 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -140.56 135.34 31.72 Favored 'General case' 0 C--N 1.317 -0.828 0 C-N-CA 120.197 -0.601 . . . . 0.0 111.13 179.07 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.545 ' O ' ' HA ' ' A' ' 37' ' ' ASN . 88.6 mt -128.41 121.47 55.45 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.044 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 178.447 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 8.1 t30 -127.8 95.07 4.11 Favored 'General case' 0 C--N 1.325 -0.463 0 O-C-N 123.908 0.755 . . . . 0.0 109.48 -179.296 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.484 HG11 ' CD2' ' A' ' 128' ' ' PHE . 31.7 m -143.65 148.58 18.83 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 N-CA-C 112.672 0.619 . . . . 0.0 112.672 -175.293 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 69.8 tt0 -150.05 154.32 37.95 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.335 -0.848 . . . . 0.0 109.553 174.863 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 44.3 t -136.28 150.8 49.09 Favored 'General case' 0 C--N 1.31 -1.146 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.107 -178.846 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -97.2 1.79 60.92 Favored Glycine 0 N--CA 1.44 -1.069 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 174.479 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -98.56 -172.68 2.37 Favored 'General case' 0 CA--C 1.507 -0.703 0 N-CA-C 109.596 -0.52 . . . . 0.0 109.596 179.716 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 10.4 p-10 -92.47 32.76 1.17 Allowed 'General case' 0 C--N 1.312 -1.028 0 CA-C-O 121.435 0.636 . . . . 0.0 109.559 176.147 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 111' ' ' GLY . . . . . 0.573 ' HA3' ' ND2' ' A' ' 32' ' ' ASN . . . 94.81 9.24 58.72 Favored Glycine 0 N--CA 1.445 -0.719 0 CA-C-N 115.618 -0.719 . . . . 0.0 113.271 -179.347 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 112' ' ' GLN . . . . . 0.519 ' HA ' ' CD1' ' A' ' 132' ' ' LEU . 97.1 mt-30 -65.08 -50.69 65.16 Favored 'General case' 0 C--O 1.24 0.593 0 CA-C-O 120.96 0.409 . . . . 0.0 111.072 179.289 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 40.2 p -129.49 130.33 45.7 Favored 'General case' 0 N--CA 1.444 -0.751 0 CA-C-N 115.899 -0.591 . . . . 0.0 109.844 178.56 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 88.6 mt -108.85 125.44 51.98 Favored 'General case' 0 C--N 1.31 -1.149 0 N-CA-C 110.075 -0.343 . . . . 0.0 110.075 179.781 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 15.7 m120 -109.84 136.37 49.25 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.173 -178.768 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 116' ' ' GLY . . . . . 0.435 ' HA3' HG12 ' A' ' 105' ' ' VAL . . . 167.33 -145.56 9.93 Favored Glycine 0 N--CA 1.439 -1.136 0 C-N-CA 119.074 -1.536 . . . . 0.0 113.584 176.408 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 26.9 p -139.17 161.58 37.05 Favored 'General case' 0 C--N 1.314 -0.951 0 C-N-CA 123.211 0.605 . . . . 0.0 110.699 -177.987 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 118' ' ' MET . . . . . 0.55 ' O ' ' HA ' ' A' ' 125' ' ' PRO . 18.4 ptp -140.28 148.59 41.66 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.303 -0.408 . . . . 0.0 109.968 178.776 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 119' ' ' THR . . . . . 0.585 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 27.7 m -128.78 130.53 47.14 Favored 'General case' 0 C--N 1.313 -0.998 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 177.973 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 120' ' ' TYR . . . . . 0.586 ' HB2' ' HB3' ' A' ' 123' ' ' GLU . 38.4 m-85 -96.56 173.08 7.52 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.006 0.431 . . . . 0.0 112.037 -179.945 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 121' ' ' ALA . . . . . 0.416 ' HA ' HG11 ' A' ' 101' ' ' VAL . . . -55.51 -36.57 66.83 Favored 'General case' 0 CA--C 1.533 0.298 0 CA-C-N 115.396 -0.82 . . . . 0.0 112.859 -178.43 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -144.2 46.01 0.84 Allowed Glycine 0 CA--C 1.506 -0.522 0 C-N-CA 120.388 -0.91 . . . . 0.0 111.668 -179.321 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 123' ' ' GLU . . . . . 0.586 ' HB3' ' HB2' ' A' ' 120' ' ' TYR . 76.1 tt0 -151.62 144.66 24.55 Favored 'General case' 0 C--N 1.315 -0.894 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 -178.032 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -68.01 160.29 50.59 Favored Glycine 0 CA--C 1.518 0.246 0 C-N-CA 121.153 -0.546 . . . . 0.0 113.002 -177.512 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 125' ' ' PRO . . . . . 0.55 ' HA ' ' O ' ' A' ' 118' ' ' MET . 30.2 Cg_endo -63.15 136.65 57.21 Favored 'Trans proline' 0 C--N 1.348 0.537 0 C-N-CA 122.416 2.077 . . . . 0.0 111.994 179.701 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 44.0 pt -129.47 165.1 30.27 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.913 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.567 -179.133 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -73.09 132.44 16.89 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 121.053 -0.594 . . . . 0.0 112.145 -179.18 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 128' ' ' PHE . . . . . 0.484 ' CD2' HG11 ' A' ' 105' ' ' VAL . 49.9 t80 -114.92 131.29 56.93 Favored 'General case' 0 C--O 1.245 0.862 0 C-N-CA 122.937 0.495 . . . . 0.0 111.793 -177.798 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 62.5 tttm -133.13 97.35 3.97 Favored 'General case' 0 N--CA 1.441 -0.89 0 CA-C-N 115.249 -0.887 . . . . 0.0 109.687 175.658 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -91.81 130.84 10.49 Favored Glycine 0 CA--C 1.502 -0.738 0 N-CA-C 111.06 -0.816 . . . . 0.0 111.06 179.917 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 28.2 m -128.5 133.94 48.58 Favored 'General case' 0 C--N 1.311 -1.093 0 CA-C-N 117.282 0.541 . . . . 0.0 110.461 -178.376 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 132' ' ' LEU . . . . . 0.519 ' CD1' ' HA ' ' A' ' 112' ' ' GLN . 80.3 mt -57.12 134.34 55.79 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-O 121.001 0.429 . . . . 0.0 110.962 177.784 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 24.1 m . . . . . 0 C--O 1.251 1.152 0 CA-C-O 118.123 -0.941 . . . . 0.0 109.61 179.682 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.701 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 3.3 tm? -98.23 132.53 43.66 Favored 'General case' 0 C--N 1.317 -0.805 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 -178.772 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' TYR . . . . . 0.459 ' CE1' ' HB ' ' A' ' 25' ' ' ILE . 96.9 m-85 -125.9 150.06 48.22 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-O 121.153 0.501 . . . . 0.0 111.256 -179.668 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 10.1 m-80 -99.0 136.56 38.79 Favored 'General case' 0 C--N 1.318 -0.791 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 174.728 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.461 HG21 ' CG ' ' A' ' 23' ' ' TRP . 53.6 t -115.87 129.83 71.57 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 N-CA-C 114.007 1.114 . . . . 0.0 114.007 -172.953 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.477 ' HA ' ' HA ' ' A' ' 19' ' ' GLU . 78.4 mt-10 -114.27 134.33 55.02 Favored 'General case' 0 N--CA 1.437 -1.09 0 CA-C-N 113.999 -1.455 . . . . 0.0 107.97 176.038 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 86.1 m-20 -116.07 136.15 53.28 Favored 'General case' 0 C--N 1.315 -0.918 0 CA-C-O 120.635 0.255 . . . . 0.0 110.517 -178.949 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' GLN . . . . . 0.53 ' HB2' ' CE3' ' A' ' 17' ' ' TRP . 58.6 tt0 -112.39 122.1 46.74 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.827 -178.166 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 15.0 p90 -139.47 141.87 37.39 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.912 -0.585 . . . . 0.0 109.654 175.079 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 127.62 2.21 6.33 Favored Glycine 0 N--CA 1.443 -0.862 0 C-N-CA 120.657 -0.782 . . . . 0.0 111.59 -179.234 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 82.03 -156.69 36.35 Favored Glycine 0 N--CA 1.445 -0.766 0 C-N-CA 121.161 -0.542 . . . . 0.0 113.892 178.776 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 8.1 m -54.45 137.54 42.27 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-N 115.011 -0.594 . . . . 0.0 111.8 179.659 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 21.0 m 64.08 18.92 11.52 Favored 'General case' 0 N--CA 1.469 0.511 0 N-CA-C 113.131 0.789 . . . . 0.0 113.131 177.616 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -79.93 140.28 54.04 Favored Pre-proline 0 C--N 1.322 -0.597 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 177.209 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 69.9 Cg_endo -71.13 158.73 54.22 Favored 'Trans proline' 0 C--O 1.238 0.505 0 C-N-CA 122.495 2.13 . . . . 0.0 112.287 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' TRP . . . . . 0.53 ' CE3' ' HB2' ' A' ' 9' ' ' GLN . 91.7 m95 -92.94 128.78 38.92 Favored 'General case' 0 C--N 1.314 -0.965 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 179.076 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 88.9 m-20 -116.37 117.12 29.07 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-N 116.7 -0.227 . . . . 0.0 110.691 -177.573 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.477 ' HA ' ' HA ' ' A' ' 7' ' ' GLU . 11.2 pt-20 -72.27 135.55 46.03 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 177.669 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -142.87 26.16 2.23 Favored Glycine 0 N--CA 1.44 -1.074 0 C-N-CA 119.375 -1.393 . . . . 0.0 113.266 179.302 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 149.85 -176.04 28.7 Favored Glycine 0 N--CA 1.447 -0.567 0 C-N-CA 119.531 -1.318 . . . . 0.0 113.583 -179.832 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 27.6 pt20 -131.32 136.97 48.57 Favored 'General case' 0 C--N 1.325 -0.478 0 C-N-CA 122.603 0.361 . . . . 0.0 110.425 -178.728 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' TRP . . . . . 0.461 ' CG ' HG21 ' A' ' 6' ' ' VAL . 29.3 m0 -112.58 154.64 25.68 Favored 'General case' 0 CA--C 1.504 -0.826 0 N-CA-C 110.126 -0.324 . . . . 0.0 110.126 179.406 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 69.5 tt0 -117.89 114.16 22.82 Favored 'General case' 0 C--N 1.31 -1.111 0 C-N-CA 119.772 -0.771 . . . . 0.0 109.085 176.185 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.459 ' HB ' ' CE1' ' A' ' 4' ' ' TYR . 96.8 mt -127.0 135.76 62.74 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.598 -175.486 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 113.5 165.13 15.89 Favored Glycine 0 N--CA 1.438 -1.183 0 C-N-CA 120.667 -0.778 . . . . 0.0 112.721 176.838 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 58.5 m -134.63 -55.77 0.84 Allowed 'General case' 0 C--N 1.309 -1.163 0 N-CA-C 108.793 -0.817 . . . . 0.0 108.793 179.454 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 93.4 mtt-85 -80.36 137.09 36.51 Favored 'General case' 0 N--CA 1.448 -0.551 0 CA-C-N 115.506 -0.77 . . . . 0.0 109.164 176.403 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 24.8 m -89.03 -19.98 24.95 Favored 'General case' 0 C--N 1.314 -0.95 0 CA-C-O 121.257 0.551 . . . . 0.0 110.884 -179.379 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 17.3 m-20 -95.68 1.01 53.3 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.781 -0.645 . . . . 0.0 111.407 -178.948 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' GLN . . . . . 0.46 ' OE1' ' HB3' ' A' ' 53' ' ' TYR . 0.4 OUTLIER -141.65 112.41 7.21 Favored 'General case' 0 C--N 1.321 -0.67 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 178.966 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 4.5 t-20 -95.2 161.2 14.2 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-O 120.958 0.409 . . . . 0.0 111.497 -176.088 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.432 ' HA ' ' HA ' ' A' ' 53' ' ' TYR . 59.6 t -98.77 134.58 37.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 C-N-CA 123.204 0.602 . . . . 0.0 110.151 -179.146 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.405 HG13 ' HB2' ' A' ' 54' ' ' ALA . 23.8 m -112.72 -15.22 10.4 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.545 0 N-CA-C 112.548 0.573 . . . . 0.0 112.548 -179.319 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.509 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -147.8 143.85 27.78 Favored 'General case' 0 C--O 1.239 0.52 0 C-N-CA 120.228 -0.589 . . . . 0.0 111.52 177.597 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.41 ' HB ' ' CG2' ' A' ' 105' ' ' VAL . 94.8 mt -141.84 124.96 15.06 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 -179.772 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 16.8 t30 -133.4 112.5 11.64 Favored 'General case' 0 C--N 1.311 -1.068 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 177.951 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.469 HG22 ' HB ' ' A' ' 103' ' ' ILE . 19.7 m -146.37 147.83 17.66 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.775 0 N-CA-C 112.202 0.445 . . . . 0.0 112.202 -174.388 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 69.2 tt0 -131.02 143.2 50.53 Favored 'General case' 0 CA--C 1.536 0.404 0 CA-C-N 115.692 -0.685 . . . . 0.0 109.629 176.768 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' SER . . . . . 0.416 ' HA ' ' O ' ' A' ' 46' ' ' THR . 22.1 p -71.13 147.64 48.2 Favored 'General case' 0 C--N 1.319 -0.754 0 N-CA-C 112.441 0.534 . . . . 0.0 112.441 179.633 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -97.87 -48.69 1.89 Allowed Glycine 0 N--CA 1.45 -0.403 0 N-CA-C 110.515 -1.034 . . . . 0.0 110.515 176.597 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 6.9 m-20 -97.26 -168.07 1.64 Allowed 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 175.783 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 28.3 m-20 -74.93 59.83 0.93 Allowed 'General case' 0 N--CA 1.469 0.501 0 CA-C-O 121.133 0.492 . . . . 0.0 111.947 -179.543 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 82.77 11.6 81.34 Favored Glycine 0 N--CA 1.452 -0.268 0 CA-C-N 115.976 -0.556 . . . . 0.0 112.75 177.477 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 63.1 tt0 -97.08 -30.51 13.0 Favored 'General case' 0 C--O 1.215 -0.715 0 C-N-CA 120.784 -0.366 . . . . 0.0 111.314 179.701 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' THR . . . . . 0.416 ' O ' ' HA ' ' A' ' 40' ' ' SER . 31.0 p -124.04 147.36 47.9 Favored 'General case' 0 C--N 1.308 -1.203 0 C-N-CA 120.818 -0.353 . . . . 0.0 110.801 -179.806 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 47' ' ' LEU . . . . . 0.526 ' HB2' ' HB3' ' A' ' 63' ' ' ALA . 94.1 mt -133.28 129.47 37.65 Favored 'General case' 0 C--N 1.318 -0.79 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 -179.7 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 51.3 m-80 -127.16 140.75 52.04 Favored 'General case' 0 C--N 1.311 -1.101 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 177.565 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.433 ' HA3' HG12 ' A' ' 38' ' ' VAL . . . 177.22 -157.75 22.8 Favored Glycine 0 N--CA 1.438 -1.197 0 C-N-CA 119.4 -1.381 . . . . 0.0 113.541 179.904 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 44.6 m -126.23 129.96 49.98 Favored 'General case' 0 N--CA 1.44 -0.973 0 CA-C-N 115.302 -0.449 . . . . 0.0 110.239 -177.272 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 19.0 ttm -110.78 141.93 43.43 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 109.69 -0.485 . . . . 0.0 109.69 179.089 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.509 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 36.2 m -126.29 122.38 35.33 Favored 'General case' 0 C--O 1.254 1.29 0 CA-C-O 120.956 0.408 . . . . 0.0 111.233 178.019 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 53' ' ' TYR . . . . . 0.561 ' HB2' ' HB2' ' A' ' 56' ' ' GLU . 78.6 m-85 -85.92 164.3 17.53 Favored 'General case' 0 C--O 1.231 0.127 0 CA-C-N 115.404 -0.816 . . . . 0.0 110.702 178.891 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 54' ' ' ALA . . . . . 0.405 ' HB2' HG13 ' A' ' 34' ' ' VAL . . . -69.58 105.44 2.67 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.895 -179.515 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 86.44 8.43 77.61 Favored Glycine 0 CA--C 1.518 0.236 0 C-N-CA 121.013 -0.613 . . . . 0.0 112.943 176.711 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' GLU . . . . . 0.561 ' HB2' ' HB2' ' A' ' 53' ' ' TYR . 78.6 mm-40 -122.12 165.56 15.9 Favored 'General case' 0 C--N 1.315 -0.893 0 N-CA-C 110.012 -0.366 . . . . 0.0 110.012 -179.003 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -77.7 161.96 50.16 Favored Glycine 0 N--CA 1.446 -0.683 0 C-N-CA 120.663 -0.779 . . . . 0.0 112.086 178.51 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -72.73 145.87 42.03 Favored 'Trans proline' 0 C--O 1.241 0.645 0 C-N-CA 122.811 2.341 . . . . 0.0 112.716 179.835 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 59' ' ' ILE . . . . . 0.542 ' HB ' ' O ' ' A' ' 76' ' ' GLN . 49.7 pt -128.86 165.83 27.72 Favored 'Isoleucine or valine' 0 C--O 1.242 0.687 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.653 179.888 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -77.13 134.84 15.47 Favored Glycine 0 C--O 1.239 0.459 0 C-N-CA 120.897 -0.668 . . . . 0.0 111.819 -179.347 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.429 ' CD2' HG11 ' A' ' 38' ' ' VAL . 72.1 t80 -117.43 127.49 54.07 Favored 'General case' 0 C--O 1.237 0.443 0 C-N-CA 122.429 0.291 . . . . 0.0 111.24 -177.556 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 50.2 ttm-85 -130.29 127.75 40.14 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.016 -0.538 . . . . 0.0 109.86 176.699 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.526 ' HB3' ' HB2' ' A' ' 47' ' ' LEU . . . -132.05 139.87 48.69 Favored 'General case' 0 C--N 1.319 -0.741 0 C-N-CA 120.796 -0.362 . . . . 0.0 111.819 178.529 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 46.7 m -122.28 127.02 49.38 Favored 'General case' 0 CA--C 1.54 0.568 0 CA-C-N 115.879 -0.601 . . . . 0.0 110.005 178.201 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -74.5 119.77 19.15 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-O 121.053 0.454 . . . . 0.0 110.678 -178.118 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 91.7 mt -94.43 -25.14 17.04 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.669 -0.696 . . . . 0.0 109.962 178.368 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 134.57 157.5 8.14 Favored Glycine 0 N--CA 1.44 -1.044 0 CA-C-N 115.675 -0.693 . . . . 0.0 111.882 179.638 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 92.4 m-20 56.69 34.33 24.37 Favored 'General case' 0 N--CA 1.481 1.114 0 C-N-CA 122.463 0.305 . . . . 0.0 111.469 179.2 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 49.1 m-80 70.15 10.49 7.36 Favored 'General case' 0 N--CA 1.481 1.087 0 C-N-CA 123.522 0.729 . . . . 0.0 112.415 -179.407 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 55.8 m -87.72 122.31 31.22 Favored 'General case' 0 C--O 1.236 0.376 0 N-CA-C 110.015 -0.365 . . . . 0.0 110.015 177.959 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.562 ' OH ' ' HB3' ' A' ' 99' ' ' ASN . 70.8 m-85 -115.44 129.96 56.73 Favored 'General case' 0 C--N 1.311 -1.065 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.217 -179.643 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 52.2 tp10 -85.31 118.82 25.09 Favored 'General case' 0 N--CA 1.438 -1.064 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 174.992 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 68.0 t -106.98 132.75 53.52 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.23 0 N-CA-C 112.937 0.717 . . . . 0.0 112.937 -173.427 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -123.72 142.85 50.69 Favored 'General case' 0 N--CA 1.446 -0.645 0 N-CA-C 107.273 -1.381 . . . . 0.0 107.273 175.801 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 93.4 m-20 -134.71 161.24 35.71 Favored 'General case' 0 C--N 1.316 -0.851 0 C-N-CA 120.869 -0.332 . . . . 0.0 111.291 -174.964 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 76' ' ' GLN . . . . . 0.542 ' O ' ' HB ' ' A' ' 59' ' ' ILE . 2.9 pt20 -130.64 129.99 43.38 Favored 'General case' 0 C--O 1.239 0.543 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.159 177.006 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 6.6 p90 -133.96 151.19 51.38 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.91 -178.408 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 98.12 -1.96 59.45 Favored Glycine 0 N--CA 1.448 -0.54 0 C-N-CA 120.713 -0.756 . . . . 0.0 111.871 -179.614 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 140.99 164.62 9.99 Favored Glycine 0 N--CA 1.441 -1.031 0 C-N-CA 121.054 -0.593 . . . . 0.0 112.2 179.072 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -65.54 -33.0 74.89 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-O 121.248 0.546 . . . . 0.0 110.473 179.44 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 32.5 p -79.85 6.87 9.95 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.257 -0.883 . . . . 0.0 112.459 -178.055 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -83.89 146.64 49.56 Favored Pre-proline 0 C--N 1.316 -0.89 0 CA-C-N 116.698 -0.228 . . . . 0.0 110.527 179.668 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -67.92 173.73 8.8 Favored 'Trans proline' 0 C--N 1.345 0.353 0 C-N-CA 122.459 2.106 . . . . 0.0 111.604 178.855 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 84' ' ' TRP . . . . . . . . . . . . . 95.2 m95 -98.37 127.72 44.43 Favored 'General case' 0 N--CA 1.444 -0.751 0 CA-C-O 121.172 0.51 . . . . 0.0 110.248 -177.666 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 97.3 m-70 -115.7 149.69 38.0 Favored 'General case' 0 C--N 1.31 -1.116 0 CA-C-N 115.398 -0.819 . . . . 0.0 110.323 -177.629 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 10.0 m -61.53 130.25 45.06 Favored 'General case' 0 C--N 1.315 -0.925 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.833 -179.562 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -105.08 -52.68 0.82 Allowed Glycine 0 N--CA 1.439 -1.107 0 C-N-CA 120.913 -0.66 . . . . 0.0 111.634 179.43 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 155.68 -172.52 33.75 Favored Glycine 0 C--O 1.22 -0.753 0 C-N-CA 120.596 -0.811 . . . . 0.0 111.774 179.605 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 21.2 t-20 -110.28 112.08 23.8 Favored 'General case' 0 C--N 1.313 -1.009 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 179.512 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 27.4 m0 -102.4 149.8 23.99 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.993 -177.749 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 47.4 mm -107.17 114.02 45.04 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 177.247 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 92' ' ' LEU . . . . . 0.414 ' HB2' ' CE1' ' A' ' 71' ' ' TYR . 85.0 mt -124.25 89.25 3.05 Favored 'General case' 0 C--O 1.272 2.279 0 CA-C-O 121.725 0.774 . . . . 0.0 112.691 -175.796 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 154.86 116.91 0.58 Allowed Glycine 0 N--CA 1.443 -0.876 0 CA-C-N 115.0 -1.0 . . . . 0.0 111.676 178.911 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 94' ' ' SER . . . . . 0.436 ' N ' ' HE1' ' A' ' 23' ' ' TRP . 76.8 p -86.0 -15.28 41.95 Favored 'General case' 0 CA--C 1.516 -0.355 0 CA-C-O 121.395 0.617 . . . . 0.0 109.913 178.849 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 58.4 mtt-85 -88.91 141.85 28.14 Favored 'General case' 0 N--CA 1.435 -1.185 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.004 -179.93 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 8.9 pt-20 -68.65 -33.11 73.43 Favored 'General case' 0 C--N 1.31 -1.117 0 CA-C-N 115.53 -0.759 . . . . 0.0 111.975 -175.376 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 31.3 p-10 -120.75 28.66 7.82 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 111.788 0.292 . . . . 0.0 111.788 -178.117 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 98' ' ' GLN . . . . . 0.704 HE21 ' HG2' ' A' ' 123' ' ' GLU . 2.3 mm-40 -142.78 118.48 10.46 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 112.326 0.491 . . . . 0.0 112.326 -176.672 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 99' ' ' ASN . . . . . 0.562 ' HB3' ' OH ' ' A' ' 71' ' ' TYR . 93.2 m-20 -89.36 157.86 18.01 Favored 'General case' 0 C--O 1.262 1.755 0 CA-C-N 115.724 -0.671 . . . . 0.0 111.166 177.673 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.445 HG21 ' CH2' ' A' ' 23' ' ' TRP . 85.9 t -84.35 134.14 27.66 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.594 0 CA-C-N 115.355 -0.839 . . . . 0.0 111.705 178.445 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 35.8 m -110.66 -29.03 2.49 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.397 0 CA-C-N 116.035 -0.529 . . . . 0.0 112.275 179.765 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 102' ' ' ALA . . . . . 0.516 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -146.24 139.37 25.77 Favored 'General case' 0 C--N 1.323 -0.585 0 C-N-CA 120.2 -0.6 . . . . 0.0 111.144 179.056 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.469 ' HB ' HG22 ' A' ' 38' ' ' VAL . 94.9 mt -131.62 124.95 55.19 Favored 'Isoleucine or valine' 0 C--O 1.244 0.771 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.57 177.796 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 41.2 t30 -125.17 94.56 4.2 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 115.676 -0.693 . . . . 0.0 109.3 175.586 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.41 ' CG2' ' HB ' ' A' ' 36' ' ' ILE . 29.3 m -133.6 135.82 55.2 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 N-CA-C 112.859 0.689 . . . . 0.0 112.859 -176.538 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 75.3 tt0 -140.15 137.55 34.51 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.415 -0.811 . . . . 0.0 110.13 179.639 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 23.2 t -146.93 145.37 29.77 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 116.468 -0.333 . . . . 0.0 110.459 177.211 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -109.18 17.07 32.12 Favored Glycine 0 N--CA 1.447 -0.609 0 C-N-CA 121.11 -0.567 . . . . 0.0 112.435 -179.195 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 40.3 p-10 -91.91 -153.61 0.34 Allowed 'General case' 0 C--N 1.319 -0.753 0 CA-C-O 120.768 0.318 . . . . 0.0 110.158 179.098 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 37.1 t70 -88.94 12.86 14.19 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-O 121.167 0.508 . . . . 0.0 110.071 179.108 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 85.7 7.39 81.68 Favored Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 120.684 -0.769 . . . . 0.0 111.939 -177.173 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 36.5 tt0 -66.57 -38.78 87.79 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-O 121.109 0.481 . . . . 0.0 110.526 -179.671 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 113' ' ' THR . . . . . 0.418 ' HA ' ' O ' ' A' ' 130' ' ' GLY . 27.5 p -124.63 131.73 53.46 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-N 115.906 -0.588 . . . . 0.0 111.056 179.224 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -109.94 113.32 25.96 Favored 'General case' 0 C--N 1.315 -0.927 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 177.999 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 93.8 m-20 -117.23 147.5 42.46 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-O 121.016 0.436 . . . . 0.0 111.26 -177.941 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 159.57 -135.61 4.22 Favored Glycine 0 N--CA 1.434 -1.457 0 C-N-CA 120.458 -0.877 . . . . 0.0 112.906 177.717 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 20.8 p -134.04 157.97 44.76 Favored 'General case' 0 C--N 1.31 -1.143 0 C-N-CA 122.905 0.482 . . . . 0.0 110.316 -177.786 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 118' ' ' MET . . . . . 0.41 ' HE1' ' CZ ' ' A' ' 120' ' ' TYR . 17.3 ptm -149.63 155.24 39.92 Favored 'General case' 0 C--N 1.312 -1.063 0 CA-C-N 116.498 -0.319 . . . . 0.0 110.391 -179.672 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 119' ' ' THR . . . . . 0.516 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 27.9 m -130.76 128.11 40.11 Favored 'General case' 0 C--O 1.249 1.055 0 CA-C-N 116.474 -0.33 . . . . 0.0 111.224 179.804 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 120' ' ' TYR . . . . . 0.41 ' CZ ' ' HE1' ' A' ' 118' ' ' MET . 31.0 m-85 -89.85 166.02 13.77 Favored 'General case' 0 CA--C 1.507 -0.687 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.294 175.975 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -66.47 45.38 0.03 OUTLIER 'General case' 0 CA--C 1.554 1.126 0 N-CA-C 114.043 1.127 . . . . 0.0 114.043 179.79 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 142.44 -25.63 2.31 Favored Glycine 0 C--N 1.334 0.429 0 C-N-CA 119.874 -1.155 . . . . 0.0 114.405 175.372 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 123' ' ' GLU . . . . . 0.704 ' HG2' HE21 ' A' ' 98' ' ' GLN . 69.4 mm-40 -67.33 -33.36 75.09 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 117.311 0.556 . . . . 0.0 112.424 -177.585 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 115.09 161.69 13.34 Favored Glycine 0 CA--C 1.519 0.334 0 C-N-CA 120.585 -0.817 . . . . 0.0 112.361 -179.542 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 20.8 Cg_exo -67.11 129.36 20.39 Favored 'Trans proline' 0 C--N 1.351 0.673 0 C-N-CA 122.782 2.321 . . . . 0.0 111.991 178.386 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 37.4 pt -135.44 161.73 38.71 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.691 179.592 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -69.8 139.25 31.17 Favored Glycine 0 C--O 1.239 0.453 0 C-N-CA 120.923 -0.656 . . . . 0.0 112.26 178.948 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 86.4 t80 -119.52 133.71 55.55 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 120.745 0.307 . . . . 0.0 111.233 -178.465 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 129' ' ' LYS . . . . . 0.427 ' HB3' ' HB2' ' A' ' 7' ' ' GLU . 63.6 tttm -140.99 118.12 11.27 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.911 -0.586 . . . . 0.0 109.519 176.718 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 130' ' ' GLY . . . . . 0.418 ' O ' ' HA ' ' A' ' 113' ' ' THR . . . -122.18 141.96 14.63 Favored Glycine 0 N--CA 1.449 -0.475 0 C-N-CA 120.735 -0.745 . . . . 0.0 111.941 -179.643 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 62.1 m -128.11 135.65 50.08 Favored 'General case' 0 C--N 1.317 -0.818 0 CA-C-N 116.619 0.21 . . . . 0.0 111.392 -179.585 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 132' ' ' LEU . . . . . 0.401 HD13 ' N ' ' A' ' 133' ' ' THR . 3.4 tm? -57.79 138.26 55.77 Favored 'General case' 0 N--CA 1.467 0.392 0 C-N-CA 123.062 0.545 . . . . 0.0 110.391 179.723 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 133' ' ' THR . . . . . 0.401 ' N ' HD13 ' A' ' 132' ' ' LEU . 24.0 m . . . . . 0 C--O 1.247 0.964 0 CA-C-O 118.503 -0.761 . . . . 0.0 110.322 -178.577 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.238 0.449 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -90.76 128.68 36.77 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-O 120.855 0.359 . . . . 0.0 110.099 -179.914 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' TYR . . . . . 0.424 ' CD1' ' HB ' ' A' ' 25' ' ' ILE . 57.4 m-85 -119.65 143.07 47.91 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.142 178.1 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 12.9 m-80 -97.24 135.52 39.05 Favored 'General case' 0 C--N 1.309 -1.159 0 N-CA-C 108.394 -0.965 . . . . 0.0 108.394 175.689 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 53.5 t -111.36 126.65 68.76 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.862 0 CA-C-O 121.803 0.811 . . . . 0.0 112.627 -174.769 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.452 ' HG2' ' HB3' ' A' ' 19' ' ' GLU . 63.6 mt-10 -118.82 133.18 56.02 Favored 'General case' 0 N--CA 1.438 -1.047 0 CA-C-N 114.684 -1.144 . . . . 0.0 108.5 176.665 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' ASN . . . . . 0.45 ' HA ' ' O ' ' A' ' 127' ' ' GLY . 89.3 m-20 -117.89 139.76 50.67 Favored 'General case' 0 C--N 1.313 -1.004 0 CA-C-O 121.072 0.463 . . . . 0.0 111.424 -176.641 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' GLN . . . . . 0.445 ' HB2' ' CE3' ' A' ' 17' ' ' TRP . 28.1 tt0 -132.6 125.86 31.43 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.059 179.131 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 24.1 p90 -128.98 141.29 51.3 Favored 'General case' 0 C--N 1.316 -0.853 0 C-N-CA 120.607 -0.437 . . . . 0.0 111.265 -179.048 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 115.77 -77.72 0.27 Allowed Glycine 0 N--CA 1.442 -0.936 0 CA-C-N 115.562 -0.744 . . . . 0.0 111.794 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -170.34 173.62 44.3 Favored Glycine 0 N--CA 1.442 -0.953 0 C-N-CA 121.085 -0.579 . . . . 0.0 111.725 -179.579 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 26.2 t -59.25 -23.8 62.65 Favored 'General case' 0 CA--C 1.538 0.506 0 N-CA-C 111.881 0.326 . . . . 0.0 111.881 -179.729 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 23.5 p -65.23 -19.65 66.07 Favored 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 112.009 0.374 . . . . 0.0 112.009 177.823 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -93.09 146.91 32.84 Favored Pre-proline 0 N--CA 1.446 -0.671 0 N-CA-C 109.978 -0.379 . . . . 0.0 109.978 179.414 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_endo -79.41 173.27 13.39 Favored 'Trans proline' 0 CA--C 1.537 0.652 0 C-N-CA 122.723 2.282 . . . . 0.0 112.869 179.457 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' TRP . . . . . 0.445 ' CE3' ' HB2' ' A' ' 9' ' ' GLN . 95.5 m95 -87.14 131.24 34.22 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.938 -0.573 . . . . 0.0 109.795 178.741 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 46.5 m-80 -114.37 118.62 34.36 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.937 -178.395 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.452 ' HB3' ' HG2' ' A' ' 7' ' ' GLU . 10.9 pt-20 -82.7 124.75 30.51 Favored 'General case' 0 C--N 1.315 -0.897 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.499 179.236 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.439 ' O ' ' HB2' ' A' ' 94' ' ' SER . . . -132.46 29.93 3.22 Favored Glycine 0 N--CA 1.442 -0.963 0 C-N-CA 120.069 -1.062 . . . . 0.0 112.838 -177.709 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 140.96 -175.12 22.36 Favored Glycine 0 N--CA 1.442 -0.907 0 C-N-CA 120.25 -0.976 . . . . 0.0 112.819 178.818 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' GLN . . . . . 0.404 ' O ' ' HD1' ' A' ' 23' ' ' TRP . 12.4 pt20 -141.46 153.05 44.74 Favored 'General case' 0 C--N 1.313 -1.01 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 179.812 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' TRP . . . . . 0.425 ' HB3' ' O ' ' A' ' 91' ' ' ILE . 45.0 m0 -127.68 174.7 8.87 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.543 -0.299 . . . . 0.0 110.787 -176.086 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 79.6 tt0 -121.01 118.11 28.97 Favored 'General case' 0 CA--C 1.51 -0.57 0 C-N-CA 120.624 -0.43 . . . . 0.0 109.902 176.776 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.424 ' HB ' ' CD1' ' A' ' 4' ' ' TYR . 98.3 mt -131.53 140.14 49.01 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.774 0 CA-C-N 115.816 -0.629 . . . . 0.0 109.609 -178.762 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 86.15 66.64 1.39 Allowed Glycine 0 N--CA 1.443 -0.886 0 C-N-CA 120.34 -0.933 . . . . 0.0 112.544 178.982 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 19.2 p -59.78 -36.88 77.61 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 121.131 0.491 . . . . 0.0 110.239 177.744 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 93.5 mtt-85 -94.88 108.23 20.26 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 175.233 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 51.0 m -73.7 -7.87 53.76 Favored 'General case' 0 C--N 1.321 -0.671 0 N-CA-C 113.082 0.771 . . . . 0.0 113.082 -174.761 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 97.9 m-20 -76.81 -18.76 58.21 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.906 0.384 . . . . 0.0 110.996 179.854 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' GLN . . . . . 0.452 ' HB3' ' CD1' ' A' ' 53' ' ' TYR . 7.4 mm100 -133.53 114.83 14.02 Favored 'General case' 0 CA--C 1.51 -0.561 0 N-CA-C 112.589 0.589 . . . . 0.0 112.589 -178.741 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 2.7 t-20 -82.21 142.43 32.16 Favored 'General case' 0 C--O 1.242 0.7 0 CA-C-N 116.011 -0.541 . . . . 0.0 110.043 179.369 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 47.0 t -92.37 129.75 42.51 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 CA-C-N 115.507 -0.77 . . . . 0.0 109.857 -178.331 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.442 ' HB ' ' O ' ' A' ' 107' ' ' SER . 30.5 m -110.13 -21.15 5.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 N-CA-C 112.38 0.511 . . . . 0.0 112.38 -179.925 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.627 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -144.85 143.13 30.46 Favored 'General case' 0 C--N 1.322 -0.605 0 C-N-CA 119.816 -0.753 . . . . 0.0 111.85 179.319 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.403 ' HB ' ' CG2' ' A' ' 105' ' ' VAL . 91.5 mt -142.08 119.38 7.47 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 CA-C-N 115.48 -0.782 . . . . 0.0 109.061 179.802 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 7.8 m-20 -126.4 109.92 12.76 Favored 'General case' 0 C--N 1.306 -1.32 0 N-CA-C 108.389 -0.967 . . . . 0.0 108.389 176.506 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.551 HG12 ' HA3' ' A' ' 49' ' ' GLY . 29.5 m -148.26 153.42 11.54 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.63 0 N-CA-C 112.111 0.411 . . . . 0.0 112.111 -173.753 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 -146.35 148.34 32.26 Favored 'General case' 0 C--O 1.245 0.82 0 CA-C-N 115.431 -0.804 . . . . 0.0 109.299 174.778 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' SER . . . . . 0.474 ' HB3' ' CD2' ' A' ' 47' ' ' LEU . 37.1 p -80.49 151.54 29.18 Favored 'General case' 0 C--N 1.313 -1.014 0 CA-C-O 121.496 0.665 . . . . 0.0 112.511 -176.88 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -92.76 -13.26 56.99 Favored Glycine 0 N--CA 1.438 -1.168 0 N-CA-C 110.084 -1.206 . . . . 0.0 110.084 173.281 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 28.3 m-20 -137.33 -155.16 0.59 Allowed 'General case' 0 N--CA 1.468 0.445 0 C-N-CA 123.203 0.601 . . . . 0.0 109.403 -179.34 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -79.4 42.12 0.49 Allowed 'General case' 0 N--CA 1.47 0.572 0 CA-C-O 121.099 0.476 . . . . 0.0 110.725 178.117 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 91.43 3.82 68.84 Favored Glycine 0 C--O 1.22 -0.743 0 C-N-CA 121.025 -0.607 . . . . 0.0 112.881 -178.834 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 55.9 tp60 -63.97 -47.67 79.48 Favored 'General case' 0 N--CA 1.462 0.17 0 CA-C-O 120.903 0.382 . . . . 0.0 111.016 179.575 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 9.4 t -133.32 127.75 34.23 Favored 'General case' 0 C--N 1.312 -1.059 0 C-N-CA 120.72 -0.392 . . . . 0.0 110.113 177.551 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' LEU . . . . . 0.474 ' CD2' ' HB3' ' A' ' 40' ' ' SER . 64.9 mt -109.08 127.96 54.58 Favored 'General case' 0 N--CA 1.447 -0.618 0 N-CA-C 109.662 -0.496 . . . . 0.0 109.662 179.636 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 65.2 m-80 -121.97 147.1 46.47 Favored 'General case' 0 C--N 1.313 -0.982 0 N-CA-C 109.558 -0.534 . . . . 0.0 109.558 176.8 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.551 ' HA3' HG12 ' A' ' 38' ' ' VAL . . . 176.13 -154.4 16.88 Favored Glycine 0 N--CA 1.433 -1.557 0 C-N-CA 119.925 -1.131 . . . . 0.0 113.064 179.602 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 89.9 m -129.35 130.7 46.39 Favored 'General case' 0 N--CA 1.436 -1.159 0 C-N-CA 122.668 0.387 . . . . 0.0 111.13 -177.483 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 44.9 mtp -110.08 151.27 27.42 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.394 -0.367 . . . . 0.0 110.927 177.846 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.627 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 23.7 m -132.84 127.77 35.2 Favored 'General case' 0 C--N 1.315 -0.898 0 N-CA-C 110.185 -0.302 . . . . 0.0 110.185 176.009 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 53' ' ' TYR . . . . . 0.452 ' CD1' ' HB3' ' A' ' 31' ' ' GLN . 83.6 m-85 -92.48 163.21 13.91 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.867 178.721 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -61.31 103.36 0.29 Allowed 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.969 -178.553 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 94.77 -6.59 70.24 Favored Glycine 0 CA--C 1.51 -0.258 0 C-N-CA 120.863 -0.684 . . . . 0.0 113.267 177.975 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 69.8 mm-40 -104.82 -179.24 3.89 Favored 'General case' 0 C--N 1.311 -1.102 0 CA-C-O 120.709 0.29 . . . . 0.0 110.836 -178.347 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -99.06 173.73 26.86 Favored Glycine 0 N--CA 1.444 -0.796 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.33 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -68.66 139.38 44.08 Favored 'Trans proline' 0 CA--C 1.538 0.709 0 C-N-CA 122.818 2.345 . . . . 0.0 112.588 179.503 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 50.2 pt -131.93 167.17 27.0 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.079 178.372 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -78.53 139.09 21.92 Favored Glycine 0 N--CA 1.446 -0.677 0 N-CA-C 111.019 -0.832 . . . . 0.0 111.019 179.459 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.547 ' CD2' HG11 ' A' ' 38' ' ' VAL . 29.1 t80 -131.31 129.71 41.82 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 120.953 0.406 . . . . 0.0 111.583 -177.479 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 55.4 ttm-85 -127.11 130.06 49.13 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.514 -0.766 . . . . 0.0 110.493 178.951 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.455 ' HB1' ' HB3' ' A' ' 71' ' ' TYR . . . -129.27 132.32 47.16 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-O 120.594 0.235 . . . . 0.0 110.796 177.175 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 85.3 m -117.31 125.47 51.12 Favored 'General case' 0 C--N 1.316 -0.861 0 CA-C-O 120.996 0.427 . . . . 0.0 110.74 179.637 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 65' ' ' LEU . . . . . 0.507 ' HG ' ' H ' ' A' ' 67' ' ' GLY . 66.6 tp -71.52 132.89 45.36 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.759 -0.655 . . . . 0.0 112.544 -177.579 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -85.94 -16.15 39.33 Favored 'General case' 0 N--CA 1.471 0.577 0 CA-C-N 115.29 -0.868 . . . . 0.0 109.898 174.743 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.507 ' H ' ' HG ' ' A' ' 65' ' ' LEU . . . 103.7 7.61 41.68 Favored Glycine 0 N--CA 1.463 0.44 0 CA-C-N 115.527 -0.76 . . . . 0.0 112.7 177.471 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 29.7 p-10 -137.73 39.65 2.39 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-O 120.851 0.358 . . . . 0.0 110.592 -179.331 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 89.0 m-20 68.9 -1.72 1.96 Allowed 'General case' 0 N--CA 1.485 1.281 0 C-N-CA 123.528 0.731 . . . . 0.0 112.128 -178.558 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 15.3 m -91.82 132.23 36.59 Favored 'General case' 0 C--N 1.314 -0.948 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 177.456 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.455 ' HB3' ' HB1' ' A' ' 63' ' ' ALA . 79.1 m-85 -124.09 133.96 53.49 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.741 -179.25 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 79.9 tt0 -87.13 123.6 32.35 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 174.691 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.481 HG13 ' CE1' ' A' ' 61' ' ' PHE . 48.8 t -99.37 128.61 50.92 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 N-CA-C 112.826 0.676 . . . . 0.0 112.826 -175.656 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 75.4 mt-10 -127.19 121.81 32.34 Favored 'General case' 0 CA--C 1.535 0.378 0 CA-C-N 114.794 -1.094 . . . . 0.0 108.467 175.194 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' ASN . . . . . 0.421 ' OD1' ' HD1' ' A' ' 61' ' ' PHE . 96.4 m-20 -108.42 153.01 23.91 Favored 'General case' 0 C--O 1.236 0.393 0 N-CA-C 112.56 0.578 . . . . 0.0 112.56 -176.283 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 60.2 tt0 -127.72 125.55 40.19 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.358 -0.837 . . . . 0.0 109.389 -179.775 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 6.6 p90 -127.29 4.4 6.33 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 112.734 0.642 . . . . 0.0 112.734 -178.246 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -84.74 -1.88 88.87 Favored Glycine 0 CA--C 1.521 0.415 0 C-N-CA 120.561 -0.828 . . . . 0.0 111.954 178.242 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 106.14 -153.83 16.99 Favored Glycine 0 CA--C 1.497 -1.037 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 -179.717 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -62.43 -32.54 73.41 Favored 'General case' 0 CA--C 1.514 -0.422 0 CA-C-N 117.675 0.738 . . . . 0.0 109.217 173.827 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 47.7 m -84.78 -175.35 5.74 Favored 'General case' 0 N--CA 1.438 -1.04 0 CA-C-N 114.947 -1.024 . . . . 0.0 110.016 176.588 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 75.78 147.22 0.12 Allowed Pre-proline 0 N--CA 1.471 0.578 0 C-N-CA 123.997 0.919 . . . . 0.0 111.701 -179.445 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -73.76 169.19 22.95 Favored 'Trans proline' 0 C--O 1.238 0.508 0 C-N-CA 122.874 2.383 . . . . 0.0 111.807 178.999 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 84' ' ' TRP . . . . . . . . . . . . . 82.7 m95 -87.87 145.65 25.96 Favored 'General case' 0 N--CA 1.447 -0.589 0 N-CA-C 109.524 -0.547 . . . . 0.0 109.524 -179.911 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 94.3 m-70 -116.97 143.38 45.78 Favored 'General case' 0 C--N 1.317 -0.836 0 N-CA-C 110.033 -0.358 . . . . 0.0 110.033 -179.551 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 13.5 m -63.01 137.02 58.14 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-O 120.802 0.334 . . . . 0.0 110.904 -178.748 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -112.83 -48.92 0.6 Allowed Glycine 0 N--CA 1.447 -0.573 0 C-N-CA 121.228 -0.511 . . . . 0.0 112.371 -179.632 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 152.95 -167.95 31.75 Favored Glycine 0 C--O 1.214 -1.155 0 C-N-CA 120.257 -0.973 . . . . 0.0 112.121 179.201 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 16.1 m120 -111.99 118.88 36.67 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 117.082 0.441 . . . . 0.0 110.488 179.868 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 27.4 m0 -111.01 155.27 22.98 Favored 'General case' 0 C--N 1.321 -0.651 0 N-CA-C 110.25 -0.278 . . . . 0.0 110.25 -179.306 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.425 ' O ' ' HB3' ' A' ' 23' ' ' TRP . 49.2 mm -110.93 116.61 52.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 N-CA-C 109.179 -0.674 . . . . 0.0 109.179 177.893 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 92' ' ' LEU . . . . . 0.45 ' HB2' ' CE1' ' A' ' 71' ' ' TYR . 77.9 mt -128.98 81.72 2.04 Favored 'General case' 0 C--O 1.272 2.267 0 CA-C-O 121.772 0.796 . . . . 0.0 112.069 -177.996 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 166.22 112.61 0.26 Allowed Glycine 0 N--CA 1.442 -0.92 0 CA-C-N 115.222 -0.899 . . . . 0.0 111.771 179.159 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 94' ' ' SER . . . . . 0.439 ' HB2' ' O ' ' A' ' 20' ' ' GLY . 77.4 p -86.01 -10.94 54.19 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 121.277 0.56 . . . . 0.0 110.761 179.887 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 98.6 mtt180 -111.44 154.24 24.96 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.556 -0.747 . . . . 0.0 109.413 -179.702 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -70.65 -53.19 16.75 Favored 'General case' 0 N--CA 1.472 0.669 0 N-CA-C 113.501 0.926 . . . . 0.0 113.501 -172.348 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 94.8 m-20 -115.0 36.47 3.86 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.75 0.31 . . . . 0.0 111.4 -176.769 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 98' ' ' GLN . . . . . 0.418 ' HG3' ' HB3' ' A' ' 120' ' ' TYR . 38.1 tp60 -103.47 -59.42 1.72 Allowed 'General case' 0 C--N 1.316 -0.853 0 C-N-CA 120.484 -0.486 . . . . 0.0 110.651 -178.681 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 88.8 m-20 74.62 133.72 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.599 0 O-C-N 123.894 0.746 . . . . 0.0 111.812 177.994 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.41 HG21 ' CH2' ' A' ' 23' ' ' TRP . 73.6 t -80.35 133.24 29.96 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.489 0 C-N-CA 120.094 -0.642 . . . . 0.0 111.736 178.727 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 26.8 m -111.19 -31.93 2.24 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.487 0 N-CA-C 112.73 0.641 . . . . 0.0 112.73 -179.621 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 102' ' ' ALA . . . . . 0.543 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -146.57 138.18 24.55 Favored 'General case' 0 C--N 1.324 -0.537 0 C-N-CA 119.809 -0.756 . . . . 0.0 111.625 179.721 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.446 ' HB ' HG22 ' A' ' 38' ' ' VAL . 96.1 mt -131.85 126.32 56.86 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.124 178.019 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 41.9 t30 -126.18 99.17 5.77 Favored 'General case' 0 C--N 1.314 -0.935 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 174.772 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.494 HG11 ' CD2' ' A' ' 128' ' ' PHE . 30.2 m -139.82 140.52 36.0 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.091 0 CA-C-N 115.85 -0.614 . . . . 0.0 111.78 -175.715 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 81.5 tt0 -144.2 145.58 32.16 Favored 'General case' 0 C--N 1.315 -0.924 0 CA-C-N 115.774 -0.648 . . . . 0.0 109.977 178.051 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 107' ' ' SER . . . . . 0.558 ' HB2' ' OD1' ' A' ' 109' ' ' ASP . 21.6 p -152.71 152.93 32.27 Favored 'General case' 0 C--N 1.312 -1.039 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.559 178.143 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -130.53 15.46 5.49 Favored Glycine 0 CA--C 1.505 -0.538 0 N-CA-C 111.105 -0.798 . . . . 0.0 111.105 178.888 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 109' ' ' ASP . . . . . 0.558 ' OD1' ' HB2' ' A' ' 107' ' ' SER . 10.4 p-10 -96.23 22.82 7.23 Favored 'General case' 0 C--N 1.316 -0.859 0 C-N-CA 123.167 0.587 . . . . 0.0 110.5 -179.521 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 110' ' ' ASP . . . . . 0.516 ' HB2' ' O ' ' A' ' 109' ' ' ASP . 4.2 m-20 81.94 10.42 0.76 Allowed 'General case' 0 N--CA 1.486 1.366 0 C-N-CA 124.131 0.972 . . . . 0.0 112.282 -179.944 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 88.12 12.59 65.45 Favored Glycine 0 N--CA 1.446 -0.661 0 C-N-CA 119.999 -1.096 . . . . 0.0 113.718 176.402 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 98.2 mt-30 -71.74 -38.74 70.39 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 117.046 0.423 . . . . 0.0 110.591 179.178 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 12.7 p -131.18 109.94 10.79 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.928 175.952 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 6.1 mp -92.07 113.55 25.85 Favored 'General case' 0 C--N 1.319 -0.722 0 N-CA-C 109.767 -0.456 . . . . 0.0 109.767 179.713 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 54.3 m-80 -108.3 145.54 34.24 Favored 'General case' 0 C--N 1.311 -1.079 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.836 -178.431 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 166.33 -139.29 5.68 Favored Glycine 0 N--CA 1.433 -1.508 0 C-N-CA 120.121 -1.038 . . . . 0.0 112.996 177.881 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 41.2 p -137.72 160.9 37.96 Favored 'General case' 0 C--N 1.31 -1.145 0 C-N-CA 123.429 0.692 . . . . 0.0 109.924 -177.75 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 19.8 ptm -149.29 161.49 41.94 Favored 'General case' 0 C--N 1.311 -1.087 0 CA-C-O 120.729 0.299 . . . . 0.0 110.698 179.302 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 119' ' ' THR . . . . . 0.543 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 23.5 m -135.39 133.15 38.39 Favored 'General case' 0 C--O 1.246 0.892 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.473 -179.813 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 120' ' ' TYR . . . . . 0.418 ' HB3' ' HG3' ' A' ' 98' ' ' GLN . 12.3 m-85 -99.81 158.81 15.53 Favored 'General case' 0 CA--C 1.515 -0.398 0 CA-C-N 115.946 -0.57 . . . . 0.0 109.798 176.618 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -61.07 122.66 15.54 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 120.608 0.242 . . . . 0.0 111.495 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 68.73 27.86 73.54 Favored Glycine 0 C--N 1.338 0.673 0 CA-C-N 115.969 -0.559 . . . . 0.0 113.243 179.847 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 80.4 tt0 -142.58 155.87 45.03 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 116.872 0.336 . . . . 0.0 110.389 -178.014 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -77.69 161.32 49.66 Favored Glycine 0 CA--C 1.521 0.441 0 C-N-CA 121.169 -0.539 . . . . 0.0 112.707 -178.907 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 23.1 Cg_exo -64.05 141.66 77.81 Favored 'Trans proline' 0 C--N 1.345 0.357 0 C-N-CA 122.802 2.334 . . . . 0.0 112.756 -179.564 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 35.9 pt -133.07 157.83 43.02 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.994 0 CA-C-N 115.402 -0.817 . . . . 0.0 109.763 178.321 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 127' ' ' GLY . . . . . 0.45 ' O ' ' HA ' ' A' ' 8' ' ' ASN . . . -70.32 139.5 30.78 Favored Glycine 0 C--O 1.235 0.209 0 C-N-CA 121.096 -0.574 . . . . 0.0 112.083 179.042 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 128' ' ' PHE . . . . . 0.494 ' CD2' HG11 ' A' ' 105' ' ' VAL . 73.0 t80 -119.05 133.53 55.75 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-O 120.887 0.375 . . . . 0.0 111.221 -177.109 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 62.7 tttm -136.19 105.42 6.0 Favored 'General case' 0 C--N 1.313 -0.986 0 CA-C-N 115.676 -0.693 . . . . 0.0 109.767 176.401 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -100.66 131.16 10.47 Favored Glycine 0 N--CA 1.439 -1.153 0 N-CA-C 110.696 -0.962 . . . . 0.0 110.696 178.917 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 28.5 m -122.24 130.53 53.26 Favored 'General case' 0 C--N 1.312 -1.039 0 N-CA-C 110.007 -0.368 . . . . 0.0 110.007 -179.139 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 132' ' ' LEU . . . . . 0.406 HD23 ' CZ ' ' A' ' 4' ' ' TYR . 3.3 tm? -67.11 135.21 53.25 Favored 'General case' 0 C--O 1.236 0.373 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.231 -178.022 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 26.6 m . . . . . 0 N--CA 1.435 -1.185 0 CA-C-O 118.18 -0.914 . . . . 0.0 109.569 -179.372 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.784 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -147.14 123.2 10.77 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 -177.783 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' TYR . . . . . 0.427 ' CD1' ' HB ' ' A' ' 25' ' ' ILE . 59.2 m-85 -118.24 141.41 48.54 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 112.351 0.5 . . . . 0.0 112.351 -178.134 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 49.3 m-80 -88.68 139.07 30.85 Favored 'General case' 0 C--N 1.316 -0.883 0 N-CA-C 107.763 -1.199 . . . . 0.0 107.763 174.858 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.464 HG21 ' CD1' ' A' ' 23' ' ' TRP . 87.3 t -99.38 115.54 40.4 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.02 0 CA-C-O 121.146 0.498 . . . . 0.0 112.323 -175.0 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.494 ' HB2' ' HB3' ' A' ' 129' ' ' LYS . 42.4 mt-10 -113.99 119.53 37.52 Favored 'General case' 0 C--N 1.311 -1.088 0 CA-C-N 115.025 -0.989 . . . . 0.0 108.58 177.329 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 84.7 m-20 -119.01 136.48 54.1 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 116.571 -0.286 . . . . 0.0 110.752 -177.504 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 58.9 tt0 -124.09 128.29 49.08 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-O 120.866 0.365 . . . . 0.0 110.839 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 14.6 p90 -141.49 148.02 38.78 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 116.153 -0.476 . . . . 0.0 109.993 177.043 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 100.89 2.1 55.08 Favored Glycine 0 N--CA 1.449 -0.47 0 C-N-CA 120.37 -0.919 . . . . 0.0 112.268 178.889 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 114.56 155.83 11.29 Favored Glycine 0 N--CA 1.441 -0.991 0 C-N-CA 120.903 -0.665 . . . . 0.0 112.442 179.543 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 7.6 t -59.1 -20.13 50.69 Favored 'General case' 0 CA--C 1.539 0.54 0 C-N-CA 122.746 0.418 . . . . 0.0 111.616 179.008 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 10.2 m -77.78 -10.01 59.32 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.765 0.317 . . . . 0.0 111.027 179.748 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -89.97 152.09 45.96 Favored Pre-proline 0 C--N 1.325 -0.494 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 179.467 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 78.9 Cg_endo -73.69 161.19 42.43 Favored 'Trans proline' 0 C--O 1.237 0.429 0 C-N-CA 122.625 2.217 . . . . 0.0 112.917 179.765 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 82.7 m95 -85.94 134.7 33.86 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 115.546 -0.752 . . . . 0.0 109.095 178.419 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 46.9 m-80 -113.54 141.68 46.87 Favored 'General case' 0 C--N 1.32 -0.701 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 -177.596 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.405 ' HA ' ' O ' ' A' ' 6' ' ' VAL . 9.2 pt-20 -116.53 122.48 44.81 Favored 'General case' 0 C--N 1.308 -1.221 0 CA-C-O 120.734 0.302 . . . . 0.0 110.455 -178.929 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -137.23 31.64 2.51 Favored Glycine 0 N--CA 1.444 -0.793 0 C-N-CA 119.814 -1.184 . . . . 0.0 113.133 -177.255 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 162.68 179.68 37.41 Favored Glycine 0 N--CA 1.447 -0.58 0 C-N-CA 119.745 -1.217 . . . . 0.0 113.015 179.767 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 26.7 pt20 -136.99 137.03 39.02 Favored 'General case' 0 C--N 1.32 -0.714 0 N-CA-C 109.419 -0.586 . . . . 0.0 109.419 178.905 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' TRP . . . . . 0.464 ' CD1' HG21 ' A' ' 6' ' ' VAL . 38.7 m0 -109.31 151.62 26.34 Favored 'General case' 0 CA--C 1.502 -0.873 0 CA-C-O 120.866 0.365 . . . . 0.0 111.23 -178.513 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 79.1 tt0 -108.86 110.88 22.34 Favored 'General case' 0 N--CA 1.44 -0.926 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 177.689 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.427 ' HB ' ' CD1' ' A' ' 4' ' ' TYR . 89.8 mt -127.79 136.5 60.19 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.892 0 CA-C-N 115.395 -0.82 . . . . 0.0 109.803 -176.679 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 90.86 93.44 1.27 Allowed Glycine 0 N--CA 1.444 -0.795 0 C-N-CA 120.67 -0.776 . . . . 0.0 112.499 177.653 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 3.7 p -94.92 10.2 36.37 Favored 'General case' 0 C--N 1.311 -1.084 0 CA-C-O 121.432 0.634 . . . . 0.0 110.38 178.795 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 39.4 mmt180 -124.84 121.05 33.44 Favored 'General case' 0 N--CA 1.445 -0.682 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 -179.88 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 43.6 m -65.95 -38.85 89.67 Favored 'General case' 0 C--N 1.314 -0.948 0 N-CA-C 112.13 0.418 . . . . 0.0 112.13 -178.205 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 75.0 m-20 -75.05 -38.44 61.4 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 112.345 0.498 . . . . 0.0 112.345 -177.047 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' GLN . . . . . 0.465 ' HA ' ' NE2' ' A' ' 31' ' ' GLN . 9.7 mm-40 -114.49 117.65 31.57 Favored 'General case' 0 CA--C 1.5 -0.942 0 N-CA-C 113.708 1.003 . . . . 0.0 113.708 -176.854 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 4.1 t30 -96.13 160.76 14.27 Favored 'General case' 0 N--CA 1.438 -1.063 0 CA-C-N 114.923 -1.035 . . . . 0.0 108.992 177.017 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 62.5 t -94.06 131.51 40.76 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.491 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.182 -176.744 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 35.5 m -112.46 -11.08 11.96 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.655 0 N-CA-C 112.701 0.63 . . . . 0.0 112.701 178.31 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.649 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -152.52 144.94 24.05 Favored 'General case' 0 CA--C 1.508 -0.66 0 C-N-CA 120.015 -0.674 . . . . 0.0 111.59 177.882 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 91.8 mt -143.97 117.74 3.38 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.373 0 N-CA-C 109.618 -0.512 . . . . 0.0 109.618 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' ASN . . . . . 0.526 ' HA ' ' O ' ' A' ' 103' ' ' ILE . 47.5 m-80 -133.63 112.27 11.3 Favored 'General case' 0 C--N 1.311 -1.078 0 N-CA-C 108.523 -0.918 . . . . 0.0 108.523 175.667 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.49 HG11 ' CD1' ' A' ' 61' ' ' PHE . 22.4 m -148.41 152.02 12.78 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 C-N-CA 120.92 -0.312 . . . . 0.0 111.655 -174.01 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 67.4 tt0 -136.13 142.47 44.24 Favored 'General case' 0 N--CA 1.443 -0.817 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 176.366 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 31.5 p -77.2 147.12 36.61 Favored 'General case' 0 C--N 1.314 -0.935 0 CA-C-O 121.033 0.444 . . . . 0.0 111.641 -177.912 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -94.78 -15.55 45.51 Favored Glycine 0 N--CA 1.451 -0.361 0 N-CA-C 110.512 -1.035 . . . . 0.0 110.512 175.512 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' ASP . . . . . 0.403 ' HB3' ' H ' ' A' ' 43' ' ' ASP . 55.0 m-20 -139.28 -154.69 0.54 Allowed 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 109.257 -0.645 . . . . 0.0 109.257 179.457 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 43' ' ' ASP . . . . . 0.403 ' H ' ' HB3' ' A' ' 42' ' ' ASP . 20.9 m-20 -73.25 38.25 0.09 Allowed 'General case' 0 N--CA 1.476 0.846 0 C-N-CA 122.893 0.477 . . . . 0.0 111.487 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 92.74 -6.7 77.22 Favored Glycine 0 C--O 1.217 -0.95 0 C-N-CA 121.173 -0.537 . . . . 0.0 112.66 179.848 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 59.3 mt-30 -63.0 -39.9 96.14 Favored 'General case' 0 C--N 1.326 -0.416 0 N-CA-C 112.137 0.421 . . . . 0.0 112.137 -178.364 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' THR . . . . . 0.506 ' HA ' ' O ' ' A' ' 63' ' ' ALA . 5.2 t -128.18 115.4 18.32 Favored 'General case' 0 C--N 1.311 -1.065 0 CA-C-O 121.187 0.518 . . . . 0.0 110.801 177.812 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 47' ' ' LEU . . . . . 0.44 ' O ' ' HA ' ' A' ' 62' ' ' ARG . 79.5 mt -99.53 130.42 45.77 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.855 -0.612 . . . . 0.0 109.595 178.442 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 49.2 m-80 -130.11 143.17 50.64 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 116.488 -0.324 . . . . 0.0 110.469 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.431 ' HA3' ' HA ' ' A' ' 38' ' ' VAL . . . 171.08 -150.79 14.32 Favored Glycine 0 N--CA 1.44 -1.086 0 C-N-CA 120.084 -1.055 . . . . 0.0 113.262 179.978 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 25.1 m -125.99 131.48 52.23 Favored 'General case' 0 C--N 1.317 -0.838 0 C-N-CA 122.965 0.506 . . . . 0.0 110.19 -177.199 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' MET . . . . . 0.44 ' SD ' ' HH2' ' A' ' 90' ' ' TRP . 62.5 ttp -125.53 150.27 47.57 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 -179.834 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.649 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 27.7 m -126.98 130.74 50.64 Favored 'General case' 0 C--O 1.243 0.723 0 CA-C-O 120.735 0.302 . . . . 0.0 111.316 -178.81 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 53' ' ' TYR . . . . . 0.437 ' HB3' ' OE1' ' A' ' 31' ' ' GLN . 47.0 m-85 -90.61 162.2 15.08 Favored 'General case' 0 C--O 1.233 0.218 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.323 177.247 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -60.42 107.84 0.73 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.799 -0.637 . . . . 0.0 112.634 -178.072 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 88.33 -0.27 83.26 Favored Glycine 0 N--CA 1.454 -0.138 0 CA-C-N 115.796 -0.638 . . . . 0.0 112.854 178.05 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 73.2 mm-40 -108.21 179.22 4.27 Favored 'General case' 0 C--N 1.314 -0.937 0 CA-C-O 120.705 0.288 . . . . 0.0 110.6 -178.744 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -97.71 176.71 31.25 Favored Glycine 0 N--CA 1.439 -1.144 0 C-N-CA 120.678 -0.773 . . . . 0.0 111.452 178.512 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo -67.13 139.5 50.81 Favored 'Trans proline' 0 CA--C 1.535 0.539 0 C-N-CA 122.501 2.134 . . . . 0.0 112.277 179.507 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 48.3 pt -133.01 166.73 28.56 Favored 'Isoleucine or valine' 0 C--O 1.24 0.554 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.137 178.243 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -75.22 138.59 23.66 Favored Glycine 0 CA--C 1.521 0.464 0 C-N-CA 120.724 -0.751 . . . . 0.0 111.957 -179.541 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.49 ' CD1' HG11 ' A' ' 38' ' ' VAL . 50.2 t80 -124.52 129.84 51.35 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 120.519 0.2 . . . . 0.0 110.916 -178.982 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 62' ' ' ARG . . . . . 0.44 ' HA ' ' O ' ' A' ' 47' ' ' LEU . 62.7 ttp85 -140.67 134.65 30.69 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.22 176.048 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.506 ' O ' ' HA ' ' A' ' 46' ' ' THR . . . -135.08 142.86 46.38 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.567 -0.288 . . . . 0.0 111.304 179.794 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 49.6 m -122.05 131.48 54.01 Favored 'General case' 0 CA--C 1.546 0.803 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.695 -179.608 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 65' ' ' LEU . . . . . 0.543 HD11 ' O ' ' A' ' 68' ' ' ASN . 55.9 tp -71.03 126.19 28.91 Favored 'General case' 0 CA--C 1.535 0.391 0 N-CA-C 113.1 0.778 . . . . 0.0 113.1 -176.9 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.405 HD13 ' HA ' ' A' ' 66' ' ' LEU . 3.9 mm? -73.4 -35.19 65.84 Favored 'General case' 0 N--CA 1.473 0.692 0 CA-C-N 115.204 -0.907 . . . . 0.0 111.751 176.349 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 133.05 2.67 3.73 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 111.052 -0.819 . . . . 0.0 111.052 -175.828 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 68' ' ' ASN . . . . . 0.543 ' O ' HD11 ' A' ' 65' ' ' LEU . 31.5 p-10 -131.41 -150.67 0.43 Allowed 'General case' 0 C--N 1.31 -1.147 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.42 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 85.6 m-20 -90.09 4.21 51.01 Favored 'General case' 0 C--N 1.323 -0.545 0 C-N-CA 120.407 -0.517 . . . . 0.0 110.33 179.58 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 24.0 m -101.27 144.56 29.98 Favored 'General case' 0 N--CA 1.448 -0.572 0 CA-C-O 121.362 0.601 . . . . 0.0 111.232 -178.833 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.5 ' HB3' ' HB1' ' A' ' 63' ' ' ALA . 96.3 m-85 -124.33 145.54 49.36 Favored 'General case' 0 C--N 1.312 -1.042 0 CA-C-N 115.463 -0.789 . . . . 0.0 110.617 179.557 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 72' ' ' GLU . . . . . 0.414 ' O ' ' HA ' ' A' ' 63' ' ' ALA . 79.5 tt0 -86.24 112.82 21.73 Favored 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 107.371 -1.344 . . . . 0.0 107.371 174.565 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 75.4 t -97.77 129.68 47.58 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.103 0 CA-C-O 121.4 0.619 . . . . 0.0 112.064 -175.311 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 45.8 mt-10 -128.05 124.76 37.87 Favored 'General case' 0 N--CA 1.438 -1.049 0 CA-C-N 114.891 -1.05 . . . . 0.0 108.748 177.474 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 90.4 m-20 -104.04 147.74 27.04 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-O 121.057 0.456 . . . . 0.0 111.286 -177.478 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 76' ' ' GLN . . . . . 0.539 ' HB2' ' CE3' ' A' ' 84' ' ' TRP . 61.6 tt0 -115.1 119.61 37.02 Favored 'General case' 0 C--N 1.31 -1.11 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.672 -179.68 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 14.9 p90 -138.81 152.85 48.22 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 116.478 -0.328 . . . . 0.0 110.458 177.806 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 147.04 -122.64 1.62 Allowed Glycine 0 N--CA 1.444 -0.825 0 N-CA-C 110.119 -1.192 . . . . 0.0 110.119 -177.295 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.523 ' O ' ' HB2' ' A' ' 80' ' ' ASP . . . -119.31 23.18 8.64 Favored Glycine 0 N--CA 1.444 -0.785 0 C-N-CA 120.291 -0.956 . . . . 0.0 111.115 178.228 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 80' ' ' ASP . . . . . 0.523 ' HB2' ' O ' ' A' ' 79' ' ' GLY . 12.8 m-20 92.24 -43.47 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.836 0 C-N-CA 124.96 1.304 . . . . 0.0 110.587 178.348 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 34.5 m -76.78 -2.46 33.26 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 121.312 0.577 . . . . 0.0 110.7 175.901 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -66.62 157.39 83.27 Favored Pre-proline 0 C--N 1.324 -0.519 0 CA-C-N 115.353 -0.84 . . . . 0.0 112.029 -178.447 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 75.6 Cg_endo -77.9 -172.86 1.6 Allowed 'Trans proline' 0 CA--C 1.537 0.644 0 C-N-CA 122.752 2.301 . . . . 0.0 112.453 179.102 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 84' ' ' TRP . . . . . 0.539 ' CE3' ' HB2' ' A' ' 76' ' ' GLN . 95.1 m95 -98.13 147.5 24.5 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.822 -178.564 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 94.4 m-70 -128.74 146.38 50.91 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.061 -0.518 . . . . 0.0 109.964 -179.662 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 28.8 p -65.21 136.56 56.78 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-O 121.04 0.448 . . . . 0.0 111.421 -178.735 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -108.27 -52.18 0.69 Allowed Glycine 0 N--CA 1.437 -1.269 0 C-N-CA 120.745 -0.74 . . . . 0.0 111.55 177.968 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 151.45 -166.72 30.74 Favored Glycine 0 CA--C 1.52 0.345 0 C-N-CA 120.918 -0.658 . . . . 0.0 112.045 -179.778 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 19.3 m120 -112.43 119.21 37.46 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 117.014 0.407 . . . . 0.0 110.195 -179.862 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 90' ' ' TRP . . . . . 0.44 ' HH2' ' SD ' ' A' ' 51' ' ' MET . 29.3 m0 -117.12 154.02 31.77 Favored 'General case' 0 N--CA 1.47 0.564 0 CA-C-N 116.467 -0.333 . . . . 0.0 111.123 -177.129 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 89.0 mt -108.6 119.19 57.73 Favored 'Isoleucine or valine' 0 C--O 1.242 0.707 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 176.991 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 92' ' ' LEU . . . . . 0.426 ' HB3' HG21 ' A' ' 100' ' ' VAL . 86.7 mt -132.05 83.3 2.07 Favored 'General case' 0 C--O 1.267 1.981 0 N-CA-C 113.127 0.788 . . . . 0.0 113.127 -174.602 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 164.16 116.58 0.37 Allowed Glycine 0 C--O 1.225 -0.439 0 CA-C-N 115.083 -0.962 . . . . 0.0 111.31 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 75.2 p -90.33 -9.36 48.05 Favored 'General case' 0 N--CA 1.463 0.191 0 CA-C-N 117.217 0.509 . . . . 0.0 111.502 -179.58 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -100.38 145.6 27.99 Favored 'General case' 0 N--CA 1.444 -0.763 0 CA-C-O 120.981 0.419 . . . . 0.0 110.872 179.606 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -68.74 -36.77 78.8 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 115.653 -0.703 . . . . 0.0 112.738 -173.463 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 30.5 p-10 -121.6 28.97 7.41 Favored 'General case' 0 C--N 1.313 -1.009 0 CA-C-O 120.715 0.293 . . . . 0.0 111.513 -176.627 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 98' ' ' GLN . . . . . 0.554 ' NE2' ' HB2' ' A' ' 123' ' ' GLU . 53.9 tt0 -157.2 124.44 5.21 Favored 'General case' 0 C--N 1.319 -0.725 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 -177.299 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 96.9 m-20 -113.52 177.66 4.56 Favored 'General case' 0 C--O 1.245 0.819 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.674 -175.355 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.461 HG11 ' CH2' ' A' ' 23' ' ' TRP . 21.2 m -80.41 141.06 15.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.75 -0.659 . . . . 0.0 112.193 -177.656 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 28.7 m -120.95 -26.45 2.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.726 176.425 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 102' ' ' ALA . . . . . 0.639 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -147.26 138.56 23.89 Favored 'General case' 0 C--N 1.324 -0.512 0 C-N-CA 120.872 -0.331 . . . . 0.0 110.65 177.404 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.526 ' O ' ' HA ' ' A' ' 37' ' ' ASN . 87.7 mt -132.23 127.03 56.9 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.029 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 178.822 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 9.6 t30 -128.04 91.06 3.2 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.13 178.414 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.501 HG11 ' HD2' ' A' ' 128' ' ' PHE . 22.3 m -145.06 153.26 14.33 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.615 0 N-CA-C 113.895 1.072 . . . . 0.0 113.895 -176.453 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 91.4 mt-10 -138.95 163.1 33.22 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 114.223 -1.353 . . . . 0.0 108.132 173.896 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 32.7 t -108.2 -51.02 2.95 Favored 'General case' 0 C--N 1.311 -1.1 0 CA-C-O 120.797 0.332 . . . . 0.0 110.893 -179.616 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 84.66 -14.79 45.35 Favored Glycine 0 N--CA 1.446 -0.66 0 N-CA-C 111.101 -0.8 . . . . 0.0 111.101 -176.768 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 109' ' ' ASP . . . . . 0.416 ' HB3' ' H ' ' A' ' 110' ' ' ASP . 54.2 m-20 -117.25 -151.29 0.48 Allowed 'General case' 0 N--CA 1.45 -0.432 0 C-N-CA 123.074 0.55 . . . . 0.0 109.999 -179.414 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 110' ' ' ASP . . . . . 0.416 ' H ' ' HB3' ' A' ' 109' ' ' ASP . 12.5 p-10 -88.55 16.43 6.59 Favored 'General case' 0 C--N 1.322 -0.618 0 C-N-CA 122.628 0.371 . . . . 0.0 111.18 -178.881 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 96.29 9.68 56.63 Favored Glycine 0 N--CA 1.444 -0.828 0 C-N-CA 120.086 -1.054 . . . . 0.0 113.045 -178.339 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 112' ' ' GLN . . . . . 0.475 ' HA ' HD12 ' A' ' 132' ' ' LEU . 28.1 tt0 -64.3 -45.4 88.12 Favored 'General case' 0 C--O 1.239 0.521 0 CA-C-O 120.833 0.349 . . . . 0.0 111.235 179.934 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 113' ' ' THR . . . . . 0.489 ' HA ' ' O ' ' A' ' 130' ' ' GLY . 21.0 p -132.73 130.38 39.92 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.289 -179.831 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 114' ' ' LEU . . . . . 0.507 ' O ' ' HA ' ' A' ' 129' ' ' LYS . 4.3 mm? -105.86 130.5 53.81 Favored 'General case' 0 C--N 1.319 -0.739 0 N-CA-C 108.49 -0.93 . . . . 0.0 108.49 176.599 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 27.7 p30 -135.1 152.25 51.47 Favored 'General case' 0 C--N 1.316 -0.861 0 C-N-CA 120.191 -0.603 . . . . 0.0 112.274 -179.152 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 152.28 -129.38 2.77 Favored Glycine 0 N--CA 1.441 -1.025 0 CA-C-N 115.461 -0.79 . . . . 0.0 112.337 178.244 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 21.4 p -131.72 156.13 46.45 Favored 'General case' 0 C--N 1.316 -0.879 0 CA-C-O 121.012 0.434 . . . . 0.0 111.02 -178.163 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 118' ' ' MET . . . . . 0.521 ' SD ' ' HB2' ' A' ' 128' ' ' PHE . 19.5 ptm -140.64 149.74 42.67 Favored 'General case' 0 C--N 1.314 -0.963 0 CA-C-N 116.062 -0.517 . . . . 0.0 109.968 -178.6 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 119' ' ' THR . . . . . 0.639 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 23.3 m -131.23 129.46 41.64 Favored 'General case' 0 C--N 1.313 -1.016 0 CA-C-O 120.804 0.335 . . . . 0.0 111.019 -179.696 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 120' ' ' TYR . . . . . 0.466 ' HB3' ' HG2' ' A' ' 98' ' ' GLN . 45.0 m-85 -101.47 161.18 13.82 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.947 178.66 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -59.84 121.83 12.72 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.094 179.779 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 66.03 24.26 71.62 Favored Glycine 0 C--N 1.336 0.536 0 C-N-CA 121.117 -0.564 . . . . 0.0 112.336 -179.214 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 123' ' ' GLU . . . . . 0.554 ' HB2' ' NE2' ' A' ' 98' ' ' GLN . 32.5 tp10 -127.95 164.87 21.37 Favored 'General case' 0 C--N 1.318 -0.78 0 N-CA-C 109.622 -0.51 . . . . 0.0 109.622 -177.083 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -93.49 159.66 24.18 Favored Glycine 0 N--CA 1.443 -0.837 0 N-CA-C 110.803 -0.919 . . . . 0.0 110.803 177.318 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 125' ' ' PRO . . . . . 0.438 ' HA ' ' O ' ' A' ' 118' ' ' MET . 37.8 Cg_endo -66.2 136.15 42.91 Favored 'Trans proline' 0 CA--C 1.53 0.286 0 C-N-CA 122.16 1.907 . . . . 0.0 112.233 179.67 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 41.7 pt -132.65 166.4 29.41 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.004 178.929 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -70.02 134.73 25.53 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.912 -0.661 . . . . 0.0 112.197 -179.7 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 128' ' ' PHE . . . . . 0.521 ' HB2' ' SD ' ' A' ' 118' ' ' MET . 25.4 t80 -124.84 134.75 52.61 Favored 'General case' 0 CA--C 1.513 -0.443 0 CA-C-O 121.173 0.511 . . . . 0.0 111.443 -179.45 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 129' ' ' LYS . . . . . 0.507 ' HA ' ' O ' ' A' ' 114' ' ' LEU . 62.3 tttm -140.86 123.64 16.21 Favored 'General case' 0 N--CA 1.435 -1.196 0 CA-C-N 115.073 -0.967 . . . . 0.0 109.494 178.591 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 130' ' ' GLY . . . . . 0.489 ' O ' ' HA ' ' A' ' 113' ' ' THR . . . -117.32 131.61 9.51 Favored Glycine 0 N--CA 1.444 -0.809 0 N-CA-C 110.973 -0.851 . . . . 0.0 110.973 178.948 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 32.1 m -125.32 133.88 52.44 Favored 'General case' 0 C--N 1.314 -0.973 0 CA-C-N 117.015 0.408 . . . . 0.0 110.709 -177.249 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 132' ' ' LEU . . . . . 0.475 HD12 ' HA ' ' A' ' 112' ' ' GLN . 78.3 mt -62.37 135.14 57.31 Favored 'General case' 0 C--O 1.238 0.473 0 CA-C-O 120.741 0.305 . . . . 0.0 110.779 177.283 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 8.6 t . . . . . 0 C--O 1.249 1.051 0 CA-C-O 118.368 -0.825 . . . . 0.0 110.34 178.391 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.468 0.474 0 N-CA-C 110.028 -0.36 . . . . 0.0 110.028 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 3' ' ' LEU . . . . . 0.525 HD13 ' N ' ' A' ' 4' ' ' TYR . 1.4 tm? -97.42 132.41 43.15 Favored 'General case' 0 C--N 1.316 -0.85 0 N-CA-C 109.584 -0.525 . . . . 0.0 109.584 -177.817 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 4' ' ' TYR . . . . . 0.525 ' N ' HD13 ' A' ' 3' ' ' LEU . 89.8 m-85 -122.91 147.74 46.24 Favored 'General case' 0 C--O 1.236 0.351 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.649 -177.96 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 5' ' ' ASN . . . . . 0.55 ' O ' ' HA2' ' A' ' 130' ' ' GLY . 18.7 m120 -94.73 134.5 37.26 Favored 'General case' 0 CA--C 1.506 -0.715 0 N-CA-C 106.34 -1.726 . . . . 0.0 106.34 174.792 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.402 HG21 ' CG ' ' A' ' 23' ' ' TRP . 59.3 t -118.2 126.84 75.28 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.891 0 C-N-CA 119.492 -0.883 . . . . 0.0 113.031 -175.443 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.547 ' HA ' ' HA ' ' A' ' 19' ' ' GLU . 98.4 mt-10 -115.06 139.72 49.64 Favored 'General case' 0 N--CA 1.439 -1.012 0 CA-C-N 114.477 -1.238 . . . . 0.0 108.792 176.326 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' ASN . . . . . 0.433 ' HB3' HD12 ' A' ' 126' ' ' ILE . 81.4 m-20 -119.35 144.05 47.07 Favored 'General case' 0 C--N 1.313 -1.013 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.309 -177.045 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 60.4 tt0 -121.68 114.89 21.78 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 174.605 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 45.8 p90 -129.16 139.08 52.06 Favored 'General case' 0 C--N 1.317 -0.832 0 C-N-CA 121.028 -0.269 . . . . 0.0 110.913 -178.309 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 102.09 11.77 35.92 Favored Glycine 0 N--CA 1.444 -0.783 0 C-N-CA 120.363 -0.922 . . . . 0.0 112.582 178.616 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 99.7 167.37 29.66 Favored Glycine 0 N--CA 1.444 -0.816 0 C-N-CA 120.446 -0.883 . . . . 0.0 113.28 -179.43 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 15.6 m -56.2 -25.61 47.76 Favored 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 123.158 0.583 . . . . 0.0 112.227 179.474 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 14.1 p -61.23 -21.04 63.49 Favored 'General case' 0 CA--C 1.542 0.671 0 N-CA-C 112.25 0.463 . . . . 0.0 112.25 177.268 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -90.84 142.93 28.05 Favored Pre-proline 0 C--N 1.321 -0.66 0 CA-C-O 120.541 0.21 . . . . 0.0 110.733 179.7 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 95.3 Cg_endo -78.37 170.51 18.36 Favored 'Trans proline' 0 C--O 1.238 0.518 0 C-N-CA 122.803 2.335 . . . . 0.0 112.241 179.692 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 96.4 m95 -86.97 124.88 33.65 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.118 -0.492 . . . . 0.0 109.905 -179.77 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 47.8 m-80 -123.26 126.19 46.46 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.991 -178.87 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.547 ' HA ' ' HA ' ' A' ' 7' ' ' GLU . 15.3 pt-20 -68.94 133.51 48.29 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 109.65 -0.5 . . . . 0.0 109.65 177.631 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -134.31 22.78 3.72 Favored Glycine 0 N--CA 1.443 -0.858 0 C-N-CA 119.566 -1.302 . . . . 0.0 112.876 -179.308 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' GLY . . . . . 0.549 ' HA3' ' HB2' ' A' ' 94' ' ' SER . . . 145.07 -170.9 26.38 Favored Glycine 0 N--CA 1.449 -0.472 0 C-N-CA 120.17 -1.014 . . . . 0.0 113.293 177.352 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 25.5 pt20 -131.73 136.05 47.3 Favored 'General case' 0 C--N 1.324 -0.514 0 C-N-CA 122.604 0.362 . . . . 0.0 110.634 -178.337 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' TRP . . . . . 0.469 ' CH2' HG21 ' A' ' 100' ' ' VAL . 26.2 m0 -110.76 165.88 11.47 Favored 'General case' 0 N--CA 1.469 0.491 0 CA-C-O 120.668 0.27 . . . . 0.0 110.482 179.01 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 40.1 tt0 -128.87 116.56 19.62 Favored 'General case' 0 C--N 1.32 -0.68 0 C-N-CA 120.46 -0.496 . . . . 0.0 110.166 175.827 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.49 ' HB ' ' CE1' ' A' ' 4' ' ' TYR . 98.7 mt -130.18 137.49 56.26 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.764 0 CA-C-N 115.5 -0.773 . . . . 0.0 110.196 -177.567 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 93.37 102.32 1.59 Allowed Glycine 0 N--CA 1.446 -0.683 0 C-N-CA 120.775 -0.726 . . . . 0.0 111.892 179.451 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 4.2 p -101.57 12.17 37.71 Favored 'General case' 0 C--N 1.312 -1.036 0 CA-C-O 121.01 0.433 . . . . 0.0 111.293 -178.832 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' ARG . . . . . 0.401 HH11 ' HD3' ' A' ' 28' ' ' ARG . 62.6 mtt-85 -130.64 130.32 43.79 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.053 -178.932 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 15.6 m -66.78 -36.64 82.87 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.094 0.473 . . . . 0.0 112.052 -179.145 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 64.8 m-20 -73.93 -43.24 58.96 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.965 -0.562 . . . . 0.0 112.387 -175.505 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 8.9 mm100 -121.41 122.12 39.08 Favored 'General case' 0 CA--C 1.506 -0.727 0 N-CA-C 113.106 0.78 . . . . 0.0 113.106 -176.42 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' ASN . . . . . 0.418 ' ND2' ' HA3' ' A' ' 111' ' ' GLY . 62.3 t30 -104.39 172.72 6.64 Favored 'General case' 0 N--CA 1.442 -0.837 0 CA-C-N 114.893 -1.049 . . . . 0.0 109.499 178.201 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 59.0 t -106.86 133.68 50.73 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.164 0 N-CA-C 112.287 0.477 . . . . 0.0 112.287 -174.803 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 29.3 m -113.73 -18.0 7.9 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.609 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.947 178.01 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.706 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -144.99 145.27 31.44 Favored 'General case' 0 CA--C 1.513 -0.459 0 C-N-CA 119.968 -0.693 . . . . 0.0 111.464 178.928 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 86.8 mt -144.67 126.71 9.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 -178.916 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' ASN . . . . . 0.487 ' HA ' ' O ' ' A' ' 103' ' ' ILE . 31.3 m-80 -136.64 109.12 7.39 Favored 'General case' 0 C--N 1.312 -1.038 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 176.888 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.467 HG11 ' CD1' ' A' ' 61' ' ' PHE . 25.3 m -151.07 157.59 5.38 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 C-N-CA 120.917 -0.313 . . . . 0.0 111.165 -172.833 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -142.71 150.71 40.48 Favored 'General case' 0 N--CA 1.447 -0.596 0 CA-C-N 115.8 -0.636 . . . . 0.0 109.925 177.253 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' SER . . . . . 0.447 ' OG ' ' HB ' ' A' ' 101' ' ' VAL . 35.1 p -79.97 153.59 28.8 Favored 'General case' 0 C--N 1.318 -0.79 0 N-CA-C 112.477 0.547 . . . . 0.0 112.477 -177.682 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -115.45 -68.31 0.44 Allowed Glycine 0 N--CA 1.434 -1.474 0 CA-C-N 115.114 -0.948 . . . . 0.0 110.848 175.151 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 22.5 m-20 -89.95 81.57 6.26 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 112.154 0.427 . . . . 0.0 112.154 -179.001 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 84.5 m-20 51.22 31.53 6.96 Favored 'General case' 0 N--CA 1.491 1.576 0 N-CA-C 113.424 0.898 . . . . 0.0 113.424 174.791 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 88.84 -14.58 59.87 Favored Glycine 0 C--O 1.223 -0.57 0 C-N-CA 120.116 -1.04 . . . . 0.0 113.139 179.229 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 61.3 mt-30 -70.11 -30.44 67.65 Favored 'General case' 0 CA--C 1.512 -0.503 0 CA-C-O 121.193 0.521 . . . . 0.0 110.749 178.99 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 31.9 m -119.37 130.61 55.42 Favored 'General case' 0 N--CA 1.434 -1.247 0 CA-C-N 115.476 -0.783 . . . . 0.0 108.9 -179.641 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 84.6 mt -124.81 133.96 52.93 Favored 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 108.892 -0.781 . . . . 0.0 108.892 -179.063 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 28.1 p30 -136.8 148.77 47.37 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-O 121.122 0.487 . . . . 0.0 111.146 178.997 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 164.28 -145.04 9.94 Favored Glycine 0 N--CA 1.445 -0.758 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.16 177.68 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' THR . . . . . 0.516 ' HA ' ' O ' ' A' ' 59' ' ' ILE . 19.6 p -129.56 141.81 50.89 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 120.904 0.383 . . . . 0.0 110.975 179.925 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 15.6 tmm? -131.92 149.01 52.56 Favored 'General case' 0 C--N 1.317 -0.839 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 179.291 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.706 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 61.7 m -124.56 126.15 45.35 Favored 'General case' 0 C--O 1.252 1.197 0 N-CA-C 112.266 0.469 . . . . 0.0 112.266 -176.61 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 59.8 m-85 -82.68 161.13 22.24 Favored 'General case' 0 C--O 1.236 0.353 0 CA-C-N 115.407 -0.815 . . . . 0.0 111.096 176.521 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -63.76 113.63 3.51 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.914 179.269 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 90.72 7.86 66.09 Favored Glycine 0 N--CA 1.443 -0.859 0 C-N-CA 120.877 -0.678 . . . . 0.0 112.62 179.556 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 81.2 mm-40 -126.72 -172.61 2.68 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.767 0.317 . . . . 0.0 111.447 179.479 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -111.92 -171.56 18.86 Favored Glycine 0 N--CA 1.443 -0.86 0 N-CA-C 111.409 -0.677 . . . . 0.0 111.409 178.615 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 96.1 Cg_endo -76.01 140.06 22.39 Favored 'Trans proline' 0 C--O 1.241 0.651 0 C-N-CA 122.488 2.126 . . . . 0.0 113.431 -178.853 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' ILE . . . . . 0.516 ' O ' ' HA ' ' A' ' 50' ' ' THR . 43.6 pt -132.17 173.12 15.24 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 CA-C-N 115.36 -0.836 . . . . 0.0 109.243 175.625 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -75.35 139.72 25.25 Favored Glycine 0 C--N 1.317 -0.502 0 N-CA-C 111.44 -0.664 . . . . 0.0 111.44 -177.725 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.467 ' CD1' HG11 ' A' ' 38' ' ' VAL . 49.2 t80 -128.34 128.43 44.55 Favored 'General case' 0 C--N 1.312 -1.049 0 CA-C-O 120.511 0.196 . . . . 0.0 110.964 -177.277 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 70.1 ttp85 -136.21 131.13 34.17 Favored 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 175.104 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.487 ' HB1' ' HB3' ' A' ' 71' ' ' TYR . . . -135.4 147.58 49.06 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-O 120.782 0.325 . . . . 0.0 111.3 -178.766 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 83.5 m -126.75 132.44 51.08 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.938 -0.573 . . . . 0.0 110.552 178.895 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 61.4 tp -71.97 123.87 23.68 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.093 0.473 . . . . 0.0 111.854 -178.255 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -66.58 -36.66 83.17 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.896 176.665 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 137.62 -6.69 3.57 Favored Glycine 0 CA--C 1.523 0.591 0 C-N-CA 120.298 -0.953 . . . . 0.0 113.011 -177.519 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 58.3 m-80 -144.14 61.35 1.35 Allowed 'General case' 0 N--CA 1.476 0.838 0 N-CA-C 111.879 0.325 . . . . 0.0 111.879 -178.95 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 90.6 m-20 59.65 5.73 0.73 Allowed 'General case' 0 N--CA 1.487 1.397 0 C-N-CA 123.169 0.587 . . . . 0.0 112.13 179.161 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 9.3 m -99.13 133.83 42.85 Favored 'General case' 0 N--CA 1.44 -0.965 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 179.193 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.487 ' HB3' ' HB1' ' A' ' 63' ' ' ALA . 65.6 m-85 -122.4 136.09 54.83 Favored 'General case' 0 C--N 1.307 -1.259 0 CA-C-O 120.83 0.348 . . . . 0.0 111.546 -178.373 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 43.1 tt0 -90.57 120.35 31.58 Favored 'General case' 0 C--N 1.316 -0.855 0 N-CA-C 107.743 -1.206 . . . . 0.0 107.743 174.785 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 77.5 t -104.85 133.29 49.44 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.201 0 N-CA-C 113.091 0.774 . . . . 0.0 113.091 -173.621 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.45 ' HG2' ' HA ' ' A' ' 86' ' ' SER . 49.7 mt-10 -127.58 126.21 41.69 Favored 'General case' 0 N--CA 1.445 -0.711 0 CA-C-N 114.482 -1.235 . . . . 0.0 108.103 174.631 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 94.7 m-20 -103.9 144.04 32.04 Favored 'General case' 0 C--O 1.241 0.622 0 CA-C-O 121.256 0.55 . . . . 0.0 111.689 -176.541 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 76' ' ' GLN . . . . . 0.57 ' HB2' ' CE3' ' A' ' 84' ' ' TRP . 55.6 tt0 -118.29 122.95 44.19 Favored 'General case' 0 C--N 1.309 -1.161 0 CA-C-N 115.449 -0.796 . . . . 0.0 109.482 -178.247 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 8.1 p90 -110.55 97.04 6.57 Favored 'General case' 0 C--N 1.311 -1.083 0 C-N-CA 119.378 -0.929 . . . . 0.0 110.994 176.974 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 156.86 -153.51 24.76 Favored Glycine 0 N--CA 1.433 -1.563 0 N-CA-C 108.339 -1.905 . . . . 0.0 108.339 -177.378 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -84.93 -148.99 10.32 Favored Glycine 0 N--CA 1.442 -0.908 0 C-N-CA 119.926 -1.13 . . . . 0.0 111.248 175.858 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 65.3 m-20 -88.77 -6.31 57.49 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 117.207 0.504 . . . . 0.0 110.894 -178.969 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 24.1 t -98.13 -4.8 34.94 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.152 -178.002 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -76.49 149.91 81.78 Favored Pre-proline 0 C--N 1.323 -0.56 0 CA-C-N 116.496 -0.32 . . . . 0.0 110.868 -178.399 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -68.23 158.4 57.66 Favored 'Trans proline' 0 C--O 1.238 0.479 0 C-N-CA 122.351 2.034 . . . . 0.0 111.793 178.491 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 84' ' ' TRP . . . . . 0.57 ' CE3' ' HB2' ' A' ' 76' ' ' GLN . 96.0 m95 -94.8 138.69 32.28 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.337 -178.608 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 74.7 m-70 -119.16 146.62 45.0 Favored 'General case' 0 C--N 1.32 -0.712 0 N-CA-C 109.549 -0.538 . . . . 0.0 109.549 179.845 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 86' ' ' SER . . . . . 0.45 ' HA ' ' HG2' ' A' ' 74' ' ' GLU . 10.8 p -71.08 139.99 50.55 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 121.192 0.52 . . . . 0.0 112.229 -176.756 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -115.41 -45.69 0.61 Allowed Glycine 0 N--CA 1.44 -1.099 0 C-N-CA 120.993 -0.622 . . . . 0.0 112.342 178.718 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 147.65 -162.28 28.67 Favored Glycine 0 C--O 1.225 -0.411 0 C-N-CA 120.279 -0.962 . . . . 0.0 112.655 179.445 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 17.9 m120 -115.11 124.55 51.83 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.842 0.321 . . . . 0.0 110.497 179.849 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 34.2 m0 -118.89 153.59 34.31 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.614 -178.581 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 46.9 mm -106.76 114.33 45.61 Favored 'Isoleucine or valine' 0 C--O 1.244 0.776 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 178.388 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 78.5 mt -128.07 77.72 1.78 Allowed 'General case' 0 C--O 1.256 1.445 0 CA-C-O 121.539 0.685 . . . . 0.0 111.559 -177.007 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 166.23 93.79 0.09 OUTLIER Glycine 0 N--CA 1.446 -0.689 0 CA-C-N 115.762 -0.654 . . . . 0.0 111.695 -179.649 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 94' ' ' SER . . . . . 0.549 ' HB2' ' HA3' ' A' ' 21' ' ' GLY . 43.8 p -92.28 -12.42 32.57 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-O 120.838 0.351 . . . . 0.0 111.816 -178.516 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 91.6 mtt180 -88.69 15.84 7.6 Favored 'General case' 0 C--N 1.317 -0.821 0 N-CA-C 114.141 1.163 . . . . 0.0 114.141 -176.339 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 77.9 tt0 69.44 -81.67 0.03 OUTLIER 'General case' 0 N--CA 1.472 0.671 0 N-CA-C 113.298 0.851 . . . . 0.0 113.298 172.86 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 61.6 m-80 -92.73 24.19 3.72 Favored 'General case' 0 N--CA 1.473 0.681 0 CA-C-O 121.006 0.432 . . . . 0.0 110.995 -176.429 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 98' ' ' GLN . . . . . 0.414 ' HG2' ' HB3' ' A' ' 120' ' ' TYR . 54.8 tt0 -145.51 116.3 7.73 Favored 'General case' 0 C--N 1.312 -1.022 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 -177.298 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 99' ' ' ASN . . . . . 0.442 ' HB3' ' OH ' ' A' ' 71' ' ' TYR . 50.3 m-80 -89.23 158.93 17.68 Favored 'General case' 0 C--O 1.248 0.983 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.731 -177.512 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.469 HG21 ' CH2' ' A' ' 23' ' ' TRP . 98.0 t -80.57 130.04 36.56 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.206 0 C-N-CA 120.536 -0.466 . . . . 0.0 110.724 177.892 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 0.447 ' HB ' ' OG ' ' A' ' 40' ' ' SER . 34.8 m -110.27 -17.15 8.5 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.59 0 N-CA-C 112.439 0.533 . . . . 0.0 112.439 -178.686 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 102' ' ' ALA . . . . . 0.713 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -155.57 145.11 21.12 Favored 'General case' 0 CA--C 1.509 -0.61 0 C-N-CA 120.16 -0.616 . . . . 0.0 111.261 176.9 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.487 ' O ' ' HA ' ' A' ' 37' ' ' ASN . 83.0 mt -135.19 125.26 43.88 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 N-CA-C 110.102 -0.333 . . . . 0.0 110.102 179.457 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 104' ' ' ASN . . . . . 0.466 ' HB3' ' OG1' ' A' ' 117' ' ' THR . 7.5 t30 -127.8 94.18 3.88 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.872 -0.604 . . . . 0.0 109.829 175.91 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 30.0 m -137.86 138.67 43.8 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.661 0 N-CA-C 113.119 0.785 . . . . 0.0 113.119 -176.343 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -142.71 96.85 3.0 Favored 'General case' 0 CA--C 1.543 0.686 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.781 176.847 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 107' ' ' SER . . . . . 0.466 ' HB2' ' H ' ' A' ' 115' ' ' ASN . 58.9 m -167.14 166.15 15.16 Favored 'General case' 0 N--CA 1.484 1.264 0 CA-C-N 115.204 -0.907 . . . . 0.0 113.38 -177.963 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 107.07 127.55 5.79 Favored Glycine 0 N--CA 1.427 -1.965 0 C-N-CA 120.488 -0.863 . . . . 0.0 112.85 175.844 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 7.3 m-20 -77.93 -48.63 15.88 Favored 'General case' 0 C--N 1.317 -0.817 0 N-CA-C 107.063 -1.458 . . . . 0.0 107.063 176.247 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 -125.63 23.3 7.43 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 113.941 -1.481 . . . . 0.0 108.998 177.708 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 111' ' ' GLY . . . . . 0.418 ' HA3' ' ND2' ' A' ' 32' ' ' ASN . . . 81.83 17.56 69.96 Favored Glycine 0 C--O 1.22 -0.723 0 C-N-CA 120.457 -0.878 . . . . 0.0 111.823 -175.818 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 112' ' ' GLN . . . . . 0.477 ' HA ' ' CD1' ' A' ' 132' ' ' LEU . 98.4 mt-30 -65.59 -43.61 89.18 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.742 0.306 . . . . 0.0 111.656 -179.17 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 34.0 p -131.77 149.51 52.45 Favored 'General case' 0 N--CA 1.441 -0.876 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.4 179.546 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 114' ' ' LEU . . . . . 0.424 ' HA ' ' HB2' ' A' ' 107' ' ' SER . 97.5 mt -128.41 131.17 48.48 Favored 'General case' 0 C--N 1.316 -0.881 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.012 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 115' ' ' ASN . . . . . 0.466 ' H ' ' HB2' ' A' ' 107' ' ' SER . 54.5 m-80 -136.16 150.29 48.99 Favored 'General case' 0 C--O 1.245 0.841 0 CA-C-O 120.792 0.33 . . . . 0.0 110.667 -178.802 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 157.51 -128.54 2.15 Favored Glycine 0 N--CA 1.442 -0.935 0 CA-C-N 115.75 -0.659 . . . . 0.0 112.049 179.042 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 117' ' ' THR . . . . . 0.466 ' OG1' ' HB3' ' A' ' 104' ' ' ASN . 25.1 p -136.2 156.43 48.69 Favored 'General case' 0 C--N 1.312 -1.03 0 CA-C-O 121.03 0.443 . . . . 0.0 110.875 179.91 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 118' ' ' MET . . . . . 0.583 ' SD ' ' HE1' ' A' ' 120' ' ' TYR . 3.4 ptp -137.66 145.2 42.37 Favored 'General case' 0 C--N 1.314 -0.969 0 CA-C-N 115.94 -0.573 . . . . 0.0 109.966 -179.278 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 119' ' ' THR . . . . . 0.713 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 20.8 m -125.5 127.12 45.96 Favored 'General case' 0 C--O 1.247 0.936 0 N-CA-C 110.125 -0.324 . . . . 0.0 110.125 178.557 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 120' ' ' TYR . . . . . 0.583 ' HE1' ' SD ' ' A' ' 118' ' ' MET . 24.3 m-85 -107.15 155.04 20.31 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.987 179.04 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -58.44 127.87 34.31 Favored 'General case' 0 C--O 1.236 0.391 0 CA-C-O 121.131 0.491 . . . . 0.0 112.121 -178.649 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 81.64 7.71 87.79 Favored Glycine 0 C--O 1.227 -0.338 0 CA-C-N 115.618 -0.719 . . . . 0.0 113.406 177.863 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 85.9 tt0 -145.05 165.2 28.91 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 117.091 0.446 . . . . 0.0 110.493 -178.599 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -87.23 176.43 46.92 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.953 -0.642 . . . . 0.0 112.784 -178.448 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 125' ' ' PRO . . . . . 0.511 ' HA ' ' O ' ' A' ' 118' ' ' MET . 71.6 Cg_endo -72.48 140.01 32.46 Favored 'Trans proline' 0 CA--C 1.534 0.523 0 C-N-CA 122.817 2.345 . . . . 0.0 112.923 -179.685 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 126' ' ' ILE . . . . . 0.433 HD12 ' HB3' ' A' ' 8' ' ' ASN . 43.6 pt -131.15 170.42 19.77 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.013 178.809 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -68.33 133.56 28.36 Favored Glycine 0 C--O 1.242 0.614 0 C-N-CA 120.929 -0.653 . . . . 0.0 112.987 -178.401 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 45.1 t80 -111.74 130.59 55.74 Favored 'General case' 0 C--O 1.236 0.378 0 C-N-CA 123.287 0.635 . . . . 0.0 110.602 -179.502 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 62.1 tttm -140.84 115.45 9.52 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 177.385 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 130' ' ' GLY . . . . . 0.55 ' HA2' ' O ' ' A' ' 5' ' ' ASN . . . -132.13 149.38 19.4 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.501 -0.857 . . . . 0.0 113.266 -178.132 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 80.8 m -141.29 143.09 33.88 Favored 'General case' 0 C--N 1.323 -0.564 0 C-N-CA 122.307 0.243 . . . . 0.0 111.079 179.256 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 132' ' ' LEU . . . . . 0.477 ' CD1' ' HA ' ' A' ' 112' ' ' GLN . 82.4 mt -53.9 136.33 40.94 Favored 'General case' 0 N--CA 1.475 0.793 0 O-C-N 123.548 0.53 . . . . 0.0 110.764 176.112 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 25.1 m . . . . . 0 C--O 1.255 1.368 0 CA-C-O 118.421 -0.799 . . . . 0.0 110.85 -179.034 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 0.622 0 N-CA-C 110.064 -0.347 . . . . 0.0 110.064 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 3' ' ' LEU . . . . . 0.433 HD12 ' HB ' ' A' ' 133' ' ' THR . 2.8 tm? -88.16 129.28 35.37 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 121.084 0.468 . . . . 0.0 110.093 -178.714 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 4' ' ' TYR . . . . . 0.501 ' CE1' ' HB ' ' A' ' 25' ' ' ILE . 35.2 m-85 -117.62 141.92 47.81 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.783 -0.644 . . . . 0.0 111.813 179.901 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 -98.21 139.61 33.74 Favored 'General case' 0 C--N 1.312 -1.037 0 N-CA-C 107.794 -1.188 . . . . 0.0 107.794 173.328 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 69.0 t -114.39 127.87 71.67 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.224 0 CA-C-O 121.222 0.534 . . . . 0.0 112.211 -174.059 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -122.55 138.76 54.47 Favored 'General case' 0 C--N 1.317 -0.84 0 N-CA-C 107.826 -1.176 . . . . 0.0 107.826 175.083 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 23.5 m120 -128.89 148.53 50.92 Favored 'General case' 0 C--N 1.313 -0.992 0 N-CA-C 112.454 0.538 . . . . 0.0 112.454 -177.319 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 51.0 tt0 -126.36 122.31 35.03 Favored 'General case' 0 C--N 1.32 -0.71 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 176.967 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 41.5 p90 -145.6 13.64 1.36 Allowed 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 114.033 1.123 . . . . 0.0 114.033 -176.376 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -110.36 21.27 24.42 Favored Glycine 0 N--CA 1.446 -0.671 0 C-N-CA 118.491 -1.814 . . . . 0.0 112.031 -177.302 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 107.72 175.9 22.36 Favored Glycine 0 N--CA 1.448 -0.56 0 C-N-CA 120.539 -0.839 . . . . 0.0 113.098 179.083 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 12.4 m -64.36 150.91 45.32 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 115.365 -0.417 . . . . 0.0 111.5 177.831 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 37.6 m 64.89 21.23 12.3 Favored 'General case' 0 N--CA 1.472 0.63 0 CA-C-N 115.706 -0.679 . . . . 0.0 111.509 -178.705 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.432 ' HA ' ' HD3' ' A' ' 16' ' ' PRO . . . -96.61 146.27 31.02 Favored Pre-proline 0 N--CA 1.448 -0.539 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.595 179.803 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.432 ' HD3' ' HA ' ' A' ' 15' ' ' ALA . 11.2 Cg_exo -71.86 159.23 51.07 Favored 'Trans proline' 0 N--CA 1.455 -0.741 0 C-N-CA 122.764 2.309 . . . . 0.0 112.302 178.502 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 80.6 m95 -90.21 131.4 36.06 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 115.658 -0.701 . . . . 0.0 109.285 178.852 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 38.8 m-80 -109.35 142.67 39.94 Favored 'General case' 0 C--N 1.308 -1.216 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 -178.854 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -69.04 125.59 27.14 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-O 121.612 0.72 . . . . 0.0 111.623 -178.299 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.614 ' O ' ' HB3' ' A' ' 94' ' ' SER . . . -100.33 -17.66 23.8 Favored Glycine 0 N--CA 1.447 -0.567 0 CA-C-N 114.661 -1.154 . . . . 0.0 113.851 -176.515 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 137.14 -151.18 20.94 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.241 -0.981 . . . . 0.0 111.887 -177.566 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 29.5 pt20 -138.62 132.83 31.6 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 120.852 0.358 . . . . 0.0 111.264 -179.912 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' TRP . . . . . 0.417 ' CZ2' HG21 ' A' ' 100' ' ' VAL . 46.0 m0 -115.34 161.65 18.22 Favored 'General case' 0 CA--C 1.507 -0.691 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.372 178.548 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 81.7 tt0 -120.07 118.96 31.97 Favored 'General case' 0 C--N 1.314 -0.973 0 C-N-CA 119.986 -0.686 . . . . 0.0 109.649 174.313 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.501 ' HB ' ' CE1' ' A' ' 4' ' ' TYR . 97.8 mt -134.45 146.09 31.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 CA-C-N 114.99 -1.005 . . . . 0.0 109.457 -176.225 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 83.71 73.54 1.25 Allowed Glycine 0 CA--C 1.505 -0.56 0 C-N-CA 120.364 -0.922 . . . . 0.0 111.605 178.955 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 16.1 m -62.21 -43.31 99.11 Favored 'General case' 0 C--N 1.314 -0.961 0 CA-C-N 115.175 -0.513 . . . . 0.0 110.77 179.55 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 84.8 mtt85 -77.64 129.78 36.01 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.903 -0.589 . . . . 0.0 111.337 -179.709 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 15.6 m -66.7 -32.77 74.29 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.607 -0.724 . . . . 0.0 111.69 179.85 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 28.6 m-20 -97.62 16.78 19.45 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.524 -176.458 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 7.2 mm-40 -155.21 102.32 2.29 Favored 'General case' 0 CA--C 1.505 -0.781 0 CA-C-O 120.909 0.385 . . . . 0.0 111.646 -174.656 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 63.7 t30 -102.34 157.86 16.61 Favored 'General case' 0 N--CA 1.443 -0.814 0 CA-C-N 115.877 -0.602 . . . . 0.0 109.945 178.305 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 57.0 t -96.22 133.11 38.68 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.66 0 CA-C-N 115.255 -0.884 . . . . 0.0 110.841 -175.166 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 30.1 m -110.13 -17.22 8.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 N-CA-C 111.78 0.289 . . . . 0.0 111.78 179.787 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.548 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -149.89 143.48 25.31 Favored 'General case' 0 C--O 1.236 0.358 0 C-N-CA 120.628 -0.429 . . . . 0.0 111.195 178.532 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.446 ' HB ' HG22 ' A' ' 105' ' ' VAL . 94.6 mt -140.72 123.32 15.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.036 -179.016 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -126.74 106.47 9.39 Favored 'General case' 0 C--N 1.319 -0.723 0 N-CA-C 108.672 -0.862 . . . . 0.0 108.672 173.896 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 23.9 m -147.67 151.1 13.9 Favored 'Isoleucine or valine' 0 C--O 1.237 0.423 0 C-N-CA 120.748 -0.381 . . . . 0.0 111.379 -174.881 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 78.7 tt0 -147.14 150.46 35.02 Favored 'General case' 0 C--N 1.319 -0.735 0 N-CA-C 108.609 -0.886 . . . . 0.0 108.609 175.612 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' SER . . . . . 0.456 ' HB2' HD23 ' A' ' 47' ' ' LEU . 8.4 t -90.91 143.46 26.69 Favored 'General case' 0 C--N 1.312 -1.027 0 CA-C-O 120.857 0.36 . . . . 0.0 111.436 -177.759 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -87.09 -15.49 62.59 Favored Glycine 0 CA--C 1.52 0.347 0 C-N-CA 120.51 -0.852 . . . . 0.0 111.132 175.892 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 42' ' ' ASP . . . . . 0.405 ' HB3' ' H ' ' A' ' 43' ' ' ASP . 15.7 m-20 -127.46 -156.01 0.73 Allowed 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.157 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 43' ' ' ASP . . . . . 0.405 ' H ' ' HB3' ' A' ' 42' ' ' ASP . 43.4 m-20 -76.72 38.72 0.2 Allowed 'General case' 0 N--CA 1.472 0.663 0 C-N-CA 122.576 0.351 . . . . 0.0 111.625 -179.316 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.524 ' O ' ' HE2' ' A' ' 71' ' ' TYR . . . 96.04 -8.39 67.61 Favored Glycine 0 C--O 1.214 -1.095 0 C-N-CA 120.917 -0.658 . . . . 0.0 111.856 -179.527 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 56.2 mt-30 -64.06 -39.66 94.56 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 113.14 0.793 . . . . 0.0 113.14 -176.711 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 4.0 t -126.81 110.56 13.22 Favored 'General case' 0 C--N 1.313 -1.011 0 C-N-CA 120.077 -0.649 . . . . 0.0 110.985 178.57 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 47' ' ' LEU . . . . . 0.456 HD23 ' HB2' ' A' ' 40' ' ' SER . 74.0 mt -93.76 125.52 38.42 Favored 'General case' 0 N--CA 1.443 -0.78 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 176.079 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 13.4 m120 -125.08 141.21 52.26 Favored 'General case' 0 C--N 1.3 -1.547 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 -178.902 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 170.64 -152.99 20.1 Favored Glycine 0 N--CA 1.444 -0.813 0 C-N-CA 119.05 -1.548 . . . . 0.0 113.987 179.333 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 38.6 m -128.47 133.15 48.44 Favored 'General case' 0 N--CA 1.443 -0.808 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 -177.235 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 46.4 ttp -122.61 144.78 48.9 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 -178.344 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.548 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 32.5 m -125.06 126.69 45.77 Favored 'General case' 0 C--O 1.247 0.958 0 CA-C-O 120.73 0.3 . . . . 0.0 111.368 -179.11 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 62.1 m-85 -90.45 162.73 14.94 Favored 'General case' 0 C--O 1.234 0.248 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.95 177.947 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -66.49 131.44 46.05 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.375 178.734 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 74.0 2.08 61.02 Favored Glycine 0 CA--C 1.519 0.34 0 CA-C-N 115.981 -0.554 . . . . 0.0 113.21 179.209 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 75.2 mm-40 -121.74 -179.03 3.98 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 120.826 0.345 . . . . 0.0 110.764 -178.424 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -105.71 173.76 20.39 Favored Glycine 0 N--CA 1.442 -0.927 0 C-N-CA 121.029 -0.605 . . . . 0.0 111.811 179.215 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 26.3 Cg_exo -63.32 136.32 54.77 Favored 'Trans proline' 0 C--O 1.242 0.712 0 C-N-CA 122.892 2.394 . . . . 0.0 112.375 179.811 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 59' ' ' ILE . . . . . 0.512 ' HB ' ' O ' ' A' ' 76' ' ' GLN . 50.9 pt -130.79 167.2 26.47 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.577 -179.671 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -73.1 135.14 20.89 Favored Glycine 0 C--O 1.249 1.068 0 C-N-CA 120.842 -0.694 . . . . 0.0 112.122 179.776 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 58.1 t80 -127.51 126.9 43.07 Favored 'General case' 0 C--O 1.243 0.717 0 C-N-CA 122.647 0.379 . . . . 0.0 110.795 -177.982 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 62.1 ttp180 -135.82 131.85 35.91 Favored 'General case' 0 N--CA 1.463 0.205 0 N-CA-C 110.016 -0.364 . . . . 0.0 110.016 176.681 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.453 ' HB2' HG22 ' A' ' 73' ' ' VAL . . . -135.21 141.11 45.75 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.649 0.262 . . . . 0.0 111.703 -179.85 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 40.9 m -121.7 132.05 54.43 Favored 'General case' 0 CA--C 1.544 0.719 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.538 179.554 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 58.8 tp -71.56 114.27 9.47 Favored 'General case' 0 CA--C 1.522 -0.13 0 CA-C-O 121.202 0.525 . . . . 0.0 112.345 -178.412 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 68.1 mt -80.87 -31.38 35.33 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.553 -0.749 . . . . 0.0 109.803 175.566 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 123.72 164.73 12.09 Favored Glycine 0 N--CA 1.445 -0.711 0 N-CA-C 110.362 -1.095 . . . . 0.0 110.362 -177.6 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 94.0 m-20 61.11 36.03 18.43 Favored 'General case' 0 N--CA 1.477 0.896 0 CA-C-N 117.343 0.571 . . . . 0.0 110.917 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 95.0 m-20 63.78 18.88 11.43 Favored 'General case' 0 N--CA 1.477 0.878 0 CA-C-N 115.389 -0.823 . . . . 0.0 111.864 179.235 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 31.6 m -108.56 131.91 54.38 Favored 'General case' 0 N--CA 1.448 -0.565 0 CA-C-O 121.123 0.487 . . . . 0.0 110.926 -179.243 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.524 ' HE2' ' O ' ' A' ' 44' ' ' GLY . 95.6 m-85 -119.13 152.14 37.06 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.212 179.911 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 58.1 tt0 -108.0 127.57 53.88 Favored 'General case' 0 C--N 1.314 -0.946 0 N-CA-C 107.997 -1.112 . . . . 0.0 107.997 174.482 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.453 HG22 ' HB2' ' A' ' 63' ' ' ALA . 56.5 t -111.64 137.56 43.77 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.855 0 N-CA-C 113.77 1.026 . . . . 0.0 113.77 -171.147 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 50.1 mt-10 -123.98 149.49 45.93 Favored 'General case' 0 C--O 1.245 0.86 0 CA-C-N 114.832 -1.076 . . . . 0.0 108.303 175.95 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 14.3 m120 -131.65 156.54 45.66 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-O 120.561 0.22 . . . . 0.0 110.47 -175.98 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 76' ' ' GLN . . . . . 0.512 ' O ' ' HB ' ' A' ' 59' ' ' ILE . 1.7 pt20 -147.18 144.07 28.68 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.402 176.315 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 31.9 p90 -147.24 168.25 22.17 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.16 -177.467 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 79.54 70.35 1.33 Allowed Glycine 0 N--CA 1.441 -0.987 0 C-N-CA 121.078 -0.582 . . . . 0.0 114.109 176.316 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.522 ' O ' ' HB3' ' A' ' 80' ' ' ASP . . . 106.22 -27.32 17.55 Favored Glycine 0 N--CA 1.445 -0.702 0 C-N-CA 120.296 -0.955 . . . . 0.0 113.827 175.733 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 80' ' ' ASP . . . . . 0.522 ' HB3' ' O ' ' A' ' 79' ' ' GLY . 19.3 t70 81.28 -28.63 0.12 Allowed 'General case' 0 N--CA 1.493 1.703 0 CA-C-O 121.328 0.585 . . . . 0.0 110.736 178.356 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 11.6 p -85.08 16.73 3.3 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-O 121.247 0.546 . . . . 0.0 110.629 174.221 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -89.33 165.45 25.97 Favored Pre-proline 0 CA--C 1.538 0.495 0 CA-C-N 115.599 -0.728 . . . . 0.0 111.073 -178.12 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 10.6 Cg_exo -70.47 166.88 27.02 Favored 'Trans proline' 0 C--N 1.357 0.979 0 C-N-CA 122.851 2.367 . . . . 0.0 111.746 178.481 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 84' ' ' TRP . . . . . . . . . . . . . 90.8 m95 -95.59 137.45 34.63 Favored 'General case' 0 N--CA 1.445 -0.691 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -178.489 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 85.4 m-70 -119.28 145.54 46.02 Favored 'General case' 0 C--N 1.313 -0.98 0 N-CA-C 109.669 -0.493 . . . . 0.0 109.669 -177.26 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 7.1 m -61.78 133.92 56.1 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 110.303 -0.258 . . . . 0.0 110.303 -179.239 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -108.77 -50.67 0.73 Allowed Glycine 0 N--CA 1.443 -0.856 0 C-N-CA 120.137 -1.03 . . . . 0.0 111.987 178.66 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 152.65 -167.7 31.55 Favored Glycine 0 C--O 1.221 -0.683 0 C-N-CA 120.699 -0.762 . . . . 0.0 111.865 179.55 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 19.8 m120 -103.66 145.5 29.97 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 116.901 0.35 . . . . 0.0 110.722 179.824 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 90' ' ' TRP . . . . . 0.49 ' CH2' HG23 ' A' ' 25' ' ' ILE . 12.4 m0 -132.88 142.54 48.98 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 -178.376 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 86.6 mt -109.25 116.41 52.02 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.962 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 177.958 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 92' ' ' LEU . . . . . 0.422 ' HB2' ' CE1' ' A' ' 71' ' ' TYR . 71.8 mt -134.81 75.89 1.6 Allowed 'General case' 0 C--O 1.263 1.789 0 CA-C-O 121.449 0.643 . . . . 0.0 111.668 -175.967 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 93' ' ' GLY . . . . . 0.423 ' O ' ' HB2' ' A' ' 94' ' ' SER . . . -148.93 -69.51 0.01 OUTLIER Glycine 0 N--CA 1.445 -0.763 0 C-N-CA 120.289 -0.958 . . . . 0.0 112.785 -179.931 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 94' ' ' SER . . . . . 0.614 ' HB3' ' O ' ' A' ' 20' ' ' GLY . 17.3 m 73.44 -34.95 0.3 Allowed 'General case' 0 N--CA 1.479 1.009 0 C-N-CA 123.478 0.711 . . . . 0.0 112.563 -178.593 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 82.6 mtp180 -101.02 153.95 19.11 Favored 'General case' 0 N--CA 1.439 -0.984 0 CA-C-O 120.868 0.366 . . . . 0.0 110.942 -179.179 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 44.5 tt0 -62.03 -54.37 42.4 Favored 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 113.51 0.93 . . . . 0.0 113.51 -172.87 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 16.4 m120 -122.29 37.1 4.46 Favored 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 111.869 0.322 . . . . 0.0 111.869 -176.475 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 98' ' ' GLN . . . . . . . . . . . . . 6.6 tt0 -148.04 116.12 6.48 Favored 'General case' 0 C--N 1.316 -0.867 0 C-N-CA 120.543 -0.463 . . . . 0.0 110.354 -178.044 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 52.7 m-80 -96.69 164.85 12.41 Favored 'General case' 0 C--O 1.247 0.946 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.716 -175.427 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.417 HG21 ' CZ2' ' A' ' 23' ' ' TRP . 86.7 t -87.36 137.11 21.58 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.735 0 CA-C-N 115.897 -0.592 . . . . 0.0 111.198 177.361 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 0.475 HG11 ' HA ' ' A' ' 121' ' ' ALA . 34.3 m -119.87 -29.59 1.78 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.743 0 N-CA-C 112.971 0.73 . . . . 0.0 112.971 -178.426 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 102' ' ' ALA . . . . . 0.629 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -141.26 138.06 32.97 Favored 'General case' 0 C--N 1.323 -0.557 0 C-N-CA 120.048 -0.661 . . . . 0.0 111.445 179.537 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 93.3 mt -134.03 128.02 52.42 Favored 'Isoleucine or valine' 0 C--O 1.244 0.78 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.836 179.154 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 43.5 t30 -129.21 99.76 5.35 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 109.033 -0.728 . . . . 0.0 109.033 174.483 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.446 HG22 ' HB ' ' A' ' 36' ' ' ILE . 25.2 m -141.99 148.31 20.68 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 N-CA-C 112.572 0.582 . . . . 0.0 112.572 -176.416 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 37.9 tt0 -149.92 154.98 39.21 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 115.156 -0.929 . . . . 0.0 108.88 175.469 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 107' ' ' SER . . . . . 0.406 ' HB2' HD23 ' A' ' 114' ' ' LEU . 37.7 t -132.84 143.65 49.68 Favored 'General case' 0 C--N 1.311 -1.078 0 CA-C-O 121.132 0.491 . . . . 0.0 111.702 -177.997 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -84.78 -9.42 81.07 Favored Glycine 0 N--CA 1.441 -0.979 0 N-CA-C 110.166 -1.174 . . . . 0.0 110.166 174.922 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 78.3 m-20 -97.29 -171.28 2.17 Favored 'General case' 0 CA--C 1.507 -0.685 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 178.404 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 99.4 m-20 -89.65 39.53 0.96 Allowed 'General case' 0 C--N 1.308 -1.221 0 CA-C-O 121.373 0.606 . . . . 0.0 110.392 177.843 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 95.18 -2.65 65.94 Favored Glycine 0 N--CA 1.447 -0.598 0 CA-C-N 115.609 -0.723 . . . . 0.0 113.152 178.571 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 112' ' ' GLN . . . . . 0.664 ' HA ' HD23 ' A' ' 132' ' ' LEU . 98.4 mt-30 -64.14 -42.7 96.69 Favored 'General case' 0 C--O 1.245 0.839 0 N-CA-C 112.755 0.65 . . . . 0.0 112.755 -176.989 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 46.5 p -124.63 106.64 10.27 Favored 'General case' 0 N--CA 1.449 -0.521 0 CA-C-O 120.954 0.407 . . . . 0.0 110.279 176.996 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 114' ' ' LEU . . . . . 0.406 HD23 ' HB2' ' A' ' 107' ' ' SER . 98.3 mt -91.33 111.84 23.51 Favored 'General case' 0 C--N 1.316 -0.883 0 CA-C-O 120.642 0.258 . . . . 0.0 110.347 -179.344 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 57.1 m-80 -108.86 143.03 38.59 Favored 'General case' 0 C--N 1.313 -0.997 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.342 -179.955 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 163.56 -141.69 7.31 Favored Glycine 0 N--CA 1.435 -1.426 0 C-N-CA 119.655 -1.26 . . . . 0.0 113.162 177.599 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 33.8 p -134.85 158.12 45.05 Favored 'General case' 0 C--N 1.315 -0.907 0 C-N-CA 122.616 0.366 . . . . 0.0 110.504 -177.99 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 25.8 ptm -144.97 152.24 39.86 Favored 'General case' 0 C--N 1.314 -0.939 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.297 -179.766 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 119' ' ' THR . . . . . 0.629 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 32.9 m -129.74 129.34 44.03 Favored 'General case' 0 C--O 1.249 1.059 0 CA-C-N 116.387 -0.37 . . . . 0.0 110.694 179.682 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 45.6 m-85 -85.34 170.48 12.71 Favored 'General case' 0 CA--C 1.517 -0.289 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.325 176.4 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 121' ' ' ALA . . . . . 0.475 ' HA ' HG11 ' A' ' 101' ' ' VAL . . . -53.21 -40.4 64.44 Favored 'General case' 0 N--CA 1.471 0.586 0 N-CA-C 113.167 0.803 . . . . 0.0 113.167 -178.13 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -151.81 87.88 0.14 Allowed Glycine 0 N--CA 1.447 -0.602 0 C-N-CA 119.579 -1.296 . . . . 0.0 112.821 -179.404 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 77.4 tt0 -169.8 -69.14 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.771 0.32 . . . . 0.0 110.842 179.436 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 153.44 161.87 10.65 Favored Glycine 0 N--CA 1.443 -0.841 0 C-N-CA 120.812 -0.708 . . . . 0.0 111.887 179.316 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 21.2 Cg_exo -66.96 136.57 41.75 Favored 'Trans proline' 0 C--O 1.24 0.582 0 C-N-CA 122.733 2.289 . . . . 0.0 111.73 178.865 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 43.1 pt -135.52 166.26 28.14 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.145 178.862 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -72.89 136.15 22.48 Favored Glycine 0 C--O 1.237 0.284 0 C-N-CA 120.712 -0.756 . . . . 0.0 111.786 -179.759 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 78.9 t80 -122.46 136.81 54.97 Favored 'General case' 0 C--O 1.24 0.569 0 CA-C-O 120.959 0.409 . . . . 0.0 111.651 -177.286 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 61.9 tttm -134.87 103.69 5.7 Favored 'General case' 0 N--CA 1.446 -0.668 0 CA-C-N 115.349 -0.841 . . . . 0.0 109.941 177.145 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -100.24 133.33 11.26 Favored Glycine 0 N--CA 1.443 -0.863 0 N-CA-C 111.183 -0.767 . . . . 0.0 111.183 177.733 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 38.7 m -129.84 137.56 50.51 Favored 'General case' 0 C--N 1.306 -1.286 0 CA-C-N 117.042 0.421 . . . . 0.0 111.187 -177.951 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 132' ' ' LEU . . . . . 0.664 HD23 ' HA ' ' A' ' 112' ' ' GLN . 2.9 mm? -59.76 137.78 57.96 Favored 'General case' 0 N--CA 1.473 0.708 0 CA-C-O 121.285 0.564 . . . . 0.0 111.727 178.752 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 133' ' ' THR . . . . . 0.433 ' HB ' HD12 ' A' ' 3' ' ' LEU . 14.4 m . . . . . 0 N--CA 1.435 -1.203 0 CA-C-N 115.528 -0.76 . . . . 0.0 110.174 178.283 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.51 -0.561 0 CA-C-O 120.694 0.283 . . . . 0.0 110.33 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 10.2 tt -99.77 131.83 45.5 Favored 'General case' 0 C--N 1.316 -0.889 0 CA-C-O 121.177 0.513 . . . . 0.0 110.486 -179.059 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 85.8 m-85 -120.81 142.64 49.42 Favored 'General case' 0 C--N 1.311 -1.083 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.201 178.964 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' ASN . . . . . 0.503 ' O ' ' HA2' ' A' ' 130' ' ' GLY . 88.9 m-20 -87.94 132.15 34.33 Favored 'General case' 0 C--N 1.308 -1.219 0 N-CA-C 107.501 -1.296 . . . . 0.0 107.501 176.786 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.6 HG21 ' CG ' ' A' ' 23' ' ' TRP . 54.2 t -113.88 128.66 70.7 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.99 0 CA-C-O 121.973 0.892 . . . . 0.0 113.191 -173.456 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.437 ' HB2' ' HB3' ' A' ' 129' ' ' LYS . 27.0 mt-10 -120.82 131.75 54.62 Favored 'General case' 0 N--CA 1.43 -1.45 0 CA-C-N 113.631 -1.622 . . . . 0.0 107.755 179.785 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 88.9 m-20 -119.9 145.32 46.8 Favored 'General case' 0 C--N 1.314 -0.939 0 CA-C-O 120.995 0.426 . . . . 0.0 111.9 -176.81 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 53.4 tt0 -122.66 110.29 15.34 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.57 -0.741 . . . . 0.0 109.138 179.554 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 3.1 p90 -128.68 -171.42 2.46 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 112.682 0.623 . . . . 0.0 112.682 -175.079 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 66.34 -90.84 0.15 Allowed Glycine 0 C--N 1.336 0.552 0 CA-C-N 114.955 -1.02 . . . . 0.0 114.938 176.084 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.466 ' C ' ' H ' ' A' ' 14' ' ' SER . . . -85.85 0.78 87.97 Favored Glycine 0 C--N 1.319 -0.376 0 C-N-CA 121.319 -0.467 . . . . 0.0 114.098 -173.52 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 13.3 t 59.17 -6.46 0.06 Allowed 'General case' 0 CA--C 1.562 1.434 0 C-N-CA 123.323 0.649 . . . . 0.0 112.662 -177.719 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' SER . . . . . 0.466 ' H ' ' C ' ' A' ' 12' ' ' GLY . 8.7 t -125.7 16.13 8.11 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-O 121.658 0.742 . . . . 0.0 109.358 -179.39 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -80.05 163.79 55.94 Favored Pre-proline 0 N--CA 1.445 -0.718 0 CA-C-N 114.877 -1.056 . . . . 0.0 110.122 -179.463 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 14.2 Cg_exo -69.71 169.6 18.47 Favored 'Trans proline' 0 N--CA 1.46 -0.488 0 C-N-CA 122.608 2.205 . . . . 0.0 111.757 177.967 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 98.5 m95 -80.92 121.71 26.34 Favored 'General case' 0 C--N 1.316 -0.868 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 -179.224 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 91.4 m-20 -106.56 114.19 28.16 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.573 -177.595 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -78.56 128.62 33.78 Favored 'General case' 0 C--N 1.319 -0.756 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 178.406 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -143.3 35.45 1.66 Allowed Glycine 0 N--CA 1.442 -0.961 0 C-N-CA 119.51 -1.329 . . . . 0.0 112.694 -179.713 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 137.62 -174.02 22.02 Favored Glycine 0 N--CA 1.443 -0.843 0 C-N-CA 120.034 -1.079 . . . . 0.0 112.782 178.185 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 88.1 mt-30 -132.0 149.21 52.49 Favored 'General case' 0 C--N 1.318 -0.788 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 -179.768 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' TRP . . . . . 0.6 ' CG ' HG21 ' A' ' 6' ' ' VAL . 38.5 m0 -119.07 153.24 35.08 Favored 'General case' 0 C--N 1.315 -0.913 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 177.947 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.443 ' H ' ' HB ' ' A' ' 91' ' ' ILE . 89.1 mt-10 -111.59 113.69 26.26 Favored 'General case' 0 C--N 1.305 -1.345 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 175.946 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 81.8 mt -130.25 140.35 49.1 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-N 116.0 -0.546 . . . . 0.0 111.904 -172.381 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 91.79 125.17 3.4 Favored Glycine 0 N--CA 1.442 -0.945 0 N-CA-C 114.761 0.665 . . . . 0.0 114.761 172.294 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 3.8 p -88.35 12.61 13.66 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 109.278 -0.638 . . . . 0.0 109.278 173.939 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 62.6 ttp85 -24.74 108.91 0.03 OUTLIER 'General case' 0 N--CA 1.474 0.727 0 C-N-CA 125.477 1.511 . . . . 0.0 113.883 179.732 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 11.0 m -102.88 -62.36 1.29 Allowed 'General case' 0 N--CA 1.436 -1.14 0 CA-C-N 115.235 -0.893 . . . . 0.0 108.83 176.733 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 27.2 m-20 -124.4 5.85 8.36 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.46 178.17 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 1.4 mm-40 -149.53 136.36 19.53 Favored 'General case' 0 C--N 1.318 -0.761 0 CA-C-N 116.009 -0.542 . . . . 0.0 111.432 -177.864 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' ASN . . . . . 0.516 ' ND2' ' HA3' ' A' ' 111' ' ' GLY . 63.7 t30 -93.36 164.45 13.21 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.947 -0.569 . . . . 0.0 111.331 -179.126 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.411 ' HA ' ' HA ' ' A' ' 53' ' ' TYR . 57.8 t -96.27 130.37 45.03 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 CA-C-N 115.422 -0.808 . . . . 0.0 110.699 -176.912 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 23.7 m -114.07 -16.33 9.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 N-CA-C 112.218 0.451 . . . . 0.0 112.218 178.754 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.403 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -145.86 142.37 28.74 Favored 'General case' 0 CA--C 1.515 -0.384 0 C-N-CA 120.377 -0.529 . . . . 0.0 111.537 178.998 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.435 ' HB ' ' CG2' ' A' ' 105' ' ' VAL . 96.3 mt -142.57 127.46 16.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 N-CA-C 108.987 -0.746 . . . . 0.0 108.987 179.124 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 37' ' ' ASN . . . . . 0.435 ' HA ' ' O ' ' A' ' 103' ' ' ILE . 3.1 t30 -138.0 113.09 9.2 Favored 'General case' 0 C--N 1.313 -0.991 0 N-CA-C 108.739 -0.837 . . . . 0.0 108.739 176.865 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.45 HG11 ' CD2' ' A' ' 61' ' ' PHE . 28.0 m -148.18 153.15 11.88 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.442 0 C-N-CA 120.918 -0.313 . . . . 0.0 111.19 -174.059 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 81.3 tt0 -139.17 145.37 39.26 Favored 'General case' 0 C--N 1.321 -0.639 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 176.714 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 12.9 t -77.04 139.93 40.19 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-O 120.883 0.373 . . . . 0.0 110.714 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -88.63 -7.07 72.29 Favored Glycine 0 N--CA 1.446 -0.672 0 C-N-CA 120.555 -0.831 . . . . 0.0 111.114 177.061 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 42' ' ' ASP . . . . . 0.442 ' HB3' ' H ' ' A' ' 43' ' ' ASP . 21.1 m-20 -141.83 -153.98 0.49 Allowed 'General case' 0 C--N 1.33 -0.242 0 C-N-CA 122.508 0.323 . . . . 0.0 110.257 -179.319 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 43' ' ' ASP . . . . . 0.442 ' H ' ' HB3' ' A' ' 42' ' ' ASP . 86.7 m-20 -78.28 44.07 0.48 Allowed 'General case' 0 N--CA 1.471 0.589 0 C-N-CA 122.664 0.386 . . . . 0.0 111.961 -178.468 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 87.49 -5.13 85.53 Favored Glycine 0 C--O 1.227 -0.335 0 C-N-CA 120.787 -0.721 . . . . 0.0 113.491 178.094 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 54.9 mt-30 -70.29 -38.89 75.1 Favored 'General case' 0 C--O 1.222 -0.362 0 N-CA-C 112.59 0.589 . . . . 0.0 112.59 179.604 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' THR . . . . . 0.606 ' HA ' ' O ' ' A' ' 63' ' ' ALA . 7.8 t -127.71 123.57 35.73 Favored 'General case' 0 C--N 1.32 -0.689 0 C-N-CA 120.426 -0.51 . . . . 0.0 111.293 -179.027 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 95.5 mt -103.15 124.81 49.29 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.037 177.912 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 48' ' ' ASN . . . . . 0.503 ' OD1' ' HG3' ' A' ' 62' ' ' ARG . 93.2 m-20 -119.61 142.11 48.7 Favored 'General case' 0 C--N 1.313 -0.985 0 CA-C-N 115.969 -0.559 . . . . 0.0 110.021 179.616 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 166.47 -146.48 10.97 Favored Glycine 0 CA--C 1.501 -0.822 0 C-N-CA 119.787 -1.197 . . . . 0.0 112.787 179.373 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 33.5 p -135.51 153.04 51.86 Favored 'General case' 0 N--CA 1.446 -0.629 0 CA-C-O 120.973 0.416 . . . . 0.0 111.066 -178.718 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 51' ' ' MET . . . . . 0.415 ' HE1' ' CZ ' ' A' ' 53' ' ' TYR . 16.6 tmm? -135.01 138.65 44.16 Favored 'General case' 0 C--N 1.317 -0.83 0 N-CA-C 109.276 -0.638 . . . . 0.0 109.276 178.148 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.403 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 29.4 m -125.24 129.26 49.71 Favored 'General case' 0 C--O 1.255 1.365 0 N-CA-C 112.527 0.566 . . . . 0.0 112.527 -175.564 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 53' ' ' TYR . . . . . 0.51 ' HB2' ' HB2' ' A' ' 56' ' ' GLU . 95.1 m-85 -85.29 165.73 17.07 Favored 'General case' 0 CA--C 1.532 0.251 0 CA-C-N 115.341 -0.845 . . . . 0.0 109.805 176.659 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -66.87 113.51 4.98 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 120.714 0.292 . . . . 0.0 111.707 -179.008 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 76.6 16.53 80.67 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.844 178.11 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 56' ' ' GLU . . . . . 0.51 ' HB2' ' HB2' ' A' ' 53' ' ' TYR . 73.0 mm-40 -121.71 177.67 5.16 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-O 120.769 0.319 . . . . 0.0 110.395 -179.397 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -93.38 153.48 21.37 Favored Glycine 0 N--CA 1.443 -0.857 0 C-N-CA 120.805 -0.712 . . . . 0.0 111.556 178.694 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -67.8 144.27 64.55 Favored 'Trans proline' 0 C--O 1.237 0.432 0 C-N-CA 122.555 2.17 . . . . 0.0 112.574 179.581 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 39.6 pt -125.86 162.69 28.74 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.818 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.284 178.644 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -71.24 145.1 38.74 Favored Glycine 0 N--CA 1.448 -0.537 0 C-N-CA 121.195 -0.526 . . . . 0.0 112.323 -177.559 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.45 ' CD2' HG11 ' A' ' 38' ' ' VAL . 69.4 t80 -130.93 126.94 37.42 Favored 'General case' 0 C--N 1.313 -1.02 0 C-N-CA 122.106 0.162 . . . . 0.0 110.972 -178.186 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 62' ' ' ARG . . . . . 0.503 ' HG3' ' OD1' ' A' ' 48' ' ' ASN . 29.0 ttp85 -135.32 128.31 31.51 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 108.798 -0.816 . . . . 0.0 108.798 174.643 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.606 ' O ' ' HA ' ' A' ' 46' ' ' THR . . . -132.87 141.76 48.58 Favored 'General case' 0 C--N 1.316 -0.857 0 C-N-CA 120.852 -0.339 . . . . 0.0 111.713 -178.378 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 31.7 m -124.06 128.97 50.1 Favored 'General case' 0 CA--C 1.539 0.527 0 CA-C-N 116.458 -0.337 . . . . 0.0 110.634 179.516 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 51.2 tp -74.73 127.6 33.53 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 112.279 0.474 . . . . 0.0 112.279 -177.514 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 10.7 mp -79.82 -24.36 41.41 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.969 177.094 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 113.64 -8.36 24.05 Favored Glycine 0 CA--C 1.521 0.465 0 C-N-CA 120.93 -0.653 . . . . 0.0 112.638 179.88 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 24.2 p-10 -115.41 30.12 7.56 Favored 'General case' 0 C--N 1.312 -1.054 0 CA-C-O 121.04 0.448 . . . . 0.0 110.445 179.937 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 87.3 m-20 76.48 -9.38 1.49 Allowed 'General case' 0 N--CA 1.485 1.278 0 C-N-CA 124.353 1.061 . . . . 0.0 111.048 -178.099 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 9.0 m -81.49 138.58 35.47 Favored 'General case' 0 N--CA 1.441 -0.884 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.433 177.828 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.524 ' HB3' ' HB1' ' A' ' 63' ' ' ALA . 43.8 m-85 -122.12 129.94 52.8 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-N 115.679 -0.691 . . . . 0.0 109.685 178.126 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 72' ' ' GLU . . . . . 0.41 ' O ' ' HA ' ' A' ' 63' ' ' ALA . 36.0 tt0 -83.45 119.02 24.14 Favored 'General case' 0 N--CA 1.44 -0.949 0 N-CA-C 107.774 -1.195 . . . . 0.0 107.774 174.99 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.449 HG22 ' HB2' ' A' ' 63' ' ' ALA . 53.0 t -108.08 133.62 52.41 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.307 0 N-CA-C 112.866 0.691 . . . . 0.0 112.866 -172.474 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 99.8 mt-10 -120.03 122.4 41.05 Favored 'General case' 0 N--CA 1.436 -1.158 0 CA-C-N 114.51 -1.223 . . . . 0.0 108.875 176.676 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 2.7 m-20 -96.29 140.57 30.78 Favored 'General case' 0 C--N 1.313 -1.018 0 CA-C-N 116.288 -0.415 . . . . 0.0 109.917 179.367 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 76' ' ' GLN . . . . . 0.508 ' HB2' ' CE3' ' A' ' 84' ' ' TRP . 61.3 tt0 -115.87 120.89 40.68 Favored 'General case' 0 C--N 1.307 -1.254 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 179.345 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 6.1 p90 -137.55 157.1 47.25 Favored 'General case' 0 C--N 1.312 -1.027 0 CA-C-O 120.723 0.297 . . . . 0.0 110.329 179.481 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 103.13 -13.84 55.51 Favored Glycine 0 N--CA 1.439 -1.115 0 C-N-CA 120.756 -0.735 . . . . 0.0 111.652 -179.838 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 131.51 170.64 12.67 Favored Glycine 0 N--CA 1.437 -1.246 0 C-N-CA 120.886 -0.673 . . . . 0.0 111.972 178.97 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 5.7 p-10 -65.73 -33.1 75.09 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 121.056 0.455 . . . . 0.0 111.127 179.864 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 40.6 m -78.45 -2.89 40.66 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 115.845 -0.616 . . . . 0.0 111.856 -178.565 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -89.61 146.11 34.99 Favored Pre-proline 0 C--N 1.325 -0.458 0 CA-C-N 116.6 -0.273 . . . . 0.0 110.341 178.606 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.82 177.09 5.98 Favored 'Trans proline' 0 CA--C 1.532 0.405 0 C-N-CA 122.738 2.292 . . . . 0.0 112.298 179.847 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 84' ' ' TRP . . . . . 0.508 ' CE3' ' HB2' ' A' ' 76' ' ' GLN . 98.5 m95 -85.89 143.09 28.41 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 109.716 -0.476 . . . . 0.0 109.716 -179.154 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 91.7 m-70 -119.61 146.11 45.83 Favored 'General case' 0 C--N 1.313 -1.021 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 -179.643 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 46.0 m -63.51 131.2 47.36 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-O 120.891 0.377 . . . . 0.0 110.898 -179.396 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -107.94 -55.2 0.61 Allowed Glycine 0 N--CA 1.441 -1.013 0 C-N-CA 120.842 -0.694 . . . . 0.0 111.694 179.536 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 157.42 -173.43 34.88 Favored Glycine 0 C--O 1.223 -0.546 0 C-N-CA 120.26 -0.971 . . . . 0.0 112.184 179.326 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 24.3 t-20 -109.7 113.26 25.88 Favored 'General case' 0 C--N 1.316 -0.879 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 178.919 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 21.0 m0 -105.96 153.14 22.41 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.432 -176.416 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.443 ' HB ' ' H ' ' A' ' 24' ' ' GLU . 46.8 mm -107.22 113.54 43.8 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.799 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 177.259 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 82.8 mt -127.08 78.51 1.82 Allowed 'General case' 0 C--O 1.268 2.066 0 CA-C-O 122.045 0.926 . . . . 0.0 112.371 -176.973 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 162.71 104.87 0.19 Allowed Glycine 0 N--CA 1.444 -0.772 0 CA-C-N 114.741 -1.118 . . . . 0.0 110.752 -179.072 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 15.7 p -106.88 -13.12 15.31 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 120.889 0.376 . . . . 0.0 111.867 -178.0 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 85.2 mtp180 -85.47 16.2 3.96 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 121.248 0.547 . . . . 0.0 111.452 -179.202 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 46.9 tp10 65.36 -74.51 0.05 Allowed 'General case' 0 N--CA 1.472 0.646 0 CA-C-N 114.459 -1.246 . . . . 0.0 113.97 174.007 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 61.9 m-80 -91.97 26.85 2.3 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-O 120.765 0.317 . . . . 0.0 111.739 -175.077 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 98' ' ' GLN . . . . . . . . . . . . . 58.1 tt0 -150.05 116.62 5.81 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.801 0.334 . . . . 0.0 110.218 -177.969 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 83.6 m-20 -84.58 160.02 20.54 Favored 'General case' 0 C--O 1.245 0.819 0 CA-C-N 115.977 -0.556 . . . . 0.0 111.77 -176.895 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 79.5 t -82.36 132.43 31.43 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.664 0 C-N-CA 120.728 -0.389 . . . . 0.0 110.818 176.699 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 34.7 m -114.44 -23.76 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.601 0 N-CA-C 113.087 0.773 . . . . 0.0 113.087 -179.457 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 102' ' ' ALA . . . . . 0.549 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -152.04 144.13 23.87 Favored 'General case' 0 CA--C 1.512 -0.49 0 C-N-CA 120.425 -0.51 . . . . 0.0 111.113 178.198 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.442 ' HB ' HG22 ' A' ' 38' ' ' VAL . 84.6 mt -135.88 125.8 41.24 Favored 'Isoleucine or valine' 0 C--O 1.236 0.393 0 CA-C-O 120.582 0.23 . . . . 0.0 110.81 179.066 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 27.2 t-20 -126.74 94.88 4.16 Favored 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 175.172 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.435 ' CG2' ' HB ' ' A' ' 36' ' ' ILE . 30.9 m -136.88 141.43 40.68 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.702 0 N-CA-C 113.633 0.975 . . . . 0.0 113.633 -174.191 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 74.6 tt0 -141.71 150.49 41.9 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 114.97 -1.014 . . . . 0.0 109.298 178.117 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 107' ' ' SER . . . . . 0.415 ' HB3' ' HA ' ' A' ' 114' ' ' LEU . 35.6 p -150.65 153.17 35.15 Favored 'General case' 0 N--CA 1.446 -0.671 0 CA-C-O 120.821 0.343 . . . . 0.0 111.219 177.545 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -123.19 5.59 9.47 Favored Glycine 0 N--CA 1.439 -1.124 0 N-CA-C 111.112 -0.795 . . . . 0.0 111.112 177.474 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -92.34 34.59 1.03 Allowed 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 121.196 0.522 . . . . 0.0 110.528 179.495 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 29.3 m-20 59.21 21.83 10.0 Favored 'General case' 0 N--CA 1.474 0.741 0 CA-C-N 115.284 -0.871 . . . . 0.0 112.507 176.997 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 111' ' ' GLY . . . . . 0.516 ' HA3' ' ND2' ' A' ' 32' ' ' ASN . . . 89.71 -0.14 79.5 Favored Glycine 0 N--CA 1.447 -0.582 0 C-N-CA 120.748 -0.739 . . . . 0.0 113.174 177.928 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 51.8 tt0 -65.62 -43.38 89.76 Favored 'General case' 0 C--O 1.235 0.335 0 CA-C-O 121.356 0.598 . . . . 0.0 110.282 178.725 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 6.4 p -128.72 125.99 39.11 Favored 'General case' 0 N--CA 1.434 -1.248 0 CA-C-N 115.428 -0.805 . . . . 0.0 109.97 176.665 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 114' ' ' LEU . . . . . 0.415 ' HA ' ' HB3' ' A' ' 107' ' ' SER . 42.4 tp -112.47 134.94 53.73 Favored 'General case' 0 C--N 1.306 -1.319 0 CA-C-N 115.899 -0.591 . . . . 0.0 109.596 -177.776 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 30.1 p30 -145.72 169.91 17.54 Favored 'General case' 0 C--N 1.32 -0.698 0 C-N-CA 119.779 -0.768 . . . . 0.0 112.301 179.92 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 147.36 -131.71 4.02 Favored Glycine 0 N--CA 1.434 -1.444 0 CA-C-N 115.127 -0.942 . . . . 0.0 111.204 179.283 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 21.9 p -133.2 159.23 40.79 Favored 'General case' 0 C--N 1.307 -1.246 0 CA-C-O 121.095 0.474 . . . . 0.0 110.72 179.923 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 118' ' ' MET . . . . . 0.404 ' HE2' ' HB2' ' A' ' 118' ' ' MET . 4.5 ppp? -153.91 163.02 40.73 Favored 'General case' 0 C--N 1.306 -1.306 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 178.802 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 119' ' ' THR . . . . . 0.549 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 32.1 m -131.47 130.2 42.13 Favored 'General case' 0 C--N 1.307 -1.254 0 CA-C-O 120.791 0.329 . . . . 0.0 111.235 -179.79 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 11.5 m-85 -94.71 161.22 14.27 Favored 'General case' 0 N--CA 1.45 -0.473 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.075 177.095 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -65.6 128.19 34.93 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 120.89 0.376 . . . . 0.0 111.89 -179.098 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 76.23 19.17 78.72 Favored Glycine 0 N--CA 1.45 -0.396 0 CA-C-N 115.775 -0.648 . . . . 0.0 112.956 176.859 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 70.5 tt0 -147.22 161.08 41.65 Favored 'General case' 0 C--N 1.317 -0.832 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 -178.393 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -80.05 -179.49 52.54 Favored Glycine 0 N--CA 1.448 -0.508 0 C-N-CA 121.017 -0.611 . . . . 0.0 112.356 179.63 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -71.56 140.37 36.05 Favored 'Trans proline' 0 CA--C 1.532 0.392 0 C-N-CA 122.714 2.276 . . . . 0.0 112.959 -178.788 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 44.0 pt -132.68 165.99 30.64 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.13 178.805 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -73.15 142.6 31.91 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 121.017 -0.611 . . . . 0.0 112.458 -179.809 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 79.4 t80 -122.76 136.88 55.01 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-O 120.911 0.386 . . . . 0.0 111.272 -179.288 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 129' ' ' LYS . . . . . 0.437 ' HB3' ' HB2' ' A' ' 7' ' ' GLU . 63.2 tttm -142.0 125.95 17.21 Favored 'General case' 0 N--CA 1.447 -0.58 0 CA-C-N 115.649 -0.705 . . . . 0.0 109.154 175.668 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 130' ' ' GLY . . . . . 0.503 ' HA2' ' O ' ' A' ' 5' ' ' ASN . . . -127.24 135.74 8.96 Favored Glycine 0 N--CA 1.432 -1.581 0 N-CA-C 110.856 -0.898 . . . . 0.0 110.856 178.918 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 30.1 m -118.55 126.94 53.08 Favored 'General case' 0 C--N 1.305 -1.338 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 -178.581 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 66.1 tp -75.24 140.71 43.39 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.782 0.325 . . . . 0.0 111.154 -178.608 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 9.8 t . . . . . 0 C--O 1.248 1.022 0 CA-C-O 118.604 -0.712 . . . . 0.0 109.533 177.987 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.467 0.394 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 3.3 tm? -90.72 128.08 36.54 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-O 121.046 0.45 . . . . 0.0 110.332 -178.331 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 47.2 m-85 -124.46 147.08 48.56 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.864 -0.607 . . . . 0.0 111.175 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 5.7 m-20 -100.97 137.83 38.82 Favored 'General case' 0 C--N 1.315 -0.931 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 175.502 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.452 HG21 ' CD2' ' A' ' 23' ' ' TRP . 68.1 t -116.02 128.26 73.36 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.774 0 CA-C-O 121.527 0.68 . . . . 0.0 112.745 -173.913 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.453 ' HB3' ' HB3' ' A' ' 17' ' ' TRP . 65.4 mt-10 -118.66 138.36 52.66 Favored 'General case' 0 N--CA 1.437 -1.101 0 CA-C-N 114.681 -1.145 . . . . 0.0 108.423 176.713 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 89.7 m-20 -127.44 147.16 50.29 Favored 'General case' 0 C--N 1.312 -1.037 0 CA-C-O 121.172 0.511 . . . . 0.0 111.896 -177.056 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 52.1 tt0 -123.38 117.24 24.75 Favored 'General case' 0 C--N 1.314 -0.955 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 178.118 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 7.6 p90 -137.93 9.44 2.81 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 114.313 1.227 . . . . 0.0 114.313 -174.84 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -93.24 31.51 6.3 Favored Glycine 0 CA--C 1.522 0.485 0 C-N-CA 118.748 -1.692 . . . . 0.0 114.353 -174.784 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.63 58.88 3.17 Favored Glycine 0 CA--C 1.525 0.67 0 C-N-CA 120.428 -0.891 . . . . 0.0 114.376 176.922 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 22.8 t 60.69 154.55 0.03 OUTLIER 'General case' 0 CA--C 1.553 1.083 0 N-CA-C 113.408 0.892 . . . . 0.0 113.408 177.325 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 49.3 m 63.3 14.42 7.82 Favored 'General case' 0 N--CA 1.472 0.671 0 CA-C-N 115.851 -0.613 . . . . 0.0 112.355 177.223 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -96.7 153.95 38.57 Favored Pre-proline 0 C--N 1.314 -0.939 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.189 -179.446 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -73.18 161.69 42.47 Favored 'Trans proline' 0 C--O 1.238 0.503 0 C-N-CA 122.634 2.223 . . . . 0.0 111.703 177.772 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' TRP . . . . . 0.453 ' HB3' ' HB3' ' A' ' 7' ' ' GLU . 92.6 m95 -85.18 129.46 34.8 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 109.664 -0.495 . . . . 0.0 109.664 179.51 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 27.6 m-80 -113.22 118.57 35.04 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.661 -178.053 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.434 ' HA ' ' HA ' ' A' ' 7' ' ' GLU . 11.5 pt-20 -75.48 129.94 38.09 Favored 'General case' 0 C--N 1.319 -0.718 0 N-CA-C 109.724 -0.473 . . . . 0.0 109.724 177.474 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -137.62 26.57 2.9 Favored Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 119.596 -1.288 . . . . 0.0 113.159 -178.661 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 147.86 179.26 23.72 Favored Glycine 0 N--CA 1.449 -0.433 0 C-N-CA 119.79 -1.195 . . . . 0.0 113.075 178.125 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 25.8 pt20 -127.99 138.74 52.72 Favored 'General case' 0 C--N 1.322 -0.601 0 C-N-CA 122.69 0.396 . . . . 0.0 110.205 -179.93 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' TRP . . . . . 0.452 ' CD2' HG21 ' A' ' 6' ' ' VAL . 45.7 m0 -116.07 171.81 7.56 Favored 'General case' 0 C--O 1.242 0.661 0 CA-C-O 120.86 0.362 . . . . 0.0 111.226 -177.802 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 76.5 tt0 -119.13 110.73 17.4 Favored 'General case' 0 CA--C 1.513 -0.465 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 178.005 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 91.1 mt -133.01 143.97 37.9 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-N 115.401 -0.818 . . . . 0.0 109.579 -178.164 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 83.94 71.73 1.31 Allowed Glycine 0 CA--C 1.508 -0.351 0 C-N-CA 120.369 -0.92 . . . . 0.0 112.014 177.891 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 15.9 m -62.68 -45.62 91.97 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 120.823 0.344 . . . . 0.0 111.279 -179.313 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 83.0 mtm-85 -88.36 133.99 33.94 Favored 'General case' 0 CA--C 1.517 -0.322 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.057 178.797 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 18.8 p -87.16 -16.13 36.3 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.956 -0.565 . . . . 0.0 111.398 179.701 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 16.5 m-20 -71.31 -43.2 67.52 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-O 121.51 0.671 . . . . 0.0 110.161 179.933 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 14.1 mm100 -131.76 122.3 25.61 Favored 'General case' 0 C--N 1.312 -1.027 0 CA-C-N 114.915 -1.039 . . . . 0.0 110.046 -179.399 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' ASN . . . . . 0.506 ' ND2' ' HA3' ' A' ' 111' ' ' GLY . 59.4 t30 -108.15 172.36 6.88 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.324 -177.575 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 14.0 t -101.71 134.24 42.76 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.92 0 N-CA-C 111.877 0.325 . . . . 0.0 111.877 -172.031 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 33.6 m -113.77 -15.34 10.25 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.356 0 CA-C-O 121.017 0.437 . . . . 0.0 111.594 177.386 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.647 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -147.48 142.67 27.19 Favored 'General case' 0 CA--C 1.506 -0.715 0 C-N-CA 120.269 -0.572 . . . . 0.0 111.181 178.199 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.402 ' HB ' HG22 ' A' ' 105' ' ' VAL . 85.9 mt -142.36 120.43 8.04 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 N-CA-C 109.155 -0.683 . . . . 0.0 109.155 -179.377 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 37' ' ' ASN . . . . . 0.452 ' HA ' ' O ' ' A' ' 103' ' ' ILE . 22.7 m-80 -132.37 109.81 10.12 Favored 'General case' 0 C--N 1.31 -1.151 0 N-CA-C 108.88 -0.785 . . . . 0.0 108.88 176.49 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.488 HG22 ' HB ' ' A' ' 103' ' ' ILE . 33.3 m -147.79 152.93 12.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 C-N-CA 120.996 -0.281 . . . . 0.0 111.254 -172.57 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 41.6 tt0 -142.45 147.27 35.84 Favored 'General case' 0 N--CA 1.446 -0.633 0 CA-C-N 115.845 -0.616 . . . . 0.0 109.433 176.755 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 19.9 p -70.42 144.38 51.53 Favored 'General case' 0 C--N 1.313 -1.005 0 CA-C-O 121.083 0.468 . . . . 0.0 111.652 -178.548 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -88.38 -59.18 1.67 Allowed Glycine 0 N--CA 1.441 -0.971 0 N-CA-C 110.366 -1.094 . . . . 0.0 110.366 177.174 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 43.9 m-20 -93.78 -147.11 0.25 Allowed 'General case' 0 C--N 1.32 -0.713 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 176.708 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 20.2 p-10 -78.99 40.66 0.41 Allowed 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.124 0.488 . . . . 0.0 111.949 -178.818 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 97.89 -22.39 41.07 Favored Glycine 0 C--O 1.219 -0.82 0 C-N-CA 120.753 -0.736 . . . . 0.0 113.736 177.351 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 56.3 mt-30 -64.34 -28.61 69.82 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 117.319 0.559 . . . . 0.0 112.111 -178.603 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 26.0 p -117.54 137.0 52.87 Favored 'General case' 0 C--N 1.312 -1.029 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.392 179.334 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 88.7 mt -127.51 128.91 46.47 Favored 'General case' 0 C--N 1.318 -0.793 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 62.7 m-80 -129.47 140.82 51.17 Favored 'General case' 0 C--N 1.318 -0.762 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 178.335 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 178.97 -156.89 19.8 Favored Glycine 0 N--CA 1.438 -1.196 0 C-N-CA 119.972 -1.108 . . . . 0.0 112.797 179.522 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 65.3 m -130.98 132.99 45.39 Favored 'General case' 0 C--N 1.312 -1.04 0 CA-C-O 120.843 0.354 . . . . 0.0 110.646 -179.536 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 46.9 mtp -115.66 148.28 39.88 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.722 177.983 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.647 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 33.0 m -126.4 125.33 42.01 Favored 'General case' 0 C--O 1.25 1.086 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.136 177.149 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 53' ' ' TYR . . . . . 0.441 ' HB2' ' HB2' ' A' ' 56' ' ' GLU . 50.8 m-85 -94.67 164.74 12.83 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.869 -179.43 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -65.14 95.97 0.19 Allowed 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.813 -0.63 . . . . 0.0 111.641 -179.47 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 98.81 4.67 56.82 Favored Glycine 0 C--N 1.318 -0.424 0 CA-C-N 115.613 -0.721 . . . . 0.0 112.434 177.153 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 56' ' ' GLU . . . . . 0.441 ' HB2' ' HB2' ' A' ' 53' ' ' TYR . 41.8 mt-10 -114.45 168.02 10.21 Favored 'General case' 0 C--N 1.314 -0.968 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 178.871 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -89.61 168.95 35.12 Favored Glycine 0 N--CA 1.437 -1.298 0 C-N-CA 120.541 -0.838 . . . . 0.0 111.413 178.756 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_exo -63.02 134.33 45.62 Favored 'Trans proline' 0 C--O 1.239 0.545 0 C-N-CA 122.345 2.03 . . . . 0.0 111.465 178.735 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 45.0 pt -130.54 166.7 27.47 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.846 179.675 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -73.6 142.49 31.23 Favored Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 121.074 -0.584 . . . . 0.0 112.338 -177.409 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 39.8 t80 -126.77 128.47 46.66 Favored 'General case' 0 C--N 1.317 -0.839 0 C-N-CA 122.451 0.3 . . . . 0.0 111.125 -179.067 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 69.5 ttp85 -136.5 132.25 35.04 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 174.348 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.654 ' HB1' ' HB3' ' A' ' 71' ' ' TYR . . . -137.28 146.26 44.48 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 111.892 0.33 . . . . 0.0 111.892 179.837 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 60.1 m -121.32 131.3 54.12 Favored 'General case' 0 CA--C 1.546 0.793 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.38 179.176 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 65' ' ' LEU . . . . . 0.511 ' O ' ' HB3' ' A' ' 66' ' ' LEU . 59.9 tp -43.2 -51.81 5.89 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 115.513 1.672 . . . . 0.0 115.513 -176.493 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.511 ' HB3' ' O ' ' A' ' 65' ' ' LEU . 3.2 tm? 75.64 -57.06 0.59 Allowed 'General case' 0 CA--C 1.549 0.935 0 CA-C-N 118.364 0.529 . . . . 0.0 110.641 177.949 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -141.35 -90.27 0.16 Allowed Glycine 0 C--N 1.333 0.398 0 C-N-CA 121.057 -0.592 . . . . 0.0 112.646 -179.405 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 9.0 p30 -160.94 133.03 5.89 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 179.705 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 94.3 m-20 57.19 24.27 9.62 Favored 'General case' 0 N--CA 1.478 0.968 0 CA-C-O 121.279 0.562 . . . . 0.0 111.172 -176.256 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 43.5 m -138.2 152.03 48.25 Favored 'General case' 0 N--CA 1.434 -1.229 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 179.336 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.654 ' HB3' ' HB1' ' A' ' 63' ' ' ALA . 97.3 m-85 -149.85 126.39 10.91 Favored 'General case' 0 C--N 1.31 -1.118 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 176.662 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 72' ' ' GLU . . . . . 0.468 ' O ' ' HA ' ' A' ' 63' ' ' ALA . 83.7 tt0 -82.81 127.53 33.55 Favored 'General case' 0 N--CA 1.439 -0.991 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 175.603 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 76.9 t -104.75 131.55 53.55 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.278 0 CA-C-N 115.352 -0.84 . . . . 0.0 112.585 -171.96 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.469 ' HG2' ' HA ' ' A' ' 86' ' ' SER . 48.1 mt-10 -129.76 126.65 38.67 Favored 'General case' 0 N--CA 1.44 -0.966 0 CA-C-N 114.275 -1.33 . . . . 0.0 107.523 175.059 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 97.0 m-20 -109.53 154.34 22.85 Favored 'General case' 0 C--N 1.314 -0.973 0 CA-C-O 121.042 0.449 . . . . 0.0 112.053 -176.132 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 76' ' ' GLN . . . . . 0.537 ' HB2' ' CE3' ' A' ' 84' ' ' TRP . 61.8 tt0 -118.47 124.52 47.82 Favored 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 115.527 -0.76 . . . . 0.0 110.608 -176.193 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 6.0 p90 -142.59 158.8 43.3 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.158 179.07 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 98.32 -12.42 63.41 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.628 -0.796 . . . . 0.0 112.697 179.931 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 134.26 169.59 12.05 Favored Glycine 0 N--CA 1.447 -0.621 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.192 179.64 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 6.5 p-10 -68.83 -30.42 68.96 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 120.71 0.291 . . . . 0.0 111.097 -179.812 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 23.6 t -71.96 -16.0 62.08 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.255 179.28 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -79.96 143.62 57.88 Favored Pre-proline 0 C--N 1.324 -0.512 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.029 -178.488 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_endo -72.3 -178.16 3.12 Favored 'Trans proline' 0 C--O 1.238 0.511 0 C-N-CA 122.881 2.387 . . . . 0.0 112.149 179.168 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 84' ' ' TRP . . . . . 0.537 ' CE3' ' HB2' ' A' ' 76' ' ' GLN . 88.3 m95 -94.39 142.4 27.47 Favored 'General case' 0 C--N 1.317 -0.829 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 -179.816 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 96.6 m-70 -116.51 142.14 47.26 Favored 'General case' 0 C--N 1.316 -0.889 0 N-CA-C 109.778 -0.452 . . . . 0.0 109.778 -178.542 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 86' ' ' SER . . . . . 0.469 ' HA ' ' HG2' ' A' ' 74' ' ' GLU . 20.8 t -65.39 132.56 49.28 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 120.874 0.368 . . . . 0.0 111.229 -176.374 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -110.75 -48.35 0.74 Allowed Glycine 0 N--CA 1.441 -1.03 0 C-N-CA 120.936 -0.65 . . . . 0.0 112.188 178.547 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 157.96 -171.74 35.02 Favored Glycine 0 C--O 1.217 -0.911 0 C-N-CA 120.57 -0.824 . . . . 0.0 111.84 -179.943 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 8.1 t-20 -112.4 115.64 29.04 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 117.54 0.67 . . . . 0.0 110.251 179.699 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 35.1 m0 -97.88 148.71 23.16 Favored 'General case' 0 C--N 1.311 -1.092 0 CA-C-O 121.037 0.446 . . . . 0.0 111.622 -177.725 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.401 ' O ' ' HB3' ' A' ' 23' ' ' TRP . 76.6 mt -108.49 118.18 55.54 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.057 0 N-CA-C 108.49 -0.93 . . . . 0.0 108.49 175.605 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 85.8 mt -134.53 83.39 2.03 Favored 'General case' 0 C--O 1.267 1.985 0 O-C-N 124.031 0.832 . . . . 0.0 112.057 -173.675 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 172.11 111.34 0.26 Allowed Glycine 0 N--CA 1.444 -0.769 0 CA-C-N 115.752 -0.658 . . . . 0.0 112.644 177.407 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 78.8 p -90.07 -7.88 52.79 Favored 'General case' 0 C--O 1.236 0.362 0 CA-C-O 121.45 0.643 . . . . 0.0 110.014 177.348 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 97.3 mtt180 -105.28 142.74 34.52 Favored 'General case' 0 N--CA 1.445 -0.692 0 CA-C-N 115.357 -0.838 . . . . 0.0 110.701 179.725 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -70.48 -34.68 72.65 Favored 'General case' 0 C--N 1.311 -1.08 0 CA-C-N 115.688 -0.687 . . . . 0.0 112.811 -175.193 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 27.2 p-10 -116.21 27.29 9.33 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 112.77 0.655 . . . . 0.0 112.77 -176.54 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 98' ' ' GLN . . . . . . . . . . . . . 72.1 mt-30 -148.82 125.76 11.27 Favored 'General case' 0 CA--C 1.511 -0.54 0 CA-C-O 121.12 0.486 . . . . 0.0 112.276 -179.855 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 99' ' ' ASN . . . . . 0.531 ' HB3' ' OH ' ' A' ' 71' ' ' TYR . 94.9 m-20 -96.17 152.87 18.15 Favored 'General case' 0 C--O 1.258 1.512 0 CA-C-N 114.985 -1.007 . . . . 0.0 109.889 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 57.5 t -73.9 134.91 28.64 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.561 0 CA-C-O 120.932 0.396 . . . . 0.0 111.057 178.424 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 23.3 m -120.08 -23.64 3.26 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.478 0 N-CA-C 112.649 0.611 . . . . 0.0 112.649 -178.848 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 102' ' ' ALA . . . . . 0.511 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -148.05 139.58 23.69 Favored 'General case' 0 C--O 1.236 0.392 0 C-N-CA 120.342 -0.543 . . . . 0.0 111.85 179.433 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.488 ' HB ' HG22 ' A' ' 38' ' ' VAL . 37.4 mm -134.02 130.0 54.74 Favored 'Isoleucine or valine' 0 C--O 1.239 0.53 0 CA-C-N 115.904 -0.589 . . . . 0.0 111.287 178.901 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 6.8 t30 -129.07 93.75 3.66 Favored 'General case' 0 CA--C 1.534 0.359 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.368 176.222 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.402 HG22 ' HB ' ' A' ' 36' ' ' ILE . 27.3 m -138.44 141.55 37.3 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.932 0 N-CA-C 113.033 0.753 . . . . 0.0 113.033 -176.561 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 85.6 tt0 -144.14 87.63 1.91 Allowed 'General case' 0 CA--C 1.534 0.358 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.676 176.447 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 107' ' ' SER . . . . . 0.464 ' HB2' ' H ' ' A' ' 115' ' ' ASN . 13.6 m -162.93 159.82 24.1 Favored 'General case' 0 C--N 1.312 -1.061 0 CA-C-N 114.667 -1.151 . . . . 0.0 111.206 -179.359 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 136.95 94.46 0.37 Allowed Glycine 0 N--CA 1.424 -2.139 0 C-N-CA 119.215 -1.469 . . . . 0.0 114.578 173.633 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 16.7 m-20 -75.68 100.47 4.67 Favored 'General case' 0 CA--C 1.502 -0.878 0 N-CA-C 105.875 -1.898 . . . . 0.0 105.875 171.918 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 70.5 m-20 62.27 24.35 14.48 Favored 'General case' 0 CA--C 1.534 0.344 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 -172.234 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 111' ' ' GLY . . . . . 0.506 ' HA3' ' ND2' ' A' ' 32' ' ' ASN . . . 77.91 22.85 67.98 Favored Glycine 0 CA--C 1.527 0.821 0 CA-C-N 115.217 -0.901 . . . . 0.0 113.539 179.928 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 52.8 tt0 -66.35 -43.49 85.9 Favored 'General case' 0 CA--C 1.541 0.597 0 N-CA-C 112.433 0.531 . . . . 0.0 112.433 -179.263 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 21.8 p -131.8 157.01 45.0 Favored 'General case' 0 C--N 1.325 -0.496 0 O-C-N 122.335 -0.228 . . . . 0.0 111.525 -177.629 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 114' ' ' LEU . . . . . 0.423 ' HA ' ' HB2' ' A' ' 107' ' ' SER . 96.4 mt -133.38 109.39 9.31 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 110.199 -0.297 . . . . 0.0 110.199 178.353 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 115' ' ' ASN . . . . . 0.464 ' H ' ' HB2' ' A' ' 107' ' ' SER . 93.3 m-20 -114.5 143.35 45.1 Favored 'General case' 0 C--O 1.252 1.207 0 CA-C-O 121.091 0.472 . . . . 0.0 111.018 -179.366 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 162.08 -135.11 3.74 Favored Glycine 0 N--CA 1.44 -1.043 0 CA-C-N 115.718 -0.674 . . . . 0.0 112.366 178.751 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 3.0 p -137.2 159.61 41.42 Favored 'General case' 0 C--N 1.311 -1.069 0 C-N-CA 122.629 0.372 . . . . 0.0 110.544 -179.241 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 23.2 ptm -146.3 160.29 42.21 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 116.501 -0.318 . . . . 0.0 110.614 -178.376 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 119' ' ' THR . . . . . 0.511 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 25.6 m -143.14 136.59 28.37 Favored 'General case' 0 C--O 1.253 1.242 0 CA-C-N 116.609 -0.269 . . . . 0.0 111.426 179.893 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 120' ' ' TYR . . . . . 0.415 ' HB2' ' HB3' ' A' ' 123' ' ' GLU . 52.5 m-85 -100.69 164.65 11.77 Favored 'General case' 0 CA--C 1.508 -0.639 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.223 177.418 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -63.46 130.19 43.36 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.058 176.66 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 63.03 27.41 70.39 Favored Glycine 0 CA--C 1.521 0.463 0 C-N-CA 121.118 -0.563 . . . . 0.0 113.117 -179.131 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 123' ' ' GLU . . . . . 0.415 ' HB3' ' HB2' ' A' ' 120' ' ' TYR . 9.9 tp10 -136.83 162.2 33.89 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -178.829 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -89.11 170.57 37.77 Favored Glycine 0 CA--C 1.522 0.479 0 C-N-CA 120.847 -0.692 . . . . 0.0 112.341 179.599 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -72.03 135.15 24.69 Favored 'Trans proline' 0 N--CA 1.46 -0.484 0 C-N-CA 122.369 2.046 . . . . 0.0 112.201 179.125 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 40.7 pt -130.83 161.56 40.56 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.269 179.673 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -72.42 134.91 21.62 Favored Glycine 0 C--O 1.238 0.391 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.119 -179.916 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 91.6 t80 -115.85 133.16 56.31 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.858 0.361 . . . . 0.0 110.99 -178.952 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 62.8 tttm -140.64 108.54 5.69 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 115.679 -0.691 . . . . 0.0 109.265 177.954 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -117.42 147.78 18.78 Favored Glycine 0 N--CA 1.44 -1.056 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.053 -179.35 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 5.4 t -137.16 142.84 42.2 Favored 'General case' 0 C--N 1.313 -1.002 0 CA-C-O 120.899 0.381 . . . . 0.0 111.231 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 63.2 tp -72.17 136.81 46.56 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.582 -0.736 . . . . 0.0 110.355 177.961 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 37.2 m . . . . . 0 C--N 1.307 -1.248 0 CA-C-O 118.802 -0.618 . . . . 0.0 110.407 -179.904 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.235 0.309 0 CA-C-O 120.655 0.264 . . . . 0.0 110.304 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 9.2 tt -90.32 132.15 35.72 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-O 120.988 0.423 . . . . 0.0 110.197 179.593 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' TYR . . . . . 0.548 ' CD1' ' HB ' ' A' ' 25' ' ' ILE . 34.5 m-85 -116.43 137.97 51.73 Favored 'General case' 0 C--N 1.317 -0.841 0 CA-C-O 121.386 0.612 . . . . 0.0 111.32 -178.926 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' ASN . . . . . 0.561 ' HB2' ' OG1' ' A' ' 133' ' ' THR . 60.8 t30 -96.51 135.61 38.16 Favored 'General case' 0 C--N 1.305 -1.339 0 N-CA-C 107.176 -1.416 . . . . 0.0 107.176 177.226 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.438 ' O ' ' HA ' ' A' ' 19' ' ' GLU . 72.2 t -116.48 126.31 73.89 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 N-CA-C 113.176 0.806 . . . . 0.0 113.176 -172.419 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -118.71 137.42 53.35 Favored 'General case' 0 N--CA 1.439 -0.991 0 CA-C-N 114.479 -1.237 . . . . 0.0 107.962 175.911 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 91.1 m-20 -128.79 151.64 49.35 Favored 'General case' 0 C--N 1.313 -1.007 0 N-CA-C 112.607 0.595 . . . . 0.0 112.607 -175.238 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 52.9 tt0 -122.33 110.33 15.53 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 107.527 -1.286 . . . . 0.0 107.527 175.988 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 40.2 p90 -134.47 4.91 3.43 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 114.556 1.317 . . . . 0.0 114.556 -172.875 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -119.32 18.99 10.08 Favored Glycine 0 N--CA 1.446 -0.65 0 C-N-CA 118.357 -1.878 . . . . 0.0 113.696 -176.11 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 152.02 -160.91 29.1 Favored Glycine 0 N--CA 1.446 -0.7 0 C-N-CA 119.541 -1.314 . . . . 0.0 112.907 179.097 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 36.6 p -102.5 -21.97 14.12 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-O 121.061 0.458 . . . . 0.0 110.462 -177.149 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 47.0 p -107.15 -1.3 22.07 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.607 -0.724 . . . . 0.0 110.423 -178.801 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -59.46 135.35 88.86 Favored Pre-proline 0 N--CA 1.453 -0.289 0 CA-C-N 115.616 -0.72 . . . . 0.0 111.068 -178.034 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -70.01 162.89 40.5 Favored 'Trans proline' 0 N--CA 1.459 -0.527 0 C-N-CA 122.653 2.235 . . . . 0.0 111.874 179.088 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 99.0 m95 -84.77 123.68 30.69 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 179.865 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 44.1 m-80 -118.68 128.46 54.54 Favored 'General case' 0 C--N 1.315 -0.898 0 N-CA-C 110.245 -0.28 . . . . 0.0 110.245 -178.869 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.438 ' HA ' ' O ' ' A' ' 6' ' ' VAL . 11.3 pt-20 -82.03 132.35 35.25 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 176.34 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -133.09 23.36 3.9 Favored Glycine 0 N--CA 1.438 -1.193 0 C-N-CA 120.028 -1.082 . . . . 0.0 112.114 -179.318 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 153.4 178.04 27.53 Favored Glycine 0 N--CA 1.439 -1.144 0 C-N-CA 120.644 -0.789 . . . . 0.0 111.969 -179.385 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 27.3 pt20 -131.5 138.66 49.07 Favored 'General case' 0 C--N 1.313 -0.997 0 N-CA-C 110.012 -0.366 . . . . 0.0 110.012 -179.456 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 44.1 m0 -113.03 175.37 5.47 Favored 'General case' 0 CA--C 1.506 -0.74 0 CA-C-O 121.081 0.467 . . . . 0.0 110.693 -178.128 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 39.4 tt0 -129.68 115.15 16.91 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-N 116.098 -0.501 . . . . 0.0 109.812 178.062 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.548 ' HB ' ' CD1' ' A' ' 4' ' ' TYR . 93.8 mt -128.33 135.62 62.14 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.962 0 CA-C-N 115.574 -0.739 . . . . 0.0 109.561 -177.29 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 86.31 71.42 1.3 Allowed Glycine 0 N--CA 1.441 -1.01 0 C-N-CA 119.935 -1.126 . . . . 0.0 111.363 -179.781 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 32.1 t -59.79 -41.07 90.36 Favored 'General case' 0 C--N 1.318 -0.796 0 N-CA-C 109.526 -0.546 . . . . 0.0 109.526 179.413 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 97.1 mtt180 -99.35 133.54 43.5 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 176.064 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 2.4 p -86.22 2.37 47.29 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-O 121.011 0.434 . . . . 0.0 111.908 -177.832 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 -66.0 -34.28 77.73 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.407 178.74 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' GLN . . . . . 0.498 ' HA ' ' NE2' ' A' ' 31' ' ' GLN . 5.6 mm-40 -143.1 126.58 16.79 Favored 'General case' 0 CA--C 1.502 -0.871 0 N-CA-C 113.367 0.877 . . . . 0.0 113.367 -177.239 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 32' ' ' ASN . . . . . 0.461 ' HB3' ' HA3' ' A' ' 111' ' ' GLY . 95.9 m-20 -90.4 156.04 18.51 Favored 'General case' 0 N--CA 1.446 -0.639 0 CA-C-N 115.022 -0.99 . . . . 0.0 110.091 177.466 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 18.0 m -105.77 137.33 36.2 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.034 0 CA-C-N 115.727 -0.67 . . . . 0.0 112.672 -175.979 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 27.7 m -111.73 -20.59 6.13 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.2 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.908 177.535 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.628 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -145.21 144.83 31.05 Favored 'General case' 0 C--N 1.321 -0.663 0 C-N-CA 119.94 -0.704 . . . . 0.0 111.533 178.68 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 91.6 mt -144.33 126.88 10.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 N-CA-C 108.709 -0.848 . . . . 0.0 108.709 -179.535 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' ASN . . . . . 0.551 ' HA ' ' O ' ' A' ' 103' ' ' ILE . 3.3 t-20 -140.22 114.31 9.04 Favored 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 179.097 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.582 HG11 ' CD2' ' A' ' 61' ' ' PHE . 16.5 m -151.96 158.77 4.28 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.931 0 CA-C-O 120.807 0.337 . . . . 0.0 111.834 -173.743 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 66.2 tt0 -139.19 147.96 42.5 Favored 'General case' 0 N--CA 1.451 -0.392 0 CA-C-N 115.229 -0.896 . . . . 0.0 109.299 174.836 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' SER . . . . . 0.426 ' OG ' ' HB ' ' A' ' 101' ' ' VAL . 95.2 p -82.31 166.05 19.84 Favored 'General case' 0 C--N 1.313 -0.984 0 CA-C-O 121.146 0.498 . . . . 0.0 111.911 -179.351 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -107.74 -52.41 0.71 Allowed Glycine 0 N--CA 1.442 -0.948 0 CA-C-N 115.528 -0.76 . . . . 0.0 111.344 175.1 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -131.14 102.12 5.87 Favored 'General case' 0 C--N 1.326 -0.431 0 C-N-CA 122.334 0.253 . . . . 0.0 111.262 -179.563 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 83.8 m-20 52.1 26.4 3.81 Favored 'General case' 0 N--CA 1.492 1.656 0 N-CA-C 113.732 1.012 . . . . 0.0 113.732 177.105 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 82.48 -6.5 68.57 Favored Glycine 0 C--N 1.312 -0.761 0 C-N-CA 120.333 -0.936 . . . . 0.0 113.396 178.184 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 81.3 mt-30 -64.95 -32.49 74.23 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 117.219 0.509 . . . . 0.0 110.842 -179.065 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 4.9 t -118.11 131.44 56.43 Favored 'General case' 0 C--N 1.307 -1.279 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 174.652 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' LEU . . . . . 0.432 ' HB2' ' HB3' ' A' ' 63' ' ' ALA . 91.7 mt -126.26 134.37 51.2 Favored 'General case' 0 C--N 1.316 -0.861 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 -177.756 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 20.7 p30 -143.89 147.43 34.01 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-O 121.207 0.527 . . . . 0.0 111.511 179.569 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 164.4 -142.49 7.83 Favored Glycine 0 N--CA 1.442 -0.934 0 N-CA-C 111.389 -0.684 . . . . 0.0 111.389 179.873 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 40.2 p -132.98 150.39 52.16 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-O 121.028 0.442 . . . . 0.0 111.846 -178.938 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 32.2 mtp -124.17 152.68 42.56 Favored 'General case' 0 C--N 1.326 -0.415 0 C-N-CA 123.341 0.656 . . . . 0.0 109.603 176.348 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.628 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 24.1 m -130.37 123.6 30.27 Favored 'General case' 0 C--O 1.25 1.081 0 C-N-CA 121.141 -0.224 . . . . 0.0 110.435 176.313 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 53' ' ' TYR . . . . . 0.456 ' HB2' ' HB2' ' A' ' 56' ' ' GLU . 71.8 m-85 -85.57 164.33 17.83 Favored 'General case' 0 C--O 1.232 0.173 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.43 178.712 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -67.22 101.88 0.97 Allowed 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.499 -179.996 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 97.06 -0.85 60.61 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.731 -0.747 . . . . 0.0 113.229 177.674 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 56' ' ' GLU . . . . . 0.456 ' HB2' ' HB2' ' A' ' 53' ' ' TYR . 79.9 mm-40 -111.19 179.77 3.95 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 117.024 0.412 . . . . 0.0 110.739 -179.982 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -95.75 168.16 26.16 Favored Glycine 0 N--CA 1.443 -0.868 0 C-N-CA 120.845 -0.693 . . . . 0.0 111.944 178.922 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 23.5 Cg_exo -64.45 139.77 66.36 Favored 'Trans proline' 0 C--O 1.238 0.523 0 C-N-CA 122.657 2.238 . . . . 0.0 112.301 179.002 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 59' ' ' ILE . . . . . 0.433 ' HB ' ' O ' ' A' ' 76' ' ' GLN . 48.9 pt -131.74 168.4 24.05 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 CA-C-N 115.801 -0.636 . . . . 0.0 109.918 179.0 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -79.95 148.31 30.02 Favored Glycine 0 C--N 1.32 -0.351 0 C-N-CA 120.874 -0.679 . . . . 0.0 111.645 -179.816 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.582 ' CD2' HG11 ' A' ' 38' ' ' VAL . 2.6 t80 -136.88 130.83 32.3 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-O 120.819 0.342 . . . . 0.0 111.18 -178.538 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 57.3 ttp180 -135.62 134.81 39.66 Favored 'General case' 0 C--O 1.232 0.142 0 CA-C-N 115.833 -0.621 . . . . 0.0 109.934 176.784 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.522 ' HB1' ' HB3' ' A' ' 71' ' ' TYR . . . -136.81 146.14 45.32 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 120.738 0.304 . . . . 0.0 111.484 179.797 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 65.0 m -125.27 131.25 53.13 Favored 'General case' 0 CA--C 1.537 0.461 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.055 178.952 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 61.1 tp -74.26 119.19 18.13 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.334 0.588 . . . . 0.0 112.311 -177.205 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 94.2 mt -90.1 -29.52 18.28 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.502 -0.772 . . . . 0.0 109.849 175.227 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 134.23 166.68 11.31 Favored Glycine 0 N--CA 1.447 -0.578 0 N-CA-C 110.962 -0.855 . . . . 0.0 110.962 -179.135 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 53.9 m-80 58.06 36.39 25.96 Favored 'General case' 0 N--CA 1.477 0.883 0 CA-C-N 117.21 0.505 . . . . 0.0 111.331 179.245 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 17.3 m120 63.59 14.08 7.8 Favored 'General case' 0 N--CA 1.479 0.987 0 CA-C-N 115.614 -0.721 . . . . 0.0 111.277 179.204 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 17.6 m -101.33 126.07 48.04 Favored 'General case' 0 C--O 1.239 0.552 0 CA-C-O 121.081 0.467 . . . . 0.0 111.156 -178.883 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.522 ' HB3' ' HB1' ' A' ' 63' ' ' ALA . 91.0 m-85 -114.52 141.98 47.01 Favored 'General case' 0 C--N 1.313 -0.997 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.494 -178.556 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 72' ' ' GLU . . . . . 0.429 ' O ' ' HA ' ' A' ' 63' ' ' ALA . 35.8 tt0 -90.39 120.16 31.28 Favored 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 108.35 -0.982 . . . . 0.0 108.35 175.574 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.492 HG13 ' CE1' ' A' ' 61' ' ' PHE . 54.2 t -103.67 132.83 49.19 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.013 0 N-CA-C 113.871 1.063 . . . . 0.0 113.871 -171.953 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 70.6 mt-10 -129.3 129.47 44.91 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 114.472 -1.24 . . . . 0.0 107.976 173.762 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 96.4 m-20 -109.12 145.48 35.63 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 121.279 0.562 . . . . 0.0 111.838 -177.781 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 76' ' ' GLN . . . . . 0.433 ' O ' ' HB ' ' A' ' 59' ' ' ILE . 10.4 tt0 -111.26 123.59 50.51 Favored 'General case' 0 C--N 1.316 -0.873 0 C-N-CA 124.032 0.933 . . . . 0.0 111.592 -177.125 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 10.0 p90 -140.27 155.61 46.79 Favored 'General case' 0 C--N 1.316 -0.89 0 N-CA-C 110.52 -0.178 . . . . 0.0 110.52 175.061 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 107.0 -9.71 39.92 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.852 -0.69 . . . . 0.0 112.279 -179.934 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 145.03 171.81 15.02 Favored Glycine 0 N--CA 1.447 -0.591 0 N-CA-C 111.581 -0.608 . . . . 0.0 111.581 178.912 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 1.8 p-10 -62.9 153.03 34.7 Favored 'General case' 0 C--O 1.241 0.609 0 CA-C-N 117.015 0.408 . . . . 0.0 110.31 178.081 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 16.3 m 65.42 -95.06 0.04 OUTLIER 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.717 -0.674 . . . . 0.0 109.497 -178.33 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 50.23 172.48 0.03 OUTLIER Pre-proline 0 CA--C 1.555 1.158 0 N-CA-C 113.533 0.938 . . . . 0.0 113.533 176.519 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_exo -69.91 144.97 54.87 Favored 'Trans proline' 0 N--CA 1.45 -1.062 0 C-N-CA 121.722 1.614 . . . . 0.0 110.161 172.255 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 84' ' ' TRP . . . . . . . . . . . . . 92.7 m95 -90.88 139.34 30.84 Favored 'General case' 0 C--N 1.313 -0.983 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 178.757 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 84.8 m-70 -111.5 138.63 47.77 Favored 'General case' 0 C--N 1.313 -1.005 0 N-CA-C 108.936 -0.764 . . . . 0.0 108.936 -178.822 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 10.5 m -66.85 135.62 54.17 Favored 'General case' 0 C--N 1.314 -0.957 0 CA-C-O 120.675 0.274 . . . . 0.0 110.922 -177.324 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -110.01 -44.59 1.01 Allowed Glycine 0 N--CA 1.443 -0.838 0 C-N-CA 120.832 -0.699 . . . . 0.0 111.742 179.376 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 143.74 -158.7 27.44 Favored Glycine 0 C--O 1.214 -1.151 0 C-N-CA 120.723 -0.751 . . . . 0.0 111.473 178.681 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 19.1 m120 -115.33 129.25 56.55 Favored 'General case' 0 C--N 1.315 -0.918 0 CA-C-N 117.303 0.551 . . . . 0.0 110.88 179.278 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 23.3 m0 -118.96 150.73 39.42 Favored 'General case' 0 N--CA 1.466 0.335 0 N-CA-C 109.981 -0.377 . . . . 0.0 109.981 179.777 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 92.1 mt -109.63 123.08 65.23 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 177.76 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 83.6 mt -134.3 84.85 2.14 Favored 'General case' 0 C--O 1.265 1.871 0 O-C-N 123.688 0.617 . . . . 0.0 112.473 -175.85 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 168.13 110.36 0.23 Allowed Glycine 0 C--O 1.218 -0.903 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.688 178.003 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 68.3 p -100.78 -9.43 21.73 Favored 'General case' 0 C--O 1.225 -0.232 0 CA-C-O 120.984 0.421 . . . . 0.0 111.116 178.379 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 92.2 mtt180 -96.69 3.79 52.23 Favored 'General case' 0 C--O 1.232 0.162 0 C-N-CA 120.574 -0.45 . . . . 0.0 111.921 179.32 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 66.6 tt0 72.83 -83.13 0.03 OUTLIER 'General case' 0 N--CA 1.467 0.401 0 C-N-CA 123.22 0.608 . . . . 0.0 112.377 173.067 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 63.4 m-80 -92.34 34.15 1.06 Allowed 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 120.831 0.348 . . . . 0.0 111.612 -174.802 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 98' ' ' GLN . . . . . . . . . . . . . 23.6 tp60 -120.08 -48.11 2.35 Favored 'General case' 0 C--N 1.316 -0.875 0 C-N-CA 120.59 -0.444 . . . . 0.0 110.284 -178.945 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 93.4 m-20 72.62 137.84 0.05 Allowed 'General case' 0 N--CA 1.485 1.308 0 O-C-N 123.735 0.647 . . . . 0.0 112.284 178.499 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 69.9 t -78.43 132.4 32.44 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.33 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.871 178.861 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 0.426 ' HB ' ' OG ' ' A' ' 40' ' ' SER . 34.4 m -113.04 -27.64 2.68 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.517 0 N-CA-C 112.555 0.576 . . . . 0.0 112.555 -179.506 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 102' ' ' ALA . . . . . 0.56 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -146.82 144.45 29.35 Favored 'General case' 0 C--N 1.322 -0.619 0 C-N-CA 119.96 -0.696 . . . . 0.0 111.546 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.551 ' O ' ' HA ' ' A' ' 37' ' ' ASN . 34.1 mm -133.98 128.05 52.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.62 179.193 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 104' ' ' ASN . . . . . 0.43 ' HB3' ' OG1' ' A' ' 117' ' ' THR . 43.4 t30 -131.27 92.08 3.13 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.292 175.714 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 29.4 m -138.12 144.26 31.11 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.566 0 N-CA-C 113.017 0.747 . . . . 0.0 113.017 -175.451 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 79.9 tt0 -148.19 101.39 3.26 Favored 'General case' 0 CA--C 1.538 0.501 0 CA-C-N 115.558 -0.746 . . . . 0.0 110.656 176.832 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 107' ' ' SER . . . . . 0.418 ' HB2' ' H ' ' A' ' 115' ' ' ASN . 69.5 m -166.69 165.82 16.27 Favored 'General case' 0 N--CA 1.475 0.821 0 CA-C-N 114.834 -1.075 . . . . 0.0 112.388 -178.909 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 116.41 117.19 2.98 Favored Glycine 0 N--CA 1.424 -2.156 0 C-N-CA 120.344 -0.932 . . . . 0.0 113.241 175.308 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 -67.38 -42.44 83.39 Favored 'General case' 0 C--N 1.319 -0.757 0 N-CA-C 107.997 -1.112 . . . . 0.0 107.997 175.639 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 30.3 t70 -142.38 33.43 1.48 Allowed 'General case' 0 C--O 1.213 -0.85 0 CA-C-N 114.428 -1.26 . . . . 0.0 108.228 175.432 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 111' ' ' GLY . . . . . 0.461 ' HA3' ' HB3' ' A' ' 32' ' ' ASN . . . 81.82 18.05 68.82 Favored Glycine 0 CA--C 1.523 0.538 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.656 -178.335 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 112' ' ' GLN . . . . . 0.446 ' HA ' ' CD1' ' A' ' 132' ' ' LEU . 98.1 mt-30 -66.66 -40.64 88.7 Favored 'General case' 0 C--O 1.244 0.794 0 CA-C-O 120.975 0.417 . . . . 0.0 111.71 -179.177 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 25.6 p -139.15 143.37 38.15 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.824 -0.626 . . . . 0.0 110.755 -178.391 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -119.4 123.35 43.89 Favored 'General case' 0 C--N 1.317 -0.814 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 176.539 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 115' ' ' ASN . . . . . 0.418 ' H ' ' HB2' ' A' ' 107' ' ' SER . 53.6 m-80 -128.66 149.6 50.6 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-O 120.851 0.358 . . . . 0.0 110.587 -178.503 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 155.48 -131.34 3.05 Favored Glycine 0 N--CA 1.438 -1.175 0 C-N-CA 120.634 -0.793 . . . . 0.0 112.343 177.971 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 117' ' ' THR . . . . . 0.43 ' OG1' ' HB3' ' A' ' 104' ' ' ASN . 23.9 p -130.25 155.37 46.39 Favored 'General case' 0 C--N 1.311 -1.089 0 CA-C-O 121.015 0.436 . . . . 0.0 110.848 -178.459 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 23.2 ptm -146.2 153.34 40.52 Favored 'General case' 0 C--N 1.313 -0.991 0 CA-C-N 115.949 -0.569 . . . . 0.0 109.67 -178.809 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 119' ' ' THR . . . . . 0.56 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 26.0 m -132.99 131.34 40.64 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-O 120.642 0.258 . . . . 0.0 111.422 -179.294 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 33.0 m-85 -95.75 163.49 13.15 Favored 'General case' 0 CA--C 1.509 -0.611 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.394 175.992 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -62.75 128.59 36.64 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.588 178.155 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 70.95 15.58 74.18 Favored Glycine 0 CA--C 1.524 0.596 0 CA-C-N 115.895 -0.593 . . . . 0.0 113.257 179.44 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -127.03 179.82 5.22 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 117.149 0.474 . . . . 0.0 111.335 -179.46 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -105.55 170.09 16.91 Favored Glycine 0 N--CA 1.445 -0.754 0 N-CA-C 111.502 -0.639 . . . . 0.0 111.502 178.533 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 22.9 Cg_exo -65.37 135.39 42.61 Favored 'Trans proline' 0 CA--C 1.534 0.511 0 C-N-CA 122.542 2.161 . . . . 0.0 112.375 -179.812 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 48.0 pt -131.21 165.09 32.49 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 116.06 -0.518 . . . . 0.0 109.941 177.931 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -73.76 132.78 16.25 Favored Glycine 0 CA--C 1.521 0.464 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.751 -179.169 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 91.6 t80 -114.8 132.96 56.3 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 120.634 0.254 . . . . 0.0 111.224 -179.526 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 63.0 tttm -137.49 101.83 4.61 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.029 176.927 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -106.37 133.51 11.66 Favored Glycine 0 N--CA 1.446 -0.645 0 C-N-CA 120.977 -0.63 . . . . 0.0 111.617 179.485 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 49.1 m -130.24 137.55 50.08 Favored 'General case' 0 C--N 1.311 -1.072 0 CA-C-N 116.638 0.219 . . . . 0.0 111.191 -179.334 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 132' ' ' LEU . . . . . 0.446 ' CD1' ' HA ' ' A' ' 112' ' ' GLN . 87.9 mt -57.7 134.93 56.64 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-O 120.858 0.361 . . . . 0.0 110.31 176.781 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 133' ' ' THR . . . . . 0.561 ' OG1' ' HB2' ' A' ' 5' ' ' ASN . 57.5 m . . . . . 0 C--O 1.251 1.182 0 CA-C-O 118.643 -0.694 . . . . 0.0 110.539 -179.086 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.692 0 N-CA-C 110.373 -0.232 . . . . 0.0 110.373 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 3' ' ' LEU . . . . . 0.458 HD13 ' N ' ' A' ' 4' ' ' TYR . 2.8 tm? -99.85 131.41 45.85 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.357 -177.663 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 4' ' ' TYR . . . . . 0.607 ' CE1' ' HB ' ' A' ' 25' ' ' ILE . 85.1 m-85 -121.41 145.11 48.25 Favored 'General case' 0 C--O 1.238 0.476 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.866 -179.215 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 93.3 m-20 -82.67 142.23 31.85 Favored 'General case' 0 N--CA 1.468 0.436 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 176.991 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.46 HG21 ' CD1' ' A' ' 23' ' ' TRP . 59.0 t -116.09 126.76 73.72 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 N-CA-C 113.464 0.913 . . . . 0.0 113.464 -176.159 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 92.0 mt-10 -128.09 132.43 49.01 Favored 'General case' 0 N--CA 1.445 -0.683 0 CA-C-N 114.634 -1.167 . . . . 0.0 108.088 175.001 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 92.5 m-20 -124.59 145.74 49.43 Favored 'General case' 0 C--N 1.313 -0.986 0 CA-C-O 120.645 0.259 . . . . 0.0 110.696 -178.158 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 52.0 tt0 -119.65 118.24 30.43 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.808 0.337 . . . . 0.0 110.464 179.071 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' TRP . . . . . 0.507 ' CZ3' ' HB2' ' A' ' 18' ' ' ASN . 2.5 m-90 -79.2 140.79 37.6 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.332 179.711 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 89.33 -42.21 3.02 Favored Glycine 0 N--CA 1.444 -0.811 0 C-N-CA 120.579 -0.82 . . . . 0.0 112.05 -179.085 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.84 21.42 71.51 Favored Glycine 0 C--O 1.227 -0.327 0 C-N-CA 120.85 -0.691 . . . . 0.0 111.581 -179.707 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 20.9 p -168.2 133.82 1.86 Allowed 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.771 -0.214 . . . . 0.0 111.188 -178.024 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 63.6 p 46.85 44.73 14.66 Favored 'General case' 0 N--CA 1.475 0.824 0 C-N-CA 123.456 0.702 . . . . 0.0 112.638 176.79 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.467 ' HA ' ' HD3' ' A' ' 16' ' ' PRO . . . -139.6 144.32 38.9 Favored Pre-proline 0 C--N 1.324 -0.517 0 C-N-CA 120.905 -0.318 . . . . 0.0 111.425 -178.158 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.467 ' HD3' ' HA ' ' A' ' 15' ' ' ALA . 11.4 Cg_exo -71.57 157.45 55.98 Favored 'Trans proline' 0 C--N 1.347 0.483 0 C-N-CA 123.033 2.489 . . . . 0.0 111.699 176.888 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 91.5 m95 -85.26 134.15 34.14 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 120.891 0.377 . . . . 0.0 110.343 179.57 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' ASN . . . . . 0.507 ' HB2' ' CZ3' ' A' ' 10' ' ' TRP . 90.7 m-20 -110.01 135.67 50.47 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.105 179.231 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 14.7 pt-20 -105.44 131.2 53.15 Favored 'General case' 0 C--N 1.314 -0.95 0 N-CA-C 109.241 -0.652 . . . . 0.0 109.241 -179.828 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -157.33 34.26 0.55 Allowed Glycine 0 N--CA 1.44 -1.045 0 C-N-CA 119.058 -1.544 . . . . 0.0 112.997 179.843 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 162.67 -179.02 38.21 Favored Glycine 0 N--CA 1.444 -0.777 0 C-N-CA 119.58 -1.295 . . . . 0.0 113.511 178.847 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 13.7 pt20 -145.29 140.66 27.94 Favored 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 179.218 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' TRP . . . . . 0.46 ' CD1' HG21 ' A' ' 6' ' ' VAL . 48.0 m0 -114.74 155.97 25.7 Favored 'General case' 0 CA--C 1.505 -0.761 0 CA-C-O 120.715 0.293 . . . . 0.0 111.443 -176.213 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 77.8 tt0 -116.6 119.52 35.79 Favored 'General case' 0 C--N 1.321 -0.633 0 C-N-CA 120.445 -0.502 . . . . 0.0 110.221 177.881 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.607 ' HB ' ' CE1' ' A' ' 4' ' ' TYR . 97.7 mt -135.32 143.37 37.12 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.72 0 CA-C-N 114.998 -1.001 . . . . 0.0 109.464 -177.681 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 84.0 60.61 1.93 Allowed Glycine 0 C--O 1.225 -0.437 0 C-N-CA 120.18 -1.01 . . . . 0.0 112.398 178.629 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 15.4 m -58.15 -40.4 81.26 Favored 'General case' 0 C--N 1.317 -0.838 0 O-C-N 123.935 0.432 . . . . 0.0 111.618 179.759 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 79.9 ttt180 -61.29 -42.27 98.37 Favored 'General case' 0 CA--C 1.538 0.518 0 CA-C-N 116.588 -0.278 . . . . 0.0 111.558 178.803 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 20.1 m 75.99 -21.98 0.29 Allowed 'General case' 0 N--CA 1.482 1.17 0 C-N-CA 123.75 0.82 . . . . 0.0 113.201 179.073 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 58.3 m-20 -68.23 -11.71 59.77 Favored 'General case' 0 N--CA 1.483 1.189 0 CA-C-O 121.06 0.457 . . . . 0.0 111.414 178.243 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -152.71 136.09 15.87 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.133 -178.963 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 32' ' ' ASN . . . . . 0.564 ' ND2' ' HA3' ' A' ' 111' ' ' GLY . 2.5 t30 -93.45 150.81 20.16 Favored 'General case' 0 C--O 1.247 0.967 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.247 178.984 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 46.3 t -93.98 131.33 41.2 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 CA-C-N 115.697 -0.683 . . . . 0.0 109.62 -178.399 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 28.1 m -102.75 -32.43 3.11 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.686 0 C-N-CA 120.596 -0.442 . . . . 0.0 111.835 -179.595 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.641 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -135.01 145.19 47.83 Favored 'General case' 0 CA--C 1.511 -0.537 0 C-N-CA 120.349 -0.54 . . . . 0.0 111.28 -179.201 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 93.9 mt -142.33 122.54 10.72 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 CA-C-N 115.744 -0.662 . . . . 0.0 109.553 -179.543 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 19.7 m120 -130.74 112.58 13.21 Favored 'General case' 0 C--N 1.316 -0.851 0 N-CA-C 108.246 -1.02 . . . . 0.0 108.246 176.07 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.489 HG22 ' HB ' ' A' ' 103' ' ' ILE . 27.3 m -147.41 150.57 14.49 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 C-N-CA 120.665 -0.414 . . . . 0.0 111.208 -175.146 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 74.6 tt0 -142.73 145.1 33.01 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 108.955 -0.758 . . . . 0.0 108.955 176.031 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 40' ' ' SER . . . . . 0.412 ' HA ' ' O ' ' A' ' 46' ' ' THR . 34.2 p -80.55 148.95 30.14 Favored 'General case' 0 C--N 1.312 -1.024 0 N-CA-C 112.203 0.446 . . . . 0.0 112.203 -176.327 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -95.06 -19.95 29.48 Favored Glycine 0 N--CA 1.449 -0.476 0 N-CA-C 111.012 -0.835 . . . . 0.0 111.012 176.831 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 15.7 m-20 -128.72 -156.56 0.76 Allowed 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 109.45 -0.574 . . . . 0.0 109.45 179.071 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 9.9 p-10 -77.23 46.89 0.52 Allowed 'General case' 0 N--CA 1.474 0.775 0 CA-C-O 121.314 0.578 . . . . 0.0 112.065 -179.11 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 88.22 -7.79 80.46 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 121.047 -0.597 . . . . 0.0 113.176 178.441 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 53.5 mt-30 -72.58 -34.83 67.71 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.964 0.382 . . . . 0.0 111.498 178.906 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' THR . . . . . 0.412 ' O ' ' HA ' ' A' ' 40' ' ' SER . 24.5 p -115.02 132.01 56.74 Favored 'General case' 0 C--N 1.314 -0.975 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.535 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 47' ' ' LEU . . . . . 0.513 ' HB2' ' HB3' ' A' ' 63' ' ' ALA . 93.8 mt -124.3 127.97 48.44 Favored 'General case' 0 CA--C 1.509 -0.607 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 -179.475 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 9.0 m120 -129.39 137.05 50.7 Favored 'General case' 0 C--N 1.313 -1.011 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 -179.696 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.435 ' HA3' ' HA ' ' A' ' 38' ' ' VAL . . . 178.18 -157.22 21.1 Favored Glycine 0 N--CA 1.445 -0.72 0 C-N-CA 119.287 -1.435 . . . . 0.0 113.795 179.275 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 38.3 m -130.0 134.35 47.37 Favored 'General case' 0 CA--C 1.545 0.756 0 C-N-CA 123.087 0.555 . . . . 0.0 110.905 -178.562 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 48.0 mtp -110.2 155.32 22.14 Favored 'General case' 0 N--CA 1.468 0.459 0 C-N-CA 122.308 0.243 . . . . 0.0 110.815 177.151 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.641 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 25.5 m -133.78 126.29 30.3 Favored 'General case' 0 CA--C 1.542 0.641 0 CA-C-N 116.491 -0.322 . . . . 0.0 110.167 175.322 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 53' ' ' TYR . . . . . 0.483 ' HB2' ' HB2' ' A' ' 56' ' ' GLU . 65.5 m-85 -92.94 166.97 12.12 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 116.664 -0.244 . . . . 0.0 110.769 177.964 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -63.34 106.48 0.91 Allowed 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.473 -179.754 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 81.78 16.03 73.9 Favored Glycine 0 CA--C 1.52 0.358 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.788 178.857 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 56' ' ' GLU . . . . . 0.483 ' HB2' ' HB2' ' A' ' 53' ' ' TYR . 80.3 mm-40 -119.99 169.62 10.02 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 120.773 0.32 . . . . 0.0 110.807 -179.93 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -90.05 172.56 38.55 Favored Glycine 0 N--CA 1.444 -0.813 0 C-N-CA 120.99 -0.624 . . . . 0.0 112.303 179.925 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_exo -67.14 137.56 44.47 Favored 'Trans proline' 0 CA--C 1.535 0.56 0 C-N-CA 122.726 2.284 . . . . 0.0 112.026 179.16 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 59' ' ' ILE . . . . . 0.414 HD12 ' HB3' ' A' ' 75' ' ' ASN . 45.0 pt -128.79 160.86 38.91 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.428 179.195 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -75.1 141.61 28.3 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.451 -178.919 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 61.8 t80 -126.01 127.04 45.27 Favored 'General case' 0 C--N 1.32 -0.712 0 C-N-CA 122.401 0.28 . . . . 0.0 110.797 -179.792 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 29.3 ttp85 -136.97 129.04 29.44 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 175.801 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.545 ' HB1' ' HB3' ' A' ' 71' ' ' TYR . . . -136.88 146.4 45.51 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 112.304 0.483 . . . . 0.0 112.304 -177.622 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 55.9 m -122.7 128.18 50.23 Favored 'General case' 0 CA--C 1.542 0.668 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.222 178.303 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 2.3 tm? -73.47 121.52 20.68 Favored 'General case' 0 CA--C 1.538 0.493 0 CA-C-O 121.134 0.492 . . . . 0.0 111.054 -178.058 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 96.0 mt -75.04 -33.94 61.81 Favored 'General case' 0 CA--C 1.534 0.354 0 CA-C-N 115.638 -0.71 . . . . 0.0 111.907 179.799 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 126.12 -14.84 6.96 Favored Glycine 0 C--O 1.219 -0.812 0 C-N-CA 120.574 -0.822 . . . . 0.0 112.476 -178.262 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 28.9 p-10 -111.75 30.23 7.17 Favored 'General case' 0 C--N 1.316 -0.856 0 CA-C-O 120.824 0.345 . . . . 0.0 110.736 -179.078 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 96.1 m-20 69.03 6.47 5.66 Favored 'General case' 0 N--CA 1.483 1.187 0 C-N-CA 123.6 0.76 . . . . 0.0 111.499 -177.25 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 35.0 t -102.46 140.35 36.86 Favored 'General case' 0 N--CA 1.438 -1.069 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 177.178 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.545 ' HB3' ' HB1' ' A' ' 63' ' ' ALA . 66.8 m-85 -116.91 139.72 50.31 Favored 'General case' 0 C--N 1.303 -1.42 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.936 -178.296 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 39.5 tt0 -85.29 112.3 20.66 Favored 'General case' 0 C--N 1.309 -1.16 0 N-CA-C 106.759 -1.571 . . . . 0.0 106.759 173.673 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.521 HG22 ' HB2' ' A' ' 63' ' ' ALA . 70.5 t -109.41 135.83 47.17 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 N-CA-C 113.475 0.917 . . . . 0.0 113.475 -171.141 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -128.54 130.48 47.48 Favored 'General case' 0 N--CA 1.443 -0.811 0 CA-C-N 114.708 -1.133 . . . . 0.0 108.917 175.281 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 75' ' ' ASN . . . . . 0.414 ' HB3' HD12 ' A' ' 59' ' ' ILE . 95.9 m-20 -108.9 150.11 28.17 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.748 -179.286 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 76' ' ' GLN . . . . . 0.41 ' HB2' ' CE3' ' A' ' 84' ' ' TRP . 61.3 tt0 -115.49 120.36 39.24 Favored 'General case' 0 C--N 1.308 -1.232 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.435 -177.534 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 8.6 p90 -142.87 162.85 34.37 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 110.24 -0.281 . . . . 0.0 110.24 179.544 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 100.91 -9.02 58.07 Favored Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.768 -0.729 . . . . 0.0 111.97 179.781 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 137.59 159.61 8.26 Favored Glycine 0 N--CA 1.442 -0.917 0 N-CA-C 111.019 -0.832 . . . . 0.0 111.019 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 5.9 m-20 -60.41 -39.59 87.93 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 116.963 0.382 . . . . 0.0 111.687 -179.319 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 4.6 m -76.57 -4.93 45.42 Favored 'General case' 0 C--N 1.321 -0.671 0 N-CA-C 112.251 0.463 . . . . 0.0 112.251 -177.476 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -75.46 153.16 85.76 Favored Pre-proline 0 C--N 1.324 -0.538 0 CA-C-O 120.587 0.232 . . . . 0.0 111.196 -178.422 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 10.7 Cg_exo -72.34 178.48 6.06 Favored 'Trans proline' 0 C--N 1.35 0.642 0 C-N-CA 122.925 2.417 . . . . 0.0 112.017 178.646 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 84' ' ' TRP . . . . . 0.41 ' CE3' ' HB2' ' A' ' 76' ' ' GLN . 90.9 m95 -92.14 138.17 31.75 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 109.322 -0.622 . . . . 0.0 109.322 179.722 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 82.8 m-70 -112.59 144.61 41.79 Favored 'General case' 0 C--N 1.318 -0.791 0 N-CA-C 109.992 -0.373 . . . . 0.0 109.992 -177.685 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 19.5 p -64.36 116.4 6.03 Favored 'General case' 0 C--N 1.316 -0.89 0 CA-C-O 120.781 0.324 . . . . 0.0 111.457 -178.376 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -89.63 -46.41 4.3 Favored Glycine 0 N--CA 1.44 -1.088 0 C-N-CA 120.388 -0.911 . . . . 0.0 111.018 178.008 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 139.87 -157.86 25.48 Favored Glycine 0 N--CA 1.442 -0.909 0 C-N-CA 120.816 -0.707 . . . . 0.0 111.629 177.471 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 19.8 m120 -105.48 134.19 49.0 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 109.697 -0.483 . . . . 0.0 109.697 178.974 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 90' ' ' TRP . . . . . 0.489 ' CH2' HG23 ' A' ' 25' ' ' ILE . 13.8 m0 -124.04 146.13 48.77 Favored 'General case' 0 C--N 1.316 -0.862 0 CA-C-N 116.203 -0.453 . . . . 0.0 109.84 -178.548 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 91.6 mt -110.57 114.63 47.6 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.285 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 177.456 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 92' ' ' LEU . . . . . 0.483 ' HB3' HG21 ' A' ' 100' ' ' VAL . 85.5 mt -133.56 79.98 1.85 Allowed 'General case' 0 C--O 1.269 2.113 0 CA-C-O 121.771 0.796 . . . . 0.0 112.312 -175.724 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 170.0 109.51 0.22 Allowed Glycine 0 N--CA 1.442 -0.966 0 CA-C-N 115.344 -0.844 . . . . 0.0 111.768 -179.498 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 19.1 m -96.67 30.27 2.68 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-O 120.902 0.382 . . . . 0.0 110.349 -179.882 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 95' ' ' ARG . . . . . 0.556 ' CB ' ' HB3' ' A' ' 98' ' ' GLN . 9.7 mmt180 -136.56 150.54 48.65 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-O 121.257 0.551 . . . . 0.0 112.317 -176.968 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 79.3 tt0 -55.99 -51.27 68.33 Favored 'General case' 0 CA--C 1.541 0.601 0 CA-C-N 114.731 -1.122 . . . . 0.0 112.602 -176.961 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 27.2 m120 -134.63 42.69 2.81 Favored 'General case' 0 N--CA 1.471 0.609 0 CA-C-O 120.965 0.412 . . . . 0.0 109.99 -179.928 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 98' ' ' GLN . . . . . 0.556 ' HB3' ' CB ' ' A' ' 95' ' ' ARG . 8.3 tt0 -144.37 110.39 5.41 Favored 'General case' 0 C--N 1.315 -0.919 0 CA-C-O 121.147 0.499 . . . . 0.0 110.614 -175.952 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 99' ' ' ASN . . . . . 0.445 ' HB3' ' OH ' ' A' ' 71' ' ' TYR . 87.7 m-20 -91.06 168.37 11.69 Favored 'General case' 0 C--O 1.244 0.782 0 CA-C-N 115.293 -0.867 . . . . 0.0 111.111 -175.73 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.483 HG21 ' HB3' ' A' ' 92' ' ' LEU . 23.6 m -83.01 140.53 16.19 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.673 0 C-N-CA 120.011 -0.676 . . . . 0.0 110.244 173.443 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 29.7 m -115.55 -27.45 2.56 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.429 0 C-N-CA 120.608 -0.437 . . . . 0.0 112.062 178.14 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 102' ' ' ALA . . . . . 0.448 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -147.87 142.06 26.12 Favored 'General case' 0 C--N 1.32 -0.677 0 C-N-CA 120.581 -0.447 . . . . 0.0 110.551 178.352 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.489 ' HB ' HG22 ' A' ' 38' ' ' VAL . 94.9 mt -138.4 125.75 27.83 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 N-CA-C 110.106 -0.331 . . . . 0.0 110.106 178.26 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 35.2 t30 -128.06 97.8 4.91 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.367 176.589 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.653 HG11 ' HD2' ' A' ' 128' ' ' PHE . 11.7 m -142.6 149.7 18.85 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 N-CA-C 113.185 0.809 . . . . 0.0 113.185 -176.454 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 41.9 tt0 -148.15 147.19 29.18 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.089 -0.959 . . . . 0.0 109.839 175.621 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 47.1 t -113.23 133.59 55.01 Favored 'General case' 0 N--CA 1.442 -0.874 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.355 -177.994 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -81.52 -5.07 90.22 Favored Glycine 0 N--CA 1.447 -0.568 0 N-CA-C 111.103 -0.799 . . . . 0.0 111.103 175.444 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 62.8 m-20 -114.06 -166.46 1.1 Allowed 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 109.362 -0.607 . . . . 0.0 109.362 -179.95 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 25.6 m-20 -77.68 34.97 0.18 Allowed 'General case' 0 N--CA 1.472 0.66 0 CA-C-O 120.847 0.356 . . . . 0.0 111.123 178.931 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 111' ' ' GLY . . . . . 0.564 ' HA3' ' ND2' ' A' ' 32' ' ' ASN . . . 81.43 8.24 87.32 Favored Glycine 0 N--CA 1.445 -0.74 0 C-N-CA 120.888 -0.672 . . . . 0.0 112.405 -178.852 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 97.3 mt-30 -66.04 -44.22 85.26 Favored 'General case' 0 C--O 1.243 0.713 0 CA-C-O 121.056 0.455 . . . . 0.0 109.995 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 22.5 p -113.12 117.61 32.44 Favored 'General case' 0 N--CA 1.441 -0.888 0 CA-C-N 115.374 -0.83 . . . . 0.0 109.259 177.548 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 34.8 tp -111.84 121.88 46.25 Favored 'General case' 0 C--N 1.311 -1.08 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 -178.957 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 26.3 p30 -145.57 164.82 30.49 Favored 'General case' 0 C--O 1.251 1.134 0 C-N-CA 120.039 -0.664 . . . . 0.0 112.677 -178.609 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 149.75 -127.78 2.53 Favored Glycine 0 N--CA 1.439 -1.12 0 CA-C-N 114.655 -1.157 . . . . 0.0 111.127 -179.636 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 31.9 p -134.0 159.75 39.82 Favored 'General case' 0 C--N 1.314 -0.96 0 CA-C-O 120.851 0.358 . . . . 0.0 111.063 -178.9 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 4.2 ppp? -157.28 161.93 39.17 Favored 'General case' 0 C--N 1.313 -1.004 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 179.154 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 119' ' ' THR . . . . . 0.448 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 48.7 m -133.39 126.3 30.99 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-N 116.46 -0.336 . . . . 0.0 110.978 -179.894 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 120' ' ' TYR . . . . . 0.426 ' HB2' ' CB ' ' A' ' 123' ' ' GLU . 64.9 m-85 -88.13 162.98 16.43 Favored 'General case' 0 CA--C 1.521 -0.147 0 CA-C-N 116.196 -0.456 . . . . 0.0 109.789 174.285 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -55.76 -30.59 61.5 Favored 'General case' 0 N--CA 1.47 0.553 0 N-CA-C 113.602 0.964 . . . . 0.0 113.602 -176.627 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -140.65 26.62 2.52 Favored Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 119.636 -1.269 . . . . 0.0 112.67 -178.434 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 123' ' ' GLU . . . . . 0.467 ' HB2' ' OE1' ' A' ' 98' ' ' GLN . 23.5 tp10 -112.6 -50.71 2.88 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.988 0.423 . . . . 0.0 110.461 -177.578 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 116.5 -179.76 17.76 Favored Glycine 0 N--CA 1.441 -0.986 0 N-CA-C 111.122 -0.791 . . . . 0.0 111.122 -177.639 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 7.4 Cg_exo -73.81 112.8 3.62 Favored 'Trans proline' 0 N--CA 1.461 -0.392 0 C-N-CA 122.735 2.29 . . . . 0.0 112.021 179.651 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 39.2 pt -129.84 162.92 36.58 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.862 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.517 179.734 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -72.84 144.41 35.1 Favored Glycine 0 N--CA 1.448 -0.517 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.728 -179.496 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 128' ' ' PHE . . . . . 0.653 ' HD2' HG11 ' A' ' 105' ' ' VAL . 21.1 t80 -125.59 132.63 52.49 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 121.162 0.506 . . . . 0.0 110.732 178.733 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 62.6 tttm -137.42 123.46 20.3 Favored 'General case' 0 C--N 1.311 -1.073 0 CA-C-N 115.0 -1.0 . . . . 0.0 108.93 -179.829 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -139.23 141.72 12.1 Favored Glycine 0 N--CA 1.436 -1.302 0 C-N-CA 120.363 -0.922 . . . . 0.0 112.725 -179.335 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 35.3 m -121.35 133.11 55.1 Favored 'General case' 0 C--N 1.311 -1.107 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.355 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 60.2 tp -66.85 139.89 57.78 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 109.754 -0.462 . . . . 0.0 109.754 178.492 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 133' ' ' THR . . . . . 0.455 HG22 ' O ' ' A' ' 3' ' ' LEU . 13.4 t . . . . . 0 C--O 1.253 1.251 0 CA-C-O 118.53 -0.748 . . . . 0.0 110.251 -179.117 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.737 0 CA-C-O 120.668 0.271 . . . . 0.0 110.42 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 3' ' ' LEU . . . . . 0.45 HD13 ' N ' ' A' ' 4' ' ' TYR . 1.7 tm? -95.16 129.89 42.09 Favored 'General case' 0 C--N 1.319 -0.739 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 178.598 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 4' ' ' TYR . . . . . 0.45 ' N ' HD13 ' A' ' 3' ' ' LEU . 78.8 m-85 -120.53 145.85 46.89 Favored 'General case' 0 C--O 1.24 0.597 0 CA-C-O 121.081 0.467 . . . . 0.0 112.158 -176.842 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 5' ' ' ASN . . . . . 0.627 ' O ' ' HA2' ' A' ' 130' ' ' GLY . 21.6 m120 -87.46 140.46 29.51 Favored 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 107.186 -1.413 . . . . 0.0 107.186 175.274 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.49 HG21 ' CD1' ' A' ' 23' ' ' TRP . 70.1 t -114.64 128.41 71.73 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 N-CA-C 113.641 0.978 . . . . 0.0 113.641 -174.274 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.436 ' HB2' ' HB3' ' A' ' 129' ' ' LYS . 99.7 mt-10 -125.44 134.09 52.22 Favored 'General case' 0 N--CA 1.444 -0.759 0 CA-C-N 114.517 -1.219 . . . . 0.0 109.098 175.358 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 91.5 m-20 -121.4 140.54 52.01 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-N 116.462 -0.336 . . . . 0.0 110.601 -178.929 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 60.8 tt0 -120.02 120.02 35.1 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.676 -178.972 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 19.6 p90 -135.72 143.18 45.21 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 110.131 -0.322 . . . . 0.0 110.131 178.708 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 106.83 8.53 31.93 Favored Glycine 0 N--CA 1.446 -0.646 0 C-N-CA 120.29 -0.957 . . . . 0.0 111.497 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 103.08 164.71 25.76 Favored Glycine 0 N--CA 1.442 -0.958 0 C-N-CA 121.344 -0.455 . . . . 0.0 112.281 178.502 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 68.8 m -59.07 -23.47 62.07 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 120.836 0.35 . . . . 0.0 111.722 178.766 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 38.8 m -73.52 -6.61 47.56 Favored 'General case' 0 CA--C 1.543 0.696 0 CA-C-O 120.7 0.286 . . . . 0.0 111.596 177.921 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.457 ' HA ' ' HD3' ' A' ' 16' ' ' PRO . . . -95.07 145.56 29.75 Favored Pre-proline 0 C--N 1.328 -0.355 0 O-C-N 122.421 -0.174 . . . . 0.0 110.881 -179.814 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.457 ' HD3' ' HA ' ' A' ' 15' ' ' ALA . 8.2 Cg_exo -73.1 163.82 37.15 Favored 'Trans proline' 0 C--N 1.347 0.492 0 C-N-CA 123.042 2.494 . . . . 0.0 112.586 179.594 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 17' ' ' TRP . . . . . 0.53 ' CZ3' ' HB2' ' A' ' 129' ' ' LYS . 91.3 m95 -83.51 131.13 35.02 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 178.939 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 41.2 m-80 -109.54 141.71 41.62 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.524 -177.833 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 13.9 pt-20 -112.18 137.5 50.18 Favored 'General case' 0 C--N 1.313 -0.991 0 N-CA-C 110.016 -0.364 . . . . 0.0 110.016 179.05 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -154.2 32.45 0.72 Allowed Glycine 0 N--CA 1.443 -0.842 0 C-N-CA 119.76 -1.21 . . . . 0.0 112.641 179.045 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 156.25 -177.61 33.18 Favored Glycine 0 N--CA 1.447 -0.613 0 C-N-CA 119.658 -1.258 . . . . 0.0 113.3 -179.16 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 25.3 pt20 -141.62 145.35 34.9 Favored 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 109.537 -0.542 . . . . 0.0 109.537 -179.828 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' TRP . . . . . 0.49 ' CD1' HG21 ' A' ' 6' ' ' VAL . 45.0 m0 -115.93 153.28 31.86 Favored 'General case' 0 C--O 1.24 0.591 0 CA-C-O 121.121 0.486 . . . . 0.0 111.895 -176.752 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 85.9 tt0 -112.17 114.47 27.29 Favored 'General case' 0 CA--C 1.508 -0.663 0 CA-C-N 115.512 -0.767 . . . . 0.0 109.072 177.998 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 96.8 mt -131.82 136.7 56.49 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-O 121.355 0.597 . . . . 0.0 112.27 -176.048 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 104.93 -26.52 22.05 Favored Glycine 0 N--CA 1.449 -0.454 0 CA-C-N 115.881 -0.6 . . . . 0.0 113.531 175.312 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 2.7 p 44.99 20.89 0.04 OUTLIER 'General case' 0 N--CA 1.486 1.335 0 C-N-CA 123.867 0.867 . . . . 0.0 112.991 -177.512 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 83.4 mtm180 -149.62 150.57 32.4 Favored 'General case' 0 C--O 1.241 0.626 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 -179.243 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 12.6 m -95.51 -15.42 22.9 Favored 'General case' 0 C--N 1.309 -1.159 0 CA-C-O 121.089 0.471 . . . . 0.0 110.268 177.828 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 23.3 m-20 -75.21 -35.5 61.5 Favored 'General case' 0 N--CA 1.468 0.475 0 CA-C-N 115.809 -0.632 . . . . 0.0 112.182 -177.052 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 5.0 mm-40 -132.49 128.23 36.93 Favored 'General case' 0 CA--C 1.509 -0.628 0 N-CA-C 113.876 1.065 . . . . 0.0 113.876 -175.34 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 3.4 m-20 -100.07 151.15 21.71 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 114.834 -1.075 . . . . 0.0 109.311 174.61 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.433 HG21 HD11 ' A' ' 36' ' ' ILE . 33.2 m -92.53 142.95 12.38 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.277 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.78 -179.818 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 27.7 m -111.4 -16.08 9.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 C-N-CA 120.931 -0.308 . . . . 0.0 111.744 178.772 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.549 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -147.94 140.75 24.74 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 120.3 -0.56 . . . . 0.0 111.597 178.972 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.433 HD11 HG21 ' A' ' 33' ' ' VAL . 88.8 mt -142.84 121.29 7.7 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 178.607 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 37' ' ' ASN . . . . . 0.485 ' HA ' ' O ' ' A' ' 103' ' ' ILE . 4.8 t-20 -136.54 111.26 8.71 Favored 'General case' 0 C--N 1.307 -1.243 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 177.984 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.462 HG11 ' CD1' ' A' ' 61' ' ' PHE . 27.0 m -148.43 154.37 10.36 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-O 120.804 0.335 . . . . 0.0 111.626 -171.843 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 45.4 tt0 -136.34 143.37 44.07 Favored 'General case' 0 N--CA 1.447 -0.61 0 CA-C-N 115.624 -0.716 . . . . 0.0 109.371 176.644 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 88.4 p -72.83 155.04 40.33 Favored 'General case' 0 C--N 1.314 -0.961 0 CA-C-O 121.131 0.491 . . . . 0.0 111.846 -178.288 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -108.26 -45.0 1.11 Allowed Glycine 0 N--CA 1.438 -1.188 0 CA-C-N 115.596 -0.729 . . . . 0.0 111.924 177.86 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 30.7 t70 -129.3 95.28 3.99 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 111.564 0.209 . . . . 0.0 111.564 -178.772 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 52.15 31.53 9.17 Favored 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 113.594 0.961 . . . . 0.0 113.594 174.989 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 75.7 1.0 65.19 Favored Glycine 0 C--N 1.32 -0.359 0 C-N-CA 120.373 -0.918 . . . . 0.0 113.09 179.828 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 23.4 mm-40 -78.48 -29.68 46.89 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-O 121.328 0.585 . . . . 0.0 109.743 178.857 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 32.1 p -121.74 144.26 48.9 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-N 115.709 -0.678 . . . . 0.0 109.912 176.738 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 47' ' ' LEU . . . . . 0.492 ' O ' ' HA ' ' A' ' 62' ' ' ARG . 93.3 mt -129.82 130.96 45.97 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 -178.185 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 94.0 m-20 -127.49 138.97 53.08 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 178.141 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.401 ' HA3' ' HA ' ' A' ' 38' ' ' VAL . . . 172.81 -153.04 17.68 Favored Glycine 0 N--CA 1.445 -0.732 0 C-N-CA 119.487 -1.339 . . . . 0.0 113.525 178.707 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 90.9 m -131.99 133.19 44.18 Favored 'General case' 0 C--N 1.317 -0.811 0 C-N-CA 122.704 0.402 . . . . 0.0 110.283 -178.904 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 51' ' ' MET . . . . . 0.566 ' HE3' HD11 ' A' ' 59' ' ' ILE . 15.7 tmm? -126.32 147.58 49.7 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 116.531 -0.304 . . . . 0.0 110.34 -178.949 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.549 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 28.4 m -128.98 129.12 44.99 Favored 'General case' 0 C--O 1.252 1.234 0 CA-C-O 120.797 0.332 . . . . 0.0 111.826 -177.505 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 53' ' ' TYR . . . . . 0.49 ' HB2' ' HB2' ' A' ' 56' ' ' GLU . 94.3 m-85 -83.47 167.4 17.47 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 115.811 -0.632 . . . . 0.0 110.419 177.582 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -63.96 103.71 0.62 Allowed 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 112.402 0.519 . . . . 0.0 112.402 -179.012 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 85.84 4.51 84.8 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.937 -0.649 . . . . 0.0 113.261 177.717 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 56' ' ' GLU . . . . . 0.49 ' HB2' ' HB2' ' A' ' 53' ' ' TYR . 81.9 mm-40 -107.97 176.99 4.95 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-O 120.697 0.284 . . . . 0.0 110.665 -179.781 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -90.11 156.82 25.52 Favored Glycine 0 N--CA 1.44 -1.048 0 C-N-CA 120.879 -0.677 . . . . 0.0 112.16 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_exo -63.67 140.32 74.03 Favored 'Trans proline' 0 CA--C 1.533 0.449 0 C-N-CA 122.758 2.305 . . . . 0.0 112.116 178.697 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 59' ' ' ILE . . . . . 0.566 HD11 ' HE3' ' A' ' 51' ' ' MET . 46.4 pt -130.75 166.0 29.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-N 116.341 -0.391 . . . . 0.0 110.649 179.633 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -73.29 138.63 25.55 Favored Glycine 0 N--CA 1.45 -0.398 0 N-CA-C 111.243 -0.743 . . . . 0.0 111.243 179.856 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.462 ' CD1' HG11 ' A' ' 38' ' ' VAL . 52.4 t80 -124.86 130.03 51.58 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-O 120.673 0.273 . . . . 0.0 111.111 -177.148 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 62' ' ' ARG . . . . . 0.492 ' HA ' ' O ' ' A' ' 47' ' ' LEU . 68.2 ttp85 -140.29 132.67 28.41 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.068 175.041 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.403 ' HB3' ' HB2' ' A' ' 47' ' ' LEU . . . -136.64 148.17 47.29 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 120.754 0.311 . . . . 0.0 111.828 -178.074 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 56.3 m -127.18 132.53 50.46 Favored 'General case' 0 CA--C 1.541 0.628 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.513 178.836 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 65' ' ' LEU . . . . . 0.419 HD22 ' O ' ' A' ' 70' ' ' SER . 3.4 tm? -77.13 114.54 16.04 Favored 'General case' 0 C--N 1.325 -0.486 0 C-N-CA 122.633 0.373 . . . . 0.0 110.447 -179.133 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 10.5 mp -81.99 -32.16 30.75 Favored 'General case' 0 N--CA 1.468 0.455 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.915 178.824 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 164.8 173.58 33.58 Favored Glycine 0 CA--C 1.497 -1.045 0 N-CA-C 110.614 -0.995 . . . . 0.0 110.614 -177.577 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 24.3 t-20 40.23 -96.32 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.134 0 C-N-CA 123.138 0.575 . . . . 0.0 111.777 -176.947 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 56.7 m-80 -140.67 19.81 2.35 Favored 'General case' 0 N--CA 1.467 0.412 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 177.29 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 70' ' ' SER . . . . . 0.419 ' O ' HD22 ' A' ' 65' ' ' LEU . 40.7 t -94.54 122.98 37.69 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.308 -0.86 . . . . 0.0 111.256 -175.742 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.634 ' OH ' ' HB3' ' A' ' 99' ' ' ASN . 73.9 m-85 -116.25 137.61 52.0 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 115.817 -0.628 . . . . 0.0 110.515 -179.673 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 82.2 tt0 -92.38 125.4 37.02 Favored 'General case' 0 N--CA 1.439 -1.004 0 N-CA-C 107.476 -1.305 . . . . 0.0 107.476 172.081 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 65.5 t -105.04 130.67 55.8 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.5 0 CA-C-O 121.432 0.634 . . . . 0.0 111.973 -174.953 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 67.0 mt-10 -126.25 120.64 30.51 Favored 'General case' 0 N--CA 1.431 -1.381 0 CA-C-N 114.455 -1.248 . . . . 0.0 107.669 176.424 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 94.4 m-20 -109.55 155.73 21.03 Favored 'General case' 0 C--N 1.317 -0.831 0 CA-C-O 121.2 0.524 . . . . 0.0 111.968 -174.507 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 76' ' ' GLN . . . . . 0.45 ' HB2' ' CE3' ' A' ' 84' ' ' TRP . 61.4 tt0 -119.39 119.9 35.31 Favored 'General case' 0 C--N 1.31 -1.13 0 CA-C-N 115.494 -0.775 . . . . 0.0 109.933 -178.344 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 7.9 p90 -137.2 155.64 49.28 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.593 -0.276 . . . . 0.0 110.727 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 97.75 -10.27 64.39 Favored Glycine 0 N--CA 1.447 -0.615 0 N-CA-C 111.151 -0.779 . . . . 0.0 111.151 -178.652 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 139.35 159.56 8.04 Favored Glycine 0 N--CA 1.44 -1.045 0 N-CA-C 111.312 -0.715 . . . . 0.0 111.312 179.465 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 7.4 p-10 -74.55 -23.37 58.78 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-O 121.046 0.45 . . . . 0.0 111.0 -179.632 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 6.9 m -76.24 -7.89 55.87 Favored 'General case' 0 CA--C 1.542 0.654 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.622 177.346 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -83.86 158.45 62.09 Favored Pre-proline 0 C--N 1.326 -0.415 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.456 -179.407 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -72.84 177.84 7.15 Favored 'Trans proline' 0 C--O 1.237 0.471 0 C-N-CA 122.279 1.986 . . . . 0.0 111.636 177.498 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 84' ' ' TRP . . . . . 0.45 ' CE3' ' HB2' ' A' ' 76' ' ' GLN . 96.4 m95 -90.24 142.23 27.92 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 179.957 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 88.9 m-70 -117.87 146.98 43.51 Favored 'General case' 0 C--N 1.313 -0.986 0 N-CA-C 109.534 -0.543 . . . . 0.0 109.534 -178.71 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 18.8 p -62.87 136.85 58.07 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-O 120.561 0.22 . . . . 0.0 111.351 -179.831 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -111.89 -50.98 0.57 Allowed Glycine 0 N--CA 1.446 -0.637 0 C-N-CA 120.821 -0.704 . . . . 0.0 111.534 178.314 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 148.58 -164.47 29.08 Favored Glycine 0 C--O 1.219 -0.807 0 C-N-CA 120.603 -0.808 . . . . 0.0 111.879 178.308 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 27.9 t-20 -111.46 120.12 41.1 Favored 'General case' 0 C--N 1.317 -0.829 0 CA-C-N 116.988 0.394 . . . . 0.0 110.121 179.205 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 28.1 m0 -114.96 148.78 38.29 Favored 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 -178.472 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 79.9 mt -108.69 118.72 56.86 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.071 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 177.2 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 92' ' ' LEU . . . . . 0.485 ' HB3' HG21 ' A' ' 100' ' ' VAL . 84.8 mt -131.81 87.38 2.44 Favored 'General case' 0 C--O 1.271 2.2 0 CA-C-O 121.939 0.876 . . . . 0.0 113.253 -174.292 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 160.61 117.04 0.44 Allowed Glycine 0 N--CA 1.446 -0.65 0 CA-C-N 115.162 -0.926 . . . . 0.0 111.829 178.502 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 70.7 p -91.32 -12.82 33.91 Favored 'General case' 0 C--O 1.223 -0.322 0 CA-C-N 117.216 0.508 . . . . 0.0 110.517 178.798 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 94.1 mtt-85 -89.17 138.56 31.32 Favored 'General case' 0 N--CA 1.444 -0.741 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.129 178.904 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -70.94 -34.65 71.68 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 115.673 -0.694 . . . . 0.0 111.408 -175.623 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 89.4 m-20 -112.91 25.89 11.0 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.019 -0.537 . . . . 0.0 111.372 -177.404 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 98' ' ' GLN . . . . . . . . . . . . . 2.0 tt0 -155.49 130.58 9.42 Favored 'General case' 0 C--N 1.333 -0.136 0 C-N-CA 120.323 -0.551 . . . . 0.0 112.244 -176.251 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 99' ' ' ASN . . . . . 0.634 ' HB3' ' OH ' ' A' ' 71' ' ' TYR . 12.0 m120 -99.32 162.66 12.91 Favored 'General case' 0 C--O 1.253 1.251 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.487 178.867 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.485 HG21 ' HB3' ' A' ' 92' ' ' LEU . 33.3 m -78.3 147.15 7.21 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 C-N-CA 119.884 -0.726 . . . . 0.0 110.979 179.282 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 35.5 m -123.4 -36.93 1.18 Allowed 'Isoleucine or valine' 0 C--O 1.219 -0.502 0 C-N-CA 120.728 -0.389 . . . . 0.0 111.821 177.657 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -136.25 132.19 35.48 Favored 'General case' 0 CA--C 1.503 -0.837 0 C-N-CA 120.407 -0.517 . . . . 0.0 110.687 -179.398 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.485 ' O ' ' HA ' ' A' ' 37' ' ' ASN . 92.3 mt -132.52 124.36 51.37 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 CA-C-N 116.472 -0.331 . . . . 0.0 110.111 178.255 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 7.9 t30 -125.29 97.82 5.37 Favored 'General case' 0 C--N 1.32 -0.708 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 176.482 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.429 ' CG2' ' HB ' ' A' ' 36' ' ' ILE . 26.9 m -139.94 142.97 31.0 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.782 0 N-CA-C 113.134 0.79 . . . . 0.0 113.134 -175.511 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 44.4 tt0 -146.32 148.95 32.93 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.111 -0.949 . . . . 0.0 109.215 177.37 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 40.8 t -137.37 145.06 42.84 Favored 'General case' 0 C--N 1.313 -1.022 0 CA-C-O 121.087 0.47 . . . . 0.0 111.573 -178.809 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -94.92 5.45 68.99 Favored Glycine 0 N--CA 1.441 -0.986 0 N-CA-C 111.011 -0.836 . . . . 0.0 111.011 176.313 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 83.3 m-20 -93.03 178.59 5.7 Favored 'General case' 0 CA--C 1.508 -0.65 0 CA-C-O 121.154 0.502 . . . . 0.0 111.077 178.509 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 10.8 p-10 -90.38 19.13 5.41 Favored 'General case' 0 C--N 1.311 -1.095 0 CA-C-N 115.512 -0.767 . . . . 0.0 110.5 179.444 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 106.11 4.82 38.38 Favored Glycine 0 N--CA 1.443 -0.839 0 CA-C-N 115.64 -0.709 . . . . 0.0 111.906 -177.688 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 30.7 tt0 -65.13 -45.6 84.4 Favored 'General case' 0 C--O 1.237 0.44 0 CA-C-O 120.865 0.364 . . . . 0.0 110.324 177.715 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 70.3 p -133.53 157.6 45.25 Favored 'General case' 0 N--CA 1.447 -0.577 0 CA-C-N 116.216 -0.447 . . . . 0.0 109.808 177.767 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 49.2 tp -139.09 131.46 28.46 Favored 'General case' 0 C--N 1.315 -0.9 0 N-CA-C 109.087 -0.708 . . . . 0.0 109.087 178.818 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 6.8 p30 -147.99 167.27 25.34 Favored 'General case' 0 C--N 1.319 -0.743 0 C-N-CA 119.853 -0.739 . . . . 0.0 112.878 -179.985 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 155.79 -130.24 2.71 Favored Glycine 0 N--CA 1.442 -0.938 0 CA-C-N 114.951 -1.022 . . . . 0.0 111.738 -179.821 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 33.0 p -133.37 156.98 46.67 Favored 'General case' 0 C--N 1.318 -0.796 0 C-N-CA 122.671 0.388 . . . . 0.0 110.621 -178.818 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 23.7 ptm -152.48 167.47 28.69 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 120.897 0.38 . . . . 0.0 111.096 -179.571 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 48.4 m -151.63 139.98 20.43 Favored 'General case' 0 CA--C 1.547 0.862 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.991 -179.936 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 120' ' ' TYR . . . . . 0.495 ' H ' ' HB3' ' A' ' 123' ' ' GLU . 67.8 m-85 -99.02 172.29 7.5 Favored 'General case' 0 N--CA 1.473 0.701 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.28 178.538 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -67.9 37.83 0.03 OUTLIER 'General case' 0 N--CA 1.487 1.421 0 C-N-CA 123.695 0.798 . . . . 0.0 113.104 -179.752 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 153.44 42.67 0.02 OUTLIER Glycine 0 CA--C 1.5 -0.879 0 N-CA-C 110.08 -1.208 . . . . 0.0 110.08 179.805 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 123' ' ' GLU . . . . . 0.495 ' HB3' ' H ' ' A' ' 120' ' ' TYR . 47.3 tp10 -139.69 160.82 39.0 Favored 'General case' 0 C--N 1.315 -0.925 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 -175.705 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -90.2 175.29 41.13 Favored Glycine 0 N--CA 1.443 -0.895 0 N-CA-C 111.023 -0.831 . . . . 0.0 111.023 177.238 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 22.5 Cg_exo -63.35 119.91 7.15 Favored 'Trans proline' 0 N--CA 1.461 -0.41 0 C-N-CA 121.939 1.759 . . . . 0.0 111.2 178.262 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 42.5 pt -127.53 154.11 37.55 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 CA-C-O 120.656 0.265 . . . . 0.0 110.811 -179.897 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -72.31 143.65 34.69 Favored Glycine 0 N--CA 1.444 -0.809 0 C-N-CA 121.087 -0.578 . . . . 0.0 112.463 179.422 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 128' ' ' PHE . . . . . 0.424 ' CD2' HG11 ' A' ' 105' ' ' VAL . 73.0 t80 -122.07 133.8 54.78 Favored 'General case' 0 C--N 1.315 -0.901 0 CA-C-O 120.689 0.281 . . . . 0.0 110.579 179.194 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 129' ' ' LYS . . . . . 0.53 ' HB2' ' CZ3' ' A' ' 17' ' ' TRP . 84.0 tttt -140.39 130.35 24.69 Favored 'General case' 0 N--CA 1.439 -0.998 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 177.539 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 130' ' ' GLY . . . . . 0.627 ' HA2' ' O ' ' A' ' 5' ' ' ASN . . . -134.4 141.22 12.5 Favored Glycine 0 N--CA 1.436 -1.325 0 C-N-CA 121.087 -0.578 . . . . 0.0 112.007 179.875 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 53.7 m -128.27 135.36 49.53 Favored 'General case' 0 C--N 1.314 -0.97 0 CA-C-O 120.481 0.182 . . . . 0.0 110.786 -179.473 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 54.8 tp -64.52 136.5 57.11 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 177.638 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 133' ' ' THR . . . . . 0.469 ' HB ' ' OD1' ' A' ' 5' ' ' ASN . 11.8 t . . . . . 0 C--O 1.252 1.221 0 CA-C-O 118.733 -0.651 . . . . 0.0 110.634 -179.251 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.419 ' O ' ' HB3' ' A' ' 3' ' ' LEU . . . . . . . . 0 N--CA 1.472 0.637 0 N-CA-C 110.014 -0.365 . . . . 0.0 110.014 . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' LEU . . . . . 0.43 HD23 ' N ' ' A' ' 4' ' ' TYR . 10.3 tt 87.41 150.74 0.06 Allowed 'General case' 0 N--CA 1.475 0.813 0 C-N-CA 124.289 1.036 . . . . 0.0 109.956 179.232 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 4' ' ' TYR . . . . . 0.43 ' N ' HD23 ' A' ' 3' ' ' LEU . 86.7 m-85 -132.45 154.13 50.18 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-O 120.951 0.405 . . . . 0.0 111.082 -175.007 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 5' ' ' ASN . . . . . 0.405 ' O ' ' HA2' ' A' ' 130' ' ' GLY . 92.7 m-20 -95.78 151.78 19.07 Favored 'General case' 0 C--N 1.314 -0.972 0 N-CA-C 107.702 -1.221 . . . . 0.0 107.702 177.664 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.47 HG21 ' CD1' ' A' ' 23' ' ' TRP . 78.5 t -111.9 121.84 65.13 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.184 0 CA-C-O 121.744 0.783 . . . . 0.0 111.73 -177.459 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.4 ' HB2' ' HB3' ' A' ' 129' ' ' LYS . 69.1 mt-10 -121.7 127.03 50.3 Favored 'General case' 0 C--N 1.311 -1.084 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 177.689 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 93.5 m-20 -126.28 148.72 49.46 Favored 'General case' 0 C--N 1.312 -1.057 0 N-CA-C 112.527 0.566 . . . . 0.0 112.527 -174.036 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 54.2 tt0 -127.3 118.38 24.08 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 175.986 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 39.7 p90 -143.9 20.46 1.8 Allowed 'General case' 0 C--N 1.322 -0.613 0 C-N-CA 120.24 -0.584 . . . . 0.0 112.555 -175.293 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -96.53 24.15 31.93 Favored Glycine 0 N--CA 1.448 -0.532 0 C-N-CA 119.321 -1.418 . . . . 0.0 113.572 -177.43 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.55 -50.21 2.83 Favored Glycine 0 N--CA 1.466 0.683 0 CA-C-N 117.152 0.476 . . . . 0.0 114.268 178.261 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 22.6 t -172.63 153.23 2.74 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 -176.216 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 19.0 m 58.8 30.05 19.55 Favored 'General case' 0 CA--C 1.536 0.409 0 CA-C-O 121.322 0.582 . . . . 0.0 110.986 179.436 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -111.02 128.93 24.53 Favored Pre-proline 0 N--CA 1.443 -0.803 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.999 -178.053 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 97.8 Cg_endo -77.06 169.6 21.26 Favored 'Trans proline' 0 N--CA 1.456 -0.692 0 C-N-CA 122.697 2.265 . . . . 0.0 111.466 177.124 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 97.8 m95 -80.35 128.73 33.9 Favored 'General case' 0 C--N 1.314 -0.969 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 179.293 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 87.4 m-20 -116.28 127.6 54.86 Favored 'General case' 0 C--N 1.311 -1.099 0 N-CA-C 109.553 -0.536 . . . . 0.0 109.553 -177.854 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 10.7 pt-20 -83.43 127.68 33.89 Favored 'General case' 0 C--N 1.314 -0.948 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 178.453 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -137.38 19.82 3.38 Favored Glycine 0 C--O 1.225 -0.454 0 C-N-CA 120.43 -0.891 . . . . 0.0 112.812 -177.695 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 156.44 -173.01 34.27 Favored Glycine 0 N--CA 1.439 -1.163 0 C-N-CA 120.603 -0.808 . . . . 0.0 111.751 179.601 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 10.2 pt20 -148.55 149.02 30.86 Favored 'General case' 0 C--N 1.311 -1.073 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 178.684 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' TRP . . . . . 0.47 ' CD1' HG21 ' A' ' 6' ' ' VAL . 48.0 m0 -118.62 150.69 39.27 Favored 'General case' 0 C--N 1.313 -1.001 0 CA-C-O 120.784 0.326 . . . . 0.0 110.473 -178.05 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 78.9 tt0 -106.13 115.14 29.71 Favored 'General case' 0 C--N 1.313 -0.983 0 C-N-CA 120.052 -0.659 . . . . 0.0 109.544 178.26 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 93.6 mt -139.19 149.47 23.17 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.891 0 CA-C-N 115.213 -0.903 . . . . 0.0 108.979 -175.85 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 90.26 83.38 1.37 Allowed Glycine 0 N--CA 1.446 -0.699 0 C-N-CA 120.482 -0.866 . . . . 0.0 112.808 179.474 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 11.6 p -94.97 13.51 24.73 Favored 'General case' 0 N--CA 1.449 -0.495 0 CA-C-O 120.969 0.414 . . . . 0.0 111.159 178.842 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 15.8 ptp180 -129.28 134.79 48.11 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 179.463 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 26.7 t -89.02 -21.92 23.24 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-O 121.121 0.486 . . . . 0.0 111.143 -179.031 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 51.8 m-20 -64.88 -36.23 83.68 Favored 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 112.746 0.647 . . . . 0.0 112.746 -177.91 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 24.4 mm-40 -135.74 134.47 39.08 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 111.938 0.348 . . . . 0.0 111.938 -175.095 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 32' ' ' ASN . . . . . 0.454 ' ND2' ' HA3' ' A' ' 111' ' ' GLY . 66.0 t30 -90.77 161.39 15.33 Favored 'General case' 0 C--O 1.24 0.572 0 CA-C-N 116.111 -0.495 . . . . 0.0 109.977 178.308 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 57.8 t -88.62 126.61 41.8 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.484 -176.756 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 30.7 m -111.46 -31.23 2.22 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.599 0 N-CA-C 113.236 0.828 . . . . 0.0 113.236 177.132 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.618 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -151.41 148.81 28.55 Favored 'General case' 0 N--CA 1.469 0.515 0 C-N-CA 119.839 -0.744 . . . . 0.0 111.959 179.828 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.401 HG12 ' HG3' ' A' ' 51' ' ' MET . 93.4 mt -141.92 126.87 17.23 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.15 -179.616 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -133.66 112.36 11.36 Favored 'General case' 0 C--N 1.321 -0.65 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 174.168 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.412 HG22 ' HB ' ' A' ' 103' ' ' ILE . 21.7 m -150.88 153.92 9.38 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-O 120.749 0.309 . . . . 0.0 111.115 -175.607 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 42.2 tt0 -145.38 151.67 38.64 Favored 'General case' 0 C--N 1.318 -0.771 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 176.414 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 27.3 p -79.46 148.08 32.03 Favored 'General case' 0 C--N 1.31 -1.14 0 CA-C-O 121.089 0.471 . . . . 0.0 111.802 -178.792 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -97.19 -10.27 54.67 Favored Glycine 0 N--CA 1.447 -0.604 0 N-CA-C 110.03 -1.228 . . . . 0.0 110.03 175.347 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 42' ' ' ASP . . . . . 0.404 ' C ' ' H ' ' A' ' 44' ' ' GLY . 18.9 m-20 -137.7 -160.63 1.08 Allowed 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 114.464 -0.868 . . . . 0.0 108.766 179.505 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 17.9 m-20 -76.5 34.51 0.14 Allowed 'General case' 0 N--CA 1.481 1.086 0 CA-C-O 120.971 0.415 . . . . 0.0 110.999 178.53 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.529 ' O ' ' HE2' ' A' ' 71' ' ' TYR . . . 103.11 -6.27 50.77 Favored Glycine 0 C--O 1.208 -1.484 0 N-CA-C 111.456 -0.658 . . . . 0.0 111.456 -178.827 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 59.7 tp60 -65.18 -40.13 93.83 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.233 0.54 . . . . 0.0 110.602 179.89 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 74.4 p -125.24 142.56 51.42 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.47 178.693 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 47' ' ' LEU . . . . . 0.494 ' HB2' ' HB3' ' A' ' 63' ' ' ALA . 92.3 mt -128.56 126.98 41.46 Favored 'General case' 0 C--N 1.322 -0.626 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 178.131 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 87.0 m-20 -129.02 142.3 50.96 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 179.94 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 173.28 -155.51 22.64 Favored Glycine 0 N--CA 1.441 -0.998 0 C-N-CA 119.547 -1.311 . . . . 0.0 113.145 177.69 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 53.7 m -128.35 130.86 48.38 Favored 'General case' 0 C--N 1.311 -1.079 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 -179.452 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 51' ' ' MET . . . . . 0.558 ' SD ' ' HH2' ' A' ' 90' ' ' TRP . 23.5 ttt -116.22 145.61 42.98 Favored 'General case' 0 C--N 1.314 -0.964 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 -179.813 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.618 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 37.6 m -122.19 126.11 47.57 Favored 'General case' 0 C--O 1.246 0.887 0 CA-C-O 121.162 0.506 . . . . 0.0 111.601 -179.19 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 74.2 m-85 -103.58 158.63 16.23 Favored 'General case' 0 N--CA 1.445 -0.705 0 CA-C-N 115.339 -0.846 . . . . 0.0 109.338 176.739 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -61.42 137.69 58.25 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.229 -179.027 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 77.02 -60.34 3.48 Favored Glycine 0 CA--C 1.524 0.595 0 N-CA-C 114.647 0.619 . . . . 0.0 114.647 176.772 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -66.36 -40.71 89.93 Favored 'General case' 0 C--O 1.239 0.504 0 N-CA-C 113.218 0.822 . . . . 0.0 113.218 -175.272 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 111.63 -162.49 12.43 Favored Glycine 0 N--CA 1.446 -0.652 0 C-N-CA 120.0 -1.095 . . . . 0.0 112.944 178.595 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 97.8 Cg_endo -79.0 141.74 16.84 Favored 'Trans proline' 0 C--O 1.237 0.454 0 C-N-CA 123.126 2.551 . . . . 0.0 113.416 -179.636 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 59' ' ' ILE . . . . . 0.739 ' HB ' ' O ' ' A' ' 76' ' ' GLN . 48.7 pt -136.07 167.99 23.45 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 CA-C-N 115.712 -0.676 . . . . 0.0 109.905 176.974 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 60' ' ' GLY . . . . . 0.456 ' HA3' ' HB3' ' A' ' 76' ' ' GLN . . . -73.95 142.66 31.07 Favored Glycine 0 C--O 1.237 0.338 0 C-N-CA 120.332 -0.937 . . . . 0.0 111.357 -179.49 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 37.8 t80 -128.1 125.0 38.36 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-O 120.611 0.243 . . . . 0.0 111.001 -177.647 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 62' ' ' ARG . . . . . 0.448 HH21 ' CD ' ' A' ' 74' ' ' GLU . 19.5 ttp85 -135.12 130.63 35.77 Favored 'General case' 0 C--O 1.217 -0.612 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 175.352 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.494 ' HB3' ' HB2' ' A' ' 47' ' ' LEU . . . -137.44 146.2 44.06 Favored 'General case' 0 C--N 1.317 -0.828 0 C-N-CA 120.835 -0.346 . . . . 0.0 111.38 -179.597 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 63.4 m -125.11 134.71 52.36 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.069 179.074 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 55.6 tp -63.83 118.5 8.44 Favored 'General case' 0 CA--C 1.509 -0.617 0 CA-C-O 121.074 0.464 . . . . 0.0 110.998 -179.767 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 52.3 tp -67.53 -39.43 85.04 Favored 'General case' 0 N--CA 1.436 -1.146 0 CA-C-N 115.374 -0.83 . . . . 0.0 111.116 -179.956 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 178.68 -37.69 0.08 OUTLIER Glycine 0 N--CA 1.446 -0.652 0 C-N-CA 120.485 -0.864 . . . . 0.0 112.557 179.763 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 18.8 p-10 -173.73 114.05 0.21 Allowed 'General case' 0 C--N 1.326 -0.414 0 C-N-CA 122.405 0.282 . . . . 0.0 110.353 -178.611 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 69' ' ' ASN . . . . . 0.405 ' OD1' ' HA3' ' A' ' 93' ' ' GLY . 96.1 m-20 68.19 -43.77 0.49 Allowed 'General case' 0 N--CA 1.484 1.273 0 C-N-CA 123.795 0.838 . . . . 0.0 113.114 -178.824 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 9.6 m -77.96 133.76 37.97 Favored 'General case' 0 C--N 1.315 -0.932 0 CA-C-O 121.113 0.482 . . . . 0.0 110.898 178.396 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.607 ' OH ' ' HB3' ' A' ' 99' ' ' ASN . 96.4 m-85 -126.41 148.74 49.57 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.037 178.586 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -95.54 117.25 30.09 Favored 'General case' 0 C--N 1.308 -1.235 0 N-CA-C 107.797 -1.186 . . . . 0.0 107.797 173.448 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 79.0 t -103.3 136.6 35.3 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.849 0 CA-C-O 121.244 0.545 . . . . 0.0 112.416 -173.635 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.465 ' HG2' ' HA ' ' A' ' 86' ' ' SER . 98.0 mt-10 -118.76 146.88 44.43 Favored 'General case' 0 N--CA 1.439 -1.025 0 CA-C-N 114.982 -1.008 . . . . 0.0 109.081 177.438 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 75' ' ' ASN . . . . . 0.439 ' HB3' HD12 ' A' ' 59' ' ' ILE . 10.0 m120 -123.99 137.18 54.64 Favored 'General case' 0 C--N 1.315 -0.904 0 CA-C-O 121.226 0.536 . . . . 0.0 110.931 -177.095 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 76' ' ' GLN . . . . . 0.739 ' O ' ' HB ' ' A' ' 59' ' ' ILE . 30.4 tt0 -110.37 115.82 30.35 Favored 'General case' 0 C--N 1.309 -1.194 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.32 -179.875 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 6.1 p90 -129.28 44.62 2.94 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-O 121.423 0.63 . . . . 0.0 110.717 179.467 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -104.8 -68.95 0.75 Allowed Glycine 0 N--CA 1.443 -0.839 0 C-N-CA 120.647 -0.787 . . . . 0.0 111.183 -178.848 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 170.81 -67.18 0.15 Allowed Glycine 0 N--CA 1.446 -0.676 0 N-CA-C 110.686 -0.965 . . . . 0.0 110.686 178.354 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 37.0 t70 -139.08 117.27 11.84 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 177.654 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 32.3 t 76.76 -75.08 0.07 Allowed 'General case' 0 C--N 1.327 -0.396 0 O-C-N 123.876 0.735 . . . . 0.0 110.092 -178.436 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 63.99 161.6 0.12 Allowed Pre-proline 0 N--CA 1.477 0.901 0 N-CA-C 112.352 0.501 . . . . 0.0 112.352 177.141 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 83' ' ' PRO . . . . . 0.593 ' O ' ' HB2' ' A' ' 84' ' ' TRP . 51.7 Cg_exo -57.07 -41.83 70.47 Favored 'Trans proline' 0 C--N 1.355 0.892 0 C-N-CA 122.526 2.151 . . . . 0.0 112.859 177.612 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 84' ' ' TRP . . . . . 0.593 ' HB2' ' O ' ' A' ' 83' ' ' PRO . 74.0 m95 94.48 116.42 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.778 0 C-N-CA 124.747 1.219 . . . . 0.0 110.231 -178.725 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 92.7 m-70 -112.15 139.04 48.0 Favored 'General case' 0 CA--C 1.517 -0.324 0 CA-C-N 116.484 -0.326 . . . . 0.0 110.531 -176.845 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 86' ' ' SER . . . . . 0.465 ' HA ' ' HG2' ' A' ' 74' ' ' GLU . 13.1 m -70.61 141.3 51.76 Favored 'General case' 0 C--N 1.311 -1.092 0 CA-C-N 116.442 -0.345 . . . . 0.0 110.096 177.134 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -109.29 -34.06 2.59 Favored Glycine 0 N--CA 1.447 -0.578 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.852 -178.349 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 147.57 -160.56 28.33 Favored Glycine 0 N--CA 1.453 -0.211 0 C-N-CA 120.315 -0.945 . . . . 0.0 112.459 178.649 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 23.8 t-20 -118.67 124.61 47.8 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.433 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 90' ' ' TRP . . . . . 0.558 ' HH2' ' SD ' ' A' ' 51' ' ' MET . 36.2 m0 -118.24 152.88 34.87 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.129 -177.721 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 79.1 mt -107.25 116.71 51.5 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 N-CA-C 110.191 -0.299 . . . . 0.0 110.191 178.494 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 92' ' ' LEU . . . . . 0.402 ' HB2' ' CE1' ' A' ' 71' ' ' TYR . 90.2 mt -126.57 76.46 1.63 Allowed 'General case' 0 C--O 1.256 1.406 0 CA-C-O 121.625 0.726 . . . . 0.0 111.036 -178.411 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 93' ' ' GLY . . . . . 0.405 ' HA3' ' OD1' ' A' ' 69' ' ' ASN . . . -176.73 105.3 0.2 Allowed Glycine 0 N--CA 1.435 -1.374 0 CA-C-N 114.842 -1.072 . . . . 0.0 111.612 -179.551 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.4 p -86.2 -11.8 51.48 Favored 'General case' 0 C--N 1.313 -1.003 0 CA-C-O 121.265 0.555 . . . . 0.0 110.695 178.384 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 97.6 mtt180 -106.92 153.39 22.6 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.563 -0.744 . . . . 0.0 111.68 178.825 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -66.69 -43.14 85.19 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 115.207 -0.906 . . . . 0.0 112.388 -175.967 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 21.4 m120 -123.04 34.1 5.22 Favored 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 111.967 0.358 . . . . 0.0 111.967 -176.364 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 98' ' ' GLN . . . . . . . . . . . . . 9.6 tt0 -146.95 121.01 9.41 Favored 'General case' 0 C--N 1.32 -0.688 0 C-N-CA 120.278 -0.569 . . . . 0.0 110.549 -178.473 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 99' ' ' ASN . . . . . 0.607 ' HB3' ' OH ' ' A' ' 71' ' ' TYR . 90.2 m-20 -95.34 159.71 14.88 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.182 -176.45 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 79.1 t -81.46 133.72 28.65 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.637 0 CA-C-N 116.509 -0.314 . . . . 0.0 110.79 176.64 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 33.7 m -113.33 -26.83 2.88 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 N-CA-C 112.83 0.678 . . . . 0.0 112.83 -178.755 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 102' ' ' ALA . . . . . 0.648 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -146.91 140.12 25.42 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 119.696 -0.801 . . . . 0.0 112.095 178.65 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.412 ' HB ' HG22 ' A' ' 38' ' ' VAL . 91.1 mt -133.22 124.64 49.73 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.929 -0.578 . . . . 0.0 111.073 178.25 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 40.2 t30 -128.78 97.45 4.67 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.317 174.703 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 28.6 m -143.48 148.37 19.18 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 N-CA-C 112.949 0.722 . . . . 0.0 112.949 -174.526 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 76.1 tt0 -142.66 138.04 30.38 Favored 'General case' 0 N--CA 1.437 -1.092 0 CA-C-N 115.072 -0.967 . . . . 0.0 108.544 175.248 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 107' ' ' SER . . . . . 0.437 ' HA ' ' HA ' ' A' ' 114' ' ' LEU . 44.8 t -74.87 -52.42 11.36 Favored 'General case' 0 C--N 1.306 -1.287 0 CA-C-N 116.09 -0.504 . . . . 0.0 111.382 -178.183 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 81.8 -9.26 57.01 Favored Glycine 0 N--CA 1.449 -0.457 0 N-CA-C 110.875 -0.89 . . . . 0.0 110.875 -176.366 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 109' ' ' ASP . . . . . 0.495 ' CG ' ' H ' ' A' ' 110' ' ' ASP . 19.4 t70 -125.07 -150.76 0.45 Allowed 'General case' 0 N--CA 1.445 -0.677 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 179.398 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 110' ' ' ASP . . . . . 0.495 ' H ' ' CG ' ' A' ' 109' ' ' ASP . 31.7 m-20 -89.86 12.88 15.99 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 120.845 0.355 . . . . 0.0 111.475 -179.426 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 111' ' ' GLY . . . . . 0.454 ' HA3' ' ND2' ' A' ' 32' ' ' ASN . . . 101.33 8.61 46.54 Favored Glycine 0 C--O 1.229 -0.217 0 C-N-CA 120.129 -1.034 . . . . 0.0 113.408 179.529 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 48.4 mt-30 -68.83 -42.37 77.27 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.487 0.66 . . . . 0.0 110.557 179.224 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 17.5 p -133.51 139.28 46.55 Favored 'General case' 0 C--N 1.317 -0.839 0 CA-C-N 115.32 -0.854 . . . . 0.0 110.837 179.104 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 114' ' ' LEU . . . . . 0.437 ' HA ' ' HA ' ' A' ' 107' ' ' SER . 9.1 mp -120.31 145.16 47.37 Favored 'General case' 0 C--N 1.316 -0.867 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 178.677 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 8.6 p30 -148.1 160.4 42.93 Favored 'General case' 0 C--N 1.314 -0.939 0 C-N-CA 120.617 -0.433 . . . . 0.0 110.939 178.486 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 153.35 -128.0 2.32 Favored Glycine 0 N--CA 1.436 -1.337 0 CA-C-N 115.683 -0.69 . . . . 0.0 111.673 179.875 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 22.1 p -135.24 158.83 43.36 Favored 'General case' 0 C--N 1.315 -0.9 0 CA-C-O 121.11 0.481 . . . . 0.0 111.055 -179.079 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 118' ' ' MET . . . . . 0.442 ' O ' ' HA ' ' A' ' 125' ' ' PRO . 4.7 ppp? -147.19 156.03 42.61 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 116.156 -0.474 . . . . 0.0 109.841 178.841 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 119' ' ' THR . . . . . 0.648 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 26.4 m -128.72 126.45 40.06 Favored 'General case' 0 C--O 1.254 1.292 0 CA-C-O 120.519 0.2 . . . . 0.0 111.115 179.91 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 70.0 m-85 -85.42 158.44 20.22 Favored 'General case' 0 C--O 1.233 0.196 0 CA-C-N 115.777 -0.647 . . . . 0.0 109.982 176.264 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -60.3 126.32 27.03 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 120.778 0.323 . . . . 0.0 110.796 177.631 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 65.03 30.81 78.95 Favored Glycine 0 CA--C 1.523 0.562 0 CA-C-N 115.964 -0.562 . . . . 0.0 114.113 178.715 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 77.2 tt0 -150.49 160.2 43.95 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 117.229 0.514 . . . . 0.0 110.218 -179.345 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -77.2 160.08 49.46 Favored Glycine 0 CA--C 1.522 0.53 0 C-N-CA 121.084 -0.579 . . . . 0.0 112.908 -178.947 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 125' ' ' PRO . . . . . 0.442 ' HA ' ' O ' ' A' ' 118' ' ' MET . 51.4 Cg_endo -68.21 142.78 56.63 Favored 'Trans proline' 0 CA--C 1.534 0.502 0 C-N-CA 122.993 2.462 . . . . 0.0 113.271 179.743 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 49.1 pt -131.6 169.42 21.8 Favored 'Isoleucine or valine' 0 C--O 1.24 0.581 0 CA-C-N 115.737 -0.665 . . . . 0.0 109.935 178.547 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -70.66 131.99 21.99 Favored Glycine 0 C--N 1.336 0.55 0 C-N-CA 120.677 -0.773 . . . . 0.0 111.981 -179.381 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 84.7 t80 -119.5 139.19 52.48 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 121.255 0.55 . . . . 0.0 111.583 -178.146 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 129' ' ' LYS . . . . . 0.4 ' HB3' ' HB2' ' A' ' 7' ' ' GLU . 62.8 tttm -140.94 134.8 30.48 Favored 'General case' 0 N--CA 1.431 -1.379 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 176.85 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 130' ' ' GLY . . . . . 0.405 ' HA2' ' O ' ' A' ' 5' ' ' ASN . . . -135.15 144.75 16.78 Favored Glycine 0 N--CA 1.436 -1.355 0 C-N-CA 120.521 -0.847 . . . . 0.0 111.428 -179.502 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 56.2 m -123.81 130.55 52.79 Favored 'General case' 0 C--N 1.311 -1.084 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 -178.72 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 61.1 tp -70.67 136.22 48.9 Favored 'General case' 0 C--O 1.237 0.436 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 179.076 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 15.4 t . . . . . 0 C--O 1.251 1.149 0 CA-C-O 119.144 -0.455 . . . . 0.0 110.069 -177.65 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.578 ' O ' ' HG3' ' A' ' 24' ' ' GLU . . . . . . . . 0 N--CA 1.48 1.047 0 N-CA-C 110.022 -0.362 . . . . 0.0 110.022 . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -91.97 128.23 37.74 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-O 121.019 0.437 . . . . 0.0 110.537 -175.743 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 11.8 m-85 -121.3 144.47 48.62 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.169 178.27 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 94.4 m-20 -94.66 140.13 30.29 Favored 'General case' 0 C--N 1.313 -0.99 0 N-CA-C 107.826 -1.176 . . . . 0.0 107.826 177.538 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 77.3 t -116.33 128.46 73.65 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.961 0 CA-C-O 121.274 0.559 . . . . 0.0 112.434 -175.629 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -125.09 138.75 54.18 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 176.691 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' ASN . . . . . 0.438 ' HB3' HD12 ' A' ' 126' ' ' ILE . 27.0 m120 -131.01 151.88 50.93 Favored 'General case' 0 C--N 1.316 -0.866 0 N-CA-C 112.653 0.612 . . . . 0.0 112.653 -177.526 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 9' ' ' GLN . . . . . 0.413 ' OE1' ' HA ' ' A' ' 13' ' ' SER . 35.7 tt0 -129.47 128.13 42.28 Favored 'General case' 0 C--O 1.238 0.498 0 CA-C-N 115.343 -0.844 . . . . 0.0 110.533 178.336 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 46.8 p90 -138.11 146.24 42.63 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 116.575 -0.284 . . . . 0.0 110.484 178.617 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 95.12 11.82 55.76 Favored Glycine 0 N--CA 1.444 -0.775 0 C-N-CA 120.545 -0.836 . . . . 0.0 111.759 179.207 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 104.88 157.38 23.27 Favored Glycine 0 N--CA 1.442 -0.919 0 C-N-CA 120.953 -0.642 . . . . 0.0 112.144 179.088 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' SER . . . . . 0.413 ' HA ' ' OE1' ' A' ' 9' ' ' GLN . 15.5 m -58.13 -21.16 45.42 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 112.128 0.418 . . . . 0.0 112.128 179.036 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 18.7 m -59.14 -33.73 71.23 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 120.806 0.336 . . . . 0.0 110.857 176.82 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -76.78 145.28 74.31 Favored Pre-proline 0 N--CA 1.45 -0.437 0 CA-C-N 116.009 -0.542 . . . . 0.0 111.132 -179.409 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 93.1 Cg_endo -73.26 163.19 38.62 Favored 'Trans proline' 0 C--O 1.236 0.375 0 C-N-CA 122.808 2.339 . . . . 0.0 112.266 -179.892 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 92.3 m95 -85.17 131.68 34.4 Favored 'General case' 0 C--N 1.319 -0.75 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 179.23 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 55.9 m-80 -124.1 144.94 49.59 Favored 'General case' 0 C--N 1.312 -1.029 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 -179.525 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -64.99 135.4 55.6 Favored 'General case' 0 C--N 1.311 -1.066 0 CA-C-O 121.598 0.713 . . . . 0.0 112.207 -177.274 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -112.2 34.82 4.98 Favored Glycine 0 CA--C 1.499 -0.912 0 CA-C-N 114.604 -1.18 . . . . 0.0 110.961 178.326 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 83.3 -156.85 34.24 Favored Glycine 0 N--CA 1.436 -1.353 0 N-CA-C 111.344 -0.702 . . . . 0.0 111.344 -177.387 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 9.2 pt20 -144.27 147.41 33.5 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-O 120.869 0.366 . . . . 0.0 110.246 178.204 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' TRP . . . . . 0.598 ' HB3' ' O ' ' A' ' 91' ' ' ILE . 54.4 m0 -128.33 -179.14 4.86 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.743 -173.893 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.578 ' HG3' ' O ' ' A' ' 2' ' ' ALA . 82.6 tt0 -123.69 116.15 22.6 Favored 'General case' 0 CA--C 1.511 -0.534 0 CA-C-O 120.943 0.401 . . . . 0.0 110.522 176.446 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 95.3 mt -126.94 134.16 66.8 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.784 0 CA-C-N 115.448 -0.796 . . . . 0.0 110.767 -177.701 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 90.94 106.74 1.38 Allowed Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.973 -0.632 . . . . 0.0 113.911 176.526 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 19.8 m -69.1 -43.04 75.29 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.369 0.604 . . . . 0.0 110.02 175.419 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -71.0 137.96 49.52 Favored 'General case' 0 N--CA 1.451 -0.396 0 CA-C-N 115.292 -0.867 . . . . 0.0 110.663 179.77 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 19.8 m -102.86 -26.16 13.23 Favored 'General case' 0 C--N 1.315 -0.924 0 CA-C-O 121.054 0.454 . . . . 0.0 110.4 178.687 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 27.1 m-20 -91.09 -5.3 55.34 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.918 179.263 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 8.6 tp-100 -139.59 120.55 14.54 Favored 'General case' 0 C--N 1.31 -1.133 0 N-CA-C 109.35 -0.611 . . . . 0.0 109.35 -178.999 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 62.0 t30 -97.74 162.76 13.11 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-O 121.172 0.51 . . . . 0.0 112.083 -175.975 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.412 ' HA ' ' HA ' ' A' ' 53' ' ' TYR . 89.5 t -98.74 133.59 40.66 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.639 0 CA-C-N 115.217 -0.902 . . . . 0.0 109.991 179.965 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 21.0 m -107.05 -27.73 2.96 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.456 0 N-CA-C 111.981 0.364 . . . . 0.0 111.981 -179.38 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.42 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -139.56 143.63 37.44 Favored 'General case' 0 CA--C 1.509 -0.634 0 C-N-CA 120.109 -0.637 . . . . 0.0 111.632 179.989 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.435 ' HB ' ' CG2' ' A' ' 105' ' ' VAL . 94.2 mt -139.64 117.73 11.4 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.832 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 179.039 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 23.0 t30 -129.02 108.25 10.24 Favored 'General case' 0 C--N 1.304 -1.388 0 N-CA-C 108.065 -1.087 . . . . 0.0 108.065 177.453 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.434 HG22 ' HB ' ' A' ' 103' ' ' ILE . 23.9 m -147.03 151.38 13.95 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.762 0 C-N-CA 120.448 -0.501 . . . . 0.0 111.339 -173.184 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 36.1 tt0 -141.1 145.56 35.95 Favored 'General case' 0 N--CA 1.437 -1.089 0 CA-C-N 115.512 -0.767 . . . . 0.0 109.001 176.433 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 30.9 t -72.26 142.6 48.93 Favored 'General case' 0 C--N 1.309 -1.176 0 CA-C-O 121.093 0.473 . . . . 0.0 111.338 -178.522 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -95.22 -25.12 14.79 Favored Glycine 0 N--CA 1.433 -1.553 0 C-N-CA 120.504 -0.855 . . . . 0.0 111.769 177.919 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 36.1 t70 -145.11 79.63 1.59 Allowed 'General case' 0 CA--C 1.536 0.405 0 N-CA-C 112.842 0.682 . . . . 0.0 112.842 -177.372 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 50.24 29.03 3.44 Favored 'General case' 0 N--CA 1.491 1.611 0 N-CA-C 114.564 1.32 . . . . 0.0 114.564 173.673 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.502 ' HA2' HG12 ' A' ' 101' ' ' VAL . . . 99.44 -16.77 58.6 Favored Glycine 0 C--N 1.312 -0.791 0 C-N-CA 120.658 -0.782 . . . . 0.0 113.189 178.187 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 59.7 tp60 -66.42 -39.01 88.72 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-O 121.04 0.448 . . . . 0.0 110.77 -179.944 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 36.8 p -125.67 147.84 49.21 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.975 178.499 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 47' ' ' LEU . . . . . 0.551 ' HB2' ' HB3' ' A' ' 63' ' ' ALA . 95.2 mt -128.36 128.15 43.99 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 109.524 -0.547 . . . . 0.0 109.524 179.254 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 83.4 m-20 -128.44 141.1 51.51 Favored 'General case' 0 C--N 1.319 -0.723 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 178.398 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 175.45 -156.26 21.73 Favored Glycine 0 N--CA 1.442 -0.948 0 C-N-CA 119.411 -1.376 . . . . 0.0 113.503 178.444 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 70.4 m -128.95 131.46 47.5 Favored 'General case' 0 N--CA 1.44 -0.971 0 C-N-CA 122.839 0.456 . . . . 0.0 110.149 -178.43 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 51' ' ' MET . . . . . 0.403 ' HE1' ' CZ ' ' A' ' 53' ' ' TYR . 14.7 tmm? -125.91 144.73 50.56 Favored 'General case' 0 C--N 1.316 -0.875 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 -179.265 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.42 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 33.6 m -126.26 130.06 50.13 Favored 'General case' 0 C--O 1.245 0.866 0 N-CA-C 112.054 0.39 . . . . 0.0 112.054 -176.57 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 53' ' ' TYR . . . . . 0.412 ' HA ' ' HA ' ' A' ' 33' ' ' VAL . 72.4 m-85 -87.15 161.8 17.87 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.946 177.176 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -63.54 106.91 1.02 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.989 -0.55 . . . . 0.0 112.069 -179.713 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 84.67 10.6 79.0 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.713 -0.756 . . . . 0.0 113.528 177.836 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 57.8 mt-10 -123.07 168.02 12.9 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 117.212 0.506 . . . . 0.0 110.793 178.26 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -79.86 155.48 38.97 Favored Glycine 0 N--CA 1.447 -0.599 0 C-N-CA 120.84 -0.695 . . . . 0.0 112.379 -179.884 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 32.9 Cg_endo -62.81 142.72 89.89 Favored 'Trans proline' 0 CA--C 1.534 0.503 0 C-N-CA 123.012 2.475 . . . . 0.0 112.546 -179.758 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 59' ' ' ILE . . . . . 0.566 ' HB ' ' O ' ' A' ' 76' ' ' GLN . 47.3 pt -128.25 167.35 23.55 Favored 'Isoleucine or valine' 0 C--O 1.239 0.501 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.736 -179.765 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -79.11 138.63 20.89 Favored Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 120.929 -0.653 . . . . 0.0 111.807 -179.702 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 60.9 t80 -118.62 123.59 45.36 Favored 'General case' 0 C--N 1.317 -0.827 0 C-N-CA 122.389 0.275 . . . . 0.0 110.799 -178.132 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 49.1 ttm-85 -126.81 128.22 46.22 Favored 'General case' 0 C--O 1.22 -0.452 0 N-CA-C 109.325 -0.62 . . . . 0.0 109.325 175.997 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.65 ' HB1' ' HB3' ' A' ' 71' ' ' TYR . . . -136.12 142.81 44.29 Favored 'General case' 0 C--N 1.32 -0.696 0 C-N-CA 120.231 -0.588 . . . . 0.0 112.094 178.574 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 57.3 m -118.7 127.45 53.58 Favored 'General case' 0 CA--C 1.54 0.573 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.084 178.249 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 65' ' ' LEU . . . . . 0.403 HD13 ' N ' ' A' ' 67' ' ' GLY . 2.4 tm? -72.74 118.31 15.51 Favored 'General case' 0 CA--C 1.544 0.749 0 CA-C-O 121.372 0.606 . . . . 0.0 112.156 -177.866 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 4.6 mm? -66.86 -38.22 85.94 Favored 'General case' 0 N--CA 1.475 0.792 0 CA-C-N 115.283 -0.871 . . . . 0.0 111.869 178.091 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.403 ' N ' HD13 ' A' ' 65' ' ' LEU . . . 125.45 -6.14 8.07 Favored Glycine 0 C--O 1.227 -0.304 0 C-N-CA 120.593 -0.813 . . . . 0.0 112.521 -176.263 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 29.7 p-10 -125.83 38.19 4.2 Favored 'General case' 0 C--N 1.316 -0.889 0 CA-C-O 121.117 0.484 . . . . 0.0 110.507 -179.372 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 96.1 m-20 66.59 5.09 3.64 Favored 'General case' 0 N--CA 1.479 0.976 0 CA-C-N 115.469 -0.787 . . . . 0.0 111.882 -178.761 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 32.8 m -99.17 138.06 36.81 Favored 'General case' 0 N--CA 1.443 -0.785 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 177.367 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.65 ' HB3' ' HB1' ' A' ' 63' ' ' ALA . 91.5 m-85 -120.38 135.65 54.97 Favored 'General case' 0 C--N 1.306 -1.296 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.329 -179.28 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 72' ' ' GLU . . . . . 0.417 ' O ' ' HA ' ' A' ' 63' ' ' ALA . 71.6 tt0 -88.76 121.31 31.0 Favored 'General case' 0 C--N 1.311 -1.077 0 N-CA-C 107.964 -1.124 . . . . 0.0 107.964 175.286 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.469 HG22 ' HB2' ' A' ' 63' ' ' ALA . 75.3 t -107.67 137.05 40.85 Favored 'Isoleucine or valine' 0 C--O 1.247 0.957 0 N-CA-C 113.661 0.986 . . . . 0.0 113.661 -170.857 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -119.17 142.67 47.76 Favored 'General case' 0 N--CA 1.444 -0.739 0 CA-C-N 114.19 -1.368 . . . . 0.0 107.84 175.565 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 94.1 m-20 -118.06 135.31 54.27 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-O 120.825 0.345 . . . . 0.0 111.251 -175.699 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 76' ' ' GLN . . . . . 0.566 ' O ' ' HB ' ' A' ' 59' ' ' ILE . 17.3 tt0 -110.09 119.35 39.02 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.889 179.124 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 7.5 p90 -139.63 156.71 46.68 Favored 'General case' 0 C--N 1.326 -0.456 0 C-N-CA 120.856 -0.338 . . . . 0.0 111.358 177.013 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 105.81 -3.95 39.13 Favored Glycine 0 N--CA 1.449 -0.498 0 C-N-CA 121.198 -0.525 . . . . 0.0 112.177 179.666 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 139.63 171.57 12.35 Favored Glycine 0 CA--C 1.503 -0.694 0 N-CA-C 110.579 -1.008 . . . . 0.0 110.579 -179.602 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -68.07 155.16 40.15 Favored 'General case' 0 C--O 1.245 0.839 0 CA-C-N 117.527 0.664 . . . . 0.0 110.047 178.448 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 14.7 m 70.95 -95.2 0.03 OUTLIER 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.467 -0.788 . . . . 0.0 109.042 -176.601 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 82' ' ' ALA . . . . . 0.547 ' HB1' ' HD2' ' A' ' 83' ' ' PRO . . . 51.46 171.07 0.04 OUTLIER Pre-proline 0 CA--C 1.557 1.25 0 N-CA-C 113.31 0.855 . . . . 0.0 113.31 176.38 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 83' ' ' PRO . . . . . 0.547 ' HD2' ' HB1' ' A' ' 82' ' ' ALA . 63.6 Cg_endo -73.27 150.6 47.49 Favored 'Trans proline' 0 N--CA 1.452 -0.943 0 C-N-CA 121.591 1.527 . . . . 0.0 109.927 170.551 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 84' ' ' TRP . . . . . . . . . . . . . 82.2 m95 -95.69 137.99 33.98 Favored 'General case' 0 C--N 1.315 -0.924 0 C-N-CA 120.54 -0.464 . . . . 0.0 109.768 -179.91 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 84.4 m-70 -113.18 138.8 49.43 Favored 'General case' 0 C--N 1.314 -0.976 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 -177.775 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 13.4 p -65.15 131.25 46.04 Favored 'General case' 0 C--N 1.32 -0.688 0 C-N-CA 121.113 -0.235 . . . . 0.0 110.447 -179.779 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -105.36 -52.3 0.83 Allowed Glycine 0 N--CA 1.443 -0.836 0 C-N-CA 120.239 -0.981 . . . . 0.0 113.23 -179.187 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 154.59 -166.27 32.24 Favored Glycine 0 C--O 1.22 -0.747 0 C-N-CA 120.187 -1.006 . . . . 0.0 112.115 -178.108 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 20.5 t-20 -113.81 119.43 37.32 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 117.01 0.405 . . . . 0.0 110.709 -179.482 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 22.4 m0 -108.89 148.1 31.16 Favored 'General case' 0 C--O 1.217 -0.621 0 N-CA-C 109.492 -0.558 . . . . 0.0 109.492 -179.867 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.598 ' O ' ' HB3' ' A' ' 23' ' ' TRP . 85.0 mt -107.7 119.56 57.51 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.072 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 178.903 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 92' ' ' LEU . . . . . 0.463 ' HB2' ' CE1' ' A' ' 71' ' ' TYR . 90.9 mt -134.08 78.95 1.79 Allowed 'General case' 0 C--O 1.267 1.984 0 CA-C-O 121.688 0.756 . . . . 0.0 111.6 -177.399 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 168.85 126.7 0.87 Allowed Glycine 0 N--CA 1.44 -1.08 0 CA-C-N 115.13 -0.941 . . . . 0.0 111.875 179.29 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 94' ' ' SER . . . . . 0.425 ' HB3' ' HE1' ' A' ' 23' ' ' TRP . 32.4 p -117.95 4.2 12.13 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-O 121.353 0.596 . . . . 0.0 110.651 178.379 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 62.3 mtt-85 -102.01 142.84 32.66 Favored 'General case' 0 N--CA 1.445 -0.702 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.521 178.903 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 -62.66 -37.61 87.09 Favored 'General case' 0 C--N 1.312 -1.029 0 CA-C-N 115.421 -0.809 . . . . 0.0 112.899 -176.143 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 29.0 p-10 -126.3 27.93 6.11 Favored 'General case' 0 C--N 1.316 -0.86 0 N-CA-C 111.827 0.306 . . . . 0.0 111.827 -176.333 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 98' ' ' GLN . . . . . . . . . . . . . 4.4 tp-100 -146.19 126.56 14.01 Favored 'General case' 0 C--N 1.322 -0.615 0 C-N-CA 119.319 -0.953 . . . . 0.0 111.688 -175.471 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 99' ' ' ASN . . . . . 0.591 ' HB3' ' OH ' ' A' ' 71' ' ' TYR . 87.2 m-20 -97.24 154.28 17.5 Favored 'General case' 0 C--O 1.249 1.048 0 CA-C-N 115.452 -0.795 . . . . 0.0 110.572 -179.439 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 70.8 t -79.03 136.86 22.9 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.791 0 C-N-CA 120.85 -0.34 . . . . 0.0 110.79 177.84 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 0.502 HG12 ' HA2' ' A' ' 44' ' ' GLY . 33.3 m -123.0 -35.52 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.714 0 N-CA-C 113.878 1.066 . . . . 0.0 113.878 -177.118 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 102' ' ' ALA . . . . . 0.43 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -127.59 127.33 43.68 Favored 'General case' 0 C--N 1.319 -0.743 0 C-N-CA 120.153 -0.619 . . . . 0.0 111.386 -178.63 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.434 ' HB ' HG22 ' A' ' 38' ' ' VAL . 94.0 mt -131.18 122.09 50.57 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.091 177.927 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 23.6 t-20 -124.79 95.4 4.5 Favored 'General case' 0 C--N 1.313 -1.001 0 N-CA-C 108.812 -0.81 . . . . 0.0 108.812 176.455 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.435 ' CG2' ' HB ' ' A' ' 36' ' ' ILE . 26.8 m -140.17 142.68 31.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 N-CA-C 112.682 0.623 . . . . 0.0 112.682 -175.612 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 -145.1 147.16 32.23 Favored 'General case' 0 N--CA 1.444 -0.759 0 CA-C-N 115.4 -0.818 . . . . 0.0 109.153 176.526 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 47.2 t -137.73 142.48 40.99 Favored 'General case' 0 C--N 1.308 -1.221 0 CA-C-O 120.797 0.332 . . . . 0.0 110.78 -178.589 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -108.01 -6.18 32.39 Favored Glycine 0 N--CA 1.44 -1.05 0 N-CA-C 110.796 -0.922 . . . . 0.0 110.796 175.766 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 68.3 m-20 -98.26 54.65 1.09 Allowed 'General case' 0 C--O 1.235 0.33 0 N-CA-C 112.643 0.609 . . . . 0.0 112.643 -177.582 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 28.7 t70 59.55 15.55 4.65 Favored 'General case' 0 N--CA 1.481 1.098 0 C-N-CA 123.3 0.64 . . . . 0.0 112.284 174.863 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 86.37 -3.85 86.66 Favored Glycine 0 N--CA 1.447 -0.625 0 C-N-CA 120.447 -0.882 . . . . 0.0 112.944 178.232 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 112' ' ' GLN . . . . . 0.42 ' O ' ' HA ' ' A' ' 131' ' ' THR . 97.6 mt-30 -64.21 -40.14 95.45 Favored 'General case' 0 CA--C 1.517 -0.29 0 CA-C-N 116.926 0.363 . . . . 0.0 111.622 -177.76 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 33.5 p -123.32 112.17 17.28 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 110.0 -0.37 . . . . 0.0 110.0 177.833 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 92.5 mt -90.93 126.95 36.21 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 116.464 -0.335 . . . . 0.0 110.477 -178.66 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 9.0 m120 -118.72 129.86 55.51 Favored 'General case' 0 C--O 1.241 0.651 0 CA-C-N 116.224 -0.444 . . . . 0.0 109.882 -178.812 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 172.21 -141.32 6.22 Favored Glycine 0 N--CA 1.445 -0.755 0 C-N-CA 119.741 -1.218 . . . . 0.0 113.608 178.098 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 16.9 p -137.29 159.32 42.27 Favored 'General case' 0 C--N 1.319 -0.726 0 C-N-CA 123.276 0.63 . . . . 0.0 110.781 -178.269 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 17.8 ptm -147.31 150.44 34.79 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 120.864 0.364 . . . . 0.0 110.898 -179.721 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 119' ' ' THR . . . . . 0.43 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 23.3 m -142.48 136.09 29.05 Favored 'General case' 0 C--O 1.252 1.194 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.064 178.053 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 120' ' ' TYR . . . . . 0.628 ' HB2' ' O ' ' A' ' 123' ' ' GLU . 37.1 m-85 -83.58 174.26 10.7 Favored 'General case' 0 C--O 1.225 -0.23 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.342 175.597 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 121' ' ' ALA . . . . . 0.496 ' HA ' HG11 ' A' ' 101' ' ' VAL . . . -51.22 -28.87 12.55 Favored 'General case' 0 N--CA 1.478 0.933 0 N-CA-C 114.058 1.133 . . . . 0.0 114.058 -175.951 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -165.54 26.84 0.18 Allowed Glycine 0 N--CA 1.447 -0.589 0 C-N-CA 119.29 -1.433 . . . . 0.0 112.742 179.986 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 123' ' ' GLU . . . . . 0.628 ' O ' ' HB2' ' A' ' 120' ' ' TYR . 13.3 pt-20 -165.97 145.59 6.25 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.132 0.491 . . . . 0.0 111.868 -178.51 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 71.87 67.92 1.74 Allowed Glycine 0 CA--C 1.531 1.084 0 N-CA-C 116.312 1.285 . . . . 0.0 116.312 173.075 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_exo -84.14 95.07 0.73 Allowed 'Trans proline' 0 N--CA 1.459 -0.53 0 C-N-CA 122.454 2.102 . . . . 0.0 108.374 170.561 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 126' ' ' ILE . . . . . 0.438 HD12 ' HB3' ' A' ' 8' ' ' ASN . 19.6 pt -130.28 165.83 29.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 N-CA-C 113.234 0.828 . . . . 0.0 113.234 -170.762 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -70.44 135.99 25.96 Favored Glycine 0 C--N 1.339 0.703 0 CA-C-N 115.488 -0.778 . . . . 0.0 111.577 178.29 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 82.5 t80 -112.54 133.26 54.69 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 121.281 0.562 . . . . 0.0 111.754 -175.688 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 63.5 tttm -137.64 110.4 7.61 Favored 'General case' 0 C--N 1.314 -0.939 0 CA-C-N 115.241 -0.891 . . . . 0.0 108.933 177.089 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -117.56 153.82 17.02 Favored Glycine 0 N--CA 1.446 -0.685 0 C-N-CA 120.298 -0.953 . . . . 0.0 112.332 -178.363 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 131' ' ' THR . . . . . 0.42 ' HA ' ' O ' ' A' ' 112' ' ' GLN . 14.9 t -143.01 144.95 32.49 Favored 'General case' 0 C--N 1.311 -1.073 0 CA-C-O 121.149 0.5 . . . . 0.0 111.945 179.625 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 68.6 tp -80.91 127.16 32.24 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.342 -0.845 . . . . 0.0 110.219 178.337 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 9.1 t . . . . . 0 C--O 1.253 1.27 0 CA-C-O 118.957 -0.544 . . . . 0.0 110.496 -179.343 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.697 0 N-CA-C 109.995 -0.372 . . . . 0.0 109.995 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 3' ' ' LEU . . . . . 0.473 HD13 ' N ' ' A' ' 4' ' ' TYR . 2.2 tm? -92.08 134.91 34.4 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 116.117 -0.492 . . . . 0.0 109.801 -178.031 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 4' ' ' TYR . . . . . 0.485 ' CE1' ' HB ' ' A' ' 25' ' ' ILE . 74.1 m-85 -123.36 146.54 47.87 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.515 -179.803 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 5' ' ' ASN . . . . . 0.428 ' O ' ' HA2' ' A' ' 130' ' ' GLY . 23.6 t-20 -96.45 140.9 30.42 Favored 'General case' 0 C--N 1.308 -1.211 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 176.627 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 69.9 t -122.77 129.53 75.1 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.916 0 N-CA-C 112.699 0.629 . . . . 0.0 112.699 -175.154 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 91.4 mt-10 -122.4 144.32 49.11 Favored 'General case' 0 C--N 1.32 -0.679 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 173.09 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 86.4 m-20 -123.49 144.67 49.39 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-O 120.921 0.391 . . . . 0.0 111.493 -177.003 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' GLN . . . . . 0.595 ' HB2' ' CE3' ' A' ' 17' ' ' TRP . 57.9 tt0 -123.88 127.14 47.59 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.766 -179.853 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 8.7 p90 -136.09 139.22 42.83 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-N 116.193 -0.458 . . . . 0.0 109.865 176.915 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 105.34 8.0 36.41 Favored Glycine 0 N--CA 1.448 -0.529 0 C-N-CA 120.286 -0.959 . . . . 0.0 112.294 179.862 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 103.24 165.71 25.68 Favored Glycine 0 N--CA 1.445 -0.724 0 C-N-CA 120.402 -0.904 . . . . 0.0 113.427 177.954 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 15.6 m -54.81 -31.81 59.6 Favored 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 123.631 0.773 . . . . 0.0 112.321 179.013 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 33.6 t -64.25 -40.0 95.11 Favored 'General case' 0 C--O 1.242 0.701 0 CA-C-O 120.97 0.414 . . . . 0.0 110.604 -179.573 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -63.43 150.55 89.56 Favored Pre-proline 0 C--O 1.235 0.34 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.403 -179.118 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 88.8 Cg_endo -75.33 156.87 41.6 Favored 'Trans proline' 0 C--O 1.238 0.477 0 C-N-CA 122.888 2.392 . . . . 0.0 112.93 -179.476 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' TRP . . . . . 0.595 ' CE3' ' HB2' ' A' ' 9' ' ' GLN . 85.7 m95 -84.91 124.59 31.82 Favored 'General case' 0 N--CA 1.446 -0.627 0 N-CA-C 107.872 -1.159 . . . . 0.0 107.872 175.71 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 55.1 m-80 -103.68 137.13 42.15 Favored 'General case' 0 C--N 1.308 -1.228 0 N-CA-C 109.122 -0.695 . . . . 0.0 109.122 -179.177 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 18.5 pt-20 -63.78 128.79 37.38 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-O 121.625 0.726 . . . . 0.0 111.673 -178.277 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.681 ' O ' ' HB2' ' A' ' 94' ' ' SER . . . -102.26 -25.28 7.92 Favored Glycine 0 N--CA 1.434 -1.467 0 CA-C-N 114.435 -1.257 . . . . 0.0 113.746 -174.851 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 139.07 -153.04 22.57 Favored Glycine 0 N--CA 1.443 -0.849 0 C-N-CA 119.684 -1.246 . . . . 0.0 112.071 -174.367 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 20.3 pt20 -138.41 134.37 34.04 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 120.733 0.302 . . . . 0.0 110.707 -179.054 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 23' ' ' TRP . . . . . 0.471 ' HE1' ' HB3' ' A' ' 94' ' ' SER . 44.9 m0 -117.61 172.74 7.15 Favored 'General case' 0 N--CA 1.47 0.568 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.637 -179.021 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 79.2 tt0 -130.93 122.49 27.04 Favored 'General case' 0 CA--C 1.518 -0.286 0 C-N-CA 120.513 -0.475 . . . . 0.0 110.142 178.006 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.571 HG23 ' CZ3' ' A' ' 90' ' ' TRP . 99.1 mt -139.72 151.39 22.26 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.769 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.189 -176.146 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 84.62 25.91 40.68 Favored Glycine 0 C--N 1.336 0.559 0 C-N-CA 121.009 -0.615 . . . . 0.0 113.81 175.26 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 4.9 m -77.85 7.94 5.25 Favored 'General case' 0 CA--C 1.549 0.93 0 N-CA-C 112.471 0.545 . . . . 0.0 112.471 -179.06 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 28' ' ' ARG . . . . . 0.499 ' HA ' ' O ' ' A' ' 87' ' ' GLY . 70.7 ttt180 -64.16 -49.68 71.15 Favored 'General case' 0 N--CA 1.474 0.756 0 CA-C-O 121.14 0.495 . . . . 0.0 111.85 -177.977 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 59.2 m -161.47 25.41 0.13 Allowed 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 -179.795 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 27.4 m-20 61.35 94.38 0.04 OUTLIER 'General case' 0 C--O 1.236 0.388 0 CA-C-N 114.486 -1.234 . . . . 0.0 108.783 -175.894 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -160.93 143.42 12.6 Favored 'General case' 0 N--CA 1.443 -0.78 0 N-CA-C 107.455 -1.313 . . . . 0.0 107.455 -176.23 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 32' ' ' ASN . . . . . 0.515 ' HB3' ' HA3' ' A' ' 111' ' ' GLY . 61.1 m-20 -83.37 134.71 34.88 Favored 'General case' 0 C--N 1.311 -1.089 0 CA-C-O 121.543 0.687 . . . . 0.0 112.589 -177.741 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.422 ' HA ' ' HA ' ' A' ' 53' ' ' TYR . 44.7 t -92.9 135.99 26.18 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.727 0 CA-C-N 114.768 -1.105 . . . . 0.0 110.153 -179.857 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 29.7 m -109.36 -18.6 7.41 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 C-N-CA 120.758 -0.377 . . . . 0.0 111.572 -179.671 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -149.92 139.1 21.22 Favored 'General case' 0 C--O 1.236 0.361 0 C-N-CA 120.787 -0.365 . . . . 0.0 111.48 178.666 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.449 ' HB ' ' CG2' ' A' ' 105' ' ' VAL . 86.8 mt -140.03 116.32 8.74 Favored 'Isoleucine or valine' 0 C--O 1.237 0.446 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 178.635 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 88.2 m-20 -123.55 106.65 10.77 Favored 'General case' 0 C--N 1.311 -1.085 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 176.716 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.413 ' CG2' ' HB ' ' A' ' 103' ' ' ILE . 18.6 m -146.56 148.11 17.26 Favored 'Isoleucine or valine' 0 C--O 1.238 0.472 0 CA-C-O 120.742 0.306 . . . . 0.0 111.236 -174.764 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 83.0 tt0 -142.61 147.41 35.78 Favored 'General case' 0 C--N 1.319 -0.759 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 178.169 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 19.4 p -70.81 150.33 45.94 Favored 'General case' 0 C--N 1.319 -0.757 0 N-CA-C 112.985 0.735 . . . . 0.0 112.985 -176.248 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -103.55 -47.39 1.3 Allowed Glycine 0 N--CA 1.443 -0.879 0 N-CA-C 110.529 -1.029 . . . . 0.0 110.529 176.252 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 45.4 m-20 -102.11 -152.8 0.45 Allowed 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 109.57 -0.53 . . . . 0.0 109.57 177.065 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 19.0 m-20 -74.17 44.41 0.19 Allowed 'General case' 0 N--CA 1.486 1.367 0 N-CA-C 112.147 0.425 . . . . 0.0 112.147 -177.927 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 79.91 3.45 89.32 Favored Glycine 0 CA--C 1.506 -0.475 0 C-N-CA 120.881 -0.676 . . . . 0.0 112.056 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 61.1 mt-30 -83.43 -21.99 32.78 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-O 121.215 0.531 . . . . 0.0 110.081 178.464 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 46' ' ' THR . . . . . 0.502 ' HA ' ' O ' ' A' ' 63' ' ' ALA . 35.2 p -129.03 142.62 50.85 Favored 'General case' 0 C--N 1.315 -0.907 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.936 178.52 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 47' ' ' LEU . . . . . 0.405 ' O ' ' HA ' ' A' ' 62' ' ' ARG . 95.9 mt -128.62 133.18 48.22 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 109.103 -0.702 . . . . 0.0 109.103 179.915 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 89.9 m-20 -126.5 139.4 53.25 Favored 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 -179.97 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 169.74 -150.51 15.13 Favored Glycine 0 N--CA 1.448 -0.538 0 C-N-CA 120.112 -1.042 . . . . 0.0 112.463 178.035 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 34.8 p -134.45 152.43 51.79 Favored 'General case' 0 C--N 1.317 -0.83 0 N-CA-C 110.031 -0.359 . . . . 0.0 110.031 179.676 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 11.0 tmm? -142.12 145.49 34.3 Favored 'General case' 0 C--N 1.315 -0.912 0 C-N-CA 121.124 -0.23 . . . . 0.0 110.85 -178.829 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 60.4 m -129.07 128.64 43.97 Favored 'General case' 0 C--O 1.248 1.014 0 CA-C-O 120.81 0.338 . . . . 0.0 111.904 -177.399 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 53' ' ' TYR . . . . . 0.494 ' HB2' ' HB2' ' A' ' 56' ' ' GLU . 78.7 m-85 -91.11 164.63 13.86 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 115.617 -0.72 . . . . 0.0 110.327 176.86 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -69.39 98.26 1.07 Allowed 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.189 179.017 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 103.9 2.16 45.78 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.946 -0.645 . . . . 0.0 112.793 177.779 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 56' ' ' GLU . . . . . 0.494 ' HB2' ' HB2' ' A' ' 53' ' ' TYR . 66.7 mm-40 -117.69 162.91 17.27 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 110.115 -0.328 . . . . 0.0 110.115 179.02 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -84.08 166.25 42.34 Favored Glycine 0 N--CA 1.441 -0.972 0 C-N-CA 120.282 -0.961 . . . . 0.0 111.784 179.114 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 23.1 Cg_exo -65.82 139.78 58.61 Favored 'Trans proline' 0 N--CA 1.462 -0.348 0 C-N-CA 122.459 2.106 . . . . 0.0 111.912 178.921 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 38.3 pt -128.88 161.29 38.36 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.792 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.386 178.85 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -74.8 134.48 17.41 Favored Glycine 0 N--CA 1.446 -0.669 0 N-CA-C 111.331 -0.707 . . . . 0.0 111.331 179.984 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 52.6 t80 -117.46 125.98 51.84 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-O 121.034 0.445 . . . . 0.0 111.562 -176.905 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 62' ' ' ARG . . . . . 0.405 ' HA ' ' O ' ' A' ' 47' ' ' LEU . 64.0 ttp85 -136.53 129.08 30.42 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.857 -0.61 . . . . 0.0 109.747 174.737 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.502 ' O ' ' HA ' ' A' ' 46' ' ' THR . . . -129.41 139.3 51.7 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 116.563 -0.289 . . . . 0.0 110.966 -177.748 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 40.6 m -122.29 128.72 51.41 Favored 'General case' 0 C--N 1.323 -0.544 0 O-C-N 123.512 0.507 . . . . 0.0 109.74 178.534 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 52.6 tp -75.58 119.28 19.42 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 112.388 0.514 . . . . 0.0 112.388 -177.082 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 84.6 mt -84.18 -27.61 27.94 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.453 -0.794 . . . . 0.0 109.438 174.847 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 129.81 158.86 9.59 Favored Glycine 0 N--CA 1.442 -0.901 0 CA-C-N 115.109 -0.95 . . . . 0.0 110.81 -178.861 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 93.0 m-20 60.89 37.29 18.55 Favored 'General case' 0 N--CA 1.476 0.86 0 CA-C-O 120.848 0.356 . . . . 0.0 111.242 178.969 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 91.6 m-20 66.37 8.15 5.48 Favored 'General case' 0 N--CA 1.485 1.309 0 C-N-CA 123.244 0.618 . . . . 0.0 112.151 179.237 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 15.8 m -92.18 121.84 34.09 Favored 'General case' 0 N--CA 1.446 -0.666 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 178.703 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 64.8 m-85 -113.58 132.73 55.62 Favored 'General case' 0 C--N 1.312 -1.04 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.999 -178.942 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 63.2 tt0 -86.96 119.76 27.51 Favored 'General case' 0 N--CA 1.438 -1.035 0 N-CA-C 106.763 -1.569 . . . . 0.0 106.763 172.952 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 79.2 t -107.27 134.51 48.76 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 CA-C-O 121.182 0.515 . . . . 0.0 112.086 -172.824 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 87.6 mt-10 -127.37 129.61 47.9 Favored 'General case' 0 N--CA 1.438 -1.072 0 N-CA-C 107.703 -1.221 . . . . 0.0 107.703 176.363 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 48.9 m-80 -112.42 154.79 25.26 Favored 'General case' 0 C--N 1.314 -0.971 0 CA-C-O 120.967 0.413 . . . . 0.0 111.041 -176.68 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 63.1 tt0 -115.45 119.95 37.91 Favored 'General case' 0 C--N 1.311 -1.099 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.152 -178.695 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 12.4 p90 -143.67 161.86 37.44 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.804 179.388 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 100.4 -7.21 58.06 Favored Glycine 0 N--CA 1.446 -0.674 0 C-N-CA 120.858 -0.687 . . . . 0.0 111.924 179.648 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 136.2 160.28 8.74 Favored Glycine 0 N--CA 1.44 -1.081 0 N-CA-C 111.574 -0.611 . . . . 0.0 111.574 179.92 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 15.7 t70 -59.74 -41.78 91.69 Favored 'General case' 0 C--N 1.319 -0.737 0 C-N-CA 123.115 0.566 . . . . 0.0 112.085 179.626 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 50.6 p -76.71 -3.97 40.79 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 112.573 0.583 . . . . 0.0 112.573 -179.205 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -76.52 150.74 82.5 Favored Pre-proline 0 C--N 1.325 -0.46 0 CA-C-O 120.518 0.199 . . . . 0.0 110.945 -179.686 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -74.07 -178.55 3.95 Favored 'Trans proline' 0 C--O 1.239 0.54 0 C-N-CA 122.633 2.222 . . . . 0.0 112.083 179.212 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 84' ' ' TRP . . . . . . . . . . . . . 89.0 m95 -95.77 140.24 30.85 Favored 'General case' 0 N--CA 1.444 -0.729 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.352 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 89.5 m-70 -118.26 142.98 46.92 Favored 'General case' 0 C--N 1.31 -1.117 0 CA-C-N 116.273 -0.421 . . . . 0.0 109.949 179.878 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 11.8 p -62.85 134.26 55.97 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.843 0.354 . . . . 0.0 111.161 -178.366 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 87' ' ' GLY . . . . . 0.499 ' O ' ' HA ' ' A' ' 28' ' ' ARG . . . -107.89 -46.43 1.03 Allowed Glycine 0 N--CA 1.438 -1.167 0 C-N-CA 120.971 -0.633 . . . . 0.0 111.909 179.76 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 148.39 -168.0 29.08 Favored Glycine 0 C--O 1.225 -0.44 0 C-N-CA 120.031 -1.081 . . . . 0.0 112.733 178.24 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 24.9 t-20 -106.0 117.05 33.02 Favored 'General case' 0 C--N 1.321 -0.674 0 N-CA-C 110.054 -0.35 . . . . 0.0 110.054 -179.012 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 90' ' ' TRP . . . . . 0.571 ' CZ3' HG23 ' A' ' 25' ' ' ILE . 18.6 m0 -113.56 148.21 36.56 Favored 'General case' 0 C--N 1.317 -0.818 0 N-CA-C 109.284 -0.635 . . . . 0.0 109.284 179.887 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 85.6 mt -105.32 117.89 51.8 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.843 0 N-CA-C 109.547 -0.538 . . . . 0.0 109.547 179.064 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 86.0 mt -129.26 78.61 1.86 Allowed 'General case' 0 C--O 1.265 1.92 0 CA-C-O 121.863 0.839 . . . . 0.0 112.092 -177.76 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 170.05 124.45 0.74 Allowed Glycine 0 N--CA 1.441 -0.987 0 CA-C-N 114.757 -1.111 . . . . 0.0 110.722 178.996 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 94' ' ' SER . . . . . 0.681 ' HB2' ' O ' ' A' ' 20' ' ' GLY . 83.7 p -106.42 -7.61 17.53 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-O 120.898 0.38 . . . . 0.0 111.665 -179.55 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 95' ' ' ARG . . . . . 0.424 HH12 ' CD ' ' A' ' 123' ' ' GLU . 99.5 mtt180 -106.76 154.61 20.73 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 121.269 0.557 . . . . 0.0 112.091 178.871 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 26.8 tp10 -68.62 -38.83 80.89 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 114.965 -1.016 . . . . 0.0 111.061 -174.258 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 10.1 p30 -116.17 21.06 13.96 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.925 -177.076 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 98' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -136.75 115.82 12.42 Favored 'General case' 0 C--N 1.32 -0.697 0 C-N-CA 119.573 -0.851 . . . . 0.0 112.89 -176.46 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 14.3 m120 -92.44 154.76 18.3 Favored 'General case' 0 C--O 1.249 1.057 0 CA-C-N 115.029 -0.987 . . . . 0.0 109.353 177.488 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.427 HG21 ' CH2' ' A' ' 23' ' ' TRP . 85.2 t -79.75 130.8 35.49 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.555 0 C-N-CA 120.092 -0.643 . . . . 0.0 110.899 178.492 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 101' ' ' VAL . . . . . 0.433 HG11 ' HA ' ' A' ' 121' ' ' ALA . 33.7 m -111.74 -19.18 7.08 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.438 0 N-CA-C 112.122 0.415 . . . . 0.0 112.122 -179.654 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 102' ' ' ALA . . . . . 0.639 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -152.12 140.07 20.08 Favored 'General case' 0 CA--C 1.511 -0.537 0 C-N-CA 119.899 -0.72 . . . . 0.0 111.588 176.975 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.413 ' HB ' ' CG2' ' A' ' 38' ' ' VAL . 95.4 mt -135.49 125.01 41.75 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.175 177.456 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 52.6 t30 -129.74 101.22 5.8 Favored 'General case' 0 C--N 1.315 -0.931 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 175.801 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.449 ' CG2' ' HB ' ' A' ' 36' ' ' ILE . 19.8 m -140.9 142.8 29.51 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.791 0 N-CA-C 113.195 0.813 . . . . 0.0 113.195 -175.547 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 99.9 mt-10 -141.58 151.25 43.02 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 114.911 -1.04 . . . . 0.0 108.615 176.507 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 36.5 t -130.12 146.94 51.81 Favored 'General case' 0 C--N 1.311 -1.106 0 CA-C-O 121.244 0.545 . . . . 0.0 111.871 -177.817 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -89.61 -10.98 64.63 Favored Glycine 0 N--CA 1.444 -0.792 0 N-CA-C 110.366 -1.094 . . . . 0.0 110.366 174.435 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 83.6 m-20 -94.16 -172.06 2.71 Favored 'General case' 0 CA--C 1.513 -0.48 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 178.28 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 13.5 p-10 -95.74 33.86 1.59 Allowed 'General case' 0 C--N 1.313 -0.988 0 CA-C-O 121.031 0.443 . . . . 0.0 109.986 176.884 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 111' ' ' GLY . . . . . 0.515 ' HA3' ' HB3' ' A' ' 32' ' ' ASN . . . 97.42 8.56 56.15 Favored Glycine 0 C--N 1.333 0.406 0 CA-C-N 115.825 -0.625 . . . . 0.0 113.803 179.13 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 28.3 tt0 -64.72 -40.88 96.08 Favored 'General case' 0 C--O 1.241 0.621 0 CA-C-O 121.537 0.684 . . . . 0.0 109.858 178.383 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 73.2 p -135.58 146.93 48.47 Favored 'General case' 0 N--CA 1.446 -0.651 0 CA-C-N 114.841 -1.072 . . . . 0.0 109.483 178.306 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 96.0 mt -119.97 126.47 50.93 Favored 'General case' 0 C--N 1.312 -1.06 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 178.951 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 86.5 m-20 -122.99 143.57 49.84 Favored 'General case' 0 C--N 1.317 -0.835 0 N-CA-C 110.01 -0.367 . . . . 0.0 110.01 -178.963 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 161.19 -142.11 7.83 Favored Glycine 0 N--CA 1.448 -0.513 0 C-N-CA 119.747 -1.216 . . . . 0.0 113.303 177.3 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 23.6 p -131.47 156.95 44.75 Favored 'General case' 0 C--N 1.316 -0.849 0 C-N-CA 122.919 0.488 . . . . 0.0 110.819 -178.709 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 19.9 ptm -149.69 157.08 42.9 Favored 'General case' 0 C--N 1.314 -0.945 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.152 179.955 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 119' ' ' THR . . . . . 0.639 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 40.6 m -132.0 130.31 41.24 Favored 'General case' 0 C--O 1.245 0.841 0 CA-C-N 116.589 -0.278 . . . . 0.0 111.269 -179.176 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 11.7 m-85 -94.22 160.52 14.65 Favored 'General case' 0 N--CA 1.455 -0.197 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.883 176.616 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 121' ' ' ALA . . . . . 0.433 ' HA ' HG11 ' A' ' 101' ' ' VAL . . . -38.7 -45.14 1.08 Allowed 'General case' 0 N--CA 1.482 1.161 0 N-CA-C 114.149 1.166 . . . . 0.0 114.149 -177.245 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -145.63 43.01 0.94 Allowed Glycine 0 CA--C 1.506 -0.514 0 C-N-CA 120.084 -1.055 . . . . 0.0 111.713 -178.972 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 123' ' ' GLU . . . . . 0.424 ' CD ' HH12 ' A' ' 95' ' ' ARG . 28.5 tp10 -116.13 -61.95 1.66 Allowed 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 121.199 0.523 . . . . 0.0 110.714 -177.712 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 134.26 -179.0 17.97 Favored Glycine 0 N--CA 1.443 -0.836 0 N-CA-C 111.264 -0.734 . . . . 0.0 111.264 -178.503 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 62.0 Cg_endo -81.46 117.15 3.04 Favored 'Trans proline' 0 N--CA 1.455 -0.738 0 C-N-CA 122.424 2.082 . . . . 0.0 112.182 179.508 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 38.0 pt -126.22 161.2 32.44 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.922 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.415 -179.894 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -72.5 138.67 26.55 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.949 -0.643 . . . . 0.0 112.609 -178.732 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 77.8 t80 -114.82 132.23 56.56 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-O 121.061 0.458 . . . . 0.0 110.994 -179.153 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 129' ' ' LYS . . . . . 0.47 ' HB2' ' CZ3' ' A' ' 17' ' ' TRP . 86.9 tttt -134.28 101.33 4.97 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.098 177.43 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 130' ' ' GLY . . . . . 0.428 ' HA2' ' O ' ' A' ' 5' ' ' ASN . . . -109.44 150.41 17.26 Favored Glycine 0 N--CA 1.435 -1.38 0 C-N-CA 120.326 -0.94 . . . . 0.0 112.0 179.3 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 6.0 t -146.39 148.77 32.68 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-O 120.718 0.294 . . . . 0.0 111.15 179.21 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 83.4 mt -63.51 132.93 52.87 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.059 -0.518 . . . . 0.0 110.107 175.796 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 6.9 p . . . . . 0 C--O 1.249 1.051 0 CA-C-O 118.511 -0.756 . . . . 0.0 110.702 178.873 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.606 ' O ' ' HG3' ' A' ' 24' ' ' GLU . . . . . . . . 0 N--CA 1.475 0.825 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' LEU . . . . . 0.46 HD12 HG21 ' A' ' 133' ' ' THR . 0.3 OUTLIER -90.94 130.58 36.86 Favored 'General case' 0 C--N 1.313 -0.994 0 CA-C-O 121.064 0.459 . . . . 0.0 109.88 -174.58 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 4' ' ' TYR . . . . . 0.435 ' N ' HD13 ' A' ' 3' ' ' LEU . 28.5 m-85 -116.99 137.39 52.25 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-N 115.854 -0.612 . . . . 0.0 111.24 -179.989 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 20.8 t-20 -87.12 131.73 34.06 Favored 'General case' 0 C--N 1.306 -1.317 0 N-CA-C 106.577 -1.638 . . . . 0.0 106.577 176.884 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.522 HG21 ' CG ' ' A' ' 23' ' ' TRP . 58.6 t -114.72 126.16 72.21 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.854 0 N-CA-C 113.204 0.816 . . . . 0.0 113.204 -172.969 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.452 ' HG2' ' HB3' ' A' ' 19' ' ' GLU . 92.3 mt-10 -120.56 135.66 55.02 Favored 'General case' 0 N--CA 1.435 -1.195 0 CA-C-N 114.575 -1.193 . . . . 0.0 108.353 176.833 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 87.8 m-20 -120.22 144.53 47.68 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-O 120.899 0.381 . . . . 0.0 111.858 -176.226 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' GLN . . . . . 0.56 ' OE1' ' HA ' ' A' ' 13' ' ' SER . 36.4 tt0 -129.2 122.01 28.85 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.557 -0.747 . . . . 0.0 109.869 178.754 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 17.5 p90 -120.94 140.93 51.17 Favored 'General case' 0 C--N 1.314 -0.945 0 CA-C-O 121.337 0.589 . . . . 0.0 111.695 -179.845 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 107.24 -69.95 0.21 Allowed Glycine 0 N--CA 1.441 -1.009 0 CA-C-N 115.429 -0.805 . . . . 0.0 111.576 179.287 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -165.09 166.78 38.41 Favored Glycine 0 N--CA 1.442 -0.929 0 N-CA-C 111.612 -0.595 . . . . 0.0 111.612 179.467 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' SER . . . . . 0.56 ' HA ' ' OE1' ' A' ' 9' ' ' GLN . 11.5 p -60.04 -20.42 57.85 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 112.9 0.704 . . . . 0.0 112.9 -179.246 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 8.1 m -78.58 -5.59 53.23 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 120.642 0.258 . . . . 0.0 111.541 179.7 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -86.68 146.7 41.98 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 120.745 0.307 . . . . 0.0 111.359 -178.943 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -65.74 149.37 87.02 Favored 'Trans proline' 0 C--O 1.235 0.331 0 C-N-CA 122.823 2.349 . . . . 0.0 112.094 179.102 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 96.9 m95 -82.88 132.27 35.16 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 178.27 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 89.1 m-20 -120.67 122.84 41.33 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.43 -178.504 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.452 ' HB3' ' HG2' ' A' ' 7' ' ' GLU . 5.1 pt-20 -90.32 127.76 36.25 Favored 'General case' 0 C--N 1.313 -0.986 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 178.111 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -139.14 29.43 2.53 Favored Glycine 0 N--CA 1.445 -0.747 0 C-N-CA 119.761 -1.209 . . . . 0.0 112.611 -178.07 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 157.21 174.88 27.48 Favored Glycine 0 N--CA 1.438 -1.224 0 C-N-CA 120.381 -0.914 . . . . 0.0 112.458 179.829 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 28.6 pt20 -134.56 139.33 45.32 Favored 'General case' 0 C--N 1.314 -0.946 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 179.643 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' TRP . . . . . 0.53 ' HB3' ' O ' ' A' ' 91' ' ' ILE . 38.8 m0 -116.72 178.44 4.34 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.404 -176.715 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.606 ' HG3' ' O ' ' A' ' 2' ' ' ALA . 76.9 tt0 -131.58 121.48 24.46 Favored 'General case' 0 N--CA 1.441 -0.879 0 C-N-CA 120.371 -0.531 . . . . 0.0 110.447 174.899 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 91.3 mt -127.59 131.99 69.57 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.955 0 CA-C-N 115.349 -0.841 . . . . 0.0 109.479 -178.668 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 91.13 121.28 2.49 Favored Glycine 0 N--CA 1.441 -0.99 0 C-N-CA 120.474 -0.869 . . . . 0.0 112.356 179.637 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' SER . . . . . 0.499 ' CB ' ' HA3' ' A' ' 88' ' ' GLY . 6.3 m -119.44 11.54 12.18 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-O 121.277 0.56 . . . . 0.0 109.819 179.957 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 63.1 mtt-85 -141.07 141.84 34.22 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.391 -0.822 . . . . 0.0 109.21 -176.485 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 37.3 p -92.09 2.5 56.54 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-O 121.145 0.498 . . . . 0.0 111.344 -178.523 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 37.0 m-20 -62.31 -38.1 88.11 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.585 -0.734 . . . . 0.0 111.509 -178.839 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 1.3 tm0? -167.35 151.36 6.63 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.937 -177.276 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 32' ' ' ASN . . . . . 0.501 ' HB3' ' HA3' ' A' ' 111' ' ' GLY . 15.6 m120 -96.91 173.14 7.44 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.679 0.752 . . . . 0.0 111.239 179.375 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.474 HG11 HD11 ' A' ' 36' ' ' ILE . 17.2 t -102.85 134.22 44.47 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.256 0 CA-C-N 115.202 -0.908 . . . . 0.0 112.51 -175.144 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.44 HG13 ' HB2' ' A' ' 54' ' ' ALA . 27.0 m -121.11 -28.14 1.87 Allowed 'Isoleucine or valine' 0 C--O 1.255 1.352 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.602 174.946 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.674 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -140.31 140.33 35.63 Favored 'General case' 0 N--CA 1.442 -0.837 0 CA-C-O 121.38 0.609 . . . . 0.0 111.986 -178.706 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.474 HD11 HG11 ' A' ' 33' ' ' VAL . 93.7 mt -146.41 129.57 9.27 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 177.608 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -127.92 109.14 11.3 Favored 'General case' 0 C--N 1.311 -1.088 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 175.087 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.495 HG11 ' CD1' ' A' ' 61' ' ' PHE . 19.4 m -147.47 149.49 15.47 Favored 'Isoleucine or valine' 0 C--O 1.242 0.685 0 C-N-CA 120.874 -0.33 . . . . 0.0 111.343 -174.906 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 77.6 tt0 -138.82 144.9 39.51 Favored 'General case' 0 N--CA 1.443 -0.813 0 CA-C-N 115.72 -0.673 . . . . 0.0 109.279 178.043 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 37.0 p -69.76 140.87 53.47 Favored 'General case' 0 C--N 1.317 -0.817 0 N-CA-C 112.533 0.568 . . . . 0.0 112.533 -176.862 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -86.83 -62.39 1.53 Allowed Glycine 0 CA--C 1.502 -0.771 0 N-CA-C 109.113 -1.595 . . . . 0.0 109.113 174.628 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 51.0 m-20 -88.36 -169.2 2.46 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 173.988 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 70.9 m-20 -77.11 57.98 1.48 Allowed 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 112.462 0.542 . . . . 0.0 112.462 -177.946 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 97.02 -20.32 51.31 Favored Glycine 0 C--O 1.218 -0.857 0 C-N-CA 121.068 -0.587 . . . . 0.0 113.419 175.542 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 56.0 mt-30 -64.99 -34.07 77.55 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 112.89 0.7 . . . . 0.0 112.89 -177.754 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 46' ' ' THR . . . . . 0.525 ' HA ' ' O ' ' A' ' 63' ' ' ALA . 14.8 t -136.14 131.64 34.98 Favored 'General case' 0 N--CA 1.438 -1.049 0 C-N-CA 120.387 -0.525 . . . . 0.0 111.239 178.622 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 47' ' ' LEU . . . . . 0.414 ' O ' ' HA ' ' A' ' 62' ' ' ARG . 80.1 mt -111.01 133.03 53.72 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.837 -0.619 . . . . 0.0 109.508 179.384 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 64.0 m-80 -125.27 146.21 49.65 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-O 120.703 0.287 . . . . 0.0 110.706 179.238 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 163.34 -140.52 6.54 Favored Glycine 0 N--CA 1.439 -1.15 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.497 178.4 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 24.5 p -133.41 150.75 51.78 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 120.908 0.385 . . . . 0.0 111.21 -179.292 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 18.4 ttt -124.82 137.0 54.32 Favored 'General case' 0 C--N 1.32 -0.68 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 179.78 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.674 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 60.6 m -124.89 122.55 37.68 Favored 'General case' 0 C--O 1.259 1.592 0 CA-C-O 121.17 0.509 . . . . 0.0 111.799 -178.303 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 53' ' ' TYR . . . . . 0.428 ' HB2' ' HB2' ' A' ' 56' ' ' GLU . 98.1 m-85 -84.66 166.0 17.44 Favored 'General case' 0 CA--C 1.52 -0.201 0 CA-C-N 115.372 -0.831 . . . . 0.0 109.835 178.512 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 54' ' ' ALA . . . . . 0.44 ' HB2' HG13 ' A' ' 34' ' ' VAL . . . -67.94 110.69 3.99 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 120.952 0.406 . . . . 0.0 111.125 179.836 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 83.41 16.84 67.87 Favored Glycine 0 CA--C 1.522 0.493 0 C-N-CA 120.667 -0.778 . . . . 0.0 113.711 179.401 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 56' ' ' GLU . . . . . 0.428 ' HB2' ' HB2' ' A' ' 53' ' ' TYR . 98.1 mt-10 -132.01 163.24 28.83 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 117.339 0.569 . . . . 0.0 111.135 178.962 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -81.08 156.42 37.79 Favored Glycine 0 N--CA 1.447 -0.612 0 CA-C-N 115.955 -0.566 . . . . 0.0 112.603 -179.273 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 21.8 Cg_exo -64.62 142.56 77.86 Favored 'Trans proline' 0 C--N 1.347 0.467 0 C-N-CA 122.924 2.416 . . . . 0.0 112.81 -179.295 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 44.7 pt -125.91 167.66 19.98 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.872 0 CA-C-N 115.527 -0.76 . . . . 0.0 109.332 177.272 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -70.37 137.63 27.97 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.19 -1.005 . . . . 0.0 111.674 -178.952 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.495 ' CD1' HG11 ' A' ' 38' ' ' VAL . 50.2 t80 -127.71 128.42 45.37 Favored 'General case' 0 C--N 1.317 -0.847 0 CA-C-O 120.757 0.313 . . . . 0.0 110.831 -177.887 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 62' ' ' ARG . . . . . 0.414 ' HA ' ' O ' ' A' ' 47' ' ' LEU . 63.7 ttp85 -138.77 132.72 31.13 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.181 175.276 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.525 ' O ' ' HA ' ' A' ' 46' ' ' THR . . . -127.74 137.02 52.31 Favored 'General case' 0 C--N 1.311 -1.09 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.653 179.658 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 61.2 m -123.55 132.41 53.89 Favored 'General case' 0 C--N 1.315 -0.913 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 178.776 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 65' ' ' LEU . . . . . 0.622 HD21 ' O ' ' A' ' 68' ' ' ASN . 3.7 mt -60.5 128.17 35.33 Favored 'General case' 0 CA--C 1.501 -0.911 0 N-CA-C 113.928 1.085 . . . . 0.0 113.928 -178.13 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.445 HD11 ' OD1' ' A' ' 89' ' ' ASN . 96.1 mt -76.43 -34.72 58.77 Favored 'General case' 0 N--CA 1.431 -1.394 0 N-CA-C 107.27 -1.381 . . . . 0.0 107.27 169.004 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -166.91 -72.66 0.03 OUTLIER Glycine 0 N--CA 1.433 -1.564 0 C-N-CA 120.405 -0.903 . . . . 0.0 115.013 -179.504 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 68' ' ' ASN . . . . . 0.622 ' O ' HD21 ' A' ' 65' ' ' LEU . 17.0 m120 -125.3 -77.34 0.59 Allowed 'General case' 0 C--O 1.214 -0.782 0 CA-C-N 118.212 1.006 . . . . 0.0 110.202 -175.85 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 12.2 m120 -100.94 -6.31 24.77 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 120.898 0.38 . . . . 0.0 110.643 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 8.3 m -95.37 121.13 36.72 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.698 -178.134 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 71' ' ' TYR . . . . . 0.416 ' CE2' ' HG ' ' A' ' 65' ' ' LEU . 96.0 m-85 -115.9 150.21 37.44 Favored 'General case' 0 C--N 1.314 -0.937 0 CA-C-N 116.323 -0.399 . . . . 0.0 111.181 -178.657 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 70.4 tt0 -105.72 125.53 51.09 Favored 'General case' 0 C--N 1.31 -1.125 0 N-CA-C 107.451 -1.315 . . . . 0.0 107.451 173.499 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 65.3 t -104.8 132.27 51.9 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.388 0 CA-C-O 121.544 0.687 . . . . 0.0 112.471 -174.172 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 47.5 mt-10 -127.35 123.54 36.52 Favored 'General case' 0 N--CA 1.436 -1.161 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 176.631 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 97.5 m-20 -110.83 153.43 25.41 Favored 'General case' 0 C--N 1.317 -0.819 0 CA-C-O 121.229 0.538 . . . . 0.0 111.934 -176.018 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 76' ' ' GLN . . . . . 0.498 ' HB2' ' CE3' ' A' ' 84' ' ' TRP . 60.0 tt0 -113.98 116.43 29.21 Favored 'General case' 0 C--N 1.312 -1.05 0 CA-C-N 115.607 -0.724 . . . . 0.0 109.933 -178.589 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 13.4 p90 -142.72 160.59 40.01 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.157 179.446 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 94.68 -3.66 68.29 Favored Glycine 0 N--CA 1.449 -0.473 0 C-N-CA 120.599 -0.81 . . . . 0.0 112.073 -179.532 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 135.21 152.44 6.49 Favored Glycine 0 N--CA 1.446 -0.65 0 N-CA-C 111.469 -0.652 . . . . 0.0 111.469 179.38 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 25.7 t70 -62.71 -36.82 84.22 Favored 'General case' 0 N--CA 1.468 0.453 0 CA-C-O 120.869 0.366 . . . . 0.0 111.932 -179.71 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 29.3 p -69.65 -15.78 63.25 Favored 'General case' 0 C--N 1.316 -0.86 0 N-CA-C 112.125 0.417 . . . . 0.0 112.125 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -75.87 142.71 73.43 Favored Pre-proline 0 C--O 1.234 0.267 0 CA-C-N 116.478 -0.328 . . . . 0.0 110.884 -179.512 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 96.7 Cg_endo -73.59 156.25 49.5 Favored 'Trans proline' 0 N--CA 1.462 -0.353 0 C-N-CA 122.712 2.274 . . . . 0.0 111.819 178.731 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 84' ' ' TRP . . . . . 0.498 ' CE3' ' HB2' ' A' ' 76' ' ' GLN . 81.7 m95 -60.98 138.31 58.18 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.305 0.574 . . . . 0.0 111.543 179.615 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 99.1 m-70 -113.03 144.65 42.24 Favored 'General case' 0 C--N 1.311 -1.096 0 CA-C-N 115.213 -0.903 . . . . 0.0 109.208 178.344 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 12.9 p -61.46 125.75 24.9 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-O 121.192 0.52 . . . . 0.0 111.941 -177.293 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -96.42 -48.85 2.11 Favored Glycine 0 N--CA 1.441 -1.032 0 CA-C-N 115.595 -0.73 . . . . 0.0 111.532 179.747 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 88' ' ' GLY . . . . . 0.499 ' HA3' ' CB ' ' A' ' 27' ' ' SER . . . 149.86 -167.17 29.92 Favored Glycine 0 C--O 1.216 -1.027 0 N-CA-C 111.326 -0.71 . . . . 0.0 111.326 178.405 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 89' ' ' ASN . . . . . 0.445 ' OD1' HD11 ' A' ' 66' ' ' LEU . 56.7 m-80 -108.53 140.84 41.3 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 117.379 0.59 . . . . 0.0 110.867 179.35 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 90' ' ' TRP . . . . . 0.435 ' HD1' ' C ' ' A' ' 89' ' ' ASN . 29.4 m0 -133.69 160.62 36.99 Favored 'General case' 0 N--CA 1.465 0.298 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 -177.16 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.53 ' O ' ' HB3' ' A' ' 23' ' ' TRP . 96.9 mt -121.19 121.6 65.31 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.035 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 175.806 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 83.7 mt -134.63 82.93 1.99 Allowed 'General case' 0 C--O 1.267 1.979 0 N-CA-C 112.765 0.654 . . . . 0.0 112.765 -175.414 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 164.64 118.5 0.44 Allowed Glycine 0 N--CA 1.448 -0.536 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.81 177.954 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 43.1 m -90.64 -0.14 57.58 Favored 'General case' 0 N--CA 1.463 0.211 0 CA-C-O 121.11 0.481 . . . . 0.0 110.64 177.922 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -120.02 152.16 37.91 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 178.788 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 78.1 tt0 -66.06 -65.44 0.68 Allowed 'General case' 0 C--N 1.32 -0.71 0 N-CA-C 112.6 0.593 . . . . 0.0 112.6 -174.86 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 93.5 m-20 -107.15 36.9 2.52 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 116.271 -0.422 . . . . 0.0 112.026 -175.409 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 98' ' ' GLN . . . . . 0.403 ' CG ' ' HB3' ' A' ' 120' ' ' TYR . 14.5 tp60 -108.67 -62.33 1.48 Allowed 'General case' 0 C--N 1.316 -0.885 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 179.646 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 91.7 m-20 71.87 149.98 0.1 Allowed 'General case' 0 C--O 1.248 1.013 0 CA-C-N 115.225 -0.898 . . . . 0.0 112.942 178.258 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 76.6 t -81.66 132.14 32.19 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.335 0 CA-C-N 115.44 -0.8 . . . . 0.0 111.191 178.279 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 26.8 m -114.49 -21.57 5.3 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.185 0 CA-C-N 116.004 -0.544 . . . . 0.0 112.356 179.571 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 102' ' ' ALA . . . . . 0.522 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -150.09 141.44 23.27 Favored 'General case' 0 C--N 1.326 -0.444 0 C-N-CA 120.161 -0.615 . . . . 0.0 111.596 178.601 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.463 ' HB ' HG22 ' A' ' 38' ' ' VAL . 32.2 mm -134.61 127.21 49.33 Favored 'Isoleucine or valine' 0 C--O 1.244 0.766 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.863 178.429 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 50.4 t30 -131.76 97.38 4.18 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.782 -0.645 . . . . 0.0 109.867 175.277 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.59 ' O ' ' HA ' ' A' ' 35' ' ' ALA . 15.5 m -130.51 135.06 61.28 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.029 0 CA-C-N 115.775 -0.648 . . . . 0.0 111.162 -176.926 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 52.8 mt-10 -139.1 27.45 2.37 Favored 'General case' 0 N--CA 1.486 1.371 0 CA-C-O 121.526 0.679 . . . . 0.0 110.953 -178.841 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 107' ' ' SER . . . . . 0.633 ' HB2' ' HB2' ' A' ' 115' ' ' ASN . 53.7 m -139.1 147.34 41.85 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 114.259 1.207 . . . . 0.0 114.259 -175.1 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 148.71 122.06 1.2 Allowed Glycine 0 N--CA 1.436 -1.341 0 CA-C-N 114.624 -1.171 . . . . 0.0 111.84 178.268 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -83.29 107.67 15.98 Favored 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 178.657 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 59.58 18.13 6.77 Favored 'General case' 0 N--CA 1.481 1.084 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.275 -177.446 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 111' ' ' GLY . . . . . 0.501 ' HA3' ' HB3' ' A' ' 32' ' ' ASN . . . 80.06 15.39 78.96 Favored Glycine 0 N--CA 1.442 -0.913 0 CA-C-N 115.818 -0.628 . . . . 0.0 112.838 179.006 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 112' ' ' GLN . . . . . 0.525 ' HA ' HD12 ' A' ' 132' ' ' LEU . 52.2 tt0 -64.15 -37.52 87.74 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-O 121.799 0.809 . . . . 0.0 109.138 177.607 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 60.5 p -133.93 164.25 27.71 Favored 'General case' 0 N--CA 1.431 -1.422 0 CA-C-N 114.56 -1.2 . . . . 0.0 108.724 177.354 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 114' ' ' LEU . . . . . 0.41 ' HA ' ' O ' ' A' ' 107' ' ' SER . 33.8 tp -134.84 114.69 12.84 Favored 'General case' 0 C--N 1.301 -1.519 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 176.937 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 115' ' ' ASN . . . . . 0.633 ' HB2' ' HB2' ' A' ' 107' ' ' SER . 1.4 m-20 -116.9 143.7 45.39 Favored 'General case' 0 C--O 1.263 1.81 0 C-N-CA 120.117 -0.633 . . . . 0.0 111.577 -176.31 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 165.02 -138.31 5.18 Favored Glycine 0 N--CA 1.437 -1.298 0 CA-C-N 115.164 -0.925 . . . . 0.0 112.25 177.208 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 29.8 p -130.51 155.48 46.4 Favored 'General case' 0 C--N 1.307 -1.265 0 C-N-CA 122.792 0.437 . . . . 0.0 109.986 -179.221 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 118' ' ' MET . . . . . 0.404 ' HE3' ' HB2' ' A' ' 118' ' ' MET . 18.0 ptm -146.94 153.32 39.95 Favored 'General case' 0 C--N 1.309 -1.194 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.465 -179.065 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 119' ' ' THR . . . . . 0.522 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 25.9 m -132.83 129.8 38.97 Favored 'General case' 0 C--O 1.248 1.0 0 CA-C-N 116.487 -0.324 . . . . 0.0 111.368 -179.811 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 120' ' ' TYR . . . . . 0.518 ' HB2' ' HB3' ' A' ' 123' ' ' GLU . 57.2 m-85 -94.1 159.16 15.27 Favored 'General case' 0 CA--C 1.516 -0.35 0 CA-C-N 115.746 -0.661 . . . . 0.0 109.58 175.298 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -66.27 134.39 52.56 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 109.662 -0.496 . . . . 0.0 109.662 176.284 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 64.95 22.44 68.6 Favored Glycine 0 CA--C 1.523 0.532 0 C-N-CA 120.815 -0.707 . . . . 0.0 113.113 -179.856 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 123' ' ' GLU . . . . . 0.518 ' HB3' ' HB2' ' A' ' 120' ' ' TYR . 39.3 tp10 -137.87 161.86 35.51 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 -178.172 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -89.06 156.51 26.28 Favored Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.284 -0.96 . . . . 0.0 111.84 178.617 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_exo -60.6 134.28 53.52 Favored 'Trans proline' 0 C--N 1.349 0.6 0 C-N-CA 122.394 2.062 . . . . 0.0 111.707 178.743 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 39.7 pt -131.57 165.44 31.71 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.812 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.51 -178.91 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -73.87 139.23 25.91 Favored Glycine 0 N--CA 1.445 -0.726 0 C-N-CA 121.206 -0.521 . . . . 0.0 112.003 179.717 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 92.2 t80 -117.35 132.63 56.56 Favored 'General case' 0 C--O 1.244 0.794 0 CA-C-O 120.974 0.416 . . . . 0.0 111.083 -178.697 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 61.7 tttm -135.48 102.37 5.11 Favored 'General case' 0 N--CA 1.442 -0.865 0 CA-C-N 115.567 -0.742 . . . . 0.0 109.694 177.867 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -100.58 140.7 15.04 Favored Glycine 0 CA--C 1.503 -0.67 0 N-CA-C 110.793 -0.923 . . . . 0.0 110.793 178.25 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 45.5 m -136.69 133.4 36.12 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-N 117.224 0.512 . . . . 0.0 111.059 179.881 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 132' ' ' LEU . . . . . 0.525 HD12 ' HA ' ' A' ' 112' ' ' GLN . 78.8 mt -60.71 129.91 43.86 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-O 120.907 0.384 . . . . 0.0 110.363 177.21 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 133' ' ' THR . . . . . 0.46 HG21 HD12 ' A' ' 3' ' ' LEU . 5.3 t . . . . . 0 C--O 1.247 0.958 0 CA-C-O 118.244 -0.884 . . . . 0.0 110.13 -179.037 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.72 0 N-CA-C 110.246 -0.279 . . . . 0.0 110.246 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' LEU . . . . . 0.412 HD13 ' N ' ' A' ' 4' ' ' TYR . 2.3 tm? -91.43 128.32 37.21 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 -177.918 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . 0.453 ' CE2' ' HB ' ' A' ' 25' ' ' ILE . 83.1 m-85 -119.31 146.77 45.0 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-O 120.991 0.424 . . . . 0.0 111.645 -179.632 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 49.0 m-80 -97.31 138.74 34.32 Favored 'General case' 0 C--N 1.315 -0.932 0 N-CA-C 107.213 -1.403 . . . . 0.0 107.213 175.89 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 69.7 t -115.95 126.7 73.57 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.878 0 N-CA-C 113.108 0.781 . . . . 0.0 113.108 -175.17 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 94.4 mt-10 -120.72 135.66 55.07 Favored 'General case' 0 N--CA 1.443 -0.811 0 CA-C-N 114.817 -1.083 . . . . 0.0 108.21 175.21 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 12.7 m120 -125.44 148.43 48.82 Favored 'General case' 0 C--N 1.313 -0.994 0 CA-C-O 121.042 0.449 . . . . 0.0 111.738 -176.665 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 58.0 tt0 -125.92 119.38 27.61 Favored 'General case' 0 C--N 1.316 -0.857 0 N-CA-C 107.471 -1.307 . . . . 0.0 107.471 177.143 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 39.3 p90 -142.04 9.74 1.92 Allowed 'General case' 0 C--N 1.319 -0.721 0 N-CA-C 114.404 1.261 . . . . 0.0 114.404 -174.814 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -120.96 18.15 9.1 Favored Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 118.351 -1.881 . . . . 0.0 112.075 -176.767 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 110.83 159.58 16.47 Favored Glycine 0 N--CA 1.443 -0.879 0 C-N-CA 120.859 -0.686 . . . . 0.0 112.203 -179.761 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 41.3 m -56.18 -33.23 65.07 Favored 'General case' 0 C--N 1.323 -0.57 0 C-N-CA 122.74 0.416 . . . . 0.0 111.967 178.855 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 20.3 m -68.21 -14.18 62.79 Favored 'General case' 0 CA--C 1.539 0.535 0 CA-C-N 116.582 -0.281 . . . . 0.0 111.499 178.454 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -96.86 138.66 21.34 Favored Pre-proline 0 C--N 1.323 -0.549 0 N-CA-C 110.013 -0.366 . . . . 0.0 110.013 178.597 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_endo -77.9 -171.78 1.29 Allowed 'Trans proline' 0 CA--C 1.534 0.52 0 C-N-CA 122.954 2.436 . . . . 0.0 113.01 -178.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 96.9 m95 -91.34 136.06 33.37 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.103 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 90.8 m-20 -119.71 122.14 40.78 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.103 -179.288 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 75.3 tt0 -78.23 132.03 37.37 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 115.924 -0.58 . . . . 0.0 109.64 178.07 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.441 ' O ' ' HB2' ' A' ' 94' ' ' SER . . . -137.1 29.8 2.69 Favored Glycine 0 N--CA 1.447 -0.612 0 C-N-CA 119.565 -1.303 . . . . 0.0 113.547 -178.919 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 137.33 179.43 16.85 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.023 -1.084 . . . . 0.0 113.333 178.564 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 98.9 mt-30 -123.02 147.56 46.53 Favored 'General case' 0 C--N 1.327 -0.384 0 C-N-CA 122.796 0.438 . . . . 0.0 110.099 179.351 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . 0.424 ' HE1' ' HB3' ' A' ' 94' ' ' SER . 45.5 m0 -121.83 171.81 8.62 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 178.813 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -127.23 117.41 22.25 Favored 'General case' 0 C--N 1.317 -0.829 0 C-N-CA 120.635 -0.426 . . . . 0.0 110.144 175.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.453 ' HB ' ' CE2' ' A' ' 4' ' ' TYR . 99.1 mt -133.98 144.49 35.39 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 CA-C-N 115.559 -0.746 . . . . 0.0 109.677 -177.827 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 81.57 35.64 22.1 Favored Glycine 0 CA--C 1.506 -0.487 0 C-N-CA 120.231 -0.985 . . . . 0.0 111.921 179.536 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 11.4 m -74.05 21.62 0.09 Allowed 'General case' 0 C--N 1.317 -0.823 0 N-CA-C 111.9 0.333 . . . . 0.0 111.9 179.83 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . 0.481 ' NH1' ' HG3' ' A' ' 31' ' ' GLN . 54.4 ttt180 -92.61 10.46 30.36 Favored 'General case' 0 CA--C 1.544 0.748 0 CA-C-O 121.686 0.755 . . . . 0.0 109.075 178.807 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 29.3 m 72.57 -79.67 0.04 OUTLIER 'General case' 0 CA--C 1.541 0.619 0 CA-C-N 114.802 -1.09 . . . . 0.0 113.288 176.135 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 28.4 m-20 -88.98 2.68 53.57 Favored 'General case' 0 N--CA 1.473 0.683 0 N-CA-C 113.106 0.78 . . . . 0.0 113.106 -175.222 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . 0.481 ' HG3' ' NH1' ' A' ' 28' ' ' ARG . 8.4 mm-40 -122.47 117.18 25.34 Favored 'General case' 0 C--N 1.309 -1.167 0 N-CA-C 113.394 0.887 . . . . 0.0 113.394 -178.869 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . 0.587 ' OD1' ' HA3' ' A' ' 111' ' ' GLY . 28.2 t-20 -92.39 145.16 24.68 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 114.932 -1.031 . . . . 0.0 110.376 177.163 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.438 HG21 ' CH2' ' A' ' 90' ' ' TRP . 53.3 t -97.62 131.95 43.42 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.148 0 CA-C-N 115.586 -0.734 . . . . 0.0 111.089 -178.814 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 29.1 m -109.36 -19.15 7.04 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.155 0 N-CA-C 112.361 0.504 . . . . 0.0 112.361 -179.597 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.479 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -148.3 143.4 26.89 Favored 'General case' 0 CA--C 1.515 -0.383 0 C-N-CA 120.403 -0.519 . . . . 0.0 111.228 179.078 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.434 ' HB ' HG22 ' A' ' 105' ' ' VAL . 90.9 mt -142.68 122.04 9.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.215 -178.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 11.7 m120 -127.7 106.78 9.37 Favored 'General case' 0 C--N 1.313 -0.989 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 175.141 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.506 HG11 ' CD1' ' A' ' 61' ' ' PHE . 29.2 m -149.17 154.53 9.44 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 C-N-CA 120.79 -0.364 . . . . 0.0 111.463 -173.693 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 73.8 tt0 -147.61 152.42 37.87 Favored 'General case' 0 N--CA 1.442 -0.844 0 N-CA-C 109.284 -0.635 . . . . 0.0 109.284 176.471 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 33.2 p -83.25 130.33 35.07 Favored 'General case' 0 C--N 1.312 -1.028 0 CA-C-N 116.498 -0.319 . . . . 0.0 111.78 -177.541 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -71.58 -43.41 52.65 Favored Glycine 0 N--CA 1.445 -0.712 0 N-CA-C 110.197 -1.161 . . . . 0.0 110.197 174.681 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 57.2 m-20 -104.71 -152.91 0.47 Allowed 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 114.898 -0.651 . . . . 0.0 109.764 178.338 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -74.81 40.27 0.14 Allowed 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 123.683 0.793 . . . . 0.0 111.308 -179.907 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.413 ' O ' ' HE2' ' A' ' 71' ' ' TYR . . . 92.92 -6.83 76.83 Favored Glycine 0 C--O 1.217 -0.924 0 C-N-CA 121.032 -0.604 . . . . 0.0 112.419 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 57.5 mt-30 -65.08 -38.84 92.05 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 112.736 0.643 . . . . 0.0 112.736 -178.086 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 5.4 t -126.06 110.84 14.01 Favored 'General case' 0 C--N 1.306 -1.285 0 CA-C-O 121.135 0.493 . . . . 0.0 110.515 179.806 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' LEU . . . . . 0.412 ' O ' ' HA ' ' A' ' 62' ' ' ARG . 79.4 mt -96.72 127.61 42.87 Favored 'General case' 0 C--N 1.316 -0.885 0 N-CA-C 108.936 -0.764 . . . . 0.0 108.936 177.354 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 24.7 p30 -135.28 152.84 51.89 Favored 'General case' 0 C--N 1.308 -1.204 0 CA-C-O 121.008 0.432 . . . . 0.0 110.966 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 162.53 -144.15 9.39 Favored Glycine 0 N--CA 1.438 -1.17 0 C-N-CA 120.447 -0.882 . . . . 0.0 112.683 179.258 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 61.6 m -127.91 130.9 49.26 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-O 120.94 0.4 . . . . 0.0 110.126 -178.013 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' MET . . . . . 0.509 ' HE2' ' HD2' ' A' ' 61' ' ' PHE . 15.0 tmm? -130.39 148.19 52.18 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-N 116.491 -0.322 . . . . 0.0 110.203 -178.414 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.479 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 30.5 m -126.21 128.2 46.86 Favored 'General case' 0 C--O 1.249 1.076 0 CA-C-O 120.909 0.385 . . . . 0.0 111.967 -176.849 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . 0.444 ' CD1' ' HB3' ' A' ' 31' ' ' GLN . 52.1 m-85 -88.15 163.21 16.3 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-N 115.676 -0.693 . . . . 0.0 110.768 177.186 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -65.05 127.45 31.68 Favored 'General case' 0 C--O 1.24 0.571 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.078 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 76.45 3.64 78.19 Favored Glycine 0 N--CA 1.446 -0.67 0 CA-C-N 115.9 -0.591 . . . . 0.0 112.766 179.032 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 78.7 mm-40 -120.3 178.89 4.48 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-O 120.828 0.347 . . . . 0.0 111.075 -177.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -101.98 174.17 24.08 Favored Glycine 0 N--CA 1.437 -1.241 0 N-CA-C 111.157 -0.777 . . . . 0.0 111.157 178.507 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_endo -66.68 137.71 46.79 Favored 'Trans proline' 0 CA--C 1.531 0.359 0 C-N-CA 122.217 1.944 . . . . 0.0 112.538 179.709 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 44.2 pt -133.61 171.73 17.52 Favored 'Isoleucine or valine' 0 C--O 1.241 0.644 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.356 179.084 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -74.67 138.11 23.44 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.684 -0.77 . . . . 0.0 111.974 -178.835 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.509 ' HD2' ' HE2' ' A' ' 51' ' ' MET . 55.4 t80 -127.01 129.57 48.33 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-O 120.488 0.185 . . . . 0.0 110.91 -178.94 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . 0.412 ' HA ' ' O ' ' A' ' 47' ' ' LEU . 59.9 ttp85 -141.74 133.05 26.51 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.305 -0.407 . . . . 0.0 109.96 175.978 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.536 ' HB1' ' HB3' ' A' ' 71' ' ' TYR . . . -133.53 139.85 46.86 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.67 -0.241 . . . . 0.0 111.373 -179.969 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 25.2 m -113.67 127.53 56.08 Favored 'General case' 0 CA--C 1.539 0.555 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.482 -179.286 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 58.0 tp -72.44 125.52 27.61 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 112.422 0.527 . . . . 0.0 112.422 -178.276 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 86.9 mt -76.28 -25.78 55.24 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.671 -0.695 . . . . 0.0 110.541 176.249 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 118.27 0.3 16.47 Favored Glycine 0 C--N 1.337 0.596 0 C-N-CA 120.808 -0.711 . . . . 0.0 113.175 178.761 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 29.0 p-10 -135.03 37.59 3.01 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-O 120.919 0.39 . . . . 0.0 111.008 -178.171 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 97.1 m-20 69.29 4.31 4.55 Favored 'General case' 0 N--CA 1.488 1.431 0 C-N-CA 123.417 0.687 . . . . 0.0 111.735 -177.708 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 16.3 t -95.43 126.07 40.48 Favored 'General case' 0 N--CA 1.435 -1.198 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 177.486 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.536 ' HB3' ' HB1' ' A' ' 63' ' ' ALA . 95.7 m-85 -116.98 129.31 55.95 Favored 'General case' 0 C--N 1.309 -1.172 0 CA-C-N 116.411 -0.359 . . . . 0.0 111.405 -178.023 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -81.52 116.25 21.21 Favored 'General case' 0 C--N 1.315 -0.907 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 175.144 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 54.2 t -102.53 132.96 47.52 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.198 0 N-CA-C 113.215 0.82 . . . . 0.0 113.215 -173.235 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 49.2 mt-10 -127.37 145.78 50.69 Favored 'General case' 0 N--CA 1.44 -0.933 0 CA-C-N 114.267 -1.333 . . . . 0.0 108.666 177.919 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 13.5 m120 -123.77 149.5 45.55 Favored 'General case' 0 C--N 1.316 -0.848 0 N-CA-C 110.246 -0.279 . . . . 0.0 110.246 -176.216 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' GLN . . . . . 0.444 ' HB2' ' CE3' ' A' ' 84' ' ' TRP . 63.1 tt0 -121.83 124.9 45.25 Favored 'General case' 0 C--N 1.315 -0.908 0 CA-C-N 116.464 -0.335 . . . . 0.0 110.385 179.724 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 8.3 p90 -144.05 162.73 35.49 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.876 -0.602 . . . . 0.0 109.628 179.063 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 101.17 -13.04 58.8 Favored Glycine 0 C--N 1.316 -0.583 0 C-N-CA 120.898 -0.667 . . . . 0.0 112.766 179.821 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 125.22 174.87 14.06 Favored Glycine 0 N--CA 1.444 -0.769 0 C-N-CA 120.505 -0.855 . . . . 0.0 112.367 178.626 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 7.5 p-10 -63.43 -34.59 78.08 Favored 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 112.303 0.483 . . . . 0.0 112.303 -179.581 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 73.1 p -78.95 -6.54 56.5 Favored 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 111.965 0.358 . . . . 0.0 111.965 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -85.34 146.18 44.21 Favored Pre-proline 0 C--N 1.322 -0.624 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.796 -179.95 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 84.5 Cg_endo -80.37 -175.09 2.52 Favored 'Trans proline' 0 C--O 1.236 0.404 0 C-N-CA 122.777 2.318 . . . . 0.0 112.768 -179.408 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' TRP . . . . . 0.444 ' CE3' ' HB2' ' A' ' 76' ' ' GLN . 90.5 m95 -94.9 144.87 25.32 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.793 -0.64 . . . . 0.0 109.979 179.412 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 87.9 m-70 -124.52 142.26 51.47 Favored 'General case' 0 C--N 1.316 -0.859 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 179.225 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 22.6 p -61.78 133.87 56.04 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-O 120.911 0.386 . . . . 0.0 111.5 -179.11 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -106.27 -46.26 1.17 Allowed Glycine 0 N--CA 1.445 -0.739 0 C-N-CA 120.667 -0.778 . . . . 0.0 111.639 178.859 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 156.25 -171.74 34.03 Favored Glycine 0 C--O 1.221 -0.685 0 C-N-CA 120.777 -0.725 . . . . 0.0 111.463 178.906 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 7.4 t30 -110.29 118.23 35.77 Favored 'General case' 0 C--N 1.312 -1.047 0 CA-C-N 117.147 0.474 . . . . 0.0 110.178 179.08 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' TRP . . . . . 0.438 ' CH2' HG21 ' A' ' 33' ' ' VAL . 28.6 m0 -107.63 150.16 27.22 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.574 -0.284 . . . . 0.0 110.399 -178.294 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 49.8 mm -107.72 114.61 46.8 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 N-CA-C 109.217 -0.66 . . . . 0.0 109.217 178.109 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 90.0 mt -127.15 79.94 1.92 Allowed 'General case' 0 C--O 1.265 1.893 0 CA-C-O 121.819 0.818 . . . . 0.0 111.814 -177.83 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 169.15 99.69 0.13 Allowed Glycine 0 N--CA 1.438 -1.201 0 CA-C-N 115.113 -0.949 . . . . 0.0 111.969 179.325 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . 0.441 ' HB2' ' O ' ' A' ' 20' ' ' GLY . 71.6 p -86.19 -7.87 58.23 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 121.308 0.575 . . . . 0.0 110.148 178.604 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -103.68 146.35 28.72 Favored 'General case' 0 N--CA 1.438 -1.055 0 CA-C-N 115.475 -0.784 . . . . 0.0 109.289 179.878 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 -90.24 -19.8 23.72 Favored 'General case' 0 C--N 1.31 -1.138 0 N-CA-C 112.187 0.44 . . . . 0.0 112.187 -172.677 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 28.3 p-10 -117.7 14.52 14.4 Favored 'General case' 0 C--N 1.313 -0.988 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.107 -178.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' GLN . . . . . . . . . . . . . 56.7 tt0 -154.55 123.25 6.18 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 120.834 0.35 . . . . 0.0 110.18 -176.656 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 1.6 m-20 -98.48 162.59 13.07 Favored 'General case' 0 C--O 1.242 0.691 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.064 -175.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 54.3 t -77.55 133.75 29.95 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.579 0 C-N-CA 120.84 -0.344 . . . . 0.0 111.283 178.114 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 35.9 m -116.43 -34.63 1.88 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.503 0 N-CA-C 113.205 0.817 . . . . 0.0 113.205 -179.036 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . 0.587 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -142.73 138.91 30.85 Favored 'General case' 0 CA--C 1.512 -0.489 0 C-N-CA 120.019 -0.672 . . . . 0.0 111.486 179.523 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 40.4 mm -131.77 125.15 55.11 Favored 'Isoleucine or valine' 0 C--O 1.244 0.79 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.287 179.614 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 45.5 t30 -123.84 95.9 4.75 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.628 -0.714 . . . . 0.0 109.311 174.229 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.434 HG22 ' HB ' ' A' ' 36' ' ' ILE . 29.9 m -136.85 138.78 45.71 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.926 0 N-CA-C 112.516 0.562 . . . . 0.0 112.516 -176.442 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -138.36 136.86 36.77 Favored 'General case' 0 C--N 1.309 -1.182 0 CA-C-N 115.132 -0.94 . . . . 0.0 108.481 177.238 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 39.3 t -118.39 129.23 55.3 Favored 'General case' 0 C--N 1.302 -1.496 0 C-N-CA 120.85 -0.34 . . . . 0.0 110.663 -179.549 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -86.45 -6.86 80.23 Favored Glycine 0 N--CA 1.441 -1.001 0 N-CA-C 110.359 -1.096 . . . . 0.0 110.359 175.937 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . 0.484 ' CG ' ' H ' ' A' ' 110' ' ' ASP . 11.1 t70 -93.88 -164.27 1.15 Allowed 'General case' 0 N--CA 1.445 -0.699 0 CA-C-N 115.286 -0.457 . . . . 0.0 110.025 179.656 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 110' ' ' ASP . . . . . 0.484 ' H ' ' CG ' ' A' ' 109' ' ' ASP . 16.2 m-20 -95.49 19.49 10.89 Favored 'General case' 0 C--N 1.318 -0.784 0 C-N-CA 122.989 0.516 . . . . 0.0 110.682 -178.016 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . 0.587 ' HA3' ' OD1' ' A' ' 32' ' ' ASN . . . 101.73 2.22 52.71 Favored Glycine 0 N--CA 1.443 -0.861 0 C-N-CA 120.605 -0.807 . . . . 0.0 112.545 -179.79 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 35.4 tt0 -64.1 -41.64 97.2 Favored 'General case' 0 C--O 1.226 -0.163 0 CA-C-O 120.984 0.421 . . . . 0.0 110.275 179.417 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 8.6 p -132.24 147.74 52.42 Favored 'General case' 0 N--CA 1.441 -0.878 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.436 177.746 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 92.8 mt -114.76 125.77 54.08 Favored 'General case' 0 C--N 1.319 -0.752 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 179.159 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 18.4 m120 -118.55 137.54 53.16 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-N 116.515 -0.312 . . . . 0.0 111.098 -177.633 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 161.62 -139.91 6.29 Favored Glycine 0 N--CA 1.442 -0.934 0 C-N-CA 119.633 -1.27 . . . . 0.0 113.424 176.299 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 27.2 p -138.05 159.97 40.6 Favored 'General case' 0 C--N 1.312 -1.06 0 C-N-CA 123.037 0.535 . . . . 0.0 110.031 -178.703 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 20.5 ptm -146.35 163.0 36.94 Favored 'General case' 0 C--N 1.31 -1.138 0 C-N-CA 121.027 -0.269 . . . . 0.0 111.071 -177.749 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 119' ' ' THR . . . . . 0.587 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 25.8 m -136.68 127.51 27.39 Favored 'General case' 0 C--O 1.251 1.175 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.177 178.727 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . 0.52 ' HB2' ' OE1' ' A' ' 123' ' ' GLU . 6.9 m-85 -94.67 162.7 13.67 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.215 -0.448 . . . . 0.0 109.946 174.705 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -58.79 119.17 6.66 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.695 0.283 . . . . 0.0 111.26 179.813 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 74.03 23.96 74.93 Favored Glycine 0 CA--C 1.52 0.376 0 C-N-CA 120.892 -0.67 . . . . 0.0 112.868 -179.792 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . 0.52 ' OE1' ' HB2' ' A' ' 120' ' ' TYR . 40.0 tt0 -130.2 158.38 39.9 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.769 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -89.14 162.89 31.31 Favored Glycine 0 N--CA 1.444 -0.791 0 N-CA-C 110.902 -0.879 . . . . 0.0 110.902 177.326 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_exo -58.43 131.54 43.38 Favored 'Trans proline' 0 CA--C 1.532 0.394 0 C-N-CA 122.261 1.974 . . . . 0.0 112.471 -179.237 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 43.1 pt -127.87 163.67 31.04 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.18 179.724 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -71.04 133.68 22.67 Favored Glycine 0 C--O 1.242 0.608 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.224 -178.89 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 87.7 t80 -118.02 133.87 55.51 Favored 'General case' 0 C--O 1.245 0.841 0 CA-C-O 121.091 0.472 . . . . 0.0 111.366 -178.083 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 76.5 tttt -137.74 111.0 7.88 Favored 'General case' 0 N--CA 1.44 -0.938 0 CA-C-N 115.165 -0.925 . . . . 0.0 108.887 178.026 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -112.16 143.65 17.56 Favored Glycine 0 C--N 1.311 -0.86 0 C-N-CA 120.377 -0.916 . . . . 0.0 111.843 179.885 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 41.3 m -130.36 130.45 44.42 Favored 'General case' 0 C--N 1.313 -0.998 0 CA-C-N 117.074 0.437 . . . . 0.0 110.401 179.203 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 64.8 tp -65.87 141.06 58.39 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.759 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 18.3 m . . . . . 0 C--O 1.251 1.132 0 CA-C-O 118.484 -0.77 . . . . 0.0 109.504 178.745 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 0.549 ' HB3' ' O ' ' A' ' 25' ' ' ILE . . . . . . . . 0 N--CA 1.474 0.775 0 N-CA-C 110.308 -0.256 . . . . 0.0 110.308 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' LEU . . . . . 0.499 HD11 HE21 ' A' ' 22' ' ' GLN . 0.9 OUTLIER -151.91 128.04 10.46 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 -178.474 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . 0.401 ' N ' HD13 ' A' ' 3' ' ' LEU . 61.7 m-85 -123.52 147.31 47.37 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 112.917 0.71 . . . . 0.0 112.917 -178.293 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 27.4 t-20 -97.92 129.72 44.83 Favored 'General case' 0 C--N 1.316 -0.864 0 N-CA-C 106.677 -1.601 . . . . 0.0 106.677 174.705 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 65.1 t -116.91 129.48 73.37 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.046 0 CA-C-O 121.437 0.637 . . . . 0.0 112.635 -173.818 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 -114.2 139.74 49.13 Favored 'General case' 0 C--O 1.249 1.032 0 CA-C-N 114.974 -1.012 . . . . 0.0 108.346 176.874 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 10.2 m120 -114.16 140.74 48.28 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 116.453 -0.34 . . . . 0.0 110.94 -176.699 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . 0.593 ' OE1' ' HA ' ' A' ' 13' ' ' SER . 36.6 tt0 -127.64 125.56 40.39 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 120.948 0.404 . . . . 0.0 111.289 177.784 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 22.8 p90 -137.29 144.75 42.81 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 116.042 -0.526 . . . . 0.0 109.83 177.192 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 99.52 9.64 49.75 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 120.568 -0.825 . . . . 0.0 111.98 179.039 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 111.17 154.95 13.4 Favored Glycine 0 N--CA 1.444 -0.773 0 C-N-CA 120.959 -0.638 . . . . 0.0 112.325 179.527 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . 0.593 ' HA ' ' OE1' ' A' ' 9' ' ' GLN . 69.9 m -65.98 -14.76 62.19 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 112.883 0.697 . . . . 0.0 112.883 -179.627 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 46.9 m -84.21 -7.93 59.21 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 121.059 0.457 . . . . 0.0 110.481 177.132 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -84.84 150.16 55.25 Favored Pre-proline 0 N--CA 1.449 -0.478 0 CA-C-N 115.924 -0.58 . . . . 0.0 109.773 178.79 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -67.33 152.35 79.27 Favored 'Trans proline' 0 C--O 1.236 0.409 0 C-N-CA 122.458 2.105 . . . . 0.0 113.046 -178.231 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' TRP . . . . . 0.414 ' CE3' ' HB2' ' A' ' 9' ' ' GLN . 90.8 m95 -83.78 130.46 34.94 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 115.52 -0.764 . . . . 0.0 109.056 178.422 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' ASN . . . . . 0.518 HD22 ' N ' ' A' ' 18' ' ' ASN . 0.8 OUTLIER -107.51 132.48 53.19 Favored 'General case' 0 C--N 1.313 -1.016 0 N-CA-C 107.524 -1.287 . . . . 0.0 107.524 179.168 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 71.8 tt0 -66.42 128.02 34.57 Favored 'General case' 0 C--N 1.308 -1.221 0 CA-C-O 121.58 0.705 . . . . 0.0 110.634 -176.793 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -100.96 -4.48 54.28 Favored Glycine 0 N--CA 1.435 -1.396 0 CA-C-N 115.026 -0.988 . . . . 0.0 113.345 -175.113 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 115.01 -153.52 17.58 Favored Glycine 0 N--CA 1.443 -0.851 0 C-N-CA 120.306 -0.95 . . . . 0.0 111.943 -178.142 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . 0.499 HE21 HD11 ' A' ' 3' ' ' LEU . 4.4 pt20 -132.52 139.41 47.88 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-O 120.701 0.286 . . . . 0.0 110.553 -179.812 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . 0.458 ' CZ2' ' HE3' ' A' ' 118' ' ' MET . 38.4 m0 -117.29 161.44 19.49 Favored 'General case' 0 CA--C 1.508 -0.665 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.887 -178.517 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . 0.412 ' HB3' ' H ' ' A' ' 91' ' ' ILE . 73.4 tt0 -112.47 107.05 15.68 Favored 'General case' 0 N--CA 1.443 -0.825 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 175.11 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.549 ' O ' ' HB3' ' A' ' 2' ' ' ALA . 92.4 mt -123.22 132.07 72.06 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.843 0 CA-C-N 115.922 -0.581 . . . . 0.0 109.872 -177.36 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 90.85 116.33 1.9 Allowed Glycine 0 N--CA 1.446 -0.641 0 C-N-CA 120.33 -0.938 . . . . 0.0 112.432 178.707 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . 0.472 ' OG ' ' HA3' ' A' ' 88' ' ' GLY . 13.2 t -112.56 14.96 20.23 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-O 121.071 0.463 . . . . 0.0 110.201 -179.848 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 75.7 mtp180 -127.64 138.69 52.91 Favored 'General case' 0 CA--C 1.513 -0.449 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.375 -179.426 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 19.4 m -93.01 -27.27 17.1 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.783 179.407 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 11.8 p-10 -77.32 -38.62 50.09 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.45 -177.618 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . 0.523 HE21 ' HA ' ' A' ' 31' ' ' GLN . 0.0 OUTLIER -130.21 121.41 26.15 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.302 179.709 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . 0.559 ' ND2' ' HA3' ' A' ' 111' ' ' GLY . 65.6 t30 -95.3 169.02 10.37 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 178.792 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 58.8 t -96.44 131.25 43.7 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.991 0 CA-C-N 116.568 -0.287 . . . . 0.0 110.934 -177.5 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 28.4 m -111.39 -20.25 6.38 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.163 0 N-CA-C 112.19 0.441 . . . . 0.0 112.19 179.002 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.532 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -147.86 145.57 28.74 Favored 'General case' 0 CA--C 1.514 -0.435 0 C-N-CA 120.296 -0.562 . . . . 0.0 111.512 179.992 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.403 ' HB ' HG22 ' A' ' 105' ' ' VAL . 92.0 mt -144.87 127.95 11.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.042 -0.526 . . . . 0.0 109.893 -179.539 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' ASN . . . . . 0.421 ' HA ' ' O ' ' A' ' 103' ' ' ILE . 0.6 OUTLIER -133.17 112.11 11.46 Favored 'General case' 0 C--N 1.317 -0.81 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 174.967 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.512 HG11 ' CD2' ' A' ' 61' ' ' PHE . 15.5 m -147.67 150.21 14.72 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.804 0 N-CA-C 112.207 0.447 . . . . 0.0 112.207 -174.871 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 70.5 tt0 -133.22 143.11 48.93 Favored 'General case' 0 N--CA 1.442 -0.851 0 CA-C-N 114.976 -1.011 . . . . 0.0 108.703 176.485 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 21.2 p -73.75 146.34 44.43 Favored 'General case' 0 C--N 1.31 -1.128 0 CA-C-O 120.728 0.299 . . . . 0.0 111.216 178.591 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -92.11 -42.48 4.64 Favored Glycine 0 N--CA 1.447 -0.576 0 N-CA-C 109.687 -1.365 . . . . 0.0 109.687 175.333 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 23.0 m-20 -102.27 -161.36 0.84 Allowed 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 114.711 -0.745 . . . . 0.0 109.116 176.042 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 29.4 p-10 -84.12 47.79 1.38 Allowed 'General case' 0 C--N 1.315 -0.895 0 CA-C-O 121.325 0.583 . . . . 0.0 110.874 179.484 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 99.53 -14.4 60.72 Favored Glycine 0 C--O 1.22 -0.778 0 CA-C-N 115.923 -0.581 . . . . 0.0 112.665 -179.411 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 58.5 tp60 -64.87 -39.39 93.47 Favored 'General case' 0 CA--C 1.534 0.362 0 CA-C-O 120.803 0.335 . . . . 0.0 111.328 -179.162 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 61.3 p -128.45 142.87 50.96 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.604 -0.271 . . . . 0.0 110.742 179.07 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 86.0 mt -126.68 133.83 50.85 Favored 'General case' 0 C--O 1.236 0.369 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 179.168 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -136.22 147.91 47.83 Favored 'General case' 0 C--N 1.32 -0.692 0 C-N-CA 120.905 -0.318 . . . . 0.0 110.951 179.981 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 165.67 -144.17 9.02 Favored Glycine 0 N--CA 1.442 -0.922 0 C-N-CA 120.497 -0.858 . . . . 0.0 112.104 177.909 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 9.4 t -133.53 145.51 50.2 Favored 'General case' 0 N--CA 1.435 -1.177 0 CA-C-O 121.103 0.477 . . . . 0.0 110.558 -179.211 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 14.6 tmm? -133.32 147.19 51.85 Favored 'General case' 0 C--N 1.314 -0.96 0 CA-C-N 115.918 -0.583 . . . . 0.0 109.685 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.532 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 28.7 m -125.96 128.01 46.84 Favored 'General case' 0 C--O 1.249 1.054 0 N-CA-C 112.045 0.387 . . . . 0.0 112.045 -176.812 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . 0.429 ' HB2' ' HB2' ' A' ' 56' ' ' GLU . 86.0 m-85 -86.27 162.29 18.34 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.565 176.781 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -64.29 122.09 15.84 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.886 178.479 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.59 5.84 89.19 Favored Glycine 0 CA--C 1.517 0.198 0 C-N-CA 120.958 -0.639 . . . . 0.0 112.499 179.925 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . 0.429 ' HB2' ' HB2' ' A' ' 53' ' ' TYR . 69.6 mm-40 -119.55 179.14 4.31 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 120.742 0.306 . . . . 0.0 110.874 -178.608 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -106.77 169.2 14.96 Favored Glycine 0 N--CA 1.44 -1.078 0 N-CA-C 111.237 -0.745 . . . . 0.0 111.237 178.881 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_exo -62.34 137.36 64.97 Favored 'Trans proline' 0 C--O 1.235 0.359 0 C-N-CA 122.583 2.189 . . . . 0.0 112.239 179.102 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . 0.475 ' HB ' ' O ' ' A' ' 76' ' ' GLN . 48.6 pt -130.32 170.98 18.3 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 CA-C-N 115.984 -0.553 . . . . 0.0 109.813 178.387 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -75.57 136.27 19.76 Favored Glycine 0 N--CA 1.446 -0.671 0 C-N-CA 120.2 -1.0 . . . . 0.0 110.889 -179.346 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.512 ' CD2' HG11 ' A' ' 38' ' ' VAL . 7.5 t80 -131.22 125.15 32.16 Favored 'General case' 0 C--N 1.31 -1.152 0 CA-C-O 120.958 0.409 . . . . 0.0 111.457 -178.046 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 61.9 ttp180 -130.03 130.99 45.66 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.608 -0.724 . . . . 0.0 110.338 178.039 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.409 ' HB1' ' HB3' ' A' ' 71' ' ' TYR . . . -130.99 138.98 49.93 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.782 179.382 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 63.6 m -121.16 130.18 53.6 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.392 179.838 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 61.7 tp -68.16 121.68 16.7 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 121.064 0.459 . . . . 0.0 111.365 -178.459 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 96.1 mt -71.32 -34.24 70.39 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.613 178.242 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 133.5 -12.16 4.91 Favored Glycine 0 CA--C 1.521 0.445 0 C-N-CA 120.485 -0.865 . . . . 0.0 113.31 -179.742 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 20.7 m120 -130.89 50.84 2.19 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-O 120.981 0.42 . . . . 0.0 111.4 -178.038 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 86.7 m-20 65.03 1.54 1.52 Allowed 'General case' 0 N--CA 1.486 1.336 0 C-N-CA 123.845 0.858 . . . . 0.0 111.98 178.835 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 25.7 t -102.62 138.19 39.84 Favored 'General case' 0 N--CA 1.436 -1.146 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 179.108 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.447 ' CE1' ' HB2' ' A' ' 92' ' ' LEU . 84.7 m-85 -118.1 140.87 49.14 Favored 'General case' 0 C--N 1.307 -1.263 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.742 -178.534 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -91.24 123.88 35.03 Favored 'General case' 0 N--CA 1.438 -1.063 0 N-CA-C 107.657 -1.238 . . . . 0.0 107.657 173.746 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.439 HG13 ' HE1' ' A' ' 61' ' ' PHE . 45.3 t -105.32 134.04 47.92 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.246 0 N-CA-C 113.413 0.894 . . . . 0.0 113.413 -173.057 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 84.7 mt-10 -129.25 126.27 38.72 Favored 'General case' 0 N--CA 1.438 -1.042 0 CA-C-N 114.367 -1.288 . . . . 0.0 107.69 176.369 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 92.8 m-20 -109.22 146.69 33.79 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-O 121.021 0.439 . . . . 0.0 111.789 -175.582 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' GLN . . . . . 0.479 ' HB2' ' CE3' ' A' ' 84' ' ' TRP . 58.4 tt0 -114.47 121.26 42.99 Favored 'General case' 0 C--N 1.312 -1.061 0 CA-C-N 115.707 -0.678 . . . . 0.0 109.645 -179.955 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 5.8 p90 -140.46 159.47 42.12 Favored 'General case' 0 C--N 1.318 -0.79 0 C-N-CA 120.874 -0.33 . . . . 0.0 110.578 179.246 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 95.35 -7.16 68.83 Favored Glycine 0 N--CA 1.447 -0.575 0 C-N-CA 120.834 -0.698 . . . . 0.0 111.846 -179.704 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 146.58 154.93 6.33 Favored Glycine 0 N--CA 1.445 -0.725 0 N-CA-C 111.684 -0.566 . . . . 0.0 111.684 178.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -72.28 -25.56 61.64 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-O 120.965 0.412 . . . . 0.0 111.198 -179.987 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 4.6 m -82.47 -11.7 58.33 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.412 177.72 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -72.63 155.3 91.09 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.445 -177.236 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -69.38 169.02 19.38 Favored 'Trans proline' 0 C--N 1.347 0.485 0 C-N-CA 122.721 2.281 . . . . 0.0 112.141 178.342 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' TRP . . . . . 0.479 ' CE3' ' HB2' ' A' ' 76' ' ' GLN . 91.8 m95 -87.49 143.29 27.29 Favored 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 -178.409 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 85.8 m-70 -118.61 157.77 26.75 Favored 'General case' 0 C--N 1.313 -0.996 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 -179.705 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 48.3 m -63.81 143.74 57.61 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-O 120.837 0.351 . . . . 0.0 111.023 179.787 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -117.18 -58.91 0.3 Allowed Glycine 0 N--CA 1.439 -1.164 0 N-CA-C 110.931 -0.867 . . . . 0.0 110.931 178.556 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.472 ' HA3' ' OG ' ' A' ' 27' ' ' SER . . . 149.38 -167.68 29.66 Favored Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 120.929 -0.653 . . . . 0.0 111.929 177.067 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' ASN . . . . . 0.407 ' C ' ' HD1' ' A' ' 90' ' ' TRP . 11.2 m120 -102.48 132.68 48.37 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-O 120.679 0.276 . . . . 0.0 110.624 178.747 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' TRP . . . . . 0.407 ' HD1' ' C ' ' A' ' 89' ' ' ASN . 12.5 m0 -130.63 151.58 50.93 Favored 'General case' 0 C--N 1.319 -0.744 0 N-CA-C 108.472 -0.936 . . . . 0.0 108.472 -179.222 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . 0.412 ' H ' ' HB3' ' A' ' 24' ' ' GLU . 95.8 mt -117.26 115.52 49.05 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.153 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 176.643 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . 0.447 ' HB2' ' CE1' ' A' ' 71' ' ' TYR . 88.8 mt -125.6 74.14 1.38 Allowed 'General case' 0 C--O 1.247 0.962 0 CA-C-O 121.683 0.754 . . . . 0.0 110.215 -177.577 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 167.72 87.39 0.07 OUTLIER Glycine 0 N--CA 1.431 -1.648 0 CA-C-N 114.892 -1.049 . . . . 0.0 110.73 -177.888 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 22.5 p -91.63 -5.68 53.46 Favored 'General case' 0 C--N 1.31 -1.116 0 CA-C-O 121.176 0.512 . . . . 0.0 110.586 -179.243 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' ARG . . . . . 0.427 HH11 ' HD3' ' A' ' 95' ' ' ARG . 61.7 mtt-85 -94.2 150.0 20.72 Favored 'General case' 0 N--CA 1.442 -0.849 0 CA-C-N 115.64 -0.709 . . . . 0.0 109.676 179.127 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 77.3 tt0 -70.06 -42.76 72.39 Favored 'General case' 0 C--N 1.315 -0.925 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.669 -174.048 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 94.4 m-20 -113.46 18.13 17.9 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.905 -176.871 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' GLN . . . . . . . . . . . . . 2.3 mt-30 -141.53 117.92 10.82 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 113.18 0.807 . . . . 0.0 113.18 -176.118 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 35.8 m-80 -98.25 166.44 11.4 Favored 'General case' 0 C--O 1.245 0.852 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.204 175.138 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 97.1 t -85.18 134.07 27.93 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.611 -179.063 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 27.9 m -115.23 -31.43 1.97 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-N 115.785 -0.643 . . . . 0.0 112.626 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . 0.601 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -144.22 139.08 28.48 Favored 'General case' 0 CA--C 1.514 -0.409 0 C-N-CA 120.097 -0.641 . . . . 0.0 111.631 179.306 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.445 ' HB ' HG22 ' A' ' 38' ' ' VAL . 92.0 mt -132.75 128.38 57.15 Favored 'Isoleucine or valine' 0 C--O 1.238 0.497 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.177 179.743 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 40.7 t30 -128.42 98.16 4.96 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.674 -0.694 . . . . 0.0 109.435 173.544 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.403 HG22 ' HB ' ' A' ' 36' ' ' ILE . 28.3 m -138.0 140.93 39.74 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 N-CA-C 112.331 0.493 . . . . 0.0 112.331 -176.634 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 42.4 tt0 -141.11 138.52 33.56 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.658 -0.701 . . . . 0.0 109.965 178.078 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 46.4 t -143.85 141.71 30.47 Favored 'General case' 0 N--CA 1.446 -0.634 0 CA-C-O 120.894 0.378 . . . . 0.0 111.24 179.18 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -106.81 6.22 37.6 Favored Glycine 0 N--CA 1.443 -0.873 0 N-CA-C 110.624 -0.991 . . . . 0.0 110.624 176.187 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 23.1 m-20 -95.78 14.33 23.62 Favored 'General case' 0 CA--C 1.516 -0.344 0 C-N-CA 123.004 0.522 . . . . 0.0 111.324 -178.176 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 85.7 m-20 63.59 23.38 13.56 Favored 'General case' 0 N--CA 1.47 0.561 0 CA-C-N 115.632 -0.713 . . . . 0.0 112.319 178.173 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . 0.559 ' HA3' ' ND2' ' A' ' 32' ' ' ASN . . . 103.45 5.21 46.05 Favored Glycine 0 N--CA 1.446 -0.653 0 C-N-CA 120.008 -1.092 . . . . 0.0 114.249 176.651 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 54.2 tt0 -62.63 -49.53 74.81 Favored 'General case' 0 C--O 1.249 1.059 0 CA-C-O 121.583 0.706 . . . . 0.0 109.891 177.612 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 14.4 p -136.12 133.17 36.99 Favored 'General case' 0 N--CA 1.442 -0.846 0 CA-C-N 115.034 -0.985 . . . . 0.0 109.555 177.163 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -107.38 122.76 47.24 Favored 'General case' 0 C--N 1.314 -0.97 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 178.787 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 88.9 m-20 -119.54 143.72 47.45 Favored 'General case' 0 C--N 1.311 -1.082 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.121 -179.063 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 160.87 -138.09 5.3 Favored Glycine 0 N--CA 1.442 -0.915 0 C-N-CA 120.216 -0.992 . . . . 0.0 112.685 177.568 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 2.1 p -131.68 153.34 50.1 Favored 'General case' 0 C--N 1.314 -0.978 0 CA-C-O 121.086 0.47 . . . . 0.0 110.789 -179.592 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 118' ' ' MET . . . . . 0.619 ' SD ' ' HD1' ' A' ' 128' ' ' PHE . 21.7 ptm -139.56 147.81 41.7 Favored 'General case' 0 C--N 1.314 -0.962 0 CA-C-N 115.813 -0.63 . . . . 0.0 109.993 -176.764 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 119' ' ' THR . . . . . 0.601 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 29.1 m -131.75 125.61 32.4 Favored 'General case' 0 C--O 1.249 1.063 0 C-N-CA 120.99 -0.284 . . . . 0.0 111.096 179.095 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . 0.4 ' HB2' ' HB3' ' A' ' 123' ' ' GLU . 63.1 m-85 -94.11 163.7 13.36 Favored 'General case' 0 CA--C 1.513 -0.476 0 CA-C-N 116.159 -0.473 . . . . 0.0 109.969 175.52 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -53.51 -33.81 55.8 Favored 'General case' 0 N--CA 1.47 0.545 0 N-CA-C 113.503 0.927 . . . . 0.0 113.503 -176.544 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -138.0 25.31 2.93 Favored Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 119.596 -1.288 . . . . 0.0 112.776 -178.017 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . 0.4 ' HB3' ' HB2' ' A' ' 120' ' ' TYR . 36.1 tp10 -111.28 -53.06 2.74 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-O 121.29 0.567 . . . . 0.0 110.326 -177.926 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 115.01 177.43 18.8 Favored Glycine 0 N--CA 1.439 -1.154 0 CA-C-N 115.541 -0.754 . . . . 0.0 111.452 -178.308 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 13.5 Cg_exo -71.16 117.13 5.0 Favored 'Trans proline' 0 N--CA 1.458 -0.561 0 C-N-CA 122.8 2.333 . . . . 0.0 112.051 179.053 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 36.7 pt -130.16 165.96 29.01 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.946 0 CA-C-N 115.93 -0.577 . . . . 0.0 109.891 178.388 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -70.26 135.72 26.0 Favored Glycine 0 C--O 1.241 0.532 0 C-N-CA 120.871 -0.68 . . . . 0.0 112.531 -178.5 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . 0.619 ' HD1' ' SD ' ' A' ' 118' ' ' MET . 72.8 t80 -112.5 132.3 55.15 Favored 'General case' 0 C--O 1.249 1.031 0 CA-C-O 120.832 0.349 . . . . 0.0 111.054 -178.793 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 129' ' ' LYS . . . . . 0.402 ' HB2' ' CZ3' ' A' ' 17' ' ' TRP . 61.0 tttm -137.59 108.9 6.85 Favored 'General case' 0 N--CA 1.447 -0.587 0 CA-C-N 115.599 -0.728 . . . . 0.0 109.213 175.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -114.03 137.12 13.85 Favored Glycine 0 N--CA 1.446 -0.648 0 C-N-CA 120.522 -0.847 . . . . 0.0 111.818 179.244 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 55.8 m -132.34 140.64 48.62 Favored 'General case' 0 C--N 1.308 -1.21 0 CA-C-N 116.645 0.223 . . . . 0.0 110.605 -179.241 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 88.1 mt -56.99 130.03 44.29 Favored 'General case' 0 N--CA 1.472 0.663 0 O-C-N 123.17 0.294 . . . . 0.0 110.939 177.5 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 14.8 p . . . . . 0 C--O 1.252 1.212 0 CA-C-O 118.145 -0.931 . . . . 0.0 110.326 178.313 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 0.406 ' O ' ' HG3' ' A' ' 24' ' ' GLU . . . . . . . . 0 N--CA 1.471 0.581 0 N-CA-C 109.713 -0.477 . . . . 0.0 109.713 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' LEU . . . . . 0.496 HD11 ' NE2' ' A' ' 22' ' ' GLN . 3.0 tm? -94.81 127.12 40.59 Favored 'General case' 0 C--N 1.317 -0.823 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 -177.153 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 40.5 m-85 -117.16 136.66 52.87 Favored 'General case' 0 C--N 1.312 -1.023 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.305 178.444 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' ASN . . . . . 0.487 ' O ' ' HA2' ' A' ' 130' ' ' GLY . 0.9 OUTLIER -85.06 132.23 34.35 Favored 'General case' 0 CA--C 1.499 -0.989 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 175.378 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.509 HG21 ' CG ' ' A' ' 23' ' ' TRP . 53.2 t -114.35 128.13 71.51 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.115 0 N-CA-C 113.182 0.808 . . . . 0.0 113.182 -173.847 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 71.6 mt-10 -124.05 135.9 53.89 Favored 'General case' 0 N--CA 1.436 -1.143 0 CA-C-N 114.577 -1.192 . . . . 0.0 108.469 177.542 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . 0.438 ' HB3' HD12 ' A' ' 126' ' ' ILE . 10.8 m120 -121.1 145.11 48.15 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 120.884 0.373 . . . . 0.0 111.415 -175.935 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . 0.465 HE22 ' HA ' ' A' ' 13' ' ' SER . 52.1 tt0 -124.97 123.39 39.77 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.717 178.264 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 40.1 p90 -133.44 142.56 48.37 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 116.653 -0.249 . . . . 0.0 110.922 179.264 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 105.16 10.31 32.22 Favored Glycine 0 CA--C 1.52 0.345 0 C-N-CA 120.327 -0.94 . . . . 0.0 112.945 177.164 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.36 171.51 33.52 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.574 -0.822 . . . . 0.0 112.887 179.56 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . 0.465 ' HA ' HE22 ' A' ' 9' ' ' GLN . 16.4 m -57.8 -26.31 61.78 Favored 'General case' 0 CA--C 1.536 0.426 0 C-N-CA 122.993 0.517 . . . . 0.0 112.061 179.311 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 14.8 m -59.24 -24.76 63.46 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 122.62 0.368 . . . . 0.0 111.695 177.5 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -91.37 144.27 29.47 Favored Pre-proline 0 C--N 1.324 -0.51 0 CA-C-N 116.75 -0.204 . . . . 0.0 110.577 179.515 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -81.13 -176.05 2.95 Favored 'Trans proline' 0 C--O 1.239 0.538 0 C-N-CA 122.657 2.238 . . . . 0.0 112.32 179.397 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 99.1 m95 -87.22 128.8 35.14 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.213 -0.449 . . . . 0.0 109.908 179.64 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 34.0 m-80 -113.65 110.74 20.69 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.384 -177.093 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 73.1 tt0 -73.35 121.29 20.2 Favored 'General case' 0 C--N 1.317 -0.837 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 177.084 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -134.68 32.59 2.59 Favored Glycine 0 N--CA 1.447 -0.624 0 C-N-CA 119.792 -1.194 . . . . 0.0 112.967 -178.634 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . 0.419 ' HA3' ' HB2' ' A' ' 94' ' ' SER . . . 136.99 -167.22 24.71 Favored Glycine 0 N--CA 1.444 -0.821 0 C-N-CA 120.103 -1.046 . . . . 0.0 112.817 178.104 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . 0.496 ' NE2' HD11 ' A' ' 3' ' ' LEU . 10.9 pt20 -147.84 153.9 39.75 Favored 'General case' 0 C--N 1.316 -0.879 0 C-N-CA 122.236 0.214 . . . . 0.0 110.543 -179.715 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . 0.509 ' CG ' HG21 ' A' ' 6' ' ' VAL . 38.4 m0 -126.82 177.04 6.84 Favored 'General case' 0 N--CA 1.47 0.531 0 CA-C-N 116.343 -0.389 . . . . 0.0 110.347 -175.623 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . 0.459 ' HB3' HG12 ' A' ' 91' ' ' ILE . 83.7 tt0 -124.61 114.44 19.38 Favored 'General case' 0 CA--C 1.505 -0.768 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.031 174.74 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 98.2 mt -124.38 132.83 70.77 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.878 0 CA-C-N 115.446 -0.797 . . . . 0.0 109.632 -178.294 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 87.75 55.21 2.33 Favored Glycine 0 N--CA 1.447 -0.606 0 C-N-CA 120.077 -1.059 . . . . 0.0 112.45 178.283 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 36.1 t -61.57 -38.14 86.43 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.575 0.226 . . . . 0.0 110.558 178.993 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 70.4 ttt180 -49.98 -42.61 49.27 Favored 'General case' 0 CA--C 1.542 0.656 0 CA-C-N 116.199 -0.455 . . . . 0.0 112.174 179.501 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 14.9 m 74.16 -42.13 0.5 Allowed 'General case' 0 N--CA 1.48 1.052 0 N-CA-C 114.36 1.244 . . . . 0.0 114.36 175.6 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 3.9 p-10 -74.98 -4.33 37.59 Favored 'General case' 0 N--CA 1.487 1.411 0 CA-C-N 118.378 0.535 . . . . 0.0 111.782 -178.237 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 1.1 tm0? -150.71 119.7 6.68 Favored 'General case' 0 C--N 1.314 -0.968 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.755 178.525 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . 0.658 ' OD1' ' HA3' ' A' ' 111' ' ' GLY . 27.0 t-20 -85.59 145.74 27.21 Favored 'General case' 0 CA--C 1.534 0.357 0 CA-C-O 121.667 0.746 . . . . 0.0 111.97 -179.696 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 15.4 t -97.14 130.07 46.29 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.12 0 CA-C-N 115.085 -0.961 . . . . 0.0 110.531 -177.698 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 17.2 m -101.3 -24.52 4.05 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 N-CA-C 112.002 0.371 . . . . 0.0 112.002 -179.599 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.572 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -141.25 146.13 36.45 Favored 'General case' 0 C--N 1.323 -0.551 0 C-N-CA 120.273 -0.571 . . . . 0.0 111.12 179.327 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.438 ' HB ' ' CG2' ' A' ' 105' ' ' VAL . 98.2 mt -142.84 125.53 13.47 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.325 -177.427 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -130.81 113.36 13.98 Favored 'General case' 0 C--N 1.316 -0.869 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 174.898 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.505 HG22 ' HB ' ' A' ' 103' ' ' ILE . 28.7 m -144.73 145.64 20.95 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 C-N-CA 120.89 -0.324 . . . . 0.0 111.214 -175.785 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 79.6 tt0 -141.03 146.22 36.93 Favored 'General case' 0 N--CA 1.45 -0.453 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.163 178.263 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . 0.557 ' OG ' ' HB ' ' A' ' 101' ' ' VAL . 26.0 p -81.89 144.86 30.69 Favored 'General case' 0 C--N 1.316 -0.864 0 N-CA-C 111.875 0.324 . . . . 0.0 111.875 -179.11 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -91.23 -21.62 34.75 Favored Glycine 0 N--CA 1.449 -0.454 0 N-CA-C 110.744 -0.942 . . . . 0.0 110.744 175.206 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . 0.4 ' C ' ' H ' ' A' ' 44' ' ' GLY . 28.2 m-20 -132.91 -150.2 0.4 Allowed 'General case' 0 CA--C 1.514 -0.415 0 N-CA-C 108.917 -0.772 . . . . 0.0 108.917 179.373 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -75.81 34.89 0.12 Allowed 'General case' 0 N--CA 1.471 0.614 0 C-N-CA 122.768 0.427 . . . . 0.0 110.818 178.517 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.42 ' O ' ' HE2' ' A' ' 71' ' ' TYR . . . 90.85 1.81 72.88 Favored Glycine 0 N--CA 1.442 -0.951 0 C-N-CA 121.057 -0.592 . . . . 0.0 112.655 -178.669 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 60.5 tp60 -62.89 -44.81 95.09 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-O 120.971 0.415 . . . . 0.0 110.547 -179.433 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 4.3 t -129.97 122.6 28.8 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.185 176.404 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 81.8 mt -102.48 132.8 48.28 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 116.139 -0.482 . . . . 0.0 109.777 178.782 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 13.0 m120 -121.34 133.39 55.11 Favored 'General case' 0 C--N 1.314 -0.964 0 N-CA-C 108.963 -0.755 . . . . 0.0 108.963 177.38 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . 0.438 ' HA3' ' HA ' ' A' ' 38' ' ' VAL . . . -173.2 -162.72 25.69 Favored Glycine 0 N--CA 1.436 -1.321 0 C-N-CA 119.367 -1.397 . . . . 0.0 113.243 179.876 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 90.4 m -131.65 130.48 42.16 Favored 'General case' 0 C--N 1.309 -1.176 0 C-N-CA 122.692 0.397 . . . . 0.0 111.4 -179.701 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 43.8 mtp -106.24 145.08 32.04 Favored 'General case' 0 N--CA 1.469 0.49 0 C-N-CA 122.689 0.396 . . . . 0.0 110.161 177.042 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.572 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 36.2 m -123.92 122.35 37.74 Favored 'General case' 0 C--O 1.249 1.076 0 CA-C-O 120.636 0.255 . . . . 0.0 110.64 177.727 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 24.0 m-85 -82.44 161.38 22.46 Favored 'General case' 0 N--CA 1.462 0.142 0 CA-C-N 115.654 -0.703 . . . . 0.0 111.491 -179.468 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -65.46 109.37 2.3 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.932 -0.576 . . . . 0.0 111.661 -179.545 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 83.32 14.93 72.94 Favored Glycine 0 N--CA 1.446 -0.649 0 C-N-CA 120.836 -0.697 . . . . 0.0 113.392 178.371 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 51.1 mt-10 -137.07 167.78 20.87 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.974 0.387 . . . . 0.0 111.513 -178.993 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -78.18 163.1 50.34 Favored Glycine 0 N--CA 1.448 -0.507 0 CA-C-N 115.87 -0.604 . . . . 0.0 113.36 -177.301 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_exo -67.5 142.85 60.78 Favored 'Trans proline' 0 CA--C 1.54 0.781 0 C-N-CA 123.188 2.592 . . . . 0.0 112.749 179.778 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . 0.512 ' HB ' ' O ' ' A' ' 76' ' ' GLN . 47.5 pt -127.14 166.0 24.71 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.329 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.818 -179.422 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -73.83 144.09 33.3 Favored Glycine 0 CA--C 1.517 0.217 0 C-N-CA 121.078 -0.582 . . . . 0.0 112.502 -177.852 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 41.5 t80 -130.45 127.8 39.99 Favored 'General case' 0 C--O 1.238 0.499 0 CA-C-O 120.829 0.347 . . . . 0.0 111.091 -178.791 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 67.3 ttp85 -136.32 127.58 28.21 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 175.585 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.436 ' HB2' HG22 ' A' ' 73' ' ' VAL . . . -135.07 146.91 49.38 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 120.565 0.221 . . . . 0.0 111.548 -178.175 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 64.3 m -124.54 129.41 50.55 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.598 178.875 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . 0.467 ' HG ' ' H ' ' A' ' 67' ' ' GLY . 56.6 tp -74.58 130.21 39.15 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.879 -178.847 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . 0.427 ' HB2' ' OD1' ' A' ' 68' ' ' ASN . 85.8 mt -84.52 -17.83 37.69 Favored 'General case' 0 CA--C 1.536 0.429 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.077 177.094 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.467 ' H ' ' HG ' ' A' ' 65' ' ' LEU . . . 105.58 -8.99 44.32 Favored Glycine 0 C--O 1.222 -0.638 0 CA-C-N 115.761 -0.654 . . . . 0.0 112.198 178.49 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' ASN . . . . . 0.427 ' OD1' ' HB2' ' A' ' 66' ' ' LEU . 29.7 p-10 -110.85 34.72 3.84 Favored 'General case' 0 C--N 1.316 -0.858 0 CA-C-O 120.921 0.391 . . . . 0.0 110.749 -179.742 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . 0.55 HD21 ' HA ' ' A' ' 96' ' ' GLU . 90.8 m-20 66.83 7.99 5.67 Favored 'General case' 0 N--CA 1.484 1.225 0 CA-C-N 115.599 -0.728 . . . . 0.0 111.11 -179.399 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 7.3 m -107.94 133.35 52.4 Favored 'General case' 0 N--CA 1.436 -1.143 0 CA-C-N 115.685 -0.689 . . . . 0.0 109.932 -179.796 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.494 ' CE1' ' HB2' ' A' ' 92' ' ' LEU . 86.4 m-85 -114.8 134.99 54.68 Favored 'General case' 0 C--N 1.308 -1.205 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.654 -179.712 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 71.8 tt0 -86.95 119.98 27.73 Favored 'General case' 0 N--CA 1.442 -0.831 0 N-CA-C 106.967 -1.494 . . . . 0.0 106.967 173.39 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.436 HG22 ' HB2' ' A' ' 63' ' ' ALA . 63.1 t -108.71 134.13 51.61 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.073 0 N-CA-C 112.943 0.72 . . . . 0.0 112.943 -172.835 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.405 ' HG2' ' HA ' ' A' ' 86' ' ' SER . 49.1 mt-10 -131.45 131.91 43.91 Favored 'General case' 0 N--CA 1.441 -0.912 0 CA-C-N 114.6 -1.182 . . . . 0.0 107.93 175.943 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 95.1 m-20 -119.28 160.62 21.87 Favored 'General case' 0 C--N 1.309 -1.18 0 CA-C-O 121.371 0.605 . . . . 0.0 112.257 -175.207 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' GLN . . . . . 0.512 ' O ' ' HB ' ' A' ' 59' ' ' ILE . 59.8 tt0 -118.95 114.26 22.28 Favored 'General case' 0 C--N 1.312 -1.025 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.569 -179.17 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 3.3 p90 -134.83 35.71 3.11 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 120.941 0.401 . . . . 0.0 111.416 -176.615 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -133.49 -6.9 2.56 Favored Glycine 0 C--N 1.318 -0.433 0 C-N-CA 120.225 -0.988 . . . . 0.0 112.742 -178.32 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 127.47 160.43 10.47 Favored Glycine 0 N--CA 1.445 -0.745 0 N-CA-C 109.805 -1.318 . . . . 0.0 109.805 -178.076 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 19.6 m-20 -58.97 -39.98 83.39 Favored 'General case' 0 N--CA 1.474 0.749 0 CA-C-N 117.72 0.76 . . . . 0.0 112.245 -177.114 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 4.7 p -81.24 -5.66 58.01 Favored 'General case' 0 C--N 1.316 -0.85 0 N-CA-C 112.436 0.532 . . . . 0.0 112.436 -177.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . 0.441 ' HA ' ' HD3' ' A' ' 83' ' ' PRO . . . -83.93 149.21 55.87 Favored Pre-proline 0 C--N 1.321 -0.67 0 CA-C-N 116.755 -0.202 . . . . 0.0 110.995 -178.644 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' PRO . . . . . 0.441 ' HD3' ' HA ' ' A' ' 82' ' ' ALA . 17.7 Cg_exo -67.33 161.31 43.73 Favored 'Trans proline' 0 C--N 1.346 0.443 0 C-N-CA 122.796 2.331 . . . . 0.0 111.939 178.242 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' TRP . . . . . . . . . . . . . 79.2 m95 -80.99 147.12 30.36 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.04 -179.496 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 89.9 m-70 -118.48 147.38 43.68 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.075 179.638 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . 0.405 ' HA ' ' HG2' ' A' ' 74' ' ' GLU . 13.0 m -62.32 134.47 56.52 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-O 121.224 0.535 . . . . 0.0 111.565 -178.073 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -105.45 -48.5 1.04 Allowed Glycine 0 N--CA 1.441 -0.982 0 CA-C-N 115.451 -0.795 . . . . 0.0 111.463 179.082 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 144.92 -163.79 27.96 Favored Glycine 0 N--CA 1.442 -0.911 0 C-N-CA 120.544 -0.836 . . . . 0.0 112.251 177.535 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 16.5 m120 -104.72 127.16 52.41 Favored 'General case' 0 C--N 1.316 -0.858 0 CA-C-O 120.812 0.339 . . . . 0.0 110.341 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 12.4 m0 -119.7 144.45 47.2 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 179.825 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . 0.482 ' O ' ' HB3' ' A' ' 23' ' ' TRP . 45.5 mm -108.38 113.36 43.72 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.933 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.027 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . 0.494 ' HB2' ' CE1' ' A' ' 71' ' ' TYR . 77.9 mt -129.23 81.53 2.03 Favored 'General case' 0 C--O 1.261 1.699 0 CA-C-O 121.47 0.653 . . . . 0.0 111.894 -177.437 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 165.56 99.55 0.14 Allowed Glycine 0 N--CA 1.445 -0.751 0 CA-C-N 115.417 -0.811 . . . . 0.0 111.292 -179.813 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . 0.419 ' HB2' ' HA3' ' A' ' 21' ' ' GLY . 3.2 p -101.69 -12.54 18.31 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 117.036 0.418 . . . . 0.0 111.844 -177.826 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' ARG . . . . . 0.404 HH12 ' CD ' ' A' ' 123' ' ' GLU . 96.6 mtt180 -83.49 -5.0 59.03 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.438 -0.346 . . . . 0.0 111.339 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . 0.55 ' HA ' HD21 ' A' ' 69' ' ' ASN . 72.3 tt0 71.29 -55.84 0.64 Allowed 'General case' 0 N--CA 1.47 0.553 0 C-N-CA 123.502 0.721 . . . . 0.0 112.724 177.113 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 44.7 m-80 -96.18 14.93 22.36 Favored 'General case' 0 C--N 1.315 -0.919 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.341 -175.309 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' GLN . . . . . 0.478 ' HG2' ' HB3' ' A' ' 120' ' ' TYR . 59.2 tt0 -152.36 115.43 4.66 Favored 'General case' 0 C--N 1.316 -0.883 0 CA-C-O 120.992 0.425 . . . . 0.0 109.944 -177.731 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 76.5 m-20 -78.71 160.97 27.2 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.581 -0.736 . . . . 0.0 111.421 -176.376 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 90.6 t -87.97 133.04 31.58 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.496 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.205 175.252 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . 0.557 ' HB ' ' OG ' ' A' ' 40' ' ' SER . 35.3 m -116.03 -28.02 2.39 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 N-CA-C 113.345 0.869 . . . . 0.0 113.345 -176.41 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . 0.504 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -146.94 137.66 23.77 Favored 'General case' 0 C--N 1.325 -0.483 0 C-N-CA 120.341 -0.544 . . . . 0.0 111.285 179.237 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.505 ' HB ' HG22 ' A' ' 38' ' ' VAL . 91.5 mt -133.85 127.91 52.88 Favored 'Isoleucine or valine' 0 C--O 1.242 0.699 0 CA-C-N 116.354 -0.384 . . . . 0.0 110.608 179.011 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . 0.473 ' C ' HD22 ' A' ' 104' ' ' ASN . 0.2 OUTLIER -126.31 99.48 5.88 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 175.258 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.438 ' CG2' ' HB ' ' A' ' 36' ' ' ILE . 19.5 m -137.92 141.11 39.5 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 N-CA-C 112.546 0.573 . . . . 0.0 112.546 -176.925 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 70.4 tt0 -142.14 138.02 31.32 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.705 -0.679 . . . . 0.0 109.583 177.466 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 28.8 t -140.7 142.24 34.89 Favored 'General case' 0 N--CA 1.448 -0.529 0 CA-C-O 121.038 0.447 . . . . 0.0 111.801 -178.682 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -107.97 9.99 37.17 Favored Glycine 0 N--CA 1.443 -0.846 0 N-CA-C 110.759 -0.936 . . . . 0.0 110.759 175.361 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 20.5 m-20 -91.64 14.03 16.3 Favored 'General case' 0 N--CA 1.466 0.348 0 C-N-CA 122.909 0.484 . . . . 0.0 110.401 -177.829 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 12.4 m-20 63.37 30.88 15.45 Favored 'General case' 0 N--CA 1.471 0.612 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.741 -177.554 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . 0.658 ' HA3' ' OD1' ' A' ' 32' ' ' ASN . . . 89.03 7.11 70.79 Favored Glycine 0 N--CA 1.449 -0.456 0 CA-C-N 115.654 -0.703 . . . . 0.0 114.273 175.271 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 52.9 tt0 -65.21 -47.85 75.45 Favored 'General case' 0 C--O 1.237 0.438 0 CA-C-N 117.438 0.619 . . . . 0.0 110.198 177.67 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . 0.438 ' HA ' ' O ' ' A' ' 130' ' ' GLY . 2.0 p -134.18 118.3 17.5 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-N 115.492 -0.776 . . . . 0.0 111.037 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -95.33 122.29 37.89 Favored 'General case' 0 C--N 1.319 -0.754 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.273 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 93.4 m-20 -123.42 148.6 45.98 Favored 'General case' 0 C--N 1.312 -1.036 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.703 -178.71 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 160.66 -135.29 3.95 Favored Glycine 0 N--CA 1.438 -1.184 0 C-N-CA 120.362 -0.923 . . . . 0.0 112.775 177.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 25.8 p -133.28 156.77 46.97 Favored 'General case' 0 C--N 1.316 -0.885 0 C-N-CA 122.858 0.463 . . . . 0.0 109.962 -178.532 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 11.3 ptm -151.4 157.61 42.64 Favored 'General case' 0 C--N 1.312 -1.046 0 CA-C-O 120.614 0.245 . . . . 0.0 110.822 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 119' ' ' THR . . . . . 0.504 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 38.0 m -132.51 131.02 41.18 Favored 'General case' 0 C--O 1.249 1.079 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.041 179.717 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . 0.478 ' HB3' ' HG2' ' A' ' 98' ' ' GLN . 78.3 m-85 -93.72 166.89 11.99 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.934 -0.575 . . . . 0.0 109.961 176.644 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -63.22 118.29 7.76 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.675 -0.239 . . . . 0.0 110.731 178.837 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 68.2 34.63 81.2 Favored Glycine 0 C--N 1.333 0.395 0 C-N-CA 120.819 -0.705 . . . . 0.0 111.613 -178.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . 0.427 ' CB ' ' HB2' ' A' ' 120' ' ' TYR . 31.6 tp10 -132.61 163.24 29.34 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 -176.723 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -94.41 159.21 23.2 Favored Glycine 0 N--CA 1.442 -0.947 0 N-CA-C 110.553 -1.019 . . . . 0.0 110.553 176.24 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_endo -62.52 132.78 39.58 Favored 'Trans proline' 0 C--O 1.237 0.464 0 C-N-CA 122.177 1.918 . . . . 0.0 111.885 -179.782 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 126' ' ' ILE . . . . . 0.438 HD12 ' HB3' ' A' ' 8' ' ' ASN . 40.9 pt -132.79 166.19 30.1 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 CA-C-N 115.932 -0.577 . . . . 0.0 110.464 -179.742 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -70.61 141.49 33.6 Favored Glycine 0 C--O 1.242 0.615 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.176 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 82.7 t80 -123.67 135.57 53.98 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-O 120.824 0.345 . . . . 0.0 111.188 -178.725 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 62.4 tttm -139.3 118.93 13.06 Favored 'General case' 0 N--CA 1.445 -0.713 0 CA-C-N 115.497 -0.774 . . . . 0.0 109.313 177.178 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . 0.487 ' HA2' ' O ' ' A' ' 5' ' ' ASN . . . -125.26 137.94 10.67 Favored Glycine 0 N--CA 1.445 -0.737 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.054 179.67 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 59.4 m -123.63 129.69 51.53 Favored 'General case' 0 C--N 1.313 -0.98 0 CA-C-N 116.853 0.327 . . . . 0.0 110.817 -179.303 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -67.45 117.7 9.78 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-O 121.186 0.517 . . . . 0.0 111.429 -178.163 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 15.0 m . . . . . 0 C--O 1.25 1.1 0 CA-C-N 115.707 -0.678 . . . . 0.0 110.612 176.229 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.807 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' LEU . . . . . 0.414 HD11 ' NE2' ' A' ' 22' ' ' GLN . 2.2 tm? -89.99 126.71 35.85 Favored 'General case' 0 C--N 1.315 -0.917 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -178.987 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . 0.474 ' CE1' ' HB ' ' A' ' 25' ' ' ILE . 58.0 m-85 -114.53 141.46 47.7 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.225 -178.796 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 23.4 t-20 -93.72 137.85 32.55 Favored 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 106.719 -1.586 . . . . 0.0 106.719 174.918 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.435 HG21 ' CG ' ' A' ' 23' ' ' TRP . 59.0 t -114.48 128.31 71.58 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.894 0 N-CA-C 113.287 0.847 . . . . 0.0 113.287 -173.679 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -118.31 133.05 56.22 Favored 'General case' 0 C--O 1.245 0.833 0 CA-C-N 114.748 -1.114 . . . . 0.0 109.283 176.907 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 12.0 m120 -110.32 135.38 51.15 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.076 -177.411 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . 0.434 ' OE1' ' HA ' ' A' ' 13' ' ' SER . 36.0 tt0 -120.45 114.23 21.48 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 120.988 0.423 . . . . 0.0 110.448 175.713 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 2.4 p90 -112.12 175.66 5.34 Favored 'General case' 0 C--N 1.311 -1.097 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.487 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 69.87 -71.34 0.56 Allowed Glycine 0 CA--C 1.529 0.948 0 CA-C-N 115.706 -0.679 . . . . 0.0 112.956 -176.847 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -165.08 168.3 39.16 Favored Glycine 0 N--CA 1.446 -0.684 0 C-N-CA 121.014 -0.612 . . . . 0.0 112.304 -178.458 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . 0.434 ' HA ' ' OE1' ' A' ' 9' ' ' GLN . 28.2 t -62.85 -19.55 64.23 Favored 'General case' 0 CA--C 1.54 0.563 0 N-CA-C 112.329 0.492 . . . . 0.0 112.329 -178.669 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 30.4 p -77.47 -6.83 54.92 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.873 0.368 . . . . 0.0 111.76 179.411 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -86.69 149.36 48.35 Favored Pre-proline 0 C--N 1.323 -0.584 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.548 179.131 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_endo -69.14 162.43 41.8 Favored 'Trans proline' 0 C--O 1.237 0.458 0 C-N-CA 122.529 2.153 . . . . 0.0 112.086 179.071 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 98.3 m95 -85.65 124.26 31.98 Favored 'General case' 0 C--N 1.317 -0.837 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 179.695 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 92.4 m-20 -111.44 113.42 25.86 Favored 'General case' 0 C--N 1.309 -1.154 0 CA-C-N 116.332 -0.394 . . . . 0.0 111.059 -175.89 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 80.6 tt0 -71.97 122.43 20.84 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-N 115.826 -0.625 . . . . 0.0 109.611 179.864 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -137.69 25.6 2.95 Favored Glycine 0 N--CA 1.446 -0.679 0 C-N-CA 120.29 -0.957 . . . . 0.0 112.559 -177.93 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . 0.414 ' HA3' ' HB3' ' A' ' 94' ' ' SER . . . 156.63 -172.39 34.33 Favored Glycine 0 N--CA 1.433 -1.524 0 C-N-CA 119.961 -1.114 . . . . 0.0 112.651 179.205 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . 0.414 ' NE2' HD11 ' A' ' 3' ' ' LEU . 19.6 pt20 -150.34 145.43 26.13 Favored 'General case' 0 C--N 1.31 -1.11 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 179.299 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . 0.435 ' CG ' HG21 ' A' ' 6' ' ' VAL . 43.7 m0 -122.47 159.45 27.61 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.749 -177.172 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . 0.409 ' H ' ' HB ' ' A' ' 91' ' ' ILE . 79.3 tt0 -118.05 119.71 35.59 Favored 'General case' 0 C--N 1.306 -1.316 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 176.079 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.474 ' HB ' ' CE1' ' A' ' 4' ' ' TYR . 98.9 mt -127.87 135.14 63.76 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-N 115.432 -0.804 . . . . 0.0 109.934 -175.011 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 89.07 71.83 1.27 Allowed Glycine 0 N--CA 1.435 -1.427 0 C-N-CA 119.718 -1.229 . . . . 0.0 111.944 -179.878 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . 0.457 ' OG ' ' HA3' ' A' ' 88' ' ' GLY . 7.5 t -59.44 -39.38 83.39 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 176.829 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 73.3 ttt180 -82.22 113.03 19.77 Favored 'General case' 0 N--CA 1.439 -1.013 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 174.599 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 30.8 m -78.3 -13.71 59.73 Favored 'General case' 0 C--N 1.315 -0.892 0 CA-C-O 120.965 0.412 . . . . 0.0 111.777 -174.963 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 23.2 t70 -72.0 -33.43 68.09 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.403 0.62 . . . . 0.0 110.987 178.865 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . 0.597 HE21 ' HA ' ' A' ' 31' ' ' GLN . 0.0 OUTLIER -126.17 120.62 30.57 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.63 -0.713 . . . . 0.0 111.012 -177.369 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . 0.546 ' ND2' ' HA3' ' A' ' 111' ' ' GLY . 64.2 t30 -95.04 154.41 17.19 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.532 -0.304 . . . . 0.0 110.235 178.943 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.451 ' HA ' ' HA ' ' A' ' 53' ' ' TYR . 62.0 t -96.22 133.53 37.15 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.541 -176.457 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 28.4 m -113.49 -14.54 10.83 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.151 0 N-CA-C 112.299 0.481 . . . . 0.0 112.299 178.891 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.513 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -147.49 138.96 23.86 Favored 'General case' 0 C--N 1.323 -0.565 0 C-N-CA 120.391 -0.524 . . . . 0.0 111.487 179.552 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.417 ' HB ' HG22 ' A' ' 105' ' ' VAL . 88.8 mt -141.42 123.3 13.97 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-N 116.058 -0.519 . . . . 0.0 109.912 -179.6 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -128.97 109.39 11.19 Favored 'General case' 0 C--N 1.309 -1.188 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 174.055 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.441 HG11 ' CD1' ' A' ' 61' ' ' PHE . 18.4 m -146.49 148.13 17.28 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 C-N-CA 120.674 -0.41 . . . . 0.0 112.012 -174.356 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 66.7 tt0 -138.42 140.54 39.36 Favored 'General case' 0 C--N 1.315 -0.899 0 CA-C-N 115.214 -0.903 . . . . 0.0 108.619 176.293 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . 0.431 ' HA ' ' O ' ' A' ' 46' ' ' THR . 94.7 p -81.55 153.8 26.58 Favored 'General case' 0 C--N 1.308 -1.216 0 CA-C-O 120.921 0.391 . . . . 0.0 111.946 -176.84 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -97.43 -57.14 1.07 Allowed Glycine 0 N--CA 1.435 -1.393 0 CA-C-N 115.765 -0.652 . . . . 0.0 111.767 176.934 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -113.54 98.4 7.04 Favored 'General case' 0 CA--C 1.533 0.315 0 N-CA-C 111.924 0.342 . . . . 0.0 111.924 -178.477 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 14.1 m-20 47.76 34.53 3.88 Favored 'General case' 0 N--CA 1.492 1.667 0 N-CA-C 114.454 1.279 . . . . 0.0 114.454 175.222 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.418 ' HA2' ' CB ' ' A' ' 40' ' ' SER . . . 80.11 0.65 86.45 Favored Glycine 0 C--N 1.319 -0.41 0 C-N-CA 120.438 -0.887 . . . . 0.0 113.793 178.196 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 59.9 mt-30 -77.4 -30.45 53.59 Favored 'General case' 0 CA--C 1.513 -0.458 0 CA-C-N 117.398 0.599 . . . . 0.0 111.331 178.999 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . 0.431 ' O ' ' HA ' ' A' ' 40' ' ' SER . 5.1 p -122.83 107.02 11.42 Favored 'General case' 0 C--N 1.308 -1.229 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.999 -179.472 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' LEU . . . . . 0.512 ' HB2' ' HB3' ' A' ' 63' ' ' ALA . 90.8 mt -89.91 129.16 36.3 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 177.534 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 15.4 m120 -126.65 136.99 53.23 Favored 'General case' 0 C--N 1.318 -0.804 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 171.03 -153.32 20.47 Favored Glycine 0 N--CA 1.443 -0.857 0 C-N-CA 118.876 -1.63 . . . . 0.0 114.057 178.813 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 52.4 m -127.43 131.92 50.16 Favored 'General case' 0 C--N 1.315 -0.899 0 C-N-CA 123.14 0.576 . . . . 0.0 109.455 -178.002 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' MET . . . . . 0.534 ' HE3' HD11 ' A' ' 59' ' ' ILE . 15.5 tmm? -128.52 139.8 52.13 Favored 'General case' 0 C--N 1.315 -0.927 0 C-N-CA 121.31 -0.156 . . . . 0.0 110.65 -178.842 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.513 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 33.8 m -124.24 128.73 49.61 Favored 'General case' 0 C--O 1.253 1.286 0 CA-C-O 121.135 0.493 . . . . 0.0 111.773 -176.718 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . 0.451 ' HA ' ' HA ' ' A' ' 33' ' ' VAL . 78.4 m-85 -84.76 163.73 18.96 Favored 'General case' 0 N--CA 1.462 0.147 0 CA-C-N 115.532 -0.758 . . . . 0.0 110.951 177.958 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -58.06 109.14 0.69 Allowed 'General case' 0 N--CA 1.469 0.478 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.957 -179.228 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 72.81 18.45 78.87 Favored Glycine 0 C--O 1.225 -0.414 0 C-N-CA 121.133 -0.556 . . . . 0.0 113.054 178.007 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . 0.432 ' HB2' ' HB2' ' A' ' 53' ' ' TYR . 70.2 mm-40 -117.76 174.19 6.32 Favored 'General case' 0 C--N 1.317 -0.817 0 N-CA-C 110.197 -0.297 . . . . 0.0 110.197 -179.062 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -86.71 157.03 29.5 Favored Glycine 0 N--CA 1.444 -0.827 0 C-N-CA 120.685 -0.769 . . . . 0.0 111.733 178.418 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -67.86 141.23 53.19 Favored 'Trans proline' 0 C--O 1.234 0.286 0 C-N-CA 122.64 2.227 . . . . 0.0 111.986 179.497 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . 0.534 HD11 ' HE3' ' A' ' 51' ' ' MET . 39.6 pt -131.33 165.53 31.33 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.852 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.678 179.92 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -72.83 136.84 23.43 Favored Glycine 0 N--CA 1.447 -0.598 0 C-N-CA 120.889 -0.672 . . . . 0.0 111.499 -179.634 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.441 ' CD1' HG11 ' A' ' 38' ' ' VAL . 47.9 t80 -121.48 124.85 45.43 Favored 'General case' 0 C--N 1.313 -0.999 0 CA-C-O 120.722 0.296 . . . . 0.0 110.943 -178.462 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . 0.494 ' HA ' ' O ' ' A' ' 47' ' ' LEU . 62.0 ttp180 -135.65 129.59 33.03 Favored 'General case' 0 N--CA 1.445 -0.691 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 173.824 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.512 ' HB3' ' HB2' ' A' ' 47' ' ' LEU . . . -127.65 136.72 52.0 Favored 'General case' 0 C--N 1.311 -1.077 0 CA-C-O 120.667 0.27 . . . . 0.0 110.584 -179.836 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 28.2 m -114.16 124.68 52.66 Favored 'General case' 0 N--CA 1.435 -1.199 0 CA-C-N 116.035 -0.53 . . . . 0.0 109.861 177.914 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . 0.538 HD11 ' O ' ' A' ' 67' ' ' GLY . 2.7 tm? -63.25 129.24 39.43 Favored 'General case' 0 C--N 1.31 -1.151 0 CA-C-N 115.604 -0.725 . . . . 0.0 110.945 -179.34 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 96.5 mt -95.74 -40.42 9.37 Favored 'General case' 0 C--O 1.225 -0.199 0 CA-C-O 121.103 0.478 . . . . 0.0 111.094 178.505 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.538 ' O ' HD11 ' A' ' 65' ' ' LEU . . . -140.27 -79.93 0.06 OUTLIER Glycine 0 CA--C 1.499 -0.964 0 N-CA-C 110.766 -0.933 . . . . 0.0 110.766 -178.3 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 65.1 m-80 -146.01 -71.32 0.25 Allowed 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 107.527 -1.286 . . . . 0.0 107.527 174.389 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . 0.422 ' HB3' HG23 ' A' ' 91' ' ' ILE . 84.4 m-20 -67.77 -39.87 84.06 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.652 -0.704 . . . . 0.0 111.458 176.501 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 23.3 t -81.48 130.45 35.05 Favored 'General case' 0 CA--C 1.538 0.492 0 N-CA-C 113.025 0.75 . . . . 0.0 113.025 -174.334 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.452 ' OH ' ' HB3' ' A' ' 99' ' ' ASN . 56.9 m-85 -127.66 145.21 50.96 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.106 -0.952 . . . . 0.0 109.919 177.08 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -105.43 125.19 50.7 Favored 'General case' 0 C--N 1.312 -1.053 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 174.401 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.456 HG22 ' HB2' ' A' ' 63' ' ' ALA . 62.2 t -111.03 137.74 42.21 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.162 0 N-CA-C 113.225 0.824 . . . . 0.0 113.225 -171.914 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 63.9 mt-10 -126.53 129.74 49.22 Favored 'General case' 0 N--CA 1.442 -0.871 0 CA-C-N 114.578 -1.192 . . . . 0.0 108.257 176.344 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' ASN . . . . . 0.509 ' HB3' HD12 ' A' ' 59' ' ' ILE . 12.1 m120 -110.12 151.51 27.16 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-O 121.167 0.508 . . . . 0.0 111.693 -178.033 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' GLN . . . . . 0.463 ' HB2' ' CE3' ' A' ' 84' ' ' TRP . 62.3 tt0 -117.19 121.04 40.11 Favored 'General case' 0 C--N 1.311 -1.071 0 CA-C-N 115.359 -0.837 . . . . 0.0 110.113 -178.725 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 4.7 p90 -142.7 161.78 37.18 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.855 -179.241 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 99.83 -12.22 60.91 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 121.026 -0.607 . . . . 0.0 112.437 178.715 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 140.53 160.1 8.18 Favored Glycine 0 N--CA 1.441 -1.029 0 N-CA-C 111.087 -0.805 . . . . 0.0 111.087 179.388 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 24.7 m-20 -62.75 -35.04 78.49 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-O 120.828 0.347 . . . . 0.0 111.617 -179.319 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 5.1 m -72.53 -12.9 61.26 Favored 'General case' 0 CA--C 1.54 0.592 0 CA-C-N 116.228 -0.442 . . . . 0.0 112.003 -179.709 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -75.96 147.83 80.99 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-O 120.518 0.199 . . . . 0.0 111.217 -178.424 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -72.14 -178.44 3.23 Favored 'Trans proline' 0 C--O 1.24 0.602 0 C-N-CA 122.733 2.289 . . . . 0.0 112.289 178.762 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' TRP . . . . . 0.463 ' CE3' ' HB2' ' A' ' 76' ' ' GLN . 92.3 m95 -91.64 139.66 30.47 Favored 'General case' 0 C--N 1.319 -0.718 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 -179.358 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 93.7 m-70 -115.48 148.46 39.43 Favored 'General case' 0 C--N 1.315 -0.922 0 N-CA-C 109.689 -0.486 . . . . 0.0 109.689 -179.32 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 13.2 p -64.59 135.36 55.89 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-O 120.778 0.323 . . . . 0.0 110.856 -178.94 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -110.37 -52.36 0.6 Allowed Glycine 0 N--CA 1.442 -0.906 0 C-N-CA 120.52 -0.848 . . . . 0.0 111.958 -179.549 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.457 ' HA3' ' OG ' ' A' ' 27' ' ' SER . . . 147.72 -162.87 28.77 Favored Glycine 0 N--CA 1.444 -0.824 0 C-N-CA 120.212 -0.994 . . . . 0.0 112.822 179.698 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 17.1 m120 -104.08 134.9 46.57 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 120.832 0.349 . . . . 0.0 110.953 -178.557 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 11.8 m0 -127.38 150.8 49.45 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.929 -0.578 . . . . 0.0 109.714 179.002 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . 0.422 HG23 ' HB3' ' A' ' 69' ' ' ASN . 50.1 mm -113.93 110.03 30.67 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.927 0 N-CA-C 109.021 -0.733 . . . . 0.0 109.021 177.729 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . 0.41 ' O ' HG13 ' A' ' 100' ' ' VAL . 78.0 mt -132.84 75.8 1.65 Allowed 'General case' 0 C--O 1.26 1.649 0 CA-C-O 121.893 0.854 . . . . 0.0 111.835 -177.325 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . 0.4 ' O ' ' HB2' ' A' ' 94' ' ' SER . . . -150.15 -91.64 0.09 OUTLIER Glycine 0 N--CA 1.448 -0.504 0 CA-C-N 115.399 -0.819 . . . . 0.0 112.9 -178.901 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . 0.414 ' HB3' ' HA3' ' A' ' 21' ' ' GLY . 69.6 m 78.29 8.56 2.26 Favored 'General case' 0 N--CA 1.482 1.13 0 C-N-CA 124.092 0.957 . . . . 0.0 112.181 -177.378 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' ARG . . . . . 0.492 ' HB2' ' O ' ' A' ' 98' ' ' GLN . 95.9 mtt180 -137.6 145.03 42.29 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 116.083 -0.508 . . . . 0.0 109.725 177.557 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 78.1 tt0 -70.44 -45.64 65.44 Favored 'General case' 0 C--N 1.315 -0.906 0 N-CA-C 112.622 0.601 . . . . 0.0 112.622 -172.729 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 7.2 p30 -117.41 20.89 13.4 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.26 0.552 . . . . 0.0 111.207 -179.269 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' GLN . . . . . 0.492 ' O ' ' HB2' ' A' ' 95' ' ' ARG . 90.5 mt-30 -139.78 115.63 10.22 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-N 115.658 -0.701 . . . . 0.0 111.12 179.635 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' ASN . . . . . 0.452 ' HB3' ' OH ' ' A' ' 71' ' ' TYR . 85.2 m-20 -108.49 176.19 5.2 Favored 'General case' 0 C--N 1.306 -1.309 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 179.575 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.41 HG13 ' O ' ' A' ' 92' ' ' LEU . 33.6 m -78.22 133.69 29.78 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.668 0 C-N-CA 119.565 -0.854 . . . . 0.0 111.352 179.348 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 35.4 m -113.92 -31.09 2.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.165 177.243 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . 0.573 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -148.18 133.32 18.32 Favored 'General case' 0 CA--C 1.511 -0.546 0 C-N-CA 120.688 -0.405 . . . . 0.0 110.475 178.003 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 89.6 mt -130.16 125.1 59.39 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.785 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.961 179.78 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 10.0 t30 -126.19 100.38 6.29 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.704 -0.68 . . . . 0.0 109.574 175.631 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.417 HG22 ' HB ' ' A' ' 36' ' ' ILE . 27.7 m -141.46 140.96 30.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-N 115.983 -0.553 . . . . 0.0 112.326 -176.121 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 61.5 mt-10 -143.66 149.53 37.39 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.2 -0.909 . . . . 0.0 109.606 177.111 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . 0.409 ' HB2' HD23 ' A' ' 114' ' ' LEU . 46.3 t -128.66 144.62 51.2 Favored 'General case' 0 C--N 1.313 -0.994 0 CA-C-O 120.966 0.412 . . . . 0.0 111.508 -178.842 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -91.63 -4.46 67.76 Favored Glycine 0 N--CA 1.439 -1.16 0 N-CA-C 110.656 -0.978 . . . . 0.0 110.656 175.161 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 35.4 m-20 -98.28 -167.62 1.53 Allowed 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 -179.528 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 110' ' ' ASP . . . . . 0.42 ' OD1' ' HG3' ' A' ' 112' ' ' GLN . 7.3 p-10 -93.86 21.22 6.79 Favored 'General case' 0 C--N 1.311 -1.082 0 CA-C-O 121.291 0.567 . . . . 0.0 109.864 178.041 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . 0.546 ' HA3' ' ND2' ' A' ' 32' ' ' ASN . . . 105.34 9.77 32.99 Favored Glycine 0 C--O 1.22 -0.753 0 C-N-CA 120.761 -0.733 . . . . 0.0 113.466 -178.525 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 112' ' ' GLN . . . . . 0.431 ' HA ' HD12 ' A' ' 132' ' ' LEU . 98.3 mt-30 -64.72 -43.8 92.26 Favored 'General case' 0 C--O 1.242 0.66 0 CA-C-N 117.439 0.62 . . . . 0.0 110.681 178.89 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 81.8 p -136.48 145.76 45.52 Favored 'General case' 0 N--CA 1.444 -0.758 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.937 176.445 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 114' ' ' LEU . . . . . 0.409 HD23 ' HB2' ' A' ' 107' ' ' SER . 88.8 mt -116.54 129.75 56.36 Favored 'General case' 0 C--N 1.315 -0.922 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 179.312 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 15.3 m120 -120.5 142.87 48.9 Favored 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 110.318 -0.253 . . . . 0.0 110.318 -178.916 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 163.77 -141.19 6.94 Favored Glycine 0 N--CA 1.444 -0.8 0 C-N-CA 119.385 -1.388 . . . . 0.0 113.426 176.586 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 3.0 p -130.91 151.02 51.79 Favored 'General case' 0 C--N 1.311 -1.1 0 C-N-CA 123.056 0.542 . . . . 0.0 110.209 -178.295 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 118' ' ' MET . . . . . 0.624 ' SD ' ' HD1' ' A' ' 128' ' ' PHE . 20.0 ptm -136.96 144.5 43.42 Favored 'General case' 0 C--N 1.31 -1.128 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.253 -177.792 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 119' ' ' THR . . . . . 0.573 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 24.5 m -128.8 126.47 39.95 Favored 'General case' 0 C--O 1.252 1.22 0 CA-C-O 120.737 0.303 . . . . 0.0 110.535 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 42.1 m-85 -98.39 162.62 13.07 Favored 'General case' 0 CA--C 1.509 -0.631 0 CA-C-N 115.616 -0.72 . . . . 0.0 111.167 179.563 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -59.17 114.91 2.85 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 115.489 -0.778 . . . . 0.0 111.169 176.842 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 78.04 17.49 78.26 Favored Glycine 0 N--CA 1.451 -0.354 0 CA-C-N 115.787 -0.642 . . . . 0.0 114.014 177.759 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 69.2 tt0 -142.26 144.02 33.12 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 117.47 0.635 . . . . 0.0 110.566 179.837 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -69.03 163.77 50.48 Favored Glycine 0 CA--C 1.522 0.53 0 CA-C-N 116.141 -0.481 . . . . 0.0 113.246 -177.436 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . 0.492 ' HA ' ' O ' ' A' ' 118' ' ' MET . 23.7 Cg_exo -63.46 138.72 66.88 Favored 'Trans proline' 0 C--N 1.347 0.492 0 C-N-CA 122.784 2.322 . . . . 0.0 112.887 -178.752 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 41.0 pt -131.04 167.75 25.4 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.806 0 CA-C-N 115.532 -0.758 . . . . 0.0 109.675 177.467 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -69.0 136.96 29.31 Favored Glycine 0 C--O 1.236 0.281 0 C-N-CA 120.994 -0.622 . . . . 0.0 112.354 -178.754 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . 0.624 ' HD1' ' SD ' ' A' ' 118' ' ' MET . 82.4 t80 -118.59 133.8 55.59 Favored 'General case' 0 C--O 1.249 1.072 0 CA-C-O 120.963 0.411 . . . . 0.0 111.526 -178.564 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 64.1 tttm -136.52 111.44 8.86 Favored 'General case' 0 N--CA 1.442 -0.861 0 CA-C-N 115.562 -0.745 . . . . 0.0 109.782 175.678 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -104.87 133.01 11.35 Favored Glycine 0 N--CA 1.441 -0.997 0 N-CA-C 110.94 -0.864 . . . . 0.0 110.94 178.314 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 25.7 m -128.97 132.9 47.63 Favored 'General case' 0 C--N 1.311 -1.102 0 CA-C-N 116.944 0.372 . . . . 0.0 110.092 -178.754 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 132' ' ' LEU . . . . . 0.431 HD12 ' HA ' ' A' ' 112' ' ' GLN . 74.0 mt -59.81 130.52 47.19 Favored 'General case' 0 N--CA 1.467 0.396 0 C-N-CA 120.301 -0.559 . . . . 0.0 110.799 177.726 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 52.8 m . . . . . 0 C--O 1.247 0.929 0 CA-C-O 118.512 -0.756 . . . . 0.0 110.734 -179.196 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.741 0 CA-C-O 120.897 0.38 . . . . 0.0 110.749 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' LEU . . . . . 0.557 HD11 HE21 ' A' ' 22' ' ' GLN . 3.2 tm? -92.68 130.39 38.32 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.064 179.313 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 81.4 m-85 -119.27 144.9 46.53 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.954 -0.566 . . . . 0.0 111.777 -179.242 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' ASN . . . . . 0.512 ' O ' ' HA2' ' A' ' 130' ' ' GLY . 11.5 t-20 -96.32 136.03 37.36 Favored 'General case' 0 C--N 1.313 -0.988 0 N-CA-C 107.706 -1.22 . . . . 0.0 107.706 179.269 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 78.7 t -116.56 127.11 74.25 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 CA-C-O 121.529 0.681 . . . . 0.0 112.703 -174.59 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.448 ' HB2' ' HB3' ' A' ' 129' ' ' LYS . 45.4 mt-10 -116.58 138.8 51.14 Favored 'General case' 0 N--CA 1.44 -0.926 0 CA-C-N 114.949 -1.023 . . . . 0.0 108.286 175.275 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 10.6 m120 -116.29 139.3 50.52 Favored 'General case' 0 C--N 1.306 -1.32 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.545 -178.442 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . 0.506 ' HB2' ' CE3' ' A' ' 17' ' ' TRP . 54.4 tt0 -129.36 124.3 33.9 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.703 -0.68 . . . . 0.0 109.767 179.33 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 20.1 p90 -122.99 136.84 55.01 Favored 'General case' 0 C--N 1.307 -1.262 0 CA-C-O 120.849 0.357 . . . . 0.0 111.222 179.213 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 111.17 -75.49 0.21 Allowed Glycine 0 N--CA 1.445 -0.752 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.851 -179.653 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -162.34 163.65 35.13 Favored Glycine 0 N--CA 1.449 -0.438 0 N-CA-C 111.617 -0.593 . . . . 0.0 111.617 179.725 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . 0.434 ' HA ' ' NE2' ' A' ' 9' ' ' GLN . 12.1 m -64.07 -19.06 64.97 Favored 'General case' 0 CA--C 1.536 0.44 0 N-CA-C 112.279 0.474 . . . . 0.0 112.279 -179.002 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 35.3 p -72.42 -18.22 61.73 Favored 'General case' 0 CA--C 1.539 0.536 0 CA-C-O 120.988 0.423 . . . . 0.0 111.231 178.799 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -80.66 155.0 73.73 Favored Pre-proline 0 CA--C 1.533 0.317 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.695 -179.755 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 66.6 Cg_endo -72.11 158.68 51.7 Favored 'Trans proline' 0 C--O 1.236 0.393 0 C-N-CA 122.47 2.113 . . . . 0.0 112.783 178.701 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' TRP . . . . . 0.506 ' CE3' ' HB2' ' A' ' 9' ' ' GLN . 94.4 m95 -89.22 138.6 31.28 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.408 179.624 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 90.5 m-20 -124.08 129.9 51.64 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 109.141 -0.689 . . . . 0.0 109.141 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 42.6 tt0 -61.37 128.04 34.43 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-O 120.962 0.41 . . . . 0.0 111.299 -178.305 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -108.7 -0.63 32.38 Favored Glycine 0 N--CA 1.448 -0.52 0 CA-C-N 115.469 -0.787 . . . . 0.0 112.805 -178.821 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 130.27 -150.11 19.09 Favored Glycine 0 N--CA 1.443 -0.881 0 C-N-CA 120.335 -0.936 . . . . 0.0 112.249 -179.83 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . 0.557 HE21 HD11 ' A' ' 3' ' ' LEU . 4.2 pt20 -145.5 138.02 25.83 Favored 'General case' 0 C--N 1.319 -0.738 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.771 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 45.3 m0 -117.14 155.23 29.69 Favored 'General case' 0 C--N 1.318 -0.761 0 CA-C-O 120.89 0.376 . . . . 0.0 111.159 -178.429 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -109.11 112.64 24.93 Favored 'General case' 0 C--N 1.317 -0.812 0 N-CA-C 109.511 -0.551 . . . . 0.0 109.511 177.481 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 95.8 mt -130.7 136.82 57.47 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.585 0 CA-C-N 115.203 -0.908 . . . . 0.0 109.762 -178.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 91.55 106.81 1.49 Allowed Glycine 0 N--CA 1.442 -0.911 0 C-N-CA 120.208 -0.996 . . . . 0.0 111.966 -179.383 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 13.9 m -111.86 13.58 20.95 Favored 'General case' 0 C--N 1.31 -1.136 0 CA-C-O 121.208 0.528 . . . . 0.0 110.311 -178.699 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 94.7 mtt-85 -137.44 128.17 27.03 Favored 'General case' 0 N--CA 1.445 -0.72 0 CA-C-N 116.004 -0.544 . . . . 0.0 109.967 -177.069 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 34.5 t -76.77 -17.43 59.05 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-O 121.207 0.527 . . . . 0.0 110.215 179.353 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 15.8 m-20 -75.0 -47.56 28.52 Favored 'General case' 0 C--O 1.224 -0.275 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.904 -178.033 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . 0.447 HE21 ' HB3' ' A' ' 53' ' ' TYR . 14.3 mm100 -128.71 123.19 32.45 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.603 -0.726 . . . . 0.0 111.234 -176.575 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . 0.663 ' ND2' ' HA3' ' A' ' 111' ' ' GLY . 62.5 t30 -101.18 161.74 13.39 Favored 'General case' 0 C--N 1.319 -0.751 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 178.348 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 46.6 t -94.69 130.73 43.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-O 120.572 0.225 . . . . 0.0 111.409 -173.771 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 28.7 m -110.59 -18.57 7.5 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.276 0 CA-C-N 116.464 -0.335 . . . . 0.0 111.731 179.224 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.533 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -154.6 149.67 26.88 Favored 'General case' 0 C--O 1.237 0.416 0 C-N-CA 120.563 -0.455 . . . . 0.0 111.685 178.682 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.495 ' HB ' ' CG2' ' A' ' 105' ' ' VAL . 89.9 mt -144.09 123.63 7.84 Favored 'Isoleucine or valine' 0 C--O 1.235 0.308 0 CA-C-N 115.97 -0.559 . . . . 0.0 109.64 -179.743 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 13.4 m120 -124.82 106.58 10.14 Favored 'General case' 0 C--N 1.313 -1.012 0 N-CA-C 107.767 -1.197 . . . . 0.0 107.767 175.844 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 36.0 m -147.68 149.56 15.32 Favored 'Isoleucine or valine' 0 C--O 1.237 0.436 0 C-N-CA 120.146 -0.622 . . . . 0.0 111.957 -172.757 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 66.7 mt-10 -142.55 149.1 38.63 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.299 -0.864 . . . . 0.0 109.325 175.337 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 20.5 p -73.97 142.62 45.84 Favored 'General case' 0 C--N 1.307 -1.25 0 N-CA-C 112.104 0.409 . . . . 0.0 112.104 -177.444 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -88.62 -42.56 5.73 Favored Glycine 0 N--CA 1.443 -0.841 0 N-CA-C 109.148 -1.581 . . . . 0.0 109.148 174.755 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 48.8 m-20 -105.18 -161.55 0.82 Allowed 'General case' 0 C--N 1.317 -0.836 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 175.045 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -76.17 47.98 0.48 Allowed 'General case' 0 N--CA 1.474 0.766 0 N-CA-C 112.303 0.483 . . . . 0.0 112.303 -178.361 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 91.64 -8.55 78.51 Favored Glycine 0 C--O 1.222 -0.649 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.223 178.969 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 56.1 mt-30 -70.23 -36.23 74.39 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.99 0.424 . . . . 0.0 110.713 178.356 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 22.0 p -122.58 139.4 53.95 Favored 'General case' 0 C--N 1.311 -1.106 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.207 179.66 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' LEU . . . . . 0.435 ' HB2' ' HB3' ' A' ' 63' ' ' ALA . 91.2 mt -125.94 127.05 45.36 Favored 'General case' 0 C--N 1.315 -0.932 0 N-CA-C 108.509 -0.923 . . . . 0.0 108.509 179.865 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 88.9 m-20 -125.3 138.07 54.08 Favored 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 109.376 -0.602 . . . . 0.0 109.376 -179.352 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 173.25 -151.23 13.26 Favored Glycine 0 N--CA 1.443 -0.873 0 C-N-CA 120.078 -1.058 . . . . 0.0 112.558 178.853 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 33.6 p -132.49 146.87 52.25 Favored 'General case' 0 N--CA 1.443 -0.8 0 CA-C-O 121.003 0.43 . . . . 0.0 110.921 179.692 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 40.7 mtp -121.12 156.49 32.18 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.74 177.18 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.533 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 26.8 m -132.1 126.35 33.53 Favored 'General case' 0 C--O 1.247 0.965 0 N-CA-C 110.04 -0.356 . . . . 0.0 110.04 175.657 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . 0.447 ' HB3' HE21 ' A' ' 31' ' ' GLN . 72.2 m-85 -98.19 162.64 13.1 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.272 178.607 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -63.6 125.21 23.51 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.577 178.541 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 74.56 12.94 82.27 Favored Glycine 0 N--CA 1.447 -0.608 0 C-N-CA 120.948 -0.644 . . . . 0.0 112.851 -179.705 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 73.8 mm-40 -127.41 177.31 6.82 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 110.137 -0.32 . . . . 0.0 110.137 -179.373 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -109.13 -179.9 21.19 Favored Glycine 0 N--CA 1.445 -0.724 0 C-N-CA 120.879 -0.677 . . . . 0.0 111.614 178.805 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_exo -63.76 137.64 59.6 Favored 'Trans proline' 0 C--N 1.349 0.555 0 C-N-CA 122.504 2.136 . . . . 0.0 112.222 178.88 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . 0.545 ' HB ' ' O ' ' A' ' 76' ' ' GLN . 45.4 pt -132.36 166.11 30.15 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 CA-C-N 115.706 -0.679 . . . . 0.0 109.713 179.316 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -75.73 145.96 33.34 Favored Glycine 0 C--N 1.321 -0.299 0 C-N-CA 120.703 -0.761 . . . . 0.0 111.886 -179.47 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 31.6 t80 -132.12 130.54 41.33 Favored 'General case' 0 C--N 1.317 -0.839 0 C-N-CA 122.477 0.311 . . . . 0.0 111.398 -178.831 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 59.3 ttp180 -138.71 130.49 27.81 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 174.015 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.435 ' HB3' ' HB2' ' A' ' 47' ' ' LEU . . . -134.87 146.66 49.43 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 120.704 0.288 . . . . 0.0 111.148 -179.648 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 48.9 m -128.33 136.26 50.71 Favored 'General case' 0 CA--C 1.544 0.724 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.748 179.065 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . 0.401 HD11 ' O ' ' A' ' 68' ' ' ASN . 59.8 tp -69.34 127.8 34.31 Favored 'General case' 0 CA--C 1.535 0.376 0 N-CA-C 112.274 0.472 . . . . 0.0 112.274 -178.539 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . 0.434 HD21 ' HB2' ' A' ' 72' ' ' GLU . 4.3 mm? -91.18 -41.3 11.08 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-N 115.972 -0.558 . . . . 0.0 112.482 178.702 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -151.8 -68.34 0.01 OUTLIER Glycine 0 CA--C 1.499 -0.922 0 C-N-CA 119.63 -1.272 . . . . 0.0 113.244 -175.835 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' ASN . . . . . 0.401 ' O ' HD11 ' A' ' 65' ' ' LEU . 20.2 m120 -133.49 -81.07 0.47 Allowed 'General case' 0 C--O 1.209 -1.036 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 -178.706 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . 0.484 ' OD1' ' HA3' ' A' ' 93' ' ' GLY . 90.7 m-20 -98.72 -5.73 30.89 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 120.77 0.319 . . . . 0.0 110.486 179.43 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 8.7 m -88.66 123.56 33.23 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 121.291 0.567 . . . . 0.0 112.017 -176.647 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 60.2 m-85 -121.88 145.53 48.0 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.659 178.805 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . 0.434 ' HB2' HD21 ' A' ' 66' ' ' LEU . 71.8 tt0 -100.26 122.56 43.26 Favored 'General case' 0 C--N 1.316 -0.869 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 173.007 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 66.5 t -103.98 132.46 50.4 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.016 0 CA-C-N 115.687 -0.688 . . . . 0.0 111.767 -175.156 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 99.6 mt-10 -127.34 125.75 41.33 Favored 'General case' 0 N--CA 1.446 -0.655 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 177.141 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' ASN . . . . . 0.445 ' HB3' HD12 ' A' ' 59' ' ' ILE . 95.1 m-20 -111.61 155.57 23.16 Favored 'General case' 0 C--N 1.312 -1.065 0 CA-C-O 121.473 0.654 . . . . 0.0 112.427 -177.204 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' GLN . . . . . 0.545 ' O ' ' HB ' ' A' ' 59' ' ' ILE . 33.8 tt0 -117.69 121.65 41.42 Favored 'General case' 0 C--N 1.311 -1.07 0 CA-C-N 114.878 -1.055 . . . . 0.0 110.285 -177.291 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -107.45 107.84 18.89 Favored 'General case' 0 C--N 1.323 -0.548 0 C-N-CA 120.221 -0.592 . . . . 0.0 110.305 176.834 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 174.04 -158.83 27.86 Favored Glycine 0 N--CA 1.439 -1.146 0 N-CA-C 110.586 -1.006 . . . . 0.0 110.586 -178.655 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -96.41 -42.61 3.39 Favored Glycine 0 N--CA 1.441 -1.008 0 C-N-CA 120.113 -1.042 . . . . 0.0 111.496 178.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 20.9 t70 -176.3 150.31 0.91 Allowed 'General case' 0 C--O 1.236 0.374 0 C-N-CA 122.56 0.344 . . . . 0.0 110.223 179.641 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 23.2 t 52.79 33.25 13.74 Favored 'General case' 0 CA--C 1.549 0.935 0 C-N-CA 123.057 0.543 . . . . 0.0 112.357 177.257 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -91.59 165.22 21.46 Favored Pre-proline 0 CA--C 1.544 0.746 0 CA-C-N 116.463 -0.335 . . . . 0.0 110.752 -179.392 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 26.9 Cg_exo -62.66 152.57 77.32 Favored 'Trans proline' 0 C--N 1.354 0.856 0 C-N-CA 122.703 2.269 . . . . 0.0 112.521 178.703 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' TRP . . . . . . . . . . . . . 96.2 m95 -98.61 143.12 29.35 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.544 -177.586 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 80.1 m-70 -129.83 141.1 50.88 Favored 'General case' 0 C--N 1.318 -0.761 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 179.298 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 42.1 m -61.38 133.89 56.32 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-O 121.216 0.531 . . . . 0.0 111.42 -178.038 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -105.23 -43.3 1.63 Allowed Glycine 0 N--CA 1.438 -1.198 0 N-CA-C 111.561 -0.616 . . . . 0.0 111.561 178.296 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 153.65 -170.03 32.37 Favored Glycine 0 C--O 1.223 -0.535 0 C-N-CA 120.456 -0.878 . . . . 0.0 112.259 178.349 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 20.2 m120 -110.6 123.11 49.36 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.465 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 44.1 m0 -114.41 152.81 30.95 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-O 121.016 0.436 . . . . 0.0 111.704 -177.363 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . 0.435 ' HA ' ' O ' ' A' ' 69' ' ' ASN . 82.8 mt -108.02 112.29 39.6 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.751 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 176.785 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . 0.436 ' HB3' HG21 ' A' ' 100' ' ' VAL . 70.0 mt -135.15 73.08 1.46 Allowed 'General case' 0 C--O 1.266 1.972 0 CA-C-O 121.692 0.758 . . . . 0.0 111.835 -175.592 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . 0.484 ' HA3' ' OD1' ' A' ' 69' ' ' ASN . . . -153.67 -78.85 0.02 OUTLIER Glycine 0 N--CA 1.447 -0.615 0 C-N-CA 120.228 -0.987 . . . . 0.0 113.278 -178.096 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 57.5 m 69.94 10.29 7.4 Favored 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 123.268 0.627 . . . . 0.0 111.869 -177.784 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' ARG . . . . . 0.721 ' HB2' ' O ' ' A' ' 98' ' ' GLN . 16.8 mmt180 -127.12 141.39 51.77 Favored 'General case' 0 N--CA 1.443 -0.783 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 177.308 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 16.6 pt-20 -67.38 -40.45 85.71 Favored 'General case' 0 C--N 1.311 -1.097 0 N-CA-C 112.96 0.726 . . . . 0.0 112.96 -176.298 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 91.8 m-20 -127.58 28.91 5.58 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 111.912 0.338 . . . . 0.0 111.912 -176.35 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' GLN . . . . . 0.721 ' O ' ' HB2' ' A' ' 95' ' ' ARG . 46.0 tt0 -155.64 132.52 10.61 Favored 'General case' 0 C--N 1.32 -0.688 0 C-N-CA 120.625 -0.43 . . . . 0.0 110.078 -177.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 91.3 m-20 -115.3 179.49 3.95 Favored 'General case' 0 C--O 1.26 1.638 0 C-N-CA 120.717 -0.393 . . . . 0.0 111.957 -177.909 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.436 HG21 ' HB3' ' A' ' 92' ' ' LEU . 22.5 m -81.06 143.33 12.48 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.427 0 CA-C-N 115.673 -0.694 . . . . 0.0 111.132 178.945 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 31.2 m -121.51 -36.43 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.694 178.223 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . 0.611 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -133.4 130.41 38.7 Favored 'General case' 0 CA--C 1.51 -0.572 0 C-N-CA 119.943 -0.703 . . . . 0.0 111.153 178.76 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 96.5 mt -133.29 122.55 45.17 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.934 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.656 178.862 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 12.0 t30 -126.67 99.27 5.71 Favored 'General case' 0 C--N 1.316 -0.882 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 176.804 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.495 ' CG2' ' HB ' ' A' ' 36' ' ' ILE . 17.8 m -135.21 135.86 51.91 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.146 0 CA-C-N 115.513 -0.767 . . . . 0.0 112.429 -174.787 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 60.2 mt-10 -141.17 142.58 34.02 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.597 -0.728 . . . . 0.0 110.256 179.85 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 35.5 t -140.33 148.65 41.67 Favored 'General case' 0 C--N 1.315 -0.913 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.878 179.366 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -96.29 1.11 62.26 Favored Glycine 0 N--CA 1.444 -0.785 0 N-CA-C 110.769 -0.932 . . . . 0.0 110.769 176.234 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 84.6 m-20 -88.93 179.13 6.25 Favored 'General case' 0 CA--C 1.511 -0.539 0 CA-C-O 120.872 0.368 . . . . 0.0 110.601 -179.635 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 7.8 p-10 -88.83 16.41 6.91 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-O 121.568 0.699 . . . . 0.0 109.602 177.577 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . 0.663 ' HA3' ' ND2' ' A' ' 32' ' ' ASN . . . 113.25 7.82 20.45 Favored Glycine 0 N--CA 1.438 -1.232 0 CA-C-N 115.384 -0.826 . . . . 0.0 112.516 -177.526 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 98.6 mt-30 -62.71 -47.91 81.56 Favored 'General case' 0 C--O 1.238 0.45 0 CA-C-O 120.759 0.314 . . . . 0.0 110.363 178.783 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 70.7 p -130.44 155.39 46.5 Favored 'General case' 0 N--CA 1.444 -0.748 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 176.151 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 40.1 tp -136.39 108.38 7.16 Favored 'General case' 0 C--N 1.314 -0.946 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 178.352 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 89.0 m-20 -119.84 155.14 33.2 Favored 'General case' 0 C--N 1.316 -0.882 0 C-N-CA 120.597 -0.441 . . . . 0.0 111.737 -175.484 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 162.34 -136.15 4.21 Favored Glycine 0 N--CA 1.438 -1.176 0 C-N-CA 120.543 -0.837 . . . . 0.0 112.737 178.016 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 26.6 p -130.89 153.28 49.31 Favored 'General case' 0 C--N 1.312 -1.032 0 C-N-CA 122.752 0.421 . . . . 0.0 110.469 -178.343 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 25.6 ptm -143.57 146.23 33.15 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.074 179.899 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 119' ' ' THR . . . . . 0.611 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 36.7 m -129.8 126.6 38.49 Favored 'General case' 0 C--N 1.305 -1.358 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.533 179.294 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 67.0 m-85 -81.18 164.43 22.34 Favored 'General case' 0 CA--C 1.508 -0.645 0 O-C-N 123.716 0.635 . . . . 0.0 109.502 176.172 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -51.54 -31.63 24.96 Favored 'General case' 0 CA--C 1.54 0.586 0 N-CA-C 113.37 0.878 . . . . 0.0 113.37 -178.827 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -155.84 15.93 0.45 Allowed Glycine 0 CA--C 1.519 0.287 0 C-N-CA 119.189 -1.481 . . . . 0.0 114.263 -178.246 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 82.9 tt0 -100.19 -23.74 14.75 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 117.619 0.709 . . . . 0.0 111.327 -179.894 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 115.03 179.67 18.54 Favored Glycine 0 N--CA 1.448 -0.507 0 C-N-CA 120.235 -0.983 . . . . 0.0 112.935 178.039 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -90.39 122.06 0.91 Allowed 'Trans proline' 0 N--CA 1.449 -1.102 0 C-N-CA 123.767 2.978 . . . . 0.0 112.408 179.749 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 41.2 pt -128.53 163.12 33.8 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.803 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.58 179.487 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -70.08 137.01 27.58 Favored Glycine 0 C--O 1.244 0.728 0 CA-C-N 116.188 -0.46 . . . . 0.0 112.165 179.37 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 83.7 t80 -115.25 133.97 55.56 Favored 'General case' 0 C--N 1.316 -0.853 0 C-N-CA 122.51 0.324 . . . . 0.0 110.678 -178.966 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 129' ' ' LYS . . . . . 0.448 ' HB3' ' HB2' ' A' ' 7' ' ' GLU . 86.3 tttt -137.45 114.99 11.17 Favored 'General case' 0 N--CA 1.437 -1.09 0 N-CA-C 109.301 -0.629 . . . . 0.0 109.301 176.53 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . 0.512 ' HA2' ' O ' ' A' ' 5' ' ' ASN . . . -115.13 136.02 12.78 Favored Glycine 0 N--CA 1.433 -1.561 0 N-CA-C 111.157 -0.777 . . . . 0.0 111.157 177.837 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 52.5 m -128.7 136.72 50.99 Favored 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -179.905 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 58.3 tp -59.89 126.03 25.96 Favored 'General case' 0 C--N 1.327 -0.379 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 178.538 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 24.5 m . . . . . 0 N--CA 1.439 -1.024 0 CA-C-O 118.745 -0.645 . . . . 0.0 110.776 -178.275 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 0.609 ' O ' ' HG3' ' A' ' 24' ' ' GLU . . . . . . . . 0 N--CA 1.479 1.004 0 N-CA-C 110.144 -0.317 . . . . 0.0 110.144 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' LEU . . . . . 0.526 HD11 HE21 ' A' ' 22' ' ' GLN . 3.0 tm? -87.3 132.21 34.0 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-O 121.271 0.558 . . . . 0.0 110.713 -175.504 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . 0.427 ' N ' HD13 ' A' ' 3' ' ' LEU . 20.0 m-85 -115.45 134.78 54.76 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 115.486 -0.779 . . . . 0.0 111.392 178.542 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 46.6 t-20 -92.9 117.37 29.97 Favored 'General case' 0 C--N 1.309 -1.158 0 N-CA-C 106.992 -1.484 . . . . 0.0 106.992 176.814 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.469 HG12 HD21 ' A' ' 8' ' ' ASN . 58.5 t -102.04 104.89 17.08 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.146 0 CA-C-O 121.146 0.498 . . . . 0.0 112.307 -174.067 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -94.3 137.62 33.24 Favored 'General case' 0 C--N 1.312 -1.028 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 175.931 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . 0.469 HD21 HG12 ' A' ' 6' ' ' VAL . 63.2 m-80 -132.69 159.17 40.41 Favored 'General case' 0 C--N 1.314 -0.972 0 CA-C-O 121.627 0.727 . . . . 0.0 112.784 -175.075 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 36.4 tt0 -124.02 106.29 10.27 Favored 'General case' 0 C--N 1.309 -1.166 0 N-CA-C 106.828 -1.545 . . . . 0.0 106.828 173.118 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 1.4 p90 -125.68 0.21 7.45 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 114.056 1.132 . . . . 0.0 114.056 -173.289 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -116.3 21.4 11.9 Favored Glycine 0 N--CA 1.446 -0.647 0 C-N-CA 119.014 -1.565 . . . . 0.0 112.296 -177.74 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 122.14 157.21 9.91 Favored Glycine 0 N--CA 1.441 -1.01 0 C-N-CA 120.8 -0.714 . . . . 0.0 111.99 -179.726 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 21.3 p -59.46 -31.88 69.73 Favored 'General case' 0 C--N 1.317 -0.822 0 C-N-CA 123.018 0.527 . . . . 0.0 112.41 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 17.1 p -81.41 -7.56 59.6 Favored 'General case' 0 C--N 1.32 -0.703 0 N-CA-C 112.26 0.467 . . . . 0.0 112.26 179.449 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -78.99 142.11 59.59 Favored Pre-proline 0 C--N 1.328 -0.353 0 CA-C-O 120.801 0.334 . . . . 0.0 111.255 -178.674 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 64.2 Cg_endo -70.8 165.37 32.38 Favored 'Trans proline' 0 C--O 1.237 0.47 0 C-N-CA 123.084 2.523 . . . . 0.0 112.54 -179.81 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 93.5 m95 -81.69 137.81 35.35 Favored 'General case' 0 N--CA 1.452 -0.354 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.357 -178.731 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 3.1 p30 -145.32 137.78 25.9 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.99 -179.827 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 8.3 pt-20 -93.16 141.37 28.49 Favored 'General case' 0 C--N 1.317 -0.833 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 178.098 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -132.71 26.98 3.57 Favored Glycine 0 N--CA 1.442 -0.956 0 C-N-CA 120.45 -0.881 . . . . 0.0 111.21 179.726 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 154.76 169.34 19.29 Favored Glycine 0 N--CA 1.437 -1.263 0 C-N-CA 120.991 -0.623 . . . . 0.0 111.846 -179.475 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . 0.526 HE21 HD11 ' A' ' 3' ' ' LEU . 4.4 pt20 -122.0 132.8 54.71 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-O 120.835 0.35 . . . . 0.0 110.339 179.913 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 40.4 m0 -113.21 172.83 6.71 Favored 'General case' 0 CA--C 1.506 -0.718 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.165 -176.409 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . 0.609 ' HG3' ' O ' ' A' ' 2' ' ' ALA . 33.5 tt0 -131.23 114.66 15.34 Favored 'General case' 0 C--N 1.317 -0.837 0 N-CA-C 108.815 -0.809 . . . . 0.0 108.815 173.572 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.44 HG23 HD11 ' A' ' 36' ' ' ILE . 97.7 mt -105.54 -36.81 3.8 Favored 'Isoleucine or valine' 0 C--O 1.199 -1.6 0 CA-C-N 115.138 -0.937 . . . . 0.0 113.156 -173.053 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -109.07 126.98 8.32 Favored Glycine 0 C--N 1.307 -1.078 0 C-N-CA 119.888 -1.149 . . . . 0.0 112.387 -179.858 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 59.6 p -117.19 8.16 13.17 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 111.875 0.324 . . . . 0.0 111.875 -179.883 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 69.1 ttt180 -122.09 135.5 54.81 Favored 'General case' 0 N--CA 1.446 -0.629 0 CA-C-O 121.162 0.506 . . . . 0.0 111.904 -177.153 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 47.9 t -77.35 149.36 35.26 Favored 'General case' 0 N--CA 1.442 -0.846 0 CA-C-N 115.294 -0.866 . . . . 0.0 109.908 176.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.453 ' O ' ' HG2' ' A' ' 31' ' ' GLN . 8.9 m-20 59.62 22.71 11.42 Favored 'General case' 0 N--CA 1.479 0.99 0 C-N-CA 123.032 0.533 . . . . 0.0 111.433 176.902 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . 0.453 ' HG2' ' O ' ' A' ' 30' ' ' ASP . 4.5 mm-40 -163.06 91.26 0.71 Allowed 'General case' 0 CA--C 1.501 -0.91 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.241 -178.058 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . 0.573 ' ND2' ' HA3' ' A' ' 111' ' ' GLY . 63.6 t30 -94.69 162.02 13.95 Favored 'General case' 0 C--N 1.309 -1.174 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.239 -179.01 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 72.6 t -95.57 129.52 45.57 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.201 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.89 -176.51 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 33.0 m -110.39 -13.06 11.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 N-CA-C 112.187 0.439 . . . . 0.0 112.187 179.154 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.518 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -156.34 149.36 24.13 Favored 'General case' 0 CA--C 1.517 -0.304 0 C-N-CA 120.464 -0.494 . . . . 0.0 111.851 178.685 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.44 HD11 HG23 ' A' ' 25' ' ' ILE . 88.2 mt -148.54 119.18 1.29 Allowed 'Isoleucine or valine' 0 CA--C 1.513 -0.46 0 N-CA-C 107.935 -1.135 . . . . 0.0 107.935 178.565 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' ASN . . . . . 0.545 ' HA ' ' O ' ' A' ' 103' ' ' ILE . 57.5 m-80 -140.05 74.91 1.48 Allowed 'General case' 0 C--N 1.301 -1.534 0 C-N-CA 120.706 -0.398 . . . . 0.0 110.759 -179.375 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.576 HG11 ' CD1' ' A' ' 61' ' ' PHE . 17.1 m -120.18 171.32 8.74 Favored 'Isoleucine or valine' 0 C--O 1.235 0.319 0 N-CA-C 112.49 0.552 . . . . 0.0 112.49 178.541 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 75.3 tt0 -140.34 153.23 46.33 Favored 'General case' 0 N--CA 1.447 -0.593 0 CA-C-N 115.234 -0.893 . . . . 0.0 109.731 179.213 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . 0.527 ' OG ' ' HB ' ' A' ' 101' ' ' VAL . 34.6 p -76.95 157.72 31.11 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-O 121.297 0.57 . . . . 0.0 112.487 -177.595 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -105.99 -49.46 0.94 Allowed Glycine 0 N--CA 1.438 -1.224 0 N-CA-C 110.177 -1.169 . . . . 0.0 110.177 174.427 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 18.9 m-20 -102.24 -149.68 0.39 Allowed 'General case' 0 C--N 1.325 -0.48 0 C-N-CA 122.889 0.476 . . . . 0.0 110.502 179.013 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 11.9 m-20 -71.96 38.19 0.07 Allowed 'General case' 0 N--CA 1.484 1.268 0 C-N-CA 123.747 0.819 . . . . 0.0 112.261 -177.988 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 83.69 2.93 89.81 Favored Glycine 0 C--N 1.316 -0.532 0 C-N-CA 120.669 -0.776 . . . . 0.0 111.571 -178.738 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' GLN . . . . . 0.476 ' HA ' ' HB3' ' A' ' 65' ' ' LEU . 62.3 mt-30 -80.5 -28.59 37.44 Favored 'General case' 0 C--O 1.218 -0.559 0 CA-C-O 120.981 0.419 . . . . 0.0 110.66 178.218 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . 0.409 ' O ' ' HA ' ' A' ' 40' ' ' SER . 22.6 p -118.54 132.49 56.21 Favored 'General case' 0 C--N 1.306 -1.298 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.637 179.877 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 90.5 mt -126.46 132.64 51.4 Favored 'General case' 0 C--N 1.319 -0.759 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 179.754 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.411 ' HA ' ' O ' ' A' ' 61' ' ' PHE . 9.4 p30 -142.65 147.61 36.05 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-O 120.789 0.328 . . . . 0.0 110.585 179.234 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 158.68 -135.05 4.05 Favored Glycine 0 C--N 1.312 -0.786 0 C-N-CA 120.601 -0.809 . . . . 0.0 111.885 178.656 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 24.7 p -130.8 149.23 52.54 Favored 'General case' 0 N--CA 1.452 -0.347 0 CA-C-O 121.175 0.512 . . . . 0.0 111.812 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' MET . . . . . 0.462 ' HG2' ' O ' ' A' ' 35' ' ' ALA . 18.4 tmm? -142.45 148.47 37.81 Favored 'General case' 0 C--N 1.316 -0.853 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 177.399 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.518 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 66.1 m -129.53 127.64 41.17 Favored 'General case' 0 C--O 1.246 0.919 0 N-CA-C 112.385 0.513 . . . . 0.0 112.385 -177.04 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 64.9 m-85 -87.99 161.76 17.22 Favored 'General case' 0 CA--C 1.515 -0.369 0 CA-C-N 115.507 -0.769 . . . . 0.0 109.458 174.46 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -66.71 129.99 41.7 Favored 'General case' 0 C--N 1.315 -0.918 0 N-CA-C 110.04 -0.356 . . . . 0.0 110.04 178.158 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 90.45 -19.99 40.53 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.869 -0.681 . . . . 0.0 113.081 179.228 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 81.5 mm-40 -107.56 170.17 8.14 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 120.736 0.303 . . . . 0.0 110.767 -178.589 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -95.46 -157.89 32.35 Favored Glycine 0 N--CA 1.446 -0.664 0 C-N-CA 120.943 -0.646 . . . . 0.0 112.354 179.52 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_endo -64.3 138.46 60.93 Favored 'Trans proline' 0 C--N 1.345 0.38 0 C-N-CA 122.462 2.108 . . . . 0.0 112.099 179.743 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . 0.455 HG23 ' HB3' ' A' ' 77' ' ' TRP . 98.3 mt -132.89 142.5 42.14 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.026 0 CA-C-N 115.578 -0.737 . . . . 0.0 109.771 -179.12 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -73.82 128.27 10.97 Favored Glycine 0 N--CA 1.443 -0.898 0 N-CA-C 110.579 -1.009 . . . . 0.0 110.579 179.058 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.576 ' CD1' HG11 ' A' ' 38' ' ' VAL . 47.5 t80 -114.41 128.08 56.16 Favored 'General case' 0 C--N 1.311 -1.08 0 CA-C-O 120.594 0.235 . . . . 0.0 110.903 -176.177 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 64.9 ttp85 -135.49 129.61 33.39 Favored 'General case' 0 N--CA 1.448 -0.536 0 CA-C-N 116.016 -0.538 . . . . 0.0 109.986 176.024 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -138.94 149.66 45.02 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 120.773 0.321 . . . . 0.0 111.754 -178.517 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 27.6 m -125.35 131.5 52.98 Favored 'General case' 0 CA--C 1.54 0.596 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.359 179.204 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . 0.476 ' HB3' ' HA ' ' A' ' 45' ' ' GLN . 3.0 tm? -80.2 113.29 18.26 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 120.981 0.419 . . . . 0.0 110.503 -178.495 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 94.6 mt -88.4 -18.96 27.24 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.498 177.799 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 125.34 167.66 12.59 Favored Glycine 0 N--CA 1.442 -0.959 0 C-N-CA 121.02 -0.609 . . . . 0.0 111.596 179.765 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 94.8 m-20 56.47 36.66 27.91 Favored 'General case' 0 N--CA 1.473 0.721 0 C-N-CA 122.56 0.344 . . . . 0.0 111.707 178.279 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 16.3 m120 66.36 9.66 6.62 Favored 'General case' 0 N--CA 1.48 1.031 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.363 179.644 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 35.1 m -97.88 123.55 41.9 Favored 'General case' 0 C--O 1.24 0.562 0 CA-C-O 121.37 0.605 . . . . 0.0 111.586 -177.537 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.534 ' OH ' ' HB3' ' A' ' 99' ' ' ASN . 59.4 m-85 -112.98 138.51 49.75 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 115.468 -0.787 . . . . 0.0 110.83 -179.613 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 42.5 tt0 -92.52 116.64 29.17 Favored 'General case' 0 N--CA 1.439 -0.976 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 174.786 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 78.2 t -105.03 133.15 50.05 Favored 'Isoleucine or valine' 0 C--O 1.248 1.019 0 N-CA-C 112.75 0.648 . . . . 0.0 112.75 -173.615 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 68.7 mt-10 -133.33 134.42 43.78 Favored 'General case' 0 C--O 1.244 0.772 0 N-CA-C 107.899 -1.148 . . . . 0.0 107.899 175.253 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 92.8 m-20 -119.46 154.43 33.76 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 112.911 0.708 . . . . 0.0 112.911 -173.797 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 35.9 tt0 -132.52 127.76 35.87 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.07 -0.968 . . . . 0.0 108.999 179.389 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' TRP . . . . . 0.455 ' HB3' HG23 ' A' ' 59' ' ' ILE . 37.9 p90 -137.58 157.47 46.44 Favored 'General case' 0 C--N 1.317 -0.835 0 C-N-CA 119.973 -0.691 . . . . 0.0 111.997 -177.046 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 81.19 12.13 82.69 Favored Glycine 0 N--CA 1.453 -0.216 0 CA-C-N 115.4 -0.818 . . . . 0.0 112.465 179.513 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 124.48 175.67 14.4 Favored Glycine 0 N--CA 1.445 -0.709 0 N-CA-C 111.259 -0.736 . . . . 0.0 111.259 -179.582 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 -89.74 -5.19 57.23 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 121.114 0.483 . . . . 0.0 110.373 -179.194 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 33.2 m -79.04 -12.96 60.03 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.413 179.367 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -90.8 128.69 47.21 Favored Pre-proline 0 C--N 1.321 -0.641 0 CA-C-N 116.54 -0.3 . . . . 0.0 110.484 -179.532 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 30.1 Cg_endo -63.21 136.2 54.59 Favored 'Trans proline' 0 N--CA 1.463 -0.289 0 C-N-CA 122.157 1.904 . . . . 0.0 111.736 179.735 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' TRP . . . . . . . . . . . . . 87.0 m95 -51.1 138.67 19.53 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-O 121.302 0.572 . . . . 0.0 112.261 178.667 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 96.1 m-70 -115.11 147.14 40.59 Favored 'General case' 0 C--N 1.314 -0.949 0 CA-C-N 115.325 -0.852 . . . . 0.0 109.299 179.361 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 6.3 m -58.37 148.59 27.26 Favored 'General case' 0 C--N 1.316 -0.851 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.629 179.004 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -124.32 -54.44 0.18 Allowed Glycine 0 N--CA 1.44 -1.065 0 N-CA-C 110.552 -1.019 . . . . 0.0 110.552 -179.591 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 149.48 -165.95 29.58 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.605 -0.807 . . . . 0.0 112.353 176.788 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 14.5 m120 -110.66 118.45 36.22 Favored 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 109.346 -0.613 . . . . 0.0 109.346 178.362 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 32.8 m0 -110.38 150.67 28.47 Favored 'General case' 0 C--N 1.313 -0.993 0 CA-C-N 116.559 -0.292 . . . . 0.0 110.707 -177.374 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 83.3 mt -105.6 115.17 46.83 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.937 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 177.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . 0.51 ' HB3' HG21 ' A' ' 100' ' ' VAL . 82.2 mt -131.53 80.5 1.93 Allowed 'General case' 0 C--O 1.27 2.182 0 CA-C-O 121.945 0.879 . . . . 0.0 112.589 -174.638 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 165.73 119.63 0.49 Allowed Glycine 0 N--CA 1.441 -0.993 0 CA-C-N 114.935 -1.029 . . . . 0.0 111.5 178.678 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 83.9 p -89.81 -1.54 58.02 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.34 0.59 . . . . 0.0 110.173 178.519 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 23.8 mtp180 -109.12 138.4 45.52 Favored 'General case' 0 N--CA 1.435 -1.181 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 178.884 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 72.5 tt0 -73.0 -38.26 66.67 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-O 121.354 0.597 . . . . 0.0 111.326 -173.324 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 53.5 m-80 -110.6 28.75 8.37 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.343 -177.934 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' GLN . . . . . 0.576 HE21 ' HB3' ' A' ' 120' ' ' TYR . 50.8 tt0 -156.96 125.2 5.61 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.119 0.485 . . . . 0.0 110.467 -177.545 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' ASN . . . . . 0.534 ' HB3' ' OH ' ' A' ' 71' ' ' TYR . 91.6 m-20 -104.64 169.69 8.32 Favored 'General case' 0 C--O 1.251 1.136 0 CA-C-N 115.647 -0.706 . . . . 0.0 111.949 -174.319 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.51 HG21 ' HB3' ' A' ' 92' ' ' LEU . 26.4 m -83.73 151.8 3.89 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.433 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.918 177.886 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . 0.527 ' HB ' ' OG ' ' A' ' 40' ' ' SER . 33.8 m -123.45 -29.66 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 C-N-CA 120.909 -0.316 . . . . 0.0 111.49 177.416 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . 0.585 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -140.56 135.34 31.72 Favored 'General case' 0 C--N 1.317 -0.828 0 C-N-CA 120.197 -0.601 . . . . 0.0 111.13 179.07 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.545 ' O ' ' HA ' ' A' ' 37' ' ' ASN . 88.6 mt -128.41 121.47 55.45 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.044 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 178.447 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 8.1 t30 -127.8 95.07 4.11 Favored 'General case' 0 C--N 1.325 -0.463 0 O-C-N 123.908 0.755 . . . . 0.0 109.48 -179.296 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.484 HG11 ' CD2' ' A' ' 128' ' ' PHE . 31.7 m -143.65 148.58 18.83 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 N-CA-C 112.672 0.619 . . . . 0.0 112.672 -175.293 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 69.8 tt0 -150.05 154.32 37.95 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.335 -0.848 . . . . 0.0 109.553 174.863 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 44.3 t -136.28 150.8 49.09 Favored 'General case' 0 C--N 1.31 -1.146 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.107 -178.846 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -97.2 1.79 60.92 Favored Glycine 0 N--CA 1.44 -1.069 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 174.479 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -98.56 -172.68 2.37 Favored 'General case' 0 CA--C 1.507 -0.703 0 N-CA-C 109.596 -0.52 . . . . 0.0 109.596 179.716 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 10.4 p-10 -92.47 32.76 1.17 Allowed 'General case' 0 C--N 1.312 -1.028 0 CA-C-O 121.435 0.636 . . . . 0.0 109.559 176.147 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . 0.573 ' HA3' ' ND2' ' A' ' 32' ' ' ASN . . . 94.81 9.24 58.72 Favored Glycine 0 N--CA 1.445 -0.719 0 CA-C-N 115.618 -0.719 . . . . 0.0 113.271 -179.347 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 112' ' ' GLN . . . . . 0.519 ' HA ' ' CD1' ' A' ' 132' ' ' LEU . 97.1 mt-30 -65.08 -50.69 65.16 Favored 'General case' 0 C--O 1.24 0.593 0 CA-C-O 120.96 0.409 . . . . 0.0 111.072 179.289 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 40.2 p -129.49 130.33 45.7 Favored 'General case' 0 N--CA 1.444 -0.751 0 CA-C-N 115.899 -0.591 . . . . 0.0 109.844 178.56 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 88.6 mt -108.85 125.44 51.98 Favored 'General case' 0 C--N 1.31 -1.149 0 N-CA-C 110.075 -0.343 . . . . 0.0 110.075 179.781 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 15.7 m120 -109.84 136.37 49.25 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.173 -178.768 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . 0.435 ' HA3' HG12 ' A' ' 105' ' ' VAL . . . 167.33 -145.56 9.93 Favored Glycine 0 N--CA 1.439 -1.136 0 C-N-CA 119.074 -1.536 . . . . 0.0 113.584 176.408 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 26.9 p -139.17 161.58 37.05 Favored 'General case' 0 C--N 1.314 -0.951 0 C-N-CA 123.211 0.605 . . . . 0.0 110.699 -177.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 118' ' ' MET . . . . . 0.55 ' O ' ' HA ' ' A' ' 125' ' ' PRO . 18.4 ptp -140.28 148.59 41.66 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.303 -0.408 . . . . 0.0 109.968 178.776 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 119' ' ' THR . . . . . 0.585 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 27.7 m -128.78 130.53 47.14 Favored 'General case' 0 C--N 1.313 -0.998 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 177.973 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . 0.586 ' HB2' ' HB3' ' A' ' 123' ' ' GLU . 38.4 m-85 -96.56 173.08 7.52 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.006 0.431 . . . . 0.0 112.037 -179.945 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . 0.416 ' HA ' HG11 ' A' ' 101' ' ' VAL . . . -55.51 -36.57 66.83 Favored 'General case' 0 CA--C 1.533 0.298 0 CA-C-N 115.396 -0.82 . . . . 0.0 112.859 -178.43 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -144.2 46.01 0.84 Allowed Glycine 0 CA--C 1.506 -0.522 0 C-N-CA 120.388 -0.91 . . . . 0.0 111.668 -179.321 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . 0.586 ' HB3' ' HB2' ' A' ' 120' ' ' TYR . 76.1 tt0 -151.62 144.66 24.55 Favored 'General case' 0 C--N 1.315 -0.894 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 -178.032 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -68.01 160.29 50.59 Favored Glycine 0 CA--C 1.518 0.246 0 C-N-CA 121.153 -0.546 . . . . 0.0 113.002 -177.512 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . 0.55 ' HA ' ' O ' ' A' ' 118' ' ' MET . 30.2 Cg_endo -63.15 136.65 57.21 Favored 'Trans proline' 0 C--N 1.348 0.537 0 C-N-CA 122.416 2.077 . . . . 0.0 111.994 179.701 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 44.0 pt -129.47 165.1 30.27 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.913 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.567 -179.133 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -73.09 132.44 16.89 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 121.053 -0.594 . . . . 0.0 112.145 -179.18 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . 0.484 ' CD2' HG11 ' A' ' 105' ' ' VAL . 49.9 t80 -114.92 131.29 56.93 Favored 'General case' 0 C--O 1.245 0.862 0 C-N-CA 122.937 0.495 . . . . 0.0 111.793 -177.798 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 62.5 tttm -133.13 97.35 3.97 Favored 'General case' 0 N--CA 1.441 -0.89 0 CA-C-N 115.249 -0.887 . . . . 0.0 109.687 175.658 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -91.81 130.84 10.49 Favored Glycine 0 CA--C 1.502 -0.738 0 N-CA-C 111.06 -0.816 . . . . 0.0 111.06 179.917 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 28.2 m -128.5 133.94 48.58 Favored 'General case' 0 C--N 1.311 -1.093 0 CA-C-N 117.282 0.541 . . . . 0.0 110.461 -178.376 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 132' ' ' LEU . . . . . 0.519 ' CD1' ' HA ' ' A' ' 112' ' ' GLN . 80.3 mt -57.12 134.34 55.79 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-O 121.001 0.429 . . . . 0.0 110.962 177.784 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 24.1 m . . . . . 0 C--O 1.251 1.152 0 CA-C-O 118.123 -0.941 . . . . 0.0 109.61 179.682 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.701 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' LEU . . . . . 0.569 HD11 HE21 ' A' ' 22' ' ' GLN . 3.3 tm? -98.23 132.53 43.66 Favored 'General case' 0 C--N 1.317 -0.805 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 -178.772 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . 0.459 ' CE1' ' HB ' ' A' ' 25' ' ' ILE . 96.9 m-85 -125.9 150.06 48.22 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-O 121.153 0.501 . . . . 0.0 111.256 -179.668 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 10.1 m-80 -99.0 136.56 38.79 Favored 'General case' 0 C--N 1.318 -0.791 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 174.728 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.461 HG21 ' CG ' ' A' ' 23' ' ' TRP . 53.6 t -115.87 129.83 71.57 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 N-CA-C 114.007 1.114 . . . . 0.0 114.007 -172.953 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.477 ' HA ' ' HA ' ' A' ' 19' ' ' GLU . 78.4 mt-10 -114.27 134.33 55.02 Favored 'General case' 0 N--CA 1.437 -1.09 0 CA-C-N 113.999 -1.455 . . . . 0.0 107.97 176.038 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 11.6 m120 -116.07 136.15 53.28 Favored 'General case' 0 C--N 1.315 -0.918 0 CA-C-O 120.635 0.255 . . . . 0.0 110.517 -178.949 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . 0.53 ' HB2' ' CE3' ' A' ' 17' ' ' TRP . 58.6 tt0 -112.39 122.1 46.74 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.827 -178.166 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 15.0 p90 -139.47 141.87 37.39 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.912 -0.585 . . . . 0.0 109.654 175.079 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 127.62 2.21 6.33 Favored Glycine 0 N--CA 1.443 -0.862 0 C-N-CA 120.657 -0.782 . . . . 0.0 111.59 -179.234 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 82.03 -156.69 36.35 Favored Glycine 0 N--CA 1.445 -0.766 0 C-N-CA 121.161 -0.542 . . . . 0.0 113.892 178.776 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 8.1 m -54.45 137.54 42.27 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-N 115.011 -0.594 . . . . 0.0 111.8 179.659 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 21.0 m 64.08 18.92 11.52 Favored 'General case' 0 N--CA 1.469 0.511 0 N-CA-C 113.131 0.789 . . . . 0.0 113.131 177.616 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -79.93 140.28 54.04 Favored Pre-proline 0 C--N 1.322 -0.597 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 177.209 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 69.9 Cg_endo -71.13 158.73 54.22 Favored 'Trans proline' 0 C--O 1.238 0.505 0 C-N-CA 122.495 2.13 . . . . 0.0 112.287 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' TRP . . . . . 0.53 ' CE3' ' HB2' ' A' ' 9' ' ' GLN . 91.7 m95 -92.94 128.78 38.92 Favored 'General case' 0 C--N 1.314 -0.965 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 179.076 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 88.9 m-20 -116.37 117.12 29.07 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-N 116.7 -0.227 . . . . 0.0 110.691 -177.573 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.477 ' HA ' ' HA ' ' A' ' 7' ' ' GLU . 11.2 pt-20 -72.27 135.55 46.03 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 177.669 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -142.87 26.16 2.23 Favored Glycine 0 N--CA 1.44 -1.074 0 C-N-CA 119.375 -1.393 . . . . 0.0 113.266 179.302 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 149.85 -176.04 28.7 Favored Glycine 0 N--CA 1.447 -0.567 0 C-N-CA 119.531 -1.318 . . . . 0.0 113.583 -179.832 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . 0.569 HE21 HD11 ' A' ' 3' ' ' LEU . 4.4 pt20 -131.32 136.97 48.57 Favored 'General case' 0 C--N 1.325 -0.478 0 C-N-CA 122.603 0.361 . . . . 0.0 110.425 -178.728 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . 0.461 ' CG ' HG21 ' A' ' 6' ' ' VAL . 29.3 m0 -112.58 154.64 25.68 Favored 'General case' 0 CA--C 1.504 -0.826 0 N-CA-C 110.126 -0.324 . . . . 0.0 110.126 179.406 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 69.5 tt0 -117.89 114.16 22.82 Favored 'General case' 0 C--N 1.31 -1.111 0 C-N-CA 119.772 -0.771 . . . . 0.0 109.085 176.185 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.459 ' HB ' ' CE1' ' A' ' 4' ' ' TYR . 96.8 mt -127.0 135.76 62.74 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.598 -175.486 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 113.5 165.13 15.89 Favored Glycine 0 N--CA 1.438 -1.183 0 C-N-CA 120.667 -0.778 . . . . 0.0 112.721 176.838 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 58.5 m -134.63 -55.77 0.84 Allowed 'General case' 0 C--N 1.309 -1.163 0 N-CA-C 108.793 -0.817 . . . . 0.0 108.793 179.454 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 93.4 mtt-85 -80.36 137.09 36.51 Favored 'General case' 0 N--CA 1.448 -0.551 0 CA-C-N 115.506 -0.77 . . . . 0.0 109.164 176.403 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 24.8 m -89.03 -19.98 24.95 Favored 'General case' 0 C--N 1.314 -0.95 0 CA-C-O 121.257 0.551 . . . . 0.0 110.884 -179.379 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 17.3 m-20 -95.68 1.01 53.3 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.781 -0.645 . . . . 0.0 111.407 -178.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . 0.46 ' OE1' ' HB3' ' A' ' 53' ' ' TYR . 0.4 OUTLIER -141.65 112.41 7.21 Favored 'General case' 0 C--N 1.321 -0.67 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 178.966 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 2.7 t30 -95.2 161.2 14.2 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-O 120.958 0.409 . . . . 0.0 111.497 -176.088 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.432 ' HA ' ' HA ' ' A' ' 53' ' ' TYR . 59.6 t -98.77 134.58 37.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 C-N-CA 123.204 0.602 . . . . 0.0 110.151 -179.146 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.405 HG13 ' HB2' ' A' ' 54' ' ' ALA . 23.8 m -112.72 -15.22 10.4 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.545 0 N-CA-C 112.548 0.573 . . . . 0.0 112.548 -179.319 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.509 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -147.8 143.85 27.78 Favored 'General case' 0 C--O 1.239 0.52 0 C-N-CA 120.228 -0.589 . . . . 0.0 111.52 177.597 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.41 ' HB ' ' CG2' ' A' ' 105' ' ' VAL . 94.8 mt -141.84 124.96 15.06 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 -179.772 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' ASN . . . . . 0.423 HD22 ' HA ' ' A' ' 37' ' ' ASN . 1.0 OUTLIER -133.4 112.5 11.64 Favored 'General case' 0 C--N 1.311 -1.068 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 177.951 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.469 HG22 ' HB ' ' A' ' 103' ' ' ILE . 19.7 m -146.37 147.83 17.66 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.775 0 N-CA-C 112.202 0.445 . . . . 0.0 112.202 -174.388 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 69.2 tt0 -131.02 143.2 50.53 Favored 'General case' 0 CA--C 1.536 0.404 0 CA-C-N 115.692 -0.685 . . . . 0.0 109.629 176.768 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . 0.416 ' HA ' ' O ' ' A' ' 46' ' ' THR . 22.1 p -71.13 147.64 48.2 Favored 'General case' 0 C--N 1.319 -0.754 0 N-CA-C 112.441 0.534 . . . . 0.0 112.441 179.633 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -97.87 -48.69 1.89 Allowed Glycine 0 N--CA 1.45 -0.403 0 N-CA-C 110.515 -1.034 . . . . 0.0 110.515 176.597 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 6.9 m-20 -97.26 -168.07 1.64 Allowed 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 175.783 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 28.3 m-20 -74.93 59.83 0.93 Allowed 'General case' 0 N--CA 1.469 0.501 0 CA-C-O 121.133 0.492 . . . . 0.0 111.947 -179.543 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 82.77 11.6 81.34 Favored Glycine 0 N--CA 1.452 -0.268 0 CA-C-N 115.976 -0.556 . . . . 0.0 112.75 177.477 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 63.1 tt0 -97.08 -30.51 13.0 Favored 'General case' 0 C--O 1.215 -0.715 0 C-N-CA 120.784 -0.366 . . . . 0.0 111.314 179.701 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . 0.416 ' O ' ' HA ' ' A' ' 40' ' ' SER . 31.0 p -124.04 147.36 47.9 Favored 'General case' 0 C--N 1.308 -1.203 0 C-N-CA 120.818 -0.353 . . . . 0.0 110.801 -179.806 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' LEU . . . . . 0.526 ' HB2' ' HB3' ' A' ' 63' ' ' ALA . 94.1 mt -133.28 129.47 37.65 Favored 'General case' 0 C--N 1.318 -0.79 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 -179.7 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 51.3 m-80 -127.16 140.75 52.04 Favored 'General case' 0 C--N 1.311 -1.101 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 177.565 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . 0.433 ' HA3' HG12 ' A' ' 38' ' ' VAL . . . 177.22 -157.75 22.8 Favored Glycine 0 N--CA 1.438 -1.197 0 C-N-CA 119.4 -1.381 . . . . 0.0 113.541 179.904 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 44.6 m -126.23 129.96 49.98 Favored 'General case' 0 N--CA 1.44 -0.973 0 CA-C-N 115.302 -0.449 . . . . 0.0 110.239 -177.272 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 19.0 ttm -110.78 141.93 43.43 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 109.69 -0.485 . . . . 0.0 109.69 179.089 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.509 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 36.2 m -126.29 122.38 35.33 Favored 'General case' 0 C--O 1.254 1.29 0 CA-C-O 120.956 0.408 . . . . 0.0 111.233 178.019 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . 0.561 ' HB2' ' HB2' ' A' ' 56' ' ' GLU . 78.6 m-85 -85.92 164.3 17.53 Favored 'General case' 0 C--O 1.231 0.127 0 CA-C-N 115.404 -0.816 . . . . 0.0 110.702 178.891 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . 0.405 ' HB2' HG13 ' A' ' 34' ' ' VAL . . . -69.58 105.44 2.67 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.895 -179.515 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 86.44 8.43 77.61 Favored Glycine 0 CA--C 1.518 0.236 0 C-N-CA 121.013 -0.613 . . . . 0.0 112.943 176.711 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . 0.561 ' HB2' ' HB2' ' A' ' 53' ' ' TYR . 78.6 mm-40 -122.12 165.56 15.9 Favored 'General case' 0 C--N 1.315 -0.893 0 N-CA-C 110.012 -0.366 . . . . 0.0 110.012 -179.003 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -77.7 161.96 50.16 Favored Glycine 0 N--CA 1.446 -0.683 0 C-N-CA 120.663 -0.779 . . . . 0.0 112.086 178.51 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -72.73 145.87 42.03 Favored 'Trans proline' 0 C--O 1.241 0.645 0 C-N-CA 122.811 2.341 . . . . 0.0 112.716 179.835 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . 0.542 ' HB ' ' O ' ' A' ' 76' ' ' GLN . 49.7 pt -128.86 165.83 27.72 Favored 'Isoleucine or valine' 0 C--O 1.242 0.687 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.653 179.888 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -77.13 134.84 15.47 Favored Glycine 0 C--O 1.239 0.459 0 C-N-CA 120.897 -0.668 . . . . 0.0 111.819 -179.347 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.429 ' CD2' HG11 ' A' ' 38' ' ' VAL . 72.1 t80 -117.43 127.49 54.07 Favored 'General case' 0 C--O 1.237 0.443 0 C-N-CA 122.429 0.291 . . . . 0.0 111.24 -177.556 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 50.2 ttm-85 -130.29 127.75 40.14 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.016 -0.538 . . . . 0.0 109.86 176.699 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.526 ' HB3' ' HB2' ' A' ' 47' ' ' LEU . . . -132.05 139.87 48.69 Favored 'General case' 0 C--N 1.319 -0.741 0 C-N-CA 120.796 -0.362 . . . . 0.0 111.819 178.529 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 46.7 m -122.28 127.02 49.38 Favored 'General case' 0 CA--C 1.54 0.568 0 CA-C-N 115.879 -0.601 . . . . 0.0 110.005 178.201 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -74.5 119.77 19.15 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-O 121.053 0.454 . . . . 0.0 110.678 -178.118 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 91.7 mt -94.43 -25.14 17.04 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.669 -0.696 . . . . 0.0 109.962 178.368 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 134.57 157.5 8.14 Favored Glycine 0 N--CA 1.44 -1.044 0 CA-C-N 115.675 -0.693 . . . . 0.0 111.882 179.638 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 92.4 m-20 56.69 34.33 24.37 Favored 'General case' 0 N--CA 1.481 1.114 0 C-N-CA 122.463 0.305 . . . . 0.0 111.469 179.2 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . 0.536 ' ND2' ' HA3' ' A' ' 93' ' ' GLY . 21.8 m120 70.15 10.49 7.36 Favored 'General case' 0 N--CA 1.481 1.087 0 C-N-CA 123.522 0.729 . . . . 0.0 112.415 -179.407 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 55.8 m -87.72 122.31 31.22 Favored 'General case' 0 C--O 1.236 0.376 0 N-CA-C 110.015 -0.365 . . . . 0.0 110.015 177.959 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.562 ' OH ' ' HB3' ' A' ' 99' ' ' ASN . 70.8 m-85 -115.44 129.96 56.73 Favored 'General case' 0 C--N 1.311 -1.065 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.217 -179.643 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 52.2 tp10 -85.31 118.82 25.09 Favored 'General case' 0 N--CA 1.438 -1.064 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 174.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 68.0 t -106.98 132.75 53.52 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.23 0 N-CA-C 112.937 0.717 . . . . 0.0 112.937 -173.427 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -123.72 142.85 50.69 Favored 'General case' 0 N--CA 1.446 -0.645 0 N-CA-C 107.273 -1.381 . . . . 0.0 107.273 175.801 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 93.4 m-20 -134.71 161.24 35.71 Favored 'General case' 0 C--N 1.316 -0.851 0 C-N-CA 120.869 -0.332 . . . . 0.0 111.291 -174.964 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' GLN . . . . . 0.542 ' O ' ' HB ' ' A' ' 59' ' ' ILE . 2.9 pt20 -130.64 129.99 43.38 Favored 'General case' 0 C--O 1.239 0.543 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.159 177.006 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 6.6 p90 -133.96 151.19 51.38 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.91 -178.408 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 98.12 -1.96 59.45 Favored Glycine 0 N--CA 1.448 -0.54 0 C-N-CA 120.713 -0.756 . . . . 0.0 111.871 -179.614 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 140.99 164.62 9.99 Favored Glycine 0 N--CA 1.441 -1.031 0 C-N-CA 121.054 -0.593 . . . . 0.0 112.2 179.072 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -65.54 -33.0 74.89 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-O 121.248 0.546 . . . . 0.0 110.473 179.44 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 32.5 p -79.85 6.87 9.95 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.257 -0.883 . . . . 0.0 112.459 -178.055 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -83.89 146.64 49.56 Favored Pre-proline 0 C--N 1.316 -0.89 0 CA-C-N 116.698 -0.228 . . . . 0.0 110.527 179.668 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -67.92 173.73 8.8 Favored 'Trans proline' 0 C--N 1.345 0.353 0 C-N-CA 122.459 2.106 . . . . 0.0 111.604 178.855 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' TRP . . . . . . . . . . . . . 95.2 m95 -98.37 127.72 44.43 Favored 'General case' 0 N--CA 1.444 -0.751 0 CA-C-O 121.172 0.51 . . . . 0.0 110.248 -177.666 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 97.3 m-70 -115.7 149.69 38.0 Favored 'General case' 0 C--N 1.31 -1.116 0 CA-C-N 115.398 -0.819 . . . . 0.0 110.323 -177.629 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 10.0 m -61.53 130.25 45.06 Favored 'General case' 0 C--N 1.315 -0.925 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.833 -179.562 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -105.08 -52.68 0.82 Allowed Glycine 0 N--CA 1.439 -1.107 0 C-N-CA 120.913 -0.66 . . . . 0.0 111.634 179.43 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 155.68 -172.52 33.75 Favored Glycine 0 C--O 1.22 -0.753 0 C-N-CA 120.596 -0.811 . . . . 0.0 111.774 179.605 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 21.2 t-20 -110.28 112.08 23.8 Favored 'General case' 0 C--N 1.313 -1.009 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 179.512 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 27.4 m0 -102.4 149.8 23.99 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.993 -177.749 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 47.4 mm -107.17 114.02 45.04 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 177.247 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . 0.414 ' HB2' ' CE1' ' A' ' 71' ' ' TYR . 85.0 mt -124.25 89.25 3.05 Favored 'General case' 0 C--O 1.272 2.279 0 CA-C-O 121.725 0.774 . . . . 0.0 112.691 -175.796 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . 0.536 ' HA3' ' ND2' ' A' ' 69' ' ' ASN . . . 154.86 116.91 0.58 Allowed Glycine 0 N--CA 1.443 -0.876 0 CA-C-N 115.0 -1.0 . . . . 0.0 111.676 178.911 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . 0.436 ' N ' ' HE1' ' A' ' 23' ' ' TRP . 76.8 p -86.0 -15.28 41.95 Favored 'General case' 0 CA--C 1.516 -0.355 0 CA-C-O 121.395 0.617 . . . . 0.0 109.913 178.849 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 58.4 mtt-85 -88.91 141.85 28.14 Favored 'General case' 0 N--CA 1.435 -1.185 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.004 -179.93 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 8.9 pt-20 -68.65 -33.11 73.43 Favored 'General case' 0 C--N 1.31 -1.117 0 CA-C-N 115.53 -0.759 . . . . 0.0 111.975 -175.376 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 31.3 p-10 -120.75 28.66 7.82 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 111.788 0.292 . . . . 0.0 111.788 -178.117 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' GLN . . . . . 0.517 HE22 ' HB3' ' A' ' 121' ' ' ALA . 0.0 OUTLIER -142.78 118.48 10.46 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 112.326 0.491 . . . . 0.0 112.326 -176.672 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' ASN . . . . . 0.562 ' HB3' ' OH ' ' A' ' 71' ' ' TYR . 93.2 m-20 -89.36 157.86 18.01 Favored 'General case' 0 C--O 1.262 1.755 0 CA-C-N 115.724 -0.671 . . . . 0.0 111.166 177.673 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.445 HG21 ' CH2' ' A' ' 23' ' ' TRP . 85.9 t -84.35 134.14 27.66 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.594 0 CA-C-N 115.355 -0.839 . . . . 0.0 111.705 178.445 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 35.8 m -110.66 -29.03 2.49 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.397 0 CA-C-N 116.035 -0.529 . . . . 0.0 112.275 179.765 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . 0.516 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -146.24 139.37 25.77 Favored 'General case' 0 C--N 1.323 -0.585 0 C-N-CA 120.2 -0.6 . . . . 0.0 111.144 179.056 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.469 ' HB ' HG22 ' A' ' 38' ' ' VAL . 94.9 mt -131.62 124.95 55.19 Favored 'Isoleucine or valine' 0 C--O 1.244 0.771 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.57 177.796 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 41.2 t30 -125.17 94.56 4.2 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 115.676 -0.693 . . . . 0.0 109.3 175.586 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.41 ' CG2' ' HB ' ' A' ' 36' ' ' ILE . 29.3 m -133.6 135.82 55.2 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 N-CA-C 112.859 0.689 . . . . 0.0 112.859 -176.538 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 75.3 tt0 -140.15 137.55 34.51 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.415 -0.811 . . . . 0.0 110.13 179.639 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 23.2 t -146.93 145.37 29.77 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 116.468 -0.333 . . . . 0.0 110.459 177.211 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -109.18 17.07 32.12 Favored Glycine 0 N--CA 1.447 -0.609 0 C-N-CA 121.11 -0.567 . . . . 0.0 112.435 -179.195 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 40.3 p-10 -91.91 -153.61 0.34 Allowed 'General case' 0 C--N 1.319 -0.753 0 CA-C-O 120.768 0.318 . . . . 0.0 110.158 179.098 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 37.1 t70 -88.94 12.86 14.19 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-O 121.167 0.508 . . . . 0.0 110.071 179.108 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 85.7 7.39 81.68 Favored Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 120.684 -0.769 . . . . 0.0 111.939 -177.173 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 36.5 tt0 -66.57 -38.78 87.79 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-O 121.109 0.481 . . . . 0.0 110.526 -179.671 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . 0.418 ' HA ' ' O ' ' A' ' 130' ' ' GLY . 27.5 p -124.63 131.73 53.46 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-N 115.906 -0.588 . . . . 0.0 111.056 179.224 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -109.94 113.32 25.96 Favored 'General case' 0 C--N 1.315 -0.927 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 177.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 93.8 m-20 -117.23 147.5 42.46 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-O 121.016 0.436 . . . . 0.0 111.26 -177.941 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 159.57 -135.61 4.22 Favored Glycine 0 N--CA 1.434 -1.457 0 C-N-CA 120.458 -0.877 . . . . 0.0 112.906 177.717 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 20.8 p -134.04 157.97 44.76 Favored 'General case' 0 C--N 1.31 -1.143 0 C-N-CA 122.905 0.482 . . . . 0.0 110.316 -177.786 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 118' ' ' MET . . . . . 0.41 ' HE1' ' CZ ' ' A' ' 120' ' ' TYR . 17.3 ptm -149.63 155.24 39.92 Favored 'General case' 0 C--N 1.312 -1.063 0 CA-C-N 116.498 -0.319 . . . . 0.0 110.391 -179.672 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 119' ' ' THR . . . . . 0.516 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 27.9 m -130.76 128.11 40.11 Favored 'General case' 0 C--O 1.249 1.055 0 CA-C-N 116.474 -0.33 . . . . 0.0 111.224 179.804 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . 0.41 ' CZ ' ' HE1' ' A' ' 118' ' ' MET . 31.0 m-85 -89.85 166.02 13.77 Favored 'General case' 0 CA--C 1.507 -0.687 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.294 175.975 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . 0.517 ' HB3' HE22 ' A' ' 98' ' ' GLN . . . -66.47 45.38 0.03 OUTLIER 'General case' 0 CA--C 1.554 1.126 0 N-CA-C 114.043 1.127 . . . . 0.0 114.043 179.79 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 142.44 -25.63 2.31 Favored Glycine 0 C--N 1.334 0.429 0 C-N-CA 119.874 -1.155 . . . . 0.0 114.405 175.372 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . 0.471 ' HG2' ' OE1' ' A' ' 98' ' ' GLN . 69.4 mm-40 -67.33 -33.36 75.09 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 117.311 0.556 . . . . 0.0 112.424 -177.585 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 115.09 161.69 13.34 Favored Glycine 0 CA--C 1.519 0.334 0 C-N-CA 120.585 -0.817 . . . . 0.0 112.361 -179.542 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 20.8 Cg_exo -67.11 129.36 20.39 Favored 'Trans proline' 0 C--N 1.351 0.673 0 C-N-CA 122.782 2.321 . . . . 0.0 111.991 178.386 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 37.4 pt -135.44 161.73 38.71 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.691 179.592 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -69.8 139.25 31.17 Favored Glycine 0 C--O 1.239 0.453 0 C-N-CA 120.923 -0.656 . . . . 0.0 112.26 178.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 86.4 t80 -119.52 133.71 55.55 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 120.745 0.307 . . . . 0.0 111.233 -178.465 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 129' ' ' LYS . . . . . 0.427 ' HB3' ' HB2' ' A' ' 7' ' ' GLU . 63.6 tttm -140.99 118.12 11.27 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.911 -0.586 . . . . 0.0 109.519 176.718 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . 0.418 ' O ' ' HA ' ' A' ' 113' ' ' THR . . . -122.18 141.96 14.63 Favored Glycine 0 N--CA 1.449 -0.475 0 C-N-CA 120.735 -0.745 . . . . 0.0 111.941 -179.643 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 62.1 m -128.11 135.65 50.08 Favored 'General case' 0 C--N 1.317 -0.818 0 CA-C-N 116.619 0.21 . . . . 0.0 111.392 -179.585 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 132' ' ' LEU . . . . . 0.401 HD13 ' N ' ' A' ' 133' ' ' THR . 3.4 tm? -57.79 138.26 55.77 Favored 'General case' 0 N--CA 1.467 0.392 0 C-N-CA 123.062 0.545 . . . . 0.0 110.391 179.723 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 133' ' ' THR . . . . . 0.401 ' N ' HD13 ' A' ' 132' ' ' LEU . 24.0 m . . . . . 0 C--O 1.247 0.964 0 CA-C-O 118.503 -0.761 . . . . 0.0 110.322 -178.577 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.238 0.449 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' LEU . . . . . 0.586 HD21 HE21 ' A' ' 22' ' ' GLN . 3.1 tm? -90.76 128.68 36.77 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-O 120.855 0.359 . . . . 0.0 110.099 -179.914 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . 0.424 ' CD1' ' HB ' ' A' ' 25' ' ' ILE . 57.4 m-85 -119.65 143.07 47.91 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.142 178.1 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 12.9 m-80 -97.24 135.52 39.05 Favored 'General case' 0 C--N 1.309 -1.159 0 N-CA-C 108.394 -0.965 . . . . 0.0 108.394 175.689 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 53.5 t -111.36 126.65 68.76 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.862 0 CA-C-O 121.803 0.811 . . . . 0.0 112.627 -174.769 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.452 ' HG2' ' HB3' ' A' ' 19' ' ' GLU . 63.6 mt-10 -118.82 133.18 56.02 Favored 'General case' 0 N--CA 1.438 -1.047 0 CA-C-N 114.684 -1.144 . . . . 0.0 108.5 176.665 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . 0.45 ' HA ' ' O ' ' A' ' 127' ' ' GLY . 13.0 m120 -117.89 139.76 50.67 Favored 'General case' 0 C--N 1.313 -1.004 0 CA-C-O 121.072 0.463 . . . . 0.0 111.424 -176.641 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . 0.445 ' HB2' ' CE3' ' A' ' 17' ' ' TRP . 28.1 tt0 -132.6 125.86 31.43 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.059 179.131 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 24.1 p90 -128.98 141.29 51.3 Favored 'General case' 0 C--N 1.316 -0.853 0 C-N-CA 120.607 -0.437 . . . . 0.0 111.265 -179.048 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 115.77 -77.72 0.27 Allowed Glycine 0 N--CA 1.442 -0.936 0 CA-C-N 115.562 -0.744 . . . . 0.0 111.794 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -170.34 173.62 44.3 Favored Glycine 0 N--CA 1.442 -0.953 0 C-N-CA 121.085 -0.579 . . . . 0.0 111.725 -179.579 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 26.2 t -59.25 -23.8 62.65 Favored 'General case' 0 CA--C 1.538 0.506 0 N-CA-C 111.881 0.326 . . . . 0.0 111.881 -179.729 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 23.5 p -65.23 -19.65 66.07 Favored 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 112.009 0.374 . . . . 0.0 112.009 177.823 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -93.09 146.91 32.84 Favored Pre-proline 0 N--CA 1.446 -0.671 0 N-CA-C 109.978 -0.379 . . . . 0.0 109.978 179.414 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_endo -79.41 173.27 13.39 Favored 'Trans proline' 0 CA--C 1.537 0.652 0 C-N-CA 122.723 2.282 . . . . 0.0 112.869 179.457 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' TRP . . . . . 0.445 ' CE3' ' HB2' ' A' ' 9' ' ' GLN . 95.5 m95 -87.14 131.24 34.22 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.938 -0.573 . . . . 0.0 109.795 178.741 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 46.5 m-80 -114.37 118.62 34.36 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.937 -178.395 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.452 ' HB3' ' HG2' ' A' ' 7' ' ' GLU . 10.9 pt-20 -82.7 124.75 30.51 Favored 'General case' 0 C--N 1.315 -0.897 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.499 179.236 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.439 ' O ' ' HB2' ' A' ' 94' ' ' SER . . . -132.46 29.93 3.22 Favored Glycine 0 N--CA 1.442 -0.963 0 C-N-CA 120.069 -1.062 . . . . 0.0 112.838 -177.709 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 140.96 -175.12 22.36 Favored Glycine 0 N--CA 1.442 -0.907 0 C-N-CA 120.25 -0.976 . . . . 0.0 112.819 178.818 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . 0.586 HE21 HD21 ' A' ' 3' ' ' LEU . 18.5 pt20 -141.46 153.05 44.74 Favored 'General case' 0 C--N 1.313 -1.01 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 179.812 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . 0.425 ' HB3' ' O ' ' A' ' 91' ' ' ILE . 45.0 m0 -127.68 174.7 8.87 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.543 -0.299 . . . . 0.0 110.787 -176.086 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 79.6 tt0 -121.01 118.11 28.97 Favored 'General case' 0 CA--C 1.51 -0.57 0 C-N-CA 120.624 -0.43 . . . . 0.0 109.902 176.776 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.424 ' HB ' ' CD1' ' A' ' 4' ' ' TYR . 98.3 mt -131.53 140.14 49.01 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.774 0 CA-C-N 115.816 -0.629 . . . . 0.0 109.609 -178.762 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 86.15 66.64 1.39 Allowed Glycine 0 N--CA 1.443 -0.886 0 C-N-CA 120.34 -0.933 . . . . 0.0 112.544 178.982 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 19.2 p -59.78 -36.88 77.61 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 121.131 0.491 . . . . 0.0 110.239 177.744 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 93.5 mtt-85 -94.88 108.23 20.26 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 175.233 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 51.0 m -73.7 -7.87 53.76 Favored 'General case' 0 C--N 1.321 -0.671 0 N-CA-C 113.082 0.771 . . . . 0.0 113.082 -174.761 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 97.9 m-20 -76.81 -18.76 58.21 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.906 0.384 . . . . 0.0 110.996 179.854 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . 0.511 ' NE2' ' HA ' ' A' ' 31' ' ' GLN . 7.2 mm-40 -133.53 114.83 14.02 Favored 'General case' 0 CA--C 1.51 -0.561 0 N-CA-C 112.589 0.589 . . . . 0.0 112.589 -178.741 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . 0.542 ' ND2' ' HA3' ' A' ' 111' ' ' GLY . 2.6 t30 -82.21 142.43 32.16 Favored 'General case' 0 C--O 1.242 0.7 0 CA-C-N 116.011 -0.541 . . . . 0.0 110.043 179.369 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 47.0 t -92.37 129.75 42.51 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 CA-C-N 115.507 -0.77 . . . . 0.0 109.857 -178.331 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.442 ' HB ' ' O ' ' A' ' 107' ' ' SER . 30.5 m -110.13 -21.15 5.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 N-CA-C 112.38 0.511 . . . . 0.0 112.38 -179.925 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.627 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -144.85 143.13 30.46 Favored 'General case' 0 C--N 1.322 -0.605 0 C-N-CA 119.816 -0.753 . . . . 0.0 111.85 179.319 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.439 ' C ' HD22 ' A' ' 37' ' ' ASN . 91.5 mt -142.08 119.38 7.47 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 CA-C-N 115.48 -0.782 . . . . 0.0 109.061 179.802 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' ASN . . . . . 0.439 HD22 ' C ' ' A' ' 36' ' ' ILE . 0.9 OUTLIER -126.4 109.92 12.76 Favored 'General case' 0 C--N 1.306 -1.32 0 N-CA-C 108.389 -0.967 . . . . 0.0 108.389 176.506 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.551 HG12 ' HA3' ' A' ' 49' ' ' GLY . 29.5 m -148.26 153.42 11.54 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.63 0 N-CA-C 112.111 0.411 . . . . 0.0 112.111 -173.753 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 -146.35 148.34 32.26 Favored 'General case' 0 C--O 1.245 0.82 0 CA-C-N 115.431 -0.804 . . . . 0.0 109.299 174.778 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . 0.474 ' HB3' ' CD2' ' A' ' 47' ' ' LEU . 37.1 p -80.49 151.54 29.18 Favored 'General case' 0 C--N 1.313 -1.014 0 CA-C-O 121.496 0.665 . . . . 0.0 112.511 -176.88 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -92.76 -13.26 56.99 Favored Glycine 0 N--CA 1.438 -1.168 0 N-CA-C 110.084 -1.206 . . . . 0.0 110.084 173.281 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 28.3 m-20 -137.33 -155.16 0.59 Allowed 'General case' 0 N--CA 1.468 0.445 0 C-N-CA 123.203 0.601 . . . . 0.0 109.403 -179.34 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -79.4 42.12 0.49 Allowed 'General case' 0 N--CA 1.47 0.572 0 CA-C-O 121.099 0.476 . . . . 0.0 110.725 178.117 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 91.43 3.82 68.84 Favored Glycine 0 C--O 1.22 -0.743 0 C-N-CA 121.025 -0.607 . . . . 0.0 112.881 -178.834 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 55.9 tp60 -63.97 -47.67 79.48 Favored 'General case' 0 N--CA 1.462 0.17 0 CA-C-O 120.903 0.382 . . . . 0.0 111.016 179.575 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 9.4 t -133.32 127.75 34.23 Favored 'General case' 0 C--N 1.312 -1.059 0 C-N-CA 120.72 -0.392 . . . . 0.0 110.113 177.551 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' LEU . . . . . 0.474 ' CD2' ' HB3' ' A' ' 40' ' ' SER . 64.9 mt -109.08 127.96 54.58 Favored 'General case' 0 N--CA 1.447 -0.618 0 N-CA-C 109.662 -0.496 . . . . 0.0 109.662 179.636 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 65.2 m-80 -121.97 147.1 46.47 Favored 'General case' 0 C--N 1.313 -0.982 0 N-CA-C 109.558 -0.534 . . . . 0.0 109.558 176.8 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . 0.551 ' HA3' HG12 ' A' ' 38' ' ' VAL . . . 176.13 -154.4 16.88 Favored Glycine 0 N--CA 1.433 -1.557 0 C-N-CA 119.925 -1.131 . . . . 0.0 113.064 179.602 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 89.9 m -129.35 130.7 46.39 Favored 'General case' 0 N--CA 1.436 -1.159 0 C-N-CA 122.668 0.387 . . . . 0.0 111.13 -177.483 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 44.9 mtp -110.08 151.27 27.42 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.394 -0.367 . . . . 0.0 110.927 177.846 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.627 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 23.7 m -132.84 127.77 35.2 Favored 'General case' 0 C--N 1.315 -0.898 0 N-CA-C 110.185 -0.302 . . . . 0.0 110.185 176.009 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . 0.452 ' CD1' ' HB3' ' A' ' 31' ' ' GLN . 83.6 m-85 -92.48 163.21 13.91 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.867 178.721 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -61.31 103.36 0.29 Allowed 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.969 -178.553 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 94.77 -6.59 70.24 Favored Glycine 0 CA--C 1.51 -0.258 0 C-N-CA 120.863 -0.684 . . . . 0.0 113.267 177.975 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 69.8 mm-40 -104.82 -179.24 3.89 Favored 'General case' 0 C--N 1.311 -1.102 0 CA-C-O 120.709 0.29 . . . . 0.0 110.836 -178.347 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -99.06 173.73 26.86 Favored Glycine 0 N--CA 1.444 -0.796 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.33 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -68.66 139.38 44.08 Favored 'Trans proline' 0 CA--C 1.538 0.709 0 C-N-CA 122.818 2.345 . . . . 0.0 112.588 179.503 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 50.2 pt -131.93 167.17 27.0 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.079 178.372 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -78.53 139.09 21.92 Favored Glycine 0 N--CA 1.446 -0.677 0 N-CA-C 111.019 -0.832 . . . . 0.0 111.019 179.459 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.547 ' CD2' HG11 ' A' ' 38' ' ' VAL . 29.1 t80 -131.31 129.71 41.82 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 120.953 0.406 . . . . 0.0 111.583 -177.479 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 55.4 ttm-85 -127.11 130.06 49.13 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.514 -0.766 . . . . 0.0 110.493 178.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.455 ' HB1' ' HB3' ' A' ' 71' ' ' TYR . . . -129.27 132.32 47.16 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-O 120.594 0.235 . . . . 0.0 110.796 177.175 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 85.3 m -117.31 125.47 51.12 Favored 'General case' 0 C--N 1.316 -0.861 0 CA-C-O 120.996 0.427 . . . . 0.0 110.74 179.637 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . 0.507 ' HG ' ' H ' ' A' ' 67' ' ' GLY . 66.6 tp -71.52 132.89 45.36 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.759 -0.655 . . . . 0.0 112.544 -177.579 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -85.94 -16.15 39.33 Favored 'General case' 0 N--CA 1.471 0.577 0 CA-C-N 115.29 -0.868 . . . . 0.0 109.898 174.743 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.507 ' H ' ' HG ' ' A' ' 65' ' ' LEU . . . 103.7 7.61 41.68 Favored Glycine 0 N--CA 1.463 0.44 0 CA-C-N 115.527 -0.76 . . . . 0.0 112.7 177.471 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 29.7 p-10 -137.73 39.65 2.39 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-O 120.851 0.358 . . . . 0.0 110.592 -179.331 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 89.0 m-20 68.9 -1.72 1.96 Allowed 'General case' 0 N--CA 1.485 1.281 0 C-N-CA 123.528 0.731 . . . . 0.0 112.128 -178.558 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 15.3 m -91.82 132.23 36.59 Favored 'General case' 0 C--N 1.314 -0.948 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 177.456 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.455 ' HB3' ' HB1' ' A' ' 63' ' ' ALA . 79.1 m-85 -124.09 133.96 53.49 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.741 -179.25 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 79.9 tt0 -87.13 123.6 32.35 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 174.691 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.481 HG13 ' CE1' ' A' ' 61' ' ' PHE . 48.8 t -99.37 128.61 50.92 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 N-CA-C 112.826 0.676 . . . . 0.0 112.826 -175.656 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 75.4 mt-10 -127.19 121.81 32.34 Favored 'General case' 0 CA--C 1.535 0.378 0 CA-C-N 114.794 -1.094 . . . . 0.0 108.467 175.194 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' ASN . . . . . 0.421 ' OD1' ' HD1' ' A' ' 61' ' ' PHE . 96.4 m-20 -108.42 153.01 23.91 Favored 'General case' 0 C--O 1.236 0.393 0 N-CA-C 112.56 0.578 . . . . 0.0 112.56 -176.283 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 60.2 tt0 -127.72 125.55 40.19 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.358 -0.837 . . . . 0.0 109.389 -179.775 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 6.6 p90 -127.29 4.4 6.33 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 112.734 0.642 . . . . 0.0 112.734 -178.246 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -84.74 -1.88 88.87 Favored Glycine 0 CA--C 1.521 0.415 0 C-N-CA 120.561 -0.828 . . . . 0.0 111.954 178.242 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 106.14 -153.83 16.99 Favored Glycine 0 CA--C 1.497 -1.037 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 -179.717 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -62.43 -32.54 73.41 Favored 'General case' 0 CA--C 1.514 -0.422 0 CA-C-N 117.675 0.738 . . . . 0.0 109.217 173.827 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 47.7 m -84.78 -175.35 5.74 Favored 'General case' 0 N--CA 1.438 -1.04 0 CA-C-N 114.947 -1.024 . . . . 0.0 110.016 176.588 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 75.78 147.22 0.12 Allowed Pre-proline 0 N--CA 1.471 0.578 0 C-N-CA 123.997 0.919 . . . . 0.0 111.701 -179.445 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -73.76 169.19 22.95 Favored 'Trans proline' 0 C--O 1.238 0.508 0 C-N-CA 122.874 2.383 . . . . 0.0 111.807 178.999 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' TRP . . . . . . . . . . . . . 82.7 m95 -87.87 145.65 25.96 Favored 'General case' 0 N--CA 1.447 -0.589 0 N-CA-C 109.524 -0.547 . . . . 0.0 109.524 -179.911 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 94.3 m-70 -116.97 143.38 45.78 Favored 'General case' 0 C--N 1.317 -0.836 0 N-CA-C 110.033 -0.358 . . . . 0.0 110.033 -179.551 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 13.5 m -63.01 137.02 58.14 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-O 120.802 0.334 . . . . 0.0 110.904 -178.748 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -112.83 -48.92 0.6 Allowed Glycine 0 N--CA 1.447 -0.573 0 C-N-CA 121.228 -0.511 . . . . 0.0 112.371 -179.632 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 152.95 -167.95 31.75 Favored Glycine 0 C--O 1.214 -1.155 0 C-N-CA 120.257 -0.973 . . . . 0.0 112.121 179.201 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 16.1 m120 -111.99 118.88 36.67 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 117.082 0.441 . . . . 0.0 110.488 179.868 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 27.4 m0 -111.01 155.27 22.98 Favored 'General case' 0 C--N 1.321 -0.651 0 N-CA-C 110.25 -0.278 . . . . 0.0 110.25 -179.306 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . 0.425 ' O ' ' HB3' ' A' ' 23' ' ' TRP . 49.2 mm -110.93 116.61 52.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 N-CA-C 109.179 -0.674 . . . . 0.0 109.179 177.893 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . 0.45 ' HB2' ' CE1' ' A' ' 71' ' ' TYR . 77.9 mt -128.98 81.72 2.04 Favored 'General case' 0 C--O 1.272 2.267 0 CA-C-O 121.772 0.796 . . . . 0.0 112.069 -177.996 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 166.22 112.61 0.26 Allowed Glycine 0 N--CA 1.442 -0.92 0 CA-C-N 115.222 -0.899 . . . . 0.0 111.771 179.159 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . 0.439 ' HB2' ' O ' ' A' ' 20' ' ' GLY . 77.4 p -86.01 -10.94 54.19 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 121.277 0.56 . . . . 0.0 110.761 179.887 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 98.6 mtt180 -111.44 154.24 24.96 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.556 -0.747 . . . . 0.0 109.413 -179.702 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -70.65 -53.19 16.75 Favored 'General case' 0 N--CA 1.472 0.669 0 N-CA-C 113.501 0.926 . . . . 0.0 113.501 -172.348 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 94.8 m-20 -115.0 36.47 3.86 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.75 0.31 . . . . 0.0 111.4 -176.769 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' GLN . . . . . 0.418 ' HG3' ' HB3' ' A' ' 120' ' ' TYR . 38.1 tp60 -103.47 -59.42 1.72 Allowed 'General case' 0 C--N 1.316 -0.853 0 C-N-CA 120.484 -0.486 . . . . 0.0 110.651 -178.681 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 88.8 m-20 74.62 133.72 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.599 0 O-C-N 123.894 0.746 . . . . 0.0 111.812 177.994 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.41 HG21 ' CH2' ' A' ' 23' ' ' TRP . 73.6 t -80.35 133.24 29.96 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.489 0 C-N-CA 120.094 -0.642 . . . . 0.0 111.736 178.727 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 26.8 m -111.19 -31.93 2.24 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.487 0 N-CA-C 112.73 0.641 . . . . 0.0 112.73 -179.621 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . 0.543 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -146.57 138.18 24.55 Favored 'General case' 0 C--N 1.324 -0.537 0 C-N-CA 119.809 -0.756 . . . . 0.0 111.625 179.721 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.446 ' HB ' HG22 ' A' ' 38' ' ' VAL . 96.1 mt -131.85 126.32 56.86 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.124 178.019 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 41.9 t30 -126.18 99.17 5.77 Favored 'General case' 0 C--N 1.314 -0.935 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 174.772 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.494 HG11 ' CD2' ' A' ' 128' ' ' PHE . 30.2 m -139.82 140.52 36.0 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.091 0 CA-C-N 115.85 -0.614 . . . . 0.0 111.78 -175.715 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 81.5 tt0 -144.2 145.58 32.16 Favored 'General case' 0 C--N 1.315 -0.924 0 CA-C-N 115.774 -0.648 . . . . 0.0 109.977 178.051 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . 0.558 ' HB2' ' OD1' ' A' ' 109' ' ' ASP . 21.6 p -152.71 152.93 32.27 Favored 'General case' 0 C--N 1.312 -1.039 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.559 178.143 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -130.53 15.46 5.49 Favored Glycine 0 CA--C 1.505 -0.538 0 N-CA-C 111.105 -0.798 . . . . 0.0 111.105 178.888 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . 0.558 ' OD1' ' HB2' ' A' ' 107' ' ' SER . 10.4 p-10 -96.23 22.82 7.23 Favored 'General case' 0 C--N 1.316 -0.859 0 C-N-CA 123.167 0.587 . . . . 0.0 110.5 -179.521 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 110' ' ' ASP . . . . . 0.516 ' HB2' ' O ' ' A' ' 109' ' ' ASP . 4.2 m-20 81.94 10.42 0.76 Allowed 'General case' 0 N--CA 1.486 1.366 0 C-N-CA 124.131 0.972 . . . . 0.0 112.282 -179.944 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . 0.542 ' HA3' ' ND2' ' A' ' 32' ' ' ASN . . . 88.12 12.59 65.45 Favored Glycine 0 N--CA 1.446 -0.661 0 C-N-CA 119.999 -1.096 . . . . 0.0 113.718 176.402 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 98.2 mt-30 -71.74 -38.74 70.39 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 117.046 0.423 . . . . 0.0 110.591 179.178 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 12.7 p -131.18 109.94 10.79 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.928 175.952 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 6.1 mp -92.07 113.55 25.85 Favored 'General case' 0 C--N 1.319 -0.722 0 N-CA-C 109.767 -0.456 . . . . 0.0 109.767 179.713 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 54.3 m-80 -108.3 145.54 34.24 Favored 'General case' 0 C--N 1.311 -1.079 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.836 -178.431 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 166.33 -139.29 5.68 Favored Glycine 0 N--CA 1.433 -1.508 0 C-N-CA 120.121 -1.038 . . . . 0.0 112.996 177.881 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 41.2 p -137.72 160.9 37.96 Favored 'General case' 0 C--N 1.31 -1.145 0 C-N-CA 123.429 0.692 . . . . 0.0 109.924 -177.75 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 19.8 ptm -149.29 161.49 41.94 Favored 'General case' 0 C--N 1.311 -1.087 0 CA-C-O 120.729 0.299 . . . . 0.0 110.698 179.302 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 119' ' ' THR . . . . . 0.543 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 23.5 m -135.39 133.15 38.39 Favored 'General case' 0 C--O 1.246 0.892 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.473 -179.813 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . 0.418 ' HB3' ' HG3' ' A' ' 98' ' ' GLN . 12.3 m-85 -99.81 158.81 15.53 Favored 'General case' 0 CA--C 1.515 -0.398 0 CA-C-N 115.946 -0.57 . . . . 0.0 109.798 176.618 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -61.07 122.66 15.54 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 120.608 0.242 . . . . 0.0 111.495 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 68.73 27.86 73.54 Favored Glycine 0 C--N 1.338 0.673 0 CA-C-N 115.969 -0.559 . . . . 0.0 113.243 179.847 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 80.4 tt0 -142.58 155.87 45.03 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 116.872 0.336 . . . . 0.0 110.389 -178.014 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -77.69 161.32 49.66 Favored Glycine 0 CA--C 1.521 0.441 0 C-N-CA 121.169 -0.539 . . . . 0.0 112.707 -178.907 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 23.1 Cg_exo -64.05 141.66 77.81 Favored 'Trans proline' 0 C--N 1.345 0.357 0 C-N-CA 122.802 2.334 . . . . 0.0 112.756 -179.564 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 35.9 pt -133.07 157.83 43.02 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.994 0 CA-C-N 115.402 -0.817 . . . . 0.0 109.763 178.321 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . 0.45 ' O ' ' HA ' ' A' ' 8' ' ' ASN . . . -70.32 139.5 30.78 Favored Glycine 0 C--O 1.235 0.209 0 C-N-CA 121.096 -0.574 . . . . 0.0 112.083 179.042 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . 0.494 ' CD2' HG11 ' A' ' 105' ' ' VAL . 73.0 t80 -119.05 133.53 55.75 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-O 120.887 0.375 . . . . 0.0 111.221 -177.109 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 62.7 tttm -136.19 105.42 6.0 Favored 'General case' 0 C--N 1.313 -0.986 0 CA-C-N 115.676 -0.693 . . . . 0.0 109.767 176.401 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -100.66 131.16 10.47 Favored Glycine 0 N--CA 1.439 -1.153 0 N-CA-C 110.696 -0.962 . . . . 0.0 110.696 178.917 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 28.5 m -122.24 130.53 53.26 Favored 'General case' 0 C--N 1.312 -1.039 0 N-CA-C 110.007 -0.368 . . . . 0.0 110.007 -179.139 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 132' ' ' LEU . . . . . 0.406 HD23 ' CZ ' ' A' ' 4' ' ' TYR . 3.3 tm? -67.11 135.21 53.25 Favored 'General case' 0 C--O 1.236 0.373 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.231 -178.022 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 26.6 m . . . . . 0 N--CA 1.435 -1.185 0 CA-C-O 118.18 -0.914 . . . . 0.0 109.569 -179.372 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.784 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' LEU . . . . . 0.43 HD11 HE21 ' A' ' 22' ' ' GLN . 2.7 tm? -147.14 123.2 10.77 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 -177.783 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . 0.427 ' CD1' ' HB ' ' A' ' 25' ' ' ILE . 59.2 m-85 -118.24 141.41 48.54 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 112.351 0.5 . . . . 0.0 112.351 -178.134 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 49.3 m-80 -88.68 139.07 30.85 Favored 'General case' 0 C--N 1.316 -0.883 0 N-CA-C 107.763 -1.199 . . . . 0.0 107.763 174.858 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.464 HG21 ' CD1' ' A' ' 23' ' ' TRP . 87.3 t -99.38 115.54 40.4 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.02 0 CA-C-O 121.146 0.498 . . . . 0.0 112.323 -175.0 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.494 ' HB2' ' HB3' ' A' ' 129' ' ' LYS . 42.4 mt-10 -113.99 119.53 37.52 Favored 'General case' 0 C--N 1.311 -1.088 0 CA-C-N 115.025 -0.989 . . . . 0.0 108.58 177.329 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 13.6 m120 -119.01 136.48 54.1 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 116.571 -0.286 . . . . 0.0 110.752 -177.504 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 58.9 tt0 -124.09 128.29 49.08 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-O 120.866 0.365 . . . . 0.0 110.839 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 14.6 p90 -141.49 148.02 38.78 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 116.153 -0.476 . . . . 0.0 109.993 177.043 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 100.89 2.1 55.08 Favored Glycine 0 N--CA 1.449 -0.47 0 C-N-CA 120.37 -0.919 . . . . 0.0 112.268 178.889 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 114.56 155.83 11.29 Favored Glycine 0 N--CA 1.441 -0.991 0 C-N-CA 120.903 -0.665 . . . . 0.0 112.442 179.543 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 7.6 t -59.1 -20.13 50.69 Favored 'General case' 0 CA--C 1.539 0.54 0 C-N-CA 122.746 0.418 . . . . 0.0 111.616 179.008 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 10.2 m -77.78 -10.01 59.32 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.765 0.317 . . . . 0.0 111.027 179.748 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -89.97 152.09 45.96 Favored Pre-proline 0 C--N 1.325 -0.494 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 179.467 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 78.9 Cg_endo -73.69 161.19 42.43 Favored 'Trans proline' 0 C--O 1.237 0.429 0 C-N-CA 122.625 2.217 . . . . 0.0 112.917 179.765 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 82.7 m95 -85.94 134.7 33.86 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 115.546 -0.752 . . . . 0.0 109.095 178.419 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 46.9 m-80 -113.54 141.68 46.87 Favored 'General case' 0 C--N 1.32 -0.701 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 -177.596 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.405 ' HA ' ' O ' ' A' ' 6' ' ' VAL . 9.2 pt-20 -116.53 122.48 44.81 Favored 'General case' 0 C--N 1.308 -1.221 0 CA-C-O 120.734 0.302 . . . . 0.0 110.455 -178.929 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -137.23 31.64 2.51 Favored Glycine 0 N--CA 1.444 -0.793 0 C-N-CA 119.814 -1.184 . . . . 0.0 113.133 -177.255 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 162.68 179.68 37.41 Favored Glycine 0 N--CA 1.447 -0.58 0 C-N-CA 119.745 -1.217 . . . . 0.0 113.015 179.767 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . 0.43 HE21 HD11 ' A' ' 3' ' ' LEU . 4.5 pt20 -136.99 137.03 39.02 Favored 'General case' 0 C--N 1.32 -0.714 0 N-CA-C 109.419 -0.586 . . . . 0.0 109.419 178.905 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . 0.464 ' CD1' HG21 ' A' ' 6' ' ' VAL . 38.7 m0 -109.31 151.62 26.34 Favored 'General case' 0 CA--C 1.502 -0.873 0 CA-C-O 120.866 0.365 . . . . 0.0 111.23 -178.513 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 79.1 tt0 -108.86 110.88 22.34 Favored 'General case' 0 N--CA 1.44 -0.926 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 177.689 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.427 ' HB ' ' CD1' ' A' ' 4' ' ' TYR . 89.8 mt -127.79 136.5 60.19 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.892 0 CA-C-N 115.395 -0.82 . . . . 0.0 109.803 -176.679 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 90.86 93.44 1.27 Allowed Glycine 0 N--CA 1.444 -0.795 0 C-N-CA 120.67 -0.776 . . . . 0.0 112.499 177.653 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 3.7 p -94.92 10.2 36.37 Favored 'General case' 0 C--N 1.311 -1.084 0 CA-C-O 121.432 0.634 . . . . 0.0 110.38 178.795 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 39.4 mmt180 -124.84 121.05 33.44 Favored 'General case' 0 N--CA 1.445 -0.682 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 -179.88 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 43.6 m -65.95 -38.85 89.67 Favored 'General case' 0 C--N 1.314 -0.948 0 N-CA-C 112.13 0.418 . . . . 0.0 112.13 -178.205 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 75.0 m-20 -75.05 -38.44 61.4 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 112.345 0.498 . . . . 0.0 112.345 -177.047 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . 0.465 ' NE2' ' HA ' ' A' ' 31' ' ' GLN . 9.7 mm-40 -114.49 117.65 31.57 Favored 'General case' 0 CA--C 1.5 -0.942 0 N-CA-C 113.708 1.003 . . . . 0.0 113.708 -176.854 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 4.1 t30 -96.13 160.76 14.27 Favored 'General case' 0 N--CA 1.438 -1.063 0 CA-C-N 114.923 -1.035 . . . . 0.0 108.992 177.017 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 62.5 t -94.06 131.51 40.76 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.491 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.182 -176.744 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 35.5 m -112.46 -11.08 11.96 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.655 0 N-CA-C 112.701 0.63 . . . . 0.0 112.701 178.31 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.649 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -152.52 144.94 24.05 Favored 'General case' 0 CA--C 1.508 -0.66 0 C-N-CA 120.015 -0.674 . . . . 0.0 111.59 177.882 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 91.8 mt -143.97 117.74 3.38 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.373 0 N-CA-C 109.618 -0.512 . . . . 0.0 109.618 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' ASN . . . . . 0.526 ' HA ' ' O ' ' A' ' 103' ' ' ILE . 47.5 m-80 -133.63 112.27 11.3 Favored 'General case' 0 C--N 1.311 -1.078 0 N-CA-C 108.523 -0.918 . . . . 0.0 108.523 175.667 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.49 HG11 ' CD1' ' A' ' 61' ' ' PHE . 22.4 m -148.41 152.02 12.78 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 C-N-CA 120.92 -0.312 . . . . 0.0 111.655 -174.01 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 67.4 tt0 -136.13 142.47 44.24 Favored 'General case' 0 N--CA 1.443 -0.817 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 176.366 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 31.5 p -77.2 147.12 36.61 Favored 'General case' 0 C--N 1.314 -0.935 0 CA-C-O 121.033 0.444 . . . . 0.0 111.641 -177.912 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -94.78 -15.55 45.51 Favored Glycine 0 N--CA 1.451 -0.361 0 N-CA-C 110.512 -1.035 . . . . 0.0 110.512 175.512 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . 0.403 ' HB3' ' H ' ' A' ' 43' ' ' ASP . 55.0 m-20 -139.28 -154.69 0.54 Allowed 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 109.257 -0.645 . . . . 0.0 109.257 179.457 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . 0.403 ' H ' ' HB3' ' A' ' 42' ' ' ASP . 20.9 m-20 -73.25 38.25 0.09 Allowed 'General case' 0 N--CA 1.476 0.846 0 C-N-CA 122.893 0.477 . . . . 0.0 111.487 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 92.74 -6.7 77.22 Favored Glycine 0 C--O 1.217 -0.95 0 C-N-CA 121.173 -0.537 . . . . 0.0 112.66 179.848 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 59.3 mt-30 -63.0 -39.9 96.14 Favored 'General case' 0 C--N 1.326 -0.416 0 N-CA-C 112.137 0.421 . . . . 0.0 112.137 -178.364 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . 0.506 ' HA ' ' O ' ' A' ' 63' ' ' ALA . 5.2 t -128.18 115.4 18.32 Favored 'General case' 0 C--N 1.311 -1.065 0 CA-C-O 121.187 0.518 . . . . 0.0 110.801 177.812 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' LEU . . . . . 0.44 ' O ' ' HA ' ' A' ' 62' ' ' ARG . 79.5 mt -99.53 130.42 45.77 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.855 -0.612 . . . . 0.0 109.595 178.442 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 49.2 m-80 -130.11 143.17 50.64 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 116.488 -0.324 . . . . 0.0 110.469 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . 0.431 ' HA3' ' HA ' ' A' ' 38' ' ' VAL . . . 171.08 -150.79 14.32 Favored Glycine 0 N--CA 1.44 -1.086 0 C-N-CA 120.084 -1.055 . . . . 0.0 113.262 179.978 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 25.1 m -125.99 131.48 52.23 Favored 'General case' 0 C--N 1.317 -0.838 0 C-N-CA 122.965 0.506 . . . . 0.0 110.19 -177.199 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' MET . . . . . 0.44 ' SD ' ' HH2' ' A' ' 90' ' ' TRP . 62.5 ttp -125.53 150.27 47.57 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 -179.834 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.649 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 27.7 m -126.98 130.74 50.64 Favored 'General case' 0 C--O 1.243 0.723 0 CA-C-O 120.735 0.302 . . . . 0.0 111.316 -178.81 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . 0.437 ' HB3' ' OE1' ' A' ' 31' ' ' GLN . 47.0 m-85 -90.61 162.2 15.08 Favored 'General case' 0 C--O 1.233 0.218 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.323 177.247 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -60.42 107.84 0.73 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.799 -0.637 . . . . 0.0 112.634 -178.072 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 88.33 -0.27 83.26 Favored Glycine 0 N--CA 1.454 -0.138 0 CA-C-N 115.796 -0.638 . . . . 0.0 112.854 178.05 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 73.2 mm-40 -108.21 179.22 4.27 Favored 'General case' 0 C--N 1.314 -0.937 0 CA-C-O 120.705 0.288 . . . . 0.0 110.6 -178.744 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -97.71 176.71 31.25 Favored Glycine 0 N--CA 1.439 -1.144 0 C-N-CA 120.678 -0.773 . . . . 0.0 111.452 178.512 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo -67.13 139.5 50.81 Favored 'Trans proline' 0 CA--C 1.535 0.539 0 C-N-CA 122.501 2.134 . . . . 0.0 112.277 179.507 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 48.3 pt -133.01 166.73 28.56 Favored 'Isoleucine or valine' 0 C--O 1.24 0.554 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.137 178.243 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -75.22 138.59 23.66 Favored Glycine 0 CA--C 1.521 0.464 0 C-N-CA 120.724 -0.751 . . . . 0.0 111.957 -179.541 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.49 ' CD1' HG11 ' A' ' 38' ' ' VAL . 50.2 t80 -124.52 129.84 51.35 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 120.519 0.2 . . . . 0.0 110.916 -178.982 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . 0.44 ' HA ' ' O ' ' A' ' 47' ' ' LEU . 62.7 ttp85 -140.67 134.65 30.69 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.22 176.048 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.506 ' O ' ' HA ' ' A' ' 46' ' ' THR . . . -135.08 142.86 46.38 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.567 -0.288 . . . . 0.0 111.304 179.794 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 49.6 m -122.05 131.48 54.01 Favored 'General case' 0 CA--C 1.546 0.803 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.695 -179.608 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . 0.543 HD11 ' O ' ' A' ' 68' ' ' ASN . 55.9 tp -71.03 126.19 28.91 Favored 'General case' 0 CA--C 1.535 0.391 0 N-CA-C 113.1 0.778 . . . . 0.0 113.1 -176.9 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . 0.405 HD13 ' HA ' ' A' ' 66' ' ' LEU . 3.9 mm? -73.4 -35.19 65.84 Favored 'General case' 0 N--CA 1.473 0.692 0 CA-C-N 115.204 -0.907 . . . . 0.0 111.751 176.349 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 133.05 2.67 3.73 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 111.052 -0.819 . . . . 0.0 111.052 -175.828 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' ASN . . . . . 0.543 ' O ' HD11 ' A' ' 65' ' ' LEU . 31.5 p-10 -131.41 -150.67 0.43 Allowed 'General case' 0 C--N 1.31 -1.147 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.42 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 85.6 m-20 -90.09 4.21 51.01 Favored 'General case' 0 C--N 1.323 -0.545 0 C-N-CA 120.407 -0.517 . . . . 0.0 110.33 179.58 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 24.0 m -101.27 144.56 29.98 Favored 'General case' 0 N--CA 1.448 -0.572 0 CA-C-O 121.362 0.601 . . . . 0.0 111.232 -178.833 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.5 ' HB3' ' HB1' ' A' ' 63' ' ' ALA . 96.3 m-85 -124.33 145.54 49.36 Favored 'General case' 0 C--N 1.312 -1.042 0 CA-C-N 115.463 -0.789 . . . . 0.0 110.617 179.557 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . 0.414 ' O ' ' HA ' ' A' ' 63' ' ' ALA . 79.5 tt0 -86.24 112.82 21.73 Favored 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 107.371 -1.344 . . . . 0.0 107.371 174.565 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 75.4 t -97.77 129.68 47.58 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.103 0 CA-C-O 121.4 0.619 . . . . 0.0 112.064 -175.311 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 45.8 mt-10 -128.05 124.76 37.87 Favored 'General case' 0 N--CA 1.438 -1.049 0 CA-C-N 114.891 -1.05 . . . . 0.0 108.748 177.474 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 14.7 m120 -104.04 147.74 27.04 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-O 121.057 0.456 . . . . 0.0 111.286 -177.478 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' GLN . . . . . 0.539 ' HB2' ' CE3' ' A' ' 84' ' ' TRP . 61.6 tt0 -115.1 119.61 37.02 Favored 'General case' 0 C--N 1.31 -1.11 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.672 -179.68 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 14.9 p90 -138.81 152.85 48.22 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 116.478 -0.328 . . . . 0.0 110.458 177.806 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 147.04 -122.64 1.62 Allowed Glycine 0 N--CA 1.444 -0.825 0 N-CA-C 110.119 -1.192 . . . . 0.0 110.119 -177.295 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.523 ' O ' ' HB2' ' A' ' 80' ' ' ASP . . . -119.31 23.18 8.64 Favored Glycine 0 N--CA 1.444 -0.785 0 C-N-CA 120.291 -0.956 . . . . 0.0 111.115 178.228 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . 0.523 ' HB2' ' O ' ' A' ' 79' ' ' GLY . 12.8 m-20 92.24 -43.47 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.836 0 C-N-CA 124.96 1.304 . . . . 0.0 110.587 178.348 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 34.5 m -76.78 -2.46 33.26 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 121.312 0.577 . . . . 0.0 110.7 175.901 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -66.62 157.39 83.27 Favored Pre-proline 0 C--N 1.324 -0.519 0 CA-C-N 115.353 -0.84 . . . . 0.0 112.029 -178.447 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 75.6 Cg_endo -77.9 -172.86 1.6 Allowed 'Trans proline' 0 CA--C 1.537 0.644 0 C-N-CA 122.752 2.301 . . . . 0.0 112.453 179.102 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' TRP . . . . . 0.539 ' CE3' ' HB2' ' A' ' 76' ' ' GLN . 95.1 m95 -98.13 147.5 24.5 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.822 -178.564 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 94.4 m-70 -128.74 146.38 50.91 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.061 -0.518 . . . . 0.0 109.964 -179.662 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 28.8 p -65.21 136.56 56.78 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-O 121.04 0.448 . . . . 0.0 111.421 -178.735 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -108.27 -52.18 0.69 Allowed Glycine 0 N--CA 1.437 -1.269 0 C-N-CA 120.745 -0.74 . . . . 0.0 111.55 177.968 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 151.45 -166.72 30.74 Favored Glycine 0 CA--C 1.52 0.345 0 C-N-CA 120.918 -0.658 . . . . 0.0 112.045 -179.778 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 19.3 m120 -112.43 119.21 37.46 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 117.014 0.407 . . . . 0.0 110.195 -179.862 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' TRP . . . . . 0.44 ' HH2' ' SD ' ' A' ' 51' ' ' MET . 29.3 m0 -117.12 154.02 31.77 Favored 'General case' 0 N--CA 1.47 0.564 0 CA-C-N 116.467 -0.333 . . . . 0.0 111.123 -177.129 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 89.0 mt -108.6 119.19 57.73 Favored 'Isoleucine or valine' 0 C--O 1.242 0.707 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 176.991 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . 0.426 ' HB3' HG21 ' A' ' 100' ' ' VAL . 86.7 mt -132.05 83.3 2.07 Favored 'General case' 0 C--O 1.267 1.981 0 N-CA-C 113.127 0.788 . . . . 0.0 113.127 -174.602 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 164.16 116.58 0.37 Allowed Glycine 0 C--O 1.225 -0.439 0 CA-C-N 115.083 -0.962 . . . . 0.0 111.31 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 75.2 p -90.33 -9.36 48.05 Favored 'General case' 0 N--CA 1.463 0.191 0 CA-C-N 117.217 0.509 . . . . 0.0 111.502 -179.58 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -100.38 145.6 27.99 Favored 'General case' 0 N--CA 1.444 -0.763 0 CA-C-O 120.981 0.419 . . . . 0.0 110.872 179.606 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -68.74 -36.77 78.8 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 115.653 -0.703 . . . . 0.0 112.738 -173.463 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 30.5 p-10 -121.6 28.97 7.41 Favored 'General case' 0 C--N 1.313 -1.009 0 CA-C-O 120.715 0.293 . . . . 0.0 111.513 -176.627 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' GLN . . . . . 0.554 ' NE2' ' HB2' ' A' ' 123' ' ' GLU . 53.9 tt0 -157.2 124.44 5.21 Favored 'General case' 0 C--N 1.319 -0.725 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 -177.299 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 96.9 m-20 -113.52 177.66 4.56 Favored 'General case' 0 C--O 1.245 0.819 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.674 -175.355 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.461 HG11 ' CH2' ' A' ' 23' ' ' TRP . 21.2 m -80.41 141.06 15.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.75 -0.659 . . . . 0.0 112.193 -177.656 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 28.7 m -120.95 -26.45 2.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.726 176.425 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . 0.639 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -147.26 138.56 23.89 Favored 'General case' 0 C--N 1.324 -0.512 0 C-N-CA 120.872 -0.331 . . . . 0.0 110.65 177.404 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.526 ' O ' ' HA ' ' A' ' 37' ' ' ASN . 87.7 mt -132.23 127.03 56.9 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.029 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 178.822 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 9.6 t30 -128.04 91.06 3.2 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.13 178.414 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.501 HG11 ' HD2' ' A' ' 128' ' ' PHE . 22.3 m -145.06 153.26 14.33 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.615 0 N-CA-C 113.895 1.072 . . . . 0.0 113.895 -176.453 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 91.4 mt-10 -138.95 163.1 33.22 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 114.223 -1.353 . . . . 0.0 108.132 173.896 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 32.7 t -108.2 -51.02 2.95 Favored 'General case' 0 C--N 1.311 -1.1 0 CA-C-O 120.797 0.332 . . . . 0.0 110.893 -179.616 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 84.66 -14.79 45.35 Favored Glycine 0 N--CA 1.446 -0.66 0 N-CA-C 111.101 -0.8 . . . . 0.0 111.101 -176.768 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . 0.416 ' HB3' ' H ' ' A' ' 110' ' ' ASP . 54.2 m-20 -117.25 -151.29 0.48 Allowed 'General case' 0 N--CA 1.45 -0.432 0 C-N-CA 123.074 0.55 . . . . 0.0 109.999 -179.414 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 110' ' ' ASP . . . . . 0.416 ' H ' ' HB3' ' A' ' 109' ' ' ASP . 12.5 p-10 -88.55 16.43 6.59 Favored 'General case' 0 C--N 1.322 -0.618 0 C-N-CA 122.628 0.371 . . . . 0.0 111.18 -178.881 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 96.29 9.68 56.63 Favored Glycine 0 N--CA 1.444 -0.828 0 C-N-CA 120.086 -1.054 . . . . 0.0 113.045 -178.339 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 112' ' ' GLN . . . . . 0.475 ' HA ' HD12 ' A' ' 132' ' ' LEU . 28.1 tt0 -64.3 -45.4 88.12 Favored 'General case' 0 C--O 1.239 0.521 0 CA-C-O 120.833 0.349 . . . . 0.0 111.235 179.934 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . 0.489 ' HA ' ' O ' ' A' ' 130' ' ' GLY . 21.0 p -132.73 130.38 39.92 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.289 -179.831 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 114' ' ' LEU . . . . . 0.507 ' O ' ' HA ' ' A' ' 129' ' ' LYS . 4.3 mm? -105.86 130.5 53.81 Favored 'General case' 0 C--N 1.319 -0.739 0 N-CA-C 108.49 -0.93 . . . . 0.0 108.49 176.599 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 27.7 p30 -135.1 152.25 51.47 Favored 'General case' 0 C--N 1.316 -0.861 0 C-N-CA 120.191 -0.603 . . . . 0.0 112.274 -179.152 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 152.28 -129.38 2.77 Favored Glycine 0 N--CA 1.441 -1.025 0 CA-C-N 115.461 -0.79 . . . . 0.0 112.337 178.244 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 21.4 p -131.72 156.13 46.45 Favored 'General case' 0 C--N 1.316 -0.879 0 CA-C-O 121.012 0.434 . . . . 0.0 111.02 -178.163 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 118' ' ' MET . . . . . 0.521 ' SD ' ' HB2' ' A' ' 128' ' ' PHE . 19.5 ptm -140.64 149.74 42.67 Favored 'General case' 0 C--N 1.314 -0.963 0 CA-C-N 116.062 -0.517 . . . . 0.0 109.968 -178.6 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 119' ' ' THR . . . . . 0.639 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 23.3 m -131.23 129.46 41.64 Favored 'General case' 0 C--N 1.313 -1.016 0 CA-C-O 120.804 0.335 . . . . 0.0 111.019 -179.696 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . 0.466 ' HB3' ' HG2' ' A' ' 98' ' ' GLN . 45.0 m-85 -101.47 161.18 13.82 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.947 178.66 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -59.84 121.83 12.72 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.094 179.779 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 66.03 24.26 71.62 Favored Glycine 0 C--N 1.336 0.536 0 C-N-CA 121.117 -0.564 . . . . 0.0 112.336 -179.214 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . 0.554 ' HB2' ' NE2' ' A' ' 98' ' ' GLN . 32.5 tp10 -127.95 164.87 21.37 Favored 'General case' 0 C--N 1.318 -0.78 0 N-CA-C 109.622 -0.51 . . . . 0.0 109.622 -177.083 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -93.49 159.66 24.18 Favored Glycine 0 N--CA 1.443 -0.837 0 N-CA-C 110.803 -0.919 . . . . 0.0 110.803 177.318 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . 0.438 ' HA ' ' O ' ' A' ' 118' ' ' MET . 37.8 Cg_endo -66.2 136.15 42.91 Favored 'Trans proline' 0 CA--C 1.53 0.286 0 C-N-CA 122.16 1.907 . . . . 0.0 112.233 179.67 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 41.7 pt -132.65 166.4 29.41 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.004 178.929 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -70.02 134.73 25.53 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.912 -0.661 . . . . 0.0 112.197 -179.7 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . 0.521 ' HB2' ' SD ' ' A' ' 118' ' ' MET . 25.4 t80 -124.84 134.75 52.61 Favored 'General case' 0 CA--C 1.513 -0.443 0 CA-C-O 121.173 0.511 . . . . 0.0 111.443 -179.45 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 129' ' ' LYS . . . . . 0.507 ' HA ' ' O ' ' A' ' 114' ' ' LEU . 62.3 tttm -140.86 123.64 16.21 Favored 'General case' 0 N--CA 1.435 -1.196 0 CA-C-N 115.073 -0.967 . . . . 0.0 109.494 178.591 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . 0.489 ' O ' ' HA ' ' A' ' 113' ' ' THR . . . -117.32 131.61 9.51 Favored Glycine 0 N--CA 1.444 -0.809 0 N-CA-C 110.973 -0.851 . . . . 0.0 110.973 178.948 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 32.1 m -125.32 133.88 52.44 Favored 'General case' 0 C--N 1.314 -0.973 0 CA-C-N 117.015 0.408 . . . . 0.0 110.709 -177.249 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 132' ' ' LEU . . . . . 0.475 HD12 ' HA ' ' A' ' 112' ' ' GLN . 78.3 mt -62.37 135.14 57.31 Favored 'General case' 0 C--O 1.238 0.473 0 CA-C-O 120.741 0.305 . . . . 0.0 110.779 177.283 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 8.6 t . . . . . 0 C--O 1.249 1.051 0 CA-C-O 118.368 -0.825 . . . . 0.0 110.34 178.391 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.468 0.474 0 N-CA-C 110.028 -0.36 . . . . 0.0 110.028 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' LEU . . . . . 0.671 HD11 HE21 ' A' ' 22' ' ' GLN . 1.4 tm? -97.42 132.41 43.15 Favored 'General case' 0 C--N 1.316 -0.85 0 N-CA-C 109.584 -0.525 . . . . 0.0 109.584 -177.817 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . 0.525 ' N ' HD13 ' A' ' 3' ' ' LEU . 89.8 m-85 -122.91 147.74 46.24 Favored 'General case' 0 C--O 1.236 0.351 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.649 -177.96 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' ASN . . . . . 0.55 ' O ' ' HA2' ' A' ' 130' ' ' GLY . 18.7 m120 -94.73 134.5 37.26 Favored 'General case' 0 CA--C 1.506 -0.715 0 N-CA-C 106.34 -1.726 . . . . 0.0 106.34 174.792 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.402 HG21 ' CG ' ' A' ' 23' ' ' TRP . 59.3 t -118.2 126.84 75.28 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.891 0 C-N-CA 119.492 -0.883 . . . . 0.0 113.031 -175.443 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.547 ' HA ' ' HA ' ' A' ' 19' ' ' GLU . 98.4 mt-10 -115.06 139.72 49.64 Favored 'General case' 0 N--CA 1.439 -1.012 0 CA-C-N 114.477 -1.238 . . . . 0.0 108.792 176.326 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . 0.433 ' HB3' HD12 ' A' ' 126' ' ' ILE . 12.1 m120 -119.35 144.05 47.07 Favored 'General case' 0 C--N 1.313 -1.013 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.309 -177.045 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 60.4 tt0 -121.68 114.89 21.78 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 174.605 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 45.8 p90 -129.16 139.08 52.06 Favored 'General case' 0 C--N 1.317 -0.832 0 C-N-CA 121.028 -0.269 . . . . 0.0 110.913 -178.309 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 102.09 11.77 35.92 Favored Glycine 0 N--CA 1.444 -0.783 0 C-N-CA 120.363 -0.922 . . . . 0.0 112.582 178.616 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 99.7 167.37 29.66 Favored Glycine 0 N--CA 1.444 -0.816 0 C-N-CA 120.446 -0.883 . . . . 0.0 113.28 -179.43 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 15.6 m -56.2 -25.61 47.76 Favored 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 123.158 0.583 . . . . 0.0 112.227 179.474 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 14.1 p -61.23 -21.04 63.49 Favored 'General case' 0 CA--C 1.542 0.671 0 N-CA-C 112.25 0.463 . . . . 0.0 112.25 177.268 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -90.84 142.93 28.05 Favored Pre-proline 0 C--N 1.321 -0.66 0 CA-C-O 120.541 0.21 . . . . 0.0 110.733 179.7 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 95.3 Cg_endo -78.37 170.51 18.36 Favored 'Trans proline' 0 C--O 1.238 0.518 0 C-N-CA 122.803 2.335 . . . . 0.0 112.241 179.692 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 96.4 m95 -86.97 124.88 33.65 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.118 -0.492 . . . . 0.0 109.905 -179.77 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 47.8 m-80 -123.26 126.19 46.46 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.991 -178.87 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.547 ' HA ' ' HA ' ' A' ' 7' ' ' GLU . 15.3 pt-20 -68.94 133.51 48.29 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 109.65 -0.5 . . . . 0.0 109.65 177.631 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -134.31 22.78 3.72 Favored Glycine 0 N--CA 1.443 -0.858 0 C-N-CA 119.566 -1.302 . . . . 0.0 112.876 -179.308 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . 0.549 ' HA3' ' HB2' ' A' ' 94' ' ' SER . . . 145.07 -170.9 26.38 Favored Glycine 0 N--CA 1.449 -0.472 0 C-N-CA 120.17 -1.014 . . . . 0.0 113.293 177.352 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . 0.671 HE21 HD11 ' A' ' 3' ' ' LEU . 4.3 pt20 -131.73 136.05 47.3 Favored 'General case' 0 C--N 1.324 -0.514 0 C-N-CA 122.604 0.362 . . . . 0.0 110.634 -178.337 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . 0.469 ' CH2' HG21 ' A' ' 100' ' ' VAL . 26.2 m0 -110.76 165.88 11.47 Favored 'General case' 0 N--CA 1.469 0.491 0 CA-C-O 120.668 0.27 . . . . 0.0 110.482 179.01 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 40.1 tt0 -128.87 116.56 19.62 Favored 'General case' 0 C--N 1.32 -0.68 0 C-N-CA 120.46 -0.496 . . . . 0.0 110.166 175.827 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.49 ' HB ' ' CE1' ' A' ' 4' ' ' TYR . 98.7 mt -130.18 137.49 56.26 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.764 0 CA-C-N 115.5 -0.773 . . . . 0.0 110.196 -177.567 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 93.37 102.32 1.59 Allowed Glycine 0 N--CA 1.446 -0.683 0 C-N-CA 120.775 -0.726 . . . . 0.0 111.892 179.451 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 4.2 p -101.57 12.17 37.71 Favored 'General case' 0 C--N 1.312 -1.036 0 CA-C-O 121.01 0.433 . . . . 0.0 111.293 -178.832 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . 0.401 HH11 ' HD3' ' A' ' 28' ' ' ARG . 62.6 mtt-85 -130.64 130.32 43.79 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.053 -178.932 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 15.6 m -66.78 -36.64 82.87 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.094 0.473 . . . . 0.0 112.052 -179.145 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 64.8 m-20 -73.93 -43.24 58.96 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.965 -0.562 . . . . 0.0 112.387 -175.505 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 8.7 mm-40 -121.41 122.12 39.08 Favored 'General case' 0 CA--C 1.506 -0.727 0 N-CA-C 113.106 0.78 . . . . 0.0 113.106 -176.42 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . 0.418 ' ND2' ' HA3' ' A' ' 111' ' ' GLY . 62.3 t30 -104.39 172.72 6.64 Favored 'General case' 0 N--CA 1.442 -0.837 0 CA-C-N 114.893 -1.049 . . . . 0.0 109.499 178.201 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 59.0 t -106.86 133.68 50.73 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.164 0 N-CA-C 112.287 0.477 . . . . 0.0 112.287 -174.803 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 29.3 m -113.73 -18.0 7.9 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.609 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.947 178.01 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.706 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -144.99 145.27 31.44 Favored 'General case' 0 CA--C 1.513 -0.459 0 C-N-CA 119.968 -0.693 . . . . 0.0 111.464 178.928 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 86.8 mt -144.67 126.71 9.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 -178.916 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' ASN . . . . . 0.487 ' HA ' ' O ' ' A' ' 103' ' ' ILE . 31.3 m-80 -136.64 109.12 7.39 Favored 'General case' 0 C--N 1.312 -1.038 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 176.888 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.467 HG11 ' CD1' ' A' ' 61' ' ' PHE . 25.3 m -151.07 157.59 5.38 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 C-N-CA 120.917 -0.313 . . . . 0.0 111.165 -172.833 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -142.71 150.71 40.48 Favored 'General case' 0 N--CA 1.447 -0.596 0 CA-C-N 115.8 -0.636 . . . . 0.0 109.925 177.253 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . 0.447 ' OG ' ' HB ' ' A' ' 101' ' ' VAL . 35.1 p -79.97 153.59 28.8 Favored 'General case' 0 C--N 1.318 -0.79 0 N-CA-C 112.477 0.547 . . . . 0.0 112.477 -177.682 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -115.45 -68.31 0.44 Allowed Glycine 0 N--CA 1.434 -1.474 0 CA-C-N 115.114 -0.948 . . . . 0.0 110.848 175.151 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 22.5 m-20 -89.95 81.57 6.26 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 112.154 0.427 . . . . 0.0 112.154 -179.001 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 84.5 m-20 51.22 31.53 6.96 Favored 'General case' 0 N--CA 1.491 1.576 0 N-CA-C 113.424 0.898 . . . . 0.0 113.424 174.791 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 88.84 -14.58 59.87 Favored Glycine 0 C--O 1.223 -0.57 0 C-N-CA 120.116 -1.04 . . . . 0.0 113.139 179.229 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 61.3 mt-30 -70.11 -30.44 67.65 Favored 'General case' 0 CA--C 1.512 -0.503 0 CA-C-O 121.193 0.521 . . . . 0.0 110.749 178.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 31.9 m -119.37 130.61 55.42 Favored 'General case' 0 N--CA 1.434 -1.247 0 CA-C-N 115.476 -0.783 . . . . 0.0 108.9 -179.641 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 84.6 mt -124.81 133.96 52.93 Favored 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 108.892 -0.781 . . . . 0.0 108.892 -179.063 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 28.1 p30 -136.8 148.77 47.37 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-O 121.122 0.487 . . . . 0.0 111.146 178.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 164.28 -145.04 9.94 Favored Glycine 0 N--CA 1.445 -0.758 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.16 177.68 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . 0.516 ' HA ' ' O ' ' A' ' 59' ' ' ILE . 19.6 p -129.56 141.81 50.89 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 120.904 0.383 . . . . 0.0 110.975 179.925 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 15.6 tmm? -131.92 149.01 52.56 Favored 'General case' 0 C--N 1.317 -0.839 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 179.291 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.706 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 61.7 m -124.56 126.15 45.35 Favored 'General case' 0 C--O 1.252 1.197 0 N-CA-C 112.266 0.469 . . . . 0.0 112.266 -176.61 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 59.8 m-85 -82.68 161.13 22.24 Favored 'General case' 0 C--O 1.236 0.353 0 CA-C-N 115.407 -0.815 . . . . 0.0 111.096 176.521 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -63.76 113.63 3.51 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.914 179.269 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 90.72 7.86 66.09 Favored Glycine 0 N--CA 1.443 -0.859 0 C-N-CA 120.877 -0.678 . . . . 0.0 112.62 179.556 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 81.2 mm-40 -126.72 -172.61 2.68 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.767 0.317 . . . . 0.0 111.447 179.479 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -111.92 -171.56 18.86 Favored Glycine 0 N--CA 1.443 -0.86 0 N-CA-C 111.409 -0.677 . . . . 0.0 111.409 178.615 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 96.1 Cg_endo -76.01 140.06 22.39 Favored 'Trans proline' 0 C--O 1.241 0.651 0 C-N-CA 122.488 2.126 . . . . 0.0 113.431 -178.853 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . 0.516 ' O ' ' HA ' ' A' ' 50' ' ' THR . 43.6 pt -132.17 173.12 15.24 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 CA-C-N 115.36 -0.836 . . . . 0.0 109.243 175.625 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -75.35 139.72 25.25 Favored Glycine 0 C--N 1.317 -0.502 0 N-CA-C 111.44 -0.664 . . . . 0.0 111.44 -177.725 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.467 ' CD1' HG11 ' A' ' 38' ' ' VAL . 49.2 t80 -128.34 128.43 44.55 Favored 'General case' 0 C--N 1.312 -1.049 0 CA-C-O 120.511 0.196 . . . . 0.0 110.964 -177.277 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 70.1 ttp85 -136.21 131.13 34.17 Favored 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 175.104 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.487 ' HB1' ' HB3' ' A' ' 71' ' ' TYR . . . -135.4 147.58 49.06 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-O 120.782 0.325 . . . . 0.0 111.3 -178.766 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 83.5 m -126.75 132.44 51.08 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.938 -0.573 . . . . 0.0 110.552 178.895 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 61.4 tp -71.97 123.87 23.68 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.093 0.473 . . . . 0.0 111.854 -178.255 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -66.58 -36.66 83.17 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.896 176.665 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 137.62 -6.69 3.57 Favored Glycine 0 CA--C 1.523 0.591 0 C-N-CA 120.298 -0.953 . . . . 0.0 113.011 -177.519 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 58.3 m-80 -144.14 61.35 1.35 Allowed 'General case' 0 N--CA 1.476 0.838 0 N-CA-C 111.879 0.325 . . . . 0.0 111.879 -178.95 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 90.6 m-20 59.65 5.73 0.73 Allowed 'General case' 0 N--CA 1.487 1.397 0 C-N-CA 123.169 0.587 . . . . 0.0 112.13 179.161 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 9.3 m -99.13 133.83 42.85 Favored 'General case' 0 N--CA 1.44 -0.965 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 179.193 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.487 ' HB3' ' HB1' ' A' ' 63' ' ' ALA . 65.6 m-85 -122.4 136.09 54.83 Favored 'General case' 0 C--N 1.307 -1.259 0 CA-C-O 120.83 0.348 . . . . 0.0 111.546 -178.373 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 43.1 tt0 -90.57 120.35 31.58 Favored 'General case' 0 C--N 1.316 -0.855 0 N-CA-C 107.743 -1.206 . . . . 0.0 107.743 174.785 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 77.5 t -104.85 133.29 49.44 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.201 0 N-CA-C 113.091 0.774 . . . . 0.0 113.091 -173.621 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.45 ' HG2' ' HA ' ' A' ' 86' ' ' SER . 49.7 mt-10 -127.58 126.21 41.69 Favored 'General case' 0 N--CA 1.445 -0.711 0 CA-C-N 114.482 -1.235 . . . . 0.0 108.103 174.631 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 94.7 m-20 -103.9 144.04 32.04 Favored 'General case' 0 C--O 1.241 0.622 0 CA-C-O 121.256 0.55 . . . . 0.0 111.689 -176.541 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' GLN . . . . . 0.57 ' HB2' ' CE3' ' A' ' 84' ' ' TRP . 55.6 tt0 -118.29 122.95 44.19 Favored 'General case' 0 C--N 1.309 -1.161 0 CA-C-N 115.449 -0.796 . . . . 0.0 109.482 -178.247 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 8.1 p90 -110.55 97.04 6.57 Favored 'General case' 0 C--N 1.311 -1.083 0 C-N-CA 119.378 -0.929 . . . . 0.0 110.994 176.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 156.86 -153.51 24.76 Favored Glycine 0 N--CA 1.433 -1.563 0 N-CA-C 108.339 -1.905 . . . . 0.0 108.339 -177.378 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -84.93 -148.99 10.32 Favored Glycine 0 N--CA 1.442 -0.908 0 C-N-CA 119.926 -1.13 . . . . 0.0 111.248 175.858 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 65.3 m-20 -88.77 -6.31 57.49 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 117.207 0.504 . . . . 0.0 110.894 -178.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 24.1 t -98.13 -4.8 34.94 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.152 -178.002 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -76.49 149.91 81.78 Favored Pre-proline 0 C--N 1.323 -0.56 0 CA-C-N 116.496 -0.32 . . . . 0.0 110.868 -178.399 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -68.23 158.4 57.66 Favored 'Trans proline' 0 C--O 1.238 0.479 0 C-N-CA 122.351 2.034 . . . . 0.0 111.793 178.491 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' TRP . . . . . 0.57 ' CE3' ' HB2' ' A' ' 76' ' ' GLN . 96.0 m95 -94.8 138.69 32.28 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.337 -178.608 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 74.7 m-70 -119.16 146.62 45.0 Favored 'General case' 0 C--N 1.32 -0.712 0 N-CA-C 109.549 -0.538 . . . . 0.0 109.549 179.845 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . 0.45 ' HA ' ' HG2' ' A' ' 74' ' ' GLU . 10.8 p -71.08 139.99 50.55 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 121.192 0.52 . . . . 0.0 112.229 -176.756 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -115.41 -45.69 0.61 Allowed Glycine 0 N--CA 1.44 -1.099 0 C-N-CA 120.993 -0.622 . . . . 0.0 112.342 178.718 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 147.65 -162.28 28.67 Favored Glycine 0 C--O 1.225 -0.411 0 C-N-CA 120.279 -0.962 . . . . 0.0 112.655 179.445 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 17.9 m120 -115.11 124.55 51.83 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.842 0.321 . . . . 0.0 110.497 179.849 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 34.2 m0 -118.89 153.59 34.31 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.614 -178.581 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 46.9 mm -106.76 114.33 45.61 Favored 'Isoleucine or valine' 0 C--O 1.244 0.776 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 178.388 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 78.5 mt -128.07 77.72 1.78 Allowed 'General case' 0 C--O 1.256 1.445 0 CA-C-O 121.539 0.685 . . . . 0.0 111.559 -177.007 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 166.23 93.79 0.09 OUTLIER Glycine 0 N--CA 1.446 -0.689 0 CA-C-N 115.762 -0.654 . . . . 0.0 111.695 -179.649 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . 0.549 ' HB2' ' HA3' ' A' ' 21' ' ' GLY . 43.8 p -92.28 -12.42 32.57 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-O 120.838 0.351 . . . . 0.0 111.816 -178.516 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 91.6 mtt180 -88.69 15.84 7.6 Favored 'General case' 0 C--N 1.317 -0.821 0 N-CA-C 114.141 1.163 . . . . 0.0 114.141 -176.339 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 77.9 tt0 69.44 -81.67 0.03 OUTLIER 'General case' 0 N--CA 1.472 0.671 0 N-CA-C 113.298 0.851 . . . . 0.0 113.298 172.86 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 61.6 m-80 -92.73 24.19 3.72 Favored 'General case' 0 N--CA 1.473 0.681 0 CA-C-O 121.006 0.432 . . . . 0.0 110.995 -176.429 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' GLN . . . . . 0.414 ' HG2' ' HB3' ' A' ' 120' ' ' TYR . 54.8 tt0 -145.51 116.3 7.73 Favored 'General case' 0 C--N 1.312 -1.022 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 -177.298 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' ASN . . . . . 0.442 ' HB3' ' OH ' ' A' ' 71' ' ' TYR . 50.3 m-80 -89.23 158.93 17.68 Favored 'General case' 0 C--O 1.248 0.983 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.731 -177.512 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.469 HG21 ' CH2' ' A' ' 23' ' ' TRP . 98.0 t -80.57 130.04 36.56 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.206 0 C-N-CA 120.536 -0.466 . . . . 0.0 110.724 177.892 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . 0.447 ' HB ' ' OG ' ' A' ' 40' ' ' SER . 34.8 m -110.27 -17.15 8.5 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.59 0 N-CA-C 112.439 0.533 . . . . 0.0 112.439 -178.686 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . 0.713 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -155.57 145.11 21.12 Favored 'General case' 0 CA--C 1.509 -0.61 0 C-N-CA 120.16 -0.616 . . . . 0.0 111.261 176.9 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.487 ' O ' ' HA ' ' A' ' 37' ' ' ASN . 83.0 mt -135.19 125.26 43.88 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 N-CA-C 110.102 -0.333 . . . . 0.0 110.102 179.457 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . 0.466 ' HB3' ' OG1' ' A' ' 117' ' ' THR . 7.5 t30 -127.8 94.18 3.88 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.872 -0.604 . . . . 0.0 109.829 175.91 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 30.0 m -137.86 138.67 43.8 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.661 0 N-CA-C 113.119 0.785 . . . . 0.0 113.119 -176.343 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -142.71 96.85 3.0 Favored 'General case' 0 CA--C 1.543 0.686 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.781 176.847 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . 0.466 ' HB2' ' H ' ' A' ' 115' ' ' ASN . 58.9 m -167.14 166.15 15.16 Favored 'General case' 0 N--CA 1.484 1.264 0 CA-C-N 115.204 -0.907 . . . . 0.0 113.38 -177.963 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 107.07 127.55 5.79 Favored Glycine 0 N--CA 1.427 -1.965 0 C-N-CA 120.488 -0.863 . . . . 0.0 112.85 175.844 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 7.3 m-20 -77.93 -48.63 15.88 Favored 'General case' 0 C--N 1.317 -0.817 0 N-CA-C 107.063 -1.458 . . . . 0.0 107.063 176.247 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 -125.63 23.3 7.43 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 113.941 -1.481 . . . . 0.0 108.998 177.708 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . 0.418 ' HA3' ' ND2' ' A' ' 32' ' ' ASN . . . 81.83 17.56 69.96 Favored Glycine 0 C--O 1.22 -0.723 0 C-N-CA 120.457 -0.878 . . . . 0.0 111.823 -175.818 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 112' ' ' GLN . . . . . 0.477 ' HA ' ' CD1' ' A' ' 132' ' ' LEU . 98.4 mt-30 -65.59 -43.61 89.18 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.742 0.306 . . . . 0.0 111.656 -179.17 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 34.0 p -131.77 149.51 52.45 Favored 'General case' 0 N--CA 1.441 -0.876 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.4 179.546 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 114' ' ' LEU . . . . . 0.424 ' HA ' ' HB2' ' A' ' 107' ' ' SER . 97.5 mt -128.41 131.17 48.48 Favored 'General case' 0 C--N 1.316 -0.881 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.012 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . 0.466 ' H ' ' HB2' ' A' ' 107' ' ' SER . 54.5 m-80 -136.16 150.29 48.99 Favored 'General case' 0 C--O 1.245 0.841 0 CA-C-O 120.792 0.33 . . . . 0.0 110.667 -178.802 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 157.51 -128.54 2.15 Favored Glycine 0 N--CA 1.442 -0.935 0 CA-C-N 115.75 -0.659 . . . . 0.0 112.049 179.042 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . 0.466 ' OG1' ' HB3' ' A' ' 104' ' ' ASN . 25.1 p -136.2 156.43 48.69 Favored 'General case' 0 C--N 1.312 -1.03 0 CA-C-O 121.03 0.443 . . . . 0.0 110.875 179.91 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 118' ' ' MET . . . . . 0.583 ' SD ' ' HE1' ' A' ' 120' ' ' TYR . 3.4 ptp -137.66 145.2 42.37 Favored 'General case' 0 C--N 1.314 -0.969 0 CA-C-N 115.94 -0.573 . . . . 0.0 109.966 -179.278 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 119' ' ' THR . . . . . 0.713 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 20.8 m -125.5 127.12 45.96 Favored 'General case' 0 C--O 1.247 0.936 0 N-CA-C 110.125 -0.324 . . . . 0.0 110.125 178.557 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . 0.583 ' HE1' ' SD ' ' A' ' 118' ' ' MET . 24.3 m-85 -107.15 155.04 20.31 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.987 179.04 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -58.44 127.87 34.31 Favored 'General case' 0 C--O 1.236 0.391 0 CA-C-O 121.131 0.491 . . . . 0.0 112.121 -178.649 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 81.64 7.71 87.79 Favored Glycine 0 C--O 1.227 -0.338 0 CA-C-N 115.618 -0.719 . . . . 0.0 113.406 177.863 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 85.9 tt0 -145.05 165.2 28.91 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 117.091 0.446 . . . . 0.0 110.493 -178.599 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -87.23 176.43 46.92 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.953 -0.642 . . . . 0.0 112.784 -178.448 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . 0.511 ' HA ' ' O ' ' A' ' 118' ' ' MET . 71.6 Cg_endo -72.48 140.01 32.46 Favored 'Trans proline' 0 CA--C 1.534 0.523 0 C-N-CA 122.817 2.345 . . . . 0.0 112.923 -179.685 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 126' ' ' ILE . . . . . 0.433 HD12 ' HB3' ' A' ' 8' ' ' ASN . 43.6 pt -131.15 170.42 19.77 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.013 178.809 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -68.33 133.56 28.36 Favored Glycine 0 C--O 1.242 0.614 0 C-N-CA 120.929 -0.653 . . . . 0.0 112.987 -178.401 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 45.1 t80 -111.74 130.59 55.74 Favored 'General case' 0 C--O 1.236 0.378 0 C-N-CA 123.287 0.635 . . . . 0.0 110.602 -179.502 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 62.1 tttm -140.84 115.45 9.52 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 177.385 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . 0.55 ' HA2' ' O ' ' A' ' 5' ' ' ASN . . . -132.13 149.38 19.4 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.501 -0.857 . . . . 0.0 113.266 -178.132 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 80.8 m -141.29 143.09 33.88 Favored 'General case' 0 C--N 1.323 -0.564 0 C-N-CA 122.307 0.243 . . . . 0.0 111.079 179.256 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 132' ' ' LEU . . . . . 0.477 ' CD1' ' HA ' ' A' ' 112' ' ' GLN . 82.4 mt -53.9 136.33 40.94 Favored 'General case' 0 N--CA 1.475 0.793 0 O-C-N 123.548 0.53 . . . . 0.0 110.764 176.112 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 25.1 m . . . . . 0 C--O 1.255 1.368 0 CA-C-O 118.421 -0.799 . . . . 0.0 110.85 -179.034 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 0.622 0 N-CA-C 110.064 -0.347 . . . . 0.0 110.064 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' LEU . . . . . 0.433 HD12 ' HB ' ' A' ' 133' ' ' THR . 2.8 tm? -88.16 129.28 35.37 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 121.084 0.468 . . . . 0.0 110.093 -178.714 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . 0.501 ' CE1' ' HB ' ' A' ' 25' ' ' ILE . 35.2 m-85 -117.62 141.92 47.81 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.783 -0.644 . . . . 0.0 111.813 179.901 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 -98.21 139.61 33.74 Favored 'General case' 0 C--N 1.312 -1.037 0 N-CA-C 107.794 -1.188 . . . . 0.0 107.794 173.328 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 69.0 t -114.39 127.87 71.67 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.224 0 CA-C-O 121.222 0.534 . . . . 0.0 112.211 -174.059 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -122.55 138.76 54.47 Favored 'General case' 0 C--N 1.317 -0.84 0 N-CA-C 107.826 -1.176 . . . . 0.0 107.826 175.083 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 23.5 m120 -128.89 148.53 50.92 Favored 'General case' 0 C--N 1.313 -0.992 0 N-CA-C 112.454 0.538 . . . . 0.0 112.454 -177.319 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 51.0 tt0 -126.36 122.31 35.03 Favored 'General case' 0 C--N 1.32 -0.71 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 176.967 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 41.5 p90 -145.6 13.64 1.36 Allowed 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 114.033 1.123 . . . . 0.0 114.033 -176.376 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -110.36 21.27 24.42 Favored Glycine 0 N--CA 1.446 -0.671 0 C-N-CA 118.491 -1.814 . . . . 0.0 112.031 -177.302 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 107.72 175.9 22.36 Favored Glycine 0 N--CA 1.448 -0.56 0 C-N-CA 120.539 -0.839 . . . . 0.0 113.098 179.083 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 12.4 m -64.36 150.91 45.32 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 115.365 -0.417 . . . . 0.0 111.5 177.831 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 37.6 m 64.89 21.23 12.3 Favored 'General case' 0 N--CA 1.472 0.63 0 CA-C-N 115.706 -0.679 . . . . 0.0 111.509 -178.705 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . 0.432 ' HA ' ' HD3' ' A' ' 16' ' ' PRO . . . -96.61 146.27 31.02 Favored Pre-proline 0 N--CA 1.448 -0.539 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.595 179.803 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.432 ' HD3' ' HA ' ' A' ' 15' ' ' ALA . 11.2 Cg_exo -71.86 159.23 51.07 Favored 'Trans proline' 0 N--CA 1.455 -0.741 0 C-N-CA 122.764 2.309 . . . . 0.0 112.302 178.502 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 80.6 m95 -90.21 131.4 36.06 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 115.658 -0.701 . . . . 0.0 109.285 178.852 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 38.8 m-80 -109.35 142.67 39.94 Favored 'General case' 0 C--N 1.308 -1.216 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 -178.854 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -69.04 125.59 27.14 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-O 121.612 0.72 . . . . 0.0 111.623 -178.299 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.614 ' O ' ' HB3' ' A' ' 94' ' ' SER . . . -100.33 -17.66 23.8 Favored Glycine 0 N--CA 1.447 -0.567 0 CA-C-N 114.661 -1.154 . . . . 0.0 113.851 -176.515 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 137.14 -151.18 20.94 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.241 -0.981 . . . . 0.0 111.887 -177.566 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 4.6 pt20 -138.62 132.83 31.6 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 120.852 0.358 . . . . 0.0 111.264 -179.912 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . 0.417 ' CZ2' HG21 ' A' ' 100' ' ' VAL . 46.0 m0 -115.34 161.65 18.22 Favored 'General case' 0 CA--C 1.507 -0.691 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.372 178.548 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 81.7 tt0 -120.07 118.96 31.97 Favored 'General case' 0 C--N 1.314 -0.973 0 C-N-CA 119.986 -0.686 . . . . 0.0 109.649 174.313 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.501 ' HB ' ' CE1' ' A' ' 4' ' ' TYR . 97.8 mt -134.45 146.09 31.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 CA-C-N 114.99 -1.005 . . . . 0.0 109.457 -176.225 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 83.71 73.54 1.25 Allowed Glycine 0 CA--C 1.505 -0.56 0 C-N-CA 120.364 -0.922 . . . . 0.0 111.605 178.955 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 16.1 m -62.21 -43.31 99.11 Favored 'General case' 0 C--N 1.314 -0.961 0 CA-C-N 115.175 -0.513 . . . . 0.0 110.77 179.55 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 84.8 mtt85 -77.64 129.78 36.01 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.903 -0.589 . . . . 0.0 111.337 -179.709 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 15.6 m -66.7 -32.77 74.29 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.607 -0.724 . . . . 0.0 111.69 179.85 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 28.6 m-20 -97.62 16.78 19.45 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.524 -176.458 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 7.2 mm-40 -155.21 102.32 2.29 Favored 'General case' 0 CA--C 1.505 -0.781 0 CA-C-O 120.909 0.385 . . . . 0.0 111.646 -174.656 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 63.7 t30 -102.34 157.86 16.61 Favored 'General case' 0 N--CA 1.443 -0.814 0 CA-C-N 115.877 -0.602 . . . . 0.0 109.945 178.305 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 57.0 t -96.22 133.11 38.68 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.66 0 CA-C-N 115.255 -0.884 . . . . 0.0 110.841 -175.166 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 30.1 m -110.13 -17.22 8.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 N-CA-C 111.78 0.289 . . . . 0.0 111.78 179.787 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.548 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -149.89 143.48 25.31 Favored 'General case' 0 C--O 1.236 0.358 0 C-N-CA 120.628 -0.429 . . . . 0.0 111.195 178.532 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.446 ' HB ' HG22 ' A' ' 105' ' ' VAL . 94.6 mt -140.72 123.32 15.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.036 -179.016 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -126.74 106.47 9.39 Favored 'General case' 0 C--N 1.319 -0.723 0 N-CA-C 108.672 -0.862 . . . . 0.0 108.672 173.896 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 23.9 m -147.67 151.1 13.9 Favored 'Isoleucine or valine' 0 C--O 1.237 0.423 0 C-N-CA 120.748 -0.381 . . . . 0.0 111.379 -174.881 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 78.7 tt0 -147.14 150.46 35.02 Favored 'General case' 0 C--N 1.319 -0.735 0 N-CA-C 108.609 -0.886 . . . . 0.0 108.609 175.612 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . 0.456 ' HB2' HD23 ' A' ' 47' ' ' LEU . 8.4 t -90.91 143.46 26.69 Favored 'General case' 0 C--N 1.312 -1.027 0 CA-C-O 120.857 0.36 . . . . 0.0 111.436 -177.759 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -87.09 -15.49 62.59 Favored Glycine 0 CA--C 1.52 0.347 0 C-N-CA 120.51 -0.852 . . . . 0.0 111.132 175.892 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . 0.405 ' HB3' ' H ' ' A' ' 43' ' ' ASP . 15.7 m-20 -127.46 -156.01 0.73 Allowed 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.157 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . 0.405 ' H ' ' HB3' ' A' ' 42' ' ' ASP . 43.4 m-20 -76.72 38.72 0.2 Allowed 'General case' 0 N--CA 1.472 0.663 0 C-N-CA 122.576 0.351 . . . . 0.0 111.625 -179.316 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.524 ' O ' ' HE2' ' A' ' 71' ' ' TYR . . . 96.04 -8.39 67.61 Favored Glycine 0 C--O 1.214 -1.095 0 C-N-CA 120.917 -0.658 . . . . 0.0 111.856 -179.527 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 56.2 mt-30 -64.06 -39.66 94.56 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 113.14 0.793 . . . . 0.0 113.14 -176.711 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 4.0 t -126.81 110.56 13.22 Favored 'General case' 0 C--N 1.313 -1.011 0 C-N-CA 120.077 -0.649 . . . . 0.0 110.985 178.57 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' LEU . . . . . 0.456 HD23 ' HB2' ' A' ' 40' ' ' SER . 74.0 mt -93.76 125.52 38.42 Favored 'General case' 0 N--CA 1.443 -0.78 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 176.079 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 13.4 m120 -125.08 141.21 52.26 Favored 'General case' 0 C--N 1.3 -1.547 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 -178.902 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 170.64 -152.99 20.1 Favored Glycine 0 N--CA 1.444 -0.813 0 C-N-CA 119.05 -1.548 . . . . 0.0 113.987 179.333 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 38.6 m -128.47 133.15 48.44 Favored 'General case' 0 N--CA 1.443 -0.808 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 -177.235 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 46.4 ttp -122.61 144.78 48.9 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 -178.344 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.548 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 32.5 m -125.06 126.69 45.77 Favored 'General case' 0 C--O 1.247 0.958 0 CA-C-O 120.73 0.3 . . . . 0.0 111.368 -179.11 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 62.1 m-85 -90.45 162.73 14.94 Favored 'General case' 0 C--O 1.234 0.248 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.95 177.947 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -66.49 131.44 46.05 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.375 178.734 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 74.0 2.08 61.02 Favored Glycine 0 CA--C 1.519 0.34 0 CA-C-N 115.981 -0.554 . . . . 0.0 113.21 179.209 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 75.2 mm-40 -121.74 -179.03 3.98 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 120.826 0.345 . . . . 0.0 110.764 -178.424 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -105.71 173.76 20.39 Favored Glycine 0 N--CA 1.442 -0.927 0 C-N-CA 121.029 -0.605 . . . . 0.0 111.811 179.215 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 26.3 Cg_exo -63.32 136.32 54.77 Favored 'Trans proline' 0 C--O 1.242 0.712 0 C-N-CA 122.892 2.394 . . . . 0.0 112.375 179.811 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . 0.512 ' HB ' ' O ' ' A' ' 76' ' ' GLN . 50.9 pt -130.79 167.2 26.47 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.577 -179.671 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -73.1 135.14 20.89 Favored Glycine 0 C--O 1.249 1.068 0 C-N-CA 120.842 -0.694 . . . . 0.0 112.122 179.776 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 58.1 t80 -127.51 126.9 43.07 Favored 'General case' 0 C--O 1.243 0.717 0 C-N-CA 122.647 0.379 . . . . 0.0 110.795 -177.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 62.1 ttp180 -135.82 131.85 35.91 Favored 'General case' 0 N--CA 1.463 0.205 0 N-CA-C 110.016 -0.364 . . . . 0.0 110.016 176.681 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.453 ' HB2' HG22 ' A' ' 73' ' ' VAL . . . -135.21 141.11 45.75 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.649 0.262 . . . . 0.0 111.703 -179.85 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 40.9 m -121.7 132.05 54.43 Favored 'General case' 0 CA--C 1.544 0.719 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.538 179.554 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 58.8 tp -71.56 114.27 9.47 Favored 'General case' 0 CA--C 1.522 -0.13 0 CA-C-O 121.202 0.525 . . . . 0.0 112.345 -178.412 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 68.1 mt -80.87 -31.38 35.33 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.553 -0.749 . . . . 0.0 109.803 175.566 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 123.72 164.73 12.09 Favored Glycine 0 N--CA 1.445 -0.711 0 N-CA-C 110.362 -1.095 . . . . 0.0 110.362 -177.6 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 94.0 m-20 61.11 36.03 18.43 Favored 'General case' 0 N--CA 1.477 0.896 0 CA-C-N 117.343 0.571 . . . . 0.0 110.917 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 95.0 m-20 63.78 18.88 11.43 Favored 'General case' 0 N--CA 1.477 0.878 0 CA-C-N 115.389 -0.823 . . . . 0.0 111.864 179.235 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 31.6 m -108.56 131.91 54.38 Favored 'General case' 0 N--CA 1.448 -0.565 0 CA-C-O 121.123 0.487 . . . . 0.0 110.926 -179.243 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.524 ' HE2' ' O ' ' A' ' 44' ' ' GLY . 95.6 m-85 -119.13 152.14 37.06 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.212 179.911 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 58.1 tt0 -108.0 127.57 53.88 Favored 'General case' 0 C--N 1.314 -0.946 0 N-CA-C 107.997 -1.112 . . . . 0.0 107.997 174.482 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.453 HG22 ' HB2' ' A' ' 63' ' ' ALA . 56.5 t -111.64 137.56 43.77 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.855 0 N-CA-C 113.77 1.026 . . . . 0.0 113.77 -171.147 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 50.1 mt-10 -123.98 149.49 45.93 Favored 'General case' 0 C--O 1.245 0.86 0 CA-C-N 114.832 -1.076 . . . . 0.0 108.303 175.95 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 14.3 m120 -131.65 156.54 45.66 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-O 120.561 0.22 . . . . 0.0 110.47 -175.98 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' GLN . . . . . 0.512 ' O ' ' HB ' ' A' ' 59' ' ' ILE . 1.7 pt20 -147.18 144.07 28.68 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.402 176.315 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 31.9 p90 -147.24 168.25 22.17 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.16 -177.467 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 79.54 70.35 1.33 Allowed Glycine 0 N--CA 1.441 -0.987 0 C-N-CA 121.078 -0.582 . . . . 0.0 114.109 176.316 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.522 ' O ' ' HB3' ' A' ' 80' ' ' ASP . . . 106.22 -27.32 17.55 Favored Glycine 0 N--CA 1.445 -0.702 0 C-N-CA 120.296 -0.955 . . . . 0.0 113.827 175.733 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . 0.522 ' HB3' ' O ' ' A' ' 79' ' ' GLY . 19.3 t70 81.28 -28.63 0.12 Allowed 'General case' 0 N--CA 1.493 1.703 0 CA-C-O 121.328 0.585 . . . . 0.0 110.736 178.356 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 11.6 p -85.08 16.73 3.3 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-O 121.247 0.546 . . . . 0.0 110.629 174.221 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -89.33 165.45 25.97 Favored Pre-proline 0 CA--C 1.538 0.495 0 CA-C-N 115.599 -0.728 . . . . 0.0 111.073 -178.12 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 10.6 Cg_exo -70.47 166.88 27.02 Favored 'Trans proline' 0 C--N 1.357 0.979 0 C-N-CA 122.851 2.367 . . . . 0.0 111.746 178.481 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' TRP . . . . . . . . . . . . . 90.8 m95 -95.59 137.45 34.63 Favored 'General case' 0 N--CA 1.445 -0.691 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -178.489 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 85.4 m-70 -119.28 145.54 46.02 Favored 'General case' 0 C--N 1.313 -0.98 0 N-CA-C 109.669 -0.493 . . . . 0.0 109.669 -177.26 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 7.1 m -61.78 133.92 56.1 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 110.303 -0.258 . . . . 0.0 110.303 -179.239 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -108.77 -50.67 0.73 Allowed Glycine 0 N--CA 1.443 -0.856 0 C-N-CA 120.137 -1.03 . . . . 0.0 111.987 178.66 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 152.65 -167.7 31.55 Favored Glycine 0 C--O 1.221 -0.683 0 C-N-CA 120.699 -0.762 . . . . 0.0 111.865 179.55 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 19.8 m120 -103.66 145.5 29.97 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 116.901 0.35 . . . . 0.0 110.722 179.824 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' TRP . . . . . 0.49 ' CH2' HG23 ' A' ' 25' ' ' ILE . 12.4 m0 -132.88 142.54 48.98 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 -178.376 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 86.6 mt -109.25 116.41 52.02 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.962 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 177.958 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . 0.422 ' HB2' ' CE1' ' A' ' 71' ' ' TYR . 71.8 mt -134.81 75.89 1.6 Allowed 'General case' 0 C--O 1.263 1.789 0 CA-C-O 121.449 0.643 . . . . 0.0 111.668 -175.967 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . 0.423 ' O ' ' HB2' ' A' ' 94' ' ' SER . . . -148.93 -69.51 0.01 OUTLIER Glycine 0 N--CA 1.445 -0.763 0 C-N-CA 120.289 -0.958 . . . . 0.0 112.785 -179.931 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . 0.614 ' HB3' ' O ' ' A' ' 20' ' ' GLY . 17.3 m 73.44 -34.95 0.3 Allowed 'General case' 0 N--CA 1.479 1.009 0 C-N-CA 123.478 0.711 . . . . 0.0 112.563 -178.593 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 82.6 mtp180 -101.02 153.95 19.11 Favored 'General case' 0 N--CA 1.439 -0.984 0 CA-C-O 120.868 0.366 . . . . 0.0 110.942 -179.179 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 44.5 tt0 -62.03 -54.37 42.4 Favored 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 113.51 0.93 . . . . 0.0 113.51 -172.87 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 47.4 m-80 -122.29 37.1 4.46 Favored 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 111.869 0.322 . . . . 0.0 111.869 -176.475 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' GLN . . . . . 0.567 HE21 ' CB ' ' A' ' 120' ' ' TYR . 39.6 tt0 -148.04 116.12 6.48 Favored 'General case' 0 C--N 1.316 -0.867 0 C-N-CA 120.543 -0.463 . . . . 0.0 110.354 -178.044 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 52.7 m-80 -96.69 164.85 12.41 Favored 'General case' 0 C--O 1.247 0.946 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.716 -175.427 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.417 HG21 ' CZ2' ' A' ' 23' ' ' TRP . 86.7 t -87.36 137.11 21.58 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.735 0 CA-C-N 115.897 -0.592 . . . . 0.0 111.198 177.361 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . 0.475 HG11 ' HA ' ' A' ' 121' ' ' ALA . 34.3 m -119.87 -29.59 1.78 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.743 0 N-CA-C 112.971 0.73 . . . . 0.0 112.971 -178.426 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . 0.629 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -141.26 138.06 32.97 Favored 'General case' 0 C--N 1.323 -0.557 0 C-N-CA 120.048 -0.661 . . . . 0.0 111.445 179.537 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 93.3 mt -134.03 128.02 52.42 Favored 'Isoleucine or valine' 0 C--O 1.244 0.78 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.836 179.154 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 43.5 t30 -129.21 99.76 5.35 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 109.033 -0.728 . . . . 0.0 109.033 174.483 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.446 HG22 ' HB ' ' A' ' 36' ' ' ILE . 25.2 m -141.99 148.31 20.68 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 N-CA-C 112.572 0.582 . . . . 0.0 112.572 -176.416 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 37.9 tt0 -149.92 154.98 39.21 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 115.156 -0.929 . . . . 0.0 108.88 175.469 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . 0.406 ' HB2' HD23 ' A' ' 114' ' ' LEU . 37.7 t -132.84 143.65 49.68 Favored 'General case' 0 C--N 1.311 -1.078 0 CA-C-O 121.132 0.491 . . . . 0.0 111.702 -177.997 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -84.78 -9.42 81.07 Favored Glycine 0 N--CA 1.441 -0.979 0 N-CA-C 110.166 -1.174 . . . . 0.0 110.166 174.922 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 78.3 m-20 -97.29 -171.28 2.17 Favored 'General case' 0 CA--C 1.507 -0.685 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 178.404 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 99.4 m-20 -89.65 39.53 0.96 Allowed 'General case' 0 C--N 1.308 -1.221 0 CA-C-O 121.373 0.606 . . . . 0.0 110.392 177.843 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 95.18 -2.65 65.94 Favored Glycine 0 N--CA 1.447 -0.598 0 CA-C-N 115.609 -0.723 . . . . 0.0 113.152 178.571 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 112' ' ' GLN . . . . . 0.664 ' HA ' HD23 ' A' ' 132' ' ' LEU . 98.4 mt-30 -64.14 -42.7 96.69 Favored 'General case' 0 C--O 1.245 0.839 0 N-CA-C 112.755 0.65 . . . . 0.0 112.755 -176.989 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 46.5 p -124.63 106.64 10.27 Favored 'General case' 0 N--CA 1.449 -0.521 0 CA-C-O 120.954 0.407 . . . . 0.0 110.279 176.996 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 114' ' ' LEU . . . . . 0.406 HD23 ' HB2' ' A' ' 107' ' ' SER . 98.3 mt -91.33 111.84 23.51 Favored 'General case' 0 C--N 1.316 -0.883 0 CA-C-O 120.642 0.258 . . . . 0.0 110.347 -179.344 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 57.1 m-80 -108.86 143.03 38.59 Favored 'General case' 0 C--N 1.313 -0.997 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.342 -179.955 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 163.56 -141.69 7.31 Favored Glycine 0 N--CA 1.435 -1.426 0 C-N-CA 119.655 -1.26 . . . . 0.0 113.162 177.599 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 33.8 p -134.85 158.12 45.05 Favored 'General case' 0 C--N 1.315 -0.907 0 C-N-CA 122.616 0.366 . . . . 0.0 110.504 -177.99 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 25.8 ptm -144.97 152.24 39.86 Favored 'General case' 0 C--N 1.314 -0.939 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.297 -179.766 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 119' ' ' THR . . . . . 0.629 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 32.9 m -129.74 129.34 44.03 Favored 'General case' 0 C--O 1.249 1.059 0 CA-C-N 116.387 -0.37 . . . . 0.0 110.694 179.682 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . 0.567 ' CB ' HE21 ' A' ' 98' ' ' GLN . 45.6 m-85 -85.34 170.48 12.71 Favored 'General case' 0 CA--C 1.517 -0.289 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.325 176.4 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . 0.475 ' HA ' HG11 ' A' ' 101' ' ' VAL . . . -53.21 -40.4 64.44 Favored 'General case' 0 N--CA 1.471 0.586 0 N-CA-C 113.167 0.803 . . . . 0.0 113.167 -178.13 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -151.81 87.88 0.14 Allowed Glycine 0 N--CA 1.447 -0.602 0 C-N-CA 119.579 -1.296 . . . . 0.0 112.821 -179.404 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 77.4 tt0 -169.8 -69.14 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.771 0.32 . . . . 0.0 110.842 179.436 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 153.44 161.87 10.65 Favored Glycine 0 N--CA 1.443 -0.841 0 C-N-CA 120.812 -0.708 . . . . 0.0 111.887 179.316 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 21.2 Cg_exo -66.96 136.57 41.75 Favored 'Trans proline' 0 C--O 1.24 0.582 0 C-N-CA 122.733 2.289 . . . . 0.0 111.73 178.865 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 43.1 pt -135.52 166.26 28.14 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.145 178.862 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -72.89 136.15 22.48 Favored Glycine 0 C--O 1.237 0.284 0 C-N-CA 120.712 -0.756 . . . . 0.0 111.786 -179.759 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 78.9 t80 -122.46 136.81 54.97 Favored 'General case' 0 C--O 1.24 0.569 0 CA-C-O 120.959 0.409 . . . . 0.0 111.651 -177.286 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 61.9 tttm -134.87 103.69 5.7 Favored 'General case' 0 N--CA 1.446 -0.668 0 CA-C-N 115.349 -0.841 . . . . 0.0 109.941 177.145 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -100.24 133.33 11.26 Favored Glycine 0 N--CA 1.443 -0.863 0 N-CA-C 111.183 -0.767 . . . . 0.0 111.183 177.733 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 38.7 m -129.84 137.56 50.51 Favored 'General case' 0 C--N 1.306 -1.286 0 CA-C-N 117.042 0.421 . . . . 0.0 111.187 -177.951 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 132' ' ' LEU . . . . . 0.664 HD23 ' HA ' ' A' ' 112' ' ' GLN . 2.9 mm? -59.76 137.78 57.96 Favored 'General case' 0 N--CA 1.473 0.708 0 CA-C-O 121.285 0.564 . . . . 0.0 111.727 178.752 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 133' ' ' THR . . . . . 0.433 ' HB ' HD12 ' A' ' 3' ' ' LEU . 14.4 m . . . . . 0 N--CA 1.435 -1.203 0 CA-C-N 115.528 -0.76 . . . . 0.0 110.174 178.283 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.51 -0.561 0 CA-C-O 120.694 0.283 . . . . 0.0 110.33 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 10.2 tt -99.77 131.83 45.5 Favored 'General case' 0 C--N 1.316 -0.889 0 CA-C-O 121.177 0.513 . . . . 0.0 110.486 -179.059 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 85.8 m-85 -120.81 142.64 49.42 Favored 'General case' 0 C--N 1.311 -1.083 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.201 178.964 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' ASN . . . . . 0.503 ' O ' ' HA2' ' A' ' 130' ' ' GLY . 88.9 m-20 -87.94 132.15 34.33 Favored 'General case' 0 C--N 1.308 -1.219 0 N-CA-C 107.501 -1.296 . . . . 0.0 107.501 176.786 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.6 HG21 ' CG ' ' A' ' 23' ' ' TRP . 54.2 t -113.88 128.66 70.7 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.99 0 CA-C-O 121.973 0.892 . . . . 0.0 113.191 -173.456 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.437 ' HB2' ' HB3' ' A' ' 129' ' ' LYS . 27.0 mt-10 -120.82 131.75 54.62 Favored 'General case' 0 N--CA 1.43 -1.45 0 CA-C-N 113.631 -1.622 . . . . 0.0 107.755 179.785 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 10.9 m120 -119.9 145.32 46.8 Favored 'General case' 0 C--N 1.314 -0.939 0 CA-C-O 120.995 0.426 . . . . 0.0 111.9 -176.81 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 53.4 tt0 -122.66 110.29 15.34 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.57 -0.741 . . . . 0.0 109.138 179.554 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 3.1 p90 -128.68 -171.42 2.46 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 112.682 0.623 . . . . 0.0 112.682 -175.079 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 66.34 -90.84 0.15 Allowed Glycine 0 C--N 1.336 0.552 0 CA-C-N 114.955 -1.02 . . . . 0.0 114.938 176.084 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.466 ' C ' ' H ' ' A' ' 14' ' ' SER . . . -85.85 0.78 87.97 Favored Glycine 0 C--N 1.319 -0.376 0 C-N-CA 121.319 -0.467 . . . . 0.0 114.098 -173.52 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 13.3 t 59.17 -6.46 0.06 Allowed 'General case' 0 CA--C 1.562 1.434 0 C-N-CA 123.323 0.649 . . . . 0.0 112.662 -177.719 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . 0.466 ' H ' ' C ' ' A' ' 12' ' ' GLY . 8.7 t -125.7 16.13 8.11 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-O 121.658 0.742 . . . . 0.0 109.358 -179.39 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -80.05 163.79 55.94 Favored Pre-proline 0 N--CA 1.445 -0.718 0 CA-C-N 114.877 -1.056 . . . . 0.0 110.122 -179.463 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 14.2 Cg_exo -69.71 169.6 18.47 Favored 'Trans proline' 0 N--CA 1.46 -0.488 0 C-N-CA 122.608 2.205 . . . . 0.0 111.757 177.967 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 98.5 m95 -80.92 121.71 26.34 Favored 'General case' 0 C--N 1.316 -0.868 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 -179.224 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 91.4 m-20 -106.56 114.19 28.16 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.573 -177.595 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -78.56 128.62 33.78 Favored 'General case' 0 C--N 1.319 -0.756 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 178.406 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -143.3 35.45 1.66 Allowed Glycine 0 N--CA 1.442 -0.961 0 C-N-CA 119.51 -1.329 . . . . 0.0 112.694 -179.713 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 137.62 -174.02 22.02 Favored Glycine 0 N--CA 1.443 -0.843 0 C-N-CA 120.034 -1.079 . . . . 0.0 112.782 178.185 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 88.1 mt-30 -132.0 149.21 52.49 Favored 'General case' 0 C--N 1.318 -0.788 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 -179.768 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . 0.6 ' CG ' HG21 ' A' ' 6' ' ' VAL . 38.5 m0 -119.07 153.24 35.08 Favored 'General case' 0 C--N 1.315 -0.913 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 177.947 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . 0.443 ' H ' ' HB ' ' A' ' 91' ' ' ILE . 89.1 mt-10 -111.59 113.69 26.26 Favored 'General case' 0 C--N 1.305 -1.345 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 175.946 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 81.8 mt -130.25 140.35 49.1 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-N 116.0 -0.546 . . . . 0.0 111.904 -172.381 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 91.79 125.17 3.4 Favored Glycine 0 N--CA 1.442 -0.945 0 N-CA-C 114.761 0.665 . . . . 0.0 114.761 172.294 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 3.8 p -88.35 12.61 13.66 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 109.278 -0.638 . . . . 0.0 109.278 173.939 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 62.6 ttp85 -24.74 108.91 0.03 OUTLIER 'General case' 0 N--CA 1.474 0.727 0 C-N-CA 125.477 1.511 . . . . 0.0 113.883 179.732 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 11.0 m -102.88 -62.36 1.29 Allowed 'General case' 0 N--CA 1.436 -1.14 0 CA-C-N 115.235 -0.893 . . . . 0.0 108.83 176.733 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 27.2 m-20 -124.4 5.85 8.36 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.46 178.17 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 1.4 mm-40 -149.53 136.36 19.53 Favored 'General case' 0 C--N 1.318 -0.761 0 CA-C-N 116.009 -0.542 . . . . 0.0 111.432 -177.864 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . 0.516 ' ND2' ' HA3' ' A' ' 111' ' ' GLY . 63.7 t30 -93.36 164.45 13.21 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.947 -0.569 . . . . 0.0 111.331 -179.126 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.411 ' HA ' ' HA ' ' A' ' 53' ' ' TYR . 57.8 t -96.27 130.37 45.03 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 CA-C-N 115.422 -0.808 . . . . 0.0 110.699 -176.912 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 23.7 m -114.07 -16.33 9.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 N-CA-C 112.218 0.451 . . . . 0.0 112.218 178.754 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.403 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -145.86 142.37 28.74 Favored 'General case' 0 CA--C 1.515 -0.384 0 C-N-CA 120.377 -0.529 . . . . 0.0 111.537 178.998 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.435 ' HB ' ' CG2' ' A' ' 105' ' ' VAL . 96.3 mt -142.57 127.46 16.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 N-CA-C 108.987 -0.746 . . . . 0.0 108.987 179.124 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' ASN . . . . . 0.435 ' HA ' ' O ' ' A' ' 103' ' ' ILE . 3.0 t-20 -138.0 113.09 9.2 Favored 'General case' 0 C--N 1.313 -0.991 0 N-CA-C 108.739 -0.837 . . . . 0.0 108.739 176.865 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.45 HG11 ' CD2' ' A' ' 61' ' ' PHE . 28.0 m -148.18 153.15 11.88 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.442 0 C-N-CA 120.918 -0.313 . . . . 0.0 111.19 -174.059 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 81.3 tt0 -139.17 145.37 39.26 Favored 'General case' 0 C--N 1.321 -0.639 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 176.714 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 12.9 t -77.04 139.93 40.19 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-O 120.883 0.373 . . . . 0.0 110.714 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -88.63 -7.07 72.29 Favored Glycine 0 N--CA 1.446 -0.672 0 C-N-CA 120.555 -0.831 . . . . 0.0 111.114 177.061 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . 0.442 ' HB3' ' H ' ' A' ' 43' ' ' ASP . 21.1 m-20 -141.83 -153.98 0.49 Allowed 'General case' 0 C--N 1.33 -0.242 0 C-N-CA 122.508 0.323 . . . . 0.0 110.257 -179.319 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . 0.442 ' H ' ' HB3' ' A' ' 42' ' ' ASP . 86.7 m-20 -78.28 44.07 0.48 Allowed 'General case' 0 N--CA 1.471 0.589 0 C-N-CA 122.664 0.386 . . . . 0.0 111.961 -178.468 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 87.49 -5.13 85.53 Favored Glycine 0 C--O 1.227 -0.335 0 C-N-CA 120.787 -0.721 . . . . 0.0 113.491 178.094 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 54.9 mt-30 -70.29 -38.89 75.1 Favored 'General case' 0 C--O 1.222 -0.362 0 N-CA-C 112.59 0.589 . . . . 0.0 112.59 179.604 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . 0.606 ' HA ' ' O ' ' A' ' 63' ' ' ALA . 7.8 t -127.71 123.57 35.73 Favored 'General case' 0 C--N 1.32 -0.689 0 C-N-CA 120.426 -0.51 . . . . 0.0 111.293 -179.027 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 95.5 mt -103.15 124.81 49.29 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.037 177.912 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.503 ' OD1' ' HG3' ' A' ' 62' ' ' ARG . 93.2 m-20 -119.61 142.11 48.7 Favored 'General case' 0 C--N 1.313 -0.985 0 CA-C-N 115.969 -0.559 . . . . 0.0 110.021 179.616 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 166.47 -146.48 10.97 Favored Glycine 0 CA--C 1.501 -0.822 0 C-N-CA 119.787 -1.197 . . . . 0.0 112.787 179.373 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 33.5 p -135.51 153.04 51.86 Favored 'General case' 0 N--CA 1.446 -0.629 0 CA-C-O 120.973 0.416 . . . . 0.0 111.066 -178.718 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' MET . . . . . 0.415 ' HE1' ' CZ ' ' A' ' 53' ' ' TYR . 16.6 tmm? -135.01 138.65 44.16 Favored 'General case' 0 C--N 1.317 -0.83 0 N-CA-C 109.276 -0.638 . . . . 0.0 109.276 178.148 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.403 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 29.4 m -125.24 129.26 49.71 Favored 'General case' 0 C--O 1.255 1.365 0 N-CA-C 112.527 0.566 . . . . 0.0 112.527 -175.564 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . 0.51 ' HB2' ' HB2' ' A' ' 56' ' ' GLU . 95.1 m-85 -85.29 165.73 17.07 Favored 'General case' 0 CA--C 1.532 0.251 0 CA-C-N 115.341 -0.845 . . . . 0.0 109.805 176.659 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -66.87 113.51 4.98 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 120.714 0.292 . . . . 0.0 111.707 -179.008 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 76.6 16.53 80.67 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.844 178.11 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . 0.51 ' HB2' ' HB2' ' A' ' 53' ' ' TYR . 73.0 mm-40 -121.71 177.67 5.16 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-O 120.769 0.319 . . . . 0.0 110.395 -179.397 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -93.38 153.48 21.37 Favored Glycine 0 N--CA 1.443 -0.857 0 C-N-CA 120.805 -0.712 . . . . 0.0 111.556 178.694 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -67.8 144.27 64.55 Favored 'Trans proline' 0 C--O 1.237 0.432 0 C-N-CA 122.555 2.17 . . . . 0.0 112.574 179.581 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 39.6 pt -125.86 162.69 28.74 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.818 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.284 178.644 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -71.24 145.1 38.74 Favored Glycine 0 N--CA 1.448 -0.537 0 C-N-CA 121.195 -0.526 . . . . 0.0 112.323 -177.559 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.45 ' CD2' HG11 ' A' ' 38' ' ' VAL . 69.4 t80 -130.93 126.94 37.42 Favored 'General case' 0 C--N 1.313 -1.02 0 C-N-CA 122.106 0.162 . . . . 0.0 110.972 -178.186 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . 0.503 ' HG3' ' OD1' ' A' ' 48' ' ' ASN . 29.0 ttp85 -135.32 128.31 31.51 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 108.798 -0.816 . . . . 0.0 108.798 174.643 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.606 ' O ' ' HA ' ' A' ' 46' ' ' THR . . . -132.87 141.76 48.58 Favored 'General case' 0 C--N 1.316 -0.857 0 C-N-CA 120.852 -0.339 . . . . 0.0 111.713 -178.378 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 31.7 m -124.06 128.97 50.1 Favored 'General case' 0 CA--C 1.539 0.527 0 CA-C-N 116.458 -0.337 . . . . 0.0 110.634 179.516 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 51.2 tp -74.73 127.6 33.53 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 112.279 0.474 . . . . 0.0 112.279 -177.514 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 10.7 mp -79.82 -24.36 41.41 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.969 177.094 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 113.64 -8.36 24.05 Favored Glycine 0 CA--C 1.521 0.465 0 C-N-CA 120.93 -0.653 . . . . 0.0 112.638 179.88 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 24.2 p-10 -115.41 30.12 7.56 Favored 'General case' 0 C--N 1.312 -1.054 0 CA-C-O 121.04 0.448 . . . . 0.0 110.445 179.937 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 87.3 m-20 76.48 -9.38 1.49 Allowed 'General case' 0 N--CA 1.485 1.278 0 C-N-CA 124.353 1.061 . . . . 0.0 111.048 -178.099 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 9.0 m -81.49 138.58 35.47 Favored 'General case' 0 N--CA 1.441 -0.884 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.433 177.828 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.524 ' HB3' ' HB1' ' A' ' 63' ' ' ALA . 43.8 m-85 -122.12 129.94 52.8 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-N 115.679 -0.691 . . . . 0.0 109.685 178.126 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . 0.41 ' O ' ' HA ' ' A' ' 63' ' ' ALA . 36.0 tt0 -83.45 119.02 24.14 Favored 'General case' 0 N--CA 1.44 -0.949 0 N-CA-C 107.774 -1.195 . . . . 0.0 107.774 174.99 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.449 HG22 ' HB2' ' A' ' 63' ' ' ALA . 53.0 t -108.08 133.62 52.41 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.307 0 N-CA-C 112.866 0.691 . . . . 0.0 112.866 -172.474 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 99.8 mt-10 -120.03 122.4 41.05 Favored 'General case' 0 N--CA 1.436 -1.158 0 CA-C-N 114.51 -1.223 . . . . 0.0 108.875 176.676 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 2.7 m-20 -96.29 140.57 30.78 Favored 'General case' 0 C--N 1.313 -1.018 0 CA-C-N 116.288 -0.415 . . . . 0.0 109.917 179.367 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' GLN . . . . . 0.508 ' HB2' ' CE3' ' A' ' 84' ' ' TRP . 61.3 tt0 -115.87 120.89 40.68 Favored 'General case' 0 C--N 1.307 -1.254 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 179.345 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 6.1 p90 -137.55 157.1 47.25 Favored 'General case' 0 C--N 1.312 -1.027 0 CA-C-O 120.723 0.297 . . . . 0.0 110.329 179.481 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 103.13 -13.84 55.51 Favored Glycine 0 N--CA 1.439 -1.115 0 C-N-CA 120.756 -0.735 . . . . 0.0 111.652 -179.838 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 131.51 170.64 12.67 Favored Glycine 0 N--CA 1.437 -1.246 0 C-N-CA 120.886 -0.673 . . . . 0.0 111.972 178.97 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 5.7 p-10 -65.73 -33.1 75.09 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 121.056 0.455 . . . . 0.0 111.127 179.864 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 40.6 m -78.45 -2.89 40.66 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 115.845 -0.616 . . . . 0.0 111.856 -178.565 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -89.61 146.11 34.99 Favored Pre-proline 0 C--N 1.325 -0.458 0 CA-C-N 116.6 -0.273 . . . . 0.0 110.341 178.606 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.82 177.09 5.98 Favored 'Trans proline' 0 CA--C 1.532 0.405 0 C-N-CA 122.738 2.292 . . . . 0.0 112.298 179.847 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' TRP . . . . . 0.508 ' CE3' ' HB2' ' A' ' 76' ' ' GLN . 98.5 m95 -85.89 143.09 28.41 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 109.716 -0.476 . . . . 0.0 109.716 -179.154 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 91.7 m-70 -119.61 146.11 45.83 Favored 'General case' 0 C--N 1.313 -1.021 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 -179.643 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 46.0 m -63.51 131.2 47.36 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-O 120.891 0.377 . . . . 0.0 110.898 -179.396 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -107.94 -55.2 0.61 Allowed Glycine 0 N--CA 1.441 -1.013 0 C-N-CA 120.842 -0.694 . . . . 0.0 111.694 179.536 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 157.42 -173.43 34.88 Favored Glycine 0 C--O 1.223 -0.546 0 C-N-CA 120.26 -0.971 . . . . 0.0 112.184 179.326 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 24.3 t-20 -109.7 113.26 25.88 Favored 'General case' 0 C--N 1.316 -0.879 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 178.919 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 21.0 m0 -105.96 153.14 22.41 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.432 -176.416 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . 0.443 ' HB ' ' H ' ' A' ' 24' ' ' GLU . 46.8 mm -107.22 113.54 43.8 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.799 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 177.259 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 82.8 mt -127.08 78.51 1.82 Allowed 'General case' 0 C--O 1.268 2.066 0 CA-C-O 122.045 0.926 . . . . 0.0 112.371 -176.973 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 162.71 104.87 0.19 Allowed Glycine 0 N--CA 1.444 -0.772 0 CA-C-N 114.741 -1.118 . . . . 0.0 110.752 -179.072 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 15.7 p -106.88 -13.12 15.31 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 120.889 0.376 . . . . 0.0 111.867 -178.0 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 85.2 mtp180 -85.47 16.2 3.96 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 121.248 0.547 . . . . 0.0 111.452 -179.202 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 46.9 tp10 65.36 -74.51 0.05 Allowed 'General case' 0 N--CA 1.472 0.646 0 CA-C-N 114.459 -1.246 . . . . 0.0 113.97 174.007 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 61.9 m-80 -91.97 26.85 2.3 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-O 120.765 0.317 . . . . 0.0 111.739 -175.077 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' GLN . . . . . . . . . . . . . 58.1 tt0 -150.05 116.62 5.81 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.801 0.334 . . . . 0.0 110.218 -177.969 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 83.6 m-20 -84.58 160.02 20.54 Favored 'General case' 0 C--O 1.245 0.819 0 CA-C-N 115.977 -0.556 . . . . 0.0 111.77 -176.895 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 79.5 t -82.36 132.43 31.43 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.664 0 C-N-CA 120.728 -0.389 . . . . 0.0 110.818 176.699 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 34.7 m -114.44 -23.76 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.601 0 N-CA-C 113.087 0.773 . . . . 0.0 113.087 -179.457 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . 0.549 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -152.04 144.13 23.87 Favored 'General case' 0 CA--C 1.512 -0.49 0 C-N-CA 120.425 -0.51 . . . . 0.0 111.113 178.198 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.442 ' HB ' HG22 ' A' ' 38' ' ' VAL . 84.6 mt -135.88 125.8 41.24 Favored 'Isoleucine or valine' 0 C--O 1.236 0.393 0 CA-C-O 120.582 0.23 . . . . 0.0 110.81 179.066 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 9.6 t30 -126.74 94.88 4.16 Favored 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 175.172 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.435 ' CG2' ' HB ' ' A' ' 36' ' ' ILE . 30.9 m -136.88 141.43 40.68 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.702 0 N-CA-C 113.633 0.975 . . . . 0.0 113.633 -174.191 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 74.6 tt0 -141.71 150.49 41.9 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 114.97 -1.014 . . . . 0.0 109.298 178.117 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . 0.415 ' HB3' ' HA ' ' A' ' 114' ' ' LEU . 35.6 p -150.65 153.17 35.15 Favored 'General case' 0 N--CA 1.446 -0.671 0 CA-C-O 120.821 0.343 . . . . 0.0 111.219 177.545 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -123.19 5.59 9.47 Favored Glycine 0 N--CA 1.439 -1.124 0 N-CA-C 111.112 -0.795 . . . . 0.0 111.112 177.474 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -92.34 34.59 1.03 Allowed 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 121.196 0.522 . . . . 0.0 110.528 179.495 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 29.3 m-20 59.21 21.83 10.0 Favored 'General case' 0 N--CA 1.474 0.741 0 CA-C-N 115.284 -0.871 . . . . 0.0 112.507 176.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . 0.516 ' HA3' ' ND2' ' A' ' 32' ' ' ASN . . . 89.71 -0.14 79.5 Favored Glycine 0 N--CA 1.447 -0.582 0 C-N-CA 120.748 -0.739 . . . . 0.0 113.174 177.928 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 51.8 tt0 -65.62 -43.38 89.76 Favored 'General case' 0 C--O 1.235 0.335 0 CA-C-O 121.356 0.598 . . . . 0.0 110.282 178.725 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 6.4 p -128.72 125.99 39.11 Favored 'General case' 0 N--CA 1.434 -1.248 0 CA-C-N 115.428 -0.805 . . . . 0.0 109.97 176.665 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 114' ' ' LEU . . . . . 0.415 ' HA ' ' HB3' ' A' ' 107' ' ' SER . 42.4 tp -112.47 134.94 53.73 Favored 'General case' 0 C--N 1.306 -1.319 0 CA-C-N 115.899 -0.591 . . . . 0.0 109.596 -177.776 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 30.1 p30 -145.72 169.91 17.54 Favored 'General case' 0 C--N 1.32 -0.698 0 C-N-CA 119.779 -0.768 . . . . 0.0 112.301 179.92 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 147.36 -131.71 4.02 Favored Glycine 0 N--CA 1.434 -1.444 0 CA-C-N 115.127 -0.942 . . . . 0.0 111.204 179.283 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 21.9 p -133.2 159.23 40.79 Favored 'General case' 0 C--N 1.307 -1.246 0 CA-C-O 121.095 0.474 . . . . 0.0 110.72 179.923 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 118' ' ' MET . . . . . 0.404 ' HB2' ' HE2' ' A' ' 118' ' ' MET . 4.5 ppp? -153.91 163.02 40.73 Favored 'General case' 0 C--N 1.306 -1.306 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 178.802 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 119' ' ' THR . . . . . 0.549 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 32.1 m -131.47 130.2 42.13 Favored 'General case' 0 C--N 1.307 -1.254 0 CA-C-O 120.791 0.329 . . . . 0.0 111.235 -179.79 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 11.5 m-85 -94.71 161.22 14.27 Favored 'General case' 0 N--CA 1.45 -0.473 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.075 177.095 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -65.6 128.19 34.93 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 120.89 0.376 . . . . 0.0 111.89 -179.098 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 76.23 19.17 78.72 Favored Glycine 0 N--CA 1.45 -0.396 0 CA-C-N 115.775 -0.648 . . . . 0.0 112.956 176.859 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 70.5 tt0 -147.22 161.08 41.65 Favored 'General case' 0 C--N 1.317 -0.832 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 -178.393 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -80.05 -179.49 52.54 Favored Glycine 0 N--CA 1.448 -0.508 0 C-N-CA 121.017 -0.611 . . . . 0.0 112.356 179.63 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -71.56 140.37 36.05 Favored 'Trans proline' 0 CA--C 1.532 0.392 0 C-N-CA 122.714 2.276 . . . . 0.0 112.959 -178.788 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 44.0 pt -132.68 165.99 30.64 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.13 178.805 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -73.15 142.6 31.91 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 121.017 -0.611 . . . . 0.0 112.458 -179.809 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 79.4 t80 -122.76 136.88 55.01 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-O 120.911 0.386 . . . . 0.0 111.272 -179.288 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 129' ' ' LYS . . . . . 0.437 ' HB3' ' HB2' ' A' ' 7' ' ' GLU . 63.2 tttm -142.0 125.95 17.21 Favored 'General case' 0 N--CA 1.447 -0.58 0 CA-C-N 115.649 -0.705 . . . . 0.0 109.154 175.668 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . 0.503 ' HA2' ' O ' ' A' ' 5' ' ' ASN . . . -127.24 135.74 8.96 Favored Glycine 0 N--CA 1.432 -1.581 0 N-CA-C 110.856 -0.898 . . . . 0.0 110.856 178.918 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 30.1 m -118.55 126.94 53.08 Favored 'General case' 0 C--N 1.305 -1.338 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 -178.581 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 66.1 tp -75.24 140.71 43.39 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.782 0.325 . . . . 0.0 111.154 -178.608 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 9.8 t . . . . . 0 C--O 1.248 1.022 0 CA-C-O 118.604 -0.712 . . . . 0.0 109.533 177.987 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.467 0.394 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' LEU . . . . . 0.493 HD11 HE21 ' A' ' 22' ' ' GLN . 3.3 tm? -90.72 128.08 36.54 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-O 121.046 0.45 . . . . 0.0 110.332 -178.331 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 47.2 m-85 -124.46 147.08 48.56 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.864 -0.607 . . . . 0.0 111.175 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 5.7 m-20 -100.97 137.83 38.82 Favored 'General case' 0 C--N 1.315 -0.931 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 175.502 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.452 HG21 ' CD2' ' A' ' 23' ' ' TRP . 68.1 t -116.02 128.26 73.36 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.774 0 CA-C-O 121.527 0.68 . . . . 0.0 112.745 -173.913 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.453 ' HB3' ' HB3' ' A' ' 17' ' ' TRP . 65.4 mt-10 -118.66 138.36 52.66 Favored 'General case' 0 N--CA 1.437 -1.101 0 CA-C-N 114.681 -1.145 . . . . 0.0 108.423 176.713 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 11.9 m120 -127.44 147.16 50.29 Favored 'General case' 0 C--N 1.312 -1.037 0 CA-C-O 121.172 0.511 . . . . 0.0 111.896 -177.056 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 52.1 tt0 -123.38 117.24 24.75 Favored 'General case' 0 C--N 1.314 -0.955 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 178.118 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 7.6 p90 -137.93 9.44 2.81 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 114.313 1.227 . . . . 0.0 114.313 -174.84 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -93.24 31.51 6.3 Favored Glycine 0 CA--C 1.522 0.485 0 C-N-CA 118.748 -1.692 . . . . 0.0 114.353 -174.784 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.63 58.88 3.17 Favored Glycine 0 CA--C 1.525 0.67 0 C-N-CA 120.428 -0.891 . . . . 0.0 114.376 176.922 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 22.8 t 60.69 154.55 0.03 OUTLIER 'General case' 0 CA--C 1.553 1.083 0 N-CA-C 113.408 0.892 . . . . 0.0 113.408 177.325 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 49.3 m 63.3 14.42 7.82 Favored 'General case' 0 N--CA 1.472 0.671 0 CA-C-N 115.851 -0.613 . . . . 0.0 112.355 177.223 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -96.7 153.95 38.57 Favored Pre-proline 0 C--N 1.314 -0.939 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.189 -179.446 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -73.18 161.69 42.47 Favored 'Trans proline' 0 C--O 1.238 0.503 0 C-N-CA 122.634 2.223 . . . . 0.0 111.703 177.772 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' TRP . . . . . 0.453 ' HB3' ' HB3' ' A' ' 7' ' ' GLU . 92.6 m95 -85.18 129.46 34.8 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 109.664 -0.495 . . . . 0.0 109.664 179.51 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 27.6 m-80 -113.22 118.57 35.04 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.661 -178.053 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.434 ' HA ' ' HA ' ' A' ' 7' ' ' GLU . 11.5 pt-20 -75.48 129.94 38.09 Favored 'General case' 0 C--N 1.319 -0.718 0 N-CA-C 109.724 -0.473 . . . . 0.0 109.724 177.474 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -137.62 26.57 2.9 Favored Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 119.596 -1.288 . . . . 0.0 113.159 -178.661 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 147.86 179.26 23.72 Favored Glycine 0 N--CA 1.449 -0.433 0 C-N-CA 119.79 -1.195 . . . . 0.0 113.075 178.125 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . 0.493 HE21 HD11 ' A' ' 3' ' ' LEU . 4.4 pt20 -127.99 138.74 52.72 Favored 'General case' 0 C--N 1.322 -0.601 0 C-N-CA 122.69 0.396 . . . . 0.0 110.205 -179.93 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . 0.452 ' CD2' HG21 ' A' ' 6' ' ' VAL . 45.7 m0 -116.07 171.81 7.56 Favored 'General case' 0 C--O 1.242 0.661 0 CA-C-O 120.86 0.362 . . . . 0.0 111.226 -177.802 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 76.5 tt0 -119.13 110.73 17.4 Favored 'General case' 0 CA--C 1.513 -0.465 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 178.005 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 91.1 mt -133.01 143.97 37.9 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-N 115.401 -0.818 . . . . 0.0 109.579 -178.164 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 83.94 71.73 1.31 Allowed Glycine 0 CA--C 1.508 -0.351 0 C-N-CA 120.369 -0.92 . . . . 0.0 112.014 177.891 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 15.9 m -62.68 -45.62 91.97 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 120.823 0.344 . . . . 0.0 111.279 -179.313 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 83.0 mtm-85 -88.36 133.99 33.94 Favored 'General case' 0 CA--C 1.517 -0.322 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.057 178.797 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 18.8 p -87.16 -16.13 36.3 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.956 -0.565 . . . . 0.0 111.398 179.701 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 16.5 m-20 -71.31 -43.2 67.52 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-O 121.51 0.671 . . . . 0.0 110.161 179.933 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 14.1 mm100 -131.76 122.3 25.61 Favored 'General case' 0 C--N 1.312 -1.027 0 CA-C-N 114.915 -1.039 . . . . 0.0 110.046 -179.399 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . 0.506 ' ND2' ' HA3' ' A' ' 111' ' ' GLY . 59.4 t30 -108.15 172.36 6.88 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.324 -177.575 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 14.0 t -101.71 134.24 42.76 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.92 0 N-CA-C 111.877 0.325 . . . . 0.0 111.877 -172.031 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 33.6 m -113.77 -15.34 10.25 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.356 0 CA-C-O 121.017 0.437 . . . . 0.0 111.594 177.386 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.647 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -147.48 142.67 27.19 Favored 'General case' 0 CA--C 1.506 -0.715 0 C-N-CA 120.269 -0.572 . . . . 0.0 111.181 178.199 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.402 ' HB ' HG22 ' A' ' 105' ' ' VAL . 85.9 mt -142.36 120.43 8.04 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 N-CA-C 109.155 -0.683 . . . . 0.0 109.155 -179.377 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' ASN . . . . . 0.452 ' HA ' ' O ' ' A' ' 103' ' ' ILE . 22.7 m-80 -132.37 109.81 10.12 Favored 'General case' 0 C--N 1.31 -1.151 0 N-CA-C 108.88 -0.785 . . . . 0.0 108.88 176.49 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.488 HG22 ' HB ' ' A' ' 103' ' ' ILE . 33.3 m -147.79 152.93 12.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 C-N-CA 120.996 -0.281 . . . . 0.0 111.254 -172.57 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 41.6 tt0 -142.45 147.27 35.84 Favored 'General case' 0 N--CA 1.446 -0.633 0 CA-C-N 115.845 -0.616 . . . . 0.0 109.433 176.755 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 19.9 p -70.42 144.38 51.53 Favored 'General case' 0 C--N 1.313 -1.005 0 CA-C-O 121.083 0.468 . . . . 0.0 111.652 -178.548 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -88.38 -59.18 1.67 Allowed Glycine 0 N--CA 1.441 -0.971 0 N-CA-C 110.366 -1.094 . . . . 0.0 110.366 177.174 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 43.9 m-20 -93.78 -147.11 0.25 Allowed 'General case' 0 C--N 1.32 -0.713 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 176.708 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 20.2 p-10 -78.99 40.66 0.41 Allowed 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.124 0.488 . . . . 0.0 111.949 -178.818 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 97.89 -22.39 41.07 Favored Glycine 0 C--O 1.219 -0.82 0 C-N-CA 120.753 -0.736 . . . . 0.0 113.736 177.351 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 56.3 mt-30 -64.34 -28.61 69.82 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 117.319 0.559 . . . . 0.0 112.111 -178.603 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 26.0 p -117.54 137.0 52.87 Favored 'General case' 0 C--N 1.312 -1.029 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.392 179.334 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 88.7 mt -127.51 128.91 46.47 Favored 'General case' 0 C--N 1.318 -0.793 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 62.7 m-80 -129.47 140.82 51.17 Favored 'General case' 0 C--N 1.318 -0.762 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 178.335 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 178.97 -156.89 19.8 Favored Glycine 0 N--CA 1.438 -1.196 0 C-N-CA 119.972 -1.108 . . . . 0.0 112.797 179.522 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 65.3 m -130.98 132.99 45.39 Favored 'General case' 0 C--N 1.312 -1.04 0 CA-C-O 120.843 0.354 . . . . 0.0 110.646 -179.536 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 46.9 mtp -115.66 148.28 39.88 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.722 177.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.647 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 33.0 m -126.4 125.33 42.01 Favored 'General case' 0 C--O 1.25 1.086 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.136 177.149 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . 0.441 ' HB2' ' HB2' ' A' ' 56' ' ' GLU . 50.8 m-85 -94.67 164.74 12.83 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.869 -179.43 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -65.14 95.97 0.19 Allowed 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.813 -0.63 . . . . 0.0 111.641 -179.47 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 98.81 4.67 56.82 Favored Glycine 0 C--N 1.318 -0.424 0 CA-C-N 115.613 -0.721 . . . . 0.0 112.434 177.153 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . 0.441 ' HB2' ' HB2' ' A' ' 53' ' ' TYR . 41.8 mt-10 -114.45 168.02 10.21 Favored 'General case' 0 C--N 1.314 -0.968 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 178.871 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -89.61 168.95 35.12 Favored Glycine 0 N--CA 1.437 -1.298 0 C-N-CA 120.541 -0.838 . . . . 0.0 111.413 178.756 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_exo -63.02 134.33 45.62 Favored 'Trans proline' 0 C--O 1.239 0.545 0 C-N-CA 122.345 2.03 . . . . 0.0 111.465 178.735 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 45.0 pt -130.54 166.7 27.47 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.846 179.675 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -73.6 142.49 31.23 Favored Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 121.074 -0.584 . . . . 0.0 112.338 -177.409 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 39.8 t80 -126.77 128.47 46.66 Favored 'General case' 0 C--N 1.317 -0.839 0 C-N-CA 122.451 0.3 . . . . 0.0 111.125 -179.067 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 69.5 ttp85 -136.5 132.25 35.04 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 174.348 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.654 ' HB1' ' HB3' ' A' ' 71' ' ' TYR . . . -137.28 146.26 44.48 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 111.892 0.33 . . . . 0.0 111.892 179.837 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 60.1 m -121.32 131.3 54.12 Favored 'General case' 0 CA--C 1.546 0.793 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.38 179.176 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . 0.511 ' O ' ' HB3' ' A' ' 66' ' ' LEU . 59.9 tp -43.2 -51.81 5.89 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 115.513 1.672 . . . . 0.0 115.513 -176.493 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . 0.511 ' HB3' ' O ' ' A' ' 65' ' ' LEU . 3.2 tm? 75.64 -57.06 0.59 Allowed 'General case' 0 CA--C 1.549 0.935 0 CA-C-N 118.364 0.529 . . . . 0.0 110.641 177.949 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -141.35 -90.27 0.16 Allowed Glycine 0 C--N 1.333 0.398 0 C-N-CA 121.057 -0.592 . . . . 0.0 112.646 -179.405 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 9.0 p30 -160.94 133.03 5.89 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 179.705 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 94.3 m-20 57.19 24.27 9.62 Favored 'General case' 0 N--CA 1.478 0.968 0 CA-C-O 121.279 0.562 . . . . 0.0 111.172 -176.256 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 43.5 m -138.2 152.03 48.25 Favored 'General case' 0 N--CA 1.434 -1.229 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 179.336 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.654 ' HB3' ' HB1' ' A' ' 63' ' ' ALA . 97.3 m-85 -149.85 126.39 10.91 Favored 'General case' 0 C--N 1.31 -1.118 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 176.662 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . 0.468 ' O ' ' HA ' ' A' ' 63' ' ' ALA . 83.7 tt0 -82.81 127.53 33.55 Favored 'General case' 0 N--CA 1.439 -0.991 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 175.603 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 76.9 t -104.75 131.55 53.55 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.278 0 CA-C-N 115.352 -0.84 . . . . 0.0 112.585 -171.96 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.469 ' HG2' ' HA ' ' A' ' 86' ' ' SER . 48.1 mt-10 -129.76 126.65 38.67 Favored 'General case' 0 N--CA 1.44 -0.966 0 CA-C-N 114.275 -1.33 . . . . 0.0 107.523 175.059 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 97.0 m-20 -109.53 154.34 22.85 Favored 'General case' 0 C--N 1.314 -0.973 0 CA-C-O 121.042 0.449 . . . . 0.0 112.053 -176.132 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' GLN . . . . . 0.537 ' HB2' ' CE3' ' A' ' 84' ' ' TRP . 61.8 tt0 -118.47 124.52 47.82 Favored 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 115.527 -0.76 . . . . 0.0 110.608 -176.193 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 6.0 p90 -142.59 158.8 43.3 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.158 179.07 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 98.32 -12.42 63.41 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.628 -0.796 . . . . 0.0 112.697 179.931 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 134.26 169.59 12.05 Favored Glycine 0 N--CA 1.447 -0.621 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.192 179.64 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 6.5 p-10 -68.83 -30.42 68.96 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 120.71 0.291 . . . . 0.0 111.097 -179.812 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 23.6 t -71.96 -16.0 62.08 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.255 179.28 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -79.96 143.62 57.88 Favored Pre-proline 0 C--N 1.324 -0.512 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.029 -178.488 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_endo -72.3 -178.16 3.12 Favored 'Trans proline' 0 C--O 1.238 0.511 0 C-N-CA 122.881 2.387 . . . . 0.0 112.149 179.168 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' TRP . . . . . 0.537 ' CE3' ' HB2' ' A' ' 76' ' ' GLN . 88.3 m95 -94.39 142.4 27.47 Favored 'General case' 0 C--N 1.317 -0.829 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 -179.816 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 96.6 m-70 -116.51 142.14 47.26 Favored 'General case' 0 C--N 1.316 -0.889 0 N-CA-C 109.778 -0.452 . . . . 0.0 109.778 -178.542 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . 0.469 ' HA ' ' HG2' ' A' ' 74' ' ' GLU . 20.8 t -65.39 132.56 49.28 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 120.874 0.368 . . . . 0.0 111.229 -176.374 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -110.75 -48.35 0.74 Allowed Glycine 0 N--CA 1.441 -1.03 0 C-N-CA 120.936 -0.65 . . . . 0.0 112.188 178.547 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 157.96 -171.74 35.02 Favored Glycine 0 C--O 1.217 -0.911 0 C-N-CA 120.57 -0.824 . . . . 0.0 111.84 -179.943 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 3.9 t30 -112.4 115.64 29.04 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 117.54 0.67 . . . . 0.0 110.251 179.699 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 35.1 m0 -97.88 148.71 23.16 Favored 'General case' 0 C--N 1.311 -1.092 0 CA-C-O 121.037 0.446 . . . . 0.0 111.622 -177.725 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . 0.401 ' O ' ' HB3' ' A' ' 23' ' ' TRP . 76.6 mt -108.49 118.18 55.54 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.057 0 N-CA-C 108.49 -0.93 . . . . 0.0 108.49 175.605 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 85.8 mt -134.53 83.39 2.03 Favored 'General case' 0 C--O 1.267 1.985 0 O-C-N 124.031 0.832 . . . . 0.0 112.057 -173.675 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 172.11 111.34 0.26 Allowed Glycine 0 N--CA 1.444 -0.769 0 CA-C-N 115.752 -0.658 . . . . 0.0 112.644 177.407 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 78.8 p -90.07 -7.88 52.79 Favored 'General case' 0 C--O 1.236 0.362 0 CA-C-O 121.45 0.643 . . . . 0.0 110.014 177.348 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 97.3 mtt180 -105.28 142.74 34.52 Favored 'General case' 0 N--CA 1.445 -0.692 0 CA-C-N 115.357 -0.838 . . . . 0.0 110.701 179.725 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -70.48 -34.68 72.65 Favored 'General case' 0 C--N 1.311 -1.08 0 CA-C-N 115.688 -0.687 . . . . 0.0 112.811 -175.193 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 27.2 p-10 -116.21 27.29 9.33 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 112.77 0.655 . . . . 0.0 112.77 -176.54 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' GLN . . . . . . . . . . . . . 72.1 mt-30 -148.82 125.76 11.27 Favored 'General case' 0 CA--C 1.511 -0.54 0 CA-C-O 121.12 0.486 . . . . 0.0 112.276 -179.855 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 99' ' ' ASN . . . . . 0.531 ' HB3' ' OH ' ' A' ' 71' ' ' TYR . 94.9 m-20 -96.17 152.87 18.15 Favored 'General case' 0 C--O 1.258 1.512 0 CA-C-N 114.985 -1.007 . . . . 0.0 109.889 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 57.5 t -73.9 134.91 28.64 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.561 0 CA-C-O 120.932 0.396 . . . . 0.0 111.057 178.424 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 23.3 m -120.08 -23.64 3.26 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.478 0 N-CA-C 112.649 0.611 . . . . 0.0 112.649 -178.848 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . 0.511 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -148.05 139.58 23.69 Favored 'General case' 0 C--O 1.236 0.392 0 C-N-CA 120.342 -0.543 . . . . 0.0 111.85 179.433 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.488 ' HB ' HG22 ' A' ' 38' ' ' VAL . 37.4 mm -134.02 130.0 54.74 Favored 'Isoleucine or valine' 0 C--O 1.239 0.53 0 CA-C-N 115.904 -0.589 . . . . 0.0 111.287 178.901 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 6.8 t30 -129.07 93.75 3.66 Favored 'General case' 0 CA--C 1.534 0.359 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.368 176.222 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.402 HG22 ' HB ' ' A' ' 36' ' ' ILE . 27.3 m -138.44 141.55 37.3 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.932 0 N-CA-C 113.033 0.753 . . . . 0.0 113.033 -176.561 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 85.6 tt0 -144.14 87.63 1.91 Allowed 'General case' 0 CA--C 1.534 0.358 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.676 176.447 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . 0.464 ' HB2' ' H ' ' A' ' 115' ' ' ASN . 13.6 m -162.93 159.82 24.1 Favored 'General case' 0 C--N 1.312 -1.061 0 CA-C-N 114.667 -1.151 . . . . 0.0 111.206 -179.359 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 136.95 94.46 0.37 Allowed Glycine 0 N--CA 1.424 -2.139 0 C-N-CA 119.215 -1.469 . . . . 0.0 114.578 173.633 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 16.7 m-20 -75.68 100.47 4.67 Favored 'General case' 0 CA--C 1.502 -0.878 0 N-CA-C 105.875 -1.898 . . . . 0.0 105.875 171.918 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 70.5 m-20 62.27 24.35 14.48 Favored 'General case' 0 CA--C 1.534 0.344 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 -172.234 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . 0.506 ' HA3' ' ND2' ' A' ' 32' ' ' ASN . . . 77.91 22.85 67.98 Favored Glycine 0 CA--C 1.527 0.821 0 CA-C-N 115.217 -0.901 . . . . 0.0 113.539 179.928 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 52.8 tt0 -66.35 -43.49 85.9 Favored 'General case' 0 CA--C 1.541 0.597 0 N-CA-C 112.433 0.531 . . . . 0.0 112.433 -179.263 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 21.8 p -131.8 157.01 45.0 Favored 'General case' 0 C--N 1.325 -0.496 0 O-C-N 122.335 -0.228 . . . . 0.0 111.525 -177.629 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 114' ' ' LEU . . . . . 0.423 ' HA ' ' HB2' ' A' ' 107' ' ' SER . 96.4 mt -133.38 109.39 9.31 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 110.199 -0.297 . . . . 0.0 110.199 178.353 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . 0.464 ' H ' ' HB2' ' A' ' 107' ' ' SER . 93.3 m-20 -114.5 143.35 45.1 Favored 'General case' 0 C--O 1.252 1.207 0 CA-C-O 121.091 0.472 . . . . 0.0 111.018 -179.366 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 162.08 -135.11 3.74 Favored Glycine 0 N--CA 1.44 -1.043 0 CA-C-N 115.718 -0.674 . . . . 0.0 112.366 178.751 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 3.0 p -137.2 159.61 41.42 Favored 'General case' 0 C--N 1.311 -1.069 0 C-N-CA 122.629 0.372 . . . . 0.0 110.544 -179.241 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 23.2 ptm -146.3 160.29 42.21 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 116.501 -0.318 . . . . 0.0 110.614 -178.376 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 119' ' ' THR . . . . . 0.511 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 25.6 m -143.14 136.59 28.37 Favored 'General case' 0 C--O 1.253 1.242 0 CA-C-N 116.609 -0.269 . . . . 0.0 111.426 179.893 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . 0.415 ' HB2' ' HB3' ' A' ' 123' ' ' GLU . 52.5 m-85 -100.69 164.65 11.77 Favored 'General case' 0 CA--C 1.508 -0.639 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.223 177.418 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -63.46 130.19 43.36 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.058 176.66 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 63.03 27.41 70.39 Favored Glycine 0 CA--C 1.521 0.463 0 C-N-CA 121.118 -0.563 . . . . 0.0 113.117 -179.131 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . 0.415 ' HB3' ' HB2' ' A' ' 120' ' ' TYR . 9.9 tp10 -136.83 162.2 33.89 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -178.829 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -89.11 170.57 37.77 Favored Glycine 0 CA--C 1.522 0.479 0 C-N-CA 120.847 -0.692 . . . . 0.0 112.341 179.599 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -72.03 135.15 24.69 Favored 'Trans proline' 0 N--CA 1.46 -0.484 0 C-N-CA 122.369 2.046 . . . . 0.0 112.201 179.125 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 40.7 pt -130.83 161.56 40.56 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.269 179.673 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -72.42 134.91 21.62 Favored Glycine 0 C--O 1.238 0.391 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.119 -179.916 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 91.6 t80 -115.85 133.16 56.31 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.858 0.361 . . . . 0.0 110.99 -178.952 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 62.8 tttm -140.64 108.54 5.69 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 115.679 -0.691 . . . . 0.0 109.265 177.954 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -117.42 147.78 18.78 Favored Glycine 0 N--CA 1.44 -1.056 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.053 -179.35 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 5.4 t -137.16 142.84 42.2 Favored 'General case' 0 C--N 1.313 -1.002 0 CA-C-O 120.899 0.381 . . . . 0.0 111.231 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 63.2 tp -72.17 136.81 46.56 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.582 -0.736 . . . . 0.0 110.355 177.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 37.2 m . . . . . 0 C--N 1.307 -1.248 0 CA-C-O 118.802 -0.618 . . . . 0.0 110.407 -179.904 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.235 0.309 0 CA-C-O 120.655 0.264 . . . . 0.0 110.304 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' LEU . . . . . 0.559 HD21 HE21 ' A' ' 22' ' ' GLN . 9.2 tt -90.32 132.15 35.72 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-O 120.988 0.423 . . . . 0.0 110.197 179.593 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . 0.548 ' CD1' ' HB ' ' A' ' 25' ' ' ILE . 34.5 m-85 -116.43 137.97 51.73 Favored 'General case' 0 C--N 1.317 -0.841 0 CA-C-O 121.386 0.612 . . . . 0.0 111.32 -178.926 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' ASN . . . . . 0.561 ' HB2' ' OG1' ' A' ' 133' ' ' THR . 60.8 t30 -96.51 135.61 38.16 Favored 'General case' 0 C--N 1.305 -1.339 0 N-CA-C 107.176 -1.416 . . . . 0.0 107.176 177.226 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.438 ' O ' ' HA ' ' A' ' 19' ' ' GLU . 72.2 t -116.48 126.31 73.89 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 N-CA-C 113.176 0.806 . . . . 0.0 113.176 -172.419 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -118.71 137.42 53.35 Favored 'General case' 0 N--CA 1.439 -0.991 0 CA-C-N 114.479 -1.237 . . . . 0.0 107.962 175.911 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 13.4 m120 -128.79 151.64 49.35 Favored 'General case' 0 C--N 1.313 -1.007 0 N-CA-C 112.607 0.595 . . . . 0.0 112.607 -175.238 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 52.9 tt0 -122.33 110.33 15.53 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 107.527 -1.286 . . . . 0.0 107.527 175.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 40.2 p90 -134.47 4.91 3.43 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 114.556 1.317 . . . . 0.0 114.556 -172.875 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -119.32 18.99 10.08 Favored Glycine 0 N--CA 1.446 -0.65 0 C-N-CA 118.357 -1.878 . . . . 0.0 113.696 -176.11 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 152.02 -160.91 29.1 Favored Glycine 0 N--CA 1.446 -0.7 0 C-N-CA 119.541 -1.314 . . . . 0.0 112.907 179.097 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 36.6 p -102.5 -21.97 14.12 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-O 121.061 0.458 . . . . 0.0 110.462 -177.149 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 47.0 p -107.15 -1.3 22.07 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.607 -0.724 . . . . 0.0 110.423 -178.801 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -59.46 135.35 88.86 Favored Pre-proline 0 N--CA 1.453 -0.289 0 CA-C-N 115.616 -0.72 . . . . 0.0 111.068 -178.034 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -70.01 162.89 40.5 Favored 'Trans proline' 0 N--CA 1.459 -0.527 0 C-N-CA 122.653 2.235 . . . . 0.0 111.874 179.088 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 99.0 m95 -84.77 123.68 30.69 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 179.865 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 44.1 m-80 -118.68 128.46 54.54 Favored 'General case' 0 C--N 1.315 -0.898 0 N-CA-C 110.245 -0.28 . . . . 0.0 110.245 -178.869 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.438 ' HA ' ' O ' ' A' ' 6' ' ' VAL . 11.3 pt-20 -82.03 132.35 35.25 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 176.34 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -133.09 23.36 3.9 Favored Glycine 0 N--CA 1.438 -1.193 0 C-N-CA 120.028 -1.082 . . . . 0.0 112.114 -179.318 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 153.4 178.04 27.53 Favored Glycine 0 N--CA 1.439 -1.144 0 C-N-CA 120.644 -0.789 . . . . 0.0 111.969 -179.385 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . 0.559 HE21 HD21 ' A' ' 3' ' ' LEU . 4.1 pt20 -131.5 138.66 49.07 Favored 'General case' 0 C--N 1.313 -0.997 0 N-CA-C 110.012 -0.366 . . . . 0.0 110.012 -179.456 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 44.1 m0 -113.03 175.37 5.47 Favored 'General case' 0 CA--C 1.506 -0.74 0 CA-C-O 121.081 0.467 . . . . 0.0 110.693 -178.128 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 39.4 tt0 -129.68 115.15 16.91 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-N 116.098 -0.501 . . . . 0.0 109.812 178.062 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.548 ' HB ' ' CD1' ' A' ' 4' ' ' TYR . 93.8 mt -128.33 135.62 62.14 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.962 0 CA-C-N 115.574 -0.739 . . . . 0.0 109.561 -177.29 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 86.31 71.42 1.3 Allowed Glycine 0 N--CA 1.441 -1.01 0 C-N-CA 119.935 -1.126 . . . . 0.0 111.363 -179.781 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 32.1 t -59.79 -41.07 90.36 Favored 'General case' 0 C--N 1.318 -0.796 0 N-CA-C 109.526 -0.546 . . . . 0.0 109.526 179.413 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 97.1 mtt180 -99.35 133.54 43.5 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 176.064 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 2.4 p -86.22 2.37 47.29 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-O 121.011 0.434 . . . . 0.0 111.908 -177.832 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 -66.0 -34.28 77.73 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.407 178.74 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . 0.498 ' NE2' ' HA ' ' A' ' 31' ' ' GLN . 5.6 mm-40 -143.1 126.58 16.79 Favored 'General case' 0 CA--C 1.502 -0.871 0 N-CA-C 113.367 0.877 . . . . 0.0 113.367 -177.239 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . 0.461 ' HB3' ' HA3' ' A' ' 111' ' ' GLY . 95.9 m-20 -90.4 156.04 18.51 Favored 'General case' 0 N--CA 1.446 -0.639 0 CA-C-N 115.022 -0.99 . . . . 0.0 110.091 177.466 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 18.0 m -105.77 137.33 36.2 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.034 0 CA-C-N 115.727 -0.67 . . . . 0.0 112.672 -175.979 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 27.7 m -111.73 -20.59 6.13 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.2 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.908 177.535 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.628 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -145.21 144.83 31.05 Favored 'General case' 0 C--N 1.321 -0.663 0 C-N-CA 119.94 -0.704 . . . . 0.0 111.533 178.68 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 91.6 mt -144.33 126.88 10.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 N-CA-C 108.709 -0.848 . . . . 0.0 108.709 -179.535 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' ASN . . . . . 0.551 ' HA ' ' O ' ' A' ' 103' ' ' ILE . 3.3 t-20 -140.22 114.31 9.04 Favored 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 179.097 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.582 HG11 ' CD2' ' A' ' 61' ' ' PHE . 16.5 m -151.96 158.77 4.28 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.931 0 CA-C-O 120.807 0.337 . . . . 0.0 111.834 -173.743 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 66.2 tt0 -139.19 147.96 42.5 Favored 'General case' 0 N--CA 1.451 -0.392 0 CA-C-N 115.229 -0.896 . . . . 0.0 109.299 174.836 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . 0.426 ' OG ' ' HB ' ' A' ' 101' ' ' VAL . 95.2 p -82.31 166.05 19.84 Favored 'General case' 0 C--N 1.313 -0.984 0 CA-C-O 121.146 0.498 . . . . 0.0 111.911 -179.351 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -107.74 -52.41 0.71 Allowed Glycine 0 N--CA 1.442 -0.948 0 CA-C-N 115.528 -0.76 . . . . 0.0 111.344 175.1 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -131.14 102.12 5.87 Favored 'General case' 0 C--N 1.326 -0.431 0 C-N-CA 122.334 0.253 . . . . 0.0 111.262 -179.563 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 83.8 m-20 52.1 26.4 3.81 Favored 'General case' 0 N--CA 1.492 1.656 0 N-CA-C 113.732 1.012 . . . . 0.0 113.732 177.105 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 82.48 -6.5 68.57 Favored Glycine 0 C--N 1.312 -0.761 0 C-N-CA 120.333 -0.936 . . . . 0.0 113.396 178.184 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 28.3 mt-30 -64.95 -32.49 74.23 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 117.219 0.509 . . . . 0.0 110.842 -179.065 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 4.9 t -118.11 131.44 56.43 Favored 'General case' 0 C--N 1.307 -1.279 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 174.652 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' LEU . . . . . 0.432 ' HB2' ' HB3' ' A' ' 63' ' ' ALA . 91.7 mt -126.26 134.37 51.2 Favored 'General case' 0 C--N 1.316 -0.861 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 -177.756 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 20.7 p30 -143.89 147.43 34.01 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-O 121.207 0.527 . . . . 0.0 111.511 179.569 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 164.4 -142.49 7.83 Favored Glycine 0 N--CA 1.442 -0.934 0 N-CA-C 111.389 -0.684 . . . . 0.0 111.389 179.873 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 40.2 p -132.98 150.39 52.16 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-O 121.028 0.442 . . . . 0.0 111.846 -178.938 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 32.2 mtp -124.17 152.68 42.56 Favored 'General case' 0 C--N 1.326 -0.415 0 C-N-CA 123.341 0.656 . . . . 0.0 109.603 176.348 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.628 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 24.1 m -130.37 123.6 30.27 Favored 'General case' 0 C--O 1.25 1.081 0 C-N-CA 121.141 -0.224 . . . . 0.0 110.435 176.313 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . 0.456 ' HB2' ' HB2' ' A' ' 56' ' ' GLU . 71.8 m-85 -85.57 164.33 17.83 Favored 'General case' 0 C--O 1.232 0.173 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.43 178.712 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -67.22 101.88 0.97 Allowed 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.499 -179.996 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 97.06 -0.85 60.61 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.731 -0.747 . . . . 0.0 113.229 177.674 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . 0.456 ' HB2' ' HB2' ' A' ' 53' ' ' TYR . 79.9 mm-40 -111.19 179.77 3.95 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 117.024 0.412 . . . . 0.0 110.739 -179.982 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -95.75 168.16 26.16 Favored Glycine 0 N--CA 1.443 -0.868 0 C-N-CA 120.845 -0.693 . . . . 0.0 111.944 178.922 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 23.5 Cg_exo -64.45 139.77 66.36 Favored 'Trans proline' 0 C--O 1.238 0.523 0 C-N-CA 122.657 2.238 . . . . 0.0 112.301 179.002 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . 0.433 ' HB ' ' O ' ' A' ' 76' ' ' GLN . 48.9 pt -131.74 168.4 24.05 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 CA-C-N 115.801 -0.636 . . . . 0.0 109.918 179.0 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -79.95 148.31 30.02 Favored Glycine 0 C--N 1.32 -0.351 0 C-N-CA 120.874 -0.679 . . . . 0.0 111.645 -179.816 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.582 ' CD2' HG11 ' A' ' 38' ' ' VAL . 2.6 t80 -136.88 130.83 32.3 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-O 120.819 0.342 . . . . 0.0 111.18 -178.538 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 57.3 ttp180 -135.62 134.81 39.66 Favored 'General case' 0 C--O 1.232 0.142 0 CA-C-N 115.833 -0.621 . . . . 0.0 109.934 176.784 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.522 ' HB1' ' HB3' ' A' ' 71' ' ' TYR . . . -136.81 146.14 45.32 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 120.738 0.304 . . . . 0.0 111.484 179.797 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 65.0 m -125.27 131.25 53.13 Favored 'General case' 0 CA--C 1.537 0.461 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.055 178.952 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 61.1 tp -74.26 119.19 18.13 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.334 0.588 . . . . 0.0 112.311 -177.205 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 94.2 mt -90.1 -29.52 18.28 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.502 -0.772 . . . . 0.0 109.849 175.227 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 134.23 166.68 11.31 Favored Glycine 0 N--CA 1.447 -0.578 0 N-CA-C 110.962 -0.855 . . . . 0.0 110.962 -179.135 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 53.9 m-80 58.06 36.39 25.96 Favored 'General case' 0 N--CA 1.477 0.883 0 CA-C-N 117.21 0.505 . . . . 0.0 111.331 179.245 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 17.3 m120 63.59 14.08 7.8 Favored 'General case' 0 N--CA 1.479 0.987 0 CA-C-N 115.614 -0.721 . . . . 0.0 111.277 179.204 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 17.6 m -101.33 126.07 48.04 Favored 'General case' 0 C--O 1.239 0.552 0 CA-C-O 121.081 0.467 . . . . 0.0 111.156 -178.883 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.522 ' HB3' ' HB1' ' A' ' 63' ' ' ALA . 91.0 m-85 -114.52 141.98 47.01 Favored 'General case' 0 C--N 1.313 -0.997 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.494 -178.556 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . 0.429 ' O ' ' HA ' ' A' ' 63' ' ' ALA . 35.8 tt0 -90.39 120.16 31.28 Favored 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 108.35 -0.982 . . . . 0.0 108.35 175.574 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.492 HG13 ' CE1' ' A' ' 61' ' ' PHE . 54.2 t -103.67 132.83 49.19 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.013 0 N-CA-C 113.871 1.063 . . . . 0.0 113.871 -171.953 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 70.6 mt-10 -129.3 129.47 44.91 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 114.472 -1.24 . . . . 0.0 107.976 173.762 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 96.4 m-20 -109.12 145.48 35.63 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 121.279 0.562 . . . . 0.0 111.838 -177.781 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' GLN . . . . . 0.433 ' O ' ' HB ' ' A' ' 59' ' ' ILE . 10.4 tt0 -111.26 123.59 50.51 Favored 'General case' 0 C--N 1.316 -0.873 0 C-N-CA 124.032 0.933 . . . . 0.0 111.592 -177.125 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 10.0 p90 -140.27 155.61 46.79 Favored 'General case' 0 C--N 1.316 -0.89 0 N-CA-C 110.52 -0.178 . . . . 0.0 110.52 175.061 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 107.0 -9.71 39.92 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.852 -0.69 . . . . 0.0 112.279 -179.934 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 145.03 171.81 15.02 Favored Glycine 0 N--CA 1.447 -0.591 0 N-CA-C 111.581 -0.608 . . . . 0.0 111.581 178.912 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 1.8 p-10 -62.9 153.03 34.7 Favored 'General case' 0 C--O 1.241 0.609 0 CA-C-N 117.015 0.408 . . . . 0.0 110.31 178.081 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 16.3 m 65.42 -95.06 0.04 OUTLIER 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.717 -0.674 . . . . 0.0 109.497 -178.33 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 50.23 172.48 0.03 OUTLIER Pre-proline 0 CA--C 1.555 1.158 0 N-CA-C 113.533 0.938 . . . . 0.0 113.533 176.519 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_exo -69.91 144.97 54.87 Favored 'Trans proline' 0 N--CA 1.45 -1.062 0 C-N-CA 121.722 1.614 . . . . 0.0 110.161 172.255 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' TRP . . . . . . . . . . . . . 92.7 m95 -90.88 139.34 30.84 Favored 'General case' 0 C--N 1.313 -0.983 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 178.757 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 84.8 m-70 -111.5 138.63 47.77 Favored 'General case' 0 C--N 1.313 -1.005 0 N-CA-C 108.936 -0.764 . . . . 0.0 108.936 -178.822 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 10.5 m -66.85 135.62 54.17 Favored 'General case' 0 C--N 1.314 -0.957 0 CA-C-O 120.675 0.274 . . . . 0.0 110.922 -177.324 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -110.01 -44.59 1.01 Allowed Glycine 0 N--CA 1.443 -0.838 0 C-N-CA 120.832 -0.699 . . . . 0.0 111.742 179.376 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 143.74 -158.7 27.44 Favored Glycine 0 C--O 1.214 -1.151 0 C-N-CA 120.723 -0.751 . . . . 0.0 111.473 178.681 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 19.1 m120 -115.33 129.25 56.55 Favored 'General case' 0 C--N 1.315 -0.918 0 CA-C-N 117.303 0.551 . . . . 0.0 110.88 179.278 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 23.3 m0 -118.96 150.73 39.42 Favored 'General case' 0 N--CA 1.466 0.335 0 N-CA-C 109.981 -0.377 . . . . 0.0 109.981 179.777 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 92.1 mt -109.63 123.08 65.23 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 177.76 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 83.6 mt -134.3 84.85 2.14 Favored 'General case' 0 C--O 1.265 1.871 0 O-C-N 123.688 0.617 . . . . 0.0 112.473 -175.85 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 168.13 110.36 0.23 Allowed Glycine 0 C--O 1.218 -0.903 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.688 178.003 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 68.3 p -100.78 -9.43 21.73 Favored 'General case' 0 C--O 1.225 -0.232 0 CA-C-O 120.984 0.421 . . . . 0.0 111.116 178.379 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 92.2 mtt180 -96.69 3.79 52.23 Favored 'General case' 0 C--O 1.232 0.162 0 C-N-CA 120.574 -0.45 . . . . 0.0 111.921 179.32 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 66.6 tt0 72.83 -83.13 0.03 OUTLIER 'General case' 0 N--CA 1.467 0.401 0 C-N-CA 123.22 0.608 . . . . 0.0 112.377 173.067 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 63.4 m-80 -92.34 34.15 1.06 Allowed 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 120.831 0.348 . . . . 0.0 111.612 -174.802 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' GLN . . . . . . . . . . . . . 23.6 tp60 -120.08 -48.11 2.35 Favored 'General case' 0 C--N 1.316 -0.875 0 C-N-CA 120.59 -0.444 . . . . 0.0 110.284 -178.945 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 93.4 m-20 72.62 137.84 0.05 Allowed 'General case' 0 N--CA 1.485 1.308 0 O-C-N 123.735 0.647 . . . . 0.0 112.284 178.499 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 69.9 t -78.43 132.4 32.44 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.33 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.871 178.861 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . 0.426 ' HB ' ' OG ' ' A' ' 40' ' ' SER . 34.4 m -113.04 -27.64 2.68 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.517 0 N-CA-C 112.555 0.576 . . . . 0.0 112.555 -179.506 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . 0.56 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -146.82 144.45 29.35 Favored 'General case' 0 C--N 1.322 -0.619 0 C-N-CA 119.96 -0.696 . . . . 0.0 111.546 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.551 ' O ' ' HA ' ' A' ' 37' ' ' ASN . 34.1 mm -133.98 128.05 52.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.62 179.193 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . 0.43 ' HB3' ' OG1' ' A' ' 117' ' ' THR . 43.4 t30 -131.27 92.08 3.13 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.292 175.714 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 29.4 m -138.12 144.26 31.11 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.566 0 N-CA-C 113.017 0.747 . . . . 0.0 113.017 -175.451 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 79.9 tt0 -148.19 101.39 3.26 Favored 'General case' 0 CA--C 1.538 0.501 0 CA-C-N 115.558 -0.746 . . . . 0.0 110.656 176.832 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . 0.418 ' HB2' ' H ' ' A' ' 115' ' ' ASN . 69.5 m -166.69 165.82 16.27 Favored 'General case' 0 N--CA 1.475 0.821 0 CA-C-N 114.834 -1.075 . . . . 0.0 112.388 -178.909 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 116.41 117.19 2.98 Favored Glycine 0 N--CA 1.424 -2.156 0 C-N-CA 120.344 -0.932 . . . . 0.0 113.241 175.308 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 -67.38 -42.44 83.39 Favored 'General case' 0 C--N 1.319 -0.757 0 N-CA-C 107.997 -1.112 . . . . 0.0 107.997 175.639 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 30.3 t70 -142.38 33.43 1.48 Allowed 'General case' 0 C--O 1.213 -0.85 0 CA-C-N 114.428 -1.26 . . . . 0.0 108.228 175.432 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . 0.461 ' HA3' ' HB3' ' A' ' 32' ' ' ASN . . . 81.82 18.05 68.82 Favored Glycine 0 CA--C 1.523 0.538 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.656 -178.335 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 112' ' ' GLN . . . . . 0.446 ' HA ' ' CD1' ' A' ' 132' ' ' LEU . 98.1 mt-30 -66.66 -40.64 88.7 Favored 'General case' 0 C--O 1.244 0.794 0 CA-C-O 120.975 0.417 . . . . 0.0 111.71 -179.177 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 25.6 p -139.15 143.37 38.15 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.824 -0.626 . . . . 0.0 110.755 -178.391 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -119.4 123.35 43.89 Favored 'General case' 0 C--N 1.317 -0.814 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 176.539 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . 0.418 ' H ' ' HB2' ' A' ' 107' ' ' SER . 53.6 m-80 -128.66 149.6 50.6 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-O 120.851 0.358 . . . . 0.0 110.587 -178.503 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 155.48 -131.34 3.05 Favored Glycine 0 N--CA 1.438 -1.175 0 C-N-CA 120.634 -0.793 . . . . 0.0 112.343 177.971 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . 0.43 ' OG1' ' HB3' ' A' ' 104' ' ' ASN . 23.9 p -130.25 155.37 46.39 Favored 'General case' 0 C--N 1.311 -1.089 0 CA-C-O 121.015 0.436 . . . . 0.0 110.848 -178.459 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 23.2 ptm -146.2 153.34 40.52 Favored 'General case' 0 C--N 1.313 -0.991 0 CA-C-N 115.949 -0.569 . . . . 0.0 109.67 -178.809 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 119' ' ' THR . . . . . 0.56 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 26.0 m -132.99 131.34 40.64 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-O 120.642 0.258 . . . . 0.0 111.422 -179.294 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 33.0 m-85 -95.75 163.49 13.15 Favored 'General case' 0 CA--C 1.509 -0.611 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.394 175.992 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -62.75 128.59 36.64 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.588 178.155 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 70.95 15.58 74.18 Favored Glycine 0 CA--C 1.524 0.596 0 CA-C-N 115.895 -0.593 . . . . 0.0 113.257 179.44 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -127.03 179.82 5.22 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 117.149 0.474 . . . . 0.0 111.335 -179.46 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -105.55 170.09 16.91 Favored Glycine 0 N--CA 1.445 -0.754 0 N-CA-C 111.502 -0.639 . . . . 0.0 111.502 178.533 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 22.9 Cg_exo -65.37 135.39 42.61 Favored 'Trans proline' 0 CA--C 1.534 0.511 0 C-N-CA 122.542 2.161 . . . . 0.0 112.375 -179.812 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 48.0 pt -131.21 165.09 32.49 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 116.06 -0.518 . . . . 0.0 109.941 177.931 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -73.76 132.78 16.25 Favored Glycine 0 CA--C 1.521 0.464 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.751 -179.169 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 91.6 t80 -114.8 132.96 56.3 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 120.634 0.254 . . . . 0.0 111.224 -179.526 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 63.0 tttm -137.49 101.83 4.61 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.029 176.927 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -106.37 133.51 11.66 Favored Glycine 0 N--CA 1.446 -0.645 0 C-N-CA 120.977 -0.63 . . . . 0.0 111.617 179.485 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 49.1 m -130.24 137.55 50.08 Favored 'General case' 0 C--N 1.311 -1.072 0 CA-C-N 116.638 0.219 . . . . 0.0 111.191 -179.334 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 132' ' ' LEU . . . . . 0.446 ' CD1' ' HA ' ' A' ' 112' ' ' GLN . 87.9 mt -57.7 134.93 56.64 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-O 120.858 0.361 . . . . 0.0 110.31 176.781 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 133' ' ' THR . . . . . 0.561 ' OG1' ' HB2' ' A' ' 5' ' ' ASN . 57.5 m . . . . . 0 C--O 1.251 1.182 0 CA-C-O 118.643 -0.694 . . . . 0.0 110.539 -179.086 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.692 0 N-CA-C 110.373 -0.232 . . . . 0.0 110.373 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' LEU . . . . . 0.61 HD11 HE21 ' A' ' 22' ' ' GLN . 2.8 tm? -99.85 131.41 45.85 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.357 -177.663 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . 0.607 ' CE1' ' HB ' ' A' ' 25' ' ' ILE . 85.1 m-85 -121.41 145.11 48.25 Favored 'General case' 0 C--O 1.238 0.476 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.866 -179.215 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 14.9 m120 -82.67 142.23 31.85 Favored 'General case' 0 N--CA 1.468 0.436 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 176.991 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.46 HG21 ' CD1' ' A' ' 23' ' ' TRP . 59.0 t -116.09 126.76 73.72 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 N-CA-C 113.464 0.913 . . . . 0.0 113.464 -176.159 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 92.0 mt-10 -128.09 132.43 49.01 Favored 'General case' 0 N--CA 1.445 -0.683 0 CA-C-N 114.634 -1.167 . . . . 0.0 108.088 175.001 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 12.8 m120 -124.59 145.74 49.43 Favored 'General case' 0 C--N 1.313 -0.986 0 CA-C-O 120.645 0.259 . . . . 0.0 110.696 -178.158 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 52.0 tt0 -119.65 118.24 30.43 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.808 0.337 . . . . 0.0 110.464 179.071 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' TRP . . . . . 0.507 ' CZ3' ' HB2' ' A' ' 18' ' ' ASN . 2.5 m-90 -79.2 140.79 37.6 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.332 179.711 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 89.33 -42.21 3.02 Favored Glycine 0 N--CA 1.444 -0.811 0 C-N-CA 120.579 -0.82 . . . . 0.0 112.05 -179.085 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.84 21.42 71.51 Favored Glycine 0 C--O 1.227 -0.327 0 C-N-CA 120.85 -0.691 . . . . 0.0 111.581 -179.707 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 20.9 p -168.2 133.82 1.86 Allowed 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.771 -0.214 . . . . 0.0 111.188 -178.024 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 63.6 p 46.85 44.73 14.66 Favored 'General case' 0 N--CA 1.475 0.824 0 C-N-CA 123.456 0.702 . . . . 0.0 112.638 176.79 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . 0.467 ' HA ' ' HD3' ' A' ' 16' ' ' PRO . . . -139.6 144.32 38.9 Favored Pre-proline 0 C--N 1.324 -0.517 0 C-N-CA 120.905 -0.318 . . . . 0.0 111.425 -178.158 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.467 ' HD3' ' HA ' ' A' ' 15' ' ' ALA . 11.4 Cg_exo -71.57 157.45 55.98 Favored 'Trans proline' 0 C--N 1.347 0.483 0 C-N-CA 123.033 2.489 . . . . 0.0 111.699 176.888 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 91.5 m95 -85.26 134.15 34.14 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 120.891 0.377 . . . . 0.0 110.343 179.57 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' ASN . . . . . 0.507 ' HB2' ' CZ3' ' A' ' 10' ' ' TRP . 90.7 m-20 -110.01 135.67 50.47 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.105 179.231 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 14.7 pt-20 -105.44 131.2 53.15 Favored 'General case' 0 C--N 1.314 -0.95 0 N-CA-C 109.241 -0.652 . . . . 0.0 109.241 -179.828 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -157.33 34.26 0.55 Allowed Glycine 0 N--CA 1.44 -1.045 0 C-N-CA 119.058 -1.544 . . . . 0.0 112.997 179.843 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 162.67 -179.02 38.21 Favored Glycine 0 N--CA 1.444 -0.777 0 C-N-CA 119.58 -1.295 . . . . 0.0 113.511 178.847 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . 0.61 HE21 HD11 ' A' ' 3' ' ' LEU . 3.3 pt20 -145.29 140.66 27.94 Favored 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 179.218 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . 0.46 ' CD1' HG21 ' A' ' 6' ' ' VAL . 48.0 m0 -114.74 155.97 25.7 Favored 'General case' 0 CA--C 1.505 -0.761 0 CA-C-O 120.715 0.293 . . . . 0.0 111.443 -176.213 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 77.8 tt0 -116.6 119.52 35.79 Favored 'General case' 0 C--N 1.321 -0.633 0 C-N-CA 120.445 -0.502 . . . . 0.0 110.221 177.881 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.607 ' HB ' ' CE1' ' A' ' 4' ' ' TYR . 97.7 mt -135.32 143.37 37.12 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.72 0 CA-C-N 114.998 -1.001 . . . . 0.0 109.464 -177.681 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 84.0 60.61 1.93 Allowed Glycine 0 C--O 1.225 -0.437 0 C-N-CA 120.18 -1.01 . . . . 0.0 112.398 178.629 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 15.4 m -58.15 -40.4 81.26 Favored 'General case' 0 C--N 1.317 -0.838 0 O-C-N 123.935 0.432 . . . . 0.0 111.618 179.759 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 79.9 ttt180 -61.29 -42.27 98.37 Favored 'General case' 0 CA--C 1.538 0.518 0 CA-C-N 116.588 -0.278 . . . . 0.0 111.558 178.803 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 20.1 m 75.99 -21.98 0.29 Allowed 'General case' 0 N--CA 1.482 1.17 0 C-N-CA 123.75 0.82 . . . . 0.0 113.201 179.073 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 58.3 m-20 -68.23 -11.71 59.77 Favored 'General case' 0 N--CA 1.483 1.189 0 CA-C-O 121.06 0.457 . . . . 0.0 111.414 178.243 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -152.71 136.09 15.87 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.133 -178.963 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . 0.564 ' ND2' ' HA3' ' A' ' 111' ' ' GLY . 2.5 t30 -93.45 150.81 20.16 Favored 'General case' 0 C--O 1.247 0.967 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.247 178.984 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 46.3 t -93.98 131.33 41.2 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 CA-C-N 115.697 -0.683 . . . . 0.0 109.62 -178.399 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 28.1 m -102.75 -32.43 3.11 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.686 0 C-N-CA 120.596 -0.442 . . . . 0.0 111.835 -179.595 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.641 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -135.01 145.19 47.83 Favored 'General case' 0 CA--C 1.511 -0.537 0 C-N-CA 120.349 -0.54 . . . . 0.0 111.28 -179.201 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 93.9 mt -142.33 122.54 10.72 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 CA-C-N 115.744 -0.662 . . . . 0.0 109.553 -179.543 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 19.7 m120 -130.74 112.58 13.21 Favored 'General case' 0 C--N 1.316 -0.851 0 N-CA-C 108.246 -1.02 . . . . 0.0 108.246 176.07 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.489 HG22 ' HB ' ' A' ' 103' ' ' ILE . 27.3 m -147.41 150.57 14.49 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 C-N-CA 120.665 -0.414 . . . . 0.0 111.208 -175.146 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 74.6 tt0 -142.73 145.1 33.01 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 108.955 -0.758 . . . . 0.0 108.955 176.031 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . 0.412 ' HA ' ' O ' ' A' ' 46' ' ' THR . 34.2 p -80.55 148.95 30.14 Favored 'General case' 0 C--N 1.312 -1.024 0 N-CA-C 112.203 0.446 . . . . 0.0 112.203 -176.327 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -95.06 -19.95 29.48 Favored Glycine 0 N--CA 1.449 -0.476 0 N-CA-C 111.012 -0.835 . . . . 0.0 111.012 176.831 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 15.7 m-20 -128.72 -156.56 0.76 Allowed 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 109.45 -0.574 . . . . 0.0 109.45 179.071 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 9.9 p-10 -77.23 46.89 0.52 Allowed 'General case' 0 N--CA 1.474 0.775 0 CA-C-O 121.314 0.578 . . . . 0.0 112.065 -179.11 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 88.22 -7.79 80.46 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 121.047 -0.597 . . . . 0.0 113.176 178.441 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 53.5 mt-30 -72.58 -34.83 67.71 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.964 0.382 . . . . 0.0 111.498 178.906 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . 0.412 ' O ' ' HA ' ' A' ' 40' ' ' SER . 24.5 p -115.02 132.01 56.74 Favored 'General case' 0 C--N 1.314 -0.975 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.535 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' LEU . . . . . 0.513 ' HB2' ' HB3' ' A' ' 63' ' ' ALA . 93.8 mt -124.3 127.97 48.44 Favored 'General case' 0 CA--C 1.509 -0.607 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 -179.475 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 9.0 m120 -129.39 137.05 50.7 Favored 'General case' 0 C--N 1.313 -1.011 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 -179.696 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . 0.435 ' HA3' ' HA ' ' A' ' 38' ' ' VAL . . . 178.18 -157.22 21.1 Favored Glycine 0 N--CA 1.445 -0.72 0 C-N-CA 119.287 -1.435 . . . . 0.0 113.795 179.275 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 38.3 m -130.0 134.35 47.37 Favored 'General case' 0 CA--C 1.545 0.756 0 C-N-CA 123.087 0.555 . . . . 0.0 110.905 -178.562 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 48.0 mtp -110.2 155.32 22.14 Favored 'General case' 0 N--CA 1.468 0.459 0 C-N-CA 122.308 0.243 . . . . 0.0 110.815 177.151 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.641 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 25.5 m -133.78 126.29 30.3 Favored 'General case' 0 CA--C 1.542 0.641 0 CA-C-N 116.491 -0.322 . . . . 0.0 110.167 175.322 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . 0.483 ' HB2' ' HB2' ' A' ' 56' ' ' GLU . 65.5 m-85 -92.94 166.97 12.12 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 116.664 -0.244 . . . . 0.0 110.769 177.964 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -63.34 106.48 0.91 Allowed 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.473 -179.754 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 81.78 16.03 73.9 Favored Glycine 0 CA--C 1.52 0.358 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.788 178.857 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . 0.483 ' HB2' ' HB2' ' A' ' 53' ' ' TYR . 80.3 mm-40 -119.99 169.62 10.02 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 120.773 0.32 . . . . 0.0 110.807 -179.93 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -90.05 172.56 38.55 Favored Glycine 0 N--CA 1.444 -0.813 0 C-N-CA 120.99 -0.624 . . . . 0.0 112.303 179.925 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_exo -67.14 137.56 44.47 Favored 'Trans proline' 0 CA--C 1.535 0.56 0 C-N-CA 122.726 2.284 . . . . 0.0 112.026 179.16 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . 0.414 HD12 ' HB3' ' A' ' 75' ' ' ASN . 45.0 pt -128.79 160.86 38.91 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.428 179.195 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -75.1 141.61 28.3 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.451 -178.919 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 61.8 t80 -126.01 127.04 45.27 Favored 'General case' 0 C--N 1.32 -0.712 0 C-N-CA 122.401 0.28 . . . . 0.0 110.797 -179.792 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 29.3 ttp85 -136.97 129.04 29.44 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 175.801 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.545 ' HB1' ' HB3' ' A' ' 71' ' ' TYR . . . -136.88 146.4 45.51 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 112.304 0.483 . . . . 0.0 112.304 -177.622 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 55.9 m -122.7 128.18 50.23 Favored 'General case' 0 CA--C 1.542 0.668 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.222 178.303 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 2.3 tm? -73.47 121.52 20.68 Favored 'General case' 0 CA--C 1.538 0.493 0 CA-C-O 121.134 0.492 . . . . 0.0 111.054 -178.058 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 96.0 mt -75.04 -33.94 61.81 Favored 'General case' 0 CA--C 1.534 0.354 0 CA-C-N 115.638 -0.71 . . . . 0.0 111.907 179.799 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 126.12 -14.84 6.96 Favored Glycine 0 C--O 1.219 -0.812 0 C-N-CA 120.574 -0.822 . . . . 0.0 112.476 -178.262 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 28.9 p-10 -111.75 30.23 7.17 Favored 'General case' 0 C--N 1.316 -0.856 0 CA-C-O 120.824 0.345 . . . . 0.0 110.736 -179.078 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 96.1 m-20 69.03 6.47 5.66 Favored 'General case' 0 N--CA 1.483 1.187 0 C-N-CA 123.6 0.76 . . . . 0.0 111.499 -177.25 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 35.0 t -102.46 140.35 36.86 Favored 'General case' 0 N--CA 1.438 -1.069 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 177.178 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.545 ' HB3' ' HB1' ' A' ' 63' ' ' ALA . 66.8 m-85 -116.91 139.72 50.31 Favored 'General case' 0 C--N 1.303 -1.42 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.936 -178.296 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 39.5 tt0 -85.29 112.3 20.66 Favored 'General case' 0 C--N 1.309 -1.16 0 N-CA-C 106.759 -1.571 . . . . 0.0 106.759 173.673 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.521 HG22 ' HB2' ' A' ' 63' ' ' ALA . 70.5 t -109.41 135.83 47.17 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 N-CA-C 113.475 0.917 . . . . 0.0 113.475 -171.141 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -128.54 130.48 47.48 Favored 'General case' 0 N--CA 1.443 -0.811 0 CA-C-N 114.708 -1.133 . . . . 0.0 108.917 175.281 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' ASN . . . . . 0.414 ' HB3' HD12 ' A' ' 59' ' ' ILE . 95.9 m-20 -108.9 150.11 28.17 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.748 -179.286 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' GLN . . . . . 0.41 ' HB2' ' CE3' ' A' ' 84' ' ' TRP . 61.3 tt0 -115.49 120.36 39.24 Favored 'General case' 0 C--N 1.308 -1.232 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.435 -177.534 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 8.6 p90 -142.87 162.85 34.37 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 110.24 -0.281 . . . . 0.0 110.24 179.544 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 100.91 -9.02 58.07 Favored Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.768 -0.729 . . . . 0.0 111.97 179.781 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 137.59 159.61 8.26 Favored Glycine 0 N--CA 1.442 -0.917 0 N-CA-C 111.019 -0.832 . . . . 0.0 111.019 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 5.9 m-20 -60.41 -39.59 87.93 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 116.963 0.382 . . . . 0.0 111.687 -179.319 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 4.6 m -76.57 -4.93 45.42 Favored 'General case' 0 C--N 1.321 -0.671 0 N-CA-C 112.251 0.463 . . . . 0.0 112.251 -177.476 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -75.46 153.16 85.76 Favored Pre-proline 0 C--N 1.324 -0.538 0 CA-C-O 120.587 0.232 . . . . 0.0 111.196 -178.422 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 10.7 Cg_exo -72.34 178.48 6.06 Favored 'Trans proline' 0 C--N 1.35 0.642 0 C-N-CA 122.925 2.417 . . . . 0.0 112.017 178.646 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' TRP . . . . . 0.41 ' CE3' ' HB2' ' A' ' 76' ' ' GLN . 90.9 m95 -92.14 138.17 31.75 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 109.322 -0.622 . . . . 0.0 109.322 179.722 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 82.8 m-70 -112.59 144.61 41.79 Favored 'General case' 0 C--N 1.318 -0.791 0 N-CA-C 109.992 -0.373 . . . . 0.0 109.992 -177.685 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 19.5 p -64.36 116.4 6.03 Favored 'General case' 0 C--N 1.316 -0.89 0 CA-C-O 120.781 0.324 . . . . 0.0 111.457 -178.376 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -89.63 -46.41 4.3 Favored Glycine 0 N--CA 1.44 -1.088 0 C-N-CA 120.388 -0.911 . . . . 0.0 111.018 178.008 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 139.87 -157.86 25.48 Favored Glycine 0 N--CA 1.442 -0.909 0 C-N-CA 120.816 -0.707 . . . . 0.0 111.629 177.471 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 19.8 m120 -105.48 134.19 49.0 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 109.697 -0.483 . . . . 0.0 109.697 178.974 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 90' ' ' TRP . . . . . 0.489 ' CH2' HG23 ' A' ' 25' ' ' ILE . 13.8 m0 -124.04 146.13 48.77 Favored 'General case' 0 C--N 1.316 -0.862 0 CA-C-N 116.203 -0.453 . . . . 0.0 109.84 -178.548 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 91.6 mt -110.57 114.63 47.6 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.285 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 177.456 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . 0.483 ' HB3' HG21 ' A' ' 100' ' ' VAL . 85.5 mt -133.56 79.98 1.85 Allowed 'General case' 0 C--O 1.269 2.113 0 CA-C-O 121.771 0.796 . . . . 0.0 112.312 -175.724 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 170.0 109.51 0.22 Allowed Glycine 0 N--CA 1.442 -0.966 0 CA-C-N 115.344 -0.844 . . . . 0.0 111.768 -179.498 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 19.1 m -96.67 30.27 2.68 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-O 120.902 0.382 . . . . 0.0 110.349 -179.882 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 95' ' ' ARG . . . . . 0.556 ' CB ' ' HB3' ' A' ' 98' ' ' GLN . 9.7 mmt180 -136.56 150.54 48.65 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-O 121.257 0.551 . . . . 0.0 112.317 -176.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 79.3 tt0 -55.99 -51.27 68.33 Favored 'General case' 0 CA--C 1.541 0.601 0 CA-C-N 114.731 -1.122 . . . . 0.0 112.602 -176.961 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 57.5 m-80 -134.63 42.69 2.81 Favored 'General case' 0 N--CA 1.471 0.609 0 CA-C-O 120.965 0.412 . . . . 0.0 109.99 -179.928 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' GLN . . . . . 0.606 ' NE2' ' HB2' ' A' ' 123' ' ' GLU . 52.8 tt0 -144.37 110.39 5.41 Favored 'General case' 0 C--N 1.315 -0.919 0 CA-C-O 121.147 0.499 . . . . 0.0 110.614 -175.952 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 99' ' ' ASN . . . . . 0.445 ' HB3' ' OH ' ' A' ' 71' ' ' TYR . 87.7 m-20 -91.06 168.37 11.69 Favored 'General case' 0 C--O 1.244 0.782 0 CA-C-N 115.293 -0.867 . . . . 0.0 111.111 -175.73 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.483 HG21 ' HB3' ' A' ' 92' ' ' LEU . 23.6 m -83.01 140.53 16.19 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.673 0 C-N-CA 120.011 -0.676 . . . . 0.0 110.244 173.443 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 29.7 m -115.55 -27.45 2.56 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.429 0 C-N-CA 120.608 -0.437 . . . . 0.0 112.062 178.14 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . 0.448 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -147.87 142.06 26.12 Favored 'General case' 0 C--N 1.32 -0.677 0 C-N-CA 120.581 -0.447 . . . . 0.0 110.551 178.352 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.489 ' HB ' HG22 ' A' ' 38' ' ' VAL . 94.9 mt -138.4 125.75 27.83 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 N-CA-C 110.106 -0.331 . . . . 0.0 110.106 178.26 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 35.2 t30 -128.06 97.8 4.91 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.367 176.589 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.653 HG11 ' HD2' ' A' ' 128' ' ' PHE . 11.7 m -142.6 149.7 18.85 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 N-CA-C 113.185 0.809 . . . . 0.0 113.185 -176.454 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 41.9 tt0 -148.15 147.19 29.18 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.089 -0.959 . . . . 0.0 109.839 175.621 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 47.1 t -113.23 133.59 55.01 Favored 'General case' 0 N--CA 1.442 -0.874 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.355 -177.994 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -81.52 -5.07 90.22 Favored Glycine 0 N--CA 1.447 -0.568 0 N-CA-C 111.103 -0.799 . . . . 0.0 111.103 175.444 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 62.8 m-20 -114.06 -166.46 1.1 Allowed 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 109.362 -0.607 . . . . 0.0 109.362 -179.95 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 25.6 m-20 -77.68 34.97 0.18 Allowed 'General case' 0 N--CA 1.472 0.66 0 CA-C-O 120.847 0.356 . . . . 0.0 111.123 178.931 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . 0.564 ' HA3' ' ND2' ' A' ' 32' ' ' ASN . . . 81.43 8.24 87.32 Favored Glycine 0 N--CA 1.445 -0.74 0 C-N-CA 120.888 -0.672 . . . . 0.0 112.405 -178.852 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 97.3 mt-30 -66.04 -44.22 85.26 Favored 'General case' 0 C--O 1.243 0.713 0 CA-C-O 121.056 0.455 . . . . 0.0 109.995 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 22.5 p -113.12 117.61 32.44 Favored 'General case' 0 N--CA 1.441 -0.888 0 CA-C-N 115.374 -0.83 . . . . 0.0 109.259 177.548 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 34.8 tp -111.84 121.88 46.25 Favored 'General case' 0 C--N 1.311 -1.08 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 -178.957 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 26.3 p30 -145.57 164.82 30.49 Favored 'General case' 0 C--O 1.251 1.134 0 C-N-CA 120.039 -0.664 . . . . 0.0 112.677 -178.609 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 149.75 -127.78 2.53 Favored Glycine 0 N--CA 1.439 -1.12 0 CA-C-N 114.655 -1.157 . . . . 0.0 111.127 -179.636 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 31.9 p -134.0 159.75 39.82 Favored 'General case' 0 C--N 1.314 -0.96 0 CA-C-O 120.851 0.358 . . . . 0.0 111.063 -178.9 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 4.2 ppp? -157.28 161.93 39.17 Favored 'General case' 0 C--N 1.313 -1.004 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 179.154 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 119' ' ' THR . . . . . 0.448 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 48.7 m -133.39 126.3 30.99 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-N 116.46 -0.336 . . . . 0.0 110.978 -179.894 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . 0.49 ' CB ' HE21 ' A' ' 98' ' ' GLN . 64.9 m-85 -88.13 162.98 16.43 Favored 'General case' 0 CA--C 1.521 -0.147 0 CA-C-N 116.196 -0.456 . . . . 0.0 109.789 174.285 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -55.76 -30.59 61.5 Favored 'General case' 0 N--CA 1.47 0.553 0 N-CA-C 113.602 0.964 . . . . 0.0 113.602 -176.627 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -140.65 26.62 2.52 Favored Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 119.636 -1.269 . . . . 0.0 112.67 -178.434 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . 0.606 ' HB2' ' NE2' ' A' ' 98' ' ' GLN . 23.5 tp10 -112.6 -50.71 2.88 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.988 0.423 . . . . 0.0 110.461 -177.578 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 116.5 -179.76 17.76 Favored Glycine 0 N--CA 1.441 -0.986 0 N-CA-C 111.122 -0.791 . . . . 0.0 111.122 -177.639 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 7.4 Cg_exo -73.81 112.8 3.62 Favored 'Trans proline' 0 N--CA 1.461 -0.392 0 C-N-CA 122.735 2.29 . . . . 0.0 112.021 179.651 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 39.2 pt -129.84 162.92 36.58 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.862 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.517 179.734 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -72.84 144.41 35.1 Favored Glycine 0 N--CA 1.448 -0.517 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.728 -179.496 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . 0.653 ' HD2' HG11 ' A' ' 105' ' ' VAL . 21.1 t80 -125.59 132.63 52.49 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 121.162 0.506 . . . . 0.0 110.732 178.733 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 62.6 tttm -137.42 123.46 20.3 Favored 'General case' 0 C--N 1.311 -1.073 0 CA-C-N 115.0 -1.0 . . . . 0.0 108.93 -179.829 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -139.23 141.72 12.1 Favored Glycine 0 N--CA 1.436 -1.302 0 C-N-CA 120.363 -0.922 . . . . 0.0 112.725 -179.335 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 35.3 m -121.35 133.11 55.1 Favored 'General case' 0 C--N 1.311 -1.107 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.355 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 60.2 tp -66.85 139.89 57.78 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 109.754 -0.462 . . . . 0.0 109.754 178.492 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 133' ' ' THR . . . . . 0.455 HG22 ' O ' ' A' ' 3' ' ' LEU . 13.4 t . . . . . 0 C--O 1.253 1.251 0 CA-C-O 118.53 -0.748 . . . . 0.0 110.251 -179.117 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.737 0 CA-C-O 120.668 0.271 . . . . 0.0 110.42 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' LEU . . . . . 0.508 HD11 HE21 ' A' ' 22' ' ' GLN . 1.7 tm? -95.16 129.89 42.09 Favored 'General case' 0 C--N 1.319 -0.739 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 178.598 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . 0.45 ' N ' HD13 ' A' ' 3' ' ' LEU . 78.8 m-85 -120.53 145.85 46.89 Favored 'General case' 0 C--O 1.24 0.597 0 CA-C-O 121.081 0.467 . . . . 0.0 112.158 -176.842 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' ASN . . . . . 0.627 ' O ' ' HA2' ' A' ' 130' ' ' GLY . 21.6 m120 -87.46 140.46 29.51 Favored 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 107.186 -1.413 . . . . 0.0 107.186 175.274 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.49 HG21 ' CD1' ' A' ' 23' ' ' TRP . 70.1 t -114.64 128.41 71.73 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 N-CA-C 113.641 0.978 . . . . 0.0 113.641 -174.274 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.436 ' HB2' ' HB3' ' A' ' 129' ' ' LYS . 99.7 mt-10 -125.44 134.09 52.22 Favored 'General case' 0 N--CA 1.444 -0.759 0 CA-C-N 114.517 -1.219 . . . . 0.0 109.098 175.358 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 12.9 m120 -121.4 140.54 52.01 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-N 116.462 -0.336 . . . . 0.0 110.601 -178.929 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 60.8 tt0 -120.02 120.02 35.1 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.676 -178.972 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 19.6 p90 -135.72 143.18 45.21 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 110.131 -0.322 . . . . 0.0 110.131 178.708 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 106.83 8.53 31.93 Favored Glycine 0 N--CA 1.446 -0.646 0 C-N-CA 120.29 -0.957 . . . . 0.0 111.497 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 103.08 164.71 25.76 Favored Glycine 0 N--CA 1.442 -0.958 0 C-N-CA 121.344 -0.455 . . . . 0.0 112.281 178.502 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 68.8 m -59.07 -23.47 62.07 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 120.836 0.35 . . . . 0.0 111.722 178.766 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 38.8 m -73.52 -6.61 47.56 Favored 'General case' 0 CA--C 1.543 0.696 0 CA-C-O 120.7 0.286 . . . . 0.0 111.596 177.921 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . 0.457 ' HA ' ' HD3' ' A' ' 16' ' ' PRO . . . -95.07 145.56 29.75 Favored Pre-proline 0 C--N 1.328 -0.355 0 O-C-N 122.421 -0.174 . . . . 0.0 110.881 -179.814 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.457 ' HD3' ' HA ' ' A' ' 15' ' ' ALA . 8.2 Cg_exo -73.1 163.82 37.15 Favored 'Trans proline' 0 C--N 1.347 0.492 0 C-N-CA 123.042 2.494 . . . . 0.0 112.586 179.594 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' TRP . . . . . 0.53 ' CZ3' ' HB2' ' A' ' 129' ' ' LYS . 91.3 m95 -83.51 131.13 35.02 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 178.939 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 41.2 m-80 -109.54 141.71 41.62 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.524 -177.833 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 13.9 pt-20 -112.18 137.5 50.18 Favored 'General case' 0 C--N 1.313 -0.991 0 N-CA-C 110.016 -0.364 . . . . 0.0 110.016 179.05 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -154.2 32.45 0.72 Allowed Glycine 0 N--CA 1.443 -0.842 0 C-N-CA 119.76 -1.21 . . . . 0.0 112.641 179.045 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 156.25 -177.61 33.18 Favored Glycine 0 N--CA 1.447 -0.613 0 C-N-CA 119.658 -1.258 . . . . 0.0 113.3 -179.16 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . 0.508 HE21 HD11 ' A' ' 3' ' ' LEU . 4.4 pt20 -141.62 145.35 34.9 Favored 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 109.537 -0.542 . . . . 0.0 109.537 -179.828 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . 0.49 ' CD1' HG21 ' A' ' 6' ' ' VAL . 45.0 m0 -115.93 153.28 31.86 Favored 'General case' 0 C--O 1.24 0.591 0 CA-C-O 121.121 0.486 . . . . 0.0 111.895 -176.752 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 85.9 tt0 -112.17 114.47 27.29 Favored 'General case' 0 CA--C 1.508 -0.663 0 CA-C-N 115.512 -0.767 . . . . 0.0 109.072 177.998 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 96.8 mt -131.82 136.7 56.49 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-O 121.355 0.597 . . . . 0.0 112.27 -176.048 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 104.93 -26.52 22.05 Favored Glycine 0 N--CA 1.449 -0.454 0 CA-C-N 115.881 -0.6 . . . . 0.0 113.531 175.312 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 2.7 p 44.99 20.89 0.04 OUTLIER 'General case' 0 N--CA 1.486 1.335 0 C-N-CA 123.867 0.867 . . . . 0.0 112.991 -177.512 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 83.4 mtm180 -149.62 150.57 32.4 Favored 'General case' 0 C--O 1.241 0.626 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 -179.243 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 12.6 m -95.51 -15.42 22.9 Favored 'General case' 0 C--N 1.309 -1.159 0 CA-C-O 121.089 0.471 . . . . 0.0 110.268 177.828 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 23.3 m-20 -75.21 -35.5 61.5 Favored 'General case' 0 N--CA 1.468 0.475 0 CA-C-N 115.809 -0.632 . . . . 0.0 112.182 -177.052 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 5.0 mm-40 -132.49 128.23 36.93 Favored 'General case' 0 CA--C 1.509 -0.628 0 N-CA-C 113.876 1.065 . . . . 0.0 113.876 -175.34 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 3.4 m-20 -100.07 151.15 21.71 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 114.834 -1.075 . . . . 0.0 109.311 174.61 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.433 HG21 HD11 ' A' ' 36' ' ' ILE . 33.2 m -92.53 142.95 12.38 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.277 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.78 -179.818 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 27.7 m -111.4 -16.08 9.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 C-N-CA 120.931 -0.308 . . . . 0.0 111.744 178.772 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.549 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -147.94 140.75 24.74 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 120.3 -0.56 . . . . 0.0 111.597 178.972 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.433 HD11 HG21 ' A' ' 33' ' ' VAL . 88.8 mt -142.84 121.29 7.7 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 178.607 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' ASN . . . . . 0.485 ' HA ' ' O ' ' A' ' 103' ' ' ILE . 4.8 t-20 -136.54 111.26 8.71 Favored 'General case' 0 C--N 1.307 -1.243 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 177.984 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.462 HG11 ' CD1' ' A' ' 61' ' ' PHE . 27.0 m -148.43 154.37 10.36 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-O 120.804 0.335 . . . . 0.0 111.626 -171.843 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 45.4 tt0 -136.34 143.37 44.07 Favored 'General case' 0 N--CA 1.447 -0.61 0 CA-C-N 115.624 -0.716 . . . . 0.0 109.371 176.644 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 88.4 p -72.83 155.04 40.33 Favored 'General case' 0 C--N 1.314 -0.961 0 CA-C-O 121.131 0.491 . . . . 0.0 111.846 -178.288 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -108.26 -45.0 1.11 Allowed Glycine 0 N--CA 1.438 -1.188 0 CA-C-N 115.596 -0.729 . . . . 0.0 111.924 177.86 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 30.7 t70 -129.3 95.28 3.99 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 111.564 0.209 . . . . 0.0 111.564 -178.772 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 52.15 31.53 9.17 Favored 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 113.594 0.961 . . . . 0.0 113.594 174.989 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 75.7 1.0 65.19 Favored Glycine 0 C--N 1.32 -0.359 0 C-N-CA 120.373 -0.918 . . . . 0.0 113.09 179.828 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 13.8 mm100 -78.48 -29.68 46.89 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-O 121.328 0.585 . . . . 0.0 109.743 178.857 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 32.1 p -121.74 144.26 48.9 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-N 115.709 -0.678 . . . . 0.0 109.912 176.738 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' LEU . . . . . 0.492 ' O ' ' HA ' ' A' ' 62' ' ' ARG . 93.3 mt -129.82 130.96 45.97 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 -178.185 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 94.0 m-20 -127.49 138.97 53.08 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 178.141 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . 0.401 ' HA3' ' HA ' ' A' ' 38' ' ' VAL . . . 172.81 -153.04 17.68 Favored Glycine 0 N--CA 1.445 -0.732 0 C-N-CA 119.487 -1.339 . . . . 0.0 113.525 178.707 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 90.9 m -131.99 133.19 44.18 Favored 'General case' 0 C--N 1.317 -0.811 0 C-N-CA 122.704 0.402 . . . . 0.0 110.283 -178.904 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' MET . . . . . 0.566 ' HE3' HD11 ' A' ' 59' ' ' ILE . 15.7 tmm? -126.32 147.58 49.7 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 116.531 -0.304 . . . . 0.0 110.34 -178.949 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.549 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 28.4 m -128.98 129.12 44.99 Favored 'General case' 0 C--O 1.252 1.234 0 CA-C-O 120.797 0.332 . . . . 0.0 111.826 -177.505 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . 0.49 ' HB2' ' HB2' ' A' ' 56' ' ' GLU . 94.3 m-85 -83.47 167.4 17.47 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 115.811 -0.632 . . . . 0.0 110.419 177.582 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -63.96 103.71 0.62 Allowed 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 112.402 0.519 . . . . 0.0 112.402 -179.012 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 85.84 4.51 84.8 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.937 -0.649 . . . . 0.0 113.261 177.717 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . 0.49 ' HB2' ' HB2' ' A' ' 53' ' ' TYR . 81.9 mm-40 -107.97 176.99 4.95 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-O 120.697 0.284 . . . . 0.0 110.665 -179.781 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -90.11 156.82 25.52 Favored Glycine 0 N--CA 1.44 -1.048 0 C-N-CA 120.879 -0.677 . . . . 0.0 112.16 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_exo -63.67 140.32 74.03 Favored 'Trans proline' 0 CA--C 1.533 0.449 0 C-N-CA 122.758 2.305 . . . . 0.0 112.116 178.697 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . 0.566 HD11 ' HE3' ' A' ' 51' ' ' MET . 46.4 pt -130.75 166.0 29.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-N 116.341 -0.391 . . . . 0.0 110.649 179.633 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -73.29 138.63 25.55 Favored Glycine 0 N--CA 1.45 -0.398 0 N-CA-C 111.243 -0.743 . . . . 0.0 111.243 179.856 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.462 ' CD1' HG11 ' A' ' 38' ' ' VAL . 52.4 t80 -124.86 130.03 51.58 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-O 120.673 0.273 . . . . 0.0 111.111 -177.148 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . 0.492 ' HA ' ' O ' ' A' ' 47' ' ' LEU . 68.2 ttp85 -140.29 132.67 28.41 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.068 175.041 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.403 ' HB3' ' HB2' ' A' ' 47' ' ' LEU . . . -136.64 148.17 47.29 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 120.754 0.311 . . . . 0.0 111.828 -178.074 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 56.3 m -127.18 132.53 50.46 Favored 'General case' 0 CA--C 1.541 0.628 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.513 178.836 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . 0.419 HD22 ' O ' ' A' ' 70' ' ' SER . 3.4 tm? -77.13 114.54 16.04 Favored 'General case' 0 C--N 1.325 -0.486 0 C-N-CA 122.633 0.373 . . . . 0.0 110.447 -179.133 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 10.5 mp -81.99 -32.16 30.75 Favored 'General case' 0 N--CA 1.468 0.455 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.915 178.824 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 164.8 173.58 33.58 Favored Glycine 0 CA--C 1.497 -1.045 0 N-CA-C 110.614 -0.995 . . . . 0.0 110.614 -177.577 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 16.2 t30 40.23 -96.32 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.134 0 C-N-CA 123.138 0.575 . . . . 0.0 111.777 -176.947 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 24.7 m120 -140.67 19.81 2.35 Favored 'General case' 0 N--CA 1.467 0.412 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 177.29 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . 0.419 ' O ' HD22 ' A' ' 65' ' ' LEU . 40.7 t -94.54 122.98 37.69 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.308 -0.86 . . . . 0.0 111.256 -175.742 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.634 ' OH ' ' HB3' ' A' ' 99' ' ' ASN . 73.9 m-85 -116.25 137.61 52.0 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 115.817 -0.628 . . . . 0.0 110.515 -179.673 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 82.2 tt0 -92.38 125.4 37.02 Favored 'General case' 0 N--CA 1.439 -1.004 0 N-CA-C 107.476 -1.305 . . . . 0.0 107.476 172.081 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 65.5 t -105.04 130.67 55.8 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.5 0 CA-C-O 121.432 0.634 . . . . 0.0 111.973 -174.953 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 67.0 mt-10 -126.25 120.64 30.51 Favored 'General case' 0 N--CA 1.431 -1.381 0 CA-C-N 114.455 -1.248 . . . . 0.0 107.669 176.424 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 94.4 m-20 -109.55 155.73 21.03 Favored 'General case' 0 C--N 1.317 -0.831 0 CA-C-O 121.2 0.524 . . . . 0.0 111.968 -174.507 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' GLN . . . . . 0.45 ' HB2' ' CE3' ' A' ' 84' ' ' TRP . 61.4 tt0 -119.39 119.9 35.31 Favored 'General case' 0 C--N 1.31 -1.13 0 CA-C-N 115.494 -0.775 . . . . 0.0 109.933 -178.344 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 7.9 p90 -137.2 155.64 49.28 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.593 -0.276 . . . . 0.0 110.727 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 97.75 -10.27 64.39 Favored Glycine 0 N--CA 1.447 -0.615 0 N-CA-C 111.151 -0.779 . . . . 0.0 111.151 -178.652 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 139.35 159.56 8.04 Favored Glycine 0 N--CA 1.44 -1.045 0 N-CA-C 111.312 -0.715 . . . . 0.0 111.312 179.465 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 7.4 p-10 -74.55 -23.37 58.78 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-O 121.046 0.45 . . . . 0.0 111.0 -179.632 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 6.9 m -76.24 -7.89 55.87 Favored 'General case' 0 CA--C 1.542 0.654 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.622 177.346 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -83.86 158.45 62.09 Favored Pre-proline 0 C--N 1.326 -0.415 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.456 -179.407 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -72.84 177.84 7.15 Favored 'Trans proline' 0 C--O 1.237 0.471 0 C-N-CA 122.279 1.986 . . . . 0.0 111.636 177.498 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' TRP . . . . . 0.45 ' CE3' ' HB2' ' A' ' 76' ' ' GLN . 96.4 m95 -90.24 142.23 27.92 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 179.957 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 88.9 m-70 -117.87 146.98 43.51 Favored 'General case' 0 C--N 1.313 -0.986 0 N-CA-C 109.534 -0.543 . . . . 0.0 109.534 -178.71 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 18.8 p -62.87 136.85 58.07 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-O 120.561 0.22 . . . . 0.0 111.351 -179.831 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -111.89 -50.98 0.57 Allowed Glycine 0 N--CA 1.446 -0.637 0 C-N-CA 120.821 -0.704 . . . . 0.0 111.534 178.314 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 148.58 -164.47 29.08 Favored Glycine 0 C--O 1.219 -0.807 0 C-N-CA 120.603 -0.808 . . . . 0.0 111.879 178.308 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 27.9 t-20 -111.46 120.12 41.1 Favored 'General case' 0 C--N 1.317 -0.829 0 CA-C-N 116.988 0.394 . . . . 0.0 110.121 179.205 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 28.1 m0 -114.96 148.78 38.29 Favored 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 -178.472 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 79.9 mt -108.69 118.72 56.86 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.071 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 177.2 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . 0.485 ' HB3' HG21 ' A' ' 100' ' ' VAL . 84.8 mt -131.81 87.38 2.44 Favored 'General case' 0 C--O 1.271 2.2 0 CA-C-O 121.939 0.876 . . . . 0.0 113.253 -174.292 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 160.61 117.04 0.44 Allowed Glycine 0 N--CA 1.446 -0.65 0 CA-C-N 115.162 -0.926 . . . . 0.0 111.829 178.502 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 70.7 p -91.32 -12.82 33.91 Favored 'General case' 0 C--O 1.223 -0.322 0 CA-C-N 117.216 0.508 . . . . 0.0 110.517 178.798 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 94.1 mtt-85 -89.17 138.56 31.32 Favored 'General case' 0 N--CA 1.444 -0.741 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.129 178.904 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -70.94 -34.65 71.68 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 115.673 -0.694 . . . . 0.0 111.408 -175.623 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 89.4 m-20 -112.91 25.89 11.0 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.019 -0.537 . . . . 0.0 111.372 -177.404 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 98' ' ' GLN . . . . . . . . . . . . . 2.0 tt0 -155.49 130.58 9.42 Favored 'General case' 0 C--N 1.333 -0.136 0 C-N-CA 120.323 -0.551 . . . . 0.0 112.244 -176.251 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 99' ' ' ASN . . . . . 0.634 ' HB3' ' OH ' ' A' ' 71' ' ' TYR . 95.2 m-20 -99.32 162.66 12.91 Favored 'General case' 0 C--O 1.253 1.251 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.487 178.867 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.485 HG21 ' HB3' ' A' ' 92' ' ' LEU . 33.3 m -78.3 147.15 7.21 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 C-N-CA 119.884 -0.726 . . . . 0.0 110.979 179.282 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 35.5 m -123.4 -36.93 1.18 Allowed 'Isoleucine or valine' 0 C--O 1.219 -0.502 0 C-N-CA 120.728 -0.389 . . . . 0.0 111.821 177.657 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -136.25 132.19 35.48 Favored 'General case' 0 CA--C 1.503 -0.837 0 C-N-CA 120.407 -0.517 . . . . 0.0 110.687 -179.398 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.485 ' O ' ' HA ' ' A' ' 37' ' ' ASN . 92.3 mt -132.52 124.36 51.37 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 CA-C-N 116.472 -0.331 . . . . 0.0 110.111 178.255 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 7.9 t30 -125.29 97.82 5.37 Favored 'General case' 0 C--N 1.32 -0.708 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 176.482 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.429 ' CG2' ' HB ' ' A' ' 36' ' ' ILE . 26.9 m -139.94 142.97 31.0 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.782 0 N-CA-C 113.134 0.79 . . . . 0.0 113.134 -175.511 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 44.4 tt0 -146.32 148.95 32.93 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.111 -0.949 . . . . 0.0 109.215 177.37 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 40.8 t -137.37 145.06 42.84 Favored 'General case' 0 C--N 1.313 -1.022 0 CA-C-O 121.087 0.47 . . . . 0.0 111.573 -178.809 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -94.92 5.45 68.99 Favored Glycine 0 N--CA 1.441 -0.986 0 N-CA-C 111.011 -0.836 . . . . 0.0 111.011 176.313 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 83.3 m-20 -93.03 178.59 5.7 Favored 'General case' 0 CA--C 1.508 -0.65 0 CA-C-O 121.154 0.502 . . . . 0.0 111.077 178.509 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 10.8 p-10 -90.38 19.13 5.41 Favored 'General case' 0 C--N 1.311 -1.095 0 CA-C-N 115.512 -0.767 . . . . 0.0 110.5 179.444 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 106.11 4.82 38.38 Favored Glycine 0 N--CA 1.443 -0.839 0 CA-C-N 115.64 -0.709 . . . . 0.0 111.906 -177.688 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 30.7 tt0 -65.13 -45.6 84.4 Favored 'General case' 0 C--O 1.237 0.44 0 CA-C-O 120.865 0.364 . . . . 0.0 110.324 177.715 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 70.3 p -133.53 157.6 45.25 Favored 'General case' 0 N--CA 1.447 -0.577 0 CA-C-N 116.216 -0.447 . . . . 0.0 109.808 177.767 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 49.2 tp -139.09 131.46 28.46 Favored 'General case' 0 C--N 1.315 -0.9 0 N-CA-C 109.087 -0.708 . . . . 0.0 109.087 178.818 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 6.8 p30 -147.99 167.27 25.34 Favored 'General case' 0 C--N 1.319 -0.743 0 C-N-CA 119.853 -0.739 . . . . 0.0 112.878 -179.985 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 155.79 -130.24 2.71 Favored Glycine 0 N--CA 1.442 -0.938 0 CA-C-N 114.951 -1.022 . . . . 0.0 111.738 -179.821 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 33.0 p -133.37 156.98 46.67 Favored 'General case' 0 C--N 1.318 -0.796 0 C-N-CA 122.671 0.388 . . . . 0.0 110.621 -178.818 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 23.7 ptm -152.48 167.47 28.69 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 120.897 0.38 . . . . 0.0 111.096 -179.571 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 48.4 m -151.63 139.98 20.43 Favored 'General case' 0 CA--C 1.547 0.862 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.991 -179.936 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . 0.495 ' H ' ' HB3' ' A' ' 123' ' ' GLU . 67.8 m-85 -99.02 172.29 7.5 Favored 'General case' 0 N--CA 1.473 0.701 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.28 178.538 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -67.9 37.83 0.03 OUTLIER 'General case' 0 N--CA 1.487 1.421 0 C-N-CA 123.695 0.798 . . . . 0.0 113.104 -179.752 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 153.44 42.67 0.02 OUTLIER Glycine 0 CA--C 1.5 -0.879 0 N-CA-C 110.08 -1.208 . . . . 0.0 110.08 179.805 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . 0.495 ' HB3' ' H ' ' A' ' 120' ' ' TYR . 47.3 tp10 -139.69 160.82 39.0 Favored 'General case' 0 C--N 1.315 -0.925 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 -175.705 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -90.2 175.29 41.13 Favored Glycine 0 N--CA 1.443 -0.895 0 N-CA-C 111.023 -0.831 . . . . 0.0 111.023 177.238 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 22.5 Cg_exo -63.35 119.91 7.15 Favored 'Trans proline' 0 N--CA 1.461 -0.41 0 C-N-CA 121.939 1.759 . . . . 0.0 111.2 178.262 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 42.5 pt -127.53 154.11 37.55 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 CA-C-O 120.656 0.265 . . . . 0.0 110.811 -179.897 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -72.31 143.65 34.69 Favored Glycine 0 N--CA 1.444 -0.809 0 C-N-CA 121.087 -0.578 . . . . 0.0 112.463 179.422 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . 0.424 ' CD2' HG11 ' A' ' 105' ' ' VAL . 73.0 t80 -122.07 133.8 54.78 Favored 'General case' 0 C--N 1.315 -0.901 0 CA-C-O 120.689 0.281 . . . . 0.0 110.579 179.194 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 129' ' ' LYS . . . . . 0.53 ' HB2' ' CZ3' ' A' ' 17' ' ' TRP . 84.0 tttt -140.39 130.35 24.69 Favored 'General case' 0 N--CA 1.439 -0.998 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 177.539 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . 0.627 ' HA2' ' O ' ' A' ' 5' ' ' ASN . . . -134.4 141.22 12.5 Favored Glycine 0 N--CA 1.436 -1.325 0 C-N-CA 121.087 -0.578 . . . . 0.0 112.007 179.875 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 53.7 m -128.27 135.36 49.53 Favored 'General case' 0 C--N 1.314 -0.97 0 CA-C-O 120.481 0.182 . . . . 0.0 110.786 -179.473 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 54.8 tp -64.52 136.5 57.11 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 177.638 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 133' ' ' THR . . . . . 0.469 ' HB ' ' OD1' ' A' ' 5' ' ' ASN . 11.8 t . . . . . 0 C--O 1.252 1.221 0 CA-C-O 118.733 -0.651 . . . . 0.0 110.634 -179.251 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 0.419 ' O ' ' HB3' ' A' ' 3' ' ' LEU . . . . . . . . 0 N--CA 1.472 0.637 0 N-CA-C 110.014 -0.365 . . . . 0.0 110.014 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' LEU . . . . . 0.569 HD21 HE21 ' A' ' 22' ' ' GLN . 10.3 tt 87.41 150.74 0.06 Allowed 'General case' 0 N--CA 1.475 0.813 0 C-N-CA 124.289 1.036 . . . . 0.0 109.956 179.232 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . 0.43 ' N ' HD23 ' A' ' 3' ' ' LEU . 86.7 m-85 -132.45 154.13 50.18 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-O 120.951 0.405 . . . . 0.0 111.082 -175.007 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' ASN . . . . . 0.405 ' O ' ' HA2' ' A' ' 130' ' ' GLY . 92.7 m-20 -95.78 151.78 19.07 Favored 'General case' 0 C--N 1.314 -0.972 0 N-CA-C 107.702 -1.221 . . . . 0.0 107.702 177.664 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.47 HG21 ' CD1' ' A' ' 23' ' ' TRP . 78.5 t -111.9 121.84 65.13 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.184 0 CA-C-O 121.744 0.783 . . . . 0.0 111.73 -177.459 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.4 ' HB2' ' HB3' ' A' ' 129' ' ' LYS . 69.1 mt-10 -121.7 127.03 50.3 Favored 'General case' 0 C--N 1.311 -1.084 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 177.689 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 12.4 m120 -126.28 148.72 49.46 Favored 'General case' 0 C--N 1.312 -1.057 0 N-CA-C 112.527 0.566 . . . . 0.0 112.527 -174.036 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 54.2 tt0 -127.3 118.38 24.08 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 175.986 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 39.7 p90 -143.9 20.46 1.8 Allowed 'General case' 0 C--N 1.322 -0.613 0 C-N-CA 120.24 -0.584 . . . . 0.0 112.555 -175.293 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -96.53 24.15 31.93 Favored Glycine 0 N--CA 1.448 -0.532 0 C-N-CA 119.321 -1.418 . . . . 0.0 113.572 -177.43 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.55 -50.21 2.83 Favored Glycine 0 N--CA 1.466 0.683 0 CA-C-N 117.152 0.476 . . . . 0.0 114.268 178.261 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 22.6 t -172.63 153.23 2.74 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 -176.216 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 19.0 m 58.8 30.05 19.55 Favored 'General case' 0 CA--C 1.536 0.409 0 CA-C-O 121.322 0.582 . . . . 0.0 110.986 179.436 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -111.02 128.93 24.53 Favored Pre-proline 0 N--CA 1.443 -0.803 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.999 -178.053 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 97.8 Cg_endo -77.06 169.6 21.26 Favored 'Trans proline' 0 N--CA 1.456 -0.692 0 C-N-CA 122.697 2.265 . . . . 0.0 111.466 177.124 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 97.8 m95 -80.35 128.73 33.9 Favored 'General case' 0 C--N 1.314 -0.969 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 179.293 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 87.4 m-20 -116.28 127.6 54.86 Favored 'General case' 0 C--N 1.311 -1.099 0 N-CA-C 109.553 -0.536 . . . . 0.0 109.553 -177.854 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 10.7 pt-20 -83.43 127.68 33.89 Favored 'General case' 0 C--N 1.314 -0.948 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 178.453 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -137.38 19.82 3.38 Favored Glycine 0 C--O 1.225 -0.454 0 C-N-CA 120.43 -0.891 . . . . 0.0 112.812 -177.695 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 156.44 -173.01 34.27 Favored Glycine 0 N--CA 1.439 -1.163 0 C-N-CA 120.603 -0.808 . . . . 0.0 111.751 179.601 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . 0.569 HE21 HD21 ' A' ' 3' ' ' LEU . 17.6 pt20 -148.55 149.02 30.86 Favored 'General case' 0 C--N 1.311 -1.073 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 178.684 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . 0.47 ' CD1' HG21 ' A' ' 6' ' ' VAL . 48.0 m0 -118.62 150.69 39.27 Favored 'General case' 0 C--N 1.313 -1.001 0 CA-C-O 120.784 0.326 . . . . 0.0 110.473 -178.05 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 78.9 tt0 -106.13 115.14 29.71 Favored 'General case' 0 C--N 1.313 -0.983 0 C-N-CA 120.052 -0.659 . . . . 0.0 109.544 178.26 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 93.6 mt -139.19 149.47 23.17 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.891 0 CA-C-N 115.213 -0.903 . . . . 0.0 108.979 -175.85 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 90.26 83.38 1.37 Allowed Glycine 0 N--CA 1.446 -0.699 0 C-N-CA 120.482 -0.866 . . . . 0.0 112.808 179.474 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 11.6 p -94.97 13.51 24.73 Favored 'General case' 0 N--CA 1.449 -0.495 0 CA-C-O 120.969 0.414 . . . . 0.0 111.159 178.842 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 15.8 ptp180 -129.28 134.79 48.11 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 179.463 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 26.7 t -89.02 -21.92 23.24 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-O 121.121 0.486 . . . . 0.0 111.143 -179.031 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 51.8 m-20 -64.88 -36.23 83.68 Favored 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 112.746 0.647 . . . . 0.0 112.746 -177.91 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . 0.63 HE21 ' HA ' ' A' ' 31' ' ' GLN . 0.0 OUTLIER -135.74 134.47 39.08 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 111.938 0.348 . . . . 0.0 111.938 -175.095 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . 0.454 ' ND2' ' HA3' ' A' ' 111' ' ' GLY . 66.0 t30 -90.77 161.39 15.33 Favored 'General case' 0 C--O 1.24 0.572 0 CA-C-N 116.111 -0.495 . . . . 0.0 109.977 178.308 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 57.8 t -88.62 126.61 41.8 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.484 -176.756 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 30.7 m -111.46 -31.23 2.22 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.599 0 N-CA-C 113.236 0.828 . . . . 0.0 113.236 177.132 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.618 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -151.41 148.81 28.55 Favored 'General case' 0 N--CA 1.469 0.515 0 C-N-CA 119.839 -0.744 . . . . 0.0 111.959 179.828 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.401 HG12 ' HG3' ' A' ' 51' ' ' MET . 93.4 mt -141.92 126.87 17.23 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.15 -179.616 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -133.66 112.36 11.36 Favored 'General case' 0 C--N 1.321 -0.65 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 174.168 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.412 HG22 ' HB ' ' A' ' 103' ' ' ILE . 21.7 m -150.88 153.92 9.38 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-O 120.749 0.309 . . . . 0.0 111.115 -175.607 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 42.2 tt0 -145.38 151.67 38.64 Favored 'General case' 0 C--N 1.318 -0.771 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 176.414 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 27.3 p -79.46 148.08 32.03 Favored 'General case' 0 C--N 1.31 -1.14 0 CA-C-O 121.089 0.471 . . . . 0.0 111.802 -178.792 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -97.19 -10.27 54.67 Favored Glycine 0 N--CA 1.447 -0.604 0 N-CA-C 110.03 -1.228 . . . . 0.0 110.03 175.347 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . 0.404 ' C ' ' H ' ' A' ' 44' ' ' GLY . 18.9 m-20 -137.7 -160.63 1.08 Allowed 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 114.464 -0.868 . . . . 0.0 108.766 179.505 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 17.9 m-20 -76.5 34.51 0.14 Allowed 'General case' 0 N--CA 1.481 1.086 0 CA-C-O 120.971 0.415 . . . . 0.0 110.999 178.53 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.529 ' O ' ' HE2' ' A' ' 71' ' ' TYR . . . 103.11 -6.27 50.77 Favored Glycine 0 C--O 1.208 -1.484 0 N-CA-C 111.456 -0.658 . . . . 0.0 111.456 -178.827 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 59.7 tp60 -65.18 -40.13 93.83 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.233 0.54 . . . . 0.0 110.602 179.89 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 74.4 p -125.24 142.56 51.42 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.47 178.693 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' LEU . . . . . 0.494 ' HB2' ' HB3' ' A' ' 63' ' ' ALA . 92.3 mt -128.56 126.98 41.46 Favored 'General case' 0 C--N 1.322 -0.626 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 178.131 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . 0.408 ' ND2' ' HG3' ' A' ' 62' ' ' ARG . 15.1 m120 -129.02 142.3 50.96 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 179.94 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 173.28 -155.51 22.64 Favored Glycine 0 N--CA 1.441 -0.998 0 C-N-CA 119.547 -1.311 . . . . 0.0 113.145 177.69 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 53.7 m -128.35 130.86 48.38 Favored 'General case' 0 C--N 1.311 -1.079 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 -179.452 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' MET . . . . . 0.558 ' SD ' ' HH2' ' A' ' 90' ' ' TRP . 23.5 ttt -116.22 145.61 42.98 Favored 'General case' 0 C--N 1.314 -0.964 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 -179.813 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.618 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 37.6 m -122.19 126.11 47.57 Favored 'General case' 0 C--O 1.246 0.887 0 CA-C-O 121.162 0.506 . . . . 0.0 111.601 -179.19 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 74.2 m-85 -103.58 158.63 16.23 Favored 'General case' 0 N--CA 1.445 -0.705 0 CA-C-N 115.339 -0.846 . . . . 0.0 109.338 176.739 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -61.42 137.69 58.25 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.229 -179.027 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 77.02 -60.34 3.48 Favored Glycine 0 CA--C 1.524 0.595 0 N-CA-C 114.647 0.619 . . . . 0.0 114.647 176.772 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -66.36 -40.71 89.93 Favored 'General case' 0 C--O 1.239 0.504 0 N-CA-C 113.218 0.822 . . . . 0.0 113.218 -175.272 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 111.63 -162.49 12.43 Favored Glycine 0 N--CA 1.446 -0.652 0 C-N-CA 120.0 -1.095 . . . . 0.0 112.944 178.595 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 97.8 Cg_endo -79.0 141.74 16.84 Favored 'Trans proline' 0 C--O 1.237 0.454 0 C-N-CA 123.126 2.551 . . . . 0.0 113.416 -179.636 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . 0.739 ' HB ' ' O ' ' A' ' 76' ' ' GLN . 48.7 pt -136.07 167.99 23.45 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 CA-C-N 115.712 -0.676 . . . . 0.0 109.905 176.974 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . 0.456 ' HA3' ' HB3' ' A' ' 76' ' ' GLN . . . -73.95 142.66 31.07 Favored Glycine 0 C--O 1.237 0.338 0 C-N-CA 120.332 -0.937 . . . . 0.0 111.357 -179.49 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 37.8 t80 -128.1 125.0 38.36 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-O 120.611 0.243 . . . . 0.0 111.001 -177.647 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . 0.448 HH21 ' CD ' ' A' ' 74' ' ' GLU . 19.5 ttp85 -135.12 130.63 35.77 Favored 'General case' 0 C--O 1.217 -0.612 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 175.352 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.494 ' HB3' ' HB2' ' A' ' 47' ' ' LEU . . . -137.44 146.2 44.06 Favored 'General case' 0 C--N 1.317 -0.828 0 C-N-CA 120.835 -0.346 . . . . 0.0 111.38 -179.597 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 63.4 m -125.11 134.71 52.36 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.069 179.074 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 55.6 tp -63.83 118.5 8.44 Favored 'General case' 0 CA--C 1.509 -0.617 0 CA-C-O 121.074 0.464 . . . . 0.0 110.998 -179.767 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 52.3 tp -67.53 -39.43 85.04 Favored 'General case' 0 N--CA 1.436 -1.146 0 CA-C-N 115.374 -0.83 . . . . 0.0 111.116 -179.956 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 178.68 -37.69 0.08 OUTLIER Glycine 0 N--CA 1.446 -0.652 0 C-N-CA 120.485 -0.864 . . . . 0.0 112.557 179.763 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 18.8 p-10 -173.73 114.05 0.21 Allowed 'General case' 0 C--N 1.326 -0.414 0 C-N-CA 122.405 0.282 . . . . 0.0 110.353 -178.611 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . 0.405 ' OD1' ' HA3' ' A' ' 93' ' ' GLY . 96.1 m-20 68.19 -43.77 0.49 Allowed 'General case' 0 N--CA 1.484 1.273 0 C-N-CA 123.795 0.838 . . . . 0.0 113.114 -178.824 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 9.6 m -77.96 133.76 37.97 Favored 'General case' 0 C--N 1.315 -0.932 0 CA-C-O 121.113 0.482 . . . . 0.0 110.898 178.396 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.607 ' OH ' ' HB3' ' A' ' 99' ' ' ASN . 96.4 m-85 -126.41 148.74 49.57 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.037 178.586 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -95.54 117.25 30.09 Favored 'General case' 0 C--N 1.308 -1.235 0 N-CA-C 107.797 -1.186 . . . . 0.0 107.797 173.448 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 79.0 t -103.3 136.6 35.3 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.849 0 CA-C-O 121.244 0.545 . . . . 0.0 112.416 -173.635 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.465 ' HG2' ' HA ' ' A' ' 86' ' ' SER . 98.0 mt-10 -118.76 146.88 44.43 Favored 'General case' 0 N--CA 1.439 -1.025 0 CA-C-N 114.982 -1.008 . . . . 0.0 109.081 177.438 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' ASN . . . . . 0.439 ' HB3' HD12 ' A' ' 59' ' ' ILE . 10.0 m120 -123.99 137.18 54.64 Favored 'General case' 0 C--N 1.315 -0.904 0 CA-C-O 121.226 0.536 . . . . 0.0 110.931 -177.095 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' GLN . . . . . 0.739 ' O ' ' HB ' ' A' ' 59' ' ' ILE . 30.4 tt0 -110.37 115.82 30.35 Favored 'General case' 0 C--N 1.309 -1.194 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.32 -179.875 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 6.1 p90 -129.28 44.62 2.94 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-O 121.423 0.63 . . . . 0.0 110.717 179.467 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -104.8 -68.95 0.75 Allowed Glycine 0 N--CA 1.443 -0.839 0 C-N-CA 120.647 -0.787 . . . . 0.0 111.183 -178.848 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 170.81 -67.18 0.15 Allowed Glycine 0 N--CA 1.446 -0.676 0 N-CA-C 110.686 -0.965 . . . . 0.0 110.686 178.354 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 37.0 t70 -139.08 117.27 11.84 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 177.654 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 32.3 t 76.76 -75.08 0.07 Allowed 'General case' 0 C--N 1.327 -0.396 0 O-C-N 123.876 0.735 . . . . 0.0 110.092 -178.436 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 63.99 161.6 0.12 Allowed Pre-proline 0 N--CA 1.477 0.901 0 N-CA-C 112.352 0.501 . . . . 0.0 112.352 177.141 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' PRO . . . . . 0.593 ' O ' ' HB2' ' A' ' 84' ' ' TRP . 51.7 Cg_exo -57.07 -41.83 70.47 Favored 'Trans proline' 0 C--N 1.355 0.892 0 C-N-CA 122.526 2.151 . . . . 0.0 112.859 177.612 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' TRP . . . . . 0.593 ' HB2' ' O ' ' A' ' 83' ' ' PRO . 74.0 m95 94.48 116.42 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.778 0 C-N-CA 124.747 1.219 . . . . 0.0 110.231 -178.725 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 92.7 m-70 -112.15 139.04 48.0 Favored 'General case' 0 CA--C 1.517 -0.324 0 CA-C-N 116.484 -0.326 . . . . 0.0 110.531 -176.845 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . 0.465 ' HA ' ' HG2' ' A' ' 74' ' ' GLU . 13.1 m -70.61 141.3 51.76 Favored 'General case' 0 C--N 1.311 -1.092 0 CA-C-N 116.442 -0.345 . . . . 0.0 110.096 177.134 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -109.29 -34.06 2.59 Favored Glycine 0 N--CA 1.447 -0.578 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.852 -178.349 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 147.57 -160.56 28.33 Favored Glycine 0 N--CA 1.453 -0.211 0 C-N-CA 120.315 -0.945 . . . . 0.0 112.459 178.649 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 23.8 t-20 -118.67 124.61 47.8 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.433 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 90' ' ' TRP . . . . . 0.558 ' HH2' ' SD ' ' A' ' 51' ' ' MET . 36.2 m0 -118.24 152.88 34.87 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.129 -177.721 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 79.1 mt -107.25 116.71 51.5 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 N-CA-C 110.191 -0.299 . . . . 0.0 110.191 178.494 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . 0.402 ' HB2' ' CE1' ' A' ' 71' ' ' TYR . 90.2 mt -126.57 76.46 1.63 Allowed 'General case' 0 C--O 1.256 1.406 0 CA-C-O 121.625 0.726 . . . . 0.0 111.036 -178.411 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . 0.405 ' HA3' ' OD1' ' A' ' 69' ' ' ASN . . . -176.73 105.3 0.2 Allowed Glycine 0 N--CA 1.435 -1.374 0 CA-C-N 114.842 -1.072 . . . . 0.0 111.612 -179.551 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.4 p -86.2 -11.8 51.48 Favored 'General case' 0 C--N 1.313 -1.003 0 CA-C-O 121.265 0.555 . . . . 0.0 110.695 178.384 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 97.6 mtt180 -106.92 153.39 22.6 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.563 -0.744 . . . . 0.0 111.68 178.825 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -66.69 -43.14 85.19 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 115.207 -0.906 . . . . 0.0 112.388 -175.967 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 21.4 m120 -123.04 34.1 5.22 Favored 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 111.967 0.358 . . . . 0.0 111.967 -176.364 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 98' ' ' GLN . . . . . . . . . . . . . 9.6 tt0 -146.95 121.01 9.41 Favored 'General case' 0 C--N 1.32 -0.688 0 C-N-CA 120.278 -0.569 . . . . 0.0 110.549 -178.473 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 99' ' ' ASN . . . . . 0.607 ' HB3' ' OH ' ' A' ' 71' ' ' TYR . 90.2 m-20 -95.34 159.71 14.88 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.182 -176.45 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 79.1 t -81.46 133.72 28.65 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.637 0 CA-C-N 116.509 -0.314 . . . . 0.0 110.79 176.64 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 33.7 m -113.33 -26.83 2.88 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 N-CA-C 112.83 0.678 . . . . 0.0 112.83 -178.755 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . 0.648 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -146.91 140.12 25.42 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 119.696 -0.801 . . . . 0.0 112.095 178.65 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.412 ' HB ' HG22 ' A' ' 38' ' ' VAL . 91.1 mt -133.22 124.64 49.73 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.929 -0.578 . . . . 0.0 111.073 178.25 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 40.2 t30 -128.78 97.45 4.67 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.317 174.703 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 28.6 m -143.48 148.37 19.18 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 N-CA-C 112.949 0.722 . . . . 0.0 112.949 -174.526 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 76.1 tt0 -142.66 138.04 30.38 Favored 'General case' 0 N--CA 1.437 -1.092 0 CA-C-N 115.072 -0.967 . . . . 0.0 108.544 175.248 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . 0.437 ' HA ' ' HA ' ' A' ' 114' ' ' LEU . 44.8 t -74.87 -52.42 11.36 Favored 'General case' 0 C--N 1.306 -1.287 0 CA-C-N 116.09 -0.504 . . . . 0.0 111.382 -178.183 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 81.8 -9.26 57.01 Favored Glycine 0 N--CA 1.449 -0.457 0 N-CA-C 110.875 -0.89 . . . . 0.0 110.875 -176.366 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . 0.495 ' CG ' ' H ' ' A' ' 110' ' ' ASP . 19.4 t70 -125.07 -150.76 0.45 Allowed 'General case' 0 N--CA 1.445 -0.677 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 179.398 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 110' ' ' ASP . . . . . 0.495 ' H ' ' CG ' ' A' ' 109' ' ' ASP . 31.7 m-20 -89.86 12.88 15.99 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 120.845 0.355 . . . . 0.0 111.475 -179.426 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . 0.454 ' HA3' ' ND2' ' A' ' 32' ' ' ASN . . . 101.33 8.61 46.54 Favored Glycine 0 C--O 1.229 -0.217 0 C-N-CA 120.129 -1.034 . . . . 0.0 113.408 179.529 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 48.4 mt-30 -68.83 -42.37 77.27 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.487 0.66 . . . . 0.0 110.557 179.224 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 17.5 p -133.51 139.28 46.55 Favored 'General case' 0 C--N 1.317 -0.839 0 CA-C-N 115.32 -0.854 . . . . 0.0 110.837 179.104 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 114' ' ' LEU . . . . . 0.437 ' HA ' ' HA ' ' A' ' 107' ' ' SER . 9.1 mp -120.31 145.16 47.37 Favored 'General case' 0 C--N 1.316 -0.867 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 178.677 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 8.6 p30 -148.1 160.4 42.93 Favored 'General case' 0 C--N 1.314 -0.939 0 C-N-CA 120.617 -0.433 . . . . 0.0 110.939 178.486 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 153.35 -128.0 2.32 Favored Glycine 0 N--CA 1.436 -1.337 0 CA-C-N 115.683 -0.69 . . . . 0.0 111.673 179.875 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 22.1 p -135.24 158.83 43.36 Favored 'General case' 0 C--N 1.315 -0.9 0 CA-C-O 121.11 0.481 . . . . 0.0 111.055 -179.079 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 118' ' ' MET . . . . . 0.442 ' O ' ' HA ' ' A' ' 125' ' ' PRO . 4.7 ppp? -147.19 156.03 42.61 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 116.156 -0.474 . . . . 0.0 109.841 178.841 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 119' ' ' THR . . . . . 0.648 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 26.4 m -128.72 126.45 40.06 Favored 'General case' 0 C--O 1.254 1.292 0 CA-C-O 120.519 0.2 . . . . 0.0 111.115 179.91 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 70.0 m-85 -85.42 158.44 20.22 Favored 'General case' 0 C--O 1.233 0.196 0 CA-C-N 115.777 -0.647 . . . . 0.0 109.982 176.264 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -60.3 126.32 27.03 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 120.778 0.323 . . . . 0.0 110.796 177.631 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 65.03 30.81 78.95 Favored Glycine 0 CA--C 1.523 0.562 0 CA-C-N 115.964 -0.562 . . . . 0.0 114.113 178.715 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 77.2 tt0 -150.49 160.2 43.95 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 117.229 0.514 . . . . 0.0 110.218 -179.345 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -77.2 160.08 49.46 Favored Glycine 0 CA--C 1.522 0.53 0 C-N-CA 121.084 -0.579 . . . . 0.0 112.908 -178.947 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . 0.442 ' HA ' ' O ' ' A' ' 118' ' ' MET . 51.4 Cg_endo -68.21 142.78 56.63 Favored 'Trans proline' 0 CA--C 1.534 0.502 0 C-N-CA 122.993 2.462 . . . . 0.0 113.271 179.743 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 49.1 pt -131.6 169.42 21.8 Favored 'Isoleucine or valine' 0 C--O 1.24 0.581 0 CA-C-N 115.737 -0.665 . . . . 0.0 109.935 178.547 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -70.66 131.99 21.99 Favored Glycine 0 C--N 1.336 0.55 0 C-N-CA 120.677 -0.773 . . . . 0.0 111.981 -179.381 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 84.7 t80 -119.5 139.19 52.48 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 121.255 0.55 . . . . 0.0 111.583 -178.146 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 129' ' ' LYS . . . . . 0.4 ' HB3' ' HB2' ' A' ' 7' ' ' GLU . 62.8 tttm -140.94 134.8 30.48 Favored 'General case' 0 N--CA 1.431 -1.379 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 176.85 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . 0.405 ' HA2' ' O ' ' A' ' 5' ' ' ASN . . . -135.15 144.75 16.78 Favored Glycine 0 N--CA 1.436 -1.355 0 C-N-CA 120.521 -0.847 . . . . 0.0 111.428 -179.502 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 56.2 m -123.81 130.55 52.79 Favored 'General case' 0 C--N 1.311 -1.084 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 -178.72 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 61.1 tp -70.67 136.22 48.9 Favored 'General case' 0 C--O 1.237 0.436 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 179.076 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 15.4 t . . . . . 0 C--O 1.251 1.149 0 CA-C-O 119.144 -0.455 . . . . 0.0 110.069 -177.65 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 0.578 ' O ' ' HG3' ' A' ' 24' ' ' GLU . . . . . . . . 0 N--CA 1.48 1.047 0 N-CA-C 110.022 -0.362 . . . . 0.0 110.022 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -91.97 128.23 37.74 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-O 121.019 0.437 . . . . 0.0 110.537 -175.743 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 11.8 m-85 -121.3 144.47 48.62 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.169 178.27 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 94.4 m-20 -94.66 140.13 30.29 Favored 'General case' 0 C--N 1.313 -0.99 0 N-CA-C 107.826 -1.176 . . . . 0.0 107.826 177.538 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 77.3 t -116.33 128.46 73.65 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.961 0 CA-C-O 121.274 0.559 . . . . 0.0 112.434 -175.629 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -125.09 138.75 54.18 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 176.691 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . 0.438 ' HB3' HD12 ' A' ' 126' ' ' ILE . 65.3 m-80 -131.01 151.88 50.93 Favored 'General case' 0 C--N 1.316 -0.866 0 N-CA-C 112.653 0.612 . . . . 0.0 112.653 -177.526 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . 0.413 ' OE1' ' HA ' ' A' ' 13' ' ' SER . 35.7 tt0 -129.47 128.13 42.28 Favored 'General case' 0 C--O 1.238 0.498 0 CA-C-N 115.343 -0.844 . . . . 0.0 110.533 178.336 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 46.8 p90 -138.11 146.24 42.63 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 116.575 -0.284 . . . . 0.0 110.484 178.617 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 95.12 11.82 55.76 Favored Glycine 0 N--CA 1.444 -0.775 0 C-N-CA 120.545 -0.836 . . . . 0.0 111.759 179.207 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 104.88 157.38 23.27 Favored Glycine 0 N--CA 1.442 -0.919 0 C-N-CA 120.953 -0.642 . . . . 0.0 112.144 179.088 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . 0.413 ' HA ' ' OE1' ' A' ' 9' ' ' GLN . 15.5 m -58.13 -21.16 45.42 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 112.128 0.418 . . . . 0.0 112.128 179.036 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 18.7 m -59.14 -33.73 71.23 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 120.806 0.336 . . . . 0.0 110.857 176.82 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -76.78 145.28 74.31 Favored Pre-proline 0 N--CA 1.45 -0.437 0 CA-C-N 116.009 -0.542 . . . . 0.0 111.132 -179.409 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 93.1 Cg_endo -73.26 163.19 38.62 Favored 'Trans proline' 0 C--O 1.236 0.375 0 C-N-CA 122.808 2.339 . . . . 0.0 112.266 -179.892 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 92.3 m95 -85.17 131.68 34.4 Favored 'General case' 0 C--N 1.319 -0.75 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 179.23 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 55.9 m-80 -124.1 144.94 49.59 Favored 'General case' 0 C--N 1.312 -1.029 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 -179.525 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -64.99 135.4 55.6 Favored 'General case' 0 C--N 1.311 -1.066 0 CA-C-O 121.598 0.713 . . . . 0.0 112.207 -177.274 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.427 ' HA3' HD22 ' A' ' 8' ' ' ASN . . . -112.2 34.82 4.98 Favored Glycine 0 CA--C 1.499 -0.912 0 CA-C-N 114.604 -1.18 . . . . 0.0 110.961 178.326 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 83.3 -156.85 34.24 Favored Glycine 0 N--CA 1.436 -1.353 0 N-CA-C 111.344 -0.702 . . . . 0.0 111.344 -177.387 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 13.6 pt20 -144.27 147.41 33.5 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-O 120.869 0.366 . . . . 0.0 110.246 178.204 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . 0.598 ' HB3' ' O ' ' A' ' 91' ' ' ILE . 54.4 m0 -128.33 -179.14 4.86 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.743 -173.893 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . 0.578 ' HG3' ' O ' ' A' ' 2' ' ' ALA . 82.6 tt0 -123.69 116.15 22.6 Favored 'General case' 0 CA--C 1.511 -0.534 0 CA-C-O 120.943 0.401 . . . . 0.0 110.522 176.446 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 95.3 mt -126.94 134.16 66.8 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.784 0 CA-C-N 115.448 -0.796 . . . . 0.0 110.767 -177.701 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 90.94 106.74 1.38 Allowed Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.973 -0.632 . . . . 0.0 113.911 176.526 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 19.8 m -69.1 -43.04 75.29 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.369 0.604 . . . . 0.0 110.02 175.419 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -71.0 137.96 49.52 Favored 'General case' 0 N--CA 1.451 -0.396 0 CA-C-N 115.292 -0.867 . . . . 0.0 110.663 179.77 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 19.8 m -102.86 -26.16 13.23 Favored 'General case' 0 C--N 1.315 -0.924 0 CA-C-O 121.054 0.454 . . . . 0.0 110.4 178.687 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 27.1 m-20 -91.09 -5.3 55.34 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.918 179.263 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . 0.486 HE21 ' HB3' ' A' ' 53' ' ' TYR . 57.6 tp60 -139.59 120.55 14.54 Favored 'General case' 0 C--N 1.31 -1.133 0 N-CA-C 109.35 -0.611 . . . . 0.0 109.35 -178.999 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 62.0 t30 -97.74 162.76 13.11 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-O 121.172 0.51 . . . . 0.0 112.083 -175.975 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.412 ' HA ' ' HA ' ' A' ' 53' ' ' TYR . 89.5 t -98.74 133.59 40.66 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.639 0 CA-C-N 115.217 -0.902 . . . . 0.0 109.991 179.965 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 21.0 m -107.05 -27.73 2.96 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.456 0 N-CA-C 111.981 0.364 . . . . 0.0 111.981 -179.38 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.42 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -139.56 143.63 37.44 Favored 'General case' 0 CA--C 1.509 -0.634 0 C-N-CA 120.109 -0.637 . . . . 0.0 111.632 179.989 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.435 ' HB ' ' CG2' ' A' ' 105' ' ' VAL . 94.2 mt -139.64 117.73 11.4 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.832 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 179.039 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' ASN . . . . . 0.447 HD22 ' HA ' ' A' ' 37' ' ' ASN . 1.3 t-20 -129.02 108.25 10.24 Favored 'General case' 0 C--N 1.304 -1.388 0 N-CA-C 108.065 -1.087 . . . . 0.0 108.065 177.453 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.434 HG22 ' HB ' ' A' ' 103' ' ' ILE . 23.9 m -147.03 151.38 13.95 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.762 0 C-N-CA 120.448 -0.501 . . . . 0.0 111.339 -173.184 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 36.1 tt0 -141.1 145.56 35.95 Favored 'General case' 0 N--CA 1.437 -1.089 0 CA-C-N 115.512 -0.767 . . . . 0.0 109.001 176.433 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 30.9 t -72.26 142.6 48.93 Favored 'General case' 0 C--N 1.309 -1.176 0 CA-C-O 121.093 0.473 . . . . 0.0 111.338 -178.522 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -95.22 -25.12 14.79 Favored Glycine 0 N--CA 1.433 -1.553 0 C-N-CA 120.504 -0.855 . . . . 0.0 111.769 177.919 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 36.1 t70 -145.11 79.63 1.59 Allowed 'General case' 0 CA--C 1.536 0.405 0 N-CA-C 112.842 0.682 . . . . 0.0 112.842 -177.372 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 50.24 29.03 3.44 Favored 'General case' 0 N--CA 1.491 1.611 0 N-CA-C 114.564 1.32 . . . . 0.0 114.564 173.673 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.502 ' HA2' HG12 ' A' ' 101' ' ' VAL . . . 99.44 -16.77 58.6 Favored Glycine 0 C--N 1.312 -0.791 0 C-N-CA 120.658 -0.782 . . . . 0.0 113.189 178.187 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 59.7 tp60 -66.42 -39.01 88.72 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-O 121.04 0.448 . . . . 0.0 110.77 -179.944 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 36.8 p -125.67 147.84 49.21 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.975 178.499 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' LEU . . . . . 0.551 ' HB2' ' HB3' ' A' ' 63' ' ' ALA . 95.2 mt -128.36 128.15 43.99 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 109.524 -0.547 . . . . 0.0 109.524 179.254 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 13.8 m120 -128.44 141.1 51.51 Favored 'General case' 0 C--N 1.319 -0.723 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 178.398 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 175.45 -156.26 21.73 Favored Glycine 0 N--CA 1.442 -0.948 0 C-N-CA 119.411 -1.376 . . . . 0.0 113.503 178.444 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 70.4 m -128.95 131.46 47.5 Favored 'General case' 0 N--CA 1.44 -0.971 0 C-N-CA 122.839 0.456 . . . . 0.0 110.149 -178.43 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' MET . . . . . 0.403 ' HE1' ' CZ ' ' A' ' 53' ' ' TYR . 14.7 tmm? -125.91 144.73 50.56 Favored 'General case' 0 C--N 1.316 -0.875 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 -179.265 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.42 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 33.6 m -126.26 130.06 50.13 Favored 'General case' 0 C--O 1.245 0.866 0 N-CA-C 112.054 0.39 . . . . 0.0 112.054 -176.57 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . 0.486 ' HB3' HE21 ' A' ' 31' ' ' GLN . 72.4 m-85 -87.15 161.8 17.87 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.946 177.176 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -63.54 106.91 1.02 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.989 -0.55 . . . . 0.0 112.069 -179.713 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 84.67 10.6 79.0 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.713 -0.756 . . . . 0.0 113.528 177.836 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 57.8 mt-10 -123.07 168.02 12.9 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 117.212 0.506 . . . . 0.0 110.793 178.26 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -79.86 155.48 38.97 Favored Glycine 0 N--CA 1.447 -0.599 0 C-N-CA 120.84 -0.695 . . . . 0.0 112.379 -179.884 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 32.9 Cg_endo -62.81 142.72 89.89 Favored 'Trans proline' 0 CA--C 1.534 0.503 0 C-N-CA 123.012 2.475 . . . . 0.0 112.546 -179.758 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . 0.566 ' HB ' ' O ' ' A' ' 76' ' ' GLN . 47.3 pt -128.25 167.35 23.55 Favored 'Isoleucine or valine' 0 C--O 1.239 0.501 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.736 -179.765 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -79.11 138.63 20.89 Favored Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 120.929 -0.653 . . . . 0.0 111.807 -179.702 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 60.9 t80 -118.62 123.59 45.36 Favored 'General case' 0 C--N 1.317 -0.827 0 C-N-CA 122.389 0.275 . . . . 0.0 110.799 -178.132 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 49.1 ttm-85 -126.81 128.22 46.22 Favored 'General case' 0 C--O 1.22 -0.452 0 N-CA-C 109.325 -0.62 . . . . 0.0 109.325 175.997 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.65 ' HB1' ' HB3' ' A' ' 71' ' ' TYR . . . -136.12 142.81 44.29 Favored 'General case' 0 C--N 1.32 -0.696 0 C-N-CA 120.231 -0.588 . . . . 0.0 112.094 178.574 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 57.3 m -118.7 127.45 53.58 Favored 'General case' 0 CA--C 1.54 0.573 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.084 178.249 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . 0.403 HD13 ' N ' ' A' ' 67' ' ' GLY . 2.4 tm? -72.74 118.31 15.51 Favored 'General case' 0 CA--C 1.544 0.749 0 CA-C-O 121.372 0.606 . . . . 0.0 112.156 -177.866 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 4.6 mm? -66.86 -38.22 85.94 Favored 'General case' 0 N--CA 1.475 0.792 0 CA-C-N 115.283 -0.871 . . . . 0.0 111.869 178.091 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.403 ' N ' HD13 ' A' ' 65' ' ' LEU . . . 125.45 -6.14 8.07 Favored Glycine 0 C--O 1.227 -0.304 0 C-N-CA 120.593 -0.813 . . . . 0.0 112.521 -176.263 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 29.7 p-10 -125.83 38.19 4.2 Favored 'General case' 0 C--N 1.316 -0.889 0 CA-C-O 121.117 0.484 . . . . 0.0 110.507 -179.372 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 96.1 m-20 66.59 5.09 3.64 Favored 'General case' 0 N--CA 1.479 0.976 0 CA-C-N 115.469 -0.787 . . . . 0.0 111.882 -178.761 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 32.8 m -99.17 138.06 36.81 Favored 'General case' 0 N--CA 1.443 -0.785 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 177.367 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.65 ' HB3' ' HB1' ' A' ' 63' ' ' ALA . 91.5 m-85 -120.38 135.65 54.97 Favored 'General case' 0 C--N 1.306 -1.296 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.329 -179.28 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . 0.417 ' O ' ' HA ' ' A' ' 63' ' ' ALA . 71.6 tt0 -88.76 121.31 31.0 Favored 'General case' 0 C--N 1.311 -1.077 0 N-CA-C 107.964 -1.124 . . . . 0.0 107.964 175.286 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.469 HG22 ' HB2' ' A' ' 63' ' ' ALA . 75.3 t -107.67 137.05 40.85 Favored 'Isoleucine or valine' 0 C--O 1.247 0.957 0 N-CA-C 113.661 0.986 . . . . 0.0 113.661 -170.857 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -119.17 142.67 47.76 Favored 'General case' 0 N--CA 1.444 -0.739 0 CA-C-N 114.19 -1.368 . . . . 0.0 107.84 175.565 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 94.1 m-20 -118.06 135.31 54.27 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-O 120.825 0.345 . . . . 0.0 111.251 -175.699 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' GLN . . . . . 0.566 ' O ' ' HB ' ' A' ' 59' ' ' ILE . 17.3 tt0 -110.09 119.35 39.02 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.889 179.124 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 7.5 p90 -139.63 156.71 46.68 Favored 'General case' 0 C--N 1.326 -0.456 0 C-N-CA 120.856 -0.338 . . . . 0.0 111.358 177.013 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 105.81 -3.95 39.13 Favored Glycine 0 N--CA 1.449 -0.498 0 C-N-CA 121.198 -0.525 . . . . 0.0 112.177 179.666 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 139.63 171.57 12.35 Favored Glycine 0 CA--C 1.503 -0.694 0 N-CA-C 110.579 -1.008 . . . . 0.0 110.579 -179.602 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -68.07 155.16 40.15 Favored 'General case' 0 C--O 1.245 0.839 0 CA-C-N 117.527 0.664 . . . . 0.0 110.047 178.448 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 14.7 m 70.95 -95.2 0.03 OUTLIER 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.467 -0.788 . . . . 0.0 109.042 -176.601 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . 0.547 ' HB1' ' HD2' ' A' ' 83' ' ' PRO . . . 51.46 171.07 0.04 OUTLIER Pre-proline 0 CA--C 1.557 1.25 0 N-CA-C 113.31 0.855 . . . . 0.0 113.31 176.38 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' PRO . . . . . 0.547 ' HD2' ' HB1' ' A' ' 82' ' ' ALA . 63.6 Cg_endo -73.27 150.6 47.49 Favored 'Trans proline' 0 N--CA 1.452 -0.943 0 C-N-CA 121.591 1.527 . . . . 0.0 109.927 170.551 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' TRP . . . . . . . . . . . . . 82.2 m95 -95.69 137.99 33.98 Favored 'General case' 0 C--N 1.315 -0.924 0 C-N-CA 120.54 -0.464 . . . . 0.0 109.768 -179.91 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 84.4 m-70 -113.18 138.8 49.43 Favored 'General case' 0 C--N 1.314 -0.976 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 -177.775 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 13.4 p -65.15 131.25 46.04 Favored 'General case' 0 C--N 1.32 -0.688 0 C-N-CA 121.113 -0.235 . . . . 0.0 110.447 -179.779 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -105.36 -52.3 0.83 Allowed Glycine 0 N--CA 1.443 -0.836 0 C-N-CA 120.239 -0.981 . . . . 0.0 113.23 -179.187 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 154.59 -166.27 32.24 Favored Glycine 0 C--O 1.22 -0.747 0 C-N-CA 120.187 -1.006 . . . . 0.0 112.115 -178.108 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 20.5 t-20 -113.81 119.43 37.32 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 117.01 0.405 . . . . 0.0 110.709 -179.482 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 22.4 m0 -108.89 148.1 31.16 Favored 'General case' 0 C--O 1.217 -0.621 0 N-CA-C 109.492 -0.558 . . . . 0.0 109.492 -179.867 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . 0.598 ' O ' ' HB3' ' A' ' 23' ' ' TRP . 85.0 mt -107.7 119.56 57.51 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.072 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 178.903 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . 0.463 ' HB2' ' CE1' ' A' ' 71' ' ' TYR . 90.9 mt -134.08 78.95 1.79 Allowed 'General case' 0 C--O 1.267 1.984 0 CA-C-O 121.688 0.756 . . . . 0.0 111.6 -177.399 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 168.85 126.7 0.87 Allowed Glycine 0 N--CA 1.44 -1.08 0 CA-C-N 115.13 -0.941 . . . . 0.0 111.875 179.29 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . 0.425 ' HB3' ' HE1' ' A' ' 23' ' ' TRP . 32.4 p -117.95 4.2 12.13 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-O 121.353 0.596 . . . . 0.0 110.651 178.379 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 62.3 mtt-85 -102.01 142.84 32.66 Favored 'General case' 0 N--CA 1.445 -0.702 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.521 178.903 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 -62.66 -37.61 87.09 Favored 'General case' 0 C--N 1.312 -1.029 0 CA-C-N 115.421 -0.809 . . . . 0.0 112.899 -176.143 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 29.0 p-10 -126.3 27.93 6.11 Favored 'General case' 0 C--N 1.316 -0.86 0 N-CA-C 111.827 0.306 . . . . 0.0 111.827 -176.333 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 98' ' ' GLN . . . . . 0.552 HE21 ' HB3' ' A' ' 121' ' ' ALA . 21.9 tp60 -146.19 126.56 14.01 Favored 'General case' 0 C--N 1.322 -0.615 0 C-N-CA 119.319 -0.953 . . . . 0.0 111.688 -175.471 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 99' ' ' ASN . . . . . 0.591 ' HB3' ' OH ' ' A' ' 71' ' ' TYR . 87.2 m-20 -97.24 154.28 17.5 Favored 'General case' 0 C--O 1.249 1.048 0 CA-C-N 115.452 -0.795 . . . . 0.0 110.572 -179.439 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 70.8 t -79.03 136.86 22.9 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.791 0 C-N-CA 120.85 -0.34 . . . . 0.0 110.79 177.84 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . 0.502 HG12 ' HA2' ' A' ' 44' ' ' GLY . 33.3 m -123.0 -35.52 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.714 0 N-CA-C 113.878 1.066 . . . . 0.0 113.878 -177.118 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . 0.43 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -127.59 127.33 43.68 Favored 'General case' 0 C--N 1.319 -0.743 0 C-N-CA 120.153 -0.619 . . . . 0.0 111.386 -178.63 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.434 ' HB ' HG22 ' A' ' 38' ' ' VAL . 94.0 mt -131.18 122.09 50.57 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.091 177.927 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 7.6 t30 -124.79 95.4 4.5 Favored 'General case' 0 C--N 1.313 -1.001 0 N-CA-C 108.812 -0.81 . . . . 0.0 108.812 176.455 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.435 ' CG2' ' HB ' ' A' ' 36' ' ' ILE . 26.8 m -140.17 142.68 31.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 N-CA-C 112.682 0.623 . . . . 0.0 112.682 -175.612 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 -145.1 147.16 32.23 Favored 'General case' 0 N--CA 1.444 -0.759 0 CA-C-N 115.4 -0.818 . . . . 0.0 109.153 176.526 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 47.2 t -137.73 142.48 40.99 Favored 'General case' 0 C--N 1.308 -1.221 0 CA-C-O 120.797 0.332 . . . . 0.0 110.78 -178.589 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -108.01 -6.18 32.39 Favored Glycine 0 N--CA 1.44 -1.05 0 N-CA-C 110.796 -0.922 . . . . 0.0 110.796 175.766 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 68.3 m-20 -98.26 54.65 1.09 Allowed 'General case' 0 C--O 1.235 0.33 0 N-CA-C 112.643 0.609 . . . . 0.0 112.643 -177.582 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 28.7 t70 59.55 15.55 4.65 Favored 'General case' 0 N--CA 1.481 1.098 0 C-N-CA 123.3 0.64 . . . . 0.0 112.284 174.863 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 86.37 -3.85 86.66 Favored Glycine 0 N--CA 1.447 -0.625 0 C-N-CA 120.447 -0.882 . . . . 0.0 112.944 178.232 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 112' ' ' GLN . . . . . 0.42 ' O ' ' HA ' ' A' ' 131' ' ' THR . 97.6 mt-30 -64.21 -40.14 95.45 Favored 'General case' 0 CA--C 1.517 -0.29 0 CA-C-N 116.926 0.363 . . . . 0.0 111.622 -177.76 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 33.5 p -123.32 112.17 17.28 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 110.0 -0.37 . . . . 0.0 110.0 177.833 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 92.5 mt -90.93 126.95 36.21 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 116.464 -0.335 . . . . 0.0 110.477 -178.66 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 9.0 m120 -118.72 129.86 55.51 Favored 'General case' 0 C--O 1.241 0.651 0 CA-C-N 116.224 -0.444 . . . . 0.0 109.882 -178.812 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 172.21 -141.32 6.22 Favored Glycine 0 N--CA 1.445 -0.755 0 C-N-CA 119.741 -1.218 . . . . 0.0 113.608 178.098 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 16.9 p -137.29 159.32 42.27 Favored 'General case' 0 C--N 1.319 -0.726 0 C-N-CA 123.276 0.63 . . . . 0.0 110.781 -178.269 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 17.8 ptm -147.31 150.44 34.79 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 120.864 0.364 . . . . 0.0 110.898 -179.721 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 119' ' ' THR . . . . . 0.43 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 23.3 m -142.48 136.09 29.05 Favored 'General case' 0 C--O 1.252 1.194 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.064 178.053 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . 0.628 ' HB2' ' O ' ' A' ' 123' ' ' GLU . 37.1 m-85 -83.58 174.26 10.7 Favored 'General case' 0 C--O 1.225 -0.23 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.342 175.597 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . 0.552 ' HB3' HE21 ' A' ' 98' ' ' GLN . . . -51.22 -28.87 12.55 Favored 'General case' 0 N--CA 1.478 0.933 0 N-CA-C 114.058 1.133 . . . . 0.0 114.058 -175.951 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -165.54 26.84 0.18 Allowed Glycine 0 N--CA 1.447 -0.589 0 C-N-CA 119.29 -1.433 . . . . 0.0 112.742 179.986 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . 0.628 ' O ' ' HB2' ' A' ' 120' ' ' TYR . 13.3 pt-20 -165.97 145.59 6.25 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.132 0.491 . . . . 0.0 111.868 -178.51 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 71.87 67.92 1.74 Allowed Glycine 0 CA--C 1.531 1.084 0 N-CA-C 116.312 1.285 . . . . 0.0 116.312 173.075 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_exo -84.14 95.07 0.73 Allowed 'Trans proline' 0 N--CA 1.459 -0.53 0 C-N-CA 122.454 2.102 . . . . 0.0 108.374 170.561 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 126' ' ' ILE . . . . . 0.438 HD12 ' HB3' ' A' ' 8' ' ' ASN . 19.6 pt -130.28 165.83 29.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 N-CA-C 113.234 0.828 . . . . 0.0 113.234 -170.762 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -70.44 135.99 25.96 Favored Glycine 0 C--N 1.339 0.703 0 CA-C-N 115.488 -0.778 . . . . 0.0 111.577 178.29 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 82.5 t80 -112.54 133.26 54.69 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 121.281 0.562 . . . . 0.0 111.754 -175.688 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 63.5 tttm -137.64 110.4 7.61 Favored 'General case' 0 C--N 1.314 -0.939 0 CA-C-N 115.241 -0.891 . . . . 0.0 108.933 177.089 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -117.56 153.82 17.02 Favored Glycine 0 N--CA 1.446 -0.685 0 C-N-CA 120.298 -0.953 . . . . 0.0 112.332 -178.363 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 131' ' ' THR . . . . . 0.42 ' HA ' ' O ' ' A' ' 112' ' ' GLN . 14.9 t -143.01 144.95 32.49 Favored 'General case' 0 C--N 1.311 -1.073 0 CA-C-O 121.149 0.5 . . . . 0.0 111.945 179.625 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 68.6 tp -80.91 127.16 32.24 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.342 -0.845 . . . . 0.0 110.219 178.337 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 9.1 t . . . . . 0 C--O 1.253 1.27 0 CA-C-O 118.957 -0.544 . . . . 0.0 110.496 -179.343 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.697 0 N-CA-C 109.995 -0.372 . . . . 0.0 109.995 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' LEU . . . . . 0.552 HD11 HE21 ' A' ' 22' ' ' GLN . 2.2 tm? -92.08 134.91 34.4 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 116.117 -0.492 . . . . 0.0 109.801 -178.031 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . 0.485 ' CE1' ' HB ' ' A' ' 25' ' ' ILE . 74.1 m-85 -123.36 146.54 47.87 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.515 -179.803 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' ASN . . . . . 0.428 ' O ' ' HA2' ' A' ' 130' ' ' GLY . 23.6 t-20 -96.45 140.9 30.42 Favored 'General case' 0 C--N 1.308 -1.211 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 176.627 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 69.9 t -122.77 129.53 75.1 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.916 0 N-CA-C 112.699 0.629 . . . . 0.0 112.699 -175.154 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 91.4 mt-10 -122.4 144.32 49.11 Favored 'General case' 0 C--N 1.32 -0.679 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 173.09 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 11.9 m120 -123.49 144.67 49.39 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-O 120.921 0.391 . . . . 0.0 111.493 -177.003 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . 0.595 ' HB2' ' CE3' ' A' ' 17' ' ' TRP . 57.9 tt0 -123.88 127.14 47.59 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.766 -179.853 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 8.7 p90 -136.09 139.22 42.83 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-N 116.193 -0.458 . . . . 0.0 109.865 176.915 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 105.34 8.0 36.41 Favored Glycine 0 N--CA 1.448 -0.529 0 C-N-CA 120.286 -0.959 . . . . 0.0 112.294 179.862 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 103.24 165.71 25.68 Favored Glycine 0 N--CA 1.445 -0.724 0 C-N-CA 120.402 -0.904 . . . . 0.0 113.427 177.954 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 15.6 m -54.81 -31.81 59.6 Favored 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 123.631 0.773 . . . . 0.0 112.321 179.013 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 33.6 t -64.25 -40.0 95.11 Favored 'General case' 0 C--O 1.242 0.701 0 CA-C-O 120.97 0.414 . . . . 0.0 110.604 -179.573 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -63.43 150.55 89.56 Favored Pre-proline 0 C--O 1.235 0.34 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.403 -179.118 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 88.8 Cg_endo -75.33 156.87 41.6 Favored 'Trans proline' 0 C--O 1.238 0.477 0 C-N-CA 122.888 2.392 . . . . 0.0 112.93 -179.476 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' TRP . . . . . 0.595 ' CE3' ' HB2' ' A' ' 9' ' ' GLN . 85.7 m95 -84.91 124.59 31.82 Favored 'General case' 0 N--CA 1.446 -0.627 0 N-CA-C 107.872 -1.159 . . . . 0.0 107.872 175.71 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 55.1 m-80 -103.68 137.13 42.15 Favored 'General case' 0 C--N 1.308 -1.228 0 N-CA-C 109.122 -0.695 . . . . 0.0 109.122 -179.177 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 18.5 pt-20 -63.78 128.79 37.38 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-O 121.625 0.726 . . . . 0.0 111.673 -178.277 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.681 ' O ' ' HB2' ' A' ' 94' ' ' SER . . . -102.26 -25.28 7.92 Favored Glycine 0 N--CA 1.434 -1.467 0 CA-C-N 114.435 -1.257 . . . . 0.0 113.746 -174.851 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 139.07 -153.04 22.57 Favored Glycine 0 N--CA 1.443 -0.849 0 C-N-CA 119.684 -1.246 . . . . 0.0 112.071 -174.367 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . 0.552 HE21 HD11 ' A' ' 3' ' ' LEU . 4.1 pt20 -138.41 134.37 34.04 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 120.733 0.302 . . . . 0.0 110.707 -179.054 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . 0.471 ' HE1' ' HB3' ' A' ' 94' ' ' SER . 44.9 m0 -117.61 172.74 7.15 Favored 'General case' 0 N--CA 1.47 0.568 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.637 -179.021 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 79.2 tt0 -130.93 122.49 27.04 Favored 'General case' 0 CA--C 1.518 -0.286 0 C-N-CA 120.513 -0.475 . . . . 0.0 110.142 178.006 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.571 HG23 ' CZ3' ' A' ' 90' ' ' TRP . 99.1 mt -139.72 151.39 22.26 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.769 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.189 -176.146 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 84.62 25.91 40.68 Favored Glycine 0 C--N 1.336 0.559 0 C-N-CA 121.009 -0.615 . . . . 0.0 113.81 175.26 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 4.9 m -77.85 7.94 5.25 Favored 'General case' 0 CA--C 1.549 0.93 0 N-CA-C 112.471 0.545 . . . . 0.0 112.471 -179.06 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . 0.499 ' HA ' ' O ' ' A' ' 87' ' ' GLY . 70.7 ttt180 -64.16 -49.68 71.15 Favored 'General case' 0 N--CA 1.474 0.756 0 CA-C-O 121.14 0.495 . . . . 0.0 111.85 -177.977 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 59.2 m -161.47 25.41 0.13 Allowed 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 -179.795 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 27.4 m-20 61.35 94.38 0.04 OUTLIER 'General case' 0 C--O 1.236 0.388 0 CA-C-N 114.486 -1.234 . . . . 0.0 108.783 -175.894 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -160.93 143.42 12.6 Favored 'General case' 0 N--CA 1.443 -0.78 0 N-CA-C 107.455 -1.313 . . . . 0.0 107.455 -176.23 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . 0.515 ' HB3' ' HA3' ' A' ' 111' ' ' GLY . 3.8 m120 -83.37 134.71 34.88 Favored 'General case' 0 C--N 1.311 -1.089 0 CA-C-O 121.543 0.687 . . . . 0.0 112.589 -177.741 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.422 ' HA ' ' HA ' ' A' ' 53' ' ' TYR . 44.7 t -92.9 135.99 26.18 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.727 0 CA-C-N 114.768 -1.105 . . . . 0.0 110.153 -179.857 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 29.7 m -109.36 -18.6 7.41 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 C-N-CA 120.758 -0.377 . . . . 0.0 111.572 -179.671 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -149.92 139.1 21.22 Favored 'General case' 0 C--O 1.236 0.361 0 C-N-CA 120.787 -0.365 . . . . 0.0 111.48 178.666 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.449 ' HB ' ' CG2' ' A' ' 105' ' ' VAL . 86.8 mt -140.03 116.32 8.74 Favored 'Isoleucine or valine' 0 C--O 1.237 0.446 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 178.635 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 14.7 m120 -123.55 106.65 10.77 Favored 'General case' 0 C--N 1.311 -1.085 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 176.716 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.413 ' CG2' ' HB ' ' A' ' 103' ' ' ILE . 18.6 m -146.56 148.11 17.26 Favored 'Isoleucine or valine' 0 C--O 1.238 0.472 0 CA-C-O 120.742 0.306 . . . . 0.0 111.236 -174.764 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 83.0 tt0 -142.61 147.41 35.78 Favored 'General case' 0 C--N 1.319 -0.759 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 178.169 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 19.4 p -70.81 150.33 45.94 Favored 'General case' 0 C--N 1.319 -0.757 0 N-CA-C 112.985 0.735 . . . . 0.0 112.985 -176.248 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -103.55 -47.39 1.3 Allowed Glycine 0 N--CA 1.443 -0.879 0 N-CA-C 110.529 -1.029 . . . . 0.0 110.529 176.252 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 45.4 m-20 -102.11 -152.8 0.45 Allowed 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 109.57 -0.53 . . . . 0.0 109.57 177.065 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 19.0 m-20 -74.17 44.41 0.19 Allowed 'General case' 0 N--CA 1.486 1.367 0 N-CA-C 112.147 0.425 . . . . 0.0 112.147 -177.927 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 79.91 3.45 89.32 Favored Glycine 0 CA--C 1.506 -0.475 0 C-N-CA 120.881 -0.676 . . . . 0.0 112.056 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 61.1 mt-30 -83.43 -21.99 32.78 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-O 121.215 0.531 . . . . 0.0 110.081 178.464 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . 0.502 ' HA ' ' O ' ' A' ' 63' ' ' ALA . 35.2 p -129.03 142.62 50.85 Favored 'General case' 0 C--N 1.315 -0.907 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.936 178.52 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' LEU . . . . . 0.405 ' O ' ' HA ' ' A' ' 62' ' ' ARG . 95.9 mt -128.62 133.18 48.22 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 109.103 -0.702 . . . . 0.0 109.103 179.915 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 14.0 m120 -126.5 139.4 53.25 Favored 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 -179.97 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 169.74 -150.51 15.13 Favored Glycine 0 N--CA 1.448 -0.538 0 C-N-CA 120.112 -1.042 . . . . 0.0 112.463 178.035 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 34.8 p -134.45 152.43 51.79 Favored 'General case' 0 C--N 1.317 -0.83 0 N-CA-C 110.031 -0.359 . . . . 0.0 110.031 179.676 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 11.0 tmm? -142.12 145.49 34.3 Favored 'General case' 0 C--N 1.315 -0.912 0 C-N-CA 121.124 -0.23 . . . . 0.0 110.85 -178.829 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 60.4 m -129.07 128.64 43.97 Favored 'General case' 0 C--O 1.248 1.014 0 CA-C-O 120.81 0.338 . . . . 0.0 111.904 -177.399 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . 0.494 ' HB2' ' HB2' ' A' ' 56' ' ' GLU . 78.7 m-85 -91.11 164.63 13.86 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 115.617 -0.72 . . . . 0.0 110.327 176.86 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -69.39 98.26 1.07 Allowed 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.189 179.017 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 103.9 2.16 45.78 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.946 -0.645 . . . . 0.0 112.793 177.779 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . 0.494 ' HB2' ' HB2' ' A' ' 53' ' ' TYR . 66.7 mm-40 -117.69 162.91 17.27 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 110.115 -0.328 . . . . 0.0 110.115 179.02 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -84.08 166.25 42.34 Favored Glycine 0 N--CA 1.441 -0.972 0 C-N-CA 120.282 -0.961 . . . . 0.0 111.784 179.114 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 23.1 Cg_exo -65.82 139.78 58.61 Favored 'Trans proline' 0 N--CA 1.462 -0.348 0 C-N-CA 122.459 2.106 . . . . 0.0 111.912 178.921 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 38.3 pt -128.88 161.29 38.36 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.792 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.386 178.85 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -74.8 134.48 17.41 Favored Glycine 0 N--CA 1.446 -0.669 0 N-CA-C 111.331 -0.707 . . . . 0.0 111.331 179.984 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 52.6 t80 -117.46 125.98 51.84 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-O 121.034 0.445 . . . . 0.0 111.562 -176.905 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . 0.405 ' HA ' ' O ' ' A' ' 47' ' ' LEU . 64.0 ttp85 -136.53 129.08 30.42 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.857 -0.61 . . . . 0.0 109.747 174.737 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.502 ' O ' ' HA ' ' A' ' 46' ' ' THR . . . -129.41 139.3 51.7 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 116.563 -0.289 . . . . 0.0 110.966 -177.748 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 40.6 m -122.29 128.72 51.41 Favored 'General case' 0 C--N 1.323 -0.544 0 O-C-N 123.512 0.507 . . . . 0.0 109.74 178.534 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 52.6 tp -75.58 119.28 19.42 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 112.388 0.514 . . . . 0.0 112.388 -177.082 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 84.6 mt -84.18 -27.61 27.94 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.453 -0.794 . . . . 0.0 109.438 174.847 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 129.81 158.86 9.59 Favored Glycine 0 N--CA 1.442 -0.901 0 CA-C-N 115.109 -0.95 . . . . 0.0 110.81 -178.861 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 93.0 m-20 60.89 37.29 18.55 Favored 'General case' 0 N--CA 1.476 0.86 0 CA-C-O 120.848 0.356 . . . . 0.0 111.242 178.969 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 16.8 m120 66.37 8.15 5.48 Favored 'General case' 0 N--CA 1.485 1.309 0 C-N-CA 123.244 0.618 . . . . 0.0 112.151 179.237 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 15.8 m -92.18 121.84 34.09 Favored 'General case' 0 N--CA 1.446 -0.666 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 178.703 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 64.8 m-85 -113.58 132.73 55.62 Favored 'General case' 0 C--N 1.312 -1.04 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.999 -178.942 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 63.2 tt0 -86.96 119.76 27.51 Favored 'General case' 0 N--CA 1.438 -1.035 0 N-CA-C 106.763 -1.569 . . . . 0.0 106.763 172.952 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 79.2 t -107.27 134.51 48.76 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 CA-C-O 121.182 0.515 . . . . 0.0 112.086 -172.824 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 87.6 mt-10 -127.37 129.61 47.9 Favored 'General case' 0 N--CA 1.438 -1.072 0 N-CA-C 107.703 -1.221 . . . . 0.0 107.703 176.363 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 48.9 m-80 -112.42 154.79 25.26 Favored 'General case' 0 C--N 1.314 -0.971 0 CA-C-O 120.967 0.413 . . . . 0.0 111.041 -176.68 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 63.1 tt0 -115.45 119.95 37.91 Favored 'General case' 0 C--N 1.311 -1.099 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.152 -178.695 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 12.4 p90 -143.67 161.86 37.44 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.804 179.388 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 100.4 -7.21 58.06 Favored Glycine 0 N--CA 1.446 -0.674 0 C-N-CA 120.858 -0.687 . . . . 0.0 111.924 179.648 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 136.2 160.28 8.74 Favored Glycine 0 N--CA 1.44 -1.081 0 N-CA-C 111.574 -0.611 . . . . 0.0 111.574 179.92 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 15.7 t70 -59.74 -41.78 91.69 Favored 'General case' 0 C--N 1.319 -0.737 0 C-N-CA 123.115 0.566 . . . . 0.0 112.085 179.626 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 50.6 p -76.71 -3.97 40.79 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 112.573 0.583 . . . . 0.0 112.573 -179.205 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -76.52 150.74 82.5 Favored Pre-proline 0 C--N 1.325 -0.46 0 CA-C-O 120.518 0.199 . . . . 0.0 110.945 -179.686 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -74.07 -178.55 3.95 Favored 'Trans proline' 0 C--O 1.239 0.54 0 C-N-CA 122.633 2.222 . . . . 0.0 112.083 179.212 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' TRP . . . . . . . . . . . . . 89.0 m95 -95.77 140.24 30.85 Favored 'General case' 0 N--CA 1.444 -0.729 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.352 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 89.5 m-70 -118.26 142.98 46.92 Favored 'General case' 0 C--N 1.31 -1.117 0 CA-C-N 116.273 -0.421 . . . . 0.0 109.949 179.878 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 11.8 p -62.85 134.26 55.97 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.843 0.354 . . . . 0.0 111.161 -178.366 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . 0.499 ' O ' ' HA ' ' A' ' 28' ' ' ARG . . . -107.89 -46.43 1.03 Allowed Glycine 0 N--CA 1.438 -1.167 0 C-N-CA 120.971 -0.633 . . . . 0.0 111.909 179.76 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 148.39 -168.0 29.08 Favored Glycine 0 C--O 1.225 -0.44 0 C-N-CA 120.031 -1.081 . . . . 0.0 112.733 178.24 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 24.9 t-20 -106.0 117.05 33.02 Favored 'General case' 0 C--N 1.321 -0.674 0 N-CA-C 110.054 -0.35 . . . . 0.0 110.054 -179.012 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 90' ' ' TRP . . . . . 0.571 ' CZ3' HG23 ' A' ' 25' ' ' ILE . 18.6 m0 -113.56 148.21 36.56 Favored 'General case' 0 C--N 1.317 -0.818 0 N-CA-C 109.284 -0.635 . . . . 0.0 109.284 179.887 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 85.6 mt -105.32 117.89 51.8 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.843 0 N-CA-C 109.547 -0.538 . . . . 0.0 109.547 179.064 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 86.0 mt -129.26 78.61 1.86 Allowed 'General case' 0 C--O 1.265 1.92 0 CA-C-O 121.863 0.839 . . . . 0.0 112.092 -177.76 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 170.05 124.45 0.74 Allowed Glycine 0 N--CA 1.441 -0.987 0 CA-C-N 114.757 -1.111 . . . . 0.0 110.722 178.996 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . 0.681 ' HB2' ' O ' ' A' ' 20' ' ' GLY . 83.7 p -106.42 -7.61 17.53 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-O 120.898 0.38 . . . . 0.0 111.665 -179.55 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 95' ' ' ARG . . . . . 0.424 HH12 ' CD ' ' A' ' 123' ' ' GLU . 99.5 mtt180 -106.76 154.61 20.73 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 121.269 0.557 . . . . 0.0 112.091 178.871 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 26.8 tp10 -68.62 -38.83 80.89 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 114.965 -1.016 . . . . 0.0 111.061 -174.258 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 10.1 p30 -116.17 21.06 13.96 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.925 -177.076 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 98' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -136.75 115.82 12.42 Favored 'General case' 0 C--N 1.32 -0.697 0 C-N-CA 119.573 -0.851 . . . . 0.0 112.89 -176.46 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 90.4 m-20 -92.44 154.76 18.3 Favored 'General case' 0 C--O 1.249 1.057 0 CA-C-N 115.029 -0.987 . . . . 0.0 109.353 177.488 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.427 HG21 ' CH2' ' A' ' 23' ' ' TRP . 85.2 t -79.75 130.8 35.49 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.555 0 C-N-CA 120.092 -0.643 . . . . 0.0 110.899 178.492 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . 0.433 HG11 ' HA ' ' A' ' 121' ' ' ALA . 33.7 m -111.74 -19.18 7.08 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.438 0 N-CA-C 112.122 0.415 . . . . 0.0 112.122 -179.654 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . 0.639 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -152.12 140.07 20.08 Favored 'General case' 0 CA--C 1.511 -0.537 0 C-N-CA 119.899 -0.72 . . . . 0.0 111.588 176.975 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.413 ' HB ' ' CG2' ' A' ' 38' ' ' VAL . 95.4 mt -135.49 125.01 41.75 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.175 177.456 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 52.6 t30 -129.74 101.22 5.8 Favored 'General case' 0 C--N 1.315 -0.931 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 175.801 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.449 ' CG2' ' HB ' ' A' ' 36' ' ' ILE . 19.8 m -140.9 142.8 29.51 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.791 0 N-CA-C 113.195 0.813 . . . . 0.0 113.195 -175.547 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 99.9 mt-10 -141.58 151.25 43.02 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 114.911 -1.04 . . . . 0.0 108.615 176.507 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 36.5 t -130.12 146.94 51.81 Favored 'General case' 0 C--N 1.311 -1.106 0 CA-C-O 121.244 0.545 . . . . 0.0 111.871 -177.817 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -89.61 -10.98 64.63 Favored Glycine 0 N--CA 1.444 -0.792 0 N-CA-C 110.366 -1.094 . . . . 0.0 110.366 174.435 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 83.6 m-20 -94.16 -172.06 2.71 Favored 'General case' 0 CA--C 1.513 -0.48 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 178.28 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 13.5 p-10 -95.74 33.86 1.59 Allowed 'General case' 0 C--N 1.313 -0.988 0 CA-C-O 121.031 0.443 . . . . 0.0 109.986 176.884 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . 0.515 ' HA3' ' HB3' ' A' ' 32' ' ' ASN . . . 97.42 8.56 56.15 Favored Glycine 0 C--N 1.333 0.406 0 CA-C-N 115.825 -0.625 . . . . 0.0 113.803 179.13 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 28.3 tt0 -64.72 -40.88 96.08 Favored 'General case' 0 C--O 1.241 0.621 0 CA-C-O 121.537 0.684 . . . . 0.0 109.858 178.383 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 73.2 p -135.58 146.93 48.47 Favored 'General case' 0 N--CA 1.446 -0.651 0 CA-C-N 114.841 -1.072 . . . . 0.0 109.483 178.306 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 96.0 mt -119.97 126.47 50.93 Favored 'General case' 0 C--N 1.312 -1.06 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 178.951 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 14.2 m120 -122.99 143.57 49.84 Favored 'General case' 0 C--N 1.317 -0.835 0 N-CA-C 110.01 -0.367 . . . . 0.0 110.01 -178.963 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 161.19 -142.11 7.83 Favored Glycine 0 N--CA 1.448 -0.513 0 C-N-CA 119.747 -1.216 . . . . 0.0 113.303 177.3 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 23.6 p -131.47 156.95 44.75 Favored 'General case' 0 C--N 1.316 -0.849 0 C-N-CA 122.919 0.488 . . . . 0.0 110.819 -178.709 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 19.9 ptm -149.69 157.08 42.9 Favored 'General case' 0 C--N 1.314 -0.945 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.152 179.955 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 119' ' ' THR . . . . . 0.639 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 40.6 m -132.0 130.31 41.24 Favored 'General case' 0 C--O 1.245 0.841 0 CA-C-N 116.589 -0.278 . . . . 0.0 111.269 -179.176 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 11.7 m-85 -94.22 160.52 14.65 Favored 'General case' 0 N--CA 1.455 -0.197 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.883 176.616 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . 0.433 ' HA ' HG11 ' A' ' 101' ' ' VAL . . . -38.7 -45.14 1.08 Allowed 'General case' 0 N--CA 1.482 1.161 0 N-CA-C 114.149 1.166 . . . . 0.0 114.149 -177.245 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -145.63 43.01 0.94 Allowed Glycine 0 CA--C 1.506 -0.514 0 C-N-CA 120.084 -1.055 . . . . 0.0 111.713 -178.972 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . 0.424 ' CD ' HH12 ' A' ' 95' ' ' ARG . 28.5 tp10 -116.13 -61.95 1.66 Allowed 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 121.199 0.523 . . . . 0.0 110.714 -177.712 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 134.26 -179.0 17.97 Favored Glycine 0 N--CA 1.443 -0.836 0 N-CA-C 111.264 -0.734 . . . . 0.0 111.264 -178.503 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 62.0 Cg_endo -81.46 117.15 3.04 Favored 'Trans proline' 0 N--CA 1.455 -0.738 0 C-N-CA 122.424 2.082 . . . . 0.0 112.182 179.508 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 38.0 pt -126.22 161.2 32.44 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.922 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.415 -179.894 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -72.5 138.67 26.55 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.949 -0.643 . . . . 0.0 112.609 -178.732 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 77.8 t80 -114.82 132.23 56.56 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-O 121.061 0.458 . . . . 0.0 110.994 -179.153 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 129' ' ' LYS . . . . . 0.47 ' HB2' ' CZ3' ' A' ' 17' ' ' TRP . 86.9 tttt -134.28 101.33 4.97 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.098 177.43 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . 0.428 ' HA2' ' O ' ' A' ' 5' ' ' ASN . . . -109.44 150.41 17.26 Favored Glycine 0 N--CA 1.435 -1.38 0 C-N-CA 120.326 -0.94 . . . . 0.0 112.0 179.3 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 6.0 t -146.39 148.77 32.68 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-O 120.718 0.294 . . . . 0.0 111.15 179.21 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 83.4 mt -63.51 132.93 52.87 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.059 -0.518 . . . . 0.0 110.107 175.796 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 6.9 p . . . . . 0 C--O 1.249 1.051 0 CA-C-O 118.511 -0.756 . . . . 0.0 110.702 178.873 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 0.606 ' O ' ' HG3' ' A' ' 24' ' ' GLU . . . . . . . . 0 N--CA 1.475 0.825 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' LEU . . . . . 0.46 HD12 HG21 ' A' ' 133' ' ' THR . 0.3 OUTLIER -90.94 130.58 36.86 Favored 'General case' 0 C--N 1.313 -0.994 0 CA-C-O 121.064 0.459 . . . . 0.0 109.88 -174.58 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . 0.435 ' N ' HD13 ' A' ' 3' ' ' LEU . 28.5 m-85 -116.99 137.39 52.25 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-N 115.854 -0.612 . . . . 0.0 111.24 -179.989 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 20.8 t-20 -87.12 131.73 34.06 Favored 'General case' 0 C--N 1.306 -1.317 0 N-CA-C 106.577 -1.638 . . . . 0.0 106.577 176.884 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.522 HG21 ' CG ' ' A' ' 23' ' ' TRP . 58.6 t -114.72 126.16 72.21 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.854 0 N-CA-C 113.204 0.816 . . . . 0.0 113.204 -172.969 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.452 ' HG2' ' HB3' ' A' ' 19' ' ' GLU . 92.3 mt-10 -120.56 135.66 55.02 Favored 'General case' 0 N--CA 1.435 -1.195 0 CA-C-N 114.575 -1.193 . . . . 0.0 108.353 176.833 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 9.9 m120 -120.22 144.53 47.68 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-O 120.899 0.381 . . . . 0.0 111.858 -176.226 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . 0.56 ' OE1' ' HA ' ' A' ' 13' ' ' SER . 36.4 tt0 -129.2 122.01 28.85 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.557 -0.747 . . . . 0.0 109.869 178.754 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 17.5 p90 -120.94 140.93 51.17 Favored 'General case' 0 C--N 1.314 -0.945 0 CA-C-O 121.337 0.589 . . . . 0.0 111.695 -179.845 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 107.24 -69.95 0.21 Allowed Glycine 0 N--CA 1.441 -1.009 0 CA-C-N 115.429 -0.805 . . . . 0.0 111.576 179.287 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -165.09 166.78 38.41 Favored Glycine 0 N--CA 1.442 -0.929 0 N-CA-C 111.612 -0.595 . . . . 0.0 111.612 179.467 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' SER . . . . . 0.56 ' HA ' ' OE1' ' A' ' 9' ' ' GLN . 11.5 p -60.04 -20.42 57.85 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 112.9 0.704 . . . . 0.0 112.9 -179.246 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 8.1 m -78.58 -5.59 53.23 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 120.642 0.258 . . . . 0.0 111.541 179.7 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -86.68 146.7 41.98 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 120.745 0.307 . . . . 0.0 111.359 -178.943 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -65.74 149.37 87.02 Favored 'Trans proline' 0 C--O 1.235 0.331 0 C-N-CA 122.823 2.349 . . . . 0.0 112.094 179.102 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 96.9 m95 -82.88 132.27 35.16 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 178.27 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 89.1 m-20 -120.67 122.84 41.33 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.43 -178.504 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.452 ' HB3' ' HG2' ' A' ' 7' ' ' GLU . 5.1 pt-20 -90.32 127.76 36.25 Favored 'General case' 0 C--N 1.313 -0.986 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 178.111 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -139.14 29.43 2.53 Favored Glycine 0 N--CA 1.445 -0.747 0 C-N-CA 119.761 -1.209 . . . . 0.0 112.611 -178.07 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 157.21 174.88 27.48 Favored Glycine 0 N--CA 1.438 -1.224 0 C-N-CA 120.381 -0.914 . . . . 0.0 112.458 179.829 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 4.4 pt20 -134.56 139.33 45.32 Favored 'General case' 0 C--N 1.314 -0.946 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 179.643 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' TRP . . . . . 0.53 ' HB3' ' O ' ' A' ' 91' ' ' ILE . 38.8 m0 -116.72 178.44 4.34 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.404 -176.715 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . 0.606 ' HG3' ' O ' ' A' ' 2' ' ' ALA . 76.9 tt0 -131.58 121.48 24.46 Favored 'General case' 0 N--CA 1.441 -0.879 0 C-N-CA 120.371 -0.531 . . . . 0.0 110.447 174.899 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 91.3 mt -127.59 131.99 69.57 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.955 0 CA-C-N 115.349 -0.841 . . . . 0.0 109.479 -178.668 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 91.13 121.28 2.49 Favored Glycine 0 N--CA 1.441 -0.99 0 C-N-CA 120.474 -0.869 . . . . 0.0 112.356 179.637 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . 0.499 ' CB ' ' HA3' ' A' ' 88' ' ' GLY . 6.3 m -119.44 11.54 12.18 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-O 121.277 0.56 . . . . 0.0 109.819 179.957 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 63.1 mtt-85 -141.07 141.84 34.22 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.391 -0.822 . . . . 0.0 109.21 -176.485 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 37.3 p -92.09 2.5 56.54 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-O 121.145 0.498 . . . . 0.0 111.344 -178.523 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 37.0 m-20 -62.31 -38.1 88.11 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.585 -0.734 . . . . 0.0 111.509 -178.839 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 1.3 tm0? -167.35 151.36 6.63 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.937 -177.276 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . 0.501 ' HB3' ' HA3' ' A' ' 111' ' ' GLY . 15.6 m120 -96.91 173.14 7.44 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.679 0.752 . . . . 0.0 111.239 179.375 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.474 HG11 HD11 ' A' ' 36' ' ' ILE . 17.2 t -102.85 134.22 44.47 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.256 0 CA-C-N 115.202 -0.908 . . . . 0.0 112.51 -175.144 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.44 HG13 ' HB2' ' A' ' 54' ' ' ALA . 27.0 m -121.11 -28.14 1.87 Allowed 'Isoleucine or valine' 0 C--O 1.255 1.352 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.602 174.946 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.674 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -140.31 140.33 35.63 Favored 'General case' 0 N--CA 1.442 -0.837 0 CA-C-O 121.38 0.609 . . . . 0.0 111.986 -178.706 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.474 HD11 HG11 ' A' ' 33' ' ' VAL . 93.7 mt -146.41 129.57 9.27 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 177.608 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -127.92 109.14 11.3 Favored 'General case' 0 C--N 1.311 -1.088 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 175.087 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.495 HG11 ' CD1' ' A' ' 61' ' ' PHE . 19.4 m -147.47 149.49 15.47 Favored 'Isoleucine or valine' 0 C--O 1.242 0.685 0 C-N-CA 120.874 -0.33 . . . . 0.0 111.343 -174.906 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 77.6 tt0 -138.82 144.9 39.51 Favored 'General case' 0 N--CA 1.443 -0.813 0 CA-C-N 115.72 -0.673 . . . . 0.0 109.279 178.043 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 37.0 p -69.76 140.87 53.47 Favored 'General case' 0 C--N 1.317 -0.817 0 N-CA-C 112.533 0.568 . . . . 0.0 112.533 -176.862 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -86.83 -62.39 1.53 Allowed Glycine 0 CA--C 1.502 -0.771 0 N-CA-C 109.113 -1.595 . . . . 0.0 109.113 174.628 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 51.0 m-20 -88.36 -169.2 2.46 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 173.988 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 70.9 m-20 -77.11 57.98 1.48 Allowed 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 112.462 0.542 . . . . 0.0 112.462 -177.946 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 97.02 -20.32 51.31 Favored Glycine 0 C--O 1.218 -0.857 0 C-N-CA 121.068 -0.587 . . . . 0.0 113.419 175.542 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 56.0 mt-30 -64.99 -34.07 77.55 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 112.89 0.7 . . . . 0.0 112.89 -177.754 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . 0.525 ' HA ' ' O ' ' A' ' 63' ' ' ALA . 14.8 t -136.14 131.64 34.98 Favored 'General case' 0 N--CA 1.438 -1.049 0 C-N-CA 120.387 -0.525 . . . . 0.0 111.239 178.622 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' LEU . . . . . 0.414 ' O ' ' HA ' ' A' ' 62' ' ' ARG . 80.1 mt -111.01 133.03 53.72 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.837 -0.619 . . . . 0.0 109.508 179.384 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 64.0 m-80 -125.27 146.21 49.65 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-O 120.703 0.287 . . . . 0.0 110.706 179.238 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 163.34 -140.52 6.54 Favored Glycine 0 N--CA 1.439 -1.15 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.497 178.4 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 24.5 p -133.41 150.75 51.78 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 120.908 0.385 . . . . 0.0 111.21 -179.292 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 18.4 ttt -124.82 137.0 54.32 Favored 'General case' 0 C--N 1.32 -0.68 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 179.78 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.674 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 60.6 m -124.89 122.55 37.68 Favored 'General case' 0 C--O 1.259 1.592 0 CA-C-O 121.17 0.509 . . . . 0.0 111.799 -178.303 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' TYR . . . . . 0.428 ' HB2' ' HB2' ' A' ' 56' ' ' GLU . 98.1 m-85 -84.66 166.0 17.44 Favored 'General case' 0 CA--C 1.52 -0.201 0 CA-C-N 115.372 -0.831 . . . . 0.0 109.835 178.512 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' ALA . . . . . 0.44 ' HB2' HG13 ' A' ' 34' ' ' VAL . . . -67.94 110.69 3.99 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 120.952 0.406 . . . . 0.0 111.125 179.836 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 83.41 16.84 67.87 Favored Glycine 0 CA--C 1.522 0.493 0 C-N-CA 120.667 -0.778 . . . . 0.0 113.711 179.401 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' GLU . . . . . 0.428 ' HB2' ' HB2' ' A' ' 53' ' ' TYR . 98.1 mt-10 -132.01 163.24 28.83 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 117.339 0.569 . . . . 0.0 111.135 178.962 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -81.08 156.42 37.79 Favored Glycine 0 N--CA 1.447 -0.612 0 CA-C-N 115.955 -0.566 . . . . 0.0 112.603 -179.273 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 21.8 Cg_exo -64.62 142.56 77.86 Favored 'Trans proline' 0 C--N 1.347 0.467 0 C-N-CA 122.924 2.416 . . . . 0.0 112.81 -179.295 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 44.7 pt -125.91 167.66 19.98 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.872 0 CA-C-N 115.527 -0.76 . . . . 0.0 109.332 177.272 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -70.37 137.63 27.97 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.19 -1.005 . . . . 0.0 111.674 -178.952 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.495 ' CD1' HG11 ' A' ' 38' ' ' VAL . 50.2 t80 -127.71 128.42 45.37 Favored 'General case' 0 C--N 1.317 -0.847 0 CA-C-O 120.757 0.313 . . . . 0.0 110.831 -177.887 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . 0.414 ' HA ' ' O ' ' A' ' 47' ' ' LEU . 63.7 ttp85 -138.77 132.72 31.13 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.181 175.276 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.525 ' O ' ' HA ' ' A' ' 46' ' ' THR . . . -127.74 137.02 52.31 Favored 'General case' 0 C--N 1.311 -1.09 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.653 179.658 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 61.2 m -123.55 132.41 53.89 Favored 'General case' 0 C--N 1.315 -0.913 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 178.776 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . 0.622 HD21 ' O ' ' A' ' 68' ' ' ASN . 3.7 mt -60.5 128.17 35.33 Favored 'General case' 0 CA--C 1.501 -0.911 0 N-CA-C 113.928 1.085 . . . . 0.0 113.928 -178.13 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . 0.595 HD11 ' ND2' ' A' ' 89' ' ' ASN . 96.1 mt -76.43 -34.72 58.77 Favored 'General case' 0 N--CA 1.431 -1.394 0 N-CA-C 107.27 -1.381 . . . . 0.0 107.27 169.004 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -166.91 -72.66 0.03 OUTLIER Glycine 0 N--CA 1.433 -1.564 0 C-N-CA 120.405 -0.903 . . . . 0.0 115.013 -179.504 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' ASN . . . . . 0.622 ' O ' HD21 ' A' ' 65' ' ' LEU . 17.0 m120 -125.3 -77.34 0.59 Allowed 'General case' 0 C--O 1.214 -0.782 0 CA-C-N 118.212 1.006 . . . . 0.0 110.202 -175.85 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 12.2 m120 -100.94 -6.31 24.77 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 120.898 0.38 . . . . 0.0 110.643 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 8.3 m -95.37 121.13 36.72 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.698 -178.134 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' TYR . . . . . 0.416 ' CE2' ' HG ' ' A' ' 65' ' ' LEU . 96.0 m-85 -115.9 150.21 37.44 Favored 'General case' 0 C--N 1.314 -0.937 0 CA-C-N 116.323 -0.399 . . . . 0.0 111.181 -178.657 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 70.4 tt0 -105.72 125.53 51.09 Favored 'General case' 0 C--N 1.31 -1.125 0 N-CA-C 107.451 -1.315 . . . . 0.0 107.451 173.499 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 65.3 t -104.8 132.27 51.9 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.388 0 CA-C-O 121.544 0.687 . . . . 0.0 112.471 -174.172 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 47.5 mt-10 -127.35 123.54 36.52 Favored 'General case' 0 N--CA 1.436 -1.161 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 176.631 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 97.5 m-20 -110.83 153.43 25.41 Favored 'General case' 0 C--N 1.317 -0.819 0 CA-C-O 121.229 0.538 . . . . 0.0 111.934 -176.018 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' GLN . . . . . 0.498 ' HB2' ' CE3' ' A' ' 84' ' ' TRP . 60.0 tt0 -113.98 116.43 29.21 Favored 'General case' 0 C--N 1.312 -1.05 0 CA-C-N 115.607 -0.724 . . . . 0.0 109.933 -178.589 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 13.4 p90 -142.72 160.59 40.01 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.157 179.446 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 94.68 -3.66 68.29 Favored Glycine 0 N--CA 1.449 -0.473 0 C-N-CA 120.599 -0.81 . . . . 0.0 112.073 -179.532 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 135.21 152.44 6.49 Favored Glycine 0 N--CA 1.446 -0.65 0 N-CA-C 111.469 -0.652 . . . . 0.0 111.469 179.38 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 25.7 t70 -62.71 -36.82 84.22 Favored 'General case' 0 N--CA 1.468 0.453 0 CA-C-O 120.869 0.366 . . . . 0.0 111.932 -179.71 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 29.3 p -69.65 -15.78 63.25 Favored 'General case' 0 C--N 1.316 -0.86 0 N-CA-C 112.125 0.417 . . . . 0.0 112.125 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -75.87 142.71 73.43 Favored Pre-proline 0 C--O 1.234 0.267 0 CA-C-N 116.478 -0.328 . . . . 0.0 110.884 -179.512 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 96.7 Cg_endo -73.59 156.25 49.5 Favored 'Trans proline' 0 N--CA 1.462 -0.353 0 C-N-CA 122.712 2.274 . . . . 0.0 111.819 178.731 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' TRP . . . . . 0.498 ' CE3' ' HB2' ' A' ' 76' ' ' GLN . 81.7 m95 -60.98 138.31 58.18 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.305 0.574 . . . . 0.0 111.543 179.615 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 99.1 m-70 -113.03 144.65 42.24 Favored 'General case' 0 C--N 1.311 -1.096 0 CA-C-N 115.213 -0.903 . . . . 0.0 109.208 178.344 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 12.9 p -61.46 125.75 24.9 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-O 121.192 0.52 . . . . 0.0 111.941 -177.293 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -96.42 -48.85 2.11 Favored Glycine 0 N--CA 1.441 -1.032 0 CA-C-N 115.595 -0.73 . . . . 0.0 111.532 179.747 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . 0.499 ' HA3' ' CB ' ' A' ' 27' ' ' SER . . . 149.86 -167.17 29.92 Favored Glycine 0 C--O 1.216 -1.027 0 N-CA-C 111.326 -0.71 . . . . 0.0 111.326 178.405 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 89' ' ' ASN . . . . . 0.595 ' ND2' HD11 ' A' ' 66' ' ' LEU . 22.7 m120 -108.53 140.84 41.3 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 117.379 0.59 . . . . 0.0 110.867 179.35 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 90' ' ' TRP . . . . . 0.435 ' HD1' ' C ' ' A' ' 89' ' ' ASN . 29.4 m0 -133.69 160.62 36.99 Favored 'General case' 0 N--CA 1.465 0.298 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 -177.16 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . 0.53 ' O ' ' HB3' ' A' ' 23' ' ' TRP . 96.9 mt -121.19 121.6 65.31 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.035 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 175.806 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 83.7 mt -134.63 82.93 1.99 Allowed 'General case' 0 C--O 1.267 1.979 0 N-CA-C 112.765 0.654 . . . . 0.0 112.765 -175.414 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 164.64 118.5 0.44 Allowed Glycine 0 N--CA 1.448 -0.536 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.81 177.954 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 43.1 m -90.64 -0.14 57.58 Favored 'General case' 0 N--CA 1.463 0.211 0 CA-C-O 121.11 0.481 . . . . 0.0 110.64 177.922 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -120.02 152.16 37.91 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 178.788 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 78.1 tt0 -66.06 -65.44 0.68 Allowed 'General case' 0 C--N 1.32 -0.71 0 N-CA-C 112.6 0.593 . . . . 0.0 112.6 -174.86 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 93.5 m-20 -107.15 36.9 2.52 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 116.271 -0.422 . . . . 0.0 112.026 -175.409 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 98' ' ' GLN . . . . . 0.403 ' CG ' ' HB3' ' A' ' 120' ' ' TYR . 14.5 tp60 -108.67 -62.33 1.48 Allowed 'General case' 0 C--N 1.316 -0.885 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 179.646 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 91.7 m-20 71.87 149.98 0.1 Allowed 'General case' 0 C--O 1.248 1.013 0 CA-C-N 115.225 -0.898 . . . . 0.0 112.942 178.258 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 76.6 t -81.66 132.14 32.19 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.335 0 CA-C-N 115.44 -0.8 . . . . 0.0 111.191 178.279 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 26.8 m -114.49 -21.57 5.3 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.185 0 CA-C-N 116.004 -0.544 . . . . 0.0 112.356 179.571 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . 0.522 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -150.09 141.44 23.27 Favored 'General case' 0 C--N 1.326 -0.444 0 C-N-CA 120.161 -0.615 . . . . 0.0 111.596 178.601 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.463 ' HB ' HG22 ' A' ' 38' ' ' VAL . 32.2 mm -134.61 127.21 49.33 Favored 'Isoleucine or valine' 0 C--O 1.244 0.766 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.863 178.429 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 50.4 t30 -131.76 97.38 4.18 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.782 -0.645 . . . . 0.0 109.867 175.277 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.59 ' O ' ' HA ' ' A' ' 35' ' ' ALA . 15.5 m -130.51 135.06 61.28 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.029 0 CA-C-N 115.775 -0.648 . . . . 0.0 111.162 -176.926 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 52.8 mt-10 -139.1 27.45 2.37 Favored 'General case' 0 N--CA 1.486 1.371 0 CA-C-O 121.526 0.679 . . . . 0.0 110.953 -178.841 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . 0.633 ' HB2' ' HB2' ' A' ' 115' ' ' ASN . 53.7 m -139.1 147.34 41.85 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 114.259 1.207 . . . . 0.0 114.259 -175.1 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 148.71 122.06 1.2 Allowed Glycine 0 N--CA 1.436 -1.341 0 CA-C-N 114.624 -1.171 . . . . 0.0 111.84 178.268 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -83.29 107.67 15.98 Favored 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 178.657 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 59.58 18.13 6.77 Favored 'General case' 0 N--CA 1.481 1.084 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.275 -177.446 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . 0.501 ' HA3' ' HB3' ' A' ' 32' ' ' ASN . . . 80.06 15.39 78.96 Favored Glycine 0 N--CA 1.442 -0.913 0 CA-C-N 115.818 -0.628 . . . . 0.0 112.838 179.006 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 112' ' ' GLN . . . . . 0.525 ' HA ' HD12 ' A' ' 132' ' ' LEU . 52.2 tt0 -64.15 -37.52 87.74 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-O 121.799 0.809 . . . . 0.0 109.138 177.607 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 60.5 p -133.93 164.25 27.71 Favored 'General case' 0 N--CA 1.431 -1.422 0 CA-C-N 114.56 -1.2 . . . . 0.0 108.724 177.354 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 114' ' ' LEU . . . . . 0.41 ' HA ' ' O ' ' A' ' 107' ' ' SER . 33.8 tp -134.84 114.69 12.84 Favored 'General case' 0 C--N 1.301 -1.519 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 176.937 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 115' ' ' ASN . . . . . 0.633 ' HB2' ' HB2' ' A' ' 107' ' ' SER . 0.8 OUTLIER -116.9 143.7 45.39 Favored 'General case' 0 C--O 1.263 1.81 0 C-N-CA 120.117 -0.633 . . . . 0.0 111.577 -176.31 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 165.02 -138.31 5.18 Favored Glycine 0 N--CA 1.437 -1.298 0 CA-C-N 115.164 -0.925 . . . . 0.0 112.25 177.208 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 29.8 p -130.51 155.48 46.4 Favored 'General case' 0 C--N 1.307 -1.265 0 C-N-CA 122.792 0.437 . . . . 0.0 109.986 -179.221 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 118' ' ' MET . . . . . 0.404 ' HE3' ' HB2' ' A' ' 118' ' ' MET . 18.0 ptm -146.94 153.32 39.95 Favored 'General case' 0 C--N 1.309 -1.194 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.465 -179.065 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 119' ' ' THR . . . . . 0.522 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 25.9 m -132.83 129.8 38.97 Favored 'General case' 0 C--O 1.248 1.0 0 CA-C-N 116.487 -0.324 . . . . 0.0 111.368 -179.811 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . 0.518 ' HB2' ' HB3' ' A' ' 123' ' ' GLU . 57.2 m-85 -94.1 159.16 15.27 Favored 'General case' 0 CA--C 1.516 -0.35 0 CA-C-N 115.746 -0.661 . . . . 0.0 109.58 175.298 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -66.27 134.39 52.56 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 109.662 -0.496 . . . . 0.0 109.662 176.284 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 64.95 22.44 68.6 Favored Glycine 0 CA--C 1.523 0.532 0 C-N-CA 120.815 -0.707 . . . . 0.0 113.113 -179.856 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . 0.518 ' HB3' ' HB2' ' A' ' 120' ' ' TYR . 39.3 tp10 -137.87 161.86 35.51 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 -178.172 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -89.06 156.51 26.28 Favored Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.284 -0.96 . . . . 0.0 111.84 178.617 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_exo -60.6 134.28 53.52 Favored 'Trans proline' 0 C--N 1.349 0.6 0 C-N-CA 122.394 2.062 . . . . 0.0 111.707 178.743 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 39.7 pt -131.57 165.44 31.71 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.812 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.51 -178.91 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -73.87 139.23 25.91 Favored Glycine 0 N--CA 1.445 -0.726 0 C-N-CA 121.206 -0.521 . . . . 0.0 112.003 179.717 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 92.2 t80 -117.35 132.63 56.56 Favored 'General case' 0 C--O 1.244 0.794 0 CA-C-O 120.974 0.416 . . . . 0.0 111.083 -178.697 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 61.7 tttm -135.48 102.37 5.11 Favored 'General case' 0 N--CA 1.442 -0.865 0 CA-C-N 115.567 -0.742 . . . . 0.0 109.694 177.867 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -100.58 140.7 15.04 Favored Glycine 0 CA--C 1.503 -0.67 0 N-CA-C 110.793 -0.923 . . . . 0.0 110.793 178.25 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 45.5 m -136.69 133.4 36.12 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-N 117.224 0.512 . . . . 0.0 111.059 179.881 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 132' ' ' LEU . . . . . 0.525 HD12 ' HA ' ' A' ' 112' ' ' GLN . 78.8 mt -60.71 129.91 43.86 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-O 120.907 0.384 . . . . 0.0 110.363 177.21 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 133' ' ' THR . . . . . 0.46 HG21 HD12 ' A' ' 3' ' ' LEU . 5.3 t . . . . . 0 C--O 1.247 0.958 0 CA-C-O 118.244 -0.884 . . . . 0.0 110.13 -179.037 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.72 0 N-CA-C 110.246 -0.279 . . . . 0.0 110.246 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . 0.412 HD13 ' N ' ' A' ' 4' ' ' TYR . 2.3 tm? -91.43 128.32 37.21 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 -177.918 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . 0.453 ' CE2' ' HB ' ' A' ' 25' ' ' ILE . 83.1 m-85 -119.31 146.77 45.0 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-O 120.991 0.424 . . . . 0.0 111.645 -179.632 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 49.0 m-80 -97.31 138.74 34.32 Favored 'General case' 0 C--N 1.315 -0.932 0 N-CA-C 107.213 -1.403 . . . . 0.0 107.213 175.89 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 69.7 t -115.95 126.7 73.57 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.878 0 N-CA-C 113.108 0.781 . . . . 0.0 113.108 -175.17 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 94.4 mt-10 -120.72 135.66 55.07 Favored 'General case' 0 N--CA 1.443 -0.811 0 CA-C-N 114.817 -1.083 . . . . 0.0 108.21 175.21 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 12.7 m120 -125.44 148.43 48.82 Favored 'General case' 0 C--N 1.313 -0.994 0 CA-C-O 121.042 0.449 . . . . 0.0 111.738 -176.665 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 58.0 tt0 -125.92 119.38 27.61 Favored 'General case' 0 C--N 1.316 -0.857 0 N-CA-C 107.471 -1.307 . . . . 0.0 107.471 177.143 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 39.3 p90 -142.04 9.74 1.92 Allowed 'General case' 0 C--N 1.319 -0.721 0 N-CA-C 114.404 1.261 . . . . 0.0 114.404 -174.814 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -120.96 18.15 9.1 Favored Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 118.351 -1.881 . . . . 0.0 112.075 -176.767 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 110.83 159.58 16.47 Favored Glycine 0 N--CA 1.443 -0.879 0 C-N-CA 120.859 -0.686 . . . . 0.0 112.203 -179.761 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 41.3 m -56.18 -33.23 65.07 Favored 'General case' 0 C--N 1.323 -0.57 0 C-N-CA 122.74 0.416 . . . . 0.0 111.967 178.855 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 20.3 m -68.21 -14.18 62.79 Favored 'General case' 0 CA--C 1.539 0.535 0 CA-C-N 116.582 -0.281 . . . . 0.0 111.499 178.454 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -96.86 138.66 21.34 Favored Pre-proline 0 C--N 1.323 -0.549 0 N-CA-C 110.013 -0.366 . . . . 0.0 110.013 178.597 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_endo -77.9 -171.78 1.29 Allowed 'Trans proline' 0 CA--C 1.534 0.52 0 C-N-CA 122.954 2.436 . . . . 0.0 113.01 -178.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 96.9 m95 -91.34 136.06 33.37 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.103 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 90.8 m-20 -119.71 122.14 40.78 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.103 -179.288 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 75.3 tt0 -78.23 132.03 37.37 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 115.924 -0.58 . . . . 0.0 109.64 178.07 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.441 ' O ' ' HB2' ' A' ' 94' ' ' SER . . . -137.1 29.8 2.69 Favored Glycine 0 N--CA 1.447 -0.612 0 C-N-CA 119.565 -1.303 . . . . 0.0 113.547 -178.919 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 137.33 179.43 16.85 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.023 -1.084 . . . . 0.0 113.333 178.564 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 98.9 mt-30 -123.02 147.56 46.53 Favored 'General case' 0 C--N 1.327 -0.384 0 C-N-CA 122.796 0.438 . . . . 0.0 110.099 179.351 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . 0.424 ' HE1' ' HB3' ' A' ' 94' ' ' SER . 45.5 m0 -121.83 171.81 8.62 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 178.813 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -127.23 117.41 22.25 Favored 'General case' 0 C--N 1.317 -0.829 0 C-N-CA 120.635 -0.426 . . . . 0.0 110.144 175.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.453 ' HB ' ' CE2' ' A' ' 4' ' ' TYR . 99.1 mt -133.98 144.49 35.39 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 CA-C-N 115.559 -0.746 . . . . 0.0 109.677 -177.827 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 81.57 35.64 22.1 Favored Glycine 0 CA--C 1.506 -0.487 0 C-N-CA 120.231 -0.985 . . . . 0.0 111.921 179.536 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 11.4 m -74.05 21.62 0.09 Allowed 'General case' 0 C--N 1.317 -0.823 0 N-CA-C 111.9 0.333 . . . . 0.0 111.9 179.83 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . 0.481 ' NH1' ' HG3' ' A' ' 31' ' ' GLN . 54.4 ttt180 -92.61 10.46 30.36 Favored 'General case' 0 CA--C 1.544 0.748 0 CA-C-O 121.686 0.755 . . . . 0.0 109.075 178.807 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 29.3 m 72.57 -79.67 0.04 OUTLIER 'General case' 0 CA--C 1.541 0.619 0 CA-C-N 114.802 -1.09 . . . . 0.0 113.288 176.135 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 28.4 m-20 -88.98 2.68 53.57 Favored 'General case' 0 N--CA 1.473 0.683 0 N-CA-C 113.106 0.78 . . . . 0.0 113.106 -175.222 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . 0.481 ' HG3' ' NH1' ' A' ' 28' ' ' ARG . 8.4 mm-40 -122.47 117.18 25.34 Favored 'General case' 0 C--N 1.309 -1.167 0 N-CA-C 113.394 0.887 . . . . 0.0 113.394 -178.869 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . 0.587 ' OD1' ' HA3' ' A' ' 111' ' ' GLY . 28.2 t-20 -92.39 145.16 24.68 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 114.932 -1.031 . . . . 0.0 110.376 177.163 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.438 HG21 ' CH2' ' A' ' 90' ' ' TRP . 53.3 t -97.62 131.95 43.42 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.148 0 CA-C-N 115.586 -0.734 . . . . 0.0 111.089 -178.814 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 29.1 m -109.36 -19.15 7.04 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.155 0 N-CA-C 112.361 0.504 . . . . 0.0 112.361 -179.597 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.479 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -148.3 143.4 26.89 Favored 'General case' 0 CA--C 1.515 -0.383 0 C-N-CA 120.403 -0.519 . . . . 0.0 111.228 179.078 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.434 ' HB ' HG22 ' A' ' 105' ' ' VAL . 90.9 mt -142.68 122.04 9.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.215 -178.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 11.7 m120 -127.7 106.78 9.37 Favored 'General case' 0 C--N 1.313 -0.989 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 175.141 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.506 HG11 ' CD1' ' A' ' 61' ' ' PHE . 29.2 m -149.17 154.53 9.44 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 C-N-CA 120.79 -0.364 . . . . 0.0 111.463 -173.693 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 73.8 tt0 -147.61 152.42 37.87 Favored 'General case' 0 N--CA 1.442 -0.844 0 N-CA-C 109.284 -0.635 . . . . 0.0 109.284 176.471 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 33.2 p -83.25 130.33 35.07 Favored 'General case' 0 C--N 1.312 -1.028 0 CA-C-N 116.498 -0.319 . . . . 0.0 111.78 -177.541 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -71.58 -43.41 52.65 Favored Glycine 0 N--CA 1.445 -0.712 0 N-CA-C 110.197 -1.161 . . . . 0.0 110.197 174.681 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 57.2 m-20 -104.71 -152.91 0.47 Allowed 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 114.898 -0.651 . . . . 0.0 109.764 178.338 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -74.81 40.27 0.14 Allowed 'General case' 0 N--CA 1.471 0.619 0 C-N-CA 123.683 0.793 . . . . 0.0 111.308 -179.907 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.413 ' O ' ' HE2' ' A' ' 71' ' ' TYR . . . 92.92 -6.83 76.83 Favored Glycine 0 C--O 1.217 -0.924 0 C-N-CA 121.032 -0.604 . . . . 0.0 112.419 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 57.5 mt-30 -65.08 -38.84 92.05 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 112.736 0.643 . . . . 0.0 112.736 -178.086 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 5.4 t -126.06 110.84 14.01 Favored 'General case' 0 C--N 1.306 -1.285 0 CA-C-O 121.135 0.493 . . . . 0.0 110.515 179.806 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . 0.412 ' O ' ' HA ' ' A' ' 62' ' ' ARG . 79.4 mt -96.72 127.61 42.87 Favored 'General case' 0 C--N 1.316 -0.885 0 N-CA-C 108.936 -0.764 . . . . 0.0 108.936 177.354 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 24.7 p30 -135.28 152.84 51.89 Favored 'General case' 0 C--N 1.308 -1.204 0 CA-C-O 121.008 0.432 . . . . 0.0 110.966 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 162.53 -144.15 9.39 Favored Glycine 0 N--CA 1.438 -1.17 0 C-N-CA 120.447 -0.882 . . . . 0.0 112.683 179.258 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 61.6 m -127.91 130.9 49.26 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-O 120.94 0.4 . . . . 0.0 110.126 -178.013 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' MET . . . . . 0.509 ' HE2' ' HD2' ' A' ' 61' ' ' PHE . 15.0 tmm? -130.39 148.19 52.18 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-N 116.491 -0.322 . . . . 0.0 110.203 -178.414 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.479 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 30.5 m -126.21 128.2 46.86 Favored 'General case' 0 C--O 1.249 1.076 0 CA-C-O 120.909 0.385 . . . . 0.0 111.967 -176.849 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . 0.444 ' CD1' ' HB3' ' A' ' 31' ' ' GLN . 52.1 m-85 -88.15 163.21 16.3 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-N 115.676 -0.693 . . . . 0.0 110.768 177.186 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -65.05 127.45 31.68 Favored 'General case' 0 C--O 1.24 0.571 0 CA-C-N 115.996 -0.547 . . . . 0.0 111.078 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 76.45 3.64 78.19 Favored Glycine 0 N--CA 1.446 -0.67 0 CA-C-N 115.9 -0.591 . . . . 0.0 112.766 179.032 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 78.7 mm-40 -120.3 178.89 4.48 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-O 120.828 0.347 . . . . 0.0 111.075 -177.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -101.98 174.17 24.08 Favored Glycine 0 N--CA 1.437 -1.241 0 N-CA-C 111.157 -0.777 . . . . 0.0 111.157 178.507 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_endo -66.68 137.71 46.79 Favored 'Trans proline' 0 CA--C 1.531 0.359 0 C-N-CA 122.217 1.944 . . . . 0.0 112.538 179.709 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 44.2 pt -133.61 171.73 17.52 Favored 'Isoleucine or valine' 0 C--O 1.241 0.644 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.356 179.084 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -74.67 138.11 23.44 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.684 -0.77 . . . . 0.0 111.974 -178.835 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.509 ' HD2' ' HE2' ' A' ' 51' ' ' MET . 55.4 t80 -127.01 129.57 48.33 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-O 120.488 0.185 . . . . 0.0 110.91 -178.94 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . 0.412 ' HA ' ' O ' ' A' ' 47' ' ' LEU . 59.9 ttp85 -141.74 133.05 26.51 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.305 -0.407 . . . . 0.0 109.96 175.978 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.536 ' HB1' ' HB3' ' A' ' 71' ' ' TYR . . . -133.53 139.85 46.86 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.67 -0.241 . . . . 0.0 111.373 -179.969 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 25.2 m -113.67 127.53 56.08 Favored 'General case' 0 CA--C 1.539 0.555 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.482 -179.286 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 58.0 tp -72.44 125.52 27.61 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 112.422 0.527 . . . . 0.0 112.422 -178.276 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 86.9 mt -76.28 -25.78 55.24 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.671 -0.695 . . . . 0.0 110.541 176.249 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 118.27 0.3 16.47 Favored Glycine 0 C--N 1.337 0.596 0 C-N-CA 120.808 -0.711 . . . . 0.0 113.175 178.761 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 29.0 p-10 -135.03 37.59 3.01 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-O 120.919 0.39 . . . . 0.0 111.008 -178.171 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 97.1 m-20 69.29 4.31 4.55 Favored 'General case' 0 N--CA 1.488 1.431 0 C-N-CA 123.417 0.687 . . . . 0.0 111.735 -177.708 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 16.3 t -95.43 126.07 40.48 Favored 'General case' 0 N--CA 1.435 -1.198 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 177.486 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.536 ' HB3' ' HB1' ' A' ' 63' ' ' ALA . 95.7 m-85 -116.98 129.31 55.95 Favored 'General case' 0 C--N 1.309 -1.172 0 CA-C-N 116.411 -0.359 . . . . 0.0 111.405 -178.023 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -81.52 116.25 21.21 Favored 'General case' 0 C--N 1.315 -0.907 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 175.144 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 54.2 t -102.53 132.96 47.52 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.198 0 N-CA-C 113.215 0.82 . . . . 0.0 113.215 -173.235 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 49.2 mt-10 -127.37 145.78 50.69 Favored 'General case' 0 N--CA 1.44 -0.933 0 CA-C-N 114.267 -1.333 . . . . 0.0 108.666 177.919 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 13.5 m120 -123.77 149.5 45.55 Favored 'General case' 0 C--N 1.316 -0.848 0 N-CA-C 110.246 -0.279 . . . . 0.0 110.246 -176.216 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' GLN . . . . . 0.444 ' HB2' ' CE3' ' A' ' 84' ' ' TRP . 63.1 tt0 -121.83 124.9 45.25 Favored 'General case' 0 C--N 1.315 -0.908 0 CA-C-N 116.464 -0.335 . . . . 0.0 110.385 179.724 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 8.3 p90 -144.05 162.73 35.49 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.876 -0.602 . . . . 0.0 109.628 179.063 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 101.17 -13.04 58.8 Favored Glycine 0 C--N 1.316 -0.583 0 C-N-CA 120.898 -0.667 . . . . 0.0 112.766 179.821 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 125.22 174.87 14.06 Favored Glycine 0 N--CA 1.444 -0.769 0 C-N-CA 120.505 -0.855 . . . . 0.0 112.367 178.626 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 7.5 p-10 -63.43 -34.59 78.08 Favored 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 112.303 0.483 . . . . 0.0 112.303 -179.581 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 73.1 p -78.95 -6.54 56.5 Favored 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 111.965 0.358 . . . . 0.0 111.965 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -85.34 146.18 44.21 Favored Pre-proline 0 C--N 1.322 -0.624 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.796 -179.95 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 84.5 Cg_endo -80.37 -175.09 2.52 Favored 'Trans proline' 0 C--O 1.236 0.404 0 C-N-CA 122.777 2.318 . . . . 0.0 112.768 -179.408 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' TRP . . . . . 0.444 ' CE3' ' HB2' ' A' ' 76' ' ' GLN . 90.5 m95 -94.9 144.87 25.32 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.793 -0.64 . . . . 0.0 109.979 179.412 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 87.9 m-70 -124.52 142.26 51.47 Favored 'General case' 0 C--N 1.316 -0.859 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 179.225 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 22.6 p -61.78 133.87 56.04 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-O 120.911 0.386 . . . . 0.0 111.5 -179.11 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -106.27 -46.26 1.17 Allowed Glycine 0 N--CA 1.445 -0.739 0 C-N-CA 120.667 -0.778 . . . . 0.0 111.639 178.859 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 156.25 -171.74 34.03 Favored Glycine 0 C--O 1.221 -0.685 0 C-N-CA 120.777 -0.725 . . . . 0.0 111.463 178.906 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 7.4 t30 -110.29 118.23 35.77 Favored 'General case' 0 C--N 1.312 -1.047 0 CA-C-N 117.147 0.474 . . . . 0.0 110.178 179.08 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' TRP . . . . . 0.438 ' CH2' HG21 ' A' ' 33' ' ' VAL . 28.6 m0 -107.63 150.16 27.22 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.574 -0.284 . . . . 0.0 110.399 -178.294 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 49.8 mm -107.72 114.61 46.8 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 N-CA-C 109.217 -0.66 . . . . 0.0 109.217 178.109 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 90.0 mt -127.15 79.94 1.92 Allowed 'General case' 0 C--O 1.265 1.893 0 CA-C-O 121.819 0.818 . . . . 0.0 111.814 -177.83 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 169.15 99.69 0.13 Allowed Glycine 0 N--CA 1.438 -1.201 0 CA-C-N 115.113 -0.949 . . . . 0.0 111.969 179.325 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . 0.441 ' HB2' ' O ' ' A' ' 20' ' ' GLY . 71.6 p -86.19 -7.87 58.23 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 121.308 0.575 . . . . 0.0 110.148 178.604 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -103.68 146.35 28.72 Favored 'General case' 0 N--CA 1.438 -1.055 0 CA-C-N 115.475 -0.784 . . . . 0.0 109.289 179.878 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 -90.24 -19.8 23.72 Favored 'General case' 0 C--N 1.31 -1.138 0 N-CA-C 112.187 0.44 . . . . 0.0 112.187 -172.677 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 28.3 p-10 -117.7 14.52 14.4 Favored 'General case' 0 C--N 1.313 -0.988 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.107 -178.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' GLN . . . . . . . . . . . . . 56.7 tt0 -154.55 123.25 6.18 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 120.834 0.35 . . . . 0.0 110.18 -176.656 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 1.6 m-20 -98.48 162.59 13.07 Favored 'General case' 0 C--O 1.242 0.691 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.064 -175.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 54.3 t -77.55 133.75 29.95 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.579 0 C-N-CA 120.84 -0.344 . . . . 0.0 111.283 178.114 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 35.9 m -116.43 -34.63 1.88 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.503 0 N-CA-C 113.205 0.817 . . . . 0.0 113.205 -179.036 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . 0.587 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -142.73 138.91 30.85 Favored 'General case' 0 CA--C 1.512 -0.489 0 C-N-CA 120.019 -0.672 . . . . 0.0 111.486 179.523 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 40.4 mm -131.77 125.15 55.11 Favored 'Isoleucine or valine' 0 C--O 1.244 0.79 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.287 179.614 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 45.5 t30 -123.84 95.9 4.75 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.628 -0.714 . . . . 0.0 109.311 174.229 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.434 HG22 ' HB ' ' A' ' 36' ' ' ILE . 29.9 m -136.85 138.78 45.71 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.926 0 N-CA-C 112.516 0.562 . . . . 0.0 112.516 -176.442 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -138.36 136.86 36.77 Favored 'General case' 0 C--N 1.309 -1.182 0 CA-C-N 115.132 -0.94 . . . . 0.0 108.481 177.238 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 39.3 t -118.39 129.23 55.3 Favored 'General case' 0 C--N 1.302 -1.496 0 C-N-CA 120.85 -0.34 . . . . 0.0 110.663 -179.549 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -86.45 -6.86 80.23 Favored Glycine 0 N--CA 1.441 -1.001 0 N-CA-C 110.359 -1.096 . . . . 0.0 110.359 175.937 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . 0.484 ' CG ' ' H ' ' A' ' 110' ' ' ASP . 11.1 t70 -93.88 -164.27 1.15 Allowed 'General case' 0 N--CA 1.445 -0.699 0 CA-C-N 115.286 -0.457 . . . . 0.0 110.025 179.656 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . 0.484 ' H ' ' CG ' ' A' ' 109' ' ' ASP . 16.2 m-20 -95.49 19.49 10.89 Favored 'General case' 0 C--N 1.318 -0.784 0 C-N-CA 122.989 0.516 . . . . 0.0 110.682 -178.016 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . 0.587 ' HA3' ' OD1' ' A' ' 32' ' ' ASN . . . 101.73 2.22 52.71 Favored Glycine 0 N--CA 1.443 -0.861 0 C-N-CA 120.605 -0.807 . . . . 0.0 112.545 -179.79 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 35.4 tt0 -64.1 -41.64 97.2 Favored 'General case' 0 C--O 1.226 -0.163 0 CA-C-O 120.984 0.421 . . . . 0.0 110.275 179.417 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 8.6 p -132.24 147.74 52.42 Favored 'General case' 0 N--CA 1.441 -0.878 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.436 177.746 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 92.8 mt -114.76 125.77 54.08 Favored 'General case' 0 C--N 1.319 -0.752 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 179.159 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 18.4 m120 -118.55 137.54 53.16 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-N 116.515 -0.312 . . . . 0.0 111.098 -177.633 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 161.62 -139.91 6.29 Favored Glycine 0 N--CA 1.442 -0.934 0 C-N-CA 119.633 -1.27 . . . . 0.0 113.424 176.299 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 27.2 p -138.05 159.97 40.6 Favored 'General case' 0 C--N 1.312 -1.06 0 C-N-CA 123.037 0.535 . . . . 0.0 110.031 -178.703 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 20.5 ptm -146.35 163.0 36.94 Favored 'General case' 0 C--N 1.31 -1.138 0 C-N-CA 121.027 -0.269 . . . . 0.0 111.071 -177.749 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' THR . . . . . 0.587 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 25.8 m -136.68 127.51 27.39 Favored 'General case' 0 C--O 1.251 1.175 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.177 178.727 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . 0.52 ' HB2' ' OE1' ' A' ' 123' ' ' GLU . 6.9 m-85 -94.67 162.7 13.67 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.215 -0.448 . . . . 0.0 109.946 174.705 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -58.79 119.17 6.66 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.695 0.283 . . . . 0.0 111.26 179.813 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 74.03 23.96 74.93 Favored Glycine 0 CA--C 1.52 0.376 0 C-N-CA 120.892 -0.67 . . . . 0.0 112.868 -179.792 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . 0.52 ' OE1' ' HB2' ' A' ' 120' ' ' TYR . 40.0 tt0 -130.2 158.38 39.9 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 -179.769 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -89.14 162.89 31.31 Favored Glycine 0 N--CA 1.444 -0.791 0 N-CA-C 110.902 -0.879 . . . . 0.0 110.902 177.326 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_exo -58.43 131.54 43.38 Favored 'Trans proline' 0 CA--C 1.532 0.394 0 C-N-CA 122.261 1.974 . . . . 0.0 112.471 -179.237 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 43.1 pt -127.87 163.67 31.04 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.18 179.724 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -71.04 133.68 22.67 Favored Glycine 0 C--O 1.242 0.608 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.224 -178.89 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 87.7 t80 -118.02 133.87 55.51 Favored 'General case' 0 C--O 1.245 0.841 0 CA-C-O 121.091 0.472 . . . . 0.0 111.366 -178.083 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 76.5 tttt -137.74 111.0 7.88 Favored 'General case' 0 N--CA 1.44 -0.938 0 CA-C-N 115.165 -0.925 . . . . 0.0 108.887 178.026 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -112.16 143.65 17.56 Favored Glycine 0 C--N 1.311 -0.86 0 C-N-CA 120.377 -0.916 . . . . 0.0 111.843 179.885 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 41.3 m -130.36 130.45 44.42 Favored 'General case' 0 C--N 1.313 -0.998 0 CA-C-N 117.074 0.437 . . . . 0.0 110.401 179.203 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 64.8 tp -65.87 141.06 58.39 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.759 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 18.3 m . . . . . 0 C--O 1.251 1.132 0 CA-C-O 118.484 -0.77 . . . . 0.0 109.504 178.745 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.549 ' HB3' ' O ' ' A' ' 25' ' ' ILE . . . . . . . . 0 N--CA 1.474 0.775 0 N-CA-C 110.308 -0.256 . . . . 0.0 110.308 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . 0.499 HD11 HE21 ' A' ' 22' ' ' GLN . 0.9 OUTLIER -151.91 128.04 10.46 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 -178.474 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . 0.401 ' N ' HD13 ' A' ' 3' ' ' LEU . 61.7 m-85 -123.52 147.31 47.37 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 112.917 0.71 . . . . 0.0 112.917 -178.293 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 27.4 t-20 -97.92 129.72 44.83 Favored 'General case' 0 C--N 1.316 -0.864 0 N-CA-C 106.677 -1.601 . . . . 0.0 106.677 174.705 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 65.1 t -116.91 129.48 73.37 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.046 0 CA-C-O 121.437 0.637 . . . . 0.0 112.635 -173.818 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 -114.2 139.74 49.13 Favored 'General case' 0 C--O 1.249 1.032 0 CA-C-N 114.974 -1.012 . . . . 0.0 108.346 176.874 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 10.2 m120 -114.16 140.74 48.28 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 116.453 -0.34 . . . . 0.0 110.94 -176.699 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . 0.593 ' OE1' ' HA ' ' A' ' 13' ' ' SER . 36.6 tt0 -127.64 125.56 40.39 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 120.948 0.404 . . . . 0.0 111.289 177.784 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 22.8 p90 -137.29 144.75 42.81 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 116.042 -0.526 . . . . 0.0 109.83 177.192 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 99.52 9.64 49.75 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 120.568 -0.825 . . . . 0.0 111.98 179.039 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 111.17 154.95 13.4 Favored Glycine 0 N--CA 1.444 -0.773 0 C-N-CA 120.959 -0.638 . . . . 0.0 112.325 179.527 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . 0.593 ' HA ' ' OE1' ' A' ' 9' ' ' GLN . 69.9 m -65.98 -14.76 62.19 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 112.883 0.697 . . . . 0.0 112.883 -179.627 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 46.9 m -84.21 -7.93 59.21 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 121.059 0.457 . . . . 0.0 110.481 177.132 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -84.84 150.16 55.25 Favored Pre-proline 0 N--CA 1.449 -0.478 0 CA-C-N 115.924 -0.58 . . . . 0.0 109.773 178.79 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -67.33 152.35 79.27 Favored 'Trans proline' 0 C--O 1.236 0.409 0 C-N-CA 122.458 2.105 . . . . 0.0 113.046 -178.231 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . 0.414 ' CE3' ' HB2' ' A' ' 9' ' ' GLN . 90.8 m95 -83.78 130.46 34.94 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 115.52 -0.764 . . . . 0.0 109.056 178.422 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' ASN . . . . . 0.518 HD22 ' N ' ' A' ' 18' ' ' ASN . 0.8 OUTLIER -107.51 132.48 53.19 Favored 'General case' 0 C--N 1.313 -1.016 0 N-CA-C 107.524 -1.287 . . . . 0.0 107.524 179.168 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 71.8 tt0 -66.42 128.02 34.57 Favored 'General case' 0 C--N 1.308 -1.221 0 CA-C-O 121.58 0.705 . . . . 0.0 110.634 -176.793 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -100.96 -4.48 54.28 Favored Glycine 0 N--CA 1.435 -1.396 0 CA-C-N 115.026 -0.988 . . . . 0.0 113.345 -175.113 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 115.01 -153.52 17.58 Favored Glycine 0 N--CA 1.443 -0.851 0 C-N-CA 120.306 -0.95 . . . . 0.0 111.943 -178.142 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . 0.499 HE21 HD11 ' A' ' 3' ' ' LEU . 4.4 pt20 -132.52 139.41 47.88 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-O 120.701 0.286 . . . . 0.0 110.553 -179.812 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . 0.458 ' CZ2' ' HE3' ' A' ' 118' ' ' MET . 38.4 m0 -117.29 161.44 19.49 Favored 'General case' 0 CA--C 1.508 -0.665 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.887 -178.517 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.412 ' HB3' ' H ' ' A' ' 91' ' ' ILE . 73.4 tt0 -112.47 107.05 15.68 Favored 'General case' 0 N--CA 1.443 -0.825 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 175.11 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.549 ' O ' ' HB3' ' A' ' 2' ' ' ALA . 92.4 mt -123.22 132.07 72.06 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.843 0 CA-C-N 115.922 -0.581 . . . . 0.0 109.872 -177.36 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 90.85 116.33 1.9 Allowed Glycine 0 N--CA 1.446 -0.641 0 C-N-CA 120.33 -0.938 . . . . 0.0 112.432 178.707 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . 0.472 ' OG ' ' HA3' ' A' ' 88' ' ' GLY . 13.2 t -112.56 14.96 20.23 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-O 121.071 0.463 . . . . 0.0 110.201 -179.848 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 75.7 mtp180 -127.64 138.69 52.91 Favored 'General case' 0 CA--C 1.513 -0.449 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.375 -179.426 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 19.4 m -93.01 -27.27 17.1 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.783 179.407 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 11.8 p-10 -77.32 -38.62 50.09 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.45 -177.618 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . 0.523 HE21 ' HA ' ' A' ' 31' ' ' GLN . 0.0 OUTLIER -130.21 121.41 26.15 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.302 179.709 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . 0.559 ' ND2' ' HA3' ' A' ' 111' ' ' GLY . 65.6 t30 -95.3 169.02 10.37 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 178.792 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 58.8 t -96.44 131.25 43.7 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.991 0 CA-C-N 116.568 -0.287 . . . . 0.0 110.934 -177.5 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 28.4 m -111.39 -20.25 6.38 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.163 0 N-CA-C 112.19 0.441 . . . . 0.0 112.19 179.002 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.532 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -147.86 145.57 28.74 Favored 'General case' 0 CA--C 1.514 -0.435 0 C-N-CA 120.296 -0.562 . . . . 0.0 111.512 179.992 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.403 ' HB ' HG22 ' A' ' 105' ' ' VAL . 92.0 mt -144.87 127.95 11.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.042 -0.526 . . . . 0.0 109.893 -179.539 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . 0.421 ' HA ' ' O ' ' A' ' 103' ' ' ILE . 0.6 OUTLIER -133.17 112.11 11.46 Favored 'General case' 0 C--N 1.317 -0.81 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 174.967 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.512 HG11 ' CD2' ' A' ' 61' ' ' PHE . 15.5 m -147.67 150.21 14.72 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.804 0 N-CA-C 112.207 0.447 . . . . 0.0 112.207 -174.871 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 70.5 tt0 -133.22 143.11 48.93 Favored 'General case' 0 N--CA 1.442 -0.851 0 CA-C-N 114.976 -1.011 . . . . 0.0 108.703 176.485 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 21.2 p -73.75 146.34 44.43 Favored 'General case' 0 C--N 1.31 -1.128 0 CA-C-O 120.728 0.299 . . . . 0.0 111.216 178.591 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -92.11 -42.48 4.64 Favored Glycine 0 N--CA 1.447 -0.576 0 N-CA-C 109.687 -1.365 . . . . 0.0 109.687 175.333 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 23.0 m-20 -102.27 -161.36 0.84 Allowed 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 114.711 -0.745 . . . . 0.0 109.116 176.042 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 29.4 p-10 -84.12 47.79 1.38 Allowed 'General case' 0 C--N 1.315 -0.895 0 CA-C-O 121.325 0.583 . . . . 0.0 110.874 179.484 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 99.53 -14.4 60.72 Favored Glycine 0 C--O 1.22 -0.778 0 CA-C-N 115.923 -0.581 . . . . 0.0 112.665 -179.411 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 58.5 tp60 -64.87 -39.39 93.47 Favored 'General case' 0 CA--C 1.534 0.362 0 CA-C-O 120.803 0.335 . . . . 0.0 111.328 -179.162 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 61.3 p -128.45 142.87 50.96 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.604 -0.271 . . . . 0.0 110.742 179.07 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 86.0 mt -126.68 133.83 50.85 Favored 'General case' 0 C--O 1.236 0.369 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 179.168 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -136.22 147.91 47.83 Favored 'General case' 0 C--N 1.32 -0.692 0 C-N-CA 120.905 -0.318 . . . . 0.0 110.951 179.981 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 165.67 -144.17 9.02 Favored Glycine 0 N--CA 1.442 -0.922 0 C-N-CA 120.497 -0.858 . . . . 0.0 112.104 177.909 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 9.4 t -133.53 145.51 50.2 Favored 'General case' 0 N--CA 1.435 -1.177 0 CA-C-O 121.103 0.477 . . . . 0.0 110.558 -179.211 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 14.6 tmm? -133.32 147.19 51.85 Favored 'General case' 0 C--N 1.314 -0.96 0 CA-C-N 115.918 -0.583 . . . . 0.0 109.685 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.532 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 28.7 m -125.96 128.01 46.84 Favored 'General case' 0 C--O 1.249 1.054 0 N-CA-C 112.045 0.387 . . . . 0.0 112.045 -176.812 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . 0.429 ' HB2' ' HB2' ' A' ' 56' ' ' GLU . 86.0 m-85 -86.27 162.29 18.34 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.565 176.781 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -64.29 122.09 15.84 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.886 178.479 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.59 5.84 89.19 Favored Glycine 0 CA--C 1.517 0.198 0 C-N-CA 120.958 -0.639 . . . . 0.0 112.499 179.925 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . 0.429 ' HB2' ' HB2' ' A' ' 53' ' ' TYR . 69.6 mm-40 -119.55 179.14 4.31 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 120.742 0.306 . . . . 0.0 110.874 -178.608 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -106.77 169.2 14.96 Favored Glycine 0 N--CA 1.44 -1.078 0 N-CA-C 111.237 -0.745 . . . . 0.0 111.237 178.881 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_exo -62.34 137.36 64.97 Favored 'Trans proline' 0 C--O 1.235 0.359 0 C-N-CA 122.583 2.189 . . . . 0.0 112.239 179.102 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . 0.475 ' HB ' ' O ' ' A' ' 76' ' ' GLN . 48.6 pt -130.32 170.98 18.3 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 CA-C-N 115.984 -0.553 . . . . 0.0 109.813 178.387 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -75.57 136.27 19.76 Favored Glycine 0 N--CA 1.446 -0.671 0 C-N-CA 120.2 -1.0 . . . . 0.0 110.889 -179.346 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.512 ' CD2' HG11 ' A' ' 38' ' ' VAL . 7.5 t80 -131.22 125.15 32.16 Favored 'General case' 0 C--N 1.31 -1.152 0 CA-C-O 120.958 0.409 . . . . 0.0 111.457 -178.046 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 61.9 ttp180 -130.03 130.99 45.66 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.608 -0.724 . . . . 0.0 110.338 178.039 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.409 ' HB1' ' HB3' ' A' ' 71' ' ' TYR . . . -130.99 138.98 49.93 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.782 179.382 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 63.6 m -121.16 130.18 53.6 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.392 179.838 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 61.7 tp -68.16 121.68 16.7 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 121.064 0.459 . . . . 0.0 111.365 -178.459 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 96.1 mt -71.32 -34.24 70.39 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.613 178.242 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 133.5 -12.16 4.91 Favored Glycine 0 CA--C 1.521 0.445 0 C-N-CA 120.485 -0.865 . . . . 0.0 113.31 -179.742 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 20.7 m120 -130.89 50.84 2.19 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-O 120.981 0.42 . . . . 0.0 111.4 -178.038 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 86.7 m-20 65.03 1.54 1.52 Allowed 'General case' 0 N--CA 1.486 1.336 0 C-N-CA 123.845 0.858 . . . . 0.0 111.98 178.835 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 25.7 t -102.62 138.19 39.84 Favored 'General case' 0 N--CA 1.436 -1.146 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 179.108 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.447 ' CE1' ' HB2' ' A' ' 92' ' ' LEU . 84.7 m-85 -118.1 140.87 49.14 Favored 'General case' 0 C--N 1.307 -1.263 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.742 -178.534 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -91.24 123.88 35.03 Favored 'General case' 0 N--CA 1.438 -1.063 0 N-CA-C 107.657 -1.238 . . . . 0.0 107.657 173.746 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.439 HG13 ' HE1' ' A' ' 61' ' ' PHE . 45.3 t -105.32 134.04 47.92 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.246 0 N-CA-C 113.413 0.894 . . . . 0.0 113.413 -173.057 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 84.7 mt-10 -129.25 126.27 38.72 Favored 'General case' 0 N--CA 1.438 -1.042 0 CA-C-N 114.367 -1.288 . . . . 0.0 107.69 176.369 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 92.8 m-20 -109.22 146.69 33.79 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-O 121.021 0.439 . . . . 0.0 111.789 -175.582 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' GLN . . . . . 0.479 ' HB2' ' CE3' ' A' ' 84' ' ' TRP . 58.4 tt0 -114.47 121.26 42.99 Favored 'General case' 0 C--N 1.312 -1.061 0 CA-C-N 115.707 -0.678 . . . . 0.0 109.645 -179.955 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 5.8 p90 -140.46 159.47 42.12 Favored 'General case' 0 C--N 1.318 -0.79 0 C-N-CA 120.874 -0.33 . . . . 0.0 110.578 179.246 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 95.35 -7.16 68.83 Favored Glycine 0 N--CA 1.447 -0.575 0 C-N-CA 120.834 -0.698 . . . . 0.0 111.846 -179.704 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 146.58 154.93 6.33 Favored Glycine 0 N--CA 1.445 -0.725 0 N-CA-C 111.684 -0.566 . . . . 0.0 111.684 178.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -72.28 -25.56 61.64 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-O 120.965 0.412 . . . . 0.0 111.198 -179.987 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 4.6 m -82.47 -11.7 58.33 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.412 177.72 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -72.63 155.3 91.09 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.445 -177.236 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -69.38 169.02 19.38 Favored 'Trans proline' 0 C--N 1.347 0.485 0 C-N-CA 122.721 2.281 . . . . 0.0 112.141 178.342 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' TRP . . . . . 0.479 ' CE3' ' HB2' ' A' ' 76' ' ' GLN . 91.8 m95 -87.49 143.29 27.29 Favored 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 -178.409 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 85.8 m-70 -118.61 157.77 26.75 Favored 'General case' 0 C--N 1.313 -0.996 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 -179.705 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 48.3 m -63.81 143.74 57.61 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-O 120.837 0.351 . . . . 0.0 111.023 179.787 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -117.18 -58.91 0.3 Allowed Glycine 0 N--CA 1.439 -1.164 0 N-CA-C 110.931 -0.867 . . . . 0.0 110.931 178.556 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.472 ' HA3' ' OG ' ' A' ' 27' ' ' SER . . . 149.38 -167.68 29.66 Favored Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 120.929 -0.653 . . . . 0.0 111.929 177.067 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' ASN . . . . . 0.407 ' C ' ' HD1' ' A' ' 90' ' ' TRP . 11.2 m120 -102.48 132.68 48.37 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-O 120.679 0.276 . . . . 0.0 110.624 178.747 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' TRP . . . . . 0.407 ' HD1' ' C ' ' A' ' 89' ' ' ASN . 12.5 m0 -130.63 151.58 50.93 Favored 'General case' 0 C--N 1.319 -0.744 0 N-CA-C 108.472 -0.936 . . . . 0.0 108.472 -179.222 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.412 ' H ' ' HB3' ' A' ' 24' ' ' GLU . 95.8 mt -117.26 115.52 49.05 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.153 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 176.643 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . 0.447 ' HB2' ' CE1' ' A' ' 71' ' ' TYR . 88.8 mt -125.6 74.14 1.38 Allowed 'General case' 0 C--O 1.247 0.962 0 CA-C-O 121.683 0.754 . . . . 0.0 110.215 -177.577 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 167.72 87.39 0.07 OUTLIER Glycine 0 N--CA 1.431 -1.648 0 CA-C-N 114.892 -1.049 . . . . 0.0 110.73 -177.888 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 22.5 p -91.63 -5.68 53.46 Favored 'General case' 0 C--N 1.31 -1.116 0 CA-C-O 121.176 0.512 . . . . 0.0 110.586 -179.243 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' ARG . . . . . 0.427 HH11 ' HD3' ' A' ' 95' ' ' ARG . 61.7 mtt-85 -94.2 150.0 20.72 Favored 'General case' 0 N--CA 1.442 -0.849 0 CA-C-N 115.64 -0.709 . . . . 0.0 109.676 179.127 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 77.3 tt0 -70.06 -42.76 72.39 Favored 'General case' 0 C--N 1.315 -0.925 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.669 -174.048 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 94.4 m-20 -113.46 18.13 17.9 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.905 -176.871 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' GLN . . . . . . . . . . . . . 2.3 mt-30 -141.53 117.92 10.82 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 113.18 0.807 . . . . 0.0 113.18 -176.118 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 35.8 m-80 -98.25 166.44 11.4 Favored 'General case' 0 C--O 1.245 0.852 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.204 175.138 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 97.1 t -85.18 134.07 27.93 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.611 -179.063 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 27.9 m -115.23 -31.43 1.97 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-N 115.785 -0.643 . . . . 0.0 112.626 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . 0.601 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -144.22 139.08 28.48 Favored 'General case' 0 CA--C 1.514 -0.409 0 C-N-CA 120.097 -0.641 . . . . 0.0 111.631 179.306 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.445 ' HB ' HG22 ' A' ' 38' ' ' VAL . 92.0 mt -132.75 128.38 57.15 Favored 'Isoleucine or valine' 0 C--O 1.238 0.497 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.177 179.743 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 40.7 t30 -128.42 98.16 4.96 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.674 -0.694 . . . . 0.0 109.435 173.544 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.403 HG22 ' HB ' ' A' ' 36' ' ' ILE . 28.3 m -138.0 140.93 39.74 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 N-CA-C 112.331 0.493 . . . . 0.0 112.331 -176.634 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 42.4 tt0 -141.11 138.52 33.56 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.658 -0.701 . . . . 0.0 109.965 178.078 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 46.4 t -143.85 141.71 30.47 Favored 'General case' 0 N--CA 1.446 -0.634 0 CA-C-O 120.894 0.378 . . . . 0.0 111.24 179.18 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -106.81 6.22 37.6 Favored Glycine 0 N--CA 1.443 -0.873 0 N-CA-C 110.624 -0.991 . . . . 0.0 110.624 176.187 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 23.1 m-20 -95.78 14.33 23.62 Favored 'General case' 0 CA--C 1.516 -0.344 0 C-N-CA 123.004 0.522 . . . . 0.0 111.324 -178.176 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 85.7 m-20 63.59 23.38 13.56 Favored 'General case' 0 N--CA 1.47 0.561 0 CA-C-N 115.632 -0.713 . . . . 0.0 112.319 178.173 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . 0.559 ' HA3' ' ND2' ' A' ' 32' ' ' ASN . . . 103.45 5.21 46.05 Favored Glycine 0 N--CA 1.446 -0.653 0 C-N-CA 120.008 -1.092 . . . . 0.0 114.249 176.651 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 54.2 tt0 -62.63 -49.53 74.81 Favored 'General case' 0 C--O 1.249 1.059 0 CA-C-O 121.583 0.706 . . . . 0.0 109.891 177.612 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 14.4 p -136.12 133.17 36.99 Favored 'General case' 0 N--CA 1.442 -0.846 0 CA-C-N 115.034 -0.985 . . . . 0.0 109.555 177.163 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -107.38 122.76 47.24 Favored 'General case' 0 C--N 1.314 -0.97 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 178.787 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 88.9 m-20 -119.54 143.72 47.45 Favored 'General case' 0 C--N 1.311 -1.082 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.121 -179.063 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 160.87 -138.09 5.3 Favored Glycine 0 N--CA 1.442 -0.915 0 C-N-CA 120.216 -0.992 . . . . 0.0 112.685 177.568 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 2.1 p -131.68 153.34 50.1 Favored 'General case' 0 C--N 1.314 -0.978 0 CA-C-O 121.086 0.47 . . . . 0.0 110.789 -179.592 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 118' ' ' MET . . . . . 0.619 ' SD ' ' HD1' ' A' ' 128' ' ' PHE . 21.7 ptm -139.56 147.81 41.7 Favored 'General case' 0 C--N 1.314 -0.962 0 CA-C-N 115.813 -0.63 . . . . 0.0 109.993 -176.764 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 119' ' ' THR . . . . . 0.601 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 29.1 m -131.75 125.61 32.4 Favored 'General case' 0 C--O 1.249 1.063 0 C-N-CA 120.99 -0.284 . . . . 0.0 111.096 179.095 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . 0.4 ' HB2' ' HB3' ' A' ' 123' ' ' GLU . 63.1 m-85 -94.11 163.7 13.36 Favored 'General case' 0 CA--C 1.513 -0.476 0 CA-C-N 116.159 -0.473 . . . . 0.0 109.969 175.52 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -53.51 -33.81 55.8 Favored 'General case' 0 N--CA 1.47 0.545 0 N-CA-C 113.503 0.927 . . . . 0.0 113.503 -176.544 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -138.0 25.31 2.93 Favored Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 119.596 -1.288 . . . . 0.0 112.776 -178.017 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . 0.4 ' HB3' ' HB2' ' A' ' 120' ' ' TYR . 36.1 tp10 -111.28 -53.06 2.74 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-O 121.29 0.567 . . . . 0.0 110.326 -177.926 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 115.01 177.43 18.8 Favored Glycine 0 N--CA 1.439 -1.154 0 CA-C-N 115.541 -0.754 . . . . 0.0 111.452 -178.308 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 13.5 Cg_exo -71.16 117.13 5.0 Favored 'Trans proline' 0 N--CA 1.458 -0.561 0 C-N-CA 122.8 2.333 . . . . 0.0 112.051 179.053 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 36.7 pt -130.16 165.96 29.01 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.946 0 CA-C-N 115.93 -0.577 . . . . 0.0 109.891 178.388 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -70.26 135.72 26.0 Favored Glycine 0 C--O 1.241 0.532 0 C-N-CA 120.871 -0.68 . . . . 0.0 112.531 -178.5 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . 0.619 ' HD1' ' SD ' ' A' ' 118' ' ' MET . 72.8 t80 -112.5 132.3 55.15 Favored 'General case' 0 C--O 1.249 1.031 0 CA-C-O 120.832 0.349 . . . . 0.0 111.054 -178.793 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 129' ' ' LYS . . . . . 0.402 ' HB2' ' CZ3' ' A' ' 17' ' ' TRP . 61.0 tttm -137.59 108.9 6.85 Favored 'General case' 0 N--CA 1.447 -0.587 0 CA-C-N 115.599 -0.728 . . . . 0.0 109.213 175.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -114.03 137.12 13.85 Favored Glycine 0 N--CA 1.446 -0.648 0 C-N-CA 120.522 -0.847 . . . . 0.0 111.818 179.244 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 55.8 m -132.34 140.64 48.62 Favored 'General case' 0 C--N 1.308 -1.21 0 CA-C-N 116.645 0.223 . . . . 0.0 110.605 -179.241 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 88.1 mt -56.99 130.03 44.29 Favored 'General case' 0 N--CA 1.472 0.663 0 O-C-N 123.17 0.294 . . . . 0.0 110.939 177.5 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 14.8 p . . . . . 0 C--O 1.252 1.212 0 CA-C-O 118.145 -0.931 . . . . 0.0 110.326 178.313 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.406 ' O ' ' HG3' ' A' ' 24' ' ' GLU . . . . . . . . 0 N--CA 1.471 0.581 0 N-CA-C 109.713 -0.477 . . . . 0.0 109.713 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . 0.496 HD11 ' NE2' ' A' ' 22' ' ' GLN . 3.0 tm? -94.81 127.12 40.59 Favored 'General case' 0 C--N 1.317 -0.823 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 -177.153 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 40.5 m-85 -117.16 136.66 52.87 Favored 'General case' 0 C--N 1.312 -1.023 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.305 178.444 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . 0.487 ' O ' ' HA2' ' A' ' 130' ' ' GLY . 0.9 OUTLIER -85.06 132.23 34.35 Favored 'General case' 0 CA--C 1.499 -0.989 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 175.378 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.509 HG21 ' CG ' ' A' ' 23' ' ' TRP . 53.2 t -114.35 128.13 71.51 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.115 0 N-CA-C 113.182 0.808 . . . . 0.0 113.182 -173.847 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 71.6 mt-10 -124.05 135.9 53.89 Favored 'General case' 0 N--CA 1.436 -1.143 0 CA-C-N 114.577 -1.192 . . . . 0.0 108.469 177.542 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . 0.438 ' HB3' HD12 ' A' ' 126' ' ' ILE . 10.8 m120 -121.1 145.11 48.15 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 120.884 0.373 . . . . 0.0 111.415 -175.935 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . 0.465 HE22 ' HA ' ' A' ' 13' ' ' SER . 52.1 tt0 -124.97 123.39 39.77 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.717 178.264 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 40.1 p90 -133.44 142.56 48.37 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 116.653 -0.249 . . . . 0.0 110.922 179.264 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 105.16 10.31 32.22 Favored Glycine 0 CA--C 1.52 0.345 0 C-N-CA 120.327 -0.94 . . . . 0.0 112.945 177.164 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 97.36 171.51 33.52 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.574 -0.822 . . . . 0.0 112.887 179.56 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . 0.465 ' HA ' HE22 ' A' ' 9' ' ' GLN . 16.4 m -57.8 -26.31 61.78 Favored 'General case' 0 CA--C 1.536 0.426 0 C-N-CA 122.993 0.517 . . . . 0.0 112.061 179.311 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 14.8 m -59.24 -24.76 63.46 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 122.62 0.368 . . . . 0.0 111.695 177.5 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -91.37 144.27 29.47 Favored Pre-proline 0 C--N 1.324 -0.51 0 CA-C-N 116.75 -0.204 . . . . 0.0 110.577 179.515 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -81.13 -176.05 2.95 Favored 'Trans proline' 0 C--O 1.239 0.538 0 C-N-CA 122.657 2.238 . . . . 0.0 112.32 179.397 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 99.1 m95 -87.22 128.8 35.14 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.213 -0.449 . . . . 0.0 109.908 179.64 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 34.0 m-80 -113.65 110.74 20.69 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.384 -177.093 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 73.1 tt0 -73.35 121.29 20.2 Favored 'General case' 0 C--N 1.317 -0.837 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 177.084 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -134.68 32.59 2.59 Favored Glycine 0 N--CA 1.447 -0.624 0 C-N-CA 119.792 -1.194 . . . . 0.0 112.967 -178.634 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . 0.419 ' HA3' ' HB2' ' A' ' 94' ' ' SER . . . 136.99 -167.22 24.71 Favored Glycine 0 N--CA 1.444 -0.821 0 C-N-CA 120.103 -1.046 . . . . 0.0 112.817 178.104 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . 0.496 ' NE2' HD11 ' A' ' 3' ' ' LEU . 10.9 pt20 -147.84 153.9 39.75 Favored 'General case' 0 C--N 1.316 -0.879 0 C-N-CA 122.236 0.214 . . . . 0.0 110.543 -179.715 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . 0.509 ' CG ' HG21 ' A' ' 6' ' ' VAL . 38.4 m0 -126.82 177.04 6.84 Favored 'General case' 0 N--CA 1.47 0.531 0 CA-C-N 116.343 -0.389 . . . . 0.0 110.347 -175.623 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.459 ' HB3' HG12 ' A' ' 91' ' ' ILE . 83.7 tt0 -124.61 114.44 19.38 Favored 'General case' 0 CA--C 1.505 -0.768 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.031 174.74 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 98.2 mt -124.38 132.83 70.77 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.878 0 CA-C-N 115.446 -0.797 . . . . 0.0 109.632 -178.294 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 87.75 55.21 2.33 Favored Glycine 0 N--CA 1.447 -0.606 0 C-N-CA 120.077 -1.059 . . . . 0.0 112.45 178.283 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 36.1 t -61.57 -38.14 86.43 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.575 0.226 . . . . 0.0 110.558 178.993 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 70.4 ttt180 -49.98 -42.61 49.27 Favored 'General case' 0 CA--C 1.542 0.656 0 CA-C-N 116.199 -0.455 . . . . 0.0 112.174 179.501 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 14.9 m 74.16 -42.13 0.5 Allowed 'General case' 0 N--CA 1.48 1.052 0 N-CA-C 114.36 1.244 . . . . 0.0 114.36 175.6 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 3.9 p-10 -74.98 -4.33 37.59 Favored 'General case' 0 N--CA 1.487 1.411 0 CA-C-N 118.378 0.535 . . . . 0.0 111.782 -178.237 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 1.1 tm0? -150.71 119.7 6.68 Favored 'General case' 0 C--N 1.314 -0.968 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.755 178.525 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . 0.658 ' OD1' ' HA3' ' A' ' 111' ' ' GLY . 27.0 t-20 -85.59 145.74 27.21 Favored 'General case' 0 CA--C 1.534 0.357 0 CA-C-O 121.667 0.746 . . . . 0.0 111.97 -179.696 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 15.4 t -97.14 130.07 46.29 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.12 0 CA-C-N 115.085 -0.961 . . . . 0.0 110.531 -177.698 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 17.2 m -101.3 -24.52 4.05 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 N-CA-C 112.002 0.371 . . . . 0.0 112.002 -179.599 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.572 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -141.25 146.13 36.45 Favored 'General case' 0 C--N 1.323 -0.551 0 C-N-CA 120.273 -0.571 . . . . 0.0 111.12 179.327 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.438 ' HB ' ' CG2' ' A' ' 105' ' ' VAL . 98.2 mt -142.84 125.53 13.47 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.325 -177.427 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -130.81 113.36 13.98 Favored 'General case' 0 C--N 1.316 -0.869 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 174.898 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.505 HG22 ' HB ' ' A' ' 103' ' ' ILE . 28.7 m -144.73 145.64 20.95 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 C-N-CA 120.89 -0.324 . . . . 0.0 111.214 -175.785 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 79.6 tt0 -141.03 146.22 36.93 Favored 'General case' 0 N--CA 1.45 -0.453 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.163 178.263 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . 0.557 ' OG ' ' HB ' ' A' ' 101' ' ' VAL . 26.0 p -81.89 144.86 30.69 Favored 'General case' 0 C--N 1.316 -0.864 0 N-CA-C 111.875 0.324 . . . . 0.0 111.875 -179.11 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -91.23 -21.62 34.75 Favored Glycine 0 N--CA 1.449 -0.454 0 N-CA-C 110.744 -0.942 . . . . 0.0 110.744 175.206 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . 0.4 ' C ' ' H ' ' A' ' 44' ' ' GLY . 28.2 m-20 -132.91 -150.2 0.4 Allowed 'General case' 0 CA--C 1.514 -0.415 0 N-CA-C 108.917 -0.772 . . . . 0.0 108.917 179.373 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -75.81 34.89 0.12 Allowed 'General case' 0 N--CA 1.471 0.614 0 C-N-CA 122.768 0.427 . . . . 0.0 110.818 178.517 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.42 ' O ' ' HE2' ' A' ' 71' ' ' TYR . . . 90.85 1.81 72.88 Favored Glycine 0 N--CA 1.442 -0.951 0 C-N-CA 121.057 -0.592 . . . . 0.0 112.655 -178.669 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 60.5 tp60 -62.89 -44.81 95.09 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-O 120.971 0.415 . . . . 0.0 110.547 -179.433 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 4.3 t -129.97 122.6 28.8 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.185 176.404 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 81.8 mt -102.48 132.8 48.28 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 116.139 -0.482 . . . . 0.0 109.777 178.782 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 13.0 m120 -121.34 133.39 55.11 Favored 'General case' 0 C--N 1.314 -0.964 0 N-CA-C 108.963 -0.755 . . . . 0.0 108.963 177.38 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.438 ' HA3' ' HA ' ' A' ' 38' ' ' VAL . . . -173.2 -162.72 25.69 Favored Glycine 0 N--CA 1.436 -1.321 0 C-N-CA 119.367 -1.397 . . . . 0.0 113.243 179.876 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 90.4 m -131.65 130.48 42.16 Favored 'General case' 0 C--N 1.309 -1.176 0 C-N-CA 122.692 0.397 . . . . 0.0 111.4 -179.701 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 43.8 mtp -106.24 145.08 32.04 Favored 'General case' 0 N--CA 1.469 0.49 0 C-N-CA 122.689 0.396 . . . . 0.0 110.161 177.042 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.572 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 36.2 m -123.92 122.35 37.74 Favored 'General case' 0 C--O 1.249 1.076 0 CA-C-O 120.636 0.255 . . . . 0.0 110.64 177.727 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 24.0 m-85 -82.44 161.38 22.46 Favored 'General case' 0 N--CA 1.462 0.142 0 CA-C-N 115.654 -0.703 . . . . 0.0 111.491 -179.468 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -65.46 109.37 2.3 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.932 -0.576 . . . . 0.0 111.661 -179.545 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 83.32 14.93 72.94 Favored Glycine 0 N--CA 1.446 -0.649 0 C-N-CA 120.836 -0.697 . . . . 0.0 113.392 178.371 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 51.1 mt-10 -137.07 167.78 20.87 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.974 0.387 . . . . 0.0 111.513 -178.993 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -78.18 163.1 50.34 Favored Glycine 0 N--CA 1.448 -0.507 0 CA-C-N 115.87 -0.604 . . . . 0.0 113.36 -177.301 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_exo -67.5 142.85 60.78 Favored 'Trans proline' 0 CA--C 1.54 0.781 0 C-N-CA 123.188 2.592 . . . . 0.0 112.749 179.778 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . 0.512 ' HB ' ' O ' ' A' ' 76' ' ' GLN . 47.5 pt -127.14 166.0 24.71 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.329 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.818 -179.422 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -73.83 144.09 33.3 Favored Glycine 0 CA--C 1.517 0.217 0 C-N-CA 121.078 -0.582 . . . . 0.0 112.502 -177.852 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 41.5 t80 -130.45 127.8 39.99 Favored 'General case' 0 C--O 1.238 0.499 0 CA-C-O 120.829 0.347 . . . . 0.0 111.091 -178.791 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 67.3 ttp85 -136.32 127.58 28.21 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 175.585 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.436 ' HB2' HG22 ' A' ' 73' ' ' VAL . . . -135.07 146.91 49.38 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 120.565 0.221 . . . . 0.0 111.548 -178.175 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 64.3 m -124.54 129.41 50.55 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.598 178.875 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . 0.467 ' HG ' ' H ' ' A' ' 67' ' ' GLY . 56.6 tp -74.58 130.21 39.15 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.879 -178.847 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.427 ' HB2' ' OD1' ' A' ' 68' ' ' ASN . 85.8 mt -84.52 -17.83 37.69 Favored 'General case' 0 CA--C 1.536 0.429 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.077 177.094 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.467 ' H ' ' HG ' ' A' ' 65' ' ' LEU . . . 105.58 -8.99 44.32 Favored Glycine 0 C--O 1.222 -0.638 0 CA-C-N 115.761 -0.654 . . . . 0.0 112.198 178.49 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' ASN . . . . . 0.427 ' OD1' ' HB2' ' A' ' 66' ' ' LEU . 29.7 p-10 -110.85 34.72 3.84 Favored 'General case' 0 C--N 1.316 -0.858 0 CA-C-O 120.921 0.391 . . . . 0.0 110.749 -179.742 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . 0.55 HD21 ' HA ' ' A' ' 96' ' ' GLU . 90.8 m-20 66.83 7.99 5.67 Favored 'General case' 0 N--CA 1.484 1.225 0 CA-C-N 115.599 -0.728 . . . . 0.0 111.11 -179.399 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 7.3 m -107.94 133.35 52.4 Favored 'General case' 0 N--CA 1.436 -1.143 0 CA-C-N 115.685 -0.689 . . . . 0.0 109.932 -179.796 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.494 ' CE1' ' HB2' ' A' ' 92' ' ' LEU . 86.4 m-85 -114.8 134.99 54.68 Favored 'General case' 0 C--N 1.308 -1.205 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.654 -179.712 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 71.8 tt0 -86.95 119.98 27.73 Favored 'General case' 0 N--CA 1.442 -0.831 0 N-CA-C 106.967 -1.494 . . . . 0.0 106.967 173.39 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.436 HG22 ' HB2' ' A' ' 63' ' ' ALA . 63.1 t -108.71 134.13 51.61 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.073 0 N-CA-C 112.943 0.72 . . . . 0.0 112.943 -172.835 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.405 ' HG2' ' HA ' ' A' ' 86' ' ' SER . 49.1 mt-10 -131.45 131.91 43.91 Favored 'General case' 0 N--CA 1.441 -0.912 0 CA-C-N 114.6 -1.182 . . . . 0.0 107.93 175.943 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 95.1 m-20 -119.28 160.62 21.87 Favored 'General case' 0 C--N 1.309 -1.18 0 CA-C-O 121.371 0.605 . . . . 0.0 112.257 -175.207 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' GLN . . . . . 0.512 ' O ' ' HB ' ' A' ' 59' ' ' ILE . 59.8 tt0 -118.95 114.26 22.28 Favored 'General case' 0 C--N 1.312 -1.025 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.569 -179.17 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 3.3 p90 -134.83 35.71 3.11 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-O 120.941 0.401 . . . . 0.0 111.416 -176.615 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -133.49 -6.9 2.56 Favored Glycine 0 C--N 1.318 -0.433 0 C-N-CA 120.225 -0.988 . . . . 0.0 112.742 -178.32 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 127.47 160.43 10.47 Favored Glycine 0 N--CA 1.445 -0.745 0 N-CA-C 109.805 -1.318 . . . . 0.0 109.805 -178.076 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 19.6 m-20 -58.97 -39.98 83.39 Favored 'General case' 0 N--CA 1.474 0.749 0 CA-C-N 117.72 0.76 . . . . 0.0 112.245 -177.114 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 4.7 p -81.24 -5.66 58.01 Favored 'General case' 0 C--N 1.316 -0.85 0 N-CA-C 112.436 0.532 . . . . 0.0 112.436 -177.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . 0.441 ' HA ' ' HD3' ' A' ' 83' ' ' PRO . . . -83.93 149.21 55.87 Favored Pre-proline 0 C--N 1.321 -0.67 0 CA-C-N 116.755 -0.202 . . . . 0.0 110.995 -178.644 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . 0.441 ' HD3' ' HA ' ' A' ' 82' ' ' ALA . 17.7 Cg_exo -67.33 161.31 43.73 Favored 'Trans proline' 0 C--N 1.346 0.443 0 C-N-CA 122.796 2.331 . . . . 0.0 111.939 178.242 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' TRP . . . . . . . . . . . . . 79.2 m95 -80.99 147.12 30.36 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.04 -179.496 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 89.9 m-70 -118.48 147.38 43.68 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.075 179.638 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . 0.405 ' HA ' ' HG2' ' A' ' 74' ' ' GLU . 13.0 m -62.32 134.47 56.52 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-O 121.224 0.535 . . . . 0.0 111.565 -178.073 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -105.45 -48.5 1.04 Allowed Glycine 0 N--CA 1.441 -0.982 0 CA-C-N 115.451 -0.795 . . . . 0.0 111.463 179.082 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 144.92 -163.79 27.96 Favored Glycine 0 N--CA 1.442 -0.911 0 C-N-CA 120.544 -0.836 . . . . 0.0 112.251 177.535 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 16.5 m120 -104.72 127.16 52.41 Favored 'General case' 0 C--N 1.316 -0.858 0 CA-C-O 120.812 0.339 . . . . 0.0 110.341 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 12.4 m0 -119.7 144.45 47.2 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 179.825 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.482 ' O ' ' HB3' ' A' ' 23' ' ' TRP . 45.5 mm -108.38 113.36 43.72 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.933 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.027 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . 0.494 ' HB2' ' CE1' ' A' ' 71' ' ' TYR . 77.9 mt -129.23 81.53 2.03 Favored 'General case' 0 C--O 1.261 1.699 0 CA-C-O 121.47 0.653 . . . . 0.0 111.894 -177.437 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 165.56 99.55 0.14 Allowed Glycine 0 N--CA 1.445 -0.751 0 CA-C-N 115.417 -0.811 . . . . 0.0 111.292 -179.813 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . 0.419 ' HB2' ' HA3' ' A' ' 21' ' ' GLY . 3.2 p -101.69 -12.54 18.31 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 117.036 0.418 . . . . 0.0 111.844 -177.826 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' ARG . . . . . 0.404 HH12 ' CD ' ' A' ' 123' ' ' GLU . 96.6 mtt180 -83.49 -5.0 59.03 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.438 -0.346 . . . . 0.0 111.339 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . 0.55 ' HA ' HD21 ' A' ' 69' ' ' ASN . 72.3 tt0 71.29 -55.84 0.64 Allowed 'General case' 0 N--CA 1.47 0.553 0 C-N-CA 123.502 0.721 . . . . 0.0 112.724 177.113 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 44.7 m-80 -96.18 14.93 22.36 Favored 'General case' 0 C--N 1.315 -0.919 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.341 -175.309 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' GLN . . . . . 0.478 ' HG2' ' HB3' ' A' ' 120' ' ' TYR . 59.2 tt0 -152.36 115.43 4.66 Favored 'General case' 0 C--N 1.316 -0.883 0 CA-C-O 120.992 0.425 . . . . 0.0 109.944 -177.731 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 76.5 m-20 -78.71 160.97 27.2 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.581 -0.736 . . . . 0.0 111.421 -176.376 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 90.6 t -87.97 133.04 31.58 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.496 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.205 175.252 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.557 ' HB ' ' OG ' ' A' ' 40' ' ' SER . 35.3 m -116.03 -28.02 2.39 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 N-CA-C 113.345 0.869 . . . . 0.0 113.345 -176.41 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . 0.504 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -146.94 137.66 23.77 Favored 'General case' 0 C--N 1.325 -0.483 0 C-N-CA 120.341 -0.544 . . . . 0.0 111.285 179.237 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.505 ' HB ' HG22 ' A' ' 38' ' ' VAL . 91.5 mt -133.85 127.91 52.88 Favored 'Isoleucine or valine' 0 C--O 1.242 0.699 0 CA-C-N 116.354 -0.384 . . . . 0.0 110.608 179.011 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . 0.473 ' C ' HD22 ' A' ' 104' ' ' ASN . 0.2 OUTLIER -126.31 99.48 5.88 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 175.258 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.438 ' CG2' ' HB ' ' A' ' 36' ' ' ILE . 19.5 m -137.92 141.11 39.5 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 N-CA-C 112.546 0.573 . . . . 0.0 112.546 -176.925 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 70.4 tt0 -142.14 138.02 31.32 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.705 -0.679 . . . . 0.0 109.583 177.466 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 28.8 t -140.7 142.24 34.89 Favored 'General case' 0 N--CA 1.448 -0.529 0 CA-C-O 121.038 0.447 . . . . 0.0 111.801 -178.682 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -107.97 9.99 37.17 Favored Glycine 0 N--CA 1.443 -0.846 0 N-CA-C 110.759 -0.936 . . . . 0.0 110.759 175.361 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 20.5 m-20 -91.64 14.03 16.3 Favored 'General case' 0 N--CA 1.466 0.348 0 C-N-CA 122.909 0.484 . . . . 0.0 110.401 -177.829 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 12.4 m-20 63.37 30.88 15.45 Favored 'General case' 0 N--CA 1.471 0.612 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.741 -177.554 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . 0.658 ' HA3' ' OD1' ' A' ' 32' ' ' ASN . . . 89.03 7.11 70.79 Favored Glycine 0 N--CA 1.449 -0.456 0 CA-C-N 115.654 -0.703 . . . . 0.0 114.273 175.271 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 52.9 tt0 -65.21 -47.85 75.45 Favored 'General case' 0 C--O 1.237 0.438 0 CA-C-N 117.438 0.619 . . . . 0.0 110.198 177.67 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . 0.438 ' HA ' ' O ' ' A' ' 130' ' ' GLY . 2.0 p -134.18 118.3 17.5 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-N 115.492 -0.776 . . . . 0.0 111.037 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -95.33 122.29 37.89 Favored 'General case' 0 C--N 1.319 -0.754 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.273 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 93.4 m-20 -123.42 148.6 45.98 Favored 'General case' 0 C--N 1.312 -1.036 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.703 -178.71 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 160.66 -135.29 3.95 Favored Glycine 0 N--CA 1.438 -1.184 0 C-N-CA 120.362 -0.923 . . . . 0.0 112.775 177.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 25.8 p -133.28 156.77 46.97 Favored 'General case' 0 C--N 1.316 -0.885 0 C-N-CA 122.858 0.463 . . . . 0.0 109.962 -178.532 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 11.3 ptm -151.4 157.61 42.64 Favored 'General case' 0 C--N 1.312 -1.046 0 CA-C-O 120.614 0.245 . . . . 0.0 110.822 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 119' ' ' THR . . . . . 0.504 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 38.0 m -132.51 131.02 41.18 Favored 'General case' 0 C--O 1.249 1.079 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.041 179.717 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . 0.478 ' HB3' ' HG2' ' A' ' 98' ' ' GLN . 78.3 m-85 -93.72 166.89 11.99 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.934 -0.575 . . . . 0.0 109.961 176.644 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -63.22 118.29 7.76 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.675 -0.239 . . . . 0.0 110.731 178.837 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 68.2 34.63 81.2 Favored Glycine 0 C--N 1.333 0.395 0 C-N-CA 120.819 -0.705 . . . . 0.0 111.613 -178.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . 0.427 ' CB ' ' HB2' ' A' ' 120' ' ' TYR . 31.6 tp10 -132.61 163.24 29.34 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 -176.723 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -94.41 159.21 23.2 Favored Glycine 0 N--CA 1.442 -0.947 0 N-CA-C 110.553 -1.019 . . . . 0.0 110.553 176.24 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_endo -62.52 132.78 39.58 Favored 'Trans proline' 0 C--O 1.237 0.464 0 C-N-CA 122.177 1.918 . . . . 0.0 111.885 -179.782 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 126' ' ' ILE . . . . . 0.438 HD12 ' HB3' ' A' ' 8' ' ' ASN . 40.9 pt -132.79 166.19 30.1 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 CA-C-N 115.932 -0.577 . . . . 0.0 110.464 -179.742 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -70.61 141.49 33.6 Favored Glycine 0 C--O 1.242 0.615 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.176 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 82.7 t80 -123.67 135.57 53.98 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-O 120.824 0.345 . . . . 0.0 111.188 -178.725 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 62.4 tttm -139.3 118.93 13.06 Favored 'General case' 0 N--CA 1.445 -0.713 0 CA-C-N 115.497 -0.774 . . . . 0.0 109.313 177.178 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . 0.487 ' HA2' ' O ' ' A' ' 5' ' ' ASN . . . -125.26 137.94 10.67 Favored Glycine 0 N--CA 1.445 -0.737 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.054 179.67 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 59.4 m -123.63 129.69 51.53 Favored 'General case' 0 C--N 1.313 -0.98 0 CA-C-N 116.853 0.327 . . . . 0.0 110.817 -179.303 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -67.45 117.7 9.78 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-O 121.186 0.517 . . . . 0.0 111.429 -178.163 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 15.0 m . . . . . 0 C--O 1.25 1.1 0 CA-C-N 115.707 -0.678 . . . . 0.0 110.612 176.229 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.807 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . 0.414 HD11 ' NE2' ' A' ' 22' ' ' GLN . 2.2 tm? -89.99 126.71 35.85 Favored 'General case' 0 C--N 1.315 -0.917 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -178.987 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . 0.474 ' CE1' ' HB ' ' A' ' 25' ' ' ILE . 58.0 m-85 -114.53 141.46 47.7 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.225 -178.796 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 23.4 t-20 -93.72 137.85 32.55 Favored 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 106.719 -1.586 . . . . 0.0 106.719 174.918 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.435 HG21 ' CG ' ' A' ' 23' ' ' TRP . 59.0 t -114.48 128.31 71.58 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.894 0 N-CA-C 113.287 0.847 . . . . 0.0 113.287 -173.679 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -118.31 133.05 56.22 Favored 'General case' 0 C--O 1.245 0.833 0 CA-C-N 114.748 -1.114 . . . . 0.0 109.283 176.907 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 12.0 m120 -110.32 135.38 51.15 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.076 -177.411 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . 0.434 ' OE1' ' HA ' ' A' ' 13' ' ' SER . 36.0 tt0 -120.45 114.23 21.48 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 120.988 0.423 . . . . 0.0 110.448 175.713 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 2.4 p90 -112.12 175.66 5.34 Favored 'General case' 0 C--N 1.311 -1.097 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.487 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 69.87 -71.34 0.56 Allowed Glycine 0 CA--C 1.529 0.948 0 CA-C-N 115.706 -0.679 . . . . 0.0 112.956 -176.847 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -165.08 168.3 39.16 Favored Glycine 0 N--CA 1.446 -0.684 0 C-N-CA 121.014 -0.612 . . . . 0.0 112.304 -178.458 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . 0.434 ' HA ' ' OE1' ' A' ' 9' ' ' GLN . 28.2 t -62.85 -19.55 64.23 Favored 'General case' 0 CA--C 1.54 0.563 0 N-CA-C 112.329 0.492 . . . . 0.0 112.329 -178.669 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 30.4 p -77.47 -6.83 54.92 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.873 0.368 . . . . 0.0 111.76 179.411 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -86.69 149.36 48.35 Favored Pre-proline 0 C--N 1.323 -0.584 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.548 179.131 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_endo -69.14 162.43 41.8 Favored 'Trans proline' 0 C--O 1.237 0.458 0 C-N-CA 122.529 2.153 . . . . 0.0 112.086 179.071 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 98.3 m95 -85.65 124.26 31.98 Favored 'General case' 0 C--N 1.317 -0.837 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 179.695 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 92.4 m-20 -111.44 113.42 25.86 Favored 'General case' 0 C--N 1.309 -1.154 0 CA-C-N 116.332 -0.394 . . . . 0.0 111.059 -175.89 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 80.6 tt0 -71.97 122.43 20.84 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-N 115.826 -0.625 . . . . 0.0 109.611 179.864 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -137.69 25.6 2.95 Favored Glycine 0 N--CA 1.446 -0.679 0 C-N-CA 120.29 -0.957 . . . . 0.0 112.559 -177.93 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . 0.414 ' HA3' ' HB3' ' A' ' 94' ' ' SER . . . 156.63 -172.39 34.33 Favored Glycine 0 N--CA 1.433 -1.524 0 C-N-CA 119.961 -1.114 . . . . 0.0 112.651 179.205 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . 0.414 ' NE2' HD11 ' A' ' 3' ' ' LEU . 19.6 pt20 -150.34 145.43 26.13 Favored 'General case' 0 C--N 1.31 -1.11 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 179.299 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . 0.435 ' CG ' HG21 ' A' ' 6' ' ' VAL . 43.7 m0 -122.47 159.45 27.61 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.749 -177.172 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.409 ' H ' ' HB ' ' A' ' 91' ' ' ILE . 79.3 tt0 -118.05 119.71 35.59 Favored 'General case' 0 C--N 1.306 -1.316 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 176.079 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.474 ' HB ' ' CE1' ' A' ' 4' ' ' TYR . 98.9 mt -127.87 135.14 63.76 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-N 115.432 -0.804 . . . . 0.0 109.934 -175.011 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 89.07 71.83 1.27 Allowed Glycine 0 N--CA 1.435 -1.427 0 C-N-CA 119.718 -1.229 . . . . 0.0 111.944 -179.878 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . 0.457 ' OG ' ' HA3' ' A' ' 88' ' ' GLY . 7.5 t -59.44 -39.38 83.39 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 176.829 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 73.3 ttt180 -82.22 113.03 19.77 Favored 'General case' 0 N--CA 1.439 -1.013 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 174.599 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 30.8 m -78.3 -13.71 59.73 Favored 'General case' 0 C--N 1.315 -0.892 0 CA-C-O 120.965 0.412 . . . . 0.0 111.777 -174.963 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 23.2 t70 -72.0 -33.43 68.09 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.403 0.62 . . . . 0.0 110.987 178.865 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . 0.597 HE21 ' HA ' ' A' ' 31' ' ' GLN . 0.0 OUTLIER -126.17 120.62 30.57 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.63 -0.713 . . . . 0.0 111.012 -177.369 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . 0.546 ' ND2' ' HA3' ' A' ' 111' ' ' GLY . 64.2 t30 -95.04 154.41 17.19 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 116.532 -0.304 . . . . 0.0 110.235 178.943 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.451 ' HA ' ' HA ' ' A' ' 53' ' ' TYR . 62.0 t -96.22 133.53 37.15 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.541 -176.457 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 28.4 m -113.49 -14.54 10.83 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.151 0 N-CA-C 112.299 0.481 . . . . 0.0 112.299 178.891 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.513 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -147.49 138.96 23.86 Favored 'General case' 0 C--N 1.323 -0.565 0 C-N-CA 120.391 -0.524 . . . . 0.0 111.487 179.552 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.417 ' HB ' HG22 ' A' ' 105' ' ' VAL . 88.8 mt -141.42 123.3 13.97 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-N 116.058 -0.519 . . . . 0.0 109.912 -179.6 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -128.97 109.39 11.19 Favored 'General case' 0 C--N 1.309 -1.188 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 174.055 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.441 HG11 ' CD1' ' A' ' 61' ' ' PHE . 18.4 m -146.49 148.13 17.28 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 C-N-CA 120.674 -0.41 . . . . 0.0 112.012 -174.356 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 66.7 tt0 -138.42 140.54 39.36 Favored 'General case' 0 C--N 1.315 -0.899 0 CA-C-N 115.214 -0.903 . . . . 0.0 108.619 176.293 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . 0.431 ' HA ' ' O ' ' A' ' 46' ' ' THR . 94.7 p -81.55 153.8 26.58 Favored 'General case' 0 C--N 1.308 -1.216 0 CA-C-O 120.921 0.391 . . . . 0.0 111.946 -176.84 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -97.43 -57.14 1.07 Allowed Glycine 0 N--CA 1.435 -1.393 0 CA-C-N 115.765 -0.652 . . . . 0.0 111.767 176.934 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -113.54 98.4 7.04 Favored 'General case' 0 CA--C 1.533 0.315 0 N-CA-C 111.924 0.342 . . . . 0.0 111.924 -178.477 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 14.1 m-20 47.76 34.53 3.88 Favored 'General case' 0 N--CA 1.492 1.667 0 N-CA-C 114.454 1.279 . . . . 0.0 114.454 175.222 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.418 ' HA2' ' CB ' ' A' ' 40' ' ' SER . . . 80.11 0.65 86.45 Favored Glycine 0 C--N 1.319 -0.41 0 C-N-CA 120.438 -0.887 . . . . 0.0 113.793 178.196 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 59.9 mt-30 -77.4 -30.45 53.59 Favored 'General case' 0 CA--C 1.513 -0.458 0 CA-C-N 117.398 0.599 . . . . 0.0 111.331 178.999 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . 0.431 ' O ' ' HA ' ' A' ' 40' ' ' SER . 5.1 p -122.83 107.02 11.42 Favored 'General case' 0 C--N 1.308 -1.229 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.999 -179.472 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . 0.512 ' HB2' ' HB3' ' A' ' 63' ' ' ALA . 90.8 mt -89.91 129.16 36.3 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 177.534 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 15.4 m120 -126.65 136.99 53.23 Favored 'General case' 0 C--N 1.318 -0.804 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 171.03 -153.32 20.47 Favored Glycine 0 N--CA 1.443 -0.857 0 C-N-CA 118.876 -1.63 . . . . 0.0 114.057 178.813 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 52.4 m -127.43 131.92 50.16 Favored 'General case' 0 C--N 1.315 -0.899 0 C-N-CA 123.14 0.576 . . . . 0.0 109.455 -178.002 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' MET . . . . . 0.534 ' HE3' HD11 ' A' ' 59' ' ' ILE . 15.5 tmm? -128.52 139.8 52.13 Favored 'General case' 0 C--N 1.315 -0.927 0 C-N-CA 121.31 -0.156 . . . . 0.0 110.65 -178.842 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.513 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 33.8 m -124.24 128.73 49.61 Favored 'General case' 0 C--O 1.253 1.286 0 CA-C-O 121.135 0.493 . . . . 0.0 111.773 -176.718 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . 0.451 ' HA ' ' HA ' ' A' ' 33' ' ' VAL . 78.4 m-85 -84.76 163.73 18.96 Favored 'General case' 0 N--CA 1.462 0.147 0 CA-C-N 115.532 -0.758 . . . . 0.0 110.951 177.958 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -58.06 109.14 0.69 Allowed 'General case' 0 N--CA 1.469 0.478 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.957 -179.228 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 72.81 18.45 78.87 Favored Glycine 0 C--O 1.225 -0.414 0 C-N-CA 121.133 -0.556 . . . . 0.0 113.054 178.007 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . 0.432 ' HB2' ' HB2' ' A' ' 53' ' ' TYR . 70.2 mm-40 -117.76 174.19 6.32 Favored 'General case' 0 C--N 1.317 -0.817 0 N-CA-C 110.197 -0.297 . . . . 0.0 110.197 -179.062 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -86.71 157.03 29.5 Favored Glycine 0 N--CA 1.444 -0.827 0 C-N-CA 120.685 -0.769 . . . . 0.0 111.733 178.418 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -67.86 141.23 53.19 Favored 'Trans proline' 0 C--O 1.234 0.286 0 C-N-CA 122.64 2.227 . . . . 0.0 111.986 179.497 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . 0.534 HD11 ' HE3' ' A' ' 51' ' ' MET . 39.6 pt -131.33 165.53 31.33 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.852 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.678 179.92 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -72.83 136.84 23.43 Favored Glycine 0 N--CA 1.447 -0.598 0 C-N-CA 120.889 -0.672 . . . . 0.0 111.499 -179.634 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.441 ' CD1' HG11 ' A' ' 38' ' ' VAL . 47.9 t80 -121.48 124.85 45.43 Favored 'General case' 0 C--N 1.313 -0.999 0 CA-C-O 120.722 0.296 . . . . 0.0 110.943 -178.462 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . 0.494 ' HA ' ' O ' ' A' ' 47' ' ' LEU . 62.0 ttp180 -135.65 129.59 33.03 Favored 'General case' 0 N--CA 1.445 -0.691 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 173.824 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.512 ' HB3' ' HB2' ' A' ' 47' ' ' LEU . . . -127.65 136.72 52.0 Favored 'General case' 0 C--N 1.311 -1.077 0 CA-C-O 120.667 0.27 . . . . 0.0 110.584 -179.836 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 28.2 m -114.16 124.68 52.66 Favored 'General case' 0 N--CA 1.435 -1.199 0 CA-C-N 116.035 -0.53 . . . . 0.0 109.861 177.914 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . 0.538 HD11 ' O ' ' A' ' 67' ' ' GLY . 2.7 tm? -63.25 129.24 39.43 Favored 'General case' 0 C--N 1.31 -1.151 0 CA-C-N 115.604 -0.725 . . . . 0.0 110.945 -179.34 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 96.5 mt -95.74 -40.42 9.37 Favored 'General case' 0 C--O 1.225 -0.199 0 CA-C-O 121.103 0.478 . . . . 0.0 111.094 178.505 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.538 ' O ' HD11 ' A' ' 65' ' ' LEU . . . -140.27 -79.93 0.06 OUTLIER Glycine 0 CA--C 1.499 -0.964 0 N-CA-C 110.766 -0.933 . . . . 0.0 110.766 -178.3 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 65.1 m-80 -146.01 -71.32 0.25 Allowed 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 107.527 -1.286 . . . . 0.0 107.527 174.389 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . 0.422 ' HB3' HG23 ' A' ' 91' ' ' ILE . 84.4 m-20 -67.77 -39.87 84.06 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.652 -0.704 . . . . 0.0 111.458 176.501 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 23.3 t -81.48 130.45 35.05 Favored 'General case' 0 CA--C 1.538 0.492 0 N-CA-C 113.025 0.75 . . . . 0.0 113.025 -174.334 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.452 ' OH ' ' HB3' ' A' ' 99' ' ' ASN . 56.9 m-85 -127.66 145.21 50.96 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.106 -0.952 . . . . 0.0 109.919 177.08 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -105.43 125.19 50.7 Favored 'General case' 0 C--N 1.312 -1.053 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 174.401 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.456 HG22 ' HB2' ' A' ' 63' ' ' ALA . 62.2 t -111.03 137.74 42.21 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.162 0 N-CA-C 113.225 0.824 . . . . 0.0 113.225 -171.914 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 63.9 mt-10 -126.53 129.74 49.22 Favored 'General case' 0 N--CA 1.442 -0.871 0 CA-C-N 114.578 -1.192 . . . . 0.0 108.257 176.344 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' ASN . . . . . 0.509 ' HB3' HD12 ' A' ' 59' ' ' ILE . 12.1 m120 -110.12 151.51 27.16 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-O 121.167 0.508 . . . . 0.0 111.693 -178.033 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' GLN . . . . . 0.463 ' HB2' ' CE3' ' A' ' 84' ' ' TRP . 62.3 tt0 -117.19 121.04 40.11 Favored 'General case' 0 C--N 1.311 -1.071 0 CA-C-N 115.359 -0.837 . . . . 0.0 110.113 -178.725 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 4.7 p90 -142.7 161.78 37.18 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.855 -179.241 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 99.83 -12.22 60.91 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 121.026 -0.607 . . . . 0.0 112.437 178.715 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 140.53 160.1 8.18 Favored Glycine 0 N--CA 1.441 -1.029 0 N-CA-C 111.087 -0.805 . . . . 0.0 111.087 179.388 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 24.7 m-20 -62.75 -35.04 78.49 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-O 120.828 0.347 . . . . 0.0 111.617 -179.319 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 5.1 m -72.53 -12.9 61.26 Favored 'General case' 0 CA--C 1.54 0.592 0 CA-C-N 116.228 -0.442 . . . . 0.0 112.003 -179.709 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -75.96 147.83 80.99 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-O 120.518 0.199 . . . . 0.0 111.217 -178.424 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -72.14 -178.44 3.23 Favored 'Trans proline' 0 C--O 1.24 0.602 0 C-N-CA 122.733 2.289 . . . . 0.0 112.289 178.762 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' TRP . . . . . 0.463 ' CE3' ' HB2' ' A' ' 76' ' ' GLN . 92.3 m95 -91.64 139.66 30.47 Favored 'General case' 0 C--N 1.319 -0.718 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 -179.358 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 93.7 m-70 -115.48 148.46 39.43 Favored 'General case' 0 C--N 1.315 -0.922 0 N-CA-C 109.689 -0.486 . . . . 0.0 109.689 -179.32 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 13.2 p -64.59 135.36 55.89 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-O 120.778 0.323 . . . . 0.0 110.856 -178.94 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -110.37 -52.36 0.6 Allowed Glycine 0 N--CA 1.442 -0.906 0 C-N-CA 120.52 -0.848 . . . . 0.0 111.958 -179.549 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.457 ' HA3' ' OG ' ' A' ' 27' ' ' SER . . . 147.72 -162.87 28.77 Favored Glycine 0 N--CA 1.444 -0.824 0 C-N-CA 120.212 -0.994 . . . . 0.0 112.822 179.698 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 17.1 m120 -104.08 134.9 46.57 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 120.832 0.349 . . . . 0.0 110.953 -178.557 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 11.8 m0 -127.38 150.8 49.45 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.929 -0.578 . . . . 0.0 109.714 179.002 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.422 HG23 ' HB3' ' A' ' 69' ' ' ASN . 50.1 mm -113.93 110.03 30.67 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.927 0 N-CA-C 109.021 -0.733 . . . . 0.0 109.021 177.729 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . 0.41 ' O ' HG13 ' A' ' 100' ' ' VAL . 78.0 mt -132.84 75.8 1.65 Allowed 'General case' 0 C--O 1.26 1.649 0 CA-C-O 121.893 0.854 . . . . 0.0 111.835 -177.325 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . 0.4 ' O ' ' HB2' ' A' ' 94' ' ' SER . . . -150.15 -91.64 0.09 OUTLIER Glycine 0 N--CA 1.448 -0.504 0 CA-C-N 115.399 -0.819 . . . . 0.0 112.9 -178.901 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . 0.414 ' HB3' ' HA3' ' A' ' 21' ' ' GLY . 69.6 m 78.29 8.56 2.26 Favored 'General case' 0 N--CA 1.482 1.13 0 C-N-CA 124.092 0.957 . . . . 0.0 112.181 -177.378 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' ARG . . . . . 0.492 ' HB2' ' O ' ' A' ' 98' ' ' GLN . 95.9 mtt180 -137.6 145.03 42.29 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 116.083 -0.508 . . . . 0.0 109.725 177.557 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 78.1 tt0 -70.44 -45.64 65.44 Favored 'General case' 0 C--N 1.315 -0.906 0 N-CA-C 112.622 0.601 . . . . 0.0 112.622 -172.729 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 7.2 p30 -117.41 20.89 13.4 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.26 0.552 . . . . 0.0 111.207 -179.269 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' GLN . . . . . 0.492 ' O ' ' HB2' ' A' ' 95' ' ' ARG . 90.5 mt-30 -139.78 115.63 10.22 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-N 115.658 -0.701 . . . . 0.0 111.12 179.635 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' ASN . . . . . 0.452 ' HB3' ' OH ' ' A' ' 71' ' ' TYR . 85.2 m-20 -108.49 176.19 5.2 Favored 'General case' 0 C--N 1.306 -1.309 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 179.575 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.41 HG13 ' O ' ' A' ' 92' ' ' LEU . 33.6 m -78.22 133.69 29.78 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.668 0 C-N-CA 119.565 -0.854 . . . . 0.0 111.352 179.348 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 35.4 m -113.92 -31.09 2.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.165 177.243 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . 0.573 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -148.18 133.32 18.32 Favored 'General case' 0 CA--C 1.511 -0.546 0 C-N-CA 120.688 -0.405 . . . . 0.0 110.475 178.003 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 89.6 mt -130.16 125.1 59.39 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.785 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.961 179.78 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 10.0 t30 -126.19 100.38 6.29 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.704 -0.68 . . . . 0.0 109.574 175.631 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.417 HG22 ' HB ' ' A' ' 36' ' ' ILE . 27.7 m -141.46 140.96 30.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-N 115.983 -0.553 . . . . 0.0 112.326 -176.121 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 61.5 mt-10 -143.66 149.53 37.39 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.2 -0.909 . . . . 0.0 109.606 177.111 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . 0.409 ' HB2' HD23 ' A' ' 114' ' ' LEU . 46.3 t -128.66 144.62 51.2 Favored 'General case' 0 C--N 1.313 -0.994 0 CA-C-O 120.966 0.412 . . . . 0.0 111.508 -178.842 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -91.63 -4.46 67.76 Favored Glycine 0 N--CA 1.439 -1.16 0 N-CA-C 110.656 -0.978 . . . . 0.0 110.656 175.161 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 35.4 m-20 -98.28 -167.62 1.53 Allowed 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 -179.528 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . 0.42 ' OD1' ' HG3' ' A' ' 112' ' ' GLN . 7.3 p-10 -93.86 21.22 6.79 Favored 'General case' 0 C--N 1.311 -1.082 0 CA-C-O 121.291 0.567 . . . . 0.0 109.864 178.041 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . 0.546 ' HA3' ' ND2' ' A' ' 32' ' ' ASN . . . 105.34 9.77 32.99 Favored Glycine 0 C--O 1.22 -0.753 0 C-N-CA 120.761 -0.733 . . . . 0.0 113.466 -178.525 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' GLN . . . . . 0.431 ' HA ' HD12 ' A' ' 132' ' ' LEU . 98.3 mt-30 -64.72 -43.8 92.26 Favored 'General case' 0 C--O 1.242 0.66 0 CA-C-N 117.439 0.62 . . . . 0.0 110.681 178.89 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 81.8 p -136.48 145.76 45.52 Favored 'General case' 0 N--CA 1.444 -0.758 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.937 176.445 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' LEU . . . . . 0.409 HD23 ' HB2' ' A' ' 107' ' ' SER . 88.8 mt -116.54 129.75 56.36 Favored 'General case' 0 C--N 1.315 -0.922 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 179.312 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 15.3 m120 -120.5 142.87 48.9 Favored 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 110.318 -0.253 . . . . 0.0 110.318 -178.916 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 163.77 -141.19 6.94 Favored Glycine 0 N--CA 1.444 -0.8 0 C-N-CA 119.385 -1.388 . . . . 0.0 113.426 176.586 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 3.0 p -130.91 151.02 51.79 Favored 'General case' 0 C--N 1.311 -1.1 0 C-N-CA 123.056 0.542 . . . . 0.0 110.209 -178.295 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 118' ' ' MET . . . . . 0.624 ' SD ' ' HD1' ' A' ' 128' ' ' PHE . 20.0 ptm -136.96 144.5 43.42 Favored 'General case' 0 C--N 1.31 -1.128 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.253 -177.792 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 119' ' ' THR . . . . . 0.573 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 24.5 m -128.8 126.47 39.95 Favored 'General case' 0 C--O 1.252 1.22 0 CA-C-O 120.737 0.303 . . . . 0.0 110.535 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 42.1 m-85 -98.39 162.62 13.07 Favored 'General case' 0 CA--C 1.509 -0.631 0 CA-C-N 115.616 -0.72 . . . . 0.0 111.167 179.563 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -59.17 114.91 2.85 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 115.489 -0.778 . . . . 0.0 111.169 176.842 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 78.04 17.49 78.26 Favored Glycine 0 N--CA 1.451 -0.354 0 CA-C-N 115.787 -0.642 . . . . 0.0 114.014 177.759 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 69.2 tt0 -142.26 144.02 33.12 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 117.47 0.635 . . . . 0.0 110.566 179.837 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -69.03 163.77 50.48 Favored Glycine 0 CA--C 1.522 0.53 0 CA-C-N 116.141 -0.481 . . . . 0.0 113.246 -177.436 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . 0.492 ' HA ' ' O ' ' A' ' 118' ' ' MET . 23.7 Cg_exo -63.46 138.72 66.88 Favored 'Trans proline' 0 C--N 1.347 0.492 0 C-N-CA 122.784 2.322 . . . . 0.0 112.887 -178.752 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 41.0 pt -131.04 167.75 25.4 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.806 0 CA-C-N 115.532 -0.758 . . . . 0.0 109.675 177.467 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -69.0 136.96 29.31 Favored Glycine 0 C--O 1.236 0.281 0 C-N-CA 120.994 -0.622 . . . . 0.0 112.354 -178.754 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . 0.624 ' HD1' ' SD ' ' A' ' 118' ' ' MET . 82.4 t80 -118.59 133.8 55.59 Favored 'General case' 0 C--O 1.249 1.072 0 CA-C-O 120.963 0.411 . . . . 0.0 111.526 -178.564 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 64.1 tttm -136.52 111.44 8.86 Favored 'General case' 0 N--CA 1.442 -0.861 0 CA-C-N 115.562 -0.745 . . . . 0.0 109.782 175.678 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -104.87 133.01 11.35 Favored Glycine 0 N--CA 1.441 -0.997 0 N-CA-C 110.94 -0.864 . . . . 0.0 110.94 178.314 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 25.7 m -128.97 132.9 47.63 Favored 'General case' 0 C--N 1.311 -1.102 0 CA-C-N 116.944 0.372 . . . . 0.0 110.092 -178.754 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 132' ' ' LEU . . . . . 0.431 HD12 ' HA ' ' A' ' 112' ' ' GLN . 74.0 mt -59.81 130.52 47.19 Favored 'General case' 0 N--CA 1.467 0.396 0 C-N-CA 120.301 -0.559 . . . . 0.0 110.799 177.726 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 52.8 m . . . . . 0 C--O 1.247 0.929 0 CA-C-O 118.512 -0.756 . . . . 0.0 110.734 -179.196 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.741 0 CA-C-O 120.897 0.38 . . . . 0.0 110.749 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . 0.557 HD11 HE21 ' A' ' 22' ' ' GLN . 3.2 tm? -92.68 130.39 38.32 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.064 179.313 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 81.4 m-85 -119.27 144.9 46.53 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.954 -0.566 . . . . 0.0 111.777 -179.242 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . 0.512 ' O ' ' HA2' ' A' ' 130' ' ' GLY . 11.5 t-20 -96.32 136.03 37.36 Favored 'General case' 0 C--N 1.313 -0.988 0 N-CA-C 107.706 -1.22 . . . . 0.0 107.706 179.269 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 78.7 t -116.56 127.11 74.25 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 CA-C-O 121.529 0.681 . . . . 0.0 112.703 -174.59 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.448 ' HB2' ' HB3' ' A' ' 129' ' ' LYS . 45.4 mt-10 -116.58 138.8 51.14 Favored 'General case' 0 N--CA 1.44 -0.926 0 CA-C-N 114.949 -1.023 . . . . 0.0 108.286 175.275 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 10.6 m120 -116.29 139.3 50.52 Favored 'General case' 0 C--N 1.306 -1.32 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.545 -178.442 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . 0.506 ' HB2' ' CE3' ' A' ' 17' ' ' TRP . 54.4 tt0 -129.36 124.3 33.9 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.703 -0.68 . . . . 0.0 109.767 179.33 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 20.1 p90 -122.99 136.84 55.01 Favored 'General case' 0 C--N 1.307 -1.262 0 CA-C-O 120.849 0.357 . . . . 0.0 111.222 179.213 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 111.17 -75.49 0.21 Allowed Glycine 0 N--CA 1.445 -0.752 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.851 -179.653 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -162.34 163.65 35.13 Favored Glycine 0 N--CA 1.449 -0.438 0 N-CA-C 111.617 -0.593 . . . . 0.0 111.617 179.725 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . 0.434 ' HA ' ' NE2' ' A' ' 9' ' ' GLN . 12.1 m -64.07 -19.06 64.97 Favored 'General case' 0 CA--C 1.536 0.44 0 N-CA-C 112.279 0.474 . . . . 0.0 112.279 -179.002 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 35.3 p -72.42 -18.22 61.73 Favored 'General case' 0 CA--C 1.539 0.536 0 CA-C-O 120.988 0.423 . . . . 0.0 111.231 178.799 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -80.66 155.0 73.73 Favored Pre-proline 0 CA--C 1.533 0.317 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.695 -179.755 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 66.6 Cg_endo -72.11 158.68 51.7 Favored 'Trans proline' 0 C--O 1.236 0.393 0 C-N-CA 122.47 2.113 . . . . 0.0 112.783 178.701 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . 0.506 ' CE3' ' HB2' ' A' ' 9' ' ' GLN . 94.4 m95 -89.22 138.6 31.28 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.408 179.624 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 90.5 m-20 -124.08 129.9 51.64 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 109.141 -0.689 . . . . 0.0 109.141 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 42.6 tt0 -61.37 128.04 34.43 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-O 120.962 0.41 . . . . 0.0 111.299 -178.305 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -108.7 -0.63 32.38 Favored Glycine 0 N--CA 1.448 -0.52 0 CA-C-N 115.469 -0.787 . . . . 0.0 112.805 -178.821 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 130.27 -150.11 19.09 Favored Glycine 0 N--CA 1.443 -0.881 0 C-N-CA 120.335 -0.936 . . . . 0.0 112.249 -179.83 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . 0.557 HE21 HD11 ' A' ' 3' ' ' LEU . 4.2 pt20 -145.5 138.02 25.83 Favored 'General case' 0 C--N 1.319 -0.738 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.771 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 45.3 m0 -117.14 155.23 29.69 Favored 'General case' 0 C--N 1.318 -0.761 0 CA-C-O 120.89 0.376 . . . . 0.0 111.159 -178.429 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -109.11 112.64 24.93 Favored 'General case' 0 C--N 1.317 -0.812 0 N-CA-C 109.511 -0.551 . . . . 0.0 109.511 177.481 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 95.8 mt -130.7 136.82 57.47 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.585 0 CA-C-N 115.203 -0.908 . . . . 0.0 109.762 -178.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 91.55 106.81 1.49 Allowed Glycine 0 N--CA 1.442 -0.911 0 C-N-CA 120.208 -0.996 . . . . 0.0 111.966 -179.383 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 13.9 m -111.86 13.58 20.95 Favored 'General case' 0 C--N 1.31 -1.136 0 CA-C-O 121.208 0.528 . . . . 0.0 110.311 -178.699 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 94.7 mtt-85 -137.44 128.17 27.03 Favored 'General case' 0 N--CA 1.445 -0.72 0 CA-C-N 116.004 -0.544 . . . . 0.0 109.967 -177.069 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 34.5 t -76.77 -17.43 59.05 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-O 121.207 0.527 . . . . 0.0 110.215 179.353 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 15.8 m-20 -75.0 -47.56 28.52 Favored 'General case' 0 C--O 1.224 -0.275 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.904 -178.033 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . 0.447 HE21 ' HB3' ' A' ' 53' ' ' TYR . 14.3 mm100 -128.71 123.19 32.45 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.603 -0.726 . . . . 0.0 111.234 -176.575 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . 0.663 ' ND2' ' HA3' ' A' ' 111' ' ' GLY . 62.5 t30 -101.18 161.74 13.39 Favored 'General case' 0 C--N 1.319 -0.751 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 178.348 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 46.6 t -94.69 130.73 43.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-O 120.572 0.225 . . . . 0.0 111.409 -173.771 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 28.7 m -110.59 -18.57 7.5 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.276 0 CA-C-N 116.464 -0.335 . . . . 0.0 111.731 179.224 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.533 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -154.6 149.67 26.88 Favored 'General case' 0 C--O 1.237 0.416 0 C-N-CA 120.563 -0.455 . . . . 0.0 111.685 178.682 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.495 ' HB ' ' CG2' ' A' ' 105' ' ' VAL . 89.9 mt -144.09 123.63 7.84 Favored 'Isoleucine or valine' 0 C--O 1.235 0.308 0 CA-C-N 115.97 -0.559 . . . . 0.0 109.64 -179.743 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 13.4 m120 -124.82 106.58 10.14 Favored 'General case' 0 C--N 1.313 -1.012 0 N-CA-C 107.767 -1.197 . . . . 0.0 107.767 175.844 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 36.0 m -147.68 149.56 15.32 Favored 'Isoleucine or valine' 0 C--O 1.237 0.436 0 C-N-CA 120.146 -0.622 . . . . 0.0 111.957 -172.757 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 66.7 mt-10 -142.55 149.1 38.63 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.299 -0.864 . . . . 0.0 109.325 175.337 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 20.5 p -73.97 142.62 45.84 Favored 'General case' 0 C--N 1.307 -1.25 0 N-CA-C 112.104 0.409 . . . . 0.0 112.104 -177.444 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -88.62 -42.56 5.73 Favored Glycine 0 N--CA 1.443 -0.841 0 N-CA-C 109.148 -1.581 . . . . 0.0 109.148 174.755 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 48.8 m-20 -105.18 -161.55 0.82 Allowed 'General case' 0 C--N 1.317 -0.836 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 175.045 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -76.17 47.98 0.48 Allowed 'General case' 0 N--CA 1.474 0.766 0 N-CA-C 112.303 0.483 . . . . 0.0 112.303 -178.361 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 91.64 -8.55 78.51 Favored Glycine 0 C--O 1.222 -0.649 0 C-N-CA 120.858 -0.687 . . . . 0.0 112.223 178.969 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 56.1 mt-30 -70.23 -36.23 74.39 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.99 0.424 . . . . 0.0 110.713 178.356 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 22.0 p -122.58 139.4 53.95 Favored 'General case' 0 C--N 1.311 -1.106 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.207 179.66 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . 0.435 ' HB2' ' HB3' ' A' ' 63' ' ' ALA . 91.2 mt -125.94 127.05 45.36 Favored 'General case' 0 C--N 1.315 -0.932 0 N-CA-C 108.509 -0.923 . . . . 0.0 108.509 179.865 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 88.9 m-20 -125.3 138.07 54.08 Favored 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 109.376 -0.602 . . . . 0.0 109.376 -179.352 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 173.25 -151.23 13.26 Favored Glycine 0 N--CA 1.443 -0.873 0 C-N-CA 120.078 -1.058 . . . . 0.0 112.558 178.853 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 33.6 p -132.49 146.87 52.25 Favored 'General case' 0 N--CA 1.443 -0.8 0 CA-C-O 121.003 0.43 . . . . 0.0 110.921 179.692 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 40.7 mtp -121.12 156.49 32.18 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.74 177.18 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.533 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 26.8 m -132.1 126.35 33.53 Favored 'General case' 0 C--O 1.247 0.965 0 N-CA-C 110.04 -0.356 . . . . 0.0 110.04 175.657 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . 0.447 ' HB3' HE21 ' A' ' 31' ' ' GLN . 72.2 m-85 -98.19 162.64 13.1 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.272 178.607 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -63.6 125.21 23.51 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.577 178.541 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 74.56 12.94 82.27 Favored Glycine 0 N--CA 1.447 -0.608 0 C-N-CA 120.948 -0.644 . . . . 0.0 112.851 -179.705 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 73.8 mm-40 -127.41 177.31 6.82 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 110.137 -0.32 . . . . 0.0 110.137 -179.373 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -109.13 -179.9 21.19 Favored Glycine 0 N--CA 1.445 -0.724 0 C-N-CA 120.879 -0.677 . . . . 0.0 111.614 178.805 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_exo -63.76 137.64 59.6 Favored 'Trans proline' 0 C--N 1.349 0.555 0 C-N-CA 122.504 2.136 . . . . 0.0 112.222 178.88 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . 0.545 ' HB ' ' O ' ' A' ' 76' ' ' GLN . 45.4 pt -132.36 166.11 30.15 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 CA-C-N 115.706 -0.679 . . . . 0.0 109.713 179.316 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -75.73 145.96 33.34 Favored Glycine 0 C--N 1.321 -0.299 0 C-N-CA 120.703 -0.761 . . . . 0.0 111.886 -179.47 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 31.6 t80 -132.12 130.54 41.33 Favored 'General case' 0 C--N 1.317 -0.839 0 C-N-CA 122.477 0.311 . . . . 0.0 111.398 -178.831 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 59.3 ttp180 -138.71 130.49 27.81 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 174.015 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.435 ' HB3' ' HB2' ' A' ' 47' ' ' LEU . . . -134.87 146.66 49.43 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 120.704 0.288 . . . . 0.0 111.148 -179.648 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 48.9 m -128.33 136.26 50.71 Favored 'General case' 0 CA--C 1.544 0.724 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.748 179.065 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . 0.401 HD11 ' O ' ' A' ' 68' ' ' ASN . 59.8 tp -69.34 127.8 34.31 Favored 'General case' 0 CA--C 1.535 0.376 0 N-CA-C 112.274 0.472 . . . . 0.0 112.274 -178.539 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.434 HD21 ' HB2' ' A' ' 72' ' ' GLU . 4.3 mm? -91.18 -41.3 11.08 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-N 115.972 -0.558 . . . . 0.0 112.482 178.702 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -151.8 -68.34 0.01 OUTLIER Glycine 0 CA--C 1.499 -0.922 0 C-N-CA 119.63 -1.272 . . . . 0.0 113.244 -175.835 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' ASN . . . . . 0.401 ' O ' HD11 ' A' ' 65' ' ' LEU . 20.2 m120 -133.49 -81.07 0.47 Allowed 'General case' 0 C--O 1.209 -1.036 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 -178.706 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . 0.484 ' OD1' ' HA3' ' A' ' 93' ' ' GLY . 90.7 m-20 -98.72 -5.73 30.89 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 120.77 0.319 . . . . 0.0 110.486 179.43 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 8.7 m -88.66 123.56 33.23 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 121.291 0.567 . . . . 0.0 112.017 -176.647 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 60.2 m-85 -121.88 145.53 48.0 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.659 178.805 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . 0.434 ' HB2' HD21 ' A' ' 66' ' ' LEU . 71.8 tt0 -100.26 122.56 43.26 Favored 'General case' 0 C--N 1.316 -0.869 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 173.007 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 66.5 t -103.98 132.46 50.4 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.016 0 CA-C-N 115.687 -0.688 . . . . 0.0 111.767 -175.156 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 99.6 mt-10 -127.34 125.75 41.33 Favored 'General case' 0 N--CA 1.446 -0.655 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 177.141 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' ASN . . . . . 0.445 ' HB3' HD12 ' A' ' 59' ' ' ILE . 95.1 m-20 -111.61 155.57 23.16 Favored 'General case' 0 C--N 1.312 -1.065 0 CA-C-O 121.473 0.654 . . . . 0.0 112.427 -177.204 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' GLN . . . . . 0.545 ' O ' ' HB ' ' A' ' 59' ' ' ILE . 33.8 tt0 -117.69 121.65 41.42 Favored 'General case' 0 C--N 1.311 -1.07 0 CA-C-N 114.878 -1.055 . . . . 0.0 110.285 -177.291 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER -107.45 107.84 18.89 Favored 'General case' 0 C--N 1.323 -0.548 0 C-N-CA 120.221 -0.592 . . . . 0.0 110.305 176.834 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 174.04 -158.83 27.86 Favored Glycine 0 N--CA 1.439 -1.146 0 N-CA-C 110.586 -1.006 . . . . 0.0 110.586 -178.655 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -96.41 -42.61 3.39 Favored Glycine 0 N--CA 1.441 -1.008 0 C-N-CA 120.113 -1.042 . . . . 0.0 111.496 178.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 20.9 t70 -176.3 150.31 0.91 Allowed 'General case' 0 C--O 1.236 0.374 0 C-N-CA 122.56 0.344 . . . . 0.0 110.223 179.641 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 23.2 t 52.79 33.25 13.74 Favored 'General case' 0 CA--C 1.549 0.935 0 C-N-CA 123.057 0.543 . . . . 0.0 112.357 177.257 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -91.59 165.22 21.46 Favored Pre-proline 0 CA--C 1.544 0.746 0 CA-C-N 116.463 -0.335 . . . . 0.0 110.752 -179.392 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 26.9 Cg_exo -62.66 152.57 77.32 Favored 'Trans proline' 0 C--N 1.354 0.856 0 C-N-CA 122.703 2.269 . . . . 0.0 112.521 178.703 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' TRP . . . . . . . . . . . . . 96.2 m95 -98.61 143.12 29.35 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.544 -177.586 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 80.1 m-70 -129.83 141.1 50.88 Favored 'General case' 0 C--N 1.318 -0.761 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 179.298 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 42.1 m -61.38 133.89 56.32 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-O 121.216 0.531 . . . . 0.0 111.42 -178.038 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -105.23 -43.3 1.63 Allowed Glycine 0 N--CA 1.438 -1.198 0 N-CA-C 111.561 -0.616 . . . . 0.0 111.561 178.296 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 153.65 -170.03 32.37 Favored Glycine 0 C--O 1.223 -0.535 0 C-N-CA 120.456 -0.878 . . . . 0.0 112.259 178.349 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 20.2 m120 -110.6 123.11 49.36 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.465 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 44.1 m0 -114.41 152.81 30.95 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-O 121.016 0.436 . . . . 0.0 111.704 -177.363 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.435 ' HA ' ' O ' ' A' ' 69' ' ' ASN . 82.8 mt -108.02 112.29 39.6 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.751 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 176.785 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . 0.436 ' HB3' HG21 ' A' ' 100' ' ' VAL . 70.0 mt -135.15 73.08 1.46 Allowed 'General case' 0 C--O 1.266 1.972 0 CA-C-O 121.692 0.758 . . . . 0.0 111.835 -175.592 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . 0.484 ' HA3' ' OD1' ' A' ' 69' ' ' ASN . . . -153.67 -78.85 0.02 OUTLIER Glycine 0 N--CA 1.447 -0.615 0 C-N-CA 120.228 -0.987 . . . . 0.0 113.278 -178.096 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 57.5 m 69.94 10.29 7.4 Favored 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 123.268 0.627 . . . . 0.0 111.869 -177.784 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' ARG . . . . . 0.721 ' HB2' ' O ' ' A' ' 98' ' ' GLN . 16.8 mmt180 -127.12 141.39 51.77 Favored 'General case' 0 N--CA 1.443 -0.783 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 177.308 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 16.6 pt-20 -67.38 -40.45 85.71 Favored 'General case' 0 C--N 1.311 -1.097 0 N-CA-C 112.96 0.726 . . . . 0.0 112.96 -176.298 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 91.8 m-20 -127.58 28.91 5.58 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 111.912 0.338 . . . . 0.0 111.912 -176.35 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' GLN . . . . . 0.721 ' O ' ' HB2' ' A' ' 95' ' ' ARG . 46.0 tt0 -155.64 132.52 10.61 Favored 'General case' 0 C--N 1.32 -0.688 0 C-N-CA 120.625 -0.43 . . . . 0.0 110.078 -177.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 91.3 m-20 -115.3 179.49 3.95 Favored 'General case' 0 C--O 1.26 1.638 0 C-N-CA 120.717 -0.393 . . . . 0.0 111.957 -177.909 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.436 HG21 ' HB3' ' A' ' 92' ' ' LEU . 22.5 m -81.06 143.33 12.48 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.427 0 CA-C-N 115.673 -0.694 . . . . 0.0 111.132 178.945 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 31.2 m -121.51 -36.43 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.694 178.223 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . 0.611 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -133.4 130.41 38.7 Favored 'General case' 0 CA--C 1.51 -0.572 0 C-N-CA 119.943 -0.703 . . . . 0.0 111.153 178.76 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 96.5 mt -133.29 122.55 45.17 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.934 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.656 178.862 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 12.0 t30 -126.67 99.27 5.71 Favored 'General case' 0 C--N 1.316 -0.882 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 176.804 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.495 ' CG2' ' HB ' ' A' ' 36' ' ' ILE . 17.8 m -135.21 135.86 51.91 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.146 0 CA-C-N 115.513 -0.767 . . . . 0.0 112.429 -174.787 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 60.2 mt-10 -141.17 142.58 34.02 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.597 -0.728 . . . . 0.0 110.256 179.85 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 35.5 t -140.33 148.65 41.67 Favored 'General case' 0 C--N 1.315 -0.913 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.878 179.366 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -96.29 1.11 62.26 Favored Glycine 0 N--CA 1.444 -0.785 0 N-CA-C 110.769 -0.932 . . . . 0.0 110.769 176.234 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 84.6 m-20 -88.93 179.13 6.25 Favored 'General case' 0 CA--C 1.511 -0.539 0 CA-C-O 120.872 0.368 . . . . 0.0 110.601 -179.635 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 7.8 p-10 -88.83 16.41 6.91 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-O 121.568 0.699 . . . . 0.0 109.602 177.577 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . 0.663 ' HA3' ' ND2' ' A' ' 32' ' ' ASN . . . 113.25 7.82 20.45 Favored Glycine 0 N--CA 1.438 -1.232 0 CA-C-N 115.384 -0.826 . . . . 0.0 112.516 -177.526 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 98.6 mt-30 -62.71 -47.91 81.56 Favored 'General case' 0 C--O 1.238 0.45 0 CA-C-O 120.759 0.314 . . . . 0.0 110.363 178.783 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 70.7 p -130.44 155.39 46.5 Favored 'General case' 0 N--CA 1.444 -0.748 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 176.151 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 40.1 tp -136.39 108.38 7.16 Favored 'General case' 0 C--N 1.314 -0.946 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 178.352 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 89.0 m-20 -119.84 155.14 33.2 Favored 'General case' 0 C--N 1.316 -0.882 0 C-N-CA 120.597 -0.441 . . . . 0.0 111.737 -175.484 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 162.34 -136.15 4.21 Favored Glycine 0 N--CA 1.438 -1.176 0 C-N-CA 120.543 -0.837 . . . . 0.0 112.737 178.016 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 26.6 p -130.89 153.28 49.31 Favored 'General case' 0 C--N 1.312 -1.032 0 C-N-CA 122.752 0.421 . . . . 0.0 110.469 -178.343 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 25.6 ptm -143.57 146.23 33.15 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.074 179.899 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 119' ' ' THR . . . . . 0.611 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 36.7 m -129.8 126.6 38.49 Favored 'General case' 0 C--N 1.305 -1.358 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.533 179.294 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 67.0 m-85 -81.18 164.43 22.34 Favored 'General case' 0 CA--C 1.508 -0.645 0 O-C-N 123.716 0.635 . . . . 0.0 109.502 176.172 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -51.54 -31.63 24.96 Favored 'General case' 0 CA--C 1.54 0.586 0 N-CA-C 113.37 0.878 . . . . 0.0 113.37 -178.827 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -155.84 15.93 0.45 Allowed Glycine 0 CA--C 1.519 0.287 0 C-N-CA 119.189 -1.481 . . . . 0.0 114.263 -178.246 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 82.9 tt0 -100.19 -23.74 14.75 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 117.619 0.709 . . . . 0.0 111.327 -179.894 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 115.03 179.67 18.54 Favored Glycine 0 N--CA 1.448 -0.507 0 C-N-CA 120.235 -0.983 . . . . 0.0 112.935 178.039 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -90.39 122.06 0.91 Allowed 'Trans proline' 0 N--CA 1.449 -1.102 0 C-N-CA 123.767 2.978 . . . . 0.0 112.408 179.749 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 41.2 pt -128.53 163.12 33.8 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.803 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.58 179.487 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -70.08 137.01 27.58 Favored Glycine 0 C--O 1.244 0.728 0 CA-C-N 116.188 -0.46 . . . . 0.0 112.165 179.37 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 83.7 t80 -115.25 133.97 55.56 Favored 'General case' 0 C--N 1.316 -0.853 0 C-N-CA 122.51 0.324 . . . . 0.0 110.678 -178.966 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 129' ' ' LYS . . . . . 0.448 ' HB3' ' HB2' ' A' ' 7' ' ' GLU . 86.3 tttt -137.45 114.99 11.17 Favored 'General case' 0 N--CA 1.437 -1.09 0 N-CA-C 109.301 -0.629 . . . . 0.0 109.301 176.53 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . 0.512 ' HA2' ' O ' ' A' ' 5' ' ' ASN . . . -115.13 136.02 12.78 Favored Glycine 0 N--CA 1.433 -1.561 0 N-CA-C 111.157 -0.777 . . . . 0.0 111.157 177.837 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 52.5 m -128.7 136.72 50.99 Favored 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -179.905 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 58.3 tp -59.89 126.03 25.96 Favored 'General case' 0 C--N 1.327 -0.379 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 178.538 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 24.5 m . . . . . 0 N--CA 1.439 -1.024 0 CA-C-O 118.745 -0.645 . . . . 0.0 110.776 -178.275 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.609 ' O ' ' HG3' ' A' ' 24' ' ' GLU . . . . . . . . 0 N--CA 1.479 1.004 0 N-CA-C 110.144 -0.317 . . . . 0.0 110.144 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . 0.526 HD11 HE21 ' A' ' 22' ' ' GLN . 3.0 tm? -87.3 132.21 34.0 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-O 121.271 0.558 . . . . 0.0 110.713 -175.504 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . 0.427 ' N ' HD13 ' A' ' 3' ' ' LEU . 20.0 m-85 -115.45 134.78 54.76 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 115.486 -0.779 . . . . 0.0 111.392 178.542 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 46.6 t-20 -92.9 117.37 29.97 Favored 'General case' 0 C--N 1.309 -1.158 0 N-CA-C 106.992 -1.484 . . . . 0.0 106.992 176.814 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.469 HG12 HD21 ' A' ' 8' ' ' ASN . 58.5 t -102.04 104.89 17.08 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.146 0 CA-C-O 121.146 0.498 . . . . 0.0 112.307 -174.067 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -94.3 137.62 33.24 Favored 'General case' 0 C--N 1.312 -1.028 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 175.931 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . 0.469 HD21 HG12 ' A' ' 6' ' ' VAL . 63.2 m-80 -132.69 159.17 40.41 Favored 'General case' 0 C--N 1.314 -0.972 0 CA-C-O 121.627 0.727 . . . . 0.0 112.784 -175.075 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 36.4 tt0 -124.02 106.29 10.27 Favored 'General case' 0 C--N 1.309 -1.166 0 N-CA-C 106.828 -1.545 . . . . 0.0 106.828 173.118 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 1.4 p90 -125.68 0.21 7.45 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 114.056 1.132 . . . . 0.0 114.056 -173.289 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -116.3 21.4 11.9 Favored Glycine 0 N--CA 1.446 -0.647 0 C-N-CA 119.014 -1.565 . . . . 0.0 112.296 -177.74 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 122.14 157.21 9.91 Favored Glycine 0 N--CA 1.441 -1.01 0 C-N-CA 120.8 -0.714 . . . . 0.0 111.99 -179.726 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 21.3 p -59.46 -31.88 69.73 Favored 'General case' 0 C--N 1.317 -0.822 0 C-N-CA 123.018 0.527 . . . . 0.0 112.41 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 17.1 p -81.41 -7.56 59.6 Favored 'General case' 0 C--N 1.32 -0.703 0 N-CA-C 112.26 0.467 . . . . 0.0 112.26 179.449 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -78.99 142.11 59.59 Favored Pre-proline 0 C--N 1.328 -0.353 0 CA-C-O 120.801 0.334 . . . . 0.0 111.255 -178.674 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 64.2 Cg_endo -70.8 165.37 32.38 Favored 'Trans proline' 0 C--O 1.237 0.47 0 C-N-CA 123.084 2.523 . . . . 0.0 112.54 -179.81 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 93.5 m95 -81.69 137.81 35.35 Favored 'General case' 0 N--CA 1.452 -0.354 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.357 -178.731 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 3.1 p30 -145.32 137.78 25.9 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.99 -179.827 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 8.3 pt-20 -93.16 141.37 28.49 Favored 'General case' 0 C--N 1.317 -0.833 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 178.098 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -132.71 26.98 3.57 Favored Glycine 0 N--CA 1.442 -0.956 0 C-N-CA 120.45 -0.881 . . . . 0.0 111.21 179.726 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 154.76 169.34 19.29 Favored Glycine 0 N--CA 1.437 -1.263 0 C-N-CA 120.991 -0.623 . . . . 0.0 111.846 -179.475 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . 0.526 HE21 HD11 ' A' ' 3' ' ' LEU . 4.4 pt20 -122.0 132.8 54.71 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-O 120.835 0.35 . . . . 0.0 110.339 179.913 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 40.4 m0 -113.21 172.83 6.71 Favored 'General case' 0 CA--C 1.506 -0.718 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.165 -176.409 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.609 ' HG3' ' O ' ' A' ' 2' ' ' ALA . 33.5 tt0 -131.23 114.66 15.34 Favored 'General case' 0 C--N 1.317 -0.837 0 N-CA-C 108.815 -0.809 . . . . 0.0 108.815 173.572 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.44 HG23 HD11 ' A' ' 36' ' ' ILE . 97.7 mt -105.54 -36.81 3.8 Favored 'Isoleucine or valine' 0 C--O 1.199 -1.6 0 CA-C-N 115.138 -0.937 . . . . 0.0 113.156 -173.053 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -109.07 126.98 8.32 Favored Glycine 0 C--N 1.307 -1.078 0 C-N-CA 119.888 -1.149 . . . . 0.0 112.387 -179.858 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 59.6 p -117.19 8.16 13.17 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 111.875 0.324 . . . . 0.0 111.875 -179.883 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 69.1 ttt180 -122.09 135.5 54.81 Favored 'General case' 0 N--CA 1.446 -0.629 0 CA-C-O 121.162 0.506 . . . . 0.0 111.904 -177.153 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 47.9 t -77.35 149.36 35.26 Favored 'General case' 0 N--CA 1.442 -0.846 0 CA-C-N 115.294 -0.866 . . . . 0.0 109.908 176.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.453 ' O ' ' HG2' ' A' ' 31' ' ' GLN . 8.9 m-20 59.62 22.71 11.42 Favored 'General case' 0 N--CA 1.479 0.99 0 C-N-CA 123.032 0.533 . . . . 0.0 111.433 176.902 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . 0.453 ' HG2' ' O ' ' A' ' 30' ' ' ASP . 4.5 mm-40 -163.06 91.26 0.71 Allowed 'General case' 0 CA--C 1.501 -0.91 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.241 -178.058 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . 0.573 ' ND2' ' HA3' ' A' ' 111' ' ' GLY . 63.6 t30 -94.69 162.02 13.95 Favored 'General case' 0 C--N 1.309 -1.174 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.239 -179.01 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 72.6 t -95.57 129.52 45.57 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.201 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.89 -176.51 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 33.0 m -110.39 -13.06 11.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 N-CA-C 112.187 0.439 . . . . 0.0 112.187 179.154 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.518 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -156.34 149.36 24.13 Favored 'General case' 0 CA--C 1.517 -0.304 0 C-N-CA 120.464 -0.494 . . . . 0.0 111.851 178.685 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.44 HD11 HG23 ' A' ' 25' ' ' ILE . 88.2 mt -148.54 119.18 1.29 Allowed 'Isoleucine or valine' 0 CA--C 1.513 -0.46 0 N-CA-C 107.935 -1.135 . . . . 0.0 107.935 178.565 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . 0.545 ' HA ' ' O ' ' A' ' 103' ' ' ILE . 57.5 m-80 -140.05 74.91 1.48 Allowed 'General case' 0 C--N 1.301 -1.534 0 C-N-CA 120.706 -0.398 . . . . 0.0 110.759 -179.375 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.576 HG11 ' CD1' ' A' ' 61' ' ' PHE . 17.1 m -120.18 171.32 8.74 Favored 'Isoleucine or valine' 0 C--O 1.235 0.319 0 N-CA-C 112.49 0.552 . . . . 0.0 112.49 178.541 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 75.3 tt0 -140.34 153.23 46.33 Favored 'General case' 0 N--CA 1.447 -0.593 0 CA-C-N 115.234 -0.893 . . . . 0.0 109.731 179.213 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . 0.527 ' OG ' ' HB ' ' A' ' 101' ' ' VAL . 34.6 p -76.95 157.72 31.11 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-O 121.297 0.57 . . . . 0.0 112.487 -177.595 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -105.99 -49.46 0.94 Allowed Glycine 0 N--CA 1.438 -1.224 0 N-CA-C 110.177 -1.169 . . . . 0.0 110.177 174.427 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 18.9 m-20 -102.24 -149.68 0.39 Allowed 'General case' 0 C--N 1.325 -0.48 0 C-N-CA 122.889 0.476 . . . . 0.0 110.502 179.013 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 11.9 m-20 -71.96 38.19 0.07 Allowed 'General case' 0 N--CA 1.484 1.268 0 C-N-CA 123.747 0.819 . . . . 0.0 112.261 -177.988 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 83.69 2.93 89.81 Favored Glycine 0 C--N 1.316 -0.532 0 C-N-CA 120.669 -0.776 . . . . 0.0 111.571 -178.738 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . 0.476 ' HA ' ' HB3' ' A' ' 65' ' ' LEU . 62.3 mt-30 -80.5 -28.59 37.44 Favored 'General case' 0 C--O 1.218 -0.559 0 CA-C-O 120.981 0.419 . . . . 0.0 110.66 178.218 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . 0.409 ' O ' ' HA ' ' A' ' 40' ' ' SER . 22.6 p -118.54 132.49 56.21 Favored 'General case' 0 C--N 1.306 -1.298 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.637 179.877 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 90.5 mt -126.46 132.64 51.4 Favored 'General case' 0 C--N 1.319 -0.759 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 179.754 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.411 ' HA ' ' O ' ' A' ' 61' ' ' PHE . 9.4 p30 -142.65 147.61 36.05 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-O 120.789 0.328 . . . . 0.0 110.585 179.234 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 158.68 -135.05 4.05 Favored Glycine 0 C--N 1.312 -0.786 0 C-N-CA 120.601 -0.809 . . . . 0.0 111.885 178.656 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 24.7 p -130.8 149.23 52.54 Favored 'General case' 0 N--CA 1.452 -0.347 0 CA-C-O 121.175 0.512 . . . . 0.0 111.812 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' MET . . . . . 0.462 ' HG2' ' O ' ' A' ' 35' ' ' ALA . 18.4 tmm? -142.45 148.47 37.81 Favored 'General case' 0 C--N 1.316 -0.853 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 177.399 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.518 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 66.1 m -129.53 127.64 41.17 Favored 'General case' 0 C--O 1.246 0.919 0 N-CA-C 112.385 0.513 . . . . 0.0 112.385 -177.04 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 64.9 m-85 -87.99 161.76 17.22 Favored 'General case' 0 CA--C 1.515 -0.369 0 CA-C-N 115.507 -0.769 . . . . 0.0 109.458 174.46 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -66.71 129.99 41.7 Favored 'General case' 0 C--N 1.315 -0.918 0 N-CA-C 110.04 -0.356 . . . . 0.0 110.04 178.158 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 90.45 -19.99 40.53 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.869 -0.681 . . . . 0.0 113.081 179.228 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 81.5 mm-40 -107.56 170.17 8.14 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 120.736 0.303 . . . . 0.0 110.767 -178.589 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -95.46 -157.89 32.35 Favored Glycine 0 N--CA 1.446 -0.664 0 C-N-CA 120.943 -0.646 . . . . 0.0 112.354 179.52 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_endo -64.3 138.46 60.93 Favored 'Trans proline' 0 C--N 1.345 0.38 0 C-N-CA 122.462 2.108 . . . . 0.0 112.099 179.743 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . 0.455 HG23 ' HB3' ' A' ' 77' ' ' TRP . 98.3 mt -132.89 142.5 42.14 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.026 0 CA-C-N 115.578 -0.737 . . . . 0.0 109.771 -179.12 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -73.82 128.27 10.97 Favored Glycine 0 N--CA 1.443 -0.898 0 N-CA-C 110.579 -1.009 . . . . 0.0 110.579 179.058 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.576 ' CD1' HG11 ' A' ' 38' ' ' VAL . 47.5 t80 -114.41 128.08 56.16 Favored 'General case' 0 C--N 1.311 -1.08 0 CA-C-O 120.594 0.235 . . . . 0.0 110.903 -176.177 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 64.9 ttp85 -135.49 129.61 33.39 Favored 'General case' 0 N--CA 1.448 -0.536 0 CA-C-N 116.016 -0.538 . . . . 0.0 109.986 176.024 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . . . . . . . . . . . -138.94 149.66 45.02 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 120.773 0.321 . . . . 0.0 111.754 -178.517 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 27.6 m -125.35 131.5 52.98 Favored 'General case' 0 CA--C 1.54 0.596 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.359 179.204 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . 0.476 ' HB3' ' HA ' ' A' ' 45' ' ' GLN . 3.0 tm? -80.2 113.29 18.26 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 120.981 0.419 . . . . 0.0 110.503 -178.495 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 94.6 mt -88.4 -18.96 27.24 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.498 177.799 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 125.34 167.66 12.59 Favored Glycine 0 N--CA 1.442 -0.959 0 C-N-CA 121.02 -0.609 . . . . 0.0 111.596 179.765 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 94.8 m-20 56.47 36.66 27.91 Favored 'General case' 0 N--CA 1.473 0.721 0 C-N-CA 122.56 0.344 . . . . 0.0 111.707 178.279 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 16.3 m120 66.36 9.66 6.62 Favored 'General case' 0 N--CA 1.48 1.031 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.363 179.644 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 35.1 m -97.88 123.55 41.9 Favored 'General case' 0 C--O 1.24 0.562 0 CA-C-O 121.37 0.605 . . . . 0.0 111.586 -177.537 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.534 ' OH ' ' HB3' ' A' ' 99' ' ' ASN . 59.4 m-85 -112.98 138.51 49.75 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 115.468 -0.787 . . . . 0.0 110.83 -179.613 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 42.5 tt0 -92.52 116.64 29.17 Favored 'General case' 0 N--CA 1.439 -0.976 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 174.786 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 78.2 t -105.03 133.15 50.05 Favored 'Isoleucine or valine' 0 C--O 1.248 1.019 0 N-CA-C 112.75 0.648 . . . . 0.0 112.75 -173.615 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 68.7 mt-10 -133.33 134.42 43.78 Favored 'General case' 0 C--O 1.244 0.772 0 N-CA-C 107.899 -1.148 . . . . 0.0 107.899 175.253 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 92.8 m-20 -119.46 154.43 33.76 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 112.911 0.708 . . . . 0.0 112.911 -173.797 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 35.9 tt0 -132.52 127.76 35.87 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.07 -0.968 . . . . 0.0 108.999 179.389 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' TRP . . . . . 0.455 ' HB3' HG23 ' A' ' 59' ' ' ILE . 37.9 p90 -137.58 157.47 46.44 Favored 'General case' 0 C--N 1.317 -0.835 0 C-N-CA 119.973 -0.691 . . . . 0.0 111.997 -177.046 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 81.19 12.13 82.69 Favored Glycine 0 N--CA 1.453 -0.216 0 CA-C-N 115.4 -0.818 . . . . 0.0 112.465 179.513 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 124.48 175.67 14.4 Favored Glycine 0 N--CA 1.445 -0.709 0 N-CA-C 111.259 -0.736 . . . . 0.0 111.259 -179.582 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 5.2 p-10 -89.74 -5.19 57.23 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 121.114 0.483 . . . . 0.0 110.373 -179.194 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 33.2 m -79.04 -12.96 60.03 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.413 179.367 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -90.8 128.69 47.21 Favored Pre-proline 0 C--N 1.321 -0.641 0 CA-C-N 116.54 -0.3 . . . . 0.0 110.484 -179.532 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 30.1 Cg_endo -63.21 136.2 54.59 Favored 'Trans proline' 0 N--CA 1.463 -0.289 0 C-N-CA 122.157 1.904 . . . . 0.0 111.736 179.735 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' TRP . . . . . . . . . . . . . 87.0 m95 -51.1 138.67 19.53 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-O 121.302 0.572 . . . . 0.0 112.261 178.667 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 96.1 m-70 -115.11 147.14 40.59 Favored 'General case' 0 C--N 1.314 -0.949 0 CA-C-N 115.325 -0.852 . . . . 0.0 109.299 179.361 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 6.3 m -58.37 148.59 27.26 Favored 'General case' 0 C--N 1.316 -0.851 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.629 179.004 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -124.32 -54.44 0.18 Allowed Glycine 0 N--CA 1.44 -1.065 0 N-CA-C 110.552 -1.019 . . . . 0.0 110.552 -179.591 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 149.48 -165.95 29.58 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.605 -0.807 . . . . 0.0 112.353 176.788 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 14.5 m120 -110.66 118.45 36.22 Favored 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 109.346 -0.613 . . . . 0.0 109.346 178.362 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 32.8 m0 -110.38 150.67 28.47 Favored 'General case' 0 C--N 1.313 -0.993 0 CA-C-N 116.559 -0.292 . . . . 0.0 110.707 -177.374 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 83.3 mt -105.6 115.17 46.83 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.937 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 177.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . 0.51 ' HB3' HG21 ' A' ' 100' ' ' VAL . 82.2 mt -131.53 80.5 1.93 Allowed 'General case' 0 C--O 1.27 2.182 0 CA-C-O 121.945 0.879 . . . . 0.0 112.589 -174.638 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 165.73 119.63 0.49 Allowed Glycine 0 N--CA 1.441 -0.993 0 CA-C-N 114.935 -1.029 . . . . 0.0 111.5 178.678 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 83.9 p -89.81 -1.54 58.02 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.34 0.59 . . . . 0.0 110.173 178.519 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 23.8 mtp180 -109.12 138.4 45.52 Favored 'General case' 0 N--CA 1.435 -1.181 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 178.884 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 72.5 tt0 -73.0 -38.26 66.67 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-O 121.354 0.597 . . . . 0.0 111.326 -173.324 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 53.5 m-80 -110.6 28.75 8.37 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.343 -177.934 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' GLN . . . . . 0.576 HE21 ' HB3' ' A' ' 120' ' ' TYR . 50.8 tt0 -156.96 125.2 5.61 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.119 0.485 . . . . 0.0 110.467 -177.545 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' ASN . . . . . 0.534 ' HB3' ' OH ' ' A' ' 71' ' ' TYR . 91.6 m-20 -104.64 169.69 8.32 Favored 'General case' 0 C--O 1.251 1.136 0 CA-C-N 115.647 -0.706 . . . . 0.0 111.949 -174.319 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.51 HG21 ' HB3' ' A' ' 92' ' ' LEU . 26.4 m -83.73 151.8 3.89 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.433 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.918 177.886 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.527 ' HB ' ' OG ' ' A' ' 40' ' ' SER . 33.8 m -123.45 -29.66 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 C-N-CA 120.909 -0.316 . . . . 0.0 111.49 177.416 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . 0.585 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -140.56 135.34 31.72 Favored 'General case' 0 C--N 1.317 -0.828 0 C-N-CA 120.197 -0.601 . . . . 0.0 111.13 179.07 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.545 ' O ' ' HA ' ' A' ' 37' ' ' ASN . 88.6 mt -128.41 121.47 55.45 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.044 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 178.447 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 8.1 t30 -127.8 95.07 4.11 Favored 'General case' 0 C--N 1.325 -0.463 0 O-C-N 123.908 0.755 . . . . 0.0 109.48 -179.296 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.484 HG11 ' CD2' ' A' ' 128' ' ' PHE . 31.7 m -143.65 148.58 18.83 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 N-CA-C 112.672 0.619 . . . . 0.0 112.672 -175.293 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 69.8 tt0 -150.05 154.32 37.95 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.335 -0.848 . . . . 0.0 109.553 174.863 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 44.3 t -136.28 150.8 49.09 Favored 'General case' 0 C--N 1.31 -1.146 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.107 -178.846 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -97.2 1.79 60.92 Favored Glycine 0 N--CA 1.44 -1.069 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 174.479 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -98.56 -172.68 2.37 Favored 'General case' 0 CA--C 1.507 -0.703 0 N-CA-C 109.596 -0.52 . . . . 0.0 109.596 179.716 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 10.4 p-10 -92.47 32.76 1.17 Allowed 'General case' 0 C--N 1.312 -1.028 0 CA-C-O 121.435 0.636 . . . . 0.0 109.559 176.147 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . 0.573 ' HA3' ' ND2' ' A' ' 32' ' ' ASN . . . 94.81 9.24 58.72 Favored Glycine 0 N--CA 1.445 -0.719 0 CA-C-N 115.618 -0.719 . . . . 0.0 113.271 -179.347 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' GLN . . . . . 0.519 ' HA ' ' CD1' ' A' ' 132' ' ' LEU . 97.1 mt-30 -65.08 -50.69 65.16 Favored 'General case' 0 C--O 1.24 0.593 0 CA-C-O 120.96 0.409 . . . . 0.0 111.072 179.289 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 40.2 p -129.49 130.33 45.7 Favored 'General case' 0 N--CA 1.444 -0.751 0 CA-C-N 115.899 -0.591 . . . . 0.0 109.844 178.56 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 88.6 mt -108.85 125.44 51.98 Favored 'General case' 0 C--N 1.31 -1.149 0 N-CA-C 110.075 -0.343 . . . . 0.0 110.075 179.781 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 15.7 m120 -109.84 136.37 49.25 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.173 -178.768 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . 0.435 ' HA3' HG12 ' A' ' 105' ' ' VAL . . . 167.33 -145.56 9.93 Favored Glycine 0 N--CA 1.439 -1.136 0 C-N-CA 119.074 -1.536 . . . . 0.0 113.584 176.408 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 26.9 p -139.17 161.58 37.05 Favored 'General case' 0 C--N 1.314 -0.951 0 C-N-CA 123.211 0.605 . . . . 0.0 110.699 -177.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 118' ' ' MET . . . . . 0.55 ' O ' ' HA ' ' A' ' 125' ' ' PRO . 18.4 ptp -140.28 148.59 41.66 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.303 -0.408 . . . . 0.0 109.968 178.776 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 119' ' ' THR . . . . . 0.585 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 27.7 m -128.78 130.53 47.14 Favored 'General case' 0 C--N 1.313 -0.998 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 177.973 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . 0.586 ' HB2' ' HB3' ' A' ' 123' ' ' GLU . 38.4 m-85 -96.56 173.08 7.52 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.006 0.431 . . . . 0.0 112.037 -179.945 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . 0.416 ' HA ' HG11 ' A' ' 101' ' ' VAL . . . -55.51 -36.57 66.83 Favored 'General case' 0 CA--C 1.533 0.298 0 CA-C-N 115.396 -0.82 . . . . 0.0 112.859 -178.43 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -144.2 46.01 0.84 Allowed Glycine 0 CA--C 1.506 -0.522 0 C-N-CA 120.388 -0.91 . . . . 0.0 111.668 -179.321 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . 0.586 ' HB3' ' HB2' ' A' ' 120' ' ' TYR . 76.1 tt0 -151.62 144.66 24.55 Favored 'General case' 0 C--N 1.315 -0.894 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 -178.032 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -68.01 160.29 50.59 Favored Glycine 0 CA--C 1.518 0.246 0 C-N-CA 121.153 -0.546 . . . . 0.0 113.002 -177.512 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . 0.55 ' HA ' ' O ' ' A' ' 118' ' ' MET . 30.2 Cg_endo -63.15 136.65 57.21 Favored 'Trans proline' 0 C--N 1.348 0.537 0 C-N-CA 122.416 2.077 . . . . 0.0 111.994 179.701 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 44.0 pt -129.47 165.1 30.27 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.913 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.567 -179.133 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -73.09 132.44 16.89 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 121.053 -0.594 . . . . 0.0 112.145 -179.18 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . 0.484 ' CD2' HG11 ' A' ' 105' ' ' VAL . 49.9 t80 -114.92 131.29 56.93 Favored 'General case' 0 C--O 1.245 0.862 0 C-N-CA 122.937 0.495 . . . . 0.0 111.793 -177.798 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 62.5 tttm -133.13 97.35 3.97 Favored 'General case' 0 N--CA 1.441 -0.89 0 CA-C-N 115.249 -0.887 . . . . 0.0 109.687 175.658 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -91.81 130.84 10.49 Favored Glycine 0 CA--C 1.502 -0.738 0 N-CA-C 111.06 -0.816 . . . . 0.0 111.06 179.917 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 28.2 m -128.5 133.94 48.58 Favored 'General case' 0 C--N 1.311 -1.093 0 CA-C-N 117.282 0.541 . . . . 0.0 110.461 -178.376 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 132' ' ' LEU . . . . . 0.519 ' CD1' ' HA ' ' A' ' 112' ' ' GLN . 80.3 mt -57.12 134.34 55.79 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-O 121.001 0.429 . . . . 0.0 110.962 177.784 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 24.1 m . . . . . 0 C--O 1.251 1.152 0 CA-C-O 118.123 -0.941 . . . . 0.0 109.61 179.682 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.701 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . 0.569 HD11 HE21 ' A' ' 22' ' ' GLN . 3.3 tm? -98.23 132.53 43.66 Favored 'General case' 0 C--N 1.317 -0.805 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 -178.772 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . 0.459 ' CE1' ' HB ' ' A' ' 25' ' ' ILE . 96.9 m-85 -125.9 150.06 48.22 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-O 121.153 0.501 . . . . 0.0 111.256 -179.668 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 10.1 m-80 -99.0 136.56 38.79 Favored 'General case' 0 C--N 1.318 -0.791 0 N-CA-C 107.62 -1.252 . . . . 0.0 107.62 174.728 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.461 HG21 ' CG ' ' A' ' 23' ' ' TRP . 53.6 t -115.87 129.83 71.57 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 N-CA-C 114.007 1.114 . . . . 0.0 114.007 -172.953 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.477 ' HA ' ' HA ' ' A' ' 19' ' ' GLU . 78.4 mt-10 -114.27 134.33 55.02 Favored 'General case' 0 N--CA 1.437 -1.09 0 CA-C-N 113.999 -1.455 . . . . 0.0 107.97 176.038 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 11.6 m120 -116.07 136.15 53.28 Favored 'General case' 0 C--N 1.315 -0.918 0 CA-C-O 120.635 0.255 . . . . 0.0 110.517 -178.949 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . 0.53 ' HB2' ' CE3' ' A' ' 17' ' ' TRP . 58.6 tt0 -112.39 122.1 46.74 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.827 -178.166 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 15.0 p90 -139.47 141.87 37.39 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.912 -0.585 . . . . 0.0 109.654 175.079 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 127.62 2.21 6.33 Favored Glycine 0 N--CA 1.443 -0.862 0 C-N-CA 120.657 -0.782 . . . . 0.0 111.59 -179.234 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 82.03 -156.69 36.35 Favored Glycine 0 N--CA 1.445 -0.766 0 C-N-CA 121.161 -0.542 . . . . 0.0 113.892 178.776 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 8.1 m -54.45 137.54 42.27 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-N 115.011 -0.594 . . . . 0.0 111.8 179.659 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 21.0 m 64.08 18.92 11.52 Favored 'General case' 0 N--CA 1.469 0.511 0 N-CA-C 113.131 0.789 . . . . 0.0 113.131 177.616 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -79.93 140.28 54.04 Favored Pre-proline 0 C--N 1.322 -0.597 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 177.209 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 69.9 Cg_endo -71.13 158.73 54.22 Favored 'Trans proline' 0 C--O 1.238 0.505 0 C-N-CA 122.495 2.13 . . . . 0.0 112.287 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . 0.53 ' CE3' ' HB2' ' A' ' 9' ' ' GLN . 91.7 m95 -92.94 128.78 38.92 Favored 'General case' 0 C--N 1.314 -0.965 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 179.076 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 88.9 m-20 -116.37 117.12 29.07 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-N 116.7 -0.227 . . . . 0.0 110.691 -177.573 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.477 ' HA ' ' HA ' ' A' ' 7' ' ' GLU . 11.2 pt-20 -72.27 135.55 46.03 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 177.669 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -142.87 26.16 2.23 Favored Glycine 0 N--CA 1.44 -1.074 0 C-N-CA 119.375 -1.393 . . . . 0.0 113.266 179.302 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 149.85 -176.04 28.7 Favored Glycine 0 N--CA 1.447 -0.567 0 C-N-CA 119.531 -1.318 . . . . 0.0 113.583 -179.832 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . 0.569 HE21 HD11 ' A' ' 3' ' ' LEU . 4.4 pt20 -131.32 136.97 48.57 Favored 'General case' 0 C--N 1.325 -0.478 0 C-N-CA 122.603 0.361 . . . . 0.0 110.425 -178.728 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . 0.461 ' CG ' HG21 ' A' ' 6' ' ' VAL . 29.3 m0 -112.58 154.64 25.68 Favored 'General case' 0 CA--C 1.504 -0.826 0 N-CA-C 110.126 -0.324 . . . . 0.0 110.126 179.406 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 69.5 tt0 -117.89 114.16 22.82 Favored 'General case' 0 C--N 1.31 -1.111 0 C-N-CA 119.772 -0.771 . . . . 0.0 109.085 176.185 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.459 ' HB ' ' CE1' ' A' ' 4' ' ' TYR . 96.8 mt -127.0 135.76 62.74 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.598 -175.486 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 113.5 165.13 15.89 Favored Glycine 0 N--CA 1.438 -1.183 0 C-N-CA 120.667 -0.778 . . . . 0.0 112.721 176.838 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 58.5 m -134.63 -55.77 0.84 Allowed 'General case' 0 C--N 1.309 -1.163 0 N-CA-C 108.793 -0.817 . . . . 0.0 108.793 179.454 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 93.4 mtt-85 -80.36 137.09 36.51 Favored 'General case' 0 N--CA 1.448 -0.551 0 CA-C-N 115.506 -0.77 . . . . 0.0 109.164 176.403 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 24.8 m -89.03 -19.98 24.95 Favored 'General case' 0 C--N 1.314 -0.95 0 CA-C-O 121.257 0.551 . . . . 0.0 110.884 -179.379 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 17.3 m-20 -95.68 1.01 53.3 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.781 -0.645 . . . . 0.0 111.407 -178.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . 0.46 ' OE1' ' HB3' ' A' ' 53' ' ' TYR . 0.4 OUTLIER -141.65 112.41 7.21 Favored 'General case' 0 C--N 1.321 -0.67 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 178.966 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 2.7 t30 -95.2 161.2 14.2 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-O 120.958 0.409 . . . . 0.0 111.497 -176.088 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.432 ' HA ' ' HA ' ' A' ' 53' ' ' TYR . 59.6 t -98.77 134.58 37.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 C-N-CA 123.204 0.602 . . . . 0.0 110.151 -179.146 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.405 HG13 ' HB2' ' A' ' 54' ' ' ALA . 23.8 m -112.72 -15.22 10.4 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.545 0 N-CA-C 112.548 0.573 . . . . 0.0 112.548 -179.319 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.509 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -147.8 143.85 27.78 Favored 'General case' 0 C--O 1.239 0.52 0 C-N-CA 120.228 -0.589 . . . . 0.0 111.52 177.597 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.41 ' HB ' ' CG2' ' A' ' 105' ' ' VAL . 94.8 mt -141.84 124.96 15.06 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 -179.772 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . 0.423 HD22 ' HA ' ' A' ' 37' ' ' ASN . 1.0 OUTLIER -133.4 112.5 11.64 Favored 'General case' 0 C--N 1.311 -1.068 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 177.951 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.469 HG22 ' HB ' ' A' ' 103' ' ' ILE . 19.7 m -146.37 147.83 17.66 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.775 0 N-CA-C 112.202 0.445 . . . . 0.0 112.202 -174.388 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 69.2 tt0 -131.02 143.2 50.53 Favored 'General case' 0 CA--C 1.536 0.404 0 CA-C-N 115.692 -0.685 . . . . 0.0 109.629 176.768 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . 0.416 ' HA ' ' O ' ' A' ' 46' ' ' THR . 22.1 p -71.13 147.64 48.2 Favored 'General case' 0 C--N 1.319 -0.754 0 N-CA-C 112.441 0.534 . . . . 0.0 112.441 179.633 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -97.87 -48.69 1.89 Allowed Glycine 0 N--CA 1.45 -0.403 0 N-CA-C 110.515 -1.034 . . . . 0.0 110.515 176.597 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 6.9 m-20 -97.26 -168.07 1.64 Allowed 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 175.783 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 28.3 m-20 -74.93 59.83 0.93 Allowed 'General case' 0 N--CA 1.469 0.501 0 CA-C-O 121.133 0.492 . . . . 0.0 111.947 -179.543 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 82.77 11.6 81.34 Favored Glycine 0 N--CA 1.452 -0.268 0 CA-C-N 115.976 -0.556 . . . . 0.0 112.75 177.477 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 63.1 tt0 -97.08 -30.51 13.0 Favored 'General case' 0 C--O 1.215 -0.715 0 C-N-CA 120.784 -0.366 . . . . 0.0 111.314 179.701 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . 0.416 ' O ' ' HA ' ' A' ' 40' ' ' SER . 31.0 p -124.04 147.36 47.9 Favored 'General case' 0 C--N 1.308 -1.203 0 C-N-CA 120.818 -0.353 . . . . 0.0 110.801 -179.806 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . 0.526 ' HB2' ' HB3' ' A' ' 63' ' ' ALA . 94.1 mt -133.28 129.47 37.65 Favored 'General case' 0 C--N 1.318 -0.79 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 -179.7 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 51.3 m-80 -127.16 140.75 52.04 Favored 'General case' 0 C--N 1.311 -1.101 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 177.565 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.433 ' HA3' HG12 ' A' ' 38' ' ' VAL . . . 177.22 -157.75 22.8 Favored Glycine 0 N--CA 1.438 -1.197 0 C-N-CA 119.4 -1.381 . . . . 0.0 113.541 179.904 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 44.6 m -126.23 129.96 49.98 Favored 'General case' 0 N--CA 1.44 -0.973 0 CA-C-N 115.302 -0.449 . . . . 0.0 110.239 -177.272 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 19.0 ttm -110.78 141.93 43.43 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 109.69 -0.485 . . . . 0.0 109.69 179.089 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.509 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 36.2 m -126.29 122.38 35.33 Favored 'General case' 0 C--O 1.254 1.29 0 CA-C-O 120.956 0.408 . . . . 0.0 111.233 178.019 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . 0.561 ' HB2' ' HB2' ' A' ' 56' ' ' GLU . 78.6 m-85 -85.92 164.3 17.53 Favored 'General case' 0 C--O 1.231 0.127 0 CA-C-N 115.404 -0.816 . . . . 0.0 110.702 178.891 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . 0.405 ' HB2' HG13 ' A' ' 34' ' ' VAL . . . -69.58 105.44 2.67 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.895 -179.515 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 86.44 8.43 77.61 Favored Glycine 0 CA--C 1.518 0.236 0 C-N-CA 121.013 -0.613 . . . . 0.0 112.943 176.711 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . 0.561 ' HB2' ' HB2' ' A' ' 53' ' ' TYR . 78.6 mm-40 -122.12 165.56 15.9 Favored 'General case' 0 C--N 1.315 -0.893 0 N-CA-C 110.012 -0.366 . . . . 0.0 110.012 -179.003 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -77.7 161.96 50.16 Favored Glycine 0 N--CA 1.446 -0.683 0 C-N-CA 120.663 -0.779 . . . . 0.0 112.086 178.51 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -72.73 145.87 42.03 Favored 'Trans proline' 0 C--O 1.241 0.645 0 C-N-CA 122.811 2.341 . . . . 0.0 112.716 179.835 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . 0.542 ' HB ' ' O ' ' A' ' 76' ' ' GLN . 49.7 pt -128.86 165.83 27.72 Favored 'Isoleucine or valine' 0 C--O 1.242 0.687 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.653 179.888 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -77.13 134.84 15.47 Favored Glycine 0 C--O 1.239 0.459 0 C-N-CA 120.897 -0.668 . . . . 0.0 111.819 -179.347 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.429 ' CD2' HG11 ' A' ' 38' ' ' VAL . 72.1 t80 -117.43 127.49 54.07 Favored 'General case' 0 C--O 1.237 0.443 0 C-N-CA 122.429 0.291 . . . . 0.0 111.24 -177.556 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 50.2 ttm-85 -130.29 127.75 40.14 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.016 -0.538 . . . . 0.0 109.86 176.699 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.526 ' HB3' ' HB2' ' A' ' 47' ' ' LEU . . . -132.05 139.87 48.69 Favored 'General case' 0 C--N 1.319 -0.741 0 C-N-CA 120.796 -0.362 . . . . 0.0 111.819 178.529 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 46.7 m -122.28 127.02 49.38 Favored 'General case' 0 CA--C 1.54 0.568 0 CA-C-N 115.879 -0.601 . . . . 0.0 110.005 178.201 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -74.5 119.77 19.15 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-O 121.053 0.454 . . . . 0.0 110.678 -178.118 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 91.7 mt -94.43 -25.14 17.04 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.669 -0.696 . . . . 0.0 109.962 178.368 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 134.57 157.5 8.14 Favored Glycine 0 N--CA 1.44 -1.044 0 CA-C-N 115.675 -0.693 . . . . 0.0 111.882 179.638 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 92.4 m-20 56.69 34.33 24.37 Favored 'General case' 0 N--CA 1.481 1.114 0 C-N-CA 122.463 0.305 . . . . 0.0 111.469 179.2 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . 0.536 ' ND2' ' HA3' ' A' ' 93' ' ' GLY . 21.8 m120 70.15 10.49 7.36 Favored 'General case' 0 N--CA 1.481 1.087 0 C-N-CA 123.522 0.729 . . . . 0.0 112.415 -179.407 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 55.8 m -87.72 122.31 31.22 Favored 'General case' 0 C--O 1.236 0.376 0 N-CA-C 110.015 -0.365 . . . . 0.0 110.015 177.959 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.562 ' OH ' ' HB3' ' A' ' 99' ' ' ASN . 70.8 m-85 -115.44 129.96 56.73 Favored 'General case' 0 C--N 1.311 -1.065 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.217 -179.643 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 52.2 tp10 -85.31 118.82 25.09 Favored 'General case' 0 N--CA 1.438 -1.064 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 174.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 68.0 t -106.98 132.75 53.52 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.23 0 N-CA-C 112.937 0.717 . . . . 0.0 112.937 -173.427 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -123.72 142.85 50.69 Favored 'General case' 0 N--CA 1.446 -0.645 0 N-CA-C 107.273 -1.381 . . . . 0.0 107.273 175.801 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 93.4 m-20 -134.71 161.24 35.71 Favored 'General case' 0 C--N 1.316 -0.851 0 C-N-CA 120.869 -0.332 . . . . 0.0 111.291 -174.964 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' GLN . . . . . 0.542 ' O ' ' HB ' ' A' ' 59' ' ' ILE . 2.9 pt20 -130.64 129.99 43.38 Favored 'General case' 0 C--O 1.239 0.543 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.159 177.006 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 6.6 p90 -133.96 151.19 51.38 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.91 -178.408 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 98.12 -1.96 59.45 Favored Glycine 0 N--CA 1.448 -0.54 0 C-N-CA 120.713 -0.756 . . . . 0.0 111.871 -179.614 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 140.99 164.62 9.99 Favored Glycine 0 N--CA 1.441 -1.031 0 C-N-CA 121.054 -0.593 . . . . 0.0 112.2 179.072 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -65.54 -33.0 74.89 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-O 121.248 0.546 . . . . 0.0 110.473 179.44 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 32.5 p -79.85 6.87 9.95 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.257 -0.883 . . . . 0.0 112.459 -178.055 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -83.89 146.64 49.56 Favored Pre-proline 0 C--N 1.316 -0.89 0 CA-C-N 116.698 -0.228 . . . . 0.0 110.527 179.668 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -67.92 173.73 8.8 Favored 'Trans proline' 0 C--N 1.345 0.353 0 C-N-CA 122.459 2.106 . . . . 0.0 111.604 178.855 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' TRP . . . . . . . . . . . . . 95.2 m95 -98.37 127.72 44.43 Favored 'General case' 0 N--CA 1.444 -0.751 0 CA-C-O 121.172 0.51 . . . . 0.0 110.248 -177.666 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 97.3 m-70 -115.7 149.69 38.0 Favored 'General case' 0 C--N 1.31 -1.116 0 CA-C-N 115.398 -0.819 . . . . 0.0 110.323 -177.629 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 10.0 m -61.53 130.25 45.06 Favored 'General case' 0 C--N 1.315 -0.925 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.833 -179.562 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -105.08 -52.68 0.82 Allowed Glycine 0 N--CA 1.439 -1.107 0 C-N-CA 120.913 -0.66 . . . . 0.0 111.634 179.43 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 155.68 -172.52 33.75 Favored Glycine 0 C--O 1.22 -0.753 0 C-N-CA 120.596 -0.811 . . . . 0.0 111.774 179.605 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 21.2 t-20 -110.28 112.08 23.8 Favored 'General case' 0 C--N 1.313 -1.009 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 179.512 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 27.4 m0 -102.4 149.8 23.99 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.993 -177.749 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 47.4 mm -107.17 114.02 45.04 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 177.247 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . 0.414 ' HB2' ' CE1' ' A' ' 71' ' ' TYR . 85.0 mt -124.25 89.25 3.05 Favored 'General case' 0 C--O 1.272 2.279 0 CA-C-O 121.725 0.774 . . . . 0.0 112.691 -175.796 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . 0.536 ' HA3' ' ND2' ' A' ' 69' ' ' ASN . . . 154.86 116.91 0.58 Allowed Glycine 0 N--CA 1.443 -0.876 0 CA-C-N 115.0 -1.0 . . . . 0.0 111.676 178.911 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . 0.436 ' N ' ' HE1' ' A' ' 23' ' ' TRP . 76.8 p -86.0 -15.28 41.95 Favored 'General case' 0 CA--C 1.516 -0.355 0 CA-C-O 121.395 0.617 . . . . 0.0 109.913 178.849 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 58.4 mtt-85 -88.91 141.85 28.14 Favored 'General case' 0 N--CA 1.435 -1.185 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.004 -179.93 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 8.9 pt-20 -68.65 -33.11 73.43 Favored 'General case' 0 C--N 1.31 -1.117 0 CA-C-N 115.53 -0.759 . . . . 0.0 111.975 -175.376 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 31.3 p-10 -120.75 28.66 7.82 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 111.788 0.292 . . . . 0.0 111.788 -178.117 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' GLN . . . . . 0.517 HE22 ' HB3' ' A' ' 121' ' ' ALA . 0.0 OUTLIER -142.78 118.48 10.46 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 112.326 0.491 . . . . 0.0 112.326 -176.672 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' ASN . . . . . 0.562 ' HB3' ' OH ' ' A' ' 71' ' ' TYR . 93.2 m-20 -89.36 157.86 18.01 Favored 'General case' 0 C--O 1.262 1.755 0 CA-C-N 115.724 -0.671 . . . . 0.0 111.166 177.673 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.445 HG21 ' CH2' ' A' ' 23' ' ' TRP . 85.9 t -84.35 134.14 27.66 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.594 0 CA-C-N 115.355 -0.839 . . . . 0.0 111.705 178.445 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 35.8 m -110.66 -29.03 2.49 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.397 0 CA-C-N 116.035 -0.529 . . . . 0.0 112.275 179.765 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . 0.516 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -146.24 139.37 25.77 Favored 'General case' 0 C--N 1.323 -0.585 0 C-N-CA 120.2 -0.6 . . . . 0.0 111.144 179.056 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.469 ' HB ' HG22 ' A' ' 38' ' ' VAL . 94.9 mt -131.62 124.95 55.19 Favored 'Isoleucine or valine' 0 C--O 1.244 0.771 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.57 177.796 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 41.2 t30 -125.17 94.56 4.2 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 115.676 -0.693 . . . . 0.0 109.3 175.586 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.41 ' CG2' ' HB ' ' A' ' 36' ' ' ILE . 29.3 m -133.6 135.82 55.2 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 N-CA-C 112.859 0.689 . . . . 0.0 112.859 -176.538 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 75.3 tt0 -140.15 137.55 34.51 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.415 -0.811 . . . . 0.0 110.13 179.639 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 23.2 t -146.93 145.37 29.77 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 116.468 -0.333 . . . . 0.0 110.459 177.211 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -109.18 17.07 32.12 Favored Glycine 0 N--CA 1.447 -0.609 0 C-N-CA 121.11 -0.567 . . . . 0.0 112.435 -179.195 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 40.3 p-10 -91.91 -153.61 0.34 Allowed 'General case' 0 C--N 1.319 -0.753 0 CA-C-O 120.768 0.318 . . . . 0.0 110.158 179.098 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 37.1 t70 -88.94 12.86 14.19 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-O 121.167 0.508 . . . . 0.0 110.071 179.108 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 85.7 7.39 81.68 Favored Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 120.684 -0.769 . . . . 0.0 111.939 -177.173 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 36.5 tt0 -66.57 -38.78 87.79 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-O 121.109 0.481 . . . . 0.0 110.526 -179.671 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . 0.418 ' HA ' ' O ' ' A' ' 130' ' ' GLY . 27.5 p -124.63 131.73 53.46 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-N 115.906 -0.588 . . . . 0.0 111.056 179.224 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -109.94 113.32 25.96 Favored 'General case' 0 C--N 1.315 -0.927 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 177.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 93.8 m-20 -117.23 147.5 42.46 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-O 121.016 0.436 . . . . 0.0 111.26 -177.941 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 159.57 -135.61 4.22 Favored Glycine 0 N--CA 1.434 -1.457 0 C-N-CA 120.458 -0.877 . . . . 0.0 112.906 177.717 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 20.8 p -134.04 157.97 44.76 Favored 'General case' 0 C--N 1.31 -1.143 0 C-N-CA 122.905 0.482 . . . . 0.0 110.316 -177.786 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 118' ' ' MET . . . . . 0.41 ' HE1' ' CZ ' ' A' ' 120' ' ' TYR . 17.3 ptm -149.63 155.24 39.92 Favored 'General case' 0 C--N 1.312 -1.063 0 CA-C-N 116.498 -0.319 . . . . 0.0 110.391 -179.672 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 119' ' ' THR . . . . . 0.516 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 27.9 m -130.76 128.11 40.11 Favored 'General case' 0 C--O 1.249 1.055 0 CA-C-N 116.474 -0.33 . . . . 0.0 111.224 179.804 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . 0.41 ' CZ ' ' HE1' ' A' ' 118' ' ' MET . 31.0 m-85 -89.85 166.02 13.77 Favored 'General case' 0 CA--C 1.507 -0.687 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.294 175.975 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . 0.517 ' HB3' HE22 ' A' ' 98' ' ' GLN . . . -66.47 45.38 0.03 OUTLIER 'General case' 0 CA--C 1.554 1.126 0 N-CA-C 114.043 1.127 . . . . 0.0 114.043 179.79 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 142.44 -25.63 2.31 Favored Glycine 0 C--N 1.334 0.429 0 C-N-CA 119.874 -1.155 . . . . 0.0 114.405 175.372 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . 0.471 ' HG2' ' OE1' ' A' ' 98' ' ' GLN . 69.4 mm-40 -67.33 -33.36 75.09 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 117.311 0.556 . . . . 0.0 112.424 -177.585 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 115.09 161.69 13.34 Favored Glycine 0 CA--C 1.519 0.334 0 C-N-CA 120.585 -0.817 . . . . 0.0 112.361 -179.542 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 20.8 Cg_exo -67.11 129.36 20.39 Favored 'Trans proline' 0 C--N 1.351 0.673 0 C-N-CA 122.782 2.321 . . . . 0.0 111.991 178.386 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 37.4 pt -135.44 161.73 38.71 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.691 179.592 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -69.8 139.25 31.17 Favored Glycine 0 C--O 1.239 0.453 0 C-N-CA 120.923 -0.656 . . . . 0.0 112.26 178.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 86.4 t80 -119.52 133.71 55.55 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 120.745 0.307 . . . . 0.0 111.233 -178.465 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 129' ' ' LYS . . . . . 0.427 ' HB3' ' HB2' ' A' ' 7' ' ' GLU . 63.6 tttm -140.99 118.12 11.27 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.911 -0.586 . . . . 0.0 109.519 176.718 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . 0.418 ' O ' ' HA ' ' A' ' 113' ' ' THR . . . -122.18 141.96 14.63 Favored Glycine 0 N--CA 1.449 -0.475 0 C-N-CA 120.735 -0.745 . . . . 0.0 111.941 -179.643 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 62.1 m -128.11 135.65 50.08 Favored 'General case' 0 C--N 1.317 -0.818 0 CA-C-N 116.619 0.21 . . . . 0.0 111.392 -179.585 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 132' ' ' LEU . . . . . 0.401 HD13 ' N ' ' A' ' 133' ' ' THR . 3.4 tm? -57.79 138.26 55.77 Favored 'General case' 0 N--CA 1.467 0.392 0 C-N-CA 123.062 0.545 . . . . 0.0 110.391 179.723 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 133' ' ' THR . . . . . 0.401 ' N ' HD13 ' A' ' 132' ' ' LEU . 24.0 m . . . . . 0 C--O 1.247 0.964 0 CA-C-O 118.503 -0.761 . . . . 0.0 110.322 -178.577 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.238 0.449 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . 0.586 HD21 HE21 ' A' ' 22' ' ' GLN . 3.1 tm? -90.76 128.68 36.77 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-O 120.855 0.359 . . . . 0.0 110.099 -179.914 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . 0.424 ' CD1' ' HB ' ' A' ' 25' ' ' ILE . 57.4 m-85 -119.65 143.07 47.91 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.142 178.1 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 12.9 m-80 -97.24 135.52 39.05 Favored 'General case' 0 C--N 1.309 -1.159 0 N-CA-C 108.394 -0.965 . . . . 0.0 108.394 175.689 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 53.5 t -111.36 126.65 68.76 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.862 0 CA-C-O 121.803 0.811 . . . . 0.0 112.627 -174.769 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.452 ' HG2' ' HB3' ' A' ' 19' ' ' GLU . 63.6 mt-10 -118.82 133.18 56.02 Favored 'General case' 0 N--CA 1.438 -1.047 0 CA-C-N 114.684 -1.144 . . . . 0.0 108.5 176.665 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . 0.45 ' HA ' ' O ' ' A' ' 127' ' ' GLY . 13.0 m120 -117.89 139.76 50.67 Favored 'General case' 0 C--N 1.313 -1.004 0 CA-C-O 121.072 0.463 . . . . 0.0 111.424 -176.641 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . 0.445 ' HB2' ' CE3' ' A' ' 17' ' ' TRP . 28.1 tt0 -132.6 125.86 31.43 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.059 179.131 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 24.1 p90 -128.98 141.29 51.3 Favored 'General case' 0 C--N 1.316 -0.853 0 C-N-CA 120.607 -0.437 . . . . 0.0 111.265 -179.048 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 115.77 -77.72 0.27 Allowed Glycine 0 N--CA 1.442 -0.936 0 CA-C-N 115.562 -0.744 . . . . 0.0 111.794 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -170.34 173.62 44.3 Favored Glycine 0 N--CA 1.442 -0.953 0 C-N-CA 121.085 -0.579 . . . . 0.0 111.725 -179.579 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 26.2 t -59.25 -23.8 62.65 Favored 'General case' 0 CA--C 1.538 0.506 0 N-CA-C 111.881 0.326 . . . . 0.0 111.881 -179.729 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 23.5 p -65.23 -19.65 66.07 Favored 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 112.009 0.374 . . . . 0.0 112.009 177.823 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -93.09 146.91 32.84 Favored Pre-proline 0 N--CA 1.446 -0.671 0 N-CA-C 109.978 -0.379 . . . . 0.0 109.978 179.414 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_endo -79.41 173.27 13.39 Favored 'Trans proline' 0 CA--C 1.537 0.652 0 C-N-CA 122.723 2.282 . . . . 0.0 112.869 179.457 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . 0.445 ' CE3' ' HB2' ' A' ' 9' ' ' GLN . 95.5 m95 -87.14 131.24 34.22 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.938 -0.573 . . . . 0.0 109.795 178.741 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 46.5 m-80 -114.37 118.62 34.36 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.937 -178.395 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.452 ' HB3' ' HG2' ' A' ' 7' ' ' GLU . 10.9 pt-20 -82.7 124.75 30.51 Favored 'General case' 0 C--N 1.315 -0.897 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.499 179.236 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.439 ' O ' ' HB2' ' A' ' 94' ' ' SER . . . -132.46 29.93 3.22 Favored Glycine 0 N--CA 1.442 -0.963 0 C-N-CA 120.069 -1.062 . . . . 0.0 112.838 -177.709 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 140.96 -175.12 22.36 Favored Glycine 0 N--CA 1.442 -0.907 0 C-N-CA 120.25 -0.976 . . . . 0.0 112.819 178.818 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . 0.586 HE21 HD21 ' A' ' 3' ' ' LEU . 18.5 pt20 -141.46 153.05 44.74 Favored 'General case' 0 C--N 1.313 -1.01 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 179.812 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . 0.425 ' HB3' ' O ' ' A' ' 91' ' ' ILE . 45.0 m0 -127.68 174.7 8.87 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.543 -0.299 . . . . 0.0 110.787 -176.086 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 79.6 tt0 -121.01 118.11 28.97 Favored 'General case' 0 CA--C 1.51 -0.57 0 C-N-CA 120.624 -0.43 . . . . 0.0 109.902 176.776 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.424 ' HB ' ' CD1' ' A' ' 4' ' ' TYR . 98.3 mt -131.53 140.14 49.01 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.774 0 CA-C-N 115.816 -0.629 . . . . 0.0 109.609 -178.762 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 86.15 66.64 1.39 Allowed Glycine 0 N--CA 1.443 -0.886 0 C-N-CA 120.34 -0.933 . . . . 0.0 112.544 178.982 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 19.2 p -59.78 -36.88 77.61 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 121.131 0.491 . . . . 0.0 110.239 177.744 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 93.5 mtt-85 -94.88 108.23 20.26 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 175.233 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 51.0 m -73.7 -7.87 53.76 Favored 'General case' 0 C--N 1.321 -0.671 0 N-CA-C 113.082 0.771 . . . . 0.0 113.082 -174.761 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 97.9 m-20 -76.81 -18.76 58.21 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.906 0.384 . . . . 0.0 110.996 179.854 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . 0.511 ' NE2' ' HA ' ' A' ' 31' ' ' GLN . 7.2 mm-40 -133.53 114.83 14.02 Favored 'General case' 0 CA--C 1.51 -0.561 0 N-CA-C 112.589 0.589 . . . . 0.0 112.589 -178.741 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . 0.542 ' ND2' ' HA3' ' A' ' 111' ' ' GLY . 2.6 t30 -82.21 142.43 32.16 Favored 'General case' 0 C--O 1.242 0.7 0 CA-C-N 116.011 -0.541 . . . . 0.0 110.043 179.369 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 47.0 t -92.37 129.75 42.51 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 CA-C-N 115.507 -0.77 . . . . 0.0 109.857 -178.331 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.442 ' HB ' ' O ' ' A' ' 107' ' ' SER . 30.5 m -110.13 -21.15 5.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 N-CA-C 112.38 0.511 . . . . 0.0 112.38 -179.925 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.627 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -144.85 143.13 30.46 Favored 'General case' 0 C--N 1.322 -0.605 0 C-N-CA 119.816 -0.753 . . . . 0.0 111.85 179.319 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.439 ' C ' HD22 ' A' ' 37' ' ' ASN . 91.5 mt -142.08 119.38 7.47 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 CA-C-N 115.48 -0.782 . . . . 0.0 109.061 179.802 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . 0.439 HD22 ' C ' ' A' ' 36' ' ' ILE . 0.9 OUTLIER -126.4 109.92 12.76 Favored 'General case' 0 C--N 1.306 -1.32 0 N-CA-C 108.389 -0.967 . . . . 0.0 108.389 176.506 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.551 HG12 ' HA3' ' A' ' 49' ' ' GLY . 29.5 m -148.26 153.42 11.54 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.63 0 N-CA-C 112.111 0.411 . . . . 0.0 112.111 -173.753 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 -146.35 148.34 32.26 Favored 'General case' 0 C--O 1.245 0.82 0 CA-C-N 115.431 -0.804 . . . . 0.0 109.299 174.778 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . 0.474 ' HB3' ' CD2' ' A' ' 47' ' ' LEU . 37.1 p -80.49 151.54 29.18 Favored 'General case' 0 C--N 1.313 -1.014 0 CA-C-O 121.496 0.665 . . . . 0.0 112.511 -176.88 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -92.76 -13.26 56.99 Favored Glycine 0 N--CA 1.438 -1.168 0 N-CA-C 110.084 -1.206 . . . . 0.0 110.084 173.281 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 28.3 m-20 -137.33 -155.16 0.59 Allowed 'General case' 0 N--CA 1.468 0.445 0 C-N-CA 123.203 0.601 . . . . 0.0 109.403 -179.34 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -79.4 42.12 0.49 Allowed 'General case' 0 N--CA 1.47 0.572 0 CA-C-O 121.099 0.476 . . . . 0.0 110.725 178.117 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 91.43 3.82 68.84 Favored Glycine 0 C--O 1.22 -0.743 0 C-N-CA 121.025 -0.607 . . . . 0.0 112.881 -178.834 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 55.9 tp60 -63.97 -47.67 79.48 Favored 'General case' 0 N--CA 1.462 0.17 0 CA-C-O 120.903 0.382 . . . . 0.0 111.016 179.575 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 9.4 t -133.32 127.75 34.23 Favored 'General case' 0 C--N 1.312 -1.059 0 C-N-CA 120.72 -0.392 . . . . 0.0 110.113 177.551 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . 0.474 ' CD2' ' HB3' ' A' ' 40' ' ' SER . 64.9 mt -109.08 127.96 54.58 Favored 'General case' 0 N--CA 1.447 -0.618 0 N-CA-C 109.662 -0.496 . . . . 0.0 109.662 179.636 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 65.2 m-80 -121.97 147.1 46.47 Favored 'General case' 0 C--N 1.313 -0.982 0 N-CA-C 109.558 -0.534 . . . . 0.0 109.558 176.8 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.551 ' HA3' HG12 ' A' ' 38' ' ' VAL . . . 176.13 -154.4 16.88 Favored Glycine 0 N--CA 1.433 -1.557 0 C-N-CA 119.925 -1.131 . . . . 0.0 113.064 179.602 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 89.9 m -129.35 130.7 46.39 Favored 'General case' 0 N--CA 1.436 -1.159 0 C-N-CA 122.668 0.387 . . . . 0.0 111.13 -177.483 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 44.9 mtp -110.08 151.27 27.42 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.394 -0.367 . . . . 0.0 110.927 177.846 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.627 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 23.7 m -132.84 127.77 35.2 Favored 'General case' 0 C--N 1.315 -0.898 0 N-CA-C 110.185 -0.302 . . . . 0.0 110.185 176.009 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . 0.452 ' CD1' ' HB3' ' A' ' 31' ' ' GLN . 83.6 m-85 -92.48 163.21 13.91 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.867 178.721 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -61.31 103.36 0.29 Allowed 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.969 -178.553 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 94.77 -6.59 70.24 Favored Glycine 0 CA--C 1.51 -0.258 0 C-N-CA 120.863 -0.684 . . . . 0.0 113.267 177.975 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 69.8 mm-40 -104.82 -179.24 3.89 Favored 'General case' 0 C--N 1.311 -1.102 0 CA-C-O 120.709 0.29 . . . . 0.0 110.836 -178.347 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -99.06 173.73 26.86 Favored Glycine 0 N--CA 1.444 -0.796 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.33 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -68.66 139.38 44.08 Favored 'Trans proline' 0 CA--C 1.538 0.709 0 C-N-CA 122.818 2.345 . . . . 0.0 112.588 179.503 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 50.2 pt -131.93 167.17 27.0 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.079 178.372 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -78.53 139.09 21.92 Favored Glycine 0 N--CA 1.446 -0.677 0 N-CA-C 111.019 -0.832 . . . . 0.0 111.019 179.459 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.547 ' CD2' HG11 ' A' ' 38' ' ' VAL . 29.1 t80 -131.31 129.71 41.82 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 120.953 0.406 . . . . 0.0 111.583 -177.479 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 55.4 ttm-85 -127.11 130.06 49.13 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.514 -0.766 . . . . 0.0 110.493 178.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.455 ' HB1' ' HB3' ' A' ' 71' ' ' TYR . . . -129.27 132.32 47.16 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-O 120.594 0.235 . . . . 0.0 110.796 177.175 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 85.3 m -117.31 125.47 51.12 Favored 'General case' 0 C--N 1.316 -0.861 0 CA-C-O 120.996 0.427 . . . . 0.0 110.74 179.637 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . 0.507 ' HG ' ' H ' ' A' ' 67' ' ' GLY . 66.6 tp -71.52 132.89 45.36 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.759 -0.655 . . . . 0.0 112.544 -177.579 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -85.94 -16.15 39.33 Favored 'General case' 0 N--CA 1.471 0.577 0 CA-C-N 115.29 -0.868 . . . . 0.0 109.898 174.743 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.507 ' H ' ' HG ' ' A' ' 65' ' ' LEU . . . 103.7 7.61 41.68 Favored Glycine 0 N--CA 1.463 0.44 0 CA-C-N 115.527 -0.76 . . . . 0.0 112.7 177.471 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 29.7 p-10 -137.73 39.65 2.39 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-O 120.851 0.358 . . . . 0.0 110.592 -179.331 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 89.0 m-20 68.9 -1.72 1.96 Allowed 'General case' 0 N--CA 1.485 1.281 0 C-N-CA 123.528 0.731 . . . . 0.0 112.128 -178.558 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 15.3 m -91.82 132.23 36.59 Favored 'General case' 0 C--N 1.314 -0.948 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 177.456 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.455 ' HB3' ' HB1' ' A' ' 63' ' ' ALA . 79.1 m-85 -124.09 133.96 53.49 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.741 -179.25 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 79.9 tt0 -87.13 123.6 32.35 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 174.691 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.481 HG13 ' CE1' ' A' ' 61' ' ' PHE . 48.8 t -99.37 128.61 50.92 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 N-CA-C 112.826 0.676 . . . . 0.0 112.826 -175.656 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 75.4 mt-10 -127.19 121.81 32.34 Favored 'General case' 0 CA--C 1.535 0.378 0 CA-C-N 114.794 -1.094 . . . . 0.0 108.467 175.194 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' ASN . . . . . 0.421 ' OD1' ' HD1' ' A' ' 61' ' ' PHE . 96.4 m-20 -108.42 153.01 23.91 Favored 'General case' 0 C--O 1.236 0.393 0 N-CA-C 112.56 0.578 . . . . 0.0 112.56 -176.283 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 60.2 tt0 -127.72 125.55 40.19 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.358 -0.837 . . . . 0.0 109.389 -179.775 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 6.6 p90 -127.29 4.4 6.33 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 112.734 0.642 . . . . 0.0 112.734 -178.246 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -84.74 -1.88 88.87 Favored Glycine 0 CA--C 1.521 0.415 0 C-N-CA 120.561 -0.828 . . . . 0.0 111.954 178.242 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 106.14 -153.83 16.99 Favored Glycine 0 CA--C 1.497 -1.037 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 -179.717 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -62.43 -32.54 73.41 Favored 'General case' 0 CA--C 1.514 -0.422 0 CA-C-N 117.675 0.738 . . . . 0.0 109.217 173.827 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 47.7 m -84.78 -175.35 5.74 Favored 'General case' 0 N--CA 1.438 -1.04 0 CA-C-N 114.947 -1.024 . . . . 0.0 110.016 176.588 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 75.78 147.22 0.12 Allowed Pre-proline 0 N--CA 1.471 0.578 0 C-N-CA 123.997 0.919 . . . . 0.0 111.701 -179.445 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -73.76 169.19 22.95 Favored 'Trans proline' 0 C--O 1.238 0.508 0 C-N-CA 122.874 2.383 . . . . 0.0 111.807 178.999 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' TRP . . . . . . . . . . . . . 82.7 m95 -87.87 145.65 25.96 Favored 'General case' 0 N--CA 1.447 -0.589 0 N-CA-C 109.524 -0.547 . . . . 0.0 109.524 -179.911 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 94.3 m-70 -116.97 143.38 45.78 Favored 'General case' 0 C--N 1.317 -0.836 0 N-CA-C 110.033 -0.358 . . . . 0.0 110.033 -179.551 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 13.5 m -63.01 137.02 58.14 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-O 120.802 0.334 . . . . 0.0 110.904 -178.748 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -112.83 -48.92 0.6 Allowed Glycine 0 N--CA 1.447 -0.573 0 C-N-CA 121.228 -0.511 . . . . 0.0 112.371 -179.632 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 152.95 -167.95 31.75 Favored Glycine 0 C--O 1.214 -1.155 0 C-N-CA 120.257 -0.973 . . . . 0.0 112.121 179.201 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 16.1 m120 -111.99 118.88 36.67 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 117.082 0.441 . . . . 0.0 110.488 179.868 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 27.4 m0 -111.01 155.27 22.98 Favored 'General case' 0 C--N 1.321 -0.651 0 N-CA-C 110.25 -0.278 . . . . 0.0 110.25 -179.306 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.425 ' O ' ' HB3' ' A' ' 23' ' ' TRP . 49.2 mm -110.93 116.61 52.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 N-CA-C 109.179 -0.674 . . . . 0.0 109.179 177.893 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . 0.45 ' HB2' ' CE1' ' A' ' 71' ' ' TYR . 77.9 mt -128.98 81.72 2.04 Favored 'General case' 0 C--O 1.272 2.267 0 CA-C-O 121.772 0.796 . . . . 0.0 112.069 -177.996 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 166.22 112.61 0.26 Allowed Glycine 0 N--CA 1.442 -0.92 0 CA-C-N 115.222 -0.899 . . . . 0.0 111.771 179.159 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . 0.439 ' HB2' ' O ' ' A' ' 20' ' ' GLY . 77.4 p -86.01 -10.94 54.19 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 121.277 0.56 . . . . 0.0 110.761 179.887 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 98.6 mtt180 -111.44 154.24 24.96 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.556 -0.747 . . . . 0.0 109.413 -179.702 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -70.65 -53.19 16.75 Favored 'General case' 0 N--CA 1.472 0.669 0 N-CA-C 113.501 0.926 . . . . 0.0 113.501 -172.348 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 94.8 m-20 -115.0 36.47 3.86 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.75 0.31 . . . . 0.0 111.4 -176.769 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' GLN . . . . . 0.418 ' HG3' ' HB3' ' A' ' 120' ' ' TYR . 38.1 tp60 -103.47 -59.42 1.72 Allowed 'General case' 0 C--N 1.316 -0.853 0 C-N-CA 120.484 -0.486 . . . . 0.0 110.651 -178.681 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 88.8 m-20 74.62 133.72 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.599 0 O-C-N 123.894 0.746 . . . . 0.0 111.812 177.994 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.41 HG21 ' CH2' ' A' ' 23' ' ' TRP . 73.6 t -80.35 133.24 29.96 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.489 0 C-N-CA 120.094 -0.642 . . . . 0.0 111.736 178.727 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 26.8 m -111.19 -31.93 2.24 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.487 0 N-CA-C 112.73 0.641 . . . . 0.0 112.73 -179.621 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . 0.543 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -146.57 138.18 24.55 Favored 'General case' 0 C--N 1.324 -0.537 0 C-N-CA 119.809 -0.756 . . . . 0.0 111.625 179.721 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.446 ' HB ' HG22 ' A' ' 38' ' ' VAL . 96.1 mt -131.85 126.32 56.86 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.124 178.019 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 41.9 t30 -126.18 99.17 5.77 Favored 'General case' 0 C--N 1.314 -0.935 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 174.772 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.494 HG11 ' CD2' ' A' ' 128' ' ' PHE . 30.2 m -139.82 140.52 36.0 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.091 0 CA-C-N 115.85 -0.614 . . . . 0.0 111.78 -175.715 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 81.5 tt0 -144.2 145.58 32.16 Favored 'General case' 0 C--N 1.315 -0.924 0 CA-C-N 115.774 -0.648 . . . . 0.0 109.977 178.051 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . 0.558 ' HB2' ' OD1' ' A' ' 109' ' ' ASP . 21.6 p -152.71 152.93 32.27 Favored 'General case' 0 C--N 1.312 -1.039 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.559 178.143 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -130.53 15.46 5.49 Favored Glycine 0 CA--C 1.505 -0.538 0 N-CA-C 111.105 -0.798 . . . . 0.0 111.105 178.888 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . 0.558 ' OD1' ' HB2' ' A' ' 107' ' ' SER . 10.4 p-10 -96.23 22.82 7.23 Favored 'General case' 0 C--N 1.316 -0.859 0 C-N-CA 123.167 0.587 . . . . 0.0 110.5 -179.521 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . 0.516 ' HB2' ' O ' ' A' ' 109' ' ' ASP . 4.2 m-20 81.94 10.42 0.76 Allowed 'General case' 0 N--CA 1.486 1.366 0 C-N-CA 124.131 0.972 . . . . 0.0 112.282 -179.944 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . 0.542 ' HA3' ' ND2' ' A' ' 32' ' ' ASN . . . 88.12 12.59 65.45 Favored Glycine 0 N--CA 1.446 -0.661 0 C-N-CA 119.999 -1.096 . . . . 0.0 113.718 176.402 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 98.2 mt-30 -71.74 -38.74 70.39 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 117.046 0.423 . . . . 0.0 110.591 179.178 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 12.7 p -131.18 109.94 10.79 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.928 175.952 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 6.1 mp -92.07 113.55 25.85 Favored 'General case' 0 C--N 1.319 -0.722 0 N-CA-C 109.767 -0.456 . . . . 0.0 109.767 179.713 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 54.3 m-80 -108.3 145.54 34.24 Favored 'General case' 0 C--N 1.311 -1.079 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.836 -178.431 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 166.33 -139.29 5.68 Favored Glycine 0 N--CA 1.433 -1.508 0 C-N-CA 120.121 -1.038 . . . . 0.0 112.996 177.881 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 41.2 p -137.72 160.9 37.96 Favored 'General case' 0 C--N 1.31 -1.145 0 C-N-CA 123.429 0.692 . . . . 0.0 109.924 -177.75 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 19.8 ptm -149.29 161.49 41.94 Favored 'General case' 0 C--N 1.311 -1.087 0 CA-C-O 120.729 0.299 . . . . 0.0 110.698 179.302 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 119' ' ' THR . . . . . 0.543 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 23.5 m -135.39 133.15 38.39 Favored 'General case' 0 C--O 1.246 0.892 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.473 -179.813 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . 0.418 ' HB3' ' HG3' ' A' ' 98' ' ' GLN . 12.3 m-85 -99.81 158.81 15.53 Favored 'General case' 0 CA--C 1.515 -0.398 0 CA-C-N 115.946 -0.57 . . . . 0.0 109.798 176.618 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -61.07 122.66 15.54 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 120.608 0.242 . . . . 0.0 111.495 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 68.73 27.86 73.54 Favored Glycine 0 C--N 1.338 0.673 0 CA-C-N 115.969 -0.559 . . . . 0.0 113.243 179.847 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 80.4 tt0 -142.58 155.87 45.03 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 116.872 0.336 . . . . 0.0 110.389 -178.014 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -77.69 161.32 49.66 Favored Glycine 0 CA--C 1.521 0.441 0 C-N-CA 121.169 -0.539 . . . . 0.0 112.707 -178.907 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 23.1 Cg_exo -64.05 141.66 77.81 Favored 'Trans proline' 0 C--N 1.345 0.357 0 C-N-CA 122.802 2.334 . . . . 0.0 112.756 -179.564 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 35.9 pt -133.07 157.83 43.02 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.994 0 CA-C-N 115.402 -0.817 . . . . 0.0 109.763 178.321 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . 0.45 ' O ' ' HA ' ' A' ' 8' ' ' ASN . . . -70.32 139.5 30.78 Favored Glycine 0 C--O 1.235 0.209 0 C-N-CA 121.096 -0.574 . . . . 0.0 112.083 179.042 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . 0.494 ' CD2' HG11 ' A' ' 105' ' ' VAL . 73.0 t80 -119.05 133.53 55.75 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-O 120.887 0.375 . . . . 0.0 111.221 -177.109 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 62.7 tttm -136.19 105.42 6.0 Favored 'General case' 0 C--N 1.313 -0.986 0 CA-C-N 115.676 -0.693 . . . . 0.0 109.767 176.401 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -100.66 131.16 10.47 Favored Glycine 0 N--CA 1.439 -1.153 0 N-CA-C 110.696 -0.962 . . . . 0.0 110.696 178.917 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 28.5 m -122.24 130.53 53.26 Favored 'General case' 0 C--N 1.312 -1.039 0 N-CA-C 110.007 -0.368 . . . . 0.0 110.007 -179.139 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 132' ' ' LEU . . . . . 0.406 HD23 ' CZ ' ' A' ' 4' ' ' TYR . 3.3 tm? -67.11 135.21 53.25 Favored 'General case' 0 C--O 1.236 0.373 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.231 -178.022 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 26.6 m . . . . . 0 N--CA 1.435 -1.185 0 CA-C-O 118.18 -0.914 . . . . 0.0 109.569 -179.372 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.784 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . 0.43 HD11 HE21 ' A' ' 22' ' ' GLN . 2.7 tm? -147.14 123.2 10.77 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 -177.783 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . 0.427 ' CD1' ' HB ' ' A' ' 25' ' ' ILE . 59.2 m-85 -118.24 141.41 48.54 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 112.351 0.5 . . . . 0.0 112.351 -178.134 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 49.3 m-80 -88.68 139.07 30.85 Favored 'General case' 0 C--N 1.316 -0.883 0 N-CA-C 107.763 -1.199 . . . . 0.0 107.763 174.858 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.464 HG21 ' CD1' ' A' ' 23' ' ' TRP . 87.3 t -99.38 115.54 40.4 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.02 0 CA-C-O 121.146 0.498 . . . . 0.0 112.323 -175.0 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.494 ' HB2' ' HB3' ' A' ' 129' ' ' LYS . 42.4 mt-10 -113.99 119.53 37.52 Favored 'General case' 0 C--N 1.311 -1.088 0 CA-C-N 115.025 -0.989 . . . . 0.0 108.58 177.329 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 13.6 m120 -119.01 136.48 54.1 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 116.571 -0.286 . . . . 0.0 110.752 -177.504 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 58.9 tt0 -124.09 128.29 49.08 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-O 120.866 0.365 . . . . 0.0 110.839 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 14.6 p90 -141.49 148.02 38.78 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 116.153 -0.476 . . . . 0.0 109.993 177.043 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 100.89 2.1 55.08 Favored Glycine 0 N--CA 1.449 -0.47 0 C-N-CA 120.37 -0.919 . . . . 0.0 112.268 178.889 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 114.56 155.83 11.29 Favored Glycine 0 N--CA 1.441 -0.991 0 C-N-CA 120.903 -0.665 . . . . 0.0 112.442 179.543 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 7.6 t -59.1 -20.13 50.69 Favored 'General case' 0 CA--C 1.539 0.54 0 C-N-CA 122.746 0.418 . . . . 0.0 111.616 179.008 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 10.2 m -77.78 -10.01 59.32 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.765 0.317 . . . . 0.0 111.027 179.748 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -89.97 152.09 45.96 Favored Pre-proline 0 C--N 1.325 -0.494 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 179.467 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 78.9 Cg_endo -73.69 161.19 42.43 Favored 'Trans proline' 0 C--O 1.237 0.429 0 C-N-CA 122.625 2.217 . . . . 0.0 112.917 179.765 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 82.7 m95 -85.94 134.7 33.86 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 115.546 -0.752 . . . . 0.0 109.095 178.419 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 46.9 m-80 -113.54 141.68 46.87 Favored 'General case' 0 C--N 1.32 -0.701 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 -177.596 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.405 ' HA ' ' O ' ' A' ' 6' ' ' VAL . 9.2 pt-20 -116.53 122.48 44.81 Favored 'General case' 0 C--N 1.308 -1.221 0 CA-C-O 120.734 0.302 . . . . 0.0 110.455 -178.929 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -137.23 31.64 2.51 Favored Glycine 0 N--CA 1.444 -0.793 0 C-N-CA 119.814 -1.184 . . . . 0.0 113.133 -177.255 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 162.68 179.68 37.41 Favored Glycine 0 N--CA 1.447 -0.58 0 C-N-CA 119.745 -1.217 . . . . 0.0 113.015 179.767 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . 0.43 HE21 HD11 ' A' ' 3' ' ' LEU . 4.5 pt20 -136.99 137.03 39.02 Favored 'General case' 0 C--N 1.32 -0.714 0 N-CA-C 109.419 -0.586 . . . . 0.0 109.419 178.905 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . 0.464 ' CD1' HG21 ' A' ' 6' ' ' VAL . 38.7 m0 -109.31 151.62 26.34 Favored 'General case' 0 CA--C 1.502 -0.873 0 CA-C-O 120.866 0.365 . . . . 0.0 111.23 -178.513 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 79.1 tt0 -108.86 110.88 22.34 Favored 'General case' 0 N--CA 1.44 -0.926 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 177.689 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.427 ' HB ' ' CD1' ' A' ' 4' ' ' TYR . 89.8 mt -127.79 136.5 60.19 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.892 0 CA-C-N 115.395 -0.82 . . . . 0.0 109.803 -176.679 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 90.86 93.44 1.27 Allowed Glycine 0 N--CA 1.444 -0.795 0 C-N-CA 120.67 -0.776 . . . . 0.0 112.499 177.653 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 3.7 p -94.92 10.2 36.37 Favored 'General case' 0 C--N 1.311 -1.084 0 CA-C-O 121.432 0.634 . . . . 0.0 110.38 178.795 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 39.4 mmt180 -124.84 121.05 33.44 Favored 'General case' 0 N--CA 1.445 -0.682 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 -179.88 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 43.6 m -65.95 -38.85 89.67 Favored 'General case' 0 C--N 1.314 -0.948 0 N-CA-C 112.13 0.418 . . . . 0.0 112.13 -178.205 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 75.0 m-20 -75.05 -38.44 61.4 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 112.345 0.498 . . . . 0.0 112.345 -177.047 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . 0.465 ' NE2' ' HA ' ' A' ' 31' ' ' GLN . 9.7 mm-40 -114.49 117.65 31.57 Favored 'General case' 0 CA--C 1.5 -0.942 0 N-CA-C 113.708 1.003 . . . . 0.0 113.708 -176.854 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 4.1 t30 -96.13 160.76 14.27 Favored 'General case' 0 N--CA 1.438 -1.063 0 CA-C-N 114.923 -1.035 . . . . 0.0 108.992 177.017 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 62.5 t -94.06 131.51 40.76 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.491 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.182 -176.744 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 35.5 m -112.46 -11.08 11.96 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.655 0 N-CA-C 112.701 0.63 . . . . 0.0 112.701 178.31 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.649 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -152.52 144.94 24.05 Favored 'General case' 0 CA--C 1.508 -0.66 0 C-N-CA 120.015 -0.674 . . . . 0.0 111.59 177.882 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 91.8 mt -143.97 117.74 3.38 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.373 0 N-CA-C 109.618 -0.512 . . . . 0.0 109.618 -179.977 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . 0.526 ' HA ' ' O ' ' A' ' 103' ' ' ILE . 47.5 m-80 -133.63 112.27 11.3 Favored 'General case' 0 C--N 1.311 -1.078 0 N-CA-C 108.523 -0.918 . . . . 0.0 108.523 175.667 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.49 HG11 ' CD1' ' A' ' 61' ' ' PHE . 22.4 m -148.41 152.02 12.78 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 C-N-CA 120.92 -0.312 . . . . 0.0 111.655 -174.01 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 67.4 tt0 -136.13 142.47 44.24 Favored 'General case' 0 N--CA 1.443 -0.817 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 176.366 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 31.5 p -77.2 147.12 36.61 Favored 'General case' 0 C--N 1.314 -0.935 0 CA-C-O 121.033 0.444 . . . . 0.0 111.641 -177.912 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -94.78 -15.55 45.51 Favored Glycine 0 N--CA 1.451 -0.361 0 N-CA-C 110.512 -1.035 . . . . 0.0 110.512 175.512 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . 0.403 ' HB3' ' H ' ' A' ' 43' ' ' ASP . 55.0 m-20 -139.28 -154.69 0.54 Allowed 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 109.257 -0.645 . . . . 0.0 109.257 179.457 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . 0.403 ' H ' ' HB3' ' A' ' 42' ' ' ASP . 20.9 m-20 -73.25 38.25 0.09 Allowed 'General case' 0 N--CA 1.476 0.846 0 C-N-CA 122.893 0.477 . . . . 0.0 111.487 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 92.74 -6.7 77.22 Favored Glycine 0 C--O 1.217 -0.95 0 C-N-CA 121.173 -0.537 . . . . 0.0 112.66 179.848 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 59.3 mt-30 -63.0 -39.9 96.14 Favored 'General case' 0 C--N 1.326 -0.416 0 N-CA-C 112.137 0.421 . . . . 0.0 112.137 -178.364 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . 0.506 ' HA ' ' O ' ' A' ' 63' ' ' ALA . 5.2 t -128.18 115.4 18.32 Favored 'General case' 0 C--N 1.311 -1.065 0 CA-C-O 121.187 0.518 . . . . 0.0 110.801 177.812 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . 0.44 ' O ' ' HA ' ' A' ' 62' ' ' ARG . 79.5 mt -99.53 130.42 45.77 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.855 -0.612 . . . . 0.0 109.595 178.442 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 49.2 m-80 -130.11 143.17 50.64 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 116.488 -0.324 . . . . 0.0 110.469 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.431 ' HA3' ' HA ' ' A' ' 38' ' ' VAL . . . 171.08 -150.79 14.32 Favored Glycine 0 N--CA 1.44 -1.086 0 C-N-CA 120.084 -1.055 . . . . 0.0 113.262 179.978 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 25.1 m -125.99 131.48 52.23 Favored 'General case' 0 C--N 1.317 -0.838 0 C-N-CA 122.965 0.506 . . . . 0.0 110.19 -177.199 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' MET . . . . . 0.44 ' SD ' ' HH2' ' A' ' 90' ' ' TRP . 62.5 ttp -125.53 150.27 47.57 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 -179.834 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.649 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 27.7 m -126.98 130.74 50.64 Favored 'General case' 0 C--O 1.243 0.723 0 CA-C-O 120.735 0.302 . . . . 0.0 111.316 -178.81 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . 0.437 ' HB3' ' OE1' ' A' ' 31' ' ' GLN . 47.0 m-85 -90.61 162.2 15.08 Favored 'General case' 0 C--O 1.233 0.218 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.323 177.247 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -60.42 107.84 0.73 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.799 -0.637 . . . . 0.0 112.634 -178.072 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 88.33 -0.27 83.26 Favored Glycine 0 N--CA 1.454 -0.138 0 CA-C-N 115.796 -0.638 . . . . 0.0 112.854 178.05 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 73.2 mm-40 -108.21 179.22 4.27 Favored 'General case' 0 C--N 1.314 -0.937 0 CA-C-O 120.705 0.288 . . . . 0.0 110.6 -178.744 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -97.71 176.71 31.25 Favored Glycine 0 N--CA 1.439 -1.144 0 C-N-CA 120.678 -0.773 . . . . 0.0 111.452 178.512 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo -67.13 139.5 50.81 Favored 'Trans proline' 0 CA--C 1.535 0.539 0 C-N-CA 122.501 2.134 . . . . 0.0 112.277 179.507 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 48.3 pt -133.01 166.73 28.56 Favored 'Isoleucine or valine' 0 C--O 1.24 0.554 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.137 178.243 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -75.22 138.59 23.66 Favored Glycine 0 CA--C 1.521 0.464 0 C-N-CA 120.724 -0.751 . . . . 0.0 111.957 -179.541 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.49 ' CD1' HG11 ' A' ' 38' ' ' VAL . 50.2 t80 -124.52 129.84 51.35 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 120.519 0.2 . . . . 0.0 110.916 -178.982 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . 0.44 ' HA ' ' O ' ' A' ' 47' ' ' LEU . 62.7 ttp85 -140.67 134.65 30.69 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.22 176.048 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.506 ' O ' ' HA ' ' A' ' 46' ' ' THR . . . -135.08 142.86 46.38 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.567 -0.288 . . . . 0.0 111.304 179.794 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 49.6 m -122.05 131.48 54.01 Favored 'General case' 0 CA--C 1.546 0.803 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.695 -179.608 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . 0.543 HD11 ' O ' ' A' ' 68' ' ' ASN . 55.9 tp -71.03 126.19 28.91 Favored 'General case' 0 CA--C 1.535 0.391 0 N-CA-C 113.1 0.778 . . . . 0.0 113.1 -176.9 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.405 HD13 ' HA ' ' A' ' 66' ' ' LEU . 3.9 mm? -73.4 -35.19 65.84 Favored 'General case' 0 N--CA 1.473 0.692 0 CA-C-N 115.204 -0.907 . . . . 0.0 111.751 176.349 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 133.05 2.67 3.73 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 111.052 -0.819 . . . . 0.0 111.052 -175.828 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' ASN . . . . . 0.543 ' O ' HD11 ' A' ' 65' ' ' LEU . 31.5 p-10 -131.41 -150.67 0.43 Allowed 'General case' 0 C--N 1.31 -1.147 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.42 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 85.6 m-20 -90.09 4.21 51.01 Favored 'General case' 0 C--N 1.323 -0.545 0 C-N-CA 120.407 -0.517 . . . . 0.0 110.33 179.58 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 24.0 m -101.27 144.56 29.98 Favored 'General case' 0 N--CA 1.448 -0.572 0 CA-C-O 121.362 0.601 . . . . 0.0 111.232 -178.833 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.5 ' HB3' ' HB1' ' A' ' 63' ' ' ALA . 96.3 m-85 -124.33 145.54 49.36 Favored 'General case' 0 C--N 1.312 -1.042 0 CA-C-N 115.463 -0.789 . . . . 0.0 110.617 179.557 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . 0.414 ' O ' ' HA ' ' A' ' 63' ' ' ALA . 79.5 tt0 -86.24 112.82 21.73 Favored 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 107.371 -1.344 . . . . 0.0 107.371 174.565 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 75.4 t -97.77 129.68 47.58 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.103 0 CA-C-O 121.4 0.619 . . . . 0.0 112.064 -175.311 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 45.8 mt-10 -128.05 124.76 37.87 Favored 'General case' 0 N--CA 1.438 -1.049 0 CA-C-N 114.891 -1.05 . . . . 0.0 108.748 177.474 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 14.7 m120 -104.04 147.74 27.04 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-O 121.057 0.456 . . . . 0.0 111.286 -177.478 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' GLN . . . . . 0.539 ' HB2' ' CE3' ' A' ' 84' ' ' TRP . 61.6 tt0 -115.1 119.61 37.02 Favored 'General case' 0 C--N 1.31 -1.11 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.672 -179.68 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 14.9 p90 -138.81 152.85 48.22 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 116.478 -0.328 . . . . 0.0 110.458 177.806 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 147.04 -122.64 1.62 Allowed Glycine 0 N--CA 1.444 -0.825 0 N-CA-C 110.119 -1.192 . . . . 0.0 110.119 -177.295 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.523 ' O ' ' HB2' ' A' ' 80' ' ' ASP . . . -119.31 23.18 8.64 Favored Glycine 0 N--CA 1.444 -0.785 0 C-N-CA 120.291 -0.956 . . . . 0.0 111.115 178.228 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . 0.523 ' HB2' ' O ' ' A' ' 79' ' ' GLY . 12.8 m-20 92.24 -43.47 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.836 0 C-N-CA 124.96 1.304 . . . . 0.0 110.587 178.348 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 34.5 m -76.78 -2.46 33.26 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 121.312 0.577 . . . . 0.0 110.7 175.901 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -66.62 157.39 83.27 Favored Pre-proline 0 C--N 1.324 -0.519 0 CA-C-N 115.353 -0.84 . . . . 0.0 112.029 -178.447 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 75.6 Cg_endo -77.9 -172.86 1.6 Allowed 'Trans proline' 0 CA--C 1.537 0.644 0 C-N-CA 122.752 2.301 . . . . 0.0 112.453 179.102 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' TRP . . . . . 0.539 ' CE3' ' HB2' ' A' ' 76' ' ' GLN . 95.1 m95 -98.13 147.5 24.5 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.822 -178.564 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 94.4 m-70 -128.74 146.38 50.91 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.061 -0.518 . . . . 0.0 109.964 -179.662 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 28.8 p -65.21 136.56 56.78 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-O 121.04 0.448 . . . . 0.0 111.421 -178.735 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -108.27 -52.18 0.69 Allowed Glycine 0 N--CA 1.437 -1.269 0 C-N-CA 120.745 -0.74 . . . . 0.0 111.55 177.968 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 151.45 -166.72 30.74 Favored Glycine 0 CA--C 1.52 0.345 0 C-N-CA 120.918 -0.658 . . . . 0.0 112.045 -179.778 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 19.3 m120 -112.43 119.21 37.46 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 117.014 0.407 . . . . 0.0 110.195 -179.862 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' TRP . . . . . 0.44 ' HH2' ' SD ' ' A' ' 51' ' ' MET . 29.3 m0 -117.12 154.02 31.77 Favored 'General case' 0 N--CA 1.47 0.564 0 CA-C-N 116.467 -0.333 . . . . 0.0 111.123 -177.129 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 89.0 mt -108.6 119.19 57.73 Favored 'Isoleucine or valine' 0 C--O 1.242 0.707 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 176.991 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . 0.426 ' HB3' HG21 ' A' ' 100' ' ' VAL . 86.7 mt -132.05 83.3 2.07 Favored 'General case' 0 C--O 1.267 1.981 0 N-CA-C 113.127 0.788 . . . . 0.0 113.127 -174.602 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 164.16 116.58 0.37 Allowed Glycine 0 C--O 1.225 -0.439 0 CA-C-N 115.083 -0.962 . . . . 0.0 111.31 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 75.2 p -90.33 -9.36 48.05 Favored 'General case' 0 N--CA 1.463 0.191 0 CA-C-N 117.217 0.509 . . . . 0.0 111.502 -179.58 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -100.38 145.6 27.99 Favored 'General case' 0 N--CA 1.444 -0.763 0 CA-C-O 120.981 0.419 . . . . 0.0 110.872 179.606 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -68.74 -36.77 78.8 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 115.653 -0.703 . . . . 0.0 112.738 -173.463 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 30.5 p-10 -121.6 28.97 7.41 Favored 'General case' 0 C--N 1.313 -1.009 0 CA-C-O 120.715 0.293 . . . . 0.0 111.513 -176.627 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' GLN . . . . . 0.554 ' NE2' ' HB2' ' A' ' 123' ' ' GLU . 53.9 tt0 -157.2 124.44 5.21 Favored 'General case' 0 C--N 1.319 -0.725 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 -177.299 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 96.9 m-20 -113.52 177.66 4.56 Favored 'General case' 0 C--O 1.245 0.819 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.674 -175.355 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.461 HG11 ' CH2' ' A' ' 23' ' ' TRP . 21.2 m -80.41 141.06 15.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.75 -0.659 . . . . 0.0 112.193 -177.656 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 28.7 m -120.95 -26.45 2.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.726 176.425 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . 0.639 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -147.26 138.56 23.89 Favored 'General case' 0 C--N 1.324 -0.512 0 C-N-CA 120.872 -0.331 . . . . 0.0 110.65 177.404 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.526 ' O ' ' HA ' ' A' ' 37' ' ' ASN . 87.7 mt -132.23 127.03 56.9 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.029 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 178.822 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 9.6 t30 -128.04 91.06 3.2 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.13 178.414 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.501 HG11 ' HD2' ' A' ' 128' ' ' PHE . 22.3 m -145.06 153.26 14.33 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.615 0 N-CA-C 113.895 1.072 . . . . 0.0 113.895 -176.453 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 91.4 mt-10 -138.95 163.1 33.22 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 114.223 -1.353 . . . . 0.0 108.132 173.896 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 32.7 t -108.2 -51.02 2.95 Favored 'General case' 0 C--N 1.311 -1.1 0 CA-C-O 120.797 0.332 . . . . 0.0 110.893 -179.616 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 84.66 -14.79 45.35 Favored Glycine 0 N--CA 1.446 -0.66 0 N-CA-C 111.101 -0.8 . . . . 0.0 111.101 -176.768 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . 0.416 ' HB3' ' H ' ' A' ' 110' ' ' ASP . 54.2 m-20 -117.25 -151.29 0.48 Allowed 'General case' 0 N--CA 1.45 -0.432 0 C-N-CA 123.074 0.55 . . . . 0.0 109.999 -179.414 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . 0.416 ' H ' ' HB3' ' A' ' 109' ' ' ASP . 12.5 p-10 -88.55 16.43 6.59 Favored 'General case' 0 C--N 1.322 -0.618 0 C-N-CA 122.628 0.371 . . . . 0.0 111.18 -178.881 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 96.29 9.68 56.63 Favored Glycine 0 N--CA 1.444 -0.828 0 C-N-CA 120.086 -1.054 . . . . 0.0 113.045 -178.339 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' GLN . . . . . 0.475 ' HA ' HD12 ' A' ' 132' ' ' LEU . 28.1 tt0 -64.3 -45.4 88.12 Favored 'General case' 0 C--O 1.239 0.521 0 CA-C-O 120.833 0.349 . . . . 0.0 111.235 179.934 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . 0.489 ' HA ' ' O ' ' A' ' 130' ' ' GLY . 21.0 p -132.73 130.38 39.92 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.289 -179.831 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' LEU . . . . . 0.507 ' O ' ' HA ' ' A' ' 129' ' ' LYS . 4.3 mm? -105.86 130.5 53.81 Favored 'General case' 0 C--N 1.319 -0.739 0 N-CA-C 108.49 -0.93 . . . . 0.0 108.49 176.599 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 27.7 p30 -135.1 152.25 51.47 Favored 'General case' 0 C--N 1.316 -0.861 0 C-N-CA 120.191 -0.603 . . . . 0.0 112.274 -179.152 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 152.28 -129.38 2.77 Favored Glycine 0 N--CA 1.441 -1.025 0 CA-C-N 115.461 -0.79 . . . . 0.0 112.337 178.244 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 21.4 p -131.72 156.13 46.45 Favored 'General case' 0 C--N 1.316 -0.879 0 CA-C-O 121.012 0.434 . . . . 0.0 111.02 -178.163 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 118' ' ' MET . . . . . 0.521 ' SD ' ' HB2' ' A' ' 128' ' ' PHE . 19.5 ptm -140.64 149.74 42.67 Favored 'General case' 0 C--N 1.314 -0.963 0 CA-C-N 116.062 -0.517 . . . . 0.0 109.968 -178.6 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 119' ' ' THR . . . . . 0.639 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 23.3 m -131.23 129.46 41.64 Favored 'General case' 0 C--N 1.313 -1.016 0 CA-C-O 120.804 0.335 . . . . 0.0 111.019 -179.696 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . 0.466 ' HB3' ' HG2' ' A' ' 98' ' ' GLN . 45.0 m-85 -101.47 161.18 13.82 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.947 178.66 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -59.84 121.83 12.72 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.094 179.779 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 66.03 24.26 71.62 Favored Glycine 0 C--N 1.336 0.536 0 C-N-CA 121.117 -0.564 . . . . 0.0 112.336 -179.214 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . 0.554 ' HB2' ' NE2' ' A' ' 98' ' ' GLN . 32.5 tp10 -127.95 164.87 21.37 Favored 'General case' 0 C--N 1.318 -0.78 0 N-CA-C 109.622 -0.51 . . . . 0.0 109.622 -177.083 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -93.49 159.66 24.18 Favored Glycine 0 N--CA 1.443 -0.837 0 N-CA-C 110.803 -0.919 . . . . 0.0 110.803 177.318 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . 0.438 ' HA ' ' O ' ' A' ' 118' ' ' MET . 37.8 Cg_endo -66.2 136.15 42.91 Favored 'Trans proline' 0 CA--C 1.53 0.286 0 C-N-CA 122.16 1.907 . . . . 0.0 112.233 179.67 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 41.7 pt -132.65 166.4 29.41 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.004 178.929 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -70.02 134.73 25.53 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.912 -0.661 . . . . 0.0 112.197 -179.7 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . 0.521 ' HB2' ' SD ' ' A' ' 118' ' ' MET . 25.4 t80 -124.84 134.75 52.61 Favored 'General case' 0 CA--C 1.513 -0.443 0 CA-C-O 121.173 0.511 . . . . 0.0 111.443 -179.45 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 129' ' ' LYS . . . . . 0.507 ' HA ' ' O ' ' A' ' 114' ' ' LEU . 62.3 tttm -140.86 123.64 16.21 Favored 'General case' 0 N--CA 1.435 -1.196 0 CA-C-N 115.073 -0.967 . . . . 0.0 109.494 178.591 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . 0.489 ' O ' ' HA ' ' A' ' 113' ' ' THR . . . -117.32 131.61 9.51 Favored Glycine 0 N--CA 1.444 -0.809 0 N-CA-C 110.973 -0.851 . . . . 0.0 110.973 178.948 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 32.1 m -125.32 133.88 52.44 Favored 'General case' 0 C--N 1.314 -0.973 0 CA-C-N 117.015 0.408 . . . . 0.0 110.709 -177.249 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 132' ' ' LEU . . . . . 0.475 HD12 ' HA ' ' A' ' 112' ' ' GLN . 78.3 mt -62.37 135.14 57.31 Favored 'General case' 0 C--O 1.238 0.473 0 CA-C-O 120.741 0.305 . . . . 0.0 110.779 177.283 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 8.6 t . . . . . 0 C--O 1.249 1.051 0 CA-C-O 118.368 -0.825 . . . . 0.0 110.34 178.391 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.468 0.474 0 N-CA-C 110.028 -0.36 . . . . 0.0 110.028 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . 0.671 HD11 HE21 ' A' ' 22' ' ' GLN . 1.4 tm? -97.42 132.41 43.15 Favored 'General case' 0 C--N 1.316 -0.85 0 N-CA-C 109.584 -0.525 . . . . 0.0 109.584 -177.817 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . 0.525 ' N ' HD13 ' A' ' 3' ' ' LEU . 89.8 m-85 -122.91 147.74 46.24 Favored 'General case' 0 C--O 1.236 0.351 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.649 -177.96 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . 0.55 ' O ' ' HA2' ' A' ' 130' ' ' GLY . 18.7 m120 -94.73 134.5 37.26 Favored 'General case' 0 CA--C 1.506 -0.715 0 N-CA-C 106.34 -1.726 . . . . 0.0 106.34 174.792 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.402 HG21 ' CG ' ' A' ' 23' ' ' TRP . 59.3 t -118.2 126.84 75.28 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.891 0 C-N-CA 119.492 -0.883 . . . . 0.0 113.031 -175.443 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.547 ' HA ' ' HA ' ' A' ' 19' ' ' GLU . 98.4 mt-10 -115.06 139.72 49.64 Favored 'General case' 0 N--CA 1.439 -1.012 0 CA-C-N 114.477 -1.238 . . . . 0.0 108.792 176.326 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . 0.433 ' HB3' HD12 ' A' ' 126' ' ' ILE . 12.1 m120 -119.35 144.05 47.07 Favored 'General case' 0 C--N 1.313 -1.013 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.309 -177.045 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 60.4 tt0 -121.68 114.89 21.78 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 174.605 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 45.8 p90 -129.16 139.08 52.06 Favored 'General case' 0 C--N 1.317 -0.832 0 C-N-CA 121.028 -0.269 . . . . 0.0 110.913 -178.309 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 102.09 11.77 35.92 Favored Glycine 0 N--CA 1.444 -0.783 0 C-N-CA 120.363 -0.922 . . . . 0.0 112.582 178.616 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 99.7 167.37 29.66 Favored Glycine 0 N--CA 1.444 -0.816 0 C-N-CA 120.446 -0.883 . . . . 0.0 113.28 -179.43 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 15.6 m -56.2 -25.61 47.76 Favored 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 123.158 0.583 . . . . 0.0 112.227 179.474 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 14.1 p -61.23 -21.04 63.49 Favored 'General case' 0 CA--C 1.542 0.671 0 N-CA-C 112.25 0.463 . . . . 0.0 112.25 177.268 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -90.84 142.93 28.05 Favored Pre-proline 0 C--N 1.321 -0.66 0 CA-C-O 120.541 0.21 . . . . 0.0 110.733 179.7 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 95.3 Cg_endo -78.37 170.51 18.36 Favored 'Trans proline' 0 C--O 1.238 0.518 0 C-N-CA 122.803 2.335 . . . . 0.0 112.241 179.692 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 96.4 m95 -86.97 124.88 33.65 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.118 -0.492 . . . . 0.0 109.905 -179.77 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 47.8 m-80 -123.26 126.19 46.46 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.991 -178.87 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.547 ' HA ' ' HA ' ' A' ' 7' ' ' GLU . 15.3 pt-20 -68.94 133.51 48.29 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 109.65 -0.5 . . . . 0.0 109.65 177.631 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -134.31 22.78 3.72 Favored Glycine 0 N--CA 1.443 -0.858 0 C-N-CA 119.566 -1.302 . . . . 0.0 112.876 -179.308 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . 0.549 ' HA3' ' HB2' ' A' ' 94' ' ' SER . . . 145.07 -170.9 26.38 Favored Glycine 0 N--CA 1.449 -0.472 0 C-N-CA 120.17 -1.014 . . . . 0.0 113.293 177.352 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . 0.671 HE21 HD11 ' A' ' 3' ' ' LEU . 4.3 pt20 -131.73 136.05 47.3 Favored 'General case' 0 C--N 1.324 -0.514 0 C-N-CA 122.604 0.362 . . . . 0.0 110.634 -178.337 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . 0.469 ' CH2' HG21 ' A' ' 100' ' ' VAL . 26.2 m0 -110.76 165.88 11.47 Favored 'General case' 0 N--CA 1.469 0.491 0 CA-C-O 120.668 0.27 . . . . 0.0 110.482 179.01 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 40.1 tt0 -128.87 116.56 19.62 Favored 'General case' 0 C--N 1.32 -0.68 0 C-N-CA 120.46 -0.496 . . . . 0.0 110.166 175.827 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.49 ' HB ' ' CE1' ' A' ' 4' ' ' TYR . 98.7 mt -130.18 137.49 56.26 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.764 0 CA-C-N 115.5 -0.773 . . . . 0.0 110.196 -177.567 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 93.37 102.32 1.59 Allowed Glycine 0 N--CA 1.446 -0.683 0 C-N-CA 120.775 -0.726 . . . . 0.0 111.892 179.451 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 4.2 p -101.57 12.17 37.71 Favored 'General case' 0 C--N 1.312 -1.036 0 CA-C-O 121.01 0.433 . . . . 0.0 111.293 -178.832 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . 0.401 HH11 ' HD3' ' A' ' 28' ' ' ARG . 62.6 mtt-85 -130.64 130.32 43.79 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.053 -178.932 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 15.6 m -66.78 -36.64 82.87 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.094 0.473 . . . . 0.0 112.052 -179.145 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 64.8 m-20 -73.93 -43.24 58.96 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.965 -0.562 . . . . 0.0 112.387 -175.505 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 8.7 mm-40 -121.41 122.12 39.08 Favored 'General case' 0 CA--C 1.506 -0.727 0 N-CA-C 113.106 0.78 . . . . 0.0 113.106 -176.42 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . 0.418 ' ND2' ' HA3' ' A' ' 111' ' ' GLY . 62.3 t30 -104.39 172.72 6.64 Favored 'General case' 0 N--CA 1.442 -0.837 0 CA-C-N 114.893 -1.049 . . . . 0.0 109.499 178.201 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 59.0 t -106.86 133.68 50.73 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.164 0 N-CA-C 112.287 0.477 . . . . 0.0 112.287 -174.803 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 29.3 m -113.73 -18.0 7.9 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.609 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.947 178.01 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.706 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -144.99 145.27 31.44 Favored 'General case' 0 CA--C 1.513 -0.459 0 C-N-CA 119.968 -0.693 . . . . 0.0 111.464 178.928 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 86.8 mt -144.67 126.71 9.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 -178.916 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . 0.487 ' HA ' ' O ' ' A' ' 103' ' ' ILE . 31.3 m-80 -136.64 109.12 7.39 Favored 'General case' 0 C--N 1.312 -1.038 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 176.888 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.467 HG11 ' CD1' ' A' ' 61' ' ' PHE . 25.3 m -151.07 157.59 5.38 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 C-N-CA 120.917 -0.313 . . . . 0.0 111.165 -172.833 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -142.71 150.71 40.48 Favored 'General case' 0 N--CA 1.447 -0.596 0 CA-C-N 115.8 -0.636 . . . . 0.0 109.925 177.253 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . 0.447 ' OG ' ' HB ' ' A' ' 101' ' ' VAL . 35.1 p -79.97 153.59 28.8 Favored 'General case' 0 C--N 1.318 -0.79 0 N-CA-C 112.477 0.547 . . . . 0.0 112.477 -177.682 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -115.45 -68.31 0.44 Allowed Glycine 0 N--CA 1.434 -1.474 0 CA-C-N 115.114 -0.948 . . . . 0.0 110.848 175.151 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 22.5 m-20 -89.95 81.57 6.26 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 112.154 0.427 . . . . 0.0 112.154 -179.001 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 84.5 m-20 51.22 31.53 6.96 Favored 'General case' 0 N--CA 1.491 1.576 0 N-CA-C 113.424 0.898 . . . . 0.0 113.424 174.791 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 88.84 -14.58 59.87 Favored Glycine 0 C--O 1.223 -0.57 0 C-N-CA 120.116 -1.04 . . . . 0.0 113.139 179.229 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 61.3 mt-30 -70.11 -30.44 67.65 Favored 'General case' 0 CA--C 1.512 -0.503 0 CA-C-O 121.193 0.521 . . . . 0.0 110.749 178.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 31.9 m -119.37 130.61 55.42 Favored 'General case' 0 N--CA 1.434 -1.247 0 CA-C-N 115.476 -0.783 . . . . 0.0 108.9 -179.641 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 84.6 mt -124.81 133.96 52.93 Favored 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 108.892 -0.781 . . . . 0.0 108.892 -179.063 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 28.1 p30 -136.8 148.77 47.37 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-O 121.122 0.487 . . . . 0.0 111.146 178.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 164.28 -145.04 9.94 Favored Glycine 0 N--CA 1.445 -0.758 0 C-N-CA 120.66 -0.781 . . . . 0.0 112.16 177.68 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . 0.516 ' HA ' ' O ' ' A' ' 59' ' ' ILE . 19.6 p -129.56 141.81 50.89 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-O 120.904 0.383 . . . . 0.0 110.975 179.925 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 15.6 tmm? -131.92 149.01 52.56 Favored 'General case' 0 C--N 1.317 -0.839 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 179.291 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.706 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 61.7 m -124.56 126.15 45.35 Favored 'General case' 0 C--O 1.252 1.197 0 N-CA-C 112.266 0.469 . . . . 0.0 112.266 -176.61 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 59.8 m-85 -82.68 161.13 22.24 Favored 'General case' 0 C--O 1.236 0.353 0 CA-C-N 115.407 -0.815 . . . . 0.0 111.096 176.521 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -63.76 113.63 3.51 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.914 179.269 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 90.72 7.86 66.09 Favored Glycine 0 N--CA 1.443 -0.859 0 C-N-CA 120.877 -0.678 . . . . 0.0 112.62 179.556 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 81.2 mm-40 -126.72 -172.61 2.68 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.767 0.317 . . . . 0.0 111.447 179.479 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -111.92 -171.56 18.86 Favored Glycine 0 N--CA 1.443 -0.86 0 N-CA-C 111.409 -0.677 . . . . 0.0 111.409 178.615 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 96.1 Cg_endo -76.01 140.06 22.39 Favored 'Trans proline' 0 C--O 1.241 0.651 0 C-N-CA 122.488 2.126 . . . . 0.0 113.431 -178.853 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . 0.516 ' O ' ' HA ' ' A' ' 50' ' ' THR . 43.6 pt -132.17 173.12 15.24 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 CA-C-N 115.36 -0.836 . . . . 0.0 109.243 175.625 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -75.35 139.72 25.25 Favored Glycine 0 C--N 1.317 -0.502 0 N-CA-C 111.44 -0.664 . . . . 0.0 111.44 -177.725 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.467 ' CD1' HG11 ' A' ' 38' ' ' VAL . 49.2 t80 -128.34 128.43 44.55 Favored 'General case' 0 C--N 1.312 -1.049 0 CA-C-O 120.511 0.196 . . . . 0.0 110.964 -177.277 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 70.1 ttp85 -136.21 131.13 34.17 Favored 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 175.104 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.487 ' HB1' ' HB3' ' A' ' 71' ' ' TYR . . . -135.4 147.58 49.06 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-O 120.782 0.325 . . . . 0.0 111.3 -178.766 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 83.5 m -126.75 132.44 51.08 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.938 -0.573 . . . . 0.0 110.552 178.895 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 61.4 tp -71.97 123.87 23.68 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.093 0.473 . . . . 0.0 111.854 -178.255 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -66.58 -36.66 83.17 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.896 176.665 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 137.62 -6.69 3.57 Favored Glycine 0 CA--C 1.523 0.591 0 C-N-CA 120.298 -0.953 . . . . 0.0 113.011 -177.519 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 58.3 m-80 -144.14 61.35 1.35 Allowed 'General case' 0 N--CA 1.476 0.838 0 N-CA-C 111.879 0.325 . . . . 0.0 111.879 -178.95 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 90.6 m-20 59.65 5.73 0.73 Allowed 'General case' 0 N--CA 1.487 1.397 0 C-N-CA 123.169 0.587 . . . . 0.0 112.13 179.161 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 9.3 m -99.13 133.83 42.85 Favored 'General case' 0 N--CA 1.44 -0.965 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 179.193 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.487 ' HB3' ' HB1' ' A' ' 63' ' ' ALA . 65.6 m-85 -122.4 136.09 54.83 Favored 'General case' 0 C--N 1.307 -1.259 0 CA-C-O 120.83 0.348 . . . . 0.0 111.546 -178.373 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 43.1 tt0 -90.57 120.35 31.58 Favored 'General case' 0 C--N 1.316 -0.855 0 N-CA-C 107.743 -1.206 . . . . 0.0 107.743 174.785 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 77.5 t -104.85 133.29 49.44 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.201 0 N-CA-C 113.091 0.774 . . . . 0.0 113.091 -173.621 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.45 ' HG2' ' HA ' ' A' ' 86' ' ' SER . 49.7 mt-10 -127.58 126.21 41.69 Favored 'General case' 0 N--CA 1.445 -0.711 0 CA-C-N 114.482 -1.235 . . . . 0.0 108.103 174.631 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 94.7 m-20 -103.9 144.04 32.04 Favored 'General case' 0 C--O 1.241 0.622 0 CA-C-O 121.256 0.55 . . . . 0.0 111.689 -176.541 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' GLN . . . . . 0.57 ' HB2' ' CE3' ' A' ' 84' ' ' TRP . 55.6 tt0 -118.29 122.95 44.19 Favored 'General case' 0 C--N 1.309 -1.161 0 CA-C-N 115.449 -0.796 . . . . 0.0 109.482 -178.247 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 8.1 p90 -110.55 97.04 6.57 Favored 'General case' 0 C--N 1.311 -1.083 0 C-N-CA 119.378 -0.929 . . . . 0.0 110.994 176.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 156.86 -153.51 24.76 Favored Glycine 0 N--CA 1.433 -1.563 0 N-CA-C 108.339 -1.905 . . . . 0.0 108.339 -177.378 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -84.93 -148.99 10.32 Favored Glycine 0 N--CA 1.442 -0.908 0 C-N-CA 119.926 -1.13 . . . . 0.0 111.248 175.858 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 65.3 m-20 -88.77 -6.31 57.49 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 117.207 0.504 . . . . 0.0 110.894 -178.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 24.1 t -98.13 -4.8 34.94 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.152 -178.002 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -76.49 149.91 81.78 Favored Pre-proline 0 C--N 1.323 -0.56 0 CA-C-N 116.496 -0.32 . . . . 0.0 110.868 -178.399 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -68.23 158.4 57.66 Favored 'Trans proline' 0 C--O 1.238 0.479 0 C-N-CA 122.351 2.034 . . . . 0.0 111.793 178.491 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' TRP . . . . . 0.57 ' CE3' ' HB2' ' A' ' 76' ' ' GLN . 96.0 m95 -94.8 138.69 32.28 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.337 -178.608 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 74.7 m-70 -119.16 146.62 45.0 Favored 'General case' 0 C--N 1.32 -0.712 0 N-CA-C 109.549 -0.538 . . . . 0.0 109.549 179.845 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . 0.45 ' HA ' ' HG2' ' A' ' 74' ' ' GLU . 10.8 p -71.08 139.99 50.55 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 121.192 0.52 . . . . 0.0 112.229 -176.756 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -115.41 -45.69 0.61 Allowed Glycine 0 N--CA 1.44 -1.099 0 C-N-CA 120.993 -0.622 . . . . 0.0 112.342 178.718 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 147.65 -162.28 28.67 Favored Glycine 0 C--O 1.225 -0.411 0 C-N-CA 120.279 -0.962 . . . . 0.0 112.655 179.445 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 17.9 m120 -115.11 124.55 51.83 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.842 0.321 . . . . 0.0 110.497 179.849 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 34.2 m0 -118.89 153.59 34.31 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.614 -178.581 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 46.9 mm -106.76 114.33 45.61 Favored 'Isoleucine or valine' 0 C--O 1.244 0.776 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 178.388 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 78.5 mt -128.07 77.72 1.78 Allowed 'General case' 0 C--O 1.256 1.445 0 CA-C-O 121.539 0.685 . . . . 0.0 111.559 -177.007 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 166.23 93.79 0.09 OUTLIER Glycine 0 N--CA 1.446 -0.689 0 CA-C-N 115.762 -0.654 . . . . 0.0 111.695 -179.649 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . 0.549 ' HB2' ' HA3' ' A' ' 21' ' ' GLY . 43.8 p -92.28 -12.42 32.57 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-O 120.838 0.351 . . . . 0.0 111.816 -178.516 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 91.6 mtt180 -88.69 15.84 7.6 Favored 'General case' 0 C--N 1.317 -0.821 0 N-CA-C 114.141 1.163 . . . . 0.0 114.141 -176.339 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 77.9 tt0 69.44 -81.67 0.03 OUTLIER 'General case' 0 N--CA 1.472 0.671 0 N-CA-C 113.298 0.851 . . . . 0.0 113.298 172.86 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 61.6 m-80 -92.73 24.19 3.72 Favored 'General case' 0 N--CA 1.473 0.681 0 CA-C-O 121.006 0.432 . . . . 0.0 110.995 -176.429 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' GLN . . . . . 0.414 ' HG2' ' HB3' ' A' ' 120' ' ' TYR . 54.8 tt0 -145.51 116.3 7.73 Favored 'General case' 0 C--N 1.312 -1.022 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 -177.298 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' ASN . . . . . 0.442 ' HB3' ' OH ' ' A' ' 71' ' ' TYR . 50.3 m-80 -89.23 158.93 17.68 Favored 'General case' 0 C--O 1.248 0.983 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.731 -177.512 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.469 HG21 ' CH2' ' A' ' 23' ' ' TRP . 98.0 t -80.57 130.04 36.56 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.206 0 C-N-CA 120.536 -0.466 . . . . 0.0 110.724 177.892 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.447 ' HB ' ' OG ' ' A' ' 40' ' ' SER . 34.8 m -110.27 -17.15 8.5 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.59 0 N-CA-C 112.439 0.533 . . . . 0.0 112.439 -178.686 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . 0.713 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -155.57 145.11 21.12 Favored 'General case' 0 CA--C 1.509 -0.61 0 C-N-CA 120.16 -0.616 . . . . 0.0 111.261 176.9 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.487 ' O ' ' HA ' ' A' ' 37' ' ' ASN . 83.0 mt -135.19 125.26 43.88 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 N-CA-C 110.102 -0.333 . . . . 0.0 110.102 179.457 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . 0.466 ' HB3' ' OG1' ' A' ' 117' ' ' THR . 7.5 t30 -127.8 94.18 3.88 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.872 -0.604 . . . . 0.0 109.829 175.91 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 30.0 m -137.86 138.67 43.8 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.661 0 N-CA-C 113.119 0.785 . . . . 0.0 113.119 -176.343 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -142.71 96.85 3.0 Favored 'General case' 0 CA--C 1.543 0.686 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.781 176.847 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . 0.466 ' HB2' ' H ' ' A' ' 115' ' ' ASN . 58.9 m -167.14 166.15 15.16 Favored 'General case' 0 N--CA 1.484 1.264 0 CA-C-N 115.204 -0.907 . . . . 0.0 113.38 -177.963 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 107.07 127.55 5.79 Favored Glycine 0 N--CA 1.427 -1.965 0 C-N-CA 120.488 -0.863 . . . . 0.0 112.85 175.844 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 7.3 m-20 -77.93 -48.63 15.88 Favored 'General case' 0 C--N 1.317 -0.817 0 N-CA-C 107.063 -1.458 . . . . 0.0 107.063 176.247 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 -125.63 23.3 7.43 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 113.941 -1.481 . . . . 0.0 108.998 177.708 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . 0.418 ' HA3' ' ND2' ' A' ' 32' ' ' ASN . . . 81.83 17.56 69.96 Favored Glycine 0 C--O 1.22 -0.723 0 C-N-CA 120.457 -0.878 . . . . 0.0 111.823 -175.818 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' GLN . . . . . 0.477 ' HA ' ' CD1' ' A' ' 132' ' ' LEU . 98.4 mt-30 -65.59 -43.61 89.18 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.742 0.306 . . . . 0.0 111.656 -179.17 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 34.0 p -131.77 149.51 52.45 Favored 'General case' 0 N--CA 1.441 -0.876 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.4 179.546 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' LEU . . . . . 0.424 ' HA ' ' HB2' ' A' ' 107' ' ' SER . 97.5 mt -128.41 131.17 48.48 Favored 'General case' 0 C--N 1.316 -0.881 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.012 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . 0.466 ' H ' ' HB2' ' A' ' 107' ' ' SER . 54.5 m-80 -136.16 150.29 48.99 Favored 'General case' 0 C--O 1.245 0.841 0 CA-C-O 120.792 0.33 . . . . 0.0 110.667 -178.802 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 157.51 -128.54 2.15 Favored Glycine 0 N--CA 1.442 -0.935 0 CA-C-N 115.75 -0.659 . . . . 0.0 112.049 179.042 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . 0.466 ' OG1' ' HB3' ' A' ' 104' ' ' ASN . 25.1 p -136.2 156.43 48.69 Favored 'General case' 0 C--N 1.312 -1.03 0 CA-C-O 121.03 0.443 . . . . 0.0 110.875 179.91 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 118' ' ' MET . . . . . 0.583 ' SD ' ' HE1' ' A' ' 120' ' ' TYR . 3.4 ptp -137.66 145.2 42.37 Favored 'General case' 0 C--N 1.314 -0.969 0 CA-C-N 115.94 -0.573 . . . . 0.0 109.966 -179.278 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 119' ' ' THR . . . . . 0.713 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 20.8 m -125.5 127.12 45.96 Favored 'General case' 0 C--O 1.247 0.936 0 N-CA-C 110.125 -0.324 . . . . 0.0 110.125 178.557 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . 0.583 ' HE1' ' SD ' ' A' ' 118' ' ' MET . 24.3 m-85 -107.15 155.04 20.31 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.987 179.04 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -58.44 127.87 34.31 Favored 'General case' 0 C--O 1.236 0.391 0 CA-C-O 121.131 0.491 . . . . 0.0 112.121 -178.649 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 81.64 7.71 87.79 Favored Glycine 0 C--O 1.227 -0.338 0 CA-C-N 115.618 -0.719 . . . . 0.0 113.406 177.863 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 85.9 tt0 -145.05 165.2 28.91 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 117.091 0.446 . . . . 0.0 110.493 -178.599 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -87.23 176.43 46.92 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.953 -0.642 . . . . 0.0 112.784 -178.448 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . 0.511 ' HA ' ' O ' ' A' ' 118' ' ' MET . 71.6 Cg_endo -72.48 140.01 32.46 Favored 'Trans proline' 0 CA--C 1.534 0.523 0 C-N-CA 122.817 2.345 . . . . 0.0 112.923 -179.685 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 126' ' ' ILE . . . . . 0.433 HD12 ' HB3' ' A' ' 8' ' ' ASN . 43.6 pt -131.15 170.42 19.77 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.013 178.809 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -68.33 133.56 28.36 Favored Glycine 0 C--O 1.242 0.614 0 C-N-CA 120.929 -0.653 . . . . 0.0 112.987 -178.401 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 45.1 t80 -111.74 130.59 55.74 Favored 'General case' 0 C--O 1.236 0.378 0 C-N-CA 123.287 0.635 . . . . 0.0 110.602 -179.502 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 62.1 tttm -140.84 115.45 9.52 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 177.385 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . 0.55 ' HA2' ' O ' ' A' ' 5' ' ' ASN . . . -132.13 149.38 19.4 Favored Glycine 0 N--CA 1.448 -0.53 0 C-N-CA 120.501 -0.857 . . . . 0.0 113.266 -178.132 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 80.8 m -141.29 143.09 33.88 Favored 'General case' 0 C--N 1.323 -0.564 0 C-N-CA 122.307 0.243 . . . . 0.0 111.079 179.256 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 132' ' ' LEU . . . . . 0.477 ' CD1' ' HA ' ' A' ' 112' ' ' GLN . 82.4 mt -53.9 136.33 40.94 Favored 'General case' 0 N--CA 1.475 0.793 0 O-C-N 123.548 0.53 . . . . 0.0 110.764 176.112 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 25.1 m . . . . . 0 C--O 1.255 1.368 0 CA-C-O 118.421 -0.799 . . . . 0.0 110.85 -179.034 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 0.622 0 N-CA-C 110.064 -0.347 . . . . 0.0 110.064 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . 0.433 HD12 ' HB ' ' A' ' 133' ' ' THR . 2.8 tm? -88.16 129.28 35.37 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 121.084 0.468 . . . . 0.0 110.093 -178.714 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . 0.501 ' CE1' ' HB ' ' A' ' 25' ' ' ILE . 35.2 m-85 -117.62 141.92 47.81 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.783 -0.644 . . . . 0.0 111.813 179.901 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 -98.21 139.61 33.74 Favored 'General case' 0 C--N 1.312 -1.037 0 N-CA-C 107.794 -1.188 . . . . 0.0 107.794 173.328 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 69.0 t -114.39 127.87 71.67 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.224 0 CA-C-O 121.222 0.534 . . . . 0.0 112.211 -174.059 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -122.55 138.76 54.47 Favored 'General case' 0 C--N 1.317 -0.84 0 N-CA-C 107.826 -1.176 . . . . 0.0 107.826 175.083 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 23.5 m120 -128.89 148.53 50.92 Favored 'General case' 0 C--N 1.313 -0.992 0 N-CA-C 112.454 0.538 . . . . 0.0 112.454 -177.319 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 51.0 tt0 -126.36 122.31 35.03 Favored 'General case' 0 C--N 1.32 -0.71 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 176.967 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 41.5 p90 -145.6 13.64 1.36 Allowed 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 114.033 1.123 . . . . 0.0 114.033 -176.376 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -110.36 21.27 24.42 Favored Glycine 0 N--CA 1.446 -0.671 0 C-N-CA 118.491 -1.814 . . . . 0.0 112.031 -177.302 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 107.72 175.9 22.36 Favored Glycine 0 N--CA 1.448 -0.56 0 C-N-CA 120.539 -0.839 . . . . 0.0 113.098 179.083 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 12.4 m -64.36 150.91 45.32 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 115.365 -0.417 . . . . 0.0 111.5 177.831 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 37.6 m 64.89 21.23 12.3 Favored 'General case' 0 N--CA 1.472 0.63 0 CA-C-N 115.706 -0.679 . . . . 0.0 111.509 -178.705 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.432 ' HA ' ' HD3' ' A' ' 16' ' ' PRO . . . -96.61 146.27 31.02 Favored Pre-proline 0 N--CA 1.448 -0.539 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.595 179.803 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.432 ' HD3' ' HA ' ' A' ' 15' ' ' ALA . 11.2 Cg_exo -71.86 159.23 51.07 Favored 'Trans proline' 0 N--CA 1.455 -0.741 0 C-N-CA 122.764 2.309 . . . . 0.0 112.302 178.502 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 80.6 m95 -90.21 131.4 36.06 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 115.658 -0.701 . . . . 0.0 109.285 178.852 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 38.8 m-80 -109.35 142.67 39.94 Favored 'General case' 0 C--N 1.308 -1.216 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 -178.854 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -69.04 125.59 27.14 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-O 121.612 0.72 . . . . 0.0 111.623 -178.299 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.614 ' O ' ' HB3' ' A' ' 94' ' ' SER . . . -100.33 -17.66 23.8 Favored Glycine 0 N--CA 1.447 -0.567 0 CA-C-N 114.661 -1.154 . . . . 0.0 113.851 -176.515 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 137.14 -151.18 20.94 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.241 -0.981 . . . . 0.0 111.887 -177.566 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 4.6 pt20 -138.62 132.83 31.6 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 120.852 0.358 . . . . 0.0 111.264 -179.912 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . 0.417 ' CZ2' HG21 ' A' ' 100' ' ' VAL . 46.0 m0 -115.34 161.65 18.22 Favored 'General case' 0 CA--C 1.507 -0.691 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.372 178.548 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 81.7 tt0 -120.07 118.96 31.97 Favored 'General case' 0 C--N 1.314 -0.973 0 C-N-CA 119.986 -0.686 . . . . 0.0 109.649 174.313 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.501 ' HB ' ' CE1' ' A' ' 4' ' ' TYR . 97.8 mt -134.45 146.09 31.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 CA-C-N 114.99 -1.005 . . . . 0.0 109.457 -176.225 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 83.71 73.54 1.25 Allowed Glycine 0 CA--C 1.505 -0.56 0 C-N-CA 120.364 -0.922 . . . . 0.0 111.605 178.955 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 16.1 m -62.21 -43.31 99.11 Favored 'General case' 0 C--N 1.314 -0.961 0 CA-C-N 115.175 -0.513 . . . . 0.0 110.77 179.55 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 84.8 mtt85 -77.64 129.78 36.01 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.903 -0.589 . . . . 0.0 111.337 -179.709 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 15.6 m -66.7 -32.77 74.29 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.607 -0.724 . . . . 0.0 111.69 179.85 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 28.6 m-20 -97.62 16.78 19.45 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.524 -176.458 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 7.2 mm-40 -155.21 102.32 2.29 Favored 'General case' 0 CA--C 1.505 -0.781 0 CA-C-O 120.909 0.385 . . . . 0.0 111.646 -174.656 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 63.7 t30 -102.34 157.86 16.61 Favored 'General case' 0 N--CA 1.443 -0.814 0 CA-C-N 115.877 -0.602 . . . . 0.0 109.945 178.305 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 57.0 t -96.22 133.11 38.68 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.66 0 CA-C-N 115.255 -0.884 . . . . 0.0 110.841 -175.166 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 30.1 m -110.13 -17.22 8.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 N-CA-C 111.78 0.289 . . . . 0.0 111.78 179.787 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.548 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -149.89 143.48 25.31 Favored 'General case' 0 C--O 1.236 0.358 0 C-N-CA 120.628 -0.429 . . . . 0.0 111.195 178.532 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.446 ' HB ' HG22 ' A' ' 105' ' ' VAL . 94.6 mt -140.72 123.32 15.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.036 -179.016 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -126.74 106.47 9.39 Favored 'General case' 0 C--N 1.319 -0.723 0 N-CA-C 108.672 -0.862 . . . . 0.0 108.672 173.896 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 23.9 m -147.67 151.1 13.9 Favored 'Isoleucine or valine' 0 C--O 1.237 0.423 0 C-N-CA 120.748 -0.381 . . . . 0.0 111.379 -174.881 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 78.7 tt0 -147.14 150.46 35.02 Favored 'General case' 0 C--N 1.319 -0.735 0 N-CA-C 108.609 -0.886 . . . . 0.0 108.609 175.612 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . 0.456 ' HB2' HD23 ' A' ' 47' ' ' LEU . 8.4 t -90.91 143.46 26.69 Favored 'General case' 0 C--N 1.312 -1.027 0 CA-C-O 120.857 0.36 . . . . 0.0 111.436 -177.759 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -87.09 -15.49 62.59 Favored Glycine 0 CA--C 1.52 0.347 0 C-N-CA 120.51 -0.852 . . . . 0.0 111.132 175.892 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . 0.405 ' HB3' ' H ' ' A' ' 43' ' ' ASP . 15.7 m-20 -127.46 -156.01 0.73 Allowed 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.157 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . 0.405 ' H ' ' HB3' ' A' ' 42' ' ' ASP . 43.4 m-20 -76.72 38.72 0.2 Allowed 'General case' 0 N--CA 1.472 0.663 0 C-N-CA 122.576 0.351 . . . . 0.0 111.625 -179.316 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.524 ' O ' ' HE2' ' A' ' 71' ' ' TYR . . . 96.04 -8.39 67.61 Favored Glycine 0 C--O 1.214 -1.095 0 C-N-CA 120.917 -0.658 . . . . 0.0 111.856 -179.527 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 56.2 mt-30 -64.06 -39.66 94.56 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 113.14 0.793 . . . . 0.0 113.14 -176.711 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 4.0 t -126.81 110.56 13.22 Favored 'General case' 0 C--N 1.313 -1.011 0 C-N-CA 120.077 -0.649 . . . . 0.0 110.985 178.57 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . 0.456 HD23 ' HB2' ' A' ' 40' ' ' SER . 74.0 mt -93.76 125.52 38.42 Favored 'General case' 0 N--CA 1.443 -0.78 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 176.079 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 13.4 m120 -125.08 141.21 52.26 Favored 'General case' 0 C--N 1.3 -1.547 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 -178.902 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 170.64 -152.99 20.1 Favored Glycine 0 N--CA 1.444 -0.813 0 C-N-CA 119.05 -1.548 . . . . 0.0 113.987 179.333 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 38.6 m -128.47 133.15 48.44 Favored 'General case' 0 N--CA 1.443 -0.808 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 -177.235 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 46.4 ttp -122.61 144.78 48.9 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 -178.344 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.548 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 32.5 m -125.06 126.69 45.77 Favored 'General case' 0 C--O 1.247 0.958 0 CA-C-O 120.73 0.3 . . . . 0.0 111.368 -179.11 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 62.1 m-85 -90.45 162.73 14.94 Favored 'General case' 0 C--O 1.234 0.248 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.95 177.947 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -66.49 131.44 46.05 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.375 178.734 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 74.0 2.08 61.02 Favored Glycine 0 CA--C 1.519 0.34 0 CA-C-N 115.981 -0.554 . . . . 0.0 113.21 179.209 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 75.2 mm-40 -121.74 -179.03 3.98 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 120.826 0.345 . . . . 0.0 110.764 -178.424 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -105.71 173.76 20.39 Favored Glycine 0 N--CA 1.442 -0.927 0 C-N-CA 121.029 -0.605 . . . . 0.0 111.811 179.215 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 26.3 Cg_exo -63.32 136.32 54.77 Favored 'Trans proline' 0 C--O 1.242 0.712 0 C-N-CA 122.892 2.394 . . . . 0.0 112.375 179.811 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . 0.512 ' HB ' ' O ' ' A' ' 76' ' ' GLN . 50.9 pt -130.79 167.2 26.47 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.577 -179.671 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -73.1 135.14 20.89 Favored Glycine 0 C--O 1.249 1.068 0 C-N-CA 120.842 -0.694 . . . . 0.0 112.122 179.776 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 58.1 t80 -127.51 126.9 43.07 Favored 'General case' 0 C--O 1.243 0.717 0 C-N-CA 122.647 0.379 . . . . 0.0 110.795 -177.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 62.1 ttp180 -135.82 131.85 35.91 Favored 'General case' 0 N--CA 1.463 0.205 0 N-CA-C 110.016 -0.364 . . . . 0.0 110.016 176.681 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.453 ' HB2' HG22 ' A' ' 73' ' ' VAL . . . -135.21 141.11 45.75 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.649 0.262 . . . . 0.0 111.703 -179.85 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 40.9 m -121.7 132.05 54.43 Favored 'General case' 0 CA--C 1.544 0.719 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.538 179.554 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 58.8 tp -71.56 114.27 9.47 Favored 'General case' 0 CA--C 1.522 -0.13 0 CA-C-O 121.202 0.525 . . . . 0.0 112.345 -178.412 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 68.1 mt -80.87 -31.38 35.33 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.553 -0.749 . . . . 0.0 109.803 175.566 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 123.72 164.73 12.09 Favored Glycine 0 N--CA 1.445 -0.711 0 N-CA-C 110.362 -1.095 . . . . 0.0 110.362 -177.6 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 94.0 m-20 61.11 36.03 18.43 Favored 'General case' 0 N--CA 1.477 0.896 0 CA-C-N 117.343 0.571 . . . . 0.0 110.917 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 95.0 m-20 63.78 18.88 11.43 Favored 'General case' 0 N--CA 1.477 0.878 0 CA-C-N 115.389 -0.823 . . . . 0.0 111.864 179.235 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 31.6 m -108.56 131.91 54.38 Favored 'General case' 0 N--CA 1.448 -0.565 0 CA-C-O 121.123 0.487 . . . . 0.0 110.926 -179.243 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.524 ' HE2' ' O ' ' A' ' 44' ' ' GLY . 95.6 m-85 -119.13 152.14 37.06 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.212 179.911 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 58.1 tt0 -108.0 127.57 53.88 Favored 'General case' 0 C--N 1.314 -0.946 0 N-CA-C 107.997 -1.112 . . . . 0.0 107.997 174.482 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.453 HG22 ' HB2' ' A' ' 63' ' ' ALA . 56.5 t -111.64 137.56 43.77 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.855 0 N-CA-C 113.77 1.026 . . . . 0.0 113.77 -171.147 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 50.1 mt-10 -123.98 149.49 45.93 Favored 'General case' 0 C--O 1.245 0.86 0 CA-C-N 114.832 -1.076 . . . . 0.0 108.303 175.95 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 14.3 m120 -131.65 156.54 45.66 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-O 120.561 0.22 . . . . 0.0 110.47 -175.98 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' GLN . . . . . 0.512 ' O ' ' HB ' ' A' ' 59' ' ' ILE . 1.7 pt20 -147.18 144.07 28.68 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.402 176.315 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 31.9 p90 -147.24 168.25 22.17 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.16 -177.467 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 79.54 70.35 1.33 Allowed Glycine 0 N--CA 1.441 -0.987 0 C-N-CA 121.078 -0.582 . . . . 0.0 114.109 176.316 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.522 ' O ' ' HB3' ' A' ' 80' ' ' ASP . . . 106.22 -27.32 17.55 Favored Glycine 0 N--CA 1.445 -0.702 0 C-N-CA 120.296 -0.955 . . . . 0.0 113.827 175.733 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . 0.522 ' HB3' ' O ' ' A' ' 79' ' ' GLY . 19.3 t70 81.28 -28.63 0.12 Allowed 'General case' 0 N--CA 1.493 1.703 0 CA-C-O 121.328 0.585 . . . . 0.0 110.736 178.356 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 11.6 p -85.08 16.73 3.3 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-O 121.247 0.546 . . . . 0.0 110.629 174.221 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -89.33 165.45 25.97 Favored Pre-proline 0 CA--C 1.538 0.495 0 CA-C-N 115.599 -0.728 . . . . 0.0 111.073 -178.12 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 10.6 Cg_exo -70.47 166.88 27.02 Favored 'Trans proline' 0 C--N 1.357 0.979 0 C-N-CA 122.851 2.367 . . . . 0.0 111.746 178.481 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' TRP . . . . . . . . . . . . . 90.8 m95 -95.59 137.45 34.63 Favored 'General case' 0 N--CA 1.445 -0.691 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 -178.489 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 85.4 m-70 -119.28 145.54 46.02 Favored 'General case' 0 C--N 1.313 -0.98 0 N-CA-C 109.669 -0.493 . . . . 0.0 109.669 -177.26 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 7.1 m -61.78 133.92 56.1 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 110.303 -0.258 . . . . 0.0 110.303 -179.239 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -108.77 -50.67 0.73 Allowed Glycine 0 N--CA 1.443 -0.856 0 C-N-CA 120.137 -1.03 . . . . 0.0 111.987 178.66 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 152.65 -167.7 31.55 Favored Glycine 0 C--O 1.221 -0.683 0 C-N-CA 120.699 -0.762 . . . . 0.0 111.865 179.55 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 19.8 m120 -103.66 145.5 29.97 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 116.901 0.35 . . . . 0.0 110.722 179.824 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' TRP . . . . . 0.49 ' CH2' HG23 ' A' ' 25' ' ' ILE . 12.4 m0 -132.88 142.54 48.98 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 -178.376 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 86.6 mt -109.25 116.41 52.02 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.962 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 177.958 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . 0.422 ' HB2' ' CE1' ' A' ' 71' ' ' TYR . 71.8 mt -134.81 75.89 1.6 Allowed 'General case' 0 C--O 1.263 1.789 0 CA-C-O 121.449 0.643 . . . . 0.0 111.668 -175.967 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . 0.423 ' O ' ' HB2' ' A' ' 94' ' ' SER . . . -148.93 -69.51 0.01 OUTLIER Glycine 0 N--CA 1.445 -0.763 0 C-N-CA 120.289 -0.958 . . . . 0.0 112.785 -179.931 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . 0.614 ' HB3' ' O ' ' A' ' 20' ' ' GLY . 17.3 m 73.44 -34.95 0.3 Allowed 'General case' 0 N--CA 1.479 1.009 0 C-N-CA 123.478 0.711 . . . . 0.0 112.563 -178.593 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 82.6 mtp180 -101.02 153.95 19.11 Favored 'General case' 0 N--CA 1.439 -0.984 0 CA-C-O 120.868 0.366 . . . . 0.0 110.942 -179.179 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 44.5 tt0 -62.03 -54.37 42.4 Favored 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 113.51 0.93 . . . . 0.0 113.51 -172.87 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 47.4 m-80 -122.29 37.1 4.46 Favored 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 111.869 0.322 . . . . 0.0 111.869 -176.475 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' GLN . . . . . 0.567 HE21 ' CB ' ' A' ' 120' ' ' TYR . 39.6 tt0 -148.04 116.12 6.48 Favored 'General case' 0 C--N 1.316 -0.867 0 C-N-CA 120.543 -0.463 . . . . 0.0 110.354 -178.044 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 52.7 m-80 -96.69 164.85 12.41 Favored 'General case' 0 C--O 1.247 0.946 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.716 -175.427 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.417 HG21 ' CZ2' ' A' ' 23' ' ' TRP . 86.7 t -87.36 137.11 21.58 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.735 0 CA-C-N 115.897 -0.592 . . . . 0.0 111.198 177.361 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.475 HG11 ' HA ' ' A' ' 121' ' ' ALA . 34.3 m -119.87 -29.59 1.78 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.743 0 N-CA-C 112.971 0.73 . . . . 0.0 112.971 -178.426 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . 0.629 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -141.26 138.06 32.97 Favored 'General case' 0 C--N 1.323 -0.557 0 C-N-CA 120.048 -0.661 . . . . 0.0 111.445 179.537 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . . . . . . . . . 93.3 mt -134.03 128.02 52.42 Favored 'Isoleucine or valine' 0 C--O 1.244 0.78 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.836 179.154 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 43.5 t30 -129.21 99.76 5.35 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 109.033 -0.728 . . . . 0.0 109.033 174.483 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.446 HG22 ' HB ' ' A' ' 36' ' ' ILE . 25.2 m -141.99 148.31 20.68 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 N-CA-C 112.572 0.582 . . . . 0.0 112.572 -176.416 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 37.9 tt0 -149.92 154.98 39.21 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 115.156 -0.929 . . . . 0.0 108.88 175.469 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . 0.406 ' HB2' HD23 ' A' ' 114' ' ' LEU . 37.7 t -132.84 143.65 49.68 Favored 'General case' 0 C--N 1.311 -1.078 0 CA-C-O 121.132 0.491 . . . . 0.0 111.702 -177.997 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -84.78 -9.42 81.07 Favored Glycine 0 N--CA 1.441 -0.979 0 N-CA-C 110.166 -1.174 . . . . 0.0 110.166 174.922 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 78.3 m-20 -97.29 -171.28 2.17 Favored 'General case' 0 CA--C 1.507 -0.685 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 178.404 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 99.4 m-20 -89.65 39.53 0.96 Allowed 'General case' 0 C--N 1.308 -1.221 0 CA-C-O 121.373 0.606 . . . . 0.0 110.392 177.843 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 95.18 -2.65 65.94 Favored Glycine 0 N--CA 1.447 -0.598 0 CA-C-N 115.609 -0.723 . . . . 0.0 113.152 178.571 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 112' ' ' GLN . . . . . 0.664 ' HA ' HD23 ' A' ' 132' ' ' LEU . 98.4 mt-30 -64.14 -42.7 96.69 Favored 'General case' 0 C--O 1.245 0.839 0 N-CA-C 112.755 0.65 . . . . 0.0 112.755 -176.989 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 46.5 p -124.63 106.64 10.27 Favored 'General case' 0 N--CA 1.449 -0.521 0 CA-C-O 120.954 0.407 . . . . 0.0 110.279 176.996 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 114' ' ' LEU . . . . . 0.406 HD23 ' HB2' ' A' ' 107' ' ' SER . 98.3 mt -91.33 111.84 23.51 Favored 'General case' 0 C--N 1.316 -0.883 0 CA-C-O 120.642 0.258 . . . . 0.0 110.347 -179.344 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 57.1 m-80 -108.86 143.03 38.59 Favored 'General case' 0 C--N 1.313 -0.997 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.342 -179.955 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 163.56 -141.69 7.31 Favored Glycine 0 N--CA 1.435 -1.426 0 C-N-CA 119.655 -1.26 . . . . 0.0 113.162 177.599 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 33.8 p -134.85 158.12 45.05 Favored 'General case' 0 C--N 1.315 -0.907 0 C-N-CA 122.616 0.366 . . . . 0.0 110.504 -177.99 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 25.8 ptm -144.97 152.24 39.86 Favored 'General case' 0 C--N 1.314 -0.939 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.297 -179.766 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 119' ' ' THR . . . . . 0.629 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 32.9 m -129.74 129.34 44.03 Favored 'General case' 0 C--O 1.249 1.059 0 CA-C-N 116.387 -0.37 . . . . 0.0 110.694 179.682 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . 0.567 ' CB ' HE21 ' A' ' 98' ' ' GLN . 45.6 m-85 -85.34 170.48 12.71 Favored 'General case' 0 CA--C 1.517 -0.289 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.325 176.4 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . 0.475 ' HA ' HG11 ' A' ' 101' ' ' VAL . . . -53.21 -40.4 64.44 Favored 'General case' 0 N--CA 1.471 0.586 0 N-CA-C 113.167 0.803 . . . . 0.0 113.167 -178.13 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -151.81 87.88 0.14 Allowed Glycine 0 N--CA 1.447 -0.602 0 C-N-CA 119.579 -1.296 . . . . 0.0 112.821 -179.404 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 77.4 tt0 -169.8 -69.14 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.771 0.32 . . . . 0.0 110.842 179.436 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 153.44 161.87 10.65 Favored Glycine 0 N--CA 1.443 -0.841 0 C-N-CA 120.812 -0.708 . . . . 0.0 111.887 179.316 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 21.2 Cg_exo -66.96 136.57 41.75 Favored 'Trans proline' 0 C--O 1.24 0.582 0 C-N-CA 122.733 2.289 . . . . 0.0 111.73 178.865 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 43.1 pt -135.52 166.26 28.14 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.145 178.862 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -72.89 136.15 22.48 Favored Glycine 0 C--O 1.237 0.284 0 C-N-CA 120.712 -0.756 . . . . 0.0 111.786 -179.759 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 78.9 t80 -122.46 136.81 54.97 Favored 'General case' 0 C--O 1.24 0.569 0 CA-C-O 120.959 0.409 . . . . 0.0 111.651 -177.286 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 61.9 tttm -134.87 103.69 5.7 Favored 'General case' 0 N--CA 1.446 -0.668 0 CA-C-N 115.349 -0.841 . . . . 0.0 109.941 177.145 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -100.24 133.33 11.26 Favored Glycine 0 N--CA 1.443 -0.863 0 N-CA-C 111.183 -0.767 . . . . 0.0 111.183 177.733 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 38.7 m -129.84 137.56 50.51 Favored 'General case' 0 C--N 1.306 -1.286 0 CA-C-N 117.042 0.421 . . . . 0.0 111.187 -177.951 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 132' ' ' LEU . . . . . 0.664 HD23 ' HA ' ' A' ' 112' ' ' GLN . 2.9 mm? -59.76 137.78 57.96 Favored 'General case' 0 N--CA 1.473 0.708 0 CA-C-O 121.285 0.564 . . . . 0.0 111.727 178.752 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 133' ' ' THR . . . . . 0.433 ' HB ' HD12 ' A' ' 3' ' ' LEU . 14.4 m . . . . . 0 N--CA 1.435 -1.203 0 CA-C-N 115.528 -0.76 . . . . 0.0 110.174 178.283 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.51 -0.561 0 CA-C-O 120.694 0.283 . . . . 0.0 110.33 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 10.2 tt -99.77 131.83 45.5 Favored 'General case' 0 C--N 1.316 -0.889 0 CA-C-O 121.177 0.513 . . . . 0.0 110.486 -179.059 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 85.8 m-85 -120.81 142.64 49.42 Favored 'General case' 0 C--N 1.311 -1.083 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.201 178.964 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . 0.503 ' O ' ' HA2' ' A' ' 130' ' ' GLY . 88.9 m-20 -87.94 132.15 34.33 Favored 'General case' 0 C--N 1.308 -1.219 0 N-CA-C 107.501 -1.296 . . . . 0.0 107.501 176.786 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.6 HG21 ' CG ' ' A' ' 23' ' ' TRP . 54.2 t -113.88 128.66 70.7 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.99 0 CA-C-O 121.973 0.892 . . . . 0.0 113.191 -173.456 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.437 ' HB2' ' HB3' ' A' ' 129' ' ' LYS . 27.0 mt-10 -120.82 131.75 54.62 Favored 'General case' 0 N--CA 1.43 -1.45 0 CA-C-N 113.631 -1.622 . . . . 0.0 107.755 179.785 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 10.9 m120 -119.9 145.32 46.8 Favored 'General case' 0 C--N 1.314 -0.939 0 CA-C-O 120.995 0.426 . . . . 0.0 111.9 -176.81 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 53.4 tt0 -122.66 110.29 15.34 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.57 -0.741 . . . . 0.0 109.138 179.554 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 3.1 p90 -128.68 -171.42 2.46 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 112.682 0.623 . . . . 0.0 112.682 -175.079 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 66.34 -90.84 0.15 Allowed Glycine 0 C--N 1.336 0.552 0 CA-C-N 114.955 -1.02 . . . . 0.0 114.938 176.084 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.466 ' C ' ' H ' ' A' ' 14' ' ' SER . . . -85.85 0.78 87.97 Favored Glycine 0 C--N 1.319 -0.376 0 C-N-CA 121.319 -0.467 . . . . 0.0 114.098 -173.52 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 13.3 t 59.17 -6.46 0.06 Allowed 'General case' 0 CA--C 1.562 1.434 0 C-N-CA 123.323 0.649 . . . . 0.0 112.662 -177.719 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . 0.466 ' H ' ' C ' ' A' ' 12' ' ' GLY . 8.7 t -125.7 16.13 8.11 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-O 121.658 0.742 . . . . 0.0 109.358 -179.39 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -80.05 163.79 55.94 Favored Pre-proline 0 N--CA 1.445 -0.718 0 CA-C-N 114.877 -1.056 . . . . 0.0 110.122 -179.463 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 14.2 Cg_exo -69.71 169.6 18.47 Favored 'Trans proline' 0 N--CA 1.46 -0.488 0 C-N-CA 122.608 2.205 . . . . 0.0 111.757 177.967 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 98.5 m95 -80.92 121.71 26.34 Favored 'General case' 0 C--N 1.316 -0.868 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 -179.224 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 91.4 m-20 -106.56 114.19 28.16 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.573 -177.595 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -78.56 128.62 33.78 Favored 'General case' 0 C--N 1.319 -0.756 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 178.406 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -143.3 35.45 1.66 Allowed Glycine 0 N--CA 1.442 -0.961 0 C-N-CA 119.51 -1.329 . . . . 0.0 112.694 -179.713 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 137.62 -174.02 22.02 Favored Glycine 0 N--CA 1.443 -0.843 0 C-N-CA 120.034 -1.079 . . . . 0.0 112.782 178.185 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 88.1 mt-30 -132.0 149.21 52.49 Favored 'General case' 0 C--N 1.318 -0.788 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 -179.768 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . 0.6 ' CG ' HG21 ' A' ' 6' ' ' VAL . 38.5 m0 -119.07 153.24 35.08 Favored 'General case' 0 C--N 1.315 -0.913 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 177.947 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.443 ' H ' ' HB ' ' A' ' 91' ' ' ILE . 89.1 mt-10 -111.59 113.69 26.26 Favored 'General case' 0 C--N 1.305 -1.345 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 175.946 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 81.8 mt -130.25 140.35 49.1 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-N 116.0 -0.546 . . . . 0.0 111.904 -172.381 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 91.79 125.17 3.4 Favored Glycine 0 N--CA 1.442 -0.945 0 N-CA-C 114.761 0.665 . . . . 0.0 114.761 172.294 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 3.8 p -88.35 12.61 13.66 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 109.278 -0.638 . . . . 0.0 109.278 173.939 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 62.6 ttp85 -24.74 108.91 0.03 OUTLIER 'General case' 0 N--CA 1.474 0.727 0 C-N-CA 125.477 1.511 . . . . 0.0 113.883 179.732 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 11.0 m -102.88 -62.36 1.29 Allowed 'General case' 0 N--CA 1.436 -1.14 0 CA-C-N 115.235 -0.893 . . . . 0.0 108.83 176.733 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 27.2 m-20 -124.4 5.85 8.36 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.46 178.17 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 1.4 mm-40 -149.53 136.36 19.53 Favored 'General case' 0 C--N 1.318 -0.761 0 CA-C-N 116.009 -0.542 . . . . 0.0 111.432 -177.864 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . 0.516 ' ND2' ' HA3' ' A' ' 111' ' ' GLY . 63.7 t30 -93.36 164.45 13.21 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.947 -0.569 . . . . 0.0 111.331 -179.126 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.411 ' HA ' ' HA ' ' A' ' 53' ' ' TYR . 57.8 t -96.27 130.37 45.03 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 CA-C-N 115.422 -0.808 . . . . 0.0 110.699 -176.912 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 23.7 m -114.07 -16.33 9.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 N-CA-C 112.218 0.451 . . . . 0.0 112.218 178.754 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.403 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -145.86 142.37 28.74 Favored 'General case' 0 CA--C 1.515 -0.384 0 C-N-CA 120.377 -0.529 . . . . 0.0 111.537 178.998 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.435 ' HB ' ' CG2' ' A' ' 105' ' ' VAL . 96.3 mt -142.57 127.46 16.3 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 N-CA-C 108.987 -0.746 . . . . 0.0 108.987 179.124 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . 0.435 ' HA ' ' O ' ' A' ' 103' ' ' ILE . 3.0 t-20 -138.0 113.09 9.2 Favored 'General case' 0 C--N 1.313 -0.991 0 N-CA-C 108.739 -0.837 . . . . 0.0 108.739 176.865 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.45 HG11 ' CD2' ' A' ' 61' ' ' PHE . 28.0 m -148.18 153.15 11.88 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.442 0 C-N-CA 120.918 -0.313 . . . . 0.0 111.19 -174.059 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 81.3 tt0 -139.17 145.37 39.26 Favored 'General case' 0 C--N 1.321 -0.639 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 176.714 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 12.9 t -77.04 139.93 40.19 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-O 120.883 0.373 . . . . 0.0 110.714 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -88.63 -7.07 72.29 Favored Glycine 0 N--CA 1.446 -0.672 0 C-N-CA 120.555 -0.831 . . . . 0.0 111.114 177.061 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . 0.442 ' HB3' ' H ' ' A' ' 43' ' ' ASP . 21.1 m-20 -141.83 -153.98 0.49 Allowed 'General case' 0 C--N 1.33 -0.242 0 C-N-CA 122.508 0.323 . . . . 0.0 110.257 -179.319 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . 0.442 ' H ' ' HB3' ' A' ' 42' ' ' ASP . 86.7 m-20 -78.28 44.07 0.48 Allowed 'General case' 0 N--CA 1.471 0.589 0 C-N-CA 122.664 0.386 . . . . 0.0 111.961 -178.468 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 87.49 -5.13 85.53 Favored Glycine 0 C--O 1.227 -0.335 0 C-N-CA 120.787 -0.721 . . . . 0.0 113.491 178.094 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 54.9 mt-30 -70.29 -38.89 75.1 Favored 'General case' 0 C--O 1.222 -0.362 0 N-CA-C 112.59 0.589 . . . . 0.0 112.59 179.604 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . 0.606 ' HA ' ' O ' ' A' ' 63' ' ' ALA . 7.8 t -127.71 123.57 35.73 Favored 'General case' 0 C--N 1.32 -0.689 0 C-N-CA 120.426 -0.51 . . . . 0.0 111.293 -179.027 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 95.5 mt -103.15 124.81 49.29 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.037 177.912 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.503 ' OD1' ' HG3' ' A' ' 62' ' ' ARG . 93.2 m-20 -119.61 142.11 48.7 Favored 'General case' 0 C--N 1.313 -0.985 0 CA-C-N 115.969 -0.559 . . . . 0.0 110.021 179.616 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 166.47 -146.48 10.97 Favored Glycine 0 CA--C 1.501 -0.822 0 C-N-CA 119.787 -1.197 . . . . 0.0 112.787 179.373 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 33.5 p -135.51 153.04 51.86 Favored 'General case' 0 N--CA 1.446 -0.629 0 CA-C-O 120.973 0.416 . . . . 0.0 111.066 -178.718 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' MET . . . . . 0.415 ' HE1' ' CZ ' ' A' ' 53' ' ' TYR . 16.6 tmm? -135.01 138.65 44.16 Favored 'General case' 0 C--N 1.317 -0.83 0 N-CA-C 109.276 -0.638 . . . . 0.0 109.276 178.148 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.403 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 29.4 m -125.24 129.26 49.71 Favored 'General case' 0 C--O 1.255 1.365 0 N-CA-C 112.527 0.566 . . . . 0.0 112.527 -175.564 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . 0.51 ' HB2' ' HB2' ' A' ' 56' ' ' GLU . 95.1 m-85 -85.29 165.73 17.07 Favored 'General case' 0 CA--C 1.532 0.251 0 CA-C-N 115.341 -0.845 . . . . 0.0 109.805 176.659 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -66.87 113.51 4.98 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 120.714 0.292 . . . . 0.0 111.707 -179.008 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 76.6 16.53 80.67 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.844 178.11 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . 0.51 ' HB2' ' HB2' ' A' ' 53' ' ' TYR . 73.0 mm-40 -121.71 177.67 5.16 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-O 120.769 0.319 . . . . 0.0 110.395 -179.397 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -93.38 153.48 21.37 Favored Glycine 0 N--CA 1.443 -0.857 0 C-N-CA 120.805 -0.712 . . . . 0.0 111.556 178.694 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -67.8 144.27 64.55 Favored 'Trans proline' 0 C--O 1.237 0.432 0 C-N-CA 122.555 2.17 . . . . 0.0 112.574 179.581 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 39.6 pt -125.86 162.69 28.74 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.818 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.284 178.644 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -71.24 145.1 38.74 Favored Glycine 0 N--CA 1.448 -0.537 0 C-N-CA 121.195 -0.526 . . . . 0.0 112.323 -177.559 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.45 ' CD2' HG11 ' A' ' 38' ' ' VAL . 69.4 t80 -130.93 126.94 37.42 Favored 'General case' 0 C--N 1.313 -1.02 0 C-N-CA 122.106 0.162 . . . . 0.0 110.972 -178.186 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . 0.503 ' HG3' ' OD1' ' A' ' 48' ' ' ASN . 29.0 ttp85 -135.32 128.31 31.51 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 108.798 -0.816 . . . . 0.0 108.798 174.643 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.606 ' O ' ' HA ' ' A' ' 46' ' ' THR . . . -132.87 141.76 48.58 Favored 'General case' 0 C--N 1.316 -0.857 0 C-N-CA 120.852 -0.339 . . . . 0.0 111.713 -178.378 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 31.7 m -124.06 128.97 50.1 Favored 'General case' 0 CA--C 1.539 0.527 0 CA-C-N 116.458 -0.337 . . . . 0.0 110.634 179.516 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 51.2 tp -74.73 127.6 33.53 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 112.279 0.474 . . . . 0.0 112.279 -177.514 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 10.7 mp -79.82 -24.36 41.41 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.969 177.094 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 113.64 -8.36 24.05 Favored Glycine 0 CA--C 1.521 0.465 0 C-N-CA 120.93 -0.653 . . . . 0.0 112.638 179.88 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 24.2 p-10 -115.41 30.12 7.56 Favored 'General case' 0 C--N 1.312 -1.054 0 CA-C-O 121.04 0.448 . . . . 0.0 110.445 179.937 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 87.3 m-20 76.48 -9.38 1.49 Allowed 'General case' 0 N--CA 1.485 1.278 0 C-N-CA 124.353 1.061 . . . . 0.0 111.048 -178.099 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 9.0 m -81.49 138.58 35.47 Favored 'General case' 0 N--CA 1.441 -0.884 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.433 177.828 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.524 ' HB3' ' HB1' ' A' ' 63' ' ' ALA . 43.8 m-85 -122.12 129.94 52.8 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-N 115.679 -0.691 . . . . 0.0 109.685 178.126 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . 0.41 ' O ' ' HA ' ' A' ' 63' ' ' ALA . 36.0 tt0 -83.45 119.02 24.14 Favored 'General case' 0 N--CA 1.44 -0.949 0 N-CA-C 107.774 -1.195 . . . . 0.0 107.774 174.99 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.449 HG22 ' HB2' ' A' ' 63' ' ' ALA . 53.0 t -108.08 133.62 52.41 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.307 0 N-CA-C 112.866 0.691 . . . . 0.0 112.866 -172.474 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 99.8 mt-10 -120.03 122.4 41.05 Favored 'General case' 0 N--CA 1.436 -1.158 0 CA-C-N 114.51 -1.223 . . . . 0.0 108.875 176.676 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 2.7 m-20 -96.29 140.57 30.78 Favored 'General case' 0 C--N 1.313 -1.018 0 CA-C-N 116.288 -0.415 . . . . 0.0 109.917 179.367 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' GLN . . . . . 0.508 ' HB2' ' CE3' ' A' ' 84' ' ' TRP . 61.3 tt0 -115.87 120.89 40.68 Favored 'General case' 0 C--N 1.307 -1.254 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 179.345 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 6.1 p90 -137.55 157.1 47.25 Favored 'General case' 0 C--N 1.312 -1.027 0 CA-C-O 120.723 0.297 . . . . 0.0 110.329 179.481 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 103.13 -13.84 55.51 Favored Glycine 0 N--CA 1.439 -1.115 0 C-N-CA 120.756 -0.735 . . . . 0.0 111.652 -179.838 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 131.51 170.64 12.67 Favored Glycine 0 N--CA 1.437 -1.246 0 C-N-CA 120.886 -0.673 . . . . 0.0 111.972 178.97 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 5.7 p-10 -65.73 -33.1 75.09 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 121.056 0.455 . . . . 0.0 111.127 179.864 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 40.6 m -78.45 -2.89 40.66 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 115.845 -0.616 . . . . 0.0 111.856 -178.565 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -89.61 146.11 34.99 Favored Pre-proline 0 C--N 1.325 -0.458 0 CA-C-N 116.6 -0.273 . . . . 0.0 110.341 178.606 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.82 177.09 5.98 Favored 'Trans proline' 0 CA--C 1.532 0.405 0 C-N-CA 122.738 2.292 . . . . 0.0 112.298 179.847 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' TRP . . . . . 0.508 ' CE3' ' HB2' ' A' ' 76' ' ' GLN . 98.5 m95 -85.89 143.09 28.41 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 109.716 -0.476 . . . . 0.0 109.716 -179.154 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 91.7 m-70 -119.61 146.11 45.83 Favored 'General case' 0 C--N 1.313 -1.021 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 -179.643 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 46.0 m -63.51 131.2 47.36 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-O 120.891 0.377 . . . . 0.0 110.898 -179.396 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -107.94 -55.2 0.61 Allowed Glycine 0 N--CA 1.441 -1.013 0 C-N-CA 120.842 -0.694 . . . . 0.0 111.694 179.536 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 157.42 -173.43 34.88 Favored Glycine 0 C--O 1.223 -0.546 0 C-N-CA 120.26 -0.971 . . . . 0.0 112.184 179.326 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 24.3 t-20 -109.7 113.26 25.88 Favored 'General case' 0 C--N 1.316 -0.879 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 178.919 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 21.0 m0 -105.96 153.14 22.41 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.432 -176.416 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.443 ' HB ' ' H ' ' A' ' 24' ' ' GLU . 46.8 mm -107.22 113.54 43.8 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.799 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 177.259 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 82.8 mt -127.08 78.51 1.82 Allowed 'General case' 0 C--O 1.268 2.066 0 CA-C-O 122.045 0.926 . . . . 0.0 112.371 -176.973 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 162.71 104.87 0.19 Allowed Glycine 0 N--CA 1.444 -0.772 0 CA-C-N 114.741 -1.118 . . . . 0.0 110.752 -179.072 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 15.7 p -106.88 -13.12 15.31 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 120.889 0.376 . . . . 0.0 111.867 -178.0 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 85.2 mtp180 -85.47 16.2 3.96 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 121.248 0.547 . . . . 0.0 111.452 -179.202 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 46.9 tp10 65.36 -74.51 0.05 Allowed 'General case' 0 N--CA 1.472 0.646 0 CA-C-N 114.459 -1.246 . . . . 0.0 113.97 174.007 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 61.9 m-80 -91.97 26.85 2.3 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-O 120.765 0.317 . . . . 0.0 111.739 -175.077 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' GLN . . . . . . . . . . . . . 58.1 tt0 -150.05 116.62 5.81 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.801 0.334 . . . . 0.0 110.218 -177.969 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 83.6 m-20 -84.58 160.02 20.54 Favored 'General case' 0 C--O 1.245 0.819 0 CA-C-N 115.977 -0.556 . . . . 0.0 111.77 -176.895 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 79.5 t -82.36 132.43 31.43 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.664 0 C-N-CA 120.728 -0.389 . . . . 0.0 110.818 176.699 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 34.7 m -114.44 -23.76 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.601 0 N-CA-C 113.087 0.773 . . . . 0.0 113.087 -179.457 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . 0.549 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -152.04 144.13 23.87 Favored 'General case' 0 CA--C 1.512 -0.49 0 C-N-CA 120.425 -0.51 . . . . 0.0 111.113 178.198 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.442 ' HB ' HG22 ' A' ' 38' ' ' VAL . 84.6 mt -135.88 125.8 41.24 Favored 'Isoleucine or valine' 0 C--O 1.236 0.393 0 CA-C-O 120.582 0.23 . . . . 0.0 110.81 179.066 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 9.6 t30 -126.74 94.88 4.16 Favored 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 175.172 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.435 ' CG2' ' HB ' ' A' ' 36' ' ' ILE . 30.9 m -136.88 141.43 40.68 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.702 0 N-CA-C 113.633 0.975 . . . . 0.0 113.633 -174.191 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 74.6 tt0 -141.71 150.49 41.9 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 114.97 -1.014 . . . . 0.0 109.298 178.117 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . 0.415 ' HB3' ' HA ' ' A' ' 114' ' ' LEU . 35.6 p -150.65 153.17 35.15 Favored 'General case' 0 N--CA 1.446 -0.671 0 CA-C-O 120.821 0.343 . . . . 0.0 111.219 177.545 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -123.19 5.59 9.47 Favored Glycine 0 N--CA 1.439 -1.124 0 N-CA-C 111.112 -0.795 . . . . 0.0 111.112 177.474 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -92.34 34.59 1.03 Allowed 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 121.196 0.522 . . . . 0.0 110.528 179.495 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 29.3 m-20 59.21 21.83 10.0 Favored 'General case' 0 N--CA 1.474 0.741 0 CA-C-N 115.284 -0.871 . . . . 0.0 112.507 176.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . 0.516 ' HA3' ' ND2' ' A' ' 32' ' ' ASN . . . 89.71 -0.14 79.5 Favored Glycine 0 N--CA 1.447 -0.582 0 C-N-CA 120.748 -0.739 . . . . 0.0 113.174 177.928 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 51.8 tt0 -65.62 -43.38 89.76 Favored 'General case' 0 C--O 1.235 0.335 0 CA-C-O 121.356 0.598 . . . . 0.0 110.282 178.725 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 6.4 p -128.72 125.99 39.11 Favored 'General case' 0 N--CA 1.434 -1.248 0 CA-C-N 115.428 -0.805 . . . . 0.0 109.97 176.665 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 114' ' ' LEU . . . . . 0.415 ' HA ' ' HB3' ' A' ' 107' ' ' SER . 42.4 tp -112.47 134.94 53.73 Favored 'General case' 0 C--N 1.306 -1.319 0 CA-C-N 115.899 -0.591 . . . . 0.0 109.596 -177.776 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 30.1 p30 -145.72 169.91 17.54 Favored 'General case' 0 C--N 1.32 -0.698 0 C-N-CA 119.779 -0.768 . . . . 0.0 112.301 179.92 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 147.36 -131.71 4.02 Favored Glycine 0 N--CA 1.434 -1.444 0 CA-C-N 115.127 -0.942 . . . . 0.0 111.204 179.283 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 21.9 p -133.2 159.23 40.79 Favored 'General case' 0 C--N 1.307 -1.246 0 CA-C-O 121.095 0.474 . . . . 0.0 110.72 179.923 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 118' ' ' MET . . . . . 0.404 ' HB2' ' HE2' ' A' ' 118' ' ' MET . 4.5 ppp? -153.91 163.02 40.73 Favored 'General case' 0 C--N 1.306 -1.306 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 178.802 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 119' ' ' THR . . . . . 0.549 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 32.1 m -131.47 130.2 42.13 Favored 'General case' 0 C--N 1.307 -1.254 0 CA-C-O 120.791 0.329 . . . . 0.0 111.235 -179.79 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 11.5 m-85 -94.71 161.22 14.27 Favored 'General case' 0 N--CA 1.45 -0.473 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.075 177.095 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -65.6 128.19 34.93 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-O 120.89 0.376 . . . . 0.0 111.89 -179.098 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 76.23 19.17 78.72 Favored Glycine 0 N--CA 1.45 -0.396 0 CA-C-N 115.775 -0.648 . . . . 0.0 112.956 176.859 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 70.5 tt0 -147.22 161.08 41.65 Favored 'General case' 0 C--N 1.317 -0.832 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 -178.393 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -80.05 -179.49 52.54 Favored Glycine 0 N--CA 1.448 -0.508 0 C-N-CA 121.017 -0.611 . . . . 0.0 112.356 179.63 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -71.56 140.37 36.05 Favored 'Trans proline' 0 CA--C 1.532 0.392 0 C-N-CA 122.714 2.276 . . . . 0.0 112.959 -178.788 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 44.0 pt -132.68 165.99 30.64 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.13 178.805 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -73.15 142.6 31.91 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 121.017 -0.611 . . . . 0.0 112.458 -179.809 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 79.4 t80 -122.76 136.88 55.01 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-O 120.911 0.386 . . . . 0.0 111.272 -179.288 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 129' ' ' LYS . . . . . 0.437 ' HB3' ' HB2' ' A' ' 7' ' ' GLU . 63.2 tttm -142.0 125.95 17.21 Favored 'General case' 0 N--CA 1.447 -0.58 0 CA-C-N 115.649 -0.705 . . . . 0.0 109.154 175.668 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . 0.503 ' HA2' ' O ' ' A' ' 5' ' ' ASN . . . -127.24 135.74 8.96 Favored Glycine 0 N--CA 1.432 -1.581 0 N-CA-C 110.856 -0.898 . . . . 0.0 110.856 178.918 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 30.1 m -118.55 126.94 53.08 Favored 'General case' 0 C--N 1.305 -1.338 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 -178.581 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 66.1 tp -75.24 140.71 43.39 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.782 0.325 . . . . 0.0 111.154 -178.608 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 9.8 t . . . . . 0 C--O 1.248 1.022 0 CA-C-O 118.604 -0.712 . . . . 0.0 109.533 177.987 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.467 0.394 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . 0.493 HD11 HE21 ' A' ' 22' ' ' GLN . 3.3 tm? -90.72 128.08 36.54 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-O 121.046 0.45 . . . . 0.0 110.332 -178.331 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 47.2 m-85 -124.46 147.08 48.56 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.864 -0.607 . . . . 0.0 111.175 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 5.7 m-20 -100.97 137.83 38.82 Favored 'General case' 0 C--N 1.315 -0.931 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 175.502 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.452 HG21 ' CD2' ' A' ' 23' ' ' TRP . 68.1 t -116.02 128.26 73.36 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.774 0 CA-C-O 121.527 0.68 . . . . 0.0 112.745 -173.913 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.453 ' HB3' ' HB3' ' A' ' 17' ' ' TRP . 65.4 mt-10 -118.66 138.36 52.66 Favored 'General case' 0 N--CA 1.437 -1.101 0 CA-C-N 114.681 -1.145 . . . . 0.0 108.423 176.713 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 11.9 m120 -127.44 147.16 50.29 Favored 'General case' 0 C--N 1.312 -1.037 0 CA-C-O 121.172 0.511 . . . . 0.0 111.896 -177.056 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 52.1 tt0 -123.38 117.24 24.75 Favored 'General case' 0 C--N 1.314 -0.955 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 178.118 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 7.6 p90 -137.93 9.44 2.81 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 114.313 1.227 . . . . 0.0 114.313 -174.84 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -93.24 31.51 6.3 Favored Glycine 0 CA--C 1.522 0.485 0 C-N-CA 118.748 -1.692 . . . . 0.0 114.353 -174.784 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.63 58.88 3.17 Favored Glycine 0 CA--C 1.525 0.67 0 C-N-CA 120.428 -0.891 . . . . 0.0 114.376 176.922 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 22.8 t 60.69 154.55 0.03 OUTLIER 'General case' 0 CA--C 1.553 1.083 0 N-CA-C 113.408 0.892 . . . . 0.0 113.408 177.325 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 49.3 m 63.3 14.42 7.82 Favored 'General case' 0 N--CA 1.472 0.671 0 CA-C-N 115.851 -0.613 . . . . 0.0 112.355 177.223 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -96.7 153.95 38.57 Favored Pre-proline 0 C--N 1.314 -0.939 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.189 -179.446 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -73.18 161.69 42.47 Favored 'Trans proline' 0 C--O 1.238 0.503 0 C-N-CA 122.634 2.223 . . . . 0.0 111.703 177.772 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . 0.453 ' HB3' ' HB3' ' A' ' 7' ' ' GLU . 92.6 m95 -85.18 129.46 34.8 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 109.664 -0.495 . . . . 0.0 109.664 179.51 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 27.6 m-80 -113.22 118.57 35.04 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.661 -178.053 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.434 ' HA ' ' HA ' ' A' ' 7' ' ' GLU . 11.5 pt-20 -75.48 129.94 38.09 Favored 'General case' 0 C--N 1.319 -0.718 0 N-CA-C 109.724 -0.473 . . . . 0.0 109.724 177.474 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -137.62 26.57 2.9 Favored Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 119.596 -1.288 . . . . 0.0 113.159 -178.661 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 147.86 179.26 23.72 Favored Glycine 0 N--CA 1.449 -0.433 0 C-N-CA 119.79 -1.195 . . . . 0.0 113.075 178.125 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . 0.493 HE21 HD11 ' A' ' 3' ' ' LEU . 4.4 pt20 -127.99 138.74 52.72 Favored 'General case' 0 C--N 1.322 -0.601 0 C-N-CA 122.69 0.396 . . . . 0.0 110.205 -179.93 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . 0.452 ' CD2' HG21 ' A' ' 6' ' ' VAL . 45.7 m0 -116.07 171.81 7.56 Favored 'General case' 0 C--O 1.242 0.661 0 CA-C-O 120.86 0.362 . . . . 0.0 111.226 -177.802 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 76.5 tt0 -119.13 110.73 17.4 Favored 'General case' 0 CA--C 1.513 -0.465 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 178.005 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 91.1 mt -133.01 143.97 37.9 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-N 115.401 -0.818 . . . . 0.0 109.579 -178.164 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 83.94 71.73 1.31 Allowed Glycine 0 CA--C 1.508 -0.351 0 C-N-CA 120.369 -0.92 . . . . 0.0 112.014 177.891 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 15.9 m -62.68 -45.62 91.97 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 120.823 0.344 . . . . 0.0 111.279 -179.313 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 83.0 mtm-85 -88.36 133.99 33.94 Favored 'General case' 0 CA--C 1.517 -0.322 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.057 178.797 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 18.8 p -87.16 -16.13 36.3 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.956 -0.565 . . . . 0.0 111.398 179.701 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 16.5 m-20 -71.31 -43.2 67.52 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-O 121.51 0.671 . . . . 0.0 110.161 179.933 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 14.1 mm100 -131.76 122.3 25.61 Favored 'General case' 0 C--N 1.312 -1.027 0 CA-C-N 114.915 -1.039 . . . . 0.0 110.046 -179.399 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . 0.506 ' ND2' ' HA3' ' A' ' 111' ' ' GLY . 59.4 t30 -108.15 172.36 6.88 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.324 -177.575 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 14.0 t -101.71 134.24 42.76 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.92 0 N-CA-C 111.877 0.325 . . . . 0.0 111.877 -172.031 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 33.6 m -113.77 -15.34 10.25 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.356 0 CA-C-O 121.017 0.437 . . . . 0.0 111.594 177.386 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.647 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -147.48 142.67 27.19 Favored 'General case' 0 CA--C 1.506 -0.715 0 C-N-CA 120.269 -0.572 . . . . 0.0 111.181 178.199 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.402 ' HB ' HG22 ' A' ' 105' ' ' VAL . 85.9 mt -142.36 120.43 8.04 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 N-CA-C 109.155 -0.683 . . . . 0.0 109.155 -179.377 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . 0.452 ' HA ' ' O ' ' A' ' 103' ' ' ILE . 22.7 m-80 -132.37 109.81 10.12 Favored 'General case' 0 C--N 1.31 -1.151 0 N-CA-C 108.88 -0.785 . . . . 0.0 108.88 176.49 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.488 HG22 ' HB ' ' A' ' 103' ' ' ILE . 33.3 m -147.79 152.93 12.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 C-N-CA 120.996 -0.281 . . . . 0.0 111.254 -172.57 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 41.6 tt0 -142.45 147.27 35.84 Favored 'General case' 0 N--CA 1.446 -0.633 0 CA-C-N 115.845 -0.616 . . . . 0.0 109.433 176.755 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 19.9 p -70.42 144.38 51.53 Favored 'General case' 0 C--N 1.313 -1.005 0 CA-C-O 121.083 0.468 . . . . 0.0 111.652 -178.548 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -88.38 -59.18 1.67 Allowed Glycine 0 N--CA 1.441 -0.971 0 N-CA-C 110.366 -1.094 . . . . 0.0 110.366 177.174 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 43.9 m-20 -93.78 -147.11 0.25 Allowed 'General case' 0 C--N 1.32 -0.713 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 176.708 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 20.2 p-10 -78.99 40.66 0.41 Allowed 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.124 0.488 . . . . 0.0 111.949 -178.818 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 97.89 -22.39 41.07 Favored Glycine 0 C--O 1.219 -0.82 0 C-N-CA 120.753 -0.736 . . . . 0.0 113.736 177.351 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 56.3 mt-30 -64.34 -28.61 69.82 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 117.319 0.559 . . . . 0.0 112.111 -178.603 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 26.0 p -117.54 137.0 52.87 Favored 'General case' 0 C--N 1.312 -1.029 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.392 179.334 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . . . . . . . . . 88.7 mt -127.51 128.91 46.47 Favored 'General case' 0 C--N 1.318 -0.793 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 -179.971 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 62.7 m-80 -129.47 140.82 51.17 Favored 'General case' 0 C--N 1.318 -0.762 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 178.335 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 178.97 -156.89 19.8 Favored Glycine 0 N--CA 1.438 -1.196 0 C-N-CA 119.972 -1.108 . . . . 0.0 112.797 179.522 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 65.3 m -130.98 132.99 45.39 Favored 'General case' 0 C--N 1.312 -1.04 0 CA-C-O 120.843 0.354 . . . . 0.0 110.646 -179.536 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 46.9 mtp -115.66 148.28 39.88 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.722 177.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.647 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 33.0 m -126.4 125.33 42.01 Favored 'General case' 0 C--O 1.25 1.086 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.136 177.149 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . 0.441 ' HB2' ' HB2' ' A' ' 56' ' ' GLU . 50.8 m-85 -94.67 164.74 12.83 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.869 -179.43 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -65.14 95.97 0.19 Allowed 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.813 -0.63 . . . . 0.0 111.641 -179.47 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 98.81 4.67 56.82 Favored Glycine 0 C--N 1.318 -0.424 0 CA-C-N 115.613 -0.721 . . . . 0.0 112.434 177.153 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . 0.441 ' HB2' ' HB2' ' A' ' 53' ' ' TYR . 41.8 mt-10 -114.45 168.02 10.21 Favored 'General case' 0 C--N 1.314 -0.968 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 178.871 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -89.61 168.95 35.12 Favored Glycine 0 N--CA 1.437 -1.298 0 C-N-CA 120.541 -0.838 . . . . 0.0 111.413 178.756 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_exo -63.02 134.33 45.62 Favored 'Trans proline' 0 C--O 1.239 0.545 0 C-N-CA 122.345 2.03 . . . . 0.0 111.465 178.735 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 45.0 pt -130.54 166.7 27.47 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.846 179.675 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -73.6 142.49 31.23 Favored Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 121.074 -0.584 . . . . 0.0 112.338 -177.409 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 39.8 t80 -126.77 128.47 46.66 Favored 'General case' 0 C--N 1.317 -0.839 0 C-N-CA 122.451 0.3 . . . . 0.0 111.125 -179.067 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 69.5 ttp85 -136.5 132.25 35.04 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 174.348 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.654 ' HB1' ' HB3' ' A' ' 71' ' ' TYR . . . -137.28 146.26 44.48 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 111.892 0.33 . . . . 0.0 111.892 179.837 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 60.1 m -121.32 131.3 54.12 Favored 'General case' 0 CA--C 1.546 0.793 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.38 179.176 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . 0.511 ' O ' ' HB3' ' A' ' 66' ' ' LEU . 59.9 tp -43.2 -51.81 5.89 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 115.513 1.672 . . . . 0.0 115.513 -176.493 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.511 ' HB3' ' O ' ' A' ' 65' ' ' LEU . 3.2 tm? 75.64 -57.06 0.59 Allowed 'General case' 0 CA--C 1.549 0.935 0 CA-C-N 118.364 0.529 . . . . 0.0 110.641 177.949 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -141.35 -90.27 0.16 Allowed Glycine 0 C--N 1.333 0.398 0 C-N-CA 121.057 -0.592 . . . . 0.0 112.646 -179.405 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 9.0 p30 -160.94 133.03 5.89 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 179.705 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 94.3 m-20 57.19 24.27 9.62 Favored 'General case' 0 N--CA 1.478 0.968 0 CA-C-O 121.279 0.562 . . . . 0.0 111.172 -176.256 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 43.5 m -138.2 152.03 48.25 Favored 'General case' 0 N--CA 1.434 -1.229 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 179.336 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.654 ' HB3' ' HB1' ' A' ' 63' ' ' ALA . 97.3 m-85 -149.85 126.39 10.91 Favored 'General case' 0 C--N 1.31 -1.118 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 176.662 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . 0.468 ' O ' ' HA ' ' A' ' 63' ' ' ALA . 83.7 tt0 -82.81 127.53 33.55 Favored 'General case' 0 N--CA 1.439 -0.991 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 175.603 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 76.9 t -104.75 131.55 53.55 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.278 0 CA-C-N 115.352 -0.84 . . . . 0.0 112.585 -171.96 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.469 ' HG2' ' HA ' ' A' ' 86' ' ' SER . 48.1 mt-10 -129.76 126.65 38.67 Favored 'General case' 0 N--CA 1.44 -0.966 0 CA-C-N 114.275 -1.33 . . . . 0.0 107.523 175.059 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 97.0 m-20 -109.53 154.34 22.85 Favored 'General case' 0 C--N 1.314 -0.973 0 CA-C-O 121.042 0.449 . . . . 0.0 112.053 -176.132 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' GLN . . . . . 0.537 ' HB2' ' CE3' ' A' ' 84' ' ' TRP . 61.8 tt0 -118.47 124.52 47.82 Favored 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 115.527 -0.76 . . . . 0.0 110.608 -176.193 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 6.0 p90 -142.59 158.8 43.3 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.158 179.07 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 98.32 -12.42 63.41 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.628 -0.796 . . . . 0.0 112.697 179.931 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 134.26 169.59 12.05 Favored Glycine 0 N--CA 1.447 -0.621 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.192 179.64 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 6.5 p-10 -68.83 -30.42 68.96 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 120.71 0.291 . . . . 0.0 111.097 -179.812 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 23.6 t -71.96 -16.0 62.08 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.255 179.28 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -79.96 143.62 57.88 Favored Pre-proline 0 C--N 1.324 -0.512 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.029 -178.488 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_endo -72.3 -178.16 3.12 Favored 'Trans proline' 0 C--O 1.238 0.511 0 C-N-CA 122.881 2.387 . . . . 0.0 112.149 179.168 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' TRP . . . . . 0.537 ' CE3' ' HB2' ' A' ' 76' ' ' GLN . 88.3 m95 -94.39 142.4 27.47 Favored 'General case' 0 C--N 1.317 -0.829 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 -179.816 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 96.6 m-70 -116.51 142.14 47.26 Favored 'General case' 0 C--N 1.316 -0.889 0 N-CA-C 109.778 -0.452 . . . . 0.0 109.778 -178.542 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . 0.469 ' HA ' ' HG2' ' A' ' 74' ' ' GLU . 20.8 t -65.39 132.56 49.28 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 120.874 0.368 . . . . 0.0 111.229 -176.374 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -110.75 -48.35 0.74 Allowed Glycine 0 N--CA 1.441 -1.03 0 C-N-CA 120.936 -0.65 . . . . 0.0 112.188 178.547 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 157.96 -171.74 35.02 Favored Glycine 0 C--O 1.217 -0.911 0 C-N-CA 120.57 -0.824 . . . . 0.0 111.84 -179.943 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 3.9 t30 -112.4 115.64 29.04 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 117.54 0.67 . . . . 0.0 110.251 179.699 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 35.1 m0 -97.88 148.71 23.16 Favored 'General case' 0 C--N 1.311 -1.092 0 CA-C-O 121.037 0.446 . . . . 0.0 111.622 -177.725 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.401 ' O ' ' HB3' ' A' ' 23' ' ' TRP . 76.6 mt -108.49 118.18 55.54 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.057 0 N-CA-C 108.49 -0.93 . . . . 0.0 108.49 175.605 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 85.8 mt -134.53 83.39 2.03 Favored 'General case' 0 C--O 1.267 1.985 0 O-C-N 124.031 0.832 . . . . 0.0 112.057 -173.675 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 172.11 111.34 0.26 Allowed Glycine 0 N--CA 1.444 -0.769 0 CA-C-N 115.752 -0.658 . . . . 0.0 112.644 177.407 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 78.8 p -90.07 -7.88 52.79 Favored 'General case' 0 C--O 1.236 0.362 0 CA-C-O 121.45 0.643 . . . . 0.0 110.014 177.348 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 97.3 mtt180 -105.28 142.74 34.52 Favored 'General case' 0 N--CA 1.445 -0.692 0 CA-C-N 115.357 -0.838 . . . . 0.0 110.701 179.725 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -70.48 -34.68 72.65 Favored 'General case' 0 C--N 1.311 -1.08 0 CA-C-N 115.688 -0.687 . . . . 0.0 112.811 -175.193 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 27.2 p-10 -116.21 27.29 9.33 Favored 'General case' 0 C--N 1.324 -0.523 0 N-CA-C 112.77 0.655 . . . . 0.0 112.77 -176.54 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' GLN . . . . . . . . . . . . . 72.1 mt-30 -148.82 125.76 11.27 Favored 'General case' 0 CA--C 1.511 -0.54 0 CA-C-O 121.12 0.486 . . . . 0.0 112.276 -179.855 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' ASN . . . . . 0.531 ' HB3' ' OH ' ' A' ' 71' ' ' TYR . 94.9 m-20 -96.17 152.87 18.15 Favored 'General case' 0 C--O 1.258 1.512 0 CA-C-N 114.985 -1.007 . . . . 0.0 109.889 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 57.5 t -73.9 134.91 28.64 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.561 0 CA-C-O 120.932 0.396 . . . . 0.0 111.057 178.424 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 23.3 m -120.08 -23.64 3.26 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.478 0 N-CA-C 112.649 0.611 . . . . 0.0 112.649 -178.848 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . 0.511 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -148.05 139.58 23.69 Favored 'General case' 0 C--O 1.236 0.392 0 C-N-CA 120.342 -0.543 . . . . 0.0 111.85 179.433 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.488 ' HB ' HG22 ' A' ' 38' ' ' VAL . 37.4 mm -134.02 130.0 54.74 Favored 'Isoleucine or valine' 0 C--O 1.239 0.53 0 CA-C-N 115.904 -0.589 . . . . 0.0 111.287 178.901 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 6.8 t30 -129.07 93.75 3.66 Favored 'General case' 0 CA--C 1.534 0.359 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.368 176.222 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.402 HG22 ' HB ' ' A' ' 36' ' ' ILE . 27.3 m -138.44 141.55 37.3 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.932 0 N-CA-C 113.033 0.753 . . . . 0.0 113.033 -176.561 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 85.6 tt0 -144.14 87.63 1.91 Allowed 'General case' 0 CA--C 1.534 0.358 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.676 176.447 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . 0.464 ' HB2' ' H ' ' A' ' 115' ' ' ASN . 13.6 m -162.93 159.82 24.1 Favored 'General case' 0 C--N 1.312 -1.061 0 CA-C-N 114.667 -1.151 . . . . 0.0 111.206 -179.359 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 136.95 94.46 0.37 Allowed Glycine 0 N--CA 1.424 -2.139 0 C-N-CA 119.215 -1.469 . . . . 0.0 114.578 173.633 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 16.7 m-20 -75.68 100.47 4.67 Favored 'General case' 0 CA--C 1.502 -0.878 0 N-CA-C 105.875 -1.898 . . . . 0.0 105.875 171.918 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 70.5 m-20 62.27 24.35 14.48 Favored 'General case' 0 CA--C 1.534 0.344 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 -172.234 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . 0.506 ' HA3' ' ND2' ' A' ' 32' ' ' ASN . . . 77.91 22.85 67.98 Favored Glycine 0 CA--C 1.527 0.821 0 CA-C-N 115.217 -0.901 . . . . 0.0 113.539 179.928 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 52.8 tt0 -66.35 -43.49 85.9 Favored 'General case' 0 CA--C 1.541 0.597 0 N-CA-C 112.433 0.531 . . . . 0.0 112.433 -179.263 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 21.8 p -131.8 157.01 45.0 Favored 'General case' 0 C--N 1.325 -0.496 0 O-C-N 122.335 -0.228 . . . . 0.0 111.525 -177.629 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 114' ' ' LEU . . . . . 0.423 ' HA ' ' HB2' ' A' ' 107' ' ' SER . 96.4 mt -133.38 109.39 9.31 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 110.199 -0.297 . . . . 0.0 110.199 178.353 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . 0.464 ' H ' ' HB2' ' A' ' 107' ' ' SER . 93.3 m-20 -114.5 143.35 45.1 Favored 'General case' 0 C--O 1.252 1.207 0 CA-C-O 121.091 0.472 . . . . 0.0 111.018 -179.366 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 162.08 -135.11 3.74 Favored Glycine 0 N--CA 1.44 -1.043 0 CA-C-N 115.718 -0.674 . . . . 0.0 112.366 178.751 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 3.0 p -137.2 159.61 41.42 Favored 'General case' 0 C--N 1.311 -1.069 0 C-N-CA 122.629 0.372 . . . . 0.0 110.544 -179.241 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 23.2 ptm -146.3 160.29 42.21 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 116.501 -0.318 . . . . 0.0 110.614 -178.376 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 119' ' ' THR . . . . . 0.511 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 25.6 m -143.14 136.59 28.37 Favored 'General case' 0 C--O 1.253 1.242 0 CA-C-N 116.609 -0.269 . . . . 0.0 111.426 179.893 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . 0.415 ' HB2' ' HB3' ' A' ' 123' ' ' GLU . 52.5 m-85 -100.69 164.65 11.77 Favored 'General case' 0 CA--C 1.508 -0.639 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.223 177.418 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -63.46 130.19 43.36 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.058 176.66 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 63.03 27.41 70.39 Favored Glycine 0 CA--C 1.521 0.463 0 C-N-CA 121.118 -0.563 . . . . 0.0 113.117 -179.131 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . 0.415 ' HB3' ' HB2' ' A' ' 120' ' ' TYR . 9.9 tp10 -136.83 162.2 33.89 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -178.829 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -89.11 170.57 37.77 Favored Glycine 0 CA--C 1.522 0.479 0 C-N-CA 120.847 -0.692 . . . . 0.0 112.341 179.599 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -72.03 135.15 24.69 Favored 'Trans proline' 0 N--CA 1.46 -0.484 0 C-N-CA 122.369 2.046 . . . . 0.0 112.201 179.125 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 40.7 pt -130.83 161.56 40.56 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.269 179.673 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -72.42 134.91 21.62 Favored Glycine 0 C--O 1.238 0.391 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.119 -179.916 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 91.6 t80 -115.85 133.16 56.31 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.858 0.361 . . . . 0.0 110.99 -178.952 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 62.8 tttm -140.64 108.54 5.69 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 115.679 -0.691 . . . . 0.0 109.265 177.954 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -117.42 147.78 18.78 Favored Glycine 0 N--CA 1.44 -1.056 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.053 -179.35 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 5.4 t -137.16 142.84 42.2 Favored 'General case' 0 C--N 1.313 -1.002 0 CA-C-O 120.899 0.381 . . . . 0.0 111.231 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 63.2 tp -72.17 136.81 46.56 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.582 -0.736 . . . . 0.0 110.355 177.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 37.2 m . . . . . 0 C--N 1.307 -1.248 0 CA-C-O 118.802 -0.618 . . . . 0.0 110.407 -179.904 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.235 0.309 0 CA-C-O 120.655 0.264 . . . . 0.0 110.304 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . 0.559 HD21 HE21 ' A' ' 22' ' ' GLN . 9.2 tt -90.32 132.15 35.72 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-O 120.988 0.423 . . . . 0.0 110.197 179.593 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . 0.548 ' CD1' ' HB ' ' A' ' 25' ' ' ILE . 34.5 m-85 -116.43 137.97 51.73 Favored 'General case' 0 C--N 1.317 -0.841 0 CA-C-O 121.386 0.612 . . . . 0.0 111.32 -178.926 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . 0.561 ' HB2' ' OG1' ' A' ' 133' ' ' THR . 60.8 t30 -96.51 135.61 38.16 Favored 'General case' 0 C--N 1.305 -1.339 0 N-CA-C 107.176 -1.416 . . . . 0.0 107.176 177.226 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.438 ' O ' ' HA ' ' A' ' 19' ' ' GLU . 72.2 t -116.48 126.31 73.89 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 N-CA-C 113.176 0.806 . . . . 0.0 113.176 -172.419 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -118.71 137.42 53.35 Favored 'General case' 0 N--CA 1.439 -0.991 0 CA-C-N 114.479 -1.237 . . . . 0.0 107.962 175.911 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 13.4 m120 -128.79 151.64 49.35 Favored 'General case' 0 C--N 1.313 -1.007 0 N-CA-C 112.607 0.595 . . . . 0.0 112.607 -175.238 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 52.9 tt0 -122.33 110.33 15.53 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 107.527 -1.286 . . . . 0.0 107.527 175.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 40.2 p90 -134.47 4.91 3.43 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 114.556 1.317 . . . . 0.0 114.556 -172.875 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -119.32 18.99 10.08 Favored Glycine 0 N--CA 1.446 -0.65 0 C-N-CA 118.357 -1.878 . . . . 0.0 113.696 -176.11 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 152.02 -160.91 29.1 Favored Glycine 0 N--CA 1.446 -0.7 0 C-N-CA 119.541 -1.314 . . . . 0.0 112.907 179.097 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 36.6 p -102.5 -21.97 14.12 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-O 121.061 0.458 . . . . 0.0 110.462 -177.149 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 47.0 p -107.15 -1.3 22.07 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.607 -0.724 . . . . 0.0 110.423 -178.801 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -59.46 135.35 88.86 Favored Pre-proline 0 N--CA 1.453 -0.289 0 CA-C-N 115.616 -0.72 . . . . 0.0 111.068 -178.034 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -70.01 162.89 40.5 Favored 'Trans proline' 0 N--CA 1.459 -0.527 0 C-N-CA 122.653 2.235 . . . . 0.0 111.874 179.088 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 99.0 m95 -84.77 123.68 30.69 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 179.865 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 44.1 m-80 -118.68 128.46 54.54 Favored 'General case' 0 C--N 1.315 -0.898 0 N-CA-C 110.245 -0.28 . . . . 0.0 110.245 -178.869 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.438 ' HA ' ' O ' ' A' ' 6' ' ' VAL . 11.3 pt-20 -82.03 132.35 35.25 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 176.34 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -133.09 23.36 3.9 Favored Glycine 0 N--CA 1.438 -1.193 0 C-N-CA 120.028 -1.082 . . . . 0.0 112.114 -179.318 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 153.4 178.04 27.53 Favored Glycine 0 N--CA 1.439 -1.144 0 C-N-CA 120.644 -0.789 . . . . 0.0 111.969 -179.385 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . 0.559 HE21 HD21 ' A' ' 3' ' ' LEU . 4.1 pt20 -131.5 138.66 49.07 Favored 'General case' 0 C--N 1.313 -0.997 0 N-CA-C 110.012 -0.366 . . . . 0.0 110.012 -179.456 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . . . . . . . . . 44.1 m0 -113.03 175.37 5.47 Favored 'General case' 0 CA--C 1.506 -0.74 0 CA-C-O 121.081 0.467 . . . . 0.0 110.693 -178.128 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 39.4 tt0 -129.68 115.15 16.91 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-N 116.098 -0.501 . . . . 0.0 109.812 178.062 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.548 ' HB ' ' CD1' ' A' ' 4' ' ' TYR . 93.8 mt -128.33 135.62 62.14 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.962 0 CA-C-N 115.574 -0.739 . . . . 0.0 109.561 -177.29 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 86.31 71.42 1.3 Allowed Glycine 0 N--CA 1.441 -1.01 0 C-N-CA 119.935 -1.126 . . . . 0.0 111.363 -179.781 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 32.1 t -59.79 -41.07 90.36 Favored 'General case' 0 C--N 1.318 -0.796 0 N-CA-C 109.526 -0.546 . . . . 0.0 109.526 179.413 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 97.1 mtt180 -99.35 133.54 43.5 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 176.064 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 2.4 p -86.22 2.37 47.29 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-O 121.011 0.434 . . . . 0.0 111.908 -177.832 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 -66.0 -34.28 77.73 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.407 178.74 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . 0.498 ' NE2' ' HA ' ' A' ' 31' ' ' GLN . 5.6 mm-40 -143.1 126.58 16.79 Favored 'General case' 0 CA--C 1.502 -0.871 0 N-CA-C 113.367 0.877 . . . . 0.0 113.367 -177.239 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . 0.461 ' HB3' ' HA3' ' A' ' 111' ' ' GLY . 95.9 m-20 -90.4 156.04 18.51 Favored 'General case' 0 N--CA 1.446 -0.639 0 CA-C-N 115.022 -0.99 . . . . 0.0 110.091 177.466 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 18.0 m -105.77 137.33 36.2 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.034 0 CA-C-N 115.727 -0.67 . . . . 0.0 112.672 -175.979 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 27.7 m -111.73 -20.59 6.13 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.2 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.908 177.535 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.628 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -145.21 144.83 31.05 Favored 'General case' 0 C--N 1.321 -0.663 0 C-N-CA 119.94 -0.704 . . . . 0.0 111.533 178.68 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 91.6 mt -144.33 126.88 10.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 N-CA-C 108.709 -0.848 . . . . 0.0 108.709 -179.535 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . 0.551 ' HA ' ' O ' ' A' ' 103' ' ' ILE . 3.3 t-20 -140.22 114.31 9.04 Favored 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 179.097 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.582 HG11 ' CD2' ' A' ' 61' ' ' PHE . 16.5 m -151.96 158.77 4.28 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.931 0 CA-C-O 120.807 0.337 . . . . 0.0 111.834 -173.743 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 66.2 tt0 -139.19 147.96 42.5 Favored 'General case' 0 N--CA 1.451 -0.392 0 CA-C-N 115.229 -0.896 . . . . 0.0 109.299 174.836 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . 0.426 ' OG ' ' HB ' ' A' ' 101' ' ' VAL . 95.2 p -82.31 166.05 19.84 Favored 'General case' 0 C--N 1.313 -0.984 0 CA-C-O 121.146 0.498 . . . . 0.0 111.911 -179.351 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -107.74 -52.41 0.71 Allowed Glycine 0 N--CA 1.442 -0.948 0 CA-C-N 115.528 -0.76 . . . . 0.0 111.344 175.1 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -131.14 102.12 5.87 Favored 'General case' 0 C--N 1.326 -0.431 0 C-N-CA 122.334 0.253 . . . . 0.0 111.262 -179.563 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 83.8 m-20 52.1 26.4 3.81 Favored 'General case' 0 N--CA 1.492 1.656 0 N-CA-C 113.732 1.012 . . . . 0.0 113.732 177.105 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 82.48 -6.5 68.57 Favored Glycine 0 C--N 1.312 -0.761 0 C-N-CA 120.333 -0.936 . . . . 0.0 113.396 178.184 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 28.3 mt-30 -64.95 -32.49 74.23 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 117.219 0.509 . . . . 0.0 110.842 -179.065 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 4.9 t -118.11 131.44 56.43 Favored 'General case' 0 C--N 1.307 -1.279 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 174.652 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . 0.432 ' HB2' ' HB3' ' A' ' 63' ' ' ALA . 91.7 mt -126.26 134.37 51.2 Favored 'General case' 0 C--N 1.316 -0.861 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 -177.756 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 20.7 p30 -143.89 147.43 34.01 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-O 121.207 0.527 . . . . 0.0 111.511 179.569 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 164.4 -142.49 7.83 Favored Glycine 0 N--CA 1.442 -0.934 0 N-CA-C 111.389 -0.684 . . . . 0.0 111.389 179.873 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 40.2 p -132.98 150.39 52.16 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-O 121.028 0.442 . . . . 0.0 111.846 -178.938 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 32.2 mtp -124.17 152.68 42.56 Favored 'General case' 0 C--N 1.326 -0.415 0 C-N-CA 123.341 0.656 . . . . 0.0 109.603 176.348 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.628 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 24.1 m -130.37 123.6 30.27 Favored 'General case' 0 C--O 1.25 1.081 0 C-N-CA 121.141 -0.224 . . . . 0.0 110.435 176.313 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . 0.456 ' HB2' ' HB2' ' A' ' 56' ' ' GLU . 71.8 m-85 -85.57 164.33 17.83 Favored 'General case' 0 C--O 1.232 0.173 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.43 178.712 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -67.22 101.88 0.97 Allowed 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.499 -179.996 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 97.06 -0.85 60.61 Favored Glycine 0 N--CA 1.45 -0.427 0 C-N-CA 120.731 -0.747 . . . . 0.0 113.229 177.674 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . 0.456 ' HB2' ' HB2' ' A' ' 53' ' ' TYR . 79.9 mm-40 -111.19 179.77 3.95 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 117.024 0.412 . . . . 0.0 110.739 -179.982 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -95.75 168.16 26.16 Favored Glycine 0 N--CA 1.443 -0.868 0 C-N-CA 120.845 -0.693 . . . . 0.0 111.944 178.922 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 23.5 Cg_exo -64.45 139.77 66.36 Favored 'Trans proline' 0 C--O 1.238 0.523 0 C-N-CA 122.657 2.238 . . . . 0.0 112.301 179.002 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . 0.433 ' HB ' ' O ' ' A' ' 76' ' ' GLN . 48.9 pt -131.74 168.4 24.05 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 CA-C-N 115.801 -0.636 . . . . 0.0 109.918 179.0 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -79.95 148.31 30.02 Favored Glycine 0 C--N 1.32 -0.351 0 C-N-CA 120.874 -0.679 . . . . 0.0 111.645 -179.816 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.582 ' CD2' HG11 ' A' ' 38' ' ' VAL . 2.6 t80 -136.88 130.83 32.3 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-O 120.819 0.342 . . . . 0.0 111.18 -178.538 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 57.3 ttp180 -135.62 134.81 39.66 Favored 'General case' 0 C--O 1.232 0.142 0 CA-C-N 115.833 -0.621 . . . . 0.0 109.934 176.784 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.522 ' HB1' ' HB3' ' A' ' 71' ' ' TYR . . . -136.81 146.14 45.32 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 120.738 0.304 . . . . 0.0 111.484 179.797 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 65.0 m -125.27 131.25 53.13 Favored 'General case' 0 CA--C 1.537 0.461 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.055 178.952 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 61.1 tp -74.26 119.19 18.13 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.334 0.588 . . . . 0.0 112.311 -177.205 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 94.2 mt -90.1 -29.52 18.28 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.502 -0.772 . . . . 0.0 109.849 175.227 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 134.23 166.68 11.31 Favored Glycine 0 N--CA 1.447 -0.578 0 N-CA-C 110.962 -0.855 . . . . 0.0 110.962 -179.135 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 53.9 m-80 58.06 36.39 25.96 Favored 'General case' 0 N--CA 1.477 0.883 0 CA-C-N 117.21 0.505 . . . . 0.0 111.331 179.245 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 17.3 m120 63.59 14.08 7.8 Favored 'General case' 0 N--CA 1.479 0.987 0 CA-C-N 115.614 -0.721 . . . . 0.0 111.277 179.204 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 17.6 m -101.33 126.07 48.04 Favored 'General case' 0 C--O 1.239 0.552 0 CA-C-O 121.081 0.467 . . . . 0.0 111.156 -178.883 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.522 ' HB3' ' HB1' ' A' ' 63' ' ' ALA . 91.0 m-85 -114.52 141.98 47.01 Favored 'General case' 0 C--N 1.313 -0.997 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.494 -178.556 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . 0.429 ' O ' ' HA ' ' A' ' 63' ' ' ALA . 35.8 tt0 -90.39 120.16 31.28 Favored 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 108.35 -0.982 . . . . 0.0 108.35 175.574 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.492 HG13 ' CE1' ' A' ' 61' ' ' PHE . 54.2 t -103.67 132.83 49.19 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.013 0 N-CA-C 113.871 1.063 . . . . 0.0 113.871 -171.953 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 70.6 mt-10 -129.3 129.47 44.91 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 114.472 -1.24 . . . . 0.0 107.976 173.762 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 96.4 m-20 -109.12 145.48 35.63 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 121.279 0.562 . . . . 0.0 111.838 -177.781 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' GLN . . . . . 0.433 ' O ' ' HB ' ' A' ' 59' ' ' ILE . 10.4 tt0 -111.26 123.59 50.51 Favored 'General case' 0 C--N 1.316 -0.873 0 C-N-CA 124.032 0.933 . . . . 0.0 111.592 -177.125 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 10.0 p90 -140.27 155.61 46.79 Favored 'General case' 0 C--N 1.316 -0.89 0 N-CA-C 110.52 -0.178 . . . . 0.0 110.52 175.061 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 107.0 -9.71 39.92 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.852 -0.69 . . . . 0.0 112.279 -179.934 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 145.03 171.81 15.02 Favored Glycine 0 N--CA 1.447 -0.591 0 N-CA-C 111.581 -0.608 . . . . 0.0 111.581 178.912 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 1.8 p-10 -62.9 153.03 34.7 Favored 'General case' 0 C--O 1.241 0.609 0 CA-C-N 117.015 0.408 . . . . 0.0 110.31 178.081 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 16.3 m 65.42 -95.06 0.04 OUTLIER 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.717 -0.674 . . . . 0.0 109.497 -178.33 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 50.23 172.48 0.03 OUTLIER Pre-proline 0 CA--C 1.555 1.158 0 N-CA-C 113.533 0.938 . . . . 0.0 113.533 176.519 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_exo -69.91 144.97 54.87 Favored 'Trans proline' 0 N--CA 1.45 -1.062 0 C-N-CA 121.722 1.614 . . . . 0.0 110.161 172.255 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' TRP . . . . . . . . . . . . . 92.7 m95 -90.88 139.34 30.84 Favored 'General case' 0 C--N 1.313 -0.983 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 178.757 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 84.8 m-70 -111.5 138.63 47.77 Favored 'General case' 0 C--N 1.313 -1.005 0 N-CA-C 108.936 -0.764 . . . . 0.0 108.936 -178.822 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 10.5 m -66.85 135.62 54.17 Favored 'General case' 0 C--N 1.314 -0.957 0 CA-C-O 120.675 0.274 . . . . 0.0 110.922 -177.324 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -110.01 -44.59 1.01 Allowed Glycine 0 N--CA 1.443 -0.838 0 C-N-CA 120.832 -0.699 . . . . 0.0 111.742 179.376 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 143.74 -158.7 27.44 Favored Glycine 0 C--O 1.214 -1.151 0 C-N-CA 120.723 -0.751 . . . . 0.0 111.473 178.681 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 19.1 m120 -115.33 129.25 56.55 Favored 'General case' 0 C--N 1.315 -0.918 0 CA-C-N 117.303 0.551 . . . . 0.0 110.88 179.278 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 23.3 m0 -118.96 150.73 39.42 Favored 'General case' 0 N--CA 1.466 0.335 0 N-CA-C 109.981 -0.377 . . . . 0.0 109.981 179.777 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 92.1 mt -109.63 123.08 65.23 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 177.76 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 83.6 mt -134.3 84.85 2.14 Favored 'General case' 0 C--O 1.265 1.871 0 O-C-N 123.688 0.617 . . . . 0.0 112.473 -175.85 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 168.13 110.36 0.23 Allowed Glycine 0 C--O 1.218 -0.903 0 C-N-CA 120.649 -0.786 . . . . 0.0 112.688 178.003 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 68.3 p -100.78 -9.43 21.73 Favored 'General case' 0 C--O 1.225 -0.232 0 CA-C-O 120.984 0.421 . . . . 0.0 111.116 178.379 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 92.2 mtt180 -96.69 3.79 52.23 Favored 'General case' 0 C--O 1.232 0.162 0 C-N-CA 120.574 -0.45 . . . . 0.0 111.921 179.32 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 66.6 tt0 72.83 -83.13 0.03 OUTLIER 'General case' 0 N--CA 1.467 0.401 0 C-N-CA 123.22 0.608 . . . . 0.0 112.377 173.067 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 63.4 m-80 -92.34 34.15 1.06 Allowed 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 120.831 0.348 . . . . 0.0 111.612 -174.802 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' GLN . . . . . . . . . . . . . 23.6 tp60 -120.08 -48.11 2.35 Favored 'General case' 0 C--N 1.316 -0.875 0 C-N-CA 120.59 -0.444 . . . . 0.0 110.284 -178.945 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 93.4 m-20 72.62 137.84 0.05 Allowed 'General case' 0 N--CA 1.485 1.308 0 O-C-N 123.735 0.647 . . . . 0.0 112.284 178.499 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 69.9 t -78.43 132.4 32.44 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.33 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.871 178.861 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.426 ' HB ' ' OG ' ' A' ' 40' ' ' SER . 34.4 m -113.04 -27.64 2.68 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.517 0 N-CA-C 112.555 0.576 . . . . 0.0 112.555 -179.506 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . 0.56 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -146.82 144.45 29.35 Favored 'General case' 0 C--N 1.322 -0.619 0 C-N-CA 119.96 -0.696 . . . . 0.0 111.546 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.551 ' O ' ' HA ' ' A' ' 37' ' ' ASN . 34.1 mm -133.98 128.05 52.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.62 179.193 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . 0.43 ' HB3' ' OG1' ' A' ' 117' ' ' THR . 43.4 t30 -131.27 92.08 3.13 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.292 175.714 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 29.4 m -138.12 144.26 31.11 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.566 0 N-CA-C 113.017 0.747 . . . . 0.0 113.017 -175.451 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 79.9 tt0 -148.19 101.39 3.26 Favored 'General case' 0 CA--C 1.538 0.501 0 CA-C-N 115.558 -0.746 . . . . 0.0 110.656 176.832 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . 0.418 ' HB2' ' H ' ' A' ' 115' ' ' ASN . 69.5 m -166.69 165.82 16.27 Favored 'General case' 0 N--CA 1.475 0.821 0 CA-C-N 114.834 -1.075 . . . . 0.0 112.388 -178.909 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 116.41 117.19 2.98 Favored Glycine 0 N--CA 1.424 -2.156 0 C-N-CA 120.344 -0.932 . . . . 0.0 113.241 175.308 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 -67.38 -42.44 83.39 Favored 'General case' 0 C--N 1.319 -0.757 0 N-CA-C 107.997 -1.112 . . . . 0.0 107.997 175.639 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 30.3 t70 -142.38 33.43 1.48 Allowed 'General case' 0 C--O 1.213 -0.85 0 CA-C-N 114.428 -1.26 . . . . 0.0 108.228 175.432 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . 0.461 ' HA3' ' HB3' ' A' ' 32' ' ' ASN . . . 81.82 18.05 68.82 Favored Glycine 0 CA--C 1.523 0.538 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.656 -178.335 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 112' ' ' GLN . . . . . 0.446 ' HA ' ' CD1' ' A' ' 132' ' ' LEU . 98.1 mt-30 -66.66 -40.64 88.7 Favored 'General case' 0 C--O 1.244 0.794 0 CA-C-O 120.975 0.417 . . . . 0.0 111.71 -179.177 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 25.6 p -139.15 143.37 38.15 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.824 -0.626 . . . . 0.0 110.755 -178.391 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -119.4 123.35 43.89 Favored 'General case' 0 C--N 1.317 -0.814 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 176.539 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . 0.418 ' H ' ' HB2' ' A' ' 107' ' ' SER . 53.6 m-80 -128.66 149.6 50.6 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-O 120.851 0.358 . . . . 0.0 110.587 -178.503 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 155.48 -131.34 3.05 Favored Glycine 0 N--CA 1.438 -1.175 0 C-N-CA 120.634 -0.793 . . . . 0.0 112.343 177.971 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . 0.43 ' OG1' ' HB3' ' A' ' 104' ' ' ASN . 23.9 p -130.25 155.37 46.39 Favored 'General case' 0 C--N 1.311 -1.089 0 CA-C-O 121.015 0.436 . . . . 0.0 110.848 -178.459 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 23.2 ptm -146.2 153.34 40.52 Favored 'General case' 0 C--N 1.313 -0.991 0 CA-C-N 115.949 -0.569 . . . . 0.0 109.67 -178.809 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 119' ' ' THR . . . . . 0.56 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 26.0 m -132.99 131.34 40.64 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-O 120.642 0.258 . . . . 0.0 111.422 -179.294 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 33.0 m-85 -95.75 163.49 13.15 Favored 'General case' 0 CA--C 1.509 -0.611 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.394 175.992 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -62.75 128.59 36.64 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.588 178.155 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 70.95 15.58 74.18 Favored Glycine 0 CA--C 1.524 0.596 0 CA-C-N 115.895 -0.593 . . . . 0.0 113.257 179.44 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -127.03 179.82 5.22 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 117.149 0.474 . . . . 0.0 111.335 -179.46 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -105.55 170.09 16.91 Favored Glycine 0 N--CA 1.445 -0.754 0 N-CA-C 111.502 -0.639 . . . . 0.0 111.502 178.533 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 22.9 Cg_exo -65.37 135.39 42.61 Favored 'Trans proline' 0 CA--C 1.534 0.511 0 C-N-CA 122.542 2.161 . . . . 0.0 112.375 -179.812 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 48.0 pt -131.21 165.09 32.49 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 116.06 -0.518 . . . . 0.0 109.941 177.931 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -73.76 132.78 16.25 Favored Glycine 0 CA--C 1.521 0.464 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.751 -179.169 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 91.6 t80 -114.8 132.96 56.3 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 120.634 0.254 . . . . 0.0 111.224 -179.526 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 63.0 tttm -137.49 101.83 4.61 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.029 176.927 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -106.37 133.51 11.66 Favored Glycine 0 N--CA 1.446 -0.645 0 C-N-CA 120.977 -0.63 . . . . 0.0 111.617 179.485 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 49.1 m -130.24 137.55 50.08 Favored 'General case' 0 C--N 1.311 -1.072 0 CA-C-N 116.638 0.219 . . . . 0.0 111.191 -179.334 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 132' ' ' LEU . . . . . 0.446 ' CD1' ' HA ' ' A' ' 112' ' ' GLN . 87.9 mt -57.7 134.93 56.64 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-O 120.858 0.361 . . . . 0.0 110.31 176.781 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 133' ' ' THR . . . . . 0.561 ' OG1' ' HB2' ' A' ' 5' ' ' ASN . 57.5 m . . . . . 0 C--O 1.251 1.182 0 CA-C-O 118.643 -0.694 . . . . 0.0 110.539 -179.086 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.692 0 N-CA-C 110.373 -0.232 . . . . 0.0 110.373 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . 0.61 HD11 HE21 ' A' ' 22' ' ' GLN . 2.8 tm? -99.85 131.41 45.85 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.357 -177.663 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . 0.607 ' CE1' ' HB ' ' A' ' 25' ' ' ILE . 85.1 m-85 -121.41 145.11 48.25 Favored 'General case' 0 C--O 1.238 0.476 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.866 -179.215 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 14.9 m120 -82.67 142.23 31.85 Favored 'General case' 0 N--CA 1.468 0.436 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 176.991 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.46 HG21 ' CD1' ' A' ' 23' ' ' TRP . 59.0 t -116.09 126.76 73.72 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 N-CA-C 113.464 0.913 . . . . 0.0 113.464 -176.159 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 92.0 mt-10 -128.09 132.43 49.01 Favored 'General case' 0 N--CA 1.445 -0.683 0 CA-C-N 114.634 -1.167 . . . . 0.0 108.088 175.001 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 12.8 m120 -124.59 145.74 49.43 Favored 'General case' 0 C--N 1.313 -0.986 0 CA-C-O 120.645 0.259 . . . . 0.0 110.696 -178.158 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 52.0 tt0 -119.65 118.24 30.43 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.808 0.337 . . . . 0.0 110.464 179.071 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' TRP . . . . . 0.507 ' CZ3' ' HB2' ' A' ' 18' ' ' ASN . 2.5 m-90 -79.2 140.79 37.6 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.332 179.711 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 89.33 -42.21 3.02 Favored Glycine 0 N--CA 1.444 -0.811 0 C-N-CA 120.579 -0.82 . . . . 0.0 112.05 -179.085 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.84 21.42 71.51 Favored Glycine 0 C--O 1.227 -0.327 0 C-N-CA 120.85 -0.691 . . . . 0.0 111.581 -179.707 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 20.9 p -168.2 133.82 1.86 Allowed 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.771 -0.214 . . . . 0.0 111.188 -178.024 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 63.6 p 46.85 44.73 14.66 Favored 'General case' 0 N--CA 1.475 0.824 0 C-N-CA 123.456 0.702 . . . . 0.0 112.638 176.79 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.467 ' HA ' ' HD3' ' A' ' 16' ' ' PRO . . . -139.6 144.32 38.9 Favored Pre-proline 0 C--N 1.324 -0.517 0 C-N-CA 120.905 -0.318 . . . . 0.0 111.425 -178.158 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.467 ' HD3' ' HA ' ' A' ' 15' ' ' ALA . 11.4 Cg_exo -71.57 157.45 55.98 Favored 'Trans proline' 0 C--N 1.347 0.483 0 C-N-CA 123.033 2.489 . . . . 0.0 111.699 176.888 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 91.5 m95 -85.26 134.15 34.14 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 120.891 0.377 . . . . 0.0 110.343 179.57 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' ASN . . . . . 0.507 ' HB2' ' CZ3' ' A' ' 10' ' ' TRP . 90.7 m-20 -110.01 135.67 50.47 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.105 179.231 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 14.7 pt-20 -105.44 131.2 53.15 Favored 'General case' 0 C--N 1.314 -0.95 0 N-CA-C 109.241 -0.652 . . . . 0.0 109.241 -179.828 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -157.33 34.26 0.55 Allowed Glycine 0 N--CA 1.44 -1.045 0 C-N-CA 119.058 -1.544 . . . . 0.0 112.997 179.843 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 162.67 -179.02 38.21 Favored Glycine 0 N--CA 1.444 -0.777 0 C-N-CA 119.58 -1.295 . . . . 0.0 113.511 178.847 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . 0.61 HE21 HD11 ' A' ' 3' ' ' LEU . 3.3 pt20 -145.29 140.66 27.94 Favored 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 179.218 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . 0.46 ' CD1' HG21 ' A' ' 6' ' ' VAL . 48.0 m0 -114.74 155.97 25.7 Favored 'General case' 0 CA--C 1.505 -0.761 0 CA-C-O 120.715 0.293 . . . . 0.0 111.443 -176.213 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 77.8 tt0 -116.6 119.52 35.79 Favored 'General case' 0 C--N 1.321 -0.633 0 C-N-CA 120.445 -0.502 . . . . 0.0 110.221 177.881 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.607 ' HB ' ' CE1' ' A' ' 4' ' ' TYR . 97.7 mt -135.32 143.37 37.12 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.72 0 CA-C-N 114.998 -1.001 . . . . 0.0 109.464 -177.681 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 84.0 60.61 1.93 Allowed Glycine 0 C--O 1.225 -0.437 0 C-N-CA 120.18 -1.01 . . . . 0.0 112.398 178.629 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 15.4 m -58.15 -40.4 81.26 Favored 'General case' 0 C--N 1.317 -0.838 0 O-C-N 123.935 0.432 . . . . 0.0 111.618 179.759 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 79.9 ttt180 -61.29 -42.27 98.37 Favored 'General case' 0 CA--C 1.538 0.518 0 CA-C-N 116.588 -0.278 . . . . 0.0 111.558 178.803 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 20.1 m 75.99 -21.98 0.29 Allowed 'General case' 0 N--CA 1.482 1.17 0 C-N-CA 123.75 0.82 . . . . 0.0 113.201 179.073 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 58.3 m-20 -68.23 -11.71 59.77 Favored 'General case' 0 N--CA 1.483 1.189 0 CA-C-O 121.06 0.457 . . . . 0.0 111.414 178.243 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -152.71 136.09 15.87 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.133 -178.963 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . 0.564 ' ND2' ' HA3' ' A' ' 111' ' ' GLY . 2.5 t30 -93.45 150.81 20.16 Favored 'General case' 0 C--O 1.247 0.967 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.247 178.984 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 46.3 t -93.98 131.33 41.2 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 CA-C-N 115.697 -0.683 . . . . 0.0 109.62 -178.399 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 28.1 m -102.75 -32.43 3.11 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.686 0 C-N-CA 120.596 -0.442 . . . . 0.0 111.835 -179.595 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.641 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -135.01 145.19 47.83 Favored 'General case' 0 CA--C 1.511 -0.537 0 C-N-CA 120.349 -0.54 . . . . 0.0 111.28 -179.201 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 93.9 mt -142.33 122.54 10.72 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 CA-C-N 115.744 -0.662 . . . . 0.0 109.553 -179.543 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 19.7 m120 -130.74 112.58 13.21 Favored 'General case' 0 C--N 1.316 -0.851 0 N-CA-C 108.246 -1.02 . . . . 0.0 108.246 176.07 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.489 HG22 ' HB ' ' A' ' 103' ' ' ILE . 27.3 m -147.41 150.57 14.49 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 C-N-CA 120.665 -0.414 . . . . 0.0 111.208 -175.146 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 74.6 tt0 -142.73 145.1 33.01 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 108.955 -0.758 . . . . 0.0 108.955 176.031 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . 0.412 ' HA ' ' O ' ' A' ' 46' ' ' THR . 34.2 p -80.55 148.95 30.14 Favored 'General case' 0 C--N 1.312 -1.024 0 N-CA-C 112.203 0.446 . . . . 0.0 112.203 -176.327 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -95.06 -19.95 29.48 Favored Glycine 0 N--CA 1.449 -0.476 0 N-CA-C 111.012 -0.835 . . . . 0.0 111.012 176.831 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 15.7 m-20 -128.72 -156.56 0.76 Allowed 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 109.45 -0.574 . . . . 0.0 109.45 179.071 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 9.9 p-10 -77.23 46.89 0.52 Allowed 'General case' 0 N--CA 1.474 0.775 0 CA-C-O 121.314 0.578 . . . . 0.0 112.065 -179.11 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 88.22 -7.79 80.46 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 121.047 -0.597 . . . . 0.0 113.176 178.441 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 53.5 mt-30 -72.58 -34.83 67.71 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.964 0.382 . . . . 0.0 111.498 178.906 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . 0.412 ' O ' ' HA ' ' A' ' 40' ' ' SER . 24.5 p -115.02 132.01 56.74 Favored 'General case' 0 C--N 1.314 -0.975 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.535 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . 0.513 ' HB2' ' HB3' ' A' ' 63' ' ' ALA . 93.8 mt -124.3 127.97 48.44 Favored 'General case' 0 CA--C 1.509 -0.607 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 -179.475 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 9.0 m120 -129.39 137.05 50.7 Favored 'General case' 0 C--N 1.313 -1.011 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 -179.696 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.435 ' HA3' ' HA ' ' A' ' 38' ' ' VAL . . . 178.18 -157.22 21.1 Favored Glycine 0 N--CA 1.445 -0.72 0 C-N-CA 119.287 -1.435 . . . . 0.0 113.795 179.275 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 38.3 m -130.0 134.35 47.37 Favored 'General case' 0 CA--C 1.545 0.756 0 C-N-CA 123.087 0.555 . . . . 0.0 110.905 -178.562 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 48.0 mtp -110.2 155.32 22.14 Favored 'General case' 0 N--CA 1.468 0.459 0 C-N-CA 122.308 0.243 . . . . 0.0 110.815 177.151 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.641 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 25.5 m -133.78 126.29 30.3 Favored 'General case' 0 CA--C 1.542 0.641 0 CA-C-N 116.491 -0.322 . . . . 0.0 110.167 175.322 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . 0.483 ' HB2' ' HB2' ' A' ' 56' ' ' GLU . 65.5 m-85 -92.94 166.97 12.12 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 116.664 -0.244 . . . . 0.0 110.769 177.964 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -63.34 106.48 0.91 Allowed 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.473 -179.754 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 81.78 16.03 73.9 Favored Glycine 0 CA--C 1.52 0.358 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.788 178.857 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . 0.483 ' HB2' ' HB2' ' A' ' 53' ' ' TYR . 80.3 mm-40 -119.99 169.62 10.02 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 120.773 0.32 . . . . 0.0 110.807 -179.93 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -90.05 172.56 38.55 Favored Glycine 0 N--CA 1.444 -0.813 0 C-N-CA 120.99 -0.624 . . . . 0.0 112.303 179.925 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_exo -67.14 137.56 44.47 Favored 'Trans proline' 0 CA--C 1.535 0.56 0 C-N-CA 122.726 2.284 . . . . 0.0 112.026 179.16 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . 0.414 HD12 ' HB3' ' A' ' 75' ' ' ASN . 45.0 pt -128.79 160.86 38.91 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.428 179.195 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -75.1 141.61 28.3 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.451 -178.919 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 61.8 t80 -126.01 127.04 45.27 Favored 'General case' 0 C--N 1.32 -0.712 0 C-N-CA 122.401 0.28 . . . . 0.0 110.797 -179.792 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 29.3 ttp85 -136.97 129.04 29.44 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 175.801 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.545 ' HB1' ' HB3' ' A' ' 71' ' ' TYR . . . -136.88 146.4 45.51 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 112.304 0.483 . . . . 0.0 112.304 -177.622 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 55.9 m -122.7 128.18 50.23 Favored 'General case' 0 CA--C 1.542 0.668 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.222 178.303 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 2.3 tm? -73.47 121.52 20.68 Favored 'General case' 0 CA--C 1.538 0.493 0 CA-C-O 121.134 0.492 . . . . 0.0 111.054 -178.058 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 96.0 mt -75.04 -33.94 61.81 Favored 'General case' 0 CA--C 1.534 0.354 0 CA-C-N 115.638 -0.71 . . . . 0.0 111.907 179.799 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 126.12 -14.84 6.96 Favored Glycine 0 C--O 1.219 -0.812 0 C-N-CA 120.574 -0.822 . . . . 0.0 112.476 -178.262 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 28.9 p-10 -111.75 30.23 7.17 Favored 'General case' 0 C--N 1.316 -0.856 0 CA-C-O 120.824 0.345 . . . . 0.0 110.736 -179.078 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 96.1 m-20 69.03 6.47 5.66 Favored 'General case' 0 N--CA 1.483 1.187 0 C-N-CA 123.6 0.76 . . . . 0.0 111.499 -177.25 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 35.0 t -102.46 140.35 36.86 Favored 'General case' 0 N--CA 1.438 -1.069 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 177.178 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.545 ' HB3' ' HB1' ' A' ' 63' ' ' ALA . 66.8 m-85 -116.91 139.72 50.31 Favored 'General case' 0 C--N 1.303 -1.42 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.936 -178.296 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 39.5 tt0 -85.29 112.3 20.66 Favored 'General case' 0 C--N 1.309 -1.16 0 N-CA-C 106.759 -1.571 . . . . 0.0 106.759 173.673 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.521 HG22 ' HB2' ' A' ' 63' ' ' ALA . 70.5 t -109.41 135.83 47.17 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 N-CA-C 113.475 0.917 . . . . 0.0 113.475 -171.141 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -128.54 130.48 47.48 Favored 'General case' 0 N--CA 1.443 -0.811 0 CA-C-N 114.708 -1.133 . . . . 0.0 108.917 175.281 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' ASN . . . . . 0.414 ' HB3' HD12 ' A' ' 59' ' ' ILE . 95.9 m-20 -108.9 150.11 28.17 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.748 -179.286 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' GLN . . . . . 0.41 ' HB2' ' CE3' ' A' ' 84' ' ' TRP . 61.3 tt0 -115.49 120.36 39.24 Favored 'General case' 0 C--N 1.308 -1.232 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.435 -177.534 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 8.6 p90 -142.87 162.85 34.37 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 110.24 -0.281 . . . . 0.0 110.24 179.544 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 100.91 -9.02 58.07 Favored Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.768 -0.729 . . . . 0.0 111.97 179.781 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 137.59 159.61 8.26 Favored Glycine 0 N--CA 1.442 -0.917 0 N-CA-C 111.019 -0.832 . . . . 0.0 111.019 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 5.9 m-20 -60.41 -39.59 87.93 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 116.963 0.382 . . . . 0.0 111.687 -179.319 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 4.6 m -76.57 -4.93 45.42 Favored 'General case' 0 C--N 1.321 -0.671 0 N-CA-C 112.251 0.463 . . . . 0.0 112.251 -177.476 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -75.46 153.16 85.76 Favored Pre-proline 0 C--N 1.324 -0.538 0 CA-C-O 120.587 0.232 . . . . 0.0 111.196 -178.422 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 10.7 Cg_exo -72.34 178.48 6.06 Favored 'Trans proline' 0 C--N 1.35 0.642 0 C-N-CA 122.925 2.417 . . . . 0.0 112.017 178.646 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' TRP . . . . . 0.41 ' CE3' ' HB2' ' A' ' 76' ' ' GLN . 90.9 m95 -92.14 138.17 31.75 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 109.322 -0.622 . . . . 0.0 109.322 179.722 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 82.8 m-70 -112.59 144.61 41.79 Favored 'General case' 0 C--N 1.318 -0.791 0 N-CA-C 109.992 -0.373 . . . . 0.0 109.992 -177.685 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 19.5 p -64.36 116.4 6.03 Favored 'General case' 0 C--N 1.316 -0.89 0 CA-C-O 120.781 0.324 . . . . 0.0 111.457 -178.376 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -89.63 -46.41 4.3 Favored Glycine 0 N--CA 1.44 -1.088 0 C-N-CA 120.388 -0.911 . . . . 0.0 111.018 178.008 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 139.87 -157.86 25.48 Favored Glycine 0 N--CA 1.442 -0.909 0 C-N-CA 120.816 -0.707 . . . . 0.0 111.629 177.471 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 19.8 m120 -105.48 134.19 49.0 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 109.697 -0.483 . . . . 0.0 109.697 178.974 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' TRP . . . . . 0.489 ' CH2' HG23 ' A' ' 25' ' ' ILE . 13.8 m0 -124.04 146.13 48.77 Favored 'General case' 0 C--N 1.316 -0.862 0 CA-C-N 116.203 -0.453 . . . . 0.0 109.84 -178.548 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 91.6 mt -110.57 114.63 47.6 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.285 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 177.456 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . 0.483 ' HB3' HG21 ' A' ' 100' ' ' VAL . 85.5 mt -133.56 79.98 1.85 Allowed 'General case' 0 C--O 1.269 2.113 0 CA-C-O 121.771 0.796 . . . . 0.0 112.312 -175.724 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 170.0 109.51 0.22 Allowed Glycine 0 N--CA 1.442 -0.966 0 CA-C-N 115.344 -0.844 . . . . 0.0 111.768 -179.498 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 19.1 m -96.67 30.27 2.68 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-O 120.902 0.382 . . . . 0.0 110.349 -179.882 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' ARG . . . . . 0.556 ' CB ' ' HB3' ' A' ' 98' ' ' GLN . 9.7 mmt180 -136.56 150.54 48.65 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-O 121.257 0.551 . . . . 0.0 112.317 -176.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 79.3 tt0 -55.99 -51.27 68.33 Favored 'General case' 0 CA--C 1.541 0.601 0 CA-C-N 114.731 -1.122 . . . . 0.0 112.602 -176.961 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 57.5 m-80 -134.63 42.69 2.81 Favored 'General case' 0 N--CA 1.471 0.609 0 CA-C-O 120.965 0.412 . . . . 0.0 109.99 -179.928 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' GLN . . . . . 0.606 ' NE2' ' HB2' ' A' ' 123' ' ' GLU . 52.8 tt0 -144.37 110.39 5.41 Favored 'General case' 0 C--N 1.315 -0.919 0 CA-C-O 121.147 0.499 . . . . 0.0 110.614 -175.952 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' ASN . . . . . 0.445 ' HB3' ' OH ' ' A' ' 71' ' ' TYR . 87.7 m-20 -91.06 168.37 11.69 Favored 'General case' 0 C--O 1.244 0.782 0 CA-C-N 115.293 -0.867 . . . . 0.0 111.111 -175.73 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.483 HG21 ' HB3' ' A' ' 92' ' ' LEU . 23.6 m -83.01 140.53 16.19 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.673 0 C-N-CA 120.011 -0.676 . . . . 0.0 110.244 173.443 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 29.7 m -115.55 -27.45 2.56 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.429 0 C-N-CA 120.608 -0.437 . . . . 0.0 112.062 178.14 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . 0.448 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -147.87 142.06 26.12 Favored 'General case' 0 C--N 1.32 -0.677 0 C-N-CA 120.581 -0.447 . . . . 0.0 110.551 178.352 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.489 ' HB ' HG22 ' A' ' 38' ' ' VAL . 94.9 mt -138.4 125.75 27.83 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 N-CA-C 110.106 -0.331 . . . . 0.0 110.106 178.26 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 35.2 t30 -128.06 97.8 4.91 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.367 176.589 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.653 HG11 ' HD2' ' A' ' 128' ' ' PHE . 11.7 m -142.6 149.7 18.85 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 N-CA-C 113.185 0.809 . . . . 0.0 113.185 -176.454 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 41.9 tt0 -148.15 147.19 29.18 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.089 -0.959 . . . . 0.0 109.839 175.621 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 47.1 t -113.23 133.59 55.01 Favored 'General case' 0 N--CA 1.442 -0.874 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.355 -177.994 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -81.52 -5.07 90.22 Favored Glycine 0 N--CA 1.447 -0.568 0 N-CA-C 111.103 -0.799 . . . . 0.0 111.103 175.444 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 62.8 m-20 -114.06 -166.46 1.1 Allowed 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 109.362 -0.607 . . . . 0.0 109.362 -179.95 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 25.6 m-20 -77.68 34.97 0.18 Allowed 'General case' 0 N--CA 1.472 0.66 0 CA-C-O 120.847 0.356 . . . . 0.0 111.123 178.931 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . 0.564 ' HA3' ' ND2' ' A' ' 32' ' ' ASN . . . 81.43 8.24 87.32 Favored Glycine 0 N--CA 1.445 -0.74 0 C-N-CA 120.888 -0.672 . . . . 0.0 112.405 -178.852 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 97.3 mt-30 -66.04 -44.22 85.26 Favored 'General case' 0 C--O 1.243 0.713 0 CA-C-O 121.056 0.455 . . . . 0.0 109.995 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 22.5 p -113.12 117.61 32.44 Favored 'General case' 0 N--CA 1.441 -0.888 0 CA-C-N 115.374 -0.83 . . . . 0.0 109.259 177.548 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 34.8 tp -111.84 121.88 46.25 Favored 'General case' 0 C--N 1.311 -1.08 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 -178.957 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 26.3 p30 -145.57 164.82 30.49 Favored 'General case' 0 C--O 1.251 1.134 0 C-N-CA 120.039 -0.664 . . . . 0.0 112.677 -178.609 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 149.75 -127.78 2.53 Favored Glycine 0 N--CA 1.439 -1.12 0 CA-C-N 114.655 -1.157 . . . . 0.0 111.127 -179.636 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 31.9 p -134.0 159.75 39.82 Favored 'General case' 0 C--N 1.314 -0.96 0 CA-C-O 120.851 0.358 . . . . 0.0 111.063 -178.9 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 4.2 ppp? -157.28 161.93 39.17 Favored 'General case' 0 C--N 1.313 -1.004 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 179.154 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 119' ' ' THR . . . . . 0.448 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 48.7 m -133.39 126.3 30.99 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-N 116.46 -0.336 . . . . 0.0 110.978 -179.894 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . 0.49 ' CB ' HE21 ' A' ' 98' ' ' GLN . 64.9 m-85 -88.13 162.98 16.43 Favored 'General case' 0 CA--C 1.521 -0.147 0 CA-C-N 116.196 -0.456 . . . . 0.0 109.789 174.285 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -55.76 -30.59 61.5 Favored 'General case' 0 N--CA 1.47 0.553 0 N-CA-C 113.602 0.964 . . . . 0.0 113.602 -176.627 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -140.65 26.62 2.52 Favored Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 119.636 -1.269 . . . . 0.0 112.67 -178.434 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . 0.606 ' HB2' ' NE2' ' A' ' 98' ' ' GLN . 23.5 tp10 -112.6 -50.71 2.88 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.988 0.423 . . . . 0.0 110.461 -177.578 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 116.5 -179.76 17.76 Favored Glycine 0 N--CA 1.441 -0.986 0 N-CA-C 111.122 -0.791 . . . . 0.0 111.122 -177.639 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 7.4 Cg_exo -73.81 112.8 3.62 Favored 'Trans proline' 0 N--CA 1.461 -0.392 0 C-N-CA 122.735 2.29 . . . . 0.0 112.021 179.651 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 39.2 pt -129.84 162.92 36.58 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.862 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.517 179.734 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -72.84 144.41 35.1 Favored Glycine 0 N--CA 1.448 -0.517 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.728 -179.496 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . 0.653 ' HD2' HG11 ' A' ' 105' ' ' VAL . 21.1 t80 -125.59 132.63 52.49 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 121.162 0.506 . . . . 0.0 110.732 178.733 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 62.6 tttm -137.42 123.46 20.3 Favored 'General case' 0 C--N 1.311 -1.073 0 CA-C-N 115.0 -1.0 . . . . 0.0 108.93 -179.829 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -139.23 141.72 12.1 Favored Glycine 0 N--CA 1.436 -1.302 0 C-N-CA 120.363 -0.922 . . . . 0.0 112.725 -179.335 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 35.3 m -121.35 133.11 55.1 Favored 'General case' 0 C--N 1.311 -1.107 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.355 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 60.2 tp -66.85 139.89 57.78 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 109.754 -0.462 . . . . 0.0 109.754 178.492 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 133' ' ' THR . . . . . 0.455 HG22 ' O ' ' A' ' 3' ' ' LEU . 13.4 t . . . . . 0 C--O 1.253 1.251 0 CA-C-O 118.53 -0.748 . . . . 0.0 110.251 -179.117 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.737 0 CA-C-O 120.668 0.271 . . . . 0.0 110.42 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . 0.508 HD11 HE21 ' A' ' 22' ' ' GLN . 1.7 tm? -95.16 129.89 42.09 Favored 'General case' 0 C--N 1.319 -0.739 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 178.598 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . 0.45 ' N ' HD13 ' A' ' 3' ' ' LEU . 78.8 m-85 -120.53 145.85 46.89 Favored 'General case' 0 C--O 1.24 0.597 0 CA-C-O 121.081 0.467 . . . . 0.0 112.158 -176.842 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . 0.627 ' O ' ' HA2' ' A' ' 130' ' ' GLY . 21.6 m120 -87.46 140.46 29.51 Favored 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 107.186 -1.413 . . . . 0.0 107.186 175.274 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.49 HG21 ' CD1' ' A' ' 23' ' ' TRP . 70.1 t -114.64 128.41 71.73 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 N-CA-C 113.641 0.978 . . . . 0.0 113.641 -174.274 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.436 ' HB2' ' HB3' ' A' ' 129' ' ' LYS . 99.7 mt-10 -125.44 134.09 52.22 Favored 'General case' 0 N--CA 1.444 -0.759 0 CA-C-N 114.517 -1.219 . . . . 0.0 109.098 175.358 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 12.9 m120 -121.4 140.54 52.01 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-N 116.462 -0.336 . . . . 0.0 110.601 -178.929 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 60.8 tt0 -120.02 120.02 35.1 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.676 -178.972 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 19.6 p90 -135.72 143.18 45.21 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 110.131 -0.322 . . . . 0.0 110.131 178.708 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 106.83 8.53 31.93 Favored Glycine 0 N--CA 1.446 -0.646 0 C-N-CA 120.29 -0.957 . . . . 0.0 111.497 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 103.08 164.71 25.76 Favored Glycine 0 N--CA 1.442 -0.958 0 C-N-CA 121.344 -0.455 . . . . 0.0 112.281 178.502 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 68.8 m -59.07 -23.47 62.07 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 120.836 0.35 . . . . 0.0 111.722 178.766 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 38.8 m -73.52 -6.61 47.56 Favored 'General case' 0 CA--C 1.543 0.696 0 CA-C-O 120.7 0.286 . . . . 0.0 111.596 177.921 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.457 ' HA ' ' HD3' ' A' ' 16' ' ' PRO . . . -95.07 145.56 29.75 Favored Pre-proline 0 C--N 1.328 -0.355 0 O-C-N 122.421 -0.174 . . . . 0.0 110.881 -179.814 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.457 ' HD3' ' HA ' ' A' ' 15' ' ' ALA . 8.2 Cg_exo -73.1 163.82 37.15 Favored 'Trans proline' 0 C--N 1.347 0.492 0 C-N-CA 123.042 2.494 . . . . 0.0 112.586 179.594 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . 0.53 ' CZ3' ' HB2' ' A' ' 129' ' ' LYS . 91.3 m95 -83.51 131.13 35.02 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 178.939 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 41.2 m-80 -109.54 141.71 41.62 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.524 -177.833 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 13.9 pt-20 -112.18 137.5 50.18 Favored 'General case' 0 C--N 1.313 -0.991 0 N-CA-C 110.016 -0.364 . . . . 0.0 110.016 179.05 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -154.2 32.45 0.72 Allowed Glycine 0 N--CA 1.443 -0.842 0 C-N-CA 119.76 -1.21 . . . . 0.0 112.641 179.045 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 156.25 -177.61 33.18 Favored Glycine 0 N--CA 1.447 -0.613 0 C-N-CA 119.658 -1.258 . . . . 0.0 113.3 -179.16 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . 0.508 HE21 HD11 ' A' ' 3' ' ' LEU . 4.4 pt20 -141.62 145.35 34.9 Favored 'General case' 0 C--N 1.32 -0.704 0 N-CA-C 109.537 -0.542 . . . . 0.0 109.537 -179.828 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . 0.49 ' CD1' HG21 ' A' ' 6' ' ' VAL . 45.0 m0 -115.93 153.28 31.86 Favored 'General case' 0 C--O 1.24 0.591 0 CA-C-O 121.121 0.486 . . . . 0.0 111.895 -176.752 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 85.9 tt0 -112.17 114.47 27.29 Favored 'General case' 0 CA--C 1.508 -0.663 0 CA-C-N 115.512 -0.767 . . . . 0.0 109.072 177.998 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 96.8 mt -131.82 136.7 56.49 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-O 121.355 0.597 . . . . 0.0 112.27 -176.048 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 104.93 -26.52 22.05 Favored Glycine 0 N--CA 1.449 -0.454 0 CA-C-N 115.881 -0.6 . . . . 0.0 113.531 175.312 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 2.7 p 44.99 20.89 0.04 OUTLIER 'General case' 0 N--CA 1.486 1.335 0 C-N-CA 123.867 0.867 . . . . 0.0 112.991 -177.512 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 83.4 mtm180 -149.62 150.57 32.4 Favored 'General case' 0 C--O 1.241 0.626 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 -179.243 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 12.6 m -95.51 -15.42 22.9 Favored 'General case' 0 C--N 1.309 -1.159 0 CA-C-O 121.089 0.471 . . . . 0.0 110.268 177.828 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 23.3 m-20 -75.21 -35.5 61.5 Favored 'General case' 0 N--CA 1.468 0.475 0 CA-C-N 115.809 -0.632 . . . . 0.0 112.182 -177.052 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 5.0 mm-40 -132.49 128.23 36.93 Favored 'General case' 0 CA--C 1.509 -0.628 0 N-CA-C 113.876 1.065 . . . . 0.0 113.876 -175.34 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 3.4 m-20 -100.07 151.15 21.71 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 114.834 -1.075 . . . . 0.0 109.311 174.61 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.433 HG21 HD11 ' A' ' 36' ' ' ILE . 33.2 m -92.53 142.95 12.38 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.277 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.78 -179.818 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 27.7 m -111.4 -16.08 9.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 C-N-CA 120.931 -0.308 . . . . 0.0 111.744 178.772 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.549 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -147.94 140.75 24.74 Favored 'General case' 0 C--N 1.327 -0.411 0 C-N-CA 120.3 -0.56 . . . . 0.0 111.597 178.972 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.433 HD11 HG21 ' A' ' 33' ' ' VAL . 88.8 mt -142.84 121.29 7.7 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 178.607 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . 0.485 ' HA ' ' O ' ' A' ' 103' ' ' ILE . 4.8 t-20 -136.54 111.26 8.71 Favored 'General case' 0 C--N 1.307 -1.243 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 177.984 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.462 HG11 ' CD1' ' A' ' 61' ' ' PHE . 27.0 m -148.43 154.37 10.36 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-O 120.804 0.335 . . . . 0.0 111.626 -171.843 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 45.4 tt0 -136.34 143.37 44.07 Favored 'General case' 0 N--CA 1.447 -0.61 0 CA-C-N 115.624 -0.716 . . . . 0.0 109.371 176.644 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 88.4 p -72.83 155.04 40.33 Favored 'General case' 0 C--N 1.314 -0.961 0 CA-C-O 121.131 0.491 . . . . 0.0 111.846 -178.288 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -108.26 -45.0 1.11 Allowed Glycine 0 N--CA 1.438 -1.188 0 CA-C-N 115.596 -0.729 . . . . 0.0 111.924 177.86 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 30.7 t70 -129.3 95.28 3.99 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 111.564 0.209 . . . . 0.0 111.564 -178.772 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 52.15 31.53 9.17 Favored 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 113.594 0.961 . . . . 0.0 113.594 174.989 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 75.7 1.0 65.19 Favored Glycine 0 C--N 1.32 -0.359 0 C-N-CA 120.373 -0.918 . . . . 0.0 113.09 179.828 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 13.8 mm100 -78.48 -29.68 46.89 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-O 121.328 0.585 . . . . 0.0 109.743 178.857 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 32.1 p -121.74 144.26 48.9 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-N 115.709 -0.678 . . . . 0.0 109.912 176.738 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . 0.492 ' O ' ' HA ' ' A' ' 62' ' ' ARG . 93.3 mt -129.82 130.96 45.97 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 -178.185 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 94.0 m-20 -127.49 138.97 53.08 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 178.141 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.401 ' HA3' ' HA ' ' A' ' 38' ' ' VAL . . . 172.81 -153.04 17.68 Favored Glycine 0 N--CA 1.445 -0.732 0 C-N-CA 119.487 -1.339 . . . . 0.0 113.525 178.707 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 90.9 m -131.99 133.19 44.18 Favored 'General case' 0 C--N 1.317 -0.811 0 C-N-CA 122.704 0.402 . . . . 0.0 110.283 -178.904 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' MET . . . . . 0.566 ' HE3' HD11 ' A' ' 59' ' ' ILE . 15.7 tmm? -126.32 147.58 49.7 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 116.531 -0.304 . . . . 0.0 110.34 -178.949 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.549 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 28.4 m -128.98 129.12 44.99 Favored 'General case' 0 C--O 1.252 1.234 0 CA-C-O 120.797 0.332 . . . . 0.0 111.826 -177.505 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . 0.49 ' HB2' ' HB2' ' A' ' 56' ' ' GLU . 94.3 m-85 -83.47 167.4 17.47 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 115.811 -0.632 . . . . 0.0 110.419 177.582 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -63.96 103.71 0.62 Allowed 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 112.402 0.519 . . . . 0.0 112.402 -179.012 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 85.84 4.51 84.8 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.937 -0.649 . . . . 0.0 113.261 177.717 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . 0.49 ' HB2' ' HB2' ' A' ' 53' ' ' TYR . 81.9 mm-40 -107.97 176.99 4.95 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-O 120.697 0.284 . . . . 0.0 110.665 -179.781 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -90.11 156.82 25.52 Favored Glycine 0 N--CA 1.44 -1.048 0 C-N-CA 120.879 -0.677 . . . . 0.0 112.16 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_exo -63.67 140.32 74.03 Favored 'Trans proline' 0 CA--C 1.533 0.449 0 C-N-CA 122.758 2.305 . . . . 0.0 112.116 178.697 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . 0.566 HD11 ' HE3' ' A' ' 51' ' ' MET . 46.4 pt -130.75 166.0 29.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-N 116.341 -0.391 . . . . 0.0 110.649 179.633 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -73.29 138.63 25.55 Favored Glycine 0 N--CA 1.45 -0.398 0 N-CA-C 111.243 -0.743 . . . . 0.0 111.243 179.856 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.462 ' CD1' HG11 ' A' ' 38' ' ' VAL . 52.4 t80 -124.86 130.03 51.58 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-O 120.673 0.273 . . . . 0.0 111.111 -177.148 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . 0.492 ' HA ' ' O ' ' A' ' 47' ' ' LEU . 68.2 ttp85 -140.29 132.67 28.41 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.068 175.041 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.403 ' HB3' ' HB2' ' A' ' 47' ' ' LEU . . . -136.64 148.17 47.29 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 120.754 0.311 . . . . 0.0 111.828 -178.074 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 56.3 m -127.18 132.53 50.46 Favored 'General case' 0 CA--C 1.541 0.628 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.513 178.836 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . 0.419 HD22 ' O ' ' A' ' 70' ' ' SER . 3.4 tm? -77.13 114.54 16.04 Favored 'General case' 0 C--N 1.325 -0.486 0 C-N-CA 122.633 0.373 . . . . 0.0 110.447 -179.133 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 10.5 mp -81.99 -32.16 30.75 Favored 'General case' 0 N--CA 1.468 0.455 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.915 178.824 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 164.8 173.58 33.58 Favored Glycine 0 CA--C 1.497 -1.045 0 N-CA-C 110.614 -0.995 . . . . 0.0 110.614 -177.577 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 16.2 t30 40.23 -96.32 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.134 0 C-N-CA 123.138 0.575 . . . . 0.0 111.777 -176.947 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 24.7 m120 -140.67 19.81 2.35 Favored 'General case' 0 N--CA 1.467 0.412 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 177.29 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . 0.419 ' O ' HD22 ' A' ' 65' ' ' LEU . 40.7 t -94.54 122.98 37.69 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.308 -0.86 . . . . 0.0 111.256 -175.742 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.634 ' OH ' ' HB3' ' A' ' 99' ' ' ASN . 73.9 m-85 -116.25 137.61 52.0 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 115.817 -0.628 . . . . 0.0 110.515 -179.673 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 82.2 tt0 -92.38 125.4 37.02 Favored 'General case' 0 N--CA 1.439 -1.004 0 N-CA-C 107.476 -1.305 . . . . 0.0 107.476 172.081 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 65.5 t -105.04 130.67 55.8 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.5 0 CA-C-O 121.432 0.634 . . . . 0.0 111.973 -174.953 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 67.0 mt-10 -126.25 120.64 30.51 Favored 'General case' 0 N--CA 1.431 -1.381 0 CA-C-N 114.455 -1.248 . . . . 0.0 107.669 176.424 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 94.4 m-20 -109.55 155.73 21.03 Favored 'General case' 0 C--N 1.317 -0.831 0 CA-C-O 121.2 0.524 . . . . 0.0 111.968 -174.507 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' GLN . . . . . 0.45 ' HB2' ' CE3' ' A' ' 84' ' ' TRP . 61.4 tt0 -119.39 119.9 35.31 Favored 'General case' 0 C--N 1.31 -1.13 0 CA-C-N 115.494 -0.775 . . . . 0.0 109.933 -178.344 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 7.9 p90 -137.2 155.64 49.28 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.593 -0.276 . . . . 0.0 110.727 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 97.75 -10.27 64.39 Favored Glycine 0 N--CA 1.447 -0.615 0 N-CA-C 111.151 -0.779 . . . . 0.0 111.151 -178.652 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 139.35 159.56 8.04 Favored Glycine 0 N--CA 1.44 -1.045 0 N-CA-C 111.312 -0.715 . . . . 0.0 111.312 179.465 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 7.4 p-10 -74.55 -23.37 58.78 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-O 121.046 0.45 . . . . 0.0 111.0 -179.632 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 6.9 m -76.24 -7.89 55.87 Favored 'General case' 0 CA--C 1.542 0.654 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.622 177.346 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -83.86 158.45 62.09 Favored Pre-proline 0 C--N 1.326 -0.415 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.456 -179.407 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -72.84 177.84 7.15 Favored 'Trans proline' 0 C--O 1.237 0.471 0 C-N-CA 122.279 1.986 . . . . 0.0 111.636 177.498 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' TRP . . . . . 0.45 ' CE3' ' HB2' ' A' ' 76' ' ' GLN . 96.4 m95 -90.24 142.23 27.92 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 179.957 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 88.9 m-70 -117.87 146.98 43.51 Favored 'General case' 0 C--N 1.313 -0.986 0 N-CA-C 109.534 -0.543 . . . . 0.0 109.534 -178.71 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 18.8 p -62.87 136.85 58.07 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-O 120.561 0.22 . . . . 0.0 111.351 -179.831 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -111.89 -50.98 0.57 Allowed Glycine 0 N--CA 1.446 -0.637 0 C-N-CA 120.821 -0.704 . . . . 0.0 111.534 178.314 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 148.58 -164.47 29.08 Favored Glycine 0 C--O 1.219 -0.807 0 C-N-CA 120.603 -0.808 . . . . 0.0 111.879 178.308 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 27.9 t-20 -111.46 120.12 41.1 Favored 'General case' 0 C--N 1.317 -0.829 0 CA-C-N 116.988 0.394 . . . . 0.0 110.121 179.205 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 28.1 m0 -114.96 148.78 38.29 Favored 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 -178.472 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 79.9 mt -108.69 118.72 56.86 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.071 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 177.2 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . 0.485 ' HB3' HG21 ' A' ' 100' ' ' VAL . 84.8 mt -131.81 87.38 2.44 Favored 'General case' 0 C--O 1.271 2.2 0 CA-C-O 121.939 0.876 . . . . 0.0 113.253 -174.292 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 160.61 117.04 0.44 Allowed Glycine 0 N--CA 1.446 -0.65 0 CA-C-N 115.162 -0.926 . . . . 0.0 111.829 178.502 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 70.7 p -91.32 -12.82 33.91 Favored 'General case' 0 C--O 1.223 -0.322 0 CA-C-N 117.216 0.508 . . . . 0.0 110.517 178.798 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 94.1 mtt-85 -89.17 138.56 31.32 Favored 'General case' 0 N--CA 1.444 -0.741 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.129 178.904 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -70.94 -34.65 71.68 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 115.673 -0.694 . . . . 0.0 111.408 -175.623 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 89.4 m-20 -112.91 25.89 11.0 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.019 -0.537 . . . . 0.0 111.372 -177.404 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' GLN . . . . . . . . . . . . . 2.0 tt0 -155.49 130.58 9.42 Favored 'General case' 0 C--N 1.333 -0.136 0 C-N-CA 120.323 -0.551 . . . . 0.0 112.244 -176.251 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' ASN . . . . . 0.634 ' HB3' ' OH ' ' A' ' 71' ' ' TYR . 95.2 m-20 -99.32 162.66 12.91 Favored 'General case' 0 C--O 1.253 1.251 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.487 178.867 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.485 HG21 ' HB3' ' A' ' 92' ' ' LEU . 33.3 m -78.3 147.15 7.21 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 C-N-CA 119.884 -0.726 . . . . 0.0 110.979 179.282 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 35.5 m -123.4 -36.93 1.18 Allowed 'Isoleucine or valine' 0 C--O 1.219 -0.502 0 C-N-CA 120.728 -0.389 . . . . 0.0 111.821 177.657 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -136.25 132.19 35.48 Favored 'General case' 0 CA--C 1.503 -0.837 0 C-N-CA 120.407 -0.517 . . . . 0.0 110.687 -179.398 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.485 ' O ' ' HA ' ' A' ' 37' ' ' ASN . 92.3 mt -132.52 124.36 51.37 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 CA-C-N 116.472 -0.331 . . . . 0.0 110.111 178.255 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 7.9 t30 -125.29 97.82 5.37 Favored 'General case' 0 C--N 1.32 -0.708 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 176.482 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.429 ' CG2' ' HB ' ' A' ' 36' ' ' ILE . 26.9 m -139.94 142.97 31.0 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.782 0 N-CA-C 113.134 0.79 . . . . 0.0 113.134 -175.511 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 44.4 tt0 -146.32 148.95 32.93 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.111 -0.949 . . . . 0.0 109.215 177.37 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 40.8 t -137.37 145.06 42.84 Favored 'General case' 0 C--N 1.313 -1.022 0 CA-C-O 121.087 0.47 . . . . 0.0 111.573 -178.809 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -94.92 5.45 68.99 Favored Glycine 0 N--CA 1.441 -0.986 0 N-CA-C 111.011 -0.836 . . . . 0.0 111.011 176.313 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 83.3 m-20 -93.03 178.59 5.7 Favored 'General case' 0 CA--C 1.508 -0.65 0 CA-C-O 121.154 0.502 . . . . 0.0 111.077 178.509 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 10.8 p-10 -90.38 19.13 5.41 Favored 'General case' 0 C--N 1.311 -1.095 0 CA-C-N 115.512 -0.767 . . . . 0.0 110.5 179.444 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 106.11 4.82 38.38 Favored Glycine 0 N--CA 1.443 -0.839 0 CA-C-N 115.64 -0.709 . . . . 0.0 111.906 -177.688 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 30.7 tt0 -65.13 -45.6 84.4 Favored 'General case' 0 C--O 1.237 0.44 0 CA-C-O 120.865 0.364 . . . . 0.0 110.324 177.715 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 70.3 p -133.53 157.6 45.25 Favored 'General case' 0 N--CA 1.447 -0.577 0 CA-C-N 116.216 -0.447 . . . . 0.0 109.808 177.767 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 49.2 tp -139.09 131.46 28.46 Favored 'General case' 0 C--N 1.315 -0.9 0 N-CA-C 109.087 -0.708 . . . . 0.0 109.087 178.818 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 6.8 p30 -147.99 167.27 25.34 Favored 'General case' 0 C--N 1.319 -0.743 0 C-N-CA 119.853 -0.739 . . . . 0.0 112.878 -179.985 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 155.79 -130.24 2.71 Favored Glycine 0 N--CA 1.442 -0.938 0 CA-C-N 114.951 -1.022 . . . . 0.0 111.738 -179.821 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 33.0 p -133.37 156.98 46.67 Favored 'General case' 0 C--N 1.318 -0.796 0 C-N-CA 122.671 0.388 . . . . 0.0 110.621 -178.818 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 23.7 ptm -152.48 167.47 28.69 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 120.897 0.38 . . . . 0.0 111.096 -179.571 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 48.4 m -151.63 139.98 20.43 Favored 'General case' 0 CA--C 1.547 0.862 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.991 -179.936 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . 0.495 ' H ' ' HB3' ' A' ' 123' ' ' GLU . 67.8 m-85 -99.02 172.29 7.5 Favored 'General case' 0 N--CA 1.473 0.701 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.28 178.538 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -67.9 37.83 0.03 OUTLIER 'General case' 0 N--CA 1.487 1.421 0 C-N-CA 123.695 0.798 . . . . 0.0 113.104 -179.752 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 153.44 42.67 0.02 OUTLIER Glycine 0 CA--C 1.5 -0.879 0 N-CA-C 110.08 -1.208 . . . . 0.0 110.08 179.805 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . 0.495 ' HB3' ' H ' ' A' ' 120' ' ' TYR . 47.3 tp10 -139.69 160.82 39.0 Favored 'General case' 0 C--N 1.315 -0.925 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 -175.705 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -90.2 175.29 41.13 Favored Glycine 0 N--CA 1.443 -0.895 0 N-CA-C 111.023 -0.831 . . . . 0.0 111.023 177.238 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 22.5 Cg_exo -63.35 119.91 7.15 Favored 'Trans proline' 0 N--CA 1.461 -0.41 0 C-N-CA 121.939 1.759 . . . . 0.0 111.2 178.262 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 42.5 pt -127.53 154.11 37.55 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 CA-C-O 120.656 0.265 . . . . 0.0 110.811 -179.897 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -72.31 143.65 34.69 Favored Glycine 0 N--CA 1.444 -0.809 0 C-N-CA 121.087 -0.578 . . . . 0.0 112.463 179.422 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . 0.424 ' CD2' HG11 ' A' ' 105' ' ' VAL . 73.0 t80 -122.07 133.8 54.78 Favored 'General case' 0 C--N 1.315 -0.901 0 CA-C-O 120.689 0.281 . . . . 0.0 110.579 179.194 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 129' ' ' LYS . . . . . 0.53 ' HB2' ' CZ3' ' A' ' 17' ' ' TRP . 84.0 tttt -140.39 130.35 24.69 Favored 'General case' 0 N--CA 1.439 -0.998 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 177.539 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . 0.627 ' HA2' ' O ' ' A' ' 5' ' ' ASN . . . -134.4 141.22 12.5 Favored Glycine 0 N--CA 1.436 -1.325 0 C-N-CA 121.087 -0.578 . . . . 0.0 112.007 179.875 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 53.7 m -128.27 135.36 49.53 Favored 'General case' 0 C--N 1.314 -0.97 0 CA-C-O 120.481 0.182 . . . . 0.0 110.786 -179.473 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 54.8 tp -64.52 136.5 57.11 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 177.638 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 133' ' ' THR . . . . . 0.469 ' HB ' ' OD1' ' A' ' 5' ' ' ASN . 11.8 t . . . . . 0 C--O 1.252 1.221 0 CA-C-O 118.733 -0.651 . . . . 0.0 110.634 -179.251 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.419 ' O ' ' HB3' ' A' ' 3' ' ' LEU . . . . . . . . 0 N--CA 1.472 0.637 0 N-CA-C 110.014 -0.365 . . . . 0.0 110.014 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . 0.569 HD21 HE21 ' A' ' 22' ' ' GLN . 10.3 tt 87.41 150.74 0.06 Allowed 'General case' 0 N--CA 1.475 0.813 0 C-N-CA 124.289 1.036 . . . . 0.0 109.956 179.232 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . 0.43 ' N ' HD23 ' A' ' 3' ' ' LEU . 86.7 m-85 -132.45 154.13 50.18 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-O 120.951 0.405 . . . . 0.0 111.082 -175.007 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . 0.405 ' O ' ' HA2' ' A' ' 130' ' ' GLY . 92.7 m-20 -95.78 151.78 19.07 Favored 'General case' 0 C--N 1.314 -0.972 0 N-CA-C 107.702 -1.221 . . . . 0.0 107.702 177.664 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.47 HG21 ' CD1' ' A' ' 23' ' ' TRP . 78.5 t -111.9 121.84 65.13 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.184 0 CA-C-O 121.744 0.783 . . . . 0.0 111.73 -177.459 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.4 ' HB2' ' HB3' ' A' ' 129' ' ' LYS . 69.1 mt-10 -121.7 127.03 50.3 Favored 'General case' 0 C--N 1.311 -1.084 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 177.689 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 12.4 m120 -126.28 148.72 49.46 Favored 'General case' 0 C--N 1.312 -1.057 0 N-CA-C 112.527 0.566 . . . . 0.0 112.527 -174.036 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 54.2 tt0 -127.3 118.38 24.08 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 108.136 -1.061 . . . . 0.0 108.136 175.986 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 39.7 p90 -143.9 20.46 1.8 Allowed 'General case' 0 C--N 1.322 -0.613 0 C-N-CA 120.24 -0.584 . . . . 0.0 112.555 -175.293 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -96.53 24.15 31.93 Favored Glycine 0 N--CA 1.448 -0.532 0 C-N-CA 119.321 -1.418 . . . . 0.0 113.572 -177.43 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.55 -50.21 2.83 Favored Glycine 0 N--CA 1.466 0.683 0 CA-C-N 117.152 0.476 . . . . 0.0 114.268 178.261 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 22.6 t -172.63 153.23 2.74 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 -176.216 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 19.0 m 58.8 30.05 19.55 Favored 'General case' 0 CA--C 1.536 0.409 0 CA-C-O 121.322 0.582 . . . . 0.0 110.986 179.436 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -111.02 128.93 24.53 Favored Pre-proline 0 N--CA 1.443 -0.803 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.999 -178.053 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 97.8 Cg_endo -77.06 169.6 21.26 Favored 'Trans proline' 0 N--CA 1.456 -0.692 0 C-N-CA 122.697 2.265 . . . . 0.0 111.466 177.124 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 97.8 m95 -80.35 128.73 33.9 Favored 'General case' 0 C--N 1.314 -0.969 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 179.293 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 87.4 m-20 -116.28 127.6 54.86 Favored 'General case' 0 C--N 1.311 -1.099 0 N-CA-C 109.553 -0.536 . . . . 0.0 109.553 -177.854 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 10.7 pt-20 -83.43 127.68 33.89 Favored 'General case' 0 C--N 1.314 -0.948 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 178.453 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -137.38 19.82 3.38 Favored Glycine 0 C--O 1.225 -0.454 0 C-N-CA 120.43 -0.891 . . . . 0.0 112.812 -177.695 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 156.44 -173.01 34.27 Favored Glycine 0 N--CA 1.439 -1.163 0 C-N-CA 120.603 -0.808 . . . . 0.0 111.751 179.601 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . 0.569 HE21 HD21 ' A' ' 3' ' ' LEU . 17.6 pt20 -148.55 149.02 30.86 Favored 'General case' 0 C--N 1.311 -1.073 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 178.684 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . 0.47 ' CD1' HG21 ' A' ' 6' ' ' VAL . 48.0 m0 -118.62 150.69 39.27 Favored 'General case' 0 C--N 1.313 -1.001 0 CA-C-O 120.784 0.326 . . . . 0.0 110.473 -178.05 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 78.9 tt0 -106.13 115.14 29.71 Favored 'General case' 0 C--N 1.313 -0.983 0 C-N-CA 120.052 -0.659 . . . . 0.0 109.544 178.26 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 93.6 mt -139.19 149.47 23.17 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.891 0 CA-C-N 115.213 -0.903 . . . . 0.0 108.979 -175.85 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 90.26 83.38 1.37 Allowed Glycine 0 N--CA 1.446 -0.699 0 C-N-CA 120.482 -0.866 . . . . 0.0 112.808 179.474 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 11.6 p -94.97 13.51 24.73 Favored 'General case' 0 N--CA 1.449 -0.495 0 CA-C-O 120.969 0.414 . . . . 0.0 111.159 178.842 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 15.8 ptp180 -129.28 134.79 48.11 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 179.463 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 26.7 t -89.02 -21.92 23.24 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-O 121.121 0.486 . . . . 0.0 111.143 -179.031 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 51.8 m-20 -64.88 -36.23 83.68 Favored 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 112.746 0.647 . . . . 0.0 112.746 -177.91 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . 0.63 HE21 ' HA ' ' A' ' 31' ' ' GLN . 0.0 OUTLIER -135.74 134.47 39.08 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 111.938 0.348 . . . . 0.0 111.938 -175.095 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . 0.454 ' ND2' ' HA3' ' A' ' 111' ' ' GLY . 66.0 t30 -90.77 161.39 15.33 Favored 'General case' 0 C--O 1.24 0.572 0 CA-C-N 116.111 -0.495 . . . . 0.0 109.977 178.308 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 57.8 t -88.62 126.61 41.8 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.484 -176.756 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 30.7 m -111.46 -31.23 2.22 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.599 0 N-CA-C 113.236 0.828 . . . . 0.0 113.236 177.132 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.618 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -151.41 148.81 28.55 Favored 'General case' 0 N--CA 1.469 0.515 0 C-N-CA 119.839 -0.744 . . . . 0.0 111.959 179.828 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.401 HG12 ' HG3' ' A' ' 51' ' ' MET . 93.4 mt -141.92 126.87 17.23 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.15 -179.616 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -133.66 112.36 11.36 Favored 'General case' 0 C--N 1.321 -0.65 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 174.168 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.412 HG22 ' HB ' ' A' ' 103' ' ' ILE . 21.7 m -150.88 153.92 9.38 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-O 120.749 0.309 . . . . 0.0 111.115 -175.607 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 42.2 tt0 -145.38 151.67 38.64 Favored 'General case' 0 C--N 1.318 -0.771 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 176.414 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 27.3 p -79.46 148.08 32.03 Favored 'General case' 0 C--N 1.31 -1.14 0 CA-C-O 121.089 0.471 . . . . 0.0 111.802 -178.792 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -97.19 -10.27 54.67 Favored Glycine 0 N--CA 1.447 -0.604 0 N-CA-C 110.03 -1.228 . . . . 0.0 110.03 175.347 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . 0.404 ' C ' ' H ' ' A' ' 44' ' ' GLY . 18.9 m-20 -137.7 -160.63 1.08 Allowed 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 114.464 -0.868 . . . . 0.0 108.766 179.505 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 17.9 m-20 -76.5 34.51 0.14 Allowed 'General case' 0 N--CA 1.481 1.086 0 CA-C-O 120.971 0.415 . . . . 0.0 110.999 178.53 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.529 ' O ' ' HE2' ' A' ' 71' ' ' TYR . . . 103.11 -6.27 50.77 Favored Glycine 0 C--O 1.208 -1.484 0 N-CA-C 111.456 -0.658 . . . . 0.0 111.456 -178.827 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 59.7 tp60 -65.18 -40.13 93.83 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.233 0.54 . . . . 0.0 110.602 179.89 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 74.4 p -125.24 142.56 51.42 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.47 178.693 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . 0.494 ' HB2' ' HB3' ' A' ' 63' ' ' ALA . 92.3 mt -128.56 126.98 41.46 Favored 'General case' 0 C--N 1.322 -0.626 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 178.131 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . 0.408 ' ND2' ' HG3' ' A' ' 62' ' ' ARG . 15.1 m120 -129.02 142.3 50.96 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 179.94 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 173.28 -155.51 22.64 Favored Glycine 0 N--CA 1.441 -0.998 0 C-N-CA 119.547 -1.311 . . . . 0.0 113.145 177.69 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 53.7 m -128.35 130.86 48.38 Favored 'General case' 0 C--N 1.311 -1.079 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 -179.452 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' MET . . . . . 0.558 ' SD ' ' HH2' ' A' ' 90' ' ' TRP . 23.5 ttt -116.22 145.61 42.98 Favored 'General case' 0 C--N 1.314 -0.964 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 -179.813 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.618 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 37.6 m -122.19 126.11 47.57 Favored 'General case' 0 C--O 1.246 0.887 0 CA-C-O 121.162 0.506 . . . . 0.0 111.601 -179.19 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . . . . . . . . . 74.2 m-85 -103.58 158.63 16.23 Favored 'General case' 0 N--CA 1.445 -0.705 0 CA-C-N 115.339 -0.846 . . . . 0.0 109.338 176.739 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -61.42 137.69 58.25 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.229 -179.027 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 77.02 -60.34 3.48 Favored Glycine 0 CA--C 1.524 0.595 0 N-CA-C 114.647 0.619 . . . . 0.0 114.647 176.772 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -66.36 -40.71 89.93 Favored 'General case' 0 C--O 1.239 0.504 0 N-CA-C 113.218 0.822 . . . . 0.0 113.218 -175.272 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 111.63 -162.49 12.43 Favored Glycine 0 N--CA 1.446 -0.652 0 C-N-CA 120.0 -1.095 . . . . 0.0 112.944 178.595 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 97.8 Cg_endo -79.0 141.74 16.84 Favored 'Trans proline' 0 C--O 1.237 0.454 0 C-N-CA 123.126 2.551 . . . . 0.0 113.416 -179.636 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . 0.739 ' HB ' ' O ' ' A' ' 76' ' ' GLN . 48.7 pt -136.07 167.99 23.45 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 CA-C-N 115.712 -0.676 . . . . 0.0 109.905 176.974 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . 0.456 ' HA3' ' HB3' ' A' ' 76' ' ' GLN . . . -73.95 142.66 31.07 Favored Glycine 0 C--O 1.237 0.338 0 C-N-CA 120.332 -0.937 . . . . 0.0 111.357 -179.49 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 37.8 t80 -128.1 125.0 38.36 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-O 120.611 0.243 . . . . 0.0 111.001 -177.647 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . 0.448 HH21 ' CD ' ' A' ' 74' ' ' GLU . 19.5 ttp85 -135.12 130.63 35.77 Favored 'General case' 0 C--O 1.217 -0.612 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 175.352 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.494 ' HB3' ' HB2' ' A' ' 47' ' ' LEU . . . -137.44 146.2 44.06 Favored 'General case' 0 C--N 1.317 -0.828 0 C-N-CA 120.835 -0.346 . . . . 0.0 111.38 -179.597 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 63.4 m -125.11 134.71 52.36 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.069 179.074 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 55.6 tp -63.83 118.5 8.44 Favored 'General case' 0 CA--C 1.509 -0.617 0 CA-C-O 121.074 0.464 . . . . 0.0 110.998 -179.767 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 52.3 tp -67.53 -39.43 85.04 Favored 'General case' 0 N--CA 1.436 -1.146 0 CA-C-N 115.374 -0.83 . . . . 0.0 111.116 -179.956 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 178.68 -37.69 0.08 OUTLIER Glycine 0 N--CA 1.446 -0.652 0 C-N-CA 120.485 -0.864 . . . . 0.0 112.557 179.763 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 18.8 p-10 -173.73 114.05 0.21 Allowed 'General case' 0 C--N 1.326 -0.414 0 C-N-CA 122.405 0.282 . . . . 0.0 110.353 -178.611 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . 0.405 ' OD1' ' HA3' ' A' ' 93' ' ' GLY . 96.1 m-20 68.19 -43.77 0.49 Allowed 'General case' 0 N--CA 1.484 1.273 0 C-N-CA 123.795 0.838 . . . . 0.0 113.114 -178.824 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 9.6 m -77.96 133.76 37.97 Favored 'General case' 0 C--N 1.315 -0.932 0 CA-C-O 121.113 0.482 . . . . 0.0 110.898 178.396 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.607 ' OH ' ' HB3' ' A' ' 99' ' ' ASN . 96.4 m-85 -126.41 148.74 49.57 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.037 178.586 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -95.54 117.25 30.09 Favored 'General case' 0 C--N 1.308 -1.235 0 N-CA-C 107.797 -1.186 . . . . 0.0 107.797 173.448 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 79.0 t -103.3 136.6 35.3 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.849 0 CA-C-O 121.244 0.545 . . . . 0.0 112.416 -173.635 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.465 ' HG2' ' HA ' ' A' ' 86' ' ' SER . 98.0 mt-10 -118.76 146.88 44.43 Favored 'General case' 0 N--CA 1.439 -1.025 0 CA-C-N 114.982 -1.008 . . . . 0.0 109.081 177.438 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' ASN . . . . . 0.439 ' HB3' HD12 ' A' ' 59' ' ' ILE . 10.0 m120 -123.99 137.18 54.64 Favored 'General case' 0 C--N 1.315 -0.904 0 CA-C-O 121.226 0.536 . . . . 0.0 110.931 -177.095 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' GLN . . . . . 0.739 ' O ' ' HB ' ' A' ' 59' ' ' ILE . 30.4 tt0 -110.37 115.82 30.35 Favored 'General case' 0 C--N 1.309 -1.194 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.32 -179.875 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 6.1 p90 -129.28 44.62 2.94 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-O 121.423 0.63 . . . . 0.0 110.717 179.467 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -104.8 -68.95 0.75 Allowed Glycine 0 N--CA 1.443 -0.839 0 C-N-CA 120.647 -0.787 . . . . 0.0 111.183 -178.848 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 170.81 -67.18 0.15 Allowed Glycine 0 N--CA 1.446 -0.676 0 N-CA-C 110.686 -0.965 . . . . 0.0 110.686 178.354 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 37.0 t70 -139.08 117.27 11.84 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 177.654 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 32.3 t 76.76 -75.08 0.07 Allowed 'General case' 0 C--N 1.327 -0.396 0 O-C-N 123.876 0.735 . . . . 0.0 110.092 -178.436 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 63.99 161.6 0.12 Allowed Pre-proline 0 N--CA 1.477 0.901 0 N-CA-C 112.352 0.501 . . . . 0.0 112.352 177.141 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . 0.593 ' O ' ' HB2' ' A' ' 84' ' ' TRP . 51.7 Cg_exo -57.07 -41.83 70.47 Favored 'Trans proline' 0 C--N 1.355 0.892 0 C-N-CA 122.526 2.151 . . . . 0.0 112.859 177.612 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' TRP . . . . . 0.593 ' HB2' ' O ' ' A' ' 83' ' ' PRO . 74.0 m95 94.48 116.42 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.778 0 C-N-CA 124.747 1.219 . . . . 0.0 110.231 -178.725 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 92.7 m-70 -112.15 139.04 48.0 Favored 'General case' 0 CA--C 1.517 -0.324 0 CA-C-N 116.484 -0.326 . . . . 0.0 110.531 -176.845 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . 0.465 ' HA ' ' HG2' ' A' ' 74' ' ' GLU . 13.1 m -70.61 141.3 51.76 Favored 'General case' 0 C--N 1.311 -1.092 0 CA-C-N 116.442 -0.345 . . . . 0.0 110.096 177.134 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -109.29 -34.06 2.59 Favored Glycine 0 N--CA 1.447 -0.578 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.852 -178.349 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 147.57 -160.56 28.33 Favored Glycine 0 N--CA 1.453 -0.211 0 C-N-CA 120.315 -0.945 . . . . 0.0 112.459 178.649 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 23.8 t-20 -118.67 124.61 47.8 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.433 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' TRP . . . . . 0.558 ' HH2' ' SD ' ' A' ' 51' ' ' MET . 36.2 m0 -118.24 152.88 34.87 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.129 -177.721 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 79.1 mt -107.25 116.71 51.5 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 N-CA-C 110.191 -0.299 . . . . 0.0 110.191 178.494 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . 0.402 ' HB2' ' CE1' ' A' ' 71' ' ' TYR . 90.2 mt -126.57 76.46 1.63 Allowed 'General case' 0 C--O 1.256 1.406 0 CA-C-O 121.625 0.726 . . . . 0.0 111.036 -178.411 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . 0.405 ' HA3' ' OD1' ' A' ' 69' ' ' ASN . . . -176.73 105.3 0.2 Allowed Glycine 0 N--CA 1.435 -1.374 0 CA-C-N 114.842 -1.072 . . . . 0.0 111.612 -179.551 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.4 p -86.2 -11.8 51.48 Favored 'General case' 0 C--N 1.313 -1.003 0 CA-C-O 121.265 0.555 . . . . 0.0 110.695 178.384 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 97.6 mtt180 -106.92 153.39 22.6 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.563 -0.744 . . . . 0.0 111.68 178.825 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -66.69 -43.14 85.19 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 115.207 -0.906 . . . . 0.0 112.388 -175.967 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 21.4 m120 -123.04 34.1 5.22 Favored 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 111.967 0.358 . . . . 0.0 111.967 -176.364 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' GLN . . . . . . . . . . . . . 9.6 tt0 -146.95 121.01 9.41 Favored 'General case' 0 C--N 1.32 -0.688 0 C-N-CA 120.278 -0.569 . . . . 0.0 110.549 -178.473 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' ASN . . . . . 0.607 ' HB3' ' OH ' ' A' ' 71' ' ' TYR . 90.2 m-20 -95.34 159.71 14.88 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.182 -176.45 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 79.1 t -81.46 133.72 28.65 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.637 0 CA-C-N 116.509 -0.314 . . . . 0.0 110.79 176.64 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 33.7 m -113.33 -26.83 2.88 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 N-CA-C 112.83 0.678 . . . . 0.0 112.83 -178.755 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . 0.648 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -146.91 140.12 25.42 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 119.696 -0.801 . . . . 0.0 112.095 178.65 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.412 ' HB ' HG22 ' A' ' 38' ' ' VAL . 91.1 mt -133.22 124.64 49.73 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.929 -0.578 . . . . 0.0 111.073 178.25 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 40.2 t30 -128.78 97.45 4.67 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.317 174.703 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 28.6 m -143.48 148.37 19.18 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 N-CA-C 112.949 0.722 . . . . 0.0 112.949 -174.526 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 76.1 tt0 -142.66 138.04 30.38 Favored 'General case' 0 N--CA 1.437 -1.092 0 CA-C-N 115.072 -0.967 . . . . 0.0 108.544 175.248 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . 0.437 ' HA ' ' HA ' ' A' ' 114' ' ' LEU . 44.8 t -74.87 -52.42 11.36 Favored 'General case' 0 C--N 1.306 -1.287 0 CA-C-N 116.09 -0.504 . . . . 0.0 111.382 -178.183 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 81.8 -9.26 57.01 Favored Glycine 0 N--CA 1.449 -0.457 0 N-CA-C 110.875 -0.89 . . . . 0.0 110.875 -176.366 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . 0.495 ' CG ' ' H ' ' A' ' 110' ' ' ASP . 19.4 t70 -125.07 -150.76 0.45 Allowed 'General case' 0 N--CA 1.445 -0.677 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 179.398 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . 0.495 ' H ' ' CG ' ' A' ' 109' ' ' ASP . 31.7 m-20 -89.86 12.88 15.99 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 120.845 0.355 . . . . 0.0 111.475 -179.426 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . 0.454 ' HA3' ' ND2' ' A' ' 32' ' ' ASN . . . 101.33 8.61 46.54 Favored Glycine 0 C--O 1.229 -0.217 0 C-N-CA 120.129 -1.034 . . . . 0.0 113.408 179.529 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 48.4 mt-30 -68.83 -42.37 77.27 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.487 0.66 . . . . 0.0 110.557 179.224 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 17.5 p -133.51 139.28 46.55 Favored 'General case' 0 C--N 1.317 -0.839 0 CA-C-N 115.32 -0.854 . . . . 0.0 110.837 179.104 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 114' ' ' LEU . . . . . 0.437 ' HA ' ' HA ' ' A' ' 107' ' ' SER . 9.1 mp -120.31 145.16 47.37 Favored 'General case' 0 C--N 1.316 -0.867 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 178.677 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 8.6 p30 -148.1 160.4 42.93 Favored 'General case' 0 C--N 1.314 -0.939 0 C-N-CA 120.617 -0.433 . . . . 0.0 110.939 178.486 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 153.35 -128.0 2.32 Favored Glycine 0 N--CA 1.436 -1.337 0 CA-C-N 115.683 -0.69 . . . . 0.0 111.673 179.875 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 22.1 p -135.24 158.83 43.36 Favored 'General case' 0 C--N 1.315 -0.9 0 CA-C-O 121.11 0.481 . . . . 0.0 111.055 -179.079 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 118' ' ' MET . . . . . 0.442 ' O ' ' HA ' ' A' ' 125' ' ' PRO . 4.7 ppp? -147.19 156.03 42.61 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 116.156 -0.474 . . . . 0.0 109.841 178.841 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 119' ' ' THR . . . . . 0.648 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 26.4 m -128.72 126.45 40.06 Favored 'General case' 0 C--O 1.254 1.292 0 CA-C-O 120.519 0.2 . . . . 0.0 111.115 179.91 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 70.0 m-85 -85.42 158.44 20.22 Favored 'General case' 0 C--O 1.233 0.196 0 CA-C-N 115.777 -0.647 . . . . 0.0 109.982 176.264 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -60.3 126.32 27.03 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 120.778 0.323 . . . . 0.0 110.796 177.631 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 65.03 30.81 78.95 Favored Glycine 0 CA--C 1.523 0.562 0 CA-C-N 115.964 -0.562 . . . . 0.0 114.113 178.715 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 77.2 tt0 -150.49 160.2 43.95 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 117.229 0.514 . . . . 0.0 110.218 -179.345 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -77.2 160.08 49.46 Favored Glycine 0 CA--C 1.522 0.53 0 C-N-CA 121.084 -0.579 . . . . 0.0 112.908 -178.947 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . 0.442 ' HA ' ' O ' ' A' ' 118' ' ' MET . 51.4 Cg_endo -68.21 142.78 56.63 Favored 'Trans proline' 0 CA--C 1.534 0.502 0 C-N-CA 122.993 2.462 . . . . 0.0 113.271 179.743 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 49.1 pt -131.6 169.42 21.8 Favored 'Isoleucine or valine' 0 C--O 1.24 0.581 0 CA-C-N 115.737 -0.665 . . . . 0.0 109.935 178.547 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -70.66 131.99 21.99 Favored Glycine 0 C--N 1.336 0.55 0 C-N-CA 120.677 -0.773 . . . . 0.0 111.981 -179.381 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 84.7 t80 -119.5 139.19 52.48 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 121.255 0.55 . . . . 0.0 111.583 -178.146 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 129' ' ' LYS . . . . . 0.4 ' HB3' ' HB2' ' A' ' 7' ' ' GLU . 62.8 tttm -140.94 134.8 30.48 Favored 'General case' 0 N--CA 1.431 -1.379 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 176.85 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . 0.405 ' HA2' ' O ' ' A' ' 5' ' ' ASN . . . -135.15 144.75 16.78 Favored Glycine 0 N--CA 1.436 -1.355 0 C-N-CA 120.521 -0.847 . . . . 0.0 111.428 -179.502 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 56.2 m -123.81 130.55 52.79 Favored 'General case' 0 C--N 1.311 -1.084 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 -178.72 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 61.1 tp -70.67 136.22 48.9 Favored 'General case' 0 C--O 1.237 0.436 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 179.076 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 15.4 t . . . . . 0 C--O 1.251 1.149 0 CA-C-O 119.144 -0.455 . . . . 0.0 110.069 -177.65 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.578 ' O ' ' HG3' ' A' ' 24' ' ' GLU . . . . . . . . 0 N--CA 1.48 1.047 0 N-CA-C 110.022 -0.362 . . . . 0.0 110.022 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -91.97 128.23 37.74 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-O 121.019 0.437 . . . . 0.0 110.537 -175.743 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 11.8 m-85 -121.3 144.47 48.62 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.169 178.27 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 94.4 m-20 -94.66 140.13 30.29 Favored 'General case' 0 C--N 1.313 -0.99 0 N-CA-C 107.826 -1.176 . . . . 0.0 107.826 177.538 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 77.3 t -116.33 128.46 73.65 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.961 0 CA-C-O 121.274 0.559 . . . . 0.0 112.434 -175.629 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -125.09 138.75 54.18 Favored 'General case' 0 C--N 1.321 -0.645 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 176.691 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . 0.438 ' HB3' HD12 ' A' ' 126' ' ' ILE . 65.3 m-80 -131.01 151.88 50.93 Favored 'General case' 0 C--N 1.316 -0.866 0 N-CA-C 112.653 0.612 . . . . 0.0 112.653 -177.526 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . 0.413 ' OE1' ' HA ' ' A' ' 13' ' ' SER . 35.7 tt0 -129.47 128.13 42.28 Favored 'General case' 0 C--O 1.238 0.498 0 CA-C-N 115.343 -0.844 . . . . 0.0 110.533 178.336 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 46.8 p90 -138.11 146.24 42.63 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 116.575 -0.284 . . . . 0.0 110.484 178.617 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 95.12 11.82 55.76 Favored Glycine 0 N--CA 1.444 -0.775 0 C-N-CA 120.545 -0.836 . . . . 0.0 111.759 179.207 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 104.88 157.38 23.27 Favored Glycine 0 N--CA 1.442 -0.919 0 C-N-CA 120.953 -0.642 . . . . 0.0 112.144 179.088 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . 0.413 ' HA ' ' OE1' ' A' ' 9' ' ' GLN . 15.5 m -58.13 -21.16 45.42 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 112.128 0.418 . . . . 0.0 112.128 179.036 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 18.7 m -59.14 -33.73 71.23 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 120.806 0.336 . . . . 0.0 110.857 176.82 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -76.78 145.28 74.31 Favored Pre-proline 0 N--CA 1.45 -0.437 0 CA-C-N 116.009 -0.542 . . . . 0.0 111.132 -179.409 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 93.1 Cg_endo -73.26 163.19 38.62 Favored 'Trans proline' 0 C--O 1.236 0.375 0 C-N-CA 122.808 2.339 . . . . 0.0 112.266 -179.892 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 92.3 m95 -85.17 131.68 34.4 Favored 'General case' 0 C--N 1.319 -0.75 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 179.23 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 55.9 m-80 -124.1 144.94 49.59 Favored 'General case' 0 C--N 1.312 -1.029 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 -179.525 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -64.99 135.4 55.6 Favored 'General case' 0 C--N 1.311 -1.066 0 CA-C-O 121.598 0.713 . . . . 0.0 112.207 -177.274 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.427 ' HA3' HD22 ' A' ' 8' ' ' ASN . . . -112.2 34.82 4.98 Favored Glycine 0 CA--C 1.499 -0.912 0 CA-C-N 114.604 -1.18 . . . . 0.0 110.961 178.326 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 83.3 -156.85 34.24 Favored Glycine 0 N--CA 1.436 -1.353 0 N-CA-C 111.344 -0.702 . . . . 0.0 111.344 -177.387 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 13.6 pt20 -144.27 147.41 33.5 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-O 120.869 0.366 . . . . 0.0 110.246 178.204 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . 0.598 ' HB3' ' O ' ' A' ' 91' ' ' ILE . 54.4 m0 -128.33 -179.14 4.86 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.743 -173.893 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.578 ' HG3' ' O ' ' A' ' 2' ' ' ALA . 82.6 tt0 -123.69 116.15 22.6 Favored 'General case' 0 CA--C 1.511 -0.534 0 CA-C-O 120.943 0.401 . . . . 0.0 110.522 176.446 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 95.3 mt -126.94 134.16 66.8 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.784 0 CA-C-N 115.448 -0.796 . . . . 0.0 110.767 -177.701 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 90.94 106.74 1.38 Allowed Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.973 -0.632 . . . . 0.0 113.911 176.526 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 19.8 m -69.1 -43.04 75.29 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.369 0.604 . . . . 0.0 110.02 175.419 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -71.0 137.96 49.52 Favored 'General case' 0 N--CA 1.451 -0.396 0 CA-C-N 115.292 -0.867 . . . . 0.0 110.663 179.77 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 19.8 m -102.86 -26.16 13.23 Favored 'General case' 0 C--N 1.315 -0.924 0 CA-C-O 121.054 0.454 . . . . 0.0 110.4 178.687 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 27.1 m-20 -91.09 -5.3 55.34 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.918 179.263 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . 0.486 HE21 ' HB3' ' A' ' 53' ' ' TYR . 57.6 tp60 -139.59 120.55 14.54 Favored 'General case' 0 C--N 1.31 -1.133 0 N-CA-C 109.35 -0.611 . . . . 0.0 109.35 -178.999 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 62.0 t30 -97.74 162.76 13.11 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-O 121.172 0.51 . . . . 0.0 112.083 -175.975 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.412 ' HA ' ' HA ' ' A' ' 53' ' ' TYR . 89.5 t -98.74 133.59 40.66 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.639 0 CA-C-N 115.217 -0.902 . . . . 0.0 109.991 179.965 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 21.0 m -107.05 -27.73 2.96 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.456 0 N-CA-C 111.981 0.364 . . . . 0.0 111.981 -179.38 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.42 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -139.56 143.63 37.44 Favored 'General case' 0 CA--C 1.509 -0.634 0 C-N-CA 120.109 -0.637 . . . . 0.0 111.632 179.989 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.435 ' HB ' ' CG2' ' A' ' 105' ' ' VAL . 94.2 mt -139.64 117.73 11.4 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.832 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 179.039 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . 0.447 HD22 ' HA ' ' A' ' 37' ' ' ASN . 1.3 t-20 -129.02 108.25 10.24 Favored 'General case' 0 C--N 1.304 -1.388 0 N-CA-C 108.065 -1.087 . . . . 0.0 108.065 177.453 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.434 HG22 ' HB ' ' A' ' 103' ' ' ILE . 23.9 m -147.03 151.38 13.95 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.762 0 C-N-CA 120.448 -0.501 . . . . 0.0 111.339 -173.184 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 36.1 tt0 -141.1 145.56 35.95 Favored 'General case' 0 N--CA 1.437 -1.089 0 CA-C-N 115.512 -0.767 . . . . 0.0 109.001 176.433 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 30.9 t -72.26 142.6 48.93 Favored 'General case' 0 C--N 1.309 -1.176 0 CA-C-O 121.093 0.473 . . . . 0.0 111.338 -178.522 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -95.22 -25.12 14.79 Favored Glycine 0 N--CA 1.433 -1.553 0 C-N-CA 120.504 -0.855 . . . . 0.0 111.769 177.919 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 36.1 t70 -145.11 79.63 1.59 Allowed 'General case' 0 CA--C 1.536 0.405 0 N-CA-C 112.842 0.682 . . . . 0.0 112.842 -177.372 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 50.24 29.03 3.44 Favored 'General case' 0 N--CA 1.491 1.611 0 N-CA-C 114.564 1.32 . . . . 0.0 114.564 173.673 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.502 ' HA2' HG12 ' A' ' 101' ' ' VAL . . . 99.44 -16.77 58.6 Favored Glycine 0 C--N 1.312 -0.791 0 C-N-CA 120.658 -0.782 . . . . 0.0 113.189 178.187 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 59.7 tp60 -66.42 -39.01 88.72 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-O 121.04 0.448 . . . . 0.0 110.77 -179.944 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 36.8 p -125.67 147.84 49.21 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.975 178.499 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . 0.551 ' HB2' ' HB3' ' A' ' 63' ' ' ALA . 95.2 mt -128.36 128.15 43.99 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 109.524 -0.547 . . . . 0.0 109.524 179.254 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 13.8 m120 -128.44 141.1 51.51 Favored 'General case' 0 C--N 1.319 -0.723 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 178.398 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 175.45 -156.26 21.73 Favored Glycine 0 N--CA 1.442 -0.948 0 C-N-CA 119.411 -1.376 . . . . 0.0 113.503 178.444 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 70.4 m -128.95 131.46 47.5 Favored 'General case' 0 N--CA 1.44 -0.971 0 C-N-CA 122.839 0.456 . . . . 0.0 110.149 -178.43 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' MET . . . . . 0.403 ' HE1' ' CZ ' ' A' ' 53' ' ' TYR . 14.7 tmm? -125.91 144.73 50.56 Favored 'General case' 0 C--N 1.316 -0.875 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 -179.265 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.42 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 33.6 m -126.26 130.06 50.13 Favored 'General case' 0 C--O 1.245 0.866 0 N-CA-C 112.054 0.39 . . . . 0.0 112.054 -176.57 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . 0.486 ' HB3' HE21 ' A' ' 31' ' ' GLN . 72.4 m-85 -87.15 161.8 17.87 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.946 177.176 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -63.54 106.91 1.02 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.989 -0.55 . . . . 0.0 112.069 -179.713 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 84.67 10.6 79.0 Favored Glycine 0 N--CA 1.45 -0.413 0 C-N-CA 120.713 -0.756 . . . . 0.0 113.528 177.836 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . . . . . . . . . 57.8 mt-10 -123.07 168.02 12.9 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 117.212 0.506 . . . . 0.0 110.793 178.26 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -79.86 155.48 38.97 Favored Glycine 0 N--CA 1.447 -0.599 0 C-N-CA 120.84 -0.695 . . . . 0.0 112.379 -179.884 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 32.9 Cg_endo -62.81 142.72 89.89 Favored 'Trans proline' 0 CA--C 1.534 0.503 0 C-N-CA 123.012 2.475 . . . . 0.0 112.546 -179.758 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . 0.566 ' HB ' ' O ' ' A' ' 76' ' ' GLN . 47.3 pt -128.25 167.35 23.55 Favored 'Isoleucine or valine' 0 C--O 1.239 0.501 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.736 -179.765 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -79.11 138.63 20.89 Favored Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 120.929 -0.653 . . . . 0.0 111.807 -179.702 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 60.9 t80 -118.62 123.59 45.36 Favored 'General case' 0 C--N 1.317 -0.827 0 C-N-CA 122.389 0.275 . . . . 0.0 110.799 -178.132 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 49.1 ttm-85 -126.81 128.22 46.22 Favored 'General case' 0 C--O 1.22 -0.452 0 N-CA-C 109.325 -0.62 . . . . 0.0 109.325 175.997 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.65 ' HB1' ' HB3' ' A' ' 71' ' ' TYR . . . -136.12 142.81 44.29 Favored 'General case' 0 C--N 1.32 -0.696 0 C-N-CA 120.231 -0.588 . . . . 0.0 112.094 178.574 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 57.3 m -118.7 127.45 53.58 Favored 'General case' 0 CA--C 1.54 0.573 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.084 178.249 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . 0.403 HD13 ' N ' ' A' ' 67' ' ' GLY . 2.4 tm? -72.74 118.31 15.51 Favored 'General case' 0 CA--C 1.544 0.749 0 CA-C-O 121.372 0.606 . . . . 0.0 112.156 -177.866 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 4.6 mm? -66.86 -38.22 85.94 Favored 'General case' 0 N--CA 1.475 0.792 0 CA-C-N 115.283 -0.871 . . . . 0.0 111.869 178.091 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.403 ' N ' HD13 ' A' ' 65' ' ' LEU . . . 125.45 -6.14 8.07 Favored Glycine 0 C--O 1.227 -0.304 0 C-N-CA 120.593 -0.813 . . . . 0.0 112.521 -176.263 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 29.7 p-10 -125.83 38.19 4.2 Favored 'General case' 0 C--N 1.316 -0.889 0 CA-C-O 121.117 0.484 . . . . 0.0 110.507 -179.372 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 96.1 m-20 66.59 5.09 3.64 Favored 'General case' 0 N--CA 1.479 0.976 0 CA-C-N 115.469 -0.787 . . . . 0.0 111.882 -178.761 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 32.8 m -99.17 138.06 36.81 Favored 'General case' 0 N--CA 1.443 -0.785 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 177.367 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.65 ' HB3' ' HB1' ' A' ' 63' ' ' ALA . 91.5 m-85 -120.38 135.65 54.97 Favored 'General case' 0 C--N 1.306 -1.296 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.329 -179.28 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . 0.417 ' O ' ' HA ' ' A' ' 63' ' ' ALA . 71.6 tt0 -88.76 121.31 31.0 Favored 'General case' 0 C--N 1.311 -1.077 0 N-CA-C 107.964 -1.124 . . . . 0.0 107.964 175.286 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.469 HG22 ' HB2' ' A' ' 63' ' ' ALA . 75.3 t -107.67 137.05 40.85 Favored 'Isoleucine or valine' 0 C--O 1.247 0.957 0 N-CA-C 113.661 0.986 . . . . 0.0 113.661 -170.857 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -119.17 142.67 47.76 Favored 'General case' 0 N--CA 1.444 -0.739 0 CA-C-N 114.19 -1.368 . . . . 0.0 107.84 175.565 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 94.1 m-20 -118.06 135.31 54.27 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-O 120.825 0.345 . . . . 0.0 111.251 -175.699 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' GLN . . . . . 0.566 ' O ' ' HB ' ' A' ' 59' ' ' ILE . 17.3 tt0 -110.09 119.35 39.02 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.889 179.124 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 7.5 p90 -139.63 156.71 46.68 Favored 'General case' 0 C--N 1.326 -0.456 0 C-N-CA 120.856 -0.338 . . . . 0.0 111.358 177.013 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 105.81 -3.95 39.13 Favored Glycine 0 N--CA 1.449 -0.498 0 C-N-CA 121.198 -0.525 . . . . 0.0 112.177 179.666 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 139.63 171.57 12.35 Favored Glycine 0 CA--C 1.503 -0.694 0 N-CA-C 110.579 -1.008 . . . . 0.0 110.579 -179.602 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -68.07 155.16 40.15 Favored 'General case' 0 C--O 1.245 0.839 0 CA-C-N 117.527 0.664 . . . . 0.0 110.047 178.448 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 14.7 m 70.95 -95.2 0.03 OUTLIER 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.467 -0.788 . . . . 0.0 109.042 -176.601 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . 0.547 ' HB1' ' HD2' ' A' ' 83' ' ' PRO . . . 51.46 171.07 0.04 OUTLIER Pre-proline 0 CA--C 1.557 1.25 0 N-CA-C 113.31 0.855 . . . . 0.0 113.31 176.38 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . 0.547 ' HD2' ' HB1' ' A' ' 82' ' ' ALA . 63.6 Cg_endo -73.27 150.6 47.49 Favored 'Trans proline' 0 N--CA 1.452 -0.943 0 C-N-CA 121.591 1.527 . . . . 0.0 109.927 170.551 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' TRP . . . . . . . . . . . . . 82.2 m95 -95.69 137.99 33.98 Favored 'General case' 0 C--N 1.315 -0.924 0 C-N-CA 120.54 -0.464 . . . . 0.0 109.768 -179.91 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 84.4 m-70 -113.18 138.8 49.43 Favored 'General case' 0 C--N 1.314 -0.976 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 -177.775 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 13.4 p -65.15 131.25 46.04 Favored 'General case' 0 C--N 1.32 -0.688 0 C-N-CA 121.113 -0.235 . . . . 0.0 110.447 -179.779 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -105.36 -52.3 0.83 Allowed Glycine 0 N--CA 1.443 -0.836 0 C-N-CA 120.239 -0.981 . . . . 0.0 113.23 -179.187 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 154.59 -166.27 32.24 Favored Glycine 0 C--O 1.22 -0.747 0 C-N-CA 120.187 -1.006 . . . . 0.0 112.115 -178.108 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 20.5 t-20 -113.81 119.43 37.32 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 117.01 0.405 . . . . 0.0 110.709 -179.482 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' TRP . . . . . . . . . . . . . 22.4 m0 -108.89 148.1 31.16 Favored 'General case' 0 C--O 1.217 -0.621 0 N-CA-C 109.492 -0.558 . . . . 0.0 109.492 -179.867 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.598 ' O ' ' HB3' ' A' ' 23' ' ' TRP . 85.0 mt -107.7 119.56 57.51 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.072 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 178.903 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . 0.463 ' HB2' ' CE1' ' A' ' 71' ' ' TYR . 90.9 mt -134.08 78.95 1.79 Allowed 'General case' 0 C--O 1.267 1.984 0 CA-C-O 121.688 0.756 . . . . 0.0 111.6 -177.399 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 168.85 126.7 0.87 Allowed Glycine 0 N--CA 1.44 -1.08 0 CA-C-N 115.13 -0.941 . . . . 0.0 111.875 179.29 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . 0.425 ' HB3' ' HE1' ' A' ' 23' ' ' TRP . 32.4 p -117.95 4.2 12.13 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-O 121.353 0.596 . . . . 0.0 110.651 178.379 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 62.3 mtt-85 -102.01 142.84 32.66 Favored 'General case' 0 N--CA 1.445 -0.702 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.521 178.903 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 -62.66 -37.61 87.09 Favored 'General case' 0 C--N 1.312 -1.029 0 CA-C-N 115.421 -0.809 . . . . 0.0 112.899 -176.143 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 29.0 p-10 -126.3 27.93 6.11 Favored 'General case' 0 C--N 1.316 -0.86 0 N-CA-C 111.827 0.306 . . . . 0.0 111.827 -176.333 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' GLN . . . . . 0.552 HE21 ' HB3' ' A' ' 121' ' ' ALA . 21.9 tp60 -146.19 126.56 14.01 Favored 'General case' 0 C--N 1.322 -0.615 0 C-N-CA 119.319 -0.953 . . . . 0.0 111.688 -175.471 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' ASN . . . . . 0.591 ' HB3' ' OH ' ' A' ' 71' ' ' TYR . 87.2 m-20 -97.24 154.28 17.5 Favored 'General case' 0 C--O 1.249 1.048 0 CA-C-N 115.452 -0.795 . . . . 0.0 110.572 -179.439 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 70.8 t -79.03 136.86 22.9 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.791 0 C-N-CA 120.85 -0.34 . . . . 0.0 110.79 177.84 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.502 HG12 ' HA2' ' A' ' 44' ' ' GLY . 33.3 m -123.0 -35.52 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.714 0 N-CA-C 113.878 1.066 . . . . 0.0 113.878 -177.118 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . 0.43 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -127.59 127.33 43.68 Favored 'General case' 0 C--N 1.319 -0.743 0 C-N-CA 120.153 -0.619 . . . . 0.0 111.386 -178.63 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.434 ' HB ' HG22 ' A' ' 38' ' ' VAL . 94.0 mt -131.18 122.09 50.57 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.091 177.927 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 7.6 t30 -124.79 95.4 4.5 Favored 'General case' 0 C--N 1.313 -1.001 0 N-CA-C 108.812 -0.81 . . . . 0.0 108.812 176.455 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.435 ' CG2' ' HB ' ' A' ' 36' ' ' ILE . 26.8 m -140.17 142.68 31.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 N-CA-C 112.682 0.623 . . . . 0.0 112.682 -175.612 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 -145.1 147.16 32.23 Favored 'General case' 0 N--CA 1.444 -0.759 0 CA-C-N 115.4 -0.818 . . . . 0.0 109.153 176.526 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 47.2 t -137.73 142.48 40.99 Favored 'General case' 0 C--N 1.308 -1.221 0 CA-C-O 120.797 0.332 . . . . 0.0 110.78 -178.589 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -108.01 -6.18 32.39 Favored Glycine 0 N--CA 1.44 -1.05 0 N-CA-C 110.796 -0.922 . . . . 0.0 110.796 175.766 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 68.3 m-20 -98.26 54.65 1.09 Allowed 'General case' 0 C--O 1.235 0.33 0 N-CA-C 112.643 0.609 . . . . 0.0 112.643 -177.582 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 28.7 t70 59.55 15.55 4.65 Favored 'General case' 0 N--CA 1.481 1.098 0 C-N-CA 123.3 0.64 . . . . 0.0 112.284 174.863 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . 86.37 -3.85 86.66 Favored Glycine 0 N--CA 1.447 -0.625 0 C-N-CA 120.447 -0.882 . . . . 0.0 112.944 178.232 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 112' ' ' GLN . . . . . 0.42 ' O ' ' HA ' ' A' ' 131' ' ' THR . 97.6 mt-30 -64.21 -40.14 95.45 Favored 'General case' 0 CA--C 1.517 -0.29 0 CA-C-N 116.926 0.363 . . . . 0.0 111.622 -177.76 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 33.5 p -123.32 112.17 17.28 Favored 'General case' 0 C--N 1.318 -0.77 0 N-CA-C 110.0 -0.37 . . . . 0.0 110.0 177.833 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 92.5 mt -90.93 126.95 36.21 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 116.464 -0.335 . . . . 0.0 110.477 -178.66 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 9.0 m120 -118.72 129.86 55.51 Favored 'General case' 0 C--O 1.241 0.651 0 CA-C-N 116.224 -0.444 . . . . 0.0 109.882 -178.812 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 172.21 -141.32 6.22 Favored Glycine 0 N--CA 1.445 -0.755 0 C-N-CA 119.741 -1.218 . . . . 0.0 113.608 178.098 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 16.9 p -137.29 159.32 42.27 Favored 'General case' 0 C--N 1.319 -0.726 0 C-N-CA 123.276 0.63 . . . . 0.0 110.781 -178.269 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 17.8 ptm -147.31 150.44 34.79 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 120.864 0.364 . . . . 0.0 110.898 -179.721 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 119' ' ' THR . . . . . 0.43 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 23.3 m -142.48 136.09 29.05 Favored 'General case' 0 C--O 1.252 1.194 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.064 178.053 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . 0.628 ' HB2' ' O ' ' A' ' 123' ' ' GLU . 37.1 m-85 -83.58 174.26 10.7 Favored 'General case' 0 C--O 1.225 -0.23 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.342 175.597 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . 0.552 ' HB3' HE21 ' A' ' 98' ' ' GLN . . . -51.22 -28.87 12.55 Favored 'General case' 0 N--CA 1.478 0.933 0 N-CA-C 114.058 1.133 . . . . 0.0 114.058 -175.951 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -165.54 26.84 0.18 Allowed Glycine 0 N--CA 1.447 -0.589 0 C-N-CA 119.29 -1.433 . . . . 0.0 112.742 179.986 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . 0.628 ' O ' ' HB2' ' A' ' 120' ' ' TYR . 13.3 pt-20 -165.97 145.59 6.25 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.132 0.491 . . . . 0.0 111.868 -178.51 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 71.87 67.92 1.74 Allowed Glycine 0 CA--C 1.531 1.084 0 N-CA-C 116.312 1.285 . . . . 0.0 116.312 173.075 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_exo -84.14 95.07 0.73 Allowed 'Trans proline' 0 N--CA 1.459 -0.53 0 C-N-CA 122.454 2.102 . . . . 0.0 108.374 170.561 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 126' ' ' ILE . . . . . 0.438 HD12 ' HB3' ' A' ' 8' ' ' ASN . 19.6 pt -130.28 165.83 29.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 N-CA-C 113.234 0.828 . . . . 0.0 113.234 -170.762 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -70.44 135.99 25.96 Favored Glycine 0 C--N 1.339 0.703 0 CA-C-N 115.488 -0.778 . . . . 0.0 111.577 178.29 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 82.5 t80 -112.54 133.26 54.69 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 121.281 0.562 . . . . 0.0 111.754 -175.688 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 63.5 tttm -137.64 110.4 7.61 Favored 'General case' 0 C--N 1.314 -0.939 0 CA-C-N 115.241 -0.891 . . . . 0.0 108.933 177.089 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -117.56 153.82 17.02 Favored Glycine 0 N--CA 1.446 -0.685 0 C-N-CA 120.298 -0.953 . . . . 0.0 112.332 -178.363 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 131' ' ' THR . . . . . 0.42 ' HA ' ' O ' ' A' ' 112' ' ' GLN . 14.9 t -143.01 144.95 32.49 Favored 'General case' 0 C--N 1.311 -1.073 0 CA-C-O 121.149 0.5 . . . . 0.0 111.945 179.625 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 68.6 tp -80.91 127.16 32.24 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.342 -0.845 . . . . 0.0 110.219 178.337 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 9.1 t . . . . . 0 C--O 1.253 1.27 0 CA-C-O 118.957 -0.544 . . . . 0.0 110.496 -179.343 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.697 0 N-CA-C 109.995 -0.372 . . . . 0.0 109.995 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . 0.552 HD11 HE21 ' A' ' 22' ' ' GLN . 2.2 tm? -92.08 134.91 34.4 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 116.117 -0.492 . . . . 0.0 109.801 -178.031 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . 0.485 ' CE1' ' HB ' ' A' ' 25' ' ' ILE . 74.1 m-85 -123.36 146.54 47.87 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.515 -179.803 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . 0.428 ' O ' ' HA2' ' A' ' 130' ' ' GLY . 23.6 t-20 -96.45 140.9 30.42 Favored 'General case' 0 C--N 1.308 -1.211 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 176.627 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 69.9 t -122.77 129.53 75.1 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.916 0 N-CA-C 112.699 0.629 . . . . 0.0 112.699 -175.154 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 91.4 mt-10 -122.4 144.32 49.11 Favored 'General case' 0 C--N 1.32 -0.679 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 173.09 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 11.9 m120 -123.49 144.67 49.39 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-O 120.921 0.391 . . . . 0.0 111.493 -177.003 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . 0.595 ' HB2' ' CE3' ' A' ' 17' ' ' TRP . 57.9 tt0 -123.88 127.14 47.59 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.766 -179.853 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 8.7 p90 -136.09 139.22 42.83 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-N 116.193 -0.458 . . . . 0.0 109.865 176.915 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 105.34 8.0 36.41 Favored Glycine 0 N--CA 1.448 -0.529 0 C-N-CA 120.286 -0.959 . . . . 0.0 112.294 179.862 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 103.24 165.71 25.68 Favored Glycine 0 N--CA 1.445 -0.724 0 C-N-CA 120.402 -0.904 . . . . 0.0 113.427 177.954 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . . . . . . . . . 15.6 m -54.81 -31.81 59.6 Favored 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 123.631 0.773 . . . . 0.0 112.321 179.013 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 33.6 t -64.25 -40.0 95.11 Favored 'General case' 0 C--O 1.242 0.701 0 CA-C-O 120.97 0.414 . . . . 0.0 110.604 -179.573 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -63.43 150.55 89.56 Favored Pre-proline 0 C--O 1.235 0.34 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.403 -179.118 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 88.8 Cg_endo -75.33 156.87 41.6 Favored 'Trans proline' 0 C--O 1.238 0.477 0 C-N-CA 122.888 2.392 . . . . 0.0 112.93 -179.476 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . 0.595 ' CE3' ' HB2' ' A' ' 9' ' ' GLN . 85.7 m95 -84.91 124.59 31.82 Favored 'General case' 0 N--CA 1.446 -0.627 0 N-CA-C 107.872 -1.159 . . . . 0.0 107.872 175.71 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 55.1 m-80 -103.68 137.13 42.15 Favored 'General case' 0 C--N 1.308 -1.228 0 N-CA-C 109.122 -0.695 . . . . 0.0 109.122 -179.177 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 18.5 pt-20 -63.78 128.79 37.38 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-O 121.625 0.726 . . . . 0.0 111.673 -178.277 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.681 ' O ' ' HB2' ' A' ' 94' ' ' SER . . . -102.26 -25.28 7.92 Favored Glycine 0 N--CA 1.434 -1.467 0 CA-C-N 114.435 -1.257 . . . . 0.0 113.746 -174.851 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 139.07 -153.04 22.57 Favored Glycine 0 N--CA 1.443 -0.849 0 C-N-CA 119.684 -1.246 . . . . 0.0 112.071 -174.367 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . 0.552 HE21 HD11 ' A' ' 3' ' ' LEU . 4.1 pt20 -138.41 134.37 34.04 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 120.733 0.302 . . . . 0.0 110.707 -179.054 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . 0.471 ' HE1' ' HB3' ' A' ' 94' ' ' SER . 44.9 m0 -117.61 172.74 7.15 Favored 'General case' 0 N--CA 1.47 0.568 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.637 -179.021 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 79.2 tt0 -130.93 122.49 27.04 Favored 'General case' 0 CA--C 1.518 -0.286 0 C-N-CA 120.513 -0.475 . . . . 0.0 110.142 178.006 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.571 HG23 ' CZ3' ' A' ' 90' ' ' TRP . 99.1 mt -139.72 151.39 22.26 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.769 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.189 -176.146 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 84.62 25.91 40.68 Favored Glycine 0 C--N 1.336 0.559 0 C-N-CA 121.009 -0.615 . . . . 0.0 113.81 175.26 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 4.9 m -77.85 7.94 5.25 Favored 'General case' 0 CA--C 1.549 0.93 0 N-CA-C 112.471 0.545 . . . . 0.0 112.471 -179.06 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . 0.499 ' HA ' ' O ' ' A' ' 87' ' ' GLY . 70.7 ttt180 -64.16 -49.68 71.15 Favored 'General case' 0 N--CA 1.474 0.756 0 CA-C-O 121.14 0.495 . . . . 0.0 111.85 -177.977 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 59.2 m -161.47 25.41 0.13 Allowed 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 -179.795 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 27.4 m-20 61.35 94.38 0.04 OUTLIER 'General case' 0 C--O 1.236 0.388 0 CA-C-N 114.486 -1.234 . . . . 0.0 108.783 -175.894 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -160.93 143.42 12.6 Favored 'General case' 0 N--CA 1.443 -0.78 0 N-CA-C 107.455 -1.313 . . . . 0.0 107.455 -176.23 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . 0.515 ' HB3' ' HA3' ' A' ' 111' ' ' GLY . 3.8 m120 -83.37 134.71 34.88 Favored 'General case' 0 C--N 1.311 -1.089 0 CA-C-O 121.543 0.687 . . . . 0.0 112.589 -177.741 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.422 ' HA ' ' HA ' ' A' ' 53' ' ' TYR . 44.7 t -92.9 135.99 26.18 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.727 0 CA-C-N 114.768 -1.105 . . . . 0.0 110.153 -179.857 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 29.7 m -109.36 -18.6 7.41 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 C-N-CA 120.758 -0.377 . . . . 0.0 111.572 -179.671 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -149.92 139.1 21.22 Favored 'General case' 0 C--O 1.236 0.361 0 C-N-CA 120.787 -0.365 . . . . 0.0 111.48 178.666 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.449 ' HB ' ' CG2' ' A' ' 105' ' ' VAL . 86.8 mt -140.03 116.32 8.74 Favored 'Isoleucine or valine' 0 C--O 1.237 0.446 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 178.635 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 14.7 m120 -123.55 106.65 10.77 Favored 'General case' 0 C--N 1.311 -1.085 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 176.716 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.413 ' CG2' ' HB ' ' A' ' 103' ' ' ILE . 18.6 m -146.56 148.11 17.26 Favored 'Isoleucine or valine' 0 C--O 1.238 0.472 0 CA-C-O 120.742 0.306 . . . . 0.0 111.236 -174.764 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 83.0 tt0 -142.61 147.41 35.78 Favored 'General case' 0 C--N 1.319 -0.759 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 178.169 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 19.4 p -70.81 150.33 45.94 Favored 'General case' 0 C--N 1.319 -0.757 0 N-CA-C 112.985 0.735 . . . . 0.0 112.985 -176.248 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -103.55 -47.39 1.3 Allowed Glycine 0 N--CA 1.443 -0.879 0 N-CA-C 110.529 -1.029 . . . . 0.0 110.529 176.252 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 45.4 m-20 -102.11 -152.8 0.45 Allowed 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 109.57 -0.53 . . . . 0.0 109.57 177.065 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 19.0 m-20 -74.17 44.41 0.19 Allowed 'General case' 0 N--CA 1.486 1.367 0 N-CA-C 112.147 0.425 . . . . 0.0 112.147 -177.927 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 79.91 3.45 89.32 Favored Glycine 0 CA--C 1.506 -0.475 0 C-N-CA 120.881 -0.676 . . . . 0.0 112.056 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 61.1 mt-30 -83.43 -21.99 32.78 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-O 121.215 0.531 . . . . 0.0 110.081 178.464 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . 0.502 ' HA ' ' O ' ' A' ' 63' ' ' ALA . 35.2 p -129.03 142.62 50.85 Favored 'General case' 0 C--N 1.315 -0.907 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.936 178.52 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . 0.405 ' O ' ' HA ' ' A' ' 62' ' ' ARG . 95.9 mt -128.62 133.18 48.22 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 109.103 -0.702 . . . . 0.0 109.103 179.915 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 14.0 m120 -126.5 139.4 53.25 Favored 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 -179.97 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 169.74 -150.51 15.13 Favored Glycine 0 N--CA 1.448 -0.538 0 C-N-CA 120.112 -1.042 . . . . 0.0 112.463 178.035 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 34.8 p -134.45 152.43 51.79 Favored 'General case' 0 C--N 1.317 -0.83 0 N-CA-C 110.031 -0.359 . . . . 0.0 110.031 179.676 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 11.0 tmm? -142.12 145.49 34.3 Favored 'General case' 0 C--N 1.315 -0.912 0 C-N-CA 121.124 -0.23 . . . . 0.0 110.85 -178.829 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 60.4 m -129.07 128.64 43.97 Favored 'General case' 0 C--O 1.248 1.014 0 CA-C-O 120.81 0.338 . . . . 0.0 111.904 -177.399 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . 0.494 ' HB2' ' HB2' ' A' ' 56' ' ' GLU . 78.7 m-85 -91.11 164.63 13.86 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 115.617 -0.72 . . . . 0.0 110.327 176.86 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . . . . . . . . . . . -69.39 98.26 1.07 Allowed 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.189 179.017 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 103.9 2.16 45.78 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.946 -0.645 . . . . 0.0 112.793 177.779 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . 0.494 ' HB2' ' HB2' ' A' ' 53' ' ' TYR . 66.7 mm-40 -117.69 162.91 17.27 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 110.115 -0.328 . . . . 0.0 110.115 179.02 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -84.08 166.25 42.34 Favored Glycine 0 N--CA 1.441 -0.972 0 C-N-CA 120.282 -0.961 . . . . 0.0 111.784 179.114 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 23.1 Cg_exo -65.82 139.78 58.61 Favored 'Trans proline' 0 N--CA 1.462 -0.348 0 C-N-CA 122.459 2.106 . . . . 0.0 111.912 178.921 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 38.3 pt -128.88 161.29 38.36 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.792 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.386 178.85 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -74.8 134.48 17.41 Favored Glycine 0 N--CA 1.446 -0.669 0 N-CA-C 111.331 -0.707 . . . . 0.0 111.331 179.984 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 52.6 t80 -117.46 125.98 51.84 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-O 121.034 0.445 . . . . 0.0 111.562 -176.905 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . 0.405 ' HA ' ' O ' ' A' ' 47' ' ' LEU . 64.0 ttp85 -136.53 129.08 30.42 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.857 -0.61 . . . . 0.0 109.747 174.737 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.502 ' O ' ' HA ' ' A' ' 46' ' ' THR . . . -129.41 139.3 51.7 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 116.563 -0.289 . . . . 0.0 110.966 -177.748 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 40.6 m -122.29 128.72 51.41 Favored 'General case' 0 C--N 1.323 -0.544 0 O-C-N 123.512 0.507 . . . . 0.0 109.74 178.534 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 52.6 tp -75.58 119.28 19.42 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 112.388 0.514 . . . . 0.0 112.388 -177.082 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 84.6 mt -84.18 -27.61 27.94 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.453 -0.794 . . . . 0.0 109.438 174.847 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 129.81 158.86 9.59 Favored Glycine 0 N--CA 1.442 -0.901 0 CA-C-N 115.109 -0.95 . . . . 0.0 110.81 -178.861 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' ASN . . . . . . . . . . . . . 93.0 m-20 60.89 37.29 18.55 Favored 'General case' 0 N--CA 1.476 0.86 0 CA-C-O 120.848 0.356 . . . . 0.0 111.242 178.969 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 16.8 m120 66.37 8.15 5.48 Favored 'General case' 0 N--CA 1.485 1.309 0 C-N-CA 123.244 0.618 . . . . 0.0 112.151 179.237 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 15.8 m -92.18 121.84 34.09 Favored 'General case' 0 N--CA 1.446 -0.666 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 178.703 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . . . . . . . . . 64.8 m-85 -113.58 132.73 55.62 Favored 'General case' 0 C--N 1.312 -1.04 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.999 -178.942 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 63.2 tt0 -86.96 119.76 27.51 Favored 'General case' 0 N--CA 1.438 -1.035 0 N-CA-C 106.763 -1.569 . . . . 0.0 106.763 172.952 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 79.2 t -107.27 134.51 48.76 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 CA-C-O 121.182 0.515 . . . . 0.0 112.086 -172.824 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 87.6 mt-10 -127.37 129.61 47.9 Favored 'General case' 0 N--CA 1.438 -1.072 0 N-CA-C 107.703 -1.221 . . . . 0.0 107.703 176.363 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 48.9 m-80 -112.42 154.79 25.26 Favored 'General case' 0 C--N 1.314 -0.971 0 CA-C-O 120.967 0.413 . . . . 0.0 111.041 -176.68 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' GLN . . . . . . . . . . . . . 63.1 tt0 -115.45 119.95 37.91 Favored 'General case' 0 C--N 1.311 -1.099 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.152 -178.695 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 12.4 p90 -143.67 161.86 37.44 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.804 179.388 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 100.4 -7.21 58.06 Favored Glycine 0 N--CA 1.446 -0.674 0 C-N-CA 120.858 -0.687 . . . . 0.0 111.924 179.648 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 136.2 160.28 8.74 Favored Glycine 0 N--CA 1.44 -1.081 0 N-CA-C 111.574 -0.611 . . . . 0.0 111.574 179.92 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 15.7 t70 -59.74 -41.78 91.69 Favored 'General case' 0 C--N 1.319 -0.737 0 C-N-CA 123.115 0.566 . . . . 0.0 112.085 179.626 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 50.6 p -76.71 -3.97 40.79 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 112.573 0.583 . . . . 0.0 112.573 -179.205 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -76.52 150.74 82.5 Favored Pre-proline 0 C--N 1.325 -0.46 0 CA-C-O 120.518 0.199 . . . . 0.0 110.945 -179.686 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -74.07 -178.55 3.95 Favored 'Trans proline' 0 C--O 1.239 0.54 0 C-N-CA 122.633 2.222 . . . . 0.0 112.083 179.212 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' TRP . . . . . . . . . . . . . 89.0 m95 -95.77 140.24 30.85 Favored 'General case' 0 N--CA 1.444 -0.729 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 -179.352 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 89.5 m-70 -118.26 142.98 46.92 Favored 'General case' 0 C--N 1.31 -1.117 0 CA-C-N 116.273 -0.421 . . . . 0.0 109.949 179.878 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 11.8 p -62.85 134.26 55.97 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.843 0.354 . . . . 0.0 111.161 -178.366 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . 0.499 ' O ' ' HA ' ' A' ' 28' ' ' ARG . . . -107.89 -46.43 1.03 Allowed Glycine 0 N--CA 1.438 -1.167 0 C-N-CA 120.971 -0.633 . . . . 0.0 111.909 179.76 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 148.39 -168.0 29.08 Favored Glycine 0 C--O 1.225 -0.44 0 C-N-CA 120.031 -1.081 . . . . 0.0 112.733 178.24 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' ASN . . . . . . . . . . . . . 24.9 t-20 -106.0 117.05 33.02 Favored 'General case' 0 C--N 1.321 -0.674 0 N-CA-C 110.054 -0.35 . . . . 0.0 110.054 -179.012 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' TRP . . . . . 0.571 ' CZ3' HG23 ' A' ' 25' ' ' ILE . 18.6 m0 -113.56 148.21 36.56 Favored 'General case' 0 C--N 1.317 -0.818 0 N-CA-C 109.284 -0.635 . . . . 0.0 109.284 179.887 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 85.6 mt -105.32 117.89 51.8 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.843 0 N-CA-C 109.547 -0.538 . . . . 0.0 109.547 179.064 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 86.0 mt -129.26 78.61 1.86 Allowed 'General case' 0 C--O 1.265 1.92 0 CA-C-O 121.863 0.839 . . . . 0.0 112.092 -177.76 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 170.05 124.45 0.74 Allowed Glycine 0 N--CA 1.441 -0.987 0 CA-C-N 114.757 -1.111 . . . . 0.0 110.722 178.996 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . 0.681 ' HB2' ' O ' ' A' ' 20' ' ' GLY . 83.7 p -106.42 -7.61 17.53 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-O 120.898 0.38 . . . . 0.0 111.665 -179.55 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' ARG . . . . . 0.424 HH12 ' CD ' ' A' ' 123' ' ' GLU . 99.5 mtt180 -106.76 154.61 20.73 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 121.269 0.557 . . . . 0.0 112.091 178.871 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 26.8 tp10 -68.62 -38.83 80.89 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 114.965 -1.016 . . . . 0.0 111.061 -174.258 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 10.1 p30 -116.17 21.06 13.96 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.925 -177.076 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -136.75 115.82 12.42 Favored 'General case' 0 C--N 1.32 -0.697 0 C-N-CA 119.573 -0.851 . . . . 0.0 112.89 -176.46 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 90.4 m-20 -92.44 154.76 18.3 Favored 'General case' 0 C--O 1.249 1.057 0 CA-C-N 115.029 -0.987 . . . . 0.0 109.353 177.488 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.427 HG21 ' CH2' ' A' ' 23' ' ' TRP . 85.2 t -79.75 130.8 35.49 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.555 0 C-N-CA 120.092 -0.643 . . . . 0.0 110.899 178.492 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . 0.433 HG11 ' HA ' ' A' ' 121' ' ' ALA . 33.7 m -111.74 -19.18 7.08 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.438 0 N-CA-C 112.122 0.415 . . . . 0.0 112.122 -179.654 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . 0.639 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -152.12 140.07 20.08 Favored 'General case' 0 CA--C 1.511 -0.537 0 C-N-CA 119.899 -0.72 . . . . 0.0 111.588 176.975 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.413 ' HB ' ' CG2' ' A' ' 38' ' ' VAL . 95.4 mt -135.49 125.01 41.75 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.175 177.456 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 52.6 t30 -129.74 101.22 5.8 Favored 'General case' 0 C--N 1.315 -0.931 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 175.801 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.449 ' CG2' ' HB ' ' A' ' 36' ' ' ILE . 19.8 m -140.9 142.8 29.51 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.791 0 N-CA-C 113.195 0.813 . . . . 0.0 113.195 -175.547 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 99.9 mt-10 -141.58 151.25 43.02 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 114.911 -1.04 . . . . 0.0 108.615 176.507 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 36.5 t -130.12 146.94 51.81 Favored 'General case' 0 C--N 1.311 -1.106 0 CA-C-O 121.244 0.545 . . . . 0.0 111.871 -177.817 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -89.61 -10.98 64.63 Favored Glycine 0 N--CA 1.444 -0.792 0 N-CA-C 110.366 -1.094 . . . . 0.0 110.366 174.435 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 83.6 m-20 -94.16 -172.06 2.71 Favored 'General case' 0 CA--C 1.513 -0.48 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 178.28 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 13.5 p-10 -95.74 33.86 1.59 Allowed 'General case' 0 C--N 1.313 -0.988 0 CA-C-O 121.031 0.443 . . . . 0.0 109.986 176.884 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . 0.515 ' HA3' ' HB3' ' A' ' 32' ' ' ASN . . . 97.42 8.56 56.15 Favored Glycine 0 C--N 1.333 0.406 0 CA-C-N 115.825 -0.625 . . . . 0.0 113.803 179.13 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 112' ' ' GLN . . . . . . . . . . . . . 28.3 tt0 -64.72 -40.88 96.08 Favored 'General case' 0 C--O 1.241 0.621 0 CA-C-O 121.537 0.684 . . . . 0.0 109.858 178.383 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 73.2 p -135.58 146.93 48.47 Favored 'General case' 0 N--CA 1.446 -0.651 0 CA-C-N 114.841 -1.072 . . . . 0.0 109.483 178.306 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 114' ' ' LEU . . . . . . . . . . . . . 96.0 mt -119.97 126.47 50.93 Favored 'General case' 0 C--N 1.312 -1.06 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 178.951 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . . . . . . . . . 14.2 m120 -122.99 143.57 49.84 Favored 'General case' 0 C--N 1.317 -0.835 0 N-CA-C 110.01 -0.367 . . . . 0.0 110.01 -178.963 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 161.19 -142.11 7.83 Favored Glycine 0 N--CA 1.448 -0.513 0 C-N-CA 119.747 -1.216 . . . . 0.0 113.303 177.3 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 23.6 p -131.47 156.95 44.75 Favored 'General case' 0 C--N 1.316 -0.849 0 C-N-CA 122.919 0.488 . . . . 0.0 110.819 -178.709 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 19.9 ptm -149.69 157.08 42.9 Favored 'General case' 0 C--N 1.314 -0.945 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.152 179.955 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 119' ' ' THR . . . . . 0.639 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 40.6 m -132.0 130.31 41.24 Favored 'General case' 0 C--O 1.245 0.841 0 CA-C-N 116.589 -0.278 . . . . 0.0 111.269 -179.176 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 11.7 m-85 -94.22 160.52 14.65 Favored 'General case' 0 N--CA 1.455 -0.197 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.883 176.616 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . 0.433 ' HA ' HG11 ' A' ' 101' ' ' VAL . . . -38.7 -45.14 1.08 Allowed 'General case' 0 N--CA 1.482 1.161 0 N-CA-C 114.149 1.166 . . . . 0.0 114.149 -177.245 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -145.63 43.01 0.94 Allowed Glycine 0 CA--C 1.506 -0.514 0 C-N-CA 120.084 -1.055 . . . . 0.0 111.713 -178.972 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . 0.424 ' CD ' HH12 ' A' ' 95' ' ' ARG . 28.5 tp10 -116.13 -61.95 1.66 Allowed 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 121.199 0.523 . . . . 0.0 110.714 -177.712 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . 134.26 -179.0 17.97 Favored Glycine 0 N--CA 1.443 -0.836 0 N-CA-C 111.264 -0.734 . . . . 0.0 111.264 -178.503 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 62.0 Cg_endo -81.46 117.15 3.04 Favored 'Trans proline' 0 N--CA 1.455 -0.738 0 C-N-CA 122.424 2.082 . . . . 0.0 112.182 179.508 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 38.0 pt -126.22 161.2 32.44 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.922 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.415 -179.894 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -72.5 138.67 26.55 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.949 -0.643 . . . . 0.0 112.609 -178.732 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 77.8 t80 -114.82 132.23 56.56 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-O 121.061 0.458 . . . . 0.0 110.994 -179.153 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 129' ' ' LYS . . . . . 0.47 ' HB2' ' CZ3' ' A' ' 17' ' ' TRP . 86.9 tttt -134.28 101.33 4.97 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.098 177.43 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . 0.428 ' HA2' ' O ' ' A' ' 5' ' ' ASN . . . -109.44 150.41 17.26 Favored Glycine 0 N--CA 1.435 -1.38 0 C-N-CA 120.326 -0.94 . . . . 0.0 112.0 179.3 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 6.0 t -146.39 148.77 32.68 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-O 120.718 0.294 . . . . 0.0 111.15 179.21 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 132' ' ' LEU . . . . . . . . . . . . . 83.4 mt -63.51 132.93 52.87 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.059 -0.518 . . . . 0.0 110.107 175.796 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 6.9 p . . . . . 0 C--O 1.249 1.051 0 CA-C-O 118.511 -0.756 . . . . 0.0 110.702 178.873 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.606 ' O ' ' HG3' ' A' ' 24' ' ' GLU . . . . . . . . 0 N--CA 1.475 0.825 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . 0.46 HD12 HG21 ' A' ' 133' ' ' THR . 0.3 OUTLIER -90.94 130.58 36.86 Favored 'General case' 0 C--N 1.313 -0.994 0 CA-C-O 121.064 0.459 . . . . 0.0 109.88 -174.58 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . 0.435 ' N ' HD13 ' A' ' 3' ' ' LEU . 28.5 m-85 -116.99 137.39 52.25 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-N 115.854 -0.612 . . . . 0.0 111.24 -179.989 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' ASN . . . . . . . . . . . . . 20.8 t-20 -87.12 131.73 34.06 Favored 'General case' 0 C--N 1.306 -1.317 0 N-CA-C 106.577 -1.638 . . . . 0.0 106.577 176.884 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.522 HG21 ' CG ' ' A' ' 23' ' ' TRP . 58.6 t -114.72 126.16 72.21 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.854 0 N-CA-C 113.204 0.816 . . . . 0.0 113.204 -172.969 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.452 ' HG2' ' HB3' ' A' ' 19' ' ' GLU . 92.3 mt-10 -120.56 135.66 55.02 Favored 'General case' 0 N--CA 1.435 -1.195 0 CA-C-N 114.575 -1.193 . . . . 0.0 108.353 176.833 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 9.9 m120 -120.22 144.53 47.68 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-O 120.899 0.381 . . . . 0.0 111.858 -176.226 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . 0.56 ' OE1' ' HA ' ' A' ' 13' ' ' SER . 36.4 tt0 -129.2 122.01 28.85 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.557 -0.747 . . . . 0.0 109.869 178.754 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' TRP . . . . . . . . . . . . . 17.5 p90 -120.94 140.93 51.17 Favored 'General case' 0 C--N 1.314 -0.945 0 CA-C-O 121.337 0.589 . . . . 0.0 111.695 -179.845 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 107.24 -69.95 0.21 Allowed Glycine 0 N--CA 1.441 -1.009 0 CA-C-N 115.429 -0.805 . . . . 0.0 111.576 179.287 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -165.09 166.78 38.41 Favored Glycine 0 N--CA 1.442 -0.929 0 N-CA-C 111.612 -0.595 . . . . 0.0 111.612 179.467 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' SER . . . . . 0.56 ' HA ' ' OE1' ' A' ' 9' ' ' GLN . 11.5 p -60.04 -20.42 57.85 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 112.9 0.704 . . . . 0.0 112.9 -179.246 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 8.1 m -78.58 -5.59 53.23 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 120.642 0.258 . . . . 0.0 111.541 179.7 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -86.68 146.7 41.98 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 120.745 0.307 . . . . 0.0 111.359 -178.943 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -65.74 149.37 87.02 Favored 'Trans proline' 0 C--O 1.235 0.331 0 C-N-CA 122.823 2.349 . . . . 0.0 112.094 179.102 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' TRP . . . . . . . . . . . . . 96.9 m95 -82.88 132.27 35.16 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 178.27 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' ASN . . . . . . . . . . . . . 89.1 m-20 -120.67 122.84 41.33 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.43 -178.504 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.452 ' HB3' ' HG2' ' A' ' 7' ' ' GLU . 5.1 pt-20 -90.32 127.76 36.25 Favored 'General case' 0 C--N 1.313 -0.986 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 178.111 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -139.14 29.43 2.53 Favored Glycine 0 N--CA 1.445 -0.747 0 C-N-CA 119.761 -1.209 . . . . 0.0 112.611 -178.07 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 157.21 174.88 27.48 Favored Glycine 0 N--CA 1.438 -1.224 0 C-N-CA 120.381 -0.914 . . . . 0.0 112.458 179.829 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 4.4 pt20 -134.56 139.33 45.32 Favored 'General case' 0 C--N 1.314 -0.946 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 179.643 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' TRP . . . . . 0.53 ' HB3' ' O ' ' A' ' 91' ' ' ILE . 38.8 m0 -116.72 178.44 4.34 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.404 -176.715 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.606 ' HG3' ' O ' ' A' ' 2' ' ' ALA . 76.9 tt0 -131.58 121.48 24.46 Favored 'General case' 0 N--CA 1.441 -0.879 0 C-N-CA 120.371 -0.531 . . . . 0.0 110.447 174.899 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 91.3 mt -127.59 131.99 69.57 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.955 0 CA-C-N 115.349 -0.841 . . . . 0.0 109.479 -178.668 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 91.13 121.28 2.49 Favored Glycine 0 N--CA 1.441 -0.99 0 C-N-CA 120.474 -0.869 . . . . 0.0 112.356 179.637 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . 0.499 ' CB ' ' HA3' ' A' ' 88' ' ' GLY . 6.3 m -119.44 11.54 12.18 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-O 121.277 0.56 . . . . 0.0 109.819 179.957 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' ARG . . . . . . . . . . . . . 63.1 mtt-85 -141.07 141.84 34.22 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.391 -0.822 . . . . 0.0 109.21 -176.485 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 37.3 p -92.09 2.5 56.54 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-O 121.145 0.498 . . . . 0.0 111.344 -178.523 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 37.0 m-20 -62.31 -38.1 88.11 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.585 -0.734 . . . . 0.0 111.509 -178.839 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 1.3 tm0? -167.35 151.36 6.63 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.937 -177.276 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . 0.501 ' HB3' ' HA3' ' A' ' 111' ' ' GLY . 15.6 m120 -96.91 173.14 7.44 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.679 0.752 . . . . 0.0 111.239 179.375 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.474 HG11 HD11 ' A' ' 36' ' ' ILE . 17.2 t -102.85 134.22 44.47 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.256 0 CA-C-N 115.202 -0.908 . . . . 0.0 112.51 -175.144 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.44 HG13 ' HB2' ' A' ' 54' ' ' ALA . 27.0 m -121.11 -28.14 1.87 Allowed 'Isoleucine or valine' 0 C--O 1.255 1.352 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.602 174.946 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.674 ' HB3' ' HB ' ' A' ' 52' ' ' THR . . . -140.31 140.33 35.63 Favored 'General case' 0 N--CA 1.442 -0.837 0 CA-C-O 121.38 0.609 . . . . 0.0 111.986 -178.706 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.474 HD11 HG11 ' A' ' 33' ' ' VAL . 93.7 mt -146.41 129.57 9.27 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 177.608 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -127.92 109.14 11.3 Favored 'General case' 0 C--N 1.311 -1.088 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 175.087 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.495 HG11 ' CD1' ' A' ' 61' ' ' PHE . 19.4 m -147.47 149.49 15.47 Favored 'Isoleucine or valine' 0 C--O 1.242 0.685 0 C-N-CA 120.874 -0.33 . . . . 0.0 111.343 -174.906 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 77.6 tt0 -138.82 144.9 39.51 Favored 'General case' 0 N--CA 1.443 -0.813 0 CA-C-N 115.72 -0.673 . . . . 0.0 109.279 178.043 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' SER . . . . . . . . . . . . . 37.0 p -69.76 140.87 53.47 Favored 'General case' 0 C--N 1.317 -0.817 0 N-CA-C 112.533 0.568 . . . . 0.0 112.533 -176.862 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -86.83 -62.39 1.53 Allowed Glycine 0 CA--C 1.502 -0.771 0 N-CA-C 109.113 -1.595 . . . . 0.0 109.113 174.628 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 51.0 m-20 -88.36 -169.2 2.46 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 173.988 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' ASP . . . . . . . . . . . . . 70.9 m-20 -77.11 57.98 1.48 Allowed 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 112.462 0.542 . . . . 0.0 112.462 -177.946 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 97.02 -20.32 51.31 Favored Glycine 0 C--O 1.218 -0.857 0 C-N-CA 121.068 -0.587 . . . . 0.0 113.419 175.542 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . . . . . . . . . 56.0 mt-30 -64.99 -34.07 77.55 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 112.89 0.7 . . . . 0.0 112.89 -177.754 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . 0.525 ' HA ' ' O ' ' A' ' 63' ' ' ALA . 14.8 t -136.14 131.64 34.98 Favored 'General case' 0 N--CA 1.438 -1.049 0 C-N-CA 120.387 -0.525 . . . . 0.0 111.239 178.622 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' LEU . . . . . 0.414 ' O ' ' HA ' ' A' ' 62' ' ' ARG . 80.1 mt -111.01 133.03 53.72 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.837 -0.619 . . . . 0.0 109.508 179.384 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 64.0 m-80 -125.27 146.21 49.65 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-O 120.703 0.287 . . . . 0.0 110.706 179.238 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 163.34 -140.52 6.54 Favored Glycine 0 N--CA 1.439 -1.15 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.497 178.4 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 24.5 p -133.41 150.75 51.78 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 120.908 0.385 . . . . 0.0 111.21 -179.292 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' MET . . . . . . . . . . . . . 18.4 ttt -124.82 137.0 54.32 Favored 'General case' 0 C--N 1.32 -0.68 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 179.78 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.674 ' HB ' ' HB3' ' A' ' 35' ' ' ALA . 60.6 m -124.89 122.55 37.68 Favored 'General case' 0 C--O 1.259 1.592 0 CA-C-O 121.17 0.509 . . . . 0.0 111.799 -178.303 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' TYR . . . . . 0.428 ' HB2' ' HB2' ' A' ' 56' ' ' GLU . 98.1 m-85 -84.66 166.0 17.44 Favored 'General case' 0 CA--C 1.52 -0.201 0 CA-C-N 115.372 -0.831 . . . . 0.0 109.835 178.512 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' ALA . . . . . 0.44 ' HB2' HG13 ' A' ' 34' ' ' VAL . . . -67.94 110.69 3.99 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 120.952 0.406 . . . . 0.0 111.125 179.836 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 83.41 16.84 67.87 Favored Glycine 0 CA--C 1.522 0.493 0 C-N-CA 120.667 -0.778 . . . . 0.0 113.711 179.401 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' GLU . . . . . 0.428 ' HB2' ' HB2' ' A' ' 53' ' ' TYR . 98.1 mt-10 -132.01 163.24 28.83 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 117.339 0.569 . . . . 0.0 111.135 178.962 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -81.08 156.42 37.79 Favored Glycine 0 N--CA 1.447 -0.612 0 CA-C-N 115.955 -0.566 . . . . 0.0 112.603 -179.273 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 21.8 Cg_exo -64.62 142.56 77.86 Favored 'Trans proline' 0 C--N 1.347 0.467 0 C-N-CA 122.924 2.416 . . . . 0.0 112.81 -179.295 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' ILE . . . . . . . . . . . . . 44.7 pt -125.91 167.66 19.98 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.872 0 CA-C-N 115.527 -0.76 . . . . 0.0 109.332 177.272 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -70.37 137.63 27.97 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.19 -1.005 . . . . 0.0 111.674 -178.952 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.495 ' CD1' HG11 ' A' ' 38' ' ' VAL . 50.2 t80 -127.71 128.42 45.37 Favored 'General case' 0 C--N 1.317 -0.847 0 CA-C-O 120.757 0.313 . . . . 0.0 110.831 -177.887 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . 0.414 ' HA ' ' O ' ' A' ' 47' ' ' LEU . 63.7 ttp85 -138.77 132.72 31.13 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.181 175.276 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.525 ' O ' ' HA ' ' A' ' 46' ' ' THR . . . -127.74 137.02 52.31 Favored 'General case' 0 C--N 1.311 -1.09 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.653 179.658 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 61.2 m -123.55 132.41 53.89 Favored 'General case' 0 C--N 1.315 -0.913 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 178.776 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . 0.622 HD21 ' O ' ' A' ' 68' ' ' ASN . 3.7 mt -60.5 128.17 35.33 Favored 'General case' 0 CA--C 1.501 -0.911 0 N-CA-C 113.928 1.085 . . . . 0.0 113.928 -178.13 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.595 HD11 ' ND2' ' A' ' 89' ' ' ASN . 96.1 mt -76.43 -34.72 58.77 Favored 'General case' 0 N--CA 1.431 -1.394 0 N-CA-C 107.27 -1.381 . . . . 0.0 107.27 169.004 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -166.91 -72.66 0.03 OUTLIER Glycine 0 N--CA 1.433 -1.564 0 C-N-CA 120.405 -0.903 . . . . 0.0 115.013 -179.504 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' ASN . . . . . 0.622 ' O ' HD21 ' A' ' 65' ' ' LEU . 17.0 m120 -125.3 -77.34 0.59 Allowed 'General case' 0 C--O 1.214 -0.782 0 CA-C-N 118.212 1.006 . . . . 0.0 110.202 -175.85 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' ASN . . . . . . . . . . . . . 12.2 m120 -100.94 -6.31 24.77 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 120.898 0.38 . . . . 0.0 110.643 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 8.3 m -95.37 121.13 36.72 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.698 -178.134 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' TYR . . . . . 0.416 ' CE2' ' HG ' ' A' ' 65' ' ' LEU . 96.0 m-85 -115.9 150.21 37.44 Favored 'General case' 0 C--N 1.314 -0.937 0 CA-C-N 116.323 -0.399 . . . . 0.0 111.181 -178.657 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 70.4 tt0 -105.72 125.53 51.09 Favored 'General case' 0 C--N 1.31 -1.125 0 N-CA-C 107.451 -1.315 . . . . 0.0 107.451 173.499 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 65.3 t -104.8 132.27 51.9 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.388 0 CA-C-O 121.544 0.687 . . . . 0.0 112.471 -174.172 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 47.5 mt-10 -127.35 123.54 36.52 Favored 'General case' 0 N--CA 1.436 -1.161 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 176.631 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' ASN . . . . . . . . . . . . . 97.5 m-20 -110.83 153.43 25.41 Favored 'General case' 0 C--N 1.317 -0.819 0 CA-C-O 121.229 0.538 . . . . 0.0 111.934 -176.018 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' GLN . . . . . 0.498 ' HB2' ' CE3' ' A' ' 84' ' ' TRP . 60.0 tt0 -113.98 116.43 29.21 Favored 'General case' 0 C--N 1.312 -1.05 0 CA-C-N 115.607 -0.724 . . . . 0.0 109.933 -178.589 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' TRP . . . . . . . . . . . . . 13.4 p90 -142.72 160.59 40.01 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.157 179.446 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 94.68 -3.66 68.29 Favored Glycine 0 N--CA 1.449 -0.473 0 C-N-CA 120.599 -0.81 . . . . 0.0 112.073 -179.532 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 135.21 152.44 6.49 Favored Glycine 0 N--CA 1.446 -0.65 0 N-CA-C 111.469 -0.652 . . . . 0.0 111.469 179.38 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 25.7 t70 -62.71 -36.82 84.22 Favored 'General case' 0 N--CA 1.468 0.453 0 CA-C-O 120.869 0.366 . . . . 0.0 111.932 -179.71 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 29.3 p -69.65 -15.78 63.25 Favored 'General case' 0 C--N 1.316 -0.86 0 N-CA-C 112.125 0.417 . . . . 0.0 112.125 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -75.87 142.71 73.43 Favored Pre-proline 0 C--O 1.234 0.267 0 CA-C-N 116.478 -0.328 . . . . 0.0 110.884 -179.512 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 96.7 Cg_endo -73.59 156.25 49.5 Favored 'Trans proline' 0 N--CA 1.462 -0.353 0 C-N-CA 122.712 2.274 . . . . 0.0 111.819 178.731 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' TRP . . . . . 0.498 ' CE3' ' HB2' ' A' ' 76' ' ' GLN . 81.7 m95 -60.98 138.31 58.18 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.305 0.574 . . . . 0.0 111.543 179.615 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 99.1 m-70 -113.03 144.65 42.24 Favored 'General case' 0 C--N 1.311 -1.096 0 CA-C-N 115.213 -0.903 . . . . 0.0 109.208 178.344 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' SER . . . . . . . . . . . . . 12.9 p -61.46 125.75 24.9 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-O 121.192 0.52 . . . . 0.0 111.941 -177.293 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -96.42 -48.85 2.11 Favored Glycine 0 N--CA 1.441 -1.032 0 CA-C-N 115.595 -0.73 . . . . 0.0 111.532 179.747 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . 0.499 ' HA3' ' CB ' ' A' ' 27' ' ' SER . . . 149.86 -167.17 29.92 Favored Glycine 0 C--O 1.216 -1.027 0 N-CA-C 111.326 -0.71 . . . . 0.0 111.326 178.405 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' ASN . . . . . 0.595 ' ND2' HD11 ' A' ' 66' ' ' LEU . 22.7 m120 -108.53 140.84 41.3 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 117.379 0.59 . . . . 0.0 110.867 179.35 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' TRP . . . . . 0.435 ' HD1' ' C ' ' A' ' 89' ' ' ASN . 29.4 m0 -133.69 160.62 36.99 Favored 'General case' 0 N--CA 1.465 0.298 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 -177.16 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.53 ' O ' ' HB3' ' A' ' 23' ' ' TRP . 96.9 mt -121.19 121.6 65.31 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.035 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 175.806 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' LEU . . . . . . . . . . . . . 83.7 mt -134.63 82.93 1.99 Allowed 'General case' 0 C--O 1.267 1.979 0 N-CA-C 112.765 0.654 . . . . 0.0 112.765 -175.414 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 164.64 118.5 0.44 Allowed Glycine 0 N--CA 1.448 -0.536 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.81 177.954 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 43.1 m -90.64 -0.14 57.58 Favored 'General case' 0 N--CA 1.463 0.211 0 CA-C-O 121.11 0.481 . . . . 0.0 110.64 177.922 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -120.02 152.16 37.91 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 178.788 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' GLU . . . . . . . . . . . . . 78.1 tt0 -66.06 -65.44 0.68 Allowed 'General case' 0 C--N 1.32 -0.71 0 N-CA-C 112.6 0.593 . . . . 0.0 112.6 -174.86 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 93.5 m-20 -107.15 36.9 2.52 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 116.271 -0.422 . . . . 0.0 112.026 -175.409 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' GLN . . . . . 0.403 ' CG ' ' HB3' ' A' ' 120' ' ' TYR . 14.5 tp60 -108.67 -62.33 1.48 Allowed 'General case' 0 C--N 1.316 -0.885 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 179.646 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 99' ' ' ASN . . . . . . . . . . . . . 91.7 m-20 71.87 149.98 0.1 Allowed 'General case' 0 C--O 1.248 1.013 0 CA-C-N 115.225 -0.898 . . . . 0.0 112.942 178.258 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 76.6 t -81.66 132.14 32.19 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.335 0 CA-C-N 115.44 -0.8 . . . . 0.0 111.191 178.279 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 101' ' ' VAL . . . . . . . . . . . . . 26.8 m -114.49 -21.57 5.3 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.185 0 CA-C-N 116.004 -0.544 . . . . 0.0 112.356 179.571 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . 0.522 ' HB3' ' HB ' ' A' ' 119' ' ' THR . . . -150.09 141.44 23.27 Favored 'General case' 0 C--N 1.326 -0.444 0 C-N-CA 120.161 -0.615 . . . . 0.0 111.596 178.601 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.463 ' HB ' HG22 ' A' ' 38' ' ' VAL . 32.2 mm -134.61 127.21 49.33 Favored 'Isoleucine or valine' 0 C--O 1.244 0.766 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.863 178.429 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 50.4 t30 -131.76 97.38 4.18 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.782 -0.645 . . . . 0.0 109.867 175.277 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.59 ' O ' ' HA ' ' A' ' 35' ' ' ALA . 15.5 m -130.51 135.06 61.28 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.029 0 CA-C-N 115.775 -0.648 . . . . 0.0 111.162 -176.926 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 52.8 mt-10 -139.1 27.45 2.37 Favored 'General case' 0 N--CA 1.486 1.371 0 CA-C-O 121.526 0.679 . . . . 0.0 110.953 -178.841 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . 0.633 ' HB2' ' HB2' ' A' ' 115' ' ' ASN . 53.7 m -139.1 147.34 41.85 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 114.259 1.207 . . . . 0.0 114.259 -175.1 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 148.71 122.06 1.2 Allowed Glycine 0 N--CA 1.436 -1.341 0 CA-C-N 114.624 -1.171 . . . . 0.0 111.84 178.268 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -83.29 107.67 15.98 Favored 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 178.657 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 110' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 59.58 18.13 6.77 Favored 'General case' 0 N--CA 1.481 1.084 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.275 -177.446 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . 0.501 ' HA3' ' HB3' ' A' ' 32' ' ' ASN . . . 80.06 15.39 78.96 Favored Glycine 0 N--CA 1.442 -0.913 0 CA-C-N 115.818 -0.628 . . . . 0.0 112.838 179.006 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 112' ' ' GLN . . . . . 0.525 ' HA ' HD12 ' A' ' 132' ' ' LEU . 52.2 tt0 -64.15 -37.52 87.74 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-O 121.799 0.809 . . . . 0.0 109.138 177.607 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 113' ' ' THR . . . . . . . . . . . . . 60.5 p -133.93 164.25 27.71 Favored 'General case' 0 N--CA 1.431 -1.422 0 CA-C-N 114.56 -1.2 . . . . 0.0 108.724 177.354 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 114' ' ' LEU . . . . . 0.41 ' HA ' ' O ' ' A' ' 107' ' ' SER . 33.8 tp -134.84 114.69 12.84 Favored 'General case' 0 C--N 1.301 -1.519 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 176.937 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 115' ' ' ASN . . . . . 0.633 ' HB2' ' HB2' ' A' ' 107' ' ' SER . 0.8 OUTLIER -116.9 143.7 45.39 Favored 'General case' 0 C--O 1.263 1.81 0 C-N-CA 120.117 -0.633 . . . . 0.0 111.577 -176.31 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 165.02 -138.31 5.18 Favored Glycine 0 N--CA 1.437 -1.298 0 CA-C-N 115.164 -0.925 . . . . 0.0 112.25 177.208 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 29.8 p -130.51 155.48 46.4 Favored 'General case' 0 C--N 1.307 -1.265 0 C-N-CA 122.792 0.437 . . . . 0.0 109.986 -179.221 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 118' ' ' MET . . . . . 0.404 ' HE3' ' HB2' ' A' ' 118' ' ' MET . 18.0 ptm -146.94 153.32 39.95 Favored 'General case' 0 C--N 1.309 -1.194 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.465 -179.065 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 119' ' ' THR . . . . . 0.522 ' HB ' ' HB3' ' A' ' 102' ' ' ALA . 25.9 m -132.83 129.8 38.97 Favored 'General case' 0 C--O 1.248 1.0 0 CA-C-N 116.487 -0.324 . . . . 0.0 111.368 -179.811 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . 0.518 ' HB2' ' HB3' ' A' ' 123' ' ' GLU . 57.2 m-85 -94.1 159.16 15.27 Favored 'General case' 0 CA--C 1.516 -0.35 0 CA-C-N 115.746 -0.661 . . . . 0.0 109.58 175.298 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 121' ' ' ALA . . . . . . . . . . . . . . . -66.27 134.39 52.56 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 109.662 -0.496 . . . . 0.0 109.662 176.284 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . 64.95 22.44 68.6 Favored Glycine 0 CA--C 1.523 0.532 0 C-N-CA 120.815 -0.707 . . . . 0.0 113.113 -179.856 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . 0.518 ' HB3' ' HB2' ' A' ' 120' ' ' TYR . 39.3 tp10 -137.87 161.86 35.51 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 -178.172 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -89.06 156.51 26.28 Favored Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.284 -0.96 . . . . 0.0 111.84 178.617 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_exo -60.6 134.28 53.52 Favored 'Trans proline' 0 C--N 1.349 0.6 0 C-N-CA 122.394 2.062 . . . . 0.0 111.707 178.743 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 126' ' ' ILE . . . . . . . . . . . . . 39.7 pt -131.57 165.44 31.71 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.812 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.51 -178.91 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -73.87 139.23 25.91 Favored Glycine 0 N--CA 1.445 -0.726 0 C-N-CA 121.206 -0.521 . . . . 0.0 112.003 179.717 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 128' ' ' PHE . . . . . . . . . . . . . 92.2 t80 -117.35 132.63 56.56 Favored 'General case' 0 C--O 1.244 0.794 0 CA-C-O 120.974 0.416 . . . . 0.0 111.083 -178.697 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 129' ' ' LYS . . . . . . . . . . . . . 61.7 tttm -135.48 102.37 5.11 Favored 'General case' 0 N--CA 1.442 -0.865 0 CA-C-N 115.567 -0.742 . . . . 0.0 109.694 177.867 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -100.58 140.7 15.04 Favored Glycine 0 CA--C 1.503 -0.67 0 N-CA-C 110.793 -0.923 . . . . 0.0 110.793 178.25 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 131' ' ' THR . . . . . . . . . . . . . 45.5 m -136.69 133.4 36.12 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-N 117.224 0.512 . . . . 0.0 111.059 179.881 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 132' ' ' LEU . . . . . 0.525 HD12 ' HA ' ' A' ' 112' ' ' GLN . 78.8 mt -60.71 129.91 43.86 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-O 120.907 0.384 . . . . 0.0 110.363 177.21 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 133' ' ' THR . . . . . 0.46 HG21 HD12 ' A' ' 3' ' ' LEU . 5.3 t . . . . . 0 C--O 1.247 0.958 0 CA-C-O 118.244 -0.884 . . . . 0.0 110.13 -179.037 . . . . . . . . 1 1 . 1 stop_ save_